PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	He, YW; Davies, CM; Harrington, BS; Hellmers, L; Sheng, YH; Broomfield, A; McGann, T; Bastick, K; Zhong, L; Wu, A; Maresh, G; McChesney, S; Wong, KY; Adams, MN; Sullivan, RC; Palmer, JS; Burke, LJ; Ewing, AD; Zhang, X; Margolin, D; Li, L; Lourie, R; Matsika, A; Srinivasan, B; McGuckin, MA; Lumley, JW; Hooper, JD				He, Yaowu; Davies, Claire M.; Harrington, Brittney S.; Hellmers, Linh; Sheng, Yonghua; Broomfield, Amy; McGann, Thomas; Bastick, Kate; Zhong, Laurie; Wu, Andy; Maresh, Grace; McChesney, Shannon; Wong, Kuan Yau; Adams, Mark N.; Sullivan, Ryan C.; Palmer, James S.; Burke, Lez J.; Ewing, Adam D.; Zhang, Xin; Margolin, David; Li, Li; Lourie, Rohan; Matsika, Admire; Srinivasan, Bhuvana; McGuckin, Michael A.; Lumley, John W.; Hooper, John D.			CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of beta-catenin and E-cadherin	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; TUMOR-INITIATING CELLS; HUMAN COLON; PHENOTYPIC CHARACTERIZATION; ELEVATED CDCP1; PKC-DELTA; CARCINOMA; SURVIVAL; TARGET; GENE	Elevated CUB-domain containing protein 1 (CDCP1) is predictive of colorectal cancer (CRC) recurrence and poor patient survival. While CDCP1 expression identifies stem cell populations that mediate lung metastasis, mechanisms underlying the role of this cell surface receptor in CRC have not been defined. We sought to identify CDCP1 regulated processes in CRC using stem cell populations, enriched from primary cells and cell lines, in extensive in vitro and in vivo assays. These experiments, demonstrating that CDCP1 is functionally important in CRC tumor initiation, growth and metastasis, identified CDCP1 as a positive regulator of Wnt signaling. Detailed cell fractionation, immunoprecipitation, microscopy, and immunohistochemical analyses demonstrated that CDCP1 promotes translocation of the key regulators of Wnt signaling, beta-catenin, and E-cadherin, to the nucleus. Of functional importance, disruption of CDCP1 reduces nuclear localized, chromatin-associated beta-catenin and nuclear localized E-cadherin, increases sequestration of these proteins in cell membranes, disrupts regulation of CRC promoting genes, and reduces CRC tumor burden. Thus, disruption of CDCP1 perturbs pro-cancerous Wnt signaling including nuclear localization of beta-catenin and E-cadherin.	[He, Yaowu; Davies, Claire M.; Harrington, Brittney S.; Sheng, Yonghua; McGann, Thomas; Bastick, Kate; Zhong, Laurie; Wu, Andy; Wong, Kuan Yau; Adams, Mark N.; Palmer, James S.; Burke, Lez J.; Ewing, Adam D.; Lourie, Rohan; Srinivasan, Bhuvana; McGuckin, Michael A.; Hooper, John D.] Univ Queensland, Mater Res Inst, Woolloongabba, Qld 4102, Australia; [Davies, Claire M.; Broomfield, Amy; Lourie, Rohan; Matsika, Admire; Srinivasan, Bhuvana] Mater Hlth Serv, South Brisbane, Qld 4101, Australia; [Hellmers, Linh; Maresh, Grace; McChesney, Shannon; Sullivan, Ryan C.; Zhang, Xin; Margolin, David; Li, Li] Ochsner Clin Fdn, New Orleans, LA USA; [Matsika, Admire] Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; [Lumley, John W.] Wesley Hosp, Auchenflower, Qld 4066, Australia	Mater Research; University of Queensland; Mater Health Services; Ochsner Health System; University of Queensland; Wesley Hospital	Hooper, JD (corresponding author), Univ Queensland, Mater Res Inst, Woolloongabba, Qld 4102, Australia.	john.hooper@mater.uq.edu.au	sheng, yong H/C-5052-2013; Adams, Mark/AAE-1209-2021; Ewing, Adam/M-3164-2014; Harrington, Brittney/P-1687-2016; Hooper, John/C-1481-2016	sheng, yong H/0000-0002-4623-9098; Adams, Mark/0000-0003-1906-5018; HE, Yaowu/0000-0002-7828-263X; McGann, Thomas/0000-0002-7699-1010; Ewing, Adam/0000-0002-4544-994X; Harrington, Brittney/0000-0001-7083-069X; Burke, Lez/0000-0002-2932-6843; McGuckin, Michael/0000-0002-8375-2675; Hooper, John/0000-0003-1054-8486; Davies, Claire/0000-0001-8651-0914; Wu, Andy C/0000-0002-0864-4447	Wesley Research Institute [2010-09]; Cancer Council Queensland [APP1021827, APP1045801]; National Health and Medical Research Council [APP1121970]; Australian Research Council [FT120100917]; NHMRC Early Career Fellowship [1091589]	Wesley Research Institute; Cancer Council Queensland(Cancer Council Queensland); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); NHMRC Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This work was funded by grant 2010-09 from the Wesley Research Institute to JWL and JDH, grants APP1021827 and APP1045801 from the Cancer Council Queensland, grant APP1121970 from the National Health and Medical Research Council to JDH, and Future Fellowship FT120100917 from the Australian Research Council to JDH, and NHMRC Early Career Fellowship 1091589 to MNA.	Adams MN, 2015, ONCOGENE, V34, P1375, DOI 10.1038/onc.2014.88; Alajati A, 2015, CELL REP, V11, P564, DOI 10.1016/j.celrep.2015.03.044; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Brocardo M, 2008, J BIOL CHEM, V283, P5950, DOI 10.1074/jbc.M708775200; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Bruun J, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00118; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Chou CT, 2015, ANN SURG ONCOL, V22, P4335, DOI 10.1245/s10434-015-4505-4; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; Dong Y, 2012, J BIOL CHEM, V287, P9792, DOI 10.1074/jbc.M111.335448; Emerling BM, 2013, P NATL ACAD SCI USA, V110, P3483, DOI 10.1073/pnas.1222435110; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Ganesh S, 2018, MOL CANCER THER, V17, P544, DOI 10.1158/1535-7163.MCT-17-0605; Gao WC, 2013, GASTROENTEROLOGY, V145, P636, DOI 10.1053/j.gastro.2013.05.049; Harrington BS, 2016, BRIT J CANCER, V114, P417, DOI 10.1038/bjc.2015.471; He Y, 2016, ONCOGENE, V35, P468, DOI 10.1038/onc.2015.101; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Huang WS, 2007, WORLD J GASTROENTERO, V13, P6581, DOI 10.3748/wjg.13.6581; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Law ME, 2013, ONCOGENE, V32, P1316, DOI 10.1038/onc.2012.138; Lin CY, 2014, CANCER RES, V74, P5229, DOI 10.1158/0008-5472.CAN-13-2995; Margolin DA, 2015, FASEB J, V29, P3571, DOI 10.1096/fj.14-268938; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morgan RG, 2014, J CELL BIOCHEM, V115, P1351, DOI 10.1002/jcb.24803; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Novellasdemunt L, 2015, AM J PHYSIOL-CELL PH, V309, pC511, DOI 10.1152/ajpcell.00117.2015; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Orsulic S, 1999, J CELL SCI, V112, P1237; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Turdo F, 2016, ONCOTARGET, V7, P69649, DOI 10.18632/oncotarget.11935; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Wright HJ, 2017, P NATL ACAD SCI USA, V114, pE6556, DOI 10.1073/pnas.1703791114; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304	47	19	19	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					219	233		10.1038/s41388-019-0983-3	http://dx.doi.org/10.1038/s41388-019-0983-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31471585				2022-12-17	WOS:000509849200015
J	Son, B; Lee, S; Kim, H; Kang, H; Jeon, J; Jo, S; Seong, KM; Lee, SJ; Youn, H; Youn, B				Son, Beomseok; Lee, Sungmin; Kim, Hyunwoo; Kang, Hyunkoo; Jeon, Jaewan; Jo, Sunmi; Seong, Ki Moon; Lee, Su-Jae; Youn, HyeSook; Youn, BuHyun			Decreased FBP1 expression rewires metabolic processes affecting aggressiveness of glioblastoma	ONCOGENE			English	Article							IN-VIVO; CANCER; GLIOMA; THERAPY; RADIORESISTANCE; GLYCOLYSIS; STRESS; EMODIN; BRAIN; CELLS	Radiotherapy is a standard treatment option for patients with glioblastoma (GBM). Although it has high therapeutic efficacy, some proportion of the tumor cells that survive after radiotherapy may cause side effects. In this study, we found that fructose 1,6-bisphosphatase 1 (FBP1), a rate-limiting enzyme in gluconeogenesis, was downregulated upon treatment with ionizing radiation (IR). Ets1, which was found to be overexpressed in IR-induced infiltrating GBM, was suggested to be a transcriptional repressor of FBP1. Furthermore, glucose uptake and extracellular acidification rates were increased upon FBP1 downregulation, which indicated an elevated glycolysis level. We found that emodin, an inhibitor of phosphoglycerate mutase 1 derived from natural substances, significantly suppressed the glycolysis rate and IR-induced GBM migration in in vivo orthotopic xenograft mouse models. We propose that the reduced FBP1 level reprogrammed the metabolic state of GBM cells, and thus, FBP1 is a potential therapeutic target regulating GBM metabolism following radiotherapy.	[Son, Beomseok; Lee, Sungmin; Kim, Hyunwoo; Kang, Hyunkoo; Jeon, Jaewan; Youn, BuHyun] Pusan Natl Univ, Dept Integrated Biol Sci, Busan 46241, South Korea; [Jo, Sunmi] Inje Univ, Sch Med, Haeundae Paik Hosp, Dept Radiat Oncol, Busan 48108, South Korea; [Seong, Ki Moon] Korea Inst Radiol & Med Sci, Natl Radiat Emergency Med Ctr, Lab Low Dose Risk Assessment, Seoul 01812, South Korea; [Lee, Su-Jae] Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 04763, South Korea; [Youn, HyeSook] Sejong Univ, Dept Integrat Biosci & Biotechnol, Seoul 05006, South Korea; [Youn, BuHyun] Pusan Natl Univ, Dept Biol Sci, Busan 46241, South Korea	Pusan National University; Inje University; Korea Institute of Radiological & Medical Sciences; Hanyang University; Sejong University; Pusan National University	Youn, B (corresponding author), Pusan Natl Univ, Dept Integrated Biol Sci, Busan 46241, South Korea.; Youn, B (corresponding author), Pusan Natl Univ, Dept Biol Sci, Busan 46241, South Korea.	bhyoun72@pusan.ac.kr		Jo, Sunmi/0000-0002-1761-8953	Nuclear Safety Research Program through the Korea Foundation Of Nuclear Safety (KoFONS); Nuclear Safety and Security Commission (NSSC) of the Republic of Korea [1805019]	Nuclear Safety Research Program through the Korea Foundation Of Nuclear Safety (KoFONS); Nuclear Safety and Security Commission (NSSC) of the Republic of Korea	This work was supported by the Nuclear Safety Research Program through the Korea Foundation Of Nuclear Safety (KoFONS) using the financial resource granted by the Nuclear Safety and Security Commission (NSSC) of the Republic of Korea (No. 1805019). We thank Dr. Akio Soeda (Gifu University) for providing patient-derived X01 GBM cells.	Abbadi S, 2014, MOL CANCER RES, V12, P1547, DOI 10.1158/1541-7786.MCR-14-0106-T; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Brady ST, 2012, BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION, P1; Chang L, 2004, MOL MED, V10, P65, DOI 10.2119/2005-00029.Saltiel; Chen J, 2011, ONCOGENE, V30, P4297, DOI 10.1038/onc.2011.137; Cong Jingjing, 2018, CELL METAB, V28, P243; Cooper LAD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012548; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Ferrer VP, 2018, GLIA, V66, P1542, DOI 10.1002/glia.23309; Graziose Rocky, 2010, Curr Drug Discov Technol, V7, P2; Halliday J, 2014, P NATL ACAD SCI USA, V111, P5248, DOI 10.1073/pnas.1321014111; Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345; Han XT, 2017, ONCOTARGET, V8, P100931, DOI 10.18632/oncotarget.21753; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haris K, 2014, ASIAN PAC J CANCER P, V15, P4499, DOI 10.7314/APJCP.2014.15.11.4499; Hitosugi T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2759; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Husain SR, 2015, CANCER GENE THER, V22, P554, DOI 10.1038/cgt.2015.58; Huse JT, 2011, GLIA, V59, P1190, DOI 10.1002/glia.21165; Jiang XL, 2014, INT J CANCER, V135, P1991, DOI 10.1002/ijc.28637; Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076; Kang J, 2017, ONCOGENE, V36, P1585, DOI 10.1038/onc.2016.328; Ke C, 2014, ONCOTARGET, V5, P1657, DOI 10.18632/oncotarget.1823; Kim MS, 2005, INT J ONCOL, V27, P839; Kim W, 2011, RADIAT RES, V176, P539, DOI 10.1667/RR2609.1; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Lee E, 2018, SEMIN CANCER BIOL, V53, P201, DOI 10.1016/j.semcancer.2018.07.006; Lee S, 2018, CELL PHYSIOL BIOCHEM, V47, P2233, DOI 10.1159/000491535; Lee S, 2017, CELL PHYSIOL BIOCHEM, V42, P1684, DOI 10.1159/000479418; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Li J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167857; Li SN, 2016, SCI REP-UK, V6, DOI 10.1038/srep28479; Li XG, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00325; Li YH, 2015, NAT CELL BIOL, V17, P1327, DOI 10.1038/ncb3240; Liu H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189353; Lu CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121046; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151; Parekh HS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-21; Peterson CW, 2010, MOL CELL BIOL, V30, P2887, DOI 10.1128/MCB.01613-09; Rahman SA, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-12; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Seyfried TN, 2015, CANCER LETT, V356, P289, DOI 10.1016/j.canlet.2014.07.015; Shi WK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0435-y; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Son B, 2017, AM J PHYSIOL-LUNG C, V313, pL916, DOI 10.1152/ajplung.00144.2017; Thakkar JP, 2014, CANCER EPIDEM BIOMAR, V23, P1985, DOI 10.1158/1055-9965.EPI-14-0275; Tran B, 2010, J CLIN NEUROSCI, V17, P417, DOI 10.1016/j.jocn.2009.09.004; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Verschoor ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013565; Wang CY, 2007, EUR J PHARMACOL, V577, P58, DOI 10.1016/j.ejphar.2007.08.033; Wang YL, 2005, BIOCHEM BIOPH RES CO, V331, P1207, DOI 10.1016/j.bbrc.2005.03.243; Weller M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.17; Winter SF, 2017, CRIT REV ONCOL HEMAT, V112, P41, DOI 10.1016/j.critrevonc.2017.02.016; Wolf A, 2010, ONCOTARGET, V1, P552, DOI 10.18632/oncotarget.190; Xie Q, 2014, NEURO-ONCOLOGY, V16, P1575, DOI 10.1093/neuonc/nou147; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200; Zuccoli G, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-33	61	19	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					36	49		10.1038/s41388-019-0974-4	http://dx.doi.org/10.1038/s41388-019-0974-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31444412				2022-12-17	WOS:000509849200004
J	Zhang, HW; Zhu, D; Zhang, ZB; Kaluz, S; Yu, B; Devi, NS; Olson, JJ; Van Meir, EG				Zhang, Hanwen; Zhu, Dan; Zhang, Zhaobin; Kaluz, Stefan; Yu, Bing; Devi, Narra S.; Olson, Jeffrey J.; Van Meir, Erwin G.			EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway	ONCOGENE			English	Article							BRAIN; P53; ANGIOGENESIS; PROTEINS; GENE	Medulloblastoma (MB) is a malignant pediatric brain tumor for which new therapies are urgently needed. We demonstrate that treatment with EPZ-6438 (Tazemetostat), an enhancer of zeste homolog 2 (EZH2) inhibitor approved for clinical trials, blocks MB cell growth in vitro and in vivo, and prolongs survival in orthotopic xenograft models. We show that the therapeutic effect is dependent on epigenetic reactivation of adhesion G-protein-coupled receptor B1 (BAI1/ADGRB1), a tumor suppressor that controls p53 stability by blocking Mdm2. Histone 3 trimethylated on lysine 27 (H3K27me3), a marker of silent chromatin conformation is present at the ADGRB1 promoter, and inhibition of EZH2, the catalytic component of the Polycomb Repressive complex 2 (PRC2) that methylates H3K27, switches the gene into an active chromatin status and reactivates BAI1 expression. Mechanistically, targeting EZH2 promotes transition from H3K27me3 to H3K27ac at the promoter, recruits the C/EBP beta (CREB-binding protein) and CBP transcription factors and activates ADGRB1 gene transcription. Taken together, our results identify key molecular players that regulate ADGRB1 gene expression in MB, demonstrate that reactivation of BAI1 expression underlies EPZ-6438 antitumorigenic action, and provide preclinical proof-of-principle evidence for targeting EZH2 in patients with MB.	[Zhang, Hanwen; Zhu, Dan; Zhang, Zhaobin; Kaluz, Stefan; Yu, Bing; Devi, Narra S.; Olson, Jeffrey J.; Van Meir, Erwin G.] Emory Univ, Sch Med, Dept Neurosurg & Hematol & Med Oncol, Lab Mol Neurooncol, Atlanta, GA 30322 USA; [Zhang, Hanwen] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410013, Peoples R China; [Zhang, Hanwen] Cent S Univ, Sch Med, Changsha 410013, Peoples R China; [Olson, Jeffrey J.; Van Meir, Erwin G.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Van Meir, Erwin G.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Van Meir, Erwin G.] UAB, Dept Neurosurg, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA; [Van Meir, Erwin G.] UAB, ONeal Comprehens Canc Ctr, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA	Emory University; Central South University; Central South University; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Sch Med, Dept Neurosurg & Hematol & Med Oncol, Lab Mol Neurooncol, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), UAB, Dept Neurosurg, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA.; Van Meir, EG (corresponding author), UAB, ONeal Comprehens Canc Ctr, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA.	evanmeir@uab.edu	Zhang, Hanwen/AFK-2928-2022; Zhang, Hanwen/AAG-1299-2022	Zhang, Hanwen/0000-0001-8955-7494; Zhang, Hanwen/0000-0001-8955-7494; Van Meir, Erwin G./0000-0003-2444-7707	NIH [CA163722, CA235162, NS096236, CA138292]; CURE Childhood Cancer Foundation; St. Baldrick's Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CURE Childhood Cancer Foundation; St. Baldrick's Foundation	This work was supported by grants from the NIH CA163722, CA235162, and NS096236 (to EGVM), CA138292 (to Winship Cancer Institute), the CURE Childhood Cancer Foundation and the St. Baldrick's Foundation.	Aust G, 2016, HANDB EXP PHARMACOL, V234, P369, DOI 10.1007/978-3-319-41523-9_17; Chan HM, 2001, J CELL SCI, V114, P2363; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Jin X, 2017, NAT MED, V23, P1352, DOI 10.1038/nm.4415; Kaur B, 2003, AM J PATHOL, V162, P19, DOI 10.1016/S0002-9440(10)63794-7; Kaur B, 2009, CANCER RES, V69, P1212, DOI 10.1158/0008-5472.CAN-08-1166; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Mohammad F, 2017, NAT MED, V23, P483, DOI 10.1038/nm.4293; Naidu SR, 2009, ONCOGENE, V28, P2492, DOI 10.1038/onc.2009.121; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Northcott PA, 2017, NATURE, V547, P311, DOI 10.1038/nature22973; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Smits M, 2012, CLIN CANCER RES, V18, P4048, DOI 10.1158/1078-0432.CCR-12-0399; Van Meir EG, 1997, INT J CANCER, V71, P310; Vo BT, 2017, CELL REP, V18, P2907, DOI 10.1016/j.celrep.2017.02.073; Yan WJ, 2016, EPIGENOMICS-UK, V8, P119, DOI 10.2217/epi.15.84; Zhang P, 2015, INT J CANCER, V137, P2007, DOI 10.1002/ijc.29566; Zhu D, 2018, CANCER CELL, V33, P1004, DOI 10.1016/j.ccell.2018.05.006; Zhu D, 2011, CANCER RES, V71, P5859, DOI 10.1158/0008-5472.CAN-11-1157	21	19	19	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1041	1048		10.1038/s41388-019-1036-7	http://dx.doi.org/10.1038/s41388-019-1036-7			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31582835	Green Accepted			2022-12-17	WOS:000511209700007
J	Zhu, S; Zhao, DY; Li, C; Li, QQ; Jiang, WH; Liu, QP; Wang, R; Fazli, L; Li, YA; Zhang, LL; Yi, Y; Meng, QS; Wang, WY; Wang, GY; Zhang, M; Zu, XB; Zhao, W; Deng, T; Yu, JD; Dong, XS; Chen, KF; Cao, Q				Zhu, Sen; Zhao, Dongyu; Li, Chao; Li, Qiaqia; Jiang, Weihua; Liu, Qipeng; Wang, Rui; Fazli, Ladan; Li, Yinan; Zhang, Lili; Yi, Yang; Meng, Qingshu; Wang, Wanyi; Wang, Guangyu; Zhang, Min; Zu, Xiongbing; Zhao, Wei; Deng, Tuo; Yu, Jindan; Dong, Xuesen; Chen, Kaifu; Cao, Qi			BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer	ONCOGENE			English	Article							CELL; PROGRESSION; EZH2	B lymphoma Mo-MLV insertion region 1 (BMI1) has been reported to be an oncoprotein. BMI1 represses tumor suppressors to promote cell proliferation, epithelial-mesenchymal transition (EMT), and cancer progression. Although it is known that the expression of BMI1 is increased in many cancer types, the mechanism of BMI1 upregulation is not yet clear. We performed integrative analysis for 3 sets of prostate cancer (PCa) genomic data, and found that BMI1 and androgen receptor (AR) were positively correlated, suggesting that AR might regulate BMI1. Next, we showed that dihydrotestosterone (DHT) upregulated both mRNA and protein levels of BMI1 and that BMI1 was increased in castration-resistant prostate cancer (CRPC) from both human patients and a mouse xenograph model. We further identified an AR binding site in the promoter/enhancer region of BMI1, and confirmed BMI1 as the direct target of AR using gene-editing technology. We also demonstrated that high expression of BMI1 is critical for the development of castration-resistance. Our data also suggest that BMI1-specific inhibitors could be an effective treatment of CRPC.	[Zhu, Sen; Li, Chao; Li, Qiaqia; Jiang, Weihua; Liu, Qipeng; Wang, Rui; Zhang, Lili; Yi, Yang; Meng, Qingshu; Cao, Qi] Houston Methodist Res Inst, Ctr Inflammat & Epigenet, Houston, TX 77030 USA; [Zhao, Dongyu; Wang, Guangyu; Chen, Kaifu] Houston Methodist Res Inst, Ctr Bioinformat & Computat Biol, Houston, TX 77030 USA; [Zhao, Dongyu; Wang, Guangyu; Chen, Kaifu] Cornell Univ, Weill Cornell Med, Dept Cardiothorac Surg, New York, NY 10065 USA; [Li, Chao; Li, Qiaqia; Yi, Yang; Meng, Qingshu; Cao, Qi] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA; [Li, Chao; Zu, Xiongbing] Cent S Univ, Xiangya Hosp, Dept Urol, Changsha 410008, Peoples R China; [Li, Qiaqia; Liu, Qipeng] Cent S Univ, Xiangya Sch Med, Changsha 410008, Peoples R China; [Fazli, Ladan; Li, Yinan; Dong, Xuesen] Vancouver Gen Hosp, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; [Fazli, Ladan; Li, Yinan; Dong, Xuesen] Univ British Columbia, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada; [Wang, Wanyi] Texas Womans Univ, Off Res & Sponsored Programs, Ctr Res Design & Anal, Houston, TX 77030 USA; [Zhang, Min] Houston Methodist Res Inst, Dept Cardiovasc Sci, Ctr Cardiovasc Regenerat, Houston, TX USA; [Zhao, Wei] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou 510080, Peoples R China; [Deng, Tuo] Cent S Univ, Minist Educ, Xiangya Hosp 2, Dept Endocrinol & Metab, Changsha 410011, Peoples R China; [Deng, Tuo] Cent S Univ, Minist Educ, Key Lab Diabet Immunol, Changsha 410011, Peoples R China; [Yu, Jindan] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Yu, Jindan; Cao, Qi] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Cao, Qi] Houston Methodist Res Inst, Houston Methodist Canc Ctr, Houston, TX 77030 USA	The Methodist Hospital System; The Methodist Hospital - Houston; The Methodist Hospital System; The Methodist Hospital - Houston; Cornell University; Northwestern University; Feinberg School of Medicine; Central South University; Central South University; University of British Columbia; University of British Columbia; Texas Womans University; The Methodist Hospital System; The Methodist Hospital - Houston; Sun Yat Sen University; Central South University; Central South University; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; The Methodist Hospital System; The Methodist Hospital - Houston	Cao, Q (corresponding author), Houston Methodist Res Inst, Ctr Inflammat & Epigenet, Houston, TX 77030 USA.; Chen, KF (corresponding author), Houston Methodist Res Inst, Ctr Bioinformat & Computat Biol, Houston, TX 77030 USA.; Chen, KF (corresponding author), Cornell Univ, Weill Cornell Med, Dept Cardiothorac Surg, New York, NY 10065 USA.; Cao, Q (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA.; Cao, Q (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.; Cao, Q (corresponding author), Houston Methodist Res Inst, Houston Methodist Canc Ctr, Houston, TX 77030 USA.	kchen2@houstonmethodist.org; qi.cao@northwestern.edu	Dong, Xuesen/AGF-9228-2022; Wang, Guangyu/AAM-5940-2021; Zhao, Dongyu/ABA-2574-2020; Cao, Qi/A-5517-2010	Wang, Guangyu/0000-0003-4803-7200; Wang, Wanyi/0000-0001-9482-9968; Cao, Qi/0000-0002-5140-3681	Houston Methodist Research Institute; Prostate Cancer Foundation [13YOUN007]; U.S. Department of Defense [W81XWH-15-1-0639, W81XWH-17-1-0357]; American Cancer Society [RSG-15-192-01-TBE]; NIH/NCI [R01CA208257, R01CA172384]; NIH/NIGMS [R01GM125632]; NIH/NHLBI [R01HL133254]; US Department of Defense [W81XWH-17-1-0405, W81XWH-17-1-0362, W81XWH-17-1-0578]; Canadian Institute of Health Research [MOP-137007]; TFRI New Frontier Grant [1062]; National Natural Science Foundation of China [81572766, 81972651, 31771630, 81770868, 91742103]; Guangdong Innovative and Entrepreneurial Research Team Program [2016ZT06S029]; Natural Science Foundation of Guangdong Province [2017A030312009]; China Scholarship Council [201706370147]; Innovation-driven Project of Central South University [2017CX011]; CPRIT [RP120348, RP170002]	Houston Methodist Research Institute; Prostate Cancer Foundation; U.S. Department of Defense(United States Department of Defense); American Cancer Society(American Cancer Society); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); US Department of Defense(United States Department of Defense); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); TFRI New Frontier Grant; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Innovative and Entrepreneurial Research Team Program; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); China Scholarship Council(China Scholarship Council); Innovation-driven Project of Central South University; CPRIT	This work is supported, in part, by grants from Houston Methodist Research Institute, Prostate Cancer Foundation (13YOUN007 to QC), U.S. Department of Defense (W81XWH-15-1-0639 and W81XWH-17-1-0357 to QC), American Cancer Society (Research Scholar Grant RSG-15-192-01-TBE to QC), and NIH/NCI (R01CA208257 to QC); KC is supported in part by grants from NIH/NIGMS (R01GM125632 to KC) and NIH/NHLBI (R01HL133254 to KC); JY is supported by NIH/NCI (R01CA172384), US Department of Defense (W81XWH-17-1-0405, W81XWH-17-1-0362, and W81XWH-17-1-0578). XD is supported by the Canadian Institute of Health Research (#MOP-137007) and TFRI New Frontier Grant #1062. WZ is supported by the National Natural Science Foundation of China (81572766,81972651 and 31771630), Guangdong Innovative and Entrepreneurial Research Team Program (2016ZT06S029), and Natural Science Foundation of Guangdong Province (2017A030312009); CL is supported by the China Scholarship Council (201706370147). TD is supported by National Natural Science Foundation of China (81770868 and 91742103), and Innovation-driven Project of Central South University (2017CX011). The University of Texas MD Anderson Cancer Center Science Park Next-Generation Sequencing (NGS) Facility is supported by CPRIT grants RP120348 and RP170002.	Bansal N, 2016, CLIN CANCER RES, V22, P6176, DOI 10.1158/1078-0432.CCR-15-3107; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen KF, 2013, GENOME RES, V23, P341, DOI 10.1101/gr.142067.112; Clyne Melanie, 2011, Nat Rev Urol, V9, P4, DOI 10.1038/nrurol.2011.208; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; Jin X, 2017, NAT MED, V23, P1352, DOI 10.1038/nm.4415; Kassi E, 2011, CANCER LETT, V302, P1, DOI 10.1016/j.canlet.2010.10.020; Kent WJ, 2010, BIOINFORMATICS, V26, P2204, DOI 10.1093/bioinformatics/btq351; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Kron KJ, 2017, NAT GENET, V49, P1336, DOI 10.1038/ng.3930; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li HL, 2016, CANCER RES, V76, P6701, DOI 10.1158/0008-5472.CAN-16-1518; Mounir Z, 2016, ELIFE, V5, DOI 10.7554/eLife.13964; Mourgues L, 2015, LEUKEMIA, V29, P1993, DOI 10.1038/leu.2015.112; Nishida Y, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.8; Ren H, 2016, J CANCER, V7, P1074, DOI 10.7150/jca.14031; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Takayama K, 2014, CANCER RES, V74, P6542, DOI 10.1158/0008-5472.CAN-14-1030; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; Yong KJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6066; Yoo YA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12943; Yu Y, 2015, PROSTATE, V75, P1043, DOI 10.1002/pros.22988; Zhu S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02863-3	31	19	19	4	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					17	29		10.1038/s41388-019-0966-4	http://dx.doi.org/10.1038/s41388-019-0966-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462713	Green Accepted			2022-12-17	WOS:000509849200002
J	Kim, YE; Won, M; Lee, SG; Park, C; Song, CH; Kim, KK				Kim, Yong-Eun; Won, Minho; Lee, Sung-Gwon; Park, Chungoo; Song, Chang-Hwa; Kim, Kee K.			RBM47-regulated alternative splicing of TJP1 promotes actin stress fiber assembly during epithelial-to-mesenchymal transition	ONCOGENE			English	Article							JUNCTION PROTEIN ZO-1; RNA-BINDING PROTEINS; TIGHT JUNCTIONS; CELLS; ISOFORMS; GROWTH; MOTIF	Morphological and functional changes in cells during the epithelial-mesenchymal transition (EMT) process are known to be regulated by alternative splicing. However, only a few splicing factors involved in EMT have been reported and their underlying mechanisms remain largely unknown. Here, we showed that an isoform of tight junction protein 1 (TJP1) lacking exon 20 (TJP1-alpha-) is predominantly expressed in tumor tissues and in A549 cells during transforming growth factor-beta (TGF-beta-induced EMT. RBM47 promoted the inclusion of exon 20 of TJP1, the alternative exon encoding the a-domain, by which RBM47 recognizes to (U)GCAUG in the downstream intronic region of exon 20. We also found that the first RNA recognition motif (RRM) domain of RBM47 is critical in the regulation of alternative splicing and its recognition to pre-mRNA of TJP1. Furthermore, we demonstrated that the TJP1-alpha- isoform enhances the assembly of actin stress fibers, thereby promoting cellular migration in a wound healing assay. Our results suggest the regulatory mechanism for the alternative splicing of TJP1 pre-mRNA by RBM47 during EMT, providing a basis for studies related to the modulation of EMT via alternative splicing.	[Kim, Yong-Eun; Kim, Kee K.] Chungnam Natl Univ, Dept Biochem, Daejeon 34134, South Korea; [Kim, Yong-Eun; Song, Chang-Hwa] Chungnam Natl Univ, Coll Med, Brain Korea Plus Project Med Sci 21, Dept Med Sci,Dept Microbiol, Daejeon 35015, South Korea; [Won, Minho] Chungnam Natl Univ, Sch Med, Dept Pharmacol, Daejeon 35015, South Korea; [Lee, Sung-Gwon; Park, Chungoo] Chonnam Natl Univ, Sch Biol Sci & Technol, Gwangju 61186, South Korea	Chungnam National University; Chungnam National University; Chungnam National University; Chonnam National University	Kim, KK (corresponding author), Chungnam Natl Univ, Dept Biochem, Daejeon 34134, South Korea.	songch@cnu.ac.kr; kimkk@cnu.ac.kr	Song, Chang-Hwa/AAD-7917-2022	Song, Chang-Hwa/0000-0002-9490-0573; Lee, Sung-Gwon/0000-0002-0928-9950; Won, Minho/0000-0002-5873-5216	National Research Foundation of Korea within the Basic Science Research Program through the Ministry of Education [NRF-2018R1A1A1A05018628]; National Research Foundation of Korea (NRF) - Korean government (MEST) [NRF-2016R1A2B2008178]	National Research Foundation of Korea within the Basic Science Research Program through the Ministry of Education(Ministry of Education (MOE), Republic of Korea); National Research Foundation of Korea (NRF) - Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of KoreaKorean Government)	This work was supported by the National Research Foundation of Korea within the Basic Science Research Program through the Ministry of Education under Grant NRF-2018R1A1A1A05018628. This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (NRF-2016R1A2B2008178).	Aparicio LA, 2013, CELL MOL LIFE SCI, V70, P4463, DOI 10.1007/s00018-013-1379-0; Balda MS, 2003, J CELL BIOL, V160, P423, DOI 10.1083/jcb.200210020; BALDA MS, 1993, AM J PHYSIOL, V264, pC918, DOI 10.1152/ajpcell.1993.264.4.C918; BIEDLER JL, 1973, CANCER RES, V33, P2643; Braeutigam C, 2014, ONCOGENE, V33, P1082, DOI 10.1038/onc.2013.50; Buratti E, 2004, MOL CELL BIOL, V24, P10505, DOI 10.1128/MCB.24.24.10505-10514.2004; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Ciana A, 2010, CELL BIOL INT, V34, P669, DOI 10.1042/CBI20090067; Cooper TA, 2005, METHODS, V37, P331, DOI 10.1016/j.ymeth.2005.07.015; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Fan Q, 2015, ONCOL REP, V34, P1787, DOI 10.3892/or.2015.4143; Fanning AS, 2002, FASEB J, V16, P1835, DOI 10.1096/fj.02-0121fje; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fong N, 2014, GENE DEV, V28, P2663, DOI 10.1101/gad.252106.114; Fossat N, 2014, EMBO REP, V15, P903, DOI 10.15252/embr.201438450; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Gonzalez-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018; Haynes J, 2011, MOL BIOL CELL, V22, P4750, DOI 10.1091/mbc.E11-02-0119; Heiner M, 2010, RNA BIOL, V7, P56, DOI 10.4161/rna.7.1.10402; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Inada M, 2016, INT J MOL MED, V37, P1521, DOI 10.3892/ijmm.2016.2568; Kadener S, 2002, P NATL ACAD SCI USA, V99, P8185, DOI 10.1073/pnas.122246099; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kim KK, 2009, J BIOL CHEM, V284, P31052, DOI 10.1074/jbc.M109.052969; Kim YE, 2016, MOL CELLS, V39, P625, DOI 10.14348/molcells.2016.0150; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Maris C, 2005, FEBS J, V272, P2118, DOI 10.1111/j.1742-4658.2005.04653.x; Nakahata S, 2005, NUCLEIC ACIDS RES, V33, P2078, DOI 10.1093/nar/gki338; Pradella D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0579-2; Ray D, 2013, NATURE, V499, P172, DOI 10.1038/nature12311; Rokavec M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04234-2; Sakurai T, 2016, ONCOGENE, V35, P5000, DOI 10.1038/onc.2016.35; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vanharanta S, 2014, ELIFE, V3, DOI 10.7554/eLife.02734; Wan LD, 2019, GUT, V68, P118, DOI 10.1136/gutjnl-2017-314983; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Yang YQ, 2016, MOL CELL BIOL, V36, P1704, DOI 10.1128/MCB.00019-16; Zhang JY, 2016, J CLIN MED, V5, DOI 10.3390/jcm5040041; Zhang K, 2013, INT J MOL MED, V32, P464, DOI 10.3892/ijmm.2013.1396; Zhao Q, 2017, CELL MOL NEUROBIOL, V37, P643, DOI 10.1007/s10571-016-0401-0	42	19	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6521	6536		10.1038/s41388-019-0892-5	http://dx.doi.org/10.1038/s41388-019-0892-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31358901				2022-12-17	WOS:000486609000004
J	Chu, TH; Huang, ST; Yang, SF; Li, CJ; Lin, HW; Weng, BC; Yang, SM; Huang, SC; Wu, JC; Chang, YC; Wen, ZH; Chen, YMA; Wu, WJ; Kung, ML; Tai, PH; Wu, DC; Tai, MH				Chu, Tian-Huei; Huang, Shih-Tsung; Yang, Sheau-Fang; Li, Chia-Jung; Lin, Hung-Wei; Weng, Bi-Chuang; Yang, Shih-Ming; Huang, Shih-Chung; Wu, Jian-Ching; Chang, Yi-Chen; Wen, Zhi-Hong; Chen, Yi-Ming Arthur; Wu, Wen-Jeng; Kung, Mei-Lang; Tai, Po-Han; Wu, Deng-Chyang; Tai, Ming-Hong			Hepatoma-derived growth factor participates in Helicobacter Pylori-induced neutrophils recruitment, gastritis and gastric carcinogenesis	ONCOGENE			English	Article							INTESTINAL METAPLASIA; KAPPA-B; HEPATOCELLULAR-CARCINOMA; SUPPRESSOR-CELLS; FACTOR HDGF; RECEPTOR 2; CANCER; TNF; EXPRESSION; INFECTION	Helicobacter pylori (Hp) infection and overexpression of hepatoma-derived growth factor (HDGF) are involved in gastric carcinogenesis. However, the relationship between Hp-induced gastric diseases and HDGF upregulation is not yet completely clear. This study aimed to elucidate the role of HDGF in Hp-induced gastric inflammation and carcinogenesis. HDGF expression in gastric biopsy and serum from patients was analyzed by immunohistochemical and ELISA analysis, respectively. Hp and gastric cells coculture system was employed to delineate the mechanism underlying HDGF overexpression during Hp infection. The gastric pathologies of wild type and HDGF knockout mice after Hp infection were investigated by immunohistochemical, immunoblot, and immunofluorescence analyses. HDGF level was significantly elevated in patients with Hp infection or intestinal metaplasia (IM, a precancerous lesion), and HDGF overexpression was positively correlated with Hp load, IM, and neutrophil infiltration in gastric biopsy. Consistently, patients with Hp infection or IM had significantly higher serum HDGF level. By using coculture assay, Hp infection led to HDGF upregulation and secretion in gastric cells. In mice model, HDGF ablation significantly suppressed the Hp-induced neutrophil infiltration and inflammatory TNF-alpha/COX-2 signaling, thereby relieving the tissue damage in stomach. This was further supported by that recombinant HDGF (rHDGF) stimulated the differentiation/chemotaxis of cultured neutrophils and oncogenic behaviors of gastric cells. Time series studies showed that Hp infection elicited an inflammatory TNF-alpha/HDGF/COX-2 cascade in stomach. HDGF secretion by Hp infection promotes the neutrophils infiltration and relays Hp-induced inflammatory signaling. Thus, HDGF may constitute a novel diagnostic marker and therapeutic target for Hp-induced gastritis and carcinogenesis.	[Chu, Tian-Huei; Tai, Po-Han; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung, Taiwan; [Chu, Tian-Huei; Lin, Hung-Wei; Yang, Shih-Ming; Huang, Shih-Chung; Chen, Yi-Ming Arthur; Tai, Po-Han; Wu, Deng-Chyang; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan; [Huang, Shih-Tsung; Wu, Jian-Ching; Chang, Yi-Chen; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung, Taiwan; [Huang, Shih-Tsung; Wu, Jian-Ching; Chang, Yi-Chen; Tai, Ming-Hong] Acad Sinica, Kaohsiung, Taiwan; [Yang, Sheau-Fang] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Pathol, Kaohsiung, Taiwan; [Yang, Sheau-Fang; Wu, Wen-Jeng] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan; [Li, Chia-Jung; Weng, Bi-Chuang; Wu, Deng-Chyang] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan; [Huang, Shih-Chung] Kaohsiung Aimed Forces Gen Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Wen, Zhi-Hong] Natl Sun Yat Sen Univ, Asia Pacific Ocean Res Ctr, Dept Marine Biotechnol & Resources, Kaohsiung, Taiwan; [Chen, Yi-Ming Arthur] Kaohsiung Med Univ, Ctr Infect Dis & Canc Res, Kaohsiung, Taiwan; [Chen, Yi-Ming Arthur] Kaohsiung Med Univ, Dept Microbiol & Immunol, Inst Med Res, Coll Med, Kaohsiung, Taiwan; [Chen, Yi-Ming Arthur] Kaohsiung Med Univ, Coll Med, Inst Clin Med, Kaohsiung, Taiwan; [Wu, Wen-Jeng] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Urol, Kaohsiung, Taiwan; [Wu, Wen-Jeng] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Urol, Kaohsiung, Taiwan; [Wu, Wen-Jeng] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Urol, Kaohsiung, Taiwan; [Wu, Wen-Jeng; Wu, Deng-Chyang; Tai, Ming-Hong] Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung, Taiwan; [Kung, Mei-Lang] Natl Sun Yat Sen Univ, Dept Chem, Kaohsiung, Taiwan; [Wu, Deng-Chyang] Kaohsiung Med Univ, Dept Med, Fac Med, Coll Med, Kaohsiung, Taiwan	National Sun Yat Sen University; National Sun Yat Sen University; National Sun Yat Sen University; Academia Sinica - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Sun Yat Sen University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; Kaohsiung Medical University; National Sun Yat Sen University; Kaohsiung Medical University	Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung, Taiwan.; Wu, DC; Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Acad Sinica, Kaohsiung, Taiwan.; Wu, DC (corresponding author), Kaohsiung Med Univ Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan.; Wu, DC; Tai, MH (corresponding author), Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung, Taiwan.; Wu, DC (corresponding author), Kaohsiung Med Univ, Dept Med, Fac Med, Coll Med, Kaohsiung, Taiwan.	dechwu@yahoo.com; minghongtai@gmail.com	Wen, Zhi-Hong/AAG-8034-2019	Chu, Tian-Huei/0000-0003-1197-5754; Wu, Deng-Chyang/0000-0003-3742-0634	National Research Program for Biopharmaceuticals [103NPP1002-3, MOST103-2325-B-110-002]; Ministry of Science and Technology [107-2320-B-110-003]; Kaohsiung Medical University Research Center Grant [KMU-TC108A02]; Center for Infectious Disease and Cancer Research, Kaohsiung Medical University [KMUTP105E20]; Kaohsiung Medical University Research Foundation [KMUOR105]; Kaohsiung Medical University Center for Stem Cell Research [KMUTP105G01]; NSYSU-KMU Joint Research Project [NSYSUKMU103-I010, NSYSUKMU-105-P023, NSYSUKMU-106-P020]; Kaohsiung Armed Forces General Hospital [103-6]	National Research Program for Biopharmaceuticals; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Kaohsiung Medical University Research Center Grant; Center for Infectious Disease and Cancer Research, Kaohsiung Medical University; Kaohsiung Medical University Research Foundation; Kaohsiung Medical University Center for Stem Cell Research; NSYSU-KMU Joint Research Project; Kaohsiung Armed Forces General Hospital	This work was supported by the grants from National Research Program for Biopharmaceuticals (103NPP1002-3, MOST103-2325-B-110-002), from Ministry of Science and Technology (107-2320-B-110-003), from Kaohsiung Medical University Research Center Grant (KMU-TC108A02), from the Center for Infectious Disease and Cancer Research, Kaohsiung Medical University (KMUTP105E20), from Kaohsiung Medical University Research Foundation (KMUOR105), from Kaohsiung Medical University Center for Stem Cell Research (KMUTP105G01), from the NSYSU-KMU Joint Research Project (NSYSUKMU103-I010, NSYSUKMU-105-P023, NSYSUKMU-106-P020) and Kaohsiung Armed Forces General Hospital (103-6). In addition, the authors thank Dr. Sebastian Franken (Institute of Physiological Chemistry, University of Bonn, Bonn, Germany) for sharing HDGF-KO mice.	Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Asaka M, 2010, HELICOBACTER, V15, P1, DOI 10.1111/j.1523-5378.2009.00738.x; Byrd JC, 2000, GASTROENTEROLOGY, V118, P1072, DOI 10.1016/S0016-5085(00)70360-X; Cao MW, 2017, J IMMUNOL, V198, P1887, DOI 10.4049/jimmunol.1600622; Chen SC, 2015, ONCOTARGET, V6, P16253, DOI 10.18632/oncotarget.3608; Chen SC, 2012, J PATHOL, V228, P158, DOI 10.1002/path.3988; Chu TH, 2018, CANCER MED-US, V7, P2567, DOI 10.1002/cam4.1487; Chu TH, 2014, ONCOTARGET, V5, P1475, DOI 10.18632/oncotarget.1745; Ding L, 2016, J CLIN INVEST, V126, P2867, DOI 10.1172/JCI82529; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Finsterbusch M, 2014, J EXP MED, V211, P1306, DOI 10.1084/jem.20132413; Gallitzendoerfer R, 2008, DEV DYNAM, V237, P1875, DOI 10.1002/dvdy.21589; Goldblum JR, 1998, GASTROENTEROLOGY, V114, P633, DOI 10.1016/S0016-5085(98)70576-1; Gomez-Mejiba SE, 2010, J BIOL CHEM, V285, P20062, DOI 10.1074/jbc.M109.086579; Gong YF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149629; Hayden MS, 2014, SEMIN IMMUNOL, V26, P253, DOI 10.1016/j.smim.2014.05.004; Hsu SS, 2012, J NEURO-ONCOL, V107, P101, DOI 10.1007/s11060-011-0733-z; Hu TH, 2003, CANCER-AM CANCER SOC, V98, P1444, DOI 10.1002/cncr.11653; Jeong M, 2015, ONCOTARGET, V6, P29513, DOI 10.18632/oncotarget.4897; Kwon HJ, 2012, GUT, V61, P53, DOI 10.1136/gutjnl-2011-300361; Lemos HP, 2009, P NATL ACAD SCI USA, V106, P5954, DOI 10.1073/pnas.0812782106; Li S, 2016, MICROB PATHOGENESIS, V98, P63, DOI 10.1016/j.micpath.2016.06.028; Liu CJ, 2018, CANCERS, V10, DOI 10.3390/cancers10120479; Lo J, 2015, HEPATOLOGY, V62, P534, DOI 10.1002/hep.27859; NAKAMURA H, 1989, CLIN CHIM ACTA, V183, P273, DOI 10.1016/0009-8981(89)90361-6; Nakamura H, 2002, J GASTROENTEROL, V37, P8, DOI 10.1007/BF03326407; Narayana JL, 2015, BIOMATERIALS, V61, P41, DOI 10.1016/j.biomaterials.2015.05.014; Nemati M, 2017, LIFE SCI, V178, P17, DOI 10.1016/j.lfs.2017.04.006; Ng GZ, 2016, GUT, V65, P1087, DOI 10.1136/gutjnl-2014-307175; Nupponen I, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e12; Park JS, 2014, P NATL ACAD SCI USA, V111, P5896, DOI 10.1073/pnas.1402087111; Patel SK, 2014, WORLD J GASTROENTERO, V20, P12847, DOI 10.3748/wjg.v20.i36.12847; Ray A, 2015, J IMMUNOL, V195, P3071, DOI 10.4049/jimmunol.1500153; Rogers AB, 2005, CANCER RES, V65, P10709, DOI 10.1158/0008-5472.CAN-05-1846; ROKKAS T, 1991, GUT, V32, P1110, DOI 10.1136/gut.32.10.1110; SCHMEKEL B, 1990, INFLAMMATION, V14, P447, DOI 10.1007/BF00914095; Shetty A, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2016.05.027; Shibata J, 1999, GUT, V45, P24, DOI 10.1136/gut.45.1.24; Sierra JC, 2018, GUT, V67, P1247, DOI 10.1136/gutjnl-2016-312888; Sozzi M, 1998, AM J GASTROENTEROL, V93, P375, DOI 10.1111/j.1572-0241.1998.00375.x; Suganuma M, 2012, CANCER LETT, V322, P133, DOI 10.1016/j.canlet.2012.03.027; Sun AM, 2015, CYTOKINE, V72, P31, DOI 10.1016/j.cyto.2014.12.001; Suzuki M, 2009, CELL HOST MICROBE, V5, P23, DOI 10.1016/j.chom.2008.11.010; Tao F, 2014, WORLD J GASTROENTERO, V20, P9564, DOI 10.3748/wjg.v20.i28.9564; Toller IM, 2010, GASTROENTEROLOGY, V138, P1455, DOI 10.1053/j.gastro.2009.12.006; Verghese MW, 1996, J BIOL CHEM, V271, P15597, DOI 10.1074/jbc.271.26.15597; Wang TT, 2017, GUT, V66, P1900, DOI 10.1136/gutjnl-2016-313075; Watanabe T, 2014, INT J CANCER, V134, P2373, DOI 10.1002/ijc.28582; Watanabe T, 2010, J CANCER RES CLIN, V136, P911, DOI 10.1007/s00432-009-0733-y; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Wong BCY, 2012, GUT, V61, P812, DOI 10.1136/gutjnl-2011-300154; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Yamamoto S, 2006, CLIN CANCER RES, V12, P117, DOI 10.1158/1078-0432.CCR-05-1347; Yang J, 2016, AM J RESP CRIT CARE, V194, P1264, DOI 10.1164/rccm.201512-2498OC; Yeh JJ, 2010, BLOOD, V115, P4247, DOI 10.1182/blood-2009-09-241166; Yoon JH, 2011, J PROTEOME RES, V10, P5315, DOI 10.1021/pr200573b; Youn JI, 2012, J LEUKOCYTE BIOL, V91, P167, DOI 10.1189/jlb.0311177; Zhao L, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01181-4	58	19	22	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2019	38	37					6461	6477		10.1038/s41388-019-0886-3	http://dx.doi.org/10.1038/s41388-019-0886-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6FR	31332288				2022-12-17	WOS:000485778800005
J	Hounjet, J; Habets, R; Schaaf, MB; Hendrickx, TC; Barbeau, LMO; Yahyanejad, S; Rouschop, KM; Groot, AJ; Vooijs, M				Hounjet, Judith; Habets, Roger; Schaaf, Marco B.; Hendrickx, Tessa C.; Barbeau, Lydie M. O.; Yahyanejad, Sanaz; Rouschop, Kasper M.; Groot, Arjan J.; Vooijs, Marc			The anti-malarial drug chloroquine sensitizes oncogenic NOTCH1 driven human T-ALL to gamma-secretase inhibition	ONCOGENE			English	Article							GENE-EXPRESSION; CELL-DEATH; AUTOPHAGY; ACTIVATION; RESISTANCE; MUTATIONS; REGULATOR; PROTEIN; CANCER; CYTOTOXICITY	T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer arising from T-cell progenitors. Although current treatments, including chemotherapy and glucocorticoids, have significantly improved survival, T-ALL remains a fatal disease and new treatment options are needed. Since more than 60% of T-ALL cases bear oncogenic NOTCH1 mutations, small molecule inhibitors of NOTCH1 signalling; gamma-secretase inhibitors (GSI), are being actively investigated for the treatment of T-ALL. Unfortunately, GSI have shown limited clinical efficacy and dose-limiting toxicities. We hypothesized that by combining known drugs, blocking NOTCH activity through another mechanism, may synergize with GSI enabling equal efficacy at a lower concentration. Here, we show that the clinically used anti-malarial drug chloroquine (CQ), an inhibitor of lysosomal function and autophagy, decreases T-ALL cell viability and proliferation. This effect of CQ was not observed in GSI-resistant T-ALL cell lines. Mechanistically, CQ impairs the redox balance, induces ds DNA breaks and activates the DNA damage response. CQ also interferes with intracellular trafficking and processing of oncogenic NOTCH1. Interestingly, we show for the first time that the addition of CQ to gamma-secretase inhibition has a synergistic therapeutic effect on T-ALL and reduces the concentration of GSI required to obtain a reduction in cell viability and a block of proliferation. Overall, our results suggest that CQ may be a promising repurposed drug in the treatment of T-ALL, as a single treatment or in combination with GSI, increasing the therapeutic ratio.	[Hounjet, Judith; Habets, Roger; Schaaf, Marco B.; Hendrickx, Tessa C.; Barbeau, Lydie M. O.; Yahyanejad, Sanaz; Rouschop, Kasper M.; Groot, Arjan J.; Vooijs, Marc] Maastricht Univ, Sch Dev Biol & Oncol, Dept Radiotherapy GROW, Maastricht, Netherlands; [Hounjet, Judith; Habets, Roger; Schaaf, Marco B.; Hendrickx, Tessa C.; Barbeau, Lydie M. O.; Yahyanejad, Sanaz; Rouschop, Kasper M.; Groot, Arjan J.; Vooijs, Marc] Maastricht Univ, Comprehens Canc Ctr Maastricht MUMC, Maastricht, Netherlands; [Hounjet, Judith] MAASTRO Clin, Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC)	Vooijs, M (corresponding author), Maastricht Univ, Sch Dev Biol & Oncol, Dept Radiotherapy GROW, Maastricht, Netherlands.; Vooijs, M (corresponding author), Maastricht Univ, Comprehens Canc Ctr Maastricht MUMC, Maastricht, Netherlands.	marc.vooijs@maastrichtuniversity.nl		Rouschop, Kasper/0000-0002-4208-5415; Barbeau, Lydie/0000-0003-4556-9789	European Research Council (ERC) under the European Community Seventh Framework Program (FP7/2007-13) ERC starting Grant [208259]; Kootstra-Talent Fellowship Program from Maastricht-UMC + [2016-7]	European Research Council (ERC) under the European Community Seventh Framework Program (FP7/2007-13) ERC starting Grant; Kootstra-Talent Fellowship Program from Maastricht-UMC +	This work was supported by the European Research Council (ERC) under the European Community Seventh Framework Program (FP7/2007-13) ERC starting Grant 208259 and the Kootstra-Talent Fellowship Program 2016-7 from Maastricht-UMC +.	Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Burikhanov R, 2017, CELL REP, V18, P508, DOI 10.1016/j.celrep.2016.12.051; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033; Childress JL, 2006, CURR BIOL, V16, P2228, DOI 10.1016/j.cub.2006.09.031; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816; Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Herranz D, 2015, NAT MED, V21, P1182, DOI 10.1038/nm.3955; Hori YS, 2015, J NEURO-ONCOL, V122, P11, DOI 10.1007/s11060-014-1686-9; Hu T, 2016, ONCOL REP, V35, P43, DOI 10.3892/or.2015.4380; Jaekel R, 2006, DEV CELL, V11, P655, DOI 10.1016/j.devcel.2006.09.019; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaether C, 2006, NEURODEGENER DIS, V3, P275, DOI 10.1159/000095267; Kim SB, 2007, CELL DEATH DIFFER, V14, P982, DOI 10.1038/sj.cdd.4402083; Liang X, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-10; Loehberg CR, 2007, CANCER RES, V67, P12026, DOI 10.1158/0008-5472.CAN-07-3058; Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700; Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025; Maes H, 2013, TRENDS MOL MED, V19, P428, DOI 10.1016/j.molmed.2013.04.005; Malecki MJ, 2006, MOL CELL BIOL, V26, P4642, DOI 10.1128/MCB.01655-05; Man JH, 2018, CELL STEM CELL, V22, P104, DOI 10.1016/j.stem.2017.10.005; Mansour MR, 2006, LEUKEMIA, V20, P537, DOI 10.1038/sj.leu.2404101; Marks DI, 2009, BLOOD, V114, P5136, DOI 10.1182/blood-2009-08-231217; Mathews JA, 2010, J BIOL CHEM, V285, P37531, DOI 10.1074/jbc.M110.141556; Mauvezin C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8007; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Natsumeda M, 2016, BRAIN PATHOL, V26, P713, DOI 10.1111/bpa.12343; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Qu XZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173712; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Ratikan JA, 2013, INT J RADIAT ONCOL, V87, P761, DOI 10.1016/j.ijrobp.2013.07.024; Roti G, 2013, CANCER CELL, V23, P390, DOI 10.1016/j.ccr.2013.01.015; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rouschop KMA, 2009, RADIOTHER ONCOL, V92, P411, DOI 10.1016/j.radonc.2009.06.029; Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370; Schneider M, 2013, J CELL SCI, V126, P645, DOI 10.1242/jcs.116590; Sethi N, 2010, J BIOL CHEM, V285, P34757, DOI 10.1074/jbc.M110.158634; Shi TT, 2017, CANCER CHEMOTH PHARM, V79, P287, DOI 10.1007/s00280-016-3197-1; Tagami S, 2008, MOL CELL BIOL, V28, P165, DOI 10.1128/MCB.00863-07; Vaccari T, 2010, DEVELOPMENT, V137, P1825, DOI 10.1242/dev.045484; Valapala M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2624; van Tetering G, 2009, J BIOL CHEM, V284, P31018, DOI 10.1074/jbc.M109.006775; Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781; Vermezovic J, 2015, NAT STRUCT MOL BIOL, V22, P417, DOI 10.1038/nsmb.3013; Wakabayashi N, 2014, MOL CELL BIOL, V34, P653, DOI 10.1128/MCB.01408-13; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; Zhang BB, 2015, FAM CANCER, V14, P19, DOI 10.1007/s10689-014-9757-9	54	19	19	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5457	5468		10.1038/s41388-019-0802-x	http://dx.doi.org/10.1038/s41388-019-0802-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967635				2022-12-17	WOS:000473842500009
J	Gowrikumar, S; Ahmad, R; Uppada, SB; Washington, MK; Shi, CJ; Singh, AB; Dhawan, P				Gowrikumar, Saiprasad; Ahmad, Rizwan; Uppada, Srijayaprakash Babu; Washington, Mary K.; Shi, Chanjuan; Singh, Amar B.; Dhawan, Punita			Upregulated claudin-1 expression promotes colitis-associated cancer by promoting beta-catenin phosphorylation and activation in Notch/p-AKT-dependent manner	ONCOGENE			English	Article							INFLAMMATORY-BOWEL-DISEASE; INTESTINAL STEM-CELLS; COLON-CANCER; COLORECTAL-CANCER; WNT/BETA-CATENIN; MODULATION; MODEL	In IBD patients, integration between a hyper-activated immune system and epithelial cell plasticity underlies colon cancer development. However, molecular regulation of such a circuity remains undefined. Claudin-1 (Cld-1), a tight-junction integral protein deregulation alters colonic epithelial cell (CEC) differentiation, and promotes colitis severity while impairing colitis-associated injury/repair. Tumorigenesis is a product of an unregulated wound-healing process and therefore we postulated that upregulated Cld-1 levels render IBD patients susceptible to the colitis-associated cancer (CAC). Villin Cld-1 mice are used to carryout overexpressed studies in mice. The role of deregulated Cld-1 expression in CAC and the underlying mechanism was determined using a well-constructed study scheme and mouse models of DSS colitis/recovery and CAC. Using an inclusive investigative scheme, we here report that upregulated Cld-1 expression promotes susceptibility to the CAC and its malignancy. Increased mucosal inflammation and defective epithelial homeostasis accompanied the increased CAC in Villin-Cld-1-Tg mice. We further found significantly increased levels of protumorigenic M2 macrophages and beta-cateninSer552 (beta-CatSer552) expression in the CAC in Cld-1 Tg vs. WT mice. Mechanistic studies identified the role of PI3K/Akt signaling in Cld-1 -dependent activation of the beta-CatSer552, which, in turn, was dependent on proinflammatory signals. Our studies identify a critical role of Cld-1 in promoting susceptibility to CAC. Importantly, these effects of deregulated Cld-1 were not associated with altered tight junction integrity, but on its noncanonical role in regulating Notch/PI3K/Wnt/beta-CatSer552 signaling. Overall, outcome from our current studies identifies Cld-1 as potential prognostic biomarker for IBD severity and CAC, and a novel therapeutic target.	[Gowrikumar, Saiprasad; Ahmad, Rizwan; Uppada, Srijayaprakash Babu; Singh, Amar B.; Dhawan, Punita] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Washington, Mary K.; Shi, Chanjuan] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Singh, Amar B.; Dhawan, Punita] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 68198 USA; [Singh, Amar B.; Dhawan, Punita] Univ Nebraska Med Ctr, Buffet Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center	Dhawan, P (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Dhawan, P (corresponding author), VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 68198 USA.; Dhawan, P (corresponding author), Univ Nebraska Med Ctr, Buffet Canc Ctr, Omaha, NE 68198 USA.	punita.dhawan@unmc.edu	Gowrikumar, Saiprasad/AAG-9611-2019; Uppada, Srijayaprakash/AAD-7728-2021		VA merit [BX002086, BX002761]; NIH/NCI [CA216746]; Fred and Pamela Buffet Cancer Center; National Cancer Institute Cancer Center Support Grant [P30 CA036727]; NIH/NIDDK [DK088902]; NATIONAL CANCER INSTITUTE [R21CA216746, P30CA036727] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002086, I01BX002761] Funding Source: NIH RePORTER	VA merit(US Department of Veterans Affairs); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fred and Pamela Buffet Cancer Center; National Cancer Institute Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by BX002086 (VA merit), CA216746 (NIH/NCI) and a pilot project award from Fred and Pamela Buffet Cancer Center, which is funded by a National Cancer Institute Cancer Center Support Grant under award number P30 CA036727 to P.D. and DK088902 (NIH/NIDDK) and BX002761 (VA merit) to A.B.S.	Ahmad R, 2017, ONCOGENE, V36, P6592, DOI 10.1038/onc.2017.259; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Breynaert C, 2008, ACTA GASTRO-ENT BELG, V71, P367; Brown JB, 2011, INFECT IMMUN, V79, P1863, DOI 10.1128/IAI.01025-10; Chassaing B., 2014, CURR PROTOC IMMUNOL, V104; Clapper ML, 2007, ACTA PHARMACOL SIN, V28, P1450, DOI 10.1111/j.1745-7254.2007.00695.x; Dave Maneesh, 2012, Gastroenterol Hepatol (N Y), V8, P29; Gonzalez ACD, 2016, AN BRAS DERMATOL, V91, P614, DOI 10.1590/abd1806-4841.20164741; Deitrick J, 2016, PROG MOL BIOL TRANSL, V144, P49, DOI 10.1016/bs.pmbts.2016.09.010; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Erben U, 2014, INT J CLIN EXP PATHO, V7, P4557; Goretsky T, 2016, J BIOL CHEM, V291, P4166, DOI 10.1074/jbc.M115.669416; Gunzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Landy J, 2016, WORLD J GASTROENTERO, V22, P3117, DOI 10.3748/wjg.v22.i11.3117; Lee G, 2010, GASTROENTEROLOGY, V139, P869, DOI 10.1053/j.gastro.2010.05.037; Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082; Liu L, 2012, AM J PHYSIOL-CELL PH, V302, pC277, DOI 10.1152/ajpcell.00341.2011; Liu Y, 2014, CELL MOL IMMUNOL, V11, P49, DOI [10.1038/cmi.2013.40, 10.1038/cmi.2014.83]; Low D, 2014, INFLAMM BOWEL DIS, V20, P2115, DOI 10.1097/MIB.0000000000000094; Mendes RD, 2016, HAEMATOLOGICA, V101, P1010, DOI 10.3324/haematol.2016.146381; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Villegas SN, 2018, CELL REP, V22, P2541, DOI 10.1016/j.celrep.2018.02.049; Neal MD, 2011, J SURG RES, V167, P1, DOI 10.1016/j.jss.2010.04.037; Ormanns S, 2014, ONCOTARGET, V5, P2999, DOI 10.18632/oncotarget.1626; Ouban A, 2018, HISTOL HISTOPATHOL, V33, P1013, DOI 10.14670/HH-11-980; Parang B, 2017, GUT, V66, P852, DOI 10.1136/gutjnl-2015-310255; Pope JL, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-167; Pope JL, 2014, GUT, V63, P622, DOI 10.1136/gutjnl-2012-304241; Sabatino L, 2014, WORLD J GASTROENTERO, V20, P7137, DOI 10.3748/wjg.v20.i23.7137; Sebio A, 2014, EXPERT OPIN THER TAR, V18, P611, DOI 10.1517/14728222.2014.906580; Sengupta N, 2016, DIGEST DIS SCI, V61, P980, DOI 10.1007/s10620-015-3979-z; Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680; Singh AB, 2011, GASTROENTEROLOGY, V141, P2140, DOI 10.1053/j.gastro.2011.08.038; Snider AJ, 2016, METHODS MOL BIOL, V1438, P245, DOI 10.1007/978-1-4939-3661-8_14; Stidham RW, 2018, CLIN COLON RECT SURG, V31, P168, DOI 10.1055/s-0037-1602237; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Waniczek D, 2017, ARCH IMMUNOL THER EX, V65, P445, DOI 10.1007/s00005-017-0463-9; Wong GW, 2012, BLOOD, V120, P1439, DOI 10.1182/blood-2011-12-395319	41	19	20	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5321	5337		10.1038/s41388-019-0795-5	http://dx.doi.org/10.1038/s41388-019-0795-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30971761	Green Accepted			2022-12-17	WOS:000473025300015
J	Chen, YL; Wu, WL; Jang, CW; Yen, YC; Wang, SH; Tsai, FY; Shen, YY; Chen, YW				Chen, Yu-Lin; Wu, Wan-Lin; Jang, Chuan-Wei; Yen, Yi-Chen; Wang, Ssu-Han; Tsai, Fang-Yu; Shen, Ying-Ying; Chen, Ya-Wen			Interferon-stimulated gene 15 modulates cell migration by interacting with Rac1 and contributes to lymph node metastasis of oral squamous cell carcinoma cells	ONCOGENE			English	Article							BREAST-CANCER; RHO FAMILY; ISG15; EXPRESSION; PROTEIN; BINDING; TUMORIGENESIS; ISGYLATION; PROTEOMICS; INVASION	In an effort to understand the underlying mechanisms of lymph node metastasis in oral squamous cell carcinoma (OSCC), through in vivo selection, LN1-1 cells were previously established from OEC-M1 cells and showed enhanced lymphangiogenesis and lymphatic metastasis capabilities. In the current study, we use a stable isotope labeling with amino acids in cell culture (SILAC) and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomic platform to compare LN1-1 to OEC-M1 cells. Interferon-stimulated gene 15 (ISG15) was found highly expressed in LN1-1 cells Immunohistochemical analysis and meta-analysis of publicly available microarray datasets revealed that the ISG15 level was increased in human OSCC tissues and associated with poor disease outcome. Knockdown of ISG15 had minimal effects on tumor growth but did decrease tumor lymphangiogenesis and lymphatic metastasis of LN1-1 cells. Consistent with the in vivo assay, ISG15 knockdown did not impair cell growth but diminished cell migration, invasion, and transendothelial migration in vitro. ISG15-induced cell migration was independent of ISGylation and associated with membrane protrusion. Ectopic expression of ISG15 increased Rac1 activity and knockdown of Rac1 impaired ISG15-enhanced migration. Furthermore, Rac1 colocalized with ISG15 to a region of membrane protrusion and ISG15 coimmunoprecipitated with Rac1, especially with the Rac1-GDP form. Importantly, as shown by proximity ligation assays, ISG15 and Rac1 physically interacted with each other. Our results indicated that ISG15 affects cell migration by interacting with Rac1 and regulating Rac1 activity and contributes to lymphatic metastasis in OSCC.	[Chen, Yu-Lin; Wu, Wan-Lin; Jang, Chuan-Wei; Yen, Yi-Chen; Wang, Ssu-Han; Tsai, Fang-Yu; Chen, Ya-Wen] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan; [Shen, Ying-Ying] Natl Hlth Res Inst, Pathol Core Lab, Miaoli, Taiwan; [Chen, Ya-Wen] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan	National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; China Medical University Taiwan	Chen, YW (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan.; Chen, YW (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.	ywc@nhri.org.tw	Chen, Ya-Wen/AAG-7549-2019	Chen, Ya-Wen/0000-0002-6080-8859; Chen, Yu-Lin/0000-0001-9564-3997	National Health Research Institutes, Taiwan [NHRI CA-107-PP-04, MOST 106-2314-B-400-026-MY3]; Ministry of Science and Technology, Taiwan [NHRI CA-107-PP-04, MOST 106-2314-B-400-026-MY3]	National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by grants NHRI CA-107-PP-04 and MOST 106-2314-B-400-026-MY3 from National Health Research Institutes and Ministry of Science and Technology, Taiwan.	Ahmad Y, 2014, TRENDS CELL BIOL, V24, P257, DOI 10.1016/j.tcb.2013.10.010; Andersen JB, 2006, CYTOKINE GROWTH F R, V17, P411, DOI 10.1016/j.cytogfr.2006.10.001; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Boureux A, 2007, MOL BIOL EVOL, V24, P203, DOI 10.1093/molbev/msl145; Burks J, 2015, ONCOTARGET, V6, P7221, DOI 10.18632/oncotarget.3372; Cajee UF, 2012, INT J MOL SCI, V13, P11804, DOI 10.3390/ijms130911804; Castillo-Lluva S, 2013, ONCOGENE, V32, P1735, DOI 10.1038/onc.2012.189; Castillo-Lluva S, 2010, NAT CELL BIOL, V12, P1078, DOI 10.1038/ncb2112; Charras G, 2014, NAT REV MOL CELL BIO, V15, P813, DOI 10.1038/nrm3897; Chen RH, 2016, ONCOTARGET, V7, P16910, DOI 10.18632/oncotarget.7626; Chen YW, 2008, CANCER RES, V68, P476, DOI 10.1158/0008-5472.CAN-07-1960; Chen YW, 2007, CANCER RES, V67, P7589, DOI 10.1158/0008-5472.CAN-07-0381; Chen YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069389; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Desai SD, 2012, EXP BIOL MED, V237, P38, DOI 10.1258/ebm.2011.011236; dos Santos PF, 2017, J INTERF CYTOK RES, V37, P246, DOI 10.1089/jir.2016.0103; Durfee LA, 2012, METHODS MOL BIOL, V832, P141, DOI 10.1007/978-1-61779-474-2_9; Estilo CL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-11; Festing Michael F W, 2002, ILAR J, V43, P244; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; Graziano BR, 2014, CURR OPIN CELL BIOL, V30, P60, DOI 10.1016/j.ceb.2014.06.007; Hermann MR, 2016, J CELL SCI, V129, P1391, DOI 10.1242/jcs.177592; Hishiki T, 2014, BIOCHEM BIOPH RES CO, V448, P95, DOI 10.1016/j.bbrc.2014.04.081; Jeon YJ, 2010, BBA-MOL BASIS DIS, V1802, P485, DOI 10.1016/j.bbadis.2010.02.006; Kim KI, 2006, MOL CELL BIOL, V26, P472, DOI 10.1128/MCB.26.2.472-479.2006; Kuriakose MA, 2004, CELL MOL LIFE SCI, V61, P1372, DOI 10.1007/s00018-004-4069-0; Laljee RP, 2013, ASIAN PAC J CANCER P, V14, P1147, DOI 10.7314/APJCP.2013.14.2.1147; Lee CH, 2013, J PATHOL, V230, P298, DOI 10.1002/path.4173; Li C, 2014, ONCOTARGET, V5, P8429, DOI 10.18632/oncotarget.2316; Liao CT, 2009, INT J RADIAT ONCOL, V73, P764, DOI 10.1016/j.ijrobp.2008.05.004; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Peng CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023452; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354; Sgorbissa A, 2012, CYTOKINE GROWTH F R, V23, P307, DOI 10.1016/j.cytogfr.2012.07.003; Spano D, 2012, SEMIN CANCER BIOL, V22, P234, DOI 10.1016/j.semcancer.2012.03.006; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Talbot SG, 2005, CANCER RES, V65, P3063, DOI 10.1158/0008-5472.CAN-04-1985; Toruner GA, 2004, CANCER GENET CYTOGEN, V154, P27, DOI 10.1016/j.cancergencyto.2004.01.026; Tyanova S, 2014, METHODS MOL BIOL, V1188, P351, DOI 10.1007/978-1-4939-1142-4_24; UEDA T, 1990, J BIOL CHEM, V265, P9373; Um K, 2014, DEV CELL, V29, P701, DOI 10.1016/j.devcel.2014.05.011; Walther TC, 2010, J CELL BIOL, V190, P491, DOI 10.1083/jcb.201004052; Wang SH, 2018, INT J CANC; Wong TY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2809192; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Ye H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-69; Yeh YH, 2013, CLIN CANCER RES, V19, P5927, DOI 10.1158/1078-0432.CCR-13-0018; Yen YC, 2015, ONCOTARGET, V6, P41837, DOI 10.18632/oncotarget.5995; Yen YC, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-6; Zhang QM, 2017, EXP THER MED, V14, P2329, DOI 10.3892/etm.2017.4720; Zhang X, 2002, CANCER-AM CANCER SOC, V95, P1663, DOI 10.1002/cncr.10837; Zhang XQ, 2015, NATURE, V517, P89, DOI 10.1038/nature13801	58	19	19	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4480	4495		10.1038/s41388-019-0731-8	http://dx.doi.org/10.1038/s41388-019-0731-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30765861				2022-12-17	WOS:000470240300004
J	Nishikawa, Y; Kodama, Y; Shiokawa, M; Matsumori, T; Marui, S; Kuriyama, K; Kuwada, T; Sogabe, Y; Kakiuchi, N; Tomono, T; Mima, A; Morita, T; Ueda, T; Tsuda, M; Yamauchi, Y; Sakuma, Y; Ota, Y; Maruno, T; Uza, N; Uesugi, M; Kageyama, R; Chiba, T; Seno, H				Nishikawa, Yoshihiro; Kodama, Yuzo; Shiokawa, Masahiro; Matsumori, Tomoaki; Marui, Saiko; Kuriyama, Katsutoshi; Kuwada, Takeshi; Sogabe, Yuko; Kakiuchi, Nobuyuki; Tomono, Teruko; Mima, Atsushi; Morita, Toshihiro; Ueda, Tatsuki; Tsuda, Motoyuki; Yamauchi, Yuki; Sakuma, Yojiro; Ota, Yuji; Maruno, Takahisa; Uza, Norimitsu; Uesugi, Motonari; Kageyama, Ryoichiro; Chiba, Tsutomu; Seno, Hiroshi			Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis	ONCOGENE			English	Article							DUCTAL ADENOCARCINOMA; CELL PLASTICITY; BETA-CELL; CANCER; ENDOCRINE; INDUCTION; LINEAGE	Most pancreatic ductal adenocarcinoma (PDAC) develops from pancreatic epithelial cells bearing activating mutant KRAS genes through precancerous lesions, i.e. acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN). During pancreatic tumorigenesis, Hes1 expression starts with the transition from acinar cells to ADM, and continues during PanIN and PDAC formation, but the role of Hes1 in pancreatic tumorigenesis is not fully elucidated. Here we show that Hes1 plays an essential role in the initiation and progression of KRAS-driven pancreatic tumorigenesis. In vitro, activation of MAPK signaling due to EGF or mutant KRAS activation induced sustained Hes1 expression in pancreatic acinar cells. In vivo, acinar cell-specific activation of mutant KRAS by Elastase1-CreERT2;Kras(G12D) induced ADM/PanIN formation with Hes1 expression in mice, and genetic ablation of Hes1 in these mice dramatically suppressed PanIN formation. Gene expression analysis and lineage tracing revealed that Hes1 regulates acinar-to-ductal reprogramming-related genes and, in a Hes1-deficient state, mutant Kras-induced ADM could not progress into PanIN, but re-differentiated into acinar cells. In the Elastase1-CreERT2; Kras(G12D); Trp53(R172H) mouse PDAC model, genetic ablation of Hes1 completely blocked PDAC formation by keeping PanIN lesions in low-grade conditions, in addition to reducing the occurrence of PanIN. Together, these findings indicate that mutant KRAS-induced Hes1 plays an essential role in PDAC initiation and progression by regulating acinar-to-ductal reprogramming-related genes.	[Nishikawa, Yoshihiro; Kodama, Yuzo; Shiokawa, Masahiro; Matsumori, Tomoaki; Marui, Saiko; Kuriyama, Katsutoshi; Kuwada, Takeshi; Sogabe, Yuko; Kakiuchi, Nobuyuki; Tomono, Teruko; Mima, Atsushi; Morita, Toshihiro; Ueda, Tatsuki; Tsuda, Motoyuki; Yamauchi, Yuki; Sakuma, Yojiro; Ota, Yuji; Maruno, Takahisa; Uza, Norimitsu; Chiba, Tsutomu; Seno, Hiroshi] Kyoto Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan; [Kodama, Yuzo] Kobe Univ, Dept Gastroenterol, Grad Sch Med, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan; [Uesugi, Motonari] Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan; [Uesugi, Motonari; Kageyama, Ryoichiro] Kyoto Univ, Inst Integrated Cell Mat Sci iCeMS, Uji, Kyoto 6110011, Japan; [Kageyama, Ryoichiro] Kyoto Univ, Inst Frontier Life & Med Sci, Sakyo Ku, Kyoto 6068507, Japan; [Chiba, Tsutomu] Kansai Elect Power Hosp, Fukushima Ku, 2-1-7 Fukushima, Osaka 5530003, Japan	Kyoto University; Kobe University; Kyoto University; Kyoto University; Kyoto University	Kodama, Y (corresponding author), Kyoto Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.; Kodama, Y (corresponding author), Kobe Univ, Dept Gastroenterol, Grad Sch Med, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kodamayu@kuhp.kyoto-u.ac.jp	Uesugi, Motonari/AAM-9777-2020	Uza, Norimitsu/0000-0002-1334-5740; Nishikawa, Yoshihiro/0000-0002-1113-6937; Morita, Toshihiro/0000-0002-4114-9894	JSPS; MEXT KAKENHI [15J05143, 16K09395, 17H06803]; AMED P-DIRECT Grant [15cm0106120h0002]	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); AMED P-DIRECT Grant	This work was supported by the JSPS and MEXT KAKENHI Grant Numbers 15J05143, 16K09395, and 17H06803; AMED P-DIRECT Grant Number 15cm0106120h0002.	Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Desai BM, 2007, J CLIN INVEST, V117, P971, DOI 10.1172/JCI29988; Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Hidalgo-Sastre A, 2016, AM J PATHOL, V186, P2934, DOI 10.1016/j.ajpath.2016.07.025; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Horn S, 2012, P NATL ACAD SCI USA, V109, P7356, DOI 10.1073/pnas.1203605109; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Imayoshi I, 2008, DEVELOPMENT, V135, P2531, DOI 10.1242/dev.021535; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kageyama R, 2007, DEVELOPMENT, V134, P1243, DOI 10.1242/dev.000786; Kawaguchi Y, 2013, J CLIN INVEST, V123, P1881, DOI 10.1172/JCI66022; Kong B, 2018, GUT, V67, P146, DOI 10.1136/gutjnl-2015-310913; Kopinke D, 2011, DEVELOPMENT, V138, P431, DOI 10.1242/dev.053843; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Krah NM, 2015, ELIFE, V4, DOI 10.7554/eLife.07125; Liu ZH, 2015, CANCER BIOL THER, V16, P353, DOI 10.1080/15384047.2015.1016662; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Perron A, 2018, J BIOL CHEM, V293, P8285, DOI 10.1074/jbc.RA118.002316; Rani A, 2016, CYTOKINE GROWTH FACT; Shi GL, 2009, GASTROENTEROLOGY, V136, P1368, DOI 10.1053/j.gastro.2008.12.066; Shih HP, 2012, DEVELOPMENT, V139, P2488, DOI 10.1242/dev.078634; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Stockhausen MT, 2005, EXP CELL RES, V310, P218, DOI 10.1016/j.yexcr.2005.07.011; Wei DY, 2016, CANCER CELL, V29, P324, DOI 10.1016/j.ccell.2016.02.005; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754	35	19	19	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4283	4296		10.1038/s41388-019-0718-5	http://dx.doi.org/10.1038/s41388-019-0718-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30705405	Green Submitted			2022-12-17	WOS:000469339100006
J	Cao, J; Zhu, Z; Wang, H; Nichols, TC; Lui, GYL; Deng, SB; Rejto, PA; VanArsdale, T; Hardwick, JS; Weinrich, SL; Wei, P				Cao, Joan; Zhu, Zhou; Wang, Hui; Nichols, Timothy C.; Lui, Goldie Y. L.; Deng, Shibing; Rejto, Paul A.; VanArsdale, Todd; Hardwick, James S.; Weinrich, Scott L.; Wei, Ping			Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer	ONCOGENE			English	Article							DEPENDENT KINASE 4/6; BREAST-CANCER; EXPRESSION; ANGIOGENESIS; PHOSPHORYLATION; TRANSCRIPTION; REPLICATION; SENSITIVITY; DISRUPTION; RECEPTOR	The CDK4/6 inhibitor palbociclib reduces tumor growth by decreasing retinoblastoma (RB) protein phosphorylation and inducing cell cycle arrest at the G1/S phase transition. Palbociclib in combination with anti-hormonal therapy brings significant benefit to breast cancer patients. In this study, novel combination approaches and underlying molecular/cellular mechanisms for palbociclib were explored in squamous cell lung cancer (SqCLC), the second most common subtype of non-small cell lung cancer. While approximate 20% lung patients benefit from immunotherapy, most SqCLC patients who receive platinum-doublet chemotherapy as first-line treatment, which often includes a taxane, are still in need of more effective combination therapies. Our results demonstrated enhanced cytotoxicity and anti-tumor effect with palbociclib plus taxanes at clinically achievable doses in multiple SqCLC models with diverse cancer genetic backgrounds. Comprehensive gene expression analysis revealed a sustained disruption of pRB-E2F signaling by combination that was accompanied with enhanced regulation of pleiotropic biological effects. These included several novel mechanisms such as abrogation of G2/M and mitotic spindle assembly checkpoints, as well as impaired induction of hypoxia-inducible factor 1 alpha (HIF-1 alpha). The decrease in HIF-1 alpha modulated a couple key angiogenic and anti-angiogenic factors, resulting in an enhanced anti-angiogenic effect. This preclinical work suggests a new therapeutic opportunity for palbociclib in lung and other cancers currently treated with taxane based chemotherapy as standard of care.	[Cao, Joan; Zhu, Zhou; Rejto, Paul A.; Hardwick, James S.; Weinrich, Scott L.; Wei, Ping] Pfizer Inc, Oncol Translat Res, San Diego, CA 92121 USA; [Wang, Hui] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; [Nichols, Timothy C.] Pfizer Inc, Drug Safety Res & Dev, San Diego, CA 92121 USA; [Lui, Goldie Y. L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Deng, Shibing] Pfizer Inc, La Jolla Labs, Biostat, San Diego, CA 92121 USA; [VanArsdale, Todd] Pfizer Inc, Tumor Cell Biol Oncol Res & Dev, San Diego, CA 92121 USA	Pfizer; Novartis; Pfizer; Fred Hutchinson Cancer Center; Pfizer; Pfizer	Wei, P (corresponding author), Pfizer Inc, Oncol Translat Res, San Diego, CA 92121 USA.	ping.wei@pfizer.com	Lui, Goldie/J-7874-2019	Lui, Goldie/0000-0003-2741-6025				Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Bakker WJ, 2013, TRANSCR-AUSTIN, V4, P62, DOI 10.4161/trns.23680; Bertoli C, 2016, CELL REP, V15, P1412, DOI 10.1016/j.celrep.2016.04.036; Bocci G, 2013, ANGIOGENESIS, V16, P481, DOI 10.1007/s10456-013-9334-0; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Bretz F, 2011, MULTIPLE COMP USING, DOI DOI 10.1201/9781420010909; Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166; Budde A, 2005, ONCOGENE, V24, P1802, DOI 10.1038/sj.onc.1208369; Dean JL, 2012, J BIOL CHEM, V287, P29075, DOI 10.1074/jbc.M112.365494; Deville JL, 2010, EXPERT OPIN THER TAR, V14, P1059, DOI 10.1517/14728222.2010.522328; Dhillon S, 2015, DRUGS, V75, P543, DOI 10.1007/s40265-015-0379-9; Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454; Escuin D, 2005, CANCER RES, V65, P9021, DOI 10.1158/0008-5472.CAN-04-4095; Ferrara R, 2016, EXPERT OPIN PHARMACO, V17, P1113, DOI 10.1517/14656566.2016.1157581; Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gabellini C, 2006, ONCOGENE, V25, P5326, DOI 10.1038/sj.onc.1209631; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gong XQ, 2017, CANCER CELL, V32, P761, DOI 10.1016/j.ccell.2017.11.006; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Johnson J, 2016, ONCOGENE, V35, P4829, DOI 10.1038/onc.2016.32; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Manchado E, 2012, CELL DEATH DIFFER, V19, P369, DOI 10.1038/cdd.2011.197; Manning AL, 2012, NAT REV CANCER, V12, P220, DOI 10.1038/nrc3216; Newcomb EW, 2005, NEURO-ONCOLOGY, V7, P225, DOI 10.1215/S1152851704000997; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Oh E, 2016, SCI REP, V6, P1; Raspe E, 2017, EMBO MOL MED, V9, P1052, DOI 10.15252/emmm.201607084; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Schaal C, 2014, ADV CANCER RES, V121, P147, DOI 10.1016/B978-0-12-800249-0.00004-4; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Socinski MA, 2014, CURR ONCOL, V21, pE691, DOI 10.3747/co.21.1997; Spilker ME, 2017, CLIN CANCER RES, V23, P1080, DOI 10.1158/1078-0432.CCR-16-1164; Stetler-Stevenson WG, 2005, TRENDS MOL MED, V11, P97, DOI 10.1016/j.molmed.2005.01.007; Subramaniam D, 2012, MOL CANCER THER, V11, P1598, DOI 10.1158/1535-7163.MCT-12-0102; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Syed YY, 2017, DRUGS, V77, P799, DOI 10.1007/s40265-017-0742-0; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; VanArsdale T, 2015, CLIN CANCER RES, V21, P2905, DOI 10.1158/1078-0432.CCR-14-0816; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Weijts BGMW, 2012, EMBO J, V31, P3871, DOI 10.1038/emboj.2012.231; Witkiewicz AK, 2012, CLIN CANCER RES, V18, P5110, DOI 10.1158/1078-0432.CCR-12-0903; Zhang XH, 2013, CANCER BIOL THER, V14, P597, DOI 10.4161/cbt.24592	53	19	19	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4125	4141		10.1038/s41388-019-0708-7	http://dx.doi.org/10.1038/s41388-019-0708-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30700828				2022-12-17	WOS:000468740200011
J	Chang, HW; Kim, MR; Lee, HJ; Lee, HM; Kim, GC; Lee, YS; Nam, HY; Lee, M; Jang, HJ; Lee, KE; Lee, JC; Byun, Y; Kim, SW; Kim, SY				Chang, Hyo Won; Kim, Mi Ra; Lee, Hyang Ju; Lee, Hye Min; Kim, Gui Chul; Lee, Yoon Sun; Nam, Hae Yun; Lee, Myungjin; Jang, Hye Jin; Lee, Kyung Eun; Lee, Jong Cheol; Byun, Youngro; Kim, Seong Who; Kim, Sang Yoon			p53/BNIP3-dependent mitophagy limits glycolytic shift in radioresistant cancer	ONCOGENE			English	Article							MITOCHONDRIAL FISSION; RADIATION-RESISTANCE; P53; PARKIN; HEAD; AUTOPHAGY; BNIP3; METABOLISM; INHIBITION; MECHANISMS	The role of p53 in genotoxic therapy-induced metabolic shift in cancers is not yet known. In this study, we investigated the role of p53 in the glycolytic shift in head and neck squamous cell carcinoma cell lines following irradiation. Isogenic p53-null radioresistant cancer cells established through cumulative irradiation showed decreased oxygen consumption and increased glycolysis with compromised mitochondria, corresponding with their enhanced sensitivity to drugs that target glycolysis. In contrast, radioresistant cancer cells with wild-type p53 preserved their primary metabolic profile with intact mitophagic processes and maintained their mitochondrial integrity. Moreover, we identified a previously unappreciated link between p53 and mitophagy, which limited the glycolytic shift through the BNIP3-dependent clearance of abnormal mitochondria. Thus, drugs targeting glycolysis could be used as an alternative strategy for overcoming radioresistant cancers, and the p53 status could be used as a biomarker for selecting participants for clinical trials.	[Chang, Hyo Won; Lee, Hye Min; Kim, Gui Chul; Lee, Yoon Sun; Lee, Myungjin; Jang, Hye Jin; Kim, Sang Yoon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Otolaryngol, Seoul, South Korea; [Kim, Mi Ra] Inje Univ, Coll Med, Haeundae Paik Hosp, Dept Otorhinolaryngol Head & Neck Surg, Busan, South Korea; [Lee, Hyang Ju; Nam, Hae Yun; Kim, Seong Who] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Biochem & Mol Biol, Seoul, South Korea; [Lee, Kyung Eun; Kim, Sang Yoon] Korea Inst Sci & Technol, Biomed Res Inst, Seoul, South Korea; [Lee, Jong Cheol] Ulsan Univ Hosp, Dept Otolaryngol, Ulsan, South Korea; [Byun, Youngro] Seoul Natl Univ, Coll Pharm, Pharmaceut Res Inst, Seoul, South Korea	University of Ulsan; Asan Medical Center; Inje University; University of Ulsan; Asan Medical Center; Korea Institute of Science & Technology (KIST); University of Ulsan; Ulsan University Hospital; Seoul National University (SNU)	Kim, SY (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Otolaryngol, Seoul, South Korea.; Kim, SW (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Biochem & Mol Biol, Seoul, South Korea.; Kim, SY (corresponding author), Korea Inst Sci & Technol, Biomed Res Inst, Seoul, South Korea.	swhokim@gmail.com; sykim3715@gmail.com			Basic Science Research Program through the National Research Foundation of Korea (NRF) - the Ministry of Science, ICT and Future planning [2018R1A2A1A05020064, 2014R1A1A1003484, 2015R1A2A2A01003235]; Ministry of Education [2018R1D1A1B07042783]; MRC grant - Korean government (MSIT) [2018R1A5A2020732]; Global High-tech Biomedicine Technology Development Program of the NRF; Korea Health Industry Development Institute (KHIDI) (MSIPMOHW) [2015M3D6A1065364]; Asan Institute for Life Science [2017-073]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - the Ministry of Science, ICT and Future planning; Ministry of Education; MRC grant - Korean government (MSIT); Global High-tech Biomedicine Technology Development Program of the NRF; Korea Health Industry Development Institute (KHIDI) (MSIPMOHW); Asan Institute for Life Science	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future planning (2018R1A2A1A05020064, 2014R1A1A1003484, 2015R1A2A2A01003235), the Ministry of Education (2018R1D1A1B07042783), MRC grant funded by the Korean government (MSIT) (2018R1A5A2020732), the Global High-tech Biomedicine Technology Development Program of the NRF & Korea Health Industry Development Institute (KHIDI) (MSIP&MOHW) (2015M3D6A1065364), and the Asan Institute for Life Science (2017-073).	Bansal N, 2014, ANTIOXID REDOX SIGN, V21, P221, DOI 10.1089/ars.2013.5690; Bernardini JP, 2017, ONCOGENE, V36, P1315, DOI 10.1038/onc.2016.302; Chang HW, 2016, HEAD NECK-J SCI SPEC, V38, pE1909, DOI 10.1002/hed.24347; Chourasia AH, 2015, EMBO REP, V16, P1145, DOI 10.15252/embr.201540759; Feng X, 2011, EMBO J, V30, P3397, DOI 10.1038/emboj.2011.248; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Gustafsson AB, 2011, PEDIATR CARDIOL, V32, P267, DOI 10.1007/s00246-010-9876-5; Hamacher-Brady A, 2016, CELL MOL LIFE SCI, V73, P775, DOI 10.1007/s00018-015-2087-8; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Hollville E, 2014, MOL CELL, V55, P451, DOI 10.1016/j.molcel.2014.06.001; Hoshino A, 2014, P NATL ACAD SCI USA, V111, P3116, DOI 10.1073/pnas.1318951111; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Lall R, 2014, CELL DEATH DIFFER, V21, P836, DOI 10.1038/cdd.2014.24; Lambrecht M, 2009, RADIOTHER ONCOL, V93, P498, DOI 10.1016/j.radonc.2009.08.038; Lee Y, 2011, AM J PHYSIOL-HEART C, V301, pH1924, DOI 10.1152/ajpheart.00368.2011; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Li GB, 2018, ONCOGENE, V37, P1485, DOI 10.1038/s41388-017-0064-4; Liu K, 2016, J BIOL CHEM, V291, P10307, DOI 10.1074/jbc.M115.703066; Lu HQ, 2013, AUTOPHAGY, V9, P1720, DOI 10.4161/auto.26550; Maes H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.94; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Mauro-Lizcano M, 2015, AUTOPHAGY, V11, P833, DOI 10.1080/15548627.2015.1034403; Mims J, 2015, RADIAT RES, V183, P291, DOI 10.1667/RR13828.1; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Palikaras K, 2018, NAT CELL BIOL, V20, P1013, DOI 10.1038/s41556-018-0176-2; Rajeshkumar NV, 2015, CANCER RES, V75, P3355, DOI 10.1158/0008-5472.CAN-15-0108; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Skinner HD, 2012, CLIN CANCER RES, V18, P290, DOI 10.1158/1078-0432.CCR-11-2260; Tang L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0758-7; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Toyama EQ, 2016, SCIENCE, V351, P275, DOI 10.1126/science.aab4138; Tracy K, 2007, AUTOPHAGY, V3, P616, DOI 10.4161/auto.4892; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Villa E, 2017, CELL REP, V20, P2846, DOI 10.1016/j.celrep.2017.08.087; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wauer T, 2015, NATURE, V524, P370, DOI 10.1038/nature14879; Wu HM, 2015, SCI REP-UK, V5, DOI 10.1038/srep12291; Yan C, 2017, CANCER LETT, V388, P34, DOI 10.1016/j.canlet.2016.11.018; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Zhang C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3935; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhang J, 2015, CANCER LETT, V363, P108, DOI 10.1016/j.canlet.2015.04.015; Zhang TM, 2016, J BIOL CHEM, V291, P21616, DOI 10.1074/jbc.M116.733410	49	19	19	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3729	3742		10.1038/s41388-019-0697-6	http://dx.doi.org/10.1038/s41388-019-0697-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664690				2022-12-17	WOS:000467379600012
J	Yoshino, Y; Qi, HC; Kanazawa, R; Sugamata, M; Suzuki, K; Kobayashi, A; Shindo, K; Matsuzawa, A; Shibata, S; Endo, S; Miyanishi, Y; Shimaoka, T; Ishioka, C; Kanno, S; Yasui, A; Chiba, N				Yoshino, Yuki; Qi, Huicheng; Kanazawa, Ryo; Sugamata, Mami; Suzuki, Kenta; Kobayashi, Akihiro; Shindo, Kazuha; Matsuzawa, Ayako; Shibata, Shun; Endo, Shino; Miyanishi, Yutaro; Shimaoka, Tatsuro; Ishioka, Chikashi; Kanno, Shin-ichiro; Yasui, Akira; Chiba, Natsuko			RACK1 regulates centriole duplication by controlling localization of BRCA1 to the centrosome in mammary tissue-derived cells	ONCOGENE			English	Article							PROTEIN; IDENTIFICATION; ASSOCIATION; INHIBITION; DOMAIN; CYCLE; OLA1	Breast cancer gene 1 (BRCA1) is a tumor suppressor that is associated with hereditary breast and ovarian cancer. BRCA1 functions in DNA repair and centrosome regulation together with BRCA1-associated RING domain protein (BARD1), a heterodimer partner of BRCA1. Obg-like ATPase 1 (OLA1) was identified as a protein that interacts with BARD1. OLA1 regulates the centrosome by binding to and collaborating with BRCA1 and BARD1. We identified receptor for activated C kinase (RACK1) as a protein that interacts with OLA1. RACK1 directly bound to OLA1, the N-terminal region of BRCA1, and gamma-tubulin, associated with BARD1, and localized the centrosomes throughout the cell cycle. Knockdown of RACK1 caused abnormal centrosomal localization of BRCA1 and abrogated centriole duplication. Overexpression of RACK1 increased the centrosomal localization of BRCA1 and caused centrosome amplification due to centriole overduplication. The number of centrioles in cells with two gamma-tubulin spots was higher in cell lines derived from mammary tissue compared to those derived from other tissues. The effects of aberrant RACK1 expression level on centriole duplication were observed in cell lines derived from mammary tissue, but not in those derived from other tissues. Two BRCA1 variants, R133H and E143K, and a RACK1 variant, K280E, associated with cancer, which weakened the BRCA1-RACK1 interaction, interfered with the centrosomal localization of BRCA1 and reduced centrosome amplification induced by overexpression of RACK1. These results suggest that RACK1 regulates centriole duplication by controlling the centrosomal localization of BRCA1 in mammary tissue-derived cells and that this is dependent on the BRCA1-RACK1 interaction.	[Yoshino, Yuki; Qi, Huicheng; Kanazawa, Ryo; Sugamata, Mami; Suzuki, Kenta; Kobayashi, Akihiro; Shindo, Kazuha; Endo, Shino; Miyanishi, Yutaro; Chiba, Natsuko] Tohoku Univ, IDAC, Dept Canc Biol, Sendai, Miyagi, Japan; [Matsuzawa, Ayako; Shibata, Shun] Tohoku Univ, IDAC, Dept Mol Immunol, Sendai, Miyagi, Japan; [Shimaoka, Tatsuro] Tokyo Univ Sci, Res Inst Biomed Sci, Div Mol Pathol, Noda, Chiba, Japan; [Ishioka, Chikashi] Tohoku Univ, IDAC, Dept Clin Oncol, Sendai, Miyagi, Japan; [Kanno, Shin-ichiro; Yasui, Akira] Tohoku Univ, IDAC, Div Dynam Proteome Aging & Canc, Sendai, Miyagi, Japan	Tohoku University; Tohoku University; Tokyo University of Science; Tohoku University; Tohoku University	Chiba, N (corresponding author), Tohoku Univ, IDAC, Dept Canc Biol, Sendai, Miyagi, Japan.	natsuko.chiba.c7@tohoku.ac.jp	Yoshino, Yuki/AAQ-9620-2021; Kanno, Shin-ichiro/AAE-4549-2019	Shibata, Shun/0000-0002-9081-1370; Ishioka, Chikashi/0000-0002-3023-1227	JSPS KAKENHI [JP24300327, JP16H04690, JP16K18409]; Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT); Program for Interdisciplinary Research in Frontier Research Institute for Interdisciplinary Sciences (FRIS), Tohoku University; Astellas Foundation for Research on Metabolic Disorders; Yasuda Medical Foundation; Princess Takamatsu Cancer Research Fund [1424621]; Daiwa Securities Health Foundation; Kobayashi Foundation for Cancer Research; Kobayashi International Scholarship Foundation; Friends of Leukemia Research Fund; Research Program of the Smart-Aging Research Center, Tohoku University; Foundation for Promotion of Cancer Research in Japan	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT); Program for Interdisciplinary Research in Frontier Research Institute for Interdisciplinary Sciences (FRIS), Tohoku University; Astellas Foundation for Research on Metabolic Disorders; Yasuda Medical Foundation; Princess Takamatsu Cancer Research Fund; Daiwa Securities Health Foundation; Kobayashi Foundation for Cancer Research(Kobayashi Foundation for Cancer Research); Kobayashi International Scholarship Foundation; Friends of Leukemia Research Fund; Research Program of the Smart-Aging Research Center, Tohoku University; Foundation for Promotion of Cancer Research in Japan	We thank Satoko Aoki for technical assistance. This study was supported by grants-in-aid from JSPS KAKENHI Grant numbers JP24300327 (to N.C.), JP16H04690 (to N.C and Y.Y.), JP16K18409 (to Y.Y.), Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) (to C.I. and N.C.), Program for Interdisciplinary Research in Frontier Research Institute for Interdisciplinary Sciences (FRIS), Tohoku University, Astellas Foundation for Research on Metabolic Disorders, the Yasuda Medical Foundation, the Princess Takamatsu Cancer Research Fund (1424621), Daiwa Securities Health Foundation, Kobayashi Foundation for Cancer Research, Kobayashi International Scholarship Foundation, Friends of Leukemia Research Fund, Research Program of the Smart-Aging Research Center, Tohoku University (to N.C.), and Foundation for Promotion of Cancer Research in Japan (to Y.Y.).	Adams DR, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-22; Ai E, 2009, MOL BIOL CELL, V20, P1629, DOI 10.1091/mbc.E08-09-0917; Al-Reefy S, 2010, BREAST CANCER RES TR, V123, P911, DOI 10.1007/s10549-010-1020-y; Bai L, 2016, ONCOTARGET, V7, P10402, DOI 10.18632/oncotarget.7224; Bettencourt-Dias M, 2011, TRENDS GENET, V27, P307, DOI 10.1016/j.tig.2011.05.004; Brodie KM, 2012, J BIOL CHEM, V287, P7701, DOI 10.1074/jbc.M111.327296; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Cao XX, 2010, BREAST CANCER RES TR, V123, P375, DOI 10.1007/s10549-009-0657-x; Cao XX, 2010, INT J CANCER, V127, P1172, DOI 10.1002/ijc.25120; Clark SL, 2012, COMPUT STRUCT BIOTEC, V1, DOI 10.5936/csbj.201204005; Ding ZH, 2016, MOL CELL BIOL, V36, P2568, DOI 10.1128/MCB.00137-16; Duff D, 2017, CELL SIGNAL, V35, P250, DOI 10.1016/j.cellsig.2017.03.005; Fujita H, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1075643; Gandin Valentina, 2013, Genes Cancer, V4, P369, DOI 10.1177/1947601913486348; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Guichard P, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201700241; Hsu LC, 2001, CANCER RES, V61, P7713; Kais Z, 2012, ONCOGENE, V31, P799, DOI 10.1038/onc.2011.271; Kershner L, 2017, NEURAL REGEN RES, V12, P1036, DOI 10.4103/1673-5374.211175; Ko MJ, 2006, ONCOGENE, V25, P298, DOI 10.1038/sj.onc.1209028; Lacombe J, 2013, INT J CANCER, V132, P1105, DOI 10.1002/ijc.27766; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Li JJ, 2015, ONCOGENE, V34, P1890, DOI 10.1038/onc.2014.127; Matsuzawa A, 2014, MOL CELL, V53, P101, DOI 10.1016/j.molcel.2013.10.028; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sankaran S, 2006, CANCER RES, V66, P4100, DOI 10.1158/0008-5472.CAN-05-4430; Sankaran S, 2005, MOL CELL BIOL, V25, P8656, DOI 10.1128/MCB.25.19.8656-8668.2005; Shimomura A, 2009, J CANCER RES CLIN, V135, P421, DOI 10.1007/s00432-008-0472-5; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Sun H, 2010, MOL CANCER RES, V8, P57, DOI 10.1158/1541-7786.MCR-09-0278; Takaoka M, 2018, INT J CLIN ONCOL, V23, P36, DOI 10.1007/s10147-017-1182-2; Towler WI, 2013, HUM MUTAT, V34, P439, DOI 10.1002/humu.22251; Verstraeten N, 2011, MICROBIOL MOL BIOL R, V75, P507, DOI 10.1128/MMBR.00009-11; Watanabe G, 2018, CANCER SCI, V109, P2027, DOI 10.1111/cas.13595; Wei LZ, 2008, MOL CELL BIOL, V28, P7380, DOI 10.1128/MCB.01075-08; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yoshino Y, 2018, MOL CANCER RES, V16, P1499, DOI 10.1158/1541-7786.MCR-18-0269	40	19	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3077	3092		10.1038/s41388-018-0647-8	http://dx.doi.org/10.1038/s41388-018-0647-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB2GE	30617304				2022-12-17	WOS:000470086900001
J	An, JN; Du, Y; Fan, XJ; Wang, YH; Ivan, C; Zhang, XG; Sood, AK; An, ZQ; Zhang, NY				An, Jingnan; Du, Yi; Fan, Xuejun; Wang, Yanhong; Ivan, Cristina; Zhang, Xue-Guang; Sood, Anil K.; An, Zhiqiang; Zhang, Ningyan			EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis	ONCOGENE			English	Article							GROWTH; EMT	EGFL6, a member of the EGF-like superfamily, plays an important role during embryonic development and has been implicated in promotion of tumor angiogenesis without affecting wound healing. There is very little known about the function of EGFL6 in cancer cells. Here, we investigated whether EGFL6 plays a direct role in cancer cells in addition to the promotion of tumor angiogenesis. Our study showed that EGFL6 promoted epithelial-mesenchymal transition (EMT) and stemness of breast cancer cells and increased cell migration and invasion in cell culture studies. We also found that EGFL6 reduced apoptotic signaling in cancer cells and promoted tumor growth in vivo. Importantly, expression of EGFL6 in cancer cells and tumor endothelial cells not only increased tumor angiogenesis but also promoted migration of cancer cells. Such dual engagement of cancer and stromal cells suggests crosstalk mediated by EGFL6 in the tumor microenvironment. Blockade of EGFL6 using our novel anti-EGFL6 monoclonal antibody significantly reduced cancer cell migration, tumor angiogenesis, and tumor growth in mouse xenograft tumor models. Silencing EGFL6 mRNA by shRNA transfection of cancer cells also significantly reduced cancer cell migration, tumor angiogenesis, and tumor growth in mouse xenograft tumor models. Taken together, the results of this study indicate that targeting EGFL6 is a unique strategy for inhibiting both cancer cell metastasis and tumor angiogenesis.	[An, Jingnan; Zhang, Xue-Guang] Soochow Univ, Jiangsu Inst Clin Immunol, Affiliated Hosp 1, 708 Renmin Rd, Suzhou, Peoples R China; [An, Jingnan; Du, Yi; Fan, Xuejun; Wang, Yanhong; An, Zhiqiang; Zhang, Ningyan] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Texas Therapeut Inst, 1825 Pressler St, Houston, TX 77030 USA; [Wang, Yanhong] Shanxi Med Univ, Dept Microbiol & Immunol, Taiyuan, Shanxi, Peoples R China; [Ivan, Cristina] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Non Coding RNA, Dept Expt Therapeut, Houston, TX 77030 USA; [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Gynecol Oncol & Reprod Med, Houston, TX 77030 USA	Soochow University - China; University of Texas System; University of Texas Health Science Center Houston; Shanxi Medical University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	An, ZQ; Zhang, NY (corresponding author), Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Texas Therapeut Inst, 1825 Pressler St, Houston, TX 77030 USA.	Zhiqiang.An@uth.tmc.edu; Ningyan.zhang@uth.tmc.edu	Sood, Anoop Kumar/A-7344-2013	Sood, Anoop Kumar/0000-0001-5702-4108; Du, Yi/0000-0002-3969-2652; An, Zhiqiang/0000-0001-9309-2335; Ivan, Cristina/0000-0002-4848-0168; Zhang, Ningyan/0000-0002-4348-2180	Welch Foundation [AU-0042-20030616]; Cancer Prevention and Research Institute of Texas (CPRIT) [RP150230, RP150551]; NIH [P50 CA217685]; Frank McGraw Memorial Chair in Cancer Research; ACS Research Professor Award; NATIONAL CANCER INSTITUTE [P50CA217685, P30CA016672] Funding Source: NIH RePORTER	Welch Foundation(The Welch Foundation); Cancer Prevention and Research Institute of Texas (CPRIT); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Frank McGraw Memorial Chair in Cancer Research; ACS Research Professor Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Wei Xiong and Ms. Hui Deng for their technical assistance in cell culture and antibody preparation. We also want to thank Dr. Yunfei Wen and Dr. Prahlad Ram for their suggestions and discussion on data analysis during the manuscript preparation. We thank Dr. Georgina Salazar for her critical editing of the manuscript. This study was supported in part by Welch Foundation grant (AU-0042-20030616) to ZA, and Cancer Prevention and Research Institute of Texas (CPRIT) Grants (RP150230 and RP150551) to ZA and NZ. This research was also supported by NIH support (P50 CA217685) to AKS, the Frank McGraw Memorial Chair in Cancer Research, and the ACS Research Professor Award.	Bai SM, 2016, CANCER RES, V76, P6396, DOI 10.1158/0008-5472.CAN-16-0225; Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Buckanovich RJ, 2007, J CLIN ONCOL, V25, P852, DOI 10.1200/JCO.2006.08.8583; Chim SM, 2011, J BIOL CHEM, V286, P22035, DOI 10.1074/jbc.M110.187633; Dhupkar Pooja, 2016, Biochem Biophys Rep, V8, P382, DOI 10.1016/j.bbrep.2016.10.009; DONG LJ, 1995, J BIOL CHEM, V270, P15838, DOI 10.1074/jbc.270.26.15838; Fan XJ, 2015, MOL CANCER THER, V14, P681, DOI 10.1158/1535-7163.MCT-14-0715; Fujiwara H, 2011, CELL, V144, P577, DOI 10.1016/j.cell.2011.01.014; Garcia-Carbonero R, 2017, ONCOLOGIST, V22, P1281, DOI 10.1634/theoncologist.2016-0133erratum; Gong C, 2017, ONCOTARGET, V8, P52527, DOI 10.18632/oncotarget.17283; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Larimer BM, 2014, J MOL BIOMARK DIAGN, V5, P178; Lu CH, 2007, CANCER RES, V67, P1757, DOI 10.1158/0008-5472.CAN-06-3700; Mas VR, 2007, TRANSPLANTATION, V84, P1262, DOI 10.1097/01.tp.0000287596.91520.1a; Nichol D, 2012, BLOOD, V119, P1345, DOI 10.1182/blood-2011-10-322446; Nichol D, 2010, BLOOD, V116, P6133, DOI 10.1182/blood-2010-03-274860; Noh K, 2017, CELL REP, V21, P2785, DOI 10.1016/j.celrep.2017.11.020; Papaioannou D, 2017, P NATL ACAD SCI USA, V114, pE4641, DOI 10.1073/pnas.1703142114; Parker LH, 2004, NATURE, V428, P754, DOI 10.1038/nature02416; Salameh A, 2017, ONCOTARGET, V8, P6526, DOI 10.18632/oncotarget.14313; Shi Y, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3637; Stankovic ND, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708420; von Pawel J, 2018, ONCOLOGIST, V23, P654, DOI 10.1634/theoncologist.2017-0690; Wang FYF, 2017, CANCER LETT, V384, P9, DOI 10.1016/j.canlet.2016.10.009; Wang XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0040711, 10.1371/journal.pone.0038932, 10.1371/journal.pone.0052082, 10.1371/journal.pone.0045036, 10.1371/journal.pone.0047429, 10.1371/journal.pone.0036663, 10.1371/journal.pone.0052707, 10.1371/journal.pone.0045380, 10.1371/journal.pone.0045939, 10.1371/journal.pone.0040857, 10.1371/journal.pone.0040084]; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Yeung G, 1999, GENOMICS, V62, P304, DOI 10.1006/geno.1999.6011; Zhang S, 2016, ONCOTARGET, V7, P65758, DOI 10.18632/oncotarget.11613	29	19	23	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2123	2134		10.1038/s41388-018-0565-9	http://dx.doi.org/10.1038/s41388-018-0565-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30455428	Green Accepted			2022-12-17	WOS:000461822600009
J	Marques, M; Jangal, M; Wang, LC; Kazanets, A; da Silva, SD; Zhao, TJ; Lovato, A; Yu, H; Jie, S; del Rincon, S; MacKey, J; Damaraju, S; Alaoui-Jamali, M; Witcher, M				Marques, Maud; Jangal, Maika; Wang, Li-Chun; Kazanets, Anna; da Silva, Sabrina Daniela; Zhao, Tiejun; Lovato, Amanda; Yu, Henry; Jie, Su; del Rincon, Sonia; MacKey, John; Damaraju, Sambasivarao; Alaoui-Jamali, Moulay; Witcher, Michael			Oncogenic activity of poly (ADP-ribose) glycohydrolase	ONCOGENE			English	Article							BREAST-CANCER; POLY(ADP-RIBOSE) POLYMERASE; MAMMARY TUMORIGENESIS; MOLECULAR PORTRAITS; DNA-DAMAGE; CELLS; GROWTH; PARP; TUMORS	Poly (ADP-ribosylation), known as PARylation, is a post-translational modification catalyzed by poly (ADP-ribose) polymerases (PARP) and primarily removed by the enzyme poly (ADP-ribose) glycohydrolase (PARG). While the aberrant removal of post-translation modifications including phosphorylation and methylation has known tumorigenic effects, deregulation of PARylation has not been widely studied. Increased hydrolysis of PARylation chains facilitates cancer growth through enhancing estrogen receptor (ER)-driven proliferation, but oncogenic transformation has not been linked to increased PARG expression. In this study, we find that elevated PARG levels are associated with a poor prognosis in breast cancers, especially in HER2-positive and triple-negative subtypes. Using both in vitro and in vivo models, we demonstrate that heightened expression of catalytically active PARG facilitates cell transformation and invasion of normal mammary epithelial cells. Catalytically inactive PARG mutants did not recapitulate these phenotypes. Consistent with clinical data showing elevated PARG predicts poor outcomes in HER2+ patients, we observed that PARG acts in synergy with HER2 to promote neoplastic growth of immortalized mammary cells. In contrast, PARG depletion significantly impairs the growth and metastasis of triple-negative breast tumors. Mechanistically, we find that PARG interacts with SMAD2/3 and significantly decreases their PARylation in non-transformed cells, leading to enhanced expression of SMAD target genes. Further linking SMAD-mediated transcription to the oncogenicity of PARG, we show that PARG-mediated anchorage-independent growth and invasion are dependent, at least in part, on SMAD expression. Overall, our study underscores the oncogenic impact of aberrant protein PARylation and highlights the therapeutic potential of PARG inhibition in breast cancer.	[Marques, Maud; Jangal, Maika; Wang, Li-Chun; Kazanets, Anna; da Silva, Sabrina Daniela; Zhao, Tiejun; Lovato, Amanda; Yu, Henry; Jie, Su; del Rincon, Sonia; Alaoui-Jamali, Moulay; Witcher, Michael] McGill Univ, Dept Oncol, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada; [Marques, Maud; Jangal, Maika; Wang, Li-Chun; Kazanets, Anna; da Silva, Sabrina Daniela; Zhao, Tiejun; Lovato, Amanda; Yu, Henry; Jie, Su; del Rincon, Sonia; Alaoui-Jamali, Moulay; Witcher, Michael] McGill Univ, Dept Expt Med, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada; [da Silva, Sabrina Daniela] McGill Univ, Dept Otolaryngol Head & Neck Surg, Sir Mortimer B Davis Jewish Gen Hosp, Montreal, PQ, Canada; [MacKey, John] Univ Alberta, Dept Oncol, Div Med Oncol, Cross Canc Inst, Edmonton, AB, Canada; [Damaraju, Sambasivarao] Univ Alberta, Dept Lab Med & Pathol, Cross Canc Inst, Edmonton, AB, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; University of Alberta; University of Alberta	Witcher, M (corresponding author), McGill Univ, Dept Oncol, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada.; Witcher, M (corresponding author), McGill Univ, Dept Expt Med, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada.	Michael.Witcher@mcgill.ca	Wurzba, Sabrina/ABF-5002-2020	Wurzba, Sabrina/0000-0002-3742-2819	Quebec Breast Cancer Foundation (QBCF); Canadian Institute of Health Research (CIHR); Fonds de recherche du Quebec Sante (FRQS); FRQS; McGill Integrated Cancer Research Training Program; CIHR studentship; MITACS; Institute NEOMED	Quebec Breast Cancer Foundation (QBCF); Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de recherche du Quebec Sante (FRQS); FRQS; McGill Integrated Cancer Research Training Program; CIHR studentship(Canadian Institutes of Health Research (CIHR)); MITACS; Institute NEOMED	This work was supported by grants from the Quebec Breast Cancer Foundation (QBCF), the Canadian Institute of Health Research (CIHR) and Fonds de recherche du Quebec Sante (FRQS) to MW, FRQS postdoctoral fellowship to MM and McGill Integrated Cancer Research Training Program fellowships to MM and MJ. AL was supported by a CIHR studentship. LCW was supported by a MITACS postdoctoral fellowship in collaboration with Institute NEOMED.	ALBINI A, 1987, CANCER RES, V47, P3239; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bruna A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2039; Canto C, 2015, CELL METAB, V22, P31, DOI 10.1016/j.cmet.2015.05.023; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang CH, 2017, ONCOTARGET, V8, P31199, DOI 10.18632/oncotarget.16105; Chiou SH, 2013, J EXP MED, V210, P85, DOI 10.1084/jem.20121044; Dahl M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103651; Docquier F, 2009, CLIN CANCER RES, V15, P5762, DOI 10.1158/1078-0432.CCR-09-0329; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Feng XX, 2013, INT REV CEL MOL BIO, V304, P227, DOI 10.1016/B978-0-12-407696-9.00005-1; Frizzell KM, 2009, J BIOL CHEM, V284, P33926, DOI 10.1074/jbc.M109.023879; Gupta PB, 2007, CANCER RES, V67, P2062, DOI 10.1158/0008-5472.CAN-06-3895; Gupte R, 2017, GENE DEV, V31, P101, DOI 10.1101/gad.291518.116; Hilmi K, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1601898; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Kasimir-Bauer S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3099; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Le May N, 2012, MOL CELL, V48, P785, DOI 10.1016/j.molcel.2012.09.021; Lee SW, 2000, MOL CELL BIOL, V20, P1723, DOI 10.1128/MCB.20.5.1723-1732.2000; Li F, 2005, DIABETES, V54, P1514, DOI 10.2337/diabetes.54.5.1514; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Livraghi L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0425-1; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Marques M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0454-9; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Masutani M, 2013, MOL ASPECTS MED, V34, P1202, DOI 10.1016/j.mam.2013.05.003; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Mortusewicz O, 2011, NUCLEIC ACIDS RES, V39, P5045, DOI 10.1093/nar/gkr099; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Pena-Hernandez R, 2015, P NATL ACAD SCI USA, V112, pE677, DOI 10.1073/pnas.1416674112; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ramadoss S, 2017, ONCOGENE, V36, P47, DOI 10.1038/onc.2016.174; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Roux Kyle J, 2013, Curr Protoc Protein Sci, V74, DOI 10.1002/0471140864.ps1923s74; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Shirai H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.133; Shirai H, 2013, BIOCHEM BIOPH RES CO, V435, P100, DOI 10.1016/j.bbrc.2013.04.048; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tong WM, 2007, ONCOGENE, V26, P3857, DOI 10.1038/sj.onc.1210156; Tong WM, 2002, CANCER RES, V62, P6990; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Verdone L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144287; Ward TM, 2013, ONCOGENE, V32, P2463, DOI 10.1038/onc.2012.256; Witt AE, 2017, ONCOGENE, V36, P1707, DOI 10.1038/onc.2016.337; Wright RHG, 2016, SCIENCE, V352, P1221, DOI 10.1126/science.aad9335; Xu YJ, 2010, J EXP MED, V207, P2421, DOI 10.1084/jem.20100433; Zhang YJ, 2013, NAT METHODS, V10, P981, DOI 10.1038/nmeth.2603; Zhao TJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092853	59	19	19	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2177	2191		10.1038/s41388-018-0568-6	http://dx.doi.org/10.1038/s41388-018-0568-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30459355	Green Published, hybrid			2022-12-17	WOS:000461822600013
J	Stieglitz, D; Lamm, S; Braig, S; Feuerer, L; Kuphal, S; Dietrich, P; Arndt, S; Echtenacher, B; Hellerbrand, C; Karrer, S; Bosserhoff, AK				Stieglitz, David; Lamm, Susanne; Braig, Simone; Feuerer, Lena; Kuphal, Silke; Dietrich, Peter; Arndt, Stephanie; Echtenacher, Bernd; Hellerbrand, Claus; Karrer, Sigrid; Bosserhoff, Anja-Katrin			BMP6-induced modulation of the tumor micro-milieu	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEINS; NECROSIS-FACTOR-ALPHA; MAST-CELLS; MELANOMA-CELLS; METABOTROPIC GLUTAMATE-RECEPTOR-1; HEPCIDIN EXPRESSION; MALIGNANT-MELANOMA; BMP6; REGULATOR; HISTAMINE	Melanoma is the deadliest form of skin cancer with rising incidence, creating a significant health problem. We discovered increased expression of bone morphogenetic protein 6 (BMP6) in melanoma cells and tissues, and observed that BMP6 deficiency caused significantly delayed tumor onset and decelerated tumor progression in a melanoma mouse model. Moreover, we determined that BMP6 inhibits dermal mast cell recruitment and found that mast cell-derived mediators significantly reduced melanoma growth in vitro. In line with this, mast cell deficiency accelerated tumor onset and progression in a melanoma mouse model. Analysis of human melanoma tissues revealed a strong negative correlation between melanoma proliferation and mast cell infiltration. This study elucidates a novel role of BMP6-induced modulation of the tumor microenvironment.	[Stieglitz, David; Lamm, Susanne; Feuerer, Lena; Kuphal, Silke; Dietrich, Peter; Hellerbrand, Claus; Bosserhoff, Anja-Katrin] Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Ctr, Dept Biochem & Mol Med, Erlangen, Germany; [Braig, Simone] Univ Munich, Dept Pharm, Pharmaceut Biol, Munich, Germany; [Arndt, Stephanie; Karrer, Sigrid] Univ Med Ctr Regensburg, Dept Dermatol, Regensburg, Germany; [Echtenacher, Bernd] Regensburg Ctr Intervent Immunol RCI, Regensburg, Germany; [Echtenacher, Bernd] Univ Med Ctr Regensburg, Regensburg, Germany; [Hellerbrand, Claus; Bosserhoff, Anja-Katrin] Erlangen EMN, CCC, Erlangen, Germany	University of Erlangen Nuremberg; University of Munich; University of Regensburg; University of Regensburg; University of Erlangen Nuremberg	Bosserhoff, AK (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Ctr, Dept Biochem & Mol Med, Erlangen, Germany.; Bosserhoff, AK (corresponding author), Erlangen EMN, CCC, Erlangen, Germany.	Anja.Bosserhoff@fau.de	Bosserhoff, Anja/GNH-4801-2022; Kuphal, Silke/AAW-2702-2020		German Cancer Aid; German research Foundation (DFG) [HE2458/18, BO1573]; German research Foundation (DFG, Research Training Group "RTG 1962/1"); Interdisciplinary Center for Clinical Research (IZKF) Erlangen [D24 (AB)]	German Cancer Aid(Deutsche Krebshilfe); German research Foundation (DFG)(German Research Foundation (DFG)); German research Foundation (DFG, Research Training Group "RTG 1962/1"); Interdisciplinary Center for Clinical Research (IZKF) Erlangen	This work was supported by the German Cancer Aid, the German research Foundation (DFG, HE2458/18; BO1573, Research Training Group "RTG 1962/1") and the Interdisciplinary Center for Clinical Research (IZKF) Erlangen (D24 (AB)).	Amelio I, 2016, CELL DEATH DIFFER, V23, P912, DOI 10.1038/cdd.2016.12; Andriopoulos B, 2009, NAT GENET, V41, P482, DOI 10.1038/ng.335; Arndt S, 2015, GUT, V64, P973, DOI 10.1136/gutjnl-2014-306968; Arndt S, 2010, GASTROENTEROLOGY, V138, P372, DOI 10.1053/j.gastro.2009.09.048; BENYON RC, 1991, J IMMUNOL, V147, P2253; Biswas A, 2014, INT J DERMATOL, V53, P806, DOI 10.1111/j.1365-4632.2012.05745.x; Bosserhoff AK, 2011, EXP DERMATOL, V20, P435, DOI 10.1111/j.1600-0625.2011.01271.x; Botchkarev VA, 2003, J INVEST DERMATOL, V120, P36, DOI 10.1046/j.1523-1747.2003.12002.x; Bragdon B, 2011, CELL SIGNAL, V23, P609, DOI 10.1016/j.cellsig.2010.10.003; Braig S, 2010, CELL MOL LIFE SCI, V67, P3535, DOI 10.1007/s00018-010-0394-7; Ch'ng S, 2006, MODERN PATHOL, V19, P149, DOI 10.1038/modpathol.3800474; DROZDOFF V, 1994, P NATL ACAD SCI USA, V91, P5528, DOI 10.1073/pnas.91.12.5528; Dyduch G, 2011, POL J PATHOL, V62, P139; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Forward NA, 2009, J IMMUNOL, V183, P3014, DOI 10.4049/jimmunol.0802509; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hellstrand K, 2002, SEMIN ONCOL, V29, P35, DOI 10.1053/sonc.2002.33081; Hsu MY, 2008, LAB INVEST, V88, P842, DOI 10.1038/labinvest.2008.55; Hu F, 2016, ONCOL REP, V35, P1823, DOI 10.3892/or.2015.4540; Jensen-Jarolim E, 2008, ALLERGY, V63, P1255, DOI 10.1111/j.1398-9995.2008.01768.x; Katagiri T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021899; Keller HR, 2017, ONCOTARGET, V8, P75675, DOI 10.18632/oncotarget.18523; Khazaie K, 2011, CANCER METAST REV, V30, P45, DOI 10.1007/s10555-011-9286-z; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; Marin YE, 2006, CELL SIGNAL, V18, P1279, DOI 10.1016/j.cellsig.2005.10.012; Meynard D, 2009, NAT GENET, V41, P478, DOI 10.1038/ng.320; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Mueller DW, 2011, INT J CANCER, V129, P1064, DOI 10.1002/ijc.25768; Na YR, 2009, CANCER SCI, V100, P2218, DOI 10.1111/j.1349-7006.2009.01301.x; Namkoong J, 2007, CANCER RES, V67, P2298, DOI 10.1158/0008-5472.CAN-06-3665; Ott CA, 2016, ONCOTARGET, V7, P62292, DOI 10.18632/oncotarget.11410; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Pulluri B, 2017, PHARMACOL RES, V123, P95, DOI 10.1016/j.phrs.2017.07.006; Ribeiro J, 2014, J ETHNOPHARMACOL, V155, P1118, DOI 10.1016/j.jep.2014.06.041; Rothhammer T, 2005, CANCER RES, V65, P448; Rothhammer T, 2008, EUR J CANCER, V44, P2526, DOI 10.1016/j.ejca.2008.07.029; Schiffner S, 2014, EXP EYE RES, V127, P59, DOI 10.1016/j.exer.2014.07.009; Schiffner S, 2012, EXP DERMATOL, V21, P786, DOI 10.1111/j.1600-0625.2012.01560.x; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Shin SS, 2010, PIGM CELL MELANOMA R, V23, P103, DOI 10.1111/j.1755-148X.2009.00648.x; Siiskonen H, 2015, MELANOMA RES, V25, P479, DOI 10.1097/CMR.0000000000000192; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.0.CO;2-8; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; Theoharides TC, 2004, TRENDS IMMUNOL, V25, P235, DOI 10.1016/j.it.2004.02.013; Voller D, 2013, BRIT J CANCER, V109, P3116, DOI 10.1038/bjc.2013.646; WALL NA, 1993, J CELL BIOL, V120, P493, DOI 10.1083/jcb.120.2.493; Weller CL, 2011, CLIN SCI, V120, P473, DOI 10.1042/CS20100459; Yang XD, 2011, NAT MED, V17, P87, DOI 10.1038/nm.2278	49	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					609	621		10.1038/s41388-018-0475-x	http://dx.doi.org/10.1038/s41388-018-0475-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171260				2022-12-17	WOS:000457300300001
J	Wang, LT; Wang, SN; Chiou, SS; Liu, KY; Chai, CY; Chiang, CM; Huang, SK; Yokoyama, KK; Hsu, SH				Wang, Li-Ting; Wang, Shen-Nien; Chiou, Shyh-Shin; Liu, Kwei-Yan; Chai, Chee-Yin; Chiang, Cheng-Ming; Huang, Shau-Ku; Yokoyama, Kazunari K.; Hsu, Shih-Hsien			TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer	ONCOGENE			English	Article							ZIP TRANSCRIPTION FACTOR; TUMOR PROGRESSION; BHLH FACTORS; TWIST GENE; PROTEIN; SPZ1; TRANSFORMATION; TUMORIGENESIS; CELLS; BRD4	Metastasis is the main cause of cancer mortality. However, the triggering mechanisms and regulation of epithelial-mesenchymal transition (EMT) factors in the commitment of metastasis have not been well characterized. Spermatogenic Zip 1 (SPZ1) acts as a proto-oncogene and an upstream regulator of EMT during tumorigenesis. Here we report that the HIV-1 Tat-interacting protein 60 kDa (Tip60) acetyltransferase mediates acetylation at lysine residues of SPZ1 at positions 369 and 374, and of TWIST1 at positions 73 and 76, which are required for SPZ1-TWIST1 complex formation and cancer cell migration in vitro and in vivo. Ectopic SPZ1 and TWIST1 expression, but not that of TWIST1 alone, enhanced vascular endothelial growth factor (VEGF) expression via the recruitment of bromodomain-containing protein 4 (BRD4), thus enhancing RNA-Pol II-dependent transcription and inducing metastasis. Neutralization of VEGF using humanized monoclonal antibodies such as Avastin, effectively abrogated the EMT and oncogenesis induced by the acetylated SPZ1-TWIST1 complex. Our findings highlight the importance of acetylation signaling in the SPZ1-TWIST1-BRD4 axis in the mediation of EMT and its regulation during tumor initiation and metastasis.	[Wang, Li-Ting; Liu, Kwei-Yan; Yokoyama, Kazunari K.; Hsu, Shih-Hsien] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan; [Wang, Shen-Nien] Kaohsiung Med Univ Hosp, Dept Surg, Kaohsiung 807, Taiwan; [Wang, Shen-Nien] Pingtung Hosp, Minist Hlth & Welf, Pingtung 900, Taiwan; [Chiou, Shyh-Shin] Kaohsiung Med Univ Hosp, Dept Pediat, Kaohsiung 807, Taiwan; [Chiou, Shyh-Shin] Kaohsiung Med Univ Hosp, Div Hematol Oncol, Kaohsiung 807, Taiwan; [Chai, Chee-Yin] Kaohsiung Med Univ Hosp, Dept Pathol, Kaohsiung 807, Taiwan; [Chiang, Cheng-Ming] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Chiang, Cheng-Ming] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Huang, Shau-Ku] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Zhunan 115, Taiwan; [Yokoyama, Kazunari K.] Kaohsiung Med Univ, Ctr Infect Dis & Canc Res, Kaohsiung 807, Taiwan; [Yokoyama, Kazunari K.] Kaohsiung Med Univ, Ctr Stem Cell Res, Kaohsiung 807, Taiwan; [Yokoyama, Kazunari K.] Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo 1130033, Japan; [Hsu, Shih-Hsien] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Health Research Institutes - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University; University of Tokyo; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Yokoyama, KK; Hsu, SH (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan.; Yokoyama, KK (corresponding author), Kaohsiung Med Univ, Ctr Infect Dis & Canc Res, Kaohsiung 807, Taiwan.; Yokoyama, KK (corresponding author), Kaohsiung Med Univ, Ctr Stem Cell Res, Kaohsiung 807, Taiwan.; Yokoyama, KK (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo 1130033, Japan.; Hsu, SH (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807, Taiwan.	kazu@kmu.edu.tw; jackhsu@kmu.edu.tw	Hsu, Shih-Hsien/D-5139-2009; Yokoyama, Kazunari K./Z-1701-2019	Yokoyama, Kazunari K./0000-0001-8508-7587; Hsu, Shih Hsien/0000-0003-2102-0505; Wang, Li-Ting/0000-0002-3335-8055; Chai, Chee-Yin/0000-0003-0486-9742	Liver Disease Prevention & Treatment Research Foundation, Taiwan; Kaohsiung Medical University Hospital [KMUH100-0R20, KMUH106-6R33]; Ministry of Science and Technology, Taiwan [MOST-105-2314-B-037-070-MY2, MOST-106-2314-B-037-090-MY2, MOST-106-2314-B-037-017, MOST-106-2314-B-037-028, MOST-107-2314-B-037-063-MY3, MOST-107-2314-B-037-028-MY3]; National Health Research of Education [NHRI-Ex106-10416S1, NHRI-Ex107-10720-S1]; Kaohsiung Medical University grant [KMU-TP105E21, KMU-TP10500 5, KMU-DK108012]; US NIH [CA103867]; CPRIT [RP140367, RP180349]; Welch Foundation [I-1805]; NATIONAL CANCER INSTITUTE [R01CA103867] Funding Source: NIH RePORTER	Liver Disease Prevention & Treatment Research Foundation, Taiwan; Kaohsiung Medical University Hospital; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research of Education; Kaohsiung Medical University grant; US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; Welch Foundation(The Welch Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge support from the Liver Disease Prevention & Treatment Research Foundation, Taiwan. This work was supported in part by research grants KMUH100-0R20 and KMUH106-6R33 from the Kaohsiung Medical University Hospital, MOST-105-2314-B-037-070-MY2, MOST-106-2314-B-037-090-MY2, MOST-106-2314-B-037-017, MOST-106-2314-B-037-028, MOST-107-2314-B-037-063-MY3, MOST-107-2314-B-037-028-MY3 from the Ministry of Science and Technology, Taiwan, the National Health Research of Education (NHRI-Ex106-10416S1; NHRI-Ex107-10720-S1), Kaohsiung Medical University grant (KMU-TP105E21, KMU-TP10500 5, KMU-DK108012) and US NIH (CA103867), CPRIT (RP140367; RP180349) and Welch Foundation (I-1805).	Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Carmeliet P, 2013, CELL MOL LIFE SCI, V70, P1763, DOI 10.1007/s00018-013-1283-7; Francart ME, 2018, DEV DYNAM, V247, P432, DOI 10.1002/dvdy.24506; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hsu SH, 2005, CANCER RES, V65, P4041, DOI 10.1158/0008-5472.CAN-04-3658; Hsu SH, 2004, EXP CELL RES, V294, P185, DOI 10.1016/j.yexcr.2003.10.029; Hsu SH, 2001, MECH DEVELOP, V100, P177, DOI 10.1016/S0925-4773(00)00513-X; Judes G, 2015, EPIGENOMICS-UK, V7, P1351, DOI 10.2217/epi.15.76; Kwok WK, 2007, CARCINOGENESIS, V28, P2467, DOI 10.1093/carcin/bgm185; Llovet JM, 2014, CANCER CELL, V25, P560, DOI 10.1016/j.ccr.2014.04.019; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marquardt T, 2001, CELL, V106, P651, DOI 10.1016/S0092-8674(01)00499-8; Martin A, 2010, NAT CELL BIOL, V12, P924, DOI 10.1038/ncb1010-924; Mattheyses AL, 2015, METHODS MOL BIOL, V1278, P329, DOI 10.1007/978-1-4939-2425-7_20; Nervi C, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0157-2; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; Tran PT, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002650; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Waldner MJ, 2010, J EXP MED, V207, P2855, DOI 10.1084/jem.20100438; Wang LT, 2017, ONCOGENE, V36, P4405, DOI 10.1038/onc.2017.69; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Zhu QQ, 2016, TUMOR BIOL, V37, P185, DOI 10.1007/s13277-015-4450-7	31	19	22	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					518	532		10.1038/s41388-018-0457-z	http://dx.doi.org/10.1038/s41388-018-0457-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30154425	Green Published, hybrid			2022-12-17	WOS:000456589800005
J	Guo, X; Zhang, Y; Mayakonda, A; Madan, V; Ding, LW; Lin, LH; Zia, S; Gery, S; Tyner, JW; Zhou, W; Yin, D; Lin, DC; Koeffler, HP				Guo, Xiao; Zhang, Yin; Mayakonda, Anand; Madan, Vikas; Ding, Ling-Wen; Lin, Le-Hang; Zia, Saadiya; Gery, Sigal; Tyner, Jeffrey W.; Zhou, Wu; Yin, Dong; Lin, De-Chen; Koeffler, H. Phillip			ARID1A and CEBP alpha cooperatively inhibit UCA1 transcription in breast cancer	ONCOGENE			English	Article							REMODELING GENE ARID1A; CLEAR-CELL CARCINOMA; NONCODING RNA UCA1; TUMOR-SUPPRESSOR; ARID1A/BAF250A EXPRESSION; BLADDER-CANCER; MUTATIONS; PROLIFERATION; ENDOMETRIOSIS; PROGNOSIS	As one of the primary members of SWI/SNF chromatin remodeling complexes, ARID1A contains frequent loss-of-function mutations in many types of cancers. However, the molecular mechanisms underlying ARID1A deficiency in cancer biology remain to be investigated. Using breast cancer as a model, we report that silencing ARID1A significantly increased cellular proliferation and migration. Mechanistically, primarily functioning as a transcriptional repressor, loss of ARID1A profoundly alters histone modifications and the transcriptome. Notably, ARID1A inhibited the expression of a long noncoding RNA, UCA1, by regulating chromatin access of the transcription factor CEBPa. Restoration experiments showed that UCA1 mediates the functions of ARID1A that induces loss of cellular proliferation and migration. Together, our findings characterize ARID1A as a key tumor-suppressor gene in breast cancer through cooperation with CEBPa, and loss-of-function mutations of ARID1A activates UCA1.	[Guo, Xiao; Zhang, Yin; Lin, Le-Hang; Yin, Dong] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Res Ctr Med, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Guangdong, Peoples R China; [Guo, Xiao; Zia, Saadiya; Gery, Sigal; Lin, De-Chen; Koeffler, H. Phillip] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Mayakonda, Anand; Madan, Vikas; Ding, Ling-Wen; Koeffler, H. Phillip] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Zhou, Wu] Lishui Univ, Coll Med & Hlth, Dept Med, Lishui, Zhejiang, Peoples R China; [Koeffler, H. Phillip] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Singapore, Singapore	Sun Yat Sen University; Cedars Sinai Medical Center; National University of Singapore; Oregon Health & Science University; Lishui University; National University of Singapore	Guo, X (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Res Ctr Med, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Guangdong, Peoples R China.; Guo, X; Lin, DC (corresponding author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.	guoxiao152@163.com; De-Chen.Lin@cshs.org	Ding, Ling-Wen/H-6916-2019	Ding, Ling-Wen/0000-0003-0022-1551; zhou, wu/0000-0003-3105-8064; Madan, Vikas/0000-0001-7876-624X	National Research Foundation Singapore under its Singapore Translational Research Investigator Award [NMRC/STaR/0021/2014]; NMRC Centre Grant; National Research Foundation Singapore; Singapore Ministry of Education under its Research Centers of Excellence initiatives; RNA Biology Center at the Cancer Science Institute of Singapore; NUS, Singapore Ministry of Education's Tier 3 grants [MOE2014-T3-1-006]; Tower Cancer Research Foundation; National Natural Science Foundation of China (NSFC) [31401594]; Michele and Ted Kaplan Family Fund; Tower Foundation	National Research Foundation Singapore under its Singapore Translational Research Investigator Award(National Research Foundation, Singapore); NMRC Centre Grant(National Medical Research Council, Singapore); National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centers of Excellence initiatives(Ministry of Education, Singapore); RNA Biology Center at the Cancer Science Institute of Singapore; NUS, Singapore Ministry of Education's Tier 3 grants(Ministry of Education, SingaporeNational University of Singapore); Tower Cancer Research Foundation; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Michele and Ted Kaplan Family Fund; Tower Foundation	ARID1A shRNA and ARID1A CRISPR-Cas9 plasmid are gifts from Vikas Madan, Cancer Science Institute of Singapore; pCDH-CMV-UCA1-EF1-copGFP is a gift from Yin-Yuan Mo, University of Mississippi Medical Center. This research was supported by the National Research Foundation Singapore under its Singapore Translational Research Investigator Award (NMRC/STaR/0021/2014) and administered by the Singapore Ministry of Health's National Medical Research Council (NMRC), the NMRC Centre Grant awarded to National University Cancer Institute, the National Research Foundation Singapore, and the Singapore Ministry of Education under its Research Centers of Excellence initiatives to H.P.K. This study was additionally funded by the RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of funding under the Singapore Ministry of Education's Tier 3 grants (MOE2014-T3-1-006). D.-C.L was supported by Tower Cancer Research Foundation. Part research was supported by National Natural Science Foundation of China (NSFC, 31401594, to X.G.) and the generous support of Michele and Ted Kaplan Family Fund and the Tower Foundation.	Alteri R, 2015, BREAST CANC FACTS FI; Baker K, 2013, IMMUNITY, V39, P1095, DOI 10.1016/j.immuni.2013.11.003; Block K, 2010, AM J PATHOL, V176, P2447, DOI 10.2353/ajpath.2010.090606; Cho H, 2013, HUM PATHOL, V44, P1365, DOI 10.1016/j.humpath.2012.11.007; Cho HD, 2015, J BREAST CANCER, V18, P339, DOI 10.4048/jbc.2015.18.4.339; Clarke C, 2013, CARCINOGENESIS, V34, P2300, DOI 10.1093/carcin/bgt208; Cornen S, 2012, ONCOGENE, V31, P4255, DOI 10.1038/onc.2011.598; Fan Y, 2014, FEBS J, V281, P1750, DOI 10.1111/febs.12737; Guan B, 2012, NEOPLASIA, V14, P986, DOI 10.1593/neo.121218; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Guo X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.349; Huang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.541; Hughes JM, 2015, ONCOTARGET, V6, P18534, DOI 10.18632/oncotarget.4069; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Li XC, 2016, TUMOR BIOL, V37, P7599, DOI 10.1007/s13277-015-4655-9; Lin DC, 2018, GUT, V67, P1769, DOI 10.1136/gutjnl-2017-314607; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; Mathur R, 2017, NAT GENET, V49, P296, DOI 10.1038/ng.3744; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Priam P, 2017, NAT GENET, V49, P753, DOI 10.1038/ng.3812; Samartzis EP, 2014, ONCOTARGET, V5, P5295, DOI 10.18632/oncotarget.2092; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Sun XX, 2016, CELL STEM CELL, V18, P456, DOI 10.1016/j.stem.2016.03.001; Takao C, 2017, J CANCER, V8, P1, DOI 10.7150/jca.16602; Takeda T, 2016, ONCOL REP, V35, P607, DOI 10.3892/or.2015.4421; Wang HH, 2017, ONCOTARGET, V8, P64638, DOI 10.18632/oncotarget.18344; Wang Z, 2017, TUMOR BIOL, V39, DOI DOI 10.1177/101042831770999028639914; Wang ZQ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.143; Wiegand KC, 2011, J PATHOL, V224, P328, DOI 10.1002/path.2911; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu JN, 2013, CANCER DISCOV, V3, P35, DOI 10.1158/2159-8290.CD-12-0361; Xiao WB, 2012, INT J CLIN EXP PATHO, V5, P642; Yuan J, 2017, CANCER RES, V77, P6614, DOI 10.1158/0008-5472.CAN-17-1143; Zhang L, 2016, CANCER CHEMOTH PHARM, V77, P629, DOI 10.1007/s00280-016-2963-4; Zhang XY, 2012, CANCER EPIDEMIOL, V36, P288, DOI 10.1016/j.canep.2011.07.006; Zhao J, 2014, TUMOR BIOL, V35, P4813, DOI 10.1007/s13277-014-1632-7	37	19	20	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5939	5951		10.1038/s41388-018-0371-4	http://dx.doi.org/10.1038/s41388-018-0371-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29980791				2022-12-17	WOS:000449562500003
J	Loria, R; Laquintana, V; Bon, G; Trisciuoglio, D; Frapolli, R; Covello, R; Amoreo, CA; Ferraresi, V; Zoccali, C; Novello, M; Del Bufalo, D; Milella, M; Biagini, R; D'Incalci, M; Falcioni, R				Loria, Rossella; Laquintana, Valentina; Bon, Giulia; Trisciuoglio, Daniela; Frapolli, Roberta; Covello, Renato; Amoreo, Carla Azzurra; Ferraresi, Virginia; Zoccali, Carmine; Novello, Mariangela; Del Bufalo, Donatella; Milella, Michele; Biagini, Roberto; D'Incalci, Maurizio; Falcioni, Rita			HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance	ONCOGENE			English	Article							SOFT-TISSUE SARCOMA; NUCLEOTIDE-EXCISION-REPAIR; MESENCHYMAL TRANSITION; MYXOID LIPOSARCOMAS; COLON-CANCER; DNA-BINDING; KAPPA-B; ECTEINASCIDIN-743; EXPRESSION; GENE	Although the medical treatments of sarcoma have evolved in the last years, a significant portion of patients develops recurrence after therapies suggesting the need to identify novel targets to improve the treatments. By the use of patient derived and established cell lines from liposarcoma, as well as specimens from patient biopsies, we found that HMGA1 is involved in the progression of dedifferentiated and myxoid liposarcoma. The immunohistochemical and RT-PCR analyses of 68 liposarcoma specimens revealed a significant high expression of HMGA1, at the protein and RNA levels, both in myxoid and dedifferentiated liposarcoma subtypes compared with differentiated ones. Loss-and gain-of-function experiments by HMGA1-specific depletion and overexpression in dedifferentiated and myxoid liposarcoma cells showed the contribution of this oncogenic factor in cell proliferation, motility, invasion, and drug resistance. The in vitro and in vivo treatment of myxoid liposarcoma with trabectedin, a drug with a potent anti-tumor activity, revealed downregulation of HMGA1, E2F1, and its-downstream targets, vimentin and ZEB1, indicating a critical role of trabectedin in inhibiting the mesenchymal markers of these tumors through the HMGA1/E2F1 axis. These data were also confirmed in patients' tumor biopsies being HMGA1, E2F1, and vimentin expression significantly reduced upon trabectedin therapy, administered as neo-adjuvant chemotherapy. Furthermore, trabectedin treatment inhibits in vitro NFkB pathway in mixoyd liposarcoma sensitive but not in resistant counterparts, and the inhibition of NFkB pathway re-sensitizes the resistant cells to trabectedin treatment. These data support the rational for combining NFkB inhibitors with trabectedin in liposarcoma patients, who have become resistant to the drug.	[Loria, Rossella; Laquintana, Valentina; Bon, Giulia; Falcioni, Rita] IRCCS Regina Elena Natl Canc Inst, Cellular Network & Mol Therapeut Target Unit, Via Elio Chianesi 53, I-00144 Rome, Italy; [Trisciuoglio, Daniela; Del Bufalo, Donatella] IRCCS Regina Elena Natl Canc Inst, Preclin Models & New Therapeut Agents Unit, Via Elio Chianesi 53, I-00144 Rome, Italy; [Trisciuoglio, Daniela] Sapienza Univ Rome, Inst Mol Biol & Pathol, CNR Natl Res Council, I-00185 Rome, Italy; [Frapolli, Roberta; D'Incalci, Maurizio] IRCCS Ist Ric Farmacol Mario Negri, Dept Oncol, Via La Masa 19, Milan, Italy; [Covello, Renato; Amoreo, Carla Azzurra; Novello, Mariangela] IRCCS Regina Elena Natl Canc Inst, Pathol Unit, Dept Res Adv Diagnost & Technol Innovat, Via Elio Chianesi 53, I-00144 Rome, Italy; [Ferraresi, Virginia; Milella, Michele] IRCCS Regina Elena Natl Canc Inst, Med Oncol A, Via Elio Chianesi 53, I-00144 Rome, Italy; [Zoccali, Carmine; Biagini, Roberto] IRCCS Regina Elena Natl Canc Inst, Dept Expt Clin Oncol, Orthoped Surg, Via Elio Chianesi 53, I-00144 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Falcioni, R (corresponding author), IRCCS Regina Elena Natl Canc Inst, Cellular Network & Mol Therapeut Target Unit, Via Elio Chianesi 53, I-00144 Rome, Italy.	rita.falcioni@ifo.gov.it	Laquintana, Valentina/U-7577-2017; Frapolli, Roberta/AAA-6729-2020; trisciuoglio, daniela/AAL-4002-2021; Zoccali, Carmine/AAR-4473-2020; Del Bufalo, Donatella/K-8673-2016; Del Bufalo, Donatella/AAC-1594-2021; ferraresi, virginia/ABH-7898-2020; D'Incalci, Maurizio/AAA-9021-2020; Falcioni, Rita/H-8869-2017; Bon, Giulia/ABH-6498-2020; Milella, Michele/ABH-8606-2020; Loria, Rossella/ABH-7374-2020; Loria, Rossella/A-6139-2015; Trisciuoglio, Daniela/H-2131-2016	Laquintana, Valentina/0000-0002-7374-5279; Frapolli, Roberta/0000-0003-2907-273X; Zoccali, Carmine/0000-0002-6616-1996; Del Bufalo, Donatella/0000-0002-3148-6096; Del Bufalo, Donatella/0000-0002-3148-6096; ferraresi, virginia/0000-0001-6419-1668; D'Incalci, Maurizio/0000-0001-8784-1360; Falcioni, Rita/0000-0002-3745-4327; Bon, Giulia/0000-0002-5409-5864; Loria, Rossella/0000-0002-1305-2825; Trisciuoglio, Daniela/0000-0002-7007-7914	Ministero della Salute (DMT Sarcoma Group IRE); Italian Association for Cancer Research (AIRC) [IG 18622, IG 19189]; PharmaMar	Ministero della Salute (DMT Sarcoma Group IRE); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); PharmaMar	We thank PharmaMar for providing us trabectedin, Dr. Alessandra Verdina for her support, and Dr. Silvia Soddu for discussion. This work was supported by Ministero della Salute (DMT Sarcoma Group IRE) and PharmaMar to RF, and Italian Association for Cancer Research (AIRC) with a IG 18622 to M.M., and IG 19189 to MD	Allavena P, 2005, CANCER RES, V65, P2964, DOI 10.1158/0008-5472.CAN-04-4037; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; ASHAR HR, 1995, CELL, V82, P57; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Belton A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030034; Bon G, 2017, ONCOTARGET, V8, P108463, DOI 10.18632/oncotarget.11400; Bonfanti M, 1999, ANTI-CANCER DRUG DES, V14, P179; Carter NJ, 2010, DRUGS, V70, P355, DOI 10.2165/11202860-000000000-00000; Casali PG, 2010, CURR OPIN ONCOL, V22, P342, DOI 10.1097/CCO.0b013e32833aaac1; Chiappetta G, 1996, ONCOGENE, V13, P2439; Crago AM, 2011, CURR OPIN ONCOL, V23, P373, DOI 10.1097/CCO.0b013e32834796e6; D'Angelo D, 2013, EUR J CANCER, V49, P1142, DOI 10.1016/j.ejca.2012.10.014; D'Incalci M, 2010, MOL CANCER THER, V9, P2157, DOI 10.1158/1535-7163.MCT-10-0263; Damia G, 2001, INT J CANCER, V92, P583, DOI 10.1002/ijc.1221; Di Giandomenico S, 2014, ONCOGENE, V33, P5201, DOI 10.1038/onc.2013.462; Doyle LA, 2014, CANCER-AM CANCER SOC, V120, P1763, DOI 10.1002/cncr.28657; Fattore L, 2015, ONCOTARGET, V6, P24823, DOI 10.18632/oncotarget.4485; Fletcher CD, 2013, WHO CLASSIFICATION T; FLETCHER JA, 1992, CANCER RES, V52, P6224; Folgiero V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001592; Frapolli R, 2010, CLIN CANCER RES, V16, P4958, DOI 10.1158/1078-0432.CCR-10-0317; Frensing T, 2008, BBA-GENE REGUL MECH, V1779, P139, DOI 10.1016/j.bbagrm.2007.11.007; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Germano G, 2010, CANCER RES, V70, P2235, DOI 10.1158/0008-5472.CAN-09-2335; Gordon EM, 2016, ADV THER, V33, P1055, DOI 10.1007/s12325-016-0344-3; Gronchi A, 2017, LANCET ONCOL, V18, P812, DOI 10.1016/S1470-2045(17)30334-0; Guirouilh-Barbat J, 2008, MOL BIOL CELL, V19, P3969, DOI 10.1091/mbc.E08-02-0215; Kazmierczak B, 1998, GENE CHROMOSOME CANC, V23, P279, DOI 10.1002/(SICI)1098-2264(199812)23:4<279::AID-GCC1>3.0.CO;2-1; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Loria R, 2015, ONCOTARGET, V6, P2779, DOI 10.18632/oncotarget.2995; Luo WR, 2012, INT J CANCER, V131, P1863, DOI 10.1002/ijc.27467; Massimi I, 2013, MOL CARCINOGEN, V52, P526, DOI 10.1002/mc.21887; Merkhofer EC, 2010, ONCOGENE, V29, P1238, DOI 10.1038/onc.2009.410; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; MORTON DL, 1978, AUST NZ J SURG, V48, P56, DOI 10.1111/j.1445-2197.1978.tb05806.x; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; Pegoraro S, 2013, ONCOTARGET, V4, P1293, DOI 10.18632/oncotarget.1136; Pentimalli F, 2008, EUR J CANCER, V44, P2668, DOI 10.1016/j.ejca.2008.07.033; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Schuldenfrei A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-549; Singer S, 2003, ANN SURG, V238, P358, DOI 10.1097/01.sla.0000086542.11899.38; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Takebayashi Y, 1999, P NATL ACAD SCI USA, V96, P7196, DOI 10.1073/pnas.96.13.7196; Takebayashi Y, 2001, NAT MED, V7, P961, DOI 10.1038/91008; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Uboldi S, 2012, INT J CANCER, V131, P59, DOI 10.1002/ijc.26340; Valoti G, 1998, CLIN CANCER RES, V4, P1977; Zoi I, 2016, TRENDS MOL MED, V22, P839, DOI 10.1016/j.molmed.2016.07.009	50	19	19	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5926	5938		10.1038/s41388-018-0394-x	http://dx.doi.org/10.1038/s41388-018-0394-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29980789	Green Published, hybrid			2022-12-17	WOS:000449562500002
J	Phoomak, C; Silsirivanit, A; Park, D; Sawanyawisuth, K; Vaeteewoottacharn, K; Wongkham, C; Lam, EWF; Pairojkul, C; Lebrilla, CB; Wongkham, S				Phoomak, Chatchai; Silsirivanit, Atit; Park, Dayoung; Sawanyawisuth, Kanlayanee; Vaeteewoottacharn, Kulthida; Wongkham, Chaisiri; Lam, Eric W. -F.; Pairojkul, Chawalit; Lebrilla, Carlito B.; Wongkham, Sopit			O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1	ONCOGENE			English	Article							ABERRANT GLYCOSYLATION; N-ACETYLGLUCOSAMINE; CANCER; CELLS; TRANSCRIPTION; EXPRESSION; OLIGOSACCHARIDES; AGGRESSIVENESS; RELEVANCE; INVASION	The leading cause of death in cancer patients is metastasis, for which an effective treatment is still necessary. During metastasis, cancer cells aberrantly express several glycans that are correlated with poor patient outcome. This study was aimed toward exploring the effects of O-GlcNAcylation on membranous N-glycans that are associated with the progression of cholangiocarcinoma (CCA). Global O-GlcNAcylation in CCA cells was depleted using specific siRNA against O-GlcNAc transferase (OGT), which transfers GlcNAc to the acceptor proteins. Using an HPLC-Chip/Time-of-Flight (Chip/ TOF) MS system, the N-glycans associated with O-GlcNAcylation were identified by comparing the membranous N-glycans of siOGT-treated cells with those of scramble siRNA-treated cells. In parallel, the membranous N-glycans of the parental cells (KKU-213 and KKU-214) were compared with those of the highly metastatic cells (KKU-213L5 and KKU-214L5). Together, these data revealed that high mannose (Hex(9)HexNAc(2)) and biantennary complex (Hex(5)HexNAc(4)Fuc(1)NeuAc(1)) N-linked glycans correlated positively with metastasis. We subsequently demonstrate that suppression of O-GlcNAcylation decreased the expression of these two N-glycans, suggesting that O-GlcNAcylation mediates their levels in CCA. In addition, the ability of highly metastatic cells to migrate and invade was reduced by the presence of Pisum Sativum Agglutinin (PSA), a mannose-specific lectin, further indicating the association of high mannose type N-glycans with CCA metastasis. The molecular mechanism of O-GlcNAc-mediated progression of CCA was shown to proceed via a series of signaling events, involving the activation of Akt/Erk (i), an increase in FOXO3 phosphorylation (ii), which results in the reduction of MAN1A1 expression (iii) and thus the accumulation of Hex(9)HexNAc(2) N-glycans (iv). This study demonstrates for the first time the association between O-GlcNAcylation, high mannose type N-glycans, and the progression of CCA metastasis, suggesting a novel therapeutic target for treatment of metastatic CCA.	[Phoomak, Chatchai; Silsirivanit, Atit; Sawanyawisuth, Kanlayanee; Vaeteewoottacharn, Kulthida; Wongkham, Chaisiri; Wongkham, Sopit] Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen 40002, Thailand; [Phoomak, Chatchai; Silsirivanit, Atit; Sawanyawisuth, Kanlayanee; Vaeteewoottacharn, Kulthida; Wongkham, Chaisiri; Pairojkul, Chawalit; Wongkham, Sopit] Khon Kaen Univ, Cholangiocarcinoma Res Inst, Khon Kaen 40002, Thailand; [Park, Dayoung; Lebrilla, Carlito B.] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; [Park, Dayoung] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02115 USA; [Lam, Eric W. -F.] Imperial Coll London, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, London W12 0NN, England; [Pairojkul, Chawalit] Khon Kaen Univ, Fac Med, Dept Pathol, Khon Kaen 40002, Thailand	Khon Kaen University; Khon Kaen University; University of California System; University of California Davis; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Imperial College London; Khon Kaen University	Wongkham, S (corresponding author), Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen 40002, Thailand.; Wongkham, S (corresponding author), Khon Kaen Univ, Cholangiocarcinoma Res Inst, Khon Kaen 40002, Thailand.; Lebrilla, CB (corresponding author), Univ Calif Davis, Dept Chem, Davis, CA 95616 USA.	cblebrilla@ucdavis.edu; sopit@kku.ac.th	Park, Dayoung/V-7537-2017; Park, Diane Dayoung/N-5390-2019; Lebrilla, Carlito Bangeles/ABE-6369-2020; Vaeteewoottacharn, Kulthida/GSE-1017-2022; Wongkham, Sopit/ABB-6966-2021; Lam, Eric W-F/AAW-8566-2020; Silsirivanit, Atit/AAN-1728-2020; Sawanyawisuth, Kanlayanee/AAU-8424-2020	Park, Dayoung/0000-0003-4983-4340; Park, Diane Dayoung/0000-0003-4983-4340; Vaeteewoottacharn, Kulthida/0000-0001-6557-9680; Lam, Eric W-F/0000-0003-1274-3576; Sawanyawisuth, Kanlayanee/0000-0003-2260-6372; Lebrilla, Carlito/0000-0001-7190-5323; Silsirivanit, Atit/0000-0002-5777-3843; Phoomak, Chatchai/0000-0002-3808-8816	Thailand Research Fund; Medical Research Council-UK [DBG5980004]; National Research University; Khon Kaen University [NRU592010]; Research Affairs and Graduate School, Khon Kaen University, Thailand [59151]; National Institutes of Health (USA) [R01GM049077]; MRC [MR/N012097/1]; CRUK [A12011]; Breast Cancer Now [2012MayPR070, 2012NovPhD016]; Cancer Research UK Imperial Centre; Imperial ECMC; NIHR Imperial BRC; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049077] Funding Source: NIH RePORTER	Thailand Research Fund(Thailand Research Fund (TRF)); Medical Research Council-UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Research University; Khon Kaen University; Research Affairs and Graduate School, Khon Kaen University, Thailand; National Institutes of Health (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Breast Cancer Now; Cancer Research UK Imperial Centre; Imperial ECMC; NIHR Imperial BRC; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project was co-supported by the Thailand Research Fund and Medical Research Council-UK (Newton Fund) project no. DBG5980004, and National Research University grant, Khon Kaen University (NRU592010), a scholarship under the Post-Doctoral Training Program from Research Affairs and Graduate School, Khon Kaen University, Thailand (59151) and National Institutes of Health (USA) R01GM049077. EW-FL work is supported by MRC (MR/N012097/1), CRUK (A12011), Breast Cancer Now (2012MayPR070; 2012NovPhD016), the Cancer Research UK Imperial Centre, Imperial ECMC and NIHR Imperial BRC.	Anderson CD, 2004, ONCOLOGIST, V9, P43, DOI 10.1634/theoncologist.9-1-43; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Chen S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.380; Christie DR, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-3; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; de Leoz MLA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002717; de Queirozl RM, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00132; Ghazarian H, 2011, ACTA HISTOCHEM, V113, P236, DOI 10.1016/j.acthis.2010.02.004; Handerson T, 2005, CLIN CANCER RES, V11, P2969, DOI 10.1158/1078-0432.CCR-04-2211; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev-biochem-060608-102511; Heath JM, 2014, CIRC RES, V114, P1094, DOI 10.1161/CIRCRESAHA.114.302968; Higashi M, 1999, HEPATOLOGY, V30, P1347, DOI 10.1002/hep.510300609; Indramanee S, 2012, ASIAN PAC J CANCER P, V13, P119, DOI 10.7314/APJCP.2012.13.KKSuppl.119; KAKU H, 1991, CARBOHYD RES, V213, P109, DOI 10.1016/S0008-6215(00)90602-5; Kannagi R, 2008, BBA-GEN SUBJECTS, V1780, P525, DOI 10.1016/j.bbagen.2007.10.007; Kronewitter SR, 2009, PROTEOMICS, V9, P2986, DOI 10.1002/pmic.200800760; Li X, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00033; Lin CY, 2011, CLIN CANCER RES, V17, P3089, DOI 10.1158/1078-0432.CCR-10-3068; Litynska A, 2006, BIOCHIMIE, V88, P527, DOI 10.1016/j.biochi.2005.10.012; Liu TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107941; Liu YB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0522-0; Lucena MC, 2016, J BIOL CHEM, V291, P12917, DOI 10.1074/jbc.M116.729236; Matsuda A, 2015, ANAL CHEM, V87, P7274, DOI 10.1021/acs.analchem.5b01329; Milde-Langosch K, 2014, BREAST CANCER RES TR, V145, P295, DOI 10.1007/s10549-014-2949-z; Morishima S, 2003, J ENDOCRINOL, V176, P285, DOI 10.1677/joe.0.1760285; Park D, 2016, MOL CELL PROTEOMICS, V15, P3653, DOI 10.1074/mcp.M116.063206; Park HM, 2015, CARBOHYD RES, V413, P5, DOI 10.1016/j.carres.2015.04.019; Patel T, 2006, NAT CLIN PRACT GASTR, V3, P33, DOI 10.1038/ncpgasthep0389; Phoomak C, 2017, SCI REP-UK, V7, DOI 10.1038/srep43842; Phoomak C, 2016, SCI REP-UK, V6, DOI 10.1038/srep27853; Phoomak C, 2012, ASIAN PAC J CANCER P, V13, P101, DOI 10.7314/APJCP.2012.13.KKSuppl.101; Pilobello KT, 2007, P NATL ACAD SCI USA, V104, P11534, DOI 10.1073/pnas.0704954104; Powers TW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106255; Saentaweesuk W, 2018, ONCOL RES, V26, P605, DOI 10.3727/096504017X15009778205068; Silsirivanit A, 2011, CANCER-AM CANCER SOC, V117, P3393, DOI 10.1002/cncr.25912; Sripa B, 2008, CURR OPIN GASTROEN, V24, P349, DOI 10.1097/MOG.0b013e3282fbf9b3; Stanley P., 2009, ESSENTIALS GLYCOBIOL; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Takahashi M, 2009, CARBOHYD RES, V344, P1387, DOI 10.1016/j.carres.2009.04.031; Tao SC, 2008, GLYCOBIOLOGY, V18, P761, DOI 10.1093/glycob/cwn063; Tolek A, 2012, EXP BIOL MED, V237, P1142, DOI 10.1258/ebm.2012.012215; Uthaisar K, 2016, ONCOL REP, V36, P1435, DOI 10.3892/or.2016.4974; Uttaravichien T, 1999, J Hepatobiliary Pancreat Surg, V6, P128, DOI 10.1007/s005340050095; Varki A, 2009, ESSENTIALS GLYCOBIOL, P617; Varki A., 2009, ESSENTIALS GLYCOBIOL, P601; Vojta A, 2016, BBA-GEN SUBJECTS, V1860, P1776, DOI 10.1016/j.bbagen.2016.01.002; Yan FX, 2016, BIOMED PHARMACOTHER, V84, P1538, DOI 10.1016/j.biopha.2016.11.027; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Zachara NE, 2006, BBA-MOL CELL BIOL L, V1761, P599, DOI 10.1016/j.bbalip.2006.04.007; Zhang P, 2015, ONCOTARGETS THER, V8, P3305, DOI 10.2147/OTT.S82845; Zhang XW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087978; Zhao YX, 2007, INDIAN J BIOCHEM BIO, V44, P145; Zhu QQ, 2012, MED ONCOL, V29, P985, DOI 10.1007/s12032-011-9912-1	54	19	19	4	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5648	5665		10.1038/s41388-018-0366-1	http://dx.doi.org/10.1038/s41388-018-0366-1			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29915392	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000447619100005
J	Wei, S; Wang, J; Oyinlade, O; Ma, D; Wang, SY; Kratz, L; Lal, B; Xu, QF; Liu, SQ; Shah, SR; Zhang, H; Li, YQ; Quinones-Hinojosa, A; Zhu, H; Huang, ZY; Cheng, LZ; Qian, J; Xia, SL				Wei, Shuang; Wang, Jie; Oyinlade, Olutobi; Ma, Ding; Wang, Shuyan; Kratz, Lisa; Lal, Bachchu; Xu, Qingfu; Liu, Senquan; Shah, Sagar R.; Zhang, Hao; Li, Yunqing; Quinones-Hinojosa, Alfredo; Zhu, Heng; Huang, Zhi-yong; Cheng, Linzhao; Qian, Jiang; Xia, Shuli			Heterozygous IDH1(R132H/WT) created by "single base editing" inhibits human astroglial cell growth by downregulating YAP	ONCOGENE			English	Article							INTEGRATED GENOMIC ANALYSIS; IDH1 MUTATION; GLIOMA-CELLS; DNA METHYLATION; GENE-EXPRESSION; ACTIVATION; CANCER; PROLIFERATION; D-2-HYDROXYGLUTARATE; CRISPR-CAS9	Mutations in the isocitrate dehydrogenase 1 (IDH1) gene have been identified in a number of cancer types, including brain cancer. The Cancer Genome Atlas project has revealed that IDH1 mutations occur in 70-80% of grade II and grade III gliomas. Until recently, most of the functional studies of IDH1 mutations in cellular models have been conducted in overexpression systems with the IDH1 wild type background. In this study, we employed a modified CRISPR/Cas9 genome editing technique called "single base editing", and efficiently introduced heterozygous IDH1 R132H mutation (IDH1(R132H/WT)) in human astroglial cells. Global DNA methylation profiling revealed hypermethylation as well as hypomethylation induced by IDH1(R132H/WT). Global gene expression analysis identified molecular targets and pathways altered by IDH1(R132H/WT), including cell proliferation, extracellular matrix (ECM), and cell migration. Our phenotype analysis indicated that compared with IDH1 wild type cells, IDH1(R132H/WT) promoted cell migration by upregulating integrin beta 4 (ITGB4); and significantly inhibited cell proliferation. Using our mutated IDH1 models generated by "single base editing", we identified novel molecular targets of IDH1(R132H/WT), namely Yes-associated protein (YAP) and its downstream signaling pathway Notch, to mediate the cell growth-inhibiting effect of IDH1(R132H/WT). In summary, the "single base editing" strategy has successfully created heterozygous IDH1 R132H mutation that recapitulates the naturally occurring IDH1 mutation. Our isogenic cellular systems that differ in a single nucleotide in one allele of the IDH1 gene provide a valuable model for novel discoveries of IDH1(R132H/WT)-driven biological events.	[Wei, Shuang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Resp & Crit Care Med, Wuhan 430030, Hubei, Peoples R China; [Wei, Shuang; Oyinlade, Olutobi; Ma, Ding; Wang, Shuyan; Kratz, Lisa; Lal, Bachchu; Xu, Qingfu; Li, Yunqing; Xia, Shuli] Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA; [Wei, Shuang; Ma, Ding; Wang, Shuyan; Lal, Bachchu; Xu, Qingfu; Li, Yunqing; Xia, Shuli] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Wang, Jie; Qian, Jiang] Johns Hopkins Sch Med, Dept Wilmer Eye Inst, Baltimore, MD 21205 USA; [Oyinlade, Olutobi; Zhu, Heng] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Liu, Senquan; Cheng, Linzhao] Johns Hopkins Sch Med, Dept Med, Baltimore, MD 21205 USA; [Shah, Sagar R.; Quinones-Hinojosa, Alfredo] Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA; [Shah, Sagar R.] Johns Hopkins Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; [Zhang, Hao] Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; [Zhu, Heng] Johns Hopkins Sch Med, Ctr High Throughput Biol, Baltimore, MD 21205 USA; [Huang, Zhi-yong] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gen Surg, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Huazhong University of Science & Technology	Xia, SL (corresponding author), Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA.; Xia, SL (corresponding author), Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA.	xia@kennedykrieger.org	Wei, Shuang/AAA-4031-2019	Wang, Jie/0000-0002-7491-7001; Huang, Zhiyong/0000-0002-2239-0674	NIH [R01NS091165, EY024580, EY023188, GM111514, T32 GM007445]; Ford Foundation predoctoral fellowship program; NATIONAL EYE INSTITUTE [R01EY023188, R01EY024580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007445, R01GM111514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS091165] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ford Foundation predoctoral fellowship program; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr. G. Major from NIH/NINDS for SVG cells, and Dr. Mingyao Ying from Kennedy Krieger Institute for YAP constructs. We thank Dr. John Laterra and Dr. Hernando Lopez for comments on this work. This work was supported by grants from NIH R01NS091165 (S.X.), NIH EY024580 (J.Q.), NIH EY023188 (J.Q.), and NIH GM111514 (H.Z. and J.Q.), Ford Foundation predoctoral fellowship program (O.O.) and NIH T32 GM007445 (O.O.).	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Assenov Y, 2014, NAT METHODS, V11, P1138, DOI [10.1038/NMETH.3115, 10.1038/nmeth.3115]; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Cui DM, 2016, INT J BIOCHEM CELL B, V73, P72, DOI 10.1016/j.biocel.2016.02.007; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Duncan CG, 2012, GENOME RES, V22, P2339, DOI 10.1101/gr.132738.111; Ferenczy MW, 2013, J NEUROIMMUNE PHARM, V8, P1303, DOI 10.1007/s11481-013-9499-8; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Fu YJ, 2012, BIOTECHNOL LETT, V34, P441, DOI 10.1007/s10529-011-0800-8; Goodwin CR, 2010, CANCER RES, V70, P2932, DOI 10.1158/0008-5472.CAN-09-3570; Gumbiner BM, 2014, J CELL SCI, V127, P709, DOI 10.1242/jcs.140103; Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Kang MR, 2009, INT J CANCER, V125, P353, DOI 10.1002/ijc.24379; Komor AC, 2016, NATURE, V533, P420, DOI 10.1038/nature17946; Konsavage WM, 2012, J BIOL CHEM, V287, P11730, DOI 10.1074/jbc.M111.327767; Labussiere M, 2010, NEUROLOGY, V74, P1886, DOI 10.1212/WNL.0b013e3181e1cf3a; Licciardello MP, 2015, ONCOGENE, V34, P3780, DOI 10.1038/onc.2014.319; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Luchman HA, 2012, NEURO-ONCOLOGY, V14, P184, DOI 10.1093/neuonc/nor207; Lynch MD, 2012, EMBO J, V31, P317, DOI 10.1038/emboj.2011.399; Ma SH, 2015, ONCOTARGET, V6, P8606, DOI 10.18632/oncotarget.3330; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Miroshnikova YA, 2016, NAT CELL BIOL, V18, P1336, DOI 10.1038/ncb3429; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Piaskowski S, 2011, BRIT J CANCER, V104, P968, DOI 10.1038/bjc.2011.27; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Richardson CD, 2016, NAT BIOTECHNOL, V34, P339, DOI 10.1038/nbt.3481; Sabit H, 2014, BRAIN TUMOR PATHOL, V31, P242, DOI 10.1007/s10014-013-0172-y; Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112; Shah SR, 2017, CELL REP, V21, P495, DOI 10.1016/j.celrep.2017.09.057; Shi JL, 2014, NEUROL SCI, V35, P839, DOI 10.1007/s10072-013-1607-2; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wan J, 2017, ELIFE, V6, DOI 10.7554/eLife.20068; Wang GL, 2014, MOL MED REP, V9, P1799, DOI 10.3892/mmr.2014.2052; Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958; Xia SL, 2016, NEURO-ONCOLOGY, V18, P507, DOI 10.1093/neuonc/nov171; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	44	19	20	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5160	5174		10.1038/s41388-018-0334-9	http://dx.doi.org/10.1038/s41388-018-0334-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849122	Green Accepted			2022-12-17	WOS:000445093100002
J	Lee, J; Yi, S; Won, M; Song, YS; Yi, HS; Park, YJ; Park, KC; Kim, JT; Chang, JY; Lee, MJ; Sul, HJ; Choi, JE; Kim, KS; Kero, J; Kim, J; Shong, M				Lee, Junguee; Yi, Shinae; Won, Minho; Song, Young Shin; Yi, Hyon-Seung; Park, Young Joo; Park, Ki Cheol; Kim, Jung Tae; Chang, Joon Young; Lee, Min Joung; Sul, Hae Joung; Choi, Ji Eun; Kim, Koon Soon; Kero, Jukka; Kim, Joon; Shong, Minho			Loss-of-function of IFT88 determines metabolic phenotypes in thyroid cancer	ONCOGENE			English	Article							INTRAFLAGELLAR TRANSPORT PROTEINS; CYSTIC KIDNEY-DISEASE; BARDET-BIEDL-SYNDROME; PRIMARY CILIA; TUMOR SUPPRESSORS; GENE TG737; SENESCENCE; COMPLEX; AURORA; CELLS	Primary cilia are microtubule-based, dynamic organelles characterized by continuous assembly and disassembly. The intraflagellar transport (IFT) machinery, including IFT88 in cilia, is involved in the maintenance of bidirectional motility along the axonemes, which is required for ciliogenesis and functional competence. Cancer cells are frequently associated with loss of primary cilia and IFT functions. However, there is little information on the role of IFT88 or primary cilia in the metabolic remodeling of cancer cells. Therefore, we investigated the cellular and metabolic effects of the loss-of-function (LOF) mutations of IFT88/primary cilia in thyroid cancer cells. IFT88-deficient 8505C thyroid cancer cells were generated using the CRISPR/Cas9 system, and RNA-sequencing analysis was performed. LOF of the IFT88 gene resulted in a marked defect in ciliogenesis and mitochondrial oxidative function. Gene expression patterns in IFT88-deficient thyroid cancer cells favored glycolysis and lipid biosynthesis. However, LOF of IFT88/primary cilia did not promote thyroid cancer cell proliferation, migration, and invasion. The results suggest that IFT88/primary mary cilia play a role in metabolic reprogramming in thyroid cancer cells.	[Lee, Junguee; Sul, Hae Joung; Choi, Ji Eun] Catholic Univ Korea, Dept Pathol, Daejeon St Marys Hosp, Coll Med, 64 Daeheung Ro, Daejeon 34943, South Korea; [Yi, Shinae; Yi, Hyon-Seung; Kim, Jung Tae; Chang, Joon Young; Kim, Koon Soon; Shong, Minho] Chungnam Natl Univ, Sch Med, Res Ctr Endocrine & Metab Dis, Div Endocrinol,Dept Internal Med, 266 Munhwa Ro, Daejeon 35015, South Korea; [Won, Minho] Chungnam Natl Univ, Sch Med, Dept Pharmacol, 266 Munhwa Ro, Daejeon 35015, South Korea; [Song, Young Shin; Park, Young Joo] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp, 101 Daehak Ro, Seoul 03080, South Korea; [Park, Ki Cheol] Catholic Univ Korea, Clin Res Inst, Daejeon St Marys Hosp, Coll Med, 64 Daeheung Ro, Daejeon 34943, South Korea; [Lee, Min Joung] Chungnam Natl Univ, Sch Med, Dept Biochem, 266 Munhwa Ro, Daejeon 35015, South Korea; [Kero, Jukka] Univ Turku, Res Ctr Integrat Physiol & Pharmacol, Inst Biomed, Kiinamyllynkatu 10, FIN-20520 Turku, Finland; [Kim, Joon] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, 291 Daehak Ro, Daejeon 34040, South Korea	Catholic University of Korea; Chungnam National University; Chungnam National University; Seoul National University (SNU); Seoul National University Hospital; Catholic University of Korea; Chungnam National University; University of Turku; Korea Advanced Institute of Science & Technology (KAIST)	Shong, M (corresponding author), Chungnam Natl Univ, Sch Med, Res Ctr Endocrine & Metab Dis, Div Endocrinol,Dept Internal Med, 266 Munhwa Ro, Daejeon 35015, South Korea.	minhos@cnu.ac.kr	/H-7803-2012; kero, jukka/G-3448-2014; Yi, Hyon-Seung/ABA-2729-2022; Kim, Joon/C-1833-2011; Choi, Ji Eun/H-4890-2016; Park, Young Joo/J-4161-2012	kero, jukka/0000-0001-8767-7222; Choi, Ji Eun/0000-0001-9132-2029; Yi, Hyon-Seung/0000-0002-3767-1954; Won, Minho/0000-0002-5873-5216; Park, Young Joo/0000-0002-3671-6364; shong, minho/0000-0002-0247-7115	NRF/MISIT, Korea [NRF-2015R1C1A1A02037434]; Catholic Medical Center Research Foundation; Daejeon St. Mary's Hospital; NRF - Ministry of Science and ICT [NRF-2014M3A9D8034464]; NRF/MISIT of Korea [NRF-2015M3A9B3028218]	NRF/MISIT, Korea; Catholic Medical Center Research Foundation; Daejeon St. Mary's Hospital; NRF - Ministry of Science and ICT; NRF/MISIT of Korea	This work was supported by a grant (NRF-2015R1C1A1A02037434) from NRF/MISIT, Korea and a grant from the Catholic Medical Center Research Foundation made in the program year of 2016, and a grant from Daejeon St. Mary's Hospital. M. S. was supported by a grant from the NRF funded by the Ministry of Science and ICT (grant number: NRF-2014M3A9D8034464) and a grant from the NRF/MISIT of Korea (grant number: NRF-2015M3A9B3028218).	Ademowo OS, 2017, BIOGERONTOLOGY, V18, P859, DOI 10.1007/s10522-017-9710-z; Bailey JM, 2009, ONCOGENE, V28, P3513, DOI 10.1038/onc.2009.220; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Berbari NF, 2008, P NATL ACAD SCI USA, V105, P4242, DOI 10.1073/pnas.0711027105; Bishop CL, 2010, MOL CELL, V40, P533, DOI 10.1016/j.molcel.2010.10.027; Boehlke C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140378; Boehlke C, 2010, NAT CELL BIOL, V12, P1115, DOI 10.1038/ncb2117; Boissan M, 2009, MOL CELL BIOCHEM, V329, P51, DOI 10.1007/s11010-009-0120-7; Bonura C, 1999, HEPATOLOGY, V30, P677, DOI 10.1002/hep.510300325; Boren J, 2012, CELL DEATH DIFFER, V19, P1561, DOI 10.1038/cdd.2012.34; Chevrollier A, 2011, BBA-BIOENERGETICS, V1807, P562, DOI 10.1016/j.bbabio.2010.10.008; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; Davenport JR, 2007, CURR BIOL, V17, P1586, DOI 10.1016/j.cub.2007.08.034; Degnim AC, 2015, BREAST CANCER RES TR, V152, P687, DOI 10.1007/s10549-015-3513-1; Desvignes T, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-256; Dupont PY, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-482; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Haferkamp S, 2009, J INVEST DERMATOL, V129, P1983, DOI 10.1038/jid.2009.5; Haycraft CJ, 2001, DEVELOPMENT, V128, P1493; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Ishikawa H, 2011, NAT REV MOL CELL BIO, V12, P222, DOI 10.1038/nrm3085; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Katoh Y, 2016, J BIOL CHEM, V291, P10962, DOI 10.1074/jbc.M116.713883; Kero J, 2007, J CLIN INVEST, V117, P2399, DOI 10.1172/JCI30380; Lai CK, 2011, MOL BIOL CELL, V22, P1104, DOI 10.1091/mbc.E10-07-0596; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Lee J, 2016, ONCOTARGET, V7, P79103, DOI 10.18632/oncotarget.12997; Lee J, 2015, CARCINOGENESIS, V36, P1407, DOI 10.1093/carcin/bgv122; Lee SE, 2017, DIABETES, V66, P2774, DOI 10.2337/db17-0333; Llona-Minguez S, 2015, PROG LIPID RES, V58, P51, DOI 10.1016/j.plipres.2015.01.004; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Mignogna C, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0238-7; Oh EC, 2015, CELL METAB, V21, P21, DOI 10.1016/j.cmet.2014.11.019; Paraskevas KI, 2006, CLIN RHEUMATOL, V25, P687, DOI 10.1007/s10067-005-0122-0; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Plotnikova OV, 2012, MOL BIOL CELL, V23, P2658, DOI 10.1091/mbc.E11-12-1056; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Qin HM, 2004, J CELL BIOL, V164, P255, DOI 10.1083/jcb.200308132; Rahmouni K, 2008, J CLIN INVEST, V118, P1458, DOI 10.1172/JCI32357; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Robert A, 2007, J CELL SCI, V120, P628, DOI 10.1242/jcs.03366; Rohrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89; Sanchez I, 2016, NAT CELL BIOL, V18, P711, DOI 10.1038/ncb3370; Schraml P, 2009, MODERN PATHOL, V22, P31, DOI 10.1038/modpathol.2008.132; Seeger-Nukpezah Tamina, 2013, Drug Discov Today Dis Mech, V10, pe135; Song Z, 2010, MOL BIOL REP, V37, P4091, DOI 10.1007/s11033-010-0069-3; Taschner M, 2016, EMBO J, V35, P773, DOI 10.15252/embj.201593164; TeSlaa T, 2014, METHOD ENZYMOL, V542, P91, DOI 10.1016/B978-0-12-416618-9.00005-4; van Diepen JA, 2013, ATHEROSCLEROSIS, V228, P306, DOI 10.1016/j.atherosclerosis.2013.02.028; Wai T, 2016, TRENDS ENDOCRIN MET, V27, P105, DOI 10.1016/j.tem.2015.12.001; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Yan S, 2015, WORLD J GASTROENTERO, V21, P3492, DOI 10.3748/wjg.v21.i12.3492; Yaqoob P, 2003, CURR OPIN CLIN NUTR, V6, P133, DOI 10.1097/00075197-200303000-00002; Yuan K, 2010, J HISTOCHEM CYTOCHEM, V58, P857, DOI 10.1369/jhc.2010.955856	55	19	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4455	4474		10.1038/s41388-018-0211-6	http://dx.doi.org/10.1038/s41388-018-0211-6			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29743590				2022-12-17	WOS:000441144300009
J	Li, NN; Zhang, Y; Sidlauskas, K; Ellis, M; Evans, I; Frankel, P; Lau, J; El-Hassan, T; Guglielmi, L; Broni, J; Richard-Loendt, A; Brandner, S				Li, Ningning; Zhang, Ying; Sidlauskas, Kastytis; Ellis, Matthew; Evans, Ian; Frankel, Paul; Lau, Joanne; El-Hassan, Tedani; Guglielmi, Loredana; Broni, Jessica; Richard-Loendt, Angela; Brandner, Sebastian			Inhibition of GPR158 by microRNA-449a suppresses neural lineage of glioma stem/progenitor cells and correlates with higher glioma grades	ONCOGENE			English	Article							INTEGRATED GENOMIC ANALYSIS; PROSTATE-CANCER CELLS; STEM-CELL; DOWN-REGULATION; CYCLE ARREST; HUMAN GLIOBLASTOMA; FATE DETERMINATION; TUMOR-SUPPRESSOR; EXPRESSION; MIR-449A	To identify biomarkers for glioma growth, invasion and progression, we used a candidate gene approach in mouse models with two complementary brain tumour phenotypes, developing either slow-growing, diffusely infiltrating gliomas or highly proliferative, non-invasive primitive neural tumours. In a microRNA screen we first identified microRNA-449a as most significantly differentially expressed between these two tumour types. miR-449a has a target dependent effect, inhibiting cell growth and migration by downregulation of CCND1 and suppressing neural phenotypes by inhibition of G protein coupled-receptor (GPR) 158. GPR158 promotes glioma stem cell differentiation and induces apoptosis and is highest expressed in the cerebral cortex and in oligodendrogliomas, lower in IDH mutant astrocytomas and lowest in the most malignant form of glioma, IDH wild-type glioblastoma. The correlation of GPR158 expression with molecular subtypes, patient survival and therapy response suggests a possible role of GPR158 as prognostic biomarker in human gliomas.	[Li, Ningning; Zhang, Ying; Sidlauskas, Kastytis; Ellis, Matthew; Lau, Joanne; Broni, Jessica; Richard-Loendt, Angela; Brandner, Sebastian] UCL, Inst Neurol, Dept Neurodegenerat, Queen Sq, London WC1N 3BG, England; [Li, Ningning] Sun Yat Sen Univ, Affiliated Hosp 7, Shenzhen 518107, Peoples R China; [Evans, Ian; Frankel, Paul] UCL, Div Med, Univ St, London WC1E 6JF, England; [El-Hassan, Tedani; Brandner, Sebastian] Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, Div Neuropathol, Queen Sq, London WC1N 3BG, England; [Guglielmi, Loredana] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England; [Broni, Jessica; Richard-Loendt, Angela] UCL, Inst Neurol, UCL IQPath Lab, Queen Sq, London WC1N 3BG, England	University of London; University College London; Sun Yat Sen University; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; Queen Mary University London; University of London; University College London	Li, NN; Brandner, S (corresponding author), UCL, Inst Neurol, Dept Neurodegenerat, Queen Sq, London WC1N 3BG, England.; Li, NN (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Shenzhen 518107, Peoples R China.; Brandner, S (corresponding author), Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, Div Neuropathol, Queen Sq, London WC1N 3BG, England.	linn29@mail.sysu.edu.cn; s.brandner@ucl.ac.uk	Evans, Ian/C-8533-2009; Brandner, Sebastian/J-4562-2014	Evans, Ian/0000-0002-0468-8274; Brandner, Sebastian/0000-0002-9821-0342; Li, Ningning/0000-0002-0414-5878; Ellis, Matthew/0000-0002-5264-0531; Zhang, Ying/0000-0003-2194-7116	Brain Tumour Charity UK (BTC) [8/128]; Centre grant from BTC [8/197]; Brain Tumour Research UK; Department of Health's NIHR Biomedical Research Centre's funding scheme; CRUK Accelerator Ed-UCL Grant [C416/A23615]; University College London (Overseas research scholarship, UCL ORS); UCLH Charity; Cancer Research UK [C1 15121 A 20256]	Brain Tumour Charity UK (BTC); Centre grant from BTC; Brain Tumour Research UK; Department of Health's NIHR Biomedical Research Centre's funding scheme(National Institute for Health Research (NIHR)); CRUK Accelerator Ed-UCL Grant; University College London (Overseas research scholarship, UCL ORS); UCLH Charity; Cancer Research UK(Cancer Research UK)	Part of this work was supported by a grant from the Brain Tumour Charity UK to NL and SB (BTC, 8/128) and by a Centre grant from BTC (8/197). LG and part of NL were supported by a Centre of Excellence grant to Queen May University London from Brain Tumour Research UK. SB is also supported by the Department of Health's NIHR Biomedical Research Centre's funding scheme. The tissue resource is supported by the CRUK Accelerator Ed-UCL Grant C416/A23615. YZ is supported by a PhD fellowship from University College London (Overseas research scholarship, UCL ORS) and by funds from UCLH Charity. ME is funded by a Cancer Research UK Accelerator grant C1 15121 A 20256. We thank M. Elizabeth Fini, UCSC Los Angeles for the pcDNA3.1 hGPR158 vector.	Al-Mayhani TMF, 2009, J NEUROSCI METH, V176, P192, DOI 10.1016/j.jneumeth.2008.07.022; Barca-Mayo O, 2014, CELL MOL LIFE SCI, V71, P2975, DOI 10.1007/s00018-014-1576-5; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bjarndottir TK, 2005, GENE, V362, P70, DOI 10.1016/j.gene.2005.07.029; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Chen SH, 2014, ONCOL LETT, V7, P568, DOI 10.3892/ol.2013.1737; Chen SP, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1738-3; Chow LML, 2011, CANCER CELL, V19, P305, DOI 10.1016/j.ccr.2011.01.039; Cimadamore F, 2013, P NATL ACAD SCI USA, V110, pE3017, DOI 10.1073/pnas.1220176110; Dahia PLM, 2014, NAT REV CANCER, V14, P108, DOI 10.1038/nrc3648; Fang YT, 2013, ONCOL REP, V30, P399, DOI 10.3892/or.2013.2465; Fededa JP, 2016, EMBO J, V35, P2386, DOI 10.15252/embj.201694056; Fernando P, 2005, FASEB J, V19, P1671, DOI 10.1096/fj.04-2981fje; Flavahan WA, 2013, NAT NEUROSCI, V16, P1373, DOI 10.1038/nn.3510; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Henriquez NV, 2013, CANCER RES, V73, P5834, DOI 10.1158/0008-5472.CAN-13-1299; Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Insel PA, 2007, BBA-BIOMEMBRANES, V1768, P994, DOI 10.1016/j.bbamem.2006.09.029; Jacques TS, 2010, EMBO J, V29, P222, DOI 10.1038/emboj.2009.327; JIANG W, 1992, CANCER RES, V52, P2980; Johnsson P, 2013, NAT STRUCT MOL BIOL, V20, P440, DOI 10.1038/nsmb.2516; Jovicic A, 2013, J NEUROSCI, V33, P5127, DOI 10.1523/JNEUROSCI.0600-12.2013; Khrimian L, 2017, J EXP MED, V214, P2859, DOI 10.1084/jem.20171320; Kwon CH, 2008, CANCER RES, V68, P3286, DOI 10.1158/0008-5472.CAN-07-6867; Lize M, 2010, CELL DEATH DIFFER, V17, P452, DOI 10.1038/cdd.2009.188; Lize M, 2011, CELL CYCLE, V10, P2874, DOI 10.4161/cc.10.17.17181; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lukaszewicz AI, 2011, P NATL ACAD SCI USA, V108, P11632, DOI 10.1073/pnas.1106230108; Ma JF, 2015, NEUROCHEM RES, V40, P1681, DOI 10.1007/s11064-015-1635-9; Mao AH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27346; Marino S, 2000, GENE DEV, V14, P994; Marino S, 2002, DEVELOPMENT, V129, P3513; Martin HC, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r51; Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19; Noonan EJ, 2010, ONCOTARGET, V1, P349, DOI 10.18632/oncotarget.167; Orlandi C, 2012, J CELL BIOL, V197, P711, DOI 10.1083/jcb.201202123; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Patel N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117758; Patel N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057843; Pham JT, 2012, AM J STEM CELLS, V1, P182; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Pratt AJ, 2009, J BIOL CHEM, V284, P17897, DOI 10.1074/jbc.R900012200; Redshaw N, 2009, BRAIN RES, V1250, P20, DOI 10.1016/j.brainres.2008.11.020; Reuss DE, 2015, ACTA NEUROPATHOL, V130, P407, DOI 10.1007/s00401-015-1454-8; Reuss DE, 2015, ACTA NEUROPATHOL, V129, P133, DOI 10.1007/s00401-014-1370-3; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Saddiki H, 2015, BIOINFORMATICS, V31, P225, DOI 10.1093/bioinformatics/btu618; Shi W, 2016, ONCOTARGET, V7, P18906, DOI 10.18632/oncotarget.7753; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Su WY, 2012, CELL RES, V22, P1374, DOI 10.1038/cr.2012.57; Sun F, 2008, FEBS LETT, V582, P1564, DOI 10.1016/j.febslet.2008.03.057; Tan SM, 2014, CELL REP, V8, P1225, DOI 10.1016/j.celrep.2014.07.023; Thompson MD, 2014, METHODS MOL BIOL, V1175, P153, DOI 10.1007/978-1-4939-0956-8_8; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vigneswaran K, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.57; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Weller M, 2013, LANCET ONCOL, V14, pE370, DOI 10.1016/S1470-2045(13)70168-2; Wu JW, 2014, P NATL ACAD SCI USA, V111, pE2851, DOI 10.1073/pnas.1407777111; Yang XJ, 2009, GENE DEV, V23, P2388, DOI 10.1101/gad.1819009; Yao MJ, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-232; Yao YL, 2015, MOL ONCOL, V9, P640, DOI 10.1016/j.molonc.2014.11.003; You JC, 2015, AM J CANCER RES, V5, P2730; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350; Zhao ZZ, 2015, RNA BIOL, V12, P538, DOI 10.1080/15476286.2015.1023495; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zhou M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0556-3	71	19	20	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4313	4333		10.1038/s41388-018-0277-1	http://dx.doi.org/10.1038/s41388-018-0277-1			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29720725	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000440566100009
J	Toosi, BM; El Zawily, A; Truitt, L; Shannon, M; Allonby, O; Babu, M; DeCoteau, J; Mousseau, D; Ali, M; Freywald, T; Gall, A; Vizeacoumar, FS; Kirzinger, MW; Geyer, CR; Anderson, DH; Kim, T; Welm, AL; Siegel, P; Vizeacoumar, FJ; Kusalik, A; Freywald, A				Toosi, Behzad M.; El Zawily, Amr; Truitt, Luke; Shannon, Matthew; Allonby, Odette; Babu, Mohan; DeCoteau, John; Mousseau, Darrell; Ali, Mohsin; Freywald, Tanya; Gall, Amanda; Vizeacoumar, Frederick S.; Kirzinger, Morgan W.; Geyer, C. Ronald; Anderson, Deborah H.; Kim, TaeHyung; Welm, Alana L.; Siegel, Peter; Vizeacoumar, Franco J.; Kusalik, Anthony; Freywald, Andrew			EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; MAMMARY STEM-CELLS; METASTATIC COLONIZATION; CARCINOMA CELLS; EXPRESSION; IDENTIFICATION; HETEROGENEITY; TRANSITION; MECHANISMS; PLASTICITY	Triple-negative breast cancer (TNBC) tumours that lack expression of oestrogen, and progesterone receptors, and do not overexpress the HER2 receptor represent the most aggressive breast cancer subtype, which is characterised by the resistance to therapy in frequently relapsing tumours and a high rate of patient mortality. This is likely due to the resistance of slowly proliferating tumour-initiating cells (TICs), and understanding molecular mechanisms that control TICs behaviour is crucial for the development of effective therapeutic approaches. Here, we present our novel findings, indicating that an intrinsically catalytically inactive member of the Eph group of receptor tyrosine kinases, EPHB6, partially suppresses the epithelial-mesenchymal transition in TNBC cells, while also promoting expansion of TICs. Our work reveals that EPHB6 interacts with the GRB2 adapter protein and that its effect on enhancing cell proliferation is mediated by the activation of the RAS-ERK pathway, which allows it to elevate the expression of the TIC-related transcription factor, OCT4. Consistent with this, suppression of either ERK or OCT4 activities blocks EPHB6-induced pro-proliferative responses. In line with its ability to trigger propagation of TICs, EPHB6 accelerates tumour growth, potentiates tumour initiation and increases TIC populations in xenograft models of TNBC. Remarkably, EPHB6 also suppresses tumour drug resistance to DNA-damaging therapy, probably by forcing TICs into a more proliferative, drug-sensitive state. In agreement, patients with higher EPHB6 expression in their tumours have a better chance for recurrence-free survival. These observations describe an entirely new mechanism that governs TNBC and suggest that it may be beneficial to enhance EPHB6 action concurrent with applying a conventional DNA-damaging treatment, as it would decrease drug resistance and improve tumour elimination.	[Toosi, Behzad M.; El Zawily, Amr; Truitt, Luke; Allonby, Odette; DeCoteau, John; Ali, Mohsin; Freywald, Tanya; Vizeacoumar, Frederick S.; Geyer, C. Ronald; Freywald, Andrew] Univ Saskatchewan, Coll Med, Dept Pathol & Lab Med, Royal Univ Hosp, Room 2841,103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada; [El Zawily, Amr] Damanhour Univ, Fac Sci, Damanhour 22516, Egypt; [Shannon, Matthew; Kirzinger, Morgan W.; Kusalik, Anthony] Univ Saskatchewan, Dept Comp Sci, 176 Thorvaldsen Bldg,110 Sci Pl, Saskatoon, SK S7N 5C9, Canada; [Babu, Mohan] Univ Regina, Dept Chem & Biochem, Fac Sci, Res & Innovat Ctr, Room 232, Regina, SK S4S 0A2, Canada; [Mousseau, Darrell] Univ Saskatchewan, Dept Psychiat, Coll Med, Cell Signaling Lab, GB41 Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada; [Gall, Amanda] Univ Saskatchewan, Dept Biochem, Coll Med, Room 2D01 Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada; [Anderson, Deborah H.; Vizeacoumar, Franco J.] Univ Saskatchewan, Saskatchewan Canc Agcy, 4D30-2 Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada; [Kim, TaeHyung] Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada; [Kim, TaeHyung] Univ Toronto, Dept Comp Sci, Toronto, ON M5S 3E1, Canada; [Welm, Alana L.] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, 2000 Circle Hope, Salt Lake City, UT 84112 USA; [Siegel, Peter] McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada	University of Saskatchewan; Egyptian Knowledge Bank (EKB); Damanhour University; University of Saskatchewan; University of Regina; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Toronto; University of Toronto; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; McGill University	Freywald, A (corresponding author), Univ Saskatchewan, Coll Med, Dept Pathol & Lab Med, Royal Univ Hosp, Room 2841,103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.; Kusalik, A (corresponding author), Univ Saskatchewan, Dept Comp Sci, 176 Thorvaldsen Bldg,110 Sci Pl, Saskatoon, SK S7N 5C9, Canada.	kusalik@cs.usask.ca; andrew.freywald@usask.ca	Mohan, Babu P./I-7362-2019; Ali, Mohsin/GRY-0476-2022; Vizeacoumar, Franco/GLS-7161-2022	Vizeacoumar, Frederick/0000-0002-4676-2911	Canadian Breast Cancer Foundation (CBCF) [C7003]	Canadian Breast Cancer Foundation (CBCF)	We thank Chelsea Cunningham for her help with qPCR experiments and Farhad Maleki for assistance with cluster validity analysis. This work was supported by Canadian Breast Cancer Foundation (CBCF) grant # C7003.	Ablett MP, 2012, EUR J CANCER, V48, P2104, DOI 10.1016/j.ejca.2012.03.019; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bailey CM, 2014, MOL CANCER RES, V12, P1303, DOI 10.1158/1541-7786.MCR-13-0673; Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019; Bhushan L, 2014, CANCER GENOM PROTEOM, V11, P239; Brantley-Sieders DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024426; Brazma A, 2003, NUCLEIC ACIDS RES, V31, P68, DOI 10.1093/nar/gkg091; Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chen J, 2015, CYTOKINE GROWTH F R, V26, P1, DOI 10.1016/j.cytogfr.2014.05.001; Denkert C, 2017, LANCET, V389, P2430, DOI 10.1016/S0140-6736(16)32454-0; DeRose Yoko S, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1423s60; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; DeVeale B, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003957; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Duggal Rohit, 2013, J Stem Cells, V8, P135, DOI jsc.2014.8.3/4.135; Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015; El Zawily AM, 2016, ONCOTARGET, V7, P77865, DOI 10.18632/oncotarget.12838; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Fox BP, 2006, BIOCHEM BIOPH RES CO, V340, P268, DOI 10.1016/j.bbrc.2005.11.174; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Fox BP, 2009, ONCOGENE, V23, P23; Funasaka T, 2009, CANCER RES, V69, P5349, DOI 10.1158/0008-5472.CAN-09-0488; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goke J, 2013, MOL CELL, V50, P844, DOI 10.1016/j.molcel.2013.04.030; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Gu Y, 2016, J CLIN PATHOL, V69, P448, DOI 10.1136/jclinpath-2015-203160; Hafner C, 2003, INT J ONCOL, V23, P1553; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Kidd ME, 2014, AM J RESP CELL MOL, V50, P1, DOI 10.1165/rcmb.2013-0314TR; Kleffel S, 2013, ADV EXP MED BIOL, V734, P145, DOI 10.1007/978-1-4614-1445-2_8; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kurpios NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058151; Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280; Li J, 2007, DIFFERENTIATION, V75, P299, DOI 10.1111/j.1432-0436.2006.00143.x; Liersch-Lohn B, 2016, INT J CANCER, V138, P1220, DOI 10.1002/ijc.29865; Lisabeth EM, 2013, COLD SPRING HARB PER, V5; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Mateo-Lozano S, 2017, SCI REP-UK, V7, DOI 10.1038/srep43702; Mayer IA, 2014, CLIN CANCER RES, V20, P782, DOI 10.1158/1078-0432.CCR-13-0583; Mohamed ER, 2015, ONCOL LETT, V9, P1672, DOI 10.3892/ol.2015.2925; Morrison BJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049752; Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388; Mustacchi G, 2015, DRUG DES DEV THER, V9, P4303, DOI 10.2147/DDDT.S86105; Nishi M, 2014, ONCOGENE, V33, P643, DOI 10.1038/onc.2012.614; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Santarpia L, 2012, EXPERT OPIN THER TAR, V16, P103, DOI 10.1517/14728222.2011.645805; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Stankic M, 2013, CELL REP, V5, P1228, DOI 10.1016/j.celrep.2013.11.014; Stratford AL, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001535; Sultan AS, 2008, CANCER SCI, V99, P272, DOI 10.1111/j.1349-7006.2007.00685.x; Tang XX, 1999, CLIN CANCER RES, V5, P1491; Tang XX, 2000, MED PEDIATR ONCOL, V35, P656, DOI 10.1002/1096-911X(20001201)35:6<656::AID-MPO37>3.0.CO;2-A; Truitt L, 2011, BIOCHEM CELL BIOL, V89, P115, DOI [10.1139/O10-145, 10.1139/o10-145]; Truitt L, 2010, CANCER RES, V70, P1141, DOI 10.1158/0008-5472.CAN-09-1710; Vizeacoumar FJ, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.54; Yu J, 2010, CLIN CANCER RES, V16, P2275, DOI 10.1158/1078-0432.CCR-09-2000; Yu J, 2009, INT J ONCOL, V35, P175, DOI 10.3892/ijo_00000326	64	19	20	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4073	4093		10.1038/s41388-018-0228-x	http://dx.doi.org/10.1038/s41388-018-0228-x			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29700392	hybrid, Green Published			2022-12-17	WOS:000439847000003
J	Castejon-Grinan, M; Herraiz, C; Olivares, C; Jimenez-Cervantes, C; Garcia-Borron, JC				Castejon-Grinan, Maria; Herraiz, Cecilia; Olivares, Conchi; Jimenez-Cervantes, Celia; Carlos Garcia-Borron, Jose			cAMP-independent non-pigmentary actions of variant melanocortin 1 receptor: AKT-mediated activation of protective responses to oxidative DNA damage	ONCOGENE			English	Article							DOUBLE-STRAND BREAK; NUCLEOTIDE EXCISION-REPAIR; RED HAIR; HUMAN MELANOCYTES; ULTRAVIOLET-RADIATION; FUNCTIONAL-ANALYSIS; CUTANEOUS MELANOMA; FUNCTION MUTATIONS; SIGNALING PATHWAY; CANCER-THERAPY	The melanocortin 1 receptor gene (MC1R), a well-established melanoma susceptibility gene, regulates the amount and type of melanin pigments formed within epidermal melanocytes. MC1R variants associated with increased melanoma risk promote the production of photosensitizing pheomelanins as opposed to photoprotective eumelanins. Wild-type (WT) MC1R activates DNA repair and antioxidant defenses in a cAMP-dependent fashion. Since melanoma-associated MC1R variants are hypomorphic in cAMP signaling, these non-pigmentary actions are thought to be defective in MC1R-variant human melanoma cells and epidermal melanocytes, consistent with a higher mutation load in MC1R-variant melanomas. We compared induction of antioxidant enzymes and DNA damage responses in melanocytic cells of defined MC1R genotype. Increased expression of catalase (CAT) and superoxide dismutase (SOD) genes following MC1R activation was cAMP-dependent and required a WT MC1R genotype. Conversely, pretreatment of melanocytic cells with an MC1R agonist before an oxidative challenge with Luperox decreased (i) accumulation of 8-oxo-7,8-dihydro-2'-deoxyguanine, a major product of oxidative DNA damage, (ii) phosphorylation of histone H2AX, a marker of DNA double-strand breaks, and (iii) formation of DNA breaks. These responses were comparable in cells WT for MC1R or harboring hypomorphic MC1R variants without detectable cAMP signaling. In MC1R-variant melanocytic cells, the DNA-protective responses were mediated by AKT. Conversely, in MC1R-WT melanocytic cells, high cAMP production downstream of MC1R blocked AKT activation and was responsible for inducing DNA repair. Accordingly, MC1R activation could promote repair of oxidative DNA damage by a cAMP-dependent pathway downstream of WT receptor, or via AKT in cells of variant MC1R genotype.	[Castejon-Grinan, Maria; Herraiz, Cecilia; Olivares, Conchi; Jimenez-Cervantes, Celia; Carlos Garcia-Borron, Jose] Univ Murcia, Dept Biochem Mol Biol & Immunol, Sch Med, Murcia, Spain; [Castejon-Grinan, Maria; Herraiz, Cecilia; Olivares, Conchi; Jimenez-Cervantes, Celia; Carlos Garcia-Borron, Jose] IMIB, Murcia, Spain	University of Murcia	Herraiz, C (corresponding author), Univ Murcia, Dept Biochem Mol Biol & Immunol, Sch Med, Murcia, Spain.; Herraiz, C (corresponding author), IMIB, Murcia, Spain.	ceciliahs@um.es	Serrano, Cecilia Herraiz/H-2550-2015; Jimenez-Cervantes, Celia/H-1953-2015; Castejón Griñán, María/AAC-8557-2022; Garcia-Borron, Jose Carlos/H-2247-2015; Olivares, Conchi/H-2794-2015	Serrano, Cecilia Herraiz/0000-0001-6912-0738; Jimenez-Cervantes, Celia/0000-0002-5821-9510; Castejón Griñán, María/0000-0003-4494-3986; Garcia-Borron, Jose Carlos/0000-0002-9192-588X; Olivares, Conchi/0000-0001-7518-3858	MINECO (Spain) [SAF2015-67092-R]; FEDER (European Community); Fundacion Seneca, Comunidad Autonoma de la Region de Murcia (CARM) [19875/GERM/15]; Fundacion Seneca	MINECO (Spain); FEDER (European Community)(European Commission); Fundacion Seneca, Comunidad Autonoma de la Region de Murcia (CARM); Fundacion Seneca(Fundacion Seneca)	Supported by grants SAF2015-67092-R from MINECO (Spain) and FEDER (European Community) and 19875/GERM/15 from Fundacion Seneca, Comunidad Autonoma de la Region de Murcia (CARM). M Castejon holds a pre-doctoral fellowship from the Fundacion Seneca. Cecilia Herraiz was a Juan de la Cierva-Incorporacion fellow of MINECO. We thank Prof. G Ghanem, from the Free University of Brussels for gift of human melanoma cell lines and Prof. Neptuno Rodriguez (University of Murcia) for Hermes melanocytes. We also thank Prof. JL Castejon for help with the statistical analysis of data, Dr. M Abrisqueta for assistance in cell cycle analysis and Dr. A Lopez-Contreras for suggestions and critical reading of the manuscript.	Abdel-Malek ZA, 2014, ARCH BIOCHEM BIOPHYS, V563, P4, DOI 10.1016/j.abb.2014.07.002; ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; Ahn JH, 2007, P NATL ACAD SCI USA, V104, P2979, DOI 10.1073/pnas.0611532104; Altieri F, 2008, ANTIOXID REDOX SIGN, V10, P891, DOI 10.1089/ars.2007.1830; Bastiaens MT, 2001, AM J HUM GENET, V68, P884, DOI 10.1086/319500; Beaumont KA, 2007, HUM MOL GENET, V16, P2249, DOI 10.1093/hmg/ddm177; Bohm M, 2005, J BIOL CHEM, V280, P5795, DOI 10.1074/jbc.M406334200; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Cadet J, 2015, PHOTOCHEM PHOTOBIOL, V91, P140, DOI 10.1111/php.12368; Cao JX, 2013, MOL CELL, V51, P409, DOI 10.1016/j.molcel.2013.08.010; Garcia-Borron JC, 2014, EXP DERMATOL, V23, P387, DOI 10.1111/exd.12310; CHEDEKEL MR, 1978, P NATL ACAD SCI USA, V75, P5395, DOI 10.1073/pnas.75.11.5395; Cho EA, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-36; Cohen-Armon M, 2007, TRENDS PHARMACOL SCI, V28, P556, DOI 10.1016/j.tips.2007.08.005; d'Ischia M, 2015, PIGM CELL MELANOMA R, V28, P520, DOI 10.1111/pcmr.12393; Robles-Espinoza CD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12064; Davies JR, 2012, PIGM CELL MELANOMA R, V25, P384, DOI 10.1111/j.1755-148X.2012.00982.x; Dessinioti C, 2011, PHOTOCHEM PHOTOBIOL, V87, P978, DOI 10.1111/j.1751-1097.2011.00970.x; Fajuyigbe D, 2016, PIGM CELL MELANOMA R, V29, P607, DOI 10.1111/pcmr.12511; FELIX CC, 1978, BIOCHEM BIOPH RES CO, V84, P335, DOI 10.1016/0006-291X(78)90175-4; Frandberg PA, 1998, BIOCHEM BIOPH RES CO, V245, P490, DOI 10.1006/bbrc.1998.8459; Garcia-Borron JC, 2014, PIGM CELL MELANOMA R, V27, P699, DOI 10.1111/pcmr.12257; Gerstenblith MR, 2007, HUM MUTAT, V28, P495, DOI 10.1002/humu.20476; Gharbi SI, 2007, BIOCHEM J, V404, P15, DOI 10.1042/BJ20061489; Habib SL, 2016, CELL CYCLE, V15, P3048, DOI 10.1080/15384101.2016.1231259; Hawkins AJ, 2011, RADIOTHER ONCOL, V101, P13, DOI 10.1016/j.radonc.2011.05.074; Hein AL, 2014, INT J ONCOL, V45, P1813, DOI 10.3892/ijo.2014.2614; Herraiz C, 2017, BBA-MOL BASIS DIS, V1863, P2448, DOI 10.1016/j.bbadis.2017.02.027; Herraiz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144757; Herraiz C, 2012, INT J BIOCHEM CELL B, V44, P2244, DOI 10.1016/j.biocel.2012.09.008; Herraiz C, 2011, MOL ENDOCRINOL, V25, P138, DOI 10.1210/me.2010-0217; Herraiz C, 2009, FEBS LETT, V583, P3269, DOI 10.1016/j.febslet.2009.09.023; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Horrell EMW, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00095; Hustedt N, 2017, NAT CELL BIOL, V19, P1, DOI 10.1038/ncb3452; Ito S, 2003, PIGM CELL RES, V16, P523, DOI 10.1034/j.1600-0749.2003.00072.x; Janjetovic Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01305-2; Jarrett SG, 2016, NUCLEIC ACIDS RES, V44, P10711, DOI 10.1093/nar/gkw871; Jarrett SG, 2017, PIGM CELL MELANOMA R, V30, P284, DOI 10.1111/pcmr.12582; Jo H, 2012, P NATL ACAD SCI USA, V109, P10581, DOI 10.1073/pnas.1202810109; Johansson PA, 2017, PIGM CELL MELANOMA R, V30, P255, DOI 10.1111/pcmr.12571; Kadekaro AL, 2005, CANCER RES, V65, P4292, DOI 10.1158/0008-5472.CAN-04-4535; Kadekaro AL, 2012, MOL CANCER RES, V10, P778, DOI 10.1158/1541-7786.MCR-11-0436; Kadekaro AL, 2010, FASEB J, V24, P3850, DOI 10.1096/fj.10-158485; Khaled M, 2002, J BIOL CHEM, V277, P33690, DOI 10.1074/jbc.M202939200; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Liu Q, 2014, NEURO-ONCOLOGY, V16, P1313, DOI 10.1093/neuonc/nou058; Lobrich M, 2010, CELL CYCLE, V9, P662, DOI 10.4161/cc.9.4.10764; Luo Z, 2009, BRIT J PHARMACOL, V157, P935, DOI 10.1111/j.1476-5381.2009.00259.x; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Maresca V, 2010, PIGM CELL MELANOMA R, V23, P263, DOI 10.1111/j.1755-148X.2010.00673.x; MEDRANO EE, 1995, CANCER RES, V55, P4047; Merlino G, 2016, PIGM CELL MELANOMA R, V29, P404, DOI 10.1111/pcmr.12475; Mitra D, 2012, NATURE, V491, P449, DOI 10.1038/nature11624; Monaghan RM, 2015, NAT CELL BIOL, V17, P782, DOI 10.1038/ncb3170; Musante V, 2017, ELIFE, V6, DOI 10.7554/eLife.24998; Nakayama K, 2006, HUM GENET, V119, P322, DOI 10.1007/s00439-006-0141-1; Napolitano A, 2014, PIGM CELL MELANOMA R, V27, P721, DOI 10.1111/pcmr.12262; Newton RA, 2005, PEPTIDES, V26, P1818, DOI 10.1016/j.peptides.2004.11.031; O'Hayre M, 2014, CURR OPIN CELL BIOL, V27, P126, DOI 10.1016/j.ceb.2014.01.005; Pan YD, 2018, EXP NEUROL, V300, P149, DOI 10.1016/j.expneurol.2017.10.030; Panzella L, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12199; Oliva ABP, 2009, HUM MUTAT, V30, P811, DOI 10.1002/humu.20971; Piao MJ, 2011, TOXICOL LETT, V207, P143, DOI 10.1016/j.toxlet.2011.09.002; Podhorecka M., 2010, J NUCL ACIDS, V2010, P1, DOI DOI 10.4061/2010/920161; Ringholm A, 2004, J INVEST DERMATOL, V123, P917, DOI 10.1111/j.0022-202X.2004.23444.x; Roberts DW, 2008, J CELL PHYSIOL, V215, P344, DOI 10.1002/jcp.21318; Rodriguez-Escudero I, 2011, HUM MOL GENET, V20, P4132, DOI 10.1093/hmg/ddr337; Sanchez-Laorden BL, 2006, J INVEST DERMATOL, V126, P172, DOI 10.1038/sj.jid.5700036; Scherer D, 2010, MUTAT RES-REV MUTAT, V705, P141, DOI 10.1016/j.mrrev.2010.06.002; Schioth HB, 1999, BIOCHEM BIOPH RES CO, V260, P488, DOI 10.1006/bbrc.1999.0935; Scott MC, 2002, J CELL SCI, V115, P2349; Shahzad M, 2015, PIGM CELL MELANOMA R, V28, P730, DOI 10.1111/pcmr.12400; Simon JD, 2010, ACCOUNTS CHEM RES, V43, P1452, DOI 10.1021/ar100079y; Singh P, 2016, FEBS LETT, V590, P3071, DOI 10.1002/1873-3468.12377; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Smith R, 1998, J INVEST DERMATOL, V111, P119, DOI 10.1046/j.1523-1747.1998.00252.x; Song XZ, 2009, PIGM CELL MELANOMA R, V22, P809, DOI 10.1111/j.1755-148X.2009.00615.x; Toulany M, 2008, MOL CANCER THER, V7, P1772, DOI 10.1158/1535-7163.MCT-07-2200; Toulany M, 2015, SEMIN CANCER BIOL, V35, P180, DOI 10.1016/j.semcancer.2015.07.003; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; Wei F, 2011, CURR MED CHEM, V18, P5476, DOI 10.2174/092986711798194388; Xu NH, 2012, J ONCOL, V2012, DOI 10.1155/2012/951724; Yang JL, 2016, THERANOSTICS, V6, P2015, DOI 10.7150/thno.15993; Zanna PT, 2008, BIOCHEM BIOPH RES CO, V368, P211, DOI 10.1016/j.bbrc.2008.01.060; Zhang TW, 2016, PIGM CELL MELANOMA R, V29, P266, DOI 10.1111/pcmr.12459	87	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3631	3646		10.1038/s41388-018-0216-1	http://dx.doi.org/10.1038/s41388-018-0216-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29622793				2022-12-17	WOS:000437975200002
J	Zimmerli, D; Cecconi, V; Valenta, T; Hausmann, G; Cantu, C; Restivo, G; Hafner, J; Basler, K; van den Broek, M				Zimmerli, Dario; Cecconi, Virginia; Valenta, Tomas; Hausmann, George; Cantu, Claudio; Restivo, Gaetana; Hafner, Jurg; Basler, Konrad; van den Broek, Maries			WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma	ONCOGENE			English	Article							STEM-CELLS; TUMOR MICROENVIRONMENT; DRUG-RESISTANCE; SKIN TUMORS; TGF-BETA; CANCER; INHIBITION; PORCUPINE; TUMORIGENESIS; INVASION	Human papillomavirus (HPV)-driven cutaneous squamous cell carcinoma (cSCC) is the most common cancer in immunosuppressed patients. Despite indications suggesting that HPV promotes genomic instability during cSCC development, the molecular pathways underpinning HPV-driven cSCC development remain unknown. We compared the transcriptome of HPV-driven mouse cSCC with normal skin and observed higher amounts of transcripts for Porcupine and WNT ligands in cSCC, suggesting a role for WNT signaling in cSCC progression. We confirmed increased Porcupine expression in human cSCC samples. Blocking the secretion of WNT ligands by the Porcupine inhibitor LGK974 significantly diminished initiation and progression of HPV-driven cSCC. Administration of LGK974 to mice with established cSCC resulted in differentiation of cancer cells and significant reduction of the cancer stem cell compartment. Thus, WNT/beta-catenin signaling is essential for HPV-driven cSCC initiation and progression as well as for maintaining the cancer stem cell niche. Interference with WNT secretion may thus represent a promising approach for therapeutic intervention.	[Zimmerli, Dario; Valenta, Tomas; Hausmann, George; Cantu, Claudio; Basler, Konrad] Univ Zurich, Inst Mol Life Sci, CH-8057 Zurich, Switzerland; [Cecconi, Virginia; van den Broek, Maries] Univ Zurich, Inst Expt Immunol, CH-8057 Zurich, Switzerland; [Restivo, Gaetana; Hafner, Jurg] Univ Hosp Zurich, Dept Dermatol, CH-8091 Zurich, Switzerland; [Cantu, Claudio] Linkoping Univ, WCMM, Fac Hlth Sci, Dept Clin & Expt Med IKE, S-58185 Linkoping, Sweden	University of Zurich; University of Zurich; University of Zurich; University Zurich Hospital; Linkoping University	Basler, K (corresponding author), Univ Zurich, Inst Mol Life Sci, CH-8057 Zurich, Switzerland.; van den Broek, M (corresponding author), Univ Zurich, Inst Expt Immunol, CH-8057 Zurich, Switzerland.	kb@imls.uzh.ch; vandenbroek@immunology.uzh.ch	van den Broek, Maries/L-6532-2019; Cantù, Claudio/AAB-7771-2019; van den Broek, Maries/G-4128-2016	Cantù, Claudio/0000-0003-1547-5415; Valenta, Tomas/0000-0002-3043-1835; van den Broek, Maries/0000-0002-9489-3692; Basler, Konrad/0000-0003-3534-1529; Restivo, Gaetana/0000-0003-4364-2364; , Dario/0000-0002-4920-0244	Swiss National Science Foundation (SNF); Swiss Cancer League; Promedica Foundation Zurich; University of Zurich Research Priority Program "Translational Cancer Research"; Kanton of Zurich	Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); Swiss Cancer League; Promedica Foundation Zurich; University of Zurich Research Priority Program "Translational Cancer Research"; Kanton of Zurich	We thank Karina Silina and Michal Beffinger (Institute of Experimental Immunology, UZH) for help with some experiments, Lukas Sommer (Institute of Anatomy, UZH) for reagents and discussions, Sabine Werner (Institute for Molecular Health Sciences, ETHZ) for discussions and sharing reagents, Herbert Pfister (Institute of Virology, University of Koln), for mouse strains (Krt14-HPV8-E6), Alexandra Franz for help with R and Martin Moser and Eliane Escher (Institute of Molecular Life Sciences, UZH) for technical support. We thank the personnel of the Laboratory Animal Service Center from the University of Zurich for expert animal care. This work was supported by the Swiss National Science Foundation (SNF) (K.B., M.v.d.B), Swiss Cancer League (K.B.), the Promedica Foundation Zurich (M.v.d.B.), University of Zurich Research Priority Program "Translational Cancer Research" and the Kanton of Zurich (K.B., M.v.d.B.). V.C and T.V. are fellows in the URPP Translational Cancer Research Program.	Accardi R, 2014, PRESSE MED, V43, pE435, DOI 10.1016/j.lpm.2014.08.008; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Blake JA, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI 10.1093/nar/gku1179; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Chockalingam R, 2015, J CLIN MED, V4, P1229, DOI 10.3390/jcm4061229; Connolly K, 2014, CANCER TREAT REV, V40, P205, DOI 10.1016/j.ctrv.2013.08.005; Melo FDE, 2016, CANCERS, V8, DOI 10.3390/cancers8070060; Haegebarth A, 2009, AM J PATHOL, V174, P715, DOI 10.2353/ajpath.2009.080758; Herr P, 2012, DEV BIOL, V361, P392, DOI 10.1016/j.ydbio.2011.11.003; Hofbauer GFL, 2010, EXP DERMATOL, V19, P473, DOI 10.1111/j.1600-0625.2010.01086.x; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Lapouge G, 2012, EMBO J, V31, P4563, DOI 10.1038/emboj.2012.312; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Latil M, 2017, CELL STEM CELL, V20, P191, DOI 10.1016/j.stem.2016.10.018; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Marcuzzi GP, 2009, J GEN VIROL, V90, P2855, DOI 10.1099/vir.0.012872-0; Nassar D, 2015, NAT MED, V21, P946, DOI 10.1038/nm.3878; Nichols AJ, 2017, JAMA DERMATOL, V153, P571, DOI 10.1001/jamadermatol.2016.5703; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Oshimori N, 2015, CELL, V160, P963, DOI 10.1016/j.cell.2015.01.043; Pourreyron C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031827; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970; Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008-5472.CAN-12-2258; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Shiokawa D, 2017, CELL REP, V19, P981, DOI 10.1016/j.celrep.2017.04.017; Sidney LE, 2014, STEM CELLS, V32, P1380, DOI 10.1002/stem.1661; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Valenta T, 2016, CELL REP, V15, P911, DOI 10.1016/j.celrep.2016.03.088; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; Wicki A, 2007, BRIT J CANCER, V96, P1, DOI 10.1038/sj.bjc.6603518; Yanofsky Valerie R, 2011, J Skin Cancer, V2011, P210813, DOI 10.1155/2011/210813; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Zimmerli D, 2017, BRIT J PHARMACOL, V174, P4600, DOI 10.1111/bph.13864; Zito G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4543	41	19	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3753	3762		10.1038/s41388-018-0244-x	http://dx.doi.org/10.1038/s41388-018-0244-x			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29662191	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000437975200011
J	Romano, G; Chagani, S; Kwong, LN				Romano, Gabriele; Chagani, Sharmeen; Kwong, Lawrence N.			The path to metastatic mouse models of colorectal cancer	ONCOGENE			English	Review							FAMILIAL ADENOMATOUS POLYPOSIS; COLON-CANCER; INTESTINAL TUMORIGENESIS; MICROSATELLITE INSTABILITY; TUMOR PROGRESSION; APC MUTATIONS; MUTANT MICE; IN-VIVO; GENES; INACTIVATION	The study and comprehension of the molecular mechanisms underlying cancer biology strongly rely on mouse modeling. An ideal mouse model should have molecular, histopathological, and etiological characteristics as close as possible to those of the corresponding human tumors. Among solid tumors, colorectal cancer (CRC) is one of the malignancies that best suits reproduction in an animal model: it evolves through a progressive set of molecular events and is generally associated with a precise histopathology and a neat cataloging of stages and grades. The development of refined CRC mouse models over several decades has seen them recently evolve toward sophisticated systems that ever more closely approximate the human pathology, with different models addressing different human CRC subtypes. In particular, a metastatic CRC model has been seen as a "holy grail" in this field, and we describe in this review the path taken to achieve metastatic models and discuss the path forward.	[Romano, Gabriele; Chagani, Sharmeen; Kwong, Lawrence N.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kwong, LN (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.	lkwong@mdanderson.org		Romano, Gabriele/0000-0001-8023-8657				Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Beach R, 2005, AM J PATHOL, V166, P1069, DOI 10.1016/S0002-9440(10)62327-9; Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Chen HJ, 2016, NAT BIOTECHNOL, V34, P845, DOI 10.1038/nbt.3586; CLARKE AR, 1995, ONCOGENE, V11, P1913; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Faller WJ, 2015, NATURE, V517, P497, DOI 10.1038/nature13896; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Halberg RB, 2009, CANCER RES, V69, P5768, DOI 10.1158/0008-5472.CAN-09-0446; Hamamoto T, 2002, CANCER RES, V62, P5955; Han T, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms15945; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Khazaie K, 2012, P NATL ACAD SCI USA, V109, P10462, DOI 10.1073/pnas.1207230109; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kucherlapati MH, 2010, GASTROENTEROLOGY, V138, P993, DOI 10.1053/j.gastro.2009.11.009; Kwong LN, 2008, ONCOGENE, V27, P1013, DOI 10.1038/sj.onc.1210708; Kwong LN, 2007, GENETICS, V176, P1237, DOI 10.1534/genetics.107.071217; Kwong LN, 2009, ADV EXP MED BIOL, V656, P85, DOI 10.1007/978-1-4419-1145-2_8; Leystra AA, 2012, CANCER RES, V72, P2931, DOI 10.1158/0008-5472.CAN-11-4097; Maggio-Price L, 2006, CANCER RES, V66, P828, DOI 10.1158/0008-5472.CAN-05-2448; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; McIntyre RE, 2015, BIOESSAYS, V37, P909, DOI 10.1002/bies.201500032; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; O'Rourke KP, 2017, NAT BIOTECHNOL, V35, P577, DOI 10.1038/nbt.3837; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pan QF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00057-3; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Reitmair AH, 1996, CANCER RES, V56, P2922; Robanus-Maandag EC, 2010, CARCINOGENESIS, V31, P946, DOI 10.1093/carcin/bgq046; Roper J, 2017, NAT BIOTECHNOL, V35, P569, DOI 10.1038/nbt.3836; Sanchez-Rivera FJ, 2015, NAT REV CANCER, V15, P387, DOI 10.1038/nrc3950; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Taketo MM, 2009, GASTROENTEROLOGY, V136, P780, DOI 10.1053/j.gastro.2008.12.049; Trobridge P, 2009, GASTROENTEROLOGY, V136, P1680, DOI 10.1053/j.gastro.2009.01.066; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Xue YB, 2010, MOL CANCER RES, V8, P1095, DOI 10.1158/1541-7786.MCR-10-0195; Yang S, 2004, AM J SURG PATHOL, V28, P1452, DOI 10.1097/01.pas.0000141404.56839.6a; Yu M, 2014, ONCOGENE, V33, P1538, DOI 10.1038/onc.2013.102; Zeineldin M, 2013, BBA-REV CANCER, V1836, P80, DOI 10.1016/j.bbcan.2013.01.001; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	62	19	20	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2481	2489		10.1038/s41388-018-0155-x	http://dx.doi.org/10.1038/s41388-018-0155-x			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29463860				2022-12-17	WOS:000431873400002
J	Fielding, AB; Concannon, M; Darling, S; Rusilowicz-Jones, EV; Sacco, JJ; Prior, IA; Clague, MJ; Urbe, S; Coulson, JM				Fielding, Andrew B.; Concannon, Matthew; Darling, Sarah; Rusilowicz-Jones, Emma V.; Sacco, Joseph J.; Prior, Ian A.; Clague, Michael J.; Urbe, Sylvie; Coulson, Judy M.			The deubiquitylase USP15 regulates topoisomerase II alpha to maintain genome integrity	ONCOGENE			English	Article							CELL-CYCLE PROGRESSION; DEUBIQUITINATING ENZYMES; MAMMALIAN-CELLS; CANCER; STABILITY; LOCALIZATION; DECATENATION; CHECKPOINT; INHIBITORS; MITOSIS	Ubiquitin-specific protease 15 (USP15) is a widely expressed deubiquitylase that has been implicated in diverse cellular processes in cancer. Here we identify topoisomerase II (TOP2A) as a novel protein that is regulated by USP15. TOP2A accumulates during G2 and functions to decatenate intertwined sister chromatids at prophase, ensuring the replicated genome can be accurately divided into daughter cells at anaphase. We show that USP15 is required for TOP2A accumulation, and that USP15 depletion leads to the formation of anaphase chromosome bridges. These bridges fail to decatenate, and at mitotic exit form micronuclei that are indicative of genome instability. We also describe the cell cycle-dependent behaviour for two major isoforms of USP15, which differ by a short serine-rich insertion that is retained in isoform-1 but not in isoform-2. Although USP15 is predominantly cytoplasmic in interphase, we show that both isoforms move into the nucleus at prophase, but that isoform-1 is phosphorylated on its unique S229 residue at mitotic entry. The micronuclei phenotype we observe on USP15 depletion can be rescued by either USP15 isoform and requires USP15 catalytic activity. Importantly, however, an S229D phospho-mimetic mutant of USP15 isoform-1 cannot rescue either the micronuclei phenotype, or accumulation of TOP2A. Thus, S229 phosphorylation selectively abrogates this role of USP15 in maintaining genome integrity in an isoform-specific manner. Finally, we show that USP15 isoform-1 is preferentially upregulated in a panel of non-small cell lung cancer cell lines, and propose that isoform imbalance may contribute to genome instability in cancer. Our data provide the first example of isoform-specific deubiquitylase phospho-regulation and reveal a novel role for USP15 in guarding genome integrity.	[Fielding, Andrew B.; Concannon, Matthew; Darling, Sarah; Rusilowicz-Jones, Emma V.; Sacco, Joseph J.; Prior, Ian A.; Clague, Michael J.; Urbe, Sylvie; Coulson, Judy M.] Univ Liverpool, Inst Translat Med, Cellular & Mol Physiol, Liverpool, Merseyside, England	University of Liverpool	Coulson, JM (corresponding author), Univ Liverpool, Inst Translat Med, Cellular & Mol Physiol, Liverpool, Merseyside, England.	jcoulson@liverpool.ac.uk	Concannon, Matthew/ABG-5026-2021; Urbe, Sylvie/S-1433-2018; Clague, Michael J/A-7199-2008	Concannon, Matthew/0000-0001-8777-4786; Urbe, Sylvie/0000-0003-4735-9814; Clague, Michael J/0000-0003-3355-9479; Fielding, Andrew/0000-0002-3170-9966; Prior, Ian/0000-0002-4055-5161; Coulson, Judy/0000-0003-2191-2001	North West Cancer Research project [CR942]; Wellcome Trust [099793/Z/12/Z, 096567/Z/11/Z]	North West Cancer Research project; Wellcome Trust(Wellcome TrustEuropean Commission)	The authors are supported by a North West Cancer Research project grant CR942 (ABF) and Wellcome Trust PhD studentships 099793/Z/12/Z (MC), and 096567/Z/11/Z (SD). We acknowledge the contribution of Ruth Owen and Bethan Gay towards experiments using the lung cell panel.	Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; Bower JJ, 2010, ONCOGENE, V29, P4787, DOI 10.1038/onc.2010.232; Broderick R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7572; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen MC, 2011, HEPATOLOGY, V53, P148, DOI 10.1002/hep.23964; Chen T, 2015, ONCOGENE, V34, P4019, DOI 10.1038/onc.2014.332; Clague MJ, 2013, PHYSIOL REV, V93, P1289, DOI 10.1152/physrev.00002.2013; Clague MJ, 2012, J CELL SCI, V125, P277, DOI 10.1242/jcs.090985; Cornelissen T, 2014, HUM MOL GENET, V23, P5227, DOI 10.1093/hmg/ddu244; Darling S, 2017, BIOCHEM SOC T, V45, P1125, DOI 10.1042/BST20170087; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; DOWNES CS, 1991, P NATL ACAD SCI USA, V88, P8895, DOI 10.1073/pnas.88.20.8895; Eichhorn PJA, 2012, NAT MED, V18, P429, DOI 10.1038/nm.2619; Faronato M, 2011, ATLAS GENET CYTOGENE, V15, P645; Faronato M, 2013, CELL CYCLE, V12, P1964, DOI 10.4161/cc.25035; Fenech M, 2011, MUTAGENESIS, V26, P125, DOI 10.1093/mutage/geq052; Fournane Sadek, 2012, Genes Cancer, V3, P697, DOI 10.1177/1947601912473477; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gauthier NP, 2008, NUCLEIC ACIDS RES, V36, pD854, DOI 10.1093/nar/gkm729; GORBSKY GJ, 1994, CANCER RES, V54, P1042; Gowher H, 2012, P NATL ACAD SCI USA, V109, P2370, DOI 10.1073/pnas.1121538109; Grabbe C, 2011, NAT REV MOL CELL BIO, V12, P295, DOI 10.1038/nrm3099; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Guturi KKN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12638; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hayes SD, 2012, J BIOL CHEM, V287, P43007, DOI 10.1074/jbc.M112.386938; Heideker J, 2015, BIOCHEM J, V467, P191, DOI 10.1042/bj4670191; Hetfeld BKJ, 2005, CURR BIOL, V15, P1217, DOI 10.1016/j.cub.2005.05.059; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Huang XH, 2009, J MOL BIOL, V391, P691, DOI 10.1016/j.jmb.2009.06.066; Inui M, 2011, NAT CELL BIOL, V13, P1368, DOI 10.1038/ncb2346; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Kang X, 2015, SCI REP-UK, V5, DOI 10.1038/srep17873; Kessler BM, 2011, CELL BIOCHEM BIOPHYS, V60, P21, DOI 10.1007/s12013-011-9176-6; Kotani Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep44293; Lim KH, 2016, CELL MOL LIFE SCI, V73, P1439, DOI 10.1007/s00018-015-2129-2; Liu HL, 2015, CELL REP, V13, P93, DOI 10.1016/j.celrep.2015.08.056; Liu WT, 2017, ONCOGENE, V36, P2715, DOI 10.1038/onc.2016.424; Long L, 2014, J BIOL CHEM, V289, P8916, DOI 10.1074/jbc.M114.551754; Luo KT, 2009, NAT CELL BIOL, V11, P204, DOI 10.1038/ncb1828; Mattiroli F, 2012, CELL, V150, P1182, DOI 10.1016/j.cell.2012.08.005; Mizuno E, 2007, EXP CELL RES, V313, P3624, DOI 10.1016/j.yexcr.2007.07.028; Moss AC, 2009, CLIN CANCER RES, V15, P274, DOI 10.1158/1078-0432.CCR-08-1163; Mu JJ, 2007, J BIOL CHEM, V282, P17330, DOI 10.1074/jbc.C700079200; Nagasaka K, 2016, NAT CELL BIOL, V18, P692, DOI 10.1038/ncb3353; Naim V, 2009, NAT CELL BIOL, V11, P761, DOI 10.1038/ncb1883; Nielsen CF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9962; Nishi R, 2014, NAT CELL BIOL, V16, P1016, DOI 10.1038/ncb3028; Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475; Pinto-Fernandez A, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00133; Rehman SAA, 2016, MOL CELL, V63, P146, DOI 10.1016/j.molcel.2016.05.009; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Sahtoe DD, 2015, TRENDS BIOCHEM SCI, V40, P456, DOI 10.1016/j.tibs.2015.05.002; Samejima K, 2012, J CELL BIOL, V199, P755, DOI 10.1083/jcb.201202155; Schweitzer K, 2007, EMBO J, V26, P1532, DOI 10.1038/sj.emboj.7601600; Shinagawa H, 2008, ANTIOXID REDOX SIGN, V10, P939, DOI 10.1089/ars.2007.1851; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Srihari S, 2013, BIOINFORMATICS, V29, P1553, DOI 10.1093/bioinformatics/btt191; Thorne C, 2011, TRAFFIC, V12, P1563, DOI 10.1111/j.1600-0854.2011.01261.x; Urbe S, 2012, MOL BIOL CELL, V23, P1095, DOI 10.1091/mbc.E11-08-0668; Vlasschaert C, 2016, SCI REP-UK, V6, DOI 10.1038/srep20039; Vos RM, 2009, J VIROL, V83, P8885, DOI 10.1128/JVI.00605-09; Wagner SA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.013284; Wiltshire TD, 2010, J BIOL CHEM, V285, P14565, DOI 10.1074/jbc.M110.104745; Xu ML, 2009, BIOCHEM BIOPH RES CO, V388, P366, DOI 10.1016/j.bbrc.2009.08.015; Zou Q, 2014, NAT IMMUNOL, V15, P562, DOI 10.1038/ni.2885	67	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2326	2342		10.1038/s41388-017-0092-0	http://dx.doi.org/10.1038/s41388-017-0092-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29429988	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000431100200009
J	Kotani, H; Adachi, Y; Kitai, H; Tomida, S; Bando, H; Faber, AC; Yoshino, T; Voon, DC; Yano, S; Ebi, H				Kotani, Hiroshi; Adachi, Yuta; Kitai, Hidenori; Tomida, Shuta; Bando, Hideaki; Faber, Anthony C.; Yoshino, Takayuki; Voon, Dominic C.; Yano, Seiji; Ebi, Hiromichi			Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers	ONCOGENE			English	Article							MEK INHIBITION; C-RAF; B-RAF; FEEDBACK ACTIVATION; COLORECTAL CANCERS; PHASE-2 TRIAL; OPEN-LABEL; WILD-TYPE; MUTATIONS; SENSITIVITY	BRAF is one of the most frequently mutated genes across a number of different cancers, with the best-characterized mutation being V600E. Despite the successes of treating BRAF mutant V600E lung cancer with BRAF pathway inhibitors, treatment strategies targeting tumors with non-V600E mutations are yet to be established. We studied cellular signaling differences between lung cancers with different BRAF mutations and determined their sensitivities to BRAF pathway inhibitors. Here, we observed that MEK inhibition induced feedback activation of the receptor tyrosine kinase (RTK) EGFR, and in some cases the RTK FGFR, resulting in transient suppression of ERK phosphorylation in BRAF non-V600E, but not BRAF V600E, mutant cells. Furthermore, we found that both EGFR and FGFR activated the MEK/ERK pathway, despite the presence of BRAF non-V600E mutations with elevated kinase activity. Moreover, in BRAF non-V600E mutants with impaired kinase activities, EGFR had even greater control over the MEK/ERK pathway, essentially contributing completely to the tonic mitogen-activated protein kinase (MAPK) signal. Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer. Furthermore, the results were recapitulated with a clinically relevant dual inhibitor of EGFR and RAF, BGB-283. Overall, although BRAF V600E mutant cells are sensitive to BRAF inhibition, non-V600E mutant cancer cells are reliant on RTKs for their MAPK activation and inhibiting both MEK and RTKs are necessary in these cancers. Our findings provide evidence of critical survival signals in BRAF non-V600E mutant cancers, which could pave the way for effective treatment of these cancers.	[Kotani, Hiroshi; Adachi, Yuta; Kitai, Hidenori; Yano, Seiji; Ebi, Hiromichi] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa, Japan; [Tomida, Shuta] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Biobank, Okayama, Japan; [Bando, Hideaki; Yoshino, Takayuki] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Chiba, Japan; [Faber, Anthony C.] Virginia Commonwealth Univ, Sch Dent, VCU Philips Inst Oral Hlth Res, Richmond, VA USA; [Faber, Anthony C.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA; [Voon, Dominic C.; Ebi, Hiromichi] Kanazawa Univ, Inst Frontier Sci Initiat, Kanazawa, Ishikawa, Japan	Kanazawa University; Okayama University; National Cancer Center - Japan; Virginia Commonwealth University; Virginia Commonwealth University; Kanazawa University	Ebi, H (corresponding author), Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa, Japan.; Ebi, H (corresponding author), Kanazawa Univ, Inst Frontier Sci Initiat, Kanazawa, Ishikawa, Japan.	hebi@staff.kanazawa-u.ac.jp	雄太, 足立/N-6838-2019; Ebi, Hiromichi/AAA-7358-2019; Kitai, Hidenori/AAD-4168-2022	Ebi, Hiromichi/0000-0003-3155-7576; Voon, Dominic Chih-Cheng/0000-0002-2963-9305; KITAI, HIDENORI/0000-0001-6372-846X; Kotani, Hiroshi/0000-0002-6001-0636	Japan Society for the Promotion of Science [26830105, 16K07164, 21390256]; Japan Agency for Medical Research and Development [16cm0106513h0001]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	This work is supported by Grants-in-Aid for Scientific Research (H. Ebi, 26830105 and 16K07164; S. Yano, 21390256) from Japan Society for the Promotion of Science, and Grant-in-Aid to Project for Cancer Research and Therapeutics Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (H. Ebi and S. Yano, 16cm0106513h0001). A.C.F. is a George and Lavinia Blick Scholar and a Harrison Endowed Scholar in Cancer Research.	Bates DM, 2012, CLASSES; Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847; Carter J, 2015, AM J CLIN PATHOL, V144, P620, DOI 10.1309/AJCP85ATMJOZOUDJ; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Dahlman KB, 2012, CANCER DISCOV, V2, P791, DOI 10.1158/2159-8290.CD-12-0097; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Langen AJ, 2017, THER ADV MED ONCOL, V9, P46, DOI 10.1177/1758834016670555; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Desai J, 2017, AACR ANN M; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Joshi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118210; Karreth FA, 2011, CANCER DISCOV, V1, P128, DOI 10.1158/2159-8290.CD-10-0044; Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377; Laquerre S, 2009, MOL CANCER THER, V8, DOI 10.1158/1535-7163.TARG-09-B88; Lin LP, 2014, P NATL ACAD SCI USA, V111, pE748, DOI 10.1073/pnas.1320956111; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009; Little AS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001752; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531; Nieto P, 2017, NATURE, V548, P239, DOI 10.1038/nature23297; Noeparast A, 2017, ONCOTARGET, V8, P60094, DOI 10.18632/oncotarget.11635; Okimoto RA, 2016, P NATL ACAD SCI USA, V113, P13456, DOI 10.1073/pnas.1610456113; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223; Tang ZY, 2015, MOL CANCER THER, V14, P2187, DOI 10.1158/1535-7163.MCT-15-0262; Team RC, 2016, LANG ENV STAT COMP; Tu NN, 2015, J THORAC ONCOL, V10, P1396, DOI 10.1097/JTO.0000000000000644; Van Cutsem E, 2015, ANN ONCOL, V26, P149, DOI 10.1093/annonc/mdu496; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Zheng G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1811-y	45	19	21	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1775	1787		10.1038/s41388-017-0035-9	http://dx.doi.org/10.1038/s41388-017-0035-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29348459				2022-12-17	WOS:000428632600007
J	Welcker, D; Jain, M; Khurshid, S; Jokic, M; Hohne, M; Schmitt, A; Frommolt, P; Niessen, CM; Spiro, J; Persigehl, T; Wittersheim, M; Buttner, R; Fanciulli, M; Schermer, B; Reinhardt, HC; Benzing, T; Hopker, K				Welcker, Daniela; Jain, Manaswita; Khurshid, Safiya; Jokic, Mladen; Hoehne, Martin; Schmitt, Anna; Frommolt, Peter; Niessen, Carien M.; Spiro, Judith; Persigehl, Thorsten; Wittersheim, Maike; Buettner, Reinhard; Fanciulli, Maurizio; Schermer, Bernhard; Reinhardt, Hans Christian; Benzing, Thomas; Hoepker, Katja			AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; CELL-CYCLE; RAS ONCOGENES; P53 TRANSCRIPTION; CHK2 KINASES; CHECKPOINT; CHE-1; ATM; PATHWAY; GROWTH	A fundamental principle in malignant tranformation is the ability of cancer cells to escape the naturally occurring cellintrinsic responses to DNA damage. Tumors progress despite the accumulation of DNA lesions. However, the underlying mechanisms of this tolerance to genotoxic stress are still poorly characterized. Here, we show that replication stress occurs in Kras-driven murine lung adenocarcinomas, as well as in proliferating murine embryonic and adult tissues. We identify the transcriptional regulator AATF/CHE-1 as a key molecule to sustain proliferative tissues and tumor progression in parts by inhibiting p53-driven apoptosis in vivo. In an autochthonous Kras-driven lung adenocarcinoma model, deletion of Aatf delayed lung cancer formation predominantly in a p53-dependent manner. Moreover, targeting Aatf in existing tumors through a dual recombinase strategy caused a halt in tumor progression. Taken together, these data suggest that AATF may serve as a drug target to treat KRAS-driven malignancies.	[Welcker, Daniela; Jain, Manaswita; Khurshid, Safiya; Hoehne, Martin; Schmitt, Anna; Schermer, Bernhard; Benzing, Thomas; Hoepker, Katja] Univ Cologne, Dept Internal Med 2, Cologne, Germany; [Welcker, Daniela; Jain, Manaswita; Khurshid, Safiya; Jokic, Mladen; Hoehne, Martin; Frommolt, Peter; Niessen, Carien M.; Schermer, Bernhard; Reinhardt, Hans Christian; Benzing, Thomas; Hoepker, Katja] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany; [Khurshid, Safiya] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Jokic, Mladen; Reinhardt, Hans Christian] Univ Cologne, Dept Internal Med 1, Cologne, Germany; [Jokic, Mladen; Hoehne, Martin; Niessen, Carien M.; Schermer, Bernhard; Reinhardt, Hans Christian; Benzing, Thomas] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany; [Hoehne, Martin; Schermer, Bernhard; Benzing, Thomas] Univ Cologne, Syst Biol Ageing Cologne Sybacol, Cologne, Germany; [Niessen, Carien M.] Univ Cologne, Dept Dermatol, Cologne, Germany; [Spiro, Judith; Persigehl, Thorsten] Univ Cologne, Dept Radiol, Cologne, Germany; [Wittersheim, Maike; Buettner, Reinhard] Univ Cologne, Dept Pathol, Cologne, Germany; [Fanciulli, Maurizio] Regina Elena Inst Canc Res, Translat Res Area, SAFU Lab, Dept Res Adv Diagnost & Technol Innovat, Rome, Italy	University of Cologne; University of Cologne; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Cologne; University of Cologne; University of Cologne; University of Cologne; University of Cologne; University of Cologne; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Benzing, T (corresponding author), Univ Cologne, Dept Internal Med 2, Cologne, Germany.; Reinhardt, HC; Benzing, T (corresponding author), Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany.; Reinhardt, HC (corresponding author), Univ Cologne, Dept Internal Med 1, Cologne, Germany.; Reinhardt, HC; Benzing, T (corresponding author), Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany.; Benzing, T (corresponding author), Univ Cologne, Syst Biol Ageing Cologne Sybacol, Cologne, Germany.	christian.reinhardt@uk-koeln.de; thomas.benzing@uk-koeln.de	Schermer, Bernhard/E-9972-2014; Benzing, Thomas/X-5476-2019; fanciulli, maurizio/ABH-6745-2020; Frommolt, Peter/L-9656-2016	Schermer, Bernhard/0000-0002-5194-9000; Frommolt, Peter/0000-0002-1966-8014; Hohne, Martin/0000-0001-8698-5389; Khurshid, Safiya/0000-0003-1620-3091; Niessen, Carien M./0000-0002-4892-9391; Jain, Manaswita/0000-0002-5107-7505	Volkswagenstiftung; Deutsche Forschungsgemeinschaft [KFO-286, SFB-829, SCHE1562/2, BE2212]; Bundesministerium fur Bildung und Forschung; German federal state North Rhine Westphalia (NRW) as part of the EFRE initiative [LS-1-1-030a]; Else Kroner-Fresenius Stiftung [EKFS-2014-A06]; Deutsche Krebshilfe [111724]; University of Cologne (Koln Fortune Program); Cologne Cardiovascular Research Center (Graduate Program); Cologne Graduate School of Ageing Research; CECAD Research Center Cologne Maternity Leave Fellowship	Volkswagenstiftung(Volkswagen); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); German federal state North Rhine Westphalia (NRW) as part of the EFRE initiative; Else Kroner-Fresenius Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); University of Cologne (Koln Fortune Program); Cologne Cardiovascular Research Center (Graduate Program); Cologne Graduate School of Ageing Research; CECAD Research Center Cologne Maternity Leave Fellowship	This work was supported by Volkswagenstiftung (Lichtenberg Program to HCR), Deutsche Forschungsgemeinschaft (KFO-286 to HCR, SFB-829 to HCR, CN and TB, SCHE1562/2 to BS, BE2212 to TB), Bundesministerium fur Bildung und Forschung (SMOOSE to HCR, SYBACOL to TB), German federal state North Rhine Westphalia (NRW) as part of the EFRE initiative (grant LS-1-1-030a to HCR), Else Kroner-Fresenius Stiftung (EKFS-2014-A06 to HCR), Deutsche Krebshilfe (111724, HCR), University of Cologne (Koln Fortune Program to KH), Cologne Cardiovascular Research Center (Graduate Program to MJ), Cologne Graduate School of Ageing Research (to SK), CECAD Research Center Cologne Maternity Leave Fellowship to DW.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahuja AK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10660; Bacalini MG, 2012, EXP HEMATOL, V40, P197, DOI 10.1016/j.exphem.2011.11.005; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; Bruno T, 2008, CELL DEATH DIFFER, V15, P515, DOI 10.1038/sj.cdd.4402284; Bruno T, 2002, CANCER CELL, V2, P387, DOI 10.1016/S1535-6108(02)00182-4; Bruno T, 2006, CANCER CELL, V10, P473, DOI 10.1016/j.ccr.2006.10.012; Bruno T, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00034; Bruno T, 2010, CANCER CELL, V18, P122, DOI 10.1016/j.ccr.2010.05.027; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; De Nicola F, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.381; Desantis A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.117; Desantis A, 2015, EMBO J, V34, P1214, DOI 10.15252/embj.201489920; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dietlein F, 2015, CELL, V162, P146, DOI 10.1016/j.cell.2015.05.053; Dobbelstein M, 2015, NAT REV DRUG DISCOV, V14, P405, DOI 10.1038/nrd4553; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Durkin M.E., 2013, BIOPROTOC, V3, pE908, DOI DOI 10.21769/BioProtoc.908; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Fikaris AJ, 2006, J BIOL CHEM, V281, P34759, DOI 10.1074/jbc.M606737200; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Grabocka E, 2015, CLIN CANCER RES, V21, P1243, DOI 10.1158/1078-0432.CCR-14-0650; Guo Q, 2004, J BIOL CHEM, V279, P4596, DOI 10.1074/jbc.M309811200; Hafner M, 2004, GENESIS, V38, P176, DOI 10.1002/gene.20016; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hopker K, 2012, CELL CYCLE, V11, P4122, DOI 10.4161/cc.21997; Hopker K, 2012, EMBO J, V31, P3961, DOI 10.1038/emboj.2012.236; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Jokic M, 2016, MOL CANCER RES, V14, P1110, DOI 10.1158/1541-7786.MCR-16-0094; Justilien V, 2017, CANCER CELL, V31, P256, DOI 10.1016/j.ccell.2016.12.010; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kaul D, 2007, INDIAN J BIOCHEM BIO, V44, P276; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Marino S, 2000, GENE DEV, V14, P994; Maya-Mendoza A, 2015, MOL ONCOL, V9, P601, DOI 10.1016/j.molonc.2014.11.001; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Ollion J, 2013, BIOINFORMATICS, V29, P1840, DOI 10.1093/bioinformatics/btt276; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Raman M, 2007, EMBO J, V26, P2005, DOI 10.1038/sj.emboj.7601668; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2013, NAT REV MOL CELL BIO, V14, P563, DOI 10.1038/nrm3640; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmitt A, 2017, CANCER RES, V77, P3040, DOI 10.1158/0008-5472.CAN-16-3398; Schonhuber N, 2014, NAT MED, V20, P1340, DOI 10.1038/nm.3646; Seidel D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006802; Shaltiel IA, 2015, J CELL SCI, V128, P607, DOI 10.1242/jcs.163766; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Thomas T, 2000, DEV BIOL, V227, P324, DOI 10.1006/dbio.2000.9915; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tubbs A, 2017, CELL; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Xie J, 2004, NEUROBIOL DIS, V16, P150, DOI 10.1016/j.nbd.2004.02.003	65	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1503	1518		10.1038/s41388-017-0054-6	http://dx.doi.org/10.1038/s41388-017-0054-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321668				2022-12-17	WOS:000427459500008
J	Li, Y; Zhao, M; Guo, C; Chu, H; Li, W; Chen, X; Wang, X; Li, Y; Jia, Y; Koussatidjoa, S; Zhu, F; Wang, J; Wang, X; Wang, Q; Zhao, W; Shi, Y; Chen, W; Zhang, L				Li, Y.; Zhao, M.; Guo, C.; Chu, H.; Li, W.; Chen, X.; Wang, X.; Li, Y.; Jia, Y.; Koussatidjoa, S.; Zhu, F.; Wang, J.; Wang, X.; Wang, Q.; Zhao, W.; Shi, Y.; Chen, W.; Zhang, L.			Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RHO GTPASES; HEPATOCELLULAR-CARCINOMA; INNATE INFLAMMATION; CYTOKINE PRODUCTION; POLYBASIC REGION; CANCER CELLS; LUNG-CANCER; IN-VIVO; INTERLEUKIN-37	IL-37, a newly found anti-inflammatory cytokine of the IL-1 family, has both extracellular and intracellular functions. Accumulating evidences indicate that it is also involved in tumor progression. However, the mechanism and its intracellular target are unclear. In this study, clinical data from 84 patients showed that loss or reduced expression of IL-37 in lung adenocarcinoma tissues was significantly associated with tumor metastasis. We further provided evidence that IL-37 inhibited effectively tumor metastasis in vitro and in vivo. Moreover, we uncovered a novel mechanism by which IL-37 suppressed tumor cell migration via its intracellular mature form (amino acids 46-218). Intracellular mature form of IL-37, but not its extracellular form, markedly inhibited migration of multiple kinds of tumor cells through inhibiting Rac1 activation. Mechanistically, intracellular mature IL-37 directly bound to the CAAX motif in the C-terminal hypervariable region of Rac1, and then inhibited Rac1 membrane translocation and subsequent downstream signaling. Our research identifies intracellular mature IL-37 as a novel endogenous inhibitor of Rac1. Given the crucial roles of Rac1 in tumor angiogenesis and metastasis, intracellular mature IL-37 might serve as a potential strategy for the control of Rac1 activity and tumor progression.	[Li, Y.; Zhao, M.; Guo, C.; Chu, H.; Li, W.; Chen, X.; Wang, X.; Li, Y.; Jia, Y.; Koussatidjoa, S.; Zhu, F.; Wang, J.; Wang, X.; Wang, Q.; Zhao, W.; Shi, Y.; Zhang, L.] Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Li, Y.; Zhao, M.; Guo, C.; Chu, H.; Li, W.; Chen, X.; Wang, X.; Li, Y.; Jia, Y.; Koussatidjoa, S.; Zhu, F.; Wang, J.; Wang, X.; Wang, Q.; Zhao, W.; Shi, Y.; Zhang, L.] Shandong Univ, Sch Basic Med Sci, Key Lab Infect & Immun Shandong Prov, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Chen, W.] NIDCR, Mucosal Immunol Sect, NIH, Bethesda, MD USA	Shandong University; Shandong University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Zhang, L (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Zhang, L (corresponding author), Shandong Univ, Sch Basic Med Sci, Key Lab Infect & Immun Shandong Prov, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	zhanglining@sdu.edu.cn		Zhao, Wei/0000-0001-8440-2274	national key research and development plan of China [2016YFC1303405]; National Natural Science Foundation of China [31470856, 91439124]; Shandong Provincial Natural Science Foundation, China [2014GSF118076, ZR2011HZ003]; Fundamental Research Funds of Shandong University [2014QY004]; Major Project of Science and Technology of Shandong Province [2015ZDJS04001]; NIH, NIDCR, USA	national key research and development plan of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation, China(Natural Science Foundation of Shandong Province); Fundamental Research Funds of Shandong University; Major Project of Science and Technology of Shandong Province; NIH, NIDCR, USA	This research is supported by the national key research and development plan of China (No. 2016YFC1303405), the National Natural Science Foundation of China (31470856 and 91439124), Shandong Provincial Natural Science Foundation, China (2014GSF118076, ZR2011HZ003), the Fundamental Research Funds of Shandong University (2014QY004) and Major Project of Science and Technology of Shandong Province (2015ZDJS04001). WC is supported by the Intramural Research Program of NIH, NIDCR, USA.	Abulkhir A, 2017, J LEUKOCYTE BIOL, V101, P395, DOI 10.1189/jlb.5RU0816-341R; Ballak DB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5711; Boraschi D, 2011, EUR CYTOKINE NETW, V22, P127, DOI 10.1684/ecn.2011.0288; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Bulau AM, 2014, P NATL ACAD SCI USA, V111, P2650, DOI 10.1073/pnas.1324140111; Bulau AM, 2011, THESCIENTIFICWORLDJO, V11, P2480, DOI 10.1100/2011/968479; Busfield SJ, 2000, GENOMICS, V66, P213, DOI 10.1006/geno.2000.6184; Cao XL, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-149; Chai M, 2015, J INTERF CYTOK RES, V35, P530, DOI 10.1089/jir.2014.0212; Chen QY, 2011, INT J MOL MED, V28, P769, DOI 10.3892/ijmm.2011.775; Chen YH, 2016, ONCOL REP, V36, P2017, DOI 10.3892/or.2016.4995; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Cherfils J, 2011, NAT CHEM BIOL, V7, P493, DOI 10.1038/nchembio.608; Coll-Miro M, 2016, P NATL ACAD SCI USA, V113, P1411, DOI 10.1073/pnas.1523212113; Dinarello CA, 2016, EUR J IMMUNOL, V46, P1067, DOI 10.1002/eji.201545828; Fang D, 2017, ONCOGENE, V36, P1546, DOI 10.1038/onc.2016.323; Gao JH, 2009, AM J TRANSL RES, V1, P312; Gao WT, 2003, J IMMUNOL, V170, P107, DOI 10.4049/jimmunol.170.1.107; Ge GQ, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0293-3; Karnoub AE, 2004, BREAST CANCER RES TR, V84, P61, DOI 10.1023/B:BREA.0000018427.84929.5c; Kreis P, 2009, CELL SIGNAL, V21, P384, DOI 10.1016/j.cellsig.2008.11.001; Kumar S, 2000, J BIOL CHEM, V275, P10308, DOI 10.1074/jbc.275.14.10308; Kumar S, 2002, CYTOKINE, V18, P61, DOI 10.1006/cyto.2002.0873; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; Li SZ, 2015, P NATL ACAD SCI USA, V112, P2497, DOI 10.1073/pnas.1424626112; Li ZQ, 2016, ONCOTARGET, V7, P62224, DOI 10.18632/oncotarget.11406; Lin Y, 2015, EXPERT OPIN DRUG DIS, V10, P991, DOI 10.1517/17460441.2015.1058775; Liu R, 2016, ONCOTARGET, V7, P85079, DOI 10.18632/oncotarget.13196; Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240; Lunding L, 2015, ALLERGY, V70, P366, DOI 10.1111/all.12566; Luo YC, 2014, P NATL ACAD SCI USA, V111, P15178, DOI 10.1073/pnas.1416714111; McNamee EN, 2011, P NATL ACAD SCI USA, V108, P16711, DOI 10.1073/pnas.1111982108; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Modha R, 2008, J BIOL CHEM, V283, P1492, DOI 10.1074/jbc.M706760200; Moretti S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004462; Nold MF, 2010, NAT IMMUNOL, V11, P1014, DOI 10.1038/ni.1944; Nold-Petry CA, 2015, NAT IMMUNOL, V16, P354, DOI 10.1038/ni.3103; Quirk S, 2014, EXPERT REV CLIN IMMU, V10, P1703, DOI 10.1586/1744666X.2014.971014; Rathinam R, 2011, FRONT BIOSCI-LANDMRK, V16, P2561, DOI 10.2741/3872; Schaefer Antje, 2014, Small GTPases, V5, P6, DOI 10.4161/21541248.2014.968004; Smithers CC, 2016, CELLS, V5, P2; Teng X, 2014, J IMMUNOL, V192, P1815, DOI 10.4049/jimmunol.1300047; Wang CQ, 2016, AM J CANCER RES, V6, P1873; Wang S, 2015, J CANCER, V6, P962, DOI 10.7150/jca.12266; Wang ZJ, 2012, P NATL ACAD SCI USA, V109, P15413, DOI 10.1073/pnas.1204525109; Wittinghofer A, 2011, ANNU REV BIOCHEM, V80, P943, DOI 10.1146/annurev-biochem-062708-134043; Wu B, 2014, CLIN EXP IMMUNOL, V176, P438, DOI 10.1111/cei.12284; Yan XF, 2017, ONCOTARGET, V8, P49064, DOI 10.18632/oncotarget.17093; Ye L, 2015, J IMMUNOL, V194, P5110, DOI 10.4049/jimmunol.1401810; Ye L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-69; Zhao JJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep05177; Zou T, 2017, CLIN GENET, V91, P520, DOI 10.1111/cge.12908	52	19	19	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1095	1106		10.1038/onc.2017.405	http://dx.doi.org/10.1038/onc.2017.405			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106392				2022-12-17	WOS:000425905700012
J	Mett, V; Komarova, EA; Greene, K; Bespalov, I; Brackett, C; Gillard, B; Gleiberman, AS; Toshkov, IA; Aygun-Sunar, S; Johnson, C; Karasik, E; Bapardekar-Nair, M; Kurnasov, OV; Osterman, AL; Stanhope-Baker, PS; Morrison, C; Moser, MT; Foster, BA; Gudkov, AV				Mett, V; Komarova, E. A.; Greene, K.; Bespalov, I; Brackett, C.; Gillard, B.; Gleiberman, A. S.; Toshkov, I. A.; Aygun-Sunar, S.; Johnson, C.; Karasik, E.; Bapardekar-Nair, M.; Kurnasov, O., V; Osterman, A. L.; Stanhope-Baker, P. S.; Morrison, C.; Moser, M. T.; Foster, B. A.; Gudkov, A., V			Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy	ONCOGENE			English	Article							RESISTANT PROSTATE-CANCER; TRANSGENIC MOUSE MODEL; ANTITUMOR IMMUNITY; HEPATIC METASTASES; CTLA-4 BLOCKADE; GENE-THERAPY; MURINE MODEL; FLAGELLIN; MELANOMA; AGONIST	Toll-like receptor 5 (TLR5) is considered an attractive target for anticancer immunotherapy. TLR5 agonists, bacterial flagellin and engineered flagellin derivatives, have been shown to have potent antitumor and metastasis-suppressive effects in multiple animal models and to be safe in both animals and humans. Anticancer efficacy of TLR5 agonists stems from TLR5-dependent activation of nuclear factor-kappa B (NF-kappa B) that mediates innate and adaptive antitumor immune responses. To extend application of TLR5-targeted anticancer immunotherapy to tumors that do not naturally express TLR5, we created an adenovirus-based vector for intratumor delivery, named Mobilan that drives expression of self-activating TLR5 signaling cassette comprising of human TLR5 and a secreted derivative of Salmonella flagellin structurally analogous to a clinical stage TLR5 agonist, entolimod. Co-expression of TLR5 receptor and agonist in Mobilan-infected cells established an autocrine/paracrine TLR5 signaling loop resulting in constitutive activation of NF-kappa B both in vitro and in vivo. Injection of Mobilan into primary tumors of the prostate cancer-prone transgenic adenocarcinoma of the mouse prostate (TRAMP) mice resulted in a strong induction of multiple genes involved in inflammatory responses and mobilization of innate immune cells into the tumors including neutrophils and NK cells and suppressed tumor progression. Intratumoral injection of Mobilan into subcutaneously growing syngeneic prostate tumors in immunocompetent hosts improved animal survival after surgical resection of the tumors, by suppression of tumor metastasis. In addition, vaccination of mice with irradiated Mobilan-transduced prostate tumor cells protected mice against subsequent tumor challenge. These results provide proof-of-concept for Mobilan as a tool for antitumor vaccination that directs TLR5-mediated immune response toward cancer cells and does not require identification of tumor antigens.	[Mett, V; Bespalov, I; Gleiberman, A. S.; Toshkov, I. A.; Aygun-Sunar, S.; Bapardekar-Nair, M.; Stanhope-Baker, P. S.; Gudkov, A., V] Cleveland Biolabs Inc, Buffalo, NY USA; [Komarova, E. A.; Greene, K.; Brackett, C.; Johnson, C.; Gudkov, A., V] Roswell Pk Canc Inst, Dept Cell Stress Biol, CGP L3-310,Elm & Carlton St, Buffalo, NY 14263 USA; [Gillard, B.; Karasik, E.; Moser, M. T.; Foster, B. A.] Roswell Pk Canc Inst, Dept Mol Pharmacol & Canc Therapeut, Buffalo, NY 14263 USA; [Kurnasov, O., V; Osterman, A. L.] Sanford Burnham Prebys Med Discovery Inst, Infect & Inflammatory Dis Ctr, La Jolla, CA USA; [Morrison, C.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Sanford Burnham Prebys Medical Discovery Institute; Roswell Park Cancer Institute	Gudkov, AV (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, CGP L3-310,Elm & Carlton St, Buffalo, NY 14263 USA.	andrei.gudkov@roswellpark.org		gleiberman, anatoli/0000-0001-8491-0826	Panacela Labs, LLC; National Cancer Institute (NCI) Cancer Center Core Grant [P30CA016056]; DOD the Roswell Park Alliance Foundation [BC140507]; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	Panacela Labs, LLC; National Cancer Institute (NCI) Cancer Center Core Grant; DOD the Roswell Park Alliance Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Cellecta, Inc. and O.D.260, Inc. help with for adenoviral vector construction and manufacturing. This work was supported by contract from Panacela Labs (a biotech company that possesses intellectual property rights for Mobilan), LLC, National Cancer Institute (NCI) Cancer Center Core Grant P30CA016056 and by grants from DOD (BC140507 to AVG) the Roswell Park Alliance Foundation to EAK and AVG.	Akira S, 2004, CR BIOL, V327, P581, DOI 10.1016/j.crvi.2004.04.002; Arlen PM, 2007, J UROLOGY, V178, P1515, DOI 10.1016/j.juro.2007.05.117; Brackett CM, 2016, P NATL ACAD SCI USA, V113, pE874, DOI 10.1073/pnas.1521359113; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Burdelya LG, 2008, SCIENCE, V320, P226, DOI 10.1126/science.1154986; Burdelya LG, 2013, P NATL ACAD SCI USA, V110, pE1857, DOI 10.1073/pnas.1222805110; Burdelya LG, 2012, INT J RADIAT ONCOL, V83, P228, DOI 10.1016/j.ijrobp.2011.05.055; Cai ZY, 2011, CANCER RES, V71, P2466, DOI 10.1158/0008-5472.CAN-10-1993; Carvalho FA, 2011, MUCOSAL IMMUNOL, V4, P102, DOI 10.1038/mi.2010.57; Cuadros C, 2004, INFECT IMMUN, V72, P2810, DOI 10.1128/IAI.72.5.2810-2816.2004; de Melo FM, 2015, IMMUNOL CELL BIOL, V93, P86, DOI 10.1038/icb.2014.74; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Eaves-Pyles TD, 2001, J IMMUNOL, V167, P7009, DOI 10.4049/jimmunol.167.12.7009; Faham A, 2010, J IMMUNOL, V185, P1744, DOI 10.4049/jimmunol.1000027; Fernandez-Garcia EM, 2015, CLIN TRANSL ONCOL, V17, P339, DOI 10.1007/s12094-014-1259-6; Forde PM, 2013, ONCOLOGIST, V18, P1203, DOI 10.1634/theoncologist.2013-0171; Foster BA, 1997, CANCER RES, V57, P3325; Fougere-Deschatrette C, 2006, STEM CELLS, V24, P2098, DOI 10.1634/stemcells.2006-0009; Galli R, 2010, J IMMUNOL, V184, P6658, DOI 10.4049/jimmunol.0902401; Garaude J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002868; Gingrich JR, 1996, TOXICOL PATHOL, V24, P502, DOI 10.1177/019262339602400414; Glavan TM, 2014, CURR PHARM DESIGN, V20, P6555, DOI 10.2174/1381612820666140826153347; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gupta S, 2000, CANCER RES, V60, P5125; Hemmi S, 1998, HUM GENE THER, V9, P2363, DOI 10.1089/hum.1998.9.16-2363; Hurwitz AA, 2000, CANCER RES, V60, P2444; Kaczanowska S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1076609; Kaczanowska S, 2013, J LEUKOCYTE BIOL, V93, P847, DOI 10.1189/jlb.1012501; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Krivokrysenko VI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135388; Kwon ED, 1999, P NATL ACAD SCI USA, V96, P15074, DOI 10.1073/pnas.96.26.15074; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Lee SE, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1081328; Leigh ND, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085587; Lubaroff DM, 2009, CLIN CANCER RES, V15, P7375, DOI 10.1158/1078-0432.CCR-09-1910; Mamalis A, 2014, ARCH DERMATOL RES, V306, P511, DOI 10.1007/s00403-014-1457-7; Marini FC, 2000, CANCER GENE THER, V7, P816, DOI 10.1038/sj.cgt.7700174; Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165; Mentor-Marcel R, 2001, CANCER RES, V61, P6777; Meyer T, 2008, EXPERT OPIN INV DRUG, V17, P1051, DOI [10.1517/13543784.17.7.1051, 10.1517/13543784.17.7.1051 ]; Michael A, 2005, CLIN CANCER RES, V11, P4469, DOI 10.1158/1078-0432.CCR-04-2337; Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156; Ott PA, 2013, CLIN CANCER RES, V19, P5300, DOI 10.1158/1078-0432.CCR-13-0143; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patil SA, 2014, GLYCOCONJUGATE J, V31, P509, DOI 10.1007/s10719-014-9548-4; Rauen KA, 2002, CANCER RES, V62, P3812; Rhee SH, 2008, GASTROENTEROLOGY, V135, P518, DOI 10.1053/j.gastro.2008.04.022; Rhee SH, 2011, J NEUROGASTROENTEROL, V17, P28, DOI 10.5056/jnm.2011.17.1.28; Rodriguez GM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1151593; Sfondrini L, 2006, J IMMUNOL, V176, P6624, DOI 10.4049/jimmunol.176.11.6624; Shi YF, 2006, CELL RES, V16, P126, DOI 10.1038/sj.cr.7310017; Simons JW, 2006, UROL ONCOL-SEMIN ORI, V24, P419, DOI 10.1016/j.urolonc.2005.08.021; Soto LJ, 2003, J PEDIATR SURG, V38, P1075, DOI 10.1016/S0022-3468(03)00196-9; Sullivan RJ, 2013, CLIN CANCER RES, V19, P5283, DOI 10.1158/1078-0432.CCR-13-2151; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tosch C, 2009, CANCER GENE THER, V16, P310, DOI 10.1038/cgt.2008.85; Vijay-Kumar M, 2010, EUR J IMMUNOL, V40, P3528, DOI 10.1002/eji.201040421; Yam C, 2010, J SURG RES, V164, P248, DOI 10.1016/j.jss.2009.02.023; Yang H, 2016, ONCOTARGET, V7, P2936, DOI 10.18632/oncotarget.6500; Yoon SI, 2012, SCIENCE, V335, P859, DOI 10.1126/science.1215584; Yu XF, 2013, CANCER RES, V73, P2093, DOI 10.1158/0008-5472.CAN-12-1740	63	19	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					439	449		10.1038/onc.2017.346	http://dx.doi.org/10.1038/onc.2017.346			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967901	Green Published, hybrid			2022-12-17	WOS:000423331600003
J	Fu, LN; Wang, YQ; Tan, J; Xu, J; Gao, QY; Chen, YX; Fang, JY				Fu, L-N; Wang, Y-Q; Tan, J.; Xu, J.; Gao, Q-Y; Chen, Y-X; Fang, J-Y			Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms	ONCOGENE			English	Article							HISTONE DEMETHYLATION; RAS-ERK; PROTEIN; DEPRIVATION; GENE; PHOSPHORYLATION; EXPRESSION; STABILITY; PATHWAY; STRESS	Metabolic stress is a common phenomenon in solid tumors. Compensatory mechanisms to overcome metabolic stress (glucose deprivation) are vital to tumor cell survival. The histone demethylase Jumonji domain-containing protein 2B (JMJD2B) is vital for the growth and progression of various cancers. However, the role of JMJD2B during glucose deprivation remains unclear. Our aim was to examine the function of JMJD2B in glucose-deprived colon cancer cells and the involvement of extracellular signal-regulated kinase (ERK) and glucose transporter 1 (GLUT1). Our study demonstrated that JMJD2B expression was upregulated via ERK phosphorylation during glucose deprivation. Further, the cell viability assay showed that the effect of p-ERK on the viability of colon cancer cells was at least partly dependent on JMJD2B expression. Glucose deprivation increased interaction between JMJD2B and p-ERK, as demonstrated by the co-immunoprecipitation and fluorescence assays. Glucose deprivation also resulted in phosphorylation of JMJD2B by p-ERK, as shown by the immunoprecipitation assay and western blotting analysis. In addition, the phosphorylation of JMJD2B via p-ERK at Thr305, Ser352, Ser566 and Thr1065 contribute to JMJD2B stability. p-ERK stabilizes the JMJD2B protein level by protecting JMJD2B from ubiquitination and proteasome degradation. We found that knockdown of JMJD2B significantly impaired colon cancer cell viability, which is accompanied by a significant reduction in glucose uptake and lactate production. Furthermore, knockdown of JMJD2B after glucose deprivation caused decreased level of GLUT1 through increasing H3K9 tri-methylation levels on its promoter, demonstrated by chromatin immunoprecipitation assay. Moreover, targeting JMJD2B in xenograft tumors also decreased the GLUT1 level. Finally, a positive correlation was observed between p-ERK, JMJD2B and GLUT1 expression in 85 human colon cancer tissue specimens. These results indicated that p-ERK-mediated phosphorylation and stabilization of JMJD2B during glucose deprivation contributes to its role in glucose uptake and cell viability, which may be modulated through epigenetically upregulation of GLUT1.	Minist Hlth, State Key Lab Oncogenes & Related Genes, Div Gastroenterol & Hepatol, Key Lab Gastroenterol & Hepatol, Shanghai, Peoples R China; Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Inst Digest Dis, Shanghai, Peoples R China	Shanghai Jiao Tong University	Chen, YX (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes,Minist Hl, Key Lab Gastroenterol & Hepatol,Sch Med,Shanghai, Div Gastroenterol & Hepatol,Renji Hosp,Renji Hosp, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.	yingxuanchen71@sjtu.edu.cn			National Key Technology RD Program [2014BAI09B05]; National Natural Science Foundation of China [81572303, 81302085, 81530072]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine [20152210]; Program of Shanghai Academic/Technology Research Leader [15XD1502600]	National Key Technology RD Program(National Key Technology R&D Program); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine; Program of Shanghai Academic/Technology Research Leader	This project was supported by the National Key Technology R&D Program (No. 2014BAI09B05), the National Natural Science Foundation of China (No. 81572303 to CYX, No. 81302085 to GQY and No. 81530072 to FJY), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20152210) & Program of Shanghai Academic/Technology Research Leader (No. 15XD1502600).	Badeaux AI, 2013, NAT REV MOL CELL BIO, V14, P211, DOI 10.1038/nrm3545; Baek SH, 2011, MOL CELL, V42, P274, DOI 10.1016/j.molcel.2011.03.022; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Calvo MB, 2010, INT J ENDOCRINOL, V2010, DOI 10.1155/2010/205357; Bramanti V, 2016, J NEUROSCI RES, V94, P90, DOI 10.1002/jnr.23678; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen L, 2014, BRIT J CANCER, V110, P1014, DOI 10.1038/bjc.2013.808; Chen XQ, 2005, J NEUROSCI RES, V79, P798, DOI 10.1002/jnr.20396; Cheng MB, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1002026; Ciccarelli R, 2007, MOL PHARMACOL, V71, P1369, DOI 10.1124/mol.106.031617; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Eckert A, 2008, ONCOGENE, V27, P1155, DOI 10.1038/sj.onc.1210732; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; Fu LN, 2012, CARCINOGENESIS, V33, P1664, DOI 10.1093/carcin/bgs217; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Graham NA, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.20; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Hong J, 2011, CANCER RES, V71, P3980, DOI 10.1158/0008-5472.CAN-10-2914; Huang C, 2015, ONCOL REP, V33, P875, DOI 10.3892/or.2014.3655; Ipenberg I, 2013, J BIOL CHEM, V288, P14681, DOI 10.1074/jbc.C113.462770; Katoh M, 2004, INT J ONCOL, V24, P1623; Kawazu M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017830; Kim MO, 2012, NAT STRUCT MOL BIOL, V19, P283, DOI 10.1038/nsmb.2217; Kim SH, 2014, STEM CELL RES, V13, P1, DOI 10.1016/j.scr.2014.04.001; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Liang CY, 2011, NUCLEIC ACIDS RES, V39, P4151, DOI 10.1093/nar/gkr040; Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028; Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166; Madak-Erdogan Z, 2011, MOL CELL BIOL, V31, P226, DOI 10.1128/MCB.00821-10; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Mayya V, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000007; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Toyokawa G, 2011, CANCER PREV RES, V4, P2051, DOI 10.1158/1940-6207.CAPR-11-0290; Traves PG, 2012, J IMMUNOL, V188, P1402, DOI 10.4049/jimmunol.1101781; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Whitmarsh AJ, 2007, BBA-MOL CELL RES, V1773, P1285, DOI 10.1016/j.bbamcr.2006.11.011; Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035; Yamashita M, 2005, J BIOL CHEM, V280, P29409, DOI 10.1074/jbc.M502333200; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254	52	19	20	4	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					389	402		10.1038/onc.2017.345	http://dx.doi.org/10.1038/onc.2017.345			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945223				2022-12-17	WOS:000422753900011
J	Xie, X; Guo, P; Yu, H; Wang, Y; Chen, G				Xie, X.; Guo, P.; Yu, H.; Wang, Y.; Chen, G.			Ribosomal proteins: insight into molecular roles and functions in hepatocellular carcinoma	ONCOGENE			English	Review							GASTRIC-CANCER CELLS; VIRUS-X PROTEIN; PROGNOSTIC MARKER; COLORECTAL-CANCER; SIGNALING PATHWAY; RACK1 PROMOTES; IN-VITRO; MITOCHONDRIAL RIBOSOME; CELLULAR PROLIFERATION; MULTIDRUG-RESISTANCE	Ribosomes, which are important sites for the synthesis of proteins related to expression and transmission of genetic information in humans, have a complex structure and diverse functions. They consist of a variety of ribosomal proteins (RPs), ribosomal RNAs (rRNAs) and small nucleolar RNAs. Owing to the involvement of ribosomes in many important biological processes of cells, their major components, rRNAs and RPs, have an important role in human diseases, including the initiation and evolvement of malignancies. However, the main mechanisms underlying the involvement of ribosomes in cancer remain unclear. This review describes the crucial role of ribosomes in various common malignant tumors; in particular, it examines the effects of RPs, including S6, the receptor for activated C-kinase and RPS15A, on the development and progression of hepatocellular carcinoma.	[Xie, X.; Guo, P.; Yu, H.; Chen, G.] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, 453 Dist, Wenzhou 325000, Zhejiang, Peoples R China; [Wang, Y.] Wenzhou Med Univ, Sch Publ Hlth & Management, Res Ctr Evidence Based Med & Clin Epidemiol, Wenzhou, Peoples R China	Wenzhou Medical University; Wenzhou Medical University	Chen, G (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, 453 Dist, Wenzhou 325000, Zhejiang, Peoples R China.	cg_2188@hotmail.com			Natural Science Foundation of Zhejiang Province [LY17H160047]; National Natural Science Foundation of China [81201953, 81772628, 81703310]; Research Found for the Doctoral Program of High Education of China from the Ministry of Education [20113321120003]	Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Found for the Doctoral Program of High Education of China from the Ministry of Education	This work was supported by the grants from the Natural Science Foundation of Zhejiang Province (LY17H160047), the National Natural Science Foundation of China (81201953, 81772628, 81703310) and the Research Found for the Doctoral Program of High Education of China from the Ministry of Education (20113321120003).	Ahuja R, 2015, BBA-MOL CELL RES, V1853, P1783, DOI 10.1016/j.bbamcr.2015.04.012; Akiyama N, 2000, MOL CELL BIOL, V20, P3266, DOI 10.1128/MCB.20.9.3266-3273.2000; Baba HA, 2009, LIVER INT, V29, P399, DOI 10.1111/j.1478-3231.2008.01798.x; Bee A, 2006, CLIN CANCER RES, V12, P2061, DOI 10.1158/1078-0432.CCR-05-2445; Bee A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022672; Ben-Shem A, 2011, SCIENCE, V334, P1524, DOI 10.1126/science.1212642; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Brar GA, 2015, NAT REV MOL CELL BIO, V16, P651, DOI 10.1038/nrm4069; Bruno PM, 2017, NAT MED, V23, P461, DOI 10.1038/nm.4291; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Chan MWY, 2005, CLIN CANCER RES, V11, P7376, DOI 10.1158/1078-0432.CCR-05-1100; Chen JW, 2016, INT J ONCOL, V48, P1628, DOI 10.3892/ijo.2016.3366; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Da Costa L, 2003, BLOOD, V101, P318, DOI 10.1182/blood-2002-04-1131; Danilova N, 2015, DIS MODEL MECH, V8, P1013, DOI 10.1242/dmm.020529; Desai N, 2017, SCIENCE, V355, P528, DOI 10.1126/science.aal2415; Donati G, 2011, ONCOGENE, V30, P3274, DOI 10.1038/onc.2011.48; Donati G, 2012, CANCER RES, V72, P1602, DOI 10.1158/0008-5472.CAN-11-3992; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Du JP, 2005, CANCER BIOL THER, V4, P242; Fatima G, 2012, J GEN VIROL, V93, P706, DOI 10.1099/vir.0.035691-0; Fumagalli S, 2011, SEMIN HEMATOL, V48, P97, DOI 10.1053/j.seminhematol.2011.02.004; Gentilella A, 2015, BBA-GENE REGUL MECH, V1849, P812, DOI 10.1016/j.bbagrm.2015.02.005; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Gruschke S, 2010, BIOESSAYS, V32, P1050, DOI 10.1002/bies.201000081; Guo XY, 2011, J CELL MOL MED, V15, P296, DOI 10.1111/j.1582-4934.2009.00969.x; Guo YY, 2013, HEPATOLOGY, V57, P140, DOI 10.1002/hep.25978; Hagner PR, 2011, ONCOGENE, V30, P1531, DOI 10.1038/onc.2010.533; He H, 2007, ONCOGENE, V26, P2707, DOI 10.1038/sj.onc.1210073; Hegde V, 2004, BIOCHEMISTRY-US, V43, P14211, DOI 10.1021/bi049234b; Hinnebusch AG, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011544; Huang CJ, 2008, J CELL MOL MED, V12, P1936, DOI 10.1111/j.1582-4934.2008.00253.x; Huang CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067043; Iadevaia V, 2014, SEMIN CELL DEV BIOL, V36, P113, DOI 10.1016/j.semcdb.2014.08.004; Jang CY, 2004, FEBS LETT, V560, P81, DOI 10.1016/S0014-5793(04)00074-2; Jimenez L, 2004, PARASITOL RES, V92, P414, DOI 10.1007/s00436-003-1021-4; Kasai H, 2003, J HISTOCHEM CYTOCHEM, V51, P567, DOI 10.1177/002215540305100502; Khatter H, 2015, NATURE, V520, P640, DOI 10.1038/nature14427; KIM J, 1995, J BIOL CHEM, V270, P13620, DOI 10.1074/jbc.270.23.13620; Kim JH, 2004, HEPATOLOGY, V39, P129, DOI 10.1002/hep.20017; Kim SH, 2013, MODERN PATHOL, V26, P327, DOI 10.1038/modpathol.2012.161; Kobayashi T, 2006, INT J MOL MED, V18, P161; Kowalczyk P, 2002, ACTA BIOCHIM POL, V49, P615; LAVOIE C, 1994, J BIOL CHEM, V269, P14625; Leung THY, 2010, LIVER INT, V30, P1315, DOI 10.1111/j.1478-3231.2010.02307.x; Li CD, 2012, MOL CELL BIOCHEM, V370, P127, DOI 10.1007/s11010-012-1404-x; Li W, 2008, ONCOL REP, V20, P713, DOI 10.3892/or_00000064; Lian ZR, 2004, MOL CARCINOGEN, V40, P34, DOI 10.1002/mc.20012; Lin KY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017193; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; McDonald JM, 2008, CLIN CANCER RES, V14, P7832, DOI 10.1158/1078-0432.CCR-08-0565; Melnikov S, 2012, NAT STRUCT MOL BIOL, V19, P560, DOI 10.1038/nsmb.2313; Milosevic N, 2013, NEOPLASIA, V15, P1354, DOI 10.1593/neo.131660; Moss T, 2007, CELL MOL LIFE SCI, V64, P29, DOI 10.1007/s00018-006-6278-1; Muro S, 2015, DIGESTION, V91, P164, DOI 10.1159/000371545; Nakhoul H, 2014, CLIN MED INSIGHTS-BL, V7, P7, DOI 10.4137/CMBD.S16952; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Ni JQ, 2006, GENE DEV, V20, P1959, DOI 10.1101/gad.390106; Orelle C, 2015, NATURE, V524, P119, DOI 10.1038/nature14862; Orsolic I, 2016, SEMIN CANCER BIOL, V37-38, P36, DOI 10.1016/j.semcancer.2015.12.004; Plas DR, 2009, CURR OPIN CELL BIOL, V21, P230, DOI 10.1016/j.ceb.2008.12.013; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; Ramesh M, 2016, RNA, V22, P1153, DOI 10.1261/rna.056705.116; Rao SY, 2012, BLOOD, V120, P3764, DOI 10.1182/blood-2012-03-415349; Ray S, 2013, GENE, V526, P46, DOI 10.1016/j.gene.2013.04.018; Raychaudhuri S, 2009, CANCER RES, V69, P2057, DOI 10.1158/0008-5472.CAN-08-3468; Robledo S, 2008, RNA, V14, P1918, DOI 10.1261/rna.1132008; Ruan YY, 2012, J CLIN INVEST, V122, P2554, DOI 10.1172/JCI58488; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Ruggero D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003477; Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Shen FR, 2013, MOL MED REP, V8, P999, DOI 10.3892/mmr.2013.1612; Shenoy N, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-32; Shi YQ, 2004, EXP CELL RES, V296, P337, DOI 10.1016/j.yexcr.2004.02.009; Shukla SK, 2012, FEBS J, V279, P3859, DOI 10.1111/j.1742-4658.2012.08745.x; Siddiqui-Jain A, 2010, CANCER RES, V70, P10288, DOI 10.1158/0008-5472.CAN-10-1893; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.biochem.55.1.801; Song MJ, 2011, PATHOL INT, V61, P638, DOI 10.1111/j.1440-1827.2011.02716.x; Stumpf CR, 2011, CURR OPIN GENET DEV, V21, P474, DOI 10.1016/j.gde.2011.03.007; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; Teng T, 2013, CURR OPIN GENET DEV, V23, P63, DOI 10.1016/j.gde.2013.02.001; Thakur A, 2008, CLIN CANCER RES, V14, P4427, DOI 10.1158/1078-0432.CCR-08-0458; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsofack SP, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-303; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Wang CM, 2015, HEPATOLOGY, V61, P200, DOI 10.1002/hep.27396; Wang HD, 1998, MOL CELL BIOL, V18, P7086, DOI 10.1128/MCB.18.12.7086; Wang H, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-91; Wang M, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-6; Wang S, 2010, NEOPLASIA, V12, P284, DOI 10.1593/neo.91610; Wang W, 2015, MED RES REV, V35, P225, DOI 10.1002/med.21327; Wang WD, 2015, ONCOL LETT, V9, P2767, DOI 10.3892/ol.2015.3129; Wei F, 2016, ONCOTARGET, V7, P85259, DOI 10.18632/oncotarget.13269; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wu J, 2013, BIOMED PHARMACOTHER, V67, P313, DOI 10.1016/j.biopha.2013.01.011; Wu Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026401; Xu MY, 2014, GENE, V536, P84, DOI 10.1016/j.gene.2013.11.075; Yang MX, 2014, ONCOL REP, V32, P139, DOI 10.3892/or.2014.3187; Yang MX, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0646-0; Yang ZY, 2013, CARCINOGENESIS, V34, P2851, DOI 10.1093/carcin/bgt226; Yu F, 2015, SCI REP-UK, V5, DOI 10.1038/srep18100; Zeng FX, 2017, NATURE, V541, P554, DOI 10.1038/nature21053; Zeng MQ, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0030-x; Zhan Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010488; Zhang YF, 2010, J GENE MED, V12, P147, DOI 10.1002/jgm.1424; Zhou SL, 2016, ONCOL LETT, V12, P5303, DOI 10.3892/ol.2016.5339; Zhou T, 2015, ONCOL REP, V33, P3006, DOI 10.3892/or.2015.3920; Zhou X, 2015, J MOL CELL BIOL, V7, P92, DOI 10.1093/jmcb/mjv014; Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014	113	19	21	3	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					277	285		10.1038/onc.2017.343	http://dx.doi.org/10.1038/onc.2017.343			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945227				2022-12-17	WOS:000422753900001
J	Chandrasinghe, P; Cereser, B; Moorghen, M; Al Bakir, I; Tabassum, N; Hart, A; Stebbing, J; Warusavitarne, J				Chandrasinghe, P.; Cereser, B.; Moorghen, M.; Al Bakir, I.; Tabassum, N.; Hart, A.; Stebbing, J.; Warusavitarne, J.			Role of SMAD proteins in colitis-associated cancer: from known to the unknown	ONCOGENE			English	Review							INFLAMMATORY-BOWEL-DISEASE; GROWTH-FACTOR-BETA; EMBRYONIC STEM-CELLS; ULCERATIVE-COLITIS; COLORECTAL-CANCER; COLON-CANCER; ANTISENSE OLIGONUCLEOTIDE; CROHNS-DISEASE; T-CELLS; SELF-RENEWAL	Small mothers against decapentaplegic (SMAD) proteins are a family of signal transduction molecules in transforming growth factor beta (TGF beta) ligand pathways that have been found to have a key role in the pathogenesis of inflammatory bowel disease (IBD). Long standing IBD predisposes individuals to colitis-associated colorectal cancer (CAC), an entity that possess unique characteristics compared to hereditary and sporadic cancer. The ligands of the TGF beta super family along with SMADs have also been implicated in several aspects of colorectal cancer formation. SMAD proteins are shown to be involved in a number of potentially carcinogenic mechanisms such as altering gene transcription, controlling stem cell differentiation to causing epigenetic changes. Modulation of these proteins has emerged as a novel therapeutic intervention for IBD although its effect on carcinogenesis remains elusive. This account reviews available evidence linking SMAD proteins to CAC and explores the potential areas for future research in this area.	[Chandrasinghe, P.; Cereser, B.; Hart, A.; Stebbing, J.; Warusavitarne, J.] Imperial Coll London, Dept Surg & Canc, London, England; [Chandrasinghe, P.; Moorghen, M.; Al Bakir, I.; Hart, A.; Warusavitarne, J.] St Marks Hosp, Harrow, Middx, England; [Chandrasinghe, P.] Univ Kelaniya, Kelaniya, Sri Lanka; [Al Bakir, I.] Queen Mary Univ London, Barts Canc Inst, London, England	Imperial College London; Imperial College London; University Kelaniya; University of London; Queen Mary University London	Warusavitarne, J (corresponding author), St Marks Hosp, Dept Surg, Watford Rd, Harrow HA1 3UJ, Middx, England.	j.warusavitarne@nhs.net	Cereser, Biancastella/U-3709-2019; hart, ailsa/AFO-1919-2022	Chandrasinghe, Pramodh/0000-0002-3485-961X; Cereser, Biancastella/0000-0003-1243-1767; Al Bakir, Ibrahim/0000-0001-8775-3459; Stebbing, Justin/0000-0002-1117-6947	Medical Research Council [MR/P00122X/1] Funding Source: Medline; Department of Health [NIHR-RP-011-053] Funding Source: Medline; MRC [MR/P00122X/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Annese V, 2013, J CROHNS COLITIS, V7, P982, DOI 10.1016/j.crohns.2013.09.016; [Anonymous], 2002, GENE CHROMOSOME CANC, V35, P121; Atfi A, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.126pe33; Aust DE, 2002, CANCER, V94, P1421, DOI 10.1002/cncr.10334; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P975, DOI 10.1053/gast.1996.v110.pm8613031; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; Boirivant M, 2006, GASTROENTEROLOGY, V131, P1786, DOI 10.1053/j.gastro.2006.09.016; Boulay JL, 2003, INT J CANCER, V104, P446, DOI 10.1002/ijc.10908; BRENTNALL TA, 1994, GASTROENTEROLOGY, V107, P369, DOI 10.1016/0016-5085(94)90161-9; Canavan C, 2006, ALIMENT PHARM THER, V23, P1097, DOI 10.1111/j.1365-2036.2006.02854.x; Choi CHR, 2015, AM J GASTROENTEROL, V110, P1022, DOI 10.1038/ajg.2015.65; Claessen MMH, 2010, CELL ONCOL, V32, P303, DOI 10.3233/CLO-2009-0503; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Damavand Behzad, 2015, Asian Pac J Cancer Prev, V16, P41; Davis H, 2016, CYTOKINE GROWTH F R, V27, P81, DOI 10.1016/j.cytogfr.2015.11.009; De Simone V, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.103; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Elston Rebecca, 2012, J Signal Transduct, V2012, P294097, DOI 10.1155/2012/294097; Fantini MC, 2009, GASTROENTEROLOGY, V136, P1308, DOI 10.1053/j.gastro.2008.12.053; Fernandes MG, 2016, STEM CELL REP, V6, P85, DOI 10.1016/j.stemcr.2015.11.012; Galvin KE, 2010, J BIOL CHEM, V285, P19747, DOI 10.1074/jbc.M109.077347; Garrity-Park MM, 2010, AM J GASTROENTEROL, V105, P1610, DOI 10.1038/ajg.2010.22; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Howe JR, 2004, J MED GENET, V41, P484, DOI 10.1136/jmg.2004.018598; Huang YS, 2016, ONCOTARGET, V7, P75561, DOI 10.18632/oncotarget.12285; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Hussain SP, 2000, CANCER RES, V60, P3333; Jess T, 2013, AM J GASTROENTEROL, V108, P1869, DOI 10.1038/ajg.2013.249; Kalo E, 2007, MOL CELL BIOL, V27, P8228, DOI 10.1128/MCB.00374-07; Kodach LL, 2008, CANCER, V112, P300, DOI 10.1002/cncr.23160; Lu JY, 2015, SCI REP-UK, V5, DOI 10.1038/srep14739; Maggio-Price L, 2006, CANCER RES, V66, P828, DOI 10.1158/0008-5472.CAN-05-2448; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marafini I, SMAD7 SUSTAINS INFLA; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Monteleone G, 2005, GASTROENTEROLOGY, V129, P1420, DOI 10.1053/j.gastro.2005.09.005; Monteleone G, 2015, NEW ENGL J MED, V372, P1104, DOI 10.1056/NEJMoa1407250; Monteleone G, 2012, MOL THER, V20, P870, DOI 10.1038/mt.2011.290; Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872; Qi Z, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13824; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; Riggins GJ, 1997, CANCER RES, V57, P2578; Rizzo A, 2011, CANCER RES, V71, P7423, DOI 10.1158/0008-5472.CAN-11-1895; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rutter M, 2004, GASTROENTEROLOGY, V126, P451, DOI 10.1053/j.gastro.2003.11.010; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Slattery ML, 2010, CANCER RES, V70, P1479, DOI 10.1158/0008-5472.CAN-08-1792; Stolfi C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.49; Stolfi C, 2013, INT J MOL SCI, V14, P23774, DOI 10.3390/ijms141223774; Thompson CL, 2009, CARCINOGENESIS, V30, P982, DOI 10.1093/carcin/bgp086; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Virchow R., 1863, CELLULAR PATHOLOGY B, P566; Voorneveld PW, 2015, BRIT J CANCER, V112, P122, DOI 10.1038/bjc.2014.560; Voorneveld PW, 2014, GASTROENTEROLOGY, V147, P196, DOI 10.1053/j.gastro.2014.03.052; Wang H, 2017, BIOCHEM BIOPH RES CO, V485, P181, DOI 10.1016/j.bbrc.2017.02.049; Willenbucher RF, 1999, AM J PATHOL, V154, P1825, DOI 10.1016/S0002-9440(10)65438-7; Xie W, 2003, CANCER J, V9, P302, DOI 10.1097/00130404-200307000-00013; Yaeger R, 2016, GASTROENTEROLOGY, V151, P278, DOI 10.1053/j.gastro.2016.04.001; Zhang ST, 2006, CELL CYCLE, V5, P2787, DOI 10.4161/cc.5.23.3523	66	19	20	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					1	7		10.1038/onc.2017.300	http://dx.doi.org/10.1038/onc.2017.300			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869601	Green Submitted			2022-12-17	WOS:000422625000001
J	Yan, F; Shen, N; Pang, J; Zhao, N; Deng, B; Li, B; Yang, Y; Yang, P; Molina, JR; Liu, S				Yan, F.; Shen, N.; Pang, J.; Zhao, N.; Deng, B.; Li, B.; Yang, Y.; Yang, P.; Molina, J. R.; Liu, S.			A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness	ONCOGENE			English	Article							DE-NOVO METHYLATION; C-KIT; PHASE-I; CISPLATIN RESISTANCE; EXPRESSION; DNMT3A; HYPOMETHYLATION; TRANSCRIPTION; CHEMOTHERAPY; DECITABINE	Overexpression of DNMT1 and KIT is prevalent in lung cancer, yet the underlying molecular mechanisms are poorly understood. While the deregulated activation of DNMT1 or KIT has been implicated in lung cancer pathogenesis, whether and how DNMT1 and KIT orchestrate lung tumorigenesis are unclear. Here, using human lung cancer tissue microarrays and fresh frozen tissues, we found that the overexpression of DNMT1 is positively correlated with the upregulation of KIT in tumor tissues. We demonstrated that DNMT1 and KIT form a positive regulatory loop, in which ectopic DNMT1 expression increases, whereas targeted DNMT1 depletion abrogates KIT signaling cascade through Sp1/miR-29b network. Conversely, an increase of KIT levels augments, but a reduction of KIT expression ablates DNMT1 transcription by STAT3 pathway leading to in-parallel modification of the DNA methylation profiles. We provided evidence that KIT inactivation induces global DNA hypomethylation, restores the expression of tumor suppressor p15(INK4B) through promoter demethylation; in turn, DNMT1 dysfunction impairs KIT kinase signaling. Functionally, KIT and DNMT1 co-expression promotes, whereas dual inactivation of them suppresses, lung cancer cell proliferation and metastatic growth in vitro and in vivo, in a synergistic manner. These findings demonstrate the regulatory and functional interplay between DNA methylation and tyrosine kinase signaling in propelling tumorigenesis, providing a widely applicable approach for targeting lung cancer.	[Yan, F.; Shen, N.; Pang, J.; Zhao, N.; Liu, S.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Deng, B.; Yang, Y.; Yang, P.] Mayo Clin, Div Epidemiol, Rochester, MN USA; [Li, B.] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA; [Molina, J. R.] Mayo Clin, Dept Med Oncol, Rochester, MN USA	University of Minnesota System; Mayo Clinic; University of Louisville; Mayo Clinic	Liu, S (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	sliu@umn.edu	Yan, Fei/G-4941-2016; , Bing/A-7536-2016	Yan, Fei/0000-0003-4750-1200; , Bing/0000-0001-5363-7070	Hormel Foundation; National Cancer Institute (Bethesda, MD, USA) [R01CA149623, R21CA155915]; NATIONAL CANCER INSTITUTE [R01CA149623, R21CA155915] Funding Source: NIH RePORTER	Hormel Foundation; National Cancer Institute (Bethesda, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by Hormel Foundation (S. Liu) and National Cancer Institute (Bethesda, MD, USA) grants R01CA149623 (S. Liu) and R21CA155915 (S. Liu).	Abidin Aidalena Z, 2010, Ther Adv Med Oncol, V2, P25, DOI 10.1177/1758834009356014; Ansari J, 2009, ANTI-CANCER AGENT ME, V9, P569, DOI 10.2174/187152009788451879; Arand J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002750; Bauer C, 2015, J BIOL CHEM, V290, P4801, DOI 10.1074/jbc.M114.605881; Boldrini L, 2004, CLIN CANCER RES, V10, P4101, DOI 10.1158/1078-0432.CCR-03-0664; Carlomagno F, 2005, CURR MED CHEM, V12, P1773, DOI 10.2174/0929867054367266; Crivellari G, 2007, ONCOLOGIST, V12, P79, DOI 10.1634/theoncologist.12-1-79; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Gao XN, 2015, LEUKEMIA, V29, P1730, DOI 10.1038/leu.2015.56; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Gauler TC, 2013, EUR J CANCER, V49, P2461, DOI 10.1016/j.ejca.2013.03.029; Gowher H, 2005, BIOCHEMISTRY-US, V44, P9899, DOI 10.1021/bi047634t; Itamochi H, 2014, INT J GYNECOL CANCER, V24, P61, DOI 10.1097/IGC.0000000000000014; Jafri Nazia F., 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P147, DOI 10.1615/JEnvPathToxOncol.v22.i3.10; Jeltsch A, 2014, TRENDS BIOCHEM SCI, V39, P310, DOI 10.1016/j.tibs.2014.05.002; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406; Levina V, 2010, CANCER RES, V70, P338, DOI 10.1158/0008-5472.CAN-09-1102; Li W, 2012, ONCOGENE, V31, P2412, DOI 10.1038/onc.2011.426; Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022; Lin RK, 2010, CANCER RES, V70, P5807, DOI 10.1158/0008-5472.CAN-09-4161; Litz J, 2006, MOL CANCER THER, V5, P1415, DOI 10.1158/1535-7163.MCT-05-0503; Liu LZ, 2007, CANCER RES, V67, P6325, DOI 10.1158/0008-5472.CAN-06-4261; Liu SJ, 2008, BLOOD, V111, P2364, DOI 10.1182/blood-2007-08-110171; Liu SJ, 2010, CANCER CELL, V17, P333, DOI 10.1016/j.ccr.2010.03.008; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; Miller AA, 2010, J THORAC ONCOL, V5, P380, DOI 10.1097/JTO.0b013e3181cee36e; Monnerat C, 2004, ANN ONCOL, V15, P316, DOI 10.1093/annonc/mdh052; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Poirier JT, 2015, ONCOGENE, V34, P5869, DOI 10.1038/onc.2015.38; Rossi Antonio, 2009, Curr Drug Discov Technol, V6, P91; Schneider BJ, 2010, CLIN LUNG CANCER, V11, P223, DOI 10.3816/CLC.2010.n.028; Schrump DS, 2006, CLIN CANCER RES, V12, P5777, DOI 10.1158/1078-0432.CCR-06-0669; Tamborini E, 2004, CLIN CANCER RES, V10, P8214, DOI 10.1158/1078-0432.CCR-04-1013; TSUURA Y, 1994, VIRCHOWS ARCH, V424, P135; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Yan F, 2017, LEUKEMIA, V31, P1434, DOI 10.1038/leu.2016.349; Yan F, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.380; Yan F, 2015, J BIOL CHEM, V290, P18480, DOI 10.1074/jbc.M114.633693; Yu W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029450; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008	42	19	19	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6919	6928		10.1038/onc.2017.305	http://dx.doi.org/10.1038/onc.2017.305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28869603	Green Accepted			2022-12-17	WOS:000418041800008
J	Makhtar, WRW; Browne, G; Karountzos, A; Stevens, C; Alghamdi, Y; Bottrill, AR; Mistry, S; Smith, E; Bushel, M; Pringle, JH; Sayan, AE; Tulchinsky, E				Makhtar, W. R. Wan; Browne, G.; Karountzos, A.; Stevens, C.; Alghamdi, Y.; Bottrill, A. R.; Mistry, S.; Smith, E.; Bushel, M.; Pringle, J. H.; Sayan, A. E.; Tulchinsky, E.			Short stretches of rare codons regulate translation of the transcription factor ZEB2 in cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION; RNA GENES; POL II; PROTEIN; BINDING; SIP1; EMT; PROGRESSION; METASTASIS	Two proteins comprising the ZEB family of zinc finger transcription factors, ZEB1 and ZEB2, execute EMT programs in embryonic development and cancer. By studying regulation of their expression, we describe a novel mechanism that limits ZEB2 protein synthesis. A protein motif located at the border of the SMAD-binding domain of ZEB2 protein induces ribosomal pausing and compromises protein synthesis. The function of this protein motif is dependent on stretches of rare codons, Leu(UUA)-Gly(GGU)-Val (GUA). Incorporation of these triplets in the homologous region of ZEB1 does not affect protein translation. Our data suggest that rare codons have a regulatory role only if they are present within appropriate protein structures. We speculate that pools of transfer RNA available for protein translation impact on the configuration of epithelial mesenchymal transition pathways in tumor cells.	[Makhtar, W. R. Wan; Browne, G.; Karountzos, A.; Stevens, C.; Alghamdi, Y.; Pringle, J. H.; Tulchinsky, E.] Univ Leicester, Dept Canc Studies, Leicester, Leics, England; [Makhtar, W. R. Wan; Smith, E.; Bushel, M.] MRC Toxicol Unit, Leicester, Leics, England; [Bottrill, A. R.; Mistry, S.] Univ Leicester, Prot & Nucle Acid Chem Lab PNACL, Leicester, Leics, England; [Sayan, A. E.] Univ Southampton, Canc Sci Div, Tremona Rd, Southampton SO16 6YD, Hants, England; [Makhtar, W. R. Wan; Browne, G.; Karountzos, A.; Stevens, C.; Alghamdi, Y.; Pringle, J. H.; Tulchinsky, E.] Univ Sains Malaysia, Sch Med Sci, George Town, Malaysia	University of Leicester; University of Leicester; University of Southampton; Universiti Sains Malaysia	Sayan, AE (corresponding author), Univ Southampton, Canc Sci Div, Tremona Rd, Southampton SO16 6YD, Hants, England.; Tulchinsky, E (corresponding author), Univ Leicester, Dept Canc Studies, RKCSB, LRI, Leicester LE2 7LX, Leics, England.; Tulchinsky, E (corresponding author), Univ Sains Malaysia, Sch Med Sci, George Town, Malaysia.	A.E.Sayan@soton.ac.uk; et32@le.ac.uk	Tulchinsky, Eugene/ABD-7070-2021; SAYAN, A. EMRE/H-7330-2012; Bottrill, Andrew/ABD-1459-2021; Alghamdi, Yousef G/N-2061-2016	SAYAN, A. EMRE/0000-0002-5291-1485; Bottrill, Andrew/0000-0002-5182-3643; Alghamdi, Yousef G/0000-0003-2671-6771; Smith, Ewan/0000-0002-3992-3748; WAN MAKHTAR, WAN RATMAAZILA/0000-0003-1630-2137	Cancer Research UK [C8851/A10844]; Wellcome Trust ISSF Grant [RM60G0406]	Cancer Research UK(Cancer Research UK); Wellcome Trust ISSF Grant(Wellcome Trust)	This research was supported by a Cancer Research UK project grant C8851/A10844 (ET), and Wellcome Trust ISSF Grant RM60G0406 (ET).	Barski A, 2010, NAT STRUCT MOL BIOL, V17, P629, DOI 10.1038/nsmb.1806; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Canella D, 2012, GENOME RES, V22, P666, DOI 10.1101/gr.130286.111; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; David A, 2011, J BIOL CHEM, V286, P20688, DOI 10.1074/jbc.M110.209452; Denecker G, 2014, CELL DEATH DIFFER, V21, P1250, DOI 10.1038/cdd.2014.44; Dittmar KA, 2006, PLOS GENET, V2, P2107, DOI 10.1371/journal.pgen.0020221; Duret L, 2000, TRENDS GENET, V16, P287, DOI 10.1016/S0168-9525(00)02041-2; Gingold H, 2014, CELL, V158, P1281, DOI 10.1016/j.cell.2014.08.011; Gingold H, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.14; Goodarzi H, 2016, CELL, V165, P1416, DOI 10.1016/j.cell.2016.05.046; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708; Kaminska M, 2009, J BIOL CHEM, V284, P13746, DOI 10.1074/jbc.M900480200; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Komar AA, 2009, TRENDS BIOCHEM SCI, V34, P16, DOI 10.1016/j.tibs.2008.10.002; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kutter C, 2011, NAT GENET, V43, P948, DOI 10.1038/ng.906; Lampson BL, 2013, CURR BIOL, V23, P70, DOI 10.1016/j.cub.2012.11.031; Lander R, 2011, J CELL BIOL, V194, P17, DOI 10.1083/jcb.201012085; Liu YQ, 2008, DEVELOPMENT, V135, P579, DOI 10.1242/dev.007047; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406; Miyoshi T, 2006, DEV DYNAM, V235, P1941, DOI 10.1002/dvdy.20799; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Oler AJ, 2010, NAT STRUCT MOL BIOL, V17, P620, DOI 10.1038/nsmb.1801; Ozturk N, 2006, P NATL ACAD SCI USA, V103, P2178, DOI 10.1073/pnas.0510877103; Pavon-Eternod M, 2009, NUCLEIC ACIDS RES, V37, P7268, DOI 10.1093/nar/gkp787; Pershing NLK, 2015, J CLIN INVEST, V125, P222, DOI 10.1172/JCI77627; Plotkin JB, 2011, NAT REV GENET, V12, P32, DOI 10.1038/nrg2899; Sayan AE, 2009, P NATL ACAD SCI USA, V106, P14884, DOI 10.1073/pnas.0902042106; Sha Z, 2009, MOL CELL, V36, P141, DOI 10.1016/j.molcel.2009.09.026; Tsimokha AS, 2017, J CELL PHYSIOL, V232, P842, DOI 10.1002/jcp.25492; Tuller T, 2010, CELL, V141, P344, DOI 10.1016/j.cell.2010.03.031; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Wang F, 2015, BIOCHIMIE, V114, P127, DOI 10.1016/j.biochi.2015.02.006; Xu M, 2015, ONCOTARGET, V6, P979, DOI 10.18632/oncotarget.2825	41	19	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6640	6648		10.1038/onc.2017.273	http://dx.doi.org/10.1038/onc.2017.273			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783176	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000416049200012
J	Wang, J; Kho, DH; Zhou, JY; Davis, RJ; Wu, GS				Wang, J.; Kho, D. H.; Zhou, J-Y; Davis, R. J.; Wu, G. S.			MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance	ONCOGENE			English	Article							PROTEIN-KINASE PHOSPHATASE-1; OVARIAN-CANCER CELLS; ADP-RIBOSE POLYMERASE; HUMAN BREAST-CANCER; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE; EXCISION-REPAIR; THERAPEUTIC TARGET; DRUG-RESISTANCE; CARCINOMA-CELLS	Understanding the mechanisms of platinum compound resistance, including cisplatin resistance, has important implications for improving cancer treatments. Previous studies identified a potential role for mitogen-activated protein kinase phosphatase-1 (MKP-1) in cisplatin resistance. This work focuses on the regulation of poly(ADP-ribose) polymerase-1 (PARP-1) expression by MKP-1. We found that MKP-1 overexpression stimulates PARP-1 and poly(ADP-ribose) (PAR) protein expression and cisplatin resistance while its downregulation suppresses PARP-1 and PAR protein expression and cisplatin resistance. Silencing MKP-1 promoted PARP-1 ubiquitination, which decreased PARP-1 protein levels. We also found that silencing c-Jun N-terminal kinase 1/2 (JNK1/2) decreased PARP-1 ubiquitination while increasing total PARP-1 protein levels. Furthermore, we showed that acquired cisplatin-resistant ovarian cancer cells expressed high levels of MKP-1 and PARP-1 proteins, and that silencing MKP-1 or PARP-1 increased cisplatin sensitivity in resistant cells. Notably, the pharmacologic inhibition of PARP activity restored cisplatin sensitivity in MKP-1 overexpressing cells. Thus, this work indicates that suppression of JNK1/2 activity by MKP-1 maintains PARP-1 levels and suggests that MKP-1-mediated cisplatin resistance can be bypassed by PARP-1 inhibition.	[Wang, J.; Kho, D. H.; Zhou, J-Y; Wu, G. S.] Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI 48201 USA; [Wang, J.; Kho, D. H.; Zhou, J-Y; Wu, G. S.] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA; [Wang, J.; Kho, D. H.; Zhou, J-Y; Wu, G. S.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; [Davis, R. J.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA; [Davis, R. J.] Howard Hughes Med Inst, Worcester, MA USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute	Wu, GS (corresponding author), Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI 48201 USA.; Wu, GS (corresponding author), Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA.; Wu, GS (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.	wug@karmanos.org		Davis, Roger/0000-0002-0130-1652	NIH [R01CA174949]; NATIONAL CANCER INSTITUTE [P30CA022453, R01CA174949] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was, in part, supported by the NIH (R01CA174949).	Annunziata CM, 2010, CLIN CANCER RES, V16, P4517, DOI 10.1158/1078-0432.CCR-10-0526; Beale PJ, 2000, BRIT J CANCER, V82, P436; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Brozovic A, 2004, INT J CANCER, V112, P974, DOI 10.1002/ijc.20522; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chattopadhyay S, 2006, ONCOGENE, V25, P3335, DOI 10.1038/sj.onc.1209364; Cheng TC, 2006, CANCER CHEMOTH PHARM, V58, P384, DOI 10.1007/s00280-005-0171-8; Christmann M, 2006, NUCLEIC ACIDS RES, V34, P6530, DOI 10.1093/nar/gkl895; Cullen KJ, 2003, CANCER RES, V63, P8097; DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Gagne JP, 2009, J PROTEOME RES, V8, P1014, DOI 10.1021/pr800810n; Hamdi M, 2005, ONCOGENE, V24, P7135, DOI 10.1038/sj.onc.1208875; Howell SB, 2010, MOL PHARMACOL, V77, P887, DOI 10.1124/mol.109.063172; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johnson SW, 1996, EXP CELL RES, V226, P133, DOI 10.1006/excr.1996.0211; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1; Kuo MT, 2007, CANCER METAST REV, V26, P71, DOI 10.1007/s10555-007-9045-3; Kwong J, 2006, NEOPLASIA, V8, P268, DOI 10.1593/neo.05502; Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Martin SA, 2008, CURR OPIN GENET DEV, V18, P80, DOI 10.1016/j.gde.2008.01.016; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Michels J, 2013, CANCER RES, V73, P2271, DOI 10.1158/0008-5472.CAN-12-3000; Perego P, 1996, CANCER RES, V56, P556; Rojo F, 2009, CLIN CANCER RES, V15, P3530, DOI 10.1158/1078-0432.CCR-08-2070; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Shen DW, 2012, PHARMACOL REV, V64, P706, DOI 10.1124/pr.111.005637; Strom CE, 2011, NUCLEIC ACIDS RES, V39, P3166, DOI 10.1093/nar/gkq1241; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tomicic MT, 2011, CELL MOL LIFE SCI, V68, P1785, DOI 10.1007/s00018-010-0546-9; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tummala Mohan K, 2005, Clin Adv Hematol Oncol, V3, P723; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Wang J, 2007, CANCER RES, V67, P11933, DOI 10.1158/0008-5472.CAN-07-5185; Wang J, 2016, AUTOPHAGY, V12, P1791, DOI 10.1080/15548627.2016.1203483; Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288; Wang J, 2009, CELL CYCLE, V8, P3191, DOI 10.4161/cc.8.19.9751; Wang ZQ, 2006, CANCER RES, V66, P8870, DOI 10.1158/0008-5472.CAN-06-1280; WHITACRE CM, 1995, CANCER RES, V55, P3697; Wu GS, 2007, CANCER METAST REV, V26, P579, DOI 10.1007/s10555-007-9079-6; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang S, 2007, CELL DEATH DIFFER, V14, P1001, DOI 10.1038/sj.cdd.4402088	52	19	19	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5939	5947		10.1038/onc.2017.197	http://dx.doi.org/10.1038/onc.2017.197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650468	Green Accepted			2022-12-17	WOS:000413841400003
J	Wang, X; Haring, MF; Rathjen, T; Lockhart, SM; Sorensen, D; Ussar, S; Rasmussen, LM; Bertagnolli, MM; Kahn, CR; Rask-Madsen, C				Wang, X.; Haering, M-F; Rathjen, T.; Lockhart, S. M.; Sorensen, D.; Ussar, S.; Rasmussen, L. M.; Bertagnolli, M. M.; Kahn, C. R.; Rask-Madsen, C.			Insulin resistance in vascular endothelial cells promotes intestinal tumour formation	ONCOGENE			English	Article							BODY-MASS INDEX; GROWTH-FACTOR; BREAST-CANCER; COLORECTAL ADENOMAS; COLON-CANCER; RISK-FACTOR; OBESITY; INFLAMMATION; MECHANISMS; NEOPLASIA	The risk of several cancers, including colorectal cancer, is increased in patients with obesity and type 2 diabetes, conditions characterised by hyperinsulinaemia and insulin resistance. Because hyperinsulinaemia itself is an independent risk factor for cancer development, we examined tissue-specific insulin action in intestinal tumour formation. In vitro, insulin increased proliferation of intestinal tumour epithelial cells by almost two-fold in primary culture of tumour cells from Apc(Min/+) mice. Surprisingly, targeted deletion of insulin receptors in intestinal epithelial cells in Apc(Min/+) mice did not change intestinal tumour number or size distribution on either a low or high-fat diet. We therefore asked whether cells in the tumour stroma might explain the association between tumour formation and insulin resistance. To this end, we generated Apc(Min/+) mice with loss of insulin receptors in vascular endothelial cells. Strikingly, these mice had 42% more intestinal tumours than controls, no change in tumour angiogenesis, but increased expression of vascular cell adhesion molecule-1 (VCAM-1) in primary culture of tumour endothelial cells. Insulin decreased VCAM-1 expression and leukocyte adhesion in quiescent tumour endothelial cells with intact insulin receptors and partly prevented increases in VCAM-1 and leukocyte adhesion after treatment with tumour necrosis factor-a. Knockout of insulin receptors in endothelial cells also increased leukocyte adhesion in mesenteric venules and increased the frequency of neutrophils in tumours. We conclude that although insulin is mitogenic for intestinal tumour cells in vitro, impaired insulin action in the tumour microenvironment may be more important in conditions where hyperinsulinaemia is secondary to insulin resistance. Insulin resistance in tumour endothelial cells produces an activated, proinflammatory state that promotes tumorigenesis. Improvement of endothelial dysfunction may reduce colorectal cancer risk in patients with obesity and type 2 diabetes.	[Wang, X.; Haering, M-F; Rathjen, T.; Lockhart, S. M.; Sorensen, D.; Ussar, S.; Kahn, C. R.; Rask-Madsen, C.] Joslin Diabet Ctr, Boston, MA 02215 USA; [Wang, X.; Haering, M-F; Rathjen, T.; Lockhart, S. M.; Sorensen, D.; Ussar, S.; Bertagnolli, M. M.; Kahn, C. R.; Rask-Madsen, C.] Harvard Med Sch, One Joslin Pl, Boston, MA 02215 USA; [Wang, X.] Fudan Univ, Huashan Hosp, Shanghai, Peoples R China; [Haering, M-F] Univ Hosp Tuebingen, Dept Internal Med 4, Div Clin Chem & Pathobiochem, Tubingen, Germany; [Rathjen, T.] Novo Nordisk AS, Malov, Denmark; [Lockhart, S. M.] Queens Univ Belfast, Belfast, Antrim, North Ireland; [Sorensen, D.; Rasmussen, L. M.] Univ Southern Denmark, Odense Univ Hosp, Odense, Denmark; [Sorensen, D.] Danish Diabet Acad, Odense, Denmark; [Ussar, S.] Helmholtz Ctr Munich Neuherberg, Inst Diabet & Obes, JRG Adipocytes & Metab, Munich, Germany; [Ussar, S.] German Ctr Diabet Res DZD, Neuherberg, Germany; [Bertagnolli, M. M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Fudan University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Novo Nordisk; Queens University Belfast; University of Southern Denmark; Odense University Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Brigham & Women's Hospital	Rask-Madsen, C (corresponding author), Harvard Med Sch, Joslin Diabet Ctr, Vasc Biol & Complicat, One Joslin Pl, Boston, MA 02215 USA.	christian.rask-madsen@joslin.harvard.edu	Lockhart, Sam/Q-2604-2015; Kahn, Ronald/AAY-2435-2021; Ussar, Siegfried/AAL-4331-2021	Lockhart, Sam/0000-0003-2092-4350; Kahn, Ronald/0000-0002-7583-9228; Ussar, Siegfried/0000-0001-7575-0920; Rasmussen, Lars Melholt/0000-0001-5795-4794; Rask-Madsen, Christian/0000-0002-8548-466X	NIH [R21 CA185196, DK031036, DK033201, 5P30DK036836]; National Natural Science Foundation of China [81370936]; Diabetes Research and Wellness Foundation; Danish Diabetes Academy - Novo Nordisk Foundation; Mary K. Iacocca Professorship; STAR Programme; NATIONAL CANCER INSTITUTE [R21CA185196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R37DK031036, R01DK033201, R01DK031036] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD021740] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Diabetes Research and Wellness Foundation; Danish Diabetes Academy - Novo Nordisk Foundation; Mary K. Iacocca Professorship; STAR Programme; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH grant R21 CA185196 (to CRM), the National Natural Science Foundation of China grant 81370936 (XW), the Diabetes Research and Wellness Foundation (SML), the Danish Diabetes Academy which receives funding from the Novo Nordisk Foundation (DS), as well as NIH grants DK031036, DK033201 and the Mary K. Iacocca Professorship (CRK). TR was an employee of Novo Nordisk and was supported by the STAR Programme. Measurement of plasma insulin and flow cytometry was done using cores in the Diabetes Research Center, supported by NIH grant 5P30DK036836, at Joslin Diabetes Center. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.	Alva JA, 2006, DEV DYNAM, V235, P759, DOI 10.1002/dvdy.20643; Anderson JC, J CLIN GASTROENTEROL, DOI [10.1136/gutjnl-2016-312893, DOI 10.1136/GUTJNL-2016-312893]; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355; Bickston SJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007571.pub2; Bruce WR, 2000, NUTR CANCER, V37, P19, DOI 10.1207/S15327914NC3701_2; Carothers AM, 2006, CANCER RES, V66, P6432, DOI 10.1158/0008-5472.CAN-06-0992; Chan AT, 2012, CANCER PREV RES, V5, P164, DOI 10.1158/1940-6207.CAPR-11-0391; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Davenport JR, 2018, GUT, V67, P456, DOI 10.1136/gutjnl-2016-312893; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Elmunzer BJ, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001352; Fischer A, 2016, GUT, V65, P1642, DOI 10.1136/gutjnl-2015-310022; Flores MBS, 2012, GASTROENTEROLOGY, V143, P741, DOI 10.1053/j.gastro.2012.05.045; FUKUMURA D, 1995, CANCER RES, V55, P4824; Gallagher EJ, 2015, PHYSIOL REV, V95, P727, DOI 10.1152/physrev.00030.2014; Gey GO, 1924, JAMA-J AM MED ASSOC, V82, P1609, DOI [DOI 10.1001/JAMA.1924.26520460003014D, 10.1001/jama.1924.26520460003014d]; GIOVANNUCCI E, 1995, CANCER CAUSE CONTROL, V6, P164, DOI 10.1007/BF00052777; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; IshShalom D, 1997, DIABETOLOGIA, V40, pS25, DOI 10.1007/s001250051393; Jamieson T, 2012, J CLIN INVEST, V122, P3127, DOI 10.1172/JCI61067; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; Khandekar MJ, 2011, NAT REV CANCER, V11, P886, DOI 10.1038/nrc3174; Kim F, 2008, ARTERIOSCL THROM VAS, V28, P1982, DOI 10.1161/ATVBAHA.108.169722; KOENUMA M, 1989, JPN J CANCER RES, V80, P51, DOI 10.1111/j.1349-7006.1989.tb02244.x; Kurtzhals P, 2000, DIABETES, V49, P999, DOI 10.2337/diabetes.49.6.999; LAAKSO M, 1992, DIABETES, V41, P1076, DOI 10.2337/diabetes.41.9.1076; Luck H, 2015, CELL METAB, V21, P527, DOI 10.1016/j.cmet.2015.03.001; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Makinen J, 2015, DIABETOLOGIA, V58, P1055, DOI 10.1007/s00125-015-3501-3; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Monteiro-Sepulveda M, 2015, CELL METAB, V22, P113, DOI 10.1016/j.cmet.2015.05.020; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Naruse K, 2006, DIABETES, V55, P691, DOI 10.2337/diabetes.55.03.06.db05-0771; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; Okabayashi K, 2012, AM J GASTROENTEROL, V107, P1175, DOI 10.1038/ajg.2012.180; OSBORNE CK, 1976, P NATL ACAD SCI USA, V73, P4536, DOI 10.1073/pnas.73.12.4536; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; RAIZADA MK, 1976, J BIOL CHEM, V251, P6445; Rask-Madsen C, 2001, DIABETES, V50, P2611, DOI 10.2337/diabetes.50.11.2611; Rask-Madsen C, 2012, ARTERIOSCL THROM VAS, V32, P2052, DOI 10.1161/ATVBAHA.111.241919; Rask-Madsen C, 2010, CELL METAB, V11, P379, DOI 10.1016/j.cmet.2010.03.013; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Rostoker R, 2015, ENDOCR-RELAT CANCER, V22, P145, DOI 10.1530/ERC-14-0490; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; Steyers CM, 2014, INT J MOL SCI, V15, P11324, DOI 10.3390/ijms150711324; Tabit CE, 2013, CIRCULATION, V127, P86, DOI 10.1161/CIRCULATIONAHA.112.127514; Targan SR, 2007, GASTROENTEROLOGY, V132, P1672, DOI 10.1053/j.gastro.2007.03.024; TEMIN HM, 1968, INT J CANCER, V3, P771, DOI 10.1002/ijc.2910030611; Treffers LW, 2016, IMMUNOL REV, V273, P312, DOI 10.1111/imr.12444; Vicent D, 2003, J CLIN INVEST, V111, P1373, DOI 10.1172/JCI200315211; Yoon YS, 2015, METABOLISM, V64, P1324, DOI 10.1016/j.metabol.2015.06.013; Yuhara H, 2011, AM J GASTROENTEROL, V106, P1911, DOI 10.1038/ajg.2011.301; Zhao LN, 2015, CLIN SCI, V129, P1025, DOI 10.1042/CS20150143	58	19	22	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					4987	4996		10.1038/onc.2017.107	http://dx.doi.org/10.1038/onc.2017.107			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459466	Green Submitted, Green Accepted			2022-12-17	WOS:000408768800004
J	Yurugi, H; Marini, F; Weber, C; David, K; Zhao, Q; Binder, H; Desaubry, L; Rajalingam, K				Yurugi, H.; Marini, F.; Weber, C.; David, K.; Zhao, Q.; Binder, H.; Desaubry, L.; Rajalingam, K.			Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours	ONCOGENE			English	Article							CELL-PROLIFERATION; SIGNALING PATHWAYS; RAS; ACTIVATION; CRAF; DIMERIZATION; MUTATIONS; BRAF	KRAS is one of the most frequently mutated oncogenes in human non-small cell lung cancers (NSCLCs). RAS proteins trigger multiple effector signalling pathways including the highly conserved RAF-MAPK pathway. CRAF, a direct RAS effector protein, is required for KRAS-mediated tumourigenesis. Thus, the molecular mechanisms driving the activation of CRAF are intensively studied. Prohibitin 1 (PHB1) is an evolutionarily conserved adaptor protein and interaction of CRAF with PHB1 at the plasma membrane is essential for CRAF activation. Here, we demonstrate that PHB1 is highly expressed in NSCLC patients and correlates with poor survival. Targeting of PHB1 with two chemical ligands (rocaglamide and fluorizoline) inhibits epidermal growth factor (EGF)/RAS-induced CRAF activation. Consistently, treatment with rocaglamide inhibited proliferation, migration and anchorage-independent growth of KRAS-mutated lung carcinoma cell lines. Surprisingly, rocaglamide treatment inhibited Ras-GTP loading in KRAS-mutated cells as well as in EGF-stimulated cells. Rocaglamide treatment further prevented the oncogenic growth of KRAS-driven lung cancer allografts and xenografts in mouse models. Our results suggest rocaglamide as a RAS inhibitor and that targeting plasma membrane-associated PHB1 with chemical ligands would be a viable therapeutic strategy to combat KRAS-mediated NSCLCs.	[Yurugi, H.; Rajalingam, K.] Univ Med Ctr Mainz, Inst Immunol, Mol Signaling Unit FZI, Mainz, Germany; [Marini, F.; Binder, H.] Univ Med Ctr Mainz, Inst Med Biostat Epidemiol & Informat, Mainz, Germany; [Weber, C.; David, K.] Indivumed GmbH, Hamburg, Germany; [Zhao, Q.; Desaubry, L.] Univ Strasbourg, Therapeut Innovat Lab, CNRS, UMR7200, Strasbourg, France; [Desaubry, L.] Tianjin Univ Sci & Technol, Coll Biotechnol, Sinofrench Joint Lab Food Nutr Safety & Med Chem, Tianjin, Peoples R China; [Rajalingam, K.] German Canc Consortium DKTK, DKFZ, Partner Site Frankfurt Mainz, UCT, Heidelberg, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Tianjin University Science & Technology; Helmholtz Association; German Cancer Research Center (DKFZ)	Rajalingam, K (corresponding author), JGU Mainz, Univ Med Ctr Mainz, Inst Immunol, Mol Signaling Unit FZI, Langebeck St 1, D-55131 Mainz, Germany.	Krishna@uni-mainz.de; Krishna@uni-mainz.de	Marini, Federico/AAQ-2427-2020; Desaubry, Laurent G/R-5446-2017; Binder, Harald/C-7413-2009	Marini, Federico/0000-0003-3252-7758; Desaubry, Laurent G/0000-0002-1192-2970; Binder, Harald/0000-0002-5666-8662	BIS-PLUS3 fellowship of the Boehringer Ingelheim Stiftuing; Association pour la Recherche sur le Cancer; 'Association Nationale de la Recherche et de la Technologie' (ANRT)	BIS-PLUS3 fellowship of the Boehringer Ingelheim Stiftuing(Boehringer Ingelheim); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); 'Association Nationale de la Recherche et de la Technologie' (ANRT)	We thank Alexandra Dimitrijevic for the excellent technical assistance, and Dr Melzer for her help and advice with the animal experiments. We thank Professors Tyler Jacks, Susan Horwitz, Scott Randell, Channing Der and Ulf Rapp for contributing several constructs and cell lines that are employed in this study. We thank Professor Hartmut Juhl and Dr Bernd Gromoll (Indivumed GmbH) for assistance with the analyses of the NSCLC tissue microarrays. This work is supported through a BIS-PLUS3 fellowship of the Boehringer Ingelheim Stiftuing to KR. KR is a Heisenberg Professor of the DFG (RA1739/4-1) and a GFK fellow. A generous financial support for this work was provided by the 'Association pour la Recherche sur le Cancer' to LD. We are also grateful to AAREC Filia Research and the 'Association Nationale de la Recherche et de la Technologie' (ANRT) for fellowships to QZ.	Ande SR, 2010, BIOCHEM CELL BIOL, V88, P553, DOI [10.1139/O09-177, 10.1139/o09-177]; Becker MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.528; Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Chiu CF, 2013, ONCOGENE, V32, P777, DOI 10.1038/onc.2012.86; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Doudican NA, 2017, ONCOGENE, V36, P423, DOI 10.1038/onc.2016.214; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 2011, NAT MED, V17, P286, DOI 10.1038/nm0311-286; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Fischer A, 2009, J BIOL CHEM, V284, P3183, DOI 10.1074/jbc.M804795200; Fleuren EDG, 2016, NAT REV CANCER, V16, P83, DOI 10.1038/nrc.2015.18; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Lovly CM, 2014, CLIN CANCER RES, V20, P2249, DOI 10.1158/1078-0432.CCR-13-1610; Luan Z, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-38; Manzano JL, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.07; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Merkwirth C, 2008, GENE DEV, V22, P476, DOI 10.1101/gad.460708; Merkwirth C, 2009, BBA-MOL CELL RES, V1793, P27, DOI 10.1016/j.bbamcr.2008.05.013; Mishra S, 2010, FEBS J, V277, P3937, DOI 10.1111/j.1742-4658.2010.07809.x; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Niault TS, 2010, CARCINOGENESIS, V31, P1165, DOI 10.1093/carcin/bgp337; Perez-Perarnau A, 2014, ANGEW CHEM INT EDIT, V53, P10150, DOI 10.1002/anie.201405758; Polier G, 2012, CHEM BIOL, V19, P1093, DOI 10.1016/j.chembiol.2012.07.012; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Sharma A, 2004, P NATL ACAD SCI USA, V101, P17492, DOI 10.1073/pnas.0407536101; Vasan N, 2014, CLIN CANCER RES, V20, P3921, DOI 10.1158/1078-0432.CCR-13-1762; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Yurugi H, 2013, BIOCHEM BIOPH RES CO, V434, P376, DOI 10.1016/j.bbrc.2013.03.085; Yurugi H, 2012, BIOCHEM BIOPH RES CO, V420, P275, DOI 10.1016/j.bbrc.2012.02.149	37	19	23	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4778	4789		10.1038/onc.2017.93	http://dx.doi.org/10.1038/onc.2017.93			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28414306				2022-12-17	WOS:000407702400010
J	Zhou, M; Mok, MTS; Sun, H; Chan, AW; Huang, Y; Cheng, ASL; Xu, G				Zhou, M.; Mok, M. T. S.; Sun, H.; Chan, A. W.; Huang, Y.; Cheng, A. S. L.; Xu, G.			The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; HEPATIC STEATOSIS; SIGNAL TRANSDUCER; MOUSE MODELS; CANCER; LIVER; ASSOCIATION; EXPRESSION	Epidemiological studies have demonstrated a close association of type 2 diabetes and hepatocellular carcinoma (HCC). Exenatide (Ex-4), a potent diabetes drug targeting glucagon-like peptide-1 receptor (GLP-1R), is protective against non-alcoholic fatty liver disease (NAFLD). However, the Ex-4 function and GLP-1R status have yet been explored in HCC. Herein we investigated the effect of Ex-4 in diethylnitrosamine (DEN)-treated mice consuming control or high-fat high-carbohydrate diet. Administration of Ex-4 significantly improved obesity-induced hyperglycemia and hyperlipidemia and reduced HCC multiplicity in obese DEN-treated mice, in which suppressed proliferation and induced apoptosis were confined to tumor cells. The tumor suppression effects of Ex-4 were associated with high expression of GLP-1R and activation of cyclic AMP ( cAMP) and protein kinase A (PKA). Importantly, Ex-4 also downregulated epidermal growth factor receptor ( EGFR) and signal transducer and activator of transcription 3 (STAT3), which lie downstream of cAMP-PKA signaling, resulting in suppression of multiple STAT3-targeted genes including c-Myc, cyclin D1, survivin, Bcl-2 and Bcl-xl. The growth inhibitory effects of Ex-4 were consistent in GLP-1R-abundant hepatoma cell lines and xenograft mouse model, wherein both PKA and EGFR had obligatory roles in mediating Ex-4 functions. In addition, Ex- 4 also effectively suppressed inflammatory and fibrotic phenotypes in mice fed with methionine-choline-deficient (MCD) diet and choline-deficient ethionine-supplemented (CDE) diet, respectively. In summary, Ex-4 elicits protective functions against NAFLD and obesity-associated HCC through cAMP-PKA-EGFR-STAT3 signaling, suggesting its administration as a novel approach to reduce HCC risk in diabetic patients.	[Zhou, M.; Sun, H.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Mok, M. T. S.; Huang, Y.; Cheng, A. S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Mok, M. T. S.; Cheng, A. S. L.] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Sun, H.] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Liver Surg, Shanghai, Peoples R China; [Chan, A. W.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Cheng, A. S. L.] Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Xu, G.] Sun Yat Sen Univ, Diabet Ctr, Affiliated Hosp 8, Shenzhen, Peoples R China; [Xu, G.] Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 8, Shenzhen, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen; Shanghai Jiao Tong University; Chinese University of Hong Kong; Chinese University of Hong Kong; Sun Yat Sen University; Sun Yat Sen University	Cheng, ASL (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.; Cheng, ASL (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China.; Xu, G (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 8, Shenzhen, Peoples R China.	alfredcheng@cuhk.edu.hk; gangxu55@yahoo.com	Chan, Anthony Wing Hung/HGB-4311-2022; Mok, Myth/M-2958-2013; Chan, Anthony W.H./N-6719-2016; Cheng, Alfred SL/C-3327-2014; Chan, Anthony/U-7768-2019; Huang, Yu/K-2866-2017	Chan, Anthony Wing Hung/0000-0002-1771-163X; Mok, Myth/0000-0003-3156-4944; Chan, Anthony W.H./0000-0002-1771-163X; Cheng, Alfred SL/0000-0003-2345-6951; Chan, Anthony/0000-0002-1771-163X; Huang, Yu/0000-0002-1277-6784	Collaborative Research Fund [C4017-14G]; Research Grants Council of Hong Kong [14120816]; National Natural Science Foundation of China [81272305, 81170722, 81270438, 81302167, 81501210]; Chinese University of Hong Kong [1907301]	Collaborative Research Fund; Research Grants Council of Hong Kong(Hong Kong Research Grants Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese University of Hong Kong(Chinese University of Hong Kong)	This study is supported by the Collaborative Research Fund (C4017-14G) and the General Research Fund (14120816) of the Research Grants Council of Hong Kong, National Natural Science Foundation of China (81272305, 81170722, 81270438, 81302167 and 81501210) and Focused Investments Scheme B (1907301) of the Chinese University of Hong Kong.	Absood A, 2008, REGUL PEPTIDES, V146, P285, DOI 10.1016/j.regpep.2007.11.002; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; Boehm AL, 2008, MOL PHARMACOL, V73, P1632, DOI 10.1124/mol.107.044636; Caretta Antonio, 2011, Cancers (Basel), V3, P913, DOI 10.3390/cancers3010913; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Chang CH, 2012, HEPATOLOGY, V55, P1462, DOI 10.1002/hep.25509; Chen HP, 2013, GUT, V62, P606, DOI 10.1136/gutjnl-2011-301708; Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X; Delghandi MP, 2005, CELL SIGNAL, V17, P1343, DOI 10.1016/j.cellsig.2005.02.003; Ding XK, 2006, HEPATOLOGY, V43, P173, DOI 10.1002/hep.21006; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; Egan AG, 2014, NEW ENGL J MED, V370, P794, DOI 10.1056/NEJMp1314078; El-Serag HB, 2006, CLIN GASTROENTEROL H, V4, P369, DOI 10.1016/j.cgh.2005.12.007; Elashoff M, 2011, GASTROENTEROLOGY, V141, P150, DOI 10.1053/j.gastro.2011.02.018; Fan R, 2010, DIABETES OBES METAB, V12, P815, DOI 10.1111/j.1463-1326.2010.01238.x; Farrell GC, 2013, NAT REV GASTRO HEPAT, V10, P307, DOI 10.1038/nrgastro.2013.34; Feng X, 2013, J PHARMACOVIGILANCE, V1, P110; Gupta NA, 2010, HEPATOLOGY, V51, P1584, DOI 10.1002/hep.23569; Hopfner M, 2004, J HEPATOL, V41, P1008, DOI 10.1016/j.jhep.2004.08.024; Hosokawa T, 2013, WORLD J GASTROENTERO, V19, P249, DOI 10.3748/wjg.v19.i2.249; HSUAN JJ, 1993, ANTICANCER RES, V13, P2521; Ito Y, 1999, HEPATOLOGY, V30, P90, DOI 10.1002/hep.510300114; Ito Y, 2001, BRIT J CANCER, V84, P1377, DOI 10.1054/bjoc.2000.1580; Kang ZF, 2013, DIABETOLOGIA, V56, P423, DOI 10.1007/s00125-012-2776-x; Koehler JA, 2006, DIABETES, V55, P1369, DOI 10.2337/db05-1145; Koehler JA, 2011, ENDOCRINOLOGY, V152, P3362, DOI 10.1210/en.2011-1201; Korner M, 2007, J NUCL MED, V48, P736, DOI 10.2967/jnumed.106.038679; Kohli R, 2010, HEPATOLOGY, V52, P934, DOI 10.1002/hep.23797; Kovach SJ, 2006, J CELL PHYSIOL, V206, P411, DOI 10.1002/jcp.20474; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Ligumsky H, 2012, BREAST CANCER RES TR, V132, P449, DOI 10.1007/s10549-011-1585-0; Mayoral R, 2005, CARCINOGENESIS, V26, P753, DOI 10.1093/carcin/bgi022; Nauck M, 2016, DIABETES OBES METAB, V18, P203, DOI 10.1111/dom.12591; Nauck MA, 2013, DIABETES CARE, V36, pS245, DOI 10.2337/dcS13-2004; Nomiyama T, 2014, DIABETES, V63, P3891, DOI 10.2337/db13-1169; Otsuka M, 2004, HEPATOLOGY, V40, P243, DOI 10.1002/hep.20260; Schiffer E, 2005, HEPATOLOGY, V41, P307, DOI 10.1002/hep.20538; Shao H, 2003, CANCER RES, V63, P3923; Svegliati-Baroni G, 2011, LIVER INT, V31, P1285, DOI 10.1111/j.1478-3231.2011.02462.x; Targher G, 2007, DIABETES CARE, V30, P1212, DOI 10.2337/dc06-2247; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526; Wang P, 2012, DIABETES-METAB RES, V28, P109, DOI 10.1002/dmrr.1291; Watanabe J, 2004, SURGERY, V135, P604, DOI 10.1016/j.surg.2003.11.015; Yang Y, 2011, MED ONCOL, V28, P796, DOI 10.1007/s12032-010-9519-y; Yu Z, 2014, GUT, V63, P1793, DOI 10.1136/gutjnl-2013-305584	46	19	20	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4135	4149		10.1038/onc.2017.38	http://dx.doi.org/10.1038/onc.2017.38			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319060				2022-12-17	WOS:000405835800005
J	Obata, Y; Horikawa, K; Takahashi, T; Akieda, Y; Tsujimoto, M; Fletcher, JA; Esumi, H; Nishida, T; Abe, R				Obata, Y.; Horikawa, K.; Takahashi, T.; Akieda, Y.; Tsujimoto, M.; Fletcher, J. A.; Esumi, H.; Nishida, T.; Abe, R.			Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors	ONCOGENE			English	Article							C-KIT; ENDOPLASMIC-RETICULUM; INHIBITOR STI571; PI 3-KINASE; IMATINIB; MUTATIONS; ACTIVATION; MECHANISMS; RESISTANT; MEMBRANE	Gastrointestinal stromal tumors (GISTs) are caused by gain-of-function mutations in the Kit receptor tyrosine kinase. Most primary GIST patients respond to the Kit inhibitor imatinib, but this drug often becomes ineffective because of secondary mutations in the Kit kinase domain. The characteristic intracellular accumulation of imatinib-sensitive and - resistant Kit protein is well documented, but its relationship to oncogenic signaling remains unknown. Here, we show that in cancer tissue from primary GIST patients as well as in cell lines, mutant Kit accumulates on the Golgi apparatus, whereas normal Kit localizes to the plasma membrane (PM). In imatinib-resistant GIST with a secondary Kit mutation, Kit localizes predominantly on the Golgi apparatus. Both imatinib-sensitive and imatinib-resistant Kit (Kit(mut)) become fully auto-phosphorylated only on the Golgi and only if in a complex-glycosylated form. Kit(mut) accumulates on the Golgi during the early secretory pathway, but not after endocytosis. The aberrant kinase activity of Kit(mut) prevents its export from the Golgi to the PM. Furthermore, Kit(mut) on the Golgi signals and activates the phosphatidylinositol 3-kinase-Akt (PI3K-Akt) pathway, signal transducer and activator of transcription 5 (STAT5), and the Mek-Erk pathway. Blocking the biosynthetic transport of Kit(mut) to the Golgi from the endoplasmic reticulum inhibits oncogenic signaling. PM localization of Kit(mut) is not required for its signaling. Activation of Src-family tyrosine kinases on the Golgi is essential for oncogenic Kit signaling. These results suggest that the Golgi apparatus serves as a platform for oncogenic Kit signaling. Our study demonstrates that Kit(mut)'s pathogenicity is related to its mislocalization, and may offer a new strategy for treating imatinib-resistant GISTs.	[Obata, Y.; Horikawa, K.; Akieda, Y.; Abe, R.] Tokyo Univ Sci, Res Inst Biomed Sci, Div Immunobiol, Yamazaki 2669, Noda, Chiba 2780022, Japan; [Takahashi, T.] Osaka Univ, Grad Sch Med, Dept Surg, Suita, Osaka, Japan; [Tsujimoto, M.] Osaka Police Hosp, Dept Diagnost Pathol, Osaka, Osaka, Japan; [Fletcher, J. A.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Fletcher, J. A.] Harvard Med Sch, Boston, MA USA; [Esumi, H.] Tokyo Univ Sci, Res Inst Biomed Sci, Div Clin Res, Noda, Chiba, Japan; [Nishida, T.] Natl Canc Ctr, Chuo Ku, Tokyo, Japan	Tokyo University of Science; Osaka University; Osaka Police Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Tokyo University of Science; National Cancer Center - Japan	Abe, R (corresponding author), Tokyo Univ Sci, Res Inst Biomed Sci, Div Immunobiol, Yamazaki 2669, Noda, Chiba 2780022, Japan.	rabe@rs.noda.tus.ac.jp		Akieda, Yuki/0000-0001-7899-3186	Japanese Ministry of Education, Culture, Sports, Science and Technology [16K18427, 16H05419, 15K06843]; Uehara Memorial Foundation; NOVARTIS FOUNDATION (Japan) for the Promotion of Science; Grants-in-Aid for Scientific Research [16K18427] Funding Source: KAKEN	Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); NOVARTIS FOUNDATION (Japan) for the Promotion of Science(Novartis); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Eiji Miyoshi (Osaka University), Satoshi Owada (Tokai University), Dr Kazuo Kurokawa, and Dr Akihiko Nakano (RIKEN) for their helpful advice. We are grateful to Dr Rie Nakatsuka (Osaka University), Dr Shota Toyoshima, Dr Yasushi Hara, and Dr Isamu Shiina (Tokyo University of Science) for their helpful advice and sharing of materials throughout this study. This work was supported by a grant-in-aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (16K18427 to YO, 16H05419 to TN, and 15K06843 to RA), a research grant from the Uehara Memorial Foundation (to YO and TN) and from the NOVARTIS FOUNDATION (Japan) for the Promotion of Science (to YO).	Agaimy A, 2013, INT J CLIN EXP PATHO, V6, P1839; Bahlawane C, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0096-8; Bauer S, 2007, ONCOGENE, V26, P7560, DOI 10.1038/sj.onc.1210558; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boissan M, 2000, J LEUKOCYTE BIOL, V67, P135, DOI 10.1002/jlb.67.2.135; Bosbach B, 2012, P NATL ACAD SCI USA, V109, pE2276, DOI 10.1073/pnas.1115240109; Bougherara H, 2009, MOL CANCER RES, V7, P1525, DOI 10.1158/1541-7786.MCR-09-0138; Burger H, 2015, MOL PHARMACOL, V88, P477, DOI 10.1124/mol.114.097451; Chaix A, 2014, ONCOGENE, V33, P872, DOI 10.1038/onc.2013.12; Chen H, 2003, INT J CANCER, V105, P130, DOI 10.1002/ijc.11025; Chi P, 2010, NATURE, V467, P849, DOI 10.1038/nature09409; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Chung BM, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-84; De Matteis MA, 2004, NAT CELL BIOL, V6, P487, DOI 10.1038/ncb0604-487; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Debiec-Rychter M, 2006, EUR J CANCER, V42, P1093, DOI 10.1016/j.ejca.2006.01.030; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Edris B, 2013, P NATL ACAD SCI USA, V110, P3501, DOI 10.1073/pnas.1222893110; Emile JF, 2009, AM J SURG PATHOL, V33, P157, DOI 10.1097/PAS.0b013e3181883765; Fu D, 2014, NAT CHEM, V6, P615, DOI [10.1038/NCHEM.1961, 10.1038/nchem.1961]; Gibbs L, 2007, BBA-MOL CELL RES, V1773, P502, DOI 10.1016/j.bbamcr.2006.12.010; Gonzalez-Campora R, 2011, ANAL QUANT CYTOL, V33, P1; Gordon PM, 2010, J BIOL CHEM, V285, P14109, DOI 10.1074/jbc.M109.078592; Goss PE, 1995, CLIN CANCER RES, V1, P935; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; Growney JD, 2005, BLOOD, V106, P721, DOI 10.1182/blood-2004-12-4617; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2001, J PATHOL, V193, P505, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E; Jaramillo S, 2012, REV ESP ENFERM DIG, V104, P128, DOI 10.4321/s1130-01082012000300005; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kon S, 2013, J CLIN INVEST, V123, P1123, DOI 10.1172/JCI63711; Lasota J, 2008, HISTOPATHOLOGY, V53, P245, DOI 10.1111/j.1365-2559.2008.02977.x; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; Ma PL, 2011, MOL CELL BIOL, V31, P4052, DOI 10.1128/MCB.05750-11; MAEDA H, 1992, DEVELOPMENT, V116, P369; Matsuda D, 2006, EXP CELL RES, V312, P1205, DOI 10.1016/j.yexcr.2006.02.003; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Nishida T, 2008, CANCER SCI, V99, P799, DOI 10.1111/j.1349-7006.2008.00727.x; Obata Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6715; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Peterson MR, 2006, APPL IMMUNOHISTO M M, V14, P390, DOI 10.1097/01.pai.0000203038.33414.a3; Pulvirenti T, 2008, NAT CELL BIOL, V10, P912, DOI 10.1038/ncb1751; Ran LL, 2015, CANCER DISCOV, V5, P304, DOI 10.1158/2159-8290.CD-14-0985; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V338, P1307, DOI 10.1016/j.bbrc.2005.09.150; Rossi F, 2006, P NATL ACAD SCI USA, V103, P12843, DOI 10.1073/pnas.0511076103; Rubin BP, 2006, LAB INVEST, V86, P981, DOI 10.1038/labinvest.3700466; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Schmidt-Arras D, 2014, J CELL SCI, V127, P341, DOI 10.1242/jcs.130294; SUCHY SF, 1995, HUM MOL GENET, V4, P2245, DOI 10.1093/hmg/4.12.2245; Tabone-Eglinger S, 2008, CLIN CANCER RES, V14, P2285, DOI 10.1158/1078-0432.CCR-07-4102; Taguchi T, 2002, LAB INVEST, V82, P663, DOI 10.1038/labinvest.3780461; Takahashi T, 2013, INT J CANCER, V133, P2737, DOI 10.1002/ijc.28282; Thomsen L, 1998, NAT MED, V4, P848, DOI 10.1038/nm0798-848; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Toffalini F, 2010, BLOOD, V116, P2429, DOI 10.1182/blood-2010-04-279752; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Vanderwinden JM, 2006, CELL SIGNAL, V18, P661, DOI 10.1016/j.cellsig.2005.06.008; von Kleist L, 2011, CELL, V146, P471, DOI 10.1016/j.cell.2011.06.025; Watanuki Z, 2014, BIOCHEM BIOPH RES CO, V455, P269, DOI 10.1016/j.bbrc.2014.11.003; Xiang ZF, 2007, MOL CELL BIOL, V27, P267, DOI 10.1128/MCB.01153-06; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120; Zhu MJ, 2007, ONCOGENE, V26, P6386, DOI 10.1038/sj.onc.1210464	72	19	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3661	3672		10.1038/onc.2016.519	http://dx.doi.org/10.1038/onc.2016.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192400	Green Published, hybrid			2022-12-17	WOS:000404349700002
J	de Jeude, JFV; Meijer, BJ; Wielenga, MCB; Spaan, CN; Baan, B; Rosekrans, SL; Meisner, S; Shen, YH; Lee, AS; Paton, JC; Paton, AW; Muncan, V; van den Brink, GR; Heijmans, J				de Jeude, J. F. van Lidth; Meijer, B. J.; Wielenga, M. C. B.; Spaan, C. N.; Baan, B.; Rosekrans, S. L.; Meisner, S.; Shen, Y. H.; Lee, A. S.; Paton, J. C.; Paton, A. W.; Muncan, V.; van den Brink, G. R.; Heijmans, J.			Induction of endoplasmic reticulum stress by deletion of Grp78 depletes Apc mutant intestinal epithelial stem cells	ONCOGENE			English	Article							RAPID LOSS; IN-VIVO; EXPRESSION; DIFFERENTIATION; TUMORIGENESIS; CANCER; COLON; GENE; APOPTOSIS; ADENOMA	Intestinal epithelial stem cells are highly sensitive to differentiation induced by endoplasmic reticulum (ER) stress. Colorectal cancer develops from mutated intestinal epithelial stem cells. The most frequent initiating mutation occurs in Apc, which results in hyperactivated Wnt signalling. This causes hyperproliferation and reduced sensitivity to chemotherapy, but whether these mutated stem cells are sensitive to ER stress induced differentiation remains unknown. Here we examined this by generating mice in which both Apc and ER stress repressor chaperone Grp78 can be conditionally deleted from the intestinal epithelium. For molecular studies, we used intestinal organoids derived from these mice. Homozygous loss of Apc alone resulted in crypt elongation, activation of the Wnt signature and accumulation of intestinal epithelial stem cells, as expected. This phenotype was however completely rescued on activation of ER stress by additional deletion of Grp78. In these Apc-Grp78 double mutant animals, stem cells were rapidly lost and repopulation occurred by non-mutant cells that had escaped recombination, suggesting that Apc-Grp78 double mutant stem cells had lost self-renewal capacity. Although in Apc-Grp78 double mutant mice the Wnt signature was lost, these intestines exhibited ubiquitous epithelial presence of nuclear beta-catenin. This suggests that ER stress interferes with Wnt signalling downstream of nuclear beta-catenin. In conclusion, our findings indicate that ER stress signalling results in loss of Apc mutated intestinal epithelial stem cells by interference with the Wnt signature. In contrast to many known inhibitors of Wnt signalling, ER stress acts downstream of beta-catenin. Therefore, ER stress poses a promising target in colorectal cancers, which develop as a result of Wnt activating mutations.	[de Jeude, J. F. van Lidth; Meijer, B. J.; Wielenga, M. C. B.; Spaan, C. N.; Baan, B.; Rosekrans, S. L.; Meisner, S.; Shen, Y. H.; Muncan, V.; van den Brink, G. R.; Heijmans, J.] Acad Med Ctr, Tygat Inst Liver & Intestinal Res, Amsterdam, Netherlands; [de Jeude, J. F. van Lidth; Meijer, B. J.; Wielenga, M. C. B.; Spaan, C. N.; Baan, B.; Rosekrans, S. L.; Meisner, S.; Shen, Y. H.; Lee, A. S.; Muncan, V.; van den Brink, G. R.; Heijmans, J.] Acad Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands; [Lee, A. S.] Univ Southern Calif, USC Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA USA; [Paton, J. C.; Paton, A. W.] Univ Adelaide, Res Ctr Infect Dis, Dept Mol & Cellular Biol, Sch Biol Sci, Adelaide, SA, Australia; [Heijmans, J.] Acad Med Ctr, Dept Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Southern California; University of Adelaide	Heijmans, J (corresponding author), Acad Med Ctr, Dept Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.heijmans@amc.nl	Meijer, Bartolomeus/AAU-5300-2021	Heijmans, Jarom/0000-0001-9615-7851; Lee, Amy/0000-0002-0378-5443	VENI grant from the Dutch Organisation for Scientific Research (NWO); Dutch Cancer Foundation (KWF)	VENI grant from the Dutch Organisation for Scientific Research (NWO); Dutch Cancer Foundation (KWF)(KWF Kankerbestrijding)	This work was supported by a VENI grant from the Dutch Organisation for Scientific Research (NWO) and by a research stipendium from the Dutch Cancer Foundation (KWF).	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Heijmans J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022620; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Holik AZ, 2013, STEM CELLS, V31, P2457, DOI 10.1002/stem.1498; Huels DJ, 2015, BRIT J CANCER, V113, P1, DOI 10.1038/bjc.2015.214; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Montgomery RK, 2011, P NATL ACAD SCI USA, V108, P179, DOI 10.1073/pnas.1013004108; Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821-06; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Niederreiter L, 2013, J EXP MED, V210, P2041, DOI 10.1084/jem.20122341; Paton AW, 2006, NATURE, V443, P548, DOI 10.1038/nature05124; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; ROBINE S, 1993, J BIOL CHEM, V268, P11426; Rosekrans SL, 2015, GUT, V64, P195, DOI 10.1136/gutjnl-2013-306347; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van der Flier LG, 2009, GASTROENTEROLOGY, V137, P15, DOI 10.1053/j.gastro.2009.05.035; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; van Dop WA, 2010, GASTROENTEROLOGY, V139, P1665, DOI 10.1053/j.gastro.2010.07.045; van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581; van Galen P, 2014, NATURE, V510, P268, DOI 10.1038/nature13228; Vermeulen L, 2014, NAT REV CANCER, V14, P468, DOI 10.1038/nrc3744; Verras M, 2008, MOL CELL BIOL, V28, P7212, DOI 10.1128/MCB.00947-08; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wielenga MCB, 2015, CELL REP, V13, P489, DOI 10.1016/j.celrep.2015.09.016; Wolfson JJ, 2008, CELL MICROBIOL, V10, P1775, DOI 10.1111/j.1462-5822.2008.01164.x; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5	44	19	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3397	3405		10.1038/onc.2016.326	http://dx.doi.org/10.1038/onc.2016.326			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	27819675	Green Accepted, hybrid			2022-12-17	WOS:000403340700004
J	Xiao, T; Zhu, JJ; Huang, S; Peng, C; He, S; Du, J; Hong, R; Chen, X; Bode, AM; Jiang, W; Dong, Z; Zheng, D				Xiao, T.; Zhu, J. J.; Huang, S.; Peng, C.; He, S.; Du, J.; Hong, R.; Chen, X.; Bode, A. M.; Jiang, W.; Dong, Z.; Zheng, D.			Phosphorylation of NFAT3 by CDK3 induces cell transformation and promotes tumor growth in skin cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NFAT1; CYCLIN-DEPENDENT KINASES; NUCLEAR FACTOR; CYCLOOXYGENASE-2 INDUCTION; BEAS-2B CELLS; CL41 CELLS; DIFFERENTIATION; ACTIVATION; EXPRESSION; PATHWAY	The nuclear factor of activated T cells (NFAT) family proteins are transcription factors that regulate the expression of pro-inflammatory cytokines and other genes during the immune response. Although the NFAT proteins have been extensively investigated in the immune system, their role in cancer progression remains controversial. Here, we report that NFAT3 is highly expressed in various skin cancer cell lines and tumor tissues. Knockdown of endogenous NFAT3 expression by short hairpin RNA (shRNA) significantly inhibited tumor cell proliferation, colony formation and anchorage-independent cell growth. Furthermore, results of the mammalian two-hybrid assay showed that cyclin-dependent kinase 3 (CDK3) directly interacted with NFAT3 and phosphorylated NFAT3 at serine 259 (Ser259), which enhanced the transactivation and transcriptional activity of NFAT3. The phosphorylation site of NFAT3 was critical for epidermal growth factor (EGF)-stimulated cell transformation of the HaCaT immortalized skin cell line and mutation of NFAT3 at Ser259 led to a reduction of colony formation in soft agar. We also found that overexpressing wildtype NFAT3, but not mutant NFAT3-S259A, promoted A431 xenograft tumor growth. Importantly, we showed that CDK3, NFAT3 and phosphorylated NFAT3-Ser259 were highly expressed in skin cancer compared with normal skin tissues. These results provided evidence supporting the oncogenic potential of NFAT3 and suggested that CDK3-mediated phosphorylation of NFAT3 has an important role in skin tumorigenesis.	[Xiao, T.; Zhu, J. J.; Huang, S.; He, S.; Du, J.; Hong, R.; Chen, X.; Jiang, W.; Zheng, D.] Shenzhen Univ, Dept Cell Biol & Genet, Hlth Sci Ctr, Shenzhen Key Lab Translat Med Tumor, 3688 Nanhai Ave, Shenzhen 518060, Peoples R China; [Peng, C.] Cent S Univ, Dept Dermatol, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, 801 16th Ave Northeast, Austin, MN 55912 USA	Shenzhen University; Central South University; University of Minnesota System	Zheng, D (corresponding author), Shenzhen Univ, Dept Cell Biol & Genet, Hlth Sci Ctr, Shenzhen Key Lab Translat Med Tumor, 3688 Nanhai Ave, Shenzhen 518060, Peoples R China.; Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave Northeast, Austin, MN 55912 USA.	zgdong@hi.umn.edu; dzheng@szu.edu.cn		Zhu, Joe/0000-0003-4416-7040	National Natural Science Foundation of China [81071655, 81372149, 81401894, 81402289]; National Science Foundation Projects of Guangdong Province [2014A030313547]; High level Talents Project of Guangdong Province; Shenzhen Municipal Government of China [KQCX20140519104925300, JCYJ20140418193546118, JCYJ20140418091413510, ZDSY20130329101130496]; Natural Science Foundation of SZU [201406]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation Projects of Guangdong Province; High level Talents Project of Guangdong Province; Shenzhen Municipal Government of China; Natural Science Foundation of SZU	This study was supported by grants from the National Natural Science Foundation of China (81071655, 81372149, 81401894, 81402289), the National Science Foundation Projects of Guangdong Province (2014A030313547), the High level Talents Project of Guangdong Province (2013), the Shenzhen Municipal Government of China (KQCX20140519104925300, JCYJ20140418193546118, JCYJ20140418091413510, ZDSY20130329101130496) and Natural Science Foundation of SZU (201406). We thank Dr Barrett J. Rollins for the pRcCMV-cdk3 (pCMV-cdk3); Dr Yong-Yeon Cho for the pACT-TFs and Dr Ke Yao for pGal4-NFAT3 and p3xFlag-NFAT3.	Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Braun K, 1998, ONCOGENE, V17, P2259, DOI 10.1038/sj.onc.1202145; Cho YY, 2007, J BIOL CHEM, V282, P8380, DOI 10.1074/jbc.M611322200; Cho YY, 2009, CANCER RES, V69, P272, DOI 10.1158/0008-5472.CAN-08-3125; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; de Carcer G, 2007, CURR MED CHEM, V14, P969, DOI 10.2174/092986707780362925; Ding J, 2006, J BIOL CHEM, V281, P24405, DOI 10.1074/jbc.M600751200; Fougere M, 2010, ONCOGENE, V29, P2292, DOI 10.1038/onc.2009.499; Friday BB, 2001, J CELL SCI, V114, P303; GLASBEY CA, 1993, CVGIP-GRAPH MODEL IM, V55, P532, DOI 10.1006/cgip.1993.1040; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; Kao SC, 2009, SCIENCE, V323, P651, DOI 10.1126/science.1166562; Keezer SM, 2002, J CELL BIOCHEM, V85, P545, DOI 10.1002/jcb.10162; Li JX, 2006, J CELL BIOCHEM, V99, P1010, DOI 10.1002/jcb.20834; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735; Mizuno H, 2006, MOL CARCINOGEN, V45, P1, DOI 10.1002/mc.20160; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Ouyang W, 2007, CARCINOGENESIS, V28, P2218, DOI 10.1093/carcin/bgm115; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Salazar C, 2005, FEBS LETT, V579, P621, DOI 10.1016/j.febslet.2004.12.029; Tang H, 2007, ARCH BIOCHEM BIOPHYS, V468, P92, DOI 10.1016/j.abb.2007.09.016; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Yamochi T, 2001, EUR J BIOCHEM, V268, P6076, DOI 10.1046/j.0014-2956.2001.02555.x; Yan Y, 2006, J CELL SCI, V119, P2985, DOI 10.1242/jcs.03014; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; Yao K, 2007, CANCER RES, V67, P8725, DOI 10.1158/0008-5472.CAN-06-4788; Zhang H, 2005, J BIOL CHEM, V280, P43188, DOI 10.1074/jbc.M506598200; Zheng D, 2008, CANCER RES, V68, P7650, DOI 10.1158/0008-5472.CAN-08-1137	31	19	19	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2835	2845		10.1038/onc.2016.434	http://dx.doi.org/10.1038/onc.2016.434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27893713	Green Published, hybrid			2022-12-17	WOS:000401697800006
J	Frank, SR; Kollmann, CP; de Jeude, JFV; Thiagarajah, JR; Engelholm, LH; Frodin, M; Hansen, SH				Frank, S. R.; Kollmann, C. P.; de Jeude, J. F. van Lidth; Thiagarajah, J. R.; Engelholm, L. H.; Frodin, M.; Hansen, S. H.			The focal adhesion-associated proteins DOCK5 and GIT2 comprise a rheostat in control of epithelial invasion	ONCOGENE			English	Article							PAXILLIN-KINASE-LINKER; TYROSINE PHOSPHORYLATION; CELL; SRC; ACTIVATION; FAMILY; FAK; COMPLEX; LOCALIZATION; RECRUITMENT	DOCK proteins are guanine nucleotide exchange factors for Rac and Cdc42 GTPases. DOCK1 is the founding member of the family and acts downstream of integrins via the canonical Crk-p130Cas complex to activate Rac GTPases in numerous contexts. In contrast, DOCK5, which possesses the greatest similarity to DOCK1, remains sparingly studied. Here we establish that DOCK5 has a non-redundant role in regulating motile and invasive capacities of epithelial cells. DOCK1 is constitutively associated with sites of integrin attachment termed focal adhesions (FAs). In contrast, we demonstrate that DOCK5 recruitment to FAs in Hela cells is restricted by GIT2, an established regulator of FA signaling. We determine that GIT2 is targeted to FAs in response to Rho-ROCK signaling and actomyosin contractility. Accordingly, inhibition of ROCK activity or MLC function promotes enrichment of DOCK5 in membrane protrusions and nascent cell-substratum adhesions. We further demonstrate that GIT2 inhibits the interaction of DOCK5 with Crk. Moreover, we show that depletion of GIT2 promotes DOCK5-dependent activation of the Crk-p130Cas signaling cascade to promote Rac1-mediated lamellipodial protrusion and FA turnover. The antagonism between GIT2 and DOCK5 extends to non-transformed MCF10A mammary epithelial cells, with DOCK5 'dialing-up' and GIT2 'dialing-down' invasiveness. Finally, we determine that DOCK5 inhibition attenuates invasion and metastasis of MDA-MB-231 cells and prolongs life span of mice injected with these cells. Collectively, our work identifies DOCK5 as a key regulator of epithelial invasion and metastasis, and demonstrates that suppression of DOCK5 by GIT2 represents a previously unappreciated mechanism for coordination of Rho and Rac GTPases.	[Frank, S. R.; Kollmann, C. P.; de Jeude, J. F. van Lidth; Thiagarajah, J. R.; Hansen, S. H.] Childrens Hosp Boston, GI Cell Biol Res Lab, Boston, MA USA; [Frank, S. R.; Kollmann, C. P.; de Jeude, J. F. van Lidth; Thiagarajah, J. R.; Hansen, S. H.] Harvard Med Sch, Enders Bldg,Room 605,300 Longwood Ave, Boston, MA 02115 USA; [Engelholm, L. H.] Rigshosp, Finsen Lab, Copenhagen Bioctr, Copenhagen, Denmark; [Frodin, M.] Univ Copenhagen, Biotech Res & Innovat Ctr, Copenhagen, Denmark	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Rigshospitalet; University of Copenhagen; University of Copenhagen	Hansen, SH (corresponding author), Harvard Med Sch, Enders Bldg,Room 605,300 Longwood Ave, Boston, MA 02115 USA.; Hansen, SH (corresponding author), Childrens Hosp Boston, GI Cell Biol, Enders Bldg,Room 605,300 Longwood Ave, Boston, MA 02115 USA.	steen.hansen@childrens.harvard.edu		Frodin, Morten/0000-0003-3691-9820; Hansen, Steen/0000-0002-9408-4676; Engelholm, Lars/0000-0002-6616-1232	NIH [R01 CA142647]; Danish Cancer Society [R40-A1936-11-S2, R2-A132-02-S2]; Roy and Lynne Frank Foundation; NATIONAL CANCER INSTITUTE [R01CA142647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854, T32DK007477] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Danish Cancer Society(Danish Cancer Society); Roy and Lynne Frank Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was funded by NIH R01 CA142647 to SHH, as well as grants from the Danish Cancer Society R40-A1936-11-S2 to SHH and R2-A132-02-S2 to MF. SHH is a recipient of an Endowed Investigatorship from the Roy and Lynne Frank Foundation.	Brown MC, 2005, MOL BIOL CELL, V16, P4316, DOI 10.1091/mbc.E05-02-0131; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Cote JF, 2006, METHOD ENZYMOL, V406, P41, DOI 10.1016/S0076-6879(06)06004-6; Feng HZ, 2012, P NATL ACAD SCI USA, V109, P3018, DOI 10.1073/pnas.1121457109; Feng HZ, 2011, J CLIN INVEST, V121, P4670, DOI 10.1172/JCI58559; Frank SR, 2008, SEMIN CELL DEV BIOL, V19, P234, DOI 10.1016/j.semcdb.2008.01.002; Frank SR, 2006, EMBO J, V25, P1848, DOI 10.1038/sj.emboj.7601092; Frank SR, 2012, CURR BIOL, V22, P1747, DOI 10.1016/j.cub.2012.07.011; Friedland JC, 2009, SCIENCE, V323, P642, DOI 10.1126/science.1168441; Guilluy C, 2011, TRENDS CELL BIOL, V21, P718, DOI 10.1016/j.tcb.2011.08.002; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kuo JC, 2011, NAT CELL BIOL, V13, P383, DOI 10.1038/ncb2216; Laurin M, 2008, P NATL ACAD SCI USA, V105, P15446, DOI 10.1073/pnas.0805546105; Laurin M, 2014, GENE DEV, V28, P533, DOI 10.1101/gad.236349.113; Laurin M, 2013, P NATL ACAD SCI USA, V110, P7434, DOI 10.1073/pnas.1213050110; Nielsen BS, 2001, AM J PATHOL, V158, P1997, DOI 10.1016/S0002-9440(10)64671-8; Nishikimi A, 2013, EXP CELL RES, V319, P2343, DOI 10.1016/j.yexcr.2013.07.024; Nishikimi A, 2012, CHEM BIOL, V19, P488, DOI 10.1016/j.chembiol.2012.03.008; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; Ogawa K, 2014, J EXP MED, V211, P1401, DOI 10.1084/jem.20131926; Pasapera AM, 2010, J CELL BIOL, V188, P877, DOI 10.1083/jcb.200906012; Patel Manishha, 2011, Small GTPases, V2, P268; Phee H, 2010, NAT IMMUNOL, V11, P503, DOI 10.1038/ni.1868; Premkumar L, 2010, J BIOL CHEM, V285, P13211, DOI 10.1074/jbc.M110.102517; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Sanders MA, 2009, J BIOL CHEM, V284, P27, DOI 10.1074/jbc.M808010200; Sanematsu F, 2013, J BIOL CHEM, V288, P8092, DOI 10.1074/jbc.M112.410423; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Terasawa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046277; Vives V, 2011, J BONE MINER RES, V26, P1099, DOI 10.1002/jbmr.282; Watanabe M, 2014, J IMMUNOL, V193, P5660, DOI 10.4049/jimmunol.1400885; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Yu JXA, 2009, MOL BIOL CELL, V20, P4706, DOI 10.1091/mbc.E09-07-0548	38	19	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1816	1828		10.1038/onc.2016.345	http://dx.doi.org/10.1038/onc.2016.345			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27669437	Green Published, Green Accepted, Green Submitted, hybrid			2022-12-17	WOS:000398128900007
J	Khan, IA; Yoo, BH; Masson, O; Baron, S; Corkery, D; Dellaire, G; Attardi, LD; Rosen, KV				Khan, I. A.; Yoo, B. H.; Masson, O.; Baron, S.; Corkery, D.; Dellaire, G.; Attardi, L. D.; Rosen, K. V.			ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells	ONCOGENE			English	Article							BCL-X-L; RAS-INDUCED TRANSFORMATION; ERBB SIGNALING NETWORK; P53/P63 TARGET PERP; IN-VIVO; ANOIKIS RESISTANCE; EXTRACELLULAR-MATRIX; PANCREATIC ADENOCARCINOMA; CONFERS RESISTANCE; BASEMENT-MEMBRANE	The ability of breast cancer cells to resist anoikis, apoptosis caused by detachment of the non-malignant epithelial cells from the extracellular matrix (ECM), is thought to be critical for breast tumor growth, invasion and metastasis. ErbB2, an oncoprotein that is often overproduced in breast tumors, can block breast cancer cell anoikis via mechanisms that are understood only in part. In an effort to understand them better we found that detachment of the non-malignant human breast epithelial cells from the ECM upregulates a protein Perp in these cells. Perp is a component of the desmosomes, multiprotein complexes involved in cell-to-cell adhesion. Perp can cause apoptosis via unknown mechanisms. We demonstrated that Perp upregulation by cell detachment is driven by detachment-induced loss of epidermal growth factor receptor (EGFR). We also found that Perp knockdown by RNA interference (RNAi) rescues detached cells from death which indicates that Perp contributes to their anoikis. We observed that ErbB2, when overexpressed in detached breast epithelial cells, causes Perp downregulation. Furthermore, ErbB2-directed RNAi or treatment with lapatinib, an ErbB2/EGFR small-molecule inhibitor used for breast cancer therapy, upregulated Perp in ErbB2positive human breast and ovarian carcinoma cells. We established that ErbB2 downregulates Perp by activating an ErbB2 effector protein kinase Mek that blocks detachment-induced EGFR loss in a manner that requires the presence of a signaling protein Sprouty-2. Finally, we observed that restoration of the wild-type Perp levels in ErbB2-overproducing breast epithelial cells increases their anoikis susceptibility and blocks their clonogenicity in the absence of adhesion to the ECM. In summary, we have identified a novel mechanism of ErbB2-mediated mechanism of anoikis resistance of ErbB2-overproducing breast epithelial cells. This mechanism allows such cells to grow without adhesion to the ECM and is driven by ErbB2-induced activation of Mek, subsequent EGFR upregulation and further EGFR-dependent Perp loss.	[Khan, I. A.; Yoo, B. H.; Masson, O.; Rosen, K. V.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; [Khan, I. A.; Yoo, B. H.; Masson, O.; Corkery, D.; Dellaire, G.; Rosen, K. V.] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS, Canada; [Baron, S.; Attardi, L. D.] Stanford Univ, Sch Med, Dept Radiat & Canc Biol, Stanford, CA 94305 USA; [Corkery, D.; Dellaire, G.] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada	Dalhousie University; Dalhousie University; Stanford University; Dalhousie University	Rosen, KV (corresponding author), Dalhousie Univ, Dept Pediat, Atlantic Res Ctr, CRC, Rm C-304,5849 Univ Ave,POB 15000, Halifax, NS B3H 4R2, Canada.	kirill.rosen@dal.ca	Dellaire, Graham/L-9948-2014	Dellaire, Graham/0000-0002-3466-6316; Rosen, Kirill/0000-0002-4317-9907; Corkery, Dale/0000-0001-7930-0134	Canadian Breast Cancer Foundation (CBCF) Atlantic Region operating grant [R13 F14]; CBCF Atlantic Region operating grant [R14 F09]; IWK Health Centre Research Associateship; CIBC Graduate Scholarship in Medical Research from Beatrice Hunter Cancer Research Institute	Canadian Breast Cancer Foundation (CBCF) Atlantic Region operating grant; CBCF Atlantic Region operating grant; IWK Health Centre Research Associateship; CIBC Graduate Scholarship in Medical Research from Beatrice Hunter Cancer Research Institute	This study was supported by the Canadian Breast Cancer Foundation (CBCF) Atlantic Region operating grant (R13 F14) awarded to KR. Contribution of GD was supported by the CBCF Atlantic Region operating grant (R14 F09). BY was a recipient of the IWK Health Centre Research Associateship. DC was a recipient of a CIBC Graduate Scholarship in Medical Research from the Beatrice Hunter Cancer Research Institute. We are grateful to Drs P Lee and A Stadnyk for the materials provided for this study.	ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Attardi LD, 2000, GENE DEV, V14, P704; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Beaudry VG, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001168; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Derouet M, 2007, NEOPLASIA, V9, P536, DOI 10.1593/neo.07217; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Dusek RL, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3171; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Frankel A, 2001, CANCER RES, V61, P4837; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Goc A, 2015, BBA-MOL CELL RES, V1853, P1626, DOI 10.1016/j.bbamcr.2015.03.016; Grassian AR, 2011, J BIOL CHEM, V286, P79, DOI 10.1074/jbc.M110.169821; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Gudjonsson T, 2002, J CELL SCI, V115, P39; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Ihrie RA, 2005, CELL CYCLE, V4, P873, DOI 10.4161/cc.4.7.1836; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Khan AJ, 2002, CLIN CANCER RES, V8, P540; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Kong CS, 2013, OR SURG OR MED OR PA, V115, P95, DOI 10.1016/j.oooo.2012.10.017; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Liu Z, 2006, ONCOGENE, V25, P7680, DOI 10.1038/sj.onc.1209753; Liu ZP, 2006, J BIOL CHEM, V281, P14738, DOI 10.1074/jbc.M508664200; Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200; LJUBIMOV AV, 1992, INT J CANCER, V50, P562, DOI 10.1002/ijc.2910500412; Mcdonald JH, 2014, HDB BIOL STAT, V3rd; Muschler J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003202; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Recondo G, 2014, WORLD J CLIN ONCOL, V5, P440, DOI 10.5306/wjco.v5.i3.440; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roepstorff K, 2008, HISTOCHEM CELL BIOL, V129, P563, DOI 10.1007/s00418-008-0401-3; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SOULE HD, 1990, CANCER RES, V50, P6075; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wilken JA, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-7; Xia WY, 1997, CLIN CANCER RES, V3, P3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoo BH, 2012, INT J CANCER, V131, P357, DOI 10.1002/ijc.26368; Yoo BH, 2011, J BIOL CHEM, V286, P38894, DOI 10.1074/jbc.M111.290692	64	19	20	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5759	5769		10.1038/onc.2016.109	http://dx.doi.org/10.1038/onc.2016.109			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27109096				2022-12-17	WOS:000386998400007
J	Lee, SC; Min, HY; Jung, HJ; Park, KH; Hyun, SY; Cho, J; Woo, JK; Kwon, SJ; Lee, HJ; Johnson, FM; Lee, HY				Lee, S. C.; Min, H-Y; Jung, H. J.; Park, K. H.; Hyun, S. Y.; Cho, J.; Woo, J. K.; Kwon, S. J.; Lee, H-J; Johnson, F. M.; Lee, H-Y			Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors	ONCOGENE			English	Article							SUBEROYLANILIDE HYDROXAMIC ACID; FACTOR RECEPTOR; VORINOSTAT; ACTIVATION; STAT3; IGF2; METHYLATION; PROMOTERS; CANCER; TRIAL	Histone deacetylase (HDAC) inhibitors (HDIs) are promising anticancer therapies and have been clinically used for the treatment of hematological malignancy. However, their efficacy in solid tumors is marginal and drug resistance hampers their further clinical utility. To develop novel strategies for the HDI-based anticancer therapeutics in non-small cell lung cancer (NSCLC), in the present study, we investigated the mechanisms underlying resistance to HDI treatment in NSCLC cells. We show the STAT3-mediated IGF2/IGF-1R signaling cascade as a key modulator for both acquired and primary HDI resistance. The treatment with HDI upregulated IGF2 transcription in NSCLC cells carrying intrinsic or acquired drug resistance via direct binding of STAT3 in IGF2 P3 and P4 promoters. Acetylated STAT3 emerged upon HDAC inhibition was protected from the proteasome-mediated degradation of STAT3 and functioned as a direct transcription factor for IGF2 expression. Genomic or pharmacological strategies targeting STAT3 diminished the HDI-induced IGF2 mRNA expression and overcame the resistance to HDI treatment in HDI-resistant NSCLC-or patient-derived tumor xenograft models. These findings provide new insights into the role of acetylated STAT3-mediated activation of IGF2 transcription in HDI resistance, suggesting IGF2 or STAT3 as novel targets to overcome HDI resistance in NSCLC.	[Lee, S. C.; Min, H-Y; Park, K. H.; Hyun, S. Y.; Cho, J.; Woo, J. K.; Lee, H-Y] Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 08826, South Korea; [Lee, S. C.; Min, H-Y; Park, K. H.; Hyun, S. Y.; Cho, J.; Woo, J. K.; Lee, H-Y] Seoul Natl Univ, Pharmaceut Sci Res Inst, 1 Gwanak Ro, Seoul 08826, South Korea; [Jung, H. J.; Lee, H-Y] Seoul Natl Univ, Interdisciplinary Program Genet Engn, Seoul, South Korea; [Kwon, S. J.; Lee, H-J] Inje Univ, Coll Pharm, Gimhae, South Korea; [Johnson, F. M.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Inje University; University of Texas System; UTMD Anderson Cancer Center	Lee, HY (corresponding author), Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 08826, South Korea.; Lee, HY (corresponding author), Seoul Natl Univ, Pharmaceut Sci Res Inst, 1 Gwanak Ro, Seoul 08826, South Korea.	hylee135@snu.ac.kr		Lee, Ho-Young/0000-0001-7556-9312; Lee, Hyo-Jong/0000-0003-4826-7954	National Research Foundation of Korea (NRF); Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea [NRF-2011-0017639, NRF-2011-0030001]; Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea (National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea) [1520250]; National Institutes of Health [R01 CA100816]; NATIONAL CANCER INSTITUTE [R01CA100816, P30CA016672] Funding Source: NIH RePORTER	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea; Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea (National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Tomas Ekstrom (Karolinska Hospital, Sweden) to kindly provide the information on the structure and sequence of IGF2 promoters. This work was supported by grants from the National Research Foundation of Korea (NRF), the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea ((Nos. NRF-2011-0017639 and NRF-2011-0030001), the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1520250)) and the National Institutes of Health (R01 CA100816).	Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023; Desbois-Mouthon C, 2006, INT J CANCER, V119, P2557, DOI 10.1002/ijc.22221; Dhe-Paganon Sirano, 2011, Int J Biochem Mol Biol, V2, P58; Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999; Eckstein N, 2009, CANCER RES, V69, P2996, DOI 10.1158/0008-5472.CAN-08-3153; Fantin VR, 2008, CANCER RES, V68, P3785, DOI 10.1158/0008-5472.CAN-07-6091; Fantin VR, 2007, CLIN CANCER RES, V13, P7237, DOI 10.1158/1078-0432.CCR-07-2114; Garcia-Manero G, 2008, BLOOD, V111, P1060, DOI 10.1182/blood-2007-06-098061; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Huang GS, 2010, CLIN CANCER RES, V16, P2999, DOI 10.1158/1078-0432.CCR-09-3233; Jin QR, 2014, CARCINOGENESIS, V35, P2232, DOI 10.1093/carcin/bgu129; Kim JS, 2015, CANCER LETT, V361, P197, DOI 10.1016/j.canlet.2015.02.038; Kirschbaum M, 2014, BRIT J HAEMATOL, V167, P185, DOI 10.1111/bjh.13016; Kohda M, 2001, MOL CARCINOGEN, V31, P184, DOI 10.1002/mc.1053; Lawson EA, 2009, J CLIN ENDOCR METAB, V94, P2226, DOI 10.1210/jc.2009-0153; Lee H, 2012, P NATL ACAD SCI USA, V109, P7765, DOI 10.1073/pnas.1205132109; Lee JG, 2015, BIG DATA RES, V2, P74, DOI 10.1016/j.bdr.2015.01.003; Lee JH, 2012, ADV CANCER RES, V116, P39, DOI 10.1016/B978-0-12-394387-3.00002-1; Licciardi PV, 2013, CURR MOL MED, V13, P640; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lui JC, 2013, P NATL ACAD SCI USA, V110, P6181, DOI 10.1073/pnas.1219079110; Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; McCue J, 2005, CURR PROTOC TOXICOL; Min HY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0392-3; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nordin M, 2014, CELL PROLIFERAT, V47, P189, DOI 10.1111/cpr.12106; O'Connor OA, 2006, J CLIN ONCOL, V24, P166, DOI 10.1200/JCO.2005.01.9679; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schoenherr CJ, 2003, NAT GENET, V33, P66, DOI 10.1038/ng1057; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Shan JJ, 2012, HEPATOLOGY, V56, P1004, DOI 10.1002/hep.25745; Shin DH, 2013, JNCI-J NATL CANCER I, V105, P1558, DOI 10.1093/jnci/djt263; Shin DH, 2011, MOL CANCER THER, V10, P2437, DOI 10.1158/1535-7163.MCT-11-0235; Singh P, 1998, GASTROENTEROLOGY, V114, P1221, DOI 10.1016/S0016-5085(98)70428-7; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; Tada Y, 2015, ONCOGENE, V34, P752, DOI 10.1038/onc.2013.599; Traynor AM, 2009, J THORAC ONCOL, V4, P522, DOI 10.1097/JTO.0b013e3181952478; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wang KP, 2008, J BIOL CHEM, V283, P34029, DOI 10.1074/jbc.M803012200; Wang XC, 2012, INT J ONCOL, V41, P1181, DOI 10.3892/ijo.2012.1568; Yee D, 2012, JNCI-J NATL CANCER I, V104, P975, DOI 10.1093/jnci/djs258; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang XD, 2008, NAT METHODS, V5, P163, DOI 10.1038/NMETH1170	50	19	22	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5515	5526		10.1038/onc.2016.92	http://dx.doi.org/10.1038/onc.2016.92			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27086926	Green Accepted			2022-12-17	WOS:000386998200006
J	Mao, X; Gauche, C; Coughtrie, MWH; Bui, C; Gulberti, S; Merhi-Soussi, F; Ramalanjaona, N; Bertin-Jung, I; Diot, A; Dumas, D; Caires, ND; Thompson, AM; Bourdon, JC; Ouzzine, M; Fournel-Gigleux, S				Mao, X.; Gauche, C.; Coughtrie, M. W. H.; Bui, C.; Gulberti, S.; Merhi-Soussi, F.; Ramalanjaona, N.; Bertin-Jung, I.; Diot, A.; Dumas, D.; Caires, N. De Freitas; Thompson, A. M.; Bourdon, J-C; Ouzzine, M.; Fournel-Gigleux, S.			The heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a novel tumor regulator and a prognostic marker in breast cancer	ONCOGENE			English	Article							FIBROBLAST-GROWTH-FACTOR; EXPRESSION; RECEPTOR; CELLS; PROTEOGLYCANS; METHYLATION; MAMMARY; HYPERMETHYLATION; BIOSYNTHESIS; SPECIFICITY	Heparan sulfate (HS) proteoglycan chains are key components of the breast tumor microenvironment that critically influence the behavior of cancer cells. It is established that abnormal synthesis and processing of HS play a prominent role in tumorigenesis, albeit mechanisms remain mostly obscure. HS function is mainly controlled by sulfotransferases, and here we report a novel cellular and pathophysiological significance for the 3-O-sulfotransferase 3-OST3A (HS3ST3A), catalyzing the final maturation step of HS, in breast cancer. We show that 3-OST3A is epigenetically repressed in all breast cancer cell lines of a panel representative of distinct molecular subgroups, except in human epidermal growth factor receptor 2-positive (HER2+) sloan-kettering breast cancer (SKBR3) cells. Epigenetic mechanisms involved both DNA methylation and histone modifications, producing different repressive chromatin environments depending on the cell molecular signature. Gain and loss of function experiments by cDNA and siRNA transfection revealed profound effects of 3-OST3A expression on cell behavior including apoptosis, proliferation, response to trastuzumab in vitro and tumor growth in xenografted mice. 3-OST3A exerted dual activities acting as tumor-suppressor in lumA-michigan cancer foundation (MCF)-7 and triple negative-MD Anderson (MDA) metastatic breast (MB)-231 cells, or as an oncogenic factor in HER2+-SKBR3 cells. Mechanistically, fluorescence-resonance energy transfer-fluorescence-lifetime imaging microscopy experiments indicated that the effects of 3-OST3A in MCF-7 cells were mediated by altered interactions between HS and fibroblast growth factor-7 (FGF-7). Further, this interplay between HS and FGF-7 modulated downstream ERK, AKT and p38 cascades, suggesting that altering 3-O-sulfation affects FGFR2IIIb-mediated signaling. Corroborating our cellular data, a clinical study conducted in a cohort of breast cancer patients uncovered that, in HER2+ patients, high level expression of 3-OST3A in tumors was associated with reduced relapse-free survival. Our findings define 3-OST3A as a novel regulator of breast cancer pathogenicity, displaying tumor-suppressive or oncogenic activities in a cell-and tumor-dependent context, and demonstrate the clinical value of the HS-O-sulfotransferase 3-OST3A as a prognostic marker in HER2+ patients.	[Mao, X.; Gauche, C.; Bui, C.; Gulberti, S.; Merhi-Soussi, F.; Ramalanjaona, N.; Bertin-Jung, I.; Dumas, D.; Ouzzine, M.; Fournel-Gigleux, S.] Univ Lorraine IMoPA, CNRS, UMR 7365, MolCelTEG Team, Vandoeuvre Les Nancy, France; [Mao, X.; Gauche, C.; Bui, C.; Gulberti, S.; Merhi-Soussi, F.; Ramalanjaona, N.; Bertin-Jung, I.; Dumas, D.; Ouzzine, M.; Fournel-Gigleux, S.] Univ Lorraine, Fac Med, Glycofluo Platform, Biopole, Campus Biol Sante, Vandoeuvre Les Nancy, France; [Mao, X.] Luxembourg Inst Hlth, Lab Expt Canc Res, Luxembourg, Luxembourg; [Coughtrie, M. W. H.; Diot, A.; Bourdon, J-C] Univ Dundee, Med Res Inst, Div Canc Res, Dundee, Scotland; [Coughtrie, M. W. H.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Dumas, D.] PTIBC IBISA Nancy, Cellular & Tissular Core Imaging Facil, Vandoeuvre Les Nancy, France; [Caires, N. De Freitas] INSERM, U1019E11, Lille, France; [Thompson, A. M.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Lorraine; Universite de Lorraine; Luxembourg Institute of Health; University of Dundee; University of British Columbia; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Texas System; UTMD Anderson Cancer Center	Fournel-Gigleux, S (corresponding author), Univ Lorraine, Univ Lorraine IMoPA, MolCelTEG Team, UMR 7365,CNRS,Biopole,Fac Med, Campus Biol Sante,CS 50184, F-54505 Vandoeuvre Les Nancy, Lorraine, France.	sylvie.fournel-gigleux@univ-lorraine.fr	JC, Bourdon/A-4439-2008; Coughtrie, Michael/C-3855-2009; Ouzzine, Mohamed/G-4368-2013	JC, Bourdon/0000-0003-4623-9386; Coughtrie, Michael/0000-0003-1989-1416; GULBERTI, Sandrine/0000-0002-9378-4697; OUZZINE, Mohamed/0000-0003-0058-4950	Agence Nationale de la Recherche (ANR-GAG Network) [ANR-08-PCVI-0023]; Royal Society; Region Lorraine; Lorraine University; International Associated Laboratory (SFGEN); Cancer Research UK (CRUK); NHS Tayside through the Chief Scientist Office; Agence Nationale de la Recherche (ANR Meca-GT) [ANR-13-BSV8-0011-01]; NHS Tayside through Health Sciences Scotland; Breast Cancer Campaign; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Agence Nationale de la Recherche (ANR-GAG Network)(French National Research Agency (ANR)); Royal Society(Royal Society of London); Region Lorraine(Region Grand-Est); Lorraine University; International Associated Laboratory (SFGEN); Cancer Research UK (CRUK)(Cancer Research UK); NHS Tayside through the Chief Scientist Office; Agence Nationale de la Recherche (ANR Meca-GT)(French National Research Agency (ANR)); NHS Tayside through Health Sciences Scotland; Breast Cancer Campaign; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr Philippe Lassalle (INSERM U1019E11, Campus Institut Pasteur de Lille, Lille, France) is gratefully acknowledged for support with the xenograft experiments and for helpful discussion. Matthieu Chabel and Anne Robert are acknowledged for excellent technical assistance and Xiaomeng Pang is acknowledged for performing methylation analysis. This work was supported by Agence Nationale de la Recherche (ANR-GAG Network ANR-08-PCVI-0023 and ANR Meca-GT ANR-13-BSV8-0011-01), a Royal Society International Joint grant (to MWHC and SF-G), grants from Region Lorraine and Lorraine University to SF-G and to NR, and was carried out under auspices of the International Associated Laboratory (SFGEN) funded between CNRS-UL (SF-G) and University of Dundee (J-CB and MWHC). Tayside Tissue Bank is supported by Breast Cancer Campaign, Cancer Research UK (CRUK) and by NHS Tayside through the Chief Scientist Office and Health Sciences Scotland (formerly the Scottish Academic Health Science Collaboration, AHSC).	Bai AL, 2010, CANCER RES, V70, P7630, DOI 10.1158/0008-5472.CAN-10-1489; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Bourdon JC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2811; Breton C, 2012, CURR OPIN STRUC BIOL, V22, P540, DOI 10.1016/j.sbi.2012.06.007; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Bui C, 2010, FASEB J, V24, P436, DOI 10.1096/fj.09-136291; Cha JY, 2008, MOL CANCER RES, V6, P435, DOI 10.1158/1541-7786.MCR-07-0187; Cha JYY, 2009, J BIOL CHEM, V284, P6227, DOI 10.1074/jbc.M803998200; Delehedde M, 2001, J MAMMARY GLAND BIOL, V6, P253, DOI 10.1023/A:1011367423085; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362; FOURNELGIGLEUX S, 1991, MOL PHARMACOL, V39, P177; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Girardin EP, 2005, J BIOL CHEM, V280, P38059, DOI 10.1074/jbc.M507997200; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Gulberti S, 2005, J BIOL CHEM, V280, P1417, DOI 10.1074/jbc.M411552200; Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627; Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790; Hwang JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079634; Jacquemier J, 1998, J PATHOL, V186, P269, DOI 10.1002/(SICI)1096-9896(1998110)186:3<269::AID-PATH187>3.0.CO;2-G; Kadamb R, 2013, EUR J CELL BIOL, V92, P237, DOI 10.1016/j.ejcb.2013.09.001; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375; Kokura K, 2010, EMBO J, V29, P3673, DOI 10.1038/emboj.2010.239; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Lofgren L, 2007, ANTICANCER RES, V27, P3045; Luo YD, 2006, J BIOL CHEM, V281, P21052, DOI 10.1074/jbc.M601559200; Marcel V, 2014, CELL DEATH DIFFER, V21, P1377, DOI 10.1038/cdd.2014.73; Mehta M, 2010, ANTICANCER RES, V30, P4883; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Nieto L, 2013, CHEMBIOCHEM, V14, P1732, DOI 10.1002/cbic.201300313; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Purdie CA, 2010, HISTOPATHOLOGY, V56, P702, DOI 10.1111/j.1365-2559.2010.03533.x; Raman Karthik, 2010, Curr Chem Biol, V4, P20; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679; Song K, 2011, CANCER BIOL THER, V12, P388, DOI 10.4161/cbt.12.5.15957; Staub J, 2007, ONCOGENE, V26, P4969, DOI 10.1038/sj.onc.1210300; Thacker BE, 2014, MATRIX BIOL, V35, P60, DOI 10.1016/j.matbio.2013.12.001; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; Xu RY, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.398826; Ye S, 2001, BIOCHEMISTRY-US, V40, P14429, DOI 10.1021/bi011000u; Zang XP, 2004, CLIN EXP METASTAS, V21, P437, DOI 10.1007/s10585-004-2051-8	48	19	19	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5043	5055		10.1038/onc.2016.44	http://dx.doi.org/10.1038/onc.2016.44			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27041583	Green Submitted			2022-12-17	WOS:000383965300008
J	Podmirseg, SR; Jakel, H; Ranches, GD; Kullmann, MK; Sohm, B; Villunger, A; Lindner, H; Hengst, L				Podmirseg, S. R.; Jaekel, H.; Ranches, G. D.; Kullmann, M. K.; Sohm, B.; Villunger, A.; Lindner, H.; Hengst, L.			Caspases uncouple p27(Kip1) from cell cycle regulated degradation and abolish its ability to stimulate cell migration and invasion	ONCOGENE			English	Article							DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; CDK-INHIBITORS; NEURONAL DIFFERENTIATION; MOLECULAR-MECHANISMS; UP-REGULATION; IN-VITRO; APOPTOSIS; PHOSPHORYLATION; P27	In addition to their role in programmed cell death, caspases exert non-lethal functions in diverse developmental processes including cell differentiation or tissue remodeling. Terminal cell cycle exit and differentiation can be promoted by increased level of the CDK inhibitor p27(Kip1). Activated caspases cause proteolytic processing of p27, and we identified a novel caspase cleavage site in human p27 that removes a C-terminal fragment of 22 amino acids from the CDK inhibitor, including a phosphodegron. Thereby, caspases protect the inhibitor from SCF-Skp2-mediated degradation in S, G2 and M phases of the cell cycle. As a consequence, p27 becomes stabilized and remains an efficient nuclear inhibitor of cell cycle progression. Besides controlling cyclin/CDK kinase activity, p27 also regulates cytoskeletal dynamics, cell motility and cell invasion. Following processing by caspases, p27 fails to bind to RhoA and to inhibit its activation, and thereby abolishes the ability of p27 to stimulate cell migration and invasion. We propose that the stabilization of the CDK inhibitor and elimination of RhoA-induced cytoskeletal remodeling upon caspase processing could contribute to cell cycle exit and cytoskeletal remodeling during non-lethal caspase controlled differentiation processes.	[Podmirseg, S. R.; Jaekel, H.; Ranches, G. D.; Kullmann, M. K.; Hengst, L.] Med Univ Innsbruck, Bioctr, Div Med Biochem, Innsbruck, Austria; [Sohm, B.] Univ Lorraine, LIEC, UMR 7360, Metz, France; [Sohm, B.] CNRS, LIEC, UMR 7360, Metz, France; [Villunger, A.] Med Univ Innsbruck, Bioctr, Div Dev Immunol, Innsbruck, Austria; [Villunger, A.] Tyrolean Canc Res Inst, Innsbruck, Austria; [Lindner, H.] Med Univ Innsbruck, Bioctr, Div Clin Biochem, Innsbruck, Austria	Medical University of Innsbruck; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Lorraine; Medical University of Innsbruck; Medical University of Innsbruck	Hengst, L (corresponding author), Bioctr, Div Med Biochem, Innrain 80-82, A-6020 Innsbruck, Austria.	ludger.hengst@i-med.ac.at	Kullmann, Michael Keith/AGY-4711-2022	SOHM, Benedicte/0000-0002-7204-5414; Kullmann, Michael Keith/0000-0003-3567-3806; Ranches, Glory/0000-0002-3623-1746; Hengst, Ludger/0000-0002-0605-0223	FWF [P24031, P26856]; Tiroler Krebshilfe; Austrian Science Fund (FWF) [P 24031] Funding Source: researchfish	FWF(Austrian Science Fund (FWF)); Tiroler Krebshilfe; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We acknowledge Stephan Geley for providing plasmids and cell lines, Jan Wiegers for useful advice with mouse experiments and all members of the Hengst lab for their help and stimulating discussions. Work was funded by the FWF-grant P24031 to Ludger Hengst, the FWF-grant P26856 to Andreas Villunger and the Tiroler Krebshilfe.	Ashkenazi A, 2014, ANNU REV CELL DEV BI, V30, P337, DOI 10.1146/annurev-cellbio-100913-013226; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bryja V, 2004, CELL MOL LIFE SCI, V61, P1384, DOI 10.1007/s00018-004-4081-4; Chen P, 1999, DEVELOPMENT, V126, P1581; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coleman ML, 2002, CELL DEATH DIFFER, V9, P493, DOI 10.1038/sj.cdd.4400987; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Crawford ED, 2013, MOL CELL PROTEOMICS, V12, P813, DOI 10.1074/mcp.O112.024372; Cremisi F, 2003, CURR OPIN NEUROBIOL, V13, P26, DOI 10.1016/S0959-4388(03)00005-9; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; De Vita F, 2012, CELL CYCLE, V11, P1583, DOI 10.4161/cc.20003; Dehay C, 2007, NAT REV NEUROSCI, V8, P438, DOI 10.1038/nrn2097; Dix MM, 2012, CELL, V150, P426, DOI 10.1016/j.cell.2012.05.040; Doetsch F, 2002, J NEUROSCI, V22, P2255, DOI 10.1523/JNEUROSCI.22-06-02255.2002; Durand B, 2000, BIOESSAYS, V22, P64; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Fan XM, 2004, J GASTROEN HEPATOL, V19, P31, DOI 10.1111/j.1440-1746.2004.03194.x; Fuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033; Godin JD, 2012, DEV CELL, V23, P729, DOI 10.1016/j.devcel.2012.08.006; Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Hyman BT, 2012, NAT REV NEUROSCI, V13, P395, DOI 10.1038/nrn3228; Jakel H, 2011, ONCOGENE, V30, P3502, DOI 10.1038/onc.2011.68; Jakel H, 2012, CELL CYCLE, V11, P1910, DOI 10.4161/cc.19957; Janzen V, 2008, CELL STEM CELL, V2, P584, DOI 10.1016/j.stem.2008.03.012; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Katayose Y, 1997, CANCER RES, V57, P5441; Kossatz U, 2006, EMBO J, V25, P5159, DOI 10.1038/sj.emboj.7601388; Kullmann MK, 2013, CELL CYCLE, V12, P2625, DOI 10.4161/cc.25622; Kumar S, 2007, CELL DEATH DIFFER, V14, P32, DOI 10.1038/sj.cdd.4402060; Kurokawa M, 2009, CELL, V138, P838, DOI 10.1016/j.cell.2009.08.021; Lacy ER, 2004, NAT STRUCT MOL BIOL, V11, P358, DOI 10.1038/nsmb746; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Mazumder S, 2002, MOL CELL BIOL, V22, P2398, DOI 10.1128/MCB.22.7.2398-2409.2002; Medina-Palazon C, 2004, EUR J BIOCHEM, V271, P2716, DOI 10.1111/j.1432-1033.2004.04200.x; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nguyen L, 2006, CELL CYCLE, V5, P2314, DOI 10.4161/cc.5.20.3381; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; PERANDONES CE, 1993, J IMMUNOL, V151, P3521; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Rots NY, 1999, BLOOD, V93, P2721, DOI 10.1182/blood.V93.8.2721.408k28_2721_2729; Schiappacassi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017673; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; See WL, 2010, CELL CYCLE, V9, P1562, DOI 10.4161/cc.9.8.11259; Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Tambyrajah WS, 2007, ARCH BIOCHEM BIOPHYS, V466, P186, DOI 10.1016/j.abb.2007.07.019; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tozser J, 2003, BIOCHEM J, V372, P137, DOI 10.1042/BJ20021901; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vosper J, 2015, ONCOTARGET, V6, P2889, DOI 10.18632/oncotarget.3068; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; Woltman AM, 2003, BLOOD, V101, P1439, DOI 10.1182/blood-2002-06-1688; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhang R, 2008, CANCER CHEMOTH PHARM, V62, P407, DOI 10.1007/s00280-007-0619-0; Zhao D, 2015, ONCOGENE, V34, P5447, DOI 10.1038/onc.2014.473; Zou P, 2011, CELL STEM CELL, V9, P247, DOI 10.1016/j.stem.2011.07.003	82	19	19	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4580	4590		10.1038/onc.2015.524	http://dx.doi.org/10.1038/onc.2015.524			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26829051	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000382336300004
J	Conley, SJ; Bosco, EE; Tice, DA; Hollingsworth, RE; Herbst, R; Xiao, Z				Conley, S. J.; Bosco, E. E.; Tice, D. A.; Hollingsworth, R. E.; Herbst, R.; Xiao, Z.			HER2 drives Mucin-like 1 to control proliferation in breast cancer cells	ONCOGENE			English	Article							FOCAL ADHESION KINASE; EPITHELIAL-SPECIFIC DISRUPTION; CYCLE PROGRESSION; EXPRESSION; IDENTIFICATION; AMPLIFICATION; ACTIVATION	Mucin-like 1 (MUCL1) was first identified as a breast-specific gene over a decade ago. Based on its highly restricted mRNA expression in breast tissue and continued expression during breast tumorigenesis and progression, MUCL1 is an attractive tumor-associated antigen and a potential therapeutic target. However, very little is known about the cellular location, biological functions and regulation of the MUCL1 protein, which will have a major impact on its druggability. Here we describe our efforts to fully characterize the cellular localization of MUCL1, investigate its regulation by key breast cancer oncogenes such as human epidermal growth factor receptor 2 (HER2) and discover its functional roles in breast cancer. Although some mucins are membrane bound, our data indicate that MUCL1 is secreted by some breast cancer cells, whereas others only express high levels of intracellular MUCL1. MUCL1 expression is highest in HER2-amplified breast tumors and inhibiting HER2 activity in tumor cells resulted in a decreased MUCL1 expression. In-depth investigation demonstrated that phosphoinositide3-kinase/Akt pathway, but not Ras/MEK pathway, controls MUCL1 expression downstream of HER2. Phenotypic assays revealed a strong dependence of HER2-positive cells on MUCL1 for cell proliferation. We further identified the mechanism by which MUCL1 regulates cell growth. Knockdown of MUCL1 induced a G1/S phase arrest concomitant with decreased cyclin D and increased p21 and p27 levels. Finally, we investigated the impact of MUCL1 loss on kinase signaling pathways in breast cancer cells through phospho-kinase array profiling. MUCL1 silencing abrogated phospho-focal adhesion kinase (FAK), Jun NH2-terminal kinase (JNK) and c-Jun signals, but not extracellular signal-regulated kinase or Akt pathway activities, thereby pointing to FAK/JNK pathway as the downstream effector of MUCL1 signaling. We are the first to identify an important role for MUCL1 in the proliferation of breast cancer cells, probably mediated via the FAK/JNK signaling pathway. Taken together, these data suggest a potential utility for therapeutic targeting of this protein in breast cancer.	[Conley, S. J.; Bosco, E. E.; Tice, D. A.; Hollingsworth, R. E.; Herbst, R.; Xiao, Z.] MedImmune LLC, Oncol Res, One MedImmune Way, Gaithersburg, MD 20878 USA	AstraZeneca; Medimmune	Conley, SJ; Xiao, Z (corresponding author), MedImmune LLC, Oncol Res, One MedImmune Way, Gaithersburg, MD 20878 USA.	conleys@medimmune.com; xiaoz@medimmune.com			MedImmune	MedImmune(AstraZenecaMedimmune)	Funding for research was provided by MedImmune. We thank John Meekin and Rosa Carrasco for the RNA library, and Terry O'Day and Xin Cao for statistical analysis.	Ayerbes MV, 2008, ADV EXP MED BIOL, V617, P331, DOI 10.1007/978-0-387-69080-3_31; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Colpitts TL, 2002, TUMOR BIOL, V23, P263, DOI 10.1159/000068566; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Gluck S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7; Houghton RL, 2001, MOL DIAGN, V6, P79, DOI 10.2165/00066982-200106020-00003; Kao KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-143; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Lambert Arthur W, 2012, ISRN Oncol, V2012, P493283, DOI 10.5402/2012/493283; Liu L, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-71; Liu ZZ, 2010, CLIN EXP METASTAS, V27, P251, DOI 10.1007/s10585-010-9323-2; Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; Miksicek RJ, 2002, CANCER RES, V62, P2736; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Skliris GP, 2008, HISTOPATHOLOGY, V52, P355, DOI 10.1111/j.1365-2559.2007.02955.x; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TIWARI RK, 1992, ANTICANCER RES, V12, P419; Valladares-Ayerbes M, 2009, J CANCER RES CLIN, V135, P1185, DOI 10.1007/s00432-009-0559-7; Wadle A, 2005, INT J CANCER, V117, P104, DOI 10.1002/ijc.21147; Weigelt B, 2004, BRIT J CANCER, V90, P1531, DOI 10.1038/sj.bjc.6601659; Yang Hua-Wei, 2005, Ai Zheng, V24, P842; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	25	19	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4225	4234		10.1038/onc.2015.487	http://dx.doi.org/10.1038/onc.2015.487			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26725324	Green Published, hybrid			2022-12-17	WOS:000382149800007
J	Ueda, T; Nakata, Y; Yamasaki, N; Oda, H; Sentani, K; Kanai, A; Onishi, N; Ikeda, K; Sera, Y; Honda, Z; Tanaka, K; Sata, M; Ogawa, S; Yasui, W; Saya, H; Takita, J; Honda, H				Ueda, T.; Nakata, Y.; Yamasaki, N.; Oda, H.; Sentani, K.; Kanai, A.; Onishi, N.; Ikeda, K.; Sera, Y.; Honda, Z-i; Tanaka, K.; Sata, M.; Ogawa, S.; Yasui, W.; Saya, H.; Takita, J.; Honda, H.			ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; ALK; GENE; LYMPHOMA; EXPRESSION; SPECTRUM; PROTEIN; TARGET; TUMORS	Overexpression of MYCN is a hallmark of neuroblastoma (NB). ALK(R1275Q), an activating mutation of ALK (anaplastic lymphoma kinase), has been found in sporadic and familial NB patients. In this report, we demonstrated that ALK(R1275Q) knock-in, MYCN transgenic compound mice developed NB with complete penetrance. Transcriptome analysis revealed that ALK(R1275Q) globally downregulated the expression of extracellular matrix (ECM)- and basement membrane (BM)-associated genes in both primary neuronal cells and NB tumors. Accordingly, ALK(R1275Q)/MYCN tumors exhibited reduced expression of ECM/BM-related proteins as compared with MYCN tumors. In addition, on MYCN transduction, ALK(R1275Q)-expressing neuronal cells exhibited increased migratory and invasive activities. Consistently, enhanced invasion and metastasis were demonstrated in ALK(R1275Q)/MYCN mice. These results collectively indicate that ALK(R1275Q) confers a malignant potential on neuronal cells that overexpress MYCN by impairing normal ECM/BM integrity and enhancing tumor growth and dissemination. Moreover, we found that crizotinib, an ALK inhibitor, almost completely inhibited the growth of ALK(R1275Q)/MYCN tumors in an allograft model. Our findings provided insights into the cooperative mechanism of the mutated ALK and overexpressed MYCN in the pathogenesis of NB and demonstrated the effectiveness of crizotinib on ALK(R1275Q)-positive tumors.	[Ueda, T.; Nakata, Y.; Yamasaki, N.; Ikeda, K.; Sera, Y.; Honda, H.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dis Model, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan; [Oda, H.] Tokyo Womens Med Univ, Dept Pathol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo, Japan; [Sentani, K.; Yasui, W.] Hiroshima Univ, Dept Mol Pathol, Inst Biomed & Hlth Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima, Japan; [Kanai, A.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Oncol, Minami Ku, 1-2-3 Kasumi, Hiroshima, Japan; [Onishi, N.; Saya, H.] Keio Univ, Inst Adv Med Res, Div Gene Regulat, Sch Med, 35 Shinanomachi, Tokyo, Japan; [Honda, Z-i] Ochanomizu Univ, Inst Environm Sci Human Life, Hlth Care Ctr, Bunkyo Ku, 2-1-1 Otsuka, Tokyo, Japan; [Honda, Z-i] Ochanomizu Univ, Inst Environm Sci Human Life, Grad Sch Humanities & Sci, Bunkyo Ku, 2-1-1 Otsuka, Tokyo, Japan; [Tanaka, K.] Univ Tokyo, Div Hlth Serv Promot, Bunkyo Ku, 7-3-1 Hongo, Tokyo, Japan; [Sata, M.] Univ Tokushima, Inst Hlth Biosci, Dept Cardiovasc Med, Grad Sch, Tokushima, Japan; [Ogawa, S.] Kyoto Univ, Grad Sch Med, Dept Pathol, Sakyo Ku, Yoshida Konoe Cho, Kyoto, Japan; [Takita, J.] Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, 7-3-1 Hongo, Tokyo, Japan	Hiroshima University; Tokyo Women's Medical University; Hiroshima University; Hiroshima University; Keio University; Ochanomizu University; Ochanomizu University; University of Tokyo; Tokushima University; Kyoto University; University of Tokyo	Honda, H (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dis Model, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	hhonda@hiroshima-u.ac.jp	Saya, Hideyuki/J-4325-2013	Saya, Hideyuki/0000-0001-6610-1902; Ueda, Takeshi/0000-0001-9823-6764	Grants-in-Aid for Scientific Research [26293227] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Berry T, 2012, CANCER CELL, V22, P117, DOI 10.1016/j.ccr.2012.06.001; Bresler SC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002950; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Carpenter EL, 2012, NAT REV CLIN ONCOL, V9, P391, DOI 10.1038/nrclinonc.2012.72; Cazes A, 2014, ONCOTARGET, V5, P2688, DOI 10.18632/oncotarget.1883; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; De Brouwer S, 2010, CLIN CANCER RES, V16, P4353, DOI 10.1158/1078-0432.CCR-09-2660; Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Hasan MK, 2013, SCI REP-UK, V3, DOI 10.1038/srep03450; Heukamp LC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003967; Honda H, 2011, P NATL ACAD SCI USA, V108, P2468, DOI 10.1073/pnas.1003403108; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Nagamachi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087425; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Ribatti D, 2004, ANN NY ACAD SCI, V1028, P133, DOI 10.1196/annals.1322.014; Saito A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1971; Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112; Schonerr C, 2012, ONCOGENE, V31, P5193, DOI 10.1038/onc.2012.12; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Zhu SZ, 2012, CANCER CELL, V21, P362, DOI 10.1016/j.ccr.2012.02.010	35	19	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4447	4458		10.1038/onc.2015.519	http://dx.doi.org/10.1038/onc.2015.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26829053				2022-12-17	WOS:000382153100003
J	Thomas, LR; Foshage, AM; Weissmiller, AM; Popay, TM; Grieb, BC; Qualls, SJ; Ng, V; Carboneau, B; Lorey, S; Eischen, CM; Tansey, WP				Thomas, L. R.; Foshage, A. M.; Weissmiller, A. M.; Popay, T. M.; Grieb, B. C.; Qualls, S. J.; Ng, V.; Carboneau, B.; Lorey, S.; Eischen, C. M.; Tansey, W. P.			Interaction of MYC with host cell factor-1 is mediated by the evolutionarily conserved Myc box IV motif	ONCOGENE			English	Article							DNA-BINDING; C-MYC; PROTEIN; VP16; COMPLEX; HCF; ASSOCIATION; RECRUITMENT; FORMS	The MYC family of oncogenes encodes a set of three related transcription factors that are overexpressed in many human tumors and contribute to the cancer-related deaths of more than 70,000 Americans every year. MYC proteins drive tumorigenesis by interacting with co-factors that enable them to regulate the expression of thousands of genes linked to cell growth, proliferation, metabolism and genome stability. One effective way to identify critical co-factors required for MYC function has been to focus on sequence motifs within MYC that are conserved throughout evolution, on the assumption that their conservation is driven by protein-protein interactions that are vital for MYC activity. In addition to their DNA-binding domains, MYC proteins carry five regions of high sequence conservation known as Myc boxes (Mb). To date, four of the Mb motifs (MbI, MbII, MbIIIa and MbIIIb) have had a molecular function assigned to them, but the precise role of the remaining Mb, MbIV, and the reason for its preservation in vertebrate Myc proteins, is unknown. Here, we show that MbIV is required for the association of MYC with the abundant transcriptional coregulator host cell factor-1 (HCF-1). We show that the invariant core of MbIV resembles the tetrapeptide HCF-binding motif (HBM) found in many HCF-interaction partners, and demonstrate that MYC interacts with HCF-1 in a manner indistinguishable from the prototypical HBM-containing protein VP16. Finally, we show that rationalized point mutations in MYC that disrupt interaction with HCF-1 attenuate the ability of MYC to drive tumorigenesis in mice. Together, these data expose a molecular function for MbIV and indicate that HCF-1 is an important co-factor for MYC.	[Thomas, L. R.; Foshage, A. M.; Weissmiller, A. M.; Popay, T. M.; Qualls, S. J.; Ng, V.; Lorey, S.; Tansey, W. P.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, 465 21st Ave S 4140 MRB 3, Nashville, TN 37232 USA; Vanderbilt Univ, Vanderbilt Int Scholar Program, 221 Kirkland Hall, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Sch Med, 221 Kirkland Hall, Nashville, TN 37235 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Tansey, WP (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, 465 21st Ave S 4140 MRB 3, Nashville, TN 37232 USA.	william.p.tansey@vanderbilt.edu		Popay, Tessa/0000-0002-4694-8804; Ng, Victoria/0000-0003-2344-8468; Grieb, Brian/0000-0003-3980-8050; Weissmiller, April/0000-0003-4505-0530	Edward P. Evans Foundation; Melanoma Research Foundation; Vanderbilt Ingram Cancer Center Support grant [NIH: CA68485]; NCI SPORE in Breast Cancer [P50 CA098131]; Cellular, Biochemical, and Molecular Sciences Training Program [T32 GM008554]; Integrated Biological Systems Training in Oncology Program [T32 CA119925]; National Center for Advancing Translational Sciences [UL1 TR000445]; Vanderbilt International Scholar Program; National Institutes of Health [R01CA148950, F30AG039164]; NATIONAL CANCER INSTITUTE [P30CA068485, T32CA119925, P50CA098131, R01CA148950, R01CA200709] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F30AG039164] Funding Source: NIH RePORTER	Edward P. Evans Foundation; Melanoma Research Foundation; Vanderbilt Ingram Cancer Center Support grant; NCI SPORE in Breast Cancer; Cellular, Biochemical, and Molecular Sciences Training Program; Integrated Biological Systems Training in Oncology Program; National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Vanderbilt International Scholar Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank S Dey, S Hiebert, H McDonald, L Neitzel and A Wilson for reagents, experimental assistance and advice. This work was supported by the Edward P. Evans Foundation (to WPT), the Melanoma Research Foundation (to WPT), the Vanderbilt Ingram Cancer Center Support grant (NIH: CA68485), the NCI SPORE in Breast Cancer (P50 CA098131), the Cellular, Biochemical, and Molecular Sciences Training Program (T32 GM008554), the Integrated Biological Systems Training in Oncology Program (T32 CA119925), the National Center for Advancing Translational Sciences (UL1 TR000445), the Vanderbilt International Scholar Program and grants R01CA148950 (to CME) and F30AG039164 (to BCG) from the National Institutes of Health.	BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Cai Y, 2010, J BIOL CHEM, V285, P4268, DOI 10.1074/jbc.C109.087981; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; Dingar D, 2015, J PROTEOMICS, V118, P95, DOI 10.1016/j.jprot.2014.09.029; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Furrer M, 2010, J BIOL CHEM, V285, P39623, DOI 10.1074/jbc.M110.140467; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Kurland JF, 2008, CANCER RES, V68, P3624, DOI 10.1158/0008-5472.CAN-07-6552; Luciano RL, 2003, J BIOL CHEM, V278, P51116, DOI 10.1074/jbc.M303470200; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08; Tansey W.P., 2014, NEW J SCI, V2014, P1; Thomas LR, 2015, MOL CELL, V58, P440, DOI 10.1016/j.molcel.2015.02.028; Thomas LR, 2015, J SCI TECHNOL, V3; Vogel JL, 2013, VIRUSES-BASEL, V5, P1272, DOI 10.3390/v5051272; Wang YL, 2008, J BIOL CHEM, V283, P33808, DOI 10.1074/jbc.M806936200; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zargar ZU, 2012, TRANSCR-AUSTIN, V3, P187, DOI 10.4161/trns.20711	23	19	19	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3613	3618		10.1038/onc.2015.416	http://dx.doi.org/10.1038/onc.2015.416			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26522729	Green Accepted			2022-12-17	WOS:000379621500014
J	Morioka, S; Sai, K; Omori, E; Ikeda, Y; Matsumoto, K; Ninomiya-Tsuji, J				Morioka, S.; Sai, K.; Omori, E.; Ikeda, Y.; Matsumoto, K.; Ninomiya-Tsuji, J.			TAK1 regulates hepatic lipid homeostasis through SREBP	ONCOGENE			English	Article							ELEMENT-BINDING PROTEINS; IL-1 SIGNALING PATHWAY; MTOR COMPLEX 1; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; DEPENDENT DEGRADATION; TRANSCRIPTION FACTORS; INSULIN-RESISTANCE; CANCER DEVELOPMENT; ADIPOSE-TISSUE	Sterol-regulatory element-binding proteins (SREBPs) are key transcription factors regulating cholesterol and fatty acid biosynthesis. SREBP activity is tightly regulated to maintain lipid homeostasis, and is modulated upon extracellular stimuli such as growth factors. While the homeostatic SREBP regulation is well studied, stimuli-dependent regulatory mechanisms are still elusive. Here we demonstrate that SREBPs are regulated by a previously uncharacterized mechanism through transforming growth factor-beta activated kinase 1 (TAK1), a signaling molecule of inflammation. We found that TAK1 binds to and inhibits mature forms of SREBPs. In an in vivo setting, hepatocyte-specific Tak1 deletion upregulates liver lipid deposition and lipogenic enzymes in the mouse model. Furthermore, hepatic Tak1 deficiency causes steatosis pathologies including elevated blood triglyceride and cholesterol levels, which are established risk factors for the development of hepatocellular carcinoma (HCC) and are indeed correlated with Tak1-deficiency-induced HCC development. Pharmacological inhibition of SREBPs alleviated the steatosis and reduced the expression level of the HCC marker gene in the Tak1-deficient liver. Thus, TAK1 regulation of SREBP critically contributes to the maintenance of liver homeostasis to prevent steatosis, which is a potentially important mechanism to prevent HCC development.	[Morioka, S.; Sai, K.; Omori, E.; Ikeda, Y.; Ninomiya-Tsuji, J.] North Carolina State Univ, Dept Biol Sci, Campus Box 7633,850 Main Campus Dr, Raleigh, NC 27695 USA; [Sai, K.; Matsumoto, K.] Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi, Japan; [Morioka, S.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA	University of North Carolina; North Carolina State University; Nagoya University; University of Virginia	Morioka, S; Ninomiya-Tsuji, J (corresponding author), North Carolina State Univ, Dept Biol Sci, Campus Box 7633,850 Main Campus Dr, Raleigh, NC 27695 USA.; Morioka, S (corresponding author), Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA.	sm9ss@virginia.edu; Jun_Tsuji@ncsu.edu	Morioka, Sho/I-2074-2019	Morioka, Sho/0000-0002-1153-4919; Ninomiya-Tsuji, Jun/0000-0002-5584-0176; Ikeda-Iwabu, Yuka/0000-0003-3550-7891	National Institutes of Health [GM068812]; Grants-in-Aid for Scientific Research [26112706] Funding Source: KAKEN; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM112986, R01GM068812] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank NC State biological animal facility for technical support, Dr Akira for Tak1-loxed mice and Simmons, A. for critical reading. This work was supported by National Institutes of Health Grant GM068812 (to JNT).	Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Braeuning A, 2006, TOXICOLOGY, V227, P127, DOI 10.1016/j.tox.2006.07.024; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Campbell JS, 2005, P NATL ACAD SCI USA, V102, P3389, DOI 10.1073/pnas.0409722102; Cohen JC, 2011, SCIENCE, V332, P1519, DOI 10.1126/science.1204265; Das M, 2011, GENE DEV, V25, P634, DOI 10.1101/gad.1989311; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Glass CK, 2012, CELL METAB, V15, P635, DOI 10.1016/j.cmet.2012.04.001; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Heindryckx F, 2009, INT J EXP PATHOL, V90, P367, DOI 10.1111/j.1365-2613.2009.00656.x; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Ikeda Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088037; Inokuchi S, 2010, P NATL ACAD SCI USA, V107, P844, DOI 10.1073/pnas.0909781107; Inokuchi-Shimizu S, 2014, J CLIN INVEST, V124, P3566, DOI 10.1172/JCI74068; Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev; Kajino T, 2007, J BIOL CHEM, V282, P9475, DOI 10.1074/jbc.M700875200; Kajino T, 2006, J BIOL CHEM, V281, P39891, DOI 10.1074/jbc.M608155200; Kajino-Sakamoto R, 2008, J IMMUNOL, V181, P1143, DOI 10.4049/jimmunol.181.2.1143; Kamisuki S, 2009, CHEM BIOL, V16, P882, DOI 10.1016/j.chembiol.2009.07.007; Kammoun HL, 2009, J CLIN INVEST, V119, P1201, DOI 10.1172/JCI37007; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kwak JH, 2008, J BIOL CHEM, V283, P19816, DOI 10.1074/jbc.M802285200; Laplante M, 2010, P NATL ACAD SCI USA, V107, P3281, DOI 10.1073/pnas.1000323107; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Mihaly SR, 2014, CELL DEATH DIFFER, V21, P1667, DOI 10.1038/cdd.2014.123; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Morioka S, 2009, ONCOGENE, V28, P2257, DOI 10.1038/onc.2009.110; Morioka S, 2014, J CELL BIOL, V204, P607, DOI 10.1083/jcb.201305070; Morioka S, 2012, BLOOD, V120, P3846, DOI 10.1182/blood-2012-03-416198; Nakayama H, 2007, METABOLISM, V56, P470, DOI 10.1016/j.metabol.2006.11.004; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Ringseis R, 2013, MOL ENDOCRINOL, V27, P781, DOI 10.1210/me.2012-1269; Ron D, 2004, J CELL BIOL, V167, P23, DOI 10.1083/jcb.200408117; Sabio G, 2009, CELL METAB, V10, P491, DOI 10.1016/j.cmet.2009.09.007; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Scholz R, 2010, J BIOL CHEM, V285, P25753, DOI 10.1074/jbc.M109.093468; Schuck S, 2009, J CELL BIOL, V187, P525, DOI 10.1083/jcb.200907074; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; SMITH JR, 1990, J BIOL CHEM, V265, P2306; Sohda T, 1998, J HUM GENET, V43, P49, DOI 10.1007/s100380050036; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Sundqvist A, 2003, P NATL ACAD SCI USA, V100, P13833, DOI 10.1073/pnas.2335135100; Tacer KF, 2007, PHYSIOL GENOMICS, V31, P216, DOI 10.1152/physiolgenomics.00264.2006; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takahashi Y, 2012, WORLD J GASTROENTERO, V18, P2300, DOI 10.3748/wjg.v18.i19.2300; Toth JI, 2004, MOL CELL BIOL, V24, P8288, DOI 10.1128/MCB.24.18.8288-8300.2004; Uemura N, 2006, J BIOL CHEM, V281, P7863, DOI 10.1074/jbc.M509834200; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Yang L, 2013, GASTROENTEROLOGY, V144, P1042, DOI 10.1053/j.gastro.2013.01.056; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yecies JL, 2011, CELL METAB, V14, P21, DOI 10.1016/j.cmet.2011.06.002; Zhang HH, 2002, DIABETES, V51, P2929, DOI 10.2337/diabetes.51.10.2929; Zhang L, 2013, CARCINOGENESIS, V34, P577, DOI 10.1093/carcin/bgs381	70	19	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3829	3838		10.1038/onc.2015.453	http://dx.doi.org/10.1038/onc.2015.453			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26973245	Green Accepted			2022-12-17	WOS:000380753200008
J	Qiang, L; Shah, P; Barcellos-Hoff, MH; He, YY				Qiang, L.; Shah, P.; Barcellos-Hoff, M. H.; He, Y. Y.			TGF-beta signaling links E-cadherin loss to suppression of nucleotide excision repair	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CELL CARCINOMA PROGRESSION; GROWTH-FACTOR-BETA; XERODERMA-PIGMENTOSUM; DOWN-REGULATION; ADHESION MOLECULE; DNA-BINDING; C-MYC; SKIN; INDUCTION	E-cadherin is a cell adhesion molecule best known for its function in suppressing tumor progression and metastasis. Here we show that E-cadherin promotes nucleotide excision repair through positively regulating the expression of xeroderma pigmentosum complementation group C (XPC) and DNA damage-binding protein 1 (DDB1). Loss of E-cadherin activates the E2F4 and p130/107 transcription repressor complexes to suppress the transcription of both XPC and DDB1 through activating the transforming growth factor-beta (TGF-beta) pathway. Adding XPC or DDB1, or inhibiting the TGF-beta pathway, increases the repair of ultraviolet (UV)-induced DNA damage in E-cadherin-inhibited cells. In the mouse skin and skin tumors, UVB radiation downregulates E-cadherin. In sunassociated premalignant and malignant skin neoplasia, E-cadherin is downregulated in association with reduced XPC and DDB1 levels. These findings demonstrate a crucial role of E-cadherin in efficient DNA repair of UV-induced DNA damage, identify a new link between epithelial adhesion and DNA repair and suggest a mechanistic link of early E-cadherin loss in tumor initiation.	[Qiang, L.; Shah, P.; He, Y. Y.] Univ Chicago, Dept Med, Dermatol Sect, Chicago, IL 60637 USA; [Barcellos-Hoff, M. H.] NYU, Sch Med, Dept Radiat Oncol & Cell Biol, New York, NY USA	University of Chicago; New York University	He, YY (corresponding author), Univ Chicago, Dept Med, Dermatol Sect, Chicago, IL 60637 USA.	yyhe@medicine.bsd.uchicago.edu	Qiang, Lei/B-2763-2012	Qiang, Lei/0000-0002-7164-3164; Barcellos-Hoff, Mary Helen/0000-0002-5994-9558	NIH/NIEHS [ES016936, ES024373]; American Cancer Society (ACS) [RSG-13-078-01]; University of Chicago Cancer Research Center [P30 CA014599]; CTSA [UL1 TR000430]; University of Chicago Friends of Dermatology Endowment Fund; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016936, R01ES024373] Funding Source: NIH RePORTER	NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); American Cancer Society (ACS)(American Cancer Society); University of Chicago Cancer Research Center; CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); University of Chicago Friends of Dermatology Endowment Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We are grateful to Dr Altaf Wani for his helpful suggestions. We thank Terri Li for immunohistochemistry and Dr Ann Motten for a critical reading of the manuscript. This work was supported by the NIH/NIEHS grants ES016936 and ES024373 (to YYH), the American Cancer Society (ACS) grant RSG-13-078-01 (to YYH), the University of Chicago Cancer Research Center (P30 CA014599), the CTSA (UL1 TR000430) and the University of Chicago Friends of Dermatology Endowment Fund.	Boyle J, 2008, HUM MUTAT, V29, P1194, DOI 10.1002/humu.20768; Bradford PT, 2011, J MED GENET, V48, P168, DOI 10.1136/jmg.2010.083022; Braithwaite E, 1998, CARCINOGENESIS, V19, P1239, DOI 10.1093/carcin/19.7.1239; Brouxhon S, 2007, CANCER RES, V67, P7654, DOI 10.1158/0008-5472.CAN-06-4415; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Cho IJ, 2010, HEPATOLOGY, V52, P2053, DOI 10.1002/hep.23931; Cleaver JE, 2009, NAT REV GENET, V10, P756, DOI 10.1038/nrg2663; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; Cui TT, 2015, ONCOTARGET, V6, P10060, DOI 10.18632/oncotarget.3542; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; DiGiovanna JJ, 2012, J INVEST DERMATOL, V132, P785, DOI 10.1038/jid.2011.426; Dominguez-Brauer C, 2009, EMBO REP, V10, P1036, DOI 10.1038/embor.2009.139; Dubrovska A, 2005, ONCOGENE, V24, P2289, DOI 10.1038/sj.onc.1208443; Fei J, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001183; Fleisch MC, 2006, ENDOCR-RELAT CANCER, V13, P379, DOI 10.1677/erc.1.01112; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Glick AB, 2012, J SKIN CANCER, V2012, DOI 10.1155/2012/249063; Gu CN, 2006, BIOCHEMISTRY-US, V45, P10739, DOI 10.1021/bi060423z; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hoot KE, 2008, J CLIN INVEST, V118, P2722, DOI 10.1172/JCI33713; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Imoto K, 2002, J INVEST DERMATOL, V119, P1177, DOI 10.1046/j.1523-1747.2002.19514.x; Jamal S, 2002, J CLIN INVEST, V110, P443, DOI 10.1172/JCI200213729; Jans J, 2005, CURR BIOL, V15, P105, DOI 10.1016/j.cub.2005.01.001; Kad NM, 2010, MOL CELL, V37, P702, DOI 10.1016/j.molcel.2010.02.003; Kao YC, 2010, MOL CELL BIOL, V30, P4767, DOI 10.1128/MCB.01021-09; Katsumi S, 2001, J INVEST DERMATOL, V117, P1156, DOI 10.1046/j.0022-202x.2001.01540.x; Kim I, 2014, GENES DIS, V1, P188, DOI 10.1016/j.gendis.2014.08.005; Kim MR, 2015, MOL CANCER RES, V13, P319, DOI 10.1158/1541-7786.MCR-14-0098-T; Kobayashi N, 2001, PIGM CELL RES, V14, P94, DOI 10.1034/j.1600-0749.2001.140204.x; Li AG, 2004, CANCER RES, V64, P7836, DOI 10.1158/0008-5472.CAN-04-1331; Li JY, 2006, CANCER RES, V66, P8590, DOI 10.1158/0008-5472.CAN-06-1115; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Ming M, 2010, P NATL ACAD SCI USA, V107, P22623, DOI 10.1073/pnas.1010377108; Mitra D, 2013, J INVEST DERMATOL, V133, P2609, DOI 10.1038/jid.2013.213; Nakagawa H, 2014, P NATL ACAD SCI USA, V111, P1090, DOI 10.1073/pnas.1322731111; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Nichols AF, 2003, NUCLEIC ACIDS RES, V31, P562, DOI 10.1093/nar/gkg152; NIGGLI HJ, 1988, J INVEST DERMATOL, V91, P579, DOI 10.1111/1523-1747.ep12477095; Oh KS, 2011, PHOTOCHEM PHOTOBIOL, V87, P729, DOI 10.1111/j.1751-1097.2011.00909.x; Orsulic S, 1999, J CELL SCI, V112, P1237; Perez-Lorenzo R, 2010, CARCINOGENESIS, V31, P1116, DOI 10.1093/carcin/bgq041; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111; Ravindran A, 2014, CARCINOGENESIS, V35, P959, DOI 10.1093/carcin/bgt486; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shah P, 2015, PHOTOCHEM PHOTOBIOL, V91, P254, DOI 10.1111/php.12406; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 2005, CELL, V121, P387, DOI 10.1016/j.cell.2005.02.035; Sugasawa K, 2008, CARCINOGENESIS, V29, P455, DOI 10.1093/carcin/bgm282; Sugasawa K, 2009, DNA REPAIR, V8, P969, DOI 10.1016/j.dnarep.2009.05.001; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; VINK AA, 1991, CARCINOGENESIS, V12, P861, DOI 10.1093/carcin/12.5.861; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wang HJ, 2005, FREE RADICAL BIO MED, V38, P890, DOI 10.1016/j.freeradbiomed.2004.12.005; Wang QE, 2013, NUCLEIC ACIDS RES, V41, P1722, DOI 10.1093/nar/gks1312; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	64	19	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3293	3302		10.1038/onc.2015.390	http://dx.doi.org/10.1038/onc.2015.390			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477308	Green Submitted, Green Accepted			2022-12-17	WOS:000378306400008
J	Palazzo, E; Kellett, M; Cataisson, C; Gormley, A; Bible, PW; Pietroni, V; Radoja, N; Hwang, J; Blumenberg, M; Yuspa, SH; Morasso, MI				Palazzo, E.; Kellett, M.; Cataisson, C.; Gormley, A.; Bible, P. W.; Pietroni, V.; Radoja, N.; Hwang, J.; Blumenberg, M.; Yuspa, S. H.; Morasso, M. I.			The homeoprotein DLX3 and tumor suppressor p53 co-regulate cell cycle progression and squamous tumor growth	ONCOGENE			English	Article							HOMEOBOX GENE; HUMAN KERATINOCYTES; BINDING-SITES; P63; DIFFERENTIATION; SKIN; EXPRESSION; CANCER; TAP63; TUMORIGENESIS	Epidermal homeostasis depends on the coordinated control of keratinocyte cell cycle. Differentiation and the alteration of this balance can result in neoplastic development. Here we report on a novel DLX3-dependent network that constrains epidermal hyperplasia and squamous tumorigenesis. By integrating genetic and transcriptomic approaches, we demonstrate that DLX3 operates through a p53-regulated network. DLX3 and p53 physically interact on the p21 promoter to enhance p21 expression. Elevating DLX3 in keratinocytes produces a G1-S blockade associated with p53 signature transcriptional profiles. In contrast, DLX3 loss promotes a mitogenic phenotype associated with constitutive activation of ERK. DLX3 expression is lost in human skin cancers and is extinguished during progression of experimentally induced mouse squamous cell carcinoma (SCC). Reinstatement of DLX3 function is sufficient to attenuate the migration of SCC cells, leading to decreased wound closure. Our data establish the DLX3-p53 interplay as a major regulatory axis in epidermal differentiation and suggest that DLX3 is a modulator of skin carcinogenesis.	[Palazzo, E.; Kellett, M.; Gormley, A.; Bible, P. W.; Pietroni, V.; Radoja, N.; Hwang, J.; Morasso, M. I.] NIAMS, Skin Biol Lab, NIH, Bldg 50,Room 1523, Bethesda, MD 20892 USA; [Cataisson, C.; Yuspa, S. H.] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA; [Blumenberg, M.] NYU, Dept Dermatol, New York, NY 10016 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); New York University	Morasso, MI (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 50,Room 1523, Bethesda, MD 20892 USA.	morasso@nih.gov	Palazzo, Elisabetta/J-5287-2016	Palazzo, Elisabetta/0000-0002-0812-5524; Blumenberg, Miroslav/0000-0002-8672-7774; McCarter, Anna/0000-0003-3828-9797	Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [ZIA AR041124-14]; NATIONAL CANCER INSTITUTE [ZIABC004504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041124, ZICAR041186] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank current and past members of the Laboratory of Skin Biology and members of the Laboratory of Cancer Biology and Genetics, and Dr Mark Udey for helpful discussions. We also thank Andrew Ryscavage (LCBG), Gustavo Gutierrez-Cruz (NIAMS Genome Analysis Core Facility), Dr Hong-Wei Sun (Biodata Mining and Discovery Section, NIAMS) and Kristina Zaal of the NIAMS Light Imaging Core Facility. This work was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (M.I.M. ZIA AR041124-14).	Aasen T, 2010, NAT PROTOC, V5, P371, DOI 10.1038/nprot.2009.241; Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Botchkarev VA, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015248; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Cai BH, 2012, J BIOCHEM, V152, P99, DOI 10.1093/jb/mvs053; Candi E, 2007, P NATL ACAD SCI USA, V104, P11999, DOI 10.1073/pnas.0703458104; Candi E, 2014, HUM MUTAT, V35, P702, DOI 10.1002/humu.22523; Cataisson C, 2012, J EXP MED, V209, P1689, DOI 10.1084/jem.20101355; Cataisson C, 2009, CANCER RES, V69, P319, DOI 10.1158/0008-5472.CAN-08-2490; Chakravarti D, 2014, P NATL ACAD SCI USA, V111, pE572, DOI 10.1073/pnas.1319743111; Crum CP, 2010, ANNU REV PATHOL-MECH, V5, P349, DOI 10.1146/annurev-pathol-121808-102117; Darwiche N, 2007, ONCOGENE, V26, P6885, DOI 10.1038/sj.onc.1210491; Di Costanzo A, 2009, CELL CYCLE, V8, P1185, DOI 10.4161/cc.8.8.8202; Dotto JE, 2006, J CUTAN PATHOL, V33, P413, DOI 10.1111/j.0303-6987.2006.00477.x; Duverger O, 2008, J CELL PHYSIOL, V216, P337, DOI 10.1002/jcp.21491; Duverger O, 2008, J BIOL CHEM, V283, P20198, DOI 10.1074/jbc.M709562200; Flores ER, 2007, CELL CYCLE, V6, P300, DOI 10.4161/cc.6.3.3793; Gandarillas A, 2012, CELL CYCLE, V11, P4507, DOI 10.4161/cc.22529; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Ha LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021877; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hwang J, 2008, DEVELOPMENT, V135, P3149, DOI 10.1242/dev.022202; Hwang J, 2011, P NATL ACAD SCI USA, V108, P11566, DOI 10.1073/pnas.1019658108; Karia PS, 2013, J AM ACAD DERMATOL, V68, P957, DOI 10.1016/j.jaad.2012.11.037; Kelder T, 2012, NUCLEIC ACIDS RES, V40, pD1301, DOI 10.1093/nar/gkr1074; King KE, 2007, MOL CARCINOGEN, V46, P716, DOI 10.1002/mc.20337; King KE, 2013, J SKIN CANCER, V2013, DOI 10.1155/2013/632028; Koh LF, 2015, EXP DERMATOL, V24, P754, DOI 10.1111/exd.12764; Koster MI, 2004, DIFFERENTIATION, V72, P364, DOI 10.1111/j.1432-0436.2004.07208002.x; Lessard JC, 2015, EXP DERMATOL, V24, P55, DOI 10.1111/exd.12568; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masse I, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.62; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Morasso Maria I., 2005, Birth Defects Research, V75, P163, DOI 10.1002/bdrc.20047; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Park GT, 1999, J BIOL CHEM, V274, P26599, DOI 10.1074/jbc.274.37.26599; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Priolo M, 2001, J MED GENET, V38, P579, DOI 10.1136/jmg.38.9.579; Radoja N, 2006, PHYSIOL GENOMICS, V27, P65, DOI 10.1152/physiolgenomics.00031.2006; Radoja N, 2007, DEVELOPMENT, V134, P13, DOI 10.1242/dev.02703; Ratushny V, 2012, J CLIN INVEST, V122, P464, DOI 10.1172/JCI57415; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Saramaki A, 2006, NUCLEIC ACIDS RES, V34, P543, DOI 10.1093/nar/gkj460; Schavolt KL, 2007, ONCOGENE, V26, P6125, DOI 10.1038/sj.onc.1210441; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tu Zhigang, 2012, Small GTPases, V3, P163, DOI 10.4161/sgtp.19884; Vanbokhoven H, 2011, J INVEST DERMATOL, V131, P1196, DOI 10.1038/jid.2011.84; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043	61	19	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3114	3124		10.1038/onc.2015.380	http://dx.doi.org/10.1038/onc.2015.380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26522723	Bronze, Green Accepted			2022-12-17	WOS:000378092700004
J	Sun, F; Qu, Z; Xiao, Y; Zhou, J; Burns, TF; Stabile, LP; Siegfried, JM; Xiao, G				Sun, F.; Qu, Z.; Xiao, Y.; Zhou, J.; Burns, T. F.; Stabile, L. P.; Siegfried, J. M.; Xiao, G.			NF-kappa B1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-kappa B function	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-2; MOUSE MODEL; CANCER; PDLIM2; INFLAMMATION; ACTIVATION; DIFFERENTIATION; REQUIREMENT; REPRESSION; STABILITY	Nuclear factor-kappa B (NF-kappa B) is generally believed to be pro-tumorigenic. Here we report a tumor-suppressive function for NF-kappa B1, the prototypical member of NF-kappa B. While NF-kappa B1 downregulation is associated with high lung cancer risk in humans and poor patient survival, NF-kappa B1-deficient mice are more vulnerable to lung tumorigenesis induced by the smoke carcinogen, urethane. Notably, the tumor-suppressive function of NF-kappa B1 is independent of its classical role as an NF-kappa B factor, but instead through stabilization of the Tpl2 kinase. NF-kappa B1-deficient tumors exhibit 'normal' NF-kappa B activity, but a decreased protein level of Tpl2. Reconstitution of Tpl2 or the NF-kappa B1 p105, but not p50 (the processed product of p105), inhibits the tumorigenicity of NF-kappa B1-deficient lung tumor cells. Remarkably, Tpl2-knockout mice resemble NF-kappa B1 knockouts in urethane-induced lung tumorigenesis. Mechanistic studies indicate that p105/Tpl2 signaling is required for suppressing urethane-induced lung damage and inflammation, and activating mutations of the K-Ras oncogene. These studies reveal an unexpected, NF-kappa B-independent but Tpl2-depenednt role of NF-kappa B1 in lung tumor suppression. These studies also reveal a previously unexplored role of p105/Tpl2 signaling in lung homeostasis.	[Sun, F.; Qu, Z.; Xiao, Y.; Zhou, J.; Burns, T. F.; Stabile, L. P.; Siegfried, J. M.; Xiao, G.] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA 15213 USA; [Sun, F.; Qu, Z.; Zhou, J.; Xiao, G.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Hillman Canc Ctr Res Pavil,5117 Ctr Ave,Room 1-19, Pittsburgh, PA 15213 USA; [Xiao, Y.] La Roche Coll, Program Biol Sci, Pittsburgh, PA USA; [Stabile, L. P.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Qu, Z; Xiao, G (corresponding author), Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Hillman Canc Ctr Res Pavil,5117 Ctr Ave,Room 1-19, Pittsburgh, PA 15213 USA.	quz@upmc.edu; xiaog2@upmc.edu	Stabile, Laura/AAE-9235-2020; SUN, FAN/K-8683-2017; SUN, FAN/GWA-1524-2022	SUN, FAN/0000-0002-3538-9701	National Institute of Health (NIH)/National Cancer Institute (NCI) [R01 CA172090, R21 CA175252, R21 CA189703, P30 CA047904, P50 CA090440]; American Lung Association (ALA) Lung Cancer Discovery Award; American Cancer Society (ACS) Fellowship [PF-12-081-01-TBG]; NATIONAL CANCER INSTITUTE [P50CA090440, R21CA175252, R01CA172090, R21CA189703, P30CA047904] Funding Source: NIH RePORTER	National Institute of Health (NIH)/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Lung Association (ALA) Lung Cancer Discovery Award; American Cancer Society (ACS) Fellowship(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Philip N Tsichlis for providing us the Tpl2<SUP>Delta/Delta</SUP> mice. This study was supported in part by the National Institute of Health (NIH)/National Cancer Institute (NCI) grants R01 CA172090, R21 CA175252, R21 CA189703, P30 CA047904 and P50 CA090440-Lung Cancer Developmental Research Award, as well as the American Lung Association (ALA) Lung Cancer Discovery Award and American Cancer Society (ACS) Fellowship PF-12-081-01-TBG.	AOKI M, 1991, ONCOGENE, V6, P1515; Basseres Daniela S, 2014, Genes Cancer, V5, P41; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Cai Zhenjian, 2011, Cancers (Basel), V3, P4258, DOI 10.3390/cancers3044258; Mulero MC, 2013, CANCER CELL, V24, P151, DOI 10.1016/j.ccr.2013.06.003; Chariot A, 2009, TRENDS CELL BIOL, V19, P404, DOI 10.1016/j.tcb.2009.05.006; Chen WS, 2011, FRONT BIOSCI-LANDMRK, V16, P1172, DOI 10.2741/3782; Dougan M, 2011, J CLIN INVEST, V121, P2436, DOI 10.1172/JCI44796; Fu J, 2010, ONCOGENE, V29, P6499, DOI 10.1038/onc.2010.374; Fu J, 2011, BLOOD, V117, P1652, DOI 10.1182/blood-2010-08-303073; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Gkirtzimanaki K, 2013, P NATL ACAD SCI USA, V110, pE1470, DOI 10.1073/pnas.1215938110; Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X; Ichikawa T, 1996, CANCER LETT, V107, P165, DOI 10.1016/0304-3835(96)04351-0; Jones DR, 2000, ANN THORAC SURG, V70, P930, DOI 10.1016/S0003-4975(00)01635-0; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Qing GL, 2005, J BIOL CHEM, V280, P40578, DOI 10.1074/jbc.M508776200; Qing GL, 2007, P NATL ACAD SCI USA, V104, P5324, DOI 10.1073/pnas.0609914104; Qu Z, 2015, CANC RES; Qu ZX, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-23; Qu ZX, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-18; Qu ZX, 2010, CANCER RES, V70, P1766, DOI 10.1158/0008-5472.CAN-09-3263; Qu ZX, 2010, J BIOL CHEM, V285, P11786, DOI 10.1074/jbc.M109.086561; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Schramek D, 2011, NAT GENET, V43, P212, DOI 10.1038/ng.767; Serebrennikova OB, 2012, P NATL ACAD SCI USA, V109, pE1082, DOI 10.1073/pnas.1115098109; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Stabile LP, 2011, CLIN CANCER RES, V17, P154, DOI 10.1158/1078-0432.CCR-10-0992; Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104; Sun F, 2015, J BIOL CHEM, V290, P7362, DOI 10.1074/jbc.C115.637918; Tsatsanis C, 2008, P NATL ACAD SCI USA, V105, P2987, DOI 10.1073/pnas.0708381104; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Wen Jing, 2011, Chin J Cancer, V30, P551, DOI 10.5732/cjc.011.10059; Wong KK, 2010, CANCER PREV RES, V3, P403, DOI 10.1158/1940-6207.CAPR-10-0042; Xiao GT, 2006, CYTOKINE GROWTH F R, V17, P281, DOI 10.1016/j.cytogfr.2006.04.005; Xiao GT, 2011, AM J CANCER RES, V1, P192; Yan PR, 2009, BLOOD, V113, P4370, DOI 10.1182/blood-2008-10-185660; Zhang DL, 2007, ANN SURG ONCOL, V14, P3581, DOI 10.1245/s10434-007-9560-z; Zhou J, 2015, ONCOGENE, V34, P3804, DOI 10.1038/onc.2014.318	45	19	19	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2299	2310		10.1038/onc.2015.299	http://dx.doi.org/10.1038/onc.2015.299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26300007	Green Accepted			2022-12-17	WOS:000376165000003
J	Ahn, JS; Li, J; Chen, E; Kent, DG; Park, HJ; Green, AR				Ahn, J. S.; Li, J.; Chen, E.; Kent, D. G.; Park, H. J.; Green, A. R.			JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; FORKHEAD TRANSCRIPTION FACTOR; HEMATOPOIETIC STEM-CELLS; ABL-EXPRESSING CELLS; MYELOPROLIFERATIVE DISORDERS; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; GENE-EXPRESSION; CANCER-CELLS; JAK2	The JAK2V617F mutation is found in most patients with a myeloproliferative neoplasm (MPN). This gain-of-function mutation dysregulates cytokine signaling and is associated with increased accumulation of DNA damage, a process likely to drive disease evolution. JAK2V617F inhibits NHE-1 upregulation in response to DNA damage and consequently represses Bcl-xL deamidation and apoptosis, thus giving rise to inappropriate cell survival. However, the mechanism whereby NHE-1 expression is inhibited by JAK2V617F is unknown. In this study, we demonstrate that the accumulation of reactive oxygen species (ROS) in cells expressing JAK2V617F compromises the NHE-1/Bcl-xL deamidation pathway by repressing NHE-1 upregulation in response to DNA damage. In JAK2V617F-positive cells, increased ROS levels results from aberrant PI3K signaling, which decreases nuclear localization of FOXO3A and decreases catalase expression. Furthermore, when compared with autologous control erythroblasts, clonally derived JAK2V617F-positive erythroblasts from MPN patients displayed increased ROS levels and reduced nuclear FOXO3A. However, in hematopoietic stem cells (HSCs), FOXO3A is largely localized within the nuclei despite the presence of JAK2V617F mutation, suggesting that JAK2-FOXO signaling has a different effect on progenitors compared with stem cells. Inactivation of FOXO proteins and elevation of intracellular ROS are characteristics common to many cancers, and hence these findings are likely to be of relevance beyond the MPN field.	[Ahn, J. S.; Li, J.; Chen, E.; Kent, D. G.; Park, H. J.; Green, A. R.] Univ Cambridge, Cambridge Inst Med Res, Cambridge, England; [Ahn, J. S.; Li, J.; Chen, E.; Kent, D. G.; Park, H. J.; Green, A. R.] Univ Cambridge, Wellcome Trust MRC Stem Cell Inst, Cambridge, England; [Ahn, J. S.; Li, J.; Chen, E.; Kent, D. G.; Park, H. J.; Green, A. R.] Univ Cambridge, Dept Haematol, Cambridge, England; [Green, A. R.] Addenbrookes Hosp, Dept Haematol, Cambridge CB2 2QQ, England	University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Green, AR (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Hills Rd, Cambridge CB2 0XY, England.	arg1000@cam.ac.uk	Kent, David/AAZ-4916-2021	Kent, David/0000-0001-7871-8811; Green, Anthony/0000-0002-9795-0218	Leukemia and Lymphoma Research, Cancer Research UK; Kay Kendall Leukaemia Fund; NIHR Cambridge Biomedical Research Centre; Cambridge Experimental Cancer Medicine Centre; Leukemia & Lymphoma Society of America; Canadian Institutes of Health Research (Ottawa, ON); Lady Tata Memorial Trust International Award for Research in Leukaemia (London, UK); Human Frontier Science Program; Cancer Research UK [12765] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10079] Funding Source: researchfish	Leukemia and Lymphoma Research, Cancer Research UK; Kay Kendall Leukaemia Fund; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Cambridge Experimental Cancer Medicine Centre; Leukemia & Lymphoma Society of America(Leukemia and Lymphoma Society); Canadian Institutes of Health Research (Ottawa, ON)(Canadian Institutes of Health Research (CIHR)); Lady Tata Memorial Trust International Award for Research in Leukaemia (London, UK); Human Frontier Science Program(Human Frontier Science Program); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We thank patients and staff of the Addenbrookes MPN clinic who have contributed samples to this study; Yvonne Silber for technical assistance; Philip Beer, Anna Godfrey, Christina Ortmann and Joanna Baxter (Translational Research Laboratory, University of Cambridge) for help with acquiring clinical samples; Peter Campbell (Sanger Institute) for helpful discussions; and Michael Murphy (MRC MBU) for supplying MitoQ. Work in the Green lab is supported by Leukemia and Lymphoma Research, Cancer Research UK, the Kay Kendall Leukaemia Fund, the NIHR Cambridge Biomedical Research Centre, the Cambridge Experimental Cancer Medicine Centre and the Leukemia & Lymphoma Society of America. DGK was supported by a postdoctoral fellowship from the Canadian Institutes of Health Research (Ottawa, ON), and a Lady Tata Memorial Trust International Award for Research in Leukaemia (London, UK). HJP was supported by a postdoctoral fellowship from the Human Frontier Science Program.	Akram S, 2006, CELL DEATH DIFFER, V13, P628, DOI 10.1038/sj.cdd.4401775; Bakker WJ, 2007, MOL CELL BIOL, V27, P3839, DOI 10.1128/MCB.01662-06; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Campbell PJ, 2006, NEW ENGL J MED, V355, P2452, DOI 10.1056/NEJMra063728; Chan DW, 2008, CARCINOGENESIS, V29, P1742, DOI 10.1093/carcin/bgn167; Chen E, 2014, P NATL ACAD SCI USA, V111, P15190, DOI 10.1073/pnas.1401873111; Chomel JC, 2011, BLOOD, V118, P3657, DOI 10.1182/blood-2011-02-335497; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Fernandes MS, 2009, BLOOD, V114, P1813, DOI 10.1182/blood-2008-07-172148; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Gaetani GF, 1996, BLOOD, V87, P1595, DOI 10.1182/blood.V87.4.1595.bloodjournal8741595; Ghaffari S, 2003, P NATL ACAD SCI USA, V100, P6523, DOI 10.1073/pnas.0731871100; Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood-2010-12-326843; Huang Y, 1998, BIOCHEM BIOPH RES CO, V249, P307, DOI 10.1006/bbrc.1998.9139; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Imai Y, 2014, CELL REP, V7, P194, DOI 10.1016/j.celrep.2014.03.006; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jhumka Z, 2009, INT J BIOCHEM CELL B, V41, P945, DOI 10.1016/j.biocel.2008.09.028; Kagoya Y, 2014, BLOOD, V124, P2996, DOI 10.1182/blood-2014-04-570572; Kent DG, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001576; Kent DG, 2009, BLOOD, V113, P6342, DOI 10.1182/blood-2008-12-192054; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kumar AP, 2007, CELL DEATH DIFFER, V14, P1733, DOI 10.1038/sj.cdd.4402176; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Levine RL, 2006, BLOOD, V107, P4139, DOI 10.1182/blood-2005-09-3900; Li J, 2014, BLOOD, V123, P3139, DOI 10.1182/blood-2013-06-510222; Li JA, 2010, BLOOD, V116, P1528, DOI 10.1182/blood-2009-12-259747; Lin B, 2014, SCI REP-UK, V4, DOI 10.1038/srep07041; Marty C, 2013, LEUKEMIA, V27, P2187, DOI 10.1038/leu.2013.102; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Miyamoto K, 2008, BLOOD, V112, P4485, DOI 10.1182/blood-2008-05-159848; Mullally A, 2010, CANCER CELL, V17, P584, DOI 10.1016/j.ccr.2010.05.015; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Naughton R, 2009, LEUKEMIA, V23, P1432, DOI 10.1038/leu.2009.49; Pellicano F, 2014, STEM CELLS, V32, P2324, DOI 10.1002/stem.1748; Plo I, 2008, BLOOD, V112, P1402, DOI 10.1182/blood-2008-01-134114; Pourova J, ACTA PHYSL OXF, V198, P15; Quentmeier H, 2006, LEUKEMIA, V20, P471, DOI 10.1038/sj.leu.2404081; Rakshit S, 2009, APOPTOSIS, V14, P298, DOI 10.1007/s10495-008-0305-7; Sedelnikova OA, 2010, MUTAT RES-REV MUTAT, V704, P152, DOI 10.1016/j.mrrev.2009.12.005; Sikora MJ, 2008, CANCER BIOL THER, V7, P767, DOI 10.4161/cbt.7.5.5767; Swerdlow SH., 2017, WHO CLASSIFICATION T; Tothova Z, 2007, CELL STEM CELL, V1, P140, DOI 10.1016/j.stem.2007.07.017; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tsai SY, 2007, CANCER SCI, V98, P1206, DOI 10.1111/j.1349-7006.2007.00513.x; Tsai WB, 2008, NAT CELL BIOL, V10, P460, DOI 10.1038/ncb1709; Vainchenker W, 2011, BLOOD, V118, P1723, DOI 10.1182/blood-2011-02-292102; Weinberg F, P NATL ACAD SCI US, V107, P8788; Yalcin S, 2008, J BIOL CHEM, V283, P25692, DOI 10.1074/jbc.M800517200; Yalcin S, 2010, EMBO J, V29, P4118, DOI 10.1038/emboj.2010.292; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Zhao R, 2007, PLOS BIOL, V5, P39, DOI 10.1371/journal.pbio.0050001; Zhao R, 2008, NEW ENGL J MED, V359, P2778, DOI 10.1056/NEJMoa0804953	58	19	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2235	2246		10.1038/onc.2015.285	http://dx.doi.org/10.1038/onc.2015.285			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26234675	Green Accepted			2022-12-17	WOS:000374986000009
J	Prudnikova, TY; Villamar-Cruz, O; Rawat, SJ; Cai, KQ; Chernoff, J				Prudnikova, T. Y.; Villamar-Cruz, O.; Rawat, S. J.; Cai, K. Q.; Chernoff, J.			Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells	ONCOGENE			English	Article							BETA-CATENIN; SIGNALING PATHWAY; TUMOR-FORMATION; WILD-TYPE; PAK1; TRANSFORMATION; ACTIVATION; BLOCKS; GROWTH; AMPLIFICATION	p21-activated kinases (Paks) are Cdc42/Rac-activated serine-threonine protein kinases that regulate several key cancer-relevant signaling pathways, such as the Mek/Erk, PI3K/Akt and Wnt/b-catenin signaling pathways. Pak1 is frequently overexpressed and/or hyperactivated in different human cancers, including human breast, ovary, prostate and brain cancer, due to amplification of the PAK1 gene in an 11q13 amplicon. Genetic or pharmacological inactivation of Pak1 has been shown to reduce proliferation of different cancer cells in vitro and reduce tumor progression in vivo. In this work, we examined the roles of Pak1 in cellular and animal models of PAK1-amplified ovarian cancer. We found that inhibition of Pak1 leads to decreased proliferation and migration in PAK1-amplified/overexpressed ovarian cancer cells, and has no effect in cell that lack such amplification/overexpression. Further, we observed that loss of Pak1 function causes 11q13-amplified ovarian cancer cells to arrest in the G2/M phase of the cell cycle. This arrest correlates with activation of p53 and p21(Cip) and decreased expression of cyclin B1. These findings suggest that small-molecule inhibitors of Pak1 may have a therapeutic role in the similar to 25% of ovarian cancers characterized by PAK1 gene amplification.	[Prudnikova, T. Y.; Villamar-Cruz, O.; Rawat, S. J.; Chernoff, J.] Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave, Philadelphia, PA 19111 USA; [Cai, K. Q.] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center	Chernoff, J (corresponding author), Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Jonathan.Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836; Villamar-Cruz, Olga/0000-0003-4265-9367	National Institutes of Health [R01-CA142928, R01-CA148805]; Ovarian SPORE [P50 CA083638]; Fox Chase Cancer Center [P30-CA006927]; State of Pennsylvania; NATIONAL CANCER INSTITUTE [R01CA148805, P50CA083638, R01CA142928, P30CA006927] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fox Chase Cancer Center; State of Pennsylvania; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M. Einarson (Fox Chase Cancer Center, High Throughput and Translational Core Facility) for assistance with cell cycle analysis and the Cell Culture Facility. We thank D. Connolly (FCCC), N. Tonks (CSHL) and G. Mills (MD Anderson) for ovarian cancer cell lines and for insightful comments on the manuscript. This work was supported by grants from the National Institutes of Health to JC (R01-CA142928 and R01-CA148805), Ovarian SPORE P50 CA083638 (Pilot Award to JC), Fox Chase Cancer Center (P30-CA006927), as well as by an appropriation from the State of Pennsylvania.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Arias-Romero LE, 2010, ONCOGENE, V29, P5839, DOI 10.1038/onc.2010.318; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Arias-Romero LE, 2013, CANCER RES, V73, P3671, DOI 10.1158/0008-5472.CAN-12-4453; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Choi JH, 2009, CANCER RES, V69, P1407, DOI 10.1158/0008-5472.CAN-08-3602; Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246; Chow HY, 2015, ONCOTARGET, V6, P1981, DOI 10.18632/oncotarget.2810; Dadke D, 2003, CANCER RES, V63, P8837; Davidson B, 2008, HUM PATHOL, V39, P1630, DOI 10.1016/j.humpath.2008.03.009; de Feraudy S, 2010, P NATL ACAD SCI USA, V107, P6870, DOI 10.1073/pnas.1002175107; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Guan YQ, 2012, BIOMATERIALS, V33, P6162, DOI 10.1016/j.biomaterials.2012.05.037; Hashimoto H, 2009, DRUG DISCOV THER, V3, P243; Hashimoto H, 2010, DRUG DISCOV THER, V4, P1; He H, 2008, BBA-MOL CELL RES, V1783, P1943, DOI 10.1016/j.bbamcr.2008.04.016; He H, 2012, CANCER LETT, V317, P65, DOI 10.1016/j.canlet.2011.11.014; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Holm K, 2012, BREAST CANCER RES TR, V133, P583, DOI 10.1007/s10549-011-1817-3; Huynh N, 2010, BBA-MOL CELL RES, V1803, P1106, DOI 10.1016/j.bbamcr.2010.05.007; Lambros MBK, 2005, J PATHOL, V205, P29, DOI 10.1002/path.1681; Limame R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046536; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Lundgren K, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2150; Merabet A, 2010, BIOCHEM J, V427, P225, DOI 10.1042/BJ20091888; Motwani M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066585; Murray BW, 2010, P NATL ACAD SCI USA, V107, P9446, DOI 10.1073/pnas.0911863107; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; Prudnikova TY, 2015, CLIN CANCER RES, V21, P24, DOI 10.1158/1078-0432.CCR-14-0827; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shrestha Y, 2012, ONCOGENE, V31, P3397, DOI 10.1038/onc.2011.515; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wang ZP, 2013, J BIOL CHEM, V288, P20093, DOI 10.1074/jbc.M112.426023; Wu JY, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0014-8; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yi CL, 2008, CANCER RES, V68, P7932, DOI 10.1158/0008-5472.CAN-08-0866	43	19	20	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2178	2185		10.1038/onc.2015.278	http://dx.doi.org/10.1038/onc.2015.278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26257058	Green Accepted			2022-12-17	WOS:000374986000004
J	Marchesini, M; Matocci, R; Tasselli, L; Cambiaghi, V; Orleth, A; Furia, L; Marinelli, C; Lombardi, S; Sammarelli, G; Aversa, F; Minucci, S; Faretta, M; Pelicci, PG; Grignani, F				Marchesini, M.; Matocci, R.; Tasselli, L.; Cambiaghi, V.; Orleth, A.; Furia, L.; Marinelli, C.; Lombardi, S.; Sammarelli, G.; Aversa, F.; Minucci, S.; Faretta, M.; Pelicci, P. G.; Grignani, F.			PML is required for telomere stability in non-neoplastic human cells	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN HEMATOPOIETIC PROGENITORS; QUADRUPLEX LIGAND RHPS4; DNA-DAMAGE; RAR-ALPHA; T(15-17) TRANSLOCATION; COMPUTATIONAL PLATFORM; HISTONE DEACETYLASE; HUMAN FIBROBLASTS; NUCLEAR-BODIES	Telomeres interact with numerous proteins, including components of the shelterin complex, whose alteration, similarly to proliferation-induced telomere shortening, initiates cellular senescence. In tumors, telomere length is maintained by Telomerase activity or by the Alternative Lengthening of Telomeres mechanism, whose hallmark is the telomeric localization of the promyelocytic leukemia (PML) protein. Whether PML contributes to telomeres maintenance in normal cells is unknown. We show that in normal human fibroblasts the PML protein associates with few telomeres, preferentially when they are damaged. Proliferation-induced telomere attrition or their damage due to alteration of the shelterin complex enhances the telomeric localization of PML, which is increased in human T-lymphocytes derived from patients genetically deficient in telomerase. In normal fibroblasts, PML depletion induces telomere damage, nuclear and chromosomal abnormalities, and senescence. Expression of the leukemia protein PML/RAR alpha in hematopoietic progenitors displaces PML from telomeres and induces telomere shortening in the bone marrow of pre-leukemic mice. Our work provides a novel view of the physiologic function of PML, which participates in telomeres surveillance in normal cells. Our data further imply that a diminished PML function may contribute to cell senescence, genomic instability, and tumorigenesis.	[Marchesini, M.; Matocci, R.; Tasselli, L.; Marinelli, C.; Grignani, F.] Univ Perugia, Dept Expt Med, Gen Pathol Sect, I-06100 Perugia, Italy; [Marchesini, M.; Tasselli, L.; Cambiaghi, V.; Orleth, A.; Furia, L.; Marinelli, C.; Lombardi, S.; Minucci, S.; Faretta, M.; Pelicci, P. G.] European Inst Oncol, Dept Expt Oncol, Via Giuseppe Ripamonti 435, I-20141 Milan, Italy; [Sammarelli, G.; Aversa, F.] Univ Parma, Dept Clin & Expt Med, Hematol & Bone Marrow Transplantat Unit, I-43100 Parma, Italy; [Minucci, S.] Univ Milan, Dept Biosci, Milan, Italy; [Pelicci, P. G.] Univ Milan, Dipartimento Med Chirurgia & Odontoiatria, Milan, Italy; [Marchesini, M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA; [Tasselli, L.] Stanford Univ, Sch Med, Dept Med, Div Endocrinol Gerontol & Metab, Stanford, CA 94305 USA; [Tasselli, L.] VA Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA USA	University of Perugia; IRCCS European Institute of Oncology (IEO); University of Parma; University Hospital of Parma; University of Milan; University of Milan; University of Texas System; UTMD Anderson Cancer Center; Stanford University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Giuseppe Ripamonti 435, I-20141 Milan, Italy.; Grignani, F (corresponding author), Dept Expt Med, Gen Pathol Sect, Piazza Lucio Severi 1, I-06132 Perugia, Italy.	piergiuseppe.pelicci@ieo.eu; francesco.grignani@unipg.it	Faretta, Mario/H-8946-2012; Tasselli, Luisa/L-8979-2016; Marchesini, Matteo/AAC-4629-2022; Tasselli, Luisa/AAM-6781-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Grignani, Francesco/AAC-2565-2022	Faretta, Mario/0000-0003-1678-5781; Tasselli, Luisa/0000-0003-3349-1371; Tasselli, Luisa/0000-0003-3349-1371; Aversa, Franco/0000-0002-8871-6817; Marchesini, Matteo/0000-0001-9489-7899	AIRC IG grant; Fondazione Cassa di Risparmio di Perugia	AIRC IG grant(Fondazione AIRC per la ricerca sul cancro); Fondazione Cassa di Risparmio di Perugia(Fondazione Cassa Risparmio Perugia)	This work was supported by AIRC IG grant to FG, and SM, and by a grant from the Fondazione Cassa di Risparmio di Perugia to FG. We thank Lucilla Luzi and Alessandro Brozzi (European Institute of Oncology, Milan) for their help in statistical analysis and Annamaria Biroccio (Istituto Nazionale Tumori Regina Elena, Roma) for kindly providing us the RHPS4 compound. We are grateful to Simona Colla (MD Anderson Cancer Center) for encouragement and critical reading of the manuscript, to Giulio Draetta and Luigi Nezi (MD Anderson Cancer Center) for their encouragement and support. This work was supported by AIRC IG grant to FG, and SM, and by a grant from the Fondazione Cassa di Risparmio di Perugia to FG.	Akbar AN, 2007, J IMMUNOL, V178, P6689, DOI 10.4049/jimmunol.178.11.6689; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Armanios M, 2013, J CLIN INVEST, V123, P996, DOI 10.1172/JCI66370; Armanios M, 2012, NAT REV GENET, V13, P693, DOI 10.1038/nrg3246; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Berardinelli F, 2010, RADIAT RES, V174, P539, DOI 10.1667/RR2127.1; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Cesare AJ, 2010, NAT REV GENET, V11, P319, DOI 10.1038/nrg2763; Chang FTM, 2013, NUCLEIC ACIDS RES, V41, P4447, DOI 10.1093/nar/gkt114; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; D'Alcontres MS, 2007, J CELL BIOL, V179, P855, DOI 10.1083/jcb.200703020; de The H, 2012, J CELL BIOL, V198, P11, DOI 10.1083/jcb.201112044; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Dellaire G, 2006, J CELL BIOL, V175, P55, DOI 10.1083/jcb.200604009; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Fenech M, 2002, MUTAT RES-FUND MOL M, V504, P131, DOI 10.1016/S0027-5107(02)00086-6; Flores I, 2006, CURR OPIN CELL BIOL, V18, P254, DOI 10.1016/j.ceb.2006.03.003; Furia L, 2013, CYTOM PART A, V83A, P333, DOI 10.1002/cyto.a.22266; Furia L, 2013, CYTOM PART A, V83A, P344, DOI 10.1002/cyto.a.22265; Ghaffari SH, 2008, ANN ONCOL, V19, P1927, DOI 10.1093/annonc/mdn394; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gunes C, 2013, CELL, V152, P390, DOI 10.1016/j.cell.2013.01.010; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hiorns LR, 1997, BRIT J HAEMATOL, V96, P314, DOI 10.1046/j.1365-2141.1997.d01-2037.x; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Leonetti C, 2004, MOL PHARMACOL, V66, P1138, DOI 10.1124/mol.104.001537; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Mazza M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00174; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2002, BLOOD, V100, P2989, DOI 10.1182/blood-2001-11-0089; Nandakumar J, 2013, NAT REV MOL CELL BIO, V14, P71, DOI 10.1038/nrm3505; Newgard CB, 2013, J CLIN INVEST, V123, P946, DOI 10.1172/JCI68833; O'Sullivan RJ, 2014, NAT STRUCT MOL BIOL, V21, P167, DOI 10.1038/nsmb.2754; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pantic M, 2000, MED ONCOL, V17, P307, DOI 10.1007/BF02782196; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Racanicchi S, 2005, EMBO J, V24, P1232, DOI 10.1038/sj.emboj.7600593; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Salvati E, 2007, J CLIN INVEST, V117, P3236, DOI 10.1172/JCI32461; Slatter T, 2010, AM J PATHOL, V177, P2694, DOI 10.2353/ajpath.2010.100468; Slatter TL, 2012, J PATHOL, V226, P509, DOI 10.1002/path.2981; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Vian L, 2014, CELL DEATH DIFFER, V21, P290, DOI 10.1038/cdd.2013.145; Yeager TR, 1999, CANCER RES, V59, P4175	62	19	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1811	1821		10.1038/onc.2015.246	http://dx.doi.org/10.1038/onc.2015.246			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26119943	Green Published, hybrid			2022-12-17	WOS:000373610400007
J	Busacca, S; Law, EWP; Powley, IR; Proia, DA; Sequeira, M; Le Quesne, J; Klabatsa, A; Edwards, JM; Matchett, KB; Luo, JL; Pringle, JH; El-Tanani, M; MacFarlane, M; Fennell, DA				Busacca, S.; Law, E. W. P.; Powley, I. R.; Proia, D. A.; Sequeira, M.; Le Quesne, J.; Klabatsa, A.; Edwards, J. M.; Matchett, K. B.; Luo, J. L.; Pringle, J. H.; El-Tanani, M.; MacFarlane, M.; Fennell, D. A.			Resistance to HSP90 inhibition involving loss of MCL1 addiction	ONCOGENE			English	Article							CANCER-CELLS; STRUCTURAL BASIS; APOPTOSIS; SENSITIVITY; EML4-ALK; BCL-2; IDENTIFICATION; EXPRESSION; DEATH; GENE	Inhibition of the chaperone heat-shock protein 90 (HSP90) induces apoptosis, and it is a promising anti-cancer strategy. The mechanisms underpinning apoptosis activation following HSP90 inhibition and how they are modified during acquired drug resistance are unknown. We show for the first time that, to induce apoptosis, HSP90 inhibition requires the cooperation of multi BH3-only proteins (BID, BIK, PUMA) and the reciprocal suppression of the pro-survival BCL-2 family member MCL1, which occurs via inhibition of STAT5A. A subset of tumour cell lines exhibit dependence on MCL1 expression for survival and this dependence is also associated with tumour response to HSP90 inhibition. In the acquired resistance setting, MCL1 suppression in response to HSP90 inhibitors is maintained; however, a switch in MCL1 dependence occurs. This can be exploited by the BH3 peptidomimetic ABT737, through non-BCL-2-dependent synthetic lethality.	[Busacca, S.; Law, E. W. P.; Le Quesne, J.; Luo, J. L.; Pringle, J. H.; Fennell, D. A.] Univ Leicester, Dept Canc Studies, Canc Res UK Leicester Ctr, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England; [Powley, I. R.; Le Quesne, J.; Edwards, J. M.; MacFarlane, M.] MRC Toxicol Unit, Leicester, Leics, England; [Proia, D. A.; Sequeira, M.] Synta Pharmaceut Corp, Lexington, MA USA; [Klabatsa, A.] Kings Coll London, Div Canc Studies, London WC2R 2LS, England; [Matchett, K. B.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [El-Tanani, M.] Univ Bradford, Sch Life Sci, Inst Canc Therapeut, Bradford BD7 1DP, W Yorkshire, England	Cancer Research UK; University of Leicester; University of London; King's College London; Queens University Belfast; University of Bradford	Fennell, DA (corresponding author), Univ Leicester, Dept Canc Studies, Canc Res UK Leicester Ctr, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	df132@leicester.ac.uk	Klampatsa, Astero/AAK-4419-2020	Klampatsa, Astero/0000-0003-0572-502X; Le Quesne, John/0000-0003-3552-7446; Matchett, Kyle/0000-0001-6148-6022; Law, Edward/0000-0001-5089-6341; Luo, Jinli/0000-0002-9241-5283; El-Tanani, Mohamed/0000-0002-4735-5445	University of Leicester; Medical Research Council (MRC); British Lung Foundation (BLF); MRC [MC_PC_15045, MC_UP_1203/1, MC_PC_14117, MC_U132685863] Funding Source: UKRI; Medical Research Council [MC_U132685863, MC_PC_14117, MC_UP_1203/1, MC_PC_15045] Funding Source: researchfish	University of Leicester; Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Lung Foundation (BLF); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Dr Meike Vogler (University of Leicester) for critically revising the manuscript. DAF and SB are supported by the University of Leicester. MMF and IRP are funded by Medical Research Council (MRC) and British Lung Foundation (BLF).	Acquaviva J, 2014, MOL CANCER RES, V12, P1042, DOI 10.1158/1541-7786.MCR-14-0004; Akgul C, 2009, CELL MOL LIFE SCI, V66, P1326, DOI 10.1007/s00018-008-8637-6; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Altieri DC, 2012, BBA-MOL CELL RES, V1823, P767, DOI 10.1016/j.bbamcr.2011.08.007; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Busacca S, 2012, J PATHOL, V227, P200, DOI 10.1002/path.3979; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Fritsch RM, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702673200; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Geserick P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.379; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heuckmann JM, 2012, CLIN CANCER RES, V18, P4682, DOI 10.1158/1078-0432.CCR-11-3260; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kotha A, 2006, MOL CANCER THER, V5, P621, DOI 10.1158/1535-7163.MCT-05-0268; Landmann H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.378; McCollum AK, 2006, CANCER RES, V66, P10967, DOI 10.1158/0008-5472.CAN-06-1629; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Moulick K, 2011, NAT CHEM BIOL, V7, P818, DOI 10.1038/nchembio.670; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nam S, 2007, MOL CANCER THER, V6, P1400, DOI 10.1158/1535-7163.MCT-06-0446; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Paraiso KHT, 2012, CLIN CANCER RES, V18, P2502, DOI 10.1158/1078-0432.CCR-11-2612; Paul I, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.186; Paul I, 2011, J PATHOL, V224, P564, DOI 10.1002/path.2925; Pillai RN, 2014, CURR OPIN ONCOL, V26, P159, DOI 10.1097/CCO.0000000000000047; Powers MV, 2013, ONCOTARGET, V4, P1963, DOI 10.18632/oncotarget.1419; Prodromou C, 2009, ACS CHEM BIOL, V4, P289, DOI 10.1021/cb9000316; Ricci MS, 2007, CANCER CELL, V12, P66, DOI 10.1016/j.ccr.2007.05.006; Richards MW, 2014, P NATL ACAD SCI USA, V111, P5195, DOI 10.1073/pnas.1322892111; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Samant RS, 2014, P NATL ACAD SCI USA, V111, P6834, DOI 10.1073/pnas.1322412111; Sathe P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5539; Shah OJ, 2010, P NATL ACAD SCI USA, V107, P12634, DOI 10.1073/pnas.0913615107; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Travers J, 2012, DRUG DISCOV TODAY, V17, P242, DOI 10.1016/j.drudis.2011.12.021; Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887; Twiddy D, 2010, BREAST CANCER RES, P58; Upton JP, 2008, MOL CELL BIOL, V28, P3943, DOI 10.1128/MCB.00013-08; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Workman P, 2013, NAT REV DRUG DISCOV, V12, P889, DOI 10.1038/nrd4184; Workman P, 2013, CURR OPIN PHARMACOL, V13, P486, DOI 10.1016/j.coph.2013.06.004	51	19	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1483	1492		10.1038/onc.2015.213	http://dx.doi.org/10.1038/onc.2015.213			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26096930	Green Published, hybrid			2022-12-17	WOS:000373063600002
J	Lee, SH; Luong, R; Johnson, DT; Cunha, GR; Rivina, L; Gonzalgo, ML; Sun, Z				Lee, S. H.; Luong, R.; Johnson, D. T.; Cunha, G. R.; Rivina, L.; Gonzalgo, M. L.; Sun, Z.			Androgen signaling is a confounding factor for beta-catenin-mediated prostate tumorigenesis	ONCOGENE			English	Article							INTRAEPITHELIAL NEOPLASIA; TUMOR-SUPPRESSOR; MURINE PROSTATE; RECEPTOR; CANCER; CELL; APC; RESISTANCE; REGENERATION; ACTIVATION	Emerging evidence has demonstrated the critical roles for both androgen and Wnt pathways in prostate tumorigenesis. A recent integrative genomic analysis of human prostate cancers (PCas) has revealed a unique enrichment of androgen and Wnt signaling in early-onset PCas, implying their clinical significance in the disease. Additionally, interaction between the androgen receptor (AR) and P-catenin has long been detected in PCa cells. However, the consequence of this interaction in prostate tumorigenesis is still unknown. Because mutations in adenomatous polyposis coli, P-catenin and other components of the destruction complex are generally rare in PCas, other mechanisms of aberrant Wnt signaling activation have been speculated. To address these critical questions, we developed Ctnnb1(L(ex3)/1) /R26hAR(L/+):PB-Cre4 mice, in which transgenic AR and stabilized beta-catenin are co-expressed in prostatic epithelial cells. We observed accelerated tumor development, aggressive tumor invasion and a decreased survival rate in Ctnnb1(L(ex3)/+) /R26hAR(L/+):PB-Cre4 compound mice compared with age-matched Ctnnb1(L(ex3)/+):PB-Cre4 littermate controls, which only have stabilized P-catenin expression in the prostate. Castration of the above transgenic mice resulted in significant tumor regression, implying an essential role of androgen signaling in tumor growth and maintenance. Implantation of the prostatic epithelial cells isolated from the transgenic mice regenerated prostate intraepithelial neoplasias and prostatic adenocarcinoma lesions. Microarray analyses of transcriptional profiles showed more robust enrichment of known tumor-and metastasis-promoting genes: Spp1, Egr1, c-Myc, Sp5, and Sp6 genes, in samples isolated from Ctnnb1(L(ex3)/+)/R26hAR(L/1) :PR-Cre4 compound mice than those from Ctnnb1(L(ex3)/+):PB-Cre4 and R26hAR(L/+) :PB-Cre4 littermate controls. Together, these data demonstrate a confounding role of androgen signaling in P-catenin-initiated oncogenic transformation in prostate tumorigenesis.	[Lee, S. H.; Johnson, D. T.; Rivina, L.; Gonzalgo, M. L.; Sun, Z.] Stanford Univ, Sch Med, Dept Urol, S221,Grant Bldg,300 Pasteur Dr, Stanford, CA 94305 USA; [Luong, R.] Stanford Univ, Sch Med, Dept Comparat Med, Stanford, CA 94305 USA; [Cunha, G. R.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA	Stanford University; Stanford University; University of California System; University of California San Francisco	Sun, Z (corresponding author), Stanford Univ, Sch Med, Dept Urol, S221,Grant Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	zsun@stanford.edu			NIH [R01-CA070297, R01-CA151623, U01-CA166894, R21-CA190021]; NATIONAL CANCER INSTITUTE [R01CA070297, R01CA151623, R21CA190021, U01CA166894, R01CA166894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK104941] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr William Tu and Dr Chunfang Zhu for their technical assistance. This work was supported by the NIH grants R01-CA070297, R01-CA151623, U01-CA166894 and R21-CA190021.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Bierie B, 2003, ONCOGENE, V22, P3875, DOI 10.1038/sj.onc.1206426; Bruxvoort KJ, 2007, CANCER RES, V67, P2490, DOI 10.1158/0008-5472.CAN-06-3028; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Y, 2013, EUR J HUM GENET, V21, P929, DOI 10.1038/ejhg.2012.281; Chesire DR, 2003, ENDOCR-RELAT CANCER, V10, P537, DOI 10.1677/erc.0.0100537; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; de Ronde JJ, 2013, BREAST CANCER RES TR, V137, P213, DOI 10.1007/s10549-012-2340-x; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Henrique R, 2007, CLIN CANCER RES, V13, P6122, DOI 10.1158/1078-0432.CCR-07-1042; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; Ibarretxe G, 2012, CELL TISSUE RES, V350, P95, DOI 10.1007/s00441-012-1459-8; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; Johnson DT, 2013, J BIOL CHEM, V288, P3727, DOI 10.1074/jbc.M112.417568; Koivisto P, 1997, CANCER RES, V57, P314; Kwak MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053476; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee J, 2007, NUCLEIC ACIDS RES, V35, P4523, DOI 10.1093/nar/gkm476; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahmoudi T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000539; Matusik RJ, 2008, DIFFERENTIATION, V76, P682, DOI 10.1111/j.1432-0436.2008.00276.x; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Pearson HB, 2009, CANCER RES, V69, P94, DOI 10.1158/0008-5472.CAN-08-2895; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Stanbrough M, 2001, P NATL ACAD SCI USA, V98, P10823, DOI 10.1073/pnas.191235898; SUGIMURA Y, 1986, BIOL REPROD, V34, P973, DOI 10.1095/biolreprod34.5.973; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Truica CI, 2000, CANCER RES, V60, P4709; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Wang YZ, 2005, PROSTATE, V64, P149, DOI 10.1002/pros.20225; Weischenfeldt J, 2013, CANCER CELL, V23, P159, DOI 10.1016/j.ccr.2013.01.002; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Zhu CF, 2011, J BIOL CHEM, V286, P33478, DOI 10.1074/jbc.M111.269894	53	19	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					702	714		10.1038/onc.2015.117	http://dx.doi.org/10.1038/onc.2015.117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25893287	Green Accepted			2022-12-17	WOS:000370331300004
J	Chen, L; Xu, S; Xu, Y; Lu, W; Liu, L; Yue, D; Teng, J; Chen, J				Chen, L.; Xu, S.; Xu, Y.; Lu, W.; Liu, L.; Yue, D.; Teng, J.; Chen, J.			Cab45S promotes cell proliferation through SERCA2b inhibition and Ca2+ signaling	ONCOGENE			English	Article							INTESTINAL EPITHELIAL-CELLS; THERAPEUTIC TARGET; ER STRESS; STORE; STIM1; CANCER; CALCINEURIN; APOPTOSIS; FAMILY; TRPC1	Cytosolic Ca2+, closely related to endoplasmic reticulum (ER) Ca2+, plays a critical role in regulating cell proliferation and tumorigenesis. However, the role of ER lumen proteins in regulating cytosolic Ca2+ level remains poorly understood. Here, we find that the Cab45S, localizes in the ER lumen, inhibits sarco/ER Ca2+-ATPase 2b (SERCA2b) activity through its first EF-hand domain directly binding to the intra-lumenal loop 4 of SERCA2b, and reduces ER Ca2+. STIM1 activation, induced by the Cab45S-dependent drop in ER Ca2+, together with the upregulation of the plasma membrane Ca2+ channel TRPC1 ultimately increases extracellular Ca2+ influx. Furthermore, increased cytosolic Ca2+ level elicits Ca2+-NFAT signaling and promotes cell proliferation. Consistently, in cervical carcinoma patients, Cab45S is upregulated. Thus, our data reveal that the ability of Cab45S to inhibit SERCA2b activity is crucial for its role as a modulator of cell proliferation and tumor growth.	[Chen, L.; Xu, S.; Xu, Y.; Lu, W.; Liu, L.; Yue, D.; Teng, J.; Chen, J.] Peking Univ, Coll Life Sci, State Key Lab Biomembrane & Membrane Bioengn, Key Lab Cell Proliferat & Differentiat,Minist Edu, Beijing 100871, Peoples R China; [Chen, J.] Peking Univ, Ctr Quantitat Biol, Beijing 100871, Peoples R China	Peking University; Peking University	Teng, J (corresponding author), Peking Univ, Coll Life Sci, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.	junlinteng@pku.edu.cn; chenjg@pku.edu.cn		Chen, Liang/0000-0002-4875-5811	National Natural Science Foundation of China [31471280, 31271424]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Weizhong Zhu (Nantong University) for providing with the Adenovirus containing GFP-tagged NFATc3; Zhili Li (Peking University Medical College), Xiaogai Yang (Peking University Medical College) and Weiguo Zhu (Peking University Medical College) for providing us with Panc1, SW1990, PC3 and SW480 cell lines, respectively. We also extend our thanks to Zhen Cai and Chuanmao Zhang (Peking University) for assistance with instruments and antibodies. This work was supported by the National Natural Science Foundation of China (31471280, 31271424).	Abdullaev IF, 2008, CIRC RES, V103, P1289, DOI 10.1161/01.RES.0000338496.95579.56; Ambudkar IS, 2007, CELL CALCIUM, V42, P213, DOI 10.1016/j.ceca.2007.01.013; Baggott RR, 2012, CARCINOGENESIS, V33, P2362, DOI 10.1093/carcin/bgs282; BEELER TJ, 1979, J BIOL CHEM, V254, P6229; Bergner A, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-25; Brandman O, 2007, CELL, V131, P1327, DOI 10.1016/j.cell.2007.11.039; Brochet DXP, 2005, P NATL ACAD SCI USA, V102, P3099, DOI 10.1073/pnas.0500059102; Buchholz M, 2007, CELL CYCLE, V6, P16, DOI 10.4161/cc.6.1.3650; Chen L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.193; Chen QQ, 2012, CAN J PHYSIOL PHARM, V90, P1611, DOI 10.1139/y2012-133; Collins SR, 2011, TRENDS CELL BIOL, V21, P202, DOI 10.1016/j.tcb.2011.01.002; Dally S, 2006, BIOCHEM J, V395, P249, DOI 10.1042/BJ20051427; Denmeade SR, 2005, CANCER BIOL THER, V4, P14; Dhitavat J, 2003, J INVEST DERMATOL, V121, P486, DOI 10.1046/j.1523-1747.2003.12410.x; Endo Y, 2004, INT J CANCER, V110, P225, DOI 10.1002/ijc.20118; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Grigoriev I, 2008, CURR BIOL, V18, P177, DOI 10.1016/j.cub.2007.12.050; Gronborg M, 2006, MOL CELL PROTEOMICS, V5, P157, DOI 10.1074/mcp.M500178-MCP200; Honore B, 2009, BIOESSAYS, V31, P262, DOI 10.1002/bies.200800186; Hovnanian A., 2007, V45, P337; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kang YK, 2005, MOL CELLS, V19, P268; Kurosaki T, 2010, PROG BIOPHYS MOL BIO, V103, P51, DOI 10.1016/j.pbiomolbio.2010.02.004; Lam PPL, 2007, MOL BIOL CELL, V18, P2473, DOI 10.1091/mbc.E06-10-0950; Lechleiter JD, 1998, BIOPHYS CHEM, V72, P123, DOI 10.1016/S0301-4622(98)00128-8; Lee JH, 2013, BIOCHEM BIOPH RES CO, V439, P327, DOI 10.1016/j.bbrc.2013.08.087; Li GL, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-20; Li Y, 2004, J CELL BIOL, V164, P35, DOI 10.1083/jcb.200307010; Liao Y, 2007, P NATL ACAD SCI USA, V104, P4682, DOI 10.1073/pnas.0611692104; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Lipskaia L, 2009, PFLUG ARCH EUR J PHY, V457, P673, DOI 10.1007/s00424-007-0428-7; Luik RM, 2008, NATURE, V454, P538, DOI 10.1038/nature07065; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Malli R, 2008, J CELL SCI, V121, P3133, DOI 10.1242/jcs.034496; Marasa BS, 2008, AM J PHYSIOL-CELL PH, V294, pC1277, DOI 10.1152/ajpcell.90635.2007; Marasa BS, 2006, BIOCHEM J, V397, P77, DOI 10.1042/BJ20060124; Mikoshiba K, 2007, BIOCHEM SOC SYMP, V74, P9, DOI 10.1042/BSS2007c02; Pacifico F, 2003, J MOL ENDOCRINOL, V30, P399, DOI 10.1677/jme.0.0300399; Pani B, 2006, MOL BIOL CELL, V17, P4446, DOI 10.1091/mbc.E06-03-0251; Parkash J, 2010, LIFE SCI, V87, P587, DOI 10.1016/j.lfs.2010.09.013; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Roti G, 2013, CANCER CELL, V23, P390, DOI 10.1016/j.ccr.2013.01.015; Savignac M, 2011, BBA-MOL CELL RES, V1813, P1111, DOI 10.1016/j.bbamcr.2010.12.006; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; Stokke MK, 2010, CARDIOVASC RES, V86, P63, DOI 10.1093/cvr/cvp401; Tsuji A, 2006, BIOCHEM J, V396, P51, DOI 10.1042/BJ20051524; Tsukamoto T, 2001, PSYCHOPHARMACOLOGY, V158, P107, DOI 10.1007/s002130100870; Vandecaetsbeek I, 2009, P NATL ACAD SCI USA, V106, P18533, DOI 10.1073/pnas.0906797106; Vangheluwe P, 2005, CELL CALCIUM, V38, P291, DOI 10.1016/j.ceca.2005.06.033; von Blume J, 2012, J CELL BIOL, V199, P1057, DOI 10.1083/jcb.201207180; Wang Qiao, 2012, Front Biosci (Elite Ed), V4, P998, DOI 10.2741/E435; Wang QA, 2010, CELL RES, V20, P713, DOI 10.1038/cr.2010.47; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhu YF, 2008, J GENET GENOMICS, V35, P153, DOI 10.1016/S1673-8527(08)60021-1	59	19	19	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					35	46		10.1038/onc.2015.56	http://dx.doi.org/10.1038/onc.2015.56			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25772237				2022-12-17	WOS:000367812400004
J	Meng, X; Carlson, NR; Dong, J; Zhang, Y				Meng, X.; Carlson, N. R.; Dong, J.; Zhang, Y.			Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways	ONCOGENE			English	Article							POLYMERASE-I TRANSCRIPTION; RIBOSOME BIOGENESIS; TUMOR SUPPRESSION; ARF; P53; PROTEIN; MICE; APOPTOSIS; CANCER; TARGET	The multifaceted oncogene c-Myc plays important roles in the development and progression of human cancer. Recent in vitro and in vivo studies have shown that the p19Arf-Mdm2-p53 and the ribosomal protein (RP)-Mdm2-p53 pathways are both essential in preventing oncogenic c-Myc-induced tumorigenesis. Disruption of each pathway individually by p19Arf deletion or by Mdm2(C305F) mutation, which disrupts RP-Mdm2 binding, accelerates E mu-myc transgene-induced pre-B/B-cell lymphoma in mice at seemingly similar paces with median survival around 10 and 11 weeks, respectively, compared to 20 weeks for E mu-myc transgenic mice. Because p19Arf can inhibit ribosomal biogenesis through its interaction with nucleophosmin (NPM/B23), RNA helicase DDX5 and RNA polymerase I transcription termination factor (TTF-I), it has been speculated that the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 pathways might be a single p19Arf-RP-Mdm2-p53 pathway, in which p19Arf activates p53 by inhibiting RP biosynthesis; thus, p19Arf deletion or Mdm2(C305F) mutation would result in similar consequences. Here, we generated mice with concurrent p19Arf deletion and Mdm2(C305F) mutation and investigated the compound mice for tumorigenesis in the absence and the presence of oncogenic c-Myc overexpression. In the absence of E mu-myc transgene, the Mdm2(C305)F mutation did not elicit spontaneous tumors in mice, nor did it accelerate spontaneous tumors in mice with p19Arf deletion. In the presence of E mu-myc transgene, however, Mdm2(C305F) mutation significantly accelerated p19Arf deletion-induced lymphomagenesis and promoted rapid metastasis. We found that when p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways are independently disrupted, oncogenic c-Myc-induced p53 stabilization and activation is only partially attenuated. When both pathways are concurrently disrupted, however, c-Myc-induced p53 stabilization and activation are essentially obliterated. Thus, the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 are non-redundant pathways possessing similar capabilities to activate p53 upon c-Myc overexpression.	[Meng, X.; Carlson, N. R.; Zhang, Y.] Univ N Carolina, Dept Radiat Oncol, Sch Med, Chapel Hill, NC 27514 USA; [Meng, X.; Carlson, N. R.; Zhang, Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27514 USA; [Meng, X.; Dong, J.] Chinese Peoples Liberat Army Gen Hosp, Hosp & Inst Hepatobiliary Surg, Beijing, Peoples R China; [Meng, X.; Dong, J.; Zhang, Y.] Xuzhou Med Coll, Inst Canc, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou, Peoples R China; [Carlson, N. R.; Zhang, Y.] Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Chinese People's Liberation Army General Hospital; Xuzhou Medical University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zhang, Y (corresponding author), Univ N Carolina, Dept Radiat Oncol, Box 7512,101 Manning Dr, Chapel Hill, NC 27514 USA.	ypzhang@med.unc.edu		Meng, Xuan/0000-0002-0257-9509	National Institutes of Health [CA127770, CA100302, CA167637]; NSFC; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy; National S&T Major Project for Infectious Diseases of China [2012ZX10002-017]; National Institute of General Medical Sciences [5T32 GM007092]; NATIONAL CANCER INSTITUTE [R01CA167637, R01CA127770, R01CA155235, R01CA100302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSFC(National Natural Science Foundation of China (NSFC)); Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy; National S&T Major Project for Infectious Diseases of China; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Congying Wu, Yizhou He, Yong Liu, Aiwen Jin and Laura Tollini for their helpful advice and technical assistance. We are in debt to Yue Xiong, Guillermina Lozano, Gerard Evan, Charles Sherr and Norman Sharpless for their generosity in sharing mouse strains and reagents. This research was supported by grants from the National Institutes of Health (CA127770, CA100302 and CA167637) to YZ. This research was also supported by grants from the NSFC and Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy to YZ, the National S&T Major Project for Infectious Diseases of China (No. 2012ZX10002-017) to JD. NRC was supported in part by a grant from the National Institute of General Medical Sciences under award 5T32 GM007092.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Aoudjit F, 1998, BLOOD, V91, P623, DOI 10.1182/blood.V91.2.623.623_623_629; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; de Marval PLM, 2011, ONCOTARGET, V2, P234; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; HOAG WG, 1963, ANN NY ACAD SCI, V108, P805, DOI 10.1111/j.1749-6632.1963.tb13421.x; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lessard F, 2010, MOL CELL, V38, P539, DOI 10.1016/j.molcel.2010.03.015; Liao JM, 2014, ONCOGENE, V33, P4916, DOI 10.1038/onc.2013.430; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Meng X, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-80; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Saporita AJ, 2011, CANCER RES, V71, P6708, DOI 10.1158/0008-5472.CAN-11-1472; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shetty S, 2012, HEPATOLOGY, V56, P1521, DOI 10.1002/hep.25790; SIDMAN CL, 1988, CURR TOP MICROBIOL, V141, P94; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Toth P, 2014, J CEREBR BLOOD F MET, V34, P1887, DOI 10.1038/jcbfm.2014.156; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; White P, 2002, J IMMUNOL, V168, P869, DOI 10.4049/jimmunol.168.2.869; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang Q, 2013, P NATL ACAD SCI USA, V110, P978, DOI 10.1073/pnas.1208334110; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	37	19	21	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5709	5717		10.1038/onc.2015.39	http://dx.doi.org/10.1038/onc.2015.39			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25823025	Green Submitted, Green Accepted			2022-12-17	WOS:000364594600003
J	Chen, HY; Hu, JY; Chen, TH; Lin, YC; Liu, X; Lin, MY; Lang, YD; Yen, Y; Chen, RH				Chen, H. Y.; Hu, J. Y.; Chen, T. H.; Lin, Y. C.; Liu, X.; Lin, M. Y.; Lang, Y. D.; Yen, Y.; Chen, R. H.			KLHL39 suppresses colon cancer metastasis by blocking KLHL20-mediated PML and DAPK ubiquitination	ONCOGENE			English	Article							KELCH FAMILY PROTEIN; TUMOR-SUPPRESSOR; COLORECTAL CANCERS; LIGASES; KINASE; KEAP1; NRF2; CELLS; DEGRADATION; INTERACTS	Cullin 3 (Cul3)-family ubiquitin ligases use the BTB-domain-containing proteins for the recruitment of substrates, but the regulation of this family of ubiquitin ligases has not been completely understood. KLHL20 is a BTB-family protein and targets tumor suppressor promyelocytic leukemia protein (PML) and death-associated protein kinase (DAPK) to its kelch-repeat domain for ubiquitination and degradation. Here, we show that another BTB-kelch protein KLHL39 is recruited to the substrate-binding domain of KLHL20 but is not a substrate of Cul3-KLHL20 complex. Interestingly, KLHL39 does not bind Cul3 because of the absence of certain conserved residues in the BTB domain. Instead, KLHL39 blocks KLHL20-mediated ubiquitination of PML and DAPK by disrupting the binding of these substrates to KLHL20 as well as the binding of KLHL20 to Cul3. Through the two mechanisms, KLHL39 increases the stability of PML and DAPK. In human colon cancers, downregulations of KLHL39, PML and DAPK are associated with metastatic progression. Furthermore, preclinical data indicate that KLHL39 promotes colon cancer migration, invasion and survival in vitro and metastasis in vivo through a PML- and DAPK-dependent mechanism. Our study identifies KLHL39 as a negative regulator of Cul3-KLHL20 ubiquitin ligase and reveals a role of KLHL39-mediated PML and DAPK stabilization in colon cancer metastasis.	[Chen, H. Y.; Liu, X.; Yen, Y.] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan; [Chen, H. Y.; Hu, J. Y.; Chen, T. H.; Lin, Y. C.; Lin, M. Y.; Chen, R. H.] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; [Hu, J. Y.; Chen, T. H.; Chen, R. H.] Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 10764, Taiwan; [Lang, Y. D.] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Chen, R. H.] Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei, Taiwan	Taipei Medical University; Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan; National Taiwan University	Chen, RH (corresponding author), Acad Sinica, Inst Biol Chem, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	rhchen@gate.sinica.edu.tw	Chen, Ruey-Hwa/G-6121-2019; Yen, Yun/H-9591-2016	Chen, Ruey-Hwa/0000-0001-8124-5832; 	Academia Sinica Investigator Award; Taipei Medical University	Academia Sinica Investigator Award(Academia Sinica - Taiwan); Taipei Medical University	We thank National RNAi Core Facility for RNAi. This work was supported by Academia Sinica Investigator Award (RHC) and Aim for the Top University Project from Taipei Medical University (HYC).	Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Bialik S, 2004, SEMIN CANCER BIOL, V14, P283, DOI 10.1016/j.semcancer.2004.04.008; Camp ND, 2012, J BIOL CHEM, V287, P6539, DOI 10.1074/jbc.M111.316471; Canning P, 2013, J BIOL CHEM, V288, P7803, DOI 10.1074/jbc.M112.437996; Chen HY, 2014, APOPTOSIS, V19, P364, DOI 10.1007/s10495-013-0923-6; Chen HY, 2012, CANCER RES, V72, P3631, DOI 10.1158/0008-5472.CAN-12-0667; Ebert MPA, 2005, NEOPLASIA, V7, P771, DOI 10.1593/neo.05235; Errington WJ, 2012, STRUCTURE, V20, P1141, DOI 10.1016/j.str.2012.04.009; Genschik P, 2013, EMBO J, V32, P2307, DOI 10.1038/emboj.2013.173; Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hast BE, 2013, CANCER RES, V73, P2199, DOI 10.1158/0008-5472.CAN-12-4400; Ji AX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060445; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Lee YR, 2010, EMBO J, V29, P1748, DOI 10.1038/emboj.2010.62; Liu XY, 2013, CLIN SCI, V124, P567, DOI 10.1042/CS20120240; Ma JL, 2012, MOL CELL BIOL, V32, P1506, DOI 10.1128/MCB.06271-11; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ohta Y, 2010, INT J ONCOL, V36, P427, DOI 10.3892/ijo_00000516; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Rabellino A, 2012, CANCER RES, V72, P2275, DOI 10.1158/0008-5472.CAN-11-3159; Reineke EL, 2010, J BIOL CHEM, V285, P9485, DOI 10.1074/jbc.M109.063362; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; Sasagawa K, 2002, J BIOL CHEM, V277, P44140, DOI 10.1074/jbc.M202596200; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Schneider-Stock R, 2006, J PATHOL, V209, P95, DOI 10.1002/path.1951; Tsai PL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003460; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Wang WJ, 2007, MOL CELL, V27, P701, DOI 10.1016/j.molcel.2007.06.037; Wolff T, 1998, J VIROL, V72, P7170, DOI 10.1128/JVI.72.9.7170-7180.1998; Wolyniec K, 2012, BLOOD, V120, P822, DOI 10.1182/blood-2011-10-387647; Wu HC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4214; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441; Yen CC, 2011, J SURG ONCOL, V103, P761, DOI 10.1002/jso.21855; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008; Zhuang M, 2009, MOL CELL, V36, P39, DOI 10.1016/j.molcel.2009.09.022	40	19	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5141	5151		10.1038/onc.2014.435	http://dx.doi.org/10.1038/onc.2014.435			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25619834				2022-12-17	WOS:000362233400004
J	Wade, MA; Sunter, NJ; Fordham, SE; Long, A; Masic, D; Russell, LJ; Harrison, CJ; Rand, V; Elstob, C; Bown, N; Rowe, D; Lowe, C; Cuthbert, G; Bennett, S; Crosier, S; Bacon, CM; Onel, K; Scott, K; Scott, D; Travis, LB; May, FEB; Allan, JM				Wade, M. A.; Sunter, N. J.; Fordham, S. E.; Long, A.; Masic, D.; Russell, L. J.; Harrison, C. J.; Rand, V.; Elstob, C.; Bown, N.; Rowe, D.; Lowe, C.; Cuthbert, G.; Bennett, S.; Crosier, S.; Bacon, C. M.; Onel, K.; Scott, K.; Scott, D.; Travis, L. B.; May, F. E. B.; Allan, J. M.			c-MYC is a radiosensitive locus in human breast cells	ONCOGENE			English	Article							ATOMIC-BOMB SURVIVORS; COMPARATIVE GENOMIC HYBRIDIZATION; INDUCED NEOPLASTIC TRANSFORMATION; IONIZING-RADIATION; ALLELIC IMBALANCE; TUMOR PROGRESSION; EPITHELIAL-CELLS; GENE-EXPRESSION; CANCER RISK; AMPLIFICATION	Ionising radiation is a potent human carcinogen. Epidemiological studies have shown that adolescent and young women are at increased risk of developing breast cancer following exposure to ionising radiation compared with older women, and that risk is dose-dependent. Although it is well understood which individuals are at risk of radiation-induced breast carcinogenesis, the molecular genetic mechanisms that underlie cell transformation are less clear. To identify genetic alterations potentially responsible for driving radiogenic breast transformation, we exposed the human breast epithelial cell line MCF-10A to fractionated doses of X-rays and examined the copy number and cytogenetic alterations. We identified numerous alterations of c-MYC that included high-level focal amplification associated with increased protein expression. c-MYC amplification was also observed in primary human mammary epithelial cells following exposure to radiation. We also demonstrate that the frequency and magnitude of c-MYC amplification and c-MYC protein expression is significantly higher in breast cancer with antecedent radiation exposure compared with breast cancer without a radiation aetiology. Our data also demonstrate extensive intratumor heterogeneity with respect to c-MYC copy number in radiogenic breast cancer, suggesting continuous evolution at this locus during disease development and progression. Taken together, these data identify c-MYC as a radiosensitive locus, implicating this oncogenic transcription factor in the aetiology of radiogenic breast cancer.	[Wade, M. A.; Sunter, N. J.; Fordham, S. E.; Long, A.; Masic, D.; Russell, L. J.; Harrison, C. J.; Rand, V.; Elstob, C.; Crosier, S.; Bacon, C. M.; May, F. E. B.; Allan, J. M.] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Bown, N.; Rowe, D.; Lowe, C.; Cuthbert, G.; Bennett, S.] Newcastle Univ, Inst Med Genet, Northern Genet Serv, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Onel, K.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Scott, K.] Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England; [Scott, D.] Harrogate Dist Hosp, Harrogate & Dist NHS Fdn Trust, Dept Histopathol, Harrogate, Yorks, England; [Travis, L. B.] Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA; [Travis, L. B.] Univ Rochester, Med Ctr, Rubin Ctr Canc Survivorship, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	Newcastle University - UK; Newcastle University - UK; University of Chicago; University of York - UK; University of Rochester; University of Rochester	Allan, JM (corresponding author), Newcastle Univ, Northern Inst Canc Res, Paul OGorman Bldg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	james.allan@newcastle.ac.uk	Wade, Mark/AAA-2685-2019; Russell, Lisa/L-2122-2019	Wade, Mark/0000-0002-4245-097X; Russell, Lisa/0000-0002-3421-3288; Allan, James/0000-0002-7580-5087; Bacon, Chris/0000-0002-8268-2812; Elstob, Claire/0000-0003-4252-493X; Fordham, Sarah/0000-0002-3778-8634; Rand, Vikki/0000-0002-2198-8949	Medical Research Council; Newcastle Healthcare Charity; Leukaemia and Lymphoma Research	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Newcastle Healthcare Charity; Leukaemia and Lymphoma Research	This work was supported by grants from the Medical Research Council (to JMA and FEBM), the Newcastle Healthcare Charity (to JMA and FEBM) and specialist programme funding from Leukaemia and Lymphoma Research (to JMA).	Arlt MF, 2006, DNA REPAIR, V5, P1126, DOI 10.1016/j.dnarep.2006.05.010; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Behrens C, 2000, CANCER EPIDEM BIOMAR, V9, P1027; Berg T, 2011, CURR TOP MICROBIOL, V348, P139, DOI 10.1007/82_2010_90; Best T, 2011, NAT MED, V17, P941, DOI 10.1038/nm.2407; Broeks A, 2010, INT J RADIAT ONCOL, V76, P540, DOI 10.1016/j.ijrobp.2009.09.004; Camats N, 2006, MUTAT RES-FUND MOL M, V595, P156, DOI 10.1016/j.mrfmmm.2005.11.002; Carmichael A, 2003, EUR J SURG ONCOL, V29, P475, DOI 10.1016/S0748-7983(03)00010-6; Chiang CS, 1998, MOL DIAGN, V3, P21, DOI 10.1016/S1084-8592(98)80023-4; Chrzan P, 2001, CLIN BIOCHEM, V34, P557, DOI 10.1016/S0009-9120(01)00260-0; Cowell JK, 2005, CANCER GENET CYTOGEN, V163, P23, DOI 10.1016/j.cancergencyto.2005.04.019; Davey RA, 2004, ANTICANCER RES, V24, P465; DAVIS FG, 1989, CANCER RES, V49, P6130; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; FELBER M, 1992, RADIAT RES, V131, P297, DOI 10.2307/3578419; Ferber MJ, 2004, CANCER GENET CYTOGEN, V154, P1, DOI 10.1016/j.cancergencyto.2004.01.028; Guo TH, 2011, GENE CHROMOSOME CANC, V50, P25, DOI 10.1002/gcc.20827; HOFFMAN DA, 1989, J NATL CANCER I, V81, P1307, DOI 10.1093/jnci/81.17.1307; HRUBEC Z, 1989, CANCER RES, V49, P229; Kadota M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009201; Kim BY, 2011, ONCOL REP, V26, P1587, DOI 10.3892/or.2011.1432; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; Li ZZ, 2012, NEOPLASIA, V14, P1190, DOI 10.1593/neo.121258; Ma HY, 2008, BREAST CANCER RES TR, V109, P77, DOI 10.1007/s10549-007-9625-5; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Miura S, 2008, CANCER-AM CANCER SOC, V112, P2143, DOI 10.1002/cncr.23414; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Oikawa M, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-168; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1; Prochownik EV, 2007, CELL CYCLE, V6, P1024, DOI 10.4161/cc.6.9.4161; Roy D, 2006, INT J ONCOL, V28, P667; Roy D, 2003, INT J CANCER, V103, P730, DOI 10.1002/ijc.10895; Roy D, 2001, CARCINOGENESIS, V22, P1685, DOI 10.1093/carcin/22.10.1685; SAUTER G, 1995, AM J PATHOL, V146, P1131; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; SOULE HD, 1990, CANCER RES, V50, P6075; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; Travis LB, 2003, JAMA-J AM MED ASSOC, V290, P465, DOI 10.1001/jama.290.4.465; Unger K, 2010, ENDOCR-RELAT CANCER, V17, P87, DOI 10.1677/ERC-09-0065; Varma G, 2005, BRIT J CANCER, V93, P699, DOI 10.1038/sj.bjc.6602784; Wang WJ, 2013, CANCER RES, V73, P1219, DOI 10.1158/0008-5472.CAN-12-1408; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691	45	19	19	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4985	4994		10.1038/onc.2014.427	http://dx.doi.org/10.1038/onc.2014.427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531321	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000361693000008
J	Cui, J; Yang, Y; Li, H; Leng, Y; Qian, K; Huang, Q; Zhang, C; Lu, Z; Chen, J; Sun, T; Wu, R; Sun, Y; Song, H; Wei, X; Jing, P; Yang, X; Zhang, C				Cui, J.; Yang, Y.; Li, H.; Leng, Y.; Qian, K.; Huang, Q.; Zhang, C.; Lu, Z.; Chen, J.; Sun, T.; Wu, R.; Sun, Y.; Song, H.; Wei, X.; Jing, P.; Yang, X.; Zhang, C.			MiR-873 regulates ER alpha transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells (vol 34, pg 3895, 2015)	ONCOGENE			English	Correction									[Cui, J.; Lu, Z.; Wu, R.; Sun, Y.; Song, H.; Zhang, C.] Acad Mil Med Sci, Inst Dis Control & Prevent, Beijing, Peoples R China; [Yang, Y.] Capital Med Univ, Beijing Inst Neurosci, Beijing, Peoples R China; [Li, H.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY USA; [Leng, Y.; Qian, K.] Jiujiang Univ, Affiliated Hosp, Jiujiang, Peoples R China; [Huang, Q.] Jilin Agr Univ, Dept Anim Sci & Technol, Changchun, Peoples R China; [Zhang, C.] Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH USA; [Chen, J.; Sun, T.] Nanchang Univ, Hosp 1, Dept Urol, Nanchang, Peoples R China; [Wei, X.] Peking Univ, Coll Chem & Mol Engn, Dept Appl Chem, Beijing 100871, Peoples R China; [Jing, P.] Indiana Univ Purdue Univ, Coll Arts & Sci, Dept Chem, Ft Wayne, IN USA; [Yang, X.] Anhui Univ, Inst Hlth Sci, Hefei 230039, Peoples R China	Academy of Military Medical Sciences - China; Capital Medical University; Chinese Academy of Sciences; University of Kentucky; Jiujiang University; Jilin Agricultural University; Cincinnati Children's Hospital Medical Center; Nanchang University; Peking University; Purdue University System; Indiana University Purdue University Fort Wayne; Anhui University	Yang, X (corresponding author), Anhui Univ, Inst Hlth Sci, Hefei, Peoples R China.			Zhang, Chunni/0000-0002-7329-7162				Cui J, 2015, ONCOGENE, V34, P3895, DOI 10.1038/onc.2014.430	1	19	20	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					4018	4018		10.1038/onc.2015.201	http://dx.doi.org/10.1038/onc.2015.201			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	26202215	Bronze			2022-12-17	WOS:000358544200015
J	Defamie, V; Sanchez, O; Murthy, A; Khokha, R				Defamie, V.; Sanchez, O.; Murthy, A.; Khokha, R.			TIMP3 controls cell fate to confer hepatocellular carcinoma resistance	ONCOGENE			English	Article							NECROSIS-FACTOR-ALPHA; COMPENSATORY PROLIFERATION; TISSUE INHIBITOR; TUMOR-FORMATION; LIVER; INFLAMMATION; P53; SUPPRESSOR; EXPRESSION; PROMOTER	Inflammation enables human cancers and is a critical promoter of hepatocellular carcinoma (HCC). TIMP3 (Tissue inhibitor of metalloproteinase 3), a natural metalloproteinase inhibitor, controls cytokine and growth factor bioavailability to keep inflammation in check and regulate cell survival in the liver. TIMP3 is also found silenced in human cancers. We therefore tested whether Timp3 affects HCC predisposition. Remarkably, genetic loss of Timp3 protected from carcinogen-induced HCC through the immediate engagement of several tumor suppressor pathways, while tumor necrosis factor (TNF) signaling was dispensable for this protection. All wild-type mice developed HCC by 12 months, whereas HCC incidence was reduced to 33% at 12 months and 57% at 15 months in Timp3 null mice. Upon acute carcinogen treatment the deficient livers exhibited greater cytokine expression, but lower cell death and higher hepatocyte senescence. We found that precocious activation of p53, p38 and Notch preceded senescence and hepatic cell differentiation, and these events were conserved throughout tumorigenesis. Timp3-deficient mouse embryo fibroblasts also responded to carcinogen by favoring senescence over apoptosis. We conclude that Timp3 status determines p53, p38 and Notch coactivation to instruct hepatic cell fate and transformation and uncover mechanisms that are protective even within a proinflammatory microenvironment.	[Defamie, V.; Murthy, A.; Khokha, R.] Univ Toronto, Ontario Canc Inst, Toronto, ON M5S 1A1, Canada; [Sanchez, O.] Univ Ontario, Inst Technol, Oshawa, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Ontario Tech University	Khokha, R (corresponding author), TMDT Res, MARS Med Discovery Tower,101 Coll St, Toronto, ON M5G 1L7, Canada.	rkhokha@uhnres.utoronto.ca		Defamie, Virginie/0000-0002-6405-0539; Khokha, Rama/0000-0002-6028-1524	Canadian Institutes of Health Research; Helena H Lam and Fondation pour la Recherche Medicale fellowships	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Helena H Lam and Fondation pour la Recherche Medicale fellowships	We would like to thank Dr Paul Waterhouse and Dr Razqallah Hakem for their constructive criticism of the manuscript. This work was supported by grants from the Canadian Institutes of Health Research to RK. VD was supported by the Helena H Lam and Fondation pour la Recherche Medicale fellowships.	Antoniou A, 2009, GASTROENTEROLOGY, V136, P2325, DOI 10.1053/j.gastro.2009.02.051; Bachman KE, 1999, CANCER RES, V59, P798; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2004, NAT GENET, V36, P934, DOI 10.1038/ng0904-934; Boggs K, 2009, CELL BIOL INT, V33, P318, DOI 10.1016/j.cellbi.2008.12.005; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Catasus L, 2013, HISTOPATHOLOGY, V62, P632, DOI 10.1111/his.12047; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Dill MT, 2013, HEPATOLOGY, V57, P1607, DOI 10.1002/hep.26165; Dolado Ignacio, 2008, V20, P99, DOI 10.1007/4735_2007_0245; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Fiorentino L, 2010, HEPATOLOGY, V51, P103, DOI 10.1002/hep.23250; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; Hui LJ, 2007, CELL CYCLE, V6, P2429, DOI 10.4161/cc.6.20.4774; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Iyoda K, 2003, CANCER-AM CANCER SOC, V97, P3017, DOI 10.1002/cncr.11425; Jeliazkova P, 2013, HEPATOLOGY, V57, P2469, DOI 10.1002/hep.26254; Kang JS, 2007, CANCER RES, V67, P11141, DOI 10.1158/0008-5472.CAN-07-1369; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Knight B, 2000, J EXP MED, V192, P1809, DOI 10.1084/jem.192.12.1809; Kohler C, 2004, HEPATOLOGY, V39, P1056, DOI 10.1002/hep.20156; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Mandinova A, 2008, EMBO J, V27, P1243, DOI 10.1038/emboj.2008.45; Masson D, 2010, EUR J CANCER, V46, P1430, DOI 10.1016/j.ejca.2010.01.009; Menghini R, 2009, GASTROENTEROLOGY, V136, P663, DOI 10.1053/j.gastro.2008.10.079; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Murthy A, 2012, IMMUNITY, V36, P105, DOI 10.1016/j.immuni.2012.01.005; Murthy A, 2010, J CLIN INVEST, V120, P2731, DOI 10.1172/JCI42686; Nakamura M, 2005, LAB INVEST, V85, P165, DOI 10.1038/labinvest.3700223; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Poehlmann A, 2010, PATHOL RES PRACT, V206, P591, DOI 10.1016/j.prp.2010.06.006; Qi RZ, 2003, CANCER RES, V63, P8323; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016; Smookler DS, 2006, J IMMUNOL, V176, P721, DOI 10.4049/jimmunol.176.2.721; Sun Hong, 2007, V383, P311, DOI 10.1007/978-1-59745-335-6_20; Tchorz JS, 2009, HEPATOLOGY, V50, P871, DOI 10.1002/hep.23048; Verna L, 1996, PHARMACOL THERAPEUT, V71, P57, DOI 10.1016/0163-7258(96)00062-9; VESSELINOVITCH SD, 1983, CANCER RES, V43, P4253; Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468; Wisniewska M, 2008, J MOL BIOL, V381, P1307, DOI 10.1016/j.jmb.2008.06.088; Xu PL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002689; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yugawa T, 2007, MOL CELL BIOL, V27, P3732, DOI 10.1128/MCB.02119-06; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zong YW, 2009, DEVELOPMENT, V136, P1727, DOI 10.1242/dev.029140	58	19	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4098	4108		10.1038/onc.2014.339	http://dx.doi.org/10.1038/onc.2014.339			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347747				2022-12-17	WOS:000358780500008
J	Satoyoshi, R; Aiba, N; Yanagihara, K; Yashiro, M; Tanaka, M				Satoyoshi, R.; Aiba, N.; Yanagihara, K.; Yashiro, M.; Tanaka, M.			Tks5 activation in mesothelial cells creates invasion front of peritoneal carcinomatosis	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; SCIRRHOUS CARCINOMA; PODOSOME FORMATION; SURGICAL-TREATMENT; INVADOPODIA; DIALYSIS; MIGRATION; MODELS; LINES	Scirrhous gastric cancer is frequently associated with peritoneal dissemination, and the interaction of cancer cells with peritoneal mesothelial cells (PMCs) is crucial for the establishment of the metastasis in the peritoneum. Although cells derived from PMCs are detected within tumors of peritoneal carcinomatosis, how PMCs are incorporated into tumor architecture is not understood. The present study shows that PMCs create the invasion front of peritoneal carcinomatosis, which depends on activation of Tks5 in PMCs. In peritoneal tumor implants, PMCs represent majority of cells located at the invasive edge of the cancer tissue. Exogenously implanted PMCs and host PMCs aggressively invade into abdominal wall upon the peritoneal inoculation of cancer cells, and PMCs locate ahead of cancer cells in the direction of invasion. Tks5, a substrate of Src kinase, is predominantly expressed in the PMCs of cancer tissue, and promotes the invasion of PMCs and cancer cells. Expression and activation of Tks5 was induced in PMCs following their exposure to gastric cancer cells, and increased Tks5 expression was detected in PMCs located at the invasion front. Reduced Tks5 expression in PMCs blocked PMC invasion, which in turn prevents cancer cell invasion both in vitro and in vivo. The peritoneal dissemination of gastric cancer was significantly increased by mixing cancer cells and PMCs, and was suppressed by knockdown of Tks5 in PMCs. These results suggest that cancer-activated PMCs create invasion front by guiding cancer cells. Signaling leading to Tks5 activation in PMCs may be a suitable therapeutic target for prevention of peritoneal carcinomatosis.	[Satoyoshi, R.; Aiba, N.; Tanaka, M.] Akita Univ, Grad Sch Med, Dept Mol Med & Biochem, Akita 0108543, Japan; [Yanagihara, K.] Natl Canc Ctr, Div Translat Res, Exploratory Oncol & Clin Trial Ctr, Chiba, Japan; [Yashiro, M.] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka 558, Japan	Akita University; National Cancer Center - Japan; Osaka Metropolitan University	Tanaka, M (corresponding author), Akita Univ, Grad Sch Med, Dept Mol Med & Biochem, 1-1-1 Hondo, Akita 0108543, Japan.	mastanak@med.akita-u.ac.jp			JSPS KAKENHI [25290042, 26640068]; National Cancer Center Research and Development Fund [23-A-9]; Takeda Science Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); National Cancer Center Research and Development Fund(National Cancer Center - Japan); Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank Murata K (Department of Environmental Health Sciences, Akita University School of Medicine) for advice and discussion about statistics. This work was supported by JSPS KAKENHI (Grant Nos 25290042 and 26640068 to MT) Takeda Science Foundation (MT) and the National Cancer Center Research and Development Fund (Grant No. 23-A-9 to MT).	Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Aroeira LS, 2005, AM J KIDNEY DIS, V46, P938, DOI 10.1053/j.ajkd.2005.08.011; Aroeira LS, 2007, J AM SOC NEPHROL, V18, P2004, DOI 10.1681/ASN.2006111292; Blouw B, 2008, EUR J CELL BIOL, V87, P555, DOI 10.1016/j.ejcb.2008.02.008; Burger KL, 2014, PROSTATE, V74, P134, DOI 10.1002/pros.22735; Burger KL, 2011, CYTOSKELETON, V68, P694, DOI 10.1002/cm.20545; Courtneidge SA, 2012, BIOCHEM SOC T, V40, P129, DOI 10.1042/BST20110685; Fekete Anna, 2013, J Mol Signal, V8, P8, DOI 10.1186/1750-2187-8-8; Fuyuhiro Y, 2011, BRIT J CANCER, V105, P996, DOI 10.1038/bjc.2011.330; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Jayne DG, 2000, BRIT J CANCER, V82, P1233; Kajiyama H, 2007, CELL TISSUE RES, V330, P221, DOI 10.1007/s00441-007-0455-x; Li CMC, 2013, GENE DEV, V27, P1557, DOI 10.1101/gad.222745.113; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Lv ZD, 2013, MOL CELL BIOCHEM, V377, P177, DOI 10.1007/s11010-013-1583-0; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; Murphy DA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022499; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Mutsaers SE, 2004, INT J BIOCHEM CELL B, V36, P9, DOI 10.1016/S1357-2725(03)00242-5; Nashimoto A, 2013, GASTRIC CANCER, V16, P1, DOI 10.1007/s10120-012-0163-4; Nishimura S, 1998, INT J ONCOL, V12, P847; Oikawa T, 2008, J CELL BIOL, V182, P157, DOI 10.1083/jcb.200801042; Otsuji E, 2004, AM J SURG, V188, P327, DOI 10.1016/j.amjsurg.2004.06.010; Sako A, 2003, J SURG RES, V115, P113, DOI 10.1016/S0022-4804(03)00307-X; Sandoval P, 2013, J PATHOL, V231, P517, DOI 10.1002/path.4281; Satoyoshi R, 2015, ONCOGENE, V34, P650, DOI 10.1038/onc.2013.584; Schauer M, 2011, EUR J MED RES, V16, P29, DOI 10.1186/2047-783X-16-1-29; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Sharma VP, 2013, CURR BIOL, V23, P2079, DOI 10.1016/j.cub.2013.08.044; Shimamura S, 2013, J BIOL CHEM, V288, P1171, DOI 10.1074/jbc.M112.386722; Stylli SS, 2009, J CELL SCI, V122, P2727, DOI 10.1242/jcs.046680; Takemura S, 2004, CANCER SCI, V95, P893, DOI 10.1111/j.1349-7006.2004.tb02199.x; Tsukada T, 2012, INT J ONCOL, V41, P476, DOI 10.3892/ijo.2012.1490; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yanagihara K, 2005, CANCER SCI, V96, P323, DOI 10.1111/j.1349-7006.2005.00054.x; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809; Yashiro M, 2010, CANCER MICROENVIRON, V3, P127, DOI 10.1007/s12307-010-0036-5; Yonemura Y, 2010, EJSO-EUR J SURG ONC, V36, P1131, DOI 10.1016/j.ejso.2010.09.006; Yung S, 2009, PERITON DIALYSIS INT, V29, pS21	41	19	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3176	3187		10.1038/onc.2014.246	http://dx.doi.org/10.1038/onc.2014.246			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25088196				2022-12-17	WOS:000356101100009
J	Vassilopoulos, A; Tominaga, Y; Kim, HS; Lahusen, T; Li, B; Yu, H; Gius, D; Deng, CX				Vassilopoulos, A.; Tominaga, Y.; Kim, H-Seok; Lahusen, T.; Li, B.; Yu, H.; Gius, D.; Deng, C-X			WEE1 murine deficiency induces hyper-activation of APC/C and results in genomic instability and carcinogenesis	ONCOGENE			English	Article							CELL-CYCLE CHECKPOINTS; DNA-DAMAGING AGENTS; FISSION YEAST; TYROSINE KINASE; CDC25 PROTEIN; MITOTIC INHIBITOR; G(2) CHECKPOINT; GENE DELETION; CANCER; P53	The tyrosine kinase WEE1 controls the timing of entry into mitosis in eukaryotes and its genetic deletion leads to pre-implantation lethality in mice. Here, we show that besides the premature mitotic entry phenotype, Wee1 mutant murine cells fail to complete mitosis properly and exhibit several additional defects that contribute to the deregulation of mitosis, allowing mutant cells to progress through mitosis at the expense of genomic integrity. WEE1 interacts with the anaphase promoting complex, functioning as a negative regulator, and the deletion of Wee1 results in hyper-activation of this complex. Mammary specific knockout mice overcome the DNA damage response pathway triggered by the mis-coordination of the cell cycle in mammary epithelial cells and heterozygote mice spontaneously develop mammary tumors. Thus, WEE1 functions as a haploinsufficient tumor suppressor that coordinates distinct cell division events to allow correct segregation of genetic information into daughter cells and maintain genome integrity.	[Vassilopoulos, A.; Tominaga, Y.; Kim, H-Seok; Lahusen, T.; Deng, C-X] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; [Vassilopoulos, A.; Gius, D.] Northwestern Univ, Feinberg Sch Med, Dept Radiat Oncol, Chicago, IL 60611 USA; [Kim, H-Seok] Ewha Womans Univ, Dept Life Sci, Seoul, South Korea; [Li, B.; Yu, H.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Northwestern University; Feinberg School of Medicine; Ewha Womans University; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10 Room 9N105, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016		NIDDK; NCI [1R01CA152601-01]; DOD [BC093803]; SPORE [P50CA98131]; Hirshberg Foundation for Pancreatic Cancer Research Seed Grant Award; CCR, NIH; NATIONAL CANCER INSTITUTE [R01CA152799, P50CA098131, R01CA168292, R01CA152601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056011, ZIADK056009] Funding Source: NIH RePORTER	NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); SPORE; Hirshberg Foundation for Pancreatic Cancer Research Seed Grant Award; CCR, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful for the critical reading and helpful discussion of members of the Deng laboratory. This work was supported in part by the Intramural Research Program of the NIDDK, NCI and CCR, NIH. DG is supported by 1R01CA152601-01 from the NCI, BC093803 from the DOD, SPORE P50CA98131 and a Hirshberg Foundation for Pancreatic Cancer Research Seed Grant Award. Melissa Stauffer, PhD, of Scientific Editing Solutions, provided editorial assistance.	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bucher N, 2008, BRIT J CANCER, V98, P523, DOI 10.1038/sj.bjc.6604208; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Dine J, 2013, CANCER METAST REV, V32, P25, DOI 10.1007/s10555-012-9403-7; Dixon H, 2002, CELL CYCLE, V1, P362, DOI 10.4161/cc.1.6.257; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Engelbert D, 2008, ONCOGENE, V27, P907, DOI 10.1038/sj.onc.1210703; FANTES PA, 1978, EXP CELL RES, V115, P317, DOI 10.1016/0014-4827(78)90286-0; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Harvey SL, 2005, CELL, V122, P407, DOI 10.1016/j.cell.2005.05.029; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hirai H, 2010, CANCER BIOL THER, V9, P514, DOI 10.4161/cbt.9.7.11115; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Iorns E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005120; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Li M, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-2; Lianga N, 2013, J CELL BIOL, V201, P843, DOI 10.1083/jcb.201212038; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; Mir SE, 2010, CANCER CELL, V18, P244, DOI 10.1016/j.ccr.2010.08.011; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Pines J, 2009, MOL CELL, V34, P135, DOI 10.1016/j.molcel.2009.04.006; PosthumaDeBoer J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-156; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Robinson GW, 2011, ANAL BIOCHEM, V412, P92, DOI 10.1016/j.ab.2011.01.020; Saeki T, 2009, INT J BIOL SCI, V5, P722; Schmit TL, 2009, CELL CYCLE, V8, P2697, DOI 10.4161/cc.8.17.9413; Simanski S, 2010, IDENTIFICATION SMALL; Simpson-Lavy KJ, 2010, CELL CYCLE, V9, P3046, DOI [10.4161/cc..9.115.12457, 10.4161/cc.9.115.12457]; Squire CJ, 2005, STRUCTURE, V13, P541, DOI 10.1016/j.str.2004.12.017; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Stumpff J, 2005, CURR BIOL, V15, P1525, DOI 10.1016/j.cub.2005.07.031; THURIAUX P, 1978, MOL GEN GENET, V161, P215, DOI 10.1007/BF00274190; Timofeev O, 2010, J BIOL CHEM, V285, P16978, DOI 10.1074/jbc.M109.096552; Tominaga Y, 2006, INT J BIOL SCI, V2, P161; Towler WI, 2013, HUM MUTAT, V34, P439, DOI 10.1002/humu.22251; Trovesi C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002263; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697; Wang YL, 2001, CANCER RES, V61, P8211	59	19	21	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3023	3035		10.1038/onc.2014.239	http://dx.doi.org/10.1038/onc.2014.239			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25088202	Green Accepted			2022-12-17	WOS:000356100500008
J	Teh, JT; Zhu, WL; Ilkayeva, OR; Li, Y; Gooding, J; Casey, PJ; Summers, SA; Newgard, CB; Wang, M				Teh, J. T.; Zhu, W. L.; Ilkayeva, O. R.; Li, Y.; Gooding, J.; Casey, P. J.; Summers, S. A.; Newgard, C. B.; Wang, M.			Isoprenylcysteine carboxylmethyltransferase regulates mitochondrial respiration and cancer cell metabolism	ONCOGENE			English	Article							TANDEM MASS-SPECTROMETRY; SMALL-MOLECULE INHIBITOR; K-RAS; CARBOXYL METHYLTRANSFERASE; MAMMALIAN-CELLS; PHOSPHORYLATION; AUTOPHAGY; ENZYMES; GROWTH; AMPK	Isoprenylcysteine carboxylmethyltransferase (Icmt) catalyzes the last of the three-step posttranslational protein prenylation process for the so-called CaaX proteins, which includes many signaling proteins, such as most small GTPases. Despite extensive studies on Icmt and its regulation of cell functions, the mechanisms of much of the impact of Icmt on cellular functions remain unclear. Our recent studies demonstrated that suppression of Icmt results in induction of autophagy, inhibition of cell growth and inhibition of proliferation in various cancer cell types, prompting this investigation of potential metabolic regulation by Icmt. We report here the findings that Icmt inhibition reduces the function of mitochondrial oxidative phosphorylation in multiple cancer cell lines. In-depth oximetry analysis demonstrated that functions of mitochondrial complex I, II and III are subject to Icmt regulation. Consistently, Icmt inhibition decreased cellular ATP and depleted critical tricarboxylic acid cycle metabolites, leading to suppression of cell anabolism and growth, and marked autophagy. Several different approaches demonstrated that the impact of Icmt inhibition on cell proliferation and viability was largely mediated by its effect on mitochondrial respiration. This previously unappreciated function of Icmt, which can be therapeutically exploited, likely has a significant role in the impact of Icmt on tumorigenic processes.	[Teh, J. T.; Zhu, W. L.; Casey, P. J.; Wang, M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Zhu, W. L.; Wang, M.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; [Ilkayeva, O. R.; Gooding, J.; Newgard, C. B.] Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC USA; [Ilkayeva, O. R.; Gooding, J.; Newgard, C. B.] Duke Univ, Med Ctr, Duke Inst Mol Physiol, Durham, NC USA; [Li, Y.; Summers, S. A.] Duke NUS Grad Med Sch, Program Cardiovasc & Metab Disorders, Singapore 169857, Singapore	National University of Singapore; National University of Singapore; Duke University; Duke University; National University of Singapore	Wang, M (corresponding author), Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	mei.wang@duke-nus.edu.sg	/AAE-5384-2020; Zhu, Wan Long/GYA-3382-2022	Wang, Mei/0000-0001-6887-6840; zhu, Wanlong/0000-0003-0025-6674; Casey, Patrick/0000-0002-7366-9309	National Medical Research Council (NMRC); Duke-NUS	National Medical Research Council (NMRC)(National Medical Research Council, Singapore); Duke-NUS	These experiments were supported by grant from National Medical Research Council (NMRC) and Duke-NUS institutional funding. Wild-type and Icmt-null MEFs are from Dr M Bergo.	An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CHACE DH, 1993, CLIN CHEM, V39, P66; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Cordell RL, 2008, J CHROMATOGR B, V871, P115, DOI 10.1016/j.jchromb.2008.07.005; Cushman I, 2011, CELL ADHES MIGR, V5, P11, DOI 10.4161/cam.5.1.13196; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; GREGOIRE M, 1984, EUR J BIOCHEM, V142, P49, DOI 10.1111/j.1432-1033.1984.tb08249.x; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jensen MV, 2006, J BIOL CHEM, V281, P22342, DOI 10.1074/jbc.M604350200; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KREBS HA, 1955, BIOCHEM J, V61, P435, DOI 10.1042/bj0610435; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Millington DS, 2011, METHODS MOL BIOL, V708, P55, DOI 10.1007/978-1-61737-985-7_3; MILLINGTON DS, 1992, PROG CLIN BIOL RES, V375, P339; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Neuzil J, 2007, MOL ASPECTS MED, V28, P607, DOI 10.1016/j.mam.2007.02.003; Pathania D, 2009, ADV DRUG DELIVER REV, V61, P1250, DOI 10.1016/j.addr.2009.05.010; POTTER VR, 1958, FED PROC, V17, P691; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Wahlstrom AM, 2008, BLOOD, V112, P1357, DOI 10.1182/blood-2007-06-094060; Wang M, 2010, ONCOGENE, V29, P4959, DOI 10.1038/onc.2010.247; Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102; Wu JY, 2004, J CLIN INVEST, V113, P434, DOI 10.1172/JCI200419574; Zhu WL, 2011, J BIOL CHEM, V286, P35291, DOI 10.1074/jbc.M111.280990	40	19	22	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3296	3304		10.1038/onc.2014.260	http://dx.doi.org/10.1038/onc.2014.260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25151967				2022-12-17	WOS:000356592300008
J	Liang, W; Miao, S; Zhang, B; He, S; Shou, C; Manivel, P; Krishna, R; Chen, Y; Shi, YE				Liang, W.; Miao, S.; Zhang, B.; He, S.; Shou, C.; Manivel, P.; Krishna, R.; Chen, Y.; Shi, Y. E.			Synuclein gamma protects Akt and mTOR and renders tumor resistance to Hsp90 disruption	ONCOGENE			English	Article							BREAST-CANCER CELLS; ENDOPLASMIC-RETICULUM STRESS; ESTROGEN-RECEPTOR; INDUCED APOPTOSIS; ALPHA-SYNUCLEIN; TYROSINE KINASE; UP-REGULATION; CHAPERONE; GENE; METASTASIS	Heat shock protein (Hsp)90 regulates many key pathways in oncogenesis, including Akt and mammalian target of rapamycin (mTOR). The strengths of disruption of Hsp90 in cancer therapy include their versatility in inhibiting a wide range of oncogenic pathways. The present study demonstrated that synuclein. (SNCG) protects the functions of Akt and mTOR in the condition when the function of Hsp90 is blocked. Disruption of Hsp90 abolished Akt activity and mTOR signaling. However, expression of SNCG restored Akt activity and mTOR signaling. SNCG bound to Akt and mTOR in the presence and absence of Hsp90. Specifically, the C-terminal (Gln106-Asp127) of SNCG bound to the loop connecting alpha C helix and beta 4 sheet of the kinase domain of Akt. SNCG renders resistance to 17-AAG-induced apoptosis both in vitro and in tumor xenograft. A clinical follow-up study indicates that patients with an SNCG-positive breast cancer have a significantly shorter disease-free survival and overall survival than patients with SNCG-negative tumors. The present study indicates that SNCG protects Hsp90 client proteins of Akt and mTOR, and renders drug resistance to Hsp90 disruption.	[Liang, W.; Miao, S.; Zhang, B.; He, S.; Shi, Y. E.] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing 210029, Jiangsu, Peoples R China; [Shou, C.] Peking Univ, Beijing Canc Hosp & Inst, Sch Oncol, Beijing 100871, Peoples R China; [Manivel, P.; Krishna, R.] Pondicherry Univ, Sch Life Sci, Ctr Bioinformat, Pondicherry, India; [Chen, Y.] Zhejiang Univ, Sch Med, Womens Hosp, Dept Surg, Hangzhou 310006, Zhejiang, Peoples R China; [Shi, Y. E.] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Peking University; Pondicherry University; Zhejiang University; Nanjing Medical University	Shi, YE (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou Rd 300, Nanjing 210029, Jiangsu, Peoples R China.	chenyiding@gmail.com; daweieric@gmail.com	Panneerselvam, Manivel/M-5453-2013	Panneerselvam, Manivel/0000-0002-5831-8404	State Key Program of National Natural Science Foundation of China [81230054, 91029739]; National Key Technology R&D Program for the 12th Five-year Plan of China [2013BAI01B06]; State Key Laboratory of Reproductive Medicine; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	State Key Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Technology R&D Program for the 12th Five-year Plan of China(National Key Technology R&D Program); State Key Laboratory of Reproductive Medicine; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This study was supported in part by grants 81230054 and 91029739 from the State Key Program of National Natural Science Foundation of China; a grant from the National Key Technology R&D Program for the 12th Five-year Plan of China (2013BAI01B06); and a grant from the State Key Laboratory of Reproductive Medicine, and a Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Bonvini P, 2002, CANCER RES, V62, P1559; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Caldas-Lopes E, 2009, P NATL ACAD SCI USA, V106, P8368, DOI 10.1073/pnas.0903392106; Chiosis G, 2001, CHEM BIOL, V8, P289, DOI 10.1016/S1074-5521(01)00015-1; Citri A, 2006, J BIOL CHEM, V281, P14361, DOI 10.1074/jbc.M512613200; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Czekierdowski A, 2006, NEUROENDOCRINOL LETT, V27, P381; Davenport EL, 2007, BLOOD, V110, P2641, DOI 10.1182/blood-2006-11-053728; Fung KM, 2003, ACTA NEUROPATHOL, V106, P167, DOI 10.1007/s00401-003-0718-x; Gaspar N, 2009, CANCER RES, V69, P1966, DOI 10.1158/0008-5472.CAN-08-3131; Guo J, 2007, INT J CANCER, V121, P1296, DOI 10.1002/ijc.22763; Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880; Hibi T, 2009, CLIN CANCER RES, V15, P2864, DOI 10.1158/1078-0432.CCR-08-2946; Hu H, 2009, CLIN CANCER RES, V15, P5485, DOI 10.1158/1078-0432.CCR-08-2491; Hua H, 2009, J PATHOL, V217, P507, DOI 10.1002/path.2465; Inaba S, 2005, BREAST CANCER RES TR, V94, P25, DOI 10.1007/s10549-005-6938-0; Iwaki H, 2004, CANCER SCI, V95, P955, DOI 10.1111/j.1349-7006.2004.tb03183.x; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; Jiang YF, 2003, CANCER RES, V63, P3899; Jiang YF, 2004, CANCER RES, V64, P4539, DOI 10.1158/0008-5472.CAN-03-3650; Li ZK, 2004, CANCER-AM CANCER SOC, V101, P58, DOI 10.1002/cncr.20321; Liu CY, 2008, CANCER LETT, V269, P148, DOI 10.1016/j.canlet.2008.04.037; Liu CY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-359; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Liu YE, 2007, ONCOGENE, V26, P2115, DOI 10.1038/sj.onc.1210000; Manivel P, 2011, J MOL MODEL, V17, P251, DOI 10.1007/s00894-010-0718-4; McCollum AK, 2006, CANCER RES, V66, P10967, DOI 10.1158/0008-5472.CAN-06-1629; Neckers L, 2007, J BIOSCIENCES, V32, P517, DOI 10.1007/s12038-007-0051-y; Nimmanapalli R, 2001, CANCER RES, V61, P1799; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Okawa Y, 2009, BLOOD, V113, P846, DOI 10.1182/blood-2008-04-151928; Pan ZZ, 2006, INT J ONCOL, V29, P1201; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Shi YE, 2010, AM J PATHOL, V177, P964, DOI 10.2353/ajpath.2010.100061; Singh VK, 2007, CANCER RES, V67, P626, DOI 10.1158/0008-5472.CAN-06-1820; Solit DB, 2003, CANCER RES, V63, P2139; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Taiyab A, 2009, BIOCHEM PHARMACOL, V78, P142, DOI 10.1016/j.bcp.2009.04.001; Wandinger SK, 2008, J BIOL CHEM, V283, P18473, DOI 10.1074/jbc.R800007200; Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012; Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Zhao W, 2006, INT J ONCOL, V28, P1081	48	19	21	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2398	2405		10.1038/onc.2014.126	http://dx.doi.org/10.1038/onc.2014.126			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24954510				2022-12-17	WOS:000353824800012
J	Delbridge, ARD; Grabow, S; Bouillet, P; Adams, JM; Strasser, A				Delbridge, A. R. D.; Grabow, S.; Bouillet, P.; Adams, J. M.; Strasser, A.			Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis	ONCOGENE			English	Article							B-CELL LYMPHOMAS; DRIVEN LYMPHOMAGENESIS; HOMOZYGOUS DELETIONS; HEMATOPOIETIC-CELLS; TRANSGENIC MICE; DEFICIENT MICE; C-MYC; PUMA; BCL-X(L); DEATH	Genomic analyses revealed that many cancers have acquired abnormalities in their expression of pro-or anti-apoptotic members of the BCL-2 protein family. It is, however, unknown whether changes in pro-or anti-apoptotic BCL-2 family members have similar impact on tumorigenesis or whether changes in one subgroup have disproportionate impact. We compared the consequences of concomitant loss of anti-apoptotic Bclx and pro-apoptotic Bim on MYC-induced lymphomagenesis. Whereas only loss of both Bclx alleles markedly forestalled tumorigenesis, loss of a single Bim allele overcame this blockade. Conversely, loss of even a single Bim allele sufficed to substantially accelerate lymphomagenesis, and only loss of both but not loss of a single allele of Bclx could attenuate this acceleration. The evidence that modest (two-fold) monoallelic changes in the expression of at least some BH3-only proteins can profoundly impact tumorigenesis suggests that such aberrations, imposed by epigenetic or genetic changes, may expedite tumorigenesis more effectively than elevated expression of pro-survival BCL-2 family members. These findings further our understanding of the mechanisms of lymphomagenesis and possibly also cancer therapy.	[Delbridge, A. R. D.; Grabow, S.; Bouillet, P.; Adams, J. M.; Strasser, A.] Walter & Eliza Hall Inst Med Res, Mol Genet Canc Div, Melbourne, Vic 3050, Australia; [Delbridge, A. R. D.; Grabow, S.; Bouillet, P.; Adams, J. M.; Strasser, A.] Univ Melbourne, Dept Mol Biol, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne	Strasser, A (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Mol Genet Canc Div, 1G Royal Parade, Parkville, Vic 3050, Australia.	strasser@wehi.edu.au	Adams, Jerry M/E-1199-2013; Strasser, Andreas/C-7581-2013; Bouillet, Philippe/E-1241-2013	Strasser, Andreas/0000-0002-5020-4891; Bouillet, Philippe/0000-0002-9012-6058; Adams, Jerry/0000-0002-4360-8628	National Health and Medical Research Council of Australia [461221/1016701, 1020363, 1046010]; Leukemia and Lymphoma Society [7413, 7001-13]; Cancer Council Victoria (CCV) [1052309]; Cancer Council of Victoria; Lady Tata Postdoctoral Fellowship; Melbourne International Research Scholarship (University of Melbourne); Melbourne International Fee Remission Scholarship (University of Melbourne); Australian Postgraduate Award; Cancer Therapeutics CRC Top-up Scholarship; Australian Government (IRISS); Victorian State Government (OIS)	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Cancer Council Victoria (CCV)(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Lady Tata Postdoctoral Fellowship; Melbourne International Research Scholarship (University of Melbourne); Melbourne International Fee Remission Scholarship (University of Melbourne); Australian Postgraduate Award(Australian Government); Cancer Therapeutics CRC Top-up Scholarship(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); Australian Government (IRISS)(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government (OIS)	We thank PN Kelly (NIH) for previously published work that laid the foundation for the present study, G Siciliano and his team for animal husbandry, the FACS facility and the histology facility at The Walter and Eliza Hall Institute. Work in the authors' laboratory was supported by the National Health and Medical Research Council of Australia (program grant 461221/1016701, Fellowship 1020363, NHMRC Project 1046010), the Leukemia and Lymphoma Society (SCOR grant #7413; 7001-13), the Cancer Council Victoria (CCV grant 1052309), and fellowships from the Cancer Council of Victoria (SG), Lady Tata Postdoctoral Fellowship (SG), Melbourne International Research Scholarship (University of Melbourne, SG), Melbourne International Fee Remission Scholarship (University of Melbourne, SG), Australian Postgraduate Award (ARDD) and Cancer Therapeutics CRC Top-up Scholarship (SG and ARDD). This work was made possible by operational infrastructure grants through the Australian Government (IRISS) and the Victorian State Government (OIS).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Akhtar RS, 2008, J HISTOCHEM CYTOCHEM, V56, P921, DOI 10.1369/jhc.2008.951749; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cragg MS, 2009, NAT REV CANCER, V9, P321, DOI 10.1038/nrc2615; Delbridge ARD, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008789; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Happo L, 2010, BLOOD, V116, P5256, DOI 10.1182/blood-2010-04-280818; KAPLAN HENRY S., 1964, NAT CANCER INST MONOGR, V14, P207; Kelly PN, 2013, CELL DEATH DIFFER, V20, P57, DOI 10.1038/cdd.2012.92; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; Kelly PN, 2011, BLOOD, V118, P6380, DOI 10.1182/blood-2011-07-367672; Labi V, 2008, J EXP MED, V205, P641, DOI 10.1084/jem.20071658; Merino D, 2012, BLOOD, V119, P5807, DOI 10.1182/blood-2011-12-400929; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Michalak EM, 2010, GENE DEV, V24, P1608, DOI 10.1101/gad.1940110; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; Swanson PJ, 2004, J IMMUNOL, V172, P6684, DOI 10.4049/jimmunol.172.11.6684; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211	27	19	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1872	1876		10.1038/onc.2014.132	http://dx.doi.org/10.1038/onc.2014.132			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24858047				2022-12-17	WOS:000352158000014
J	Bolt, MJ; Stossi, F; Callison, AM; Mancini, MG; Dandekar, R; Mancini, MA				Bolt, M. J.; Stossi, F.; Callison, A. M.; Mancini, M. G.; Dandekar, R.; Mancini, M. A.			Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-alpha protein levels and activity	ONCOGENE			English	Article						estrogen receptor; UBR5; high content screening; high throughput microscopy; ubiquitin ligase	BREAST-CANCER; ER-ALPHA; GENE-EXPRESSION; CHROMATIN DYNAMICS; POLYMERASE-II; CELLS; TRANSCRIPTION; ACTIVATION; PROMOTER; DEGRADATION	Estrogen receptor-alpha (ER alpha) is a central transcription factor that regulates mammary gland physiology and a key driver in breast cancer. In the present study, we aimed to identify novel modulators of ER alpha-mediated transcriptional regulation via a custom-built siRNA library screen. This screen was directed against a variety of coregulators, transcription modifiers, signaling molecules and DNA damage response proteins. By utilizing a microscopy-based, multi-end point, estrogen responsive biosensor cell line platform, the primary screen identified a wide range of factors that altered ER alpha protein levels, chromatin remodeling and mRNA output. We then focused on UBR5, a ubiquitin ligase and known oncogene that modulates ER alpha protein levels and transcriptional output. Finally, we demonstrated that UBR5 also affects endogenous ER alpha target genes and E2-mediated cell proliferation in breast cancer cells. In conclusion, our multi-end point RNAi screen identified novel modulators of ER alpha levels and activity, and provided a robust systems level view of factors involved in mechanisms of nuclear receptor action and pathophysiology. Utilizing a high throughput RNAi screening approach we identified UBR5, a protein commonly amplified in breast cancer, as a novel regulator of ER alpha protein levels and transcriptional activity.	[Bolt, M. J.; Stossi, F.; Callison, A. M.; Mancini, M. G.; Dandekar, R.; Mancini, M. A.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Mancini, MA (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,DeBakey Bldg,Room 132C, Houston, TX 77030 USA.	mancini@bcm.edu			NIEHS [7RC2ES018789]; Keck Foundation; Keck Center NLM Training Program in Biomedical Informatics of the Gulf Coast Consortia National Library of Medicine [T15LM007093]; Integrated Microscopy Core at Baylor College of Medicine; NIH [HD007495, DK56338, CA125123]; Dan L Duncan Cancer Center; John S Dunn Gulf Coast Consortium for Chemical Genomics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD007495] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA125123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [RC2ES018789] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007093] Funding Source: NIH RePORTER	NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Keck Foundation(W.M. Keck Foundation); Keck Center NLM Training Program in Biomedical Informatics of the Gulf Coast Consortia National Library of Medicine; Integrated Microscopy Core at Baylor College of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dan L Duncan Cancer Center; John S Dunn Gulf Coast Consortium for Chemical Genomics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We gratefully acknowledge ZD Sharp for aid in the development of the PRL-HeLA cell line, FJ Ashcroft for creation of the GFP-ERa:PRL-HeLa cells, and I Mikic, TJ Moran and JY Newberg for help in developing the automated high-content analysis tools used in this study. We also acknowledge R Lanz and C Stephan for curation, handling and upkeep of the RNAi library. We acknowledge NIEHS funding from 7RC2ES018789 (MAM), the Keck Foundation pre-doctoral fellowship and imaging/automation resource support from the John S Dunn Gulf Coast for Chemical Genomics (PJ Davies and MAM), Dan L Duncan Baylor Cancer Center (K Osborne), Center for Reproductive Biology (FJ Demayo), Keck Center NLM Training Program in Biomedical Informatics of the Gulf Coast Consortia National Library of Medicine (T15LM007093 to MB), and the Diana Helis Henry Medical Research Foundation (MAM) through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine and the Cancer Program. This project was supported by the Integrated Microscopy Core at Baylor College of Medicine with funding from the NIH (HD007495, DK56338 and CA125123), the Dan L Duncan Cancer Center, and the John S Dunn Gulf Coast Consortium for Chemical Genomics.	Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Ansari SA, 2013, CELL MOL LIFE SCI, V70, P2743, DOI 10.1007/s00018-013-1265-9; Ashcroft FJ, 2011, GENE, V477, P42, DOI 10.1016/j.gene.2011.01.009; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Berno V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002286; Bhatt S, 2012, MOL CELL BIOL, V32, P1928, DOI 10.1128/MCB.06561-11; Bolt MJ, 2013, NUCLEIC ACIDS RES, V41, P4036, DOI 10.1093/nar/gkt100; Bourdoncle A, 2005, J MOL BIOL, V347, P921, DOI 10.1016/j.jmb.2005.01.048; Burandt E, 2013, BREAST CANCER RES TR, V137, P745, DOI 10.1007/s10549-013-2406-4; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen YJ, 2008, ENDOCRINOLOGY, V149, P4658, DOI 10.1210/en.2008-0063; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Clancy JL, 2003, ONCOGENE, V22, P5070, DOI 10.1038/sj.onc.1206775; Cojocaru M, 2011, J BIOL CHEM, V286, P5012, DOI 10.1074/jbc.M110.176628; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Dickson R B, 1988, Cancer Treat Res, V40, P119; Dong J, 2006, J BIOL CHEM, V281, P18825, DOI 10.1074/jbc.M512826200; DUBIK D, 1992, ONCOGENE, V7, P1587; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; Esslimani-Sahla M, 2004, CLIN CANCER RES, V10, P5769, DOI 10.1158/1078-0432.CCR-04-0389; Fan MY, 2005, MOL ENDOCRINOL, V19, P2901, DOI 10.1210/me.2005-0111; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Garcia-Becerra R, 2010, GENE, V458, P37, DOI 10.1016/j.gene.2010.03.007; Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351; Gonzalez-Arenas A, 2012, BBA-MOL CELL RES, V1823, P379, DOI 10.1016/j.bbamcr.2011.11.004; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Gururaj AE, 2007, MOL ENDOCRINOL, V21, P1847, DOI 10.1210/me.2006-0514; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Hirose Y, 2007, J BIOCHEM, V141, P601, DOI 10.1093/jb/mvm090; Horner-Glister E, 2005, J MOL ENDOCRINOL, V35, P421, DOI 10.1677/jme.1.01784; JACQUEMIER JD, 1990, BREAST CANCER RES TR, V15, P109, DOI 10.1007/BF01810783; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Karmakar S, 2009, ENDOCRINOLOGY, V150, P1588, DOI 10.1210/en.2008-1001; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; La Rosa P, 2011, CELL SIGNAL, V23, P1128, DOI 10.1016/j.cellsig.2011.02.006; Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884; Li XF, 2013, CYTOKINE, V61, P876, DOI 10.1016/j.cyto.2012.12.017; Long XH, 2006, J BIOL CHEM, V281, P9607, DOI 10.1074/jbc.M510809200; Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mook ORF, 2009, CANCER GENE THER, V16, P532, DOI 10.1038/cgt.2008.104; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rudnik V, 2008, J CELL BIOCHEM, V103, P896, DOI 10.1002/jcb.21459; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schaufele F, 1999, MOL ENDOCRINOL, V13, P935, DOI 10.1210/me.13.6.935; Sharp ZD, 2006, J CELL SCI, V119, P4101, DOI 10.1242/jcs.03161; Smits VAJ, 2012, CELL CYCLE, V11, P715, DOI 10.4161/cc.11.4.19154; Snow BE, 2003, CURR BIOL, V13, P698, DOI 10.1016/S0960-9822(03)00210-0; Stanlie A, 2012, PLOS GENET, V8; Stokes K, 2004, J MOL ENDOCRINOL, V33, P315, DOI 10.1677/jme.1.01456; Sun J, 2012, MOL ENDOCRINOL, V26, P1567, DOI 10.1210/me.2012-1140; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Toth-Petroczy A, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000243; Willis IM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000112; Wu Q, 2004, J BIOL CHEM, V279, P53602, DOI 10.1074/jbc.M409778200; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zwart W, 2010, J CELL SCI, V123, P1253, DOI 10.1242/jcs.061135	61	19	21	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					154	164		10.1038/onc.2013.550	http://dx.doi.org/10.1038/onc.2013.550			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24441042	Green Accepted			2022-12-17	WOS:000347790500003
J	Liu, J; Visser-Grieve, S; Boudreau, J; Yeung, B; Lo, S; Chamberlain, G; Yu, F; Sun, T; Papanicolaou, T; Lam, A; Yang, X; Chin-Sang, I				Liu, J.; Visser-Grieve, S.; Boudreau, J.; Yeung, B.; Lo, S.; Chamberlain, G.; Yu, F.; Sun, T.; Papanicolaou, T.; Lam, A.; Yang, X.; Chin-Sang, I.			Insulin activates the insulin receptor to downregulate the PTEN tumour suppressor	ONCOGENE			English	Article						PTEN; C. elegans; tumour suppressor; cancer; insulin signaling; genetics	GROWTH-FACTOR RECEPTOR; CAENORHABDITIS-ELEGANS; C-ELEGANS; BREAST-CANCER; LIFE-SPAN; SIGNALING PATHWAY; DAUER FORMATION; CELL-MIGRATION; DAF-2; PHOSPHATASE	Insulin and insulin-like growth factor-1 signaling have fundamental roles in energy metabolism, growth and development. Recent research suggests hyperactive insulin receptor (IR) and hyperinsulinemia are cancer risk factors. However, the mechanisms that account for the link between the hyperactive insulin signaling and cancer risk are not well understood. Here we show that an insulin-like signaling inhibits the DAF-18/(phosphatase and tensin homolog) PTEN tumour suppressor in Caenorhabditis elegans and that this regulation is conserved in human breast cancer cells. We show that inhibiting the IR increases PTEN protein levels, while increasing insulin signaling decreases PTEN protein levels. Our results show that the kinase region of IR beta subunit physically binds to PTEN and phosphorylates on Y27 and Y174. Our genetic results also show that DAF-2/IR negatively regulates DAF-18/PTEN during C. elegans axon guidance. As PTEN is an important tumour suppressor, our results therefore suggest a possible mechanism for increased cancer risk observed in hyperinsulinemia and hyperactive IR individuals.	[Liu, J.; Boudreau, J.; Lo, S.; Chamberlain, G.; Yu, F.; Papanicolaou, T.; Lam, A.; Chin-Sang, I.] Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; [Visser-Grieve, S.; Yeung, B.; Yang, X.] Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; [Sun, T.] Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada	Chin-Sang, I (corresponding author), Queens Univ, Dept Biol, 116 Barrie St, Kingston, ON K7L 3N6, Canada.	chinsang@queensu.ca		Liu, Jun/0000-0001-6472-3871; Yu, Fabian/0000-0002-0358-2793; Grieve, Stacy/0000-0003-3090-5583; Chin-Sang, Ian/0000-0001-7480-9775	Natural Sciences and Engineering Research Council of Canada [NSERC 249779]; Canadian Cancer Society Research Institute [CCSRI 700219]; NIH Office of Research Infrastructure Programs [P40 OD010440]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P40OD010440] Funding Source: NIH RePORTER	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); NIH Office of Research Infrastructure Programs(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The work in the Chin-Sang lab is supported by grants from the Natural Sciences and Engineering Research Council of Canada (NSERC 249779) and the Canadian Cancer Society Research Institute (CCSRI 700219). We are grateful to Caenorhabditis Genomic Center for providing strains, which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440). The daf-18 (ok480) mutant was obtained from the C. elegans knockout consortium (Oklahoma Medical Research Foundation). We thank Drs Mei Zhen and Scott Clark for sharing strains. We thank all members of the Chin-Sang Lab, and Drs William Bendena and Hanzhi Wang for helpful discussion.	Adler CE, 2006, NAT NEUROSCI, V9, P511, DOI 10.1038/nn1666; Belfiore A, 2011, ENDOCR-RELAT CANCER, V18, pR125, DOI 10.1530/ERC-11-0074; Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558; BRENNER S, 1974, GENETICS, V77, P71; Brisbin S, 2009, DEV CELL, V17, P459, DOI 10.1016/j.devcel.2009.08.009; Chin-Sang ID, 1999, CELL, V99, P781, DOI 10.1016/S0092-8674(00)81675-X; Christensen R, 2011, DEVELOPMENT, V138, P5257, DOI 10.1242/dev.069062; Clark SG, 2003, DEVELOPMENT, V130, P3781, DOI 10.1242/dev.00571; Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371; DORMAN JB, 1995, GENETICS, V141, P1399; Eckardt K, 2007, DIABETOLOGIA, V50, P2534, DOI 10.1007/s00125-007-0815-9; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Finch CE, 2001, ANNU REV GENOM HUM G, V2, P435, DOI 10.1146/annurev.genom.2.1.435; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Gallagher EJ, 2011, ENDOCRINOLOGY, V152, P2546, DOI 10.1210/en.2011-0231; Halaschek-Wiener J, 2005, GENOME RES, V15, P603, DOI 10.1101/gr.3274805; Kenyon C, 2010, ANN NY ACAD SCI, V1204, P156, DOI 10.1111/j.1749-6632.2010.05640.x; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Li WQ, 2003, GENE DEV, V17, P844, DOI 10.1101/gad.1066503; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Malone EA, 1996, GENETICS, V143, P1193; MILAZZO G, 1992, CANCER RES, V52, P3924; Mohamed AM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002513; Mohamed AM, 2006, DEV BIOL, V290, P164, DOI 10.1016/j.ydbio.2005.11.019; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Naguib A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-123; Nakdimon I, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002881; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Patel DS, 2008, GENETICS, V178, P931, DOI 10.1534/genetics.107.070813; Pocock R, 2008, NAT NEUROSCI, V11, P894, DOI 10.1038/nn.2152; Pollak M, 2012, CLIN CANCER RES, V18, P40, DOI 10.1158/1078-0432.CCR-11-0998; Porte D, 2005, DIABETES, V54, P1264, DOI 10.2337/diabetes.54.5.1264; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; Solari F, 2005, ONCOGENE, V24, P20, DOI 10.1038/sj.onc.1207978; Song JB, 2003, SCIENCE, V300, P502, DOI 10.1126/science.1081203; Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tibarewal P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002138; Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Yang XL, 2011, CELL RES, V21, P715, DOI 10.1038/cr.2011.63; Yim EK, 2009, CANCER CELL, V15, P304, DOI 10.1016/j.ccr.2009.02.012; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Zhang H, 2010, ONCOGENE, V29, P2517, DOI 10.1038/onc.2010.17	47	19	21	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3878	3885		10.1038/onc.2013.347	http://dx.doi.org/10.1038/onc.2013.347			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23995781				2022-12-17	WOS:000339394100014
J	Donley, C; McClelland, K; McKeen, HD; Nelson, L; Yakkundi, A; Jithesh, PV; Burrows, J; McClements, L; Valentine, A; Prise, KM; McCarthy, HO; Robson, T				Donley, C.; McClelland, K.; McKeen, H. D.; Nelson, L.; Yakkundi, A.; Jithesh, P. V.; Burrows, J.; McClements, L.; Valentine, A.; Prise, K. M.; McCarthy, H. O.; Robson, T.			Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen	ONCOGENE			English	Article						RBCK1; FKBPL; estrogen receptor; p21; tamoxifen	PROTEIN-KINASE-C; UBIQUITIN LIGASE COMPLEX; ESTROGEN-RECEPTOR-ALPHA; KAPPA-B ACTIVATION; BREAST-CANCER; CELL-PROLIFERATION; BINDING-PROTEIN; DEGRADATION; GENE; TRANSCRIPTION	FKBPL has been implicated in processes associated with cancer, including regulation of tumor growth and angiogenesis with high levels of FKBPL prognosticating for improved patient survival. Understanding how FKBPL levels are controlled within the cell is therefore critical. We have identified a novel role for RBCK1 as an FKBPL-interacting protein, which regulates FKBPL stability at the post-translational level via ubiquitination. Both RBCK1 and FKBPL are upregulated by 17-beta-estradiol and interact within heat shock protein 90 chaperone complexes, together with estrogen receptor-alpha (ER alpha). Furthermore, FKBPL and RBCK1 associate with ER alpha at the promoter of the estrogen responsive gene, pS2, and regulate pS2 levels. MCF-7 clones stably overexpressing RBCK1 were shown to have reduced proliferation and increased levels of FKBPL and p21. Furthermore, these clones were resistant to tamoxifen therapy, suggesting that RBCK1 could be a predictive marker of response to endocrine therapy. RBCK1 knockdown using targeted small interfering RNA resulted in increased proliferation and increased sensitivity to tamoxifen treatment. Moreover, in support of our in vitro data, analysis of mRNA microarray data sets demonstrated that high levels of FKBPL and RBCK1 correlated with increased patient survival, whereas high RBCK1 predicted for a poor response to tamoxifen. Our findings support a role for RBCK1 in the regulation of FKBPL with important implications for estrogen receptor signaling, cell proliferation and response to endocrine therapy.	[Donley, C.; McClelland, K.; McKeen, H. D.; Nelson, L.; Yakkundi, A.; Burrows, J.; McClements, L.; Valentine, A.; McCarthy, H. O.; Robson, T.] Queens Univ Belfast, Sch Pharm, McClay Res Ctr, Belfast BT9 7BL, Antrim, North Ireland; [Jithesh, P. V.] Univ Liverpool, Liverpool Canc Res UK Ctr, Liverpool L69 3BX, Merseyside, England; [Prise, K. M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland	Queens University Belfast; University of Liverpool; Queens University Belfast	Robson, T (corresponding author), Queens Univ Belfast, Sch Pharm, McClay Res Ctr, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	t.robson@qub.ac.uk	Prise, Kevin/N-7872-2015; Jithesh, Puthen Veettil/O-6262-2019; McClements, Lana/S-9458-2019	Prise, Kevin/0000-0001-6134-7946; Jithesh, Puthen Veettil/0000-0001-7747-0930; McClements, Lana/0000-0002-4911-1014; McCarthy, Helen/0000-0002-1254-3745; Cochrane, Keeva/0000-0001-7961-0474; Robson, Tracy/0000-0003-4262-6872	Department of Employment and Learning, Northern Ireland; Action Cancer, Northern Ireland; Breast Cancer Campaign, United Kingdom; Medical Research Council, United Kingdom; Biotechnology and Biological Sciences Research Council, United Kingdom; Biotechnology and Biological Sciences Research Council [BB/I006958/1] Funding Source: researchfish; Medical Research Council [G1001473] Funding Source: researchfish; BBSRC [BB/I006958/1] Funding Source: UKRI; MRC [G1001473] Funding Source: UKRI	Department of Employment and Learning, Northern Ireland; Action Cancer, Northern Ireland; Breast Cancer Campaign, United Kingdom; Medical Research Council, United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council, United Kingdom(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The financial support for this work was provided by PhD studentships awarded to C Donley and K McClelland from Department of Employment and Learning, Northern Ireland and Action Cancer, Northern Ireland, respectively. HD McKeen was supported by grants from Breast Cancer Campaign, United Kingdom and then the Medical Research Council, United Kingdom and A Yakkundi was supported by a grant from the Biotechnology and Biological Sciences Research Council, United Kingdom. All grants were awarded to T Robson.	Bublik DR, 2010, J BIOL CHEM, V285, P5274, DOI 10.1074/jbc.M109.045948; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Burrows JF, 2009, J BIOL CHEM, V284, P9587, DOI 10.1074/jbc.M807216200; Cong YS, 1997, J BIOL CHEM, V272, P16482, DOI 10.1074/jbc.272.26.16482; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Galigniana MD, 2010, MOL CELL BIOL, V30, P1285, DOI 10.1128/MCB.01190-09; Gustafsson N, 2010, CANCER RES, V70, P1265, DOI 10.1158/0008-5472.CAN-09-2674; Gustafsson-Sheppard NN, 2012, J MOL ENDOCRINOL, V49, P277; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Inn KS, 2011, MOL CELL, V41, P354, DOI 10.1016/j.molcel.2010.12.029; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Landgraf K, 2010, MOL CELL BIOL, V30, P5764, DOI 10.1128/MCB.01645-09; Li Yue-Ying, 2007, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V15, P733; McKeen HD, 2008, ENDOCRINOLOGY, V149, P5724, DOI 10.1210/en.2008-0168; McKeen HD, 2011, BIOCHEM SOC T, V39, P663, DOI 10.1042/BST0390663; McKeen HD, 2010, CANCER RES, V70, P1090, DOI 10.1158/0008-5472.CAN-09-2515; Mullenders J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004798; Nakamura M, 2006, BIOCHEM BIOPH RES CO, V351, P340, DOI 10.1016/j.bbrc.2006.09.163; Ni L, 2010, MOL CELL BIOL, V30, P1243, DOI 10.1128/MCB.01891-08; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Robson T, 1999, RADIAT RES, V152, P451, DOI 10.2307/3580140; Sinars CR, 2003, P NATL ACAD SCI USA, V100, P868, DOI 10.1073/pnas.0231020100; Sunnotel O, 2010, REPROD BIOL ENDOCRIN, V8, DOI 10.1186/1477-7827-8-22; Tian Y, 2007, J BIOL CHEM, V282, P16776, DOI 10.1074/jbc.M701913200; Tokunaga C, 1998, BIOCHEM BIOPH RES CO, V244, P353, DOI 10.1006/bbrc.1998.8270; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Valentine A, 2011, CLIN CANCER RES, V17, P1044, DOI 10.1158/1078-0432.CCR-10-2241; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952; Yao YL, 2011, CURR OPIN PHARMACOL, V11, P301, DOI 10.1016/j.coph.2011.03.005; Zenke-Kawasaki Y, 2007, MOL CELL BIOL, V27, P6962, DOI 10.1128/MCB.02415-06; Zhang M, 2008, CELL RES, V18, P1096, DOI 10.1038/cr.2008.277; Zhang Y, 2009, BREAST CANCER RES TR, V116, P303, DOI 10.1007/s10549-008-0183-2	36	19	21	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3441	3450		10.1038/onc.2013.306	http://dx.doi.org/10.1038/onc.2013.306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23912458				2022-12-17	WOS:000338779300011
J	Mukhopadhyay, NK; Kim, J; You, S; Morello, M; Hager, MH; Huang, WC; Ramachandran, A; Yang, J; Cinar, B; Rubin, MA; Adam, RM; Oesterreich, S; Di Vizio, D; Freeman, MR				Mukhopadhyay, N. K.; Kim, J.; You, S.; Morello, M.; Hager, M. H.; Huang, W-C; Ramachandran, A.; Yang, J.; Cinar, B.; Rubin, M. A.; Adam, R. M.; Oesterreich, S.; Di Vizio, D.; Freeman, M. R.			Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2	ONCOGENE			English	Article						AR; MST1/STK4; Hippo-RASSF1-LATS; prostate cancer; castration resistance	BREAST-CANCER CELLS; PROSTATE-CANCER; CHROMATIN CONDENSATION; ACTIVATION; PROTEIN; GENE; PROGRESSION; EXPRESSION; PATHWAY; PHOSPHORYLATION	The androgen receptor (AR) is a transcription factor that employs many diverse interactions with coregulatory proteins in normal physiology and in prostate cancer (PCa). The AR mediates cellular responses in association with chromatin complexes and kinase cascades. Here we report that the nuclear matrix protein, scaffold attachment factor B1 (SAFB1), regulates AR activity and AR levels in a manner that suggests its involvement in PCa. SAFB1 mRNA expression was lower in PCa in comparison with normal prostate tissue in a majority of publicly available RNA expression data sets. SAFB1 protein levels were also reduced with disease progression in a cohort of human PCa that included metastatic tumors. SAFB1 bound to AR and was phosphorylated by the MST1 (Hippo homolog) serine-threonine kinase, previously shown to be an AR repressor, and MST1 localization to AR-dependent promoters was inhibited by SAFB1 depletion. Knockdown of SAFB1 in androgen-dependent LNCaP PCa cells increased AR and prostate-specific antigen (PSA) levels, stimulated growth of cultured cells and subcutaneous xenografts and promoted a more aggressive phenotype, consistent with a repressive AR regulatory function. SAFB1 formed a complex with the histone methyltransferase EZH2 at AR-interacting chromatin sites in association with other polycomb repressive complex 2 (PRC2) proteins. We conclude that SAFB1 acts as a novel AR co-regulator at gene loci where signals from the MST1/Hippo and EZH2 pathways converge.	[Mukhopadhyay, N. K.; Kim, J.; You, S.; Morello, M.; Huang, W-C; Yang, J.; Cinar, B.; Di Vizio, D.; Freeman, M. R.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Canc Biol Program, Dept Surg, Los Angeles, CA 90048 USA; [Mukhopadhyay, N. K.; Kim, J.; You, S.; Morello, M.; Huang, W-C; Yang, J.; Cinar, B.; Di Vizio, D.; Freeman, M. R.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Canc Biol Program, Dept Med, Los Angeles, CA 90048 USA; [Mukhopadhyay, N. K.; Kim, J.; You, S.; Morello, M.; Huang, W-C; Yang, J.; Cinar, B.; Di Vizio, D.; Freeman, M. R.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Canc Biol Program, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Kim, J.; Hager, M. H.; Ramachandran, A.; Adam, R. M.; Di Vizio, D.; Freeman, M. R.] Harvard Univ, Sch Med, Dept Surg, Urol Dis Res Ctr,Boston Childrens Hosp, Boston, MA 02115 USA; [Rubin, M. A.] Weill Cornell Med Ctr, Dept Pathol & Lab Med, New York, NY USA; [Oesterreich, S.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Harvard University; Boston Children's Hospital; Harvard Medical School; Cornell University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Freeman, MR (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Canc Biol & Therapeut, Davis 5072, Los Angeles, CA 90048 USA.	Michael.freeman@cshs.org	You, Sungyong/AAJ-7372-2020; CİNAR, BEKIR MURAT/AAL-4474-2021; Huang, Wen-Chin/X-5879-2019	You, Sungyong/0000-0003-3513-1783; CİNAR, BEKIR MURAT/0000-0002-7906-5039; Huang, Wen-Chin/0000-0003-2342-9099; Rubin, Mark/0000-0002-8321-9950; Cinar, Bekir/0000-0003-4028-7600	NIH [1R01CA143777]; US Department of Defense [PC093459, NIH 5R00CA131472, NIH R01 CA097213];  [1R01CA112303]; NATIONAL CANCER INSTITUTE [R01CA112303, R00CA131472, R01CA097213, R01CA143777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087806] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Thomas Roberts (Dana-Farber Cancer Institute) for critical comments and Delia Lopez, Kristine Pelton and Paul Guthrie for technical assistance. This study was supported by NIH 1R01CA143777, 1R01CA112303, and US Department of Defense PC093459 (to MRF), NIH 5R00CA131472 (to DDV) and NIH R01 CA097213 (to SO).	Aldiri I, 2009, DEV DYNAM, V238, P3185, DOI 10.1002/dvdy.22120; Baek SH, 2011, MOL CELL, V42, P274, DOI 10.1016/j.molcel.2011.03.022; Beisel C, 2011, NAT REV GENET, V12, P123, DOI 10.1038/nrg2932; Burd CJ, 2006, ENDOCR-RELAT CANCER, V13, P979, DOI 10.1677/erc.1.01115; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Z, 2010, EPIGENOMICS-UK, V2, P551, DOI 10.2217/EPI.10.31; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Cinar B, 2007, EMBO J, V26, P4523, DOI 10.1038/sj.emboj.7601872; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Cinar B, 2011, CANCER RES, V71, P4303, DOI 10.1158/0008-5472.CAN-10-4532; Collak FK, 2012, J BIOL CHEM, V287, P23698, DOI 10.1074/jbc.M112.358713; Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Debril MB, 2005, J MOL ENDOCRINOL, V35, P503, DOI 10.1677/jme.1.01856; Di Vizio D, 2009, CELL CYCLE, V8, P2420, DOI 10.4161/cc.8.15.9116; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; Garee JP, 2010, J CELL BIOCHEM, V109, P312, DOI 10.1002/jcb.22420; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Hammerich-Hille S, 2010, J BIOL CHEM, V285, P3608, DOI 10.1074/jbc.M109.066431; Hara T, 2003, CANCER RES, V63, P5622; Hara T, 2008, CANCER RES, V68, P1128, DOI 10.1158/0008-5472.CAN-07-1929; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hu Y, 2007, CELL DEATH DIFFER, V14, P2035, DOI 10.1038/sj.cdd.4402214; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; Kim J, 2011, IN VITRO CELL DEV-AN, V47, P2, DOI 10.1007/s11626-010-9350-y; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Lawrence MG, 2010, ENDOCR REV, V31, P407, DOI 10.1210/er.2009-0034; Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010; LI SSL, 1993, GENOMICS, V17, P765, DOI 10.1006/geno.1993.1403; Magee JA, 2006, ENDOCRINOLOGY, V147, P590, DOI 10.1210/en.2005-1001; Mukhopadhyay NK, 2007, MOL ENDOCRINOL, V21, P2056, DOI 10.1210/me.2006-0503; Mukhopadhyay NK, 2006, EXP CELL RES, V312, P3782, DOI 10.1016/j.yexcr.2006.07.017; Mukhopadhyay NK, 2009, CANCER RES, V69, P2210, DOI 10.1158/0008-5472.CAN-08-2308; Oesterreich S, 2003, J CELL BIOCHEM, V90, P653, DOI 10.1002/jcb.10685; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.3.CO;2-5; Vicent GP, 2011, GENE DEV, V25, P845, DOI 10.1101/gad.621811; Pinskaya M, 2009, EPIGENETICS-US, V4, P302, DOI 10.4161/epi.4.5.9369; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Ross PJ, 2008, REPRODUCTION, V136, P777, DOI 10.1530/REP-08-0045; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Townson SM, 2004, J BIOL CHEM, V279, P26074, DOI 10.1074/jbc.M313726200; Townson SM, 2003, J BIOL CHEM, V278, P20059, DOI 10.1074/jbc.M212988200; Ura S, 2007, MOL CELL BIOL, V27, P5514, DOI 10.1128/MCB.00199-07; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Wiklund F, 2003, PROSTATE, V57, P290, DOI 10.1002/pros.10303; Xu LL, 2000, GENOMICS, V66, P257, DOI 10.1006/geno.2000.6214; Yamamoto S, 2003, J CLIN INVEST, V111, P1463, DOI 10.1172/JCI200317459	53	19	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3235	3245		10.1038/onc.2013.294	http://dx.doi.org/10.1038/onc.2013.294			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23893242	Green Accepted			2022-12-17	WOS:000338443400003
J	Dieterle, AM; Bohler, P; Keppeler, H; Alers, S; Berleth, N; Driessen, S; Hieke, N; Pietkiewicz, S; Loffler, AS; Peter, C; Gray, A; Leslie, NR; Shinohara, H; Kurosaki, T; Engelke, M; Wienands, J; Bonin, M; Wesselborg, S; Stork, B				Dieterle, A. M.; Boehler, P.; Keppeler, H.; Alers, S.; Berleth, N.; Driessen, S.; Hieke, N.; Pietkiewicz, S.; Loeffler, A. S.; Peter, C.; Gray, A.; Leslie, N. R.; Shinohara, H.; Kurosaki, T.; Engelke, M.; Wienands, J.; Bonin, M.; Wesselborg, S.; Stork, B.			PDK1 controls upstream PI3K expression and PIP3 generation	ONCOGENE			English	Article						Akt; PDK1; PI3K; survival; B lymphocytes	3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; SMALL-MOLECULE INHIBITORS; P70 S6 KINASE; SIGNALING PATHWAY; PHOSPHOINOSITIDE PHOSPHATASES; ONCOGENIC TRANSFORMATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MTOR COMPLEX; IN-VITRO	The PI3K/PDK1/Akt signaling axis is centrally involved in cellular homeostasis and controls cell growth and proliferation. Due to its key function as regulator of cell survival and metabolism, the dysregulation of this pathway is manifested in several human pathologies including cancers and immunological diseases. Thus, current therapeutic strategies target the components of this signaling cascade. In recent years, numerous feedback loops have been identified that attenuate PI3K/PDK1/Akt-dependent signaling. Here, we report the identification of an additional level of feedback regulation that depends on the negative transcriptional control of phosphatidylinositol 3-kinase (PI3K) class IA subunits. Genetic deletion of 3-phosphoinositide-dependent protein kinase 1 (PDK1) or the pharmacological inhibition of its downstream effectors, that is, Akt and mammalian target of rapamycin (mTOR), relieves this suppression and leads to the upregulation of PI3K subunits, resulting in enhanced generation of phosphatidylinositol-3,4,5-trisphosphate (PIP3). Apparently, this transcriptional induction is mediated by the concerted action of different transcription factor families, including the transcription factors cAMP-responsive element-binding protein and forkhead box O. Collectively, we propose that PDK1 functions as a cellular sensor that balances basal PIP3 generation at levels sufficient for survival but below a threshold being harmful to the cell. Our study suggests that the efficiency of therapies targeting the aberrantly activated PI3K/PDK1/Akt pathway might be increased by the parallel blockade of feedback circuits.	[Dieterle, A. M.; Keppeler, H.; Alers, S.] Univ Tubingen Hosp, Dept Internal Med 1, Tubingen, Germany; [Boehler, P.; Berleth, N.; Driessen, S.; Hieke, N.; Pietkiewicz, S.; Loeffler, A. S.; Peter, C.; Wesselborg, S.; Stork, B.] Univ Hosp Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; [Gray, A.; Leslie, N. R.] Univ Dundee, Coll Life Sci, Div Cell Signaling & Immunol, Dundee, Scotland; [Shinohara, H.; Kurosaki, T.] RIKEN Res Ctr Allergy & Immunol, Lab Lymphocyte Differentiat, Yokohama, Kanagawa, Japan; [Engelke, M.; Wienands, J.] Univ Tubingen Hosp, Inst Cellular & Mol Immunol, Tubingen, Germany; [Bonin, M.] Univ Tubingen Hosp, MFT Serv, Dept Med Genet, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; University of Dundee; RIKEN; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Stork, B (corresponding author), Univ Hosp Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	bjoern.stork@uni-duesseldorf.de	Stork, Björn/C-2160-2011; Shinohara, Hisaaki/E-3969-2010; Peter, Christoph/ABB-4684-2020; Kurosaki, Tomohiro/D-1306-2009	Stork, Björn/0000-0002-4167-7806; Shinohara, Hisaaki/0000-0002-6331-2138; Peter, Christoph/0000-0002-0048-2279; Kurosaki, Tomohiro/0000-0002-6352-304X; Alers, Sebastian/0000-0002-9813-9451; Gray, Alexander/0000-0001-9227-0363; Bohler, Philip/0000-0002-7792-8304; LESLIE, Nicholas/0000-0001-5131-0541; Alers, Alexandra Maria/0000-0002-7863-3559; Wesselborg, Sebastian/0000-0002-5236-942X	Deutsche Forschungsgemeinschaft [SFB 773, GRK 1302]; Interdisciplinary Center of Clinical Research, Faculty of Medicine, Tubingen (Nachwuchsgruppe) [1866-0-0]; Medical Research Council [G0801865] Funding Source: researchfish; MRC [G0801865] Funding Source: UKRI	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Interdisciplinary Center of Clinical Research, Faculty of Medicine, Tubingen (Nachwuchsgruppe); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Dario Alessi for providing Akti-1/2/3 (MK-2206) and for helpful discussions. This study was supported by grants from the Deutsche Forschungsgemeinschaft SFB 773 and GRK 1302 (to SW and BS) and from the Interdisciplinary Center of Clinical Research, Faculty of Medicine, Tubingen (Nachwuchsgruppe 1866-0-0, to BS).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Bayascas JR, 2008, MOL CELL BIOL, V28, P3258, DOI 10.1128/MCB.02032-07; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bujor AM, 2010, EXP DERMATOL, V19, P347, DOI 10.1111/j.1600-0625.2010.01065.x; Bunney TD, 2010, NAT REV CANCER, V10, P342, DOI 10.1038/nrc2842; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Carnero A, 2010, CURR PHARM DESIGN, V16, P34, DOI 10.2174/138161210789941865; Caron E, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.108; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Denley A, 2009, MOL CANCER RES, V7, P1132, DOI 10.1158/1541-7786.MCR-09-0068; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fayard E, 2010, CURR TOP MICROBIOL, V346, P31, DOI 10.1007/82_2010_58; Feldman RI, 2005, J BIOL CHEM, V280, P19867, DOI 10.1074/jbc.M501367200; Figueroa C, 2003, ONCOGENE, V22, P5554, DOI 10.1038/sj.onc.1206496; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Gray A, 2003, ANAL BIOCHEM, V313, P234, DOI 10.1016/S0003-2697(02)00607-3; Guertin DA, 2006, CURR BIOL, V16, P958, DOI 10.1016/j.cub.2006.03.084; Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Jiang XN, 2010, J BIOL CHEM, V285, P14980, DOI 10.1074/jbc.M109.085696; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kok K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005145; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kurosaki T, 2011, MOL IMMUNOL, V48, P1287, DOI 10.1016/j.molimm.2010.12.007; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lindsley CW, 2010, CURR TOP MED CHEM, V10, P458, DOI 10.2174/156802610790980602; Liu Y, 2010, PROG LIPID RES, V49, P201, DOI 10.1016/j.plipres.2009.12.001; Los M, 2009, BIOESSAYS, V31, P492, DOI 10.1002/bies.200900005; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714; Najafov A, 2012, BIOCHEM J, V448, P285, DOI 10.1042/BJ20121287; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Parcellier A, 2008, CELL SIGNAL, V20, P21, DOI 10.1016/j.cellsig.2007.07.010; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82_2010_43; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shin HW, 2005, J CELL BIOL, V170, P607, DOI 10.1083/jcb.200505128; Shinohara H, 2007, J EXP MED, V204, P3285, DOI 10.1084/jem.20070379; So L, 2012, BIOCHEM J, V442, P465, DOI 10.1042/BJ20112092; Song KS, 2008, J BIOL CHEM, V283, P26869, DOI 10.1074/jbc.M802507200; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; van den Bout I, 2009, J CELL SCI, V122, P3837, DOI 10.1242/jcs.056127; van Gorp AGM, 2006, CANCER RES, V66, P10760, DOI 10.1158/0008-5472.CAN-06-1111; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Yamazoe M, 2004, DNA REPAIR, V3, P1175, DOI 10.1016/j.dnarep.2004.03.039	66	19	22	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3043	3053		10.1038/onc.2013.266	http://dx.doi.org/10.1038/onc.2013.266			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23893244				2022-12-17	WOS:000337232200011
J	Murakami, S; Chishima, S; Uemoto, H; Sakamoto, E; Sato, T; Kurabe, N; Kawasaki, Y; Shibata, T; Akiyama, H; Tashiro, F				Murakami, S.; Chishima, S.; Uemoto, H.; Sakamoto, E.; Sato, T.; Kurabe, N.; Kawasaki, Y.; Shibata, T.; Akiyama, H.; Tashiro, F.			The male-specific factor Sry harbors an oncogenic function	ONCOGENE			English	Article						SRY; SGF29; c-Myc; STAGA complex; hepatocarcinogenesis	HISTONE ACETYLTRANSFERASE COMPLEXES; C-MYC; HEPATOCELLULAR-CARCINOMA; ORNITHINE-DECARBOXYLASE; ESSENTIAL COFACTOR; SEX DETERMINATION; EXPRESSION; CELLS; GROWTH; TRRAP	Sgf29, a component of the SPT-ADA-GCN5 acetyltransferase (SAGA) complex, binds H3K4me2/3 marks and leads to histone H3 acetylation. Previously, we found that downregulation of Sgf29 suppresses c-Myc-mediated malignant transformation. Nonetheless, the upstream regulator of the Sgf29 gene is not yet known. Here, we report that Sry (sex-determining region Y), an HMG (high-mobility group) domain containing transcription factor, directly upregulates Sgf29 gene expression. Sry expression was deregulated in two out of the four tested male rodent hepatocellular carcinoma (rHCC) cell lines. Luciferase reporter and chromatin immunoprecipitation assays indicated that Sry could bind HMG-boxes in the proximal promoter region of the Sgf29 gene. Knockdown of Sry robustly lowered anchorage-independent growth, invasiveness and tumorigenicity of rHCC cells, whereas ectopic expression of Sry conferred more malignant properties. Thus, these data show that Sry is involved in male-specific malignant conversion of rHCCs via Sgf29 upregulation.	[Murakami, S.; Chishima, S.; Uemoto, H.; Sakamoto, E.; Sato, T.; Kurabe, N.; Kawasaki, Y.; Akiyama, H.; Tashiro, F.] Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Tokyo 1258585, Japan; [Shibata, T.] Natl Canc Ctr, Res Inst, Div Canc Gen, Tokyo 104, Japan	Tokyo University of Science; National Cancer Center - Japan	Tashiro, F (corresponding author), Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Katsushika Ku, Niijuku 6-3-1, Tokyo 1258585, Japan.	ftashir@rs.noda.tus.ac.jp	Shibata, Tatsuhiro/AAO-1278-2021; Shibata, Tatsuhiro/ABA-8234-2020		'Academic Frontier' project for Private University - MEXT (Ministry of Education, Culture, Sports, Science and Technology); Grants-in-Aid for Scientific Research [23501271] Funding Source: KAKEN	'Academic Frontier' project for Private University - MEXT (Ministry of Education, Culture, Sports, Science and Technology); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to K Katagiri for the technical assistance. This work was partly supported by the 'Academic Frontier' project for Private University: a matching fund subsidy from MEXT (Ministry of Education, Culture, Sports, Science and Technology), 2006-2010 (to FT) and 2010-2012 (to HA).	Albrecht KH, 2001, DEV BIOL, V240, P92, DOI 10.1006/dbio.2001.0438; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Bian CB, 2011, EMBO J, V30, P2829, DOI 10.1038/emboj.2011.193; Bradford ST, 2009, HUM MOL GENET, V18, P3429, DOI 10.1093/hmg/ddp283; Bullejos M, 2001, DEV DYNAM, V221, P201, DOI 10.1002/dvdy.1134; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Iyengar RV, 2001, CANCER RES, V61, P3045; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; Katoh H, 2007, GASTROENTEROLOGY, V133, P1475, DOI 10.1053/j.gastro.2007.08.038; Kawasaki Y., 2007, Mycotoxins, V57, P87, DOI 10.2520/myco.57.87; Komiya Y, 2008, J BIOL CHEM, V283, P18753, DOI 10.1074/jbc.M802530200; Kurabe N, 2007, ONCOGENE, V26, P5626, DOI 10.1038/sj.onc.1210349; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MURRAY JD, 1982, J VIROL, V44, P1072, DOI 10.1128/JVI.44.3.1072-1075.1982; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Nishino K, 2004, J BIOL CHEM, V279, P22306, DOI 10.1074/jbc.M309513200; Palaskas N, 2011, CANCER RES, V71, P5164, DOI 10.1158/0008-5472.CAN-10-4633; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Phillips NB, 2006, J MOL BIOL, V358, P172, DOI 10.1016/j.jmb.2006.01.060; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sekido R, 2008, NATURE, V453, P930, DOI 10.1038/nature06944; Sugiyama A, 2003, CARCINOGENESIS, V24, P1549, DOI 10.1093/carcin/bgg113; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomsen MK, 2010, CANCER RES, V70, P979, DOI 10.1158/0008-5472.CAN-09-2370; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	36	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2978	2986		10.1038/onc.2013.262	http://dx.doi.org/10.1038/onc.2013.262			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23893245				2022-12-17	WOS:000337232200004
J	Ordonez-Moran, P; Irmisch, A; Barbachano, A; Chicote, I; Tenbaum, S; Landolfi, S; Tabernero, J; Huelsken, J; Munoz, A; Palmer, HG				Ordonez-Moran, P.; Irmisch, A.; Barbachano, A.; Chicote, I.; Tenbaum, S.; Landolfi, S.; Tabernero, J.; Huelsken, J.; Munoz, A.; Palmer, H. G.			SPROUTY2 is a beta-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer	ONCOGENE			English	Article						SPROUTY2; wnt pathway; beta-catenin; FOXO3a; colon cancer	GROWTH-FACTOR RECEPTOR; E-CADHERIN; EXPRESSION; PROTEINS; CELLS; TRANSCRIPTION; INHIBITOR; PHOSPHORYLATION; DIFFERENTIATION; BINDING	SPROUTY2 (SPRY2) is an intracellular regulator of receptor tyrosine kinase signaling involved in cell growth, differentiation and tumorigenesis. Here, we show that SPRY2 is a target gene of the Wnt/beta-catenin pathway that is abnormally activated in more than 90% of colon carcinomas. In human colon cancer cells, SPRY2 expression is induced by beta-catenin in co-operation with the transcription factor FOXO3a instead of lymphoid enhancer factor/T-cell factor proteins. We found binding of beta-catenin to the SPRY2 promoter at FOXO3a response elements. In vivo, cells marked by nuclear beta-catenin and FOXO3a express SPRY2 in proliferative epithelial tissues, such as intestinal mucosa and epidermis. Consistently, inducible beta-catenin deletion in mice reduced Spry2 expression in the small intestine. Moreover, SPRY2 protein expression correlated with nuclear beta-catenin and FOXO3a colocalization in human colon carcinomas. Importantly, the amount of SPRY2 protein correlated with shorter overall survival of colon cancer patients. Our data reveal SPRY2 as a novel Wnt beta-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer.	[Ordonez-Moran, P.; Barbachano, A.; Munoz, A.] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Ordonez-Moran, P.; Irmisch, A.; Huelsken, J.] Ecole Polytech Fed Lausanne, Swiss Inst Expt Canc Res, Lausanne, Switzerland; [Chicote, I.; Tenbaum, S.; Palmer, H. G.] VHIO, Stem Cells & Canc Lab, Translat Res Program, Barcelona 08035, Spain; [Landolfi, S.] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Pathol, Barcelona, Spain; [Tabernero, J.] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron	Palmer, HG (corresponding author), VHIO, Stem Cells & Canc Lab, Translat Res Program, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	hgpalmer@vhio.net	Barbachano, Antonio/O-7731-2015; Palmer, Héctor G./AAG-8332-2019; Huelsken, Joerg/AAC-9581-2021; Munoz, Alberto/O-6393-2014; Tabernero, Josep/AAG-5026-2019; Ordonez-Moran, Paloma/B-6371-2016	Barbachano, Antonio/0000-0002-1248-5143; Huelsken, Joerg/0000-0003-3105-9606; Munoz, Alberto/0000-0003-3890-4251; Tabernero, Josep/0000-0002-2495-8139; Ordonez-Moran, Paloma/0000-0001-7688-1252; Palmer, Hector/0000-0002-9823-5638; Landolfi, Stefania/0000-0002-1059-635X	Fondo Europeo de Desarrollo Regional-Instituto de Salud Carlos III; Spanish Cooperative Research Network on Cancer (RTICC) [FIS-PI081356, RD12/0036/0001, RD12/0036/0021, RD12/0036/0012]; Plan Nacional de Biomedicina, Ministerio de Economia y Competitividad [SAF-18302]; Comunidad de Madrid [S2010/BMD-2344 Colomics2]; Miguel Servet Program; Instituto de Salud Carlos III (ISCIII); EMBO	Fondo Europeo de Desarrollo Regional-Instituto de Salud Carlos III; Spanish Cooperative Research Network on Cancer (RTICC); Plan Nacional de Biomedicina, Ministerio de Economia y Competitividad; Comunidad de Madrid(Comunidad de Madrid); Miguel Servet Program; Instituto de Salud Carlos III (ISCIII)(Instituto de Salud Carlos IIIEuropean Commission); EMBO(European Molecular Biology Organization (EMBO))	We thank T Martinez for technical assistance and Hans Clevers for providing the LS174T-tetOn-Delta NTCF4 cells. Experiments were supported by grants from Fondo Europeo de Desarrollo Regional-Instituto de Salud Carlos III and Spanish Cooperative Research Network on Cancer (RTICC) (FIS-PI081356, RD12/0036/0001, RD12/0036/0021 and RD12/0036/0012), Plan Nacional de Biomedicina, Ministerio de Economia y Competitividad (SAF-18302) and Comunidad de Madrid (S2010/BMD-2344 Colomics2). HGP was supported by the Miguel Servet Program, Instituto de Salud Carlos III (ISCIII) and PO-M by an EMBO research fellowship.	Barbachano A, 2010, ONCOGENE, V29, P4800, DOI 10.1038/onc.2010.225; Barker N, 2007, GASTROENTEROLOGY, V133, P1755, DOI 10.1053/j.gastro.2007.10.029; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Ding W, 2003, GENE, V322, P175, DOI 10.1016/j.gene.2003.09.004; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Fiske WH, 2009, EXP CELL RES, V315, P583, DOI 10.1016/j.yexcr.2008.10.043; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Frank MJ, 2009, BLOOD, V113, P2478, DOI 10.1182/blood-2008-05-156943; Guy GR, 2009, J ENDOCRINOL, V203, P191, DOI 10.1677/JOE-09-0110; Haglund K, 2005, EMBO REP, V6, P635, DOI 10.1038/sj.embor.7400453; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Holgren C, 2010, ONCOGENE, V29, P5241, DOI 10.1038/onc.2010.264; Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Kim HJ, 2007, CURR BIOL, V17, P455, DOI 10.1016/j.cub.2007.01.059; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lao DH, 2007, J BIOL CHEM, V282, P9117, DOI 10.1074/jbc.M607563200; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; Olson LE, 2006, CELL, V125, P593, DOI 10.1016/j.cell.2006.02.046; Oriol A, 2012, PROTOCOL EXCHANGE; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Palmer HG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001483; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Raghav SK, 2012, METHODS MOL BIOL, V786, P247, DOI 10.1007/978-1-61779-292-2_15; Sanchez A, 2008, ONCOGENE, V27, P4969, DOI 10.1038/onc.2008.129; Schneider MR, 2008, AM J PATHOL, V173, P14, DOI 10.2353/ajpath.2008.070942; Shim K, 2005, DEV CELL, V8, P553, DOI 10.1016/j.devcel.2005.02.009; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Song K, 2012, HEPATOB PANCREAT DIS, V11, P177, DOI 10.1016/S1499-3872(12)60145-3; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; Watt FM, 2009, EMBO MOL MED, V1, P260, DOI 10.1002/emmm.200900033; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493	51	19	20	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1975	1985		10.1038/onc.2013.140	http://dx.doi.org/10.1038/onc.2013.140			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23624922	Green Submitted			2022-12-17	WOS:000334346300010
J	Zhou, W; Bao, S				Zhou, W.; Bao, S.			PML-mediated signaling and its role in cancer stem cells	ONCOGENE			English	Review						PML; cancer stem cells; cell signaling; oncogenesis	PROMYELOCYTIC LEUKEMIA PROTEIN; ALPHA-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR PML; UBIQUITIN-LIKE PROTEIN; FAS-INDUCED APOPTOSIS; NUCLEAR-BODIES; RAR-ALPHA; DNA-DAMAGE; TRANSCRIPTIONAL REPRESSION; SUBNUCLEAR LOCALIZATION	The promyelocytic leukemia (PML) protein, initially discovered as a part of the PML/retinoic acid receptor alpha fusion protein, has been found to be a critical player in oncogenesis and tumor progression. Multiple cellular activities, including DNA repair, alternative lengthening of telomeres, transcriptional control, apoptosis and senescence, are regulated by PML and its featured subcellular structure, the PML nuclear body. In correspondence with its role in many important life processes, PML mediates several complex downstream signaling pathways. The determinant function of PML in tumorigenesis and cancer progression raises the interest in its involvement in cancer stem cells (CSCs), a subpopulation of cancer cells that share properties with stem cells and are critical for tumor propagation. Recently, there are exciting discoveries concerning the requirement of PML in CSC maintenance. Growing evidences strongly suggest a positive role of PML in regulating CSCs in both hematopoietic cancers and solid tumors, whereas the underlying mechanisms may be different and remain elusive. Here we summarize and discuss the PML-mediated signaling pathways in cancers and their potential roles in regulating CSCs.	[Zhou, W.; Bao, S.] Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Bao, S (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, 9500 Euclid Ave,NE30, Cleveland, OH 44195 USA.	baos@ccf.org			Cleveland Clinic Foundation; NIH R01 Grant [NS070315]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070315] Funding Source: NIH RePORTER	Cleveland Clinic Foundation; NIH R01 Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Cleveland Clinic Foundation and a NIH R01 Grant (NS070315) to SB. We thank other members in the Bao's lab for helpful discussion. We apologize for not including all PML references in this review due to space limit.	Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Aoto T, 2006, DEV BIOL, V298, P354, DOI 10.1016/j.ydbio.2006.04.450; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao-Lei T, 2006, J CELL BIOCHEM, V97, P561, DOI 10.1002/jcb.20584; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Boddy MN, 1996, ONCOGENE, V13, P971; Boddy MN, 1997, J CELL SCI, V110, P2197; Boe SO, 2006, J CELL SCI, V119, P3284, DOI 10.1242/jcs.03068; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Brouwer AK, 2009, MOL BIOL CELL, V20, P4804, DOI 10.1091/mbc.E09-04-0309; Butler JT, 2009, J CELL BIOCHEM, V107, P609, DOI 10.1002/jcb.22183; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Carracedo A, 2012, J CLIN INVEST, V122, P3088, DOI 10.1172/JCI62129; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Cho S, 2011, J BIOL CHEM, V286, P41115, DOI 10.1074/jbc.M111.248534; Chuang YS, 2011, STEM CELLS, V29, P660, DOI 10.1002/stem.623; Chung I, 2011, J CELL SCI, V124, P3603, DOI 10.1242/jcs.084681; Condemine W, 2007, J CELL SCI, V120, P3219, DOI 10.1242/jcs.007492; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Crowder C, 2005, BLOOD, V105, P1280, DOI 10.1182/blood-2004-04-1614; Croxton R, 2006, CANCER RES, V66, P9026, DOI 10.1158/0008-5472.CAN-06-1047; Culjkovic B, 2008, J CELL BIOL, V181, P51, DOI 10.1083/jcb.200707018; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; de The H, 2010, NAT REV CANCER, V10, P775, DOI 10.1038/nrc2943; Dellaire G, 2006, J CELL BIOL, V175, P55, DOI 10.1083/jcb.200604009; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Draskovic I, 2009, P NATL ACAD SCI USA, V106, P15726, DOI 10.1073/pnas.0907689106; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Eskiw CH, 2003, J CELL SCI, V116, P4455, DOI 10.1242/jcs.00758; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Fang WZ, 2002, ONCOGENE, V21, P5557, DOI 10.1038/sj.onc.1205666; Fasching CL, 2007, CANCER RES, V67, P7072, DOI 10.1158/0008-5472.CAN-07-1556; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fu CH, 2005, ONCOGENE, V24, P5401, DOI 10.1038/sj.onc.1208714; Geng YY, 2012, J BIOL CHEM, V287, P30729, DOI 10.1074/jbc.M112.374769; Geoffroy MC, 2010, MOL BIOL CELL, V21, P4227, DOI 10.1091/mbc.E10-05-0449; Giorgi C, 2010, SCIENCE, V330, P1247, DOI 10.1126/science.1189157; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gong L, 2006, J BIOL CHEM, V281, P15869, DOI 10.1074/jbc.M511658200; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grobelny JV, 2000, J CELL SCI, V113, P4577; Guan D, 2013, ONCOGENE, V32, P3819, DOI 10.1038/onc.2012.406; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gupta P, 2008, P NATL ACAD SCI USA, V105, P11424, DOI 10.1073/pnas.0710561105; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Haupt S, 2009, CANCER RES, V69, P4818, DOI 10.1158/0008-5472.CAN-08-4010; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Hayakawa F, 2008, J BIOL CHEM, V283, P24420, DOI 10.1074/jbc.M802217200; Herzer K, 2009, CANCER RES, V69, P855, DOI 10.1158/0008-5472.CAN-08-2831; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hsu JK, 2012, J CELL BIOL, V197, P613, DOI 10.1083/jcb.201109038; Hubackova S, 2012, J BIOL CHEM, V287, P26702, DOI 10.1074/jbc.M111.316869; ISHOV AM, 1999, J CELL BIOL, V147, P221, DOI [DOI 10.1083/JCB.147.2.221, 10.1083/jcb.147.2.221]; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kawasaki A, 2003, BLOOD, V101, P3668, DOI 10.1182/blood-2002-08-2474; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim TK, 2007, CANCER RES, V67, P11133, DOI 10.1158/0008-5472.CAN-07-1342; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lallemand-Breitenbach V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000661; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; LAVAU C, 1995, ONCOGENE, V11, P871; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li Q, 2011, ONCOGENE, V30, P1194, DOI 10.1038/onc.2010.499; Li W, 2009, P NATL ACAD SCI USA, V106, P4725, DOI 10.1073/pnas.0807640106; Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736; Lim JH, 2011, J BIOL CHEM, V286, P44403, DOI 10.1074/jbc.M111.289512; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Lin DY, 2003, J BIOL CHEM, V278, P15958, DOI 10.1074/jbc.M300387200; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Louria-Hayon I, 2009, CELL DEATH DIFFER, V16, P1156, DOI 10.1038/cdd.2009.31; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Martin N, 2012, EMBO J, V31, P95, DOI 10.1038/emboj.2011.370; Matic I, 2008, MOL CELL PROTEOMICS, V7, P132, DOI 10.1074/mcp.M700173-MCP200; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Meinecke I, 2007, P NATL ACAD SCI USA, V104, P5073, DOI 10.1073/pnas.0608773104; Moller A, 2003, CANCER RES, V63, P4310; Morgan M, 2002, J CELL BIOL, V157, P975, DOI 10.1083/jcb.200204039; Mukhopadhyay D, 2006, J CELL BIOL, V174, P939, DOI 10.1083/jcb.200510103; Nabetani A, 2004, J BIOL CHEM, V279, P25849, DOI 10.1074/jbc.M312652200; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Park J, 2005, MOL CELL BIOL, V25, P8202, DOI 10.1128/MCB.25.18.8202-8214.2005; Park SW, 2007, NAT STRUCT MOL BIOL, V14, P68, DOI 10.1038/nsmb1185; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Peche LY, 2012, CELL DEATH DIFFER, V19, P926, DOI 10.1038/cdd.2011.173; Percherancier Y, 2009, J BIOL CHEM, V284, P16595, DOI 10.1074/jbc.M109.006387; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rabellino A, 2012, CANCER RES, V72, P2275, DOI 10.1158/0008-5472.CAN-11-3159; Regad T, 2009, NAT NEUROSCI, V12, P132, DOI 10.1038/nn.2251; Reineke EL, 2008, MOL CELL BIOL, V28, P997, DOI 10.1128/MCB.01848-07; Renner F, 2010, MOL CELL, V37, P503, DOI 10.1016/j.molcel.2010.01.018; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Scaglioni PP, 2012, EMBO MOL MED, V4, P594, DOI 10.1002/emmm.201200233; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Shima Y, 2008, MOL CELL BIOL, V28, P7126, DOI 10.1128/MCB.00897-08; Shin J, 2004, J BIOL CHEM, V279, P40994, DOI 10.1074/jbc.M407369200; Shtutman Michael, 2002, Cancer Research, V62, P5947; Silvestre DC, 2011, STEM CELLS, V29, P440, DOI 10.1002/stem.600; Slatter TL, 2012, J PATHOL, V226, P509, DOI 10.1002/path.2981; Smith KP, 2004, J CELL BIOCHEM, V93, P1282, DOI 10.1002/jcb.20273; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Takahashi K, 2007, MOL BIOL CELL, V18, P1701, DOI 10.1091/mbc.E06-08-0747; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Ulbricht T, 2012, J CELL BIOL, V199, P49, DOI 10.1083/jcb.201112015; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Vernier M, 2011, GENE DEV, V25, P41, DOI 10.1101/gad.1975111; Vlasakova J, 2007, BLOOD, V109, P1373, DOI 10.1182/blood-2006-02-003418; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Welch JS, 2011, J CLIN INVEST, V121, P1636, DOI 10.1172/JCI42953; Wolyniec K, 2012, BLOOD, V120, P822, DOI 10.1182/blood-2011-10-387647; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Wu WS, 2002, J BIOL CHEM, V277, P31734, DOI 10.1074/jbc.M201648200; Wu WS, 2002, ONCOGENE, V21, P3925, DOI 10.1038/sj.onc.1205491; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Xu ZX, 2003, MOL CELL BIOL, V23, P4247, DOI 10.1128/MCB.23.12.4247-4256.2003; Yang Q, 2013, ONCOGENE, V32, P3156, DOI 10.1038/onc.2012.332; Yang ST, 2006, J BIOL CHEM, V281, P26645, DOI 10.1074/jbc.M604391200; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Ye XF, 2007, MOL CELL BIOL, V27, P2452, DOI 10.1128/MCB.01592-06; Ye XF, 2007, MOL CELL, V27, P183, DOI 10.1016/j.molcel.2007.05.034; Yeager TR, 1999, CANCER RES, V59, P4175; Yeung PL, 2012, J CELL BIOCHEM, V113, P1787, DOI 10.1002/jcb.24050; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008; Zhang P, 2008, CURR BIOL, V18, P1489, DOI 10.1016/j.cub.2008.08.048; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	164	19	19	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1475	1484		10.1038/onc.2013.111	http://dx.doi.org/10.1038/onc.2013.111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23563177				2022-12-17	WOS:000333244200001
J	Ganapathy, S; Xiao, S; Seo, SJ; Lall, R; Yang, M; Xu, T; Su, H; Shadfan, M; Ha, CS; Yuan, ZM				Ganapathy, S.; Xiao, S.; Seo, S-J; Lall, R.; Yang, M.; Xu, T.; Su, H.; Shadfan, M.; Ha, C. S.; Yuan, Z-M			Low-dose arsenic induces chemotherapy protection via p53/NF-kappa B-mediated metabolic regulation	ONCOGENE			English	Article						chemoprotection; p53; NF-kappa B; metabolism; colon cancer	NF-KAPPA-B; SIGNALING PATHWAYS; DRINKING-WATER; P53; CANCER; CROSSTALK; CELLS	Most chemotherapeutical drugs kill cancer cells chiefly by inducing DNA damage, which unfortunately also causes undesirable injuries to normal tissues, mainly due to p53 activation. We report a novel strategy of normal tissue protection that involves p53/NF-kappa B coordinated metabolic regulation. Pretreatment of untransformed cells with low doses of arsenic induced concerted p53 suppression and NF-kappa B activation, which elicited a marked induction of glycolysis. Significantly, this metabolic shift provided cells effective protection against cytotoxic chemotherapy, coupling the metabolic pathway to cellular resistance. Using both in vitro and in vivo models, we demonstrated an absolute requirement of functional p53 in arsenic-mediated protection. Consistently, a brief arsenic pretreatment selectively protected only normal tissues, but not tumors, from toxicity of chemotherapy. An indispensable role of glycolysis in protecting normal tissues was demonstrated by using an inhibitor of glycolysis, 2-deoxyglucose, which almost totally abolished low-dose arsenic-mediated protection. Together, our work demonstrates that low-dose arsenic renders normal cells and tissues resistant to chemotherapy-induced toxicity by inducting glycolysis.	[Ganapathy, S.; Xiao, S.; Seo, S-J; Lall, R.; Yang, M.; Xu, T.; Su, H.; Shadfan, M.; Ha, C. S.; Yuan, Z-M] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Dept Radiat Oncol, San Antonio, TX 78229 USA; [Ganapathy, S.; Yang, M.; Yuan, Z-M] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; Harvard University; Harvard T.H. Chan School of Public Health	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 655 Huntington Ave,SPH Bldg 1, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Ha, C/GZL-9046-2022	yang, mei/0000-0001-9574-2282	NCI/NIH [2 R01 CA085679, R01 CA125144]; NATIONAL CANCER INSTITUTE [R01CA125144, R01CA085679, R01CA167814] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI/NIH grants 2 R01 CA085679 and R01 CA125144 (to ZMY). We are grateful to Dr Gigi Lozano (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) for the p53-mutant mice. Mouse imaging was performed by Suresh Prajapati, gratefully acknowledged.	Ak P, 2010, FASEB J, V24, P3643, DOI 10.1096/fj.10-160549; Andrew AS, 2003, ENVIRON HEALTH PERSP, V111, P825, DOI 10.1289/ehp.111-1241504; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Hinkal G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006654; Huang YL, 2008, CANCER RES, V68, P9131, DOI 10.1158/0008-5472.CAN-08-3025; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lamm SH, 2004, J OCCUP ENVIRON MED, V46, P298, DOI 10.1097/01.jom.0000116801.67556.8f; Mahata J, 2004, MUTAGENESIS, V19, P223, DOI 10.1093/mutage/geh022; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Tergaonkar V, 2007, MOL CELL, V26, P158, DOI 10.1016/j.molcel.2007.04.006; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0	16	19	20	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1359	1366		10.1038/onc.2013.81	http://dx.doi.org/10.1038/onc.2013.81			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23524579	Green Accepted, Green Submitted			2022-12-17	WOS:000332943500003
J	Berglund, FM; Weerasinghe, NR; Davidson, L; Lim, JC; Eickholt, BJ; Leslie, NR				Berglund, F. M.; Weerasinghe, N. R.; Davidson, L.; Lim, J. C.; Eickholt, B. J.; Leslie, N. R.			Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110 alpha/PIK3CA but not by HER2 or mutant AKT1	ONCOGENE			English	Article						phosphoinositides; phosphoinositide 3-kinase; epithelia; breast cancer; AKT; cell polarity	LIPID PHOSPHATASE PTEN; CELL-POLARITY; PIK3CA MUTATIONS; BREAST-CANCER; MAMMARY-GLAND; PROLIFERATION; MORPHOGENESIS; TUMORIGENESIS; PATHWAY; EXPRESSION	Genetic changes in HER2, PTEN, PIK3CA and AKT1 are all common in breast cancer and lead to the elevated phosphorylation of downstream targets of the PI3K/AKT signalling pathway. Changes in HER2, PTEN, PIK3CA and AKT have all been reported to lead to both enhanced proliferation and failures in hollow lumen formation in three dimensional epithelial culture models, but it is not clear whether these failures in lumen formation are caused by any failure in the spatial coordination of lumen formation (hollowing) or purely a failure in the apoptosis and clearance of luminal cells (cavitation). Here, we use normal murine mammary gland (NMuMG) epithelial cells, which form a hollow lumen without significant apoptosis, to compare the transformation by these four genetic changes. We find that either mutant PIK3CA expression or PTEN loss, but not mutant AKT1 E17K, cause disrupted epithelial architecture, whereas HER2 overexpression drives strong proliferation without affecting lumen formation in these cells. We also show that PTEN requires both lipid and protein phosphatase activity, its extreme C-terminal PDZ binding sequence and probably Myosin 5A to control lumen formation through a mechanism that does not correlate with its ability to control AKT, but which is selectively lost through mutation in some tumours. These findings correlate AKT-independent signalling activated by mutant PIK3CA or PTEN loss, but not strongly by HER2, with disrupted epithelial architecture and tumour formation.	[Berglund, F. M.; Weerasinghe, N. R.; Davidson, L.; Lim, J. C.; Leslie, N. R.] Univ Dundee, Coll Life Sci, Div Cell Signalling & Immunol, Dundee DD1 5EH, Scotland; [Eickholt, B. J.] Charite, Cluster Excellence NeuroCure, D-13353 Berlin, Germany; [Eickholt, B. J.] Inst Biochem, Berlin, Germany	University of Dundee; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Leslie, NR (corresponding author), Univ Dundee, Coll Life Sci, Div Cell Signalling & Immunol, Dow St, Dundee DD1 5EH, Scotland.	n.r.leslie@dundee.ac.uk	Eickholt, Britta/C-5337-2009	Eickholt, Britta/0000-0001-7873-8687; LESLIE, Nicholas/0000-0001-5131-0541	Association for International Cancer Research; Wellcome Trust; Medical Research Council; DSTT consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono and Pfizer); MRC [G0802289, G0801865, G9403619] Funding Source: UKRI; Medical Research Council [G0801865, G0802289, G9403619] Funding Source: researchfish	Association for International Cancer Research; Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); DSTT consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono and Pfizer); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Jon Backer (Albert Einstein College of Medicine) and Dario Alessi, David Meek, Francis Fuller-Pace, Virginia Appleyard, Alastair Thompson, Emily Davis, John Rouse, Inke Nathke and Paul Crocker (all University of Dundee) for reagents and Peter Downes (University of Dundee) for helpful discussions. We thank Sam Swift, Paul Appleton, Martin Kierans and John James (University of Dundee, CHIPS microscopy facility) for assistance with light and electron microscopy. FB and JCL have been funded by a project grant from the Association for International Cancer Research and NRW is a Wellcome Trust Prize Student. Work in the Inositol Lipid Signalling laboratory is funded by the Medical Research Council, the Association for International Cancer Research and the pharmaceutical companies of the DSTT consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono and Pfizer). We wish to dedicate this work to the memory of Joseph Lim, a valued colleague and friend.	Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Datta A, 2011, CURR BIOL, V21, pR126, DOI 10.1016/j.cub.2010.12.003; Davidson L, 2010, ONCOGENE, V29, P687, DOI 10.1038/onc.2009.384; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dunlap J, 2010, BREAST CANCER RES TR, V120, P409, DOI 10.1007/s10549-009-0406-1; Duronio V, 2008, BIOCHEM J, V415, P333, DOI 10.1042/BJ20081056; Feng W, 2008, J BIOL CHEM, V283, P23440, DOI 10.1074/jbc.M802482200; Gonzalez-Angulo AM, 2009, CLIN CANCER RES, V15, P2472, DOI 10.1158/1078-0432.CCR-08-1763; Han SY, 2000, CANCER RES, V60, P3147; Hogan C, 2009, NAT CELL BIOL, V11, P460, DOI 10.1038/ncb1853; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108; Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238; Lauring J, 2010, ONCOGENE, V29, P2337, DOI 10.1038/onc.2009.516; Leslie NR, 2008, ONCOGENE, V27, P5464, DOI 10.1038/onc.2008.243; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Li G, 2002, DEVELOPMENT, V129, P4159; Lin HH, 1999, KIDNEY INT, V55, P168, DOI 10.1046/j.1523-1755.1999.00249.x; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Marsh V, 2008, NAT GENET, V40, P1436, DOI 10.1038/ng.256; Martin-Belmonte F, 2008, CURR BIOL, V18, P507, DOI 10.1016/j.cub.2008.02.076; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; McCaffrey LM, 2011, TRENDS CELL BIOL, V21, P727, DOI 10.1016/j.tcb.2011.06.005; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pang H, 2009, CANCER RES, V69, P8868, DOI 10.1158/0008-5472.CAN-09-1968; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Pinal N, 2006, CURR BIOL, V16, P140, DOI 10.1016/j.cub.2005.11.068; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; STOKER M, 1985, J CELL SCI, V77, P209; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Tibarewal P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002138; van Diepen MT, 2009, NAT CELL BIOL, V11, P1191, DOI 10.1038/ncb1961; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045	53	19	20	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4417	4426		10.1038/onc.2012.459	http://dx.doi.org/10.1038/onc.2012.459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085752	Green Accepted			2022-12-17	WOS:000324404200010
J	Castelli, M; Pieroni, S; Brunacci, C; Piobbico, D; Bartoli, D; Bellet, MM; Colombo, E; Pelicci, PG; Della Fazia, MA; Servillo, G				Castelli, M.; Pieroni, S.; Brunacci, C.; Piobbico, D.; Bartoli, D.; Bellet, M. M.; Colombo, E.; Pelicci, P. G.; Della Fazia, M. A.; Servillo, G.			Hepatocyte odd protein shuttling (HOPS) is a bridging protein in the nucleophosmin-p19(Arf) network	ONCOGENE			English	Article						nucleophosmin (NPM); p19(Arf); hepatocyte odd protein shuttling (HOPS); Tmub1; tumor suppressor gene	ACUTE MYELOID-LEUKEMIA; ARF TUMOR-SUPPRESSOR; ACUTE MYELOGENOUS LEUKEMIA; CYTOPLASMIC NUCLEOPHOSMIN; NORMAL KARYOTYPE; NPMC(+) AML; STABILITY; B23; TUMORIGENESIS; MUTATIONS	Nucleophosmin (NPM), a ubiquitously and abundantly expressed protein, occurs in the nucleolus, shuttling between the nucleoplasm and cytoplasm. The NPM gene is mutated in almost 30% of human acute myeloid leukemia cells. NPM interacts with p53 and p19(Arf), directs localization of p19(Arf) in the nucleolus and protects the latter from degradation. Hepatocyte odd protein shuttling (HOPS) is also a ubiquitously expressed protein that moves between the nucleus and cytoplasm. Within the nucleus of resting cells, HOPS overexpression causes cell cycle arrest in G0/G1. HOPS knockdown causes centrosome hyperamplification leading to multinucleated cells and the formation of micronuclei. We demonstrate a direct interaction of HOPS with NPM and p19(Arf), resulting in a functionally active trimeric complex. NPM appeared to regulate HOPS half-life, which, in turn, stabilized p19(Arf) and controlled its localization in the nucleolus. These findings suggest that HOPS acts as a functional bridge in the interaction between NPM and p19(Arf), providing new mechanistic insight into how NPM and p19(Arf) will oppose tumor cell proliferation.	[Castelli, M.; Pieroni, S.; Brunacci, C.; Piobbico, D.; Bartoli, D.; Bellet, M. M.; Della Fazia, M. A.; Servillo, G.] Univ Perugia, Dept Clin & Expt Med, I-06124 Perugia, Italy; [Colombo, E.; Pelicci, P. G.] Inst Europeo Oncol, Dept Expt Oncol, Milan, Italy	University of Perugia; IRCCS European Institute of Oncology (IEO)	Servillo, G (corresponding author), Univ Perugia, Dept Clin & Expt Med, Via E dal Pozzo,Pad AW, I-06124 Perugia, Italy.	giuseppe.servillo@unipg.it	Colombo, Emanuela/AAO-8113-2020; Colombo, Emanuela/AAO-7810-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Bellet, Marina Maria/K-7794-2016	Colombo, Emanuela/0000-0003-2079-7398; Bellet, Marina Maria/0000-0001-7604-0189; Della Fazia, Maria Agnese/0000-0002-5373-8477; Servillo, Giuseppe/0000-0001-7960-7689; Piobbico, Danilo/0000-0003-4240-1526	Associazione Umbra Contro il Cancro (AUCC); Fondazione Guido Berlucchi; Associazione Italiana Ricerca sul Cancro (AIRC); Only the Brave Foundation; Fondazione Cassa di Risparmio di Perugia; PRIN Project [2008BH7KA2_003]; AUCC fellowship program	Associazione Umbra Contro il Cancro (AUCC); Fondazione Guido Berlucchi; Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Only the Brave Foundation; Fondazione Cassa di Risparmio di Perugia; PRIN Project(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AUCC fellowship program	We thank Paolo Puccetti and Stefano Brancorsini for the critical reading of the manuscript, Silvano Pagnotta for technical assistance. This study was supported by grants from the Associazione Umbra Contro il Cancro (AUCC), Fondazione Guido Berlucchi, the Associazione Italiana Ricerca sul Cancro (AIRC), Only the Brave Foundation and Fondazione Cassa di Risparmio di Perugia. GS is recipient of a PRIN Project n. 2008BH7KA2_003. DB, CB and DP are recipient of the AUCC fellowship program.	Alcalay M, 2005, BLOOD, V106, P899, DOI 10.1182/blood-2005-02-0560; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Braoudaki M, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-41; Brunacci C, 2010, LIVER INT, V30, P388, DOI 10.1111/j.1478-3231.2009.02174.x; Campisi J, 2007, AGING CELL, V6, P261, DOI 10.1111/j.1474-9726.2007.00292.x; Cazzaniga G, 2005, BLOOD, V106, P1419, DOI 10.1182/blood-2005-03-0899; Chou WC, 2006, CANCER RES, V66, P3310, DOI 10.1158/0008-5472.CAN-05-4316; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cordell JL, 1999, BLOOD, V93, P632, DOI 10.1182/blood.V93.2.632; Coutts AS, 2007, CELL CYCLE, V6, P827, DOI 10.4161/cc.6.7.4086; Della Fazia MA, 2005, J CELL SCI, V118, P3185, DOI 10.1242/jcs.02452; den Besten W, 2005, CELL CYCLE, V4, P1593; Enomoto T, 2006, J BIOL CHEM, V281, P18463, DOI 10.1074/jbc.M602788200; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Gjerset RA, 2006, CELL CYCLE, V5, P686, DOI 10.4161/cc.5.7.2623; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Moulin S, 2008, ONCOGENE, V27, P2382, DOI 10.1038/sj.onc.1210887; Pasqualucci L, 2006, BLOOD, V108, P4146, DOI 10.1182/blood-2006-06-026716; Pieroni S, 2008, CELL CYCLE, V7, P1462, DOI 10.4161/cc.7.10.5882; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shinmura K, 2005, FEBS LETT, V579, P6621, DOI 10.1016/j.febslet.2005.10.057; Szebeni A, 1999, PROTEIN SCI, V8, P905; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Yang HJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002809; Zhang WD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011261	38	19	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2013	32	28					3350	3358		10.1038/onc.2012.353	http://dx.doi.org/10.1038/onc.2012.353			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22890319				2022-12-17	WOS:000321620200005
J	Kobayashi, K; Jakt, LM; Nishikawa, SI				Kobayashi, K.; Jakt, L. M.; Nishikawa, S-I			Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn	ONCOGENE			English	Article						Arid3b; Mycn; neuroblastoma; embryonic stems cell; molecular network for pluripotency; epigenetics	CELL-DIFFERENTIATION CULTURE; PLURIPOTENT STEM-CELLS; EMBRYONIC STEM; GROUND-STATE; SELF-RENEWAL; NETWORK; CANCER; TRANSCRIPTION; TRANSGENE; ENDODERM	AT-rich interaction domain molecule 3B (ARID3B) and MYCN are expressed in a portion of neuroblastoma, and form a combination that has strong oncogenic activity in mouse embryonic fibroblasts (MEFs). Here, we show that this combination can also convert neural stem cells to neuroblastoma-like tumor. To address whether there are common mechanisms regulating the expression of this combination of genes, we examined public repositories of gene expression data and found that although these genes are rarely expressed together, co-expression was observed in a proportion of germ cell tumors (GCTs), in embryonic stem (ES) cells and in testis. These cell types and tissues are related to pluripotency and we show here that in mouse ES cells, Arid3b and Mycn are indeed involved in cell proliferation; the former in avoiding cell death and the latter in driving cell cycle progression. Accordingly, the two genes are induced during somatic cell reprogramming to iPS, and this induction is accompanied by the switching of promoter histone marks from H3K27me3 to H3K4me3. Conversely, the switch from H3K4me3 to H3K27me3 in these genes occurs during the differentiation of neural crest to mature sympathetic ganglia cells. In many, if not most, neuroblastomas these genes carry H3K4me3 marks within their promoters. Thus, a failure of the epigenetic silencing of these genes during development may be an underlying factor responsible for neuroblastoma.	[Kobayashi, K.; Jakt, L. M.; Nishikawa, S-I] RIKEN, Ctr Dev Biol, Lab Stem Cell Biol, Kobe, Hyogo 6500047, Japan	RIKEN	Kobayashi, K (corresponding author), RIKEN, Ctr Dev Biol, Lab Stem Cell Biol, Kobe, Hyogo 6500047, Japan.	kkobayashi@cdb.riken.jp		Jakt, Lars Martin/0000-0002-3787-8138	Grants-in-Aid for Scientific Research [20229005] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Aiden AP, 2010, CELL STEM CELL, V6, P591, DOI 10.1016/j.stem.2010.03.016; Ban H, 2011, P NATL ACAD SCI USA, V108, P14234, DOI 10.1073/pnas.1103509108; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Guo G, 2009, DEVELOPMENT, V136, P1063, DOI 10.1242/dev.030957; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kobayashi K, 2006, CANCER RES, V66, P8331, DOI 10.1158/0008-5472.CAN-06-0756; Larsson LG, 2010, EXP CELL RES, V316, P1429, DOI 10.1016/j.yexcr.2010.03.025; Li ZL, 2009, CELL CYCLE, V8, P2703, DOI 10.4161/cc.8.17.9418; Maris JM, 2002, CANCER CELL, V2, P447, DOI 10.1016/S1535-6108(02)00206-4; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Miyoshi Hiroyuki, 2004, Methods Mol Biol, V246, P429; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Nakagawara A, 2004, PROG BRAIN RES, V146, P233, DOI 10.1016/S0079-6123(03)46015-9; Nishishita N, 2011, BIOMATERIALS, V32, P3555, DOI 10.1016/j.biomaterials.2010.12.063; Numata S, 1999, CANCER RES, V59, P3741; Pardo M, 2010, CELL STEM CELL, V6, P382, DOI 10.1016/j.stem.2010.03.004; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; SAWAI S, 1993, DEVELOPMENT, V117, P1445; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Smith KN, 2010, CELL STEM CELL, V7, P343, DOI 10.1016/j.stem.2010.06.023; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Tachibana M, 2008, EMBO J, V27, P2681, DOI 10.1038/emboj.2008.192; Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takebe A, 2006, DEV BIOL, V293, P25, DOI 10.1016/j.ydbio.2005.12.016; Varlakhanova NV, 2010, DIFFERENTIATION, V80, P9, DOI 10.1016/j.diff.2010.05.001; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Yoshimizu T, 1999, DEV GROWTH DIFFER, V41, P675	34	19	19	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 23	2013	32	21					2640	2648		10.1038/onc.2012.285	http://dx.doi.org/10.1038/onc.2012.285			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22751132	hybrid, Green Published			2022-12-17	WOS:000319806700005
J	Mythreye, K; Knelson, EH; Gatza, CE; Gatza, ML; Blobe, GC				Mythreye, K.; Knelson, E. H.; Gatza, C. E.; Gatza, M. L.; Blobe, G. C.			T beta RIII/beta-arrestin2 regulates integrin alpha 5 beta 1 trafficking, function, and localization in epithelial cells	ONCOGENE			English	Article						integrin alpha 5 beta 1; beta-arrestin2; TGF-beta; betaglycan	TGF-BETA RECEPTOR; FOCAL ADHESION KINASE; CANCER; BETAGLYCAN; PROTEIN; ALPHA-V-BETA-3; EXPRESSION; MEMBRANE; BINDING; INVASIVENESS	The type III TGF-beta receptor (T beta RIII) is a ubiquitous co-receptor for TGF-beta superfamily ligands with roles in suppressing cancer progression, in part through suppressing cell motility. Here we demonstrate that T beta RIII promotes epithelial cell adhesion to fibronectin in a beta-arrestin2 dependent and TGF-beta/BMP independent manner by complexing with active integrin alpha 5 beta 1, and mediating beta-arrestin2-dependent alpha 5 beta 1 internalization and trafficking to nascent focal adhesions. T beta RIII-mediated integrin alpha 5 beta 1 trafficking regulates cell adhesion and fibronectin fibrillogenesis in epithelial cells, as well as alpha 5 localization in breast cancer patients. We further demonstrate that increased T beta RIII expression correlates with increased alpha 5 localization at sites of cell-cell adhesion in breast cancer patients, while higher T beta RIII expression is a strong predictor of overall survival in breast cancer patients. These data support a novel, clinically relevant role for T beta RIII in regulating integrin alpha 5 localization, reveal a novel crosstalk mechanism between the integrin and TGF-beta superfamily signaling pathways and identify beta-arrestin2 as a regulator of alpha 5 beta 1 trafficking. Oncogene (2013) 32, 1416-1427; doi:10.1038/onc.2012.157; published online 7 May 2012	[Mythreye, K.; Gatza, C. E.; Blobe, G. C.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27708 USA; [Knelson, E. H.; Blobe, G. C.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA; [Gatza, M. L.] Duke Univ, Med Ctr, Duke IGSP, Durham, NC 27708 USA	Duke University; Duke University; Duke University	Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Med, B354 LSRC,Box 91004 DUMC, Durham, NC 27708 USA.	blobe001@mc.duke.edu	Blobe, Gerard/AAJ-5945-2020; Karthikeyan, Mythreye/ABC-7345-2020	Blobe, Gerard/0000-0002-4274-8901; Karthikeyan, Mythreye/0000-0001-5478-0098; Knelson, Erik/0000-0003-4087-2017; Gatza, Michael/0000-0001-6796-7791	NIH Grants [R01-CA135006, R01-CA136786]; Komen for the Cure Grants [KG090154, SAC100002]; Department of Defense grant [W81 XWH-09-1-0265]; NATIONAL CANCER INSTITUTE [R01CA136786, R01CA135006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171] Funding Source: NIH RePORTER	NIH Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Komen for the Cure Grants; Department of Defense grant(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We sincerely thank Sue Craig and Martin Humphries for generously providing us with SNAKA51, L. Attisano for BMPRII construct, Tam How and Alisha Holtzhausen for technical help in generation of the ratT beta RIII-T841A plasmid and plasmid purifications respectively, Duke University Light Microscopy facility for help in training individuals with the use of the TIRFM and confocal microscopes. This work was supported in part by NIH Grants R01-CA135006 and R01-CA136786 (GCB), Komen for the Cure Grants KG090154 and SAC100002 (GCB) and Department of Defense grant W81 XWH-09-1-0265 (KM).	AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Bilandzic M, 2011, MOL CELL ENDOCRINOL, V28; Bilandzic M, 2009, MOL ENDOCRINOL, V23, P539, DOI 10.1210/me.2008-0300; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; BRETSCHER MS, 1992, EMBO J, V11, P383, DOI 10.1002/j.1460-2075.1992.tb05066.x; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Clark K, 2005, J CELL SCI, V118, P291, DOI 10.1242/jcs.01623; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DeFea KA, 2007, ANNU REV PHYSIOL, V69, P535, DOI 10.1146/annurev.physiol.69.022405.154804; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; Finger EC, 2008, CARCINOGENESIS, V29, P528, DOI 10.1093/carcin/bgm289; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Gordon KJ, 2008, CARCINOGENESIS, V29, P252, DOI 10.1093/carcin/bgm249; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hempel N, 2007, CANCER RES, V67, P5231, DOI 10.1158/0008-5472.CAN-07-0035; Kirkbride KC, 2008, J BIOL CHEM, V283, P7628, DOI 10.1074/jbc.M704883200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; Lee NY, 2009, MOL BIOL CELL, V20, P4362, DOI 10.1091/mbc.E09-07-0539; Lee-Hoeflich ST, 2004, EMBO J, V23, P4792, DOI 10.1038/sj.emboj.7600418; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Molteni R, 2009, BLOOD, V114, P1073, DOI 10.1182/blood-2008-10-183699; Morgan MR, 2009, IUBMB LIFE, V61, P731, DOI 10.1002/iub.200; Mythreye K, 2009, CELL SIGNAL, V8; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Nam JM, 2010, CANCER RES, V70, P5238, DOI 10.1158/0008-5472.CAN-09-2319; PARSONS JT, 1994, J CELL SCI, P109; Pellinen T, 2006, J CELL SCI, V119, P3723, DOI 10.1242/jcs.03216; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Roberts MS, 2004, MOL CELL BIOL, V24, P1505, DOI 10.1128/MCB.24.4.1505-1515.2004; Robertson D, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-13; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Toutant M, 2002, MOL CELL BIOL, V22, P7731, DOI 10.1128/MCB.22.22.7731-7743.2002; Turley RS, 2007, CANCER RES, V67, P1090, DOI 10.1158/0008-5472.CAN-06-3117; White DP, 2007, J CELL BIOL, V177, P515, DOI 10.1083/jcb.200609004; Woods AJ, 2004, EMBO J, V23, P2531, DOI 10.1038/sj.emboj.7600267; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; You HJ, 2007, CARCINOGENESIS, V28, P2491, DOI 10.1093/carcin/bgm195; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	53	19	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1416	1427		10.1038/onc.2012.157	http://dx.doi.org/10.1038/onc.2012.157			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22562249	Green Accepted			2022-12-17	WOS:000316455600008
J	Lee, PC; Lee, HJ; Kakadiya, R; Sanjiv, K; Su, TL; Lee, TC				Lee, P-C; Lee, H-J; Kakadiya, R.; Sanjiv, K.; Su, T-L; Lee, T-C			Multidrug-resistant cells overexpressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src/nuclear EGFR cascade-activated DNA repair activity	ONCOGENE			English	Article						DNA crosslinking agents; nnultidrug resistance; Src/nuclear EGFR cascade; DNA repair; DNA-PK nuclear translocation	GROWTH-FACTOR RECEPTOR; DEPENDENT PROTEIN-KINASE; HAMSTER OVARY CELLS; STRAND BREAK REPAIR; IN-VITRO; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; HUMAN CANCER; TUMOR-CELLS; SRC	We synthesized several novel bifunctional alkylating derivatives of 3a-aza-cyclopenta[a]indene (BO-1012, BO-1005, BO-1099 and BO-1101) that are potent DNA interstrand crosslinking agents. In in vitro cytotoxicity assay, these compounds were more cytotoxic to multidrug-resistant (MDR) cells, such as KBvin10, KBtax50 and CEM/VBL, than their parental cells. Using a xenograft model, BO-1012, at a dose of 5 mg/kg, partially suppressed the growth of parental KB cells but completely suppressed the growth of KBvin10 cells in nude mice. In exploring the possible mechanism, we found that DNA double-strand break (DSB) repair activity in MDR cells, KBvin10 and CEM/VBL, was significantly reduced compared with their parental cells, KB and CEM. Reduced DSB repair activity in KBvin10 cells was likely due to a defect in nuclear translocation of DNA-dependent protein kinase (DNA-PK), a component of the non-homologous end-joining repair machinery. Furthermore, BO-1012-induced DNA-PK translocation from the cytosol into the nucleus in KB cells is associated with the activation of the Src/nuclear epidermal growth factor receptor (EGFR) cascade, which is defective in MDR cells. As knockdown of P-glycoprotein (P-gp) by siRNA reactivated the Src/nuclear EGFR cascade, DNA-PK translocation and DNA repair activity in MDR cells, overexpression of P-gp attenuates the activity of DNA DSB repair through suppression of Src/nuclear EGFR cascade. Therefore, DNA interstrand crosslinking agents may have potential therapeutic use against P-gp-overexpressing MDR cells. Oncogene (2013) 32, 1144-1154; doi:10.1038/onc.2012.133; published online 23 April 2012	[Lee, P-C; Lee, H-J; Kakadiya, R.; Sanjiv, K.; Su, T-L; Lee, T-C] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Lee, P-C; Lee, T-C] Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Lee, TC (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.	tlsu@ibms.sinica.edu.tw; bmtcl@ibms.sinica.edu.tw			Academia Sinica [AS-96-TP-B06, AS-100-TP-B13]; National Science Councils, Taiwan (ROC) [NSC-100-2325-B-001-003]	Academia Sinica(Academia Sinica - Taiwan); National Science Councils, Taiwan (ROC)	We thank Dr Ling-Hui Yih for helpful suggestions and critical comments. This work was supported by grants from the Academia Sinica (AS-96-TP-B06 and AS-100-TP-B13) and the National Science Councils (NSC-100-2325-B-001-003), Taiwan (ROC).	Aleshin A, 2010, NEOPLASIA, V12, P599, DOI 10.1593/neo.10328; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Bell SE, 1998, BRIT J CANCER, V78, P1464, DOI 10.1038/bjc.1998.708; Bergman AM, 2003, BRIT J CANCER, V88, P1963, DOI 10.1038/sj.bjc.6601011; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Borowski E, 2005, ACTA BIOCHIM POL, V52, P609; Bradshaw JM, 2010, CELL SIGNAL, V22, P1175, DOI 10.1016/j.cellsig.2010.03.001; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; Chaniyara R, 2011, BIOORGAN MED CHEM, V19, P275, DOI 10.1016/j.bmc.2010.11.030; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dittmann K, 2011, RADIOTHER ONCOL, V99, P317, DOI 10.1016/j.radonc.2011.06.001; Dittmann K, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-69; Egloff AM, 2008, SEMIN ONCOL, V35, P286, DOI 10.1053/j.seminoncol.2008.03.008; ERBA E, 1995, INT J CANCER, V62, P170, DOI 10.1002/ijc.2910620211; FORD JM, 1990, PHARMACOL REV, V42, P155; Friedmann BJ, 2006, MOL CANCER THER, V5, P209, DOI 10.1158/1535-7163.MCT-05-0239; Frosina G, 2009, MOL CANCER RES, V7, P989, DOI 10.1158/1541-7786.MCR-09-0030; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; GUPTA RS, 1985, CANCER TREAT REP, V69, P515; Hall MD, 2011, J MED CHEM, V54, P5878, DOI 10.1021/jm2006047; Hall MD, 2009, TRENDS PHARMACOL SCI, V30, P546, DOI 10.1016/j.tips.2009.07.003; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; He SN, 2010, INT J MOL SCI, V11, P3039, DOI 10.3390/ijms11093039; Huo LF, 2010, P NATL ACAD SCI USA, V107, P16125, DOI 10.1073/pnas.1000743107; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Juang SH, 2007, MOL CANCER THER, V6, P193, DOI 10.1158/1535-7163.MCT-06-0482; Kakadiya R, 2009, BIOORGAN MED CHEM, V17, P5614, DOI 10.1016/j.bmc.2009.06.018; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kimura Y, 2004, MICROBIOL-SGM, V150, P631, DOI 10.1099/mic.0.26786-0; Lage H, 2006, CURR DRUG TARGETS, V7, P813, DOI 10.2174/138945006777709566; Lai KC, 2008, MOL CANCER RES, V6, P1431, DOI 10.1158/1541-7786.MCR-08-0141; Lee CH, 2010, METHODS MOL BIOL, V596, P325, DOI 10.1007/978-1-60761-416-6_14; Lee PC, 2010, NEOPLASIA, V12, P376, DOI 10.1593/neo.10110; LEE TC, 1994, CANCER RES, V54, P1660; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Lurje G, 2009, ONCOLOGY-BASEL, V77, P400, DOI 10.1159/000279388; Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834; Medunjanin S, 2010, MOL BIOL CELL, V21, P1620, DOI 10.1091/mbc.E09-08-0724; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Miyagawa K, 2008, CANCER SCI, V99, P187, DOI 10.1111/j.1349-7006.2007.00644.x; Norgaard JM, 1998, BRIT J HAEMATOL, V100, P534, DOI 10.1046/j.1365-2141.1998.00593.x; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Pan GD, 2009, WORLD J GASTROENTERO, V15, P431, DOI 10.3748/wjg.15.431; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; RONINSON IB, 1992, BIOCHEM PHARMACOL, V43, P95, DOI 10.1016/0006-2952(92)90666-7; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Szumiel I, 2006, CELL SIGNAL, V18, P1537, DOI 10.1016/j.cellsig.2006.03.010; Takara K, 2006, CURR PHARM DESIGN, V12, P273, DOI 10.2174/138161206775201965; Turk D, 2009, CANCER RES, V69, P8293, DOI 10.1158/0008-5472.CAN-09-2422; WANG HF, 1993, BIOCHEM BIOPH RES CO, V192, P1093, DOI 10.1006/bbrc.1993.1529; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yih LH, 2006, CANCER RES, V66, P2098, DOI 10.1158/0008-5472.CAN-05-2308	62	19	19	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2013	32	9					1144	1154		10.1038/onc.2012.133	http://dx.doi.org/10.1038/onc.2012.133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22525278				2022-12-17	WOS:000316428800008
J	Sher, YP; Chang, CM; Juo, CG; Chen, CT; Hsu, JL; Lin, CY; Han, Z; Shiah, SG; Hung, MC				Sher, Y-P; Chang, C-M; Juo, C-G; Chen, C-T; Hsu, J. L.; Lin, C-Y; Han, Z.; Shiah, S-G; Hung, M-C			Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth	ONCOGENE			English	Article						ovarian cancer; anti-angiogenesis; VISA; gene therapy	EXPRESSION; CANCER; SURVIVIN; DELIVERY; CELLS; YEAST; 5-FLUOROURACIL; ANGIOGENESIS; CHEMOTHERAPY; CISPLATIN	There are currently no effective therapies for cancer patients with advanced ovarian cancer, therefore developing an efficient and safe strategy is urgent. To ensure cancer-specific targeting, efficient delivery, and efficacy, we developed an ovarian cancer-specific construct (Survivin-VISA-hEndoyCD) composed of the cancer specific promoter survivin in a transgene amplification vector (VISA; VP16-GAL4-WPRE integrated systemic amplifier) to express a secreted human endostatin-yeast cytosine deaminase fusion protein (hEndoyCD) for advanced ovarian cancer treatment. hEndoyCD contains an endostatin domain that has tumor-targeting ability for anti-angiogenesis and a cytosine deaminase domain that converts the prodrug 5-fluorocytosine (5-FC) into the chemotherapeutic drug, 5-fluorouracil. Survivin-VISA-hEndoyCD was found to be highly specific, selectively express secreted hEndoyCD from ovarian cancer cells, and induce cancer-cell killing in vitro and in vivo in the presence of 5-FC without affecting normal cells. In addition, Survivin-VISA-hEndoyCD plus 5-FC showed strong synergistic effects in combination with cisplatin in ovarian cancer cell lines. Intraperitoneal (i.p.) treatment with Survivin-VISA-hEndoyCD coupled with liposome attenuated tumor growth and prolonged survival in mice bearing advanced ovarian tumors. Importantly, there was virtually no severe toxicity when hEndoyCD is expressed by Survivin-VISA plus 5-FC compared with CMV plus 5-FC. Thus, the current study demonstrates an effective cancer-targeted gene therapy that is worthy of development in clinical trials for treating advanced ovarian cancer. Oncogene (2013) 32, 1082-1090; doi:10.1038/onc.2012.134; published online 7 May 2012	[Sher, Y-P; Chang, C-M; Hung, M-C] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Lin, C-Y] China Med Univ Hosp, Div Hematol & Oncol, Taichung, Taiwan; [Sher, Y-P; Lin, C-Y] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Hung, M-C] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Juo, C-G] Chang Gung Univ, Mol Med Res Ctr, Tao Yuan, Taiwan; [Shiah, S-G] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan; [Chen, C-T; Hsu, J. L.; Han, Z.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hsu, J. L.; Hung, M-C] Asia Univ, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; Chang Gung University; National Health Research Institutes - Taiwan; University of Texas System; UTMD Anderson Cancer Center; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mdanderson.org	Shiah, Shine-Gwo/D-2087-2010; Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	National Science Council [NSC100-3112-B-039-003]; Private University [N5C99-2314-B-039-029-MY3, NSC99-2632-B]; Department of Health Cancer Research Center of Excellence [DOH99-TD-C-111-005]; Sister Institution Fund of China Medical University and Hospital; University of Texas MD Anderson Cancer Center	National Science Council(Ministry of Science and Technology, Taiwan); Private University; Department of Health Cancer Research Center of Excellence; Sister Institution Fund of China Medical University and Hospital; University of Texas MD Anderson Cancer Center	This work was supported by grants from National Science Council (NSC100-3112-B-039-003), Private University (N5C99-2314-B-039-029-MY3 to Y-PS and NSC99-2632-B to M-CH), Department of Health Cancer Research Center of Excellence (DOH99-TD-C-111-005), and The Sister Institution Fund of China Medical University and Hospital and The University of Texas MD Anderson Cancer Center.	Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chen CT, 2011, MOL CANCER THER, V10, P1327, DOI 10.1158/1535-7163.MCT-10-1117; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dixelius J, 2002, CANCER RES, V62, P1944; Erbs P, 2000, CANCER RES, V60, P3813; Glover CPJ, 2002, MOL THER, V5, P509, DOI 10.1006/mthe.2002.0588; Gunther Michael, 2005, Curr Med Chem Anticancer Agents, V5, P157, DOI 10.2174/1568011053174855; Hydzik Catherine, 2009, Oncology (Williston Park), V23, P15; Iyer M, 2001, P NATL ACAD SCI USA, V98, P14595, DOI 10.1073/pnas.251551098; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kievit E, 1999, CANCER RES, V59, P1417; Kim YM, 2000, CANCER RES, V60, P5410; KISH JA, 1988, AM J CLIN ONCOL-CANC, V11, P553, DOI 10.1097/00000421-198810000-00009; Lang JY, 2011, CANCER CELL, V20, P341, DOI 10.1016/j.ccr.2011.07.017; Li FZ, 2006, J CELL PHYSIOL, V208, P476, DOI 10.1002/jcp.20634; Markman M, 2009, CANCER J, V15, P105, DOI 10.1097/PPO.0b013e31819e31f2; Miller DS, 2009, J CLIN ONCOL, V27, P2686, DOI 10.1200/JCO.2008.19.2963; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; OLSON TA, 1994, CANCER RES, V54, P276; Ou-Yang F, 2006, CANCER RES, V66, P378, DOI 10.1158/0008-5472.CAN-05-1578; Parsons SL, 1996, EUR J SURG ONCOL, V22, P237, DOI 10.1016/S0748-7983(96)80009-6; Pisano R, 2005, J PHARMACEUT BIOMED, V38, P738, DOI 10.1016/j.jpba.2005.01.039; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Sher YP, 2009, ONCOGENE, V28, P3286, DOI 10.1038/onc.2009.187; Sim BKL, 2000, CANCER METAST REV, V19, P181, DOI 10.1023/A:1026551202548; Subramanian IV, 2006, CANCER RES, V66, P4319, DOI 10.1158/0008-5472.CAN-05-3297; Sui L, 2002, INT J ONCOL, V21, P315; Tanaka T, 2001, ANTICANCER RES, V21, P2463; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Xie XM, 2009, MOL CANCER THER, V8, P2375, DOI 10.1158/1535-7163.MCT-09-0056; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; YU DH, 1993, CANCER RES, V53, P891; Zaffaroni N, 2005, J CELL MOL MED, V9, P360, DOI 10.1111/j.1582-4934.2005.tb00361.x; Zhang LQ, 2003, CANCER RES, V63, P4552; Zhang M, 2003, CANCER RES, V63, P658; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	40	19	20	0	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1082	1090		10.1038/onc.2012.134	http://dx.doi.org/10.1038/onc.2012.134			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22562248				2022-12-17	WOS:000316428800002
J	Bensimon, J; Altmeyer-Morel, S; Benjelloun, H; Chevillard, S; Lebeau, J				Bensimon, J.; Altmeyer-Morel, S.; Benjelloun, H.; Chevillard, S.; Lebeau, J.			CD24(-/low) stem-like breast cancer marker defines the radiation-resistant cells involved in memorization and transmission of radiation-induced genomic instability	ONCOGENE			English	Article						radiation effects; breast cancer stem cells; genomic instability	IONIZING-RADIATION; CD24 EXPRESSION; INITIATING CELLS; GROWTH ARREST; DNA-DAMAGE; TUMOR CELL; METASTASIS; DEATH; PROPAGATION; MECHANISMS	A growing body of evidence attributes properties of chemo- and/or radiation-resistance to cancer stem cells (CSCs). Moreover, non-targeted delayed effects such as genomic instability, transmitted through many generations, can be observed in the progeny of surviving irradiated cells. As a consequence, we propose that radiation-resistance properties associated to CSCs could confer a key role to this subpopulation in the transmission of genomic instability. To test this hypothesis, we searched the CSC markers associated to radiation-resistance in breast cancer cell lines and studied the role of the resistant cells in the transmission of genomic instability. First, we show that irradiation induces a 2-4 weeks period of intense cell death leading to the emergence of chromosomal unstable cells during more than 35 population doublings. Then, among seven breast CSC markers, we identify CD24(-/low) labelling as a marker of radiation-resistance. We demonstrate that CD24(+) progeny of irradiated cells exclusively descends from CD24(-/low) cells. Finally, we show that delayed chromosomal instability is only expressed by CD24(+) cells, but is transmitted by stable surviving CD24(-/low) cells. So, for the first time a CSC marker, CD24, is associated with the transmission of genomic instability. This work may assign a new deleterious role to breast CSCs in aggressive recurrence after radiotherapy, as the transmitted genomic instability potentially leads tumour cells to acquire more aggressive characteristics. Oncogene (2013) 32, 251-258; doi:10.1038/onc.2012.31; published online 13 February 2012	[Bensimon, J.; Altmeyer-Morel, S.; Chevillard, S.; Lebeau, J.] CEA, DSV, iRCM, SREIT,LCE, F-92265 Fontenay Aux Roses, France; [Benjelloun, H.] CEA, DSV, iRCM, SCSR, F-92265 Fontenay Aux Roses, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Lebeau, J (corresponding author), CEA, DSV, iRCM, SREIT,LCE, F-92265 Fontenay Aux Roses, France.	jerome.lebeau@cea.fr		Etzol, Julie/0000-0002-5572-6197; Chevillard, Sylvie/0000-0001-5889-4041	Electricite de France (EDF); MELODI Network; DoReMi Network	Electricite de France (EDF)(Electricite de France (EDF)); MELODI Network; DoReMi Network	We thank Dr P-H. Romeo for constructive criticism on this manuscript. We also thank Drs J Baijer, D Lewandowski and P Fouchet for flow cytometry technical assistance and advices. This work was supported by grants from Electricite de France (EDF) and from MELODI and DoReMi Networks.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aypar U, 2011, INT J RADIAT BIOL, V87, P179, DOI 10.3109/09553002.2010.522686; Aypar U, 2011, MUTAT RES-FUND MOL M, V707, P24, DOI 10.1016/j.mrfmmm.2010.12.003; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Bircan S, 2006, PATHOL RES PRACT, V202, P569, DOI 10.1016/j.prp.2006.05.004; Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105; Debeb BG, 2009, J MAMMARY GLAND BIOL, V14, P11, DOI 10.1007/s10911-009-9114-z; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gewirtz DA, 2000, BREAST CANCER RES TR, V62, P223, DOI 10.1023/A:1006414422919; Gewirtz DA, 2000, CELL BIOCHEM BIOPHYS, V33, P19, DOI 10.1385/CBB:33:1:19; Giatromanolaki A, 2011, MED ONCOL, V28, P745, DOI 10.1007/s12032-010-9530-3; Hernandez-Vargas H, 2011, EPIGENETICS-US, V6, P429, DOI 10.4161/epi.6.4.14515; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Kai K, 2010, BREAST CANCER-TOKYO, V17, P80, DOI 10.1007/s12282-009-0176-y; Kristiansen G, 2003, CLIN CANCER RES, V9, P4906; Lagadec C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2479; Lahtz C, 2011, J MOL CELL BIOL, V3, P51, DOI 10.1093/jmcb/mjq053; Little JB, 1998, INT J RADIAT BIOL, V74, P663, DOI 10.1080/095530098140925; Luce A, 2009, CARCINOGENESIS, V30, P432, DOI 10.1093/carcin/bgp008; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Mothersill C, 1998, MUTAGENESIS, V13, P421, DOI 10.1093/mutage/13.5.421; Nguyen NP, 2010, CANCER TREAT REV, V36, P485, DOI 10.1016/j.ctrv.2010.02.016; Olivier M, 1998, MOL CARCINOGEN, V23, P1; Pajonk F, 2010, STEM CELLS, V28, P639, DOI 10.1002/stem.318; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Ponnaiya B, 1997, RADIAT RES, V147, P288, DOI 10.2307/3579335; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Resetkova E, 2010, BREAST CANCER RES TR, V123, P97, DOI 10.1007/s10549-009-0619-3; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Rossi L, 2011, METHODS MOL BIOL, V750, P47, DOI 10.1007/978-1-61779-145-1_3; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Sudo H, 2008, RADIAT RES, V170, P23, DOI 10.1667/RR1317.1; Suzuki K, 2006, MUTAT RES-FUND MOL M, V597, P73, DOI 10.1016/j.mrfmmm.2005.04.024; Vlashi E, 2009, J CELL BIOCHEM, V108, P339, DOI 10.1002/jcb.22275; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	39	19	19	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2013	32	2					251	258		10.1038/onc.2012.31	http://dx.doi.org/10.1038/onc.2012.31			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22330142				2022-12-17	WOS:000314075500013
J	Shi, Y; Frost, P; Hoang, B; Yang, Y; Fukunaga, R; Gera, J; Lichtenstein, A				Shi, Y.; Frost, P.; Hoang, B.; Yang, Y.; Fukunaga, R.; Gera, J.; Lichtenstein, A.			MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; rapamycin; mTOR inhibitors; c-myc; IRES activity; MNK kinases	INTERNAL RIBOSOME ENTRY; INITIATION-FACTOR 4E; MAMMALIAN TARGET; CYCLIN D1; ENHANCED SENSITIVITY; PROTEIN-SYNTHESIS; BINDING-PROTEIN; SITE FUNCTION; AKT ACTIVITY; N-TERMINI	When mTOR inhibitor rapalogs prevent cap-dependent translation of cell-cycle proteins like c-myc, continuing tumor cell growth depends on cap-independent translation, which is mediated by internal ribosome entry sites (IRESes) located in the 5'-UTR (untranslated region) of transcripts. To investigate if rapalog-induced activation of MNK kinases had a role in such IRES activity, we studied multiple myeloma (MM) cells. Rapamycin (RAP)-activated MNK1 kinase activity in MM cell lines and primary specimens by a mitogen-activated protein kinase-dependent mechanism. Pharmacological inhibition of MNK activity or genetic silencing of MNK1 prevented a rapalog-induced upregulation of c-myc IRES activity. Although RAP, used alone, had little effect on myc protein expression, when combined with a MNK inhibitor, myc protein expression was abrogated. In contrast, there was no inhibition of myc RNA, consistent with an effect on myc translation. In a RAP-resistant MM cell lines as well as a resistant primary MM specimen, co-exposure to a MNK inhibitor or MNK1 knockdown significantly sensitized cells for RAP-induced cytoreduction. Studies in MNK-null murine embryonic fibroblasts additionally supported a role for MNK kinases in RAP-induced myc IRES stimulation. These results indicate that MNK kinase activity has a critical role in the fail-safe mechanism of IRES-dependent translation when mTOR is inhibited. As kinase activity also regulated sensitivity to RAP, the data also provide a rationale for therapeutically targeting MNK kinases for combined treatment with mTOR inhibitors. Oncogene (2013) 32, 190-197; doi:10.1038/onc.2012.43; published online 27 February 2012	[Shi, Y.; Frost, P.; Hoang, B.; Yang, Y.; Fukunaga, R.; Gera, J.; Lichtenstein, A.] Univ Calif Los Angeles, Med Ctr, Dept Med, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA 90024 USA; [Shi, Y.; Frost, P.; Hoang, B.; Yang, Y.; Fukunaga, R.; Gera, J.; Lichtenstein, A.] Univ Calif Los Angeles, Med Ctr, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Shi, Y.; Frost, P.; Hoang, B.; Yang, Y.; Fukunaga, R.; Gera, J.; Lichtenstein, A.] Osaka Univ Pharmaceut Sci, Dept Biochem, Biochem Lab, Takatsuki, Osaka, Japan	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Osaka University of Pharmaceutical Sciences	Lichtenstein, A (corresponding author), W LA VA Hosp, W111H,11301 Wilshire Blvd,Bldg 500,Rm 4237, Los Angeles, CA 90073 USA.	alan.lichtenstein@med.va.gov	Fukunaga, Rikiro/CAG-2891-2022	Gera, Joseph/0000-0002-2908-6894; Frost, Patrick/0000-0003-3348-5983	Veteran's Administration; Multiple Myeloma Research Foundation; Department of Defense; NIH [RO1 CA109312, RO1 CA111448]; Grants-in-Aid for Scientific Research [24590105] Funding Source: KAKEN; NATIONAL CANCER INSTITUTE [R01CA109312, R01CA111448, R01CA168700, R01CA132778] Funding Source: NIH RePORTER	Veteran's Administration(US Department of Veterans Affairs); Multiple Myeloma Research Foundation; Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the UCLA Jonsson Comprehensive Cancer Center vector core lab for assistance in generating the lentiviral shRNA vectors. This work was supported by research funds of the Veteran's Administration, the Multiple Myeloma Research Foundation and the Department of Defense and NIH Grants RO1 CA109312 and RO1 CA111448.	Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Chrestensen CA, 2007, J BIOL CHEM, V282, P4243, DOI 10.1074/jbc.M607368200; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Farag SS, 2009, LEUKEMIA RES, V33, P1475, DOI 10.1016/j.leukres.2009.01.039; Frost P, 2004, BLOOD, V104, P4181, DOI 10.1182/blood-2004-03-1153; Frost P, 2009, MOL CANCER THER, V8, P83, DOI 10.1158/1535-7163.MCT-08-0254; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Hoang B, 2010, BLOOD, V116, P4560, DOI 10.1182/blood-2010-05-285726; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Ogata A, 1997, J IMMUNOL, V159, P2212; Paquette RL, 1990, ONCOGENE, V5, P1569; Parra JL, 2005, J BIOL CHEM, V280, P37623, DOI 10.1074/jbc.M508356200; Parra-Palau JL, 2003, J BIOL CHEM, V278, P44197, DOI 10.1074/jbc.M302398200; Paulin FEM, 1996, ONCOGENE, V13, P505; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Ross G, 2006, J NEUROCHEM, V97, P79, DOI 10.1111/j.1471-4159.2006.03704.x; Scheper GC, 2003, MOL CELL BIOL, V23, P5692, DOI 10.1128/MCB.23.16.5692-5705.2003; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Shi YJ, 2002, CANCER RES, V62, P5027; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wang XR, 2007, MOL CELL BIOL, V27, P7405, DOI 10.1128/MCB.00760-07; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Zhu Y, 2002, NEUROSCIENCE, V110, P191, DOI 10.1016/S0306-4522(01)00522-X	32	19	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					190	197		10.1038/onc.2012.43	http://dx.doi.org/10.1038/onc.2012.43			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22370634	Green Accepted			2022-12-17	WOS:000314075500007
J	Wade, M; Li, YC; Matani, AS; Braun, SMG; Milanesi, F; Rodewald, LW; Wahl, GM				Wade, M.; Li, Y. C.; Matani, A. S.; Braun, S. M. G.; Milanesi, F.; Rodewald, L. W.; Wahl, G. M.			Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells	ONCOGENE			English	Article						Mdm2; ligase; p53; RING; ubiquitin; Nutlin	DNA-DAMAGE; P53 ACTIVATION; IN-VIVO; ALLOSTERIC ACTIVATION; RING; DEGRADATION; DOMAIN; CANCER; HDM2; ATM	Mdm2 is the major negative regulator of p53 tumor-suppressor activity. This oncoprotein is overexpressed in many human tumors that retain the wild-type p53 allele. As such, targeted inhibition of Mdm2 is being considered as a therapeutic anticancer strategy. The N-terminal hydrophobic pocket of Mdm2 binds to p53 and thereby inhibits the transcription of p53 target genes. Additionally, the C-terminus of Mdm2 contains a RING domain with intrinsic ubiquitin E3 ligase activity. By recruiting E2 ubiquitin-conjugating enzyme(s), Mdm2 acts as a molecular scaffold to facilitate p53 ubiquitination and proteasome-dependent degradation. Mdmx (Mdm4), an Mdm2 homolog, also has a RING domain and hetero-oligomerizes with Mdm2 to stimulate its E3 ligase activity. Recent studies have shown that C-terminal residues adjacent to the RING domain of both Mdm2 and Mdmx contribute to Mdm2 E3 ligase activity. However, the molecular mechanisms mediating this process remain unclear, and the biological consequences of inhibiting Mdm2/Mdmx co-operation or blocking Mdm2 ligase function are relatively unexplored. This study presents biochemical and cell biological data that further elucidate the mechanisms by which Mdm2 and Mdmx co-operate to regulate p53 level and activity. We use chemical and genetic approaches to demonstrate that functional inhibition of Mdm2 ubiquitin ligase activity is insufficient for p53 activation. This unexpected result suggests that concomitant treatment with Mdm2/Mdmx antagonists may be needed to achieve therapeutic benefit.	[Wade, M.; Li, Y. C.; Matani, A. S.; Braun, S. M. G.; Rodewald, L. W.; Wahl, G. M.] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; [Wade, M.; Milanesi, F.] IIT SEMM, Ctr Genom Sci, I-20139 Milan, Italy; [Matani, A. S.] Univ Calif San Diego, Div Biol Sci, San Diego, CA 92103 USA	Salk Institute; Istituto Italiano di Tecnologia - IIT; University of California System; University of California San Diego	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mark.wade@iit.it; wahl@salk.edu	Wade, Mark/B-6719-2009	Wade, Mark/0000-0002-2688-5965; Braun, Simon/0000-0003-2622-9914; Wade, Mark/0000-0002-8355-9680	National Institutes of Health [CA61449]; sanofi-aventis; NATIONAL CANCER INSTITUTE [R01CA061449, P30CA014195] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); sanofi-aventis(Sanofi-Aventis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by a National Institutes of Health R01 Grant CA61449 and a Discovery Research Grant from sanofi-aventis awarded to GMW. We thank all members of the Wahl lab for input on various aspects of this project, Dimitris Xirodimas (Dundee University) for advice on the ubiquitylation assays and Masha Poyurovsky (Columbia University) for productive discussions. We also thank Rachel Klevit and Chris Pierini (University of Washington) for their comments and insight into ubiquitylation during this project.	Aranda-Anzaldo A, 2007, MECH AGEING DEV, V128, P293, DOI 10.1016/j.mad.2007.01.001; Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Das R, 2009, MOL CELL, V34, P674, DOI 10.1016/j.molcel.2009.05.010; Dastidar SG, 2011, CELL CYCLE, V10, P82, DOI 10.4161/cc.10.1.14345; De Clercq S, 2010, MOL CELL BIOL, V30, P5394, DOI 10.1128/MCB.00330-10; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Joseph TL, 2010, CELL CYCLE, V9, P1167, DOI 10.4161/cc.9.6.11067; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kitagaki J, 2008, MOL CANCER THER, V7, P2445, DOI 10.1158/1535-7163.MCT-08-0063; Kostic M, 2006, J MOL BIOL, V363, P433, DOI 10.1016/j.jmb.2006.08.027; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; Maetens M, 2007, BLOOD, V109, P2630, DOI 10.1182/blood-2006-03-013656; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Ozkan E, 2005, P NATL ACAD SCI USA, V102, P18890, DOI 10.1073/pnas.0509418102; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Popowicz GM, 2008, CELL CYCLE, V7, P2441, DOI 10.4161/cc.6365; Poyurovsky MV, 2007, EMBO J, V26, P90, DOI 10.1038/sj.emboj.7601465; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Terzian T, 2007, MOL CELL BIOL, V27, P5479, DOI 10.1128/MCB.00555-06; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Wade M, 2008, CELL CYCLE, V7, P1973, DOI 10.4161/cc.7.13.6072; Wade M, 2009, MOL CANCER RES, V7, P1, DOI 10.1158/1541-7786.MCR-08-0423; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Wang YYV, 2009, CANCER CELL, V16, P33, DOI 10.1016/j.ccr.2009.05.008; Weissman A M, 2008, Ernst Schering Found Symp Proc, P171; Wong ET, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni145; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Zuckerman V, 2009, J BIOL CHEM, V284, P4031, DOI 10.1074/jbc.M809211200	46	19	19	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	45					4789	4797		10.1038/onc.2011.625	http://dx.doi.org/10.1038/onc.2011.625			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266850	Green Accepted			2022-12-17	WOS:000311033000007
J	Cutrupi, S; Reineri, S; Panetto, A; Grosso, E; Caizzi, L; Ricci, L; Friard, O; Agati, S; Scatolini, M; Chiorino, G; Lykkesfeldt, AE; De Bortoli, M				Cutrupi, S.; Reineri, S.; Panetto, A.; Grosso, E.; Caizzi, L.; Ricci, L.; Friard, O.; Agati, S.; Scatolini, M.; Chiorino, G.; Lykkesfeldt, A. E.; De Bortoli, M.			Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells	ONCOGENE			English	Article						Tab2; tamoxifen resistance; estrogen receptor; breast cancer	ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; ANTIESTROGEN RESISTANCE; N-COR; KINASE; GROWTH; TAK1; PHOSPHORYLATION; METAANALYSIS; ACTIVATION	Pharmacological resistance is a serious threat to the clinical success of hormone therapy for breast cancer. The antiproliferative response to antagonistic drugs such as tamoxifen (Tam) critically depends on the recruitment of NCoR/SMRT corepressors to estrogen receptor alpha (ER alpha) bound to estrogen target genes. Under certain circumstances, as demonstrated in the case of interleukin-1 beta (IL-1 beta) treatment, the protein Tab2 interacts with ER alpha/NCoR and causes dismissal of NCoR from these genes, leading to loss of the antiproliferative response. In Tam-resistant (TamR) ER-positive breast cancer cells, we observed that Tab2 presents a shift in mobility on sodium dodecyl sulfate-PAGE (SDS-PAGE) similar to that seen in MCF7 wt upon stimulation with IL-1 beta, suggesting constitutive activation. Accordingly, TamR treatment with Tab2-specific short interfering RNA, restored the antiproliferative response to Tam in these cells. As Tab2 is known to directly interact with the N-terminal domain of ER alpha , we synthesized a peptide composed of a 14-aa motif of this domain, which effectively competes with ER alpha/Tab2 interaction in pull-down and co-immunoprecipitation experiments, fused to the carrier TAT peptide to allow internalization. Treatment of TamR cells with this peptide resulted in partial recovery of the antiproliferative response to Tam, suggesting a strategy to revert pharmacological resistance in breast cancer. Silencing of Tab2 in TamR cells by siRNA caused modulation of a gene set related to the control of cell cycle and extensively connected to BRCA1 in a functional network. These genes were able to discern two groups of patients, from a published data set of Tam-treated breast cancer profiles, with significantly different disease-free survival. Altogether, our data implicate Tab2 as a mediator of resistance to endocrine therapy and as a potential new target to reverse pharmacological resistance and potentiate antiestrogen action. Oncogene (2012) 31, 4353-4361; doi:10.1038/onc.2011.627; published online 16 January 2012	[Cutrupi, S.; Reineri, S.; Panetto, A.; Grosso, E.; Caizzi, L.; Ricci, L.; Friard, O.; De Bortoli, M.] Univ Turin, Ctr Mol Syst Biol, I-10060 Turin, Italy; [Cutrupi, S.] Univ Turin, Dept Human & Anim Biol, I-10060 Turin, Italy; [Reineri, S.; Caizzi, L.; Agati, S.; De Bortoli, M.] Univ Turin, Dept Oncol Sci, I-10060 Turin, Italy; [Panetto, A.; Ricci, L.] Bioind Pk Silvano Fumero, Turin, Italy; [Grosso, E.; Scatolini, M.; Chiorino, G.] Fdn Edo & Elvo Tempia Valenta, Lab Canc Genom, Biella, Italy; [Lykkesfeldt, A. E.] Danish Canc Soc, Inst Canc Biol, Dept Breast Canc Res, Copenhagen, Denmark	University of Turin; University of Turin; University of Turin; Danish Cancer Society	De Bortoli, M (corresponding author), Univ Turin, Ctr Mol Syst Biol, C-O IRCC SP142,Km 3-95, I-10060 Turin, Italy.	michele.debortoli@unito.it	cutrupi, santina/AAC-4479-2022; Scatolini, Maria/ABA-7311-2020; Friard, Olivier/ABG-2435-2021; De Bortoli, Michele/B-5418-2013; Caizzi, Livia/AAO-2725-2021; Chiorino, Giovanna/K-5037-2016	Friard, Olivier/0000-0002-0374-9872; De Bortoli, Michele/0000-0002-6666-9052; Chiorino, Giovanna/0000-0002-9502-6400; CUTRUPI, SANTINA/0000-0002-2358-5852; Caizzi, Livia/0000-0001-9723-6893	PRIN [2008PC9CFW_002]; Associazione Italiana per la Ricerca sul Cancro [IG9397]; public grant 'ERSF -DOCUP (Misura 3.4)' - hitechplat project; Associazione Sviluppo Piemonte (Turin); Compagnia di San Paolo (Turin) grant; UICC travel fellowship	PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); public grant 'ERSF -DOCUP (Misura 3.4)' - hitechplat project; Associazione Sviluppo Piemonte (Turin); Compagnia di San Paolo (Turin) grant(Compagnia di San Paolo); UICC travel fellowship	This work was supported by grants from PRIN (2008PC9CFW_002) and from the Associazione Italiana per la Ricerca sul Cancro (Grant number IG9397), and in part by the public grant 'ERSF -DOCUP 2000-2006 (Misura 3.4)' - hitechplat project. LR is a CRT Fondazione Lagrange (Turin) fellow. AP was supported in part by the Associazione Sviluppo Piemonte (Turin). EG was a CRT Fondazione Lagrange (Turin) fellow and was supported in part by a Compagnia di San Paolo (Turin) grant and by a UICC travel fellowship.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Broglie P, 2010, J BIOL CHEM, V285, P2333, DOI 10.1074/jbc.M109.090522; Carroll JS, 2003, CANCER RES, V63, P4322; Cicatiello L, 2004, J MOL ENDOCRINOL, V32, P719, DOI 10.1677/jme.0.0320719; Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837; Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274; Frankel LB, 2007, BREAST CANCER RES TR, V104, P165, DOI 10.1007/s10549-006-9399-1; Frogne T, 2005, ENDOCR-RELAT CANCER, V12, P599, DOI 10.1677/erc.1.00946; Hackshaw A, 2011, J CLIN ONCOL, V29, P1657, DOI 10.1200/JCO.2010.32.2933; Henriksen K, 2009, ACTA ONCOL, V48, P522, DOI 10.1080/02841860802676383; Hughes-Davies L, 2009, BRIT J CANCER, V101, P875, DOI 10.1038/sj.bjc.6605231; Jansen MPHM, 2005, J CLIN ONCOL, V23, P732, DOI 10.1200/JCO.2005.05.145; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lee YH, 2001, GENE DEV, V25, P176; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; LYKKESFELDT AE, 1986, BRIT J CANCER, V53, P29, DOI 10.1038/bjc.1986.5; Madsen MW, 1997, CANCER RES, V57, P585; Mendoza H, 2008, BIOCHEM J, V409, P711, DOI 10.1042/BJ20071149; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nabha SM, 2005, ONCOGENE, V24, P3166, DOI 10.1038/sj.onc.1208502; Ochsner SA, 2009, CANCER RES, V69, P23, DOI 10.1158/0008-5472.CAN-08-3492; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Pancholi S, 2008, ENDOCR-RELAT CANCER, V15, P985, DOI 10.1677/ERC-07-0240; Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Schiff R, 2005, CANCER CHEMOTH PHARM, V56, pS10, DOI 10.1007/s00280-005-0108-2; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shin MS, 2009, BBA-MOL CELL RES, V1793, P1156, DOI 10.1016/j.bbamcr.2009.04.005; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Yue W, 2007, J STEROID BIOCHEM, V106, P102, DOI 10.1016/j.jsbmb.2007.05.008; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	40	19	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4353	4361		10.1038/onc.2011.627	http://dx.doi.org/10.1038/onc.2011.627			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22249258	Green Published			2022-12-17	WOS:000309591300002
J	Zarnegar, MA; Rothenberg, EV				Zarnegar, M. A.; Rothenberg, E. V.			Ikaros represses and activates PU.1 cell-type-specifically through the multifunctional Sfpi1 URE and a myeloid specific enhancer	ONCOGENE			English	Article						cis-regulatory element; hematopoiesis; chromatin immune precipitation; context dependent regulation; RNA polymerase II	TRANSCRIPTION FACTOR PU.1; EXPRESSION; LINEAGE; GENE; COMMITMENT; FATE; DIFFERENTIATION; HEMATOPOIESIS; PROGENITORS; REDUCTION	Generation of myeloid and lymphoid cells from progenitors involves dynamic changes in transcription factor expression and use, and disruption of hematopoietic transcription factor function and expression can contribute to leukemic transformation. PU.1 and Ikaros are pivotal factors whose expression and utilization are dynamically altered during hematopoietic development. Here, we demonstrate that expression of PU.1, encoded by the Sfpi1 gene, is divergently regulated by Ikaros in distinct cell type-specific contexts. Chromatin immune precipitation analysis and functional perturbations revealed that Ikaros can directly repress or activate Sfpi1 transcription via different PU.1 cis-elements, with PU.1 and Ikaros collaborating at myeloid-specific elements but not at other elements. Our results thus shed light on how PU.1 and Ikaros can act as lineage competency factors to facilitate both myeloid and lymphoid developmental programs.	[Zarnegar, M. A.; Rothenberg, E. V.] CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Rothenberg, EV (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.	evroth@its.caltech.edu		Rothenberg, Ellen/0000-0002-3901-347X	NIH [R01 CA90233]; LA Garfinkle Memorial Laboratory Fund; Al Sherman Foundation; AB Ruddock Professorship; NATIONAL CANCER INSTITUTE [R01CA090233] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); LA Garfinkle Memorial Laboratory Fund; Al Sherman Foundation; AB Ruddock Professorship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant R01 CA90233, the LA Garfinkle Memorial Laboratory Fund, the Al Sherman Foundation and the AB Ruddock Professorship to EVR.	Anderson MK, 1999, DEVELOPMENT, V126, P3131; Back J, 2005, EXP HEMATOL, V33, P395, DOI 10.1016/j.exphem.2004.12.010; Carotta S, 2010, IMMUNITY, V32, P628, DOI 10.1016/j.immuni.2010.05.005; CHEN HM, 1995, ONCOGENE, V11, P1549; Chou ST, 2009, BLOOD, V114, P983, DOI 10.1182/blood-2009-03-207944; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dijon M, 2008, BLOOD, V111, P1138, DOI 10.1182/blood-2007-07-098202; Ebralidze AK, 2008, GENE DEV, V22, P2085, DOI 10.1101/gad.1654808; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Georgopoulos K, 1997, CURR OPIN IMMUNOL, V9, P222, DOI 10.1016/S0952-7915(97)80139-2; Hoogenkamp M, 2007, MOL CELL BIOL, V27, P7425, DOI 10.1128/MCB.00905-07; Houston IB, 2007, EXP HEMATOL, V35, P1056, DOI 10.1016/j.exphem.2007.04.005; Iwasaki H, 2007, ONCOGENE, V26, P6687, DOI 10.1038/sj.onc.1210754; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Laiosa CV, 2006, ANNU REV IMMUNOL, V24, P705, DOI 10.1146/annurev.immunol.24.021605.090742; Leddin M, 2011, BLOOD, V117, P2827, DOI 10.1182/blood-2010-08-302976; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Ng SYM, 2009, IMMUNITY, V30, P493, DOI 10.1016/j.immuni.2009.01.014; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Papathanasiou P, 2003, IMMUNITY, V19, P131, DOI 10.1016/S1074-7613(03)00168-7; Reynaud D, 2008, NAT IMMUNOL, V9, P927, DOI 10.1038/ni.1626; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Spooner CJ, 2009, IMMUNITY, V31, P576, DOI 10.1016/j.immuni.2009.07.011; Stehling-Sun S, 2009, NAT IMMUNOL, V10, P289, DOI 10.1038/ni.1694; Swiers G, 2006, DEV BIOL, V294, P525, DOI 10.1016/j.ydbio.2006.02.051; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; Yagi T, 2002, BLOOD, V99, P1350, DOI 10.1182/blood.V99.4.1350; Yoshida T, 2006, NAT IMMUNOL, V7, P382, DOI 10.1038/ni1314; Zarnegar MA, 2010, MOL CELL BIOL, V30, P4922, DOI 10.1128/MCB.00354-10	32	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2012	31	43					4647	4654		10.1038/onc.2011.597	http://dx.doi.org/10.1038/onc.2011.597			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22231443	Green Accepted			2022-12-17	WOS:000310528200008
J	Diaz-Rodriguez, E; Garcia-Lavandeira, M; Perez-Romero, S; Senra, A; Canibano, C; Palmero, I; Borrello, MG; Dieguez, C; Alvarez, CV				Diaz-Rodriguez, E.; Garcia-Lavandeira, M.; Perez-Romero, S.; Senra, A.; Canibano, C.; Palmero, I.; Borrello, M. G.; Dieguez, C.; Alvarez, C. V.			Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells	ONCOGENE			English	Article						dependence receptor; apoptosis; p19Arf; p53; Pit-1; OIA	ARF TUMOR-SUPPRESSOR; REGULATES P53-DEPENDENT APOPTOSIS; RET-GENE-EXPRESSION; NONCODING RNA; CYCLE ARREST; P53 PATHWAY; DAP KINASE; RB+/-MICE; GROWTH; SENESCENCE	Somatotrophs produce growth hormone (GH) and are the most abundant secretory cells of the pituitary. Somatotrophs express the transcription factor Pit-1 and the dependence receptor RET, its co-receptor GFRa1 and ligand GDNF. Pit-1 is a transcription factor essential for somatotroph proliferation and differentiation and for GH expression. GDNF represses excess Pit-1 expression preventing excess GH. In the absence of GDNF, RET behaves as a dependence receptor, becomes intracellularly processed and induces strong Pit-1 expression leading to p53 accumulation and apoptosis. How accumulation of Pit-1 leads to p53 expression is unknown. We have unveiled the relationship of Pit-1 with the p19Arf gene. There is a parallel correlation of RET processing, Pit-1 increase and ARF protein and mRNA expression. Interfering the pathway with RET, Pit-1 or p19Arf siRNA blocked apoptosis. We have found a Pit-1 DNA-binding element within the ARF promoter. Pit-1 directly regulates the CDKN2A locus and binds to the p19Arft promoter inducing p19Arf gene expression. The Pit-1-binding element is conserved in rodents and humans. RET/Pit-1 induces p19Arf/p53 and apoptosis not only in a somatotroph cell line but also in primary cultures of pituitary somatotrophs, where ARF siRNA interference also blocks p53 and apoptosis. Analyses of the somatotrophs in whole pituitaries supported the above findings. Thus Pit-1, a differentiation factor, activates the oncogene-induced apoptosis (OIA) pathway as oncogenes exerting a tight control in somatotrophs to prevent the disease due to excess of GH (insulin-resistance, metabolic disease, acromegaly). Oncogene (2012) 31, 2824-2835; doi:10.1038/onc.2011.458; published online 24 October 2011	[Diaz-Rodriguez, E.; Garcia-Lavandeira, M.; Perez-Romero, S.; Senra, A.; Canibano, C.; Dieguez, C.; Alvarez, C. V.] Univ Santiago de Compostela, CIMUS, IDIS Neoplasia & Endocrine Differentiat, Dept Physiol,Sch Med, Santiago De Compostela, Spain; [Palmero, I.] Alberto Sols CSIC UAM, Inst Invest Biomed, Madrid, Spain; [Borrello, M. G.] IRCCS Ist Nazl Tumori Fdn, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, Milan, Italy	Universidade de Santiago de Compostela; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Fondazione IRCCS Istituto Nazionale Tumori Milan	Alvarez, CV (corresponding author), Univ Santiago de Compostela, Dept Physiol, Sch Med, IDIS CIMUS, Santiago De Compostela 15782, Spain.	clara.alvarez@usc.es	Lavandeira, Montserrat García/R-4708-2019; Palmero, Ignacio/B-4346-2013; Borrello, Maria Grazia/C-3161-2017; Alvarez, Clara V/AAN-4173-2020	Lavandeira, Montserrat García/0000-0001-9208-2418; Borrello, Maria Grazia/0000-0002-6854-2848; Perez, Sihara/0000-0003-1744-0208; dieguez, carlos/0000-0002-0919-4337; Alvarez, Clara V/0000-0003-1500-4058	Xunta de Galicia-MICINN-FEDER [06PXIB208107PR, 09CSA011208PR, BFU2007-60571, BFU2010-16652]; European Community (Fondo Social Europeo)	Xunta de Galicia-MICINN-FEDER; European Community (Fondo Social Europeo)	We thank Susana Bravo and Maria Garcia-Rendueles for helpful methodological advice. This project has been supported by grants Xunta de Galicia-MICINN-FEDER, 06PXIB208107PR, 09CSA011208PR, BFU2007-60571 and BFU2010-16652 to CVA. E D-R has been an Anxeles Alvarino fellow and M G-L is a Lucas Labrada fellow (Xunta de Galicia). These programs are co-financed by the European Community (Fondo Social Europeo). The text has been reviewed by G Lockhart, a professional editor of biomedical English.	Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Bravo SB, 2003, ONCOGENE, V22, P7819, DOI 10.1038/sj.onc.1207029; Bravo SB, 2010, ANAL BIOCHEM, V400, P219, DOI 10.1016/j.ab.2010.01.034; Canibano C, 2007, EMBO J, V26, P2015, DOI 10.1038/sj.emboj.7601636; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; Chesnokova V, 2005, MOL ENDOCRINOL, V19, P2371, DOI 10.1210/me.2005-0137; Chesnokova V, 2008, P NATL ACAD SCI USA, V105, P17498, DOI 10.1073/pnas.0804810105; Chesnokova V, 2008, RES PERSPECT END INT, P83, DOI 10.1007/978-3-540-73855-8_8; Chesnokova V, 2007, CANCER RES, V67, P10564, DOI 10.1158/0008-5472.CAN-07-0974; Clayton PE, 2011, NAT REV ENDOCRINOL, V7, P11, DOI 10.1038/nrendo.2010.171; Colao A, 2010, FRONT HORM RES, V38, P94, DOI 10.1159/000318499; Coya R, 1999, J NEUROENDOCRINOL, V11, P351; Cunnington MS, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000899; Davis SW, 2010, MOL CELL ENDOCRINOL, V323, P4, DOI 10.1016/j.mce.2009.12.012; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; del Arroyo AG, 2007, CELL CYCLE, V6, P2697; Evan GI, 2009, CURR OPIN GENET DEV, V19, P25, DOI 10.1016/j.gde.2008.11.009; Garcia A, 2001, MOL ENDOCRINOL, V15, P1484, DOI 10.1210/me.15.9.1484; Garcia-Lavandeira M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004815; Garcia-Lavandeira M, 2010, FRONT HORM RES, V38, P127, DOI 10.1159/000318502; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Guenebeaud C, 2010, MOL CELL, V40, P863, DOI 10.1016/j.molcel.2010.11.021; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HERMAN V, 1993, J CLIN ENDOCR METAB, V77, P50, DOI 10.1210/jc.77.1.50; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Itahana K, 2008, CANCER CELL, V13, P542, DOI 10.1016/j.ccr.2008.04.002; Japon MA, 2002, J CLIN ENDOCR METAB, V87, P1879, DOI 10.1210/jc.87.4.1879; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P1117, DOI 10.1177/42.8.8027530; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Khutornenko AA, 2010, P NATL ACAD SCI USA, V107, P12828, DOI 10.1073/pnas.0910885107; Kirsch M, 2009, GENE CHROMOSOME CANC, V48, P143, DOI 10.1002/gcc.20621; Kovi RC, 2010, CELL DEATH DIFFER, V17, P513, DOI 10.1038/cdd.2009.140; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Leontieva OV, 2010, CELL CYCLE, V9, P4323, DOI 10.4161/cc.9.21.13584; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Melmed S, 2003, J CLIN INVEST, V112, P1603, DOI 10.1172/JCI200320401; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Nikoletopoulou V, 2010, NATURE, V467, P59, DOI 10.1038/nature09336; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Serrano M, 2010, CELL CYCLE, V9, P4256, DOI 10.4161/cc.9.21.13785; Solloso A, 2008, J CELL PHYSIOL, V215, P140, DOI 10.1002/jcp.21295; Taneja P, 2010, CANCER RES, V70, P9084, DOI 10.1158/0008-5472.CAN-10-0159; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Urbano AG, 2000, ENDOCRINOLOGY, V141, P1893, DOI 10.1210/en.141.5.1893; van Beek AP, 2010, J CLIN ENDOCR METAB, V95, P3664, DOI 10.1210/jc.2009-2506; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang H, 2008, BIOCHEM BIOPH RES CO, V370, P594, DOI 10.1016/j.bbrc.2008.03.152; Ward RD, 2006, MOL ENDOCRINOL, V20, P1378, DOI 10.1210/me.2005-0409; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zhou ZX, 2005, CANCER RES, V65, P787; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	62	19	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	23					2824	2835		10.1038/onc.2011.458	http://dx.doi.org/10.1038/onc.2011.458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	22020338				2022-12-17	WOS:000305277900003
J	Pakay, JL; Diesch, J; Gilan, O; Yip, YY; Sayan, E; Kolch, W; Mariadason, JM; Hannan, RD; Tulchinsky, E; Dhillon, AS				Pakay, J. L.; Diesch, J.; Gilan, O.; Yip, Y-Y; Sayan, E.; Kolch, W.; Mariadason, J. M.; Hannan, R. D.; Tulchinsky, E.; Dhillon, A. S.			A 19S proteasomal subunit cooperates with an ERK MAPK-regulated degron to regulate accumulation of Fra-1 in tumour cells	ONCOGENE			English	Article						Fra-1; turnover; TBP-1; cancer; ERK; RAS	TAT-BINDING PROTEIN-1; UBIQUITIN-INDEPENDENT DEGRADATION; C-FOS; 26S PROTEASOME; IN-VITRO; RAS; TRANSCRIPTION; GROWTH; AP-1; TRANSFORMATION	Fos-related antigen-1 (Fra-1) is a member of the Activator Protein-1 (AP-1) transcription factor superfamily that is overexpressed in a variety of cancers, including colon, breast, lung, bladder and brain. High Fra-1 levels are associated with enhanced cell proliferation, survival, migration and invasion. Despite its frequent overexpression, the molecular mechanisms that regulate the accumulation of Fra-1 proteins in tumour cells are not well understood. Here, we show that turnover of Fra-1, which does not require ubiquitylation, is cooperatively regulated by two distinct mechanisms-association with the 19S proteasomal subunit, TBP-1, and by a C-terminal degron, which acts independently of TBP-1, but is regulated by RAS-ERK (extracellular signal-regulated kinase) signalling. TBP-1 depletion stabilized Fra-1 and further increased its levels in tumour cells expressing RAS-ERK pathway oncogenes. These effects correlated with increased AP-1 transcriptional activity. We suggest that during Fra-1 degradation, association with TBP-1 provides a mechanism for ubiquitin-independent proteasomal recognition, while the C terminus of the protein regulates its subsequent proteolytic processing. Oncogene (2012) 31, 1817-1824; doi: 10.1038/onc.2011.375; published online 29 August 2011	[Diesch, J.; Gilan, O.; Hannan, R. D.; Dhillon, A. S.] Univ Melbourne, Div Res, Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia; [Pakay, J. L.; Diesch, J.; Gilan, O.; Yip, Y-Y; Hannan, R. D.] Univ Melbourne, Inst Bio21, Parkville, Vic 3052, Australia; [Sayan, E.; Tulchinsky, E.] Univ Leicester, Leicester LE1 9HN, Leics, England; [Kolch, W.] Univ Coll Dublin, Dublin 2, Ireland; [Mariadason, J. M.] Austin Hlth, Ludwig Inst Canc Res, Heidelberg, Vic, Australia; [Hannan, R. D.] Monash Univ, Clayton, Vic, Australia	Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; University of Leicester; University College Dublin; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Monash University	Dhillon, AS (corresponding author), Univ Melbourne, Div Res, Peter MacCallum Canc Ctr, St Andrews Pl, Melbourne, Vic 3002, Australia.	et32@leicester.ac.uk; Amardeep.Dhillon@petermac.org	Mariadason, John/N-2003-2013; Tulchinsky, Eugene/ABD-7070-2021; Admin, SBI/HGB-2738-2022; Kolch, Walter/ABF-2102-2021; SAYAN, A. EMRE/H-7330-2012; Diesch, Jeannine/J-8558-2017	SAYAN, A. EMRE/0000-0002-5291-1485; Diesch, Jeannine/0000-0002-4667-3468; Hannan, Ross/0000-0002-2166-4493; Kolch, Walter/0000-0001-5777-5016; Mariadason, John/0000-0001-9123-7684; Dhillon, Amardeep/0000-0002-6065-663X	National Health and Medical Research Council of Australia; Association for International Cancer Research	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Association for International Cancer Research	We thank Drs Nishida, Satoh, Greer and Gillespie for generously providing reagents used in this study, and Dr Willie Bienvenut for assistance with the mass spectrometry experiments. This work was supported by grants from the National Health and Medical Research Council of Australia (to ASD and RDH) and the Association for International Cancer Research (to ET).	Acquaviva C, 2001, ONCOGENE, V20, P7563, DOI 10.1038/sj.onc.1204880; Adiseshaiah P, 2007, CANCER RES, V67, P6204, DOI 10.1158/0008-5472.CAN-06-4687; Andreolas C, 2008, INT J CANCER, V122, P1745, DOI 10.1002/ijc.23309; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Basbous J, 2008, BIOCHIMIE, V90, P296, DOI 10.1016/j.biochi.2007.07.016; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Baugh JM, 2009, J MOL BIOL, V386, P814, DOI 10.1016/j.jmb.2008.12.081; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Burch PM, 2004, MOL CELL BIOL, V24, P4696, DOI 10.1128/MCB.24.11.4696-4709.2004; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; Chen CS, 2007, FEBS LETT, V581, P1124, DOI 10.1016/j.febslet.2007.02.018; Chen XY, 2007, MOL CELL, V26, P843, DOI 10.1016/j.molcel.2007.05.022; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cohn MA, 2001, NUCLEIC ACIDS RES, V29, P3335, DOI 10.1093/nar/29.16.3335; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; Debinski W, 2005, MOL CANCER RES, V3, P237; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Dong ZG, 1996, J BIOL CHEM, V271, P9942, DOI 10.1074/jbc.271.17.9942; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Gallastegui N, 2010, TRENDS BIOCHEM SCI, V35, P634, DOI 10.1016/j.tibs.2010.05.005; Gomard T, 2008, BIOCHEM SOC T, V36, P858, DOI 10.1042/BST0360858; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hoyt MA, 2004, CELL MOL LIFE SCI, V61, P1596, DOI 10.1007/s00018-004-4133-9; Ishizuka T, 2001, MOL ENDOCRINOL, V15, P1329, DOI 10.1210/me.15.8.1329; Jariel-Encontre I, 2008, BBA-REV CANCER, V1786, P153, DOI 10.1016/j.bbcan.2008.05.004; Kakumoto K, 2006, P NATL ACAD SCI USA, V103, P5490, DOI 10.1073/pnas.0601222103; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Park BW, 1999, P NATL ACAD SCI USA, V96, P6434, DOI 10.1073/pnas.96.11.6434; Pollice A, 2007, ONCOGENE, V26, P5154, DOI 10.1038/sj.onc.1210313; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; Satoh T, 2009, ENDOCRINOLOGY, V150, P3283, DOI 10.1210/en.2008-1122; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Takeuchi J, 2007, EMBO J, V26, P123, DOI 10.1038/sj.emboj.7601476; Talotta F, 2010, ONCOGENE, V29, P4732, DOI 10.1038/onc.2010.211; Terasawa K, 2003, GENES CELLS, V8, P263, DOI 10.1046/j.1365-2443.2003.00631.x; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; von Kriegsheim A, 2006, NAT CELL BIOL, V8, P1011, DOI 10.1038/ncb1465; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	50	19	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1817	1824		10.1038/onc.2011.375	http://dx.doi.org/10.1038/onc.2011.375			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21874050	Green Submitted			2022-12-17	WOS:000302785200007
J	Helman, E; Naxerova, K; Kohane, IS				Helman, E.; Naxerova, K.; Kohane, I. S.			DNA hypermethylation in lung cancer is targeted at differentiation-associated genes	ONCOGENE			English	Article						Hypermethylation; development; non-small cell lung cancer; gene expression	TUMOR-SUPPRESSOR GENE; CPG-ISLAND METHYLATION; EMBRYONIC STEM-CELLS; EARLY EVENT; GENOME; MARKERS; GERM; HYPOMETHYLATION; CARDIOMYOCYTES; RETINOBLASTOMA	Aberrant DNA hypermethylation of tumor suppressor genes is thought to be an early event in tumorigenesis. Many studies have reported the methylation status of individual genes with known involvement in cancer, but an unbiased assessment of the biological function of the collective of hypermethylated genes has not been conducted so far. Based on the observation that a variety of human cancers recapitulate developmental gene expression patterns ( that is activate genes normally expressed in early development and suppress late developmental genes), we hypothesized that the silencing of differentiation-associated genes in cancer could be attributed in part to DNA hypermethylation. To this end, we investigated the developmental expression patterns of genes with hypermethylated CpG islands in primary human lung carcinomas and lung cancer cell lines. We found that DNA hypermethylation primarily affects genes that are expressed in late stages of murine lung development. Gene ontology characterization of these genes shows that they are almost exclusively involved in morphogenetic differentiation processes. Our results indicate that DNA hypermethylation in cancer functions as a selective silencing mechanism of genes that are required for the maintenance of a differentiated state. The process of cellular de-differentiation that is evident on both the microscopic and transcriptional level in cancer might at least partly be mediated by these epigenetic events. Our observations provide a mechanistic explanation for induction of differentiation upon treatment with DNA methyltransferase inhibitors. Oncogene (2012) 31, 1181-1188; doi:10.1038/onc.2011.307; published online 1 August 2011	[Kohane, I. S.] Childrens Hosp, Informat Program, Harvard Mit Div Hlth Sci & Technol, Boston, MA 02115 USA; [Naxerova, K.] Harvard Univ, Sch Med, Boston, MA USA; [Naxerova, K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Kohane, IS (corresponding author), Childrens Hosp, Informat Program, Harvard Mit Div Hlth Sci & Technol, 300 Longwood Ave,Enders 6L, Boston, MA 02115 USA.	Isaac_Kohane@hms.harvard.edu	Kohane, Isaac Kohane/K-3716-2012	Kohane, Isaac Kohane/0000-0003-2192-5160; Naxerova, Kamila/0000-0001-7744-5110				ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Armstrong L, 2006, STEM CELLS, V24, P805, DOI 10.1634/stemcells.2005-0350; Banerjee S, 2010, EXP CELL RES, V316, P172, DOI 10.1016/j.yexcr.2009.08.011; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 2001, CANCER RES, V61, P3225; Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; Hayslip J, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-44; Heller G, 2010, CANCER METAST REV, V29, P95, DOI 10.1007/s10555-010-9203-x; HERMAN JG, 1995, CANCER RES, V55, P4525; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; Kho AT, 2004, GENE DEV, V18, P629, DOI 10.1101/gad.1182504; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Liu HY, 2006, PLOS MED, V3, P1090, DOI 10.1371/journal.pmed.0030232; Marchevsky AM, 2004, J MOL DIAGN, V6, P28, DOI 10.1016/S1525-1578(10)60488-6; McLaren A, 2000, MOL CELL ENDOCRINOL, V163, P3, DOI 10.1016/S0303-7207(99)00234-8; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOMPARLER RL, 1985, LEUKEMIA RES, V9, P1361, DOI 10.1016/0145-2126(85)90123-7; Naxerova K, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-7-r108; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Pfeifer GP, 2009, SEMIN CANCER BIOL, V19, P181, DOI 10.1016/j.semcancer.2009.02.008; Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104; Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; SAKAI T, 1991, AM J HUM GENET, V48, P880; Sasaki H, 2008, NAT REV GENET, V9, P129, DOI 10.1038/nrg2295; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Wang Y, 2004, BIOINFORMATICS, V20, P1170, DOI 10.1093/bioinformatics/bth059; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91; Yoon BS, 2006, DIFFERENTIATION, V74, P149, DOI 10.1111/j.1432-0436.2006.00063.x	49	19	19	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1181	1188		10.1038/onc.2011.307	http://dx.doi.org/10.1038/onc.2011.307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21804601				2022-12-17	WOS:000300945900011
J	Bug, M; Dobbelstein, M				Bug, M.; Dobbelstein, M.			Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms	ONCOGENE			English	Article						anthracyclines; doxorubicin; idarubicin; p53; WRAP53; E2F1	DRUG-INTERACTION DOMAINS; TOPOISOMERASE-II; DNA-DAMAGE; APOPTOTIC RESPONSE; MOUSE MODEL; TRANSCRIPTION; P73; PHOSPHORYLATION; GAIN; GENE	Mutant p53 frequently accumulates in cancer cells and promotes tumor cell invasion, as part of its gain of function. Its accumulation is partially due to enhanced stability, but little is known about how the mRNA levels of mutant p53 can be regulated. Likewise, the impact of cancer therapy on the levels of mutant p53 is poorly understood. We show here that the anthracyclines doxorubicin, daunorubicin and epirubicin further increase the amounts of mutant p53 mRNA and protein in cancer cells. Moreover, we show for the first time that the transcription factor E2F1 associates with the promoter DNA of TP53. Upon genotoxic treatment, E2F1 contributed to the expression of mutant p53, both directly and through induction of TAp73. In contrast, the anthracycline idarubicin and also another topoisomerase inhibitor, etoposide, failed to increase the levels of p53 mRNA, despite their ability to induce the synthesis of TAp73 mRNA. Instead, a natural antisense transcript of TP53, WRAP53, was strongly augmented by idarubicin and etoposide, but only less so by the other anthracyclines under study. RNA corresponding to the first exon of WRAP53 was mainly found in cell nuclei and it reduced the levels of mutant p53. Taken together, this suggests a reciprocal activation pattern of TP53 and WRAP53 by different chemotherapeutics. Reducing the levels of mutant p53 by small-interfering RNA increased chemosensitivity, and idarubicin prevented cell survival more efficiently than the mutant p53-inducing doxorubicin. We conclude that even closely related anthracyclines induce the synthesis of different, opposing transcripts from the TP53 locus. When using these drugs for cancer therapy, the increased levels of mutant p53 may augment its gain of function and thus favor unwanted chemoresistance and tumor progression. Oncogene (2011) 30, 3612-3624; doi:10.1038/onc.2011.72; published online 28 March 2011	[Bug, M.; Dobbelstein, M.] Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci GZMB, D-37077 Gottingen, Germany	University of Gottingen	Dobbelstein, M (corresponding author), Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci GZMB, Ernst Caspari Haus,Justus von Liebig Weg 11, D-37077 Gottingen, Germany.	mdobbel@uni-goettingen.de		Dobbelstein, Matthias/0000-0001-5052-3967	German excellence initiative; German Cancer Aid/Dr Mildred Scheel Stiftung; EU; German Research Foundation DFG; Wilhelm Sander Stiftung	German excellence initiative; German Cancer Aid/Dr Mildred Scheel Stiftung(Deutsche Krebshilfe); EU(European Commission); German Research Foundation DFG(German Research Foundation (DFG)); Wilhelm Sander Stiftung	We thank M Haubrock for the analysis of E2F1 promoter sequences and C Hippel and A Dickmanns for excellent technical assistance. We further thank M Farnebo, K Wiman, K Heyninck and C Bamberger for providing plasmids used in this study and helpful advice. MB was supported by the Master/PhD Program Molecular Biology and the Gottingen Graduate School of Neurosciences and Molecular Biosciences, funded by the German excellence initiative (funding line 1). Our work was supported by the German Cancer Aid/Dr Mildred Scheel Stiftung, the EU 6th Framework Program, the German Research Foundation DFG and the Wilhelm Sander Stiftung.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bush JA, 2002, INT J CANCER, V98, P323, DOI 10.1002/ijc.10226; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CAPRANICO G, 1995, CANCER RES, V55, P312; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; Cashman DJ, 2004, J MED CHEM, V47, P1360, DOI 10.1021/jm030529h; Collins I, 2001, MOL CELL BIOL, V21, P8437, DOI 10.1128/MCB.21.24.8437-8451.2001; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; Crampton N, 2006, NUCLEIC ACIDS RES, V34, P5416, DOI 10.1093/nar/gkl668; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; HARGRAVE RM, 1995, ANTI-CANCER DRUG, V6, P432, DOI 10.1097/00001813-199506000-00011; Heinlein C, 2008, INT J CANCER, V122, P1701, DOI 10.1002/ijc.23317; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lavorgna G, 2004, TRENDS BIOCHEM SCI, V29, P88, DOI 10.1016/j.tibs.2003.12.002; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu H, 2007, MOL CELL BIOL, V27, P8480, DOI 10.1128/MCB.01126-07; Liu HS, 2009, BIOCHEM J, V422, P543, DOI 10.1042/BJ20090342; Lotfi K, 2002, CANCER LETT, V178, P141, DOI 10.1016/S0304-3835(01)00824-2; Lozano G, 2007, CURR OPIN GENET DEV, V17, P66, DOI 10.1016/j.gde.2006.12.003; Mahmoudi S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000521; Mahmoudi S, 2009, MOL CELL, V33, P462, DOI 10.1016/j.molcel.2009.01.028; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nitiss JL, 2009, NAT REV CANCER, V9, P327, DOI 10.1038/nrc2608; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Prescott EM, 2002, P NATL ACAD SCI USA, V99, P8796, DOI 10.1073/pnas.132270899; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tanaka T, 2007, CELL CYCLE, V6, P371, DOI 10.4161/cc.6.3.3835; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; van Hille B, 1999, ANTI-CANCER DRUG, V10, P551, DOI 10.1097/00001813-199907000-00007; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang SL, 2006, CANCER RES, V66, P6982, DOI 10.1158/0008-5472.CAN-06-0511; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	51	19	19	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	33					3612	3624		10.1038/onc.2011.72	http://dx.doi.org/10.1038/onc.2011.72			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21441950				2022-12-17	WOS:000294005100005
J	Merrell, KW; Crofts, JD; Smith, RL; Sin, JH; Kmetzsch, KE; Merrell, A; Miguel, RO; Candelaria, NR; Lin, CY				Merrell, K. W.; Crofts, J. D.; Smith, R. L.; Sin, J. H.; Kmetzsch, K. E.; Merrell, A.; Miguel, R. O.; Candelaria, N. R.; Lin, C-Y			Differential recruitment of nuclear receptor coregulators in ligand-dependent transcriptional repression by estrogen receptor-alpha	ONCOGENE			English	Article						estrogen receptor; transcriptional regulation; hormonal carcinogenesis; coregulators	HUMAN BREAST-CANCER; SURGICAL ADJUVANT BREAST; BOWEL PROJECT P-1; TARGET GENES; HORMONE-RECEPTORS; BINDING-SITES; EXPRESSION; ACTIVATION; MECHANISMS; TAMOXIFEN	Estrogen receptors (ERs) are normally expressed in breast tissues and mediate hormonal functions during development and in female reproductive physiology. In the majority of breast cancers, ERs are involved in regulating tumor cell proliferation and serve as prognostic markers and therapeutic targets in the management of hormone-dependent tumors. At the molecular level, ERs function as ligand-dependent transcription factors and activate target-gene expression following hormone stimulation. Recent transcriptomic and whole-genome-binding studies suggest, however, that ligand-activated ERs can also repress the expression of a significant subset of target genes. To characterize the molecular mechanisms of transcriptional repression by ERs, we examined recruitment of nuclear receptor coregulators, histone modifications and RNA polymerase II docking at ER-binding sites and cis-regulatory regions adjacent to repressed target genes. Moreover, we utilized gene expression data from patient samples to determine potential roles of repressed target genes in breast cancer biology. Results from these studies indicate that nuclear receptor corepressor recruitment is a key feature of ligand-dependent transcriptional repression by ERs, and some repressed target genes are associated with disease progression and response to endocrine therapy. These findings provide preliminary insights into a novel aspect of the molecular mechanisms of ER functions and their potential roles in hormonal carcinogenesis and breast cancer biology. Oncogene (2011) 30, 1608-1614; doi: 10.1038/onc.2010.528; published online 22 November 2010	[Merrell, K. W.; Crofts, J. D.; Smith, R. L.; Sin, J. H.; Kmetzsch, K. E.; Merrell, A.; Miguel, R. O.; Candelaria, N. R.; Lin, C-Y] Brigham Young Univ, Dept Microbiol & Mol Biol, Provo, UT 84602 USA	Brigham Young University	Lin, CY (corresponding author), Brigham Young Univ, Dept Microbiol & Mol Biol, 753 WIDB, Provo, UT 84602 USA.	clin23@central.uh.edu		Lin, Chin-Yo/0000-0002-4461-6216	Brigham Young University; Women's Research Institute; NIH [R03CA143981]; BYU Cancer Research Center; NATIONAL CANCER INSTITUTE [R03CA143981] Funding Source: NIH RePORTER	Brigham Young University; Women's Research Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BYU Cancer Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Mentoring Environment Grant (CYL) from Brigham Young University, a research grant (CYL) from the Women's Research Institute, NIH award number R03CA143981 (CYL) and summer research fellowships (KWM, JDC, RLS, KEK and NRC) from the BYU Cancer Research Center.	Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bookman MA, 2005, INT J GYNECOL CANCER, V15, P291, DOI 10.1111/j.1525-1438.2005.00442.x; Cappelletti V, 2004, ENDOCR-RELAT CANCER, V11, P761, DOI 10.1677/erc.1.00822; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Lin CY, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1667; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nilsson S, 2002, CRIT REV EUKAR GENE, V12, P237, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i4.10; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; Soulez M, 2001, J MOL ENDOCRINOL, V27, P259, DOI 10.1677/jme.0.0270259; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; Stossi F, 2009, MOL CELL BIOL, V29, P1749, DOI 10.1128/MCB.01476-08; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; Wei LN, 2000, J BIOL CHEM, V275, P40782, DOI 10.1074/jbc.M004821200; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776	44	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	13					1608	1614		10.1038/onc.2010.528	http://dx.doi.org/10.1038/onc.2010.528			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21102521				2022-12-17	WOS:000288998300011
J	Smart, CE; Wronski, A; French, JD; Edwards, SL; Asselin-Labat, ML; Waddell, N; Peters, K; Brewster, BL; Brooks, K; Simpson, K; Manning, N; Lakhani, SR; Grimmond, S; Lindeman, GJ; Visvader, JE; Brown, MA				Smart, C. E.; Wronski, A.; French, J. D.; Edwards, S. L.; Asselin-Labat, M-L; Waddell, N.; Peters, K.; Brewster, B. L.; Brooks, K.; Simpson, K.; Manning, N.; Lakhani, S. R.; Grimmond, S.; Lindeman, G. J.; Visvader, J. E.; Brown, M. A.			Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit	ONCOGENE			English	Article						Brca1; mammary gland; mammary epithelial morphogenesis; luminal progenitor; expression profiling; c-kit	EPITHELIAL-CELLS; STEM-CELL; MUTATION CARRIERS; TRANSGENIC MICE; TUMOR-FORMATION; BREAST-TUMORS; CANCER CELLS; EXPRESSION; GENE; RECEPTOR	Disruption of the breast cancer susceptibility gene Brca1 results in defective lobular-alveolar development in the mammary gland and a predisposition to breast tumourigenesis in humans and in mice. Recent evidence suggests that BRCA1 loss in humans is associated with an expansion of the luminal progenitor cell compartment in the normal breast and tumours with a luminal progenitor-like expression profile. To further investigate the role of BRCA1 in the mammary gland, we examined the consequences of Brca1 loss in mouse mammary epithelial cells in vitro and in vivo. Here, we show that Brca1 loss is associated with defective morphogenesis of SCp2 and HC11 mouse mammary epithelial cell lines and that in the MMTV-Cre Brca1(Co/Co) mouse model of Brca1 loss, there is an accumulation of luminal progenitor (CD61(+)CD29(lo)CD24(+)) cells during pregnancy. By day 1 of lactation, there are marked differences in the expression of 1379 genes, with most significantly altered pathways and networks, including lactation, the immune response and cancer. One of the most differentially expressed genes was the luminal progenitor marker, c-kit. Immunohistochemical analysis revealed that the increase in c-kit levels is associated with an increase in c-kit positivity. Interestingly, an inverse association between Brca1 and c-kit expression was also observed during mammary epithelial differentiation, and small interfering RNA-mediated knockdown of Brca1 resulted in a significant increase in c-kit mRNA levels. We found no evidence that c-kit plays a direct role in regulating differentiation of HC11 cells, suggesting that Brca1-mediated induction of c-kit probably contributes to Brca1-associated tumourigenesis via another cellular process, and that c-kit is likely to be a marker rather than a mediator of defective lobular-alveolar development resulting from Brca1 loss. Oncogene (2011) 30, 1597-1607; doi: 10.1038/onc.2010.538; published online 6 December 2010	[Smart, C. E.; Wronski, A.; French, J. D.; Edwards, S. L.; Peters, K.; Brewster, B. L.; Brooks, K.; Brown, M. A.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia; [Smart, C. E.; Lakhani, S. R.] Univ Queensland, Royal Brisbane & Womens Hosp, Clin Res Ctr, Herston, Qld, Australia; [Smart, C. E.; Lakhani, S. R.] Sch Med, Herston, Qld, Australia; [Asselin-Labat, M-L; Lindeman, G. J.; Visvader, J. E.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; [Waddell, N.; Grimmond, S.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; [Simpson, K.; Manning, N.; Brown, M. A.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	University of Queensland; Royal Brisbane & Women's Hospital; University of Queensland; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Queensland; University of Melbourne	Brown, MA (corresponding author), Univ Queensland, Sch Chem & Mol Biosci, Coopers Rd, St Lucia, Qld 4072, Australia.	melissa.brown@uq.edu.au	Grimmond, Sean M/J-5304-2016; Lakhani, Sunil R/I-1970-2018; French, Juliet D/A-4982-2011; Brown, Melissa A/F-1451-2010; Edwards, Stacey/A-4980-2011; Smart, Chanel E/C-9583-2011; Grimmond, Sean/K-3246-2019; French, Juliet/AAV-4435-2020; Waddell, Nicola/H-4929-2015; Brooks, Kelly M/F-8248-2017	Grimmond, Sean M/0000-0002-8102-7998; Lakhani, Sunil R/0000-0003-4067-2760; Grimmond, Sean/0000-0002-8102-7998; French, Juliet/0000-0002-9770-0198; Waddell, Nicola/0000-0002-3950-2476; Brooks, Kelly M/0000-0002-9751-5961; Simpson, Kaylene/0000-0001-9136-1781; Lindeman, Geoffrey/0000-0001-9386-2416; Brown, Melissa/0000-0002-2830-9259; Edwards, Stacey/0000-0001-7428-4139; Manning, Nathan/0000-0002-9914-6311	National Breast Cancer Foundation of Australia; University of Queensland; NBCF; NHMRC	National Breast Cancer Foundation of Australia; University of Queensland(University of Queensland); NBCF; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	We are grateful to Bob Simpson for advice on real-time PCR, Kym Kelly-Taylor for animal husbandry, Vani Selvarajan for mouse genotyping and Lynne Reid for cryosectioning. We acknowledge the ARC Special Research Centre for Functional and Applied Genomics at The Institute of Molecular Bioscience, University of Queensland for support with microarray profiling and analysis. This work was supported by a National Breast Cancer Foundation of Australia and The University of Queensland. JF was supported by an NBCF Training fellowship, SE was supported by an NHMRC CJ Martin Fellowship and JV, GL and SG are Research Fellows of the National Health and Medical Research Council of Australia.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117; Bogorad RL, 2008, P NATL ACAD SCI USA, V105, P14533, DOI 10.1073/pnas.0800685105; Brown MA, 2002, TRANSGENIC RES, V11, P467, DOI 10.1023/A:1020348025139; Clarkson RWE, 2004, BREAST CANCER RES, V6, pR92, DOI 10.1186/bcr754; Cui Y, 2002, J BIOL CHEM, V277, P17830, DOI 10.1074/jbc.M200186200; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Jernstrom H, 1998, BREAST, V7, P320, DOI 10.1016/S0960-9776(98)90074-1; Kijima T, 2002, CANCER RES, V62, P6304; Kubista M, 2002, ONCOGENE, V21, P4747, DOI 10.1038/sj.onc.1205580; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; LaMarca HL, 2008, ENDOCRINOLOGY, V149, P4317, DOI 10.1210/en.2008-0450; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maddison K, 2005, J PATHOL, V205, P181, DOI 10.1002/path.1698; Maia CJB, 2008, MOL CELL BIOCHEM, V314, P113, DOI 10.1007/s11010-008-9771-z; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naylor MJ, 2005, MOL ENDOCRINOL, V19, P1868, DOI 10.1210/me.2004-0254; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Oakes SR, 2008, GENE DEV, V22, P581, DOI 10.1101/gad.1614608; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Raafat A, 2007, ONCOGENE, V26, P662, DOI 10.1038/sj.onc.1209823; Russo J, 2001, Breast J, V7, P278, DOI 10.1046/j.1524-4741.2001.21033.x; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shakya R, 2008, P NATL ACAD SCI USA, V105, P7040, DOI 10.1073/pnas.0711032105; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; Smalley MJ, 2005, CYTOTHERAPY, V7, P497, DOI 10.1080/14653240500361145; Smart CE, 2008, BREAST CANCER RES TR, V112, P237, DOI 10.1007/s10549-007-9859-2; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stein T, 2004, BREAST CANCER RES, V6, pR75, DOI 10.1186/bcr753; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Triplett AA, 2008, NEOPLASIA, V10, P1325, DOI 10.1593/neo.08524; Tsai MH, 2007, CANCER RES, V67, P3845, DOI 10.1158/0008-5472.CAN-06-4250; Tsuda H, 2005, CANCER SCI, V96, P333, DOI 10.1111/j.1349-7006.2005.00060.x; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Vandenbark GR, 1996, CELL GROWTH DIFFER, V7, P1383; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Wright MH, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-29; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yamaji D, 2009, GENE DEV, V23, P2382, DOI 10.1101/gad.1840109	55	19	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	13					1597	1607		10.1038/onc.2010.538	http://dx.doi.org/10.1038/onc.2010.538			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21132007	hybrid			2022-12-17	WOS:000288998300010
J	Yagi, R; Tanaka, M; Sasaki, K; Kamata, R; Nakanishi, Y; Kanai, Y; Sakai, R				Yagi, R.; Tanaka, M.; Sasaki, K.; Kamata, R.; Nakanishi, Y.; Kanai, Y.; Sakai, R.			ARAP3 inhibits peritoneal dissemination of scirrhous gastric carcinoma cells by regulating cell adhesion and invasion	ONCOGENE			English	Article						ARAP3; scirrhous gastric carcinoma; Rho-GAP; cell-ECM adhesion; invasion	DEPENDENT MANNER; SRC; CANCER; RHO; TRAFFICKING; PROTEINS; KINASES	During the analysis of phosphotyrosine-containing proteins in scirrhous gastric carcinoma cell lines, we observed an unusual expression of Arf-GAP with Rho-GAP domain, ankyrin repeat and PH domain 3 (ARAP3), a multimodular signaling protein that is a substrate of Src family kinases. Unlike other phosphotyrosine proteins, such as CUB domain-containing protein 1 (CDCP1) and Homo sapiens chromosome 9 open reading frame 10/oxidative stress-associated Src activator (C9orf10/Ossa), which are overexpressed and hyperphosphorylated in scirrhous gastric carcinoma cell lines, ARAP3 was underexpressed in cancerous human gastric tissues. In this study, we found that overexpression of ARAP3 in the scirrhous gastric carcinoma cell lines significantly reduced peritoneal dissemination. In vitro studies also showed that ARAP3 regulated cell attachment to the extracellular matrix, as well as invasive activities. These effects were suppressed by mutations in the Rho-GTPase-activating protein (GAP) domain or in the C-terminal two tyrosine residues that are phosphorylated by Src. Thus, the expression and phosphorylation state of ARAP3 may affect the invasiveness of cancer by modulating cell adhesion and motility. Our results suggest that ARAP3 is a unique Src substrate that suppresses peritoneal dissemination of scirrhous gastric carcinoma cells. Oncogene (2011) 30, 1413-1421; doi:10.1038/onc.2010.522; published online 15 November 2010	[Sakai, R.] Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan; [Tanaka, M.] Akita Univ, Sch Med, Dept Mol Med & Biochem, Akita 010, Japan; [Sasaki, K.] Natl Cerebral & Cardiovasc Ctr, Dept Pharmacol, Res Inst, Suita, Osaka, Japan; [Nakanishi, Y.; Kanai, Y.] Natl Canc Ctr, Res Inst, Div Pathol, Tokyo 104, Japan	National Cancer Center - Japan; Akita University; National Cerebral & Cardiovascular Center - Japan; National Cancer Center - Japan	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rsakai@ncc.go.jp	Kanai, Yae/AAE-6987-2019	Sakai, Ryuichi/0000-0001-6833-1103	Ministry of Education, Culture, Science and Technology of Japan; Grants-in-Aid for Scientific Research [23650590] Funding Source: KAKEN	Ministry of Education, Culture, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The pEGFP-ARAP3 plasmid was a kind gift from Krugmann S (Cambridge, UK). This work was supported by a Grant-in-Aid for Cancer Research and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Science and Technology of Japan for the Third Term Comprehensive 10-Year Strategy for Cancer Control.	Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Carramusa L, 2007, J CELL SCI, V120, P3870, DOI 10.1242/jcs.014365; Chen TJ, 2006, J NEUROBIOL, V66, P103, DOI 10.1002/neu.20204; Daniele T, 2008, TRAFFIC, V9, P2221, DOI 10.1111/j.1600-0854.2008.00823.x; Faix J, 2006, DEV CELL, V10, P693, DOI 10.1016/j.devcel.2006.05.001; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kim HS, 2010, J NEUROCHEM, V113, P1565, DOI 10.1111/j.1471-4159.2010.06713.x; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Krugmann S, 2006, J CELL SCI, V119, P425, DOI 10.1242/jcs.02755; Krugmann S, 2004, CURR BIOL, V14, P1380, DOI 10.1016/j.cub.2004.07.058; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Matsuoka T, 1998, CLIN EXP METASTAS, V16, P381; Nishimura S, 1996, BRIT J CANCER, V74, P1406, DOI 10.1038/bjc.1996.556; Raaijmakers JH, 2007, CELL SIGNAL, V19, P1249, DOI 10.1016/j.cellsig.2006.12.015; Sarmiento C, 2008, J CELL BIOL, V180, P1245, DOI 10.1083/jcb.200708123; Tanaka M, 2009, MOL CELL BIOL, V29, P402, DOI 10.1128/MCB.01035-08; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Yanagihara K, 2005, CANCER SCI, V96, P323, DOI 10.1111/j.1349-7006.2005.00054.x; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yoon HY, 2008, TRAFFIC, V9, P2236, DOI 10.1111/j.1600-0854.2008.00839.x; 2004, J CELL SCI, V117, P6071	24	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1413	1421		10.1038/onc.2010.522	http://dx.doi.org/10.1038/onc.2010.522			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21076469				2022-12-17	WOS:000288743800004
J	Garcia-Silva, S; Martinez-Iglesias, O; Ruiz-Llorente, L; Aranda, A				Garcia-Silva, S.; Martinez-Iglesias, O.; Ruiz-Llorente, L.; Aranda, A.			Thyroid hormone receptor beta 1 domains responsible for the antagonism with the ras oncogene: role of corepressors	ONCOGENE			English	Article						thyroid hormone receptor; Ras; transformation; cyclin D1; corepressors; coactivators	TUMOR INVASIVENESS; SMRT COREPRESSOR; LIGAND-BINDING; RETINOIC ACID; MOUSE MODEL; CYCLIN D1; N-COR; TRANSCRIPTION; SUPPRESSOR; PATHWAY	The thyroid hormone receptor (TR) is a suppressor of ras-mediated responses. To characterize the receptor domains involved in this function, we analyzed a panel of TR beta 1 mutants for their ability to interfere with ras-driven cyclin D1 activation, formation of transformation foci and tumor growth in nude mice. Our results show that the domains and mechanisms responsible for the anti-transforming and anti-tumorigenic actions of the receptor are divergent from those operating in classical T3-dependent transcriptional activation. TR beta 1 mutants that do not bind co-activators and do not transactivate retained the capacity of suppressing cellular transformation and tumor growth, whereas selective mutations in the hinge region affecting corepressors recruitment abolished these actions, while preserving ligand-dependent transcription. There was a strict parallelism between anti-transforming activity of the various mutants and their ability to antagonize cyclin D1 stimulation by ras, indicating that transrepression mechanisms may have an important function in suppression of the transforming effects of the oncogene by TR beta 1. The inhibitory action of T3 on transformation was further enhanced after over-expression of corepressors, while corepressor depletion by means of small-interference RNA reversed significantly hormonal action. This shows an important functional role of endogenous corepressors in suppression of ras-mediated transformation and tumorigenesis by TR beta 1 Oncogene (2011) 30, 854-864; doi:10.1038/onc.2010.464; published online 18 October 2010	[Aranda, A.] CSIC, Inst Invest Biomed, Dept Endocrine & Nervous Syst Physiopathol, E-28029 Madrid, Spain; [Aranda, A.] Univ Autonoma Madrid, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Dept Endocrine & Nervous Syst Physiopathol, Arturo Duperier 4, E-28029 Madrid, Spain.	aaranda@iib.uam.es	Garcia-Silva, Susana/AAW-8528-2021; Martínez-Iglesias, Olaia Antía/A-9793-2018; Ruiz, Lidia/L-1620-2014; Aranda, Ana/ABG-8820-2020	Garcia-Silva, Susana/0000-0003-1065-0245; Martínez-Iglesias, Olaia Antía/0000-0002-7021-6865; Ruiz, Lidia/0000-0003-1430-9618; Aranda, Ana/0000-0002-8338-9589	Ministerio de Educacion y Ciencia [BFU2007-62402, RD06/0020/0036]; Fondo de Investigaciones Sanitarias; European Grant CRESCENDO [FP-018652]	Ministerio de Educacion y Ciencia(Spanish Government); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); European Grant CRESCENDO	We are grateful to M Sanchez-Prieto and PA Chavez for technical help and to A Zambrano for TR mutants. This work was supported by Grant BFU2007-62402 from Ministerio de Educacion y Ciencia, RD06/0020/0036 and Accion Transversal de Cancer from the Fondo de Investigaciones Sanitarias and by the European Grant CRESCENDO (FP-018652).	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Aranda A, 2009, TRENDS ENDOCRIN MET, V20, P318, DOI 10.1016/j.tem.2009.03.011; Berghagen H, 2002, J BIOL CHEM, V277, P49517, DOI 10.1074/jbc.M209546200; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Castillo AI, 2004, MOL CELL BIOL, V24, P502, DOI 10.1128/MCB.24.2.502-513.2004; Chan IH, 2006, ONCOGENE, V25, P3576, DOI 10.1038/sj.onc.1209389; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; De Bosscher K, 2008, EUR J PHARMACOL, V583, P290, DOI 10.1016/j.ejphar.2007.11.076; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fernandez-Majada V, 2007, CELL CYCLE, V6, P1748, DOI 10.4161/cc.6.14.4429; FILMUS J, 1994, ONCOGENE, V9, P3627; Flamant F, 2006, PHARMACOL REV, V58, P705, DOI 10.1124/pr.58.4.3; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Furuya F, 2009, STEROIDS, V74, P628, DOI 10.1016/j.steroids.2008.10.009; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lazar Mitchell A, 2003, Nucl Recept Signal, V1, pe001; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; Martinez-Iglesias O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006428; Martinez-Iglesias O, 2009, CANCER RES, V69, P501, DOI 10.1158/0008-5472.CAN-08-2198; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; Mendez-Pertuz M, 2003, EMBO J, V22, P3102, DOI 10.1093/emboj/cdg295; Pascual G, 2006, TRENDS ENDOCRIN MET, V17, P321, DOI 10.1016/j.tem.2006.08.005; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Peterson TJ, 2007, MOL CELL BIOL, V27, P5933, DOI 10.1128/MCB.00237-07; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; Sanchez-Martinez R, 2006, EMBO REP, V7, P1030, DOI 10.1038/sj.embor.7400776; Song L, 2005, CANCER RES, V65, P4554, DOI 10.1158/0008-5472.CAN-04-4108; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zhu XG, 2010, ONCOGENE, V29, P1909, DOI 10.1038/onc.2009.476	45	19	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					854	864		10.1038/onc.2010.464	http://dx.doi.org/10.1038/onc.2010.464			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20956942				2022-12-17	WOS:000287444600009
J	Kufe, D				Kufe, D.			Oncogenic function of the MUC1 receptor subunit in gene regulation	ONCOGENE			English	Editorial Material						MUC1; MUC1-C subunit; nuclear localization; transcriptional regulation; Wnt/beta-catenin; p53	BETA-CATENIN; BREAST; TUMORIGENICITY; CARCINOMA; CANCER	The mucin 1 (MUC1) oncoprotein is overexpressed by diverse human cancers; however, it has remained largely unclear how MUC1 contributes to tumorigenesis. In this issue of Oncogene and in concert with published work, Behrens et al. report that the MUC1 receptor subunit activates genes involved in invasion, angiogenesis and metastasis. Oncogene (2010) 29, 5663-5666; doi:10.1038/onc.2010.334; published online 16 August 2010	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Room D830, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA097098, R01CA042802] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA097098-01, R01 CA097098, R01 CA042802, R01 CA042802-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens ME, 2010, ONCOGENE, V29, P5667, DOI 10.1038/onc.2010.327; Deng YZ, 2007, J BIOL CHEM, V282, P36571, DOI 10.1074/jbc.M704141200; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Khodarev N, 2010, ONCOGENE, V29, P920, DOI 10.1038/onc.2009.391; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Pitroda SP, 2009, P NATL ACAD SCI USA, V106, P5837, DOI 10.1073/pnas.0812029106; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008	10	19	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	42					5663	5666		10.1038/onc.2010.334	http://dx.doi.org/10.1038/onc.2010.334			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20711235	Green Accepted			2022-12-17	WOS:000283262500002
J	Liu, Q; Basu, S; Qiu, Y; Tang, F; Dong, F				Liu, Q.; Basu, S.; Qiu, Y.; Tang, F.; Dong, F.			A role of Miz-1 in Gfi-1-mediated transcriptional repression of CDKN1A	ONCOGENE			English	Article						Gfi-1; Miz-1; CKD inhibitors; proliferation	ZINC-FINGER PROTEIN; GROWTH-FACTOR INDEPENDENCE-1; HEMATOPOIETIC STEM-CELLS; TGF-BETA RECEPTOR; C-MYC; T-CELLS; FACTOR GFI1; DIFFERENTIATION; EXPRESSION; SMAD	Zinc-finger (ZF) transcriptional repressor growth factor independence 1 (Gfi-1) has an important role in hematopoiesis and inner ear development, and also functions as an oncoprotein that cooperates with c-Myc in lymphomagenesis. Gfi-1 represses transcription by directly binding to conserved sequences in the promoters of its target genes. CDKN1A encoding p21(Cip1) has been identified as a Gfi-1 target gene and has been shown to contain Gfi-1 binding sites in the upstream promoter region. We show here that Gfi-1 represses CDKN1A in a manner that is independent of its DNA binding activity. Gfi-1 interacts with POZ-ZF transcription factor Miz-1, originally shown to be a c-Myc-interacting partner, and through Miz-1 binds to the CDKN1A core promoter. Interestingly, Gfi-1 and c-Myc, through Miz-1, form a ternary complex on the CDKN1A promoter, and function in collaboration to repress CDKN1A. Gfi-1 knockdown results in enhanced levels of p21(Cip1) and attenuated cell proliferation. Notably, similar to c-Myc, the expression of Gfi-1 is downregulated by transforming growth factor-beta (TGF beta) and the level of Gfi-1 influences the response of cells to the cytostatic effect of TGF beta(.) Our data reveal an important mechanism by which Gfi-1 regulates cell proliferation and may also have implications for understanding the role of Gfi-1 in lymphomagenesis. Oncogene (2010) 29, 2843-2852; doi: 10.1038/onc.2010.48; published online 1 March 2010	[Liu, Q.; Basu, S.; Qiu, Y.; Tang, F.; Dong, F.] Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Dong, F (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St,MS 601, Toledo, OH 43606 USA.	fdong@utnet.utoledo.edu			National Institutes of Health [R15HL091511]; American Cancer Society [RSG-08-307-01]; Ohio Cancer Research Associates Inc; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL091511] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Ohio Cancer Research Associates Inc; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Drs M Eilers, PN Tsichlis, XF Wang and Jinfang Zhu for providing the reagents used in this study, and Dr A Quinn and S Rasche for help with [3H] thymidine incorporation assays. This work was supported in part by grants R15HL091511 (FD) from the National Institutes of Health, RSG-08-307-01 (FD) from The American Cancer Society and a grant (FD) from Ohio Cancer Research Associates Inc.	Basu S, 2009, P NATL ACAD SCI USA, V106, P1433, DOI 10.1073/pnas.0804863106; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Duan ZJ, 2005, MOL CELL BIOL, V25, P10338, DOI 10.1128/MCB.25.23.10338-10351.2005; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; Dwivedi PP, 2005, ENDOCR-RELAT CANCER, V12, P351, DOI 10.1677/erc.1.00920; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Horman SR, 2009, BLOOD, V113, P5466, DOI 10.1182/blood-2008-09-179747; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Kazanjian A, 2004, CANCER RES, V64, P6874, DOI 10.1158/0008-5472.CAN-04-0633; Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; Letterio JJ, 2005, ONCOGENE, V24, P5701, DOI 10.1038/sj.onc.1208922; Lin HK, 2005, ONCOGENE, V24, P5693, DOI 10.1038/sj.onc.1208923; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; McGhee L, 2003, J CELL BIOCHEM, V89, P1005, DOI 10.1002/jcb.10548; Moroy T, 2005, INT J BIOCHEM CELL B, V37, P541, DOI 10.1016/j.biocel.2004.08.011; Pargmann D, 2007, EUR J IMMUNOL, V37, P3551, DOI 10.1002/eji.200737130; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shroyer NF, 2005, GENE DEV, V19, P2412, DOI 10.1101/gad.1353905; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Wallis D, 2003, DEVELOPMENT, V130, P221, DOI 10.1242/dev.00190; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419; Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074-7613(02)00317-5; Zhu JF, 2006, P NATL ACAD SCI USA, V103, P18214, DOI 10.1073/pnas.0608981103; Zhu JF, 2009, J EXP MED, V206, P329, DOI 10.1084/jem.20081666; Zhuang DZ, 2006, J BIOL CHEM, V281, P10745, DOI 10.1074/jbc.M510924200; Zornig M, 1996, ONCOGENE, V12, P1789	45	19	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	19					2843	2852		10.1038/onc.2010.48	http://dx.doi.org/10.1038/onc.2010.48			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190815	Green Accepted			2022-12-17	WOS:000277591900009
J	El-Tanani, MK; Jin, D; Campbell, FC; Johnston, PG				El-Tanani, M. K.; Jin, D.; Campbell, F. C.; Johnston, P. G.			Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression	ONCOGENE			English	Article						osteopontin; INFTM3; interferon; inhibition; breast cancer and metastasis	PROGNOSTIC-SIGNIFICANCE; TRANSCRIPTION FACTOR; METASTASIS; IDENTIFICATION; PROTEIN; GENE; CARCINOMA; FAMILY; CELLS	Osteopontin is a secreted, integrin-binding and phosphorylated acidic glycoprotein, which has an important role in tumour progression. We have shown that Wnt, Ets, AP-1, c-jun and beta-catenin/Lef-1/Tcf-1 stimulates OPN transcription in rat mammary carcinoma cells by binding to a specific promoter sequence. However, co-repressors of OPN have not been identified. In this study, we have used the bacterial two-hybrid system to isolate cDNA-encoding proteins that bind to OPN and modulate its role in malignant transformation. Using this approach we isolated interferon-induced transmembrane protein 3 gene (IFITM3) as a potential protein partner. We show that IFITM3 and OPN interact in vitro and in vivo and that IFITM3 reduces osteopontin (OPN) mRNA expression, possibly by affecting OPN mRNA stability. Stable transfection of IFITM3 inhibits OPN, which mediates anchorage-independent growth, cell adhesion and cell invasion. Northern blot analysis revealed an inverse mRNA expression pattern of IFITM3 and OPN in human mammary cell lines. Inhibition of IFITM3 by antisense RNA promoted OPN protein expression, enhanced cell invasion by parental benign non-invasive Rama 37 cells, indicating that the two proteins interact functionally as well. We also identified an IFITM3 DNA-binding domain, which interacts with OPN, deletion of which abolished its inhibitive effect on OPN. This work has shown for the first time that IFITM3 physically interacts with OPN and reduces OPN mRNA expression, which mediates cell adhesion, cell invasion, colony formation in soft agar and metastasis in a rat model system. Oncogene (2010) 29, 752-762; doi: 10.1038/onc.2009.379; published online 9 November 2009	[El-Tanani, M. K.; Jin, D.; Campbell, F. C.; Johnston, P. G.] Queens Univ Belfast, CCRCB, Belfast BT9 7LB, Antrim, North Ireland	Queens University Belfast	El-Tanani, MK (corresponding author), Queens Univ Belfast, CCRCB, 97 Lisburn Rd, Belfast BT9 7LB, Antrim, North Ireland.	m.el-tanani@qub.ac.uk		El-Tanani, Mohamed/0000-0002-4735-5445	Research and Development Office (R&D), Queen's University Belfast, Northern Ireland, United Kingdom	Research and Development Office (R&D), Queen's University Belfast, Northern Ireland, United Kingdom	We acknowledge support from Research and Development Office (R&D), Queen's University Belfast, Northern Ireland, United Kingdom.	Andreu P, 2006, CANCER RES, V66, P1949, DOI 10.1158/0008-5472.CAN-05-2731; BEHREND EI, 1994, CANCER RES, V54, P832; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brem R, 2003, CELL MOL LIFE SCI, V60, P1235, DOI 10.1007/s00018-003-3016-9; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; El-Tanani MK, 2006, J BIOL CHEM, V281, P26587, DOI 10.1074/jbc.M604403200; Euer N, 2002, ANTICANCER RES, V22, P733; EVANS SS, 1993, J IMMUNOL, V150, P736; Geissinger E, 2002, CANCER RES, V62, P4820; Green CD, 2007, MOL CANCER RES, V5, P1191, DOI 10.1158/1541-7786.MCR-07-0123; Hsieh YH, 2006, CANCER RES, V66, P7119, DOI 10.1158/0008-5472.CAN-06-1002; Jin DC, 2006, INT J ONCOL, V29, P1591; Khan SA, 2002, J CELL BIOCHEM, V85, P728, DOI 10.1002/jcb.10170; Lange U C, 2003, BMC Dev Biol, V3, P1, DOI 10.1186/1471-213X-3-1; LEWIN AR, 1991, EUR J BIOCHEM, V199, P417, DOI 10.1111/j.1432-1033.1991.tb16139.x; Liu D, 2002, BRIT J CANCER, V87, P423, DOI 10.1038/sj.bjc.6600456; Meller R, 2005, J CEREBR BLOOD F MET, V25, P217, DOI 10.1038/sj.jcbfm.9600022; Nicolini A, 2006, CYTOKINE GROWTH F R, V17, P325, DOI 10.1016/j.cytogfr.2006.07.002; Oates AJ, 1996, ONCOGENE, V13, P97; OLESEN JT, 1991, MOL CELL BIOL, V11, P611, DOI 10.1128/MCB.11.2.611; Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X; Real SM, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-38; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rudland PS, 2000, CANCER RES, V60, P1595; Rudland PS, 2002, CANCER RES, V62, P3417; Singhal H, 1997, CLIN CANCER RES, V3, P605; Tanaka SS, 2005, DEV CELL, V9, P745, DOI 10.1016/j.devcel.2005.10.010; Tanaka SS, 2004, DEV DYNAM, V230, P651, DOI 10.1002/dvdy.20085; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Yang HL, 2005, BIOCHEM BIOPH RES CO, V328, P265, DOI 10.1016/j.bbrc.2004.12.159; Yang Y, 2005, CANCER LETT, V221, P191, DOI 10.1016/j.canlet.2004.08.022; Zhang JP, 2009, EXP CELL RES, V315, P304, DOI 10.1016/j.yexcr.2008.10.042	37	19	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					752	762		10.1038/onc.2009.379	http://dx.doi.org/10.1038/onc.2009.379			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901966				2022-12-17	WOS:000274223700011
J	Brady, SN; Maggi, LB; Winkeler, CL; Toso, EA; Gwinn, AS; Pelletier, CL; Weber, JD				Brady, S. N.; Maggi, L. B., Jr.; Winkeler, C. L.; Toso, E. A.; Gwinn, A. S.; Pelletier, C. L.; Weber, J. D.			Nucleophosmin protein expression level, but not threonine 198 phosphorylation, is essential in growth and proliferation	ONCOGENE			English	Article						NPM; ribosome; p19ARF; centrosome	CELL-CYCLE PROGRESSION; NUCLEOLAR PHOSPHOPROTEIN B23; ARF TUMOR-SUPPRESSOR; CENTROSOME DUPLICATION; RIBOSOME BIOGENESIS; DEPENDENT KINASE; NUCLEAR EXPORT; P19(ARF); P53; IDENTIFICATION	Nucleophosmin (NPM), an oligomeric phosphoprotein and nucleolar target of the ARF tumor suppressor, contributes to several critical cellular processes. Previous studies have shown that the human NPM's phosphorylation by cyclin E cyclin-dependent kinase 2 (cdk2) on threonine (Thr) 199 regulates its translocation from the centrosome during cell cycle progression. Given our previous finding that ARF directly binds NPM, impeding its transit to the cytoplasm and arresting cells before S-phase entry, we hypothesized that ARF might also inhibit NPM phosphorylation. However, ARF induction did not impair phosphorylation of the cdk2 target residue in murine NPM, Thr(198). Furthermore, phosphorylation of Thr(198) occurred throughout the cell cycle and was concomitant with increases in overall NPM expression. To investigate the cell's presumed requirement for NPM-Thr(198) phosphorylation in promoting the processes of growth and proliferation, we examined the effects of a non-phosphorylatable NPM mutant, T198A, in a clean cell system in which endogenous NPM had been removed by RNA interference. Here, we show that the T198A mutant is fully capable of executing NPM's described roles in nucleocytoplasmic shuttling, ribosome export and cell cycle progression. Moreover, the proliferative defects observed with stable NPM knockdown were restored by mutant NPM-T198A expression. Thus, we demonstrate that the reduction in NPM protein expression blocks cellular growth and proliferation, whereas phosphorylation of NPM-Thr(198) is not essential for NPM's capacity to drive cell cycle progression and proliferation. Oncogene (2009) 28, 3209-3220; doi: 10.1038/onc.2009.178; published online 29 June 2009	[Weber, J. D.] Washington Univ, Sch Med, Div Mol Oncol, Dept Internal Med,Siteman Canc Ctr, St Louis, MO 63110 USA; [Weber, J. D.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL)	Weber, JD (corresponding author), Washington Univ, Sch Med, Div Mol Oncol, Dept Internal Med,Siteman Canc Ctr, 660 S Euclid Ave,Campus Box 8069, St Louis, MO 63110 USA.	jweber@im.wustl.edu	Maggi, Leonard/L-5217-2019	Maggi, Leonard/0000-0003-0138-0984; Weber, Jason/0000-0002-1069-6983	National Institutes of Health and Department of Defense Era of Hope Scholar Award in Breast Cancer Research; NATIONAL CANCER INSTITUTE [R01CA120436] Funding Source: NIH RePORTER	National Institutes of Health and Department of Defense Era of Hope Scholar Award in Breast Cancer Research(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are indebted to Sheila Stewart, Gregory Longmore, J Alan Diehl, Martine Roussel, Charles Sherr and Gerard Zambetti for gifts of plasmid constructs, antibodies and primary TKO MEFs. In addition, we would like to thank Sheila Stewart, Helen Piwnica-Worms, Michael Tomasson and John Majors for insightful discussions throughout the course of this study. SNB was supported by the Cancer Biology Pathway. CLP was a trainee in the Lucille P Markey Special Emphasis Pathway in Human Pathobiology. JDW was funded through the National Institutes of Health and Department of Defense Era of Hope Scholar Award in Breast Cancer Research.	Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Cha H, 2004, BIOCHEM J, V378, P857, DOI 10.1042/BJ20031173; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Gao H, 2005, J BIOL CHEM, V280, P10988, DOI 10.1074/jbc.M412720200; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; Liu HT, 1999, CANCER LETT, V144, P45, DOI 10.1016/S0304-3835(99)00184-6; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Namboodiri VMH, 2004, ACTA CRYSTALLOGR D, V60, P2325, DOI 10.1107/S0907444904023959; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Okuwaki M, 2002, MOL BIOL CELL, V13, P2016, DOI 10.1091/mbc.02-03-0036; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Pelletier CL, 2007, CANCER RES, V67, P1609, DOI 10.1158/0008-5472.CAN-06-2875; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shinmura K, 2005, FEBS LETT, V579, P6621, DOI 10.1016/j.febslet.2005.10.057; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Uetake Y, 2007, J CELL BIOL, V176, P173, DOI 10.1083/jcb.200607073; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Winey M, 1999, CURR BIOL, V9, pR449, DOI 10.1016/S0960-9822(99)80279-6; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; Yu Y, 2006, MOL CELL BIOL, V26, P3798, DOI 10.1128/MCB.26.10.3798-3809.2006; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; Zatsepina OV, 1999, J CELL SCI, V112, P455	41	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3209	3220		10.1038/onc.2009.178	http://dx.doi.org/10.1038/onc.2009.178			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19561638	Green Accepted			2022-12-17	WOS:000269673400004
J	Kim, MA; Kim, HJ; Jee, HJ; Kim, AJ; Bae, YS; Bae, SS; Yun, J				Kim, M-A; Kim, H-J; Jee, H. J.; Kim, A. J.; Bae, Y-S; Bae, S. S.; Yun, J.			Akt2, but not Akt1, is required for cell survival by inhibiting activation of JNK and p38 after UV irradiation	ONCOGENE			English	Article						Akt1; Akt2; isotype-specific function; UV; JNK; p38	PROTEIN-KINASE-B; ISOFORM-SPECIFIC REGULATION; INSULIN-RESISTANCE; PHOSPHORYLATION; PATHWAY; CANCER; APOPTOSIS; AKT/PKB; ALPHA; MICE	The serine/threonine protein kinase, Akt/PKB, has an essential function in cell survival during response to various stresses. Recent studies have demonstrated that Akt isoforms exhibit some distinct physiological functions, but the isotype-specific functions for Akt in the stress response have not been fully identified. In this study, we analysed the cellular response to genotoxic stress using isogenic wild-type, Akt1(-/-) and Akt2(-/-) mouse embryonic fibroblasts (MEFs). Marked hypersensitivity of Akt2(-/-) MEFs was observed to UV irradiation, whereas wild-type and Akt1(-/-) MEFs showed comparable levels of resistance. Akt2(-/-) mouse aortic endothelial cells also showed hypersensitivity to UV and the reconstitution of Akt2 expression in the Akt2(-/-) MEFs restored the UV resistance of the cells. Interestingly, upon UV irradiation, JNK and p38 were significantly upregulated in Akt2(-/-) MEFs, compared to wild-type and Akt1(-/-) MEFs. Additionally, inhibition of JNK and p38 activation reduced UV-induced cell death. Furthermore, both the hyperactivation of JNK and p38 and the UV-induced cell death in Akt2(-/-) MEFs were completely inhibited by restoring Akt2 expression. These results indicate that Akt2, but not Akt1, is essential for cell survival upon UV irradiation, and that Akt2 prevents UV-induced cell death by inhibiting activation of JNK and p38.	[Kim, M-A; Kim, H-J; Jee, H. J.; Kim, A. J.; Bae, Y-S; Yun, J.] Dong A Univ, Coll Med, Dept Biochem, Pusan 602714, South Korea; [Bae, S. S.] Pusan Natl Univ, Coll Med, Dept Pharmacol, Pusan, South Korea	Dong A University; Pusan National University	Yun, J (corresponding author), Dong A Univ, Coll Med, Dept Biochem, 3-1 Dongdaesin Dong, Pusan 602714, South Korea.	yunj@dau.ac.kr			National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea [0620060-2]; KOSEF (Korea Science and Engineering Foundation) [M1075604000107N560400110]	National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); KOSEF (Korea Science and Engineering Foundation)(Korea Science and Engineering Foundation)	This work was supported by a grant of the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (0620060-2) and Research Program of dual regulation mechanisms of aging and cancer from KOSEF (Korea Science and Engineering Foundation) (M1075604000107N560400110).	Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; Heron-Milhavet L, 2006, MOL CELL BIOL, V26, P8267, DOI 10.1128/MCB.00201-06; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim MA, 2007, EXP MOL MED, V39, P205, DOI 10.1038/emm.2007.23; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Ronai Z, 1999, ONCOGENE, V18, P6084, DOI 10.1038/sj.onc.1203175; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Yun JH, 2005, ONCOGENE, V24, P4009, DOI 10.1038/sj.onc.1208575; Yun SJ, 2008, BIOCHEM BIOPH RES CO, V371, P138, DOI 10.1016/j.bbrc.2008.04.029	24	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1241	1247		10.1038/onc.2008.487	http://dx.doi.org/10.1038/onc.2008.487			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151757				2022-12-17	WOS:000263906200008
J	Zubia, A; Ropero, S; Otaegui, D; Ballestar, E; Fraga, MF; Boix-Chornet, M; Berdasco, M; Martinez, A; Coll-Mulet, L; Gil, J; Cossio, FP; Esteller, M				Zubia, A.; Ropero, S.; Otaegui, D.; Ballestar, E.; Fraga, M. F.; Boix-Chornet, M.; Berdasco, M.; Martinez, A.; Coll-Mulet, L.; Gil, J.; Cossio, F. P.; Esteller, M.			Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity	ONCOGENE			English	Article						angiogenesis; cancer; computational modeling; epigenetics; histones; histone deacetylase inhibitors	HUMAN HDAC8; MECHANISMS; DISCOVERY; DISEASE; SAHA	Histone deacetylases (HDACs) play a key role in the regulation of gene expression and chromatin structure, and drugs targeting these enzymes might have an important impact in the treatment of human cancer. Herein, we report the characterization of (1H)-pyrroles as a new subfamily of HDAC inhibitors obtained by computational modeling of class-I human HDACs. From a functional standpoint, (1H)-pyrroles are powerful inductors of acetylation of histones H3 and H4, and restore the expression of growth-inhibitory genes. From a cellular view, these compounds cause a marked decrease in the viability of cancer cells in vitro and in vivo, associated with a cell-cycle arrest at G2/M and an inhibition of angiogenesis. Thus, (1H)-pyrroles emerge as a novel group of HDAC inhibitors with promising antitumoral features.	[Zubia, A.; Otaegui, D.; Cossio, F. P.] Univ Pais Vasco Euskal Herriko Unibertsitatea, Sch Chem Quim Kim Fak, Donostia San Sebastian, Euskadi, Spain; [Ropero, S.; Ballestar, E.; Fraga, M. F.; Boix-Chornet, M.; Berdasco, M.; Esteller, M.] Spanish Natl Canc Res Ctr CNIO, Canc Epigenet Lab, Madrid, Spain; [Zubia, A.] IkerChem SL, San Sebastian, Spain; [Ropero, S.; Ballestar, E.; Berdasco, M.; Esteller, M.] Bellvitge Inst Biomed Res IDIBELL, PEBC, Barcelona, Catalonia, Spain; [Ropero, S.; Ballestar, E.; Berdasco, M.; Esteller, M.] ICO, Barcelona, Catalonia, Spain; [Ropero, S.] Univ Alcala de Henares, Fac Med, Dept Bioquim & Biol Mol, Madrid, Spain; [Martinez, A.] CSIC, Inst Cajal, Dept Cell Biol & Neuroanat, E-28002 Madrid, Spain; [Coll-Mulet, L.; Gil, J.] Univ Barcelona, IDIBELL, Dept Ciencias Fisiol 2, Barcelona, Catalonia, Spain; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	University of Basque Country; Centro Nacional de Investigaciones Oncologicas (CNIO); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Universidad de Alcala; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, PEBC, 3rd Floor,Av Gran Via Hosp 199-203, Barcelona 08907, Catalonia, Spain.	mesteller@iconcologia.net	Esteller, Manel/L-5956-2014; Martinez, Alfredo/GQH-5998-2022; Ballestar, Esteban/ABG-8561-2020; Fraga, Mario F/H-7824-2017	Esteller, Manel/0000-0003-4490-6093; Martinez, Alfredo/0000-0003-4882-4044; Fraga, Mario F/0000-0001-8450-2603; Cossio, Fernando P./0000-0002-4526-2122; Ballestar, Esteban/0000-0002-1400-2440; Gil, Joan/0000-0002-3686-3903; Otaegui Ansa, Dorleta/0000-0002-8215-354X; ZUBIA OLASCOAGA, AIZPEA/0000-0002-0657-801X	Consolider [CSD2006-49]; Spanish Association Against Cancer (AECC); SMARTER, Ikerchem Ltd.; Universidad del Pais Vasco-Euskal Herriko Unibertsitatea [UE07/16]; Gobierno Vasco-Eusko Jaurlaritza [9/UPV00170.215-13548]; Spanish Ministerio de Educacion y Ciencia [CTQ2007-67528/BQU];  [SAF2007-00027-65134]; ICREA Funding Source: Custom	Consolider(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Association Against Cancer (AECC); SMARTER, Ikerchem Ltd.; Universidad del Pais Vasco-Euskal Herriko Unibertsitatea; Gobierno Vasco-Eusko Jaurlaritza(Basque Government); Spanish Ministerio de Educacion y Ciencia(Spanish Government); ; ICREA(ICREA)	This work was supported by Grants SAF2007-00027-65134, Consolider CSD2006-49, the Spanish Association Against Cancer (AECC), FP6 Grant SMARTER, Ikerchem Ltd., The Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (Grant UE07/16), the Gobierno Vasco-Eusko Jaurlaritza (Grant 9/UPV00170.215-13548) and the Spanish Ministerio de Educacion y Ciencia (CTQ2007-67528/BQU). SR is a 'Ramon y Cajal' Researcher. ME is an ICREA Research Professor.	Balakin KV, 2007, ANTI-CANCER AGENT ME, V7, P576, DOI 10.2174/187152007781668698; Chiorazzi N., 2005, NEW ENGL J MED, V352, P804, DOI [10.1002/9781444300857.ch36, DOI 10.1056/NEJMRA041720, 10.1056/NEJMra041720]; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; MAIER T, 2006, Patent No. 2006105979; Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204; Massa S, 2001, J MED CHEM, V44, P2069, DOI 10.1021/jm015515v; Richardson B, 2007, NAT CLIN PRACT RHEUM, V3, P521, DOI 10.1038/ncprheum0573; Sadri-Vakili G, 2006, NAT CLIN PRACT NEURO, V2, P330, DOI 10.1038/ncpneuro0199; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; Vivanco S, 2000, J AM CHEM SOC, V122, P6078, DOI 10.1021/ja9945360; Wang DF, 2004, J MED CHEM, V47, P3409, DOI 10.1021/jm0498497	19	19	19	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1477	1484		10.1038/onc.2008.501	http://dx.doi.org/10.1038/onc.2008.501			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19169274				2022-12-17	WOS:000264354400009
J	Schiewer, MJ; Morey, LM; Burd, CJ; Liu, Y; Merry, DE; Ho, SM; Knudsen, KE				Schiewer, M. J.; Morey, L. M.; Burd, C. J.; Liu, Y.; Merry, D. E.; Ho, S-M; Knudsen, K. E.			Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer	ONCOGENE			English	Article						androgen receptor; testosterone; prostatic adenocarcinoma; cell cycle	ANDROGEN-RECEPTOR REGULATION; D-DEPENDENT KINASE; INDEPENDENT MECHANISM; CELL-PROLIFERATION; ESTROGEN-RECEPTOR; GENE-EXPRESSION; CARCINOMA-CELLS; CO-REPRESSOR; DNA-BINDING; ACTIVATION	Regulation of the androgen receptor (AR) is critical to prostate cancer (PCa) development; therefore, AR is the first line therapeutic target for disseminated tumors. Cell cycle-dependent accumulation of cyclin D1 negatively modulates the transcriptional regulation of AR through discrete, CDK4-independent mechanisms. The transcriptional corepressor function of cyclin D1 resides within a defined motif termed repressor domain (RD), and it was hypothesized that this motif could be utilized as a platform to develop new strategies for blocking AR function. Here, we demonstrate that expression of the RD peptide is sufficient to disrupt AR transcriptional activation of multiple, prostate-specific AR target genes. Importantly, these actions are sufficient to specifically inhibit S-phase progression in AR-positive PCa cells, but not in AR-negative cells or tested AR-positive cells of other lineages. As expected, impaired cell cycle progression resulted in a suppression of cell doubling. Additionally, cell death was observed in AR-positive cells that maintain androgen dependence and in a subset of castrate-resistant PCa cells, dependent on Akt activation status. Lastly, the ability of RD to cooperate with existing hormone therapies was examined, which revealed that RD enhanced the cellular response to an AR antagonist. Together, these data demonstrate that RD is sufficient to disrupt AR-dependent transcriptional and proliferative responses in PCa, and can enhance efficacy of AR antagonists, thus establishing the impetus for development of RD-based mimetics.	[Merry, D. E.; Knudsen, K. E.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Schiewer, M. J.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Morey, L. M.; Ho, S-M] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Burd, C. J.] NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA; [Liu, Y.; Merry, D. E.] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA; [Ho, S-M] Univ Cincinnati, Coll Med, Cter Environm Genet, Cincinnati, OH USA; [Ho, S-M] Univ Cincinnati, Coll Med, UC Barrett Canc Ctr, Cincinnati, OH USA; [Knudsen, K. E.] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Jefferson University; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Jefferson University	Knudsen, KE (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Bluemle Life Sci Bldg,233 S 10th St,Room 1008A, Philadelphia, PA 19107 USA.	karen.knudsen@kimmelcancercenter.org		Schiewer, Matthew/0000-0002-2325-4228; Burd, Craig/0000-0002-6899-6751; Knudsen, Karen/0000-0002-1301-890X	NIH [CA099996, CA116777, CA015776, CA062269, CA112532];  [T32-CA117846]; NATIONAL CANCER INSTITUTE [T32CA117846, R01CA112532, R01CA099996, R01CA015776, R01CA116777, R01CA062269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank the K Knudsen lab for critical input, especially SM Godoy Tundidor; S Schwemberger, S Fox and M Faradaugh for technical assistance, and the E Knudsen laboratory for commentary. This work was supported by NIH grants CA099996 and CA116777 (to KEK); CA015776, CA062269, CA112532 (to SMH). LMM was supported by training grant T32-CA117846.	Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Balk SP, 2008, NUCL RECEPT SIGNAL, V6; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; Burd CJ, 2005, MOL ENDOCRINOL, V19, P607, DOI 10.1210/me.2004-0266; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng H, 2006, CANCER RES, V66, P10613, DOI 10.1158/0008-5472.CAN-06-0028; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Davies MA, 1999, CANCER RES, V59, P2551; ESQUENET M, 1995, MOL CELL ENDOCRINOL, V109, P105, DOI 10.1016/0303-7207(95)03490-X; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Ghosh PM, 2005, ENDOCR-RELAT CANCER, V12, P119, DOI 10.1677/erc.1.00835; Gottschalk AR, 2005, INT J RADIAT ONCOL, V61, P1183, DOI 10.1016/j.ijrobp.2004.12.024; Gregory CW, 2001, CANCER RES, V61, P2892; Hadaschik BA, 2007, UROL ONCOL-SEMIN ORI, V25, P413, DOI 10.1016/j.urolonc.2007.05.010; Hess-Wilson JK, 2006, CANCER RES, V66, P11998, DOI 10.1158/0008-5472.CAN-06-2249; Hu B, 2007, CANCER RES, V67, P8810, DOI 10.1158/0008-5472.CAN-07-1140; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kato A, 1998, BIOCHEM BIOPH RES CO, V245, P70, DOI 10.1006/bbrc.1998.8377; Knudsen KE, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-15; Knudsen KE, 1999, CANCER RES, V59, P2297; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Li JW, 2006, MOL ENDOCRINOL, V20, P776, DOI 10.1210/me.2005-0298; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Lilja H, 2008, NAT REV CANCER, V8, P268, DOI 10.1038/nrc2351; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAUCHER A, 1993, J CANCER RES CLIN, V119, P669, DOI 10.1007/BF01215986; McMenamin ME, 1999, CANCER RES, V59, P4291; Mehra R, 2007, CANCER RES, V67, P7991, DOI 10.1158/0008-5472.CAN-07-2043; Mehra R, 2007, MODERN PATHOL, V20, P538, DOI 10.1038/modpathol.3800769; Minamiguchi K, 2004, MOL CELL ENDOCRINOL, V214, P175, DOI 10.1016/j.mce.2003.10.060; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mullany LK, 2008, CELL CYCLE, V7, P2215, DOI 10.4161/cc.7.14.6274; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Olshavsky NA, 2008, ONCOGENE, V27, P3111, DOI 10.1038/sj.onc.1210981; Parry D, 1999, MOL CELL BIOL, V19, P1775; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Petre-Draviam CE, 2005, ONCOGENE, V24, P431, DOI 10.1038/sj.onc.1208200; Petre-Draviam CE, 2003, CANCER RES, V63, P4903; Petrylak DP, 2005, UROLOGY, V65, P3, DOI 10.1016/j.urology.2005.03.053; Pienta KJ, 2006, CLIN CANCER RES, V12, P1665, DOI 10.1158/1078-0432.CCR-06-0067; Quayle SN, 2007, P NATL ACAD SCI USA, V104, P1331, DOI 10.1073/pnas.0606718104; Quayle SN, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-32; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; Salesi N, 2005, J EXP CLIN CANC RES, V24, P175; Shand RL, 2006, CURR OPIN UROL, V16, P123, DOI 10.1097/01.mou.0000193384.39351.64; Sharifi N, 2005, JAMA-J AM MED ASSOC, V294, P238, DOI 10.1001/jama.294.2.238; Sharifi N, 2002, J MOL MED, V80, P219, DOI 10.1007/s00109-001-0305-3; Shen MM, 2007, CANCER RES, V67, P6535, DOI 10.1158/0008-5472.CAN-07-1271; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Subbarayan V, 2005, NEOPLASIA, V7, P280, DOI 10.1593/neo.04457; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Walcott JL, 2002, J BIOL CHEM, V277, P50855, DOI 10.1074/jbc.M209466200; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wang CG, 2006, P NATL ACAD SCI USA, V103, P11567, DOI 10.1073/pnas.0603363103; Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066; WONG CI, 1993, J BIOL CHEM, V268, P19004; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	78	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					1016	1027		10.1038/onc.2008.446	http://dx.doi.org/10.1038/onc.2008.446			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079343	Green Accepted			2022-12-17	WOS:000263457400008
J	Hemmati, PG; Normand, G; Gillissen, B; Wendt, J; Doerken, B; Daniel, PT				Hemmati, P. G.; Normand, G.; Gillissen, B.; Wendt, J.; Doerken, B.; Daniel, P. T.			Cooperative effect of p21(Cip1/WAF-1) and 14-3-3 sigma on cell cycle arrest and apoptosis induction by p14(ARF)	ONCOGENE			English	Article						p14(ARF); 14-3-3 sigma; p21; cell cycle; apoptosis; mitotic catastrophe	ARF TUMOR-SUPPRESSOR; NF-KAPPA-B; HUMAN CARCINOMA-CELLS; HUMAN CANCER-CELLS; DNA-DAMAGE; G(2) ARREST; P53-DEPENDENT APOPTOSIS; PROTEIN-BINDING; G2 ARREST; P21	P14(ARF) (p19(ARF) in the mouse) plays a central role in the regulation of cellular proliferation. Although the capacity of p14(ARF) to induce a cell cycle arrest in G1 phase depends on a functional p53/p21-signaling axis, the G2 arrest triggered by p14(ARF) is p53/p21-independent. Using isogeneic HCT116 cells either wild-type or homozygously deleted for p21, 14-3-3 sigma or both, we further investigated the cooperative effect of p21 and 14-3-3 sigma on cell cycle regulation and apoptosis induction by p14(ARF). In contrast to DNA damage, which induces mitotic catastrophe in 14-3-3 sigma-deficient cells, we show here that the expression of p14(ARF) triggers apoptotic cell death, as evidenced by nuclear DNA fragmentation and induction of pan-caspase activities, irrespective of the presence or absence of 14-3-3 sigma. The activation of the intrinsic mitochondrial apoptosis pathway by p14(ARF) was confirmed by cytochrome c release from mitochondria and induction of caspase-9- (LEHDase) and caspase-3/7-like (DEVDase) activities. Moreover, 14-3-3 sigma/p21 double-deficient cells were exceedingly sensitive to apoptosis induction by p14(ARF) as compared to wild-type cells or cells lacking either gene alone. Notably, p14(ARF)-induced apoptosis was preceded by an arrest in the G2 phase of cell cycle, which coincided with downregulation of cdc2 (cdk1) protein expression and lack of its nuclear localization. This indicates that p14(ARF) impairs mitotic entry by targeting the distal DNA damage-signaling pathway and induces apoptotic cell death, rather than mitotic catastrophe, out of a transient G2 arrest. Furthermore, our data delineate that the disruption of G2/M cell cycle checkpoint control critically determines the sensitivity of the cell toward p14(ARF)-induced mitochondrial apoptosis.	[Hemmati, P. G.; Gillissen, B.; Doerken, B.; Daniel, P. T.] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Hemmati, P. G.; Normand, G.; Gillissen, B.; Wendt, J.; Doerken, B.; Daniel, P. T.] Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Daniel, PT (corresponding author), Max Delbruck Ctr Mol Med, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Normand, Guillaume/A-1975-2010	Gillissen, Bernhard/0000-0002-1815-2091; Normand, Guillaume/0000-0003-1228-3813	Deutsche Krebshilfe [10-2088-Da3]	Deutsche Krebshilfe(Deutsche Krebshilfe)	This work was supported by the Deutsche Krebshilfe Grant 10-2088-Da3 to PTD and PGH. We would like to thank Ms Antje and Anja Richter for expert technical assistance.	Bhonde MR, 2006, J BIOL CHEM, V281, P8675, DOI 10.1074/jbc.M511333200; Bhonde MR, 2006, ONCOGENE, V25, P165, DOI 10.1038/sj.onc.1209017; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DURO D, 1995, ONCOGENE, V11, P21; Eymin B, 2006, CELL CYCLE, V5, P759, DOI 10.4161/cc.5.7.2625; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Eymin B, 2006, MOL CELL BIOL, V26, P4339, DOI 10.1128/MCB.02240-05; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Hemmati PG, 2006, ONCOGENE, V25, P6582, DOI 10.1038/sj.onc.1209668; Hemmati PG, 2005, ONCOGENE, V24, P4114, DOI 10.1038/sj.onc.1208579; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Janicke RU, 2007, CELL CYCLE, V6, P407; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Li YX, 2004, ONCOGENE, V23, P7355, DOI 10.1038/sj.onc.1207957; MAO L, 1995, CANCER RES, V55, P2995; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Martinez LA, 2002, CARCINOGENESIS, V23, P1289, DOI 10.1093/carcin/23.8.1289; Morgan DO, 1998, CANCER J SCI AM, V4, pS77; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rocha S, 2005, CELL CYCLE, V4, P756, DOI 10.4161/cc.4.6.1739; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wendt J, 2006, ONCOGENE, V25, P972, DOI 10.1038/sj.onc.1209031; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	50	19	19	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2008	27	53					6707	6719		10.1038/onc.2008.193	http://dx.doi.org/10.1038/onc.2008.193			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18806827				2022-12-17	WOS:000260866200001
J	Koyama, N; Zhang, J; Huqun; Miyazawa, H; Tanaka, T; Su, X; Hagiwara, K				Koyama, N.; Zhang, J.; Huqun; Miyazawa, H.; Tanaka, T.; Su, X.; Hagiwara, K.			Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B	ONCOGENE			English	Article						semaphorin 3B; insulin-like growth factor-binding protein-6; beta-catenin; microarray; tumor suppression	INSULIN-LIKE-GROWTH; FACTOR BINDING PROTEIN-6; CHEMOREPELLENT SEMAPHORIN-III; CANCER CELLS; MEDIATED APOPTOSIS; BREAST-CANCER; RECEPTOR; LUNG; GENES; DIFFERENTIATION	SEMA3B, a member of class 3 semaphorins, is a tumor suppressor. Competition with vascular endothelial growth factor ( VEGF)(165) explains a portion of the activity, whereas the VEGF-independent mechanism was not elucidated. We employed a microarray and screened for the genes whose expression was increased by SEMA3B in NCI-H1299 cells. Insulin-like growth factor-binding protein-6 (IGFBP-6), a tumor suppressor, showed greatest difference in the expression level. Introduction of IGFBP-6 cDNA reduced colony formation both on the dish surface and in soft agar. Insulin-like growth factor II, which antagonizes IGFBP-6, partly abrogated the effect. Inhibition of IGFBP-6 by small interfering RNA diminished the sub-G0/G1 population that was induced by SEMA3B and abrogated the growth suppressive effect of SEMA3B. We concluded that IGFBP-6 is the effector of tumor suppressor activity of SEMA3B in NCI-H1299 cells. It has been reported that beta-catenin suppresses the expression of IGFBP-6. Introduction of beta-catenin into the cells partly abrogated the growth suppressive effect of SEMA3B. Our result indicates that semaphorin signaling and beta-catenin signaling converge on IGFBP-6 and antithetically affect their functions.	[Koyama, N.; Zhang, J.; Huqun; Miyazawa, H.; Tanaka, T.; Hagiwara, K.] Saitama Med Univ, Dept Resp Med, Moroyama, Saitama 3500495, Japan; [Zhang, J.; Su, X.] Inner Mongolia Med Coll, Clin Res Ctr, Hohhot, Inner Mongolia, Peoples R China	Saitama Medical University; Inner Mongolia Medical University	Koyama, N (corresponding author), Saitama Med Univ, Dept Resp Med, 38 Morohongo, Moroyama, Saitama 3500495, Japan.	nkoyama@saitama-med.ac.jp			Japan Society for the Promotion of Science [18390242, 16590738]; Comprehensive Research on Aging and Health from the Ministry of Health, Labor and Welfare, Japan	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Comprehensive Research on Aging and Health from the Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	We thank Ms Akemi Yokote for technical assistance. This study was supported in part by the following grants-in-aid: 1) for scientific research ( nos. 18390242 and 16590738) from the Japan Society for the Promotion of Science and 2) for Comprehensive Research on Aging and Health from the Ministry of Health, Labor and Welfare, Japan.	Bach LA, 1999, HORM METAB RES, V31, P226, DOI 10.1055/s-2007-978723; BACH LA, 1995, ENDOCRINOLOGY, V136, P5061, DOI 10.1210/en.136.11.5061; BACH LA, 1994, ENDOCRINOLOGY, V135, P2168, DOI 10.1210/en.135.5.2168; Barz T, 2006, CANCER RES, V66, P11975, DOI 10.1158/0008-5472.CAN-06-1529; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Chow LSN, 2006, ONCOGENE, V25, P310, DOI 10.1038/sj.onc.1209001; Christensen CRL, 1998, CANCER RES, V58, P1238; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Denys H, 2004, ONCOGENE, V23, P654, DOI 10.1038/sj.onc.1207160; Feng XL, 2006, MOL CELL BIOL, V26, P9244, DOI 10.1128/MCB.01538-06; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Gallicchio MA, 2001, INT J CANCER, V94, P645, DOI 10.1002/ijc.1519; Grellier P, 1998, CANCER RES, V58, P1670; Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; KATO M, 1995, J BIOL CHEM, V270, P12373, DOI 10.1074/jbc.270.21.12373; Koike H, 2005, BRIT J CANCER, V92, P1538, DOI 10.1038/sj.bjc.6602520; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Leng SL, 2001, MOL CELL ENDOCRINOL, V174, P121, DOI 10.1016/S0303-7207(00)00444-5; Mac Gabhann F, 2006, PLOS COMPUT BIOL, V2, P1649, DOI 10.1371/journal.pcbi.0020180; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Nasarre P, 2005, NEOPLASIA, V7, P180, DOI 10.1593/neo.04481; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211; Pasterkamp RJ, 1998, J NEUROSCI, V18, P9962; Scholl FA, 2000, BRIT J CANCER, V82, P1239; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Sueoka N, 2000, ONCOGENE, V19, P4432, DOI 10.1038/sj.onc.1203813; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Tran TS, 2007, ANNU REV CELL DEV BI, V23, P263, DOI 10.1146/annurev.cellbio.22.010605.093554; Usami N, 2003, ONCOGENE, V22, P7922, DOI 10.1038/sj.onc.1206533; Yao RS, 2002, ONCOGENE, V21, P5814, DOI 10.1038/sj.onc.1205422; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	40	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2008	27	51					6581	6589		10.1038/onc.2008.263	http://dx.doi.org/10.1038/onc.2008.263			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18985860				2022-12-17	WOS:000260501700005
J	Chae, HD; Kim, BM; Yun, UJ; Shin, DY				Chae, H. D.; Kim, B. M.; Yun, U. J.; Shin, D. Y.			Deregulation of Cdk2 causes Bim-mediated apoptosis in p53-deficient tumors following actin damage	ONCOGENE			English	Article						actin; apoptosis; polyploidy; Bim; Cdk2	Y TRANSCRIPTION FACTOR; CDK2-DEPENDENT PHOSPHORYLATION; CELL-DEATH; P53; CHECKPOINT; EXPRESSION; INHIBITORS; ARREST; DNA; REREPLICATION	We previously reported that actin damage by treatment with an actin-depolymerizing agent including pectenotoxin-2 induces Bim-mediated apoptosis in p53-deficient human tumors. In this study, we investigated a molecular mechanism underlying Bim-mediated apoptosis of p53-deficient tumor cells following actin damage. We found that actin inhibitors increased the protein levels of p53 and p21 and thereby inactivated both Cdk2 and Cdc2 kinases. However, p53- or p21-knockout cells fail to induce p21 and hence kept both Cdk2 and Cdc2 kinases active even after treatment with actin inhibitor. The p53- or p21-knockout cells became multinucleate and polyploidy in association with induction of apoptosis. Expression of Bcl-x(L) resulted in accumulation of polyploid cells in association with inhibition of apoptosis. However, expression of a dominant negative mutant ( Cdk2dn) and treatment with chemical inhibitors for Cdk2 suppressed not only accumulation of multinucleated cells, but also induction of Bim expression and apoptosis. Therefore, these results suggest that Bim-mediated apoptosis following actin damage due to deregulation of Cdk2 and the cell cycle by the absence of functional p53.	[Chae, H. D.; Kim, B. M.; Yun, U. J.; Shin, D. Y.] Dankook Univ Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea; [Chae, H. D.; Kim, B. M.; Yun, U. J.; Shin, D. Y.] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea	Dankook University; Seoul National University (SNU)	Shin, DY (corresponding author), Dankook Univ Coll Med, Dept Microbiol, Natl Res Lab, Anseo 29, Cheonan 330714, South Korea.	dreamer@dku.edu	Chae, Hee-Don/D-2620-2011					Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Barreyro FJ, 2007, J BIOL CHEM, V282, P27141, DOI 10.1074/jbc.M704391200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chae HD, 2005, ONCOGENE, V24, P4813, DOI 10.1038/sj.onc.1208640; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Di Leonardo A, 1997, CANCER RES, V57, P1013; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1991, CANCER RES, V51, P2212; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Khan SH, 1998, CANCER RES, V58, P396; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Torres K, 1998, CANCER RES, V58, P3620; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200	26	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4115	4121		10.1038/onc.2008.46	http://dx.doi.org/10.1038/onc.2008.46			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18345036				2022-12-17	WOS:000257325100011
J	Hao, H; d'Alincourt-Salazar, M; Kelley, KMM; Shatnawi, A; Mukherjee, S; Shah, YM; Ratnam, M				Hao, H.; d'Alincourt-Salazar, M.; Kelley, K. M. M.; Shatnawi, A.; Mukherjee, S.; Shah, Y. M.; Ratnam, M.			Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by tamoxifen	ONCOGENE			English	Article						estrogen; estrogen receptor; folate receptor; SERM; TAFII30; gene repression	NUCLEAR HORMONE-RECEPTORS; TATA-BINDING PROTEIN; BREAST-CANCER CELLS; THYROID-HORMONE; TRANSCRIPTIONAL REPRESSION; RETINOIC ACID; N-COR; EXPRESSION; ACTIVATION; COMPLEX	Estradiol (E-2) acts through the estrogen receptor ( ER) to downregulate many genes, and tamoxifen (Tam) largely reverses this repression but the underlying mechanisms are unclear. Repression of the folate receptor (FR)-alpha P4 core promoter by ER is enhanced by E-2 and reversed by Tam. This effect was unaffected by inhibition of new protein synthesis and required the E/F and the DNA-binding domains of ER without direct binding of ER to DNA. The repression by E-2/ER was not specific for either Sp1 or TATA elements but was loosely selective for the initiator and flanking sequence. Insertion of a response element or a relatively strong Sp1 cluster to recruit ER upstream of the core promoters caused a switch to activation by E-2/ER that was inhibited by Tam. In nuclear extracts, association of ER witha biotinylated core promoter fragment was promoted by E-2 but Tam blocked this effect. Repression/ de-repression of the P4 promoter and endogenous FR-alpha expression by E-2/Tam required SMRT and/ or NCoR. ER associated with the chromosomal P4 promoter and SMRT and NCoR associated with it in an ER-dependent manner; these associations were favored by E-2 but disrupted by Tam, in the short term, without changes in ER expression. TAFII30 was required for optimal P4 promoter activity and for the repressive association of ER. E-2 may thus maintain a low transcriptional status of genes by favoring direct TAFII30-dependent association of ER with the core promoter in a co-repressor complex containing SMRT and/ or NCoR; this repression is overridden in target genes containing an upstream element that strongly recruits ER. In addition to suppressing the activation of classical E-2 target genes, Tam may upregulate genes by passively dissociating the ER co-repressor complex.	[Hao, H.; d'Alincourt-Salazar, M.; Kelley, K. M. M.; Shatnawi, A.; Mukherjee, S.; Shah, Y. M.; Ratnam, M.] Med Univ Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA		Ratnam, M (corresponding author), Med Univ Ohio, Dept Biochem & Canc Biol, Block Hlth Sci Bldg,3035 Arlington Ave, Toledo, OH 43614 USA.	mratnam@meduohio.edu	shatnawi, Aymen/AAF-5661-2020		NCI NIH HHS [CA 80183, R01 CA080183, CA 103964, R01 CA103964] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080183, R01CA103964] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Glass CK, 2000, GENE DEV, V14, P121; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hao H, 2003, BLOOD, V101, P4551, DOI 10.1182/blood-2002-10-3174; Hayashi SI, 2004, BIOMED PHARMACOTHER, V58, P1, DOI 10.1016/j.biopha.2003.09.005; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kelley KMM, 2003, CANCER RES, V63, P2820; Kershah SM, 2004, GYNECOL ONCOL, V92, P304, DOI 10.1016/j.ygyno.2003.10.007; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; McDonnell DP, 2005, CLIN CANCER RES, V11, p871S; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Moehren U, 2004, ESSAYS BIOCHEM, V40, P89, DOI 10.1042/bse0400089; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; PARKER MG, 1993, BREAST CANCER RES TR, V26, P131, DOI 10.1007/BF00689686; Pink JJ, 1996, CANCER RES, V56, P2321; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Safe S, 2004, PROG NUCLEIC ACID RE, V77, P1, DOI 10.1016/S0079-6603(04)77001-4; SAIKAWA Y, 1995, BIOCHEMISTRY-US, V34, P9951, DOI 10.1021/bi00031a018; SCHMITT M, 1995, J NEUROSCI RES, V40, P152, DOI 10.1002/jnr.490400203; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; STEINER MS, 1995, MOL ENDOCRINOL, V6, P15; Stoner M, 2000, J BIOL CHEM, V275, P22769, DOI 10.1074/jbc.M002188200; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; Varshochi R, 2005, J BIOL CHEM, V280, P3185, DOI 10.1074/jbc.M408063200; Wang DY, 2004, MOL ENDOCRINOL, V18, P402, DOI 10.1210/me.2003-0202; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120	42	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7872	7884		10.1038/sj.onc.1210592	http://dx.doi.org/10.1038/sj.onc.1210592			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599049				2022-12-17	WOS:000252163500005
J	Li, Q; Falsey, RR; Gaitonde, S; Sotello, V; Kislin, K; Martinez, JD				Li, Q.; Falsey, R. R.; Gaitonde, S.; Sotello, V.; Kislin, K.; Martinez, J. D.			Genetic analysis of p53 nuclear importation	ONCOGENE			English	Article						p53; temperature sensitive; mutant; nuclear localization	LOCALIZATION; PROTEIN; SIGNAL	A key step in activation of the p53 tumor suppressor is its transport into the nucleus; however, despite intensive study of p53, the regulation of its subcellular localization is still poorly understood. Here we examined the p53 nuclear importation using a series of mutant cell lines that were resistant to the growth inhibitory effects of temperature-sensitive murine p53 (tsp53). Examination of the p53 subcellular localization in these cell lines showed that the protein was cytoplasmic in most of them. Using a digitonin-permeabilized cell in vitro nuclear import system, we show that cytosols from these cell lines do not support nuclear translocation of a p53 nuclear localization signal (NLS)-containing substrate protein, but promote nuclear localization of a SV40TAgNLS-containing substrate. Complementation assays and use of the mutant cells themselves in the in vitro assays demonstrate that both soluble and insoluble protein components are involved in p53 nuclear import. Collectively, our results suggest that there is a p53 NLS-selective nuclear import pathway and that both soluble and insoluble proteins are involved in its function.	[Li, Q.; Sotello, V.; Martinez, J. D.] Univ Arizona, Dept Cell Biol & Anat, Arizona Canc Ctr, Tucson, AZ 85724 USA; [Falsey, R. R.; Gaitonde, S.; Kislin, K.] Univ Arizona, Canc Biol Interdisciplinary Program, Tucson, AZ 85724 USA; [Falsey, R. R.] Univ Arizona, Undergrad Biol Res Program, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Dept Cell Biol & Anat, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	jmartinez@azcc.arizona.edu			NCI NIH HHS [CA090776, R01 CA090776-03, R01 CA090776, P30 CA023074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090776, P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; Goldman SC, 1996, AM J PATHOL, V148, P1381; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; NISHI K, 1994, J BIOL CHEM, V269, P6320; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Tran EJ, 2006, CELL, V125, P1041, DOI 10.1016/j.cell.2006.05.027	11	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7885	7893		10.1038/sj.onc.1210597	http://dx.doi.org/10.1038/sj.onc.1210597			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599045	Green Accepted			2022-12-17	WOS:000252163500006
J	Flinterman, MB; Mymryk, JS; Klanrit, P; Yousef, AF; Lowe, SW; Caldas, C; Gaken, J; Farzaneh, F; Tavassoli, M				Flinterman, M. B.; Mymryk, J. S.; Klanrit, P.; Yousef, A. F.; Lowe, S. W.; Caldas, C.; Gaken, J.; Farzaneh, F.; Tavassoli, M.			p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing	ONCOGENE			English	Article						p400; EGFR; E1A; apoptosis; head and neck cancer	GROWTH-FACTOR RECEPTOR; SIMIAN ADENOVIRUSES; SEQUENCE-ANALYSIS; E1A PROTEINS; TYPE-5 E1A; APOPTOSIS; P53; INDUCTION; BINDING; CANCER	We have recently shown that E1A protein of human adenovirus downregulates epidermal growth factor receptor (EGFR) expression and induces apoptosis in head and neck (HNSCC) and lung cancer cells independently of their p53 status. E1A has five isoforms of which the major ones E1A12S and E1A13S regulate transcription of cellular genes by binding to transcriptional modulators such as pRB, CtBP, p300 and p400. In this study, we have identified E1A12S isoform to) have the highest effect on EGFR suppression and induction of apoptosis in HNSCC cells. Similar to Ad5, E1A12S from human adenovirus types 2, 3, 9 and 12 suppressed EGFR, whereas E1A12S of adenovirus types 4 and 40 had no effect on EGFR expression. Using deletion mutants of E1A12S we have shown that interaction of E1A with p400, but not p300 or pRB, is required for EGFR suppression and apoptosis. Inhibition of p400 by short hairpin RNA confirmed that HNSCC cells with reduced p400 expression were less sensitive to E1A-induced suppression of EGFR and apoptosis. p300 function was shown to be dispensable, as cells expressing E1A mutants that are unable to bind p300, or p300 knockout cells., remained sensitive to E1A-induced apoptosis. In summary, this study identifies p400 as an important mediator of E1A-induced downregulation of EGFR and apoptosis.	Kings Coll London, Guys Kings & St Thomass Hosp, Inst Dent, Head & Neck Oncol Grp, London SE5 9NU, England; Univ Western Ontario, London Reg Canc Ctr, Dept Oncol & Microbiol, London, ON, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Immunol, London, ON, Canada; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Cambridge, Hutchison MRC Res Ctr, Canc Genom Program, Dept Oncol, Cambridge, England; Kings Coll London, Dept Haematol & Mol Med, London WC2R 2LS, England	University of London; King's College London; Western University (University of Western Ontario); Western University (University of Western Ontario); Cold Spring Harbor Laboratory; University of Cambridge; University of London; King's College London	Tavassoli, M (corresponding author), Kings Coll London, Guys Kings & St Thomass Hosp, Inst Dent, Head & Neck Oncol Grp, 123 Coldharbour Lane, London SE5 9NU, England.	mahvash.tavassoli@kcl.ac.uk	Caldas, Carlos/U-7250-2019; Farzaneh, Farzin/B-4902-2009; Caldas, Carlos/A-7543-2008	Caldas, Carlos/0000-0003-3547-1489; Farzaneh, Farzin/0000-0002-9275-2415; Yousef, Ahmed F./0000-0001-5734-489X	NCI NIH HHS [P01 CA013106, P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; BARBEAU D, 1994, ONCOGENE, V9, P359; Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Flinterman M, 2003, ONCOGENE, V22, P1965, DOI 10.1038/sj.onc.1206190; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Mymryk JS, 1998, NUCLEIC ACIDS RES, V26, P292, DOI 10.1093/nar/26.1.292; PATERSON IC, 1995, BRIT J CANCER, V72, P922, DOI 10.1038/bjc.1995.434; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Samuelson AV, 2005, J BIOL CHEM, V280, P21915, DOI 10.1074/jbc.M414564200; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; YAN DH, 1991, ONCOGENE, V6, P343; Yu DH, 1998, CANCER METAST REV, V17, P195, DOI 10.1023/A:1006054421970	35	19	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6863	6874		10.1038/sj.onc.1210497	http://dx.doi.org/10.1038/sj.onc.1210497			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486071	Green Accepted			2022-12-17	WOS:000250188400002
J	Aleksic, T; Bechtel, M; Krndija, D; von Wichert, G; Knobel, B; Giehl, K; Gress, TM; Michl, P				Aleksic, T.; Bechtel, M.; Krndija, D.; von Wichert, G.; Knobel, B.; Giehl, K.; Gress, T. M.; Michl, P.			CUTL1 promotes tumor cell migration by decreasing proteasome-mediated Src degradation	ONCOGENE			English	Article						CUTL1; migration; Src; Csk; spreading	PROTEIN-TYROSINE KINASES; FAMILY KINASES; ACTIVATION; ADHESION; BETA; DISPLACEMENT; MODULATION; MECHANISMS; MOTILITY; INTEGRIN	Recently, we identified the homeodomain transcription factor CUTL1 as important mediator of cell migration and tumor invasion downstream of transforming growth factor beta ( TGFb). The molecular mechanisms and effectors mediating the pro-migratory and pro-invasive phenotype induced by CUTL1 have not been elucidated so far. Therefore, the aim of this study was to identify signaling pathways downstream of CUTL1 which are responsible for its effects on tumor cell migration. We found that the reduced motility seen after knock down of CUTL1 by RNA interference is accompanied by a delay in tumor cell spreading. This spreading defect is paralleled by a marked reduction of Src protein levels. We show that CUTL1 leads to Src protein stabilization and activation of Src-regulated downstream signaling molecules such as RhoA, Rac1, Cdc42 and ROCK. In addition, we demonstrate that CUTL1 decreases proteasome-mediated Src protein degradation, possibly via transcriptionally upregulating C-terminal Src kinase (Csk). Based on experiments using Src knockout cells ( SYF), we present evidence that Src plays a crucial role in CUTL1-induced tumor cell migration. In conclusion, our findings linking the pro-invasive transcription factor CUTL1 and the Src pathway provide important new insights in the molecular effector pathways mediating CUTL-induced migration and invasion.	Univ Marburg, Dept Internal Med, Div Gastroenterol & Endocrinol, D-35043 Marburg, Germany; Univ Ulm, Dept Internal Med 1, D-7900 Ulm, Germany; Univ Ulm, Dept Pharmacol & Toxicol, D-7900 Ulm, Germany	Philipps University Marburg; Ulm University; Ulm University	Michl, P (corresponding author), Univ Marburg, Dept Internal Med, Div Gastroenterol, Baklingerstr, D-35043 Marburg, Germany.	michlp@med.uni-marburg.de	Krndija, Denis/AAR-5918-2020; Michl, Patrick/HDN-4172-2022; Michl, Patrick/AAG-3987-2021	Krndija, Denis/0000-0001-8686-7542; Gress, Thomas/0000-0002-9333-5461				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757; Kaido T, 2004, J BIOL CHEM, V279, P53762, DOI 10.1074/jbc.M411202200; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; STOVER DR, 1994, J BIOL CHEM, V269, P26885; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	25	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5939	5949		10.1038/sj.onc.1210398	http://dx.doi.org/10.1038/sj.onc.1210398			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369846				2022-12-17	WOS:000249123100011
J	Shimokawa, T; Svard, J; Heby-Henricson, K; Teglund, S; Toftgard, R; Zaphiropoulos, PG				Shimokawa, T.; Svard, J.; Heby-Henricson, K.; Teglund, S.; Toftgard, R.; Zaphiropoulos, P. G.			Distinct roles of first exon variants of the tumor-suppressor Patched1 in Hedgehog signaling	ONCOGENE			English	Article						alternative splicing; GLI; post-transcriptional regulation	BASAL-CELL CARCINOMA; SONIC HEDGEHOG; TRANSCRIPTIONAL ACTIVITY; HUMAN HOMOLOG; HUMAN GLI2; GENE; PATHWAY; PTCH2; EXPRESSION; PROTEIN	Patched1 (PTCH1) is one of the key molecules involved in the Hedgehog (HH) signaling pathway and acts as the receptor of HH ligands. Additionally, PTCH1 inhibits the positive signal transductor Smoothened (SMO). Several PTCH1 splice variants are known but the functional differences among them are not clear. Here, we demonstrate the unique biological properties of the PTCH1 isoforms generated by alternative. rst exon usage. All isoforms examined worked as functional receptors of both Sonic HH and Dese rt HH. However, the signaling upregulated isoform s PTCH1-1B and-1C inhibited SMO and the pathway transcription factors glioma 1 (GLI1) andGL I2 to a higher extent than PTCH1-1 and-1Ckid. Moreover, in situ hybridizations allowed the detection of the Ptch1 isoforms in speci. fic structures of the developing mouse embryo. Additionally, the differences in the N-terminal tail had a dramatic in. uence on the steady states of the proteins, with PTCH1-1B and-1C levels being signifi. cantly higher than PTCH1-1 and-1Ckid. This implies that the pronounced signaling inhibitory properties of PTCH1-1B and-1C may be mostly due to this high-protein expression rather than to intrinsic functional differences. Thus, our study supports a role of splicing variation and prom oter choice for HH signaling regulation.	Karolinska Inst, Dept biosci & Nutr, S-14157 Huddinge, Sweden	Karolinska Institutet	Shimokawa, T (corresponding author), Karolinska Inst, Dept biosci & Nutr, S-14157 Huddinge, Sweden.	Tash@biosci.ki.se; peza@cnt.ki.se	Shimokawa, Takashi/AAA-5870-2020	Shimokawa, Takashi/0000-0001-6549-9277; Zaphiropoulos, Peter/0000-0003-4298-3861				Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Bai CB, 2002, DEVELOPMENT, V129, P4753; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hughes TA, 2006, TRENDS GENET, V22, P119, DOI 10.1016/j.tig.2006.01.001; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kalderon D, 2005, BIOCHEM SOC T, V33, P1509, DOI 10.1042/BST0331509; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kogerman P, 2002, ONCOGENE, V21, P6007, DOI 10.1038/sj.onc.1205865; Lee Y, 2006, CANCER RES, V66, P6964, DOI 10.1158/0008-5472.CAN-06-0505; Liu W, 2002, DEV BIOL, V248, P240, DOI 10.1006/dbio.2002.0733; Motoyama J, 1998, NAT GENET, V18, P104, DOI 10.1038/ng0298-104; Nagao K, 2005, GENOMICS, V85, P462, DOI 10.1016/j.ygeno.2004.11.014; Nybakken K, 2005, NAT GENET, V37, P1323, DOI 10.1038/ng1682; Rahnama F, 2006, BIOCHEM J, V394, P19, DOI 10.1042/BJ20050941; Rahnama F, 2004, BIOCHEM J, V378, P325, DOI 10.1042/BJ20031200; Roessler E, 2005, HUM MOL GENET, V14, P2181, DOI 10.1093/hmg/ddi222; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Shimokawa T, 2004, FEBS LETT, V578, P157, DOI 10.1016/j.febslet.2004.11.006; Smyth I, 1998, HUM GENET, V102, P598, DOI 10.1007/s004390050747; Smyth I, 1999, HUM MOL GENET, V8, P291, DOI 10.1093/hmg/8.2.291; Speek M, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-13; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Uchikawa H, 2006, BIOCHEM BIOPH RES CO, V349, P277, DOI 10.1016/j.bbrc.2006.08.046; Wang XQ, 2001, J BIOL CHEM, V276, P1311, DOI 10.1074/jbc.M005191200; Zaphiropoulos PG, 1999, CANCER RES, V59, P787	31	19	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4889	4896		10.1038/sj.onc.1210301	http://dx.doi.org/10.1038/sj.onc.1210301			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310997				2022-12-17	WOS:000248322500001
J	Allende-Vega, N; Saville, MK; Meek, DW				Allende-Vega, N.; Saville, M. K.; Meek, D. W.			Transcription factor TAFII250 promotes Mdm2-dependent turnover of p53	ONCOGENE			English	Article						p53; Mdm2; TAFII250; transcription factor; ubiquitylation	IN-VIVO; ACIDIC DOMAIN; BINDING-SITE; DNA-DAMAGE; CELL-LINE; MDM2; TAF(II)250; PHOSPHORYLATION; UBIQUITINATION; PROTEIN	The p53 tumour suppressor is regulated mainly by Mdm2, an E3 ubiquitin ligase that promotes the ubiquitylation and proteasome-mediated degradation of p53. Many agents that induce p53 are inhibitors of transcription, suggesting that the p53 pathway can detect a signal(s) arising from transcriptional malfunction. Mdm2 associates with TAFII250, a component of the general transcription factor TFIID. Inactivation of TAFII250 in ts13 cells, which express a temperature-sensitive mutant of TAFII250, leads to the induction of p53 and cell cycle arrest. In the present study, we show that TAFII250 stimulates the ubiquitylation and degradation of p53 in a manner that is dependent upon Mdm2 and requires its acidic domain. Mechanistically, TAFII250 downregulates Mdm2 auto-ubiquitylation, leading to Mdm2 stabilization, and promotes p53-Mdm2 association through a recently defined second binding site in the acidic domain of Mdm2. These data provide a novel route through which TAFII250 can directly influence p53 levels and are consistent with the idea that the maintenance of p53 turnover is coupled to the integrity of RNA polymerase II transcription.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Div Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Meek, DW (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	david.meek@cancer.org.uk		Allende-Vega, Nerea/0000-0001-5569-6461	Cancer Research UK [A6613] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Buchmann AM, 2004, MOL CELL BIOL, V24, P5332, DOI 10.1128/MCB.24.12.5332-5339.2004; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kulikov R, 2006, J BIOL CHEM, V281, P28575, DOI 10.1074/jbc.M513311200; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wassarman DA, 2001, J CELL SCI, V114, P2895; Wasylyk C, 2000, MOL CELL BIOL, V20, P5554, DOI 10.1128/MCB.20.15.5554-5570.2000; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yee KS, 2005, CARCINOGENESIS, V26, P1317, DOI 10.1093/carcin/bgi122; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103; Zhu Y, 2001, Respir Res, V2, P300, DOI 10.1186/rr73	34	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4234	4242		10.1038/sj.onc.1210209	http://dx.doi.org/10.1038/sj.onc.1210209			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237821	Green Accepted			2022-12-17	WOS:000247619900006
J	Aiyar, SE; Blair, AL; Hopkinson, DA; Bekiranov, S; Li, R				Aiyar, S. E.; Blair, A. L.; Hopkinson, D. A.; Bekiranov, S.; Li, R.			Regulation of clustered gene expression by cofactor of BRCA1 (COBRA1) in breast cancer cells	ONCOGENE			English	Article						COBRA1; clustered gene expression; estrogen; transcription; NELF	INTESTINAL TREFOIL FACTOR; TRANSCRIPTION ELONGATION-FACTOR; X-CHROMOSOME INACTIVATION; APOLIPOPROTEIN-D; PROSTATE-CANCER; TISSUE INHIBITOR; RETINOIC ACID; MESSENGER-RNA; ESTROGEN; NELF	Eucaryotic genes that are coordinately expressed tend to be clustered. Furthermore, gene clusters across chromosomal regions are often upregulated in various tumors. However, relatively little is known about how gene clusters are coordinately expressed in physiological or pathological conditions. Cofactor of BRCA1 (COBRA1), a subunit of the human negative elongation factor, has been shown to repress estrogen-stimulated transcription of trefoil factor 1 (TFF1 or pS2) by stalling RNA polymerase II. Here, we carried out a genome-wide study to identify additional physiological target genes of COBRA1 in breast cancer cells. The study identified a total of 134 genes that were either activated or repressed upon small hairpin RNA-mediated reduction of COBRA1. Interestingly, many COBRA1-regulated genes reside as clusters on the chromosomes and have been previously implicated in cancer development. Detailed examination of two such clusters on chromosome 21 (21q22) and chromosome X (Xp11) reveal s that COBRA1 is physically associated with a subset of its regulated genes in each cluster. In addition, COBRA1 was shown to regulate both estrogen-dependent and - independent transcription of the gene cluster at 21q22, which encompasses the previously identified COBRA1-regulated TFF1 (pS2) locus. Thus, COBRA1 plays a critical role in the regulation of clustered gene expression at preferred chromosomal domains in breast cancer cells.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Li, R (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	rl2t@virginia.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064604] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK064604] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiyar SE, 2004, GENE DEV, V18, P2134, DOI 10.1101/gad.1214104; Anderson CL, 2002, HUM GENET, V110, P271, DOI 10.1007/s00439-002-0676-8; Anderson CL, 1999, AM J HUM GENET, V65, P699, DOI 10.1086/302556; Balleine RL, 1999, HISTOL HISTOPATHOL, V14, P571, DOI 10.14670/HH-14.571; Banerjee S, 2003, NEOPLASIA, V5, P63, DOI 10.1016/S1476-5586(03)80018-0; BLAIS Y, 1995, INT J CANCER, V62, P732, DOI 10.1002/ijc.2910620614; Bodey B, 2002, EXPERT OPIN BIOL TH, V2, P577, DOI 10.1517/14712598.2.6.577; Burton JD, 2004, CLIN CANCER RES, V10, P6606, DOI 10.1158/1078-0432.CCR-04-0182; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Carsol JL, 2002, MOL ENDOCRINOL, V16, P1696, DOI 10.1210/me.16.7.1696; CHEN L, 1990, ONCOGENE, V5, P1391; Chen ME, 1998, J BIOL CHEM, V273, P17618, DOI 10.1074/jbc.273.28.17618; Chinery R, 1996, GENOMICS, V32, P281, DOI 10.1006/geno.1996.0117; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Clark JW, 1999, BRIT J CANCER, V81, P1002, DOI 10.1038/sj.bjc.6690799; De Backer O, 1999, CANCER RES, V59, P3157; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Duan ZF, 2003, CLIN CANCER RES, V9, P2778; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fata JE, 2004, BREAST CANCER RES, V6, P1, DOI 10.1186/bcr634; Gallagher PG, 2003, TOXICON, V41, P429, DOI 10.1016/S0041-0101(02)00359-8; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Gonzalez MA, 2003, J CLIN ONCOL, V21, P4306, DOI 10.1200/JCO.2003.04.121; Gott P, 1996, EUR J HUM GENET, V4, P308; HAHNEL E, 1994, PATHOBIOLOGY, V62, P82, DOI 10.1159/000163882; HIROTA S, 1995, LAB INVEST, V72, P64; Hoevel T, 2002, J CELL PHYSIOL, V191, P60, DOI 10.1002/jcp.10076; Hurst LD, 2004, NAT REV GENET, V5, P299, DOI 10.1038/nrg1319; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Jazaeri Amir A, 2004, J Transl Med, V2, P32, DOI 10.1186/1479-5876-2-32; Koon N, 2004, NEOPLASIA, V6, P143, DOI 10.1593/neo.03385; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; LOPEZBOADO YS, 1994, J BIOL CHEM, V269, P26871; Mashino K, 2001, BRIT J CANCER, V85, P713, DOI 10.1054/bjoc.2001.1974; May FEB, 1997, J PATHOL, V183, P4; McChesney PA, 2006, CANCER RES, V66, P1346, DOI 10.1158/0008-5472.CAN-05-3593; Mikhitarian K, 2005, CLIN CANCER RES, V11, P3697, DOI 10.1158/1078-0432.CCR-04-2164; Moggs JG, 2005, J MOL ENDOCRINOL, V34, P535, DOI 10.1677/jme.1.01677; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Nakopoulou L, 2003, APMIS, V111, P1027, DOI 10.1111/j.1600-0463.2003.apm1111105.x; Narita T, 2003, MOL CELL BIOL, V23, P1863, DOI 10.1128/MCB.23.6.1863-1873.2003; PAGANI A, 1994, VIRCHOWS ARCH, V425, P459; Palangat M, 2005, P NATL ACAD SCI USA, V102, P15036, DOI 10.1073/pnas.0409405102; Poulsom R, 1997, J PATHOL, V183, P30, DOI 10.1002/(SICI)1096-9896(199709)183:1<30::AID-PATH1085>3.0.CO;2-K; Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Schmitt H, 1996, CYTOGENET CELL GENET, V72, P299, DOI 10.1159/000134208; SHEIKH MS, 1993, MOL CELL ENDOCRINOL, V92, P153, DOI 10.1016/0303-7207(93)90002-2; Shetty A, 2005, BRIT J CANCER, V93, P1295, DOI 10.1038/sj.bjc.6602829; Singer GAC, 2005, MOL BIOL EVOL, V22, P767, DOI 10.1093/molbev/msi062; Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5; Tian W, 2004, CANCER SCI, V95, P491, DOI 10.1111/j.1349-7006.2004.tb03238.x; Toi M, 1998, BREAST CANCER RES TR, V52, P113, DOI 10.1023/A:1006167202856; Tokes AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983; TOMASETTO C, 1992, GENOMICS, V13, P1328, DOI 10.1016/0888-7543(92)90059-2; Vestergaard EM, 2006, CLIN CANCER RES, V12, P807, DOI 10.1158/1078-0432.CCR-05-1545; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wu CH, 2005, NUCLEIC ACIDS RES, V33, P1269, DOI 10.1093/nar/gki274; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403; Wu YM, 2005, ENDOCRINOLOGY, V146, P237, DOI 10.1210/en.2004-0889; Wurtz SO, 2005, ENDOCR-RELAT CANCER, V12, P215, DOI 10.1677/erc.1.00719; Xu XQ, 2005, J BIOL CHEM, V280, P23987, DOI 10.1074/jbc.M503869200; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhong HJ, 2004, BIOCHEM BIOPH RES CO, V325, P568, DOI 10.1016/j.bbrc.2004.10.079; Zhou Y, 2003, CANCER RES, V63, P5781	71	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2543	2553		10.1038/sj.onc.1210047	http://dx.doi.org/10.1038/sj.onc.1210047			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043641	Bronze			2022-12-17	WOS:000245831200002
J	Abdulrahman, M; Maina, EN; Morris, MR; Zatyka, M; Raval, RR; Banks, RE; Wiesener, MS; Richards, FM; Johnson, CM; Latif, F; Maher, ER				Abdulrahman, M.; Maina, E. N.; Morris, M. R.; Zatyka, M.; Raval, R. R.; Banks, R. E.; Wiesener, M. S.; Richards, F. M.; Johnson, C. M.; Latif, F.; Maher, E. R.			Identification of novel VHL targets that are associated with the development of renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; VHL; microarray; gene expression	HIPPEL-LINDAU-DISEASE; PROTEINASE-ACTIVATED RECEPTOR-2; HYPOXIA-INDUCIBLE FACTOR; TUMOR-SUPPRESSOR PROTEIN; CYCLIN D1; DIFFERENTIAL EXPRESSION; GERMLINE MUTATIONS; ENDOTHELIAL-CELLS; THYMOSIN BETA(4); MOUSE MODEL	von Hippel-Lindau (VHL) disease is a dominantly inherited family cancer syndrome characterized by the development of retinal and central nervous system haemangioblastomas, renal cell carcinoma (RCC) and phaeochromocytoma. Specific germline VHL mutations may predispose to haemangioblastomas, RCC and phaeochromocytoma to a varying extent. Although dysregulation of the hypoxia-inducible transcription factor-2 and JunB have been linked to the development of RCC and phaeochromocytoma, respectively, the precise basis for genotype-phenotype correlations in VHL disease have not been defined. To gain insights into the pathogenesis of RCC in VHL disease we compared gene expression microarray profiles in a RCC cell line expressing a Type 1 or Type 2B mutant pVHL (RCC-associated) to those of a Type 2A or 2C mutant (not associated with RCC). We identified 19 differentially expressed novel VHL target genes linked to RCC development. Eight targets were studied in detail by quantitative real-time polymerase chain reaction (three downregulated and five upregulated by wild-type VHL) and for six genes the effect of VHL inactivation was mimicked by hypoxia (but hypoxic-induction of smooth muscle alpha-actin 2 was specific for a RCC cell line). The potential role of four RCC-associated VHL target genes was assessed in vitro. NB thymosin beta (TMSNB) and proteinase-activated receptor 2 (PAR2) (both downregulated by wt pVHL) increased cell growth and motility in a RCC cell line, but aldehyde dehydrogenase (ALDH)1 and ALDH7 had no effect. These findings implicate TMSNB and PAR2 candidate oncogenes in the pathogenesis of VHL-associated RCC.	Univ Birmingham, Sch Med, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Med, Canc Res UK, Renal Mol Oncol Res Grp, Birmingham B15 2TT, W Midlands, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England; St James Univ Hosp, Canc Res UK, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England; Univ Erlangen Nurnberg, Interdisciplinary Ctr Clin Res, IZKF, Erlangen, Germany; Pfizer Globaol R&D, Discovery Biol, Sandwich, Kent, England	University of Birmingham; Cancer Research UK; University of Birmingham; University of Oxford; Wellcome Centre for Human Genetics; Cancer Research UK; Saint James's University Hospital; University of Erlangen Nuremberg; Pfizer	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	E.R.Maher@bham.ac.uk	Morris, Mark/C-6413-2008; MAHER, EAMONN R/A-9507-2008; Zatyka, Malgorzata/D-9340-2017	MAHER, EAMONN R/0000-0002-6226-6918; Zatyka, Malgorzata/0000-0003-3427-1653; Banks, Rosamonde/0000-0002-0042-8715; Johnson, Claire/0000-0003-4428-3594; Morris, Mark/0000-0002-0700-355X; Abdulrahman, Mahera/0000-0001-6271-3776				Baba M, 2003, ONCOGENE, V22, P2728, DOI 10.1038/sj.onc.1206373; Bertog M, 1999, J PHYSIOL-LONDON, V521, P3, DOI 10.1111/j.1469-7793.1999.00003.x; Bindra RS, 2002, CANCER RES, V62, P3014; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHA HJ, 2003, J NATL CANCER I, P1674; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cocks TM, 1999, GASTROENTEROLOGY, V116, P586, DOI 10.1016/S0016-5085(99)70180-0; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Danahay H, 2001, AM J PHYSIOL-CELL PH, V280, pC1455, DOI 10.1152/ajpcell.2001.280.6.C1455; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Frungieri MB, 2002, P NATL ACAD SCI USA, V99, P15072, DOI 10.1073/pnas.232422999; GRANT DS, 1995, J CELL SCI, V108, P3685; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; HALL AK, 1994, MED HYPOTHESES, V43, P125, DOI 10.1016/0306-9877(94)90135-X; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hollenberg MD, 2002, AM J PHYSIOL-CELL PH, V283, pC1347, DOI 10.1152/ajpcell.00304.2002; Hoogerwerf WA, 2001, J NEUROSCI, V21, P9036, DOI 10.1523/JNEUROSCI.21-22-09036.2001; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Iguchi K, 1999, BIOCHEM PHARMACOL, V57, P1105, DOI 10.1016/S0006-2952(99)00030-1; Jiang YD, 2003, MOL CANCER RES, V1, P453; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Knauth K, 2006, ONCOGENE, V25, P370, DOI 10.1038/sj.onc.1209062; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Li DS, 2004, MOL CELL BIOL, V24, P3838, DOI 10.1128/MCB.24.9.3838-3848.2004; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maher ER, 2004, CURR MOL MED, V4, P833, DOI 10.2174/1566524043359827; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; Maina EN, 2005, ONCOGENE, V24, P4549, DOI 10.1038/sj.onc.1208649; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Milia AF, 2002, CIRC RES, V91, P346, DOI 10.1161/01.RES.0000031958.92781.9E; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; NEUMANN HPH, 1995, JAMA-J AM MED ASSOC, V274, P1149; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Niu M, 2000, CELL ADHES COMMUN, V7, P311, DOI 10.3109/15419060009015002; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Vergnolle N, 2001, TRENDS PHARMACOL SCI, V22, P146, DOI 10.1016/S0165-6147(00)01634-5; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Webster AR, 1998, AM J HUM GENET, V63, P1025, DOI 10.1086/302037; Wiesener MS, 2001, CANCER RES, V61, P5215; Woodward ER, 1997, HUM MOL GENET, V6, P1051, DOI 10.1093/hmg/6.7.1051; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Zatyka M, 2002, CANCER RES, V62, P3803; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.3.CO;2-9	57	19	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1661	1672		10.1038/sj.onc.1209932	http://dx.doi.org/10.1038/sj.onc.1209932			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	17001320	Bronze			2022-12-17	WOS:000244782500017
J	Klampfer, L; Huang, J; Kaler, P; Sasazuki, T; Shirasawa, S; Augenlicht, L				Klampfer, L.; Huang, J.; Kaler, P.; Sasazuki, T.; Shirasawa, S.; Augenlicht, L.			STAT1-independent inhibition of cyclooxygenase-2 expression by IFN gamma; a common pathway of IFN gamma-mediated gene repression but not gene activation	ONCOGENE			English	Article						STAT1; COX-2; JAK; IFN; colon ucancer	COLORECTAL-CANCER PREVENTION; CELL LUNG-CANCER; INTERFERON-GAMMA; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; SIGNALING PATHWAY; BINDING PROTEIN; DNA-BINDING; KI-RAS	Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in the synthesis of prostaglandins, promotes the development of colorectal cancer, and is a key molecular target of nonsteroidal anti-inflammatory drugs, compounds that reduce the relative risk of developing colon cancer. In this study, we showed that interferon gamma (IFN gamma) inhibits the expression of COX-2 protein in intestinal epithelial cells (IECs) through a pathway that requires Janus-activated kinase (JAK) activity. In contrast, we demonstrated that transcriptional inhibition of COX-2 by IFN beta or IFN gamma occurs in cells with silenced signal transducer and activator of transcription 1 (STAT1) expression and that IFNs retained the ability to inhibit COX-2 transcription in cells with activated RasV12, in which IFN gamma failed to induce STAT1. Thus, unlike the activity of JAK, STAT1 is not required for the inhibition of COX-2 expression by IFN gamma. In contrast to COX-2, the activation of genes in response to IFN gamma, such as interferon regulatory factor-1, was severely impaired by both STAT1 silencing and by constitutive Ras signaling. To determine whether there is a general differential requirement for STAT1 in gene activation and gene repression in response to IFN gamma in intestinal cells, we performed genome-wide analysis of IFN gamma target genes in an IEC line in which STAT1 expression was silenced by small interfering RNA. The results confirmed that the activation of the majority of genes by IFN gamma required STAT1. In contrast, the repression of several genes, as we showed for COX-2 specifically, was largely unaffected in cells with silenced STAT1. Our results therefore demonstrate that in general gene activation by IFNc is more sensitive to STAT1 deficiency than gene repression, and suggest that IFNc activates and represses gene expression via distinct pathways that can be distinguished, at least in part, by their requirement for STAT1.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Int Med Ctr Japan, Inst Res, Shinjuku Ku, Tokyo, Japan	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; National Center for Global Health & Medicine - Japan	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NATIONAL CANCER INSTITUTE [U54CA100926, R01CA111361] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111361, U54 CA100926] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Araki Y, 2003, CANCER RES, V63, P728; Battcock SA, 2006, J VIROL, V80, P4422, DOI 10.1128/JVI.80.9.4422-4430.2006; Biasco G, 2002, DIGEST LIVER DIS, V34, P339, DOI 10.1016/S1590-8658(02)80127-X; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Blanco JCG, 2000, J EXP MED, V191, P2131, DOI 10.1084/jem.191.12.2131; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Clifford JL, 2002, CLIN CANCER RES, V8, P2067; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Guy-Grand D, 1998, EUR J IMMUNOL, V28, P730, DOI 10.1002/(SICI)1521-4141(199802)28:02<730::AID-IMMU730>3.0.CO;2-U; Hanna N, 2004, AM J REPROD IMMUNOL, V51, P311, DOI 10.1111/j.1600-0897.2004.00162.x; Higaki S, 1999, J GASTROEN HEPATOL, V14, P709, DOI 10.1046/j.1440-1746.1999.01938.x; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Janabi N, 2004, J NEUROIMMUNOL, V156, P113, DOI 10.1016/j.jneuroim.2004.07.012; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200; Klampfer L, 2003, J BIOL CHEM, V278, P46278, DOI 10.1074/jbc.M304721200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Landolfo S, 2000, Hematol J, V1, P7, DOI 10.1038/sj.thj.6200004; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lindner Daniel J, 2002, Curr Oncol Rep, V4, P510, DOI 10.1007/s11912-002-0065-4; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Muller-Tidow C, 2004, LUNG CANCER, V45, pS145, DOI 10.1016/j.lungcan.2004.07.000; Navarro A, 2003, J LEUKOCYTE BIOL, V73, P540, DOI 10.1189/jlb.1002508; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Ramsauer K, 2002, P NATL ACAD SCI USA, V99, P12859, DOI 10.1073/pnas.192264999; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Sheng HM, 2001, CANCER RES, V61, P2670; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sol VVD, 2005, J IMMUNOL, V174, P2825, DOI 10.4049/jimmunol.174.5.2825; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Wright KL, 2004, BRIT J PHARMACOL, V141, P1091, DOI 10.1038/sj.bjp.0705719	50	19	20	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2071	2081		10.1038/sj.onc.1210015	http://dx.doi.org/10.1038/sj.onc.1210015			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016440				2022-12-17	WOS:000245313400009
J	Sui, Y; Yang, Z; Xiong, S; Zhang, L; Blanchard, KL; Peiper, SC; Dynan, WS; Tuan, D; Ko, L				Sui, Y.; Yang, Z.; Xiong, S.; Zhang, L.; Blanchard, K. L.; Peiper, S. C.; Dynan, W. S.; Tuan, D.; Ko, L.			Gene amplification and associated loss of 5 ' regulatory sequences of CoAA in human cancers	ONCOGENE			English	Article						gene amplification; CoAA oncogene; transcriptional coactivator	BINDING PROTEIN; CHROMOSOMAL TRANSLOCATIONS; RECEPTOR COREGULATORS; SYNOVIAL SARCOMA; DNA METHYLATION; FRAGILE SITES; COACTIVATOR; EXPRESSION; IDENTIFICATION; TRANSCRIPTION	CoAA is an RRM-containing transcriptional coactivator that stimulates transcriptional activation and regulates alternative splicing. We show that the CoAA gene is amplified at the chromosome 11q13 locus in a subset of primary human cancers including non-small cell lung carcinoma, squamous cell skin carcinoma and lymphoma. Analysis of 42 primary tumors suggests that CoAA amplifies independently from the CCND1 locus. Detailed mapping of three CoAA amplicons reveals that the amplified CoAA gene is consistently located at the 50 boundaries of the amplicons. The CoAA coding and basal promoter sequences are retained within the amplicons but upstream silencing sequences are lost. CoAA protein is overexpressed in tumors containing the amplified CoAA gene. RNA dot blot analysis of 100 cases of primary tumors suggests elevated CoAA mRNA expression. CoAA positively regulates its own basal promoter in transfection assays. Thus, gene amplification, loss of silencing sequence and positive feedback regulation may lead to drastic upregulation of CoAA protein. CoAA has transforming activities when tested in soft agar assays, and CoAA is homologous to oncoproteins EWS and TLS, which regulate alternative splicing. These data imply that CoAA may share a similar oncogenic mechanism with oncogene EWS and that CoAA deregulation may alter the alternative splicing of target genes.	Med Coll Georgia, Dept Pathol, IMMAG, Augusta, GA 30912 USA; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Lilly Res Labs, Indianapolis, IN USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Eli Lilly	Ko, L (corresponding author), Med Coll Georgia, Dept Pathol, IMMAG, 1120 15th St,CB2803, Augusta, GA 30912 USA.	lko@mcg.edu		Dynan, William/0000-0002-4045-5662; Ko, Lan/0000-0002-0089-9090	NATIONAL CANCER INSTITUTE [R01CA098239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073453] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA098239-03, R01 CA098239] Funding Source: Medline; NHLBI NIH HHS [R01 HL089519, R01 HL073453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Auboeuf D, 2005, MOL CELL BIOL, V25, P5307, DOI 10.1128/MCB.25.13.5307-5316.2005; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; Bystritskiy AA, 2004, CRIT REV EUKAR GENE, V14, P65, DOI 10.1615/CritRevEukaryotGeneExpr.v14.40; Caiafa P, 2005, J CELL BIOCHEM, V94, P257, DOI 10.1002/jcb.20325; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Gibbons R, 2005, GENOME, V48, P160, DOI 10.1139/G04-085; Grandinetti KB, 2006, ONCOGENE, V25, P706, DOI 10.1038/sj.onc.1209095; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Guan XY, 1996, CANCER RES, V56, P3446; Iwasaki T, 2001, J BIOL CHEM, V276, P33375, DOI 10.1074/jbc.M101517200; Jasinska A, 2004, FEBS LETT, V567, P136, DOI 10.1016/j.febslet.2004.03.109; Kalnina Z, 2005, GENE CHROMOSOME CANC, V42, P342, DOI 10.1002/gcc.20156; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim J, 1999, PHYSIOL GENOMICS, V1, P127, DOI 10.1152/physiolgenomics.1999.1.3.127; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Koreth J, 1999, J PATHOL, V187, P28, DOI 10.1002/(SICI)1096-9896(199901)187:1<28::AID-PATH166>3.0.CO;2-R; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; Lee JW, 2005, STEM CELLS, V23, P738, DOI 10.1634/stemcells.2004-0375; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Penalva LOF, 2003, MICROBIOL MOL BIOL R, V67, P343, DOI 10.1128/MMBR.67.3.343-359.2003; Rabbitts TH, 1999, J PATHOL, V187, P39; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Schmid CW, 1998, NUCLEIC ACIDS RES, V26, P4541, DOI 10.1093/nar/26.20.4541; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zainabadi K, 2005, GENOMICS, V85, P704, DOI 10.1016/j.ygeno.2005.02.014; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	40	19	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					822	835		10.1038/sj.onc.1209847	http://dx.doi.org/10.1038/sj.onc.1209847			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16878147	Green Accepted			2022-12-17	WOS:000244063800004
J	Braun, S; Mauch, C; Boukamp, P; Werner, S				Braun, S.; Mauch, C.; Boukamp, P.; Werner, S.			Novel roles of NM23 proteins in skin homeostasis, repair and disease	ONCOGENE			English	Article						skin; keratinocyte; NM23; wound healing; epidermis; differentiation	KERATINOCYTE GROWTH-FACTOR; NUCLEOSIDE DIPHOSPHATE KINASE; GENE-EXPRESSION; TGF-ALPHA; EPIDERMIS; ORGANIZATION; DIFFERENTIATION; STROMELYSIN-2; NEUROBLASTOMA; PROLIFERATION	Keratinocyte growth factor (KGF) is an important regulator of epidermal homeostasis and repair. Therefore, the identification of KGF target genes in keratinocytes should contribute to our understanding of the molecular mechanisms underlying these processes. In a search for KGF-regulated genes, we identified the gene encoding the nucleoside diphosphate kinase NM23-H1. Apart from a housekeeping function, NM23 proteins are involved in the regulation of many cellular processes as well as in tumor metastasis, but their functions in epidermal homeostasis and repair are largely unknown. Here, we show a high expression of NM23-H1 and NM23-H2 in the KGF-responsive keratinocytes of the hyperprotiferative epidermis of mouse skin wounds and of patients suffering from the skin disease psoriasis. To determine if this overexpression is functionally important, we generated HaCaT keratinocyte cell lines overexpressing NM23-Hl and/or-H2. Whereas the enhanced levels of NM23 did not affect cell proliferation in monoculture, NM23-H2 and double transfectants but not NM23-Hl transfectants formed a strongly hyperthickened epithelium in three-dimensional organotypic cultures. The abnormal epithelial morphology resulted from enhanced proliferation, reduced apoptosis and alterations in the differentiation pattern. These findings suggest that epidermal homeostasis depends on a tight regulation of the levels of NM23 isoforms.	ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Cologne, Dept Dermatol & Venerol, Cologne, Germany; German Canc Res Ctr, Dept Genet Skin Carcinogenesis, D-6900 Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Cologne; Helmholtz Association; German Cancer Research Center (DKFZ)	Werner, S (corresponding author), ETH, Inst Cell Biol, Schafmattstr 18, CH-8093 Zurich, Switzerland.	Sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710				Beer HD, 2002, J BIOL CHEM, V277, P20740, DOI 10.1074/jbc.M111233200; BERNARD BA, 1988, J INVEST DERMATOL, V90, P801, DOI 10.1111/1523-1747.ep12462014; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chang CL, 1996, ONCOGENE, V12, P659; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Finch PW, 1997, AM J PATHOL, V151, P1619; Finch PW, 2004, ADV CANCER RES, V91, P69, DOI 10.1016/S0065-230X(04)91003-2; Fournier HN, 2003, J BIOENERG BIOMEMBR, V35, P81, DOI 10.1023/A:1023450008347; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; Gassmann MG, 1999, ONCOGENE, V18, P6667, DOI 10.1038/sj.onc.1203120; Gassmann MG, 2000, EXP CELL RES, V258, P23, DOI 10.1006/excr.2000.4904; GILLES AM, 1991, J BIOL CHEM, V266, P8784; Gromov P, 2003, MOL CELL PROTEOMICS, V2, P70, DOI 10.1074/mcp.M200051-MCP200; GROTENDORST GR, 1989, J CELL PHYSIOL, V139, P617, DOI 10.1002/jcp.1041390323; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; IGAWA M, 1994, CANCER RES, V54, P1313; KADUNCE DP, 1995, DERMATOL CLIN, V13, P723, DOI 10.1016/S0733-8635(18)30037-8; Kanitakis J, 1997, J CUTAN PATHOL, V24, P151, DOI 10.1111/j.1600-0560.1997.tb01569.x; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; Keller UAD, 2006, MOL CELL BIOL, V26, P3773, DOI 10.1128/MCB.26.10.3773-3784.2006; Kimura N, 2000, J BIOENERG BIOMEMBR, V32, P309, DOI 10.1023/A:1005549315846; KING LE, 1990, J INVEST DERMATOL, V95, pS10, DOI 10.1111/1523-1747.ep12505661; Krampert M, 2004, MOL BIOL CELL, V15, P5242, DOI 10.1091/mbc.E04-02-0109; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; Madlener M, 1996, BIOCHEM J, V320, P659, DOI 10.1042/bj3200659; Narayanan R, 2003, J BIOENERG BIOMEMBR, V35, P49, DOI 10.1023/A:1023441806530; Ornitz DM, 2001, GENOME BIOL, V2; Postel EH, 2003, J BIOENERG BIOMEMBR, V35, P31, DOI 10.1023/A:1023485505621; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sato Y, 2000, PATHOL INT, V50, P200, DOI 10.1046/j.1440-1827.2000.01030.x; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407; STAHL JA, 1991, CANCER RES, V51, P445; Stark Hans-Jurgen, 2004, Biol Proced Online, V6, P55, DOI 10.1251/bpo72; STEEG PS, 1993, BREAST CANCER RES TR, V25, P175, DOI 10.1007/BF00662142; STEEG PS, 1989, INVAS METAST, V9, P351; Wei SJ, 2004, J BIOL CHEM, V279, P5993, DOI 10.1074/jbc.M310820200; WEINSTEIN GD, 1985, J INVEST DERMATOL, V85, P579, DOI 10.1111/1523-1747.ep12283594; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	49	19	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					532	542		10.1038/sj.onc.1209822	http://dx.doi.org/10.1038/sj.onc.1209822			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862176				2022-12-17	WOS:000243731600006
J	Mathur, M; Samuels, HH				Mathur, M.; Samuels, H. H.			Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas	ONCOGENE			English	Article						PSF-TFE3; siRNA; growth inhibition; apoptosis; transformation; dedifferentiation	PROXIMAL TUBULE CELLS; SOFT PART SARCOMA; TUMOR-CELLS; GENE FUSION; CLEAR-CELL; TFE3; CLASSIFICATION; CONTEXT; TYPE-1; GROWTH	A subset of papillary renal cell carcinomas (RCC) is characterized by the expression of a TFE3 fusion protein, where the fusion partner can be any of the several proteins identified so far such as PSF (PTB associated splicing factor), NonO, PRCC, CLTC and ASPL. These proteins result from chromosomal translocations involving the TFE3 gene located on the X chromosome. Our present study documents the central role of PSF-TFE3 in oncogenic transformation. We show that the inhibition of PSF-TFE3 expression through siRNA or shRNA leads to impaired growth, proliferation, invasion potential and long-term survival of UOK-145 papillary renal carcinoma-derived cells, which endogenously express PSF-TFE3. The oncogenic potential of PSF-TFE3 became evident by stable expression of PSF-TFE3 in NIH-3T3 mouse fibroblast cells, which leads to the acquisition of anchorage-independent growth as revealed by soft agar assay. In addition, the expression of PSF-TFE3 in normal renal proximal tubular epithelial cells from where such tumors originate leads to dedifferentiation and loss of some key functional proteins, which may reflect an initial step in the multistep process of tumor development. This suggests that the expression of PSF-TFE3 in renal epithelial cells plays an important role in the initiation and maintenance of oncogenic phenotype in papillary RCC.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University; New York University	Mathur, M (corresponding author), NYU, Sch Med, Dept Pharmacol, MSB-411,550 1st Ave, New York, NY 10016 USA.	mathum01@med.nyu.edu; herbert.samuels@med.nyu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R37DK016636, R01DK016636] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR02083] Funding Source: Medline; NIDDK NIH HHS [DK16636] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBINI A, 1987, CANCER RES, V47, P3239; Argani P, 2003, ONCOGENE, V22, P5374, DOI 10.1038/sj.onc.1206686; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Bennicelli JL, 2002, CURR OPIN ONCOL, V14, P412, DOI 10.1097/00001622-200207000-00008; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bodmer D, 2002, HUM MOL GENET, V11, P2489, DOI 10.1093/hmg/11.20.2489; Gao CF, 2005, P NATL ACAD SCI USA, V102, P10528, DOI 10.1073/pnas.0504367102; Guo Hong-feng, 2004, Zhonghua Wai Ke Za Zhi, V42, P196; Kolb RJ, 2004, HYPERTENSION, V44, P352, DOI 10.1161/01.HYP.0000136645.90116.1a; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074; Le TH, 2004, PHYSIOL GENOMICS, V18, P290, DOI 10.1152/physiolgenomics.00120.2003; Lindor NM, 2001, GENET TEST, V5, P101, DOI 10.1089/109065701753145547; Mathur M, 2003, ONCOGENE, V22, P5031, DOI 10.1038/sj.onc.1206643; Morrissey C, 2001, CANCER RES, V61, P7277; Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373; Orosz DE, 2004, IN VITRO CELL DEV-AN, V40, P22; Radisky D, 2001, SEMIN CANCER BIOL, V11, P87, DOI 10.1006/scbi.2000.0360; Sanders ME, 2002, AM J PATHOL, V161, P997, DOI 10.1016/S0002-9440(10)64260-5; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Weterman MAJ, 2001, ONCOGENE, V20, P1414, DOI 10.1038/sj.onc.1204213; Weterman MAJ, 2001, P NATL ACAD SCI USA, V98, P13808, DOI 10.1073/pnas.241304198; Wiesener MS, 2001, CANCER RES, V61, P5215; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491	25	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					277	283		10.1038/sj.onc.1209783	http://dx.doi.org/10.1038/sj.onc.1209783			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832349				2022-12-17	WOS:000243398300011
J	Yoon, K; Zhu, S; Ewing, SJ; Smart, RC				Yoon, K.; Zhu, S.; Ewing, S. J.; Smart, R. C.			Decreased survival of C/EBP beta-deficient keratinocytes is due to aberrant regulation of p53 levels and function	ONCOGENE			English	Article						apoptosis; p53; C/EBP beta; keratinocytes	BINDING-PROTEIN-BETA; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; DEPENDENT PHOSPHORYLATION; EPITHELIAL-CELLS; GENE-EXPRESSION; STABILIZES P53; MDM2; DIFFERENTIATION; REPRESSION	Recent studies have identified roles for C/EBP beta in cellular survival and tumorigenesis, however, the mechanisms through which C/EBPb regulates these processes are not fully understood. Previously, we demonstrated that C/EBP beta(-/-) mice are resistant to carcinogen-induced skin tumorigenesis and in response to topical carcinogen treatment display a 17-fold increase in keratinocyte apoptosis compared to wild-type mice. Here, we have investigated the mechanisms through which C/EBPb regulates apoptosis in response to carcinogenic stress. Analysis of carcinogen-treated C/EBP beta(-/-) mouse skin revealed a striking increase in the number of p53 immunopositive keratinocytes in the epidermis of C/EBP beta(-/-) mice compared to wild-type mice and this increase was temporally associated with a concomitant anomalous increase in apoptosis. The increased levels of p53 were functional as Mdm2, Bcl-2, C/EBP alpha and p21 were differentially regulated in the epidermis of carcinogenic treated C/EBP beta(-/-) mice. The increase in p53 protein was not associated with an increase in p53 mRNA levels. To determine whether p53 is required for the increased apoptosis in C/EBPb-/- mice, C/EBP beta/p53 compound knockout mice were generated. Carcinogen-treated C/EBP beta/p53 compound knockout mice did not display increased apoptosis demonstrating p53 is required for the proapoptotic phenotype in C/EBP beta(-/-) mice. Our results demonstrate that altered keratinocyte survival in C/EBP beta(-/-) mice results from aberrant regulation of p53 protein and function and indicate C/EBP beta has a role in the negative regulation of p53 protein levels in response to carcinogen-induced stress.	N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Smart, RC (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA.	rcsmart@unity.ncsu.edu		Smart, Robert/0000-0002-6767-6756	NATIONAL CANCER INSTITUTE [R29CA046637, R01CA046637] Funding Source: NIH RePORTER; NCI NIH HHS [CA46637] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Burkart AD, 2005, ENDOCRINOLOGY, V146, P1909, DOI 10.1210/en.2004-0842; Corbi AL, 2000, FEBS LETT, V474, P201, DOI 10.1016/S0014-5793(00)01591-X; Di-Poi N, 2005, J BIOL CHEM, V280, P38700, DOI 10.1074/jbc.M507782200; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Sankpal NV, 2005, BBA-GENE STRUCT EXPR, V1728, P1, DOI 10.1016/j.bbaexp.2004.12.014; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Sterneck E, 2006, ONCOGENE, V25, P1272, DOI 10.1038/sj.onc.1209144; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wessells J, 2004, MOL CELL BIOL, V24, P3238, DOI 10.1128/MCB.24.8.3238-3250.2004; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	35	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					360	367		10.1038/sj.onc.1209797	http://dx.doi.org/10.1038/sj.onc.1209797			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832342				2022-12-17	WOS:000243544000005
J	Huang, CL; Ueno, M; Liu, D; Masuya, D; Nakano, J; Yokomise, H; Nakagawa, T; Miyake, M				Huang, C-L; Ueno, M.; Liu, D.; Masuya, D.; Nakano, J.; Yokomise, H.; Nakagawa, T.; Miyake, M.			MRP-1/CD9 gene transduction regulates the actin cytoskeleton through the downregulation of WAVE2	ONCOGENE			English	Article						MRP-1/CD9; WAVE2; actin; motility	ARP2/3 COMPLEX; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-MIGRATION; MAJOR CD9; N-WASP; PROTEIN; MOTILITY; KINASE; ACTIVATION; EXPRESSION	Motility-related protein-1 (MRP-1/CD9) is involved in cell motility. We studied the change in the actin cytoskeleton, and the expression of actin-related protein (Arp) 2 and Arp3 and the Wiskott-Aldrich syndrome protein ( WASP) family according to MRP-1/CD9 gene transduction into HT1080 cells. The frequency of cells with lamellipodia was significantly lower in MRP-1/CD9-transfected HT1080 cells than in control HT1080 cells (P < 0.0001). MRP-1/CD9 gene transduction affected the subcellular localization of Arp2 and Arp3 proteins. Furthermore, MRP-1/CD9 gene transduction induced a downregulation of WAVE2 expression (P < 0.0001). However, no difference was observed in the expression of Arp2, Arp3 or other WASPs. A neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited downregulation of WAVE2 in MRP-1/CD9-transfected HT1080 cells (P < 0.0001 ), and reversed the morphological effects of MRP-1/CD9 gene transduction. Furthermore, downregulation of WAVE2 by transfection of WAVE2-specific small interfering RNA ( siRNA) mimicked the morphological effects of MRP-1/CD9 gene transduction and suppressed cell motility. However, transfection of each siRNA for Wnt1, Wnt2b1 or Wnt5a did not affect WAVE2 expression. Transfection of WAVE2-specific siRNA also did not affect expressions of these Wnts. These results indicate that MRP-1/CD9 regulates the actin cytoskeleton by downregulating of the WAVE2, through the Wnt-independent signal pathway.	Kagawa Univ, Dept Surg 2, Fac Med, Kagawa 7610793, Japan; Kagawa Univ, Fac Med, Dept Pathol & Host Def, Kagawa, Japan; Kagawa Univ, Life Sci Res Ctr, Kagawa, Japan; Kitano Hosp, Dept Oncol 5, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka, Japan	Kagawa University; Kagawa University; Kagawa University; Kitano Hospital	Huang, CL (corresponding author), Kagawa Univ, Dept Surg 2, Fac Med, 1750-1,Miki Cho, Kagawa 7610793, Japan.	chuang@kms.ac.jp						Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Gutierrez-Lopez MD, 2003, J BIOL CHEM, V278, P208, DOI 10.1074/jbc.M207805200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; Huang CL, 2004, ONCOGENE, V23, P7475, DOI 10.1038/sj.onc.1208063; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Le Naour F, 2004, CANCER IMMUNOL IMMUN, V53, P148, DOI 10.1007/s00262-003-0477-5; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Park KR, 2000, MOL HUM REPROD, V6, P719, DOI 10.1093/molehr/6.8.719; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Soderling SH, 2003, P NATL ACAD SCI USA, V100, P1723, DOI 10.1073/pnas.0438033100; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Takenawa T, 2001, J CELL SCI, V114, P1801; Vartiainen MK, 2004, CURR OPIN CELL BIOL, V16, P174, DOI 10.1016/j.ceb.2004.02.004; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Yan C, 2003, EMBO J, V22, P3602, DOI 10.1093/emboj/cdg350; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhu BM, 2005, GENOMICS, V85, P657, DOI 10.1016/j.ygeno.2005.02.012; Zilber MT, 2005, BLOOD, V106, P3074, DOI 10.1182/blood-2004-10-4094	34	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6480	6488		10.1038/sj.onc.1209654	http://dx.doi.org/10.1038/sj.onc.1209654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16682943				2022-12-17	WOS:000241395100004
J	VanderBorght, A; Valckx, A; Van Dun, J; Grand-Perret, T; De Schepper, S; Vialard, J; Janicot, M; Arts, J				VanderBorght, A.; Valckx, A.; Van Dun, J.; Grand-Perret, T.; De Schepper, S.; Vialard, J.; Janicot, M.; Arts, J.			Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells	ONCOGENE			English	Article						hdm-2; antagonistic peptide; p-53 deficient	MDM2 ONCOPROTEIN; IN-VIVO; P53; PROTEIN; DNA; ABNORMALITIES; PATHWAY; P73	The hdm-2 oncogene is overexpressed in several types of malignancies including osteosarcomas, soft tissue sarcomas and gliomas and hdm-2 has been associated with accelerated tumor formation in both hereditary and sporadic cancers. Among the other key binding partners, hdm-2 forms a complex with the tumor suppressor p53, resulting in a rapid proteasome-mediated degradation of the p53 protein. This positions the hdm-2-p53 complex as an attractive target for the development of anticancer therapy and recently the first small molecule hdm-2 antagonist has been reported. Development of hdm-2 antagonists is currently focused on malignancies containing a wild-type p53 genotype, which is the case in approximately half of human cancer indications. However, hdm-2 has also been implicated in oncogenesis in the absence of p53. We therefore studied the effect of hdm-2 antagonists in p53-deficient human H1299 lung carcinoma cells. The hdm-2 antagonistic peptide caused G1 cell cycle arrest, inhibited colony growth and induced expression of G1 checkpoint regulatory proteins, such as p21(waf1,cip1). These data demonstrate that hdm-2 regulates the G1 cell cycle checkpoint in a p53-independent manner, suggesting that hdm-2 antagonists represent a novel class of anticancer therapeutics with broad applicability towards tumors with different p53 genetic backgrounds.	Johnson & Johnson Pharmaceut Res & Dev, Oncol Dicovery Res & Early Dev, B-2340 Beerse, Belgium	Johnson & Johnson; Janssen Pharmaceuticals	Arts, J (corresponding author), Johnson & Johnson Pharmaceut Res & Dev, Oncol Dicovery Res & Early Dev, Turnhoutseweg 30, B-2340 Beerse, Belgium.	jarts@prdbe.jnj.com						Blattner C, 1999, MOL CELL BIOL, V19, P3704; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; CORDONCARDO C, 1994, CANCER RES, V54, P794; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; FAKHARZADEH SS, 1993, GENOMICS, V15, P283, DOI 10.1006/geno.1993.1058; Fischer PM, 2004, TRENDS PHARMACOL SCI, V25, P343, DOI 10.1016/j.tips.2004.04.011; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LANE DP, 1992, NATURE, V358, P16; Lorens JB, 2000, MOL THER, V1, P438, DOI 10.1006/mthe.2000.0063; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Momand J, 1997, J CELL BIOCHEM, V64, P343; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; SWIFT S, 1999, CURRENT PROTOCOLS S, V31; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; VINDELOV LL, 1983, CYTOMETRY, V3, P332, DOI 10.1002/cyto.990030505; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	22	19	20	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	50					6672	6677		10.1038/sj.onc.1209667	http://dx.doi.org/10.1038/sj.onc.1209667			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16732328				2022-12-17	WOS:000241569700012
J	Jackson-Fisher, AJ; Bellinger, G; Shum, E; Duong, JK; Perkins, AS; Gassmann, M; Muller, W; Lloyd, KCK; Stern, DF				Jackson-Fisher, A. J.; Bellinger, G.; Shum, E.; Duong, J. K.; Perkins, A. S.; Gassmann, M.; Muller, W.; Lloyd, K. C. Kent; Stern, D. F.			Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4	ONCOGENE			English	Article						ErbB; HER-4; breast cancer; MMTV-Neu; carcinoma	GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; CONSTITUTIVELY ACTIVE ERBB4; TRANSGENIC MICE; NEU PROTOONCOGENE; TYROSINE KINASES; PROGNOSTIC-SIGNIFICANCE; ACTIVATING MUTATIONS; NEUREGULIN RECEPTOR; MESSENGER-RNA	The four members of the ErbB family of receptor tyrosine kinases are involved in development and tumorigenesis of the mammary gland. Whereas the epidermal growth factor receptor, ErbB2 and ErbB3 are positively associated with various cancers, clinical studies of ErbB4 in breast cancer are contradictory. Results from tissue culture analyses and some clinical studies suggested that ErbB4 is either a tumor suppressor or is a negative regulator of ErbB2-driven tumors. Neu-Cre-ErbB4(flox/null) mice in which ErbB4 was inactivated by Cre-lox-mediated recombination in the mammary gland developed MMTV-Neu-driven mammary tumors with a similar latency period to mice with one or two wild-type ErbB4 alleles. Moreover, there was no difference in the histologies of tumors that developed, nor in the propensity to form lung metastases. Taken together these results suggest that ErbB4 is not a potent, highly penetrant tumor suppressor, nor is it a factor in Neu-mediated tumorigenesis in this model.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Columbia Univ, Sch Publ Hlth, New York, NY USA; Univ Basel, Dept Physiol, Biozentrum, Pharmazentrum, Basel, Switzerland; McGill Univ, Royal Univ Hosp, Mol Oncol Grp, Montreal, PQ, Canada; Univ Calif Davis, Sch Vet Med, Ctr Comparat Med, Davis, CA 95616 USA	Yale University; Columbia University; University of Basel; McGill University; University of Saskatchewan; University of California System; University of California Davis	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,Room BML 342,POB 208023, New Haven, CT 06520 USA.	df.stern@yale.edu		Lloyd, David/0000-0002-5656-0571; Gassmann, Martin/0000-0001-6201-3032	NATIONAL CANCER INSTITUTE [R01CA080065] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA80065] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abd El-Rehim DM, 2004, BRIT J CANCER, V91, P1532, DOI 10.1038/sj.bjc.6602184; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Bacus SS, 1996, AM J PATHOL, V148, P549; Barnes NLP, 2005, CLIN CANCER RES, V11, P2163, DOI 10.1158/1078-0432.CCR-04-1633; Bieche I, 2003, INT J CANCER, V106, P758, DOI 10.1002/ijc.11273; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cohen BM, 1996, J BIOL CHEM, V271, P4813; DiGiovanna MP, 2005, J CLIN ONCOL, V23, P1152, DOI 10.1200/JCO.2005.09.055; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Haugen DRF, 1996, CANCER RES, V56, P1184; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kew TY, 2000, BRIT J CANCER, V82, P1163, DOI 10.1054/bjoc.1999.1057; Knowlden JM, 1998, ONCOGENE, V17, P1949, DOI 10.1038/sj.onc.1202107; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Lodge AJ, 2003, J CLIN PATHOL, V56, P300, DOI 10.1136/jcp.56.4.300; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pawlowski V, 2000, CLIN CANCER RES, V6, P4217; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Soung YH, 2006, INT J CANCER, V118, P1426, DOI 10.1002/ijc.21507; Srinivasan R, 2000, CANCER RES, V60, P1483; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Suo Z, 2002, J PATHOL, V196, P17, DOI 10.1002/path.1003; Suo ZH, 2001, VIRCHOWS ARCH, V439, P62, DOI 10.1007/s004280000392; Tang CK, 1999, CANCER RES, V59, P5315; Tang CK, 1998, CANCER RES, V58, P3415; Thor AD, 2002, HUM PATHOL, V33, P628, DOI 10.1053/hupa.2002.124034; Thuret S, 2004, J NEUROCHEM, V91, P1302, DOI 10.1111/j.1471-4159.2004.02809.x; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; von Mehren M, 2005, J CLIN ONCOL, V23, P8, DOI 10.1200/JCO.2005.09.961; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Williams EE, 2003, CANCER LETT, V192, P67, DOI 10.1016/S0304-3835(02)00690-0; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	55	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5664	5672		10.1038/sj.onc.1209574	http://dx.doi.org/10.1038/sj.onc.1209574			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16652155				2022-12-17	WOS:000240599100008
J	Cayrol, C; Clerc, P; Bertrand, C; Gigoux, V; Portolan, G; Fourmy, D; Dufresne, M; Seva, C				Cayrol, C.; Clerc, P.; Bertrand, C.; Gigoux, V.; Portolan, G.; Fourmy, D.; Dufresne, M.; Seva, C.			Cholecystokinin-2 receptor modulates cell adhesion through beta 1-integrin in human pancreatic cancer cells	ONCOGENE			English	Article						gastrin; integrin; pancreatic cancer; cell adhesion	GROWTH-FACTOR ACTION; TYROSINE PHOSPHORYLATION; CYCLOOXYGENASE-2 EXPRESSION; MOLECULAR-MECHANISMS; SIGNALING PATHWAY; MURINE PANCREAS; MESSENGER-RNA; GASTRIN; INTEGRIN; ACTIVATION	Several lines of evidence suggest that gastrin and the CCK-2 receptor (CCK2R) could contribute to pancreatic carcinogenesis by modulating processes such as proliferation, cell adhesion or migration. In the current study, we used a 'cancer gene array' and identified beta 1-integrin subunit as a new gastrin-regulated gene in human pancreatic cancer cells. We also demonstrated that Src family kinases and the phosphatidylinositol-3-kinase (PI-3-kinase) pathway play a crucial role in the expression of beta 1-integrin induced by gastrin. Our results also showed that gastrin modulates cell-substrate adhesion via beta 1-integrin. Indeed, using blocking anti-beta 1-integrin monoclonal antibodies, we completely reversed the increase in cell substrate adhesion induced by gastrin. In addition, we observed that in response to gastrin, beta 1-integrin is tyrosine phosphorylated by Src family kinases and associates with paxillin, a scaffold protein involved in focal adhesion and integrin signalling. This mechanism might be involved in gastrin-induced cell adhesion. Moreover, we showed in vivo that targeted CCK2R expression in the pancreas of Elas-CCK2 mice leads to the overexpression of beta 1-integrin. This process may contribute to pancreatic tumour development observed in these transgenic animals.	INSERM, U531, IFR31, Inst Louis Bugnard, F-31432 Toulouse 4, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Seva, C (corresponding author), INSERM, U531, IFR31, Inst Louis Bugnard, F-31432 Toulouse 4, France.	sevac@toulouse.inserm.fr	Gigoux, Véronique/AAE-6090-2020; Dufresne, Marlène/M-6332-2014; SEVA, Catherine/O-9166-2014; Fourmy, Daniel/AAE-3703-2019	Gigoux, Véronique/0000-0003-1408-5335; SEVA, Catherine/0000-0002-4265-7372; Fourmy, Daniel/0000-0001-9910-4827				Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; Bierkamp C, 2004, AM J PATHOL, V165, P2135, DOI 10.1016/S0002-9440(10)63263-4; Bierkamp C, 2002, ONCOGENE, V21, P7656, DOI 10.1038/sj.onc.1205999; Butler B, 2005, J BIOL CHEM, V280, P14556, DOI 10.1074/jbc.M411765200; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; CHAO JT, 2005, AM J PHYSL CELL PHYS; Chiu SJ, 2002, J BIOMED SCI, V9, P261, DOI 10.1159/000059427; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; Colucci R, 2005, BRIT J PHARMACOL, V144, P338, DOI 10.1038/sj.bjp.0706053; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Daulhac L, 1999, FEBS LETT, V445, P251, DOI 10.1016/S0014-5793(99)00129-5; de Weerth A, 1999, HEPATO-GASTROENTEROL, V46, P472; Eliceiri BP, 2000, CANCER J, V6, pS245; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Ferrand A, 2005, J BIOL CHEM, V280, P10710, DOI 10.1074/jbc.M413309200; Ferrand A, 2004, EXP CELL RES, V301, P128, DOI 10.1016/j.yexcr.2004.07.037; Fontana MG, 1999, EUR SURG RES, V31, P406, DOI 10.1159/000008719; Fukui H, 1998, GASTROENTEROLOGY, V115, P1483, DOI 10.1016/S0016-5085(98)70027-7; Funahashi H, 2003, PANCREAS, V27, P190, DOI 10.1097/00006676-200308000-00013; Gao CL, 2005, J BIOL CHEM, V280, P15422, DOI 10.1074/jbc.M414457200; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Grippo PJ, 2003, CANCER RES, V63, P2016; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Guo YS, 2002, J BIOL CHEM, V277, P48755, DOI 10.1074/jbc.M209016200; Halatsch ME, 1997, CANCER LETT, V118, P7, DOI 10.1016/S0304-3835(97)00217-6; Hocker M, 2004, ANN NY ACAD SCI, V1014, P97, DOI 10.1196/annals.1294.010; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Kaufmann R, 1997, NEUROPEPTIDES, V31, P573, DOI 10.1016/S0143-4179(97)90003-2; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; Lohr M, 1996, PANCREAS, V12, P248; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Prasad NB, 2005, CANCER RES, V65, P1619, DOI 10.1158/0008-5472.CAN-04-1413; Ross RS, 2004, CARDIOVASC RES, V63, P381, DOI 10.1016/j.cardiores.2004.04.027; Shimoyama S, 1995, INT J PANCREATOL, V18, P227; Sinclair NF, 2004, AM J PHYSIOL-GASTR L, V286, pG992, DOI 10.1152/ajpgi.00206.2002; Slice LW, 2003, J CELL PHYSIOL, V196, P454, DOI 10.1002/jcp.10304; Smith JP, 1999, CANCER LETT, V135, P107; Smith JP, 1998, INT J MOL MED, V2, P309; SMITH JP, 1995, AM J PHYSIOL-REG I, V268, pR135, DOI 10.1152/ajpregu.1995.268.1.R135; Smith JP, 1996, AM J PHYSIOL-REG I, V270, pR1078, DOI 10.1152/ajpregu.1996.270.5.R1078; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG1363, DOI 10.1152/ajpgi.1999.276.6.G1363; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG415, DOI 10.1152/ajpgi.1999.276.2.G415; TANIGUCHI T, 1994, ONCOGENE, V9, P861; Taniguchi T, 1996, ONCOGENE, V12, P1357; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; Turner CE, 2000, J CELL SCI, V113, P4139; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wagner M, 1998, GASTROENTEROLOGY, V115, P1254, DOI 10.1016/S0016-5085(98)70098-8; Wang JY, 1995, AM J PHYSIOL-CELL PH, V269, pC1474, DOI 10.1152/ajpcell.1995.269.6.C1474; Wroblewski LE, 2002, BIOCHEM J, V365, P873, DOI 10.1042/BJ20020068; Zhukova E, 2001, J CELL PHYSIOL, V189, P291, DOI 10.1002/jcp.10018	55	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4421	4428		10.1038/sj.onc.1209484	http://dx.doi.org/10.1038/sj.onc.1209484			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547500				2022-12-17	WOS:000239326000005
J	Muromoto, R; Nakao, K; Watanabe, T; Sato, N; Sekine, Y; Sugiyama, K; Oritani, K; Shimoda, K; Matsuda, T				Muromoto, R; Nakao, K; Watanabe, T; Sato, N; Sekine, Y; Sugiyama, K; Oritani, K; Shimoda, K; Matsuda, T			Physical and functional interactions between Daxx and STAT3	ONCOGENE			English	Article						IL-6; LIF; STAT3; Daxx; transcriptional regulation	INTERFERON-ALPHA; TRANSCRIPTIONAL ACTIVATION; PML; PROTEIN; EXPRESSION; APOPTOSIS; MELANOMA; GROWTH; CELLS	Signal transducer and activator of transcription 3 (STAT3) play key roles in the intracellular signaling pathways of the interleukin (IL)-6 family of cytokines, which exhibit a diverse set of cellular responses, including cell proliferation and differentiation. Dysregulated IL-6/STAT3 signaling is involved in the pathogenesis of several diseases, for example autoimmune diseases and tumors. Type I interferon (IFN) induces the expression of proapoptotic genes and has been used in the clinical treatment of several tumors. In the present study, we found that type I IFN suppressed IL-6/STAT3-mediated transcription and gene expression. Furthermore, a type I IFN-induced protein, Daxx, also suppressed STAT3-mediated transcriptional activation, while overexpression of Daxx inhibited IL-6/STAT3-mediated gene expression. Importantly, small-interfering RNA-mediated reduction of Daxx expression enhanced IL-6/leukemia inhibitory factor (LIF)-induced STAT3-dependent transcription. Co-immunoprecipitation studies revealed a physical interaction between Daxx and STAT3 in transiently transfected 293T cells. We further found that Daxx and STAT3 were co-localized in the nucleus. These results indicate that Daxx may serve as a transcriptional regulator of type I IFN-mediated suppression of the IL-6/STAT3 signaling pathway.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Nippon Boehringer Ingelheim Co Ltd, Kawanishi Pharma Res Inst, Kawanishi, Hyogo, Japan; Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka, Japan; Kyushu Univ, Fac Med, Dept Internal Med 1, Higashi Ku, Fukuoka, Japan	Hokkaido University; Boehringer Ingelheim; Osaka University; Kyushu University	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Muromoto, Ryuta/E-4203-2012; Matsuda, Tadashi/A-3835-2012; Sekine, Yuichi/S-8813-2019	Muromoto, Ryuta/0000-0002-7474-493X; Matsuda, Tadashi/0000-0002-3089-3757; Sekine, Yuichi/0000-0002-2861-603X				Brender C, 2001, EXP CLIN IMMUNOGENET, V18, P80, DOI 10.1159/000049186; Bromberg J, 2000, BREAST CANCER RES, V2, P86, DOI 10.1186/bcr38; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; Kirkwood JM, 1999, MOL MED, V5, P11, DOI 10.1007/BF03402135; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Li Z, 2004, J INVEST DERMATOL, V123, P737, DOI 10.1111/j.0022-202X.2004.23408.x; Muromoto R, 2004, BIOCHEM BIOPH RES CO, V316, P827, DOI 10.1016/j.bbrc.2004.02.126; Muromoto R, 2004, J IMMUNOL, V172, P2985, DOI 10.4049/jimmunol.172.5.2985; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	23	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2131	2136		10.1038/sj.onc.1209235	http://dx.doi.org/10.1038/sj.onc.1209235			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16331268	Green Submitted			2022-12-17	WOS:000236359700017
J	Lee, JY; Moon, HJ; Lee, WK; Chun, HJ; Han, CW; Jeon, YW; Lim, Y; Kim, YH; Yao, TP; Lee, KH; Jun, TY; Rha, HK; Kang, JK				Lee, JY; Moon, HJ; Lee, WK; Chun, HJ; Han, CW; Jeon, YW; Lim, Y; Kim, YH; Yao, TP; Lee, KH; Jun, TY; Rha, HK; Kang, JK			Merlin facilitates ubiquitination and degradation of transactivation-responsive RNA-binding protein	ONCOGENE			English	Article						Nf2; merlin; tarbp2; TRBP; ubiquitination; degradation	NF2 TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS TYPE-2; GROWTH SUPPRESSION; UNITED-KINGDOM; ERM PROTEINS; GENE-PRODUCT; KINASE PKR; PHOSPHORYLATION; DOMAIN; TRBP	The Nf2 tumor suppressor codes for merlin, a protein whose function is largely unknown. We have previously demonstrated a novel interaction between merlin and TRBP, which inhibits the oncogenic activity of TRBP. In spite of the significance of their functional interaction, its molecular mechanism still remains to be elucidated. In this report, we investigated how merlin inhibits the oncogenic activity of TRBP in association with cell growth conditions. In the human embryonic kidney 293 cell line, the level of endogenous merlin increased, whereas that of endogenous TRBP significantly decreased along with the increase in cell confluence. We demonstrated that the carboxyl-terminal region of TRBP was responsible for this phenomenon using stable cell lines expressing deletion mutants of TRBP. The overexpression of merlin decreased the protein level of TRBP, and the ubiquitin-like subdomain of merlin's FERM domain was important for this activity. We also demonstrated that TRBP is ubiquitinylated and the ubiquitinylated forms of TRBP are accumulated by ectopically expressed merlin or cell confluence in the presence of MG132, a proteasome inhibitor. Furthermore, we showed that the regulation of TRBP in response to cell confluence was abolished upon knockdown of merlin expression by specific small interfering RNA. Finally, we showed that ectopically expressed merlin restored cell-cell contact inhibition in cells stably expressing TRBP but not in TRBP Delta c. These results suggest that merlin is involved in the regulation of TRBP protein level by facilitating its ubiquitination in response to such cues as cell-cell contacts.	Catholic Univ Korea, Neurosci Gen Res Cr, Catholic Res Inst Med Sci, Socho Ku, Seoul 137701, South Korea; Catholic Univ Korea, Dept Pharmacol, Seoul, South Korea; Catholic Univ Korea, Dept Biomed Sci, Seoul, South Korea; Catholic Univ Korea, Dept Orthoped Surg, Seoul, South Korea; Catholic Univ Korea, Dept Psychiat, Seoul, South Korea; Catholic Univ Korea, Dept Occupat & Environm Med, Seoul, South Korea; Duke Univ, Durham, NC USA; Catholic Univ Korea, Dept Neurosurg, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Duke University; Catholic University of Korea	Kim, YH (corresponding author), Catholic Univ Korea, Neurosci Gen Res Cr, Catholic Res Inst Med Sci, Socho Ku, 4011,505 Banpo Dong, Seoul 137701, South Korea.	ngrc@catholic.ac.kr		Chun, Heung Jae/0000-0002-0446-9901				Bannwarth S, 2001, J BIOL CHEM, V276, P48803, DOI 10.1074/jbc.M104645200; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Daher A, 2001, J BIOL CHEM, V276, P33899, DOI 10.1074/jbc.M103584200; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FISHER HW, 1967, SCIENCE, V155, P581, DOI 10.1126/science.155.3762.581; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; Gautreau A, 2002, J BIOL CHEM, V277, P31279, DOI 10.1074/jbc.C200125200; Giovannini M, 2000, GENE DEV, V14, P1617; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lee JY, 2004, J BIOL CHEM, V279, P30265, DOI 10.1074/jbc.M312083200; Lee RB, 1996, IEEE MICRO, V16, P6, DOI 10.1109/MM.1996.526920; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684	35	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1143	1152		10.1038/sj.onc.1209150	http://dx.doi.org/10.1038/sj.onc.1209150			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247459				2022-12-17	WOS:000235537500002
J	Brunori, M; Mathieu, N; Ricoul, M; Bauwens, S; Koering, CE; de Climens, AR; Belleville, A; Wang, Q; Puisieux, I; Decimo, D; Puisieux, A; Sabatier, L; Gilson, E				Brunori, M; Mathieu, N; Ricoul, M; Bauwens, S; Koering, CE; de Climens, AR; Belleville, A; Wang, Q; Puisieux, I; Decimo, D; Puisieux, A; Sabatier, L; Gilson, E			TRF2 inhibition promotes anchorage-independent growth of telomerase-positive human fibroblasts	ONCOGENE			English	Article						telomere; TRF2; malignant transformation	REPEAT BINDING-FACTORS; NORMAL HUMAN-CELLS; HUMAN TUMOR-CELLS; TO-END FUSIONS; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; EPITHELIAL-CELLS; CANCER-CELLS; MOUSE CELLS; DNA-DAMAGE	Although telomere instability is observed in human tumors and is associated with the development of cancers in mice, it has yet to be established that it can contribute to the malignant transformation of human cells. We show here that in checkpoint-compromised telomerase-positive human. fibroblasts an episode of TRF2 inhibition promotes heritable changes that increase the ability to grow in soft agar, but not tumor growth in nude mice. This transforming activity is associated to a burst of telomere instability but is independent of an altered control of telomere length. Moreover, it cannot be recapitulated by an increase in chromosome breaks induced by an exposure to gamma-radiations. Since it can be revealed in the context of telomerase-proficient human cells, telomere dysfunction might contribute to cancer progression even at late stages of the oncogenesis process, after the telomerase reactivation step.	Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS, UMR,INRA,ENS, F-69364 Lyon 07, France; CEA, Commissariat Energ Atom, Lab Radiobiol & Oncol, Fontenay Aux Roses, France; Ctr Leon Berard, INSERM, Unite Oncol Mol, Unite 590, F-69373 Lyon, France; Ctr Hosp Lyon Sud, Tumor Biol Unit, F-69310 Pierre Benite, France; Ecole Normale Super Lyon, Lab Human Virol, INSERM, ENS, F-69364 Lyon, France	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; CEA; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Gilson, E (corresponding author), Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS, UMR,INRA,ENS, 46 Allee Italie, F-69364 Lyon 07, France.	Eric.Gilson@ens-lyon.fr		PUISIEUX, Alain/0000-0002-9938-3798; Sabatier, Laure/0000-0003-0552-6549; Decimo, Didier/0000-0002-0390-1205				Ancelin K, 2002, MOL CELL BIOL, V22, P3474, DOI 10.1128/MCB.22.10.3474-3487.2002; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bradshaw PS, 2005, NAT GENET, V37, P193, DOI 10.1038/ng1506; Callen E, 2004, MUTAT RES-REV MUTAT, V567, P85, DOI 10.1016/j.mrrev.2004.06.003; Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Colgin L, 2004, CURR BIOL, V14, pR901, DOI 10.1016/j.cub.2004.09.075; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; FEUER G, 1995, J VIROL, V69, P1328, DOI 10.1128/JVI.69.2.1328-1333.1995; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Klapper W, 2003, LEUKEMIA, V17, P2007, DOI 10.1038/sj.leu.2403086; Koering CE, 2002, EMBO REP, V3, P1055, DOI 10.1093/embo-reports/kvf215; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lechel A, 2005, EMBO REP, V6, P275, DOI 10.1038/sj.embor.7400352; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Miyachi K, 2002, J EXP CLIN CANC RES, V21, P269; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakanishi K, 2003, CLIN CANCER RES, V9, P1105; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Oh BK, 2005, AM J PATHOL, V166, P73, DOI 10.1016/S0002-9440(10)62233-X; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Teixeira MT, 2004, CELL, V117, P323, DOI 10.1016/S0092-8674(04)00334-4; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Woo RA, 2004, GENE DEV, V18, P1317, DOI 10.1101/gad.1165204; Yamada K, 2002, ANTICANCER RES, V22, P1315; Yamada M, 2002, ANTICANCER RES, V22, P3303; Zhang AJ, 2004, ONCOGENE, V23, P7441, DOI 10.1038/sj.onc.1207527; Zimonjic D, 2001, CANCER RES, V61, P8838	59	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2006	25	7					990	997		10.1038/sj.onc.1209135	http://dx.doi.org/10.1038/sj.onc.1209135			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205637				2022-12-17	WOS:000235361000004
J	Kumar, RN; Shore, SK; Dhanasekaran, N				Kumar, RN; Shore, SK; Dhanasekaran, N			Neoplastic transformation by the gep oncogene, G alpha(12), involves signaling by STAT3	ONCOGENE			English	Article						gep; G alpha(12); STAT3; transformation; JAK3; PDGFR alpha	N-TERMINAL KINASE; PROTEIN-KINASE; CONSTITUTIVE ACTIVATION; SERINE PHOSPHORYLATION; MAXIMAL ACTIVATION; ALPHA-SUBUNIT; HUMAN OVARIAN; C-DELTA; SRC; GROWTH	G alpha(12), the alpha-subunit of G12, which has been referred to as the gep oncogene, stimulates mitogenic pathways in different cell types and readily induces neoplastic transformation of. fibroblast cell lines. Recently, we have shown that the oncogenic pathway activated by G alpha(12) involves the receptor tyrosine kinase platelet derived growth factor receptor-alpha ( PDGFR alpha) and JAK3. In the present study, we demonstrate that the GTPase-deficient activated mutant of G alpha(12) activates signal transducer and activator of transcription 3 (STAT3) via PDGFRa as well as JAK3. Here we show that G alpha(12) stimulates the phosphorylation of STAT3 at both Tyrosine-705 and Serine-727 residues. Studies to delineate the mechanism by which G alpha(12) stimulates STAT3 have indicated that the Tyrosine-705-phosphorylation of STAT3 involves the tyrosine kinases, Janus Kinase-3 as well as Src kinase, whereas the Serine-727 phosphorylation of STAT3 occurs via the receptor tyrosine kinase, PDGFRa and phosphatidylinositol 3-OH kinase pathway. Our results also indicate that the coexpression of the dominant negative, DNA binding mutant of STAT3 (STAT3DB) inhibits the foci formation as well as anchorage- independent growth of G alpha(12)QL-transfectants, thereby establishing the critical role of STAT3 in G alpha(12)QL-mediated neoplastic cell growth. The results presented here demonstrate, for the. rst time, the ability of G alpha(12) to recruit multiple receptor-, nonreceptor-, and Ser/Thr kinases to stimulate STAT3-signaling to promote neoplastic transformation.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St,556 AHB, Philadelphia, PA 19140 USA.	danny001@temple.edu			NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berclaz G, 2001, INT J ONCOL, V19, P1155; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Fung MM, 2003, CELL SIGNAL, V15, P625, DOI 10.1016/S0898-6568(03)00003-2; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gutkind JS, 1998, CONT ENDOCRINOL, V6, P101; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; Kumar RN, 2004, CELL BIOCHEM BIOPHYS, V41, P63, DOI 10.1385/CBB:41:1:063; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lo RKH, 2004, MOL PHARMACOL, V65, P1427, DOI 10.1124/mol.65.6.1427; Lo RKH, 2003, J BIOL CHEM, V278, P52154, DOI 10.1074/jbc.M307299200; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Pedranzini L, 2004, J CLIN INVEST, V114, P619, DOI 10.1172/JCI200422800; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; Sambrook J, 2001, MOL CLONING LAB MANU; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; SHORE SK, 1989, ONCOGENE, V4, P1411; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479; Zhang YG, 2003, J BIOL CHEM, V278, P12650, DOI 10.1074/jbc.M210368200	47	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					899	906		10.1038/sj.onc.1209132	http://dx.doi.org/10.1038/sj.onc.1209132			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247467				2022-12-17	WOS:000235212700009
J	Mei, J; Webb, S; Zhang, B; Shu, HB				Mei, J; Webb, S; Zhang, B; Shu, HB			The p53-inducible apoptotic protein AMID is not required for normal development and tumor suppression	ONCOGENE			English	Article						AMID; p53; apoptosis; knockout; tumor suppression	PROGRAMMED CELL-DEATH; CYTOCHROME-C; FACTOR AIF; P53; MITOCHONDRIA; PATHWAYS; GENE; LETHALITY; HOMOLOG; GROWTH	AMID is an apoptosis-inducing factor (AIF)-homologous and mitochondria-associated protein that has been implicated in caspase-independent apoptosis. Transcription of human AMID gene is upregulated by p53 and downregulated in tumors in comparison to their matched normal tissues, suggesting the possibility that AMID is involved in the downstream effects of p53. To investigate the physiological functions of AMID, we generated AMID-deficient mice by gene targeting. AMID-deficient mice are viable and fertile, develop normally and lack obvious phenotypic changes compared to wild-type mice up to 1 year old. AMID(-/-) mice up to 1 year old have no spontaneous tumors and show similar fibrosarcoma incidence after MCA inoculation compared to wild-type mice. AMID(-/-) embryonic fibroblasts exhibit normal proliferation but slightly increased resistance to genotoxin-induced growth arrest. These findings suggest that AMID is not required for normal development and p53-mediated tumor suppression.	Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China; Natl Jewish Med & Res Ctr, Denver, CO USA	Wuhan University; National Jewish Health	Shu, HB (corresponding author), Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China.	shuh@whu.edu.cn			NATIONAL CANCER INSTITUTE [R01CA108771] Funding Source: NIH RePORTER; NCI NIH HHS [CA 108771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; Prives C, 1999, J PATHOL, V187, P112; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Wu M, 2004, ONCOGENE, V23, P6815, DOI 10.1038/sj.onc.1207909; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang PM, 2002, NAT GENET, V30, P31, DOI 10.1038/ng797	28	19	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					849	856		10.1038/sj.onc.1209121	http://dx.doi.org/10.1038/sj.onc.1209121			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16186796				2022-12-17	WOS:000235212700004
J	Bi, XL; Jones, T; Abbasi, F; Lee, H; Stultz, B; Hursh, DA; Mortin, MA				Bi, XL; Jones, T; Abbasi, F; Lee, H; Stultz, B; Hursh, DA; Mortin, MA			Drosophila caliban, a nuclear export mediator, can function as a tumor suppressor in human lung cancer cells	ONCOGENE			English	Article						caliban; Sdccag1; tumor suppressor; nuclear export; lung cancer; interference RNA	PROSPERO GENE; CRM1; LOCALIZATION; HOMOLOG; REVEALS; ENCODES; SIGNALS; PROTEIN; SYSTEM; DOMAIN	We previously showed that the Drosophila DNA binding homeodomain of Prospero included a 28 amino-acid sequence (HDA) that functions as a nuclear export signal. We describe here the identification of a protein we named Caliban, which can directly interact with the HDA. Caliban is homologous to human Sdccag1, which has been implicated in colon and lung cancer. Here we show that Caliban and Sdccag1 are mediators of nuclear export in fly and human cells, as interference RNA abrogates export of EYFP-HDA in normal fly and human lung cells. Caliban functions as a bipartite mediator nuclear export as the carboxy terminus binds HDA and the amino terminus itself functions as an NES, which directly binds the NES receptor Exportin. Finally, while non-cancerous lung cells have functional Sdccag1, five human lung carcinoma cell lines do not, even though Exportin still functions in these cells. Expression of fly Caliban in these human lung cancer cells restores EYFP-HDA nuclear export, reduces a cell's ability to form colonies on soft agar and reduces cell invasiveness. We suggest that Sdccag1 inactivation contributes to the transformed state of human lung cancer cells and that Caliban should be considered a candidate for use in lung cancer gene therapy.	NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA; NICHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); US Food & Drug Administration (FDA)	Mortin, MA (corresponding author), NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA.	mortinm@mail.nih.gov	Mortin, Mark A/B-4251-2008; Bi, Xiaolin/C-7038-2014; Bi, Xiaolin/E-7469-2010	Bi, Xiaolin/0000-0003-2837-9457; Bi, Xiaolin/0000-0002-7172-7851; Hursh, Deborah/0000-0002-5614-7111	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001005] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000367] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bi XL, 2003, MOL CELL BIOL, V23, P1014, DOI 10.1128/MCB.23.3.1014-1024.2003; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BURGLIN TR, 1994, TRENDS BIOCHEM SCI, V19, P70, DOI 10.1016/0968-0004(94)90035-3; Carbonnelle D, 2001, INT J CANCER, V92, P388, DOI 10.1002/ijc.1197; Collier S, 2000, GENETICS, V155, P1799; Demidenko Z, 2001, DEVELOPMENT, V128, P1359; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Ryter JM, 2002, STRUCTURE, V10, P1541, DOI 10.1016/S0969-2126(02)00883-3; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yousef M, 2005, STRUCTURE, V13, P601, DOI 10.1016/j.str.2005.01.023	21	19	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8229	8239		10.1038/sj.onc.1208962	http://dx.doi.org/10.1038/sj.onc.1208962			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16103875				2022-12-17	WOS:000233956500002
J	Ahlbory, DR; Appl, H; Lang, D; Klempnauer, KH				Ahlbory, DR; Appl, H; Lang, D; Klempnauer, KH			Disruption of B-myb in DT40 cells reveals novel function for B-Myb in the response to DNA-damage	ONCOGENE			English	Article						B-myb; DT40; homologous recombination; DNA-damage	DROSOPHILA-MYB; C-MYB; PROTEIN; GENE; PROLIFERATION; EXPRESSION; APOPTOSIS	B-Myb is a highly conserved vertebrate member of the Myb transcription factor family, which is expressed in virtually all proliferating cells. A large body of evidence suggests that B-Myb plays an important role in cell cycle regulation; however, the exact nature of its function has not yet been clarified. We have used gene targeting in chicken DT40 cells, a cell line exhibiting very high rates of homologous recombination, to create cells expressing endogenous B-myb in a doxycyclin-dependent manner. We find that the cells proliferate well in the absence of B-Myb, suggesting that B-Myb is not essential for cell proliferation per se. However, cells lacking B-Myb are more sensitive to DNA-damage induced by UV-irradiation and alkylation. Our work provides the first direct evidence for a novel function of B-Myb in the response to DNA-damage. The cells described here should be a useful model to characterize this function in more detail.	Univ Munster, Inst Biochem, D-48149 Munster, Germany; Univ Munster, Dept Med D, D-48149 Munster, Germany	University of Munster; University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Beall EL, 2002, NATURE, V420, P833, DOI 10.1038/nature01228; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Davidson CJ, 2005, GENETICS, V169, P215, DOI 10.1534/genetics.104.034132; Fitzpatrick CA, 2002, DEVELOPMENT, V129, P4497; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Grassilli E, 1999, CANCER RES, V59, P2451; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Joaquin M, 2002, ONCOGENE, V21, P7923, DOI 10.1038/sj.onc.1206001; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; Kamano H, 1995, ONCOGENE, V11, P2575; Katzen AL, 1998, GENE DEV, V12, P831, DOI 10.1101/gad.12.6.831; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Lang D, 2002, J IMMUNOL, V168, P6152, DOI 10.4049/jimmunol.168.12.6152; Lang G, 2005, IMMUNOLOGY, V114, P25, DOI 10.1111/j.1365-2567.2004.02073.x; Manak JR, 2002, P NATL ACAD SCI USA, V99, P7438, DOI 10.1073/pnas.122231599; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Sitzmann J, 1996, ONCOGENE, V12, P1889; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	29	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7127	7134		10.1038/sj.onc.1208869	http://dx.doi.org/10.1038/sj.onc.1208869			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170378				2022-12-17	WOS:000232990100002
J	O'Keefe, LV; Liu, YH; Perkins, A; Dayan, S; Saint, R; Richards, RI				O'Keefe, LV; Liu, YH; Perkins, A; Dayan, S; Saint, R; Richards, RI			FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila	ONCOGENE			English	Article						chromosomal fragile site; oxidoreductase; radiation sensitivity; gene rescue	TUMOR-SUPPRESSOR GENE; DOMAIN-CONTAINING OXIDOREDUCTASE; CELL LUNG-CANCER; HOMOZYGOUS DELETIONS; DNA-DAMAGE; WWOX; EXPRESSION; CARCINOMA; PARKIN; IDENTIFICATION	Fragile sites are chromosomal structures that have been proposed to have a determining role in cancer-associated DNA instability. The human WWOX gene spans the FRA16D chromosomal fragile site, the common minimal region of homozygous deletion found in adenocarcinomas and three out of five translocation breakpoints in multiple myeloma. Transcripts from the alternatively spliced WWOX gene encode proteins with common N-terminal WW domains and variable homology to the oxidoreductase family of proteins. In this study, the Drosophila orthologue of the WWOX gene was identified and subjected to mutagenesis via homologous recombination. The resultant DmWWOX(1) mutants were viable but exhibited an increased sensitivity to ionizing radiation. This radiation sensitivity was rescued by reintroduction and expression of either the wild-type Drosophila or human WWOX genes. Thus, the protective function of DmWWOX in response to irradiation in Drosophila is conserved with human WWOX (hWWOX). This is consistent with a protective role for hWWOX where aberrant expression, as a result of breakage at the associated fragile site, could contribute directly to cancer progression.	Univ Adelaide, Sch Mol & Biomed Sci, Res Network Genes & Environm Dev, ARC,NHMRC, Adelaide, SA 5005, Australia; Univ Adelaide, ARC, Special Res Ctr Mol Genet Dev, Adelaide, SA 5005, Australia; Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia	University of Adelaide; University of Adelaide; Australian National University	Richards, RI (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Res Network Genes & Environm Dev, ARC,NHMRC, Mol Life Sci Bldg,Gate 8,Victoria Dr, Adelaide, SA 5005, Australia.	robert.richards@adelaide.edu.au	O'Keefe, Louise V/B-9856-2008; Saint, Robert/A-4190-2008; Dayan, Sonia/D-7960-2013; Dayan, Sonia/U-9400-2017; Richards, Robert/ABE-6423-2020	Saint, Robert/0000-0002-7989-6043; Dayan, Sonia/0000-0002-5616-7542; Dayan, Sonia/0000-0002-5616-7542; Richards, Robert Ian/0000-0002-5978-6453				Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Aqeilan RI, 2004, CLIN CANCER RES, V10, P3053, DOI 10.1158/1078-0432.CCR-03-0594; Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Finnis M, 2005, HUM MOL GENET, V14, P1341, DOI 10.1093/hmg/ddi144; Glover TW, 1998, CANCER RES, V58, P3409; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; Ishii H, 2003, MOL CANCER RES, V1, P940; Jaklevic BR, 2004, CURR BIOL, V14, P23, DOI 10.1016/j.cub.2003.12.032; Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047; Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096; Kuroki T, 2002, CANCER RES, V62, P2258; Lee JH, 2003, FEBS LETT, V550, P5, DOI 10.1016/S0014-5793(03)00771-3; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Nioi P, 2004, MUTAT RES-FUND MOL M, V555, P149, DOI 10.1016/j.mrfmmm.2004.05.023; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Rong YKS, 2002, GENE DEV, V16, P1568, DOI 10.1101/gad.986602; Rozier L, 2004, ONCOGENE, V23, P6872, DOI 10.1038/sj.onc.1207809; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Sze CI, 2004, J BIOL CHEM, V279, P30498, DOI 10.1074/jbc.M401399200; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020; Watanabe A, 2003, CANCER RES, V63, P8629; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674; Yendamuri S, 2003, CANCER RES, V63, P878; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	39	19	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6590	6596		10.1038/sj.onc.1208806	http://dx.doi.org/10.1038/sj.onc.1208806			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007179				2022-12-17	WOS:000232204100013
J	Ryu, CH; Kim, SW; Lee, KH; Lee, JY; Kim, H; Lee, WK; Choi, BH; Lim, Y; Kim, YH; Lee, KH; Hwang, TK; Jun, TY; Rha, HK				Ryu, CH; Kim, SW; Lee, KH; Lee, JY; Kim, H; Lee, WK; Choi, BH; Lim, Y; Kim, YH; Lee, KH; Hwang, TK; Jun, TY; Rha, HK			The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity	ONCOGENE			English	Article						NF2; merlin; tumor suppressor; RalGDS; oncogenic signals	GROWTH-FACTOR RECEPTOR; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; CELLULAR-TRANSFORMATION; BINDING PROTEIN-1; SIGNALING PATHWAY; SPLICED ISOFORMS; FERM DOMAIN; SCHWANNOMIN; ACTIVATION	Neurofibromatosis type 2 (NF2) is the most commonly mutated gene in benign tumors of the human nervous system such as schwannomas and meningiomas. The NF2 gene encodes a protein called schwannomin or merlin, which is involved in regulating cell growth and proliferation through protein-protein interactions with various cellular proteins. In order to better understand the mechanism by which merlin exerts its function, yeast two-hybrid screening was performed and Ral guanine nucleotide dissociation stimulator (RalGDS), a downstream molecule of Ras, was identified as a merlin-binding protein. The direct interaction between merlin and RalGDS was confirmed both in vitro and in the NIH3T3 cells. The domain analyses revealed that the broad C-terminal region of merlin (aa 141-595) is necessary for the interaction with the C-terminal Ras-binding domain (RBD) of RalGDS. Functional studies showed that merlin inhibits the RalGDS-induced RalA activation, the colony formation and the cell migration in mammalian cells. These results suggest that merlin can function as a tumor suppressor by inhibiting the RalGDS-mediated oncogenic signals.	Catholic Univ Korea, Catholic Neurosci Ctr, Dept Psychiat, Seoul 137701, South Korea; Catholic Univ, Dept Urol, Seoul 137701, South Korea; Catholic Univ, Dept Pharmacol, Seoul 137701, South Korea; Catholic Univ, Dept Occupat & Environm Med, Seoul 137701, South Korea; Catholic Univ, Dept Psychiat, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Jun, TY (corresponding author), Catholic Univ Korea, Catholic Neurosci Ctr, Dept Psychiat, 505 Banpo Dong, Seoul 137701, South Korea.	ngrc@catholic.ac.kr						Arvelo Francisco, 2001, Acta Cientifica Venezolana, V52, P304; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gildea JJ, 2002, CANCER RES, V62, P982; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Jannatipour M, 2001, J BIOL CHEM, V276, P33093, DOI 10.1074/jbc.M105792200; Joffe E B, 2001, Medicina (B Aires), V61, P658; Johnson KC, 2002, ONCOGENE, V21, P5990, DOI 10.1038/sj.onc.1205693; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kim H, 2002, MOL CELLS, V14, P108; Kim JY, 2002, BIOCHEM BIOPH RES CO, V296, P1295, DOI 10.1016/S0006-291X(02)02077-6; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; Kressel M, 2002, HUM MOL GENET, V11, P2269, DOI 10.1093/hmg/11.19.2269; Lee IK, 2004, BIOCHEM BIOPH RES CO, V325, P774, DOI 10.1016/j.bbrc.2004.10.095; Lee JY, 2004, J BIOL CHEM, V279, P30265, DOI 10.1074/jbc.M312083200; Lee T, 1996, DEVELOPMENT, V122, P409; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Matthews J N S, 2002, Dev Biol (Basel), V107, P87; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Sainio M, 1997, J CELL SCI, V110, P2249; Schmucker B, 1999, HUM MOL GENET, V8, P1561, DOI 10.1093/hmg/8.8.1561; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Scoles DR, 2002, BIOCHEM BIOPH RES CO, V290, P366, DOI 10.1006/bbrc.2001.6178; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Takaya A, 2004, MOL BIOL CELL, V15, P2549, DOI 10.1091/mbc.E03-11-0857; THOMAS G, 1994, EUR J CANCER, V30A, P1981, DOI 10.1016/0959-8049(94)00390-Q; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	52	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5355	5364		10.1038/sj.onc.1208633	http://dx.doi.org/10.1038/sj.onc.1208633			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007223				2022-12-17	WOS:000231158500009
J	Hay, T; Patrick, T; Winton, D; Sansom, OJ; Clarke, AR				Hay, T; Patrick, T; Winton, D; Sansom, OJ; Clarke, AR			Brca2 deficiency in the murine small intestine sensitizes to p53-dependent apoptosis and leads to the spontaneous deletion of stem cells	ONCOGENE			English	Article						Brca2; p53; small intestine; apoptosis; DNA damage	RADIATION; HYPERSENSITIVITY; BREAST; RAD51; P53; RECOMBINATION; INSTABILITY; EXPRESSION; MICE	The gene encoding the human BRCA2 tumour suppressor is mutated in a number of different tumour types, most notably inherited breast cancers. The primary role of BRCA2 is thought to lie in the maintenance of genomic stability via its role in the homologous recombination pathway. We generated mice in which Brca2 was deleted from virtually all cells within the adult small intestine, using a CYP1A1-driven Cre-Lox approach. We noted a significant p53-dependent increase in the levels of spontaneous apoptosis which persisted for several months after removal of the gene and ultimately we observed the spontaneous deletion of Brca2-deficient stem cells. Brca2 deficiency did not lead to gross changes in intestinal physiology but did enhance sensitivity to a variety of DNA crosslinking agents. Taken together, our results indicate that Brca2 plays an important role in the response to DNA damage in the small intestine. Furthermore, we show that Brca2 deficiency results in the spontaneous deletion of stem cells, thereby protecting the small intestine against tumorigenesis.	Cardiff Univ, Sch Biosci, Cardiff CF10 3US, Wales; Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England	Cardiff University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, Museum Ave, Cardiff CF10 3US, Wales.	clarkear@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X				Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Cheung AMY, 2004, CANCER RES, V64, P1959, DOI 10.1158/0008-5472.CAN-03-2270; Cheung AMY, 2002, CANCER RES, V62, P6194; D'Andrea Antonello, 2002, Ital Heart J, V3, P34; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Marshman E, 2001, J PATHOL, V195, P285; Morimatsu M, 1998, CANCER RES, V58, P3441; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Scully R, 2000, BREAST CANCER RES, V2, P324, DOI 10.1186/bcr76; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242	26	19	21	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3842	3846		10.1038/sj.onc.1208533	http://dx.doi.org/10.1038/sj.onc.1208533			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15735671				2022-12-17	WOS:000229346300015
J	Huang, YP; Wernyj, RP; Norton, DD; Precht, P; Seminario, MC; Wange, RL				Huang, YP; Wernyj, RP; Norton, DD; Precht, P; Seminario, MC; Wange, RL			Modulation of specific protein expression levels by PTEN: identification of AKAP121, DHFR, G3BP, Rap1, and RCC1 as potential targets of PTEN	ONCOGENE			English	Article						PTEN; RCC1; G3BP; proteomics; leukemia; tumor suppressor	GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR GENE; JURKAT T-CELLS; PHOSPHATASE-ACTIVITY; BINDING-PROTEIN; GROWTH; RAS; DEGRADATION; INHIBITOR; MECHANISM	The tumor suppressor PTEN is mutated in a high percentage of human cancers, and is implicated in pathways regulating cell growth, proliferation, survival, and migration. Despite significant advances, our understanding of its mechanisms of action remains incomplete. We have used a high-throughput proteomic immunoblotting approach to identify proteins whose expression levels are modulated by PTEN. Out of over 800 proteins screened, 22 proteins showed significant changes in expression. Five proteins that exhibited two-fold or greater changes in expression level were further characterized. AKAP121 and G3BP expression was reduced, while dihydrofolate reductase ( DHFR), Rap1 and RCC1 expression was elevated in response to PTEN expression in a PTEN-null T-cell leukemia line. The phosphatase activity of PTEN was required for these effects. However, direct inhibition of PI-3 Kinase could mimic PTEN in modulating expression of DHFR, G3BP, Rap1 and RCC1, but not AKAP121. Real-time PCR showed that the effects of PTEN were primarily post-transcriptional, and would not have been revealed by mRNA-based screens. We conclude from these data that PTEN can modulate the expression level of a number of different proteins. The identified proteins have the potential to serve as previously unrecognized effectors of PTEN, and suggest the existence of additional complexity in the modes by which PTEN can regulate cellular biology.	NIA, Cellular & Mol Biol Lab, IRP NIH DHHS, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wange, RL (corresponding author), NIA, Cellular & Mol Biol Lab, IRP NIH DHHS, 5600 Nathan Shock Dr,MSC-12, Baltimore, MD 21224 USA.	wanger@grc.nia.nih.gov	Wange, Ronald/AAI-2505-2021	Wange, Ronald/0000-0001-9593-3572				Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Furnari FB, 1998, CANCER RES, V58, P5002; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kociok N, 1999, J CELL BIOCHEM, V74, P194, DOI 10.1002/(SICI)1097-4644(19990801)74:2<194::AID-JCB5>3.0.CO;2-M; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu K, 2001, J IMMUNOL, V166, P7335, DOI 10.4049/jimmunol.166.12.7335; LIVAK KJ, 2004, USER B PE APPL BIOSY, V2; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Parker F, 1996, MOL CELL BIOL, V16, P2561; Pazman C, 2000, DEVELOPMENT, V127, P1715; Pilarski R, 2004, J MED GENET, V41, P323, DOI 10.1136/jmg.2004.018036; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; POWIS G, 1994, CANCER RES, V54, P2419; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Seminario MC, 2003, ONCOGENE, V22, P8195, DOI 10.1038/sj.onc.1206872; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Yamaguchi R, 2003, CELL, V113, P115, DOI 10.1016/S0092-8674(03)00200-9	43	19	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3819	3829		10.1038/sj.onc.1208527	http://dx.doi.org/10.1038/sj.onc.1208527			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782128				2022-12-17	WOS:000229346300012
J	Su, ZZ; Emdad, L; Sarkar, D; Randolph, A; Valerie, K; Yacoub, A; Dent, P; Fisher, PB				Su, ZZ; Emdad, L; Sarkar, D; Randolph, A; Valerie, K; Yacoub, A; Dent, P; Fisher, PB			Potential molecular mechanism for rodent tumorigenesis: mutational generation of Progression Elevated Gene-3 (PEG-3)	ONCOGENE			English	Article						dominant negative; GADD34; PEG-3; tumorigenesis	DAMAGE-INDUCIBLE GENE; RAT EMBRYO CELLS; GROWTH ARREST; PROTEIN GADD34; P38 KINASE; TRANSFORMATION PROGRESSION; UV-RADIATION; SERINE 15; HUMAN P53; APOPTOSIS	Progression Elevated Gene-3 (PEG-3) was cloned using subtraction hybridization as an upregulated transcript associated with transformation and tumor progression of rat embryo fibroblast cells. PEG-3 is a unique gene facilitating tumor progression by modulating multiple pathways in transformed cells, including genomic stability, angiogenesis and invasion. PEG-3 originates from mutation in the growth arrest and DNA damage inducible gene GADD34. A one base deletion in rat GADD34 results in a frame-shift and premature appearance of a stop-codon resulting in a C-terminally truncated molecule that is PEG3. We now document that mutation in the GADD34 gene is a frequent event during transformation and/or immortalization of rodent cells. Sequencing of the GADD34 gene in a number of independent rat tumor cell lines revealed that in a majority of these the GADD34 gene is mutated to either PEG-3 or a PEG-3-like gene with similar C-terminal truncations. An important function of GADD34 is to inhibit cell growth, predominantly by apoptosis, and we demonstrate that PEG-3 or C-terminal truncations of human GADD34 resembling PEG-3 prevent growth inhibition by both human and rat GADD34. Phosphorylation of p53 by GADD34 is one mechanism by which it inhibits growth and PEG-3 could prevent GADD34-induced p53 phosphorylation. In contrast, PEG-3 was unable to block other GADD34-induced changes, including eIF2 alpha dephosphorylation, indicating that its effects on GADD34 may be related more to its effect on cell growth rather than a global inhibitor of all GADD34 functions. We hypothesize that mutational generation of PEG-3 or a similar molecule is a critical event during rodent carcinogenesis. T he inherent property of PEG-3 to function as a dominant negative of the growth inhibitory property of GADD34 might rescue cells from DNA damage-induced apoptosis leading to growth independence and tumorigenesis.	Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Pathol, New York, NY 10032 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	Columbia University; Virginia Commonwealth University	Fisher, PB (corresponding author), Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Valerie, Kristoffer/AAL-8299-2021					Adler HT, 1999, MOL CELL BIOL, V19, P7050; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Emdad L, 2005, J CELL PHYSIOL, V202, P135, DOI 10.1002/jcp.20097; FISCELLA M, 1993, ONCOGENE, V8, P1519; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Grishin AV, 2001, P NATL ACAD SCI USA, V98, P10172, DOI 10.1073/pnas.191130798; Hasegawa T, 1999, BBA-GEN SUBJECTS, V1428, P161, DOI 10.1016/S0304-4165(99)00060-4; Hasegawa T, 2000, BIOCHEM BIOPH RES CO, V267, P593, DOI 10.1006/bbrc.1999.1991; Hasegawa T, 2000, BIOCHEM J, V352, P795, DOI 10.1042/0264-6021:3520795; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097-0215(20010220)96:1<22::AID-IJC3>3.0.CO;2-K; Hollander MC, 2003, ONCOGENE, V22, P3827, DOI 10.1038/sj.onc.1206567; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Kojima E, 2003, FASEB J, V17, P1573, DOI 10.1096/fj.02-1184fje; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2001, CANCER RES, V61, P1604; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SU ZZ, 1993, ONCOGENE, V8, P1211; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2002, J CELL PHYSIOL, V192, P34, DOI 10.1002/jcp.10114; SU ZZ, 1994, CANCER RES, V54, P1865; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Valerie K, 1999, BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT, P69; Yagi A, 2003, J CELL BIOCHEM, V90, P1242, DOI 10.1002/jcb.10711; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	36	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2247	2255		10.1038/sj.onc.1208420	http://dx.doi.org/10.1038/sj.onc.1208420			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15674324				2022-12-17	WOS:000227857900012
J	Kuiperij, HB; van der Horst, A; Raaijmakers, J; Weijzen, S; Medema, RH; Bos, JL; Burgering, BMT; Zwartkruis, FJT				Kuiperij, HB; van der Horst, A; Raaijmakers, J; Weijzen, S; Medema, RH; Bos, JL; Burgering, BMT; Zwartkruis, FJT			Activation of FoxO transcription factors contributes to the antiproliferative effect of cAMP	ONCOGENE			English	Article						cAMP; protein kinase B; FoxO; p27(Kip1); cyclin D1; growth arrest	KINASE INHIBITOR P27(KIP1); CELL-CYCLE PROGRESSION; SIGNAL-REGULATED KINASE-2; BREAST-CANCER CELLS; G1 PHASE ARREST; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; D1 EXPRESSION; DEPENDENT DEGRADATION; ERK INHIBITION	cAMP is a potent inhibitor of cell proliferation in a variety of cell lines. Downregulation of cyclin D1 and upregulation of the cell cycle inhibitor p27(Kip1) are two mechanisms by which cAMP may induce a G1-arrest. Here we show that cAMP inhibits proliferation of cells that constitutively express cyclin D1 or are deficient for Rb, demonstrating that changes in these cell cycle regulators do not account for the cAMP-induced growth effects in mouse embryo fibroblasts (MEFs). Interestingly, the antiproliferative effect of cAMP mimics the effect previously observed for FoxO transcription factors. These transcription factors are under negative control of protein kinase B (PKB). We show that in MEFs cAMP strongly induces transcriptional activation of FoxO4 through the inhibition of PKB. Accordingly, not only p27(Kip1) but also the FoxO target MnSOD is upregulated by cAMP. Importantly, introduction of dominant-negative FoxO partially rescues cAMP-induced inhibition of proliferation. From these results we conclude that inhibition of PKB and subsequent activation of FoxO transcription factors mediates an antiproliferative effect of cAMP.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Utrecht University; Utrecht University; Netherlands Cancer Institute	Zwartkruis, FJT (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, Universiteitsweg 100, NL-3584 CG Utrecht, Netherlands.	G.J.T.Zwartkruis@med.uu.nl	Medema, Rene H/G-5415-2011; Kuiperij, Bea/A-4737-2013; Medema, Rene H/E-2981-2013	Kuiperij, Bea/0000-0002-0635-7428; Medema, Rene/0000-0002-6754-0381				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Balmanno K, 2003, MOL CELL BIOL, V23, P9303, DOI 10.1128/MCB.23.24.9303-9317.2003; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Boucher MJ, 2001, BIOCHEM BIOPH RES CO, V285, P207, DOI 10.1006/bbrc.2001.5147; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kim TY, 2001, INVEST OPHTH VIS SCI, V42, P3142; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P3816, DOI 10.1167/iovs.03-0147; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rao S, 1999, EXP CELL RES, V252, P211, DOI 10.1006/excr.1999.4620; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; SEWING A, 1993, J CELL SCI, V104, P545; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Vadiveloo PK, 1997, ATHEROSCLEROSIS, V133, P61, DOI 10.1016/S0021-9150(97)00116-0; van Oirschot BA, 2001, J BIOL CHEM, V276, P33854, DOI 10.1074/jbc.M104395200; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Williamson EA, 1997, LEUKEMIA, V11, P73, DOI 10.1038/sj.leu.2400551; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	57	19	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2087	2095		10.1038/sj.onc.1208450	http://dx.doi.org/10.1038/sj.onc.1208450			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688004				2022-12-17	WOS:000227681900013
J	Budde, A; Schneiderhan-Marra, N; Petersen, G; Brune, B				Budde, A; Schneiderhan-Marra, N; Petersen, G; Brune, B			Retinoblastoma susceptibility gene product pRB activates hypoxia-inducible factor-1 (HIF-1)	ONCOGENE			English	Article						HIF-1 alpha; pRB; transcriptional activation	FACTOR-ALPHA; S-PHASE; PROTEIN; HIF-1-ALPHA; INTERACTS; BINDING; STRESS; P53; FACTOR-1-ALPHA; RECRUITMENT	Hypoxia-inducible factor-1 alpha (HIF-1alpha) constitutes a regulatory subunit of HIF-1, a major transcriptional activator of genes that coordinate physiological and pathological responses towards hypoxia. In order to identify novel interaction partners of HIF-1alpha we have applied T7 phage display system and identified a domain inherent in the retinoblastoma protein ( pRB). The interaction between pRB and HIF-1alpha was confirmed by in vitro experiments and in transfected cells. Thereby, an HIF-1alpha domain spanning amino acids 530-694 was mapped to be required for pRB binding. Overexpression of pRB provoked transcriptional activation of HIF-1alpha under normoxia. Furthermore, the domain of pRB identified to bind HIF-1alpha in vitro is sufficient to cause HIF-1alpha transcriptional activation with the further notion that phosphorylation deficient pRB shows stronger HIF-1alpha transactivation. Using ChIP analysis, we show that HIF-1alpha responsive elements (HREs) are precipitated using alpha-pRB antibodies. Additionally, a functional interaction between pRB and HIF-1alpha is confirmed by showing that HIF-1alpha reverses the transcription repressor function of pRB.	Univ Kaiserslautern, Fac Biol, Dept Cell Biol, D-67663 Kaiserslautern, Germany; Univ Erlangen Nurnberg, Fac Med, Dept Med, Expt Div 4, D-91054 Erlangen, Germany; Heidelberg Univ, Inst Zool, D-69120 Heidelberg, Germany	University of Kaiserslautern; University of Erlangen Nuremberg; Ruprecht Karls University Heidelberg	Brune, B (corresponding author), Univ Kaiserslautern, Fac Biol, Dept Cell Biol, D-67663 Kaiserslautern, Germany.	bruene@rhrk.uni.kl.de						Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Danielsen T, 1998, BRIT J CANCER, V78, P1547, DOI 10.1038/bjc.1998.722; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Green SL, 2001, MOL CELL BIOL, V21, P1196, DOI 10.1128/MCB.21.4.1196-1206.2001; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Hui AM, 1999, INT J CANCER, V84, P604, DOI 10.1002/(SICI)1097-0215(19991222)84:6<604::AID-IJC11>3.0.CO;2-Y; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Krtolica A, 1996, CANCER RES, V56, P1168; LUDLOW JW, 1993, ONCOGENE, V8, P331; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Marlowe JL, 2004, J BIOL CHEM, V279, P29013, DOI 10.1074/jbc.M404315200; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Rodi DJ, 1999, CURR OPIN BIOTECH, V10, P87, DOI 10.1016/S0958-1669(99)80016-0; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sche PP, 1999, CHEM BIOL, V6, P707, DOI 10.1016/S1074-5521(00)80018-6; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Wang F, 2004, J BIOL CHEM, V279, P46733, DOI 10.1074/jbc.M409002200; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	38	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1802	1808		10.1038/sj.onc.1208369	http://dx.doi.org/10.1038/sj.onc.1208369			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674338				2022-12-17	WOS:000227345100016
J	Lechpammer, M; Xu, XJ; Ellis, FH; Bhattacharaya, N; Shapiro, GI; Loda, M				Lechpammer, M; Xu, XJ; Ellis, FH; Bhattacharaya, N; Shapiro, GI; Loda, M			Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice	ONCOGENE			English	Article						Barrett's esophagus; Barrett's associated adenocarcinoma; p27; flavopiridol; mouse model	DEPENDENT KINASE INHIBITOR; BARRETTS-ESOPHAGUS; CYCLIN D1; ADENOCARCINOMA; CANCER; APOPTOSIS; CELLS; TRIAL; CHEMOPREVENTION; NEOPLASMS	The cyclin-dependent kinase (cdk) inhibitor p27 preferentially inactivates cdk complexes required for progression through the G1/S transition. Loss of p27 is associated with aggressive behavior in a variety of tumors, including Barrett's associated adenocarcinoma (BAA). We have previously shown that gastroduodenal-esophageal reflux (GDER) together with N-methyl-N-benzylnitrosamine (MBN) induces Barrett's esophagus (BE) and malignant transformation of the esophageal mucosa in mice. This process is enhanced in a p27 null background. Here, we show that chronic flavopiridol administration sharply reduced the prevalence of BE in GDER/MBN-treated p27 knockout mice when compared to animals treated with diluent only (7 vs 26%, P = 0.0079). Similarly, flavopiridol reduced the prevalence of BAA (11 vs 32%, P = 0.0098) and overall cancer prevalence (15 vs 60%, P < 0.0001). In addition, appropriate molecular targeting by flavopiridol in tumor cells was confirmed by downregulation of cyclin D1, a known target of this pan-cdk inhibitor. The results of this study represent the experimental basis for chemoprevention with cdk inhibitors in human BE and BAA.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiothorac Surg, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Loda, M (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, D740 44 Binney St, Boston, MA 02115 USA.	massimo_loda@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [P20CA090578, P50CA090381, R01CA090687, P01CA089021] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90381, P01 CA89021, R01 CA90687, P20 CA90578] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson M, 2003, BIOORG MED CHEM LETT, V13, P3021, DOI 10.1016/S0960-894X(03)00638-3; Arguello F, 1998, BLOOD, V91, P2482; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; Buttar NS, 2002, GASTROENTEROLOGY, V122, P1101, DOI 10.1053/gast.2002.32371; Bytzer P, 1999, AM J GASTROENTEROL, V94, P86; Carlson B, 1999, CANCER RES, V59, P4634; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Ellis F H Jr, 1997, Dis Esophagus, V10, P165; Ellis FH, 2001, J THORAC CARDIOV SUR, V122, P809, DOI 10.1067/mtc.2001.116471; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Heath EI, 2003, DIS ESOPHAGUS, V16, P177, DOI 10.1046/j.1442-2050.2003.00325.x; Jenkins GJS, 2002, BRIT J SURG, V89, P824, DOI 10.1046/j.1365-2168.2002.02107.x; Lam LT, 2001, GENOME BIOL, V2; MCCORMICK J, 2003, P AN M AM SOC CLIN, V22, pA835; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Phillips RW, 2003, AM J SURG PATHOL, V27, P1442, DOI 10.1097/00000478-200311000-00006; PIERGA JY, 2003, P AN M AM SOC CLIN, V22, pA840; Schrump DS, 1998, CLIN CANCER RES, V4, P2885; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Shapiro GI, 2001, CLIN CANCER RES, V7, P1590; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Singh SP, 1998, CANCER RES, V58, P1730; Tan AR, 2002, J CLIN ONCOL, V20, P4074, DOI 10.1200/JCO.2002.01.043; Xu XJ, 2000, J SURG RES, V88, P120, DOI 10.1006/jsre.1999.5774; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	26	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1683	1688		10.1038/sj.onc.1208375	http://dx.doi.org/10.1038/sj.onc.1208375			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674336				2022-12-17	WOS:000227345100004
J	Bergonzini, V; Delbue, S; Wang, JY; Reiss, K; Prisco, M; Amini, S; Khalili, K; Peruzzi, F				Bergonzini, V; Delbue, S; Wang, JY; Reiss, K; Prisco, M; Amini, S; Khalili, K; Peruzzi, F			HIV-Tat promotes cellular proliferation and inhibits NGF-induced differentiation through mechanisms involving Id1 regulation	ONCOGENE			English	Article						HIV-1 TAT; NGF; neuronal signaling; Id1	LOOP-HELIX PROTEIN; NERVE GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; DNA-BINDING; MYELOID DIFFERENTIATION; NEURONAL APOPTOSIS; SIGNALING PATHWAYS; ACTIVATION; RECEPTOR	Id1 is a helix - loop - helix transcriptional factor that controls growth and survival of neuronal cells. Downregulation of Id1 expression is required to initiate differentiation and cell-cycle withdrawal in primary neuronal culture as well as in PC12 cells. The HIV-1 transactivating factor, Tat, has been suspected of causing neuronal dysfunction that often leads to the development of HIV-associated dementia in AIDS patients. We found that the expression of Tat in PC12 cells promotes serum-independent growth, formation of large colonies in soft agar, and the acceleration of tumor growth in nude mice. In addition, Tat showed the ability to inhibit the nerve growth factor (NGF)-induced neuronal differentiation of PC12 cells. Our results show that the Tat-mediated signaling events, which lead to serum-independent growth and the inhibition of NGF-induced differentiation, have a common cellular target: the upregulation of Id1 expression. In the absence of NGF, expression of Id1 is required to promote serum-independent proliferation of PC12/Tat cells, as the inhibition of Id1 by antisense DNA restored the serum-dependent growth of PC12/Tat cells. In the presence of NGF, Tat utilizes an additional pathway that involves phosphorylation of Stat5a, to upregulate Id1 expression and block neuronal cell differentiation. Suppression of Stat5a by use of its dominant-negative mutant reversed the transient expression of Id1 and the blockage of NGF-mediated differentiation in PC12/Tat cells. Finally, the treatment of PC12 cells with recombinant Tat also enhanced the NGF-induced Id1 expression, further pointing to Id1 as a target for Tat. Taken together, these studies suggest additional targets for Tat action in neuronal cells and provide new insights into the mechanisms involved in the dysregulation of neuronal functions.	Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Fdn Don C Gnocchi, Milan, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; IRCCS Fondazione Don Carlo Gnocchi Onlus	Peruzzi, F (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, 1900 12th North St, Philadelphia, PA 19122 USA.	fperuzzi@temple.edu	Peruzzi, Francesca/M-9804-2014; delbue, serena/A-1145-2010	Delbue, Serena/0000-0002-3199-9369				Belletti B, 2002, EXP CELL RES, V277, P107, DOI 10.1006/excr.2002.5542; BENEZRA R, 1990, ANN NY ACAD SCI, V599, P1, DOI 10.1111/j.1749-6632.1990.tb42359.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Borgatti P, 1998, BIOCHEM BIOPH RES CO, V242, P332, DOI 10.1006/bbrc.1997.7877; Bovolenta C, 1999, BLOOD, V94, P4202, DOI 10.1182/blood.V94.12.4202.424k22_4202_4209; Bovolenta C, 2002, J IMMUNOL, V169, P4443, DOI 10.4049/jimmunol.169.8.4443; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Cai L, 2000, DEVELOPMENT, V127, P3021; Caldenhoven E, 1998, STEM CELLS, V16, P397, DOI 10.1002/stem.160397; Cantaluppi V, 2001, AIDS RES HUM RETROV, V17, P965, DOI 10.1089/088922201750290087; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; de la Fuente C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-14; De-Fraja C, 2000, INT J DEV NEUROSCI, V18, P439, DOI 10.1016/S0736-5748(00)00007-1; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; EINARSON MB, 1995, MOL CELL BIOL, V15, P4175; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ENSOLI F, 1994, VIROLOGY, V200, P668, DOI 10.1006/viro.1994.1230; GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51; Groner B, 2000, GROWTH HORM IGF RES, V10, P15, DOI 10.1016/S1096-6374(00)80004-0; Israel MA, 1999, CANCER RES, V59, p1726S; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; Lin CQ, 2000, CANCER RES, V60, P1332; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; Milani D, 1996, J BIOL CHEM, V271, P22961, DOI 10.1074/jbc.271.38.22961; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; Milani D, 1998, AIDS, V12, P1275, DOI 10.1097/00002030-199811000-00008; MIN X, 2003, EMBO J, V22, P893; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Ramirez SH, 2001, J NEUROCHEM, V78, P874, DOI 10.1046/j.1471-4159.2001.00467.x; Recio JA, 1997, J BIOL CHEM, V272, P26807, DOI 10.1074/jbc.272.43.26807; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 2001, CLIN CANCER RES, V7, P2134; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; Seve M, 1999, ARCH BIOCHEM BIOPHYS, V361, P165, DOI 10.1006/abbi.1998.0942; Shi B, 1998, J NEUROVIROL, V4, P281, DOI 10.3109/13550289809114529; Wang JY, 2003, VIROLOGY, V305, P66, DOI 10.1006/viro.2002.1690; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Wu YY, 1996, J BIOL CHEM, V271, P13033, DOI 10.1074/jbc.271.22.13033; ZAULI G, 1993, CANCER RES, V53, P4481; ZAULI G, 1995, BLOOD, V86, P3823, DOI 10.1182/blood.V86.10.3823.bloodjournal86103823; Zhong HY, 2001, LIFE SCI, V68, P2269, DOI 10.1016/S0024-3205(01)01015-3	59	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7701	7711		10.1038/sj.onc.1207828	http://dx.doi.org/10.1038/sj.onc.1207828			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361847				2022-12-17	WOS:000224306700011
J	Rebouissou, S; Rosty, C; Lecuru, F; Boisselier, S; Bui, H; Le Frere-Belfa, MA; Sastre, X; Laurent-Puig, P; Zucman-Rossi, J				Rebouissou, S; Rosty, C; Lecuru, F; Boisselier, S; Bui, H; Le Frere-Belfa, MA; Sastre, X; Laurent-Puig, P; Zucman-Rossi, J			Mutation of TCF1 encoding hepatocyte nuclear factor 1 alpha in gynecological cancer	ONCOGENE			English	Article						endometrial cancer; ovarian cancer; breast cancer; hepatocyte nuclear factor 1; HNF1 alpha; gene mutation; liver cell adenoma; microsatellite instability; MSI-H	DNA-BINDING; POU DOMAIN; GENE; INACTIVATION; HNF-1-ALPHA; EXPRESSION; PROMOTER; LF-B1; YOUNG; PCR	TCF1 ( transcription factor 1) encoding hepatocyte nuclear factor 1alpha (HNF1alpha) is mutated in 50% of liver cell adenomas, a benign tumor closely associated with oral contraceptive use. These genetic alterations inactivate both alleles, leading to the absence of wild-type HNF1alpha expression in liver cell adenomas. To search for a role of HNF1alpha in other hormone-related neoplasias, we screened for HNF1alpha mutations in a series of 36 endometrial carcinomas, 29 breast carcinomas and 20 ovarian epithelial tumors. HNF1alpha mutations were identified in 4/ 36 (11%) of endometrial tumors. No mutation was found in ovarian and breast tumors. HNF1alpha mutations were somatic in all cases, monoallelic in three cases and biallelic in one case. These results suggest that HNF1alpha may contribute to endometrial carcinogenesis through complete HNF1alpha inactivation like in liver cell adenoma or by haploinsufficiency like in MSI-H colorectal cancer.	INSERM, U434, F-75010 Paris, France; Ctr Etud Polymorphisme Humain, Fdn Jean Dausset, F-75010 Paris, France; Inst Curie, Serv Anatomopathol, F-75005 Paris, France; Assistance Publ Hop Paris, Hop Europeen Georges Pompidou, Gynecol Serv, F-75015 Paris, France; Assistance Publ Hop Paris, Hop Europeen Georges Pompidou, Serv Anatomopathol, F-75015 Paris, France; INSERM, U490, Mol Toxicol Lab, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Foundation Jean Dausset-CEPH; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Zucman-Rossi, J (corresponding author), INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.	zucman@cephb.fr	Rosty, Christophe/F-1796-2010; laurent-puig, pierre/B-2226-2013; j, zucman-rossi/AAV-3594-2021; Rebouissou, Sandra/O-5938-2017; zucman-rossi, Jessica/B-5098-2009; Laurent-Puig, Pierre/K-3641-2019	laurent-puig, pierre/0000-0001-8475-5459; j, zucman-rossi/0000-0002-5687-0334; Rebouissou, Sandra/0000-0003-0188-2271; zucman-rossi, Jessica/0000-0002-5687-0334; Laurent-Puig, Pierre/0000-0001-8475-5459; Rosty, Christophe/0000-0001-7671-2651				Aguanno A, 1996, J BIOL CHEM, V271, P4528; Akiyama TE, 2000, J BIOL CHEM, V275, P27117; Bacq Y, 2003, GASTROENTEROLOGY, V125, P1470, DOI 10.1016/j.gastro.2003.07.012; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Bluteau O, 1999, BIOTECHNIQUES, V27, P1100, DOI 10.2144/99276bm01; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Bluteau O, 1999, GASTROEN CLIN BIOL, V23, P1225; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; Chi YI, 2002, MOL CELL, V10, P1129, DOI 10.1016/S1097-2765(02)00704-9; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Ellard S, 2000, HUM MUTAT, V16, P377, DOI 10.1002/1098-1004(200011)16:5<377::AID-HUMU1>3.0.CO;2-2; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; HENDERSON BE, 1988, CANCER RES, V48, P246; Ishii Y, 2000, MOL PHARMACOL, V57, P940; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Laurent-Puig P, 2003, GASTROENTEROLOGY, V124, P1311, DOI 10.1016/S0016-5085(03)00268-3; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	19	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7588	7592		10.1038/sj.onc.1207989	http://dx.doi.org/10.1038/sj.onc.1207989			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326484	Bronze			2022-12-17	WOS:000224176500016
J	Robanus-Maandag, E; Giovannini, M; van der Valk, M; Niwa-Kawakita, M; Abramowski, V; Antonescu, C; Thomas, G; Berns, A				Robanus-Maandag, E; Giovannini, M; van der Valk, M; Niwa-Kawakita, M; Abramowski, V; Antonescu, C; Thomas, G; Berns, A			Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin	ONCOGENE			English	Article						MPNST; neural crest; P0 promoter; conditional knockout mice; compensatory signalling	SUPPRESSOR GENE-PRODUCT; NEUROFIBROMATOSIS TYPE-2; P53-DEFICIENT MICE; MOUSE; SPECTRUM; PROTEIN; CD44; ORGANIZATION; MERLIN; CELLS	Previously, we have mimicked human neuro. bromatosis type 2 (NF2) in conditional Nf2 mutant (P0Cre; Nf2(flox2/flox2)) mice. Schwannomas, characteristic for NF2, were found at low frequency in older mice. Here, we report that these mice, upon additional hemizygosity for p53, rapidly develop multiple tumours showing features consistent with malignant peripheral nerve sheath tumours. Thus, p53 hemizygosity promotes tumorigenesis of mutant Nf2 peripheral nerve cells. In contrast, young P0Cre; Nf2(flox2/+); p53(+/-) cis mice mainly succumb to Nf2/p53-related osteogenic tumours. Therefore, Cre-mediated early biallelic loss of Nf2 function in neural crest-derived cells hemizygous for p53 results in resistance to osteogenic tumours and increased susceptibility to peripheral nerve sheath tumours.	Netherlands Canc Inst, Div Mol Genet, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; INSERM, Fdn Jean Dausset, CEPH, F-75010 Paris, France; Netherlands Canc Inst, Dept Anim Pathol, NL-1066 CX Amsterdam, Netherlands; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Netherlands Cancer Institute; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); Netherlands Cancer Institute; Memorial Sloan Kettering Cancer Center	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl		Kawakita, Michiko/0000-0002-9450-583X				BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; ERLANDSON RA, 1982, CANCER, V49, P273, DOI 10.1002/1097-0142(19820115)49:2<273::AID-CNCR2820490213>3.0.CO;2-R; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Kleihues P, 2000, CANCER, V88, P2887, DOI 10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Mckusick V.A., 1994, MENDELIAN INHERITANC; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MESSING A, 1994, J NEUROSCI, V14, P3533; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; PURDIE CA, 1994, ONCOGENE, V9, P603; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sherman L, 1998, GENE DEV, V12, P1058, DOI 10.1101/gad.12.7.1058; Sherman L, 1999, ONCOGENE, V18, P6692, DOI 10.1038/sj.onc.1203055; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Zorick TS, 1996, CURR OPIN CELL BIOL, V8, P870, DOI 10.1016/S0955-0674(96)80090-1	27	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6541	6547		10.1038/sj.onc.1207858	http://dx.doi.org/10.1038/sj.onc.1207858			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221010				2022-12-17	WOS:000223530800001
J	Zhang, H; Herbert, BS; Pan, KH; Shay, JW; Cohen, SN				Zhang, H; Herbert, BS; Pan, KH; Shay, JW; Cohen, SN			Disparate effects of telomere attrition on gene expression during replicative senescence of human mammary epithelial cells cultured under different conditions	ONCOGENE			English	Article						replicative senescence; telomere shortening; microarray; mammary epithelial cells; culture conditions	LIFE-SPAN; REVERSE-TRANSCRIPTASE; PREMATURE SENESCENCE; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; DNA MICROARRAYS; MITOTIC CLOCK; P16(INK4A); EXTENSION; IMMORTALIZATION	Telomere shortening in populations of human mammary epithelial cells (HMECs) that survive early replicative arrest (M0) by the inactivation of p16(INK4A) during cell culture on plastic dishes leads to a state of permanent replicative arrest termed senescence. While culture of HMECs on feeder layers abrogates M0 and p16(INK4A) inactivation, progressive telomere attrition in these cells also eventually results in permanent replicative arrest. Expression of telomerase prevents both senescence on plastic (S-P) and senescence on feeder layers (S-FL) in HMECs, as it does also in cultured primary human fibroblasts. We report here that the gene expression profiles of senescence in HMECs of the same lineage maintained under different culture conditions showed surprisingly little commonality. Moreover, neither of these senescence-associated profiles in HMECs resembles the pro. le for senescence in human fibroblasts. These results indicate that senescence-associated alterations in gene expression resulting from telomere attrition are affected by culture conditions as well as by cell origins, and argue that replicative senescence at the molecular level is a diverse rather than unique cellular process.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Stanford Univ, Sch Med, Program Biomed Informat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University-Purdue University Indianapolis; Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.	sncohen@stanford.edu	Shay, Jerry W/F-7878-2011		NCI NIH HHS [CA70907] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; Pan KH, 2002, P NATL ACAD SCI USA, V99, P2118, DOI 10.1073/pnas.251687398; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yaswen P, 2001, J MAMMARY GLAND BIOL, V6, P223, DOI 10.1023/A:1011364925259; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	40	19	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6193	6198		10.1038/sj.onc.1207834	http://dx.doi.org/10.1038/sj.onc.1207834			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15195144				2022-12-17	WOS:000223399000003
J	Leong, CTC; Ng, CY; Ng, CP; Ma, ZS; Nguyen, TH; Tay, SK; Huynh, H				Leong, CTC; Ng, CY; Ng, CP; Ma, ZS; Nguyen, TH; Tay, SK; Huynh, H			Molecular cloning, characterization and isolation of novel spliced variants of the human ortholog of a rat estrogen-regulated membrane-associated protein, UO-44	ONCOGENE			English	Article						estrogen regulated; membrane associated; CUB domains; zona-pellucida and HuUO-44	TUMOR-SUPPRESSOR GENE; LONG ARM; EXPRESSION; IDENTIFICATION; CHROMOSOME-10; TAMOXIFEN; UTERUS; DOMAIN; DMBT1; LOCALIZATION	We have previously reported the characterization of an estrogen-regulated rat uterine-ovarian-specific complementary DNA (UO-44). To understand the involvement of this protein in the initiation and progression of human ovarian and uterine cancers, we now report the cloning and characterization of the human ortholog (HuUO-44). HuUO-44 is mapped to chromosome 10q26.13 and contains nine exons. Multiple tissue Northern blot detected two HuU044 transcripts of approximately 2 and 3kb in the pancreas. RT-PCR demonstrated that HuU044 undergoes a complex series of alternative splicing events between exons 2 and 6 that yielded four novel splice variants, HuUO-44A, HuUO-44B, HuUO-44C and HuUO-44D. Putative functional motifs identified in HuU044 are two CUB domains and a zona-pellucida domain. Transfection studies demonstrated the membrane-associated nature of HuU044. By immunohistochemistry, HuU044 was located to the normal ovarian and ovarian tumor epithelial cells; in NIH-OVCAR3 ovarian cancer cells, HuU044 was detected only at the leading edge of the dividing cells. Most importantly, a marked loss in cell attachment and proliferation was observed in NIH-OVCAR3 cells cultured in the presence of a polyclonal HuU044 antiserum. These findings suggest the potential role of HuU044 in cell motility, cell-cell matrices.	Natl Canc Ctr, Mol Endocrinol Lab, Div Cellular & Mol Res, Singapore 169610, Singapore; Singapore Gen Hosp, Dept Obstet & Gynaecol, Singapore 169608, Singapore	National Cancer Centre Singapore (NCCS); Singapore General Hospital	Huynh, H (corresponding author), Natl Canc Ctr, Mol Endocrinol Lab, Div Cellular & Mol Res, Singapore 169610, Singapore.	cmrhth@nccs.com.sg	Nguyen, Hung/M-8118-2014	Nguyen, Hung/0000-0001-8378-555X; Ong, Choon Kiat/0000-0001-6402-4288				AUERSPERG N, 1984, IN VITRO CELL DEV B, V20, P743; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Chen DH, 1999, J BIOL CHEM, V274, P32215, DOI 10.1074/jbc.274.45.32215; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; EINSPANIER R, 1991, BIOCHEM BIOPH RES CO, V179, P1006, DOI 10.1016/0006-291X(91)91918-3; FUKUSHIMA D, 1993, J BIOL CHEM, V268, P22710; GRAY IC, 1995, CANCER RES, V55, P4800; Gregoire L, 2001, CLIN CANCER RES, V7, P4280; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Huynh H, 2001, ENDOCRINOLOGY, V142, P2985, DOI 10.1210/en.142.7.2985; HUYNH HT, 1993, CANCER RES, V53, P5585; Imamura T, 2002, J BIOL CHEM, V277, P50725, DOI 10.1074/jbc.M204159200; Jovine L, 2002, NAT CELL BIOL, V4, P457, DOI 10.1038/ncb802; Kasik JW, 1998, BIOCHEM J, V330, P947; KATZENELLENBOGE.BS, 1975, BIOCHEMICAL ACTION H, V3, P187; Katzenellenbogen BS, 1997, ENDOCRINOLOGY, V138, P861, DOI 10.1210/en.138.3.861; Kazandi M, 2002, EUR J GYNAECOL ONCOL, V23, P257; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; Lualdi E, 2000, BIOCHEM BIOPH RES CO, V270, P673, DOI 10.1006/bbrc.2000.2478; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mollenhauer J, 2000, CANCER RES, V60, P1704; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Nielsen S, 1998, EUR EAT DISORD REV, V6, P4, DOI 10.1002/(SICI)1099-0968(199803)6:1<4::AID-ERV237>3.3.CO;2-G; Nitta M, 2001, GYNECOL ONCOL, V81, P10, DOI 10.1006/gyno.2000.6084; PEIFFER SL, 1995, CANCER RES, V55, P1922; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Stoffel W., 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; WHITE MM, 1995, ENDOCR REV, V16, P739, DOI 10.1210/er.16.6.739; Wu WG, 1999, CANCER RES, V59, P1846; YOSHINAGA K, 1969, ENDOCRINOLOGY, V85, P103, DOI 10.1210/endo-85-1-103	37	19	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5707	5718		10.1038/sj.onc.1207754	http://dx.doi.org/10.1038/sj.onc.1207754			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184879				2022-12-17	WOS:000222629500018
J	Pickett, HA; Baird, DM; Hoff-Olsen, P; Meling, GI; Rognum, TO; Shaw, J; West, KP; Royle, NJ				Pickett, HA; Baird, DM; Hoff-Olsen, P; Meling, GI; Rognum, TO; Shaw, J; West, KP; Royle, NJ			Telomere instability detected in sporadic colon cancers, some showing mutations in a mismatch repair gene	ONCOGENE			English	Article						telomere; mutation; microsatellite instability; mismatch repair; colon cancer	HUMAN XP/YP TELOMERE; SMALL POOL PCR; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; REPEAT INSTABILITY; SOMATIC MOSAICISM; HUMAN-CELLS; DNA; MAINTENANCE; CARCINOMAS	Human telomeres are essential for genome stability and are composed of long simple tandem repeat arrays (STRs), comprising the consensus TTAGGG repeat interspersed, at the proximal end, with sequence-variant repeats. While the dynamics of telomere attrition through incomplete replication has been studied extensively, the effects on telomeres of error-prone DNA repair processes, known to affect other STRs, are poorly understood. We have compared the TTAGGG and sequence-variant interspersion patterns in the proximal 720 bp of telomeres in colon cancer and normal DNA samples. The frequency of telomere mutations was 5.8% per allele in a randomly collected panel of sporadic colon cancers, showing that telomere mutations occur in vivo. The mutation frequency rose to 18.6% per allele in sporadic tumours that exhibit instability at the polyA tract in the TGFbetaRII gene and to 35% per allele in tumours with somatic mutations in the hMSH2 gene. The majority of the characterized mutations resulted in the loss of one or a few repeats. If the mutation spectrum and frequency described here is reiterated in the rest of the array, there is the potential for extensive telomere destabilization especially in mismatch repair-defective cells. This may in turn lead to a greater requirement for telomere length maintenance earlier in tumourigenesis.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Oslo, Rikshosp, Univ Hosp, Inst Forens Med, N-0027 Oslo, Norway; Univ Leicester, Dept Pathol, Leicester LE2 7LX, Leics, England	University of Leicester; University of Oslo; National Hospital Norway; University of Leicester	Royle, NJ (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	njr@le.ac.uk	Baird, Duncan M/C-9671-2011	Baird, Duncan M/0000-0001-8408-5467; Royle, Nicola/0000-0003-1174-6329; Shaw, Jacqui/0000-0003-4227-503X				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; BAIRD DM, 1995, EMBO J, V14, P5433, DOI 10.1002/j.1460-2075.1995.tb00227.x; Baird DM, 1997, HUM MOL GENET, V6, P2291, DOI 10.1093/hmg/6.13.2291; Baird DM, 2000, AM J HUM GENET, V66, P235, DOI 10.1086/302721; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cheng AJ, 1998, J NATL CANCER I, V90, P316, DOI 10.1093/jnci/90.4.316; Coleman J, 1999, HUM MOL GENET, V8, P1637, DOI 10.1093/hmg/8.9.1637; Coleman MG, 2001, BRIT J CANCER, V85, P1486, DOI 10.1054/bjoc.2001.2058; Crawford DC, 2000, HUM MOL GENET, V9, P2909, DOI 10.1093/hmg/9.19.2909; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ellegren H, 2000, NAT GENET, V24, P400, DOI 10.1038/74249; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Fortune MT, 2000, HUM MOL GENET, V9, P439, DOI 10.1093/hmg/9.3.439; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HOFFOLSEN P, 1995, HUM MUTAT, V5, P329, DOI 10.1002/humu.1380050410; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; Jiricny J, 2003, CURR OPIN GENET DEV, V13, P61, DOI 10.1016/S0959-437X(03)00004-2; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOTHE RA, 1993, CANCER RES, V53, P5849; Lundblad V, 2002, ONCOGENE, V21, P522, DOI 10.1038/sj.onc.1205079; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Martorell L, 1998, HUM MOL GENET, V7, P307, DOI 10.1093/hmg/7.2.307; MONCKTON DG, 1995, HUM MOL GENET, V4, P1; PARSONS R, 1995, CANCER RES, V55, P5548; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Savouret C, 2003, EMBO J, V22, P2264, DOI 10.1093/emboj/cdg202; Sharma R, 2002, HUM MOL GENET, V11, P2175, DOI 10.1093/hmg/11.18.2175; Sinden RR, 2001, NATURE, V411, P757, DOI 10.1038/35081234; Takayanagi H, 2000, NTT REVIEW, V12, P17; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; van den Broek WJAA, 2002, HUM MOL GENET, V11, P191, DOI 10.1093/hmg/11.2.191; Varley H, 2002, NAT GENET, V30, P301, DOI 10.1038/ng834; Xu X, 2000, NAT GENET, V24, P396, DOI 10.1038/74238; Yamamoto H, 1999, GASTROENTEROLOGY, V116, P1348, DOI 10.1016/S0016-5085(99)70499-3	42	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3434	3443		10.1038/sj.onc.1207477	http://dx.doi.org/10.1038/sj.onc.1207477			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15048084				2022-12-17	WOS:000220975000018
J	Lanvin, O; Gouilleux, F; Mullie, C; Maziere, C; Fuentes, V; Bissac, E; Dantin, F; Maziere, JC; Regnier, A; Lassoued, K; Gouilleux-Gruart, V				Lanvin, O; Gouilleux, F; Mullie, C; Maziere, C; Fuentes, V; Bissac, E; Dantin, F; Maziere, JC; Regnier, A; Lassoued, K; Gouilleux-Gruart, V			Interleukin-7 induces apoptosis of 697 pre-B cells expressing dominant-negative forms of STAT5: evidence for caspase-dependent and -independent mechanisms	ONCOGENE			English	Article						transcription factors; apoptosis; cytokines; pre-B cells	RECEPTOR-GAMMA CHAIN; GENE-EXPRESSION; T-LYMPHOCYTES; TRANSACTIVATION DOMAIN; LYMPHOID DEVELOPMENT; HEMATOPOIETIC-CELLS; CYCLE PROGRESSION; DNA-BINDING; MICE; ACTIVATION	The transcription factors STAT5A and STAT5B (STAT: signal transducer and activator of transcription) play a major role in the signaling events elicited by a number of growth factor and cytokine receptors. In this work, we aimed to investigate the role of STAT5 in human precursor B cell survival by introducing dominant-negative (DN) forms of STAT5A or STAT5B in the 697 pre-B cell line. All clones expressing DN forms of either transcription factor exhibited a higher spontaneous apoptotic rate that was massively enhanced upon interleukin-7 (IL-7) stimulation. This was associated with caspase 8 cleavage, mitochondrial transmembrane potential disruption and caspase 3 activation. However, the DN forms of STAT5 did not alter the expression of Bcl-2, Bax, Bcl-x, Bim, Al and Mcl1 proteins in IL-7-stimulated cells. The pancaspase inhibitor Z-Val-Ala-Asp-fluoromylmethyl ketone partially suppressed IL-7-mediated mitochondrial transmembrane potential disruption and cell death, suggesting that IL-7 induced the death of DN STAT5 expressing 697 cells through caspase-dependent and -independent mechanisms that both require mitochondrial activation.	INSERM, Immunol Lab, F-80036 Amiens, France; CHU Amiens, Biochim Lab, F-80054 Amiens, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens	Gouilleux-Gruart, V (corresponding author), INSERM, Immunol Lab, EMI 0351,3 Rue Louvels, F-80036 Amiens, France.	valerie.gouilleux@sa.u-picardie.fr	Mullié, Catherine/AAW-2304-2020	Mullié, Catherine/0000-0001-8986-9666; Regnier, Jean-Claude/0000-0001-6992-9027; Gouilleux, Fabrice/0000-0001-6047-1718				Ahonen TJ, 2003, J BIOL CHEM, V278, P27287, DOI 10.1074/jbc.M304307200; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; BILLIPS LG, 1995, J EXP MED, V182, P973, DOI 10.1084/jem.182.4.973; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Deas O, 1998, J IMMUNOL, V161, P3375; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; DITTEL BN, 1995, J IMMUNOL, V154, P58; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; FINDLEY HW, 1982, BLOOD, V60, P1305; Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Isaksen DE, 1999, J IMMUNOL, V163, P5971; Karras JG, 1996, J IMMUNOL, V157, P39; Kieslinger M, 2000, GENE DEV, V14, P232; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Komoriya A, 2000, J EXP MED, V191, P1819, DOI 10.1084/jem.191.11.1819; LeBien TW, 2000, BLOOD, V96, P9, DOI 10.1182/blood.V96.1.9; Levy Y, 1997, CLIN EXP IMMUNOL, V110, P329; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Mahajan S, 2001, J BIOL CHEM, V276, P31216, DOI 10.1074/jbc.M104874200; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qin JZ, 2001, J INVEST DERMATOL, V117, P583, DOI 10.1046/j.0022-202x.2001.01436.x; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shelburne CP, 2002, MOL IMMUNOL, V38, P1187, DOI 10.1016/S0161-5890(02)00061-5; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; vanderPlas DC, 1996, LEUKEMIA, V10, P1317; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; WOLF ML, 1993, J IMMUNOL, V151, P138; Zamorano J, 1998, J IMMUNOL, V160, P3502	44	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3040	3047		10.1038/sj.onc.1207450	http://dx.doi.org/10.1038/sj.onc.1207450			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048088	Green Published			2022-12-17	WOS:000220845200008
J	Shim, JS; Kim, DH; Kwon, HJ				Shim, JS; Kim, DH; Kwon, HJ			Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells	ONCOGENE			English	Article						histone deacetylase; transcriptional repression; plakoglobin; oncogene	BETA-CATENIN; TUMOR-SUPPRESSOR; GAMMA-CATENIN; EXPRESSION; INHIBITORS; DROSOPHILA; PROTEIN; AGENTS; CANCER; CARCINOGENESIS	Histone deacetylase ( HDAC) plays a key role in gene expression, by suppressing the transcription of a number of target genes. Identification of such genes is important for deciphering the functional role of HDAC. Here, using cancer gene-focused DNA microarray analysis, we identified plakoglobin as a new target gene of HDAC. Functional inhibition of HDAC by its specific inhibitors induced the expression of plakoglobin by eight-fold in human fibrosarcoma HT1080 cells. However, the expression of beta-catenin, which is closely related to plakoglobin, was not altered, implying the specific function of HDAC in plakoglobin expression. Using antiacetyl-H4 antibody, chromatin immunoprecipitation analysis revealed that the distal region ( - 945 similar to - 646) of the promoter of plakoglobin is responsible for the HDAC-mediated repression of the gene. Moreover, the induced expression of plakoglobin by the inhibition of HDAC activated the Tcf/ Lef-dependent luciferase reporter gene, a well-known downstream effector of the Wnt signaling pathway. Furthermore, transient transfection of plakoglobin also activated Tcf/ Lef reporter gene expression. Taken together, our results demonstrate that plakoglobin is a new target gene governed by HDAC, and that it acts as an oncogene in HT1080 cells.	Sejong Univ, Dept Biosci & Biotechnol, Inst Biosci, Seoul 143747, South Korea	Sejong University	Kwon, HJ (corresponding author), Sejong Univ, Dept Biosci & Biotechnol, Inst Biosci, 98 Kunja Dong, Seoul 143747, South Korea.	kwonhj@sejong.ac.kr	Shim, Joong Sup/G-8383-2011; 권, 호정/AAS-3642-2021; Shim, Joong Sup/O-2848-2016	Shim, Joong Sup/0000-0003-0167-7307; Shim, Joong Sup/0000-0003-0167-7307				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; Kim JH, 2002, JPN J CANCER RES, V93, P1378, DOI 10.1111/j.1349-7006.2002.tb01247.x; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kolligs FT, 2000, GENE DEV, V14, P1319; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Ogden SK, 2001, J BIOL CHEM, V276, P42057, DOI 10.1074/jbc.C100381200; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Potter E, 2001, EUR J ENDOCRINOL, V145, P625, DOI 10.1530/eje.0.1450625; Richon VM, 2002, CLIN CANCER RES, V8, P662; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VanLint C, 1996, GENE EXPRESSION, V5, P245; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963	30	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1704	1711		10.1038/sj.onc.1207289	http://dx.doi.org/10.1038/sj.onc.1207289			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14661058				2022-12-17	WOS:000220029300006
J	Amin, DN; Perkins, AS; Stern, DF				Amin, DN; Perkins, AS; Stern, DF			Gene expression profiling of ErbB receptor and ligand-dependent transcription	ONCOGENE			English	Article						ErbB; HER-2; breast cancer; microarray; immediate early genes	HUMAN-BREAST-CANCER; EPIDERMAL-GROWTH-FACTOR; CONSTITUTIVELY ACTIVE ERBB4; CDNA MICROARRAY ANALYSIS; TRANSGENIC MICE REVEALS; MAMMARY-GLAND; LOBULOALVEOLAR DEVELOPMENT; TYROSINE KINASES; PROTEIN-KINASE; UP-REGULATION	Overexpression of ErbB2 and ErbB4 receptors in breast cancers may be accompanied by contrasting clinical outcomes. To investigate the molecular mechanisms contributing to these differences, we undertook a comparative study of gene expression regulated by the two receptors. Agonistic antibodies were employed to activate ErbB2 and ErbB4 in isolation from the other ErbBs in breast cancer cells. Gene expression pro. ling using a 16 755-gene oligonucleotide array was performed to identify transcriptional targets of receptor activation. Our results indicate that, in the same cell line, ErbB2 and ErbB4 activation influence gene transcription differentially. Although there are genes that are regulated by signaling from both receptors, there are also receptor-specific targets that are preferentially regulated by each receptor. We further show that two ligands acting via the same receptor homodimer may activate different subsets of genes. Many of the induced genes are hitherto unidentified targets of ErbB signaling. These include ErbB4 targets EPS15R, GATA4, and RAB2 and ErbB2-activated HRY/HES1 and PPAP2A. Targets of ErbB2 homodimer signaling may be especially important as markers in breast cancer, where ErbB2 homodimerization mediated by overexpression and ligand-independent activation is common.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University; Yale University	Stern, DF (corresponding author), Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA.	DF.Stern@yale.edu			NATIONAL CANCER INSTITUTE [R01CA080065] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA80065] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alaoui-Jamali MA, 2003, CANCER RES, V63, P3764; Andrechek ER, 2003, CANCER RES, V63, P4920; Bacus SS, 1996, AM J PATHOL, V148, P549; Baulida J, 1996, J BIOL CHEM, V271, P5251; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Cohen BM, 1996, J BIOL CHEM, V271, P4813; da Silva AJ, 2002, J INTERF CYTOK RES, V22, P173, DOI 10.1089/107999002753536149; DECKER SJ, 1990, BIOCHEM BIOPH RES CO, V166, P615, DOI 10.1016/0006-291X(90)90853-F; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Dupont J, 2003, RECENT PROG HORM RES, V58, P325, DOI 10.1210/rp.58.1.325; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Evans PC, 2001, BIOCHEM J, V357, P617, DOI 10.1042/0264-6021:3570617; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Geymayer S, 2000, FASEB J, V14, P1159, DOI 10.1096/fasebj.14.9.1159; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Halgren RG, 2001, NUCLEIC ACIDS RES, V29, P582, DOI 10.1093/nar/29.2.582; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Hobbs SS, 2002, ONCOGENE, V21, P8442, DOI 10.1038/sj.onc.1205960; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Kew TY, 2000, BRIT J CANCER, V82, P1163, DOI 10.1054/bjoc.1999.1057; Knowlden JM, 1998, ONCOGENE, V17, P1949, DOI 10.1038/sj.onc.1202107; Kumar-Sinha C, 2003, CANCER RES, V63, P132; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; Li L, 2002, ONCOGENE, V21, P4900, DOI 10.1038/sj.onc.1205634; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Oh JJ, 1999, NUCLEIC ACIDS RES, V27, P4008, DOI 10.1093/nar/27.20.4008; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POLLARD JW, 1994, P NATL ACAD SCI USA, V91, P9312, DOI 10.1073/pnas.91.20.9312; PUPA SM, 1993, ONCOGENE, V8, P2917; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sapi E, 1998, J SOC GYNECOL INVEST, V5, P94, DOI 10.1016/S1071-5576(97)00108-1; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Suo Z, 2002, J PATHOL, V196, P17, DOI 10.1002/path.1003; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Tang CK, 1999, CANCER RES, V59, P5315; Taylor E, 2001, BIOTECHNIQUES, V31, P62, DOI 10.2144/01311st01; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vadlamudi RK, 2000, MOL CELL BIOL, V20, P9092, DOI 10.1128/MCB.20.23.9092-9101.2000; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vogt U, 1998, GENE, V223, P375, DOI 10.1016/S0378-1119(98)00454-5; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Williams EE, 2003, CANCER LETT, V192, P67, DOI 10.1016/S0304-3835(02)00690-0; Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yip SS, 2000, INT J CANCER, V88, P363, DOI 10.1002/1097-0215(20001101)88:3<363::AID-IJC7>3.0.CO;2-4; Zhou W, 2002, INFLAMM RES, V51, P91, DOI 10.1007/BF02684009	83	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1428	1438		10.1038/sj.onc.1207257	http://dx.doi.org/10.1038/sj.onc.1207257			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973552				2022-12-17	WOS:000189035800010
J	Kuang, CZ; Chen, Y				Kuang, CZ; Chen, Y			Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction	ONCOGENE			English	Article						TGF-beta; Smad4; mutations; cancer	GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; STRUCTURAL BASIS; L3 LOOP; PROTEINS; GENE; SUPPRESSOR; PROMOTER; RECEPTOR; SIGNAL	Smad4 is a critical component in transforming growth factor beta (TGF-beta) signaling and frequently mutated in pancreatic and colorectal cancers. Smad4 has two important functional domains, MH1 and MH2, that are involved in different biological processes. The MH1 domain comprises a DNA binding domain and the MH2 domain is mainly implicated in transcriptional activation and homo- and heteromeric complex formation among Smad proteins. In the present study, a total of nine Smad4 mutations at both MH1 and MH2 domains were analysed and all of them had a reduced activity to stimulate transcription of a TGF-beta-responsive reporter gene. All four MH1 mutations had a markedly reduced ability to bind a consensus Smad binding element by an in vitro assay using GST fusion proteins. Among the MH2 mutations, R497H, K507Q, and R515G mutations of Smad4 gave rise to a reduced DNA binding capacity. The R497H mutation had a slightly reduced interaction with Smad2 upon activation of TGF-beta receptor. However, the K507Q and R515G mutations greatly lost their ability to associate with Smad2. Using a GST pull-down assay, it was found that the Smad4 MH2 domain bearing R497H and R515G mutations had an enhanced interaction with the MH1 region of the Smad4 protein, indicating that an increased intramolecular interaction by these mutations may alleviate the DNA binding activity at the MH1 domain. Consistent with these observations, the MH2 domain with R497H mutation had an enhanced ability to inhibit TGF-beta receptor-mediated transcription. In addition, the full-length R497H mutation was able to antagonize TGF-beta signaling in a dominant-negative manner. Therefore, these studies revealed novel mechanisms by which the Smad4 mutations utilize to abrogate their functions in transducing the signaling of TGF-beta, which plays an important role in various stages of cancer formation.	Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Chinese Acad Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Chinese Academy of Sciences	Chen, Y (corresponding author), Indiana Univ, Sch Med, Dept Med & Mol Genet, 975 W Walnut St,IB130, Indianapolis, IN 46202 USA.	ychen3@iupui.edu			NIDDK NIH HHS [R01 DK55991] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055991] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li W, 2001, BIOCHEM BIOPH RES CO, V286, P1163, DOI 10.1006/bbrc.2001.5529; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 2000, BIOCHEM J, V350, P253, DOI 10.1042/0264-6021:3500253; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xiao Z, 2003, ONCOGENE, V22, P1057, DOI 10.1038/sj.onc.1206212	29	19	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1021	1029		10.1038/sj.onc.1207219	http://dx.doi.org/10.1038/sj.onc.1207219			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647410				2022-12-17	WOS:000188749900001
J	Ohno, H; Hirabayashi, S; Kansaku, A; Yao, I; Tajima, M; Nishimura, W; Ohnishi, H; Mashima, H; Fujita, T; Omata, M; Hata, Y				Ohno, H; Hirabayashi, S; Kansaku, A; Yao, I; Tajima, M; Nishimura, W; Ohnishi, H; Mashima, H; Fujita, T; Omata, M; Hata, Y			Carom: a novel membrane-associated guanylate kinase-interacting protein with two SH3 domains	ONCOGENE			English	Article						epithelial junctions; MAGI-1; CASK; SH3; PDZ	TIGHT JUNCTION PROTEIN; CELL-ADHESION; PDZ DOMAIN; BASOLATERAL MEMBRANE; EPITHELIAL-CELLS; KIDNEY-CELLS; MAGI-1; CASK/LIN-2; BINDS; LOCALIZATION	MAGI-1 and CASK are membrane-associated guanylate kinases of epithelial junctions. MAGI-1 is localized at tight junctions in polarized epithelial cells, whereas CASK is localized along the lateral membranes. We obtained the KIAA0769 gene product through the yeast two-hybrid screening using MAGI-1 as a bait and named it Carom. Carom has a coiled-coil domain in the middle region, and two src homology 3 domains and a PSD-95/Dlg-A/ZO-1 (PDZ)-binding motif in the C-terminal region. Carom binds to the fifth PDZ domain of MAGI-1 and the calmodulin kinase domain of CASK in vitro. MAGI-1 and CASK bind to the distinct sequences in the C-terminal region of Carom, but still compete with each other for Carom binding. The study using a stable transformant of Madine Darby canine kidney (MDCK) cells expressing GFP-Carom revealed that Carom was partially overlapped by MAGI-1 in MDCK cells, which have not yet established mature cell junctions, but became separated from MAGI-1 and colocalized with CASK in polarized cells. Carom was highly resistant to Triton X-100 extractions and recruited CASK to the Triton X-100-insoluble structures. Carom is a binding partner of CASK, which interacts with CASK in polarized epithelial cells and may link it to the cytoskeleton.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo, Japan; Jichi Med Sch, Dept Gastroenterol, Minami Kawachi, Tochigi 32904, Japan; Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); University of Tokyo; Jichi Medical University; University of Tokyo	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.		Nishimura, Wataru/R-9215-2019	Nishimura, Wataru/0000-0002-8068-1277				ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BIERDERER T, 2001, J BIOL CHEM, V276, P47869; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Christensen EI, 2002, NAT REV MOL CELL BIO, V3, P258, DOI 10.1038/nrm778; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dimitratos SD, 1997, MECH DEVELOP, V63, P127, DOI 10.1016/S0925-4773(97)00668-0; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Hata Y, 1996, J NEUROSCI, V16, P2488; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARINEZESTRADA OM, 2001, J BIOL CHEM, V276, P9291; Maximov A, 2002, J NEUROSCI, V22, P6939; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mino A, 2000, GENES CELLS, V5, P1009, DOI 10.1046/j.1365-2443.2000.00385.x; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Ohno H, 2002, ONCOGENE, V21, P7042, DOI 10.1038/sj.onc.1205852; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tabuchi K, 2002, J NEUROSCI, V22, P4264, DOI 10.1523/JNEUROSCI.22-11-04264.2002	35	19	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8422	8431		10.1038/sj.onc.1206996	http://dx.doi.org/10.1038/sj.onc.1206996			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627983				2022-12-17	WOS:000186650300006
J	Peller, S; Frenkel, J; Lapidot, T; Kahn, J; Rahimi-Levene, N; Yona, R; Nissim, L; Goldfinger, N; Sherman, DJ; Rotter, V				Peller, S; Frenkel, J; Lapidot, T; Kahn, J; Rahimi-Levene, N; Yona, R; Nissim, L; Goldfinger, N; Sherman, DJ; Rotter, V			The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts	ONCOGENE			English	Article						p53; erythropoiesis; differentiation; apoptosis	WILD-TYPE P53; ERYTHROID PRECURSORS; CASPASE ACTIVATION; DNA-DAMAGE; PROTEIN; EXPRESSION; CELLS; ERYTHROPOIETIN; DEATH; GENE	The p53 tumor suppressor gene was found to play a role in the differentiation of several tissue types. We report here that p53-dependent apoptosis plays a role in the final stages of physiological differentiation of normoblasts, resulting in nuclear condensation and expulsion without cell death. Blood samples of healthy newborns, cord blood as well as bone marrow, were analysed for apoptosis by TUNEL and p53 expression by immunostaining. While some samples exhibited simultaneously several distinct patterns of apoptosis, such as perinuclear, diffused nuclear or nuclear apoptotic bodies, others presented a single defined pattern. Overexpression of p53 protein was detected in normoblasts exhibiting either perinuclear or diffused nuclear p53, corresponding to the nuclear apoptotic pattern in the same sample. Similar results were also evident with colonies cultivated for 12-14 days in culture. Differentiated erythroid colonies exhibited overexpression of p53 and positive TUNEL staining only in the normoblasts. We further examined the state of caspase 3/7 and observed a decrease of this activated enzyme during erythroid differentiation in culture. This study suggests a novel role for apoptosis in normoblast differentiation where nuclear degradation occurs with a delay in the actual cell death. A pivotal role for the p53-dependent apoptosis in the erythroid lineage development is implied. However, this apoptotic process is not fully executed because of the exhaustion in caspase 3/7 and thus cells are diverted towards final stages of differentiation.	Assaf Harofeh Med Ctr, Dept Hematol, IL-70300 Zerifin, Israel; Assaf Harofeh Med Ctr, Dept Obstet & Gynecol, IL-70300 Zerifin, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Weizmann Institute of Science; Weizmann Institute of Science	Peller, S (corresponding author), Assaf Harofeh Med Ctr, Dept Hematol, IL-70300 Zerifin, Israel.	SPELLER@asaf.health.gov.il	Lapidot, Tsvee/A-1812-2010	Nissim, Lior/0000-0001-6495-4741				Aljurf M, 1996, BLOOD, V87, P2049; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; BETKE K, 1967, NATURE, V214, P188, DOI 10.1038/214188a0; CHANDRASEKARAN K, 1981, P NATL ACAD SCI-BIOL, V78, P6953, DOI 10.1073/pnas.78.11.6953; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Kastan MB, 1996, BIOESSAYS, V18, P617, DOI 10.1002/bies.950180804; KASTAN MB, 1991, CANCER RES, V51, P4279; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; KELLEY LL, 1993, BLOOD, V82, P2340; KELLY RM, 1994, WOMEN POLIT, V14, P3; Kollet O, 1999, BLOOD, V94, P923, DOI 10.1182/blood.V94.3.923.415k08_923_931; Koury MJ, 1997, BLOOD, V89, P4617, DOI 10.1182/blood.V89.12.4617; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; Mahdi T, 1996, EXP HEMATOL, V24, P702; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; Morioka K, 1998, EXP CELL RES, V240, P206, DOI 10.1006/excr.1997.3927; Peller S, 1998, GENE CHROMOSOME CANC, V21, P2, DOI 10.1002/(SICI)1098-2264(199801)21:1<2::AID-GCC2>3.0.CO;2-5; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rehberger PA, 1997, CELL GROWTH DIFFER, V8, P851; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; Schwartz D, 1999, CELL GROWTH DIFFER, V10, P665; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Silva M, 1998, NEW ENGL J MED, V338, P564, DOI 10.1056/NEJM199802263380902; WINTROBE, 1999, WINTROBES CLIN HEMAT; Wlodarski P, 1998, BLOOD, V91, P2998, DOI 10.1182/blood.V91.8.2998.2998_2998_3006; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN J, 1993, BLOOD, V82, P374, DOI 10.1182/blood.V82.2.374.bloodjournal822374; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	37	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4648	4655		10.1038/sj.onc.1206541	http://dx.doi.org/10.1038/sj.onc.1206541			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879009				2022-12-17	WOS:000184157000005
J	Syken, J; Macian, F; Agarwal, S; Rao, A; Munger, K				Syken, J; Macian, F; Agarwal, S; Rao, A; Munger, K			TID1, a mammalian homologue of the drosophila tumor suppressor lethal(2) tumorous imaginal discs, regulates activation-induced cell death in Th2 cells	ONCOGENE			English	Article						tumor suppressor; apoptosis; DnaJ protein; T cells	ESCHERICHIA-COLI DNAJ; T-CELL; MOLECULAR CHAPERONES; ATPASE ACTIVITY; UP-REGULATION; EXPRESSION; APOPTOSIS; PROTEIN; GENE; SUBSETS	We previously described two human DnaJ proteins, hTid-1(L) and hTid-1(S), which are derived from alternative splicing of the TID1 gene, the human homologue of the Drosophila tumor suppressor lethal(2) tumorous imaginal discs, and showed that hTid-1(L) promoted while hTid-1(S) antagonized apoptosis. There are two subsets of helper T cells, Th1 and Th2, of which Th2 cells are significantly less prone to apoptosis induced by stimulation through the T-cell receptor. This apoptotic process is known as activation-induced cell death (AICD). The molecular basis for the differential susceptibility of Th1 and Th2 cells to AICD is not known. Here we show that the antiapoptotic variant, Tid-1(S), is selectively induced in murine Th2 cells following activation. Expression of a dominant-negative mutant of hTid-1(S) in a Th2 cell line strikingly enhanced activation of caspase 3 in response to CD3 stimulation, and caused the cells to become sensitive to AICD. Hence, the accumulation of Tid-1(S) in Th2 cells following activation represents a novel mechanism that may contribute to the induction of apoptosis resistance during the activation of Th2 cells.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave,D2-544A, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu		Macian, Fernando/0000-0003-2666-035X; Munger, Karl/0000-0003-3288-9935				Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Baumann Sven, 2002, Current Molecular Medicine (Hilversum), V2, P257, DOI 10.2174/1566524024605671; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; Carter LL, 1998, J IMMUNOTHER, V21, P181, DOI 10.1097/00002371-199805000-00003; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Kirchhoff S, 2002, J IMMUNOL, V168, P1226, DOI 10.4049/jimmunol.168.3.1226; Kurzik-Dumke U, 1998, CELL STRESS CHAPERON, V3, P12, DOI 10.1379/1466-1268(1998)003<0012:MLATEO>2.3.CO;2; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Li-Weber M, 2002, CELL DEATH DIFFER, V9, P1256, DOI 10.1038/sj.cdd.4401102; Li-Weber M, 2002, CELL DEATH DIFFER, V9, P101, DOI 10.1038/sj.cdd.4400984; Li-Weber M, 2002, J CLIN INVEST, V110, P681, DOI [10.1172/JCI0215073, 10.1172/JCI200215073]; Lohman BL, 1998, J VIROL, V72, P7815, DOI 10.1128/JVI.72.10.7815-7821.1998; OGARRA A, 1994, CURR OPIN IMMUNOL, V6, P458, DOI 10.1016/0952-7915(94)90128-7; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Sasaki S, 2002, ONCOGENE, V21, P5024, DOI 10.1038/sj.onc.1205627; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; Varadhachary AS, 1997, P NATL ACAD SCI USA, V94, P5778, DOI 10.1073/pnas.94.11.5778; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; WALL D, 1994, J BIOL CHEM, V269, P5446; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	41	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4636	4641		10.1038/sj.onc.1206569	http://dx.doi.org/10.1038/sj.onc.1206569			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879007				2022-12-17	WOS:000184157000003
J	Bigler, D; Gulding, KM; Dann, R; Sheabar, FZ; Conaway, MR; Theodorescu, D				Bigler, D; Gulding, KM; Dann, R; Sheabar, FZ; Conaway, MR; Theodorescu, D			Gene profiling and promoter reporter assays: Novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action	ONCOGENE			English	Article						prostate neoplasms; gene profiling; androgen; estrogen; prostate-specific antigen/PSA; plant extracts	PC-SPES; IN-VITRO; EXPRESSION; ANDROGEN; LNCAP; DIETHYLSTILBESTROL; IDENTIFICATION; THERAPY	The use of botanical mixtures is commonplace in patients with prostate cancer, yet the majority of these products have not been rigorously tested in clinical trials. Here we use PC-SPES, a combination of eight herbs that has been shown to be effective in clinical trials in patients with prostate cancer, as a model system to demonstrate 'proof of principle' as to how gene expression profiling coupled with promoter assays can evaluate the effect of herbal cocktails on human prostate cancer. In addition, we demonstrate how such approaches may be used for standardization of herbal extract activity by comparing the gene profile of PC-SPES with that of PC-CARE, a product with a similar herbal composition. Since prior studies have shown that PC-SPES contains estrogenic organic compounds, and such compounds are known to affect prostate cancer, an important issue is whether these are the primary drivers of the gene profile. Our data suggest that gene expression profiles of LNCaP human prostate cancer cells in response to PC-SPES are different from those found when diethylstilbestrol (DES), a synthetic estrogen, is used, suggesting that the estrogenic moieties within PC-SPES do not drive this expression signature. In contrast, the expression profile of PC-CARE was almost identical to that of DES, highlighting that mixtures containing similar herbal compositions do not necessarily result in similar biological activities. Interestingly, these three agents cause similar in vitro morphological changes and growth effects on LNCaP. To validate the expression profiling data, we evaluated the protein expression and promoter activity of prostate-specific antigen (PSA), a gene induced by PC-SPES but repressed by DES. In order to gain a mechanistic understanding of how PC-SPES and DES affect PSA expression differently, LNCaP cells were transiently transfected with wild-type and mutagenized PSA promoter, ARE concatemers and appropriate controls. We provide evidence that androgen response elements (ARE) II and III within the promoter region are responsible for the suppressive effects of DES and stimulatory effects of PC-SPES. In addition, we show that the effects on PSA transcription are ARE specific in the case of DES while PC-SPES affects this promoter nonspecifically. In conclusion, expression profiting coupled with mechanistic target validation yield valuable clues as to the mode of action of complex botanical mixtures and provides a new way to compare objectively mixtures with similar components either for effect or quality assurance prior to their use in clinical trials.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA; Kemin Foods, Prot & Bioassays Dev Grp, Des Moines, IA USA; Univ Virginia, Hlth Sci Ctr, Dept Hlth Evaluat Sci Biostat, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu						Averboukh L, 1996, PROSTATE, V29, P350; Bonham M, 2002, CANCER RES, V62, P3920; Bubley GJ, 1999, J CLIN ONCOL, V17, P3461, DOI 10.1200/JCO.1999.17.11.3461; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Darzynkiewicz Z, 2000, INT J ONCOL, V17, P729; De la Taille A, 2000, J UROLOGY, V164, P1229, DOI 10.1097/00005392-200010000-00021; DiPaola RS, 1998, NEW ENGL J MED, V339, P785, DOI 10.1056/NEJM199809173391201; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hsieh TC, 1997, BIOCHEM MOL BIOL INT, V42, P535; Kubota T, 2000, PROSTATE, V42, P163; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Malkowicz SB, 2001, UROLOGY, V58, P108, DOI 10.1016/S0090-4295(01)01252-3; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; Oh MK, 2001, UROLOGY, V57, P122, DOI 10.1016/S0090-4295(00)00986-9; Schadt EE, 2001, J CELL BIOCHEM, V84, P120, DOI 10.1002/jcb.10073; Schadt EE, 2000, J CELL BIOCHEM, V80, P192; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Small EJ, 2000, J CLIN ONCOL, V18, P3595, DOI 10.1200/JCO.2000.18.21.3595; SMALL EJ, 2002, J CLIN ONCOL, V21; Sovak M, 2002, J NATL CANCER I, V94, P1275, DOI 10.1093/jnci/94.17.1275; Takezawa Y, 2001, SCAND J UROL NEPHROL, V35, P283; Turner KJ, 2001, MOL CELL ENDOCRINOL, V178, P73, DOI 10.1016/S0303-7207(01)00413-0; White J, 2002, JNCI-J NATL CANCER I, V94, P1261, DOI 10.1093/jnci/94.17.1261; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319	25	19	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1261	1272		10.1038/sj.onc.1206242	http://dx.doi.org/10.1038/sj.onc.1206242			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606954				2022-12-17	WOS:000181249700016
J	Ma, YX; Fan, SJ; Xiong, JB; Yuan, RQ; Meng, QH; Gao, M; Goldberg, ID; Fuqua, SA; Pestell, RG; Rosen, EM				Ma, YX; Fan, SJ; Xiong, JB; Yuan, RQ; Meng, QH; Gao, M; Goldberg, ID; Fuqua, SA; Pestell, RG; Rosen, EM			Role of BRCA1 in heat shock response	ONCOGENE			English	Article						BRCA1; prostate cancer; breast cancer; DU-145; MCF-7; heat shock; HSP27; HSP70; HSP90	BREAST-CANCER CELLS; HUMAN PROSTATE-CANCER; DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR; DIFFERENTIAL REGULATION; ACTIN POLYMERIZATION; ANTISENSE INHIBITION; PROTEIN-DEGRADATION; NEGATIVE REGULATION; THERMAL PROTECTION	The heat shock response is an evolutionarily conserved response to heat and other stresses that promotes the maintenance of key metabolic functions and cell survival. We report that exposure of human prostate (DU-145) and breast (MCF-7) cancer cells to heat (42degreesC caused a rapid disappearance of the breast cancer susceptibility gene-1 (BRCA1) protein, starting at 1 h after the onset of heating and slightly lagging behind the increase in heat shock protein 70 (HSP70) levels. The heat-induced loss of BRCA1 occurred at the protein level, since: (1) BRCA1 mRNA expression was unaffected; and (2) the BRCA1 protein loss was also observed in DU-145 cells that expressed exogenous wild-type BRCA1 (wtBRCA1). In addition to heat regulation of BRCA1 protein levels, we also found that BRCA1 could modulate the heat shock response. Thus, wtBRCA1 overexpressing DU-145 cell clones showed significantly decreased sensitivity to heat-induced cytotoxicity; and Brca1 mutant mouse embryo fibroblasts showed increased sensitivity to heat. The DU-145 wtBRCA1 clones also showed increased expression of the small heat shock protein HSP27; and reporter assays revealed that wtBRCA1 stimulated a two to four-fold increase in HSP27 promoter activity, consistent with its ability to upregulate HSP27 mRNA and protein levels. In studies using epitope-tagged truncated BRCA1 proteins, the ability to stimulate the HSP27 promoter and to mediate heat-induced degradation required the amino-terminus but not the carboxyl-terminus of BRCA1 Although the heat-induced loss of BRCA1 appeared to be due to protein degradation, various protein metabolic agents (or combinations) failed to block this event, including: MG132 (a 26S proteasomal inhibitor), N-Wacetyl-leucyl-leucyl-norleucinal (a calpain inhibitor), z-VAD-fmk (a pan-caspase inhibitor), and ammonium chloride and chloroquine (which stabilize lysosomes). These findings suggest that in addition to its other functions, BRCA1 may participate in mammalian heat shock response pathways.	Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, New Hyde Pk, NY 11040 USA; Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA	Northwell Health; Yeshiva University; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rosen, EM (corresponding author), Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, Long Isl Campus,270-05 76th Ave, New Hyde Pk, NY 11040 USA.		Meng, Q./GSI-6185-2022		NATIONAL CANCER INSTITUTE [R01CA080000, R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA80000, R01-CA82599] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEY MC, 1988, CANCER RES, V48, P589; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; BATES PJ, 1982, BIOCHIM BIOPHYS ACTA, V719, P377, DOI 10.1016/0304-4165(82)90113-1; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Chen YM, 1996, CANCER RES, V56, P3168; Cornford PA, 2000, CANCER RES, V60, P7099; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; Gao B, 2001, FEBS LETT, V488, P179, DOI 10.1016/S0014-5793(00)02430-3; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Horman S, 1999, INT J CANCER, V82, P574, DOI 10.1002/(SICI)1097-0215(19990812)82:4<574::AID-IJC17>3.0.CO;2-L; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Mairesse N, 1996, CELL BIOL INT, V20, P205, DOI 10.1006/cbir.1996.0025; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakamoto H, 2000, FEBS LETT, V483, P169, DOI 10.1016/S0014-5793(00)02097-4; Newton EM, 1996, MOL CELL BIOL, V16, P839; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.3.CO;2-5; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Payne J, 2000, INT J HYPERTHER, V16, P492, DOI 10.1080/02656730050199340; Pfleger CM, 2000, GENE DEV, V14, P655; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; POOLE B, 1997, ACTA BIOL MED GER, V36, P1777; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STREUWING JP, 1997, NEW ENGL J MED, V336, P1401; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Tirkkonen M, 1997, CANCER RES, V57, P1222; Trautinger F, 1997, J PHOTOCH PHOTOBIO B, V39, P90, DOI 10.1016/S1011-1344(96)00010-3; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yuan RQ, 1999, PROSTATE, V40, P37; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V	76	19	20	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					10	27		10.1038/sj.onc.1206061	http://dx.doi.org/10.1038/sj.onc.1206061			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527903				2022-12-17	WOS:000180166900002
J	Amin, ARMR; Machida, K; Oshima, K; Oo, ML; Thant, AA; Senga, T; Matsuda, S; Akhand, AA; Maeda, A; Kurosaki, T; Hamaguchi, M				Amin, ARMR; Machida, K; Oshima, K; Oo, ML; Thant, AA; Senga, T; Matsuda, S; Akhand, AA; Maeda, A; Kurosaki, T; Hamaguchi, M			A role for SHPS-1/SIRP alpha 1 in IL-1 beta- and TNF alpha-dependent signaling	ONCOGENE			English	Article						cytokines; signal transduction; tyrosine kinases; tyrosine phosphatases; Erk 1/2; Akt	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; PROTEIN-TYROSINE-PHOSPHATASE; MOLECULAR-CLONING; V-SRC; KINASE; INTERLEUKIN-1; ACTIVATION; PATHWAY; FAMILY	We investigated the role of SHPS-1/SIRPalpha1 in IL-1beta-and TNFalpha-dependent signaling that leads to the activation of Erk 1/2 and Akt. Treatment of Balb3T3 cells with IL-1beta or TNFalpha activated tyrosine phosphorylation of SHPS-1, its association with SHP-2 and the phosphorylation of Erk 1/2 and Akt. PP1, a specific inhibitor for the Src family protein tyrosine kinases, strongly inhibited tyrosine phosphorylation of SHPS-1 and complex formation of SHPS-1 with SHP-2 by IL-1beta. In addition, PP1 substantially inhibited the IL-2beta-and TNFalpha-dependent activation of Erk 1/2 and Akt. Exogenous expression of either SHPS-1 mutants that lack SHP-2 binding function or a dominant negative mutant of SHP-2 markedly inhibited the activation of Erk 1/2 and Akt by IL-1beta, whereas wild type SHPS-1 did not. Moreover, IL-1beta-stimulation induced association of SHPS-1 with IL-1RAcP, a second subunit of IL-1 receptor, whereas expression of SHPS-1 mutant that lack SHP-2 binding function clearly blocked the association and tyrosine phosphorylation of endogenous SHPS-1: Taken together, our results strongly suggest that activation of Erk 1/2 and Akt by proinflammatory cytokines requires tyrosine phosphorylation of SHPS-1 and subsequent association of SHPS-1 with SHP-2.	Nagoya Univ, Grad Sch Med, Lab Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan; Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 5708506, Japan	Nagoya University; Nagoya University; Kansai Medical University	Hamaguchi, M (corresponding author), Nagoya Univ, Grad Sch Med, Lab Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Kurosaki, Tomohiro/D-1306-2009; Maeda, Akito/AAX-6252-2020	Kurosaki, Tomohiro/0000-0002-6352-304X; AMIN, ARM/0000-0001-9144-2960				ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; Araki T, 2000, J NEUROCHEM, V75, P1502, DOI 10.1046/j.1471-4159.2000.0751502.x; BankersFulbright JL, 1996, LIFE SCI, V59, P61, DOI 10.1016/0024-3205(96)00135-X; Cullinan EB, 1998, J IMMUNOL, V161, P5614; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; KAMPSCHMIDT RF, 1984, J LEUKOCYTE BIOL, V36, P341, DOI 10.1002/jlb.36.3.341; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Machida K, 2000, ONCOGENE, V19, P1710, DOI 10.1038/sj.onc.1203497; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Ozes ON, 1999, NATURE, V401, P82; Senga T, 2000, ONCOGENE, V19, P273, DOI 10.1038/sj.onc.1203296; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Yang CM, 2000, BRIT J PHARMACOL, V130, P891, DOI 10.1038/sj.bjp.0703359; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101	27	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8871	8877		10.1038/sj.onc.1206018	http://dx.doi.org/10.1038/sj.onc.1206018			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483539				2022-12-17	WOS:000179734400020
J	Duval, A; Reperant, M; Hamelin, R				Duval, A; Reperant, M; Hamelin, R			Comparative analysis of mutation frequency of coding and non coding short mononucleotide repeats in mismatch repair deficient colorectal cancers	ONCOGENE			English	Article						short mononucleotide repeats; MSI tumors	REPLICATION ERROR PHENOTYPE; MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; GENE; COLON; SEQUENCES; RECEPTOR; TUMORS	Coding repeats are usually short mononucleotide tracts (SM7) of 10 or less base pairs in size. A number of such sequences contained in genes suspected to play a role in human carcinogenesis have been found to be mutated in mismatch repair deficient tumors (MSI-H cancers). Because of the high background of instability characterizing these cancers and in the absence of functional criteria, the significance of most frameshift gene alterations is unclear. In the present work, we analysed a series of 22 transcribed but non-coding SMT that are thus unlikely to play a tumorigenic role. Their frequency of size alteration in germline DNA and in DNA from MSI-H and microsatellite stable (MSS) tumors were compared to those previously reported in a series of 25 coding SMT of similar size. Non-coding SMT were either monomorphic or polymorphic in germline DNA whereas coding SMT were all monomorphic. In MSI-H tumors, non-coding SMT showed infrequent alterations (0 - 44%), as opposed to coding SMT which were altered at extremely variable frequencies (0 to 92%). Seven of the 22 non-coding SMT were monomorphic in MSS tumors but presented size alterations in MSI-H tumors with variable frequencies (3-28%). They were thus selected for further comparative statistical analyses for instability in coding SMT in MSI-H colorectal cancers. Only seven out of 25 of the coding SMT showed a significantly higher mutation frequency in these tumors. In the absence of functional criteria, we propose this as a novel and comprehensive approach for distinguishing real target genes amongst the numerous proposed gene mutations. It should allow identification of those that are genuinely selected for during MSI-H tumoral progression from others that play a less important role, if any, in NISI-H carcinogenesis.	CEPH, INSERM, U434, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Hamelin, R (corresponding author), CEPH, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Boland CR, 1998, CANCER RES, V58, P5248; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2002, CANCER RES, V62, P2447; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kim NG, 2001, CANCER RES, V61, P36; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Schwartz S, 1999, CANCER RES, V59, P2995; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Suzuki K, 2002, CANCER RES, V62, P1961; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Zhang L, 2001, CANCER RES, V61, P3801; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	17	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					8062	8066		10.1038/sj.onc.1206013	http://dx.doi.org/10.1038/sj.onc.1206013			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439756				2022-12-17	WOS:000179097200015
J	Duan, WR; Ding, HM; Subler, MA; Zhu, WG; Zhang, HM; Stoner, GD; Windle, JJ; Otterson, GA; Villalona-Calero, MA				Duan, WR; Ding, HM; Subler, MA; Zhu, WG; Zhang, HM; Stoner, GD; Windle, JJ; Otterson, GA; Villalona-Calero, MA			Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice	ONCOGENE			English	Article						lung; adenocarcinoma; p53; SP-C; transgenic mice	TUMOR-SUPPRESSOR GENE; CANCER CELL-LINES; WILD-TYPE; T-ANTIGEN; P53 MUTATIONS; DNA-BINDING; IMMUNOCHEMICAL ANALYSIS; SV40-TRANSFORMED CELLS; TERMINAL DOMAIN; RAS MUTATIONS	To investigate the tumorigenic potential of mutant p53 when selectively expressed in lung tissue, a transgenic mouse model was developed in which a mutant form of p53 (p53-273H) was placed under the transcriptional control of the lung-specific human surfactant protein C (SP-C) promoter. Two founder mice were identified, and a line of SP-C/p53-273H transgenic mice was established from one of the founders. Human p53-273H protein was detected specifically in lung tissue from transgenic mice. Malignant tumors, which were histologically characterized as adenocarcinomas, were observed in transgenic mice, with the earliest onset documented at 4 months of age. To further evaluate incidence and onset of tumor formation, transgenic mice (n = 113) were sacrificed at age intervals ranging from 4-15 months. At 13-15 months of age, transgenic mice were significantly more likely to have lung tumors at necropsy than age-matched non-transgenic littermates (9 out of 39 (23%) versus 2 out of 35 (5.7%), chi(2) test, P = 0.036). The SP-C/p53-273H transgenic mice described here thus represent a genetically defined model with which to study the role of p53 mutations in lung tumorigenesis, as well as the potential complementary contributions of other genetic alterations or environmental carcinogens to lung tumor development.	Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH 43210 USA; Ohio State Univ, Richard J Solove Res Inst, Coll Med & Publ Hlth, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Coll Med & Publ Hlth, Columbus, OH 43210 USA; Ohio State Univ, Dept Publ Hlth, Coll Med & Publ Hlth, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Coll Med & Publ Hlth, Columbus, OH 43210 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA 23298 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Virginia Commonwealth University; Virginia Commonwealth University	Villalona-Calero, MA (corresponding author), Ohio State Univ, Arthur G James Canc Hosp, 320 W 10th Ave,B406 Starling Loving Hall, Columbus, OH 43210 USA.		zhu, wei-guo/E-1334-2012	Zhu, Wei-Guo/0000-0001-8385-6581; Windle, Jolene/0000-0001-6690-385X; duan, wenrui/0000-0001-6512-7350	NCI NIH HHS [K01 CA76970, P30 CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA076970, P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albor A, 1998, CANCER RES, V58, P2091; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARTEK J, 1990, ONCOGENE, V5, P893; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chao HHA, 2000, MOL CELL BIOL, V20, P7624, DOI 10.1128/MCB.20.20.7624-7633.2000; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DAMICO D, 1992, ONCOGENE, V7, P339; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEMAYO FJ, 1991, AM J PHYSIOL, V261, pL70, DOI 10.1152/ajplung.1991.261.2.L70; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duan W, 2002, BIOTECHNIQUES, V33, P58, DOI 10.2144/02331st02; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Glasser SW, 2000, AM J PHYSIOL-LUNG C, V278, pL933, DOI 10.1152/ajplung.2000.278.5.L933; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Hernandez-Boussard TM, 1998, ENVIRON HEALTH PERSP, V106, P385, DOI 10.2307/3434065; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOGAN B, 1994, MANIPULATING MOUSE E; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kawamura M, 1996, ONCOGENE, V12, P2361; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko JL, 1996, GENE DEV, V10, P1054; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MITSUDOMI T, 1992, ONCOGENE, V7, P171; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; PARK DJ, 1994, ONCOGENE, V9, P1899; PURDIE CA, 1994, ONCOGENE, V9, P603; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Sambrook J, 1989, MOL CLONING LAB MANU; Shafarenko M, 1997, CARCINOGENESIS, V18, P1423, DOI 10.1093/carcin/18.7.1423; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TIMME TL, 1994, BIOTECHNIQUES, V17, P461; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YonishRouach E, 1996, EXPERIENTIA, V52, P1001, DOI 10.1007/BF01920109; ZHANG W, 1993, ONCOGENE, V8, P2555	58	19	19	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 7	2002	21	51					7831	7838		10.1038/sj.onc.1205909	http://dx.doi.org/10.1038/sj.onc.1205909			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420220				2022-12-17	WOS:000178946000008
J	Kong, G; Chua, SS; Yi, YJ; Kittrell, F; Moraes, RC; Medina, D; Said, TK				Kong, G; Chua, SS; Yi, YJ; Kittrell, F; Moraes, RC; Medina, D; Said, TK			Functional analysis of cyclin D2 and p27(kip1) in cyclin D2 transgenic mouse mammary gland during development	ONCOGENE			English	Article						cyclin D2; transgenic mice; mammary gland development; cyclin D1 phosphorylation; p27(kip1)	G1 PHASE PROGRESSION; RETINOBLASTOMA PROTEIN; INCREASED EXPRESSION; BREAST CANCERS; CELL; D1; OVEREXPRESSION; ONCOGENE; GROWTH; MYC	Two mammary gland phenotypes were detected in pregnant MMTV-cyclin D2 transgenic mice; line D2-53 exhibited a lack of alveologenesis and failure to nurse, whereas line D2-58 featured a reduction in alveologenesis, but retained normal nursing behavior. In pregnant mammary glands, cyclin D2 protein levels were twofold (P<0.107) and 3.8-fold (P<0.0076) higher in line D258 and D2-53, respectively, compared to wild type. Concomitantly with the increase in cyclin D2 was a fivefold decrease in cyclin D1 hyper-phosphorylated isoform in mammary glands of pregnant cyclin D2-58 mice. Because cyclin D1 is a critical molecule in normal mammary lobuloalveolar development, these data suggest that overexpression of cyclin D2 may block mammary lobuloalveolar development through inhibition of cyclin D1 phosphorylation. During mammary gland development, p27(kip1) protein level oscillated in a similar profile in wild type and cyclin D2 transgenic mice, but was consistently higher in the cyclin D2 mice suggesting that P27(kip1) functions downstream of cyclin D2. The ratio of p27(kip1)-cdk4/p27(kip1)-cdk2 was 6.5-fold (P<0.0003) higher in cyclin D2 mammary glands compared to wild type in pregnant animals. This ratio reversed to 2.2-fold (P<0.005) higher in wild type compared to cyclin D2 mammary glands in involution suggesting that overexpression of cyclin D2 moderately induced apoptosis during pregnancy but accelerated involution. Collectively, the effects of cyclin D2 overexpression on mammary gland development during pregnancy and involution are attributed to two major factors, altered p27(kip1) protein level and inhibition of cyclin D1 phosphorylation.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Said, TK (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	tsaid@bcm.tmc.edu		Moraes, Ricardo/0000-0001-5455-092X	NATIONAL CANCER INSTITUTE [R01CA011944] Funding Source: NIH RePORTER; NCI NIH HHS [CA-11944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Evron E, 2001, CANCER RES, V61, P2782; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; HAN EKH, 1995, ONCOGENE, V10, P953; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Janz S, 1995, Curr Top Microbiol Immunol, V194, P373; JIANG W, 1993, ONCOGENE, V8, P3447; LAMMIE GA, 1991, ONCOGENE, V6, P439; LUKAS J, 1995, ONCOGENE, V10, P2125; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; MOTPOKURA T, 1991, NATURE, V350, P512; MURRAY AW, 1992, NATURE, V349, P603; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNELL MJ, 1994, CURR OPIN CELL BIOL, V6, P867, DOI 10.1016/0955-0674(94)90058-2; Oyama T, 1998, CANCER RES, V58, P2876; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; Rasmussen S. B., 2000, METHODS MAMMARY GLAN, P75; Ravanko K, 2000, CANCER RES, V60, P5244; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823; Said TK, 1998, MOL CARCINOGEN, V22, P128; SAID TK, 1995, CARCINOGENESIS, V16, P2507, DOI 10.1093/carcin/16.10.2507; Scovassi AI, 1997, EXP CELL RES, V237, P127, DOI 10.1006/excr.1997.3770; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Yasogawa Y, 1998, PATHOL INT, V48, P717, DOI 10.1111/j.1440-1827.1998.tb03972.x; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	44	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7214	7225		10.1038/sj.onc.1205895	http://dx.doi.org/10.1038/sj.onc.1205895			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370811				2022-12-17	WOS:000178504600009
J	Erez, N; Milyavsky, M; Goldfinger, N; Peles, E; Gudkov, AV; Rotter, V				Erez, N; Milyavsky, M; Goldfinger, N; Peles, E; Gudkov, AV; Rotter, V			Falkor, a novel cell growth regulator isolated by a functional genetic screen	ONCOGENE			English	Article						Falkor; GSE; MEF; cisplatin	SMOOTH-MUSCLE; DNA-DAMAGE; EXPRESSION; PROTEIN; SM-20; P53; IDENTIFICATION; APOPTOSIS; FAMILY; PROLIFERATION	A novel cell growth regulator, named Falkor, was identified using a functional approach to mammalian gene cloning, the Genetic Supressor Elements (GSE) method. In this screen, expression of the C-terminal domain of Falkor conferred cells with resistance to cisplatin-induced growth arrest. Expression of the C-terminus of Falkor, but not of the full-length protein, enhanced cell growth both following genotoxic stress and under normal conditions suggesting a general role for this protein in cell growth control. This effect of the C-terminus fragment was abrogated by over-expression of the full-length Falkor, suggesting that the fragment counteracts the function of the full-length protein. Falkor is encoded by a 2-kb mRNA which is present at different levels in various tissues, and is localized in the nucleus of cells. The C-terminal domain of Falkor, isolated from the GSE library, has significant homology to a known human and rat cell growth regulator, SM-20, and to the C. elegans protein EGL-9, recently shown to modify the Hypoxia Inducible Factor-la. The homology suggests that these proteins share a functional domain that is conserved among a family of growth regulation proteins.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Weizmann Institute of Science; Cleveland Clinic Foundation	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Milyavsky, Michael/E-8306-2011	Peles, Elior/0000-0002-3325-0597; Gudkov, Andrei/0000-0003-2548-0154; Erez, Neta/0000-0001-6506-9074				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ARAVIND L, 2001, GENOME BIOL, V2; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Foca C, 2000, MOL HUM REPROD, V6, P712, DOI 10.1093/molehr/6.8.712; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; KASTAN MB, 1991, CANCER RES, V51, P6304; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Madden SL, 1996, CANCER RES, V56, P5384; PATANJALI SR, 1991, P NATL ACAD SCI USA, V88, P1943, DOI 10.1073/pnas.88.5.1943; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Seth P, 2002, ONCOGENE, V21, P836, DOI 10.1038/sj.onc.1205113; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; Wax SD, 1996, LAB INVEST, V74, P797; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wei YF, 1996, NUCLEIC ACIDS RES, V24, P931, DOI 10.1093/nar/24.5.931	23	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6713	6721		10.1038/sj.onc.1205867	http://dx.doi.org/10.1038/sj.onc.1205867			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360397				2022-12-17	WOS:000178315800001
J	Santoni-Rugiu, E; Duro, D; Farkas, T; Mathiasen, IS; Jaattela, M; Bartek, J; Lukas, J				Santoni-Rugiu, E; Duro, D; Farkas, T; Mathiasen, IS; Jaattela, M; Bartek, J; Lukas, J			E2F activity is essential for survival of Myc-overexpressing human cancer cells	ONCOGENE			English	Article						Myc; E2F; human cancer cells; survival	TUMOR-SUPPRESSOR PATHWAY; CYCLIN-DEPENDENT KINASES; C-MYC; RETINOBLASTOMA PROTEIN; INDUCED APOPTOSIS; PRB/E2F PATHWAY; S-PHASE; EPITHELIAL-CELLS; BETA-TRANSCRIPT; DNA-REPLICATION	Effective cell cycle completion requires both Myc and E2F activities. However, whether these two activities interact to regulate cell survival remains to be tested. Here we have analysed survival of inducible c-Myc-overexpressing cell lines derived from U2OS human osteosarcoma cells, which carry wild-type pRb and p53 and are deficient for p16 and ARF expression. Induced U2OS-Myc cells neither underwent apoptosis spontaneously nor upon reconstitution of the ARF-p53 axis and/or serum-starvation. However, they died massively when concomitantly exposed to inhibitors of EN activity, including a constitutively active pRb (RbDeltacdk) mutant, p16, a stable p27 (p27T187A) mutant, a dominant-negative (dn) CDK2, or dnDP-1. Similar apoptotic effect was observed upon down-modulation of endogenous E2Fs through overexpression of E2F binding site oligonucleotides in U2OS-Myc cells, upon expression of RbDeltacdk or dnDP-1 in the Myc-amplified HL-60 (ARF-; p53-) human leukemia cells, and upon cotransfection of Myc and RbDeltacdk in SAOS-2 (ARF+; p53-) human osteosarcoma cells but not in human primary fibroblasts. Consistent with these results, a dnp53 mutant did not abrogate the Myc-induced apoptotic phenotype, which instead strictly depended on caspase-3-like proteases and on Myc transcriptional activity. Our data indicate that in contrast to normal cells, Myc-overexpressing human cancer cells need E2F activity for their survival, regardless of their ARF and p53 status, a notion that may have important implications for antineoplastic treatment strategies.	Danish Canc Soc, Inst Canc Biol, Dept Cell Cycle & Canc, DK-2100 Copenhagen E, Denmark; Danish Canc Soc, Inst Canc Biol, Apoptosis Lab, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Danish Cancer Society	Santoni-Rugiu, E (corresponding author), Rigshosp, Dept Pathol, Frederik D Vs Vej 11, DK-2100 Copenhagen O, Denmark.		Jäättelä, Marja/AAT-7932-2021; Santoni-Rugiu, Eric/H-4913-2019; Bartek, Jiri/G-5870-2014; Santoni-Rugiu, Eric/AAH-3368-2020	Jäättelä, Marja/0000-0001-5950-7111; Santoni-Rugiu, Eric/0000-0002-2283-3535; Farkas, Thomas/0000-0003-1903-6081; Lukas, Jiri/0000-0001-9087-506X				Amundadottir LT, 1996, ONCOGENE, V13, P757; Asadi F. K., 1995, International Urology and Nephrology, V27, P67; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bowen C, 1998, CANCER RES, V58, P3275; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DURO D, 1995, ONCOGENE, V11, P21; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Gazzeri S, 1998, CANCER RES, V58, P3926; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Hotti A, 2000, ONCOGENE, V19, P2354, DOI 10.1038/sj.onc.1203567; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Li Q, 1999, MOL CELL BIOL, V19, P5339; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Mangano R, 1998, ONCOGENE, V17, P2771, DOI 10.1038/sj.onc.1202434; Markl IDC, 1998, CANCER RES, V58, P5348; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mathiasen IS, 1999, CANCER RES, V59, P4848; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; NAG A, 1989, PROSTATE, V15, P115, DOI 10.1002/pros.2990150205; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; O'Connor L, 2000, CURR OPIN CELL BIOL, V12, P257, DOI 10.1016/S0955-0674(99)00084-8; Packham G, 1996, ONCOGENE, V13, P461; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; QUELLE DE, 1995, CELL, V83, P993; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VONHOFF DD, 1990, J CLIN INVEST, V85, P1887, DOI 10.1172/JCI114650; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	81	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6498	6509		10.1038/sj.onc.1205828	http://dx.doi.org/10.1038/sj.onc.1205828			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226753				2022-12-17	WOS:000177925300010
J	Benihoud, K; Bonardelle, D; Soual-Hoebeke, E; Durand-Gasselin, I; Emilie, D; Kiger, N; Bobe, P				Benihoud, K; Bonardelle, D; Soual-Hoebeke, E; Durand-Gasselin, I; Emilie, D; Kiger, N; Bobe, P			Unusual expression of LINE-1 transposable element in the MRL autoimmune lymphoproliferative syndrome-prone strain	ONCOGENE			English	Article						LINE-1; retrotransposon; endogenous retroviruses; Fas; autoimmunity	MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODIES; IA ANTIGENS; L1 ELEMENT; CELL; INSERTION; RNA; SEQUENCE; MICE; TRANSCRIPTION	LINE-1 are endogenous mobile genetic elements that have dispersed and accumulated in the genomes of eukaryotes via germline transposition, with up to 100 000 copies in mammalian genomes. LINE- I elements transpose by reverse transcription of their own transcript. Transposition requires synthesis of a full-length, sense-strand transcripts and proteins encoded by open reading frame (ORF) 1 and ORF2. Although severely repressed in most normal tissues, LINE-I occasionally leads to disease by insertional mutagenesis. In the present study, Northern blot and in situ hybridization analyses revealed a template-strand transcription of LINE-I ORF2 (encoding reverse transcriptase, RT) in lymphoid organs and the liver from MRL-+/+ and Fas-deficient MRL/lpr strains and their normal ancestors. While these Sense transcripts are restricted to the nucleus in hepatocytes, they are also found in the cytoplasm in splenocytes. In contrast to transcription, ORF2 translation was detected only in MRL strains, as shown by the cytoplasmic labelling of splenic cells obtained with a monoclonal antibody recognizing the LINE-1 RT. This antibody coprecipitated two proteins of 45 and 12 kDa from MRL/lpr lymphoid organ lysates that were removed by pretreatment with anti-beta2-microglobulin antiserum, suggesting a structural association between a LINE-I product and a major histocompatibility complex class I or class I-like molecule.	CNRS, UPR 9045, Inst Andre Lwoff, F-94801 Villejuif, France; INSERM, U 267, F-94807 Villejuif, France; INSERM, U 131, F-92140 Clamart, France; Univ Paris 11, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bobe, P (corresponding author), CNRS, UPR 9045, Inst Andre Lwoff, 7 Rue Guy Moquet, F-94801 Villejuif, France.	bobe@infobiogen.fr	, BENIHOUD/O-4334-2019	Bobe, Pierre/0000-0002-8835-6786				BEHARKA AA, 1995, P NATL ACAD SCI USA, V92, P6294, DOI 10.1073/pnas.92.14.6294; BOBE P, 1987, IMMUNOGENETICS, V25, P251, DOI 10.1007/BF00404695; BOBE P, 1993, J IMMUNOL, V151, P2813; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; CHVATCHKO Y, 1983, FEBS LETT, V163, P207, DOI 10.1016/0014-5793(83)80820-5; DELARBRE C, 1988, J IMMUNOGENET, V15, P307; Dhellin O, 1997, EMBO J, V16, P6590, DOI 10.1093/emboj/16.21.6590; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DUDLEY JP, 1987, NUCLEIC ACIDS RES, V15, P2581, DOI 10.1093/nar/15.6.2581; DUE C, 1986, P NATL ACAD SCI USA, V83, P6007, DOI 10.1073/pnas.83.16.6007; EVANS JP, 1991, P NATL ACAD SCI USA, V88, P8792, DOI 10.1073/pnas.88.19.8792; Furano AV, 2000, PROG NUCLEIC ACID RE, V64, P255, DOI 10.1016/S0079-6603(00)64007-2; Herrmann Martin, 1998, Current Opinion in Rheumatology, V10, P347; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; JACKSON M, 1985, NUCLEIC ACIDS RES, V13, P3389, DOI 10.1093/nar/13.9.3389; JACOBSON BA, 1995, IMMUNITY, V3, P509, DOI 10.1016/1074-7613(95)90179-5; KATZIR N, 1985, P NATL ACAD SCI USA, V82, P1054, DOI 10.1073/pnas.82.4.1054; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; Kono D H, 2000, Int Rev Immunol, V19, P367, DOI 10.3109/08830180009055504; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; Maestre J, 1995, EMBO J, V14, P6333, DOI 10.1002/j.1460-2075.1995.tb00324.x; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MIKI Y, 1992, CANCER RES, V52, P643; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nakagawa K, 1996, IMMUNOL REV, V152, P193, DOI 10.1111/j.1600-065X.1996.tb00917.x; NATORI T, 1974, TRANSPLANTATION, V18, P550, DOI 10.1097/00007890-197412000-00015; OZATO K, 1980, J IMMUNOL, V124, P533; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; PADGETT RW, 1988, NUCLEIC ACIDS RES, V16, P739, DOI 10.1093/nar/16.2.739; PEUCHMAUR M, 1990, AM J PATHOL, V136, P383; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; SCHICHMAN SA, 1992, J MOL BIOL, V224, P559, DOI 10.1016/0022-2836(92)90544-T; SEVERYNSE DM, 1992, MAMM GENOME, V2, P41, DOI 10.1007/BF00570439; SKOWRONSKI J, 1985, P NATL ACAD SCI USA, V82, P6050, DOI 10.1073/pnas.82.18.6050; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; TCHENIO T, 1993, EMBO J, V12, P1487, DOI 10.1002/j.1460-2075.1993.tb05792.x; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WEBER T, 1987, GENE, V53, P105, DOI 10.1016/0378-1119(87)90097-7; Wilson IA, 1998, CURR OPIN IMMUNOL, V10, P67, DOI 10.1016/S0952-7915(98)80034-4; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	46	19	22	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5593	5600		10.1038/sj.onc.1205730	http://dx.doi.org/10.1038/sj.onc.1205730			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165858				2022-12-17	WOS:000177442000009
J	Fagard, R; Mouas, H; Dusanter-Fourt, I; Devillers, C; Bissieres, P; Martin, A; Lenoir, G; Van Tan, H; Feuillard, J; Raphael, M				Fagard, R; Mouas, H; Dusanter-Fourt, I; Devillers, C; Bissieres, P; Martin, A; Lenoir, G; Van Tan, H; Feuillard, J; Raphael, M			Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells	ONCOGENE			English	Article						EBV; apoptosis; Burkitt cell line; fludarabine; STAT-1	CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR SUPPRESSION; CANCER-THERAPY; STAT PROTEINS; P53; INDUCTION; BCL-2; DEATH; LYMPHOMA; MDM2	The Epstein-Barr virus (EBV) transforms B cells in part by inhibiting the cellular apoptotic programme. This is also observed when Burkitt lymphoma cell lines are infected with EBV. Induction of apoptosis is one of the mechanisms by which fludarabine inhibits the growth of cells with low proliferative capacity. This compound can also inhibit several other mechanisms in the cell, including inhibition of the synthesis of factors such as STAT1. To analyse the relationship between EBV status, fludarabine-induced apoptosis, and transcription factors we studied the EBV-negative Burkitt lymphoma cell line BL2, its EBV-infected counterpart BL2.B95.8 and the EBV-transformed cell line PRI. The BL2 cell line was found to be very sensitive to fludarabine. The BL2.B95.8 and PRI cells were both resistant but the latter to a lesser extent. In the PRI cells fludarabine activated p53, but not in the BL2.B95.8 cells in which the p53 pathway is inactivated. We observed that this inactivation results in part from the lack of expression of the MDM2 inhibitor p14ARF. Conversely, there was a substantial constitutive activation of STAT1, and not of the other STATs, in the BL2.B95.8 cells and a modest one in the PRI cells. Furthermore, expression of STAT1 was significantly reduced by fludarabine treatment in the PRI cells, but not in the BL2.BL95.8 cells. Finally, the expression of p21WAFI/CIP1 was detected only in the BL2.B95.8 and PRI cells. This protein, known to play a role in cell survival, may therefore be involved in the resistance of the BL2.B95.8 cells to fludarabine.	Univ Paris 13, EA 3406, ATHSCO, UFR SMBH, Bobigny, France; Hop Avicenne, APHP, Serv Biochem, F-93009 Bobigny, France; Hop Avicenne, APHP, Serv Hematol Biol, F-93009 Bobigny, France; Hop Avicenne, APHP, Serv Anat Pathol, F-93009 Bobigny, France; INSERM, ICGM, U363, F-75014 Paris, France; Inst Gustave Roussy, Villejuif, France	Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Avicenne - APHP; Universite Paris 13; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Gustave Roussy	Fagard, R (corresponding author), Univ Paris 13, EA 3406, ATHSCO, UFR SMBH, Bobigny, France.		Dusanter-Fourt, Isabelle/P-4558-2017; Feuillard, Jean/O-8587-2016	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Feuillard, Jean/0000-0001-6223-2454				Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Consoli U, 1998, BLOOD, V91, P1742, DOI 10.1182/blood.V91.5.1742.1742_1742_1748; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Foghsgaard L, 1997, J VIROL, V71, P7509, DOI 10.1128/JVI.71.10.7509-7517.1997; Frank DA, 1999, NAT MED, V5, P444, DOI 10.1038/7445; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KORSMEYER SJ, 1992, BLOOD, V80, P879; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Petersen AJ, 1996, EUR J HAEMATOL, V56, P213; Pettitt AR, 1999, BRIT J HAEMATOL, V106, P1049; ROSS SR, 1993, DRUGS, V45, P737, DOI 10.2165/00003495-199345050-00009; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Ruf IK, 1999, MOL CELL BIOL, V19, P1651; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thomas A, 1996, ONCOGENE, V12, P1055; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; WeberNordt RM, 1996, BLOOD, V88, P809; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0	34	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4473	4480		10.1038/sj.onc.1205554	http://dx.doi.org/10.1038/sj.onc.1205554			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085225				2022-12-17	WOS:000176476700001
J	Pierce, A; Spooncer, E; Ainsworth, S; Whetton, AD				Pierce, A; Spooncer, E; Ainsworth, S; Whetton, AD			BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor	ONCOGENE			English	Article						BCR-ABL; c-kit; CML; differentiation; haemopoietic	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; CHRONIC MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; TRANSGENIC MICE; PHILADELPHIA-CHROMOSOME; PROGENITOR CELLS; CD34(+) CELLS; KIT-LIGAND; LINE	Chronic myeloid leukaemia (CML), a hematopoietic stem cell disorder is characterized by the expression of BCR-ABL. To investigate the effects of BCR-ABL on multipotent hematopoietic cells, a temperature sensitive BCR-ABL tyrosine kinase was expressed in the cell line, FDCP-Mix. BCR-ABL mediated an increase in c-kit expression that correlated with an enhanced mitogenic response to SCF. This was not observed in the absence of Ber-Abl kinase activity or presence of the BCR-ABL inhibitor STI571, which also inhibits c-kit. When cultured in a combination of SCF plus G-CSF the FDCP-Mix cells undergo neutrophilic differentiation over a 7-10 day period. When BCR-ABL was active there was a marked inhibition of cell maturation compared to control cells in which BCR-ABL was either inactive or not present. However, BCR-ABL did not block differentiation as the cells eventually undergo terminal maturation. These data argue that BCR-ABL is directly responsible for the enhanced response to SCF reported in CML progenitor cells. Furthermore, although the primary effect of STI571 is via direct inhibition of BCR-ABL, STI571 additionally reduces the enhanced response to SCF. Thus there are two sites of STI571 action of potential importance in Bcr-Abl expressing cells.	Univ Manchester, Dept Biomol Sci, Leukaemia Res Fund Cellular Dev Unit, Manchester M60 1QD, Lancs, England	University of Manchester	Whetton, AD (corresponding author), Univ Manchester, Dept Biomol Sci, Leukaemia Res Fund Cellular Dev Unit, Sackville St, Manchester M60 1QD, Lancs, England.	Tony.Whetton@Umist.ac.uk		WHETTON, ANTHONY D/0000-0002-1098-3878; Pierce, Andrew/0000-0001-5995-2469				AGARWAL R, 1995, BLOOD, V85, P1306, DOI 10.1182/blood.V85.5.1306.bloodjournal8551306; Al-Taher A, 2000, YEAST, V17, P201, DOI 10.1002/1097-0061(20000930)17:3<201::AID-YEA30>3.0.CO;2-R; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Darley RL, 1999, EXP HEMATOL, V27, P1599, DOI 10.1016/S0301-472X(99)00100-9; Eaves A C, 1998, Stem Cells, V16 Suppl 1, P77; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gotoh A, 1997, Curr Opin Hematol, V4, P3; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; Hallek M, 1996, BRIT J HAEMATOL, V94, P5, DOI 10.1046/j.1365-2141.1996.6102053.x; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Moore S, 1998, BLOOD, V92, P2461, DOI 10.1182/blood.V92.7.2461.2461_2461_2470; Pierce A, 1998, J CELL SCI, V111, P815; Pierce A, 2000, ONCOGENE, V19, P5487, DOI 10.1038/sj.onc.1203940; Pierce A, 1998, ONCOGENE, V17, P667, DOI 10.1038/sj.onc.1201969; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309064268; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; Verfaillie CM, 1998, HEMATOL ONCOL CLIN N, V12, P1, DOI 10.1016/S0889-8588(05)70495-0; WANG J Y J, 1992, Current Biology, V2, P70, DOI 10.1016/0960-9822(92)90198-J; Wisniewski D, 1996, LEUKEMIA, V10, P229	32	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3068	3075		10.1038/sj.onc.1205424	http://dx.doi.org/10.1038/sj.onc.1205424			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082538				2022-12-17	WOS:000175262700015
J	Ghosh, AK; Majumder, M; Steele, R; Liu, TJ; Ray, RB				Ghosh, AK; Majumder, M; Steele, R; Liu, TJ; Ray, RB			MBP-1 mediated apoptosis involves cytochrome c release from mitochondria	ONCOGENE			English	Article						apoptosis; Bcl-x(L); cytochrome c; MBP-1	SQUAMOUS-CELL CARCINOMA; BINDING PROTEIN MBP-1; MYC PROMOTER; BCL-X; GENE-TRANSFER; FUNCTIONAL DOMAINS; MAMMARY-TUMORS; MESSENGER-RNA; BREAST-CANCER; INDUCTION	MBP-1, a cellular factor, appears to be involved in multiple functions, including transcriptional modulation, apoptosis and cell growth regulation. In this study, we have investigated the signaling pathway involved in MBP-1 mediated apoptotic cell death. Human carcinoma cells infected with a replication deficient adenovirus expressing MBP-1 (AdMBP-1) induced apoptosis, when compared with cells infected by replication-defective adenovirus (d1312) as a negative control. Transduction of MBP-1 in carcinoma cells releases cytochrome c from mitochondria into the cytosol leading to activation of procaspase-9, procaspase-3 and PARP cleavage. We previously observed that MBP-1 mediated apoptosis can be protected by Bcl-2, although MBP-1 does not share a homology with the BH domain of the Bcl-2 family member of proteins. To further understand the mechanism of MBP-1 mediated apoptosis, we examined whether MBP-1 modulates the Bcl-2 gene family. Our results demonstrated that human breast carcinoma cells infected with AdMBP-1 selectively reduced Bcl-x(L) mRNA and protein expression when compared with d1312 infected negative control cells. An in vitro transient reporter assay also suggested repression of the Bcl-x promoter activity by MBP-1. Additional studies indicated that MBP-1 modulates Ets family protein function, thereby downregulating Bcl-x(L) expression. Taken together, our results suggest that MBP-1 selectively represses Bcl-x(L) expression in MCF-7 cells and induces mitochondrial involvement in the apoptotic process.	St Louis Univ, Dept Pathol, St Louis, MO 63104 USA; St Louis Univ, Div Infect Dis, St Louis, MO 63104 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA	Saint Louis University; Saint Louis University; University of Texas System; UTMD Anderson Cancer Center	Ray, RB (corresponding author), St Louis Univ, Dept Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rayrb@slu.edu			NCI NIH HHS [CA52799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052799, R29CA052799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHAUDHARY D, 1995, BIOCHEMISTRY-US, V34, P3438, DOI 10.1021/bi00010a036; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Ealovega MW, 1996, CANCER RES, V56, P1965; Feo S, 2000, FEBS LETT, V473, P47, DOI 10.1016/S0014-5793(00)01494-0; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Ghosh AK, 1999, MOL CELL BIOL, V19, P2880; Ghosh AK, 2001, MOL CELL BIOL, V21, P655, DOI 10.1128/MCB.21.2.655-662.2001; GIALLONGO A, 1986, P NATL ACAD SCI USA, V83, P6741, DOI 10.1073/pnas.83.18.6741; Graham FL, 2000, IMMUNOL TODAY, V21, P426, DOI 10.1016/S0167-5699(00)01676-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; LIU TJ, 1995, CANCER RES, V55, P3117; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Olopade OI, 1997, CANCER J SCI AM, V3, P230; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; RAY R, 1989, ONCOGENE, V4, P593; RAY RB, 1995, CELL GROWTH DIFFER, V6, P1089; RAY RB, 1995, CANCER RES, V55, P3747; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; RAY RB, 1994, INT J ONCOL, V5, P1433; Reed JC, 1998, CANCER J, V4, pS8; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shimizu S, 1996, ONCOGENE, V13, P21; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Subramanian A, 2000, J BIOL CHEM, V275, P5958, DOI 10.1074/jbc.275.8.5958; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tu YP, 1998, CANCER RES, V58, P256; White RA, 1997, GENOMICS, V39, P406, DOI 10.1006/geno.1996.4499; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YASUSHI F, 1997, J CLIN INVEST, V99, P2898; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	58	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2775	2784		10.1038/sj.onc.1205384	http://dx.doi.org/10.1038/sj.onc.1205384			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973636				2022-12-17	WOS:000175063700001
J	Amicone, L; Terradillos, O; Calvo, L; Costabile, B; Cicchini, C; Della Rocca, C; Lozupone, F; Piacentini, M; Buendia, MA; Tripodi, M				Amicone, L; Terradillos, O; Calvo, L; Costabile, B; Cicchini, C; Della Rocca, C; Lozupone, F; Piacentini, M; Buendia, MA; Tripodi, M			Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: Importance of TGF-beta signalling in the control of liver homeostasis and transformation	ONCOGENE			English	Article						apoptosis; hepatocyte proliferation; liver mass homeostasis; oncogene cooperation	HEPATOCYTE GROWTH-FACTOR; FACTOR-SCATTER FACTOR; TRANSGENIC MICE; FACTOR-RECEPTOR; CELL-PROLIFERATION; IN-SITU; EXPRESSION; HEPATOCARCINOGENESIS; GENE; OVEREXPRESSION	The c-Met tyrosine kinase receptor and its ligand, Hepatocyte Growth Factor/ Scatter Factor, have been implicated in human cancer. We have previously described that the transgenic expression of a truncated form of human c-Met (cyto-Met) in the liver confers resistance to several apoptotic stimuli. Here we show the impact of cyto-Met expression on liver proliferation and transformation. Despite a sixfold increase of hepatocyte proliferation, adult transgenic livers displayed normal size and architecture. We present evidence showing that activation of TGF-beta1 signalling controls the liver mass in cyto-Met mice. The oncogenic potential of cyto-Met was further assessed in the context of c-Myc-induced hepatocarcinogenesis, using WHV/c-Myc transgenic mice. Co-expression of cyto-Met and c-Myc further enhanced hepatocyte proliferation and caused a dramatic acceleration of the Myc-induced tumorigenesis, leading to the emergence of hepatocarcinomas in 3-4-month-old animals. Importantly, the TGF-beta receptor type 11 expression was strongly downregulated in most tumours, indicating that impairment of TGF-beta1-mediated growth inhibition plays a major role in accelerated neoplastic development. The strong potential of cyto-Met for oncogenic cooperation without direct transforming activity designates cyto-Met mice as an ideal tool for studying the early steps of multistage hepatocarcinogenesis and for identification of prognostic markers of transformation.	Univ Roma La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Fondaz Ist Pasteur Cenci Bolognetti, I-00161 Rome, Italy; Inst Pasteur, Dept Retrovirus, Unite Recombinaison & Express Genet, F-75724 Paris 15, France; Univ Roma La Sapienza, Sez Anat Patol, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; IRCCS L Spallanzani, Ist Nazl Malattie Infett, Rome, Italy	Sapienza University Rome; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Sapienza University Rome; University of Rome Tor Vergata; IRCCS Lazzaro Spallanzani	Tripodi, M (corresponding author), Univ Roma La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Fondaz Ist Pasteur Cenci Bolognetti, I-00161 Rome, Italy.	tripodi@bce.med.uniroma1.it	Lozupone, Francesco/H-2998-2016; Piacentini, Mauro/I-2411-2016; Tripodi, Marco/ABO-1160-2022; Tripodi, Marco/F-1143-2011	Lozupone, Francesco/0000-0002-4959-9400; Piacentini, Mauro/0000-0003-2919-1296; Tripodi, Marco/0000-0001-6135-971X; Tripodi, Marco/0000-0001-6135-971X; Amicone, Laura/0000-0002-3487-5740; CICCHINI, Carla/0000-0003-4662-5674				AMICONE L, 1995, GENE, V162, P323, DOI 10.1016/0378-1119(95)00277-D; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BENEDETTI A, 1988, J HEPATOL, V6, P137, DOI 10.1016/S0168-8278(88)80024-2; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BLOCH B, 1993, J HISTOCHEM CYTOCHEM, V41, P1751, DOI 10.1177/41.12.8245422; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURSCH W, 1986, ARCH TOXICOL, V59, P221, DOI 10.1007/BF00290542; Clifford SC, 1998, BRIT J CANCER, V77, P1420, DOI 10.1038/bjc.1998.235; Columbano A, 1984, Toxicol Pathol, V12, P89; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Desiderio MA, 1998, EXP CELL RES, V242, P401, DOI 10.1006/excr.1998.4073; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; ETIEMBLE J, 1994, ONCOGENE, V9, P727; Factor VM, 1997, CANCER RES, V57, P2089; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; Grippo PJ, 2000, AM J PATHOL, V157, P805, DOI 10.1016/S0002-9440(10)64594-4; HUANG SN, 1995, HEPATOLOGY, V21, P620, DOI 10.1002/hep.1840210303; Jansen AP, 2001, CANCER RES, V61, P808; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; JIRTLE RL, 1991, J BIOL CHEM, V266, P22444; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Santoni-Rugiu E, 1999, AM J PATHOL, V154, P1693, DOI 10.1016/S0002-9440(10)65425-9; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; SHULTEHERMANN R, 1995, APOPTOSIS HEPATOEARC, P141; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; von Schweinitz D, 2000, INT J CANCER, V85, P151, DOI 10.1002/(SICI)1097-0215(20000115)85:2<151::AID-IJC1>3.0.CO;2-6; WEBBER EM, 1994, AM J PATHOL, V145, P398; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; ZHEN Z, 1994, ONCOGENE, V9, P1691	43	19	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1335	1345		10.1038/sj.onc.1205199	http://dx.doi.org/10.1038/sj.onc.1205199			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857077				2022-12-17	WOS:000173861000004
J	Huang, ZY; Baldwin, RL; Hedrick, NM; Gutmann, DH				Huang, ZY; Baldwin, RL; Hedrick, NM; Gutmann, DH			Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo	ONCOGENE			English	Article						glioma; astrocytoma; p53; retinoblastoma; tumor suppressor	HUMAN-MALIGNANT GLIOMAS; P53-DEPENDENT APOPTOSIS; MUTANT MICE; CELL-GROWTH; GENE; AMPLIFICATION; RB; GLIOBLASTOMAS; INACTIVATION; SUPPRESSION	The development of malignant gliomas (astrocytomas) involves the accumulation of multiple genetic changes, including mutations in the p53 and retinoblastoma (Rb) cell cycle regulatory pathways. One Rb pathway alteration seen in high-grade astrocytomas is amplification of cyclin dependent kinase-4 (CDK4). To define the function of CDK4 amplification/overexpression in astrocytoma pathogenesis, we generated three transgenic mouse lines that overexpress human CDK4 (hCDK4) in astrocytes using the human glial fibrillary acidic protein (GFAP) promoter. CFAP-hCDK4 mice do not develop brain tumors, but exhibit a small increase in astrocyte number. Cultured astrocytes from these mice do not demonstrate a cell-autonomous growth advantage in vitro and lack properties of transformed cells. To determine whether cdk4 overexpression provides a cooperative growth advantage in vitro, CDK4-overexpressing C6 glioma cell lines were generated and found to exhibit increased cell growth. In addition, GFAP-hCDK4; p53 + / - as well as p53 + / -; Rb + / - mice exhibited increased numbers of astrocytes compared to GFAP-hCDK4, p53 + / -, or Rb + / - mice in vivo. No cooperative effect was observed with CFAP-hCDK4; Rb+/- mice. These results support the hypothesis that cdk4 overexpression alone is not sufficient for astrocytoma formation, but can provide a cooperative growth advantage in concert with genetic alterations in the p53 pathway.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111 660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041097] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41097] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bajenaru ML, 2001, GLIA, V33, P314, DOI 10.1002/1098-1136(20010315)33:4<314::AID-GLIA1030>3.0.CO;2-Q; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Bogler O, 1999, CELL GROWTH DIFFER, V10, P73; BOGLER O, 1995, CANCER RES, V55, P2746; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; Ding H, 2001, CANCER RES, V61, P3826; DING H, 2000, NEURO-ONCOLOGY, V2, P259; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829; Gutmann DH, 2000, NEUROPATH APPL NEURO, V26, P361, DOI 10.1046/j.1365-2990.2000.00258.x; Hegi ME, 2000, CANCER RES, V60, P3019; HEWETT SJ, 1993, BRAIN RES, V625, P337, DOI 10.1016/0006-8993(93)91078-7; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; Ichimura K, 2000, CANCER RES, V60, P417; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kleihues P., 2000, WORLD HLTH ORG CLASS; Lau N, 2000, J NEUROPATH EXP NEUR, V59, P759, DOI 10.1093/jnen/59.9.759; LI FP, 1969, J NATL CANCER I, V43, P1365; Listernick R, 1999, AM J MED GENET, V89, P38, DOI 10.1002/(SICI)1096-8628(19990326)89:1<38::AID-AJMG8>3.0.CO;2-M; Marino S, 2000, GENE DEV, V14, P994; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; ROSE K, 1993, VITRO BIOL METHODS, P46; Schlegel J, 1999, PATHOBIOLOGY, V67, P202, DOI 10.1159/000028073; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Timiryasova TM, 1999, INT J ONCOL, V14, P845; Ueki K, 1996, CANCER RES, V56, P150; Wakabayashi T, 1999, BIOTECHNIQUES, V26, P302, DOI 10.2144/99262st04; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAHANDA AM, 1995, MOL CELL BIOL, V15, P4249; YIN DL, 1995, NEUROSURGERY, V37, P758, DOI 10.1227/00006123-199510000-00021; ZHOU L, 1997, DEV BIOL, V187, P36	41	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1325	1334		10.1038/sj.onc.1205206	http://dx.doi.org/10.1038/sj.onc.1205206			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857076				2022-12-17	WOS:000173861000003
J	Bartunek, P; Pajer, P; Karafiat, V; Blendinger, G; Dvorak, M; Zenke, M				Bartunek, P; Pajer, P; Karafiat, V; Blendinger, G; Dvorak, M; Zenke, M			bFGF signaling and v-Myb cooperate in sustained growth of primitive erythroid progenitors	ONCOGENE			English	Article						v-Myb; Myb; FGF; FGF receptor; erythropoiesis; signaling	BLOOD-CELL DIFFERENTIATION; C-MYB; TRANSFORMING GROWTH-FACTOR-BETA-1; TERMINAL DIFFERENTIATION; HEMATOPOIETIC-CELLS; NEURORETINA CELLS; TYROSINE KINASE; SELF-RENEWAL; MIM-1 GENE; RECEPTOR	The development of red blood cells from hematopoietic progenitors requires the interplay of specific extracellular factors and transcriptional regulators. Here we have identified an erythroid progenitor that is critically dependent on bFGF and requires expression of AMV v-Myb for sustained proliferation in vitro, indicating that bFGF and Myb proteins cooperate in these cells. In the presence of bFGF such v-Myb cells are completely blocked in their ability to differentiate and exhibit an exceptionally high proliferative potential and long life-span in vitro. Interestingly, in the absence of bFGF cells effectively differentiate into mature erythrocytes, irrespective of constitutive and elevated levels of v-Myb. We also demonstrate that these cells express high levels of FGF receptor type 1 (FGFR1) and that phospholipase Cgamma (PLC)gamma) is one of the important molecules in FGF receptor signaling. Our studies suggest that bFGF, in cooperation with Myb proteins, represents an important factor for determining erythroid lineage choice. These findings unravel a so far unidentified link between extracellular signaling and Myb in hematopoietic cells.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Acad Sci Czech Republ, Inst Mol Genet, CR-16637 Prague 6, Czech Republic	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Zenke, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	zenke@mdc-berlin.de	Pajer, Petr/G-5869-2014; Bartunek, Petr/J-3897-2014; Dvořák, Michal/I-9939-2014; Dvorak, Michal/G-5861-2014	Bartunek, Petr/0000-0002-6202-7650; 				Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; ALLOUCHE M, 1995, LEUKEMIA, V9, P937; Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; Bartunek P, 1998, MOL ENDOCRINOL, V12, P1269, DOI 10.1210/mend.12.9.0173; Beug H, 1996, CURR TOP MICROBIOL, V211, P29; BEUG H, 1995, METHOD ENZYMOL, V254, P41; Briegel K, 1996, DEVELOPMENT, V122, P3839; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; BRUNNER G, 1993, BLOOD, V81, P631; Cross MA, 1997, CURR OPIN GENET DEV, V7, P609, DOI 10.1016/S0959-437X(97)80007-X; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Faloon P, 2000, DEVELOPMENT, V127, P1931; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GORDONTHOMSON C, 1994, DEVELOPMENT, V120, P3571; Graf T, 1998, CURR BIOL, V8, pR353, DOI 10.1016/S0960-9822(98)70220-9; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Huber TL, 1998, BLOOD, V92, P4128, DOI 10.1182/blood.V92.11.4128.423k46_4128_4137; Karafiat V, 2001, BLOOD, V98, P3668, DOI 10.1182/blood.V98.13.3668; KLINT P, 1999, FRONT BIOSCI, V4, P165; Koritschoner NP, 1999, ONCOGENE, V18, P5904, DOI 10.1038/sj.onc.1202979; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KRANTZ SB, 1991, BLOOD, V77, P419; KRYSTAL G, 1994, J EXP MED, V180, P851, DOI 10.1084/jem.180.3.851; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; Mead P E, 1998, Curr Opin Hematol, V5, P156; Mink S, 1996, MOL CELL BIOL, V16, P1316; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; Orkin SH, 2000, NAT MED, V6, P1212, DOI 10.1038/81303; Orkin SH, 1996, CURR OPIN GENET DEV, V6, P597, DOI 10.1016/S0959-437X(96)80089-X; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P129; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHMIDT JA, 1986, EXP CELL RES, V164, P71, DOI 10.1016/0014-4827(86)90455-6; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Turque N, 1997, J VIROL, V71, P9778, DOI 10.1128/JVI.71.12.9778-9781.1997; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yuen D, 1998, BLOOD, V91, P3202, DOI 10.1182/blood.V91.9.3202.3202_3202_3209; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	51	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					400	410		10.1038/sj/onc/1205103	http://dx.doi.org/10.1038/sj/onc/1205103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821952				2022-12-17	WOS:000173311200008
J	Brennan, PJ; Kumagai, T; Berezov, A; Murali, R; Greene, MI				Brennan, PJ; Kumagai, T; Berezov, A; Murali, R; Greene, MI			HER2/Neu: mechanisms of dimerization/oligomerization (vol 19, pg 6093, 2000)	ONCOGENE			English	Correction														Murali, Ramachandran/0000-0002-8384-2793				Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967	1	19	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					328	328		10.1038/sj/onc/1205119	http://dx.doi.org/10.1038/sj/onc/1205119			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11840330	Bronze			2022-12-17	WOS:000173026200017
J	Deb, D; Scian, M; Roth, KE; Li, W; Keiger, J; Chakraborti, AS; Deb, SP; Deb, S				Deb, D; Scian, M; Roth, KE; Li, W; Keiger, J; Chakraborti, AS; Deb, SP; Deb, S			Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants	ONCOGENE			English	Article						p53; transcriptional activation; repression; oligomerization	WILD-TYPE P53; SUPPRESSOR PROTEIN P53; C-TERMINAL DOMAIN; DNA-BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; GROWTH SUPPRESSION; KINASE-C; P53-MEDIATED REPRESSION; FUNCTION PHENOTYPE	Tumor-derived p53 mutants activate transcription from promoters of various growth-related genes. We tested whether this transactivation function of the mutant protein is sufficient to induce tumorigenesis ('gain of function'). Tumor-derived mutant p53-281G transactivates. the promoters of human epidermal growth factor receptor (EGFR) and human multiple drug resistance gene (MDR-1). To determine whether the C-terminal domain functions only as an oligomerization domain in mutant p53-mediated transactivation, we have replaced the tetramerization domain of p53 by a heterologous tetramerization domain; although this mutant protein formed tetramers in solution, it failed to transactivate significantly. Therefore, for successful mutant p53-mediated transactivation, sequences near the C-terminus of mutant p53 are required to perform functions in addition to tetramerization. We also demonstrate that co-expression of a deletion mutant of p53 (p53 del 1-293), which retains the p53 oligomerization domain, inhibits this transactivation. p53 del 1-293 co-immunoprecipitates with p53-281G suggesting that hetero-oligomers of p53-281G and p53 del 1-293 are defective in transactivation. We also show that a cell line stably transfected with p53-281G expresses higher levels of endogenous NF-KB and proliferating cell nuclear antigen (PCNA) compared to that transfected with vector alone. On co-expression, p53 del 1-293 lowered the levels of NF-KB and PCNA in p53-281G-expressing cells. However, on co-expression, p53 del 1-293 did not inhibit the tumorigenicity and colony forming ability of p53-281G expressing cells. Our earlier work showed that a deletion of the C-terminal sequences of p53-281G overlapping the oligomerization domain obliterates 'gain of function'. Taken together, the above information suggests that the C-terminal sequences have some critical role in 'gain of function' in addition to transactivation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Deb, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA.	SDEB@HSC.VCU.EDU			NATIONAL CANCER INSTITUTE [R01CA074172, R01CA070712] Funding Source: NIH RePORTER; NCI NIH HHS [CA70712, CA74172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABARZUA P, 1995, CANCER RES, V55, P3490; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BRAIN R, 1994, ONCOGENE, V9, P1775; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Deb D, 2001, INT J ONCOL, V18, P401; Deb D, 1999, INT J ONCOL, V15, P413; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Kelavkar UP, 1999, P NATL ACAD SCI USA, V96, P4378, DOI 10.1073/pnas.96.8.4378; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LENG P, 1995, ONCOGENE, V10, P1275; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Reed Michael, 1993, Gene Expression, V3, P95; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tanguay RL, 2000, BBA-GENE STRUCT EXPR, V1494, P117, DOI 10.1016/S0167-4781(00)00225-6; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Waterman MJF, 1996, CANCER RES, V56, P158; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	91	19	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					176	189		10.1038/sj/onc/1205035	http://dx.doi.org/10.1038/sj/onc/1205035			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803461				2022-12-17	WOS:000173026200002
J	Cheng, GJ; Meinkoth, JL				Cheng, GJ; Meinkoth, JL			Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells	ONCOGENE			English	Article						Ras; Rap1A; thyroid; apoptosis	PROTEIN-KINASE-A; EPITHELIAL-CELLS; MUTANT RAS; EXPRESSION; ONCOGENE; PROLIFERATION; GENE; DIFFERENTIATION; ACTIVATION; PATHWAYS	Ras. mutations, occur at high frequency in thyroid cancer. In vitro, the effects of Ras in thyroid cells are pleiotropic in that expression of activated Ras has been reported to, stimulate proliferation and apoptosis. An understanding of the factors that contribute to the survival versus demise of Ras-transformed cells is essential to our understanding, of the contribution of Ras to thyroid neoplasia and other cancers. Constitutive expression of oncogenic H-Ras sensitized Wistar rat thyroid (WRT) cells to apoptosis stimulated by multiple insults. When deprived of matrix attachment, Ras-transformed cells perished by apoptotic cell death at a high frequency. In contrast, parental cells were more resistant to suspension-induced cell death. Ras effects on anchorage-independent cell death were reproduced by a mutant protein that signals selectively to Raf-1, but not by mutant Ras that preferentially binds, to RalGDS. Expression of a Ras mutant that selectively activates PI3K resulted in substantial protection from detachment-induced cell death., MAPK activity was increased in, adherent Ras12V- and Rasl2V35S-expressing cells, but abolished upon detachment. Interestingly, impaired MAPK activity was sufficient to stimulate apoptosis in adherent Ras-transformed cells, but not in parental cells. Treatment with a PI3-K inhibitor also stimulated apoptosis, selectively in Ras-transformed cells. These results, demonstrate that constitutive expression of activated Ras elicits differential effects on the survival of thyroid cells., Moreover, Ras, expression results in a greater dependence of thyroid cells on MAPK and PI3K activity for their survival.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.		Meinkoth, Judy L/G-2900-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055757] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55757] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arscott PL, 1997, ENDOCRINOLOGY, V138, P5019, DOI 10.1210/en.138.11.5019; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; AVVEDIMENTO VE, 1985, EUR J BIOCHEM, V149, P467, DOI 10.1111/j.1432-1033.1985.tb08948.x; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P281; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Di Matola T, 2000, J CLIN ENDOCR METAB, V85, P1188, DOI 10.1210/jc.85.3.1188; DREMIER S, 1994, BIOCHEM BIOPH RES CO, V200, P52, DOI 10.1006/bbrc.1994.1412; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; JESO BD, 1995, BIOCHEM BIOPH RES CO, V214, P819; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Li X, 1999, ENDOCRINOLOGY, V140, P5962, DOI 10.1210/en.140.12.5962; Lin TH, 1997, J BIOL CHEM, V272, P8849; MALY FE, 1994, J BIOL CHEM, V269, P18743; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; NAMBA H, 1990, J CLIN ENDOCR METAB, V71, P223, DOI 10.1210/jcem-71-1-223; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; SUAREZ HG, 1990, ONCOGENE, V5, P565; Tsygankova OM, 2000, ONCOGENE, V19, P3609, DOI 10.1038/sj.onc.1203680; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Vitale M, 1999, FEBS LETT, V462, P57, DOI 10.1016/S0014-5793(99)01512-4; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	37	19	19	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7334	7341		10.1038/sj.onc.1204928	http://dx.doi.org/10.1038/sj.onc.1204928			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704863				2022-12-17	WOS:000171894200006
J	Wang, BL; Xiong, QH; Shi, Q; Le, XD; Xie, KP				Wang, BL; Xiong, QH; Shi, Q; Le, XD; Xie, KP			Genetic disruption of host interferon-gamma drastically enhances the metastasis of pancreatic adenocarcinoma through impaired expression of inducible nitric oxide synthase	ONCOGENE			English	Article						interferon-gamma; knockout; nitric oxide; metastasis; pancreas	CELL-LINES; CANCER; TUMORS; REGRESSION; THERAPY; MICE; MECHANISMS; BETA; P53	Synergistic induction of the inducible nitric oxide synthase (NOS II) gene requires a combination of interferon-gamma (IFN-gamma) and lipopolysaccharide (LPS). In this study, we determined whether the induction of IFN-gamma was required for NOS U-mediated antitumor activity in viro. Highly metastatic H7 murine pancreatic adenocarcinoma cells were implanted into the subcutis, footpad, and pancreas of syngeneic IFN-gamma (+/+) and IFN-gamma (-/-) mice. These cells grew and produced metastases and ascites in IFN-gamma (+/+) mice. In sharp contrast, the same tumor cells grew much more aggressively, metastasized more extensively, and produced a larger amount of malignant ascites in IFN-gamma (-/-) mice. Also, induction of IFN-gamma correlated with NOS II gene expression and NO production in IFN-gamma (+/+) injected with the tumor cells but not in IFN-gamma (-/-) mice or IFN-gamma (+/+) mice without tumor challenge. In vitro, only LPS plus IFN-gamma induced a high level of NO production and cytotoxicity against H7 cells. These data suggested that the tumor cells stimulated IFN-gamma secretion from host cells, which in turn stimulated NO production by host cells and suppressed tumor growth and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xie, KP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA 16672-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Chinje EC, 1997, ESSAYS BIOCHEM, V32, P61; CORBETT TH, 1984, CANCER RES, V44, P717; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JOHNS TG, 1992, J NATL CANCER I, V84, P1185, DOI 10.1093/jnci/84.15.1185; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KROWN SE, 1988, J NATL CANCER I, V80, P306, DOI 10.1093/jnci/80.5.306; Kundu N, 1998, INT J CANCER, V76, P713, DOI 10.1002/(SICI)1097-0215(19980529)76:5<713::AID-IJC17>3.0.CO;2-4; LOKSHIN A, 1995, JNCI-J NATL CANCER I, V87, P206, DOI 10.1093/jnci/87.3.206; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Onier N, 1999, INT J CANCER, V81, P755, DOI 10.1002/(SICI)1097-0215(19990531)81:5<755::AID-IJC15>3.0.CO;2-3; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Shi Q, 2000, INT J ONCOL, V17, P217; Shi Q, 1999, CANCER RES, V59, P2072; SHI Q, 2000, CANCER RES, V60, P2645; Tannenbaum CS, 2000, SEMIN CANCER BIOL, V10, P113, DOI 10.1006/scbi.2000.0314; THOMAS H, 1991, PHARMACOL THERAPEUT, V52, P307, DOI 10.1016/0163-7258(91)90030-P; Tozer G M, 1997, Clin Oncol (R Coll Radiol), V9, P357, DOI 10.1016/S0936-6555(97)80128-8; Wang BL, 2001, INT J CANCER, V91, P607, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1109>3.0.CO;2-D; Wang BL, 2001, CANCER RES, V61, P71; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; XIE K, 1997, CLIN CANCER RES, V3, P2189; XIE KP, 1995, CANCER RES, V55, P3123; Xie KP, 1998, CANCER METAST REV, V17, P55, DOI 10.1023/A:1005956721457; Zhang JF, 1996, P NATL ACAD SCI USA, V93, P4513, DOI 10.1073/pnas.93.9.4513	31	19	21	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6930	6937		10.1038/sj.onc.1204871	http://dx.doi.org/10.1038/sj.onc.1204871			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687972				2022-12-17	WOS:000171641000014
J	Kuttler, F; Ame, P; Clark, H; Haughey, C; Mougin, C; Cahn, JY; Dang, CV; Raffeld, M; Fest, T				Kuttler, F; Ame, P; Clark, H; Haughey, C; Mougin, C; Cahn, JY; Dang, CV; Raffeld, M; Fest, T			c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli	ONCOGENE			English	Article						Burkitt's lymphoma; c-Myc; apoptosis; staurosporine; TNF alpha	TRANSCRIPTIONAL ACTIVATION DOMAIN; TRANSACTIVATION DOMAIN; CYCLE; FIBROBLASTS; PROTEIN; GENE; BINDING; ARREST; REGION; GROWTH	In addition to c-myc rearrangement, over 50% of Burkitt's lymphoma cases present clustered mutations in exon 2, where many of the functional activities of c-Myc protein are based. This report describes the functional consequences induced by tumour-derived c-myc mutations located in c-myc box II. Two mutated alleles were studied, focusing on the P138C mutation, and compared to wild-type c-myc. The c-Myc transformation, transactivation and apoptosis activities were explored based on cells over-expressing c-Myc. While the transcriptional activation activity was not affected, our experiments exploring the anchorage-independent growth capacity of c-Myc-transfected Rat1a cells showed that c-Myc box II mutants were less potent than wild-type c-Myc in promoting cell transformation. Considering the possibility that these mutations could be interfering with the ability of c-Myc to promote apoptosis, we tested c-Myc-transfected Rat1a fibroblasts under several conditions: serum deprivation-, staurosporine- and TNF alpha -induced cell death. Interestingly, the mutated alleles were characterized by an overall decrease in ability to mediate apoptosis. Our study indicates that point mutations located in c-Myc box II can decrease the ability of the protein to promote both transformation and apoptosis without modifying its transactivating activity.	Univ Hosp Jean Minjoz, Inst Etud & Transfert Genes, Dept Haematol & Cell Biol, F-25030 Besancon, France; NCI, Hematopathol Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA	Universite de Franche-Comte; CHU Besancon; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Fest, T (corresponding author), Univ Hosp Jean Minjoz, Inst Etud & Transfert Genes, Dept Haematol & Cell Biol, F-25030 Besancon, France.		Amé-Thomas, Patricia/C-3131-2017; Dang, Chi/Y-3375-2019	Amé-Thomas, Patricia/0000-0001-8042-9250; Kuttler, Fabien/0000-0003-2575-1989; MOUGIN, CHRISTIANE/0000-0002-1573-8695; fest, thierry/0000-0002-6437-4189; Dang, Chi/0000-0002-4031-2522				ASKEW DS, 1991, ONCOGENE, V6, P1915; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bernard B, 2001, CELL DEATH DIFFER, V8, P234, DOI 10.1038/sj.cdd.4400796; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; CLARK HM, 1994, CANCER RES, V54, P3383; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dhanaraj SN, 1996, EXP CELL RES, V224, P52, DOI 10.1006/excr.1996.0110; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HSU B, 1995, ONCOGENE, V11, P175; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; PULVERER BJ, 1994, ONCOGENE, V9, P59; Raffeld M, 1995, Curr Top Microbiol Immunol, V194, P265; Sakamuro D, 1995, ONCOGENE, V11, P2411; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stone B., 1987, ED RES Q, V11, P7; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; YANO T, 1993, ONCOGENE, V8, P2741; YANO T, 1992, BLOOD, V80, P758	37	19	19	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6084	6094		10.1038/sj.onc.1204827	http://dx.doi.org/10.1038/sj.onc.1204827			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593416				2022-12-17	WOS:000171056300016
J	Maslyar, DJ; Aoki, M; Vogt, PK				Maslyar, DJ; Aoki, M; Vogt, PK			The growth-promoting activity of the Bad protein in chicken embryo fibroblasts requires binding to protein 14-3-3	ONCOGENE			English	Article						anchorage-independent growth; apoptosis; BH3 proteins; 14-3-3	BH3 DOMAIN; PHOSPHORYLATION; EXPRESSION; APOPTOSIS; BCL-2; INACTIVATE; INDUCTION; DISPLACES; AKT2; DNA	Phosphorylation of the Bad protein is a key regulatory event in the prevention of apoptosis by survival factors. Phosphorylated Bad binds to the cytosolic 14-3-3 protein and is sequestered from the apoptotic machinery of the mitochondrial membrane. To examine the role of Bad in cell growth and apoptosis in primary cultures, we produced stable Bad transfectants of chicken embryo fibroblasts (CEF). As expected, serum starvation of Bad transfectants promoted apoptosis. However, Bad-transfected CEF maintained in media with a high serum concentration were capable of anchorage-independent growth and grew to a higher saturation density than control CEF transfected with the empty vector. High dilutions of the infectious retroviral vector RCAS expressing Bad led to the formation of multilayered cell foci. The growth-promoting effects of Bad were dependent on the serine 136 phosphorylation site and correlated directly with binding of Bad to 14-3-3. These results suggest that phosphorylated Bad promotes cell growth and in oncogenic transformation may contribute to the neoplastic phenotype of the cell.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,BCC 239, La Jolla, CA USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490	NATIONAL CANCER INSTITUTE [R35CA042564, R01CA078230] Funding Source: NIH RePORTER; NCI NIH HHS [CA78230, CA42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreeff M, 1999, LEUKEMIA, V13, P1881, DOI 10.1038/sj.leu.2401573; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kitada S, 1998, AM J PATHOL, V152, P51; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	24	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5087	5092		10.1038/sj.onc.1204662	http://dx.doi.org/10.1038/sj.onc.1204662			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526496				2022-12-17	WOS:000170464000001
J	Gage, BM; Alroy, D; Shin, CY; Ponomareva, ON; Dhar, S; Sharma, GG; Pandita, TK; Thayer, MJ; Turker, MS				Gage, BM; Alroy, D; Shin, CY; Ponomareva, ON; Dhar, S; Sharma, GG; Pandita, TK; Thayer, MJ; Turker, MS			Spontaneously immortalized cell lines obtained from adult Atm null mice retain sensitivity to ionizing radiation and exhibit a mutational pattern suggestive of oxidative stress	ONCOGENE			English	Article						immortalized Atm null cells; ionizing radiation; mutagenesis oxidative stress	ATAXIA-TELANGIECTASIA; DEFICIENT MICE; POSTCONFLUENCE INHIBITION; TELOMERASE ACTIVITY; MUTATOR PHENOTYPE; END ASSOCIATIONS; MOUSE APRT; RESISTANCE; DEFECTS; CANCER	The study of Ataxia-telangiectasia (A-T) has benefited significantly from mouse models with knockout mutations for the Atm (A-T mutation) locus. While these models have proven useful for in vivo studies, cell cultures from Atm null embryos have been reported to grow poorly and then senesce. In this study, we initiated primary cultures from adult ears and kidneys of Atm homozygous mice and found that these cultures immortalized readily without loss of sensitivity to ionizing radiation and other Atm related cell cycle defects. A mutational analysis for loss of expression of an autosomal locus showed that ionizing radiation had a mutagenic effect, Interestingly, some spontaneous mutants exhibited a mutational pattern that is characteristic of oxidative mutagenesis, This result is consistent with chronic oxidative stress in Atm null cells. In total, the results demonstrate that permanent cell lines can be established from the tissues of adult mice homozygous for Atm and that these cell lines will exhibit expected and novel consequences of this deficiency.	Oregon Hlth Sci Univ, CROET, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA; Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Oregon Health & Science University; Columbia University; Oregon Health & Science University; Oregon Health & Science University	Turker, MS (corresponding author), Oregon Hlth Sci Univ, CROET, Ctr Res Occupat & Environm Toxicol, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Pandita, Tej K/AAM-9188-2020		NCI NIH HHS [CA56383, CA76528] Funding Source: Medline; NIGMS NIH HHS [GM49334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076528, R01CA056383] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; COLE J, 1988, INT J RADIAT BIOL, V54, P929, DOI 10.1080/09553008814552331; COOPER GE, 1992, SOMAT CELL MOLEC GEN, V18, P215, DOI 10.1007/BF01233858; COOPER GE, 1991, SOMAT CELL MOLEC GEN, V17, P105, DOI 10.1007/BF01232969; DICKERMAN LH, 1978, MUTAT RES, V49, P83, DOI 10.1016/0027-5107(78)90080-5; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Freyer GA, 1996, MUTAT RES-FUND MOL M, V357, P237, DOI 10.1016/0027-5107(96)00130-3; Gatei M, 2001, ONCOGENE, V20, P289, DOI 10.1038/sj.onc.1204111; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HEIM RA, 1992, MUTAT RES, V284, P25, DOI 10.1016/0027-5107(92)90022-T; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HORN PL, 1984, J CELL PHYSIOL, V121, P309, DOI 10.1002/jcp.1041210207; Khattar NH, 1997, SOMAT CELL MOLEC GEN, V23, P51, DOI 10.1007/BF02679955; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Pandita TK, 1996, RADIAT RES, V145, P730, DOI 10.2307/3579364; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; REZNIKOFF CA, 1973, CANCER RES, V33, P3239; ROSCHEISEN C, 1994, SOMAT CELL MOLEC GEN, V20, P493, DOI 10.1007/BF02255840; Rose JA, 2000, CANCER RES, V60, P3404; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Stambrook PJ, 1996, ENVIRON MOL MUTAGEN, V28, P471; TURKER M, 1995, MUTAT RES-FUND MOL M, V329, P97, DOI 10.1016/0027-5107(95)00046-L; Turker MS, 1999, CANCER RES, V59, P1837; Turker MS, 1999, CANCER RES, V59, P4781; Walker KA, 1997, SOMAT CELL MOLEC GEN, V23, P111, DOI 10.1007/BF02679970; Westphal CH, 1998, CANCER RES, V58, P5637; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411	34	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4291	4297		10.1038/sj.onc.1204509	http://dx.doi.org/10.1038/sj.onc.1204509			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466609				2022-12-17	WOS:000169912600002
J	Feng, L; Lee, KAW				Feng, L; Lee, KAW			A repetitive element containing a critical tyrosine residue is required for transcriptional activation by the EWS/ATF1 oncogene	ONCOGENE			English	Article						EWS/ATF1 oncogene; transcription; activation domain; tyrosine	TUMOR-SUPPRESSOR GENE; EWS/FLI-1 FUSION GENE; RNA-POLYMERASE-II; EWINGS-SARCOMA; CHROMOSOME-TRANSLOCATION; MALIGNANT-MELANOMA; CHIMERIC PROTEIN; BINDING DOMAIN; SOFT PARTS; EWS	Chromosomal fusion of the N-terminal region of the Ewings Sarcoma Oncogene (EWS-activation-domain, EAD) to the DNA-binding domains of a variety of cellular transcription factors produce oncogenic proteins (EWS-fusion proteins (EFPs)) that cause distinct malignancies. In EFPs, the EAD acts as a potent transcriptional activation domain and this ability is repressed in the context of normal, non-tumorigenic, EWS, Trans-activation by the EAD is therefore a specific characteristic of EFPs and it is thought that EFPs induce tumorigenesis via improper transcriptional activation of cellular genes. Functional elements required for transcriptional activation are dispersed throughout the EAD, as are thirty-one copies of a Degenerate Hexapeptide Repeat (DHR, consensus SYCQQS), This suggests that the EAD contains a highly reiterated functional element related to DHRs. Here we show that in the context of EWS/ATF1, the EFP that causes malignant melanoma of soft parts, trans-cooperation by small regions of the EAD (similar to 30 residues) results in potent transcriptional activation dependent on the conserved tyrosine residues present in DHRs, These findings provide the first evidence for a role of DHRs in EAD-mediated trans-activation and demonstrate that the EAD represents a novel tyrosine-dependent transcriptional activation domain.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Lee, KAW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.	bokaw@usthk.ust.hk						Benuck ML, 1999, J BIOL CHEM, V274, P25419, DOI 10.1074/jbc.274.36.25419; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BROWN AD, 1995, ONCOGENE, V10, P1749; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; Fujimura Y, 1996, ONCOGENE, V12, P159; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Kim J, 1999, P NATL ACAD SCI USA, V96, P14300, DOI 10.1073/pnas.96.25.14300; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; KIM TK, 1994, NUCLEIC ACIDS RES, V22, P251, DOI 10.1093/nar/22.2.251; Kovar Heinrich, 1999, Current Opinion in Oncology, V11, P275, DOI 10.1097/00001622-199907000-00007; KRAJEWSKI W, 1994, MOL CELL BIOL, V14, P7204, DOI 10.1128/MCB.14.11.7204; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Nyanguile O, 1997, P NATL ACAD SCI USA, V94, P13402, DOI 10.1073/pnas.94.25.13402; OHNO T, 1993, CANCER RES, V53, P5859; Pan S, 1998, ONCOGENE, V16, P1625, DOI 10.1038/sj.onc.1201671; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Pollock R, 1997, P NATL ACAD SCI USA, V94, P13388, DOI 10.1073/pnas.94.25.13388; PRASAD DDK, 1994, ONCOGENE, V9, P3717; Rauscher FJ, 1997, CURR TOP MICROBIOL, V220, P151; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RIBEIRO A, 1994, J BIOL CHEM, V269, P31124; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; Zhou HQ, 2001, ONCOGENE, V20, P1519, DOI 10.1038/sj.onc.1204135; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	45	19	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4161	4168		10.1038/sj.onc.1204522	http://dx.doi.org/10.1038/sj.onc.1204522			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464282				2022-12-17	WOS:000169857200006
J	Ma, XR; Karra, S; Lindner, DJ; Hu, JB; Reddy, SPM; Kimchi, A; Yodoi, J; Kalvakolanu, DD				Ma, XR; Karra, S; Lindner, DJ; Hu, JB; Reddy, SPM; Kimchi, A; Yodoi, J; Kalvakolanu, DD			Thioredoxin participates in a cell death pathway induced by interferon and retinoid combination	ONCOGENE			English	Article						cytokines; vitamin-A; apoptosis; redox control; tumor growth	ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT PROTEIN-KINASE; MOLECULAR-CLONING; INDUCED APOPTOSIS; REDOX REGULATION; MAMMALIAN THIOREDOXIN; MEDIATED APOPTOSIS; CYTOCHROME-C; CYCLE ARREST; VITAMIN-A	Interferons (IFNs) and retinoids are potent tumor growth suppressors, We have shown earlier that the IFN-P and all-trans retinoic acid combination, but not the single agents, induces death in several tumor cell lines. Employing a genetic approach we have recently identified several Genes associated with Retinoid-IFN induced Mortality (GRIM) that mediate the cell death effect of IFN/RA combination. One of the GRIMs, GRIM-12, was identical to human thioredoxin reductase (TR), an enzyme that controls intracellular redox state. To define the participants of TR mediated death pathway we have examined the role of thioredoxin (Trx), its downstream substrate, and its influence on IFN/RA-induced death regulation. Inhibition of the thioredoxin expression by antisense RNA suppressed cell death. Similarly, a mutant Trx1 lacking the critical cysteine residues blocked cell death. In contrast, overexpression of wildtype thioredoxin augmented cell death. This effect of Trx1 was in part due to its ability to augment cell death via caspase-8, The redox inactive Trx1 mutant inhibits the cell death induced by caspase-8 but not caspase-3, These studies identify a novel mechanism of cell death regulation by IFN/RA combination involving redox enzymes.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Mol & Cellular Biol Program,Greenebaun Canc Ctr, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Sci, Baltimore, MD 21218 USA; Weizmann Inst Sci, Dept Mol Genet & Virol, IL-76100 Rehovot, Israel; Inst Virus Res, Dept Biol Responses, Shogin, Japan	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Weizmann Institute of Science	Kalvakolanu, DD (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Mol & Cellular Biol Program,Greenebaun Canc Ctr, Baltimore, MD 21201 USA.		Lindner, Daniel/ABB-5440-2020		NCI NIH HHS [CA 71401, CA 78282] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071401, R01CA078282] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cao L, 2000, J CELL BIOCHEM, V77, P569, DOI 10.1002/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; Gallegos A, 1996, CANCER RES, V56, P5765; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; PellicenaPalle A, 1997, MECH DEVELOP, V62, P61, DOI 10.1016/S0925-4773(96)00650-8; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBARTELLI A, 1995, CANCER RES, V55, P675; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SALZ HK, 1994, GENETICS, V136, P1075; Sen CK, 1999, CELL DEATH DIFFER, V6, P481, DOI 10.1038/sj.cdd.4400514; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun SY, 2000, CLIN CANCER RES, V6, P1563; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Ueda S, 1998, J IMMUNOL, V161, P6689; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang ZG, 1998, SCIENCE, V279, P1547; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xiao WH, 1997, J BIOL CHEM, V272, P9742, DOI 10.1074/jbc.272.15.9742; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	84	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3703	3715		10.1038/sj.onc.1204477	http://dx.doi.org/10.1038/sj.onc.1204477			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439333				2022-12-17	WOS:000169400200011
J	Goetz, F; Tzeng, YJ; Guhl, E; Merker, J; Graessmann, M; Graessmann, A				Goetz, F; Tzeng, YJ; Guhl, E; Merker, J; Graessmann, M; Graessmann, A			The SV40 small t-antigen prevents mammary gland differentiation and induces breast cancer formation in transgenic mice; truncated large T-antigen molecules harboring the intact p53 and pRb binding region do not have this effect	ONCOGENE			English	Article						SV40 small t-antigen; transgenic animals; cyclin D1; mammary gland differentiation; breast cancer	PROTEIN PHOSPHATASE 2A; CELL-GROWTH; TRANSFORMATION; P21(WAF1/CIP1); INVOLUTION; APOPTOSIS; CARCINOMA; MUTATION; ANIMALS	We report here for the first time, that the SV40 small t-antigen inhibits mammary gland differentiation during mid-pregnancy and that about. 10% of multiparous WAP-SVt transgenic animals develop breast tumors with latencies ranging from 10-17 months, Cyclin D1 is deregulated and over expressed in the small t-antigen positive mammary gland epithelial cells (ME-cells) and in the breast tumor cells, SV40 small t-antigen immortalized ME-cells (t-ME-cells) exhibit a strong intranuclear cyclin D1 staining, also in the absence of external growth factors and the cells continue to divide for several days without serum. In addition, the expression rate of cyclin E acid p21(Waf1) but not of p53 is increased, Coimmunoprecipitation experiments revealed that p21(Waf1) is mainly associated with the cyclin D/CDK4 but not with the cyclin E/CDK2 complex, WAP-SVT transgenic animals exhibit an almost regular mammary gland development until late pregnancy but the majority of the ME-cells are eliminated by apoptosis during the early lactation period. Tumor formation is delayed and less efficient than in T/t-antigen positive animals, Sequestration of p53 and pRb by the N-terminal truncated T-antigen molecules (T1-antigen and T2-antigen) does not affect mammary gland differentiation and the transgenic animals (WAP-SVBst-Bam) do not develop breast tumors.	Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany; Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien 970, Taiwan; Free Univ Berlin, Inst Anat, D-14195 Berlin, Germany	Free University of Berlin; Tzu Chi University; Free University of Berlin	Graessmann, A (corresponding author), Free Univ Berlin, Inst Mol Biol & Biochem, Arnimallee 22, D-14195 Berlin, Germany.							CICALA C, 1994, J VIROL, V68, P3138, DOI 10.1128/JVI.68.5.3138-3144.1994; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Garcia A, 2000, J BIOL CHEM, V275, P9385, DOI 10.1074/jbc.275.13.9385; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kohlhoff S, 2000, FREE RADICAL BIO MED, V29, P497, DOI 10.1016/S0891-5849(00)00340-3; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; MARTIN RG, 1979, J VIROL, V31, P596, DOI 10.1128/JVI.31.3.596-607.1979; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MUMBY MC, 1991, CELL REGUL, V2, P589, DOI 10.1091/mbc.2.8.589; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; Santarelli R, 1996, ONCOGENE, V12, P495; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; SENKITI S, 1979, BIOCHIM BIOPHYS ACTA, V582, P79; Siegel PM, 2000, BIOESSAYS, V22, P554, DOI 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Tzeng YJ, 1996, FEBS LETT, V380, P215, DOI 10.1016/0014-5793(96)00021-X; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wakasugi E, 1997, AM J CLIN PATHOL, V107, P684; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0	26	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2325	2332		10.1038/sj.onc.1204355	http://dx.doi.org/10.1038/sj.onc.1204355			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402328				2022-12-17	WOS:000168404500015
J	Zhou, HQ; Lee, KAW				Zhou, HQ; Lee, KAW			An hsRPB4/7-dependent yeast assay for trans-activation by the EWS oncogene	ONCOGENE			English	Article						EWS oncogene; transcriptional activation; yeast; RPB4; RPB7	RNA-POLYMERASE-II; 2 DISSOCIABLE SUBUNITS; TUMOR-SUPPRESSOR GENE; TRANSCRIPTIONAL ACTIVATION; EWINGS-SARCOMA; CHROMOSOME-TRANSLOCATION; CHIMERIC PROTEIN; STRESS SURVIVAL; CELL VIABILITY; FUSION	Chromosomal fusions of the N-terminal region of the Ewings Sarcoma Oncogene (EWS-Activation-Domain, EAD) to the DNA-binding domains of a variety of cellular transcription factors, produce oncogenic proteins (EWS-fusion proteins (EFPs)) that cause a variety of malignancies. The EAD can act as a potent transcriptional activation domain and is required for the oncogenic activity of EFPs. Previous studies demonstrating a physical interaction between the EAD and the human RNA Polymerase II subunit hsRPB7 suggest a crucial role for RPB7 and its partner, RPB4, in EAD function. Homologues of hsRPB4/7 exist in S. cerevisiae, and here we describe an RPB4/7-dependent yeast assay for EAD-mediated trans-activation. Conditional yeast strains lacking RPB4 are defective for transactivation by a Gal4/EAD fusion protein at the permissive temperature. Introduction of hsRPB4 alone is unable to rescue trans-activation, while a combination of hsRPB4 and hsRPB7 significantly rescues activity. These findings provide the first functional evidence for a direct role of the RPB4/7 complex in EAD-mediated trans-activation. In addition, the yeast assay provides a tractable system for further molecular analysis of EAD and RPB4/7 action.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Lee, KAW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.		Zhou, Huiqing/B-1721-2013	Zhou, Huiqing/0000-0002-2434-3986				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BROWN AD, 1995, ONCOGENE, V10, P1749; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Fujimura Y, 1996, ONCOGENE, V12, P159; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; Khazak V, 1998, MOL CELL BIOL, V18, P1935, DOI 10.1128/MCB.18.4.1935; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Kovar Heinrich, 1999, Current Opinion in Oncology, V11, P275, DOI 10.1097/00001622-199907000-00007; Larkin RM, 1998, J BIOL CHEM, V273, P5631, DOI 10.1074/jbc.273.10.5631; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; OHNO T, 1993, CANCER RES, V53, P5859; Pan S, 1998, ONCOGENE, V16, P1625, DOI 10.1038/sj.onc.1201671; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PRASAD DDK, 1994, ONCOGENE, V9, P3717; Rauscher FJ, 1997, CURR TOP MICROBIOL, V220, P151; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; Sakurai H, 1999, MOL CELL BIOL, V19, P7511; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; Schaller S, 1999, FEBS LETT, V461, P253, DOI 10.1016/S0014-5793(99)01441-6; Shen XQ, 1999, ENDOCRINE, V10, P281, DOI 10.1007/BF02738627; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	29	19	20	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1519	1524		10.1038/sj.onc.1204135	http://dx.doi.org/10.1038/sj.onc.1204135			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313895				2022-12-17	WOS:000167595200012
J	Mukherjee, S; Louie, SG; Campbell, M; Esserman, L; Shyamala, G				Mukherjee, S; Louie, SG; Campbell, M; Esserman, L; Shyamala, G			Ductal growth is impeded in mammary glands of C-neu transgenic mice	ONCOGENE			English	Article						estrogen; estrogen receptor; C-neu; mammary gland; ductal growth	HUMAN-BREAST-CANCER; PROGESTERONE RECEPTORS; ESTROGEN-RECEPTOR; ERBB RECEPTORS; A-FORM; EXPRESSION; MORPHOGENESIS; PROTOONCOGENE; ABNORMALITIES; SUPERFAMILY	The steroid hormone, estradiol, is essential for both the growth of normal breast and induction of mammary carcinomas, The growth promoting effects of estrogen are presumed to be mediated by growth factors, in particular, epidermal growth factor, which mediates its effects through erbB receptors, erbB1 and erbB2/C-neu. C-neu is amplified and over-expressed in a large number of human cancers and transgenic mice over-expressing C-neu also develop mammary tumors, However, as set, the impact of C-neu over-expression on estrogen action during normal mammary development and hence, its precise role in carcinogenesis, remains unclear, In the present studies, we demonstrate that estradiol-dependent mammary ductal growth accompanying puberty is impaired in transgenic mice expressing wild type C-neu, and is intrinsic to the tissue. The impairment is not due to an overall impairment in estrogen action, since progesterone receptor expression is unaffected in C-neu mice. It is also not due to an intrinsic inability of the epithelial cells to proliferate, since impeded ductal growth co-exists,vith alveolar growth during pregnancy. Therefore, we propose that, depending on the physiological state, C-neu may either promote or inhibit the growth of mammary epithelial cells, and discuss its potential significance to carcinogenesis.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Francisco	Shyamala, G (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,Bldg 74, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R01CA066541] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66541] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIOTTI S, 1992, EUR J CANCER, V28A, P318, DOI 10.1016/S0959-8049(05)80045-0; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; BRESCIANI FRANCESCO, 1968, CELL TISSUE KINET, V1, P51, DOI 10.1111/j.1365-2184.1968.tb00193.x; COLEMAN S, 1990, DEV BIOL, V137, P425, DOI 10.1016/0012-1606(90)90267-M; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DeckardJanatpour K, 1997, INT J ONCOL, V11, P235; DEOME KB, 1959, CANCER RES, V78, P515; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HASLAM SZ, 1988, ENDOCRINOLOGY, V122, P464, DOI 10.1210/endo-122-2-464; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Raafat AM, 1999, ENDOCRINOLOGY, V140, P2570, DOI 10.1210/en.140.6.2570; READ LD, 1990, CANCER RES, V50, P3947; RUSSELL KS, 1992, CANCER RES, V52, P6624; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; Shyamala G, 1997, J STEROID BIOCHEM, V63, P251, DOI 10.1016/S0960-0760(97)00128-3; SHYAMALA G, 1992, RECEPTOR, V2, P121; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; Shyamala G., 1980, Perspectives in steroid receptor research, P193; SHYAMALA G, 1987, ENDOCRINOLOGY, P127; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SILBERSTEIN GB, 1994, ENDOCRINOLOGY, V134, P84, DOI 10.1210/en.134.1.84; Silberstein GB, 1996, CELL GROWTH DIFFER, V7, P945; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244	36	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5982	5987		10.1038/sj.onc.1203964	http://dx.doi.org/10.1038/sj.onc.1203964			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146549				2022-12-17	WOS:000165827900004
J	Bogliolo, M; Taylor, RM; Caldecott, KW; Frosina, G				Bogliolo, M; Taylor, RM; Caldecott, KW; Frosina, G			Reduced ligation during DNA base excision repair supported by BRCA2 mutant cells	ONCOGENE			English	Article						DNA base excision repair; BRCA2; DNA ligation; abasic sites; uracil	BREAST-CANCER SUSCEPTIBILITY; LIGASE-III; POLYMERASE-BETA; IN-VITRO; PANCREATIC CARCINOMAS; MAMMALIAN-CELLS; RADIATION; MUTATIONS; COMPLEX; XRCC1	The brest cancer predisposing genes BRCA1 and BRCA2 appear to be involved in DNA repair. In particular, the sensitivity of BRCA2-deficient mouse embryonic fibroblasts to ionizing radiation and the demonstrated interaction of the BRCA2 protein with Rad51, a major factor in recombinational repair, indicate that BRCA2 is important for double strand break repair. The human BRCA2-deficient human cell line Capan-1, whilst being sensitive to ionizing radiation, is also sensitive to the alkylating agent methymethanesulfonate, The major lesions induced by this agent are methylated bases which are removed primarily by the base excision repair (BER) pathway. We have investigated the efficiency of BER in Capan-1 cells by an in vitro assay in which plasmid substrates containing a single lesion are repaired by mammalian cell extracts. In comparison to the control cell lines BxPC-3, T24 and MCF7, Capan-1 cells exhibited a reduced rate of DNA ligation during both the single-nucleotide insertion and PCNA-dependent pathways of BER, The reduced rate of DNA ligation exhibited by Capan-1 cell extracts was complemented by addition of bacteriophage T4 DNA ligase or human DNA ligase III, BXCA2-mutant Capan-1 cells may possess reduced DNA ligase activity during BER.	Ist Nazl Ric Canc, DNA Repair Unit, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Manchester, Sch Biol Sci, AstraZeneca Lab Cell & Mol Biol, Manchester M13 9PT, Lancs, England	University of Genoa; IRCCS AOU San Martino IST; AstraZeneca; University of Manchester	Frosina, G (corresponding author), Ist Nazl Ric Canc, DNA Repair Unit, Mutagenesis Lab, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.		Bogliolo, Massimo/J-1631-2019; Caldecott, Keith/S-4245-2019; Frosina, Guido/Z-2382-2019	Frosina, Guido/0000-0002-6717-5097; Bogliolo, Massimo/0000-0001-8240-7784; Caldecott, Keith/0000-0003-4255-9016	Telethon [E.0728] Funding Source: Medline	Telethon(Fondazione Telethon)		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; Cappelli E, 2000, CARCINOGENESIS, V21, P1135, DOI 10.1093/carcin/21.6.1135; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Frosina G, 1999, METH MOL B, V113, P301; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Goggins M, 1996, CANCER RES, V56, P5360; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Livingston DM, 1997, JAMA-J AM MED ASSOC, V277, P1476; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Morimatsu M, 1998, CANCER RES, V58, P3441; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; REDSTON MS, 1994, CANCER RES, V54, P3025; Schutte M, 1997, CANCER RES, V57, P3126; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Su LK, 1998, ONCOGENE, V17, P2377, DOI 10.1038/sj.onc.1202162; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Yuan SSF, 1999, CANCER RES, V59, P3547	32	19	19	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5781	5787		10.1038/sj.onc.1203951	http://dx.doi.org/10.1038/sj.onc.1203951			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126365				2022-12-17	WOS:000165477700010
J	Adnane, J; Bizouarn, FA; Chen, Z; Ohkanda, J; Hamilton, AD; Munoz-Antonia, T; Sebti, SM				Adnane, J; Bizouarn, FA; Chen, Z; Ohkanda, J; Hamilton, AD; Munoz-Antonia, T; Sebti, SM			Inhibition of farnesyltransferase increases TGF beta type II receptor expression and enhances the responsiveness of human cancer cells to TGF beta	ONCOGENE			English	Article						farnesyltransferase inhibitors; Ras; transforming growth factor beta; tumor growth and transformation	GROWTH-FACTOR-BETA; TRANSFORMED THYROID-CELLS; FAMILY MEDIATOR SMAD1; GTP-BINDING PROTEIN; K-RAS; SIGNALING PATHWAYS; TRANSGENIC MICE; H-RAS; N-RAS; EPITHELIAL-CELLS	Several small GTPases of the Ras superfamily have been shown to antagonize TGF beta signaling in human tumor cell lines. Some of these GTPases are post-translationally modified by farnesylation, a lipid modification catalyzed by farnesyltransferase and required for the proteins to attach to membranes and to function. In this study, we investigated the effect of the farnesyltransferase inhibitor FTI-277 on TGF beta -regulated cell growth and transcription. Treatment of the human pancreatic tumor cell line, Panc-1, with FTI-277 enhanced the ability of TGF beta to inhibit both anchorage-dependent and -independent tumor cell growth. FTI-277 also enhanced the ability of TGF beta to induce transcription, as measured by p3TP-lux reporter activity and collagen synthesis. The enhancement of TGF beta responses by FTI-277 correlated with the stimulation of transcription and protein expression of type II TGF beta receptor (T beta RII). Consequently, FTI-277-treated cells exhibited a higher level of TGF beta binding to its receptor. Thus, inhibition of protein farnesylation stimulates T beta RII expression, which leads to increased TGF beta receptor binding and signaling as well as inhibition of tumor cell growth and transformation.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Ohkanda, Junko/I-6102-2019	Ohkanda, Junko/0000-0001-9663-5104	NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; CARMICHAEL J, 1987, CANCER RES, V47, P936; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; Choi SE, 1999, CELL SIGNAL, V11, P71, DOI 10.1016/S0898-6568(98)00033-3; Coppa A, 1997, J CELL PHYSIOL, V172, P200, DOI 10.1002/(SICI)1097-4652(199708)172:2<200::AID-JCP7>3.0.CO;2-S; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; FILMUS J, 1992, ONCOGENE, V7, P521; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; HOWE PH, 1993, J BIOL CHEM, V268, P21448; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jennings MT, 1998, J NEURO-ONCOL, V36, P123, DOI 10.1023/A:1005863419880; Kim YS, 1999, ARCH PHARM RES, V22, P1, DOI 10.1007/BF02976427; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kohl NE, 1999, ANN NY ACAD SCI, V886, P91, DOI 10.1111/j.1749-6632.1999.tb09404.x; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lobell RB, 1998, CANCER METAST REV, V17, P203, DOI 10.1023/A:1006018922878; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Mangues R, 1998, CANCER RES, V58, P1253; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; MunozAntonia T, 1996, CANCER RES, V56, P4831; Norgaard P, 1999, ANN NY ACAD SCI, V886, P265, DOI 10.1111/j.1749-6632.1999.tb09432.x; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Omer CA, 2000, CANCER RES, V60, P2680; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SERRA R, 1992, CELL GROWTH DIFFER, V3, P693; SIPES NJ, 1990, MOL CARCINOGEN, V3, P12, DOI 10.1002/mc.2940030106; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; SPORN MB, 1990, ANN NY ACAD SCI, V593, P1, DOI 10.1111/j.1749-6632.1990.tb16095.x; SUN JZ, 1995, CANCER RES, V55, P4243; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Turco A, 1999, INT J CANCER, V80, P85, DOI 10.1002/(SICI)1097-0215(19990105)80:1<85::AID-IJC17>3.0.CO;2-P; Ventura F, 1996, J BIOL CHEM, V271, P13931, DOI 10.1074/jbc.271.24.13931; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZHAO J, 1995, CANCER RES, V55, P6181; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	70	19	24	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5525	5533		10.1038/sj.onc.1203920	http://dx.doi.org/10.1038/sj.onc.1203920			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114730				2022-12-17	WOS:000165396100013
J	Hirst, SK; Grandori, C				Hirst, SK; Grandori, C			Differential activity of conditional MYC and its variant MYC-S in human mortal fibroblasts	ONCOGENE			English	Article						Myc-ER; Myc-S; WI38; human fibroblasts; cell-cycle; apoptosis; Myc target genes	C-MYC; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; TARGET GENES; CELL-GROWTH; IN-VIVO; MAX; APOPTOSIS; PROTEINS; TRANSFORMATION	We have explored the effects of the conditional MYC-estrogen receptor fusion protein, MYC-ERT(TM), in human mortal fibroblasts, WI38, on cell-cycle entry, apoptosis and gene expression, The results indicate that activation of MYC-ER(TM) in WI38 cells is sufficient to cause S phase entry of quiescent cells, which is preceded by phosphorylation of Rb and activation of the Cdk2-associated kinase, We also analysed the MYC protein variant, MYC-S, which lacks part of the transcriptional activation domain but includes the conserved MYC box II and 26 amino acids N-terminal to it, MYC-S was previously shown to promote proliferation and apoptosis of immortalized rodent cell lines, The results indicate that MYC-S has undetectable activity as an inducer of S phase or apoptosis of quiescent WI38 cells. However, Myc-S stimulates proliferation of WI38 cells in the presence of 10% fetal calf serum, Surprisingly, we found that MYC-S, previously considered solely a repressor of specific reporter genes, is instead a weak transactivator of endogenous target genes both in mortal and immortalized cells. In addition, MYC-S exhibit a weak repressor activity upon an endogenous target gene only in immortalized cells, MYC-S transcriptional properties suggest that MYC box II and the adjacent N-terminal amino acids, while not sufficient for full repression function, participate in transactivation of endogenous target genes.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Grandori, C (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.				NCI NIH HHS [CA75125, CA20525] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA020525, R01CA020525, R29CA075125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; Dang CV, 1999, MOL CELL BIOL, V19, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Eilers M, 1999, MOL CELLS, V9, P1; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hurlin PJ, 1996, EMBO J, V15, P2030, DOI 10.1002/j.1460-2075.1996.tb00555.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; QUELLE DE, 1995, ONCOGENE, V11, P635; RABINOVITCH PS, 1994, METHOD CELL BIOL, V41, P263; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	19	19	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5189	5197		10.1038/sj.onc.1203904	http://dx.doi.org/10.1038/sj.onc.1203904			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064456				2022-12-17	WOS:000090124100008
J	Santoro, MM; Penengo, L; Orecchia, S; Cilli, M; Gaudino, G				Santoro, MM; Penengo, L; Orecchia, S; Cilli, M; Gaudino, G			The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site	ONCOGENE			English	Article						Ron; substrate specificity; tumorigenesis; tyrosine phosphorylation	MACROPHAGE-STIMULATING PROTEIN; KINASE CATALYTIC DOMAIN; INVASIVE GROWTH; RECEPTOR FAMILY; MUTATIONS; ACTIVATION; TRANSFORMATION; GENE; IDENTIFICATION; PROTOONCOGENE	Oncogenic activation of the Ron tyrosine kinase (Macrophage Stimulating Protein receptor) relies on substitutions of two highly conserved residues in the catalytic domain (D1232V and M1254T), which result in ligand-independent activation of the receptor, in vivo tumorigenesis and metastasis. We show here that the Y/F conversion of the Y-1317 residue in the kinase domain impairs tumorigenic and metastatic properties of Ron activated by the MEN2B-like mutation (Ron(M1254T)), but not by other two oncogenic substitutions, Furthermore, Ron(M1254T) lacking the multifunctional docking site retains transforming and metastatic activity, These data reveal that the transforming activity of Ron(M1254T) mutant is dependent on Y-1317 phosphorylation, suggesting a shift in intramolecular substrate specificity. Consistently, a shift of Ron(M1254T) kinase substrate specificity was observed by in vitro peptide phosphorylation assays and in vitro receptor autophosphorylation, The Y-1317 phosphorylation elicits by itself activation of PI-3K/Akt and MAPK signalling pathways, Our data indicate that the accomplishment of the full oncogenic phenotype of Ron(M1254T) requires the phosphorylation both of the canonical C-terminal docking site and of the unique Y-1317 residue in the tyrosine kinase domain.	Dibit HSR, I-20138 Milan, Italy; Univ Piemonte Orientale Amedeo Avogadro, Dept Med Sci, I-28100 Novara, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Genoa; IRCCS AOU San Martino IST	Gaudino, G (corresponding author), Dibit HSR, Via Olgettina 58, I-20138 Milan, Italy.		Cilli, Michele/AAB-8529-2019	PENENGO, Lorenza/0000-0001-7888-4473; Cilli, Michele/0000-0003-4083-8986; SANTORO, Massimo Mattia/0000-0003-4605-5085				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jeffers M, 1999, ONCOGENE, V18, P5120, DOI 10.1038/sj.onc.1202902; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Petti LM, 1998, ONCOGENE, V16, P843, DOI 10.1038/sj.onc.1201590; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STENBERG MJE, 1989, NATURE, V339, P587; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	25	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5208	5211		10.1038/sj.onc.1203819	http://dx.doi.org/10.1038/sj.onc.1203819			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064459	Green Published			2022-12-17	WOS:000090124100011
J	Varma, H; Conrad, SE				Varma, H; Conrad, SE			Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain	ONCOGENE			English	Article						antiestrogen; breast cancer; cell cycle; pRb; T antigen	LARGE T-ANTIGEN; HUMAN-BREAST-CANCER; SV40 LARGE-T; CARCINOMA-CELLS; SV40-TRANSFORMED CELLS; TRANSCRIPTION FACTOR; SUSCEPTIBILITY GENE; ESTROGEN-RECEPTOR; E-CDK2 ACTIVATION; QUIESCENT CELLS	Proliferation of MCF-7 cells is estrogen dependent and antiestrogen sensitive. In the absence of estrogens or presence of antiestrogens MCF-7 cells arrest in the G(1) phase of the cell cycle, and this arrest is associated with an accumulation of the active, hypophosphorylated form of the retinoblastoma protein (pRb), Because active pRb negatively regulates passage from G(1) to S phase, this suggests that pRb is a crucial target of estrogen action, and that its inactivation might lead to antiestrogen resistance. We tested this hypothesis by expressing viral tumor antigens (T antigens), which bind and inactivate pRb, in MCF-7 cells, and determining the effects on cell proliferation in the presence of antiestrogens. The results of these experiments demonstrate that T antigen expression confers antiestrogen resistance to MCF-7 cells, Using a panel of mutant T antigens, we further demonstrate that the pRb-binding, but not the p53 binding domain is required to confer antiestrogen resistance. Thus, pRb is an important target of estrogen action, and its inactivation can contribute to the development of antiestrogen resistance.	Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Grad Program, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Conrad, SE (corresponding author), Michigan State Univ, Dept Microbiol, Giltner Hall, E Lansing, MI 48824 USA.				NCI NIH HHS [CA76647] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076647] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson JJ, 1996, J PATHOL, V180, P65, DOI 10.1002/(SICI)1096-9896(199609)180:1<65::AID-PATH607>3.0.CO;2-C; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; BRUNNER N, 1993, CANCER RES, V53, P3229; Brunner N, 1997, CANCER RES, V57, P3486; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; Cole Charles N., 1996, P917; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Gao QS, 1996, CANCER RES, V56, P3129; GLUZMAN Y, 1979, COLD SPRING HARB SYM, V44, P293; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Howes SH, 1996, J VIROL, V70, P3581, DOI 10.1128/JVI.70.6.3581-3588.1996; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Johnston SD, 1996, J VIROL, V70, P1191, DOI 10.1128/JVI.70.2.1191-1202.1996; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KATO J, 1993, GENE DEV, V7, P331; KELLER JM, 1984, CELL, V36, P381, DOI 10.1016/0092-8674(84)90231-9; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAROSE A, 1990, VIROLOGY, V176, P98, DOI 10.1016/0042-6822(90)90234-I; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIPPMAN M, 1976, CANCER RES, V36, P4595; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MELORA DB, 1998, PRINCIPLES MOL MED; Nemethova M, 1999, J VIROL, V73, P1734, DOI 10.1128/JVI.73.2.1734-1739.1999; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; OSBORNE CK, 1985, CANCER RES, V45, P584; Pacilio C, 1998, CANCER RES, V58, P871; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1980, CANCER LETT, V10, P177, DOI 10.1016/0304-3835(80)90042-7; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P615, DOI 10.1016/0277-5379(83)90177-3; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P307, DOI 10.1016/0277-5379(83)90127-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WAKELING AE, 1991, CANCER RES, V51, P3867; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	56	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4746	4753		10.1038/sj.onc.1203827	http://dx.doi.org/10.1038/sj.onc.1203827			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032025				2022-12-17	WOS:000089528800009
J	Milner, J; Fuks, F; Hughes-Davies, L; Kouzarides, T				Milner, J; Fuks, F; Hughes-Davies, L; Kouzarides, T			The BRCA2 activation domain associates with and is phosphorylated by a cellular protein kinase	ONCOGENE			English	Article						BRCA2; protein kinase; phosphorylation	GENE; RAD51; ACETYLTRANSFERASE; IDENTIFICATION; INTERACT; MOUSE; BINDS; JNK	A substantial proportion of familiar breast cancers have mutations within the BRCA2 gene. The product of this gene has been implicated in DNA repair and in the regulation of transcription. We have previously identified at the amino-terminus of BRCA2 a transcriptional activation domain whose importance is highlighted by the presence of predisposing mutations and in-frame deletions in breast cancer families. This activation domain shows sequence similarity to a region of c-Jun which has been defined as a binding site for the c-Jun N-terminal kinase, Here, we show that the analogous region in BRCA2 is also a binding site for a cellular kinase, although this kinase is distinct from JNK, The BRCA2 associated enzyme Is able to phosphorylate residues within the BRCA2 activation domain. Consistent with this observation, we find that the activation domain of BRCA2 is phosphorylated in vivo. Our results indicate that the BRCA2 activation domain possesses a binding site for a kinase that may regulate BRCA2 activity by phosphorylation.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England; Addenbrookes Hosp, CRC, Human Canc Genet Res Grp, Cambridge, England	University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Kouzarides, Tony/0000-0002-8918-4162				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; May GHW, 1999, GENE CHROMOSOME CANC, V25, P407, DOI 10.1002/(SICI)1098-2264(199908)25:4<407::AID-GCC16>3.0.CO;2-I; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Nordling M, 1998, CANCER RES, V58, P1372; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	19	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4441	4445		10.1038/sj.onc.1203793	http://dx.doi.org/10.1038/sj.onc.1203793			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980621				2022-12-17	WOS:000089271900016
J	Nieborowska-Skorska, M; Slupianek, A; Skorski, T				Nieborowska-Skorska, M; Slupianek, A; Skorski, T			Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells	ONCOGENE			English	Article						BCR/ABL; signaling; Akt; STAT5	CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; DNA-BINDING ACTIVITY; HEMATOPOIETIC-CELLS; TYROSINE KINASE; ANTISENSE OLIGODEOXYNUCLEOTIDES; PHILADELPHIA-CHROMOSOME; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED TRANSFORMATION; CONSTITUTIVE ACTIVATION	Our previous study indicated that BCR/ABL SH2 domain and BCR/ABL SH3 domain+SH2 domain complex are required for immediate activation of the phosphatidylinositol-3 kinase PI-3k) --> Akt serine/threonine kinase pathway and of the signal transducer and activator of transcription 5 (STAT5), respectively, in hematopoietic cells. We show here that the defect in activation of PI-3k/Akt by BCR/ABL Delta SH2 mutant (SH2 domain deleted) and of STAT5 by BCR/ABL Delta SH3 + Delta SH2 mutant (SH3 and SH2 domains deleted) is not permanent and both Akt and STAT5 could be 'reactivated' by in vitro culture. This phenomenon was responsible for increased resistance to apoptosis, growth factor-independent proliferation and leukemogenesis in SCID mice. Incubation of cells with BCR/ABL tyrosine kinase inhibitor STI571 abrogated the 're-activation' of Akt or STAT5 by BCR/ABL SH3+SH2 mutants in some clones, in the others Akt and STAT5 activation became independent on BCR/ABL kinase activity. The immediate upstream activators of Akt and STAT5 such as PI-3k and Jak-2 were also activated. In addition, the common beta subunit of IL-3/IL-5/GM-CSF receptor was tyrosine phosphorylated in the clones in which 'reactivation' was dependent on the BCR/ABL kinase activity, These results suggested that 're-activation' of Akt and STAT5, in the absence of functional BCR/ABL SH3+SH2 domains, may be achieved by two different mechanisms: (i) BCR/ABL kinase-dependent activation of alternative pathway(s) and (ii) additional genetic changes stimulating Akt and STAT5 independently of BCR/ABL.	Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Poznan Tech Univ, Dept Canc Immunol, Sch Med Sci, Great Poland Canc Ctr, PL-60965 Poznan, Poland	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Poznan University of Technology; Wielkopolskie Centrum Onkologii	Skorski, T (corresponding author), Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA.							AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Anderson SM, 1996, BLOOD, V87, P238; BEDI A, 1994, BLOOD, V83, P2038; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Frank DA, 1996, LEUKEMIA, V10, P1724; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Majewski M, 1999, CANCER RES, V59, P2815; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SIRARD C, 1994, BLOOD, V83, P1575; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; SKORSKI T, 1995, CANCER RES, V55, P2275; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1993, J CLIN INVEST, V92, P194, DOI 10.1172/JCI116549; Skorski T, 1997, J NATL CANCER I, V89, P124, DOI 10.1093/jnci/89.2.124; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; WilsonRawls J, 1996, CANCER RES, V56, P3426	57	19	19	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4117	4124		10.1038/sj.onc.1203754	http://dx.doi.org/10.1038/sj.onc.1203754			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962572				2022-12-17	WOS:000088955100005
J	Brassac, T; Castro, A; Lorca, T; Le Peuch, C; Doree, M; Labbe, JC; Galas, S				Brassac, T; Castro, A; Lorca, T; Le Peuch, C; Doree, M; Labbe, JC; Galas, S			The polo-like kinase Plx1 prevents premature inactivation of the APC(Fizzy)-dependent pathway in the early Xenopus cell cycle	ONCOGENE			English	Article						Plx1; cyclin; APC/cyclosome; microcystin; phosphatase	ANAPHASE-PROMOTING COMPLEX; AMPHIBIAN EGGS; CHROMOSOME SEGREGATION; INTERPHASE EXTRACTS; MEIOTIC METAPHASE; MITOTIC CYCLINS; OKADAIC ACID; M-PHASE; MITOSIS; PROTEOLYSIS	Members of the polo-like family of protein kinases have been involved in the control of APC (anaphase-promoting complex) during the cell cycle, Set how they activate APC is not understood in any detail. In Xenopus oocytes, Cati-dependent degradation of cyclin B associated with release from arrest at second meiotic metaphase was demonstrated to require the polo-like kinase Plx1. The aim of the present study mas to examine, beyond Ca2+-dependent resumption of meiosis, the possible role of Plx1 in the control of cyclin degradation during the early mitotic cell cycle, Plx1 was found to be dispensable for MPF to turn on the cyclin degradation machinery, However, it is required to prevent premature inactivation of the APC-dependent proteolytic pathway. Microcystin suppresses the requirement for Plx1 in both Ca2+-dependent exit from meiosis, associated with degradation of both cyclin B and A downstream of CaMK2 activation, and prevention of premature APC(Fizzy) inactivation in the early mitotic cell cycle, These results are consistent with the view that Plx1 antagonizes an unidentified microcystin-sensitive phosphatase that inactivates APC(Fizzy).	CNRS, Ctr Rech Biochim Macromol, UPR 1086, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Galas, S (corresponding author), CNRS, Ctr Rech Biochim Macromol, UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.		Galas, Simon/X-1312-2019; labbe, jean-claude/B-2277-2009; CASTRO, ANNA/F-4350-2010	Galas, Simon/0000-0002-1717-1266; CASTRO, ANNA/0000-0002-3655-1352; Lorca, Thierry/0000-0003-2007-8924				Abrieu A, 1998, J CELL SCI, V111, P1751; Abrieu A, 1997, MOL BIOL CELL, V8, P249, DOI 10.1091/mbc.8.2.249; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Brown KD, 1996, J CELL SCI, V109, P961; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1992, J CELL SCI, V102, P55; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	44	19	22	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3782	3790		10.1038/sj.onc.1203724	http://dx.doi.org/10.1038/sj.onc.1203724			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949933				2022-12-17	WOS:000088568400011
J	Frost, V; Sinclair, AJ				Frost, V; Sinclair, AJ			p27(KIP1) is down-regulated by two different mechanisms in human lymphoid cells undergoing apoptosis	ONCOGENE			English	Article						p27KIP1; apoptosis; caspase; z-VAD-fmk; EBV	DEPENDENT KINASE INHIBITOR; EPSTEIN-BARR-VIRUS; GROWTH-FACTOR-BETA; CYCLE ARREST; MDM2 ONCOPROTEIN; ACTIVATION; CLEAVAGE; PROTEIN; RAPAMYCIN; DEATH	The cyclin-dependent kinase inhibitor p27(KIP1) is a crucial component of the mammalian restriction point, and as such is subject to multiple regulatory mechanisms. It has recently been shown that the abundance of p27(KIP1) is also regulated during apoptosis; p27K'P' is cleaved by a Z-VAD-fmk-sensitive caspase during apoptosis induced by growth factor deprivation in endothelial cells, and also following exposure of myeloid leukaemia cells to etoposide. Here, we investigate p27(KIP1) regulation in B- and T-lymphoid cells undergoing apoptosis, We observe that p27(KIP1) is down-regulated following exposure to a variety of apoptotic stimuli including an agonistic anti-Fas antibody, cycloheximide and etoposide. Further investigation revealed the existence of two different routes of p27K'P' regulation in lymphoid cells undergoing apoptosis. The first pathway is utilized by lymphoid cells stimulated through Fas, is abrogated in a caspase-8-deficient T-cell line, and is blocked by the caspase inhibitors z-VAD-fmk and Boc-D-fmk. In contrast, the loss of p27(KIP1) in cells exposed to cycloheximide and etoposide occurs in the absence of caspase-8 or any z-VAD-fmk- or Boc-D-fmk-sensitive caspase activities. Thus the down-regulation of p27(KIP1) is a common occurrence in lymphoid cells undergoing apoptosis but, depending on the apoptotic trigger, this can be affected by two different mechanisms.	Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Frost, V (corresponding author), Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England.			Sinclair, Alison/0000-0001-8510-8691				Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Cannell EJ, 1998, FEBS LETT, V439, P297, DOI 10.1016/S0014-5793(98)01391-X; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; KING W, 1980, J VIROL, V36, P506, DOI 10.1128/JVI.36.2.506-518.1980; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Luo Y, 1996, MOL CELL BIOL, V16, P6744; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MENEZES J, 1975, BIOMEDICINE, V22, P276; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	35	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3115	3120		10.1038/sj.onc.1203657	http://dx.doi.org/10.1038/sj.onc.1203657			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871865				2022-12-17	WOS:000087903900010
J	Carayol, G; Giron-Michel, J; Azzarone, B; Castagna, L; Cambier, N; Mishal, Z; Bourhis, JH; Chouaib, S; Caignard, A				Carayol, G; Giron-Michel, J; Azzarone, B; Castagna, L; Cambier, N; Mishal, Z; Bourhis, JH; Chouaib, S; Caignard, A			Altered natural killer cell differentiation in CD34(+) progenitors from chronic myeloid leukemia patients	ONCOGENE			English	Article						IL-15; IL-15R; chronic myeloid leukemia; NK cell differentiation	CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; INTERLEUKIN-2 RECEPTOR; INTERFERON-GAMMA; HUMAN MONOCYTES; IL-2 RECEPTOR; EXPRESSION; ACTIVATION; IDENTIFICATION; TRANSFORMATION	IL-15 and SCF fail to induce NK differentiation and proliferation of CD34(+) hematopoietic progenitors from chronic myeloid leukemia patients in contrast to normal stem cells although, both normal and leukemic CD34(+) cells display comparable expression of c-kit or IL-15 receptor subunits, Interestingly, confocal microscopy analysis revealed that leukemic and most normal CD34(+) cells produce and secrete IL-15, as shown by its trafficking through the Golgi apparatus and early endosomes, However, only leukemic progenitors express the membrane bound IL-15, Colocalization and internalization of IL-15R beta/gamma c and IL-15R alpha/gamma c complexes indicated that IL-15 was specifically uptaken by leukemic progenitors. We also demonstrated that in both normal and leukemic progenitors, the signaling kinase Jak3 is constitutively pre-associated with the gamma c chain. Anti-IL-15 neutralizing mAb treatment resulted in downregulation of gamma c chain and disruption of gamma c/Jak3 interaction in normal but had no effect in leukemic progenitors. Our results suggest the existence in both normal and leukemic CD34(+) cells of a constitutive production of a bioactive IL-15 that does not lead to NK differentiation and further indicate that membrane bound IL-15 and constitutive activation of gamma c are hallmarks of leukemic progenitors.	Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France; Inst Gustave Roussy, Serv Hematol, F-94805 Villejuif, France; Hop Paul Brousse, INSERM 506, F-94807 Villejuif, France; CHU Lille, Serv Hematol, F-59037 Lille, France; Lab Cytometrie, CNRS, UPS 47, F-94807 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Centre National de la Recherche Scientifique (CNRS)	Caignard, A (corresponding author), Inst Gustave Roussy, INSERM, U487, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Chouaib, Salem/F-7939-2016; Castagna, L/ABC-7613-2021; Azzarone, Bruno/AAH-9251-2019; Caignard, Anne/F-8159-2013; Giron-Michel, Julien/Q-4503-2018	Azzarone, Bruno/0000-0002-5962-3849; Caignard, Anne/0000-0001-9923-6045; Giron-Michel, Julien/0000-0001-6613-6099; Castagna, Luca/0000-0002-6239-7387				Alleva DG, 1997, J IMMUNOL, V159, P2941; Barzegar C, 1998, ONCOGENE, V16, P2503, DOI 10.1038/sj.onc.1201775; BOSCO MC, 1994, BLOOD, V83, P2995, DOI 10.1182/blood.V83.10.2995.2995; CALIGIURI MA, 1990, J EXP MED, V171, P1509, DOI 10.1084/jem.171.5.1509; Carayol G, 1998, EUR J IMMUNOL, V28, P1991, DOI 10.1002/(SICI)1521-4141(199806)28:06<1991::AID-IMMU1991>3.0.CO;2-7; Carella AM, 1999, BLOOD, V93, P1534, DOI 10.1182/blood.V93.5.1534.405a05_1534_1539; Carson WE, 1997, J CLIN INVEST, V99, P937, DOI 10.1172/JCI119258; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Cervantes F, 1996, BLOOD, V87, P2476, DOI 10.1182/blood.V87.6.2476.bloodjournal8762476; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Frassoni F, 1999, BRIT J HAEMATOL, V104, P538, DOI 10.1046/j.1365-2141.1999.01201.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KANTARJIAN HM, 1993, BLOOD, V82, P691; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Meazza R, 1996, ONCOGENE, V12, P2187; Mingari MC, 1997, EUR J IMMUNOL, V27, P1374, DOI 10.1002/eji.1830270612; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; Musso T, 1999, BLOOD, V93, P3531; NOWELL PC, 1960, SCIENCE, V132, P1497; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Takahashi N, 1998, BLOOD, V92, P4758, DOI 10.1182/blood.V92.12.4758; VERFAILLIE C, 1990, BLOOD, V76, P401; Washizu J, 1998, IMMUNOGENETICS, V48, P1, DOI 10.1007/s002510050393; WETZLER M, 1995, AM J MED, V99, P402, DOI 10.1016/S0002-9343(99)80189-2	29	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2758	2766		10.1038/sj.onc.1203584	http://dx.doi.org/10.1038/sj.onc.1203584			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851076				2022-12-17	WOS:000087318500004
J	Wang, X; Weng, LP; Yu, Q				Wang, X; Weng, LP; Yu, Q			Specific inhibition of FGF-induced MAPK activation by the receptor-like protein tyrosine phosphatase LAR	ONCOGENE			English	Article						PTPase; tyrosine phosphorylation; growth factor	EPIDERMAL GROWTH-FACTOR; MOTOR AXON GUIDANCE; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; MICE LACKING; KINASES; CELLS; SIGMA; OVEREXPRESSION; ASSOCIATION	LAR is a widely expressed receptor-like protein tyrosine phosphatase that is implicated in regulation of intracellular signaling triggered by both cell adhesion and peptide growth factors, Genetic studies revealed that LAR regulates neuron axon path finding in Drosophila and mammary gland epithelial cell differentiation in mice. The molecular mechanism underlying the tissue specific function of LAR has not been clearly understood. We investigated the role and mechanism of LAR in peptide growth factors EGF and FGF signaling in human tissue culture cells in which the expression of LAR is under the control of an inducible promoter. We found that although both EGF and FGF induce activation of mitogen-activated protein kinase (MAPK), LAR only inhibits FGF-induced MAPK activation. LAR does not interact directly with the peptide growth factor receptors, since the ligand-induced autophosphorylation of growth factor receptors was not affected by induction of LAR, The specific effect of LAR on FGF-induced MAPK activation appeared to be mediated by specific inhibition of the phosphorylation of two signal transducers that act downstream of the FGF receptor, FRS2 and a 180 kDa protein, and by prevention of their interaction with the adaptor protein GRB2, In contrast, LAR selectively inhibited the epidermal growth factor (EGF)-induced phosphorylation of p130(CAS) and the formation of the complex between p130(CAS) and GRB2 but this effect did not influence the activation of MAPK by EGF, These data suggest that LAR and similar receptor-like protein tyrosine phosphatases may contribute to the regulation of transmembrane signaling by selectively inhibiting the tyrosine phosphorylation of specific signal transducers that act downstream of the plasma membrane-associated tyrosine kinases, The consequent inhibition of the Formation of signaling complexes by these proteins may contribute to the specificity of the signals generated by specific peptide growth factors as well as extracellular matrix proteins.	Boston Univ, Med Ctr, Ctr Pulm, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Ctr Pulm, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Yu, Q (corresponding author), Boston Univ, Med Ctr, Ctr Pulm, Dept Med, Boston, MA 02118 USA.				NHLBI NIH HHS [R01 HL 54044] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad F, 1997, J BIOL CHEM, V272, P448; AHN NG, 1993, MOL CELL BIOCHEM, V128, P201, DOI 10.1007/BF01076771; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; Elchebly M, 1999, NAT GENET, V21, P330, DOI 10.1038/6859; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; IMAMURA T, 1988, BIOCHEM BIOPH RES CO, V155, P583, DOI 10.1016/S0006-291X(88)80534-5; KATSURA H, 1995, DEV DYNAM, V204, P89, DOI 10.1002/aja.1002040111; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li PM, 1996, CELL SIGNAL, V8, P467, DOI 10.1016/S0898-6568(96)00101-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mooney RA, 1997, BIOCHEM BIOPH RES CO, V235, P709, DOI 10.1006/bbrc.1997.6889; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wallace MJ, 1999, NAT GENET, V21, P334, DOI 10.1038/6866; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; YU Q, 1992, ONCOGENE, V7, P1051; Zinn K, 1998, CURR BIOL, V8, pR725, DOI 10.1016/S0960-9822(98)70459-2	38	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2346	2353		10.1038/sj.onc.1203558	http://dx.doi.org/10.1038/sj.onc.1203558			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822386				2022-12-17	WOS:000086974300010
J	Ji, QS; Carpenter, G				Ji, QS; Carpenter, G			Role of basal calcium in the EGF activation of MAP kinases	ONCOGENE			English	Article						calcium; MAP kinase; EGF	PROTEIN-TYROSINE PHOSPHATASE; EPIDERMAL GROWTH-FACTOR; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; TRANSCRIPTION; BMK1/ERK5	The role of intracellular Ca2+ pools in the regulation of growth factor signal transduction pathways and mitogenesis is not well understood. We have examined the roles of basal and transiently mobilized Ca2+ in the regulation of MAP kinases by EGF, To assess the influence of Ca2+ transients we utilized Plcg1(-/-) and Plcg1(+/+) mouse embryonic fibroblasts, while BAPTA/AM was employed to chelate total intracellular Ca2+ in the same cell lines, The MAP kinases erk-1, erk-2 and erk-5 exhibited similar patterns of activation in wild-type and Plcg1(-/-) cells treated with EGF, However, pretreatment with BAPTA/AM significantly increased and prolonged erk-1 and erk-2 activation in both cell types, In contrast, BAPTA/AM prevented the EGF activation of erk-5 in wild-type and Plcg1(-/-) cells. These data indicate that basal Ca2+, but not growth factor provoked Ca2+ transients, has a significant influence on the activation of these MAP kinases, AG1478, a specific EGF receptor kinase inhibitor, abolished the prolonged erk-1 and erk-2 activation produced by EGF in cells pretreated with BAPTA/AM, This indicates that the prolonged activation of erk-1 and erk-2 produced in the presence of BAPTA/AM requires continuous signaling from the EGF receptor kinase.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA075195] Funding Source: NIH RePORTER; NCI NIH HHS [CA75195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BOHMER FD, 1995, ANAL BIOCHEM, V228, P267, DOI 10.1006/abio.1995.1349; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1999, MOL CELL BIOL, V19, P4961; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kamat Asha, 1997, Cytokine and Growth Factor Reviews, V8, P109, DOI 10.1016/S1359-6101(97)00003-8; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; STOSCHECK CM, 1983, ARCH BIOCHEM BIOPHYS, V227, P457, DOI 10.1016/0003-9861(83)90476-9; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	30	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1853	1856		10.1038/sj.onc.1203517	http://dx.doi.org/10.1038/sj.onc.1203517			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777220				2022-12-17	WOS:000086292500014
J	Reynaud, EG; Guillier, M; Leibovitch, MP; Leibovitch, SA				Reynaud, EG; Guillier, M; Leibovitch, MP; Leibovitch, SA			Dimerization of the amino terminal domain of p57(Kip2) inhibits cyclin D1-Cdk4 kinase activity	ONCOGENE			English	Article						p57(Kip2); homodimerization; cyclin-Cdk inhibition	DEPENDENT KINASES; CDK INHIBITORS; P27(KIP1); P21; GENE; PROTEIN; CANCER; FAMILY; CELLS	Previous studies have led to the proposal that a single molecule of Cki can associate with the cyclin/Cdk complex to repress its activity. On the other hand, multiple inhibitor molecules are required to inhibit Cdks. In the present work, by using differently tagged p57(Kip2) proteins we demonstrate that p57(Kip2),,, bind to itself in vitro and in vivo. Mutational deletion analysis showed that the NH2 terminal domain of p57(Kip2) is necessary and sufficient to dimerization, Using an in vitro competition/association assay, we demonstrate that cyclin D1 alone, Cdk4 alone and/or cyclin D1/Cdk4 complexes do not compete for the p57(Kip2) homodimers formation. However, a mutation in the cc-helix domain of p57(Kip2) (R33L) strongly reduced homodimer formation but did not modify interaction with cyclin D1-Cdk4 complexes. Also, increasing amounts of p57(Kip2) lead in vivo to a significant augmentation in the level of p57(Kip2) homodimerization associated with cyclin D1-Cdk4 complexes and to a marked inhibition of the cyclin D1-Cdk4 kinase activity. Altogether, these data suggest a model whereby p57(Kip2) associates with itself by using the NH2 domain to form a homodimeric species which interacts with and inhibits the cyclin D1-Cdk4 complexes.	Inst Gustave Roussy, Lab Genet Oncol, CNRS, UMR 1599, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Leibovitch, SA (corresponding author), Inst Gustave Roussy, Lab Genet Oncol, CNRS, UMR 1599, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Reynaud, Emamnuel/H-2928-2019	Reynaud, Emamnuel/0000-0003-1502-661X				Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Chen IT, 1996, ONCOGENE, V12, P595; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hashimoto Y, 1998, J BIOL CHEM, V273, P16544, DOI 10.1074/jbc.273.26.16544; HENGST L, 1998, CURR OPIN MICROBIOL, V227, P57; KERR L D, 1992, Current Opinion in Cell Biology, V4, P496, DOI 10.1016/0955-0674(92)90017-7; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LASSAR AB, 1995, CELL, V92, P7297; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LENORMAND JL, 1997, MOL CELL BIOL, V17, P583; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	29	19	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1147	1152		10.1038/sj.onc.1203403	http://dx.doi.org/10.1038/sj.onc.1203403			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713702				2022-12-17	WOS:000085567800004
J	Tamrakar, S; Mittnacht, S; Ludlow, JW				Tamrakar, S; Mittnacht, S; Ludlow, JW			Binding of select forms of pRB to protein phosphatase type 1 independent of catalytic activity	ONCOGENE			English	Article						retinoblastoma protein; protein phosphatase type 1; pRB dephosphorylation; PPI activity; phosphatase inhibitors	RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; OKADAIC ACID; SUSCEPTIBILITY GENE; SPONGE TOXIN; PHOSPHORYLATION; SUBUNIT; DEPHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION	The product of the retinoblastoma susceptibility gene, pRB, is a demonstrated substrate for the type 1 serine/threonine protein phosphatases (PPI). Curiously, there has been a paucity of data supporting the idea that phosphorylated pRB can be found in a complex with PP1. To more fully characterize the association between these two proteins, we utilized a PP1-affinity chromatography approach to increase our ability to capture from mammalian cell lysate populations of pRB capable of binding to PPI. Western blot analysis of the bound proteins indicates that both faster migrating, hypophosphorylated pRB, as web as slower migrating, hyperphosphorylated pRB can bind. Phosphorylated pRB binding was confirmed by immunoprecipitation of eluted P-32-labeled pRB. In addition, Western blotting of eluted proteins with pRB phosphorylated-site-specific antibodies revealed select phosphorylated forms of pRB binding to PP1. Similar binding studies performed with toxin-inhibited PP1 indicate that catalytic activity of PPI is not required for pRB binding. The significance of this finding with respect to the functional importance of this interaction is discussed.	Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Inst Canc Res, Dept Cell & Mol Biol, London SW3 6JB, England	University of Rochester; University of Rochester; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ludlow, JW (corresponding author), Univ Rochester, Ctr Canc, Box 704,601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; Ludlow JW, 1996, J VIROL METHODS, V59, P105, DOI 10.1016/0166-0934(96)02027-7; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUSSOW AR, 1991, EUR J IMMUNOL, V21, P2297, DOI 10.1002/eji.1830211002; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Siegert JL, 1999, MOL CELL BIOL, V19, P846; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; Takemura M, 1997, ONCOGENE, V15, P2483, DOI 10.1038/sj.onc.1201431; Tognarini M, 1998, METH MOL B, V93, P169; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang LF, 1996, BIOCHEMISTRY-US, V35, P1606, DOI 10.1021/bi9521396	41	19	19	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7803	7809		10.1038/sj.onc.1203211	http://dx.doi.org/10.1038/sj.onc.1203211			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618721				2022-12-17	WOS:000084256900010
J	McCullagh, P; Chaplin, T; Meerabux, J; Grenzelias, D; Lillington, D; Poulsom, R; Gregorini, A; Saha, V; Young, BD				McCullagh, P; Chaplin, T; Meerabux, J; Grenzelias, D; Lillington, D; Poulsom, R; Gregorini, A; Saha, V; Young, BD			The cloning, mapping and expression of a novel gene, BRL, related to the AF10 leukaemia gene	ONCOGENE			English	Article						chromosome translocation; leukaemia; MLL; AF10	HISTONE ACETYLTRANSFERASE ACTIVITY; ACUTE MONOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NUCLEAR-PROTEIN CBP; TRANSCRIPTIONAL ACTIVATION; T(10-11) TRANSLOCATION; BINDING-PROTEIN; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; MOLECULAR-CLONING	The MLL gene is reciprocally translocated with one of a number of different partner genes in a proportion of human acute leukaemias. The precise mechanism of oncogenic transformation is unclear since most of the partner genes encode unrelated proteins, However, two partner genes, AF10 and AF17 are related through the presence of a cysteine rich region and a leucine zipper. The identification of other proteins with these structures will aid our understanding of their role in normal and leukaemic cells. We report the cloning of a novel human gene (BRL) which encodes a protein containing a cysteine rich region related to that of AF10 and AF17 and is overall most closely related to the previously known protein BR140, BRL maps to chromosome 22q13 and shows high levels of expression in testis and several cell lines. The deduced protein sequence also contains a bromodomain, four potential LXXLL motifs and four predicted nuclear localization signals. A monoclonal antibody raised to a BRL peptide sequence confirmed its widespread expression as a 120 Kd protein and demonstrated localization to the nucleus within spermatocytes.	St Bartholomews & Royal London Sch Med & Dent, Dept Med Oncol, Imperial Canc Res Fund, London EC1M 6BQ, England; Imperial Canc Res Fund, In Situ Hybridizat Serv, London WC2A 3PX, England	Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK	Young, BD (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Med Oncol, Imperial Canc Res Fund, Charterhouse Sq, London EC1M 6BQ, England.			Saha, Vaskar/0000-0002-2916-9649				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BEVERLOO HB, 1995, CANCER RES, V55, P4220; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, MOL CELL BIOL, V16, P593; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Gregorini A, 1996, GENE CHROMOSOME CANC, V17, P269; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Harlow E, 1998, ANTIBODIES LAB MANUA; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAI JL, 1992, CANCER GENET CYTOGEN, V60, P180, DOI 10.1016/0165-4608(92)90013-X; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEBEAU MM, 1985, LEUKEMIA RES, V9, P605, DOI 10.1016/0145-2126(85)90140-7; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACCOLLIN M, 1993, GENOMICS, V15, P680, DOI 10.1006/geno.1993.1125; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nicolas RH, 1996, GENE, V175, P233, DOI 10.1016/0378-1119(96)82845-9; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Rinderle C, 1999, HUM MOL GENET, V8, P277, DOI 10.1093/hmg/8.2.277; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SCHINDLER U, 1993, PLANT J, V4, P137, DOI 10.1046/j.1365-313X.1993.04010137.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Soenen V, 1996, GENE CHROMOSOME CANC, V15, P191, DOI 10.1002/(SICI)1098-2264(199603)15:3<191::AID-GCC9>3.0.CO;2-Y; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tanabe S, 1996, BLOOD, V88, P3535; THOMPSON KA, 1994, BIOCHEM BIOPH RES CO, V198, P1143, DOI 10.1006/bbrc.1994.1162; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TROFATTER JA, 1995, GENOME RES, V5, P214, DOI 10.1101/gr.5.3.214; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	57	19	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7442	7452		10.1038/sj.onc.1203117	http://dx.doi.org/10.1038/sj.onc.1203117			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602503				2022-12-17	WOS:000084119600005
J	Campbell, IG; Manolitsas, T				Campbell, IG; Manolitsas, T			Absence of PPP2R1B gene alterations in primary ovarian cancers	ONCOGENE			English	Article						ovarian cancer; PPP2R1B; loss of heterozygosity; chromosome 11q23; mutation analysis	MOLECULAR-CLONING; REGION; HETEROZYGOSITY; FREQUENT; PROTEIN; TUMORS; REFINEMENT; CARCINOMA; DELETIONS; 11Q23	The PPP2R1B gene has recently been implicated as a tumor suppressor based on the finding of somatic alterations in lung and colon cancers. PPP2R1B is located on chromosome 11q22-24 which coincides with the site of frequent loss of heterozygosity (LOH) in ovarian cancer. We investigated if the PPP2R1B gene was inactivated in ovarian cancer by single strand conformational polymorphism (SSCP) and heteroduplex (HD) analysis of 99% of the coding region. LOH at the PPP2R1B locus was detected in 32% of the malignant tumors but no somatic alterations were detected in any of 65 malignant, five borderline or six benign tumors. A germline G>A transition (GGC>GAC) in codon 90 was detected in 4/76 tumors. This alteration has previously been described as a mutation but on further investigation we found that the frequency of this variant among 167 ovarian cancers (4.2%) was not statistically significantly different from that observed in 247 noncancer random controls (2.4%). We conclude that the PPP2R1B gene is not involved in the pathogenesis of ovarian cancer. The codon 90 Gly>Asp alteration may represent a non-pathological polymorphism and consequently the mutation frequency reported in lung cancers may have been overstated and the designation of PPP2R1B as a tumor suppressor gene should be regarded with caution.	Univ Southampton, Princess Anne Hosp, Dept Obstet & Gynaecol, Southampton SO16 5YA, Hants, England; Peter MacCallum Canc Inst, E Melbourne, Vic 3002, Australia	University of Southampton; Peter Maccallum Cancer Center	Campbell, IG (corresponding author), Peter MacCallum Canc Inst, Sir Donald & Lady Trescowthick Res Labs, Locked Bag 1,A Beckett St, Melbourne, Vic 3000, Australia.		campbell, Ian G/F-6006-2011	Campbell, Ian/0000-0002-7773-4155				Baysal BE, 1998, GENE, V217, P107, DOI 10.1016/S0378-1119(98)00350-3; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; Davis M, 1996, CANCER RES, V56, P741; Evans MF, 1998, ONCOGENE, V16, P2557, DOI 10.1038/sj.onc.1202039; Gabra H, 1996, CANCER RES, V56, P950; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Herbst RA, 1999, INT J CANCER, V80, P205, DOI 10.1002/(SICI)1097-0215(19990118)80:2<205::AID-IJC8>3.0.CO;2-J; Hui ABY, 1996, CANCER RES, V56, P3225; Koreth J, 1997, ONCOGENE, V14, P431, DOI 10.1038/sj.onc.1200847; Monaco C, 1998, GENOMICS, V52, P358, DOI 10.1006/geno.1998.5419; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Obata K, 1998, CANCER RES, V58, P2095; Skomedal H, 1997, J PATHOL, V181, P158; Wang L, 1998, ONCOGENE, V16, P635, DOI 10.1038/sj.onc.1201576; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284	16	19	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6367	6369		10.1038/sj.onc.1203070	http://dx.doi.org/10.1038/sj.onc.1203070			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597236				2022-12-17	WOS:000083934100021
J	Greeve, J; Lellek, H; Apostel, F; Hundoegger, K; Barialai, A; Kirsten, R; Welker, S; Greten, H				Greeve, J; Lellek, H; Apostel, F; Hundoegger, K; Barialai, A; Kirsten, R; Welker, S; Greten, H			Absence of APOBEC-1 mediated mRNA editing in human carcinomas	ONCOGENE			English	Article						mRNA editing; APOBEC-1; human carcinoma; apo B; NAT1	B MESSENGER-RNA; TISSUE-SPECIFIC EXPRESSION; CATALYTIC SUBUNIT; KINETOPLASTID PROTOZOA; CYTIDINE DEAMINASE; PROTEIN; GENE; ENZYME; CLONING; MOTIF	The transgene expression of the catalytic subunit APOBEC-1 of the apo B mRNA editing enzyme-complex can cause hepatocellular carcinoma in mice and rabbits. It has been proposed that aberrant editing of mRNA may represent a novel oncogenic principle. This investigation aimed to define whether such aberrant hyperediting mediated by APOBEC-1 occurs in human carcinomas. Editing and hyperediting of apo B, NAT1 or NF1 mRNA was not identified in any of 28 resected tumor specimens, including hepatocellular, bile duct, gastric, colorectal, pancreatic adeno- and neuroendocrine, lung adeno-, medullary thyroid and breast carcinoma, soft tissue sarcoma and neuroblastoma. In most types of carcinoma, significant length for full-length APOBEC-1 mRNA could not be detected. Low level expression of APOBEC-1 was found in colorectal and gastric carcinoma where most of the APOBEC-1 mRNA is inactivated by alternate splicing. The 'auxiliary' components of the apo B mRNA editing enzyme-complex are missing in many tumors including colorectal and gastric carcinoma, but are highly expressed in hepatocellular, lung adeno- and breast carcinoma all of which lack APOBEC-1. Taken together, either APOBEC-1 or the 'auxiliary' components of the apo B mRNA editing enzyme-complex or both are missing in human carcinomas resulting in the absence of mRNA editing. Currently, there is no evidence that aberrant editing mediated by APOBEC-1 contributes to the tumorigenesis of natural human carcinomas.	Univ Hamburg, Hosp Eppendorf, Med Kernklin & Poliklin, D-20246 Hamburg, Germany	University of Hamburg	Greeve, J (corresponding author), Univ Hamburg, Hosp Eppendorf, Med Kernklin & Poliklin, Martinistr 52, D-20246 Hamburg, Germany.							ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Cappione AJ, 1997, AM J HUM GENET, V60, P305; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Fujino T, 1998, GENOMICS, V47, P266, DOI 10.1006/geno.1997.5110; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; Greeve J, 1998, ARTERIOSCL THROM VAS, V18, P1079, DOI 10.1161/01.ATV.18.7.1079; Greeve J, 1996, J LIPID RES, V37, P2001; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; GREEVE J, 1993, J LIPID RES, V34, P1367; Hirano H, 1997, J LIPID RES, V38, P847; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Lee RM, 1998, GASTROENTEROLOGY, V115, P1096, DOI 10.1016/S0016-5085(98)70080-0; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Powell-Braxton L, 1998, NAT MED, V4, P934, DOI 10.1038/nm0898-934; Qian XB, 1997, J BIOL CHEM, V272, P18060, DOI 10.1074/jbc.272.29.18060; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; SIMPSON L, 1995, CELL, V81, P837, DOI 10.1016/0092-8674(95)90003-9; Skuse GR, 1996, NUCLEIC ACIDS RES, V24, P478, DOI 10.1093/nar/24.3.478; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Yamanaka S, 1996, J BIOL CHEM, V271, P11506, DOI 10.1074/jbc.271.19.11506; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321	33	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6357	6366		10.1038/sj.onc.1203039	http://dx.doi.org/10.1038/sj.onc.1203039			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597235				2022-12-17	WOS:000083934100020
J	Nguyen, H; Teskey, L; Lin, RT; Hiscott, J				Nguyen, H; Teskey, L; Lin, RT; Hiscott, J			Identification of the secretory leukocyte protease inhibitor (SLPI) as a target of IRF-1 regulation	ONCOGENE			English	Article						interferon regulatory factor (IRF)-1; secretory leukocyte protease inhibitor (SLPI); transcription	IFN-INDUCIBLE GENES; TRANSCRIPTION FACTOR; LEUKOPROTEASE INHIBITOR; NITRIC-OXIDE; FACTOR-I; INTERFERON SYSTEM; EPITHELIAL-CELLS; EXPRESSION; INDUCTION; BETA	Interferon Regulatory Factor (IRF)-1 is a multifunctional transcription factor, involved in cell growth regulation, pathogen response and immune activation. To identify novel gene targets that may contribute to IRF-1 mediated activities, RNA fingerprinting was performed using NIH3T3 cells that inducibly express a hybrid form of IRF-1 under tetracycline regulated control. Secretory leukocyte protease inhibitor (SLPI)-a regulator of inflammation and an inhibitor of the LPS response-was identified as a gene repressed after doxycycline induced IRF-1 expression, Preliminary analysis of the human SLPI promoter identified an ISRE-like site located within the -221 to -200 region to which IRF-1 binds and a second, putative IRF-1 binding site upstream of the TATA box. Furthermore, co-transfection studies demonstrated that SLPI expression was inhibited by IRF-1 co-expression. The identification of SLPI as a target of IRF-1 regulation reveals a unique involvement of IRF-1 in repression of gene transcription and assigns a novel role for IRF-1 in inflammation.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Hiscott, J (corresponding author), Lady Davis Inst Med Res, 3755 Cote St Catherine,Room 526, Montreal, PQ H3T 1E2, Canada.		Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				CHA Y, 1994, J BIOL CHEM, V269, P5279; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; COHEN L, 1991, CELL GROWTH DIFFER, V2, P323; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P445; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; LEE CH, 1993, AM REV RESPIR DIS, V147, P710, DOI 10.1164/ajrccm/147.3.710; LIN R, 1992, J BACTERIOL, V174, P2779, DOI 10.1128/JB.174.9.2779-2784.1992; LIN RT, 1994, J BIOL CHEM, V269, P17542; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MARUYAMA M, 1994, J CLIN INVEST, V94, P368, DOI 10.1172/JCI117331; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nonkwelo C, 1997, J VIROL, V71, P6887, DOI 10.1128/JVI.71.9.6887-6897.1997; PENNINGER JM, 1994, IMMUNOL REV, V142, P231, DOI 10.1111/j.1600-065X.1994.tb00892.x; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733, DOI 10.1165/ajrcmb.11.6.7946401; TAKI S, 1997, IMMUNITY, V6, P1; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vogelmeier C, 1996, CHEST, V110, pS261, DOI 10.1378/chest.110.6_Supplement.261S; Wang IM, 1996, MOL CELL BIOL, V16, P6313; [No title captured]	37	19	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5455	5463		10.1038/sj.onc.1202924	http://dx.doi.org/10.1038/sj.onc.1202924			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498899				2022-12-17	WOS:000082718600010
J	Zapf-Colby, A; Eichhorn, J; Webster, NJG; Olefsky, JM				Zapf-Colby, A; Eichhorn, J; Webster, NJG; Olefsky, JM			Inhibition of PLC-gamma 1 activity converts nerve growth factor from an anti-mitogenic to a mitogenic signal in CHO cells	ONCOGENE			English	Article						MAPK; PLC-gamma 1; SNT-1; FRS2; NGF; IGF-I	ACTIVATED PROTEIN-KINASE; PC12 CELLS; MAP KINASE; NEURONAL DIFFERENTIATION; PHOSPHOLIPASE C-GAMMA-1; TYROSINE PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; NEUROTROPHIC FACTOR; TRK PROTOONCOGENE; EGF RECEPTOR	Nerve growth factor (NGF) treatment of Chinese hamster ovary fibroblast (CHO) cells exogenously expressing 2.5x10(5) TrkA receptors (CHO/TrkA) results in inhibition of serum and insulin-like growth factor-I (IGF-I) stimulated cell proliferation in a dose-dependent manner, Furthermore, NGF does not stimulate [H-3]thymidine incorporation and inhibits IGF-I mediated DNA synthesis in CHO/TrkA cells. NGF and IGF-I induce extracellular-signal regulated kinase 1 (ERK1) and ERK2 activation, but NGF is able to stimulate a higher and more sustained activation of these enzymes compared with IGF-I, Cotreatment with NGF and IGF-I yields an ERK1/2 activity profile similar to that of NGF treatment alone. While pretreatment with mitogen activated protein kinase kinase (MKK) inhibitor PD98059 (30 mu M) results in 100% inhibition of IGF-I stimulated MAPK phosphorylation (IC50 < 1 mu M), NGF mediated MAPK phosphorylation is only decreased by 50% (IC50 = 3 mu M). NGF, but not IGF-I, stimulates tyrosine phosphorylation and activation of PLC-gamma 1 which can be inhibited in a dose-dependent manner by phosphoinositide-specific phospholipase C (PI-PLC) inhibitor U73122 (IC50 = 4 mu M). Pretreatment with U73122 (IC50 = 7 mu M) results in an 87% inhibition of NGF mediated MAPK phosphorylation, while cotreatment with PD98059 and U73122 results in 97% inhibition. U73122 pretreatment has no effect on NGF stimulated Akt activation. NGF, but not IGF-I, stimulates the tyrosine phosphorylation of Suc1-associated neurotrophic factor-induced tyrosine phosphorylation target (SNT-1) fibroblast growth factor receptor substrate 2 (FRS2) which can be completely prevented by pretreatment with 10 mu M U73122, Finally, inhibition of PI-PLC results in NGF's ability to stimulate DNA synthesis in the absence and presence of IGF-I.	Univ Calif San Diego, Sch Med, Biomed Sci Grad Program, Dept Med,Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Whittier Diabet Res Program, La Jolla, CA 92093 USA; Dept Vet Affairs Med Ctr, Med Res Serv, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Sch Med, Biomed Sci Grad Program, Dept Med,Div Endocrinol & Metab, La Jolla, CA 92093 USA.		Webster, Nick/AAI-8410-2021		NIA NIH HHS [AG 00216-05] Funding Source: Medline; NIDDK NIH HHS [DK-33651] Funding Source: Medline; PHS HHS [5 T32] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; Billon N, 1996, ONCOGENE, V13, P2047; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANMEY PA, 1991, METHOD ENZYMOL, V196, P92; KIM UH, 1991, J BIOL CHEM, V266, P1359; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; SETH A, 1991, J BIOL CHEM, V266, P23521; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WADMAN IA, 1994, ONCOGENE, V9, P3713; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yan GZ, 1997, J NEUROSCI, V17, P6122; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zapf-Colby A, 1998, ENDOCRINOLOGY, V139, P3232, DOI 10.1210/en.139.7.3232; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	56	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4908	4919		10.1038/sj.onc.1202861	http://dx.doi.org/10.1038/sj.onc.1202861			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490825				2022-12-17	WOS:000082321700003
J	Sekiguchi, T; Nishimoto, T; Hunter, T				Sekiguchi, T; Nishimoto, T; Hunter, T			Overexpression of D-type cyclins, E2F-1, SV40 large T antigen and HPV16 E7 rescue cell cycle arrest of tsBN462 cells caused by the CCG1/TAF(II)250 mutation	ONCOGENE			English	Article						CCG1/TAF(II)250; ELF-1; SV40; large T antigen; HPV16 E7; cyclin D; TFIID	BASAL TRANSCRIPTION FACTOR; BOX-BINDING PROTEIN; RETINOBLASTOMA PROTEIN; PROMOTER SELECTIVITY; TAF(II)250 SUBUNIT; BHK CELLS; EXPRESSION; GENE; ACTIVATION; TEMPERATURE	tsBN462 cells which have a point mutation in CCG1/TAF(11)250, a component of TFIID complex, arrest in G1 at the nonpermissive temperature of 39.5 degrees C. Overexpression of D-type cyclins rescued the cell cycle arrest of tsBN462 cells, suggesting that the cell cycle arrest was through Rb, Consistent,vith this, overexpression of E2F-1, whose function is repressed by the hypophosphorylated form of Rb, also rescued the cell cycle arrest, Moreover, expression of the viral oncoproteins SV40 large T antigen and HPV16 E7, which both bind Rb and inactivate its function, rescued the cell cycle arrest, whereas HPV16 E6 did not. Mutation of the Rb-binding motif in E7 abrogated its ability to rescue the cell cycle arrest, Expression of exogenous cyclin D1, SV40 large T antigen or CCG1/TAF(11)250 increased cyclin A expression at 39.5 degrees C. Coexpression of HPV16 E7 and adenovirus E1b19K, which blocks apoptosis, rescued the proliferation of tsBN462 cells at 38.5 degrees C. To investigate the mechanism underlying the lack of cyclin D1 expression, deletion analysis of cyclin D1 promoter was performed. The 0.15 kbp cyclin D1 core promoter region, which lacks any transcription factor binding motifs, still exhibited a temperature-sensitive phenotype in tsBN462 cells suggesting that CCG1/TAF(11)250 is critical for the function of the cyclin D1 core promoter.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 812, Japan	Salk Institute; Kyushu University	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA39780, CA14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Boyer SN, 1996, CANCER RES, V56, P4620; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAYASHIDA T, 1994, GENE, V141, P267; HERBER B, 1994, ONCOGENE, V9, P1295; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; Massimi P, 1996, ONCOGENE, V12, P2325; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NISHIMOTO T, 1982, SOMAT CELL GENET, V8, P811, DOI 10.1007/BF01543021; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Rushton JJ, 1997, CELL GROWTH DIFFER, V8, P1099; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; SEKIGUCHI T, 1987, EXP CELL RES, V169, P395, DOI 10.1016/0014-4827(87)90200-X; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; Sekiguchi T, 1996, GENES CELLS, V1, P687, DOI 10.1046/j.1365-2443.1996.00259.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; Tooze J., 1980, MOL BIOL TUMOR VIR 2; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014	42	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1797	1806		10.1038/sj.onc.1202508	http://dx.doi.org/10.1038/sj.onc.1202508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086334				2022-12-17	WOS:000079090000003
J	Buess, M; Engler, O; Hirsch, HH; Moroni, C				Buess, M; Engler, O; Hirsch, HH; Moroni, C			Search for oncogenic regulators in an autocrine tumor model using differential display PCR: Identification of novel candidate genes including the calcium channel mtrp6	ONCOGENE			English	Article						mast cells; serine protease; ras; mRNA fingerprinting; differential cloning	INTERLEUKIN-3 MESSENGER-RNA; 3' UNTRANSLATED REGION; MAST-CELLS; MOLECULAR-CLONING; GM-CSF; EXPRESSION; ENTRY; TRP; TRANSFORMATION; ACTIVATION	A hemopoietic multistep tumor model, in which IL-3 dependent PB-3c mast cells, following expression of v-H-ras progress in vivo to IL-3 producing autocrine tumors has previously been established. Central for this oncogenic progression is a recessive step, which is reversible by cell fusion and leads to stabilization of IL-3 mRNA with concomitant activation of the autocrine loop. Comparing the IL-3 dependent PB-3c and the IL-3 autocrine V2D1 tumor cells with differential display PCR revealed 12 differentially expressed genes of which eight were upregulated and four downregulated in the tumor. They included four proteases (mouse mast cell protease 2, granzyme B, pepsinogen F and serine protease 1) and two metabolic enzymes (adenine phosphoribosyltransferase and fructose1,6-bisphosphatase). For validation, expression of the identified genes was tested in independent PB-3c precursor clones and their tumor derivatives. Expression of an endogenous retroviral IAP element and three unknown transcripts were consistently upregulated in all tumor lines. In somatic cell hybrids, two of these unknown cDNAs showed a dominant and one a recessive expression pattern. One transcript, expressed in the precursor but downregulated in the tumor cells, was cloned and identified as the murine calcium channel mtrp6.	Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland	University of Basel	Moroni, C (corresponding author), Univ Basel, Inst Med Microbiol, Peterspl 10, CH-4003 Basel, Switzerland.			Hirsch, Hans H./0000-0003-0883-0423				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; Banholzer R, 1997, MOL CELL BIOL, V17, P3254, DOI 10.1128/MCB.17.6.3254; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BERTIOLI DJ, 1995, NUCLEIC ACIDS RES, V23, P4520, DOI 10.1093/nar/23.21.4520; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; BRUNET JF, 1987, J IMMUNOL, V138, P4102; Buess M, 1997, NUCLEIC ACIDS RES, V25, P2233, DOI 10.1093/nar/25.11.2233; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HAWLEY RG, 1984, MOL CELL BIOL, V4, P2565, DOI 10.1128/MCB.4.12.2565; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; HIRSCH HH, 1995, J BIOL CHEM, V270, P20629, DOI 10.1074/jbc.270.35.20629; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; NOMURA M, 1994, FEBS LETT, V348, P201, DOI 10.1016/0014-5793(94)00608-3; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURKER MS, 1993, J MOL EVOL, V36, P31, DOI 10.1007/BF02407304; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	43	19	24	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1487	1494		10.1038/sj.onc.1202445	http://dx.doi.org/10.1038/sj.onc.1202445			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050885	Bronze			2022-12-17	WOS:000078651600010
J	Hengstschlager, M; Holzl, G; Hengstschlager-Ottnad, E				Hengstschlager, M; Holzl, G; Hengstschlager-Ottnad, E			Different regulation of c-Myc- and E2F-1-induced apoptosis during the ongoing cell cycle	ONCOGENE			English	Article						apoptosis; cell cycle; c-Myc; E2F-1; centrifugal elutriation	UBIQUITIN-PROTEASOME PATHWAY; S-PHASE ENTRY; DEREGULATED EXPRESSION; DNA-SYNTHESIS; E2F-1; INDUCTION; FIBROBLASTS; LEADS; PROLIFERATION; DEGRADATION	The transcription factors c-Myc and E2F-1 have been shown to harbour both mitogenic and apoptotic properties. Both factors have been implicated in the regulation of the transition from the G1 phase to the S phase in the mammalian cell cycle, However, whether cell death triggered by these molecules is dependent on the cell's position in the ongoing cell cycle remained elusive. Using centrifugal elutriation we here show for the first time that c-Myc induces apoptosis in G1 and in G2 phase, whereas E2F-l-induced apoptosis specifically occurs in G1, S phase cells are resistant to cell death triggered by these factors. We demonstrate that this is not a general phenomenon, since S phase cells are susceptible to apoptosis induced by treatment with actinomycin D and to the anti-apoptotic activity of Bcl-2, Our data indicate that S phase cells harbour specific protective activities against c-Myc- and E2F-l-induced apoptosis, Our results demonstrate that these transcription factors, although probably sharing specific apoptotic pathways, also take distinct routes to induce cell death and that apoptosis can occur at different phases of the cell cycle depending on the apoptotic stimulus. In this report we present the usefulness of a new approach to determine the regulation of apoptosis in the ongoing unperturbated cell cycle. This approach has clear implications for the identification of target genes involved in the regulation of cell death.	Univ Vienna, Dept Prenatal Diagnosis & Therapy, A-1090 Vienna, Austria; Univ Vienna, Inst Genet Mol, A-1030 Vienna, Austria	University of Vienna; University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Dept Prenatal Diagnosis & Therapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.							ASKEW DS, 1991, ONCOGENE, V6, P1915; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Dao T, 1997, J IMMUNOL, V159, P4261; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hengstschlager M, 1997, BIOTECHNIQUES, V23, P232, DOI 10.2144/97232bm12; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Packham G, 1996, ONCOGENE, V13, P461; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Reed J C, 1996, Behring Inst Mitt, P72; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; STRASSER A, 1996, BEHRING I MITT, V97, P101; Vairo G, 1996, ONCOGENE, V13, P1511; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	30	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					843	848		10.1038/sj.onc.1202342	http://dx.doi.org/10.1038/sj.onc.1202342			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989838				2022-12-17	WOS:000078394400033
J	Sheppard, RD; Samant, SA; Rosenberg, M; Silver, LM; Cole, MD				Sheppard, RD; Samant, SA; Rosenberg, M; Silver, LM; Cole, MD			Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors	ONCOGENE			English	Article						N-myc; indolent B cell lymphoma; retroviral insertion; tumor progression	E-MU-MYC; PUTATIVE ONCOGENE PIM-1; FOLLICULAR LYMPHOMA; C-MYC; BCL-2 GENE; DIFFERENTIAL EXPRESSION; HUMAN NEUROBLASTOMAS; PROVIRAL INSERTION; LYMPHOCYTES-B; MICE BEARING	Little is known about stepwise deregulation of specific genes leading to lymphoid malignancy. Aberrant myc gene expression in transgenic mice is correlated with B cell lymphomagenesis. We generated a unique transgenic mouse model in which deregulated murine E mu-N-myc transgene expression leads to development of indolent B cell lymphoma. Tumor cells were monoclonal, morphologically mature and surface immunoglobulin expressing B cells. Tumors arose in a disease course and exhibited a cytoarchitectural appearance reminiscent of human follicular lymphoma. Yet tumor cells were staged as preB since they failed to rearrange the immunoglobulin light chain genes. Retroviral insertion mutagenesis analyses of adult transgenic mice infected as newborns with murine leukemia virus revealed decreased disease latency, increased lymphoma incidence and a histologically more mature tumor type. Proviral insertion sites were not equivalent when accelerated E mu-N-myc indolent lymphomas were compared to accelerated c-myc preB cell lymphomas. The bcl-2 gene was not disrupted in either spontaneous or provirally accelerated E mu-N-myc lymphomas. These findings suggest that tumor progression in N-myc-associated indolent B cell lymphoma can proceed along diverse pathways involving distinctly different combinations of deregulated and/or intact genes than those pathways described in highly aggressive forms of myc-related murine preB cell disease.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA	Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Sheppard, RD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Lindhurst, Marjorie/AHD-3412-2022		NATIONAL CANCER INSTITUTE [R01CA039192] Funding Source: NIH RePORTER; NCI NIH HHS [CA39192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALEXANDER WS, 1989, ONCOGENE, V4, P575; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; BERNS A, 1989, INT J CANCER, P22; BREUER M, 1991, CANCER RES, V51, P958; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLUM RG, 1990, CANCER CELL-MON REV, V2, P69; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CUYPERS HT, 1984, CELL, V37, P141; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOLCETTI R, 1989, ONCOGENE, V4, P1009; FINKE J, 1993, J CLIN ONCOL, V11, P1668, DOI 10.1200/JCO.1993.11.9.1668; FRIZZERA G, 1991, AM J CLIN PATHOL, V95, P684, DOI 10.1093/ajcp/95.5.684; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GOATES JJ, 1994, AM J SURG PATHOL, V18, P37, DOI 10.1097/00000478-199401000-00004; GRAY DA, 1991, CANCER INVEST, V9, P295; HAMILTON MS, 1991, LEUKEMIA, V5, P768; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Harris NL, 1992, NEOPLASTIC HEMATOPAT, P645; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HILKENS J, 1986, SOMAT CELL MOLEC GEN, V12, P81, DOI 10.1007/BF01560730; HILLION J, 1991, ONCOGENE, V6, P169; HIRVONEN H, 1991, BLOOD, V78, P3012; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; INGHIRAMI G, 1992, NEOPLASTIC HEMATOPAT, P27; JAFFE ES, 1985, SURF PATH LYMPH ORGA; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.iy.11.040193.002441; Kincade Paul W., 1993, P43; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; Kung H. T., 1991, Computation and Cognition. Proceedings of the First NEC Research Symposium, P1; KURIE JM, 1990, ONCOGENE, V5, P577; LADANYI M, 1992, BLOOD, V79, P2124; LANGDON WY, 1989, ONCOGENE RES, V4, P253; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Lee W M, 1989, Cancer Treat Res, V47, P37; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEVINE PH, 1992, CANCER RES, V52, pS5425; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MAGRATH I, 1992, CANCER RES, V52, pS5529; MARIN MC, 1994, ONCOGENE, V9, P3107; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; MITANI S, 1993, JPN J CANCER RES, V84, P37, DOI 10.1111/j.1349-7006.1993.tb02781.x; Mizukami Y, 1995, ANTICANCER RES, V15, P2899; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MOROY T, 1991, ONCOGENE, V6, P1941; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; NADEAU JH, 1987, GENETICS, V117, P533; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISEN PD, 1986, CANCER RES, V46, P6217; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Osmond D G, 1990, Semin Immunol, V2, P173; POTTER M, 1990, CARCINOGENESIS, V11, P1, DOI 10.1093/carcin/11.1.1; PRICE CGA, 1991, J CLIN ONCOL, V9, P1527, DOI 10.1200/JCO.1991.9.9.1527; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; RIMOKH R, 1993, BLOOD, V81, P136; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; RONCALLI M, 1994, CANCER-AM CANCER SOC, V74, P134, DOI 10.1002/1097-0142(19940701)74:1<134::AID-CNCR2820740122>3.0.CO;2-M; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SHEPPARD RD, 1991, MAMM GENOME, V1, P104, DOI 10.1007/BF02443786; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH RK, 1992, MOL CELL BIOL, V12, P1578, DOI 10.1128/MCB.12.4.1578; SOLE F, 1994, CANCER GENET CYTOGEN, V75, P72, DOI 10.1016/0165-4608(94)90219-4; STRAKA C, 1993, LEUKEMIA, V7, P268; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAKAO S, 1991, Kobe Journal of Medical Sciences, V37, P227; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WANG J, 1993, LEUKEMIA, V7, P1834; WEISS R, 1985, RNA TUMOR VIRUSES, V2; WEISS RA, 1985, RNA TUMOR VIRUSES, V1; WETHERALL NT, 1992, PATHOBIOLOGY, V60, P87, DOI 10.1159/000163704; WLODARSKA I, 1994, GENE CHROMOSOME CANC, V10, P171, DOI 10.1002/gcc.2870100304; YANO T, 1992, BLOOD, V80, P758; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZELENETZ AD, 1991, J EXP MED, V173, P197, DOI 10.1084/jem.173.1.197; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; ZUTTER M, 1991, BLOOD, V78, P1062	97	19	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	1998	17	16					2073	2085		10.1038/sj.onc.1202125	http://dx.doi.org/10.1038/sj.onc.1202125			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798678				2022-12-17	WOS:000076540900006
J	Smilenov, LB; Mellado, W; Rao, PH; Sawant, SG; Umbricht, CB; Sukumar, S; Pandita, TK				Smilenov, LB; Mellado, W; Rao, PH; Sawant, SG; Umbricht, CB; Sukumar, S; Pandita, TK			Molecular cloning and chromosomal localization of Chinese hamster telomeric protein chTRF1. Its potential role in chromosomal instability	ONCOGENE			English	Article						chTRF1; identity; localization	END ASSOCIATIONS; CELLS; TRF1; SEQUENCES; TELOBOX; LENGTH; YEAST	Chinese hamster cells frequently have altered karyotypes, To investigate the basis of recent observations that karyotypic alterations are related to telomeric fusions, we asked whether these alterations are due to lack of telomere repeat binding factor/s, Further, Chinese hamster chromosomes contain large blocks of interstitial telomeric repeats, which are preferentially involved in chromosome breakage and exchange, rendering it an interesting model for such studies. Here, we report on the cloning and the chromosomal localization of the Chinese hamster telomere repeat binding factor, chTRF1, The sequence analysis revealed, similar to human TRF1 (hTRF1), an N-terminal acidic domain, a TRF1 specific DNA binding motif and a C-terminal Myb type domain, Unlike mouse TRF1 (mTRF1), chTRF1 shows 97.5% identity to hTRF1, chTRF1 gene was localized on the long arm of chromosome 5. In vitro translation of chTRF1 resulted in protein product similar in molecular weight to hTRF1, Immunostaining of Chinese hamster ovary cells (CHO) with anti-TRF1 antibody revealed punctate nuclear staining. At metaphase, antibodies failed to detect TRF1 on most of the chromosome ends and the interstitial telomeric repeat bands. These studies suggest that chTRF1 does not bind the interstitial telomeric repeats, and its presence at the metaphase chromosome ends is limited. The later could be a factor contributing to frequent karyotypic alterations observed in Chinese hamster cells.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Johns Hopkins Univ, Ctr Oncol, Baltimore, MD 21205 USA	Columbia University; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine	Pandita, TK (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.		Pandita, Tej K/AAM-9188-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOUFFLER S, 1993, GENE CHROMOSOME CANC, V6, P98, DOI 10.1002/gcc.2870060206; Bouffler SD, 1996, MUTAT RES-REV GENET, V366, P129, DOI 10.1016/S0165-1110(96)90033-0; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DEAVEN LL, 1973, CHROMOSOMA, V41, P129, DOI 10.1007/BF00319690; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KAO FT, 1969, J CELL PHYSIOL, V74, P245, DOI 10.1002/jcp.1040740305; KATINKA MD, 1992, EMBO J, V11, P725, DOI 10.1002/j.1460-2075.1992.tb05105.x; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; SHEN M, 1997, P NATL ACAD SCI USA, V98, P13618; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Zakian VA, 1996, TRENDS CELL BIOL, V6, P29, DOI 10.1016/0962-8924(96)81035-X; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	30	19	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2137	2142		10.1038/sj.onc.1202138	http://dx.doi.org/10.1038/sj.onc.1202138			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798685				2022-12-17	WOS:000076540900013
J	Faure, S; Morin, N; Doree, M				Faure, S; Morin, N; Doree, M			Inactivation of protein kinase A is not required for c-mos translation during meiotic maturation of Xenopus oocytes	ONCOGENE			English	Article						c-mos oncogene; protein kinase A translation; oocyte maturation	MAP KINASE; CYTOPLASMIC POLYADENYLATION; MESSENGER-RNA; FROG OOCYTES; SOMATIC-CELLS; ACTIVATION; CYCLIN; PHOSPHATASE; METAPHASE; NUCLEAR	It has been shown previously that protein kinase A (PKA) maintains Xenopus oocytes arrested at G2, at least in part by preventing c-mos translation, but how PKA controls c-mos translation is not known. Using microinjection of recombinant c-mos, which still activates MAP kinase in the presence of active PKA, we have found that PKA does not exert any effect on translation of endogenous c-mos if MAP kinase is first activated, Even though they accumulate c-mos and contain MAP kinase activity as high as control oocytes, oocytes do not exit G2 in the presence of active PKA, These results are discussed in connection with recent findings on regulation of c-raf activity.	CNRS, Ctr Rech Biochim Macromol, Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Doree, M (corresponding author), CNRS, Ctr Rech Biochim Macromol, 1919 Route Mende, F-34293 Montpellier 5, France.		FAURE, Sandrine/N-6506-2018	FAURE, Sandrine/0000-0002-8902-8274; Morin, Nathalie/0000-0001-8677-1401				Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DAAR I, 1993, J CELL BIOL, V120, P1197, DOI 10.1083/jcb.120.5.1197; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GEBAUER F, 1994, EMBO J, V13, P5712, DOI 10.1002/j.1460-2075.1994.tb06909.x; GODEAU F, 1978, CR ACAD SCI D NAT, V286, P685; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; HUCHON D, 1979, BIOL CELLULAIRE, V35, P15; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KISHIMOTO T, 1982, EXP CELL RES, V137, P121, DOI 10.1016/0014-4827(82)90014-3; Kuge H, 1995, EMBO J, V14, P6301, DOI 10.1002/j.1460-2075.1995.tb00320.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1991, METHOD ENZYMOL, V201, P291; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MALLER J, 1977, J BIOL CHEM, V525, P1712; MALLER JL, 1983, ADV CYCL NUCL RES<D>, V15, P295; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MELTON DA, 1979, CELL, V18, P1165, DOI 10.1016/0092-8674(79)90229-0; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; RIME H, 1994, BIOL CELL, V82, P11, DOI 10.1016/0248-4900(94)90061-2; RIME H, 1992, DEV BIOL, V151, P105, DOI 10.1016/0012-1606(92)90217-5; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; Shibuya EK, 1996, CELL GROWTH DIFFER, V7, P235; SPEAKER MG, 1977, NATURE, V267, P848, DOI 10.1038/267848a0; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666	44	19	20	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1215	1221		10.1038/sj.onc.1202056	http://dx.doi.org/10.1038/sj.onc.1202056			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771964				2022-12-17	WOS:000075803300003
J	Kim, JO; Nau, MM; Allikian, KA; Makela, TP; Alitalo, K; Johnson, BE; Kelley, MJ				Kim, JO; Nau, MM; Allikian, KA; Makela, TP; Alitalo, K; Johnson, BE; Kelley, MJ			Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines	ONCOGENE			English	Article						gene amplification; L-myc; cyclophilin; small cell lung cancer; tumor cell line; alternative splicing	NEURONAL CEROID-LIPOFUSCINOSIS; COMPLEX PATTERN; EXPRESSION; IDENTIFICATION; IMMUNOPHILINS; PROTEINS; ONCOGENE; BINDING; RLF	Specific genetic alterations affecting proto-oncogenes of the myc gene family are frequently detected in human lung cancer. Among 11 SCLC cell lines with L-myc gene amplification, four were found to have alteration of the RLF gene by Southern blot and RT-PCR analyses. One cell line, NCI-H378, contained aberrantly-sized L-myc-hybridizing bands by Southern and Northern blot hybridization but had no alteration of RLF: Some L-myc-hybridizing cDNAs from NCI-H378 contained a novel sequence with close homology to the cyclophilins joined to antisense L-myc exon 2 sequence. Full length cDNAs isolated from human skeletal muscle containing only the novel sequence identify open reading frames of 301 and 296 amino acids and differ in the C-terminal region by 22 and 17 amino acids. This gene, tentatively named PPIE (peptidyl-prolyl cis-trans isomerase E), has 83% amino acid identity with the central conserved region of cyclophilin A, is evolutionarily conserved by Southern blot, and exhibits differential tissue expression with highest levels found in muscle and brain. Coamplification of PPIE was observed in seven of eleven L-myc amplified cell lines. Analysis of radiation hybrids suggests that the gene order is RLF-PPIE-L-myc on chromosome Ip and pulse-field gel electrophoresis localizes all three genes to an 800 megabase Mlu I fragment. The prognostic and functional consequences of PPIE gene amplification in SCLC can now be determined.	NCI, Lung Canc Biol Sect, Med Branch, Div Clin Sci, Bethesda, MD 20889 USA; Univ Helsinki, Canc Biol Lab, Dept Virol & Pathol, FIN-00290 Helsinki, Finland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Helsinki	Kelley, MJ (corresponding author), NCI, Lung Canc Biol Sect, Med Branch, Div Clin Sci, Bethesda, MD 20889 USA.		Alitalo, Kari K/J-5013-2014; Kelley, Michael/AAC-8939-2019; makela, tomi/B-3734-2009	Alitalo, Kari K/0000-0002-7331-0902; Kelley, Michael/0000-0001-9523-6080; makela, tomi/0000-0002-4869-8044				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; CARNEY DN, 1985, CANCER RES, V45, P2913; CELANO P, 1992, J BIOL CHEM, V267, P15092; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; GAZDAR AF, 1985, CANCER RES, V45, P2924; HAENDLER B, 1990, EUR J BIOCHEM, V190, P477, DOI 10.1111/j.1432-1033.1990.tb15598.x; HELLSTEN E, 1995, GENOMICS, V25, P404, DOI 10.1016/0888-7543(95)80040-S; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; Johnson BE, 1996, J CELL BIOCHEM, P210; JOHNSON BE, 1996, LUNG CANC PRINCIPLES, P83; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MACLEANHUNTER S, 1994, ONCOGENE, V9, P3509; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; Phelps RM, 1996, J CELL BIOCHEM, P32; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SPICER DB, 1992, MOL CELL BIOL, V12, P1324, DOI 10.1128/MCB.12.3.1324; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	27	19	21	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	1998	17	8					1019	1026		10.1038/sj.onc.1202006	http://dx.doi.org/10.1038/sj.onc.1202006			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747881				2022-12-17	WOS:000075560900010
J	Sithanandam, G; Ramakrishna, G; Diwan, BA; Anderson, LM				Sithanandam, G; Ramakrishna, G; Diwan, BA; Anderson, LM			Selective mutation of K-ras by N-ethylnitrosourea shifts from codon 12 to codon 61 during fetal mouse lung maturation	ONCOGENE			English	Article						fetal lung; lung tumor; gestation stage; N-ethylnitrosourea; K-ras; mutation; K-ras p21	ONCOGENE ACTIVATION; GENE-MUTATIONS; DNA-DAMAGE; A/J MICE; TUMORS; 1-ETHYL-1-NITROSOUREA; CARCINOGENESIS; ADENOCARCINOMA; NITROSAMINES; MUTAGENESIS	Fetal mouse lung before gestation day 17 shows unique sensitivity to causation of rapidly growing tumors by N-ethylnitrosourea (ENU). Since mouse lung tumors present a mutated K-ras oncogene, we hypothesized that this special susceptibility might reflect an unusual vulnerability of the K-ras gene. Of the lung tumors caused by ENU exposure of BALB/c mice on gestation day 14, 8/25 had a codon 12 mutation in K-ras, vs 4/25 in codon 61, Of 15 tumors after day 16 exposure, three had codon 12 and four codon 61 changes. Tumors from day 18 exposure had only codon 61 mutations (11/16), all A:T to G:C changes (CGA), By contrast, codon 12 (GGT) changes included G:C to T:A, to A:T,and to C:G, These results show significant (P<0.01) shift in the sensitivity of particular K-ras codons to ENU mutation, during fetal mouse lung maturation. In a test of a possible relationship to expression of K-ras, K-ras p21 was measured in lungs of fetal mice, and found to increase markedly on day 18 in comparison to days 14 and 16, Both alkylation of DIVA and base damage due to reactive oxygen species are postulated as mechanisms for mutation by ENU, whose efficacies vary with state of fetal lung maturation and K-rns expression.	SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA; NCI, Comparat Carcinogenesis Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Sithanandam, G (corresponding author), SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA.							AHOTUPA M, 1987, BIOCHEM BIOPH RES CO, V146, P1047, DOI 10.1016/0006-291X(87)90753-4; AKASAKA S, 1994, MUTAT RES-DNA REPAIR, V315, P105, DOI 10.1016/0921-8777(94)90011-6; ANDERSON LM, 1989, FUND APPL TOXICOL, V12, P604, DOI 10.1016/0272-0590(89)90033-X; ANDERSON LM, 1985, NEW APPROACHES TOXIC, P179; Bal W, 1996, CHEM RES TOXICOL, V9, P535, DOI 10.1021/tx950157i; BARTSCH H, 1989, FREE RADICAL BIO MED, V7, P637, DOI 10.1016/0891-5849(89)90144-5; BRANSTETTER DG, 1987, CANCER RES, V47, P348; BRANSTETTER DG, 1988, CANCER RES, V48, P379; CHUNG FL, 1992, CARCINOGENESIS, V13, P1269, DOI 10.1093/carcin/13.7.1269; CORREA P, 1983, LANCET, V2, P595; Driscoll KE, 1997, CARCINOGENESIS, V18, P423, DOI 10.1093/carcin/18.2.423; Enright H, 1996, CARCINOGENESIS, V17, P1175, DOI 10.1093/carcin/17.5.1175; FRENKEL K, 1992, PHARMACOL THERAPEUT, V53, P127, DOI 10.1016/0163-7258(92)90047-4; Hanawalt PC, 1996, ENVIRON HEALTH PERSP, V104, P547, DOI 10.2307/3432821; Harty LC, 1996, CANCER EPIDEM BIOMAR, V5, P997; HILL DL, 1975, CANCER RES, V35, P296; Hoffmann D, 1996, CRIT REV TOXICOL, V26, P199, DOI 10.3109/10408449609017931; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; Horio Y, 1996, MOL CARCINOGEN, V17, P217, DOI 10.1002/(SICI)1098-2744(199612)17:4<217::AID-MC5>3.0.CO;2-A; HUANG X, 1995, CARCINOGENESIS, V16, P1753, DOI 10.1093/carcin/16.8.1753; Ichikawa T, 1996, CANCER LETT, V107, P165, DOI 10.1016/0304-3835(96)04351-0; JACKSON JH, 1997, ONCOGENE, V14, P2083; KAMIYA H, 1995, CARCINOGENESIS, V16, P833; KAUFFMAN SL, 1976, J NATL CANCER I, V57, P821, DOI 10.1093/jnci/57.4.821; KAWANO R, 1995, JPN J CANCER RES, V86, P802, DOI 10.1111/j.1349-7006.1995.tb03089.x; Keohavong P, 1996, CLIN CANCER RES, V2, P411; LEPAGE F, 1995, CARCINOGENESIS, V16, P2779; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MALKINSON AM, 1992, CANCER RES, V52, pS2670; Marker PC, 1997, GENETICS, V145, P435; MATZINGER SA, 1994, MOL CARCINOGEN, V11, P42, DOI 10.1002/mc.2940110108; Mooney LA, 1997, CARCINOGENESIS, V18, P503, DOI 10.1093/carcin/18.3.503; Munoz EF, 1996, CARCINOGENESIS, V17, P2741, DOI 10.1093/carcin/17.12.2741; Nakae D, 1997, CANCER RES, V57, P1281; OHMORI H, 1992, CARCINOGENESIS, V13, P851, DOI 10.1093/carcin/13.5.851; Ramakrishna G, 1998, CARCINOGENESIS, V19, P463, DOI 10.1093/carcin/19.3.463; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; REHM S, 1991, TOXICOL PATHOL, V19, P35, DOI 10.1177/019262339101900105; REID TM, 1994, ENVIRON HEALTH PERSP, V102, P57, DOI 10.2307/3431764; RICE JM, 1969, ANN NY ACAD SCI, V163, P813, DOI 10.1111/j.1749-6632.1969.tb24900.x; RICE JM, 1969, TRANSPLACENTAL CARCI, P71; Rodriguez H, 1997, CANCER RES, V57, P2394; Samson L, 1997, CARCINOGENESIS, V18, P919, DOI 10.1093/carcin/18.5.919; SHIBUYA T, 1993, MUTAT RES, V297, P3, DOI 10.1016/0165-1110(93)90005-8; SILINI EM, 1994, VIRCHOWS ARCH, V424, P367; SILLS RC, 1995, CARCINOGENESIS, V16, P1623, DOI 10.1093/carcin/16.7.1623; Sipowicz MA, 1997, CANCER LETT, V117, P87, DOI 10.1016/S0304-3835(97)00208-5; STORM SM, 1993, TOXICOL LETT, V67, P201, DOI 10.1016/0378-4274(93)90056-4; THOMALE J, 1994, J BIOL CHEM, V269, P1681; Thrane EV, 1997, EXP LUNG RES, V23, P35, DOI 10.3109/01902149709046046; VESSELINOVITCH S D, 1973, P14; WARNER RL, 1995, AM J RESP CELL MOL, V12, P649, DOI 10.1165/ajrcmb.12.6.7539274; Westra WH, 1996, CANCER RES, V56, P2224; YOU M, 1992, CARCINOGENESIS, V13, P1583, DOI 10.1093/carcin/13.9.1583; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Ziegler RG, 1996, CANCER CAUSE CONTROL, V7, P157, DOI 10.1007/BF00115646	56	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					493	502		10.1038/sj.onc.1201958	http://dx.doi.org/10.1038/sj.onc.1201958			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696043				2022-12-17	WOS:000075043000012
J	Takahama, Y; Ochiya, T; Sasaki, H; Baba-Toriyama, H; Konishi, H; Nakano, H; Terada, M				Takahama, Y; Ochiya, T; Sasaki, H; Baba-Toriyama, H; Konishi, H; Nakano, H; Terada, M			Molecular cloning and functional analysis of cDNA encoding a rat leukemia inhibitory factor: towards generation of pluripotent rat embryonic stem cells	ONCOGENE			English	Article						sequence; gene targeting; gene expression; LIF; ES cell	KREBS ASCITES-CELLS; CONDITIONED MEDIUM; FEEDER CELLS; FACTOR LIF; IN-VITRO; DIFFERENTIATION; PURIFICATION; EXPRESSION; LINES; CARCINOMA	Embryonic stem (ES) cells are pluripotent cell lines established directly from the early embryo. Maintenance of the stem-cell phenotype of ES cells in vitro requires the presence of a feeder layer of fibroblasts or of a soluble factor, differentiation inhibitory activity (DIA) such as leukemia inhibitory factor (LIF). Here we report the cloning of complete rat LIF cDNA and its nucleotide sequence so as to facilitate studies of rat ES cell technologies on tumor biology. The nucleotide sequence of the rat LIF cDNA indicated that the rat LIF has 91% amino acid sequence identity with murine LIF. The cloned rat LTP cDNA has a putative biological activity as a differentiation-inducing factor on the murine myeloid leukemia cell line MI cells. Culture supernatant of the rat LIF cDNA-transduced rat fibroblast cell line could maintain the stem-cell phenotype of rat ES cells which shelved alkaline phosphatase activity, and this effect was much stronger than that by murine LIF. The availability of rat LIF which shows DIA will assist the in vitro analysis of rat ES cells, and culture of these cells is a route for the generation of gene targeting in rat.	Natl Canc Ctr, Res Inst, Div Genet, Tokyo 104, Japan; Natl Canc Ctr, Res Inst, Chemotherapy Div, Tokyo 104, Japan; Nara Med Univ, Dept Surg 1, Kashihara, Nara 634, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Nara Medical University	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Div Genet, Tokyo 104, Japan.		Ochiya, Takahiro/AAH-7585-2019					ABE E, 1986, P NATL ACAD SCI USA, V83, P5958, DOI 10.1073/pnas.83.16.5958; Akiyama N, 1997, CANCER RES, V57, P3548; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FIRST NL, 1994, REPROD FERT DEVELOP, V6, P553, DOI 10.1071/RD9940553; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GODARD A, 1988, BLOOD, V71, P1618; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; GOUGH NM, 1988, P NATL ACAD SCI USA, V85, P2623, DOI 10.1073/pnas.85.8.2623; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1988, ANAL BIOCHEM, V173, P359, DOI 10.1016/0003-2697(88)90200-X; HOGAN B, 1986, MANIPULATING MOUSE E, P207; IANNACCONE PM, 1994, DEV BIOL, V163, P288, DOI 10.1006/dbio.1994.1146; Ide H, 1997, ONCOGENE, V14, P1377, DOI 10.1038/sj.onc.1200964; Joyner A. L., 1993, GENE TARGETING PRACT, P36; KINOSHITA K, 1994, FEBS LETT, V337, P221, DOI 10.1016/0014-5793(94)80195-9; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; KOOPMAN P, 1984, EXP CELL RES, V154, P233, DOI 10.1016/0014-4827(84)90683-9; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAGLIA D, 1995, J INTERF CYTOK RES, V15, P455, DOI 10.1089/jir.1995.15.455; Pain B, 1996, DEVELOPMENT, V122, P2339; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; Savatier P, 1996, ONCOGENE, V12, P309; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SMITH TA, 1983, EXP CELL RES, V145, P458, DOI 10.1016/0014-4827(83)90025-3; SUKOYAN MA, 1992, MOL REPROD DEV, V33, P418, DOI 10.1002/mrd.1080330408; SUN L, 1995, MOL MAR BIOL BIOTECH, V4, P193; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; TOMIDA M, 1984, J BIOL CHEM, V259, P978; WHEELER MB, 1994, REPROD FERT DEVELOP, V6, P288; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; ZIOMEK CA, 1990, J HISTOCHEM CYTOCHEM, V38, P437, DOI 10.1177/38.3.1689343	37	19	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3189	3196		10.1038/sj.onc.1201826	http://dx.doi.org/10.1038/sj.onc.1201826			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671398				2022-12-17	WOS:000074261300012
J	Knudsen, ES; Wang, JYJ				Knudsen, ES; Wang, JYJ			Hyperphosphorylated p107 and p130 bind to T-antigen: identification of a critical regulatory sequence present in RB but not in p107/p130	ONCOGENE			English	Article						cell cycle; E1A; E2F-1; E2F-4; tumor suppressor	RETINOBLASTOMA GENE-PRODUCT; CYCLIN-DEPENDENT KINASE; TUMOR-SUPPRESSOR PROTEINS; E2F TRANSCRIPTION FACTOR; CELL-CYCLE; GROWTH SUPPRESSION; FAMILY MEMBERS; IN-VIVO; PHOSPHORYLATION; PRB	The retinoblastoma tumor suppressor RE and its related proteins, p107 and p130, are targets of several viral oncoproteins, including SV40 large T-antigen (T-Ag) and adenovirus E1A. T-Ag and E1A each contains an LXCXE-peptide motif through which binding to the conserved 'A/B pocket' present in RE, p107 and p130 is achieved, The LXCXE-binding activity of RB, we have previously shown, is inhibited by phosphorylation at Thr 821 and 826 in the C-terminal region of RE. Thr 821 and its surrounding sequence is unique to RE and not found in p107 or p130. Interestingly, hyperphosphorylation of p107 does not disrupt its ability to bind T-Ag or to inhibit the transactivating function of E1A. Insertion of a fourteen amino acid sequence of RE containing Thr 821 into p107 prevents binding of T-Ag and E1A to phosphorylated p107. These results show that the RE sequence surrounding Thr 821 plays a critical role in the regulation of the 'A/B pocket' function. In addition, these data indicate that the protein binding functions of RE and p107 are not equivalently regulated by phosphorylation.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Dept Biol, 0322,Bonner Hall 3326,9500 Gilman Dr, La Jolla, CA 92093 USA.				NCI NIH HHS [CA58320, R01 CA058320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BEIJERSBERGEN RL, 1996, BIOCHIM BIOPHYS ACTA, P1287; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Gibbs E, 1996, J BIOL CHEM, V271, P22847, DOI 10.1074/jbc.271.37.22847; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HAMEL PA, 1992, ONCOGENE, V7, P693; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kaelin WG, 1997, CANCER INVEST, V15, P243, DOI 10.3109/07357909709039722; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KNUDSEN ES, 1997, MOL CELL BIOL, V22, P1773; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIN BTY, 1992, CIBA F SYMP, V170, P227; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	61	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1655	1663		10.1038/sj.onc.1201682	http://dx.doi.org/10.1038/sj.onc.1201682			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582013				2022-12-17	WOS:000072807600003
J	Matsumoto, K; Saitoh, K; Koike, C; Narita, T; Yasugi, S; Iba, H				Matsumoto, K; Saitoh, K; Koike, C; Narita, T; Yasugi, S; Iba, H			Differential expression of fos and jun family members in the developing chicken gastrointestinal tract	ONCOGENE			English	Article						AP-1; chicken embryo; fos family; jun family; Sonic hedgehog; Indian hedgehog	TISSUE-SPECIFIC EXPRESSION; C-FOS; GENE-EXPRESSION; CELLULAR-TRANSFORMATION; MOUSE DEVELOPMENT; PEPSINOGEN GENE; NERVOUS-SYSTEM; AP-1 COMPLEX; FRA-2 GENE; ONCOGENE	We have analysed the expression patterns of all the known fos/jun family genes, which encode the components of the transcription factor AP-1, in the chicken embryonic digestive tract that develops into the esophagus, proventriculus, gizzard, small intestine, ceca and large intestine, From soon after formation of the tubular structure, each gene transcript was localized in distinct domains of the epithelium and mesenchyme in all of these major gastrointestinal organs, independently of the anterior-posterior axis, fra-2 was expressed predominantly in epithelium, which also expressed junD, while low-level expression of junD was also detected in smooth muscle cell precursors in mesenchyme, Expression of c-jun and c-fos was detectable in both mesenchyme and epithelium through the whole tract, In the differentiated proventriculus, the developed glandular epithelium expressed c-jun and junD, but not fra-2, while luminal epithelium expressed fra-2 and junD, but not c-jun. These results suggest that distinct Fos/Jun protein heterodimers play important roles in maintaining the epithelial-mesenchymal interactions. Similar expression patterns to those of fra-2 and junD were established from earlier stages by Sonic hedgehog gene and the Indian hedgehog gene, respectively, both of which are important in forming the inductive network between epithelium and mesenchyme of the digestive tract.	Univ Tokyo, Inst Med Sci, Dept Gene Regulat, Minato Ku, Tokyo 108, Japan; Tokyo Metropolitan Univ, Fac Sci, Dept Biol, Hachioji, Tokyo 19203, Japan	University of Tokyo; Tokyo Metropolitan University	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Gene Regulat, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bellusci S, 1997, DEVELOPMENT, V124, P53; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BRITT M, 1991, ONCOGENE, V6, P1959; CARRASCO D, 1995, ONCOGENE, V10, P1069; CAUBET JF, 1989, MOL CELL BIOL, V9, P2269, DOI 10.1128/MCB.9.5.2269; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FOLETTA VC, 1994, ONCOGENE, V9, P3305; FUJIWARA KT, 1987, J VIROL, V61, P4012, DOI 10.1128/JVI.61.12.4012-4018.1987; FUKUDA K, 1994, DEVELOPMENT, V120, P3487; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARTL M, 1991, ONCOGENE, V6, P1623; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; NARITA T, 1998, IN PRESS DEV GROWTH, V39; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; REZZONICO R, 1995, ONCOGENE, V11, P1069; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; SATO K, 1997, IN PRESS DEV GROWTH, V38; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SONOBE MH, 1995, ONCOGENE, V10, P689; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P3994, DOI 10.1073/pnas.94.8.3994; Welter JF, 1995, ONCOGENE, V11, P2681; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YASUGI S, 1994, INT J DEV BIOL, V38, P273; YASUGI S, 1981, J BIOCHEM-TOKYO, V89, P311, DOI 10.1093/oxfordjournals.jbchem.a133195; YASUGI S, 1993, DEV GROWTH DIFFER, V35, P1; YASUGI S, 1995, TISS CULT RES COMMUN, V14, P177; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715	35	19	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1611	1616		10.1038/sj.onc.1201675	http://dx.doi.org/10.1038/sj.onc.1201675			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569029				2022-12-17	WOS:000072743200012
J	Sasahara, M; Amano, S; Sato, H; Yang, JG; Hayase, Y; Kaneko, M; Sato, I; Suzaki, M; Hazama, F				Sasahara, M; Amano, S; Sato, H; Yang, JG; Hayase, Y; Kaneko, M; Sato, I; Suzaki, M; Hazama, F			Normal developing rat brain expresses a platelet-derived growth factor B chain (c-sis) mRNA truncated at the 5 ' end	ONCOGENE			English	Article						platelet-derived growth factor; cloning; in situ hybridization; truncation; development; neuron	CENTRAL-NERVOUS-SYSTEM; SIMIAN SARCOMA-VIRUS; PDGF RECEPTOR GENES; MESSENGER-RNA; NEURONS; PROMOTER; IMMUNOREACTIVITY; PURIFICATION; INDUCTION; PITUITARY	The 5' untranslated sequence (5' UTS) of platelet-derived growth factor B (PDGF-B/c-sis) mRNA is highly preserved through evolution, and inhibits translation of downstream coding sequences, In this study, using Northern analysis we identified two PDGF-B/c-sis mRNAs (3.5 kb and 2.6 kb) expressed in normal developing rat brain. In contrast to the constitutive expression of 3.5 kb mRNA, the expression of 2.6 kb mRNA increased markedly in accordance with those stages of brain development at which we had previously demonstrated an increased immunoreactivity for PDGF-B/c-SIS in neurons (Sasahara ef al., 1992). By PCR cloning and the RNase protection assay, we determined the complete sequence of rat PDGF-B/c-sis, and found that the 2.6 kb transcript was a form of the 3.5 kb message truncated at the 5' end, and that the predominant 2.6 kb mRNA commenced 15 nt upstream of the signal peptide, Accordingly, it is suggested that the truncation of 5' UTS contributes to the expression of PDGF-B/c-SIS protein in the CNS, Lack of translational inhibitory 5' UTS of PDGF-B/c-sis transcript and resultant efficient protein translation have been reported in only a few transformed cells and cultured umbilical vein endothelial cells, We have extended this knowledge to the developing rat brain, and suggest that a similar mechanism could operate widely in non-transformed tissue in vivo.	Shiga Univ Med Sci, Dept Pathol, Otsu, Shiga 52021, Japan; Shiga Univ Med Sci, Dept Biol, Otsu, Shiga 52021, Japan; Shiga Univ Med Sci, Dept Neurosurg, Otsu, Shiga 52021, Japan; Shiga Univ Med Sci, Cent Res Lab, Otsu, Shiga 52021, Japan; Mochida Pharmaceut Co, Tokyo 160, Japan; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia	Shiga University of Medical Science; Shiga University of Medical Science; Shiga University of Medical Science; Shiga University of Medical Science; Mochida Pharmaceutical Co Ltd; University of Sydney	Sasahara, M (corresponding author), Shiga Univ Med Sci, Dept Pathol, Otsu, Shiga 52021, Japan.							ADAMS TE, 1995, MOL CELL ENDOCRINOL, V108, P23, DOI 10.1016/0303-7207(95)92575-9; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BESMER P, 1983, J VIROL, V46, P606, DOI 10.1128/JVI.46.2.606-613.1983; BONTHRON DT, 1991, GENOMICS, V10, P287, DOI 10.1016/0888-7543(91)90515-G; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHENG B, 1995, J NEUROSCI, V15, P7095; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P2815, DOI 10.1093/nar/23.15.2815; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FEN Z, 1991, ONCOGENE, V6, P953; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HORVATH P, 1995, CELL GROWTH DIFFER, V6, P1103; HUTCHINS JB, 1992, DEV BRAIN RES, V67, P121, DOI 10.1016/0165-3806(92)90213-G; IIHARA K, 1994, J CEREBR BLOOD F MET, V14, P818, DOI 10.1038/jcbfm.1994.102; Iihara K, 1996, J CEREBR BLOOD F MET, V16, P941, DOI 10.1097/00004647-199609000-00018; Krupinski J, 1997, STROKE, V28, P564, DOI 10.1161/01.STR.28.3.564; LANS MS, 1994, J BIOL CHEM, V269, P14170; LOY R, 1980, ANAT EMBRYOL, V159, P257, DOI 10.1007/BF00317650; MALDONADO PE, 1988, J MEMBRANE BIOL, V106, P203, DOI 10.1007/BF01872158; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEKADA A, 1996, ACTA HISTOCHEM CYT S, V29, P1057; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; POKORNY J, 1981, BRAIN RES BULL, V7, P113, DOI 10.1016/0361-9230(81)90075-7; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; REDDY UR, 1992, J NEUROSCI RES, V31, P670, DOI 10.1002/jnr.490310411; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; Sambrook J., 1989, MOL CLONING; SASAHARA A, 1992, DEV BRAIN RES, V68, P41, DOI 10.1016/0165-3806(92)90246-S; SASAHARA M, 1995, MOL BRAIN RES, V32, P63, DOI 10.1016/0169-328X(95)00060-6; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; SMITS A, 1993, EUR J NEUROSCI, V5, P986, DOI 10.1111/j.1460-9568.1993.tb00950.x; TAKAYAMA S, 1994, BRAIN RES, V653, P131, DOI 10.1016/0006-8993(94)90381-6; Valenzuela CF, 1996, J BIOL CHEM, V271, P16151, DOI 10.1074/jbc.271.27.16151; VANDENOUWELAND AMW, 1996, NUCLEIC ACIDS RES, V14, P756; VIGNAIS L, 1995, NEUROREPORT, V6, P1993, DOI 10.1097/00001756-199510010-00010; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEIS JH, 1994, NUCLEIC ACIDS RES, V22, P3427, DOI 10.1093/nar/22.16.3427; YEH HJ, 1993, P NATL ACAD SCI USA, V90, P1952, DOI 10.1073/pnas.90.5.1952; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	46	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	1998	16	12					1571	1578		10.1038/sj.onc.1201679	http://dx.doi.org/10.1038/sj.onc.1201679			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569024				2022-12-17	WOS:000072743200007
J	Ostrowski, J; Florio, SK; Denis, GV; Suzuki, H; Bomsztyk, K				Ostrowski, J; Florio, SK; Denis, GV; Suzuki, H; Bomsztyk, K			Stimulation of p85/RING3 kinase in multiple organs after systemic administration of mitogens into mice	ONCOGENE			English	Article						RING3 nuclear kinase; EGF; IL-1; leukemia	ACTIVATED-PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; MOUSE-LIVER; MAP KINASE; CASCADE; PHOSPHORYLATES; INTERLEUKIN-1; DOMAIN	Using an autophosphorylation membrane assay, we examined activation of kinases in different organs after intraperitoneal injections of mitogens and cytokines into mice, In the multiple organs examined administration of either epidermal growth factor (EGF), phorbol 12-myristate 13-acetate (PMA) or interleukin-1 beta (IL-1 beta) activated a number of kinases, Most notably among those was a kinase of approximately 85 kDa (p85) that was activated by EGF, PMA and IL-1 beta in the lung, kidney, brain, liver and heart, The size and properties of this enzyme are indistinguishable from the RING3 kinase that has a very high activity in leukocytes of patients with leukemia, In animals treated with PMA, antibodies against RING3 kinase immunoprecipitated PMA-responsive p85 activity from the lung and brain suggesting that p85 and RING3 kinases are the same enzymes, Activation of p85/RING3 kinase by growth factors in multiple organs might reflect involvement of this enzyme in the pathogenesis of leukemias and other proliferative diseases.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA; Ctr Canc, Dept Gastroenterol, Warsaw, Poland	University of Washington; University of Washington Seattle; Boston University	Bomsztyk, K (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.			Ostrowski, Jerzy/0000-0003-1363-3766; Denis, Gerald/0000-0001-9886-0401	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45134, GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPINI G, 1994, HEPATOLOGY, V20, P494, DOI 10.1002/hep.1840200231; Beck S, 1992, DNA Seq, V2, P203, DOI 10.3109/10425179209020804; BIRD TA, 1994, FEBS LETT, V338, P31, DOI 10.1016/0014-5793(94)80111-8; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Denis GV, 1996, GENE DEV, V10, P261, DOI 10.1101/gad.10.3.261; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DINARELLO CA, 1991, BLOOD, V77, P1627; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; LAURENCE DJR, 1990, TUMOR BIOL, V11, P229, DOI 10.1159/000217659; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; OBRIAN CA, 1989, CANCER METAST REV, V8, P199, DOI 10.1007/BF00047337; RACHIE NA, 1993, J BIOL CHEM, V268, P22143; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976	25	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	1998	16	9					1223	1227		10.1038/sj.onc.1201624	http://dx.doi.org/10.1038/sj.onc.1201624			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528865				2022-12-17	WOS:000072336000014
J	Kao, MC; Liu, GY; Chuang, TC; Lin, YS; Wuu, JA; Law, SL				Kao, MC; Liu, GY; Chuang, TC; Lin, YS; Wuu, JA; Law, SL			The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene	ONCOGENE			English	Article						HER-2/neu; SV30 large T antigen; p185; cancer gene therapy	E1A GENE-PRODUCTS; LARGE TUMOR-ANTIGEN; VIRUS-40 LARGE-T; NEU ONCOGENE; OVARIAN-CANCER; PROTO-ONCOGENE; EGF RECEPTOR; TRANSCRIPTIONAL REPRESSION; C-ERBB-2 GENE; BREAST-CANCER	The deregulation of the HER-2/neu protooncogene was demonstrated in a wide variety of human cancers and shown to be correlated with the progress of malignancy and metastasis in animal models. Repression of HER-2/neu overexpression suppressed the malignant phenotypes of HER-2/neu-overexpressing cancer cells. This suggested that HER-2/neu may be a good target for developing anti-cancer drugs, We found a deletion mutant of simian virus 40 (SV40) large T antigen (LT) suppresses the Her-2/neu oncogene expression at the transcriptional level, PCR clones of this mutant SV40LT, named LT425, which contains the N-terminal region of amino acid residues 1-178 of SV40LT, were subcloned and stably transfected into the HER-2/neu-overexpressing human ovarian cancer SKOV3.ip1 cells. These LT425 clones were found to be able to down-regulate the endogenous production of p185(HER-2/neu). In addition, the LT425-expressing stable transfectants showed reduced growth rate, low soft agarose colony forming ability, and low tumorigenic potential as compared with the parental line. These data suggested that the N-terminal 178 amino acids domain only of SV40LT may act as a transforming repressor of HER-2/neu oncogene.	Natl Def Med Ctr, Dept Biochem, Taipei 10764, Taiwan; Cheng Hsin Phys Med & Rehabil Ctr, Taipei, Taiwan; Vet Gen Hosp, Dept Med Res, Taipei 11217, Taiwan	National Defense Medical Center	Kao, MC (corresponding author), Natl Def Med Ctr, Dept Biochem, Taipei 10764, Taiwan.		Liu, Gary/A-6200-2009					Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERCHUCK A, 1990, CANCER RES, V50, P4087; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CHUANG TC, 1996, THESIS NATL DEFENSE; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Cozen SD, 1995, ONCOGENE, V11, P2295; DEMILIA J, 1989, ONCOGENE, V4, P1233; Eckner R, 1996, MOL CELL BIOL, V16, P3454; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GANNON JV, 1991, NATURE, V349, P802; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gu KF, 1996, CANCER LETT, V99, P185, DOI 10.1016/0304-3835(95)04061-7; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; HUNG MC, 1986, BIOCH MOL EPIDEMIOL, V40, P391; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MATIN A, 1993, CELL GROWTH DIFFER, V4, P1; MILLER SJ, 1994, INT J ONCOL, V4, P965; MITRA AB, 1994, CANCER RES, V54, P637; Monier R., 1986, PAPOVAVIRIDAE, V1, P247; Mymryk JS, 1996, ONCOGENE, V13, P1581; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; REDDY VB, 1978, SCIENCE, V200, P494, DOI 10.1126/science.205947; ROBB JA, 1972, J VIROL, V9, P562, DOI 10.1128/JVI.9.3.562-563.1972; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SALZMAN NP, 1986, PAPOVAVIRIDAE, P27; SAWAI ET, 1994, VIROLOGY, V189, P782; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINER DB, 1990, CANCER RES, V50, P421; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHANG X, 1989, ONCOGENE, V4, P985; ZHAU HE, 1990, MOL CARCINOGEN, V3, P254, DOI 10.1002/mc.2940030503	63	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					547	554		10.1038/sj.onc.1201513	http://dx.doi.org/10.1038/sj.onc.1201513			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484845				2022-12-17	WOS:000071739400014
J	Mor, O; Read, M; Fried, M				Mor, O; Read, M; Fried, M			p53 in polyoma virus transformed REF52 cells	ONCOGENE			English	Article						p53; polyoma virus; cell cycle; DNA damage; p21; MDM2	WILD-TYPE P53; P53-DEPENDENT G(1) ARREST; DNA-DAMAGE RESPONSE; GROWTH ARREST; HUMAN FIBROBLASTS; T-ANTIGEN; PROTEIN; EXPRESSION; ONCOGENES; IDENTIFICATION	While cellular transformation by small DNA tumour viruses usually involves targeting the product of the p53 tumour suppressor gene by a virally encoded protein, none of the three polyoma virus (Py) specified T antigens have been observed to interact with p53, We show that primary mouse embryo fibroblasts and REF52 cells, which resemble primary cells in requiring co-operating oncogenes for transformation, cannot be transformed by the Py oncogene, middle T-antigen (PyMT), alone, These cells can be transformed by the complete Py early region, which encodes the Py large, middle and small T-antigens, We find that PyMT can transform rodent cells lacking a functional p53 protein (p53 null mouse embryo fibroblasts and DN-REF52 cells which contain a dominant negative p53), In Py transformed REF52 cells (Py-REF52) there is no significant accumulation of p53 protein, as opposed to SV40 transformed REF52 cells (SV-REF52) in which the amount of steady state p53 protein is elevated, However accumulation of p53 is observed following exposure of Py-REF52 cells to u.v. Treatment of Py-REF52 cells with X-rays results in a rapid increase in the levels of the p53-induced proteins p21/WAF1 and MDM2. In untransformed REF52 cells, S-irradiation causes p53 activation, which results in induction of both G1/S and G2/M blocks, In SV-REF52 and DN-REF52 cells, p53 abrogation results in the absence of both the G1/S and G2/M blocks, Only the absence of a G1/S block is observed in Py-REF52 cells exposed to S-irradiation, Together these results indicate that in contrast to most other DNA tumour viruses, Py does not appear to interefere with the DNA damage induced transactivation activities of the p53 protein but absence of a functional p53 protein can mediate transformation by the PyMT oncogene in the absence of other co-operating oncogenes, Possible modes of transformation by Py are discussed.	Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, London WC2A 3PX, England	Cancer Research UK	Fried, M (corresponding author), Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, POB 123, London WC2A 3PX, England.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CUZIN F, 1984, BIOCHIM BIOPHYS ACTA, V781, P193, DOI 10.1016/0167-4781(84)90084-8; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dilworth S M, 1990, Semin Cancer Biol, V1, P407; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3691; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLSON DC, 1993, ONCOGENE, V8, P2353; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sambrook J., 1982, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; STEWART N, 1995, ONCOGENE, V10, P109; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	42	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3113	3119		10.1038/sj.onc.1201549	http://dx.doi.org/10.1038/sj.onc.1201549			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444959				2022-12-17	WOS:000070968000011
J	Curtis, DJ; Robb, L; Strasser, A; Begley, CG				Curtis, DJ; Robb, L; Strasser, A; Begley, CG			The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice	ONCOGENE			English	Article						scl; tal-1; p53; ras; lymphomagenesis	ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEIN; PEDIATRIC-ONCOLOGY-GROUP; SCL GENE-PRODUCT; WILD-TYPE P53; CELL LEUKEMIA; ERYTHROID-DIFFERENTIATION; THYMOCYTE DEVELOPMENT; POINT MUTATIONS; TAL1	Abnormal expression of SCL (TAL-1/TCL5) occurs in the majority of paediatric cases of acute T-cell lymphoblastic leukemia (T-ALL), Unexpectedly however, transgenic mice carrying scl coupled to the human T-cell specific CD2 enhancer (CD2-scl) did not spontaneously develop T-cell lymphomas despite high levels of scl expression in their thymocytes, Analogous to other transgenic models of lymphomagenesis, it is likely that additional genetic abnormalities are required to cooperate with scl to trigger lymphomagenesis, Two possible candidates are the p53 and N-ras genes which are mutated in some cases of T-ALL, particularly in relapsed disease, Therefore, we examined lymphomagenesis in the progeny of CD2-scl mice crossed with N-ras transgenic mice or p53 deficient, Surprisingly, the frequency of lymphomas in the p53 nullizygous or N-ras transgenic mice was not enhanced by expression of the scl transgene, In fact, expression of scl in both genetic backgrounds paradoxically reduced the frequency of thymic lymphomas and, at least in the p53 nullizygous mice, shifted the pattern of organ involvement to the peripheral lymphoid organs, In contrast, CD2-scl transgene expression accelerated lymphomagenesis in p53 heterozygous mice, These data suggest that the collaborative effects of scl with N-ras or p53 vary according to the developmental stage of the T-cell.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC, AUSTRALIA; ROYAL MELBOURNE HOSP, COOPERAT RES CTR CELLULAR GROWTH FACTORS, MELBOURNE, VIC, AUSTRALIA; ROYAL MELBOURNE HOSP, ROTARY BONE MARROW RES LAB, MELBOURNE, VIC, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Royal Melbourne Hospital			Strasser, Andreas/C-7581-2013; Curtis, David/H-4996-2014	Strasser, Andreas/0000-0002-5020-4891; Curtis, David/0000-0001-9497-0996	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, CANCER SURV, V15, P119; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BORN W, 1988, J IMMUNOL, V140, P3228; BOS JL, 1989, CANCER RES, V49, P4682; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; Condorelli GL, 1996, CANCER RES, V56, P5113; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DICCIANNI MB, 1994, BLOOD, V84, P3105; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELWOOD NJ, 1993, ONCOGENE, V8, P3093; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; LANIER LL, 1986, J IMMUNOL, V137, P2501; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; LUBBERT M, 1990, BLOOD, V75, P1163; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PURDIE CA, 1994, ONCOGENE, V9, P603; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROBB L, 1995, ONCOGENE, V10, P205; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADA M, 1993, BLOOD, V82, P3163; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	45	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	1997	15	24					2975	2983		10.1038/sj.onc.1201467	http://dx.doi.org/10.1038/sj.onc.1201467			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416841				2022-12-17	WOS:A1997YK37700010
J	Hu, JF; Cheng, ZQ; Chisari, FV; Vu, TH; Hoffman, AR; Campbell, TC				Hu, JF; Cheng, ZQ; Chisari, FV; Vu, TH; Hoffman, AR; Campbell, TC			Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet	ONCOGENE			English	Article						hepatitis B virus; dietary protein; IGF2; IGF1; HGF; gene expression	GROWTH-FACTOR-II; PRIMARY HEPATOCELLULAR-CARCINOMA; LARGE ENVELOPE POLYPEPTIDE; INSITU HYBRIDIZATION; PARTIAL-HEPATECTOMY; INTEGRATION SITE; CARRIER STATE; RISK-FACTORS; EXPRESSION; MICE	Persistent infection with hepatitis B virus (HBV) is one of the primary risk factors for human hepatocellular carcinoma (HCC). In a human ecological study, we have shown that, in addition to HBV, animal food consumption also significantly contributes to the variance of HCC. To test the interacting effect of HBV and animal food consumption on the development of HCC, we investigated HBV expression in HBV transgenic mice fed three levels of casein diet. HBV expression in transgenic animals was substantially inhibited when dietary casein was reduced from the traditional level of 22% to the level of 6%. Northern analysis revealed that suppression of HBV was derived from both the; upstream albumin promoter and the internal HBV promoter. Immunochemical staining of liver sections indicated that only a few hepatocytes around the central vein expressed viral surface antigen (HBsAg) in the 6% casein animals, whereas virtually all hepatocytes stained positively for HBsAg in the 22% dietary casein animals. Serum HBsAg concentrations at 4 months were increased by 1.6-, 2.1-, and 5.1-fold over baseline for animals fed the 6%, 14%, and 22% casein diets, respectively. Correspondingly, liver injury was much less severe in animals fed 6% casein diet than in those fed 14% and 22% casein diets. These results demonstrate that a low casein diet is a potent suppresser of HBV transgene and HBV-induced liver injury, suggesting that diet management may be a practical means to aid in the control HBV infection.	VET ADM MED CTR, GRECC, PALO ALTO, CA 94304 USA; STANFORD UNIV, DEPT MED, DIV ENDOCRINOL, PALO ALTO, CA 94304 USA; Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA; CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; Scripps Research Institute; Cornell University	Hu, JF (corresponding author), VET ADM MED CTR, MED SERV, PALO ALTO, CA 94304 USA.		Chisari, Francis V/A-3086-2008; Hu, Jifan/Q-3003-2019	Chisari, Francis/0000-0002-4832-1044; HU, Jifan/0000-0002-2174-0361	NCI NIH HHS [R01-CA34205] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034205] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BEASLEY RP, 1981, LANCET, V2, P1129; BOSCH FX, 1988, IARC SCI PUBLICATION, V89; CAMPBELL TC, 1990, CANCER RES, V50, P6882; CHANG MH, 1991, HEPATOLOGY, V13, P316, DOI 10.1016/0270-9139(91)92446-F; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; CLEMMONS DR, 1991, ANNU REV NUTR, V11, P393, DOI 10.1146/annurev.nu.11.070191.002141; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DIBISCEGLIE AM, 1987, PRINCIPLES PRACT ONC, V1, P1; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; Hu JF, 1996, J BIOL CHEM, V271, P18253, DOI 10.1074/jbc.271.30.18253; *INT AG RES CANC, 1988, IARC MON EV CARC RIS, P416; *INT AG RES CANC, 1987, IARC MON EV CARC RIS, P83; Kew MC, 1996, CLIN LAB MED, V16, P395, DOI 10.1016/S0272-2712(18)30276-2; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; LONDON WT, 1981, HUM PATHOL, V12, P1085, DOI 10.1016/S0046-8177(81)80329-2; LUTWICK LI, 1979, LANCET, V1, P755; Maier JAM, 1996, INT J CANCER, V65, P168, DOI 10.1002/(SICI)1097-0215(19960117)65:2<168::AID-IJC7>3.0.CO;2-X; MAITER D, 1988, J ENDOCRINOL, V118, P113, DOI 10.1677/joe.0.1180113; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PASQUINELLI C, 1994, TRANSGENICS, V1, P451; POPPER H, 1987, HEPATOLOGY, V7, P764, DOI 10.1002/hep.1840070425; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROGLER CE, 1985, SCIENCE, V230, P319, DOI 10.1126/science.2996131; SALLIE R, 1994, GASTROENTEROL CLIN N, V23, P567; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; STRAUS DS, 1990, ENDOCRINOLOGY, V127, P1849, DOI 10.1210/endo-127-4-1849; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; Szmuness W, 1978, Prog Med Virol, V24, P40; TANAKA K, 1995, CANCER CAUSE CONTROL, V6, P91, DOI 10.1007/BF00052768; TANAKA T, 1986, HUM PATHOL, V17, P202; VATANASAPT V, 1995, CANCER EPIDEM BIOMAR, V4, P475; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; YANG DY, 1991, CARCINOGENESIS, V12, P1893, DOI 10.1093/carcin/12.10.1893; YOUNGMAN LD, 1992, CARCINOGENESIS, V13, P1607, DOI 10.1093/carcin/13.9.1607; YOUNGMAN LD, 1992, CANCER LETT, V66, P165, DOI 10.1016/0304-3835(92)90229-O; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K	47	19	19	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2795	2801		10.1038/sj.onc.1201444	http://dx.doi.org/10.1038/sj.onc.1201444			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419970				2022-12-17	WOS:A1997YJ80300005
J	Walsh, AB; Dhanasekaran, M; BarSagi, D; Kumar, CC				Walsh, AB; Dhanasekaran, M; BarSagi, D; Kumar, CC			SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway	ONCOGENE			English	Article						RAS; RAC; membrane ruffles; signaling pathways	SIGNAL-TRANSDUCTION; FARNESYLTRANSFERASE INHIBITORS; ACTIN POLYMERIZATION; KINASE; ACTIVATION; PROTEINS; GROWTH; FARNESYLATION; ONCOGENES; INDUCTION	RAS interacts with multiple targets in the cell and controls at least two signaling pathways, one regulating extracellular signal-regulated kinase (ERK) activation and the other controlling membrane ruffling formation. These two pathways appear to act synergistically to cause: transformation. SCH 51344 is a pyrazolo-quinoline derivative identified based on its ability to derepress transformation sensitive alpha-actin promoter in RAS-transformed cells, Previous studies have shown that SCH 51344 is a potent inhibitor of RAS-transformation, However, SCH 51344 had very little effect on the activities of proteins in the ERI( pathway, suggesting that it inhibits RAS-transformation by a novel mechanism. In this study, we show that SCH 51344 specifically blocks membrane ruffling induced by activated forms of H-RAS, II-RAS, N-RAS and RAG. Treatment of fibroblast cells with this compound had very little effect on RAS-mediated activation of ERK and JUN kinase activities. SCH 51344 was effective in inhibiting the anchorage-independent growth of Rat-2 fibroblast cells transformed by the three forms of oncogenic RAS and RBC V12, These results indicate that SCH 51344 inhibits a critical component of the membrane ruffling pathway downstream from RAC and suggest that targeting this pathway may be an effective approach to inhibit transformation by RAS and other oncogenes.	SCHERING PLOUGH CORP,RES INST,DEPT TUMOR BIOL,KENILWORTH,NJ 07033; SUNY STONY BROOK,DEPT MICROBIOL & MOL GENET,STONY BROOK,NY 11794; SUNY STONY BROOK,GRAD PROGRAM PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; TEMPLE UNIV,SCH MED,FELS INST CANC RES,PHILADELPHIA,PA 19140	Merck & Company; Schering Plough Corporation; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA 55360] Funding Source: Medline; NIGMS NIH HHS [GM 49897] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055360, R37CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; BOS JL, 1989, CANCER RES, V49, P4682; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX LR, 1991, CANCER RES, V51, P4810; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; ITOH O, 1989, CANCER RES, V49, P996; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KUMAR CC, 1995, CANCER RES, V55, P5106; KUMAR CC, 1992, CANCER RES, V52, P6877; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; QUI RG, 1995, NATURE, V374, P457; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459	35	19	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2553	2560		10.1038/sj.onc.1201424	http://dx.doi.org/10.1038/sj.onc.1201424			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399643				2022-12-17	WOS:A1997YG73200005
J	Golubovskaya, VM; Presnell, SC; Hooth, MJ; Smith, GJ; Kaufmann, WK				Golubovskaya, VM; Presnell, SC; Hooth, MJ; Smith, GJ; Kaufmann, WK			Expression of telomerase in normal and malignant rat hepatic epithelia	ONCOGENE			English	Article						telomerase; rat liver; hepatocyte; stem cell; hepatocarcinogenesis	STEM-LIKE CELLS; IMMORTAL CELLS; RNA COMPONENT; CANCER; LIVER; TISSUES; HEPATOCARCINOGENESIS; DIFFERENTIATION; PROLIFERATION; PROGRESSION	Telomerase is a ribonucleoprotein that synthesizes telomeric DNA repeats onto the ends of chromosomes. More than 85% of human cancers express telomerase activity and a large proportion of human hepatocellular carcinomas are positive, To study the role of telomerase expression in rat hepatocarcinogenesis, telomerase activity was assayed in various rat tissues and in two types of liver epithelial cells: hepatocytes and hepatic epithelial stem-like cells. In the present study, we demonstrate that telomerase activity in rats is tissue-specific and stable with animal aging. Liver and testis were found to be telomerase positive, spleen had low or no activity, and kidney was negative, Telomerase activity did not change significantly in 18 month-old rats compared to 2 month-old rats, but was moderately (twofold) increased during liver regeneration induced by a 2/3's partial hepatectomy. Telomerase activity was detected in isolated rat hepatocytes and low passage hepatic epithelial stem-like cells (WB-F344). Telomerase activity displayed significant variations in a propagable clone of WB-F344 cells. At low passage levels after establishment in vitro (passages 4-9) non-tumorigenic WB-F344 cells expressed telomerase activity. During further in vitro passaging these cells lost expression of telomerase. Expression of telomerase in the tumor-derived lines of WB-F344 cells but not in the selectively cycled, parental lineages of these cells suggests that there may be a role for telomerase in hepatocarcinogenesis.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL & LAB MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM TOXICOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA 64340, CA 59495, CA 59486] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059486, R01CA064340] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACCHETTI S, 1995, INT J ONCOL, V7, P423; BIESSMANN H, 1992, ADV GENET, V30, P185, DOI 10.1016/S0065-2660(08)60321-1; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CAYAMA E, 1978, NATURE, V275, P60, DOI 10.1038/275060a0; CHADENEAU C, 1995, ONCOGENE, V11, P893; CHIAO C, 1995, AM J PATHOL, V146, P1248; COLEMAN WB, 1993, AM J PATHOL, V142, P1373; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gilley D, 1996, MOL CELL BIOL, V16, P66; Greaves M, 1996, TRENDS GENET, V12, P127, DOI 10.1016/0168-9525(96)30016-4; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GRISHAM JW, 1993, P SOC EXP BIOL MED, V204, P270; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HEALY KC, 1995, ONCOL RES, V7, P121; HUFF J, 1991, ENVIRON HEALTH PERSP, V93, P247, DOI 10.2307/3431195; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KAUFMANN WK, 1981, CANCER RES, V41, P4653; KAUFMANN WK, 1986, CARCINOGENESIS, V7, P669, DOI 10.1093/carcin/7.4.669; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; Kyo S, 1997, CANCER RES, V57, P610; LEE LW, 1989, AM J PATHOL, V135, P63; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; MAKAROV VL, 1993, CELL, V73, P775, DOI 10.1016/0092-8674(93)90256-P; McClintock B, 1941, GENETICS, V26, P234; OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394; PROWSE K, 1995, P NATL ACAD SCI USA, V201, P4818; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Strahl C, 1996, MOL CELL BIOL, V16, P53; TAHARA H, 1995, CANCER RES, V55, P2734; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; Yoshimi N, 1996, MOL CARCINOGEN, V16, P1, DOI 10.1002/(SICI)1098-2744(199605)16:1<1::AID-MC1>3.0.CO;2-N; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHANG Y, 1995, LIVER REGENERATION C, P179	45	19	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1233	1240		10.1038/sj.onc.1201278	http://dx.doi.org/10.1038/sj.onc.1201278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294617				2022-12-17	WOS:A1997XU99100013
J	Simms, LA; Zou, TT; Young, J; Shi, YQ; Lei, JY; Appel, R; Rhyu, MG; Sugimura, H; ChenevixTrench, G; Souza, RF; Meltzer, SJ; Leggett, BA				Simms, LA; Zou, TT; Young, J; Shi, YQ; Lei, JY; Appel, R; Rhyu, MG; Sugimura, H; ChenevixTrench, G; Souza, RF; Meltzer, SJ; Leggett, BA			Apparent protection from instability of repeat sequences in cancer-related genes in replication error positive gastrointestinal cancers	ONCOGENE			English	Article						microsatellite instability; repeats; colorectal cancer; gastric cancer	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; ESTROGEN-RECEPTOR; COLON-CANCER; RETINOIC ACID; MISMATCH REPAIR; II RECEPTOR; LUNG-CANCER	Genomic instability at simple repeated sequences has been observed in various types of human cancers and is considered an important mechanism in tumorigenesis. Alterations at microsatellite loci have been reported scattered throughout the genome. Recently, the transforming growth factor-beta receptor type II (TGF-beta RII) and the insulin-like growth factor II receptor (IGF-IIR) genes were shown to have inactivating mutations within coding microsatellite sequences. The demonstration of mutations in two growth regulatory genes supports the idea that other regulatory genes with repeat sequences may also be targets in tumours with defective mismatch repair. We examined genes involved in tumour suppression, cell adhesion and cell cycle regulation for mutations at small repeat sequences in replication error positive gastrointestinal cancers. Several polymorphisms were found which exhibited instability, but no other instability was present in the regions examined.	UNIV MARYLAND, SCH MED, DEPT MED, GI DIV, BALTIMORE, MD 21201 USA; BALTIMORE VA HOSP, BALTIMORE, MD 21201 USA; CATHOLIC UNIV, COLL MED, DEPT MICROBIOL, SEOUL 137701, SOUTH KOREA; HAMAMATSU UNIV SCH MED, DEPT PATHOL 1, HAMAMATSU, SHIZUOKA 43131, JAPAN; QUEENSLAND INST MED RES, BRISBANE, QLD 4029, AUSTRALIA	University System of Maryland; University of Maryland Baltimore; Catholic University of Korea; Hamamatsu University School of Medicine; QIMR Berghofer Medical Research Institute	Simms, LA (corresponding author), ROYAL BRISBANE HOSP FDN, CLIN RES CTR, GLAXO CONJOINT GASTROENTEROL LAB, BRISBANE, QLD 4029, AUSTRALIA.		Young, Joanne P/H-7774-2014; Leggett, Barbara A/D-3579-2011; Chenevix-Trench, Georgia/AAV-2014-2020; Young, Joanne P/B-9981-2011	Chenevix-Trench, Georgia/0000-0002-1878-2587; Simms, Lisa/0000-0002-5387-7397; Leggett, Barbara/0000-0003-2062-7380				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELKIND NB, 1995, ONCOGENE, V11, P841; FIELD JK, 1995, BRIT J CANCER, V71, P1065, DOI 10.1038/bjc.1995.205; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONTANA JA, 1990, CANCER RES, V50, P1977; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; Greenblatt MS, 1996, CANCER RES, V56, P2130; HAN HJ, 1993, CANCER RES, V53, P5087; HEINEN CD, 1995, CANCER RES, V55, P4797; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUDDART RA, 1995, BRIT J CANCER, V72, P642, DOI 10.1038/bjc.1995.387; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JEGO N, 1993, ONCOGENE, V8, P209; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; KRAHE R, 1995, AM J HUM GENET, V56, P1067; KRUYER H, 1994, AM J HUM GENET, V54, P437; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LOTAN R, 1993, J CELL BIOCHEM, P167; MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MYEROFF LL, 1995, CANCER RES, V55, P5545; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; PATEL U, 1994, ONCOGENE, V9, P3695; PERUCHO M, 1994, COLD SPRING HARB SYM, V59, P339, DOI 10.1101/SQB.1994.059.01.038; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; UCHIDA T, 1995, ONCOGENE, V10, P1019; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; XU XM, 1994, MOL CELL ENDOCRINOL, V105, P197; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505; ZAJCHOWSKI DA, 1993, CANCER RES, V53, P5004	57	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	1997	14	21					2613	2618		10.1038/sj.onc.1201094	http://dx.doi.org/10.1038/sj.onc.1201094			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191061				2022-12-17	WOS:A1997XA94900013
J	Sabe, H; Hamaguchi, M; Hanafusa, H				Sabe, H; Hamaguchi, M; Hanafusa, H			Cell to substratum adhesion is involved in v-Src-induced cellular protein tyrosine phosphorylation: Implication for the adhesion-regulated protein tyrosine phosphatase activity	ONCOGENE			English	Article						v-Src; cell substratum adhesion; transformation; protein tyrosine phosphatase; tyrosine phosphorylation	ROUS-SARCOMA VIRUS; GTPASE-ACTIVATING PROTEIN; CHICKEN-EMBRYO FIBROBLASTS; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; TRANSFORMED-CELLS; PHOSPHOTYROSINE PHOSPHATASE; SURFACE PROTEIN; MONOCLONAL-ANTIBODIES; STABLE ASSOCIATION	Protein tyrosine phosphorylation accompanies the integrin-mediated cell to substratum adhesion, and is essential for the progression of G(1)/S phase of the cell-cycle in normal fibroblasts, To examine how cellular protein tyrosine phosphatase (PTPase) activity is involved in regulating the adhesion-dependent protein tyrosine phosphorylation, we employed fibroblast cells bearing an active form of a protein tyrosine kinase (PTK), v-Src. We found that the v-Src induced tyrosine phosphorylation in certain proteins such as tensin, talin, p120, p80/85 (cortactin) and paxillin was greatly reduced when the cell to substratum adhesion was lost. Re-adhesion of the cells onto fibronectin restored these phosphorylation events, while this was inhibited by the addition of RGD peptide. The kinase activity of the v-Src was unchanged by the loss of cell to substratum adhesion. On the other hand, treatment with a protein tyrosine phosphatase inhibitor vanadate caused much the same increase in the v-Src-mediated cellular tyrosine phosphorylation between cells adhered to the culture environments and cells kept in suspension. These data suggest that PTPase(s) appears to be more critical than the v-Src PTK in determining the cell adhesion-dependent protein tyrosine phosphorylation, Moreover, most of the protein tyrosine phosphorylations that are mediated by the v-Src but still dependent on the cell adhesion were indeed greatly reduced during an anchorage-independent growth of v-Src cells, Thus our data collectively indicate that the v-Src induced high level of tyrosine phosphorylation in certain types of proteins are still under the control of the integrin(s) or the cell adhesion to culture substratum, and most of these adhesion-regulated high levels of tyrosine phosphorylations are not essential for the transformed phenotype.	ROCKEFELLER UNIV, MOL ONCOL LAB, NEW YORK, NY 10021 USA; NAGOYA UNIV, SCH MED, SYOWA KU, NAGOYA, AICHI 466, JAPAN; JAPAN SCI & TECHNOL CORP, PRECURSORY RES EMBRYON SCI & TECHNOL, SAKYO KU, KYOTO 606, JAPAN	Rockefeller University; Nagoya University; Japan Science & Technology Agency (JST)	Sabe, H (corresponding author), KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 606, JAPAN.		Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022		NCI NIH HHS [CA44356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CHEN WT, 1984, J CELL BIOL, V98, P1546, DOI 10.1083/jcb.98.4.1546; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FAIRBAIRN S, 1985, J CELL BIOL, V101, P1790, DOI 10.1083/jcb.101.5.1790; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAYMAN EG, 1982, J CELL BIOL, V94, P28, DOI 10.1083/jcb.94.1.28; HAYMAN EG, 1981, J CELL BIOL, V88, P352, DOI 10.1083/jcb.88.2.352; HYNES RO, 1975, VIROLOGY, V64, P492, DOI 10.1016/0042-6822(75)90126-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TAPLEY P, 1989, ONCOGENE, V4, P325; TAVOLONI N, 1994, J CELL BIOL, V126, P475, DOI 10.1083/jcb.126.2.475; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TYAGI JS, 1983, J BIOL CHEM, V258, P5787; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217	59	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	1997	14	15					1779	1788		10.1038/sj.onc.1201022	http://dx.doi.org/10.1038/sj.onc.1201022			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150383				2022-12-17	WOS:A1997WW16600003
J	Butzler, C; Zou, XG; Popov, AV; Bruggemann, M				Butzler, C; Zou, XG; Popov, AV; Bruggemann, M			Rapid induction of B-cell lymphomas in mice carrying a human IgH/c-mycYAC	ONCOGENE			English	Article						c-myc deregulation; chromosomal translocation; Burkitt's lymphoma; translocus control; immunoglobulin intron enhancer	YEAST ARTIFICIAL CHROMOSOME; HEAVY-CHAIN LOCUS; C-MYC; TRANSGENIC MICE; BURKITT-LYMPHOMA; GENE; ENHANCER; TUMORS; TRANSLOCATION; EXPRESSION	Activation of the c-myc proto-oncogene by one of the imnunoglobulin (Ig) loci after chromosomal translocation is a consistent feature of Burkitt's lymphoma. Different subtypes of this tumor vary in the molecular architecture of the translocation region. In most cases there are no known regulatory elements of the Ig locus neighboring the oncogene and this considerably obscures the mechanism of its deregulation. In order to assess possible oncogene activation signals, we produced an experimental translocation region by insertion of a c-myc gene about 50 kb from the IgH intron enhancer in a yeast artificial chromosome (YAC) containing a 220 kb region of the human Ig heavy chain (IgH) locus. Single copy integration of this YAC into the genome of mouse embryonic stem (ES) cells was achieved by spheroplast fusion. Chimeric mice derived from these ES cells developed monoclonal B-cell lymphomas expressing surface IgM by 8-16 weeks of age. The IgH/c-myc translocus showed different V(H)DJ(H) rearrangement in almost all tumors without any alterations of the distance between c-myc and the IgH intron enhancer. This mouse model can be used for the in vivo analysis of c-myc deregulation and the tumor formation capacity of the IgH locus in aberrant rearrangements.	BABRAHAM INST, DEPT DEV & GENET, CAMBRIDGE CB2 4AT, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute								ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Bruggemann M, 1996, IMMUNOL TODAY, V17, P391, DOI 10.1016/0167-5699(96)10025-6; BULUWELA L, 1988, EUR J IMMUNOL, V18, P1843, DOI 10.1002/eji.1830181130; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; BURKITT D, 1958, BRIT J SURG, V46, P218, DOI 10.1002/bjs.18004619704; CROCE CM, 1993, SEMIN ONCOL, V20, P31; DAVIES NP, 1993, BIO-TECHNOL, V11, P911, DOI 10.1038/nbt0893-911; DAVIES NP, 1992, NUCLEIC ACIDS RES, V20, P2693, DOI 10.1093/nar/20.11.2693; DAVIES NP, 1996, ANTIBODY ENG PRACTIC, P59; GERSTER T, 1986, CELL, V45, P45, DOI 10.1016/0092-8674(86)90536-2; GUNVEN P, 1980, INT J CANCER, V25, P711, DOI 10.1002/ijc.2910250605; GUTIERREZ MI, 1992, BLOOD, V79, P3261; HAMLYN PH, 1983, NATURE, V304, P135, DOI 10.1038/304135a0; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; LAVENU A, 1994, ONCOGENE, V9, P527; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARKIE D, 1996, METHODS MOL BIOL, V54; Mautner J, 1996, ONCOGENE, V12, P1299; MILSTEIN CP, 1984, NUCLEIC ACIDS RES, V12, P6523, DOI 10.1093/nar/12.16.6523; MORELLO D, 1993, ONCOGENE, V8, P1921; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; Schedl A, 1996, Methods Mol Biol, V54, P293; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; SPANOPOULOU E, 1989, NATURE, V342, P185, DOI 10.1038/342185a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; Wagner SD, 1996, GENOMICS, V35, P405, DOI 10.1006/geno.1996.0379; YUKAWA K, 1989, J EXP MED, V170, P711, DOI 10.1084/jem.170.3.711; Zou XG, 1996, FASEB J, V10, P1227, DOI 10.1096/fasebj.10.10.8751726	40	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	1997	14	11					1383	1388		10.1038/sj.onc.1200968	http://dx.doi.org/10.1038/sj.onc.1200968			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178899				2022-12-17	WOS:A1997WP10900014
J	Oberst, C; Weiskirchen, R; Hartl, M; Bister, K				Oberst, C; Weiskirchen, R; Hartl, M; Bister, K			Suppression in transformed avian fibroblasts of a gene (CO6) encoding a membrane protein related to mammalian potassium channel regulatory subunits	ONCOGENE			English	Article						cell transformation; oncogenes; differential gene expression; membrane proteins; potassium channels	CHICKEN-EMBRYO FIBROBLASTS; CYSTEINE-RICH PROTEIN; GATED K+ CHANNELS; DNA-BINDING; C-MYC; BETA-SUBUNIT; SIGNAL-TRANSDUCTION; SMOOTH-MUSCLE; JUN ONCOGENE; CELL-CYCLE	Gene expression patterns in normal and v-myc-transformed quail embryo fibroblasts were compared by mRNA differential display, Displaying approximately 2500 mRNA species by reverse transcription/PCR, reamplification of 73 differential cDNA fragments and rescreening by Northern analysis led to the isolation of a clone, termed CO6, that hybridized to an mRNA species present only in the normal but not in the transformed fibroblasts. Further analyses revealed that the 0.95-kb CO6 mRNA was present in all normal quail and chicken embryo fibroblasts tested, but that it was undetectable in a variety of established quail cell lines transformed by the v-myc, v-myc/v-mil, v-jun/junD or v-src oncogenes or by a chemical carcinogen, Furthermore, CO6 mRNA was not detectable in fibroblasts newly transformed by retroviral constructs carrying v-myc or v-jun alleles or by the avian sarcoma virus ASV17. In fibroblasts transformed by a temperature-sensitive v-src mutant, expression of CO6 was strongly induced at the non-permissive temperature and reduced at the permissive temperature. Nucleotide sequence analysis of quail CO6 cDNA indicated that the corresponding gene encodes a 200-amino acid protein with 46 to 48% amino acid sequence identity to the regulatory beta subunits (K-vCa)beta of the bovine, human and canine high conductance Ca2+- activated K+ channels. No sequence homology to other ion channel subunits or to any other proteins in the databases was found, Like the K(vCa)beta subunits, the CO6 protein contains two putative transmembrane segments, Based on the relationship to mammalian K(VCa)beta both in primary structure and domain topology, the CO6 protein may represent the regulatory subunit of a yet unidentified avian Ca2+-activated potassium channel or a related membrane protein possibly involved in the regulation of cell proliferation.	UNIV INNSBRUCK, INST BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck			Hartl, Markus/O-4655-2014; Weiskirchen, Ralf/O-1734-2018; Bister, Klaus/AFA-9400-2022	Hartl, Markus/0000-0001-7447-5920; Weiskirchen, Ralf/0000-0003-3888-0931; Bister, Klaus/0000-0001-6545-5653				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DAY ML, 1993, NATURE, V365, P560, DOI 10.1038/365560a0; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Doonan J, 1996, NATURE, V380, P481, DOI 10.1038/380481a0; DRAHEIM H, 1994, PFLUG ARCH EUR J PHY, V427, P17, DOI 10.1007/BF00585937; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HUANG Y, 1994, J BIOL CHEM, V269, P31183; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Jain MK, 1996, J BIOL CHEM, V271, P10194, DOI 10.1074/jbc.271.17.10194; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KNAUS HG, 1994, CELL SIGNAL, V6, P861, DOI 10.1016/0898-6568(94)90019-1; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WEISKIRCHEN R, 1995, J BIOL CHEM, V270, P28946, DOI 10.1074/jbc.270.48.28946; WEISKIRCHEN R, 1993, GENE, V128, P269, DOI 10.1016/0378-1119(93)90573-L; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0	52	19	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	1997	14	9					1109	1116		10.1038/sj.onc.1200930	http://dx.doi.org/10.1038/sj.onc.1200930			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070660				2022-12-17	WOS:A1997WM07000013
J	Roberts, T; Cowell, JK				Roberts, T; Cowell, JK			Cloning of the human Gfi-1 gene and its mapping to chromosome region 1p22	ONCOGENE			English	Article						human Gfi gene; cDNA sequence; chromosome 1p22	TRANSLOCATION; PROTEIN	Recently the rat and mouse Growth Factor Independence (Gfi-1) genes have been cloned (Gilks et al., 1993; Zoring ed al; 1996), This gene allows cells in culture to overcome the depletion of growth factors in the culture medium and maintain their proliferative potential, As part of a cloning strategy to isolated genes from human chromosome 1p22 which are associated with a constitutional chromosome translocation from a patient with stage 4S neuroblastoma, we have identified the human homologue of the Gfi gene and defined a 50 Kb map position within a well characterised YAC contig from the region, The full length cDNA sequence is 81% homologous with the rodent counterparts and, at the protein level, is even more highly conserved.	CLEVELAND CLIN FDN,DEPT NEUROSCI,RES INST,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Roberts, Terry/A-8211-2014	Cowell, John/0000-0002-2079-5950				BICKMORE WA, 1992, METHOD ENZYMOL, V216, P224; BRODEUR GM, 1983, CANCER GENET CYTOGEN, V8, P93, DOI 10.1016/0165-4608(83)90041-9; CARBONE P, 1988, CANCER GENET CYTOGEN, V32, P143, DOI 10.1016/0165-4608(88)90321-4; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KAPLAN J, 1993, NAT GENET, V5, P308, DOI 10.1038/ng1193-308; KOOLS PFJ, 1995, CANCER GENET CYTOGEN, V79, P1, DOI 10.1016/0165-4608(94)00137-Z; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MEAD RS, 1995, CANCER GENET CYTOGEN, V81, P151; Zornig M, 1996, ONCOGENE, V12, P1789	10	19	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					1003	1005		10.1038/sj.onc.1200910	http://dx.doi.org/10.1038/sj.onc.1200910			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9051000				2022-12-17	WOS:A1997WK34400014
J	Guerrin, M; Scotet, E; Malecaze, F; Houssaint, E; Plouet, J				Guerrin, M; Scotet, E; Malecaze, F; Houssaint, E; Plouet, J			Overexpression of vascular endothelial growth factor induces cell transformation in cooperation with fibroblast growth factor 2	ONCOGENE			English	Article						VEGF; FGF-2; retinal pigment epithelial cells; transformation	PIGMENT EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; PERMEABILITY FACTOR; NUCLEOTIDE-SEQUENCE; TYROSINE KINASE; ANGIOGENESIS; RECEPTOR; MITOGEN; VASCULOTROPIN; EXPRESSION	Vascular endothelial growth factor (VEGF) is a family of homodimeric proteins produced from a single gene by alternative splicing of the VEGF transcript. VEGF induces irt vivo angiogenesis and vascular permeability. We have recently demonstrated that VEGF is an autocrine growth factor for retinal pigment epithelial (RPE) cells. To further understand the role of VEGF, we overexpressed VEGF in rat RPE cells. The transfected cells exhibited a growth advantage in vitro and an increased response to the mitogenic effect of fibroblasts growth factor-2 (FGF-2), and formed colonies in soft agar upon FGF-2 addition. Moreover, analysis of FGF-receptors evidenced a dramatic increase in FGFR-1 mRNA and protein level, supporting the hypothesis that this receptor mediates the transforming effect of FGF-2. These results reveal that the oncogenic role of VEGF is exerted through a cross regulation between VEGF and FGF signal transduction pathways.	UPR 9006 CNRS, LAB BIOL MOL EUCARYOTE, F-31062 TOULOUSE, FRANCE; INST BIOL, INSERM U211, F-44035 NANTES, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			SCOTET, Emmanuel/AAC-9971-2019; SCOTET, Emmanuel/L-2576-2015	SCOTET, Emmanuel/0000-0001-8010-9556; SCOTET, Emmanuel/0000-0001-8010-9556				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; ASSOIAN RK, 1984, NATURE, V309, P804, DOI 10.1038/309804a0; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EDWARDS RB, 1977, IN VITRO CELL DEV B, V13, P301; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; Ferrara N, 1991, NEUROENDOCRINE PERSP, P127; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; GOTO F, 1993, LAB INVEST, V69, P508; GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Lachgar S, 1996, J INVEST DERMATOL, V106, P17, DOI 10.1111/1523-1747.ep12326964; LESCHEY KH, 1990, INVEST OPHTH VIS SCI, V31, P839; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; MOUKADIRI H, 1992, GROWTH FACTORS OF THE VASCULAR AND NERVOUS SYSTEMS, P123; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; PLOUET J, 1992, GENETIC HYPERTENSION, V218, P207; PRALORAN V, 1991, CR ACAD SCI III-VIE, V313, P21; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P934, DOI 10.1016/0006-291X(87)90340-8; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816	58	19	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					463	471		10.1038/sj.onc.1200846	http://dx.doi.org/10.1038/sj.onc.1200846			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053843				2022-12-17	WOS:A1997WE36400009
J	Okada, K; Urano, T; Baba, H; Furukawa, K; Furukawa, K; Shiku, H				Okada, K; Urano, T; Baba, H; Furukawa, K; Furukawa, K; Shiku, H			Independent and differential expression of two isotypes of human Nm23: Analysis of the promoter regions of the nm23-H1 and H2 genes	ONCOGENE			English	Article						nm23; NDP kinase; promoter; transcription; metastasis	NUCLEOSIDE DIPHOSPHATE KINASE; TUMOR-METASTASIS; RNA; DNA; AMPLIFICATION; CARCINOMAS; SUPPRESSOR; CELLS; LINE; RAT	We isolated genomic clones of two isotypes of human NDP kinase, nm23-H1 and H2, The nm23-H1 and H2 genes located in a tandem array contained 5 exons and most of the splicing sites in the exon-intron junctions of two isotypes were essentially identical, The regulatory elements of nm23-H1 and H2 genes were also analysed, One major and several minor transcriptional initiation sites were detected in the two isotypes by 5' RACE analysis in HeLa cell, We also identified them by means of an RNase protection assay and primer extension Promoter activities were found in the 5' sequences of the two genes when placed upstream of the chloramphenicol acetyltransferase gene, Transcriptional activities of nm23-H1 and H2 regulatory regions were measured in a series of human cancer lines, The nm23-H1/nm23-H2 gene transcriptional activity ratio varied depending on the cell line, DNA sequencing of these two genes showed that their promoter regions contain distinct binding sites for known transcriptional factors, These studies suggest that the two isotypes of the nm23 genes might be regulated dissimilarly, and in cell type specific manner.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT ORTHOPAED SURG,NAGASAKI 852,JAPAN; MIE UNIV,SCH MED,DEPT INTERNAL MED 2,TSU,MIE 514,JAPAN; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Nagasaki University; Nagasaki University; Mie University; Tufts University				Urano, Takeshi/0000-0003-3383-3554				BABA H, 1995, CANCER RES, V55, P1977; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CHEN HC, 1994, ONCOGENE, V9, P2905; FISHMAN JR, 1994, J UROLOGY, V152, P202, DOI 10.1016/S0022-5347(17)32862-8; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HIGASHIYAMA M, 1992, BRIT J CANCER, V66, P533, DOI 10.1038/bjc.1992.308; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; OKADA K, 1994, CANCER RES, V54, P3979; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIFERT M, 1995, BIOCHEM BIOPH RES CO, V215, P910, DOI 10.1006/bbrc.1995.2550; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; URANO T, 1992, INT J ONCOL, V1, P425; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMASHIRO S, 1994, ONCOGENE, V9, P2461	26	19	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1937	1943						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934540				2022-12-17	WOS:A1996VR79500013
J	Valente, P; Melchiori, A; Paggi, MG; Masiello, L; Ribatti, D; Santi, L; Takahashi, R; Albini, A; Noonan, DM				Valente, P; Melchiori, A; Paggi, MG; Masiello, L; Ribatti, D; Santi, L; Takahashi, R; Albini, A; Noonan, DM			RB1 oncosuppressor gene over-expression inhibits tumor progression and induces melanogenesis in metastatic melanoma cells	ONCOGENE			English	Article						retinoblastoma; melanoma; melanin; tumor progression; invasion	RETINOBLASTOMA SUSCEPTIBILITY GENE; CARCINOMA-CELLS; CYCLE ARREST; PRODUCT; DIFFERENTIATION; PROTEIN; GROWTH; INDUCTION; ANTIGEN; TRANSFORMATION	The retinoblastoma gene (RB1) is frequently deleted or mutated in many tumor types and in all cases of retinoblastoma. Apart from its role in regulation of the cell cycle, the RB1 gene product (p110(RB1)) appears to be involved in control of differentiation, Malignant metastatic cells show many properties of poorly differentiated cells, and are highly invasive in vitro and in vivo. We have transfected the human RB1 cDNA in an expression vector under the control of the beta-actin promoter into B16F10 murine melanoma cells. These cells highly overexpress RB1 mRNA and the p110(RB1) product, show reduced growth rate and increased melanogenesis in vitro. Vector control transfectants showed no alteration of invasiveness. The p110(RB1) over-expressing cells also had a reduced capacity to migrate and invade through an artificial basement membrane, key characteristics of metastatic cells. When injected into nude mice, the p110(RB1) over-expressing cells showed reduced tumor growth and reduced metastatic potential, The few metastasis observed were predominantly melanotic. These data indicate that RB1 gene expression is involved in melanoma cell differentiation and plays a role in downregulation of migration, invasion and metastatic potential of these cells.	IST NAZL RIC CANC, DEPT EXPT ONCOL, I-16132 GENOA, ITALY; IST REGINA ELENA STUDIO & CURA TUMORI, ROME, ITALY; UNIV BARI, IST ANAT UMANA NORMALE & ISTOL EMBRIOL, BARI, ITALY; KYOTO UNIV, KYOTO, JAPAN	University of Genoa; IRCCS AOU San Martino IST; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita degli Studi di Bari Aldo Moro; Kyoto University			Paggi, Marco G./K-3494-2018; Noonan, Douglas M/A-8620-2010	Noonan, Douglas M/0000-0001-8058-0719; Albini, Adriana/0000-0002-9624-5103				ALBINI A, 1989, CLIN EXP METASTAS, V7, P437, DOI 10.1007/BF01753664; ALBINI A, 1987, CANCER RES, V47, P3239; ALLAVENA G, 1988, CANCER METASTASIS, P215; BENNETT DC, 1986, CANCER RES, V46, P3239; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Elias H, 1983, GUIDE PRACTICAL STER, P25; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FUNG YKT, 1993, ONCOGENE, V8, P2659; FURUKAWA Y, 1991, ONCOGENE, V6, P1343; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HANSEN M, 1989, CC MOL BIOL, P125; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1995, ONCOGENE, V11, P1179; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARPEH MS, 1995, BRIT J CANCER, V72, P986, DOI 10.1038/bjc.1995.447; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KREIDER JW, 1975, JNCI-J NATL CANCER I, V55, P641, DOI 10.1093/jnci/55.3.641; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; Li J., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P78; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MANIATIS T, 1989, MOL CLONING LAB MANU, P133; MARTELLI F, 1994, ONCOGENE, V9, P3579; MENSING H, 1984, INT J CANCER, V33, P43, DOI 10.1002/ijc.2910330109; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUFSON RA, 1979, CANCER RES, V39, P3915; MUNCASTER MM, 1992, CANCER RES, V52, P654; NEVINS JR, 1992, SCIENCE, V258, P424; PAGGI MG, 1994, CANCER RES, V54, P1098; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUPINO R, 1992, MELANOMA RES, V2, P377, DOI 10.1097/00008390-199212000-00012; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; VARLEY JM, 1989, ONCOGENE, V4, P735; WEINBERG RA, 1992, CANCER SURV, V12, P43; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITTAKER JR, 1963, DEV BIOL, V8, P99, DOI 10.1016/0012-1606(63)90028-9; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAVUZER U, 1995, ONCOGENE, V10, P123	63	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1169	1178						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808691				2022-12-17	WOS:A1996VJ20200008
J	Zhang, N; Song, QZ; Lu, H; Lavin, MF				Zhang, N; Song, QZ; Lu, H; Lavin, MF			Induction of p53 and increased sensitivity to cisplatin in ataxia-telangiectasia cells	ONCOGENE			English	Article						ataxia-telangiectasia; cisplatin; p53 stability; functional assays	WILD-TYPE P53; DNA-DAMAGING AGENTS; IONIZING-RADIATION; GENE-EXPRESSION; PROTEIN; UV; ACCUMULATION; APOPTOSIS; ARREST; GROWTH	Several reports have demonstrated a defective p53 response to ionizing radiation exposure in ataxia-telangiectasia (A-T) cells. On the other hand, p53 induction was normal after u.v. irradiation, an agent to which A-T cells are not hypersensitive. We show here that A-T cells are more sensitive than normal lymphoblastoid cells to cisplatin treatment but the rate of induction of p53 by cisplatin is similar in both cell types. In addition, the half-life of p53, both in the induced and uninduced forms, is the same in A-T and normal lymphoblastoid cells. The use of a reporter assay to determine the functional status of p53 confirmed the results obtained in the induction experiments with cisplatin. These results demonstrate that p53 induction status in A-T cells does not correlate with sensitivity to the inducting agent and there is no inherent defect in the turn-over of p53 in the induced or uninduced states in A-T.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,ROYAL BRISBANE HOSP,DEPT SURG,BRISBANE,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Royal Brisbane & Women's Hospital; University of Queensland			Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769				ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRITSCHE M, 1993, ONCOGENE, V8, P307; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MEYN MS, 1994, INT J RADIAT BIOL, V66, P141; MIRZAYANS R, 1989, CANCER RES, V49, P5523; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WOOD KV, 1991, BIOLUMINESCENCE CHEM, pP543; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	33	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					655	659						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760308				2022-12-17	WOS:A1996VB32800024
J	Niikura, M; Dornadula, G; Zhang, H; Mukhtar, M; Duan, LX; Khalili, K; Bagasra, O; Pomerantz, RJ				Niikura, M; Dornadula, G; Zhang, H; Mukhtar, M; Duan, LX; Khalili, K; Bagasra, O; Pomerantz, RJ			Mechanisms of transcriptional transactivation and restriction of human immunodeficiency virus type I replication in an astrocytic glial cell	ONCOGENE			English	Article						HIV-1; astrocytes; glia; transcription; tat	IMMUNE-DEFICIENCY SYNDROME; LONG TERMINAL REPEAT; HIV-1 TAT PROTEIN; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; RNA-BINDING PROTEIN; TRANS-ACTIVATION; HUMAN-BRAIN; INDEPENDENT ACTIVATION; GENE-EXPRESSION	Unique transcriptional transactivation by the human immunodeficiency virus type 1 (HIV-1) Tat protein of long terminal repeat (LTR)-driven RNA expression, in the absence of the transactivator responsive element (TAR), was previously demonstrated in central nervous system (CNS)-derived astrocytic cell-lines, including U87MG. In the present study, RNase protection assays were utilized to reveal the molecular mechanism(s) underlying transactivation of the HIV-1-LTR in these cells. Short transcripts, which represent abortive HIV-1 transcription, could not be detected either in the absence or presence of Tat, and no differences in transcript levels were detected using 5' probes, as compared to 3' probes, in the experiments. Thus, the transactivational effects of Tat, in U87MG cells, were potentially based on the increase of transcriptional initiation, both in TAR-dependent and -independent states. Further, by using newly established stable cellular transformant, containing HIV-1-LTR-reporter gene constructs, TAR-independent transactivation was demonstrated to efficiently function primarily in transiently-transfected U87MG cells. U87MG cells, stably-transfected with the intact HIV-1 proviral genome, produced very low levels of virus after long-term culture, as previously reported in other astrocytic cells. These cells demonstrated profoundly restricted transcription of the HIV-1 genome, with no detectable levels of HIV-1-specific RNA by Northern blotting, indicating that the restriction of viral production in these cells is principally due to the low level of overall transcription from the 5' HIV-1-LTR. Transcription of HIV-1 RNA in this cell could not be significantly up-regulated by various stimulators, such as phorbol 12-myristate 13-acetate (PMA), tumor necrosis factor-alpha (TNF-alpha) and sodium butyrate. These data suggest that the restriction of HIV-1 transcription in these cells may be controlled by different mechanism(s) from those in lymphocytic or monocytic cells.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,DORRANCE H HAMILTON LABS,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOL BIOL,JEFFERSON INST MOL MED,MOL NEUROVIROL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030916] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31836] Funding Source: Medline; NINDS NIH HHS [NS30916] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; ALDOVINI A, 1990, TECHNIQUES HIV RES, P147; BAGASRA O, 1992, J VIROL, V66, P7522, DOI 10.1128/JVI.66.12.7522-7528.1992; BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BLUMBERG BM, 1994, VIRUS RES, V32, P253, DOI 10.1016/0168-1702(94)90044-2; BRACKWERNER R, 1992, AIDS, V6, P273, DOI 10.1097/00002030-199203000-00003; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CHIODI F, 1987, J VIROL, V61, P1244, DOI 10.1128/JVI.61.4.1244-1247.1987; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DUAN LX, 1994, VIROLOGY, V199, P474, DOI 10.1006/viro.1994.1148; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FUNKE I, 1987, J EXP MED, V165, P1230, DOI 10.1084/jem.165.4.1230; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; HARRICH D, 1994, J VIROL, V68, P5899, DOI 10.1128/JVI.68.9.5899-5910.1994; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; JEANG KT, 1993, J BIOL CHEM, V268, P24940; JEANG KT, 1992, J B IOL CHEM, V25, P17891; Jones KA, 1993, CURR OPIN CELL BIOL, V5, P461, DOI 10.1016/0955-0674(93)90012-F; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KESSLER M, 1991, P NATL ACAD SCI USA, V88, P10018, DOI 10.1073/pnas.88.22.10018; KOVAL V, 1995, J VIROL, V69, P1645, DOI 10.1128/JVI.69.3.1645-1651.1995; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAUGHLIN MA, 1993, VIROLOGY, V196, P496, DOI 10.1006/viro.1993.1505; LEE SHC, 1993, AM J PATHOL, V143, P1032; LU XB, 1993, J VIROL, V67, P1752, DOI 10.1128/JVI.67.4.1752-1760.1993; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MICHAELS J, 1988, ACTA NEUROPATHOL, V76, P373, DOI 10.1007/BF00686974; MOSES AV, 1993, P NATL ACAD SCI USA, V90, P10474, DOI 10.1073/pnas.90.22.10474; NAHREINI P, 1995, J VIROL, V69, P1296, DOI 10.1128/JVI.69.2.1296-1301.1995; NEUMANN M, 1995, J VIROL, V69, P2159, DOI 10.1128/JVI.69.4.2159-2167.1995; NEWSTEIN M, 1990, J VIROL, V64, P4565, DOI 10.1128/JVI.64.9.4565-4567.1990; NUOVO GJ, 1994, AM J PATHOL, V144, P659; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; RHODES RH, 1993, HUM PATHOL, V24, P1189, DOI 10.1016/0046-8177(93)90215-3; Sambrook J, 1989, MOL CLONING LAB MANU; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SESHAMMA T, 1992, J VIROL METHODS, V40, P331, DOI 10.1016/0166-0934(92)90091-Q; SHAHABUDDIN M, 1992, PATHOBIOLOGY, V60, P195, DOI 10.1159/000163723; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SONG CZ, 1994, P NATL ACAD SCI USA, V91, P9357, DOI 10.1073/pnas.91.20.9357; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SUNE C, 1995, J VIROL, V69, P3098; SWINGLER S, 1994, BIOCHEM BIOPH RES CO, V203, P623, DOI 10.1006/bbrc.1994.2228; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1995, ONCOGENE, V10, P395; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TORNATORE C, 1994, J VIROL, V68, P93, DOI 10.1128/JVI.68.1.93-102.1994; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; ZHANG H, 1993, AIDS RES HUM RETROV, V9, P1287, DOI 10.1089/aid.1993.9.1287; ZHU M, 1996, IN PRESS AIDS RES HU	66	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					313	322						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710370				2022-12-17	WOS:A1996VA25200010
J	Mysliwiec, T; Perego, R; Kruh, GD				Mysliwiec, T; Perego, R; Kruh, GD			Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain	ONCOGENE			English	Article						tyrosine kinase; Arg/Abl chimera; transforming activity	MURINE LEUKEMIA-VIRUS; ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; ONCOGENIC ACTIVATION; TRANSFORMING ABILITY; GENE-PRODUCT; PROTEIN; BINDING; CELLS; BCR	Arg and c-Abl represent the mammalian member of the Abelson family of nonreceptor protein tyrosine kinases. The two proteins are composed of SH2, SH3, kinase and C-terminal domains, To examine Arg structure-function relationships we analysed a Gag-Arg fusion protein, analogous to the oncogenic Gag-Abl fusion protein of Abelson Murine Leukaemia Virus and found that in contrast to Gag-Abl, it lacked transforming activity, Three observations indicated that the difference in the transforming activity was mediated by the distinct Arg and Abl C-terminal domains, (1) The analysis of chimeric Gag-Arg/Abl molecules revealed that the Arg C-terminal domain completely abrogated Gag-Abl transforming activity and that the Abl C-terminus conferred transforming activity to Gag-Arg, Substitutions of SH2 and kinase domains did not affect activity, (2) Alterations in the Arg C-terminus were observed in spontaneous foci that developed in transfections of two nontransforming chimera. (3) An engineered Gag-Arg molecule containing a truncation of almost the entire C-terminal domain, including three SH3 domain-binding sites, was oncogenic, whereas a slightly smaller truncation that deleted two of three SH3 domain-binding sites, lacked transforming activity, These observations indicate that the C-terminal domain regulates Arg biological activity in a manner distinct from c-Abl and suggest that this effect may be mediated in part by SH3 domain-binding sites.	FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111; UNIV MILAN,INST GEN PATHOL,MILAN,ITALY; CNR,CTR RES CELL PATHOL,MILAN,ITALY	Fox Chase Cancer Center; University of Milan; Consiglio Nazionale delle Ricerche (CNR)					NATIONAL CANCER INSTITUTE [R55CA057273, P30CA006927, R01CA057273, F32CA060453] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60453, CA06927, CA-57273] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOLEN J, 1993, ONCOGENE, V3, P2025; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LUGO TG, 1990, SCIENCE, V237, P532; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PEREGO R, 1991, ONCOGENE, V6, P1899; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SRINIVASAN A, 1982, P NATL ACAD SCI-BIOL, V79, P5508, DOI 10.1073/pnas.79.18.5508; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	46	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					631	640						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637720				2022-12-17	WOS:A1996TV59700020
J	CARNERO, A; LIYANAGE, M; STABEL, S; LACAL, JC				CARNERO, A; LIYANAGE, M; STABEL, S; LACAL, JC			EVIDENCE FOR DIFFERENT SIGNALING PATHWAYS OF PKC-ZETA AND RAS-P21 IN XENOPUS OOCYTES	ONCOGENE			English	Article						OOCYTE MATURATION; PROTEIN KINASE C-ZETA; RAS-P21; MPF AND CDC2 KINASE; MAP KINASE; S6 KINASE II	PROTEIN-KINASE-C; MAP KINASE; CELL-CYCLE; TYROSINE PHOSPHORYLATION; MEIOTIC MATURATION; ONCOGENE PRODUCT; LAEVIS OOCYTES; ACTIVATION; TRANSDUCTION; EXPRESSION	Considerable effort has been devoted to identifying critical steps in mitogenic signal transduction pathways. Recently, the atypical PKC zeta isoform has attracted great interest since it has been reported to induce GVBD in Xenopus oocytes and transformation of NIH3T3 fibroblasts, two processes closely linked with the regulation of cell division. Furthermore, PKC zeta has been proposed as an essential effector for ras-p21 function and therefore may be an essential component of the signalling pathway(s) activated by mitogens. In this study we have analysed the responses induced in Xenopus oocytes after microinjection of purified recombinant PKC zeta protein. Microinjection of PKC zeta induced the early activation of MPF which precedes GVBD and also induced the activation of MAP kinase and S6 kinase II. The activation of MPF, MAP kinase and S6 kinase II by PKC zeta was sensitive to cycloheximide, while induction of GVBD was independent of protein synthesis. These results indicate that PKC zeta induces the activation of at least two pathways, only one of them leading to the activation of MAP kinase. By contrast, neither the induction of GVBD nor the activation of MPF, MAPK and S6 kinase II induced by the ras-p21 protein were dependent on protein synthesis. Thus, the comparison of these responses suggests that PKC zeta most likely does not mediate the uas-induced signal transduction pathway in Xenopus laevis oocytes.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN; MAX PLANCK GESELL,MAX DELLBRUCK LAB,D-50829 COLOGNE,GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Max Planck Society			Lacal, Juan Carlos/AAL-2235-2020; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/N-9064-2015	Carnero, Amancio/0000-0003-4357-3979; Lacal, Juan Carlos/0000-0002-1908-2777				ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; CACACE AM, 1993, ONCOGENE, V8, P2095; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; CARNERO A, 1994, J CELL BIOCHEM, V55, P1; CARRERO A, 1994, J CELL BIOCHEM, V54, P478; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1995, BIOCHEM BIOPH RES CO, V213, P266, DOI 10.1006/bbrc.1995.2125; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; JACOBS T, 1992, DEV BIOL, V153, P1, DOI 10.1016/0012-1606(92)90087-W; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MONTANER S, 1995, ONCOGENE, V10, P2213; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEBREDA AR, 1993, ONCOGENE, V8, P467; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PRICE BD, 1989, BIOCHEM J, V260, P157, DOI 10.1042/bj2600157; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETH A, 1991, J BIOL CHEM, V266, P23521; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; Stabel S., 1993, INTRACELLULAR MESSEN, P167; STABEL S, 1993, METH NEUROSCI, V18, P154; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1992, J BIOL CHEM, V267, P4799; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1992, NATURE, V355, P645	66	19	19	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1541	1547						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478578				2022-12-17	WOS:A1995TC53500012
J	YAO, R; COOPER, GM				YAO, R; COOPER, GM			REGULATION OF THE RAS SIGNALING PATHWAY BY GTPASE-ACTIVATING PROTEIN IN PC12 CELLS	ONCOGENE			English	Article						RAS; GAP; PC12 CELLS	NERVE GROWTH-FACTOR; NIH 3T3 CELLS; MAP KINASE; SACCHAROMYCES-CEREVISIAE; COMPLEX-FORMATION; THREONINE KINASE; MAMMALIAN-CELLS; FACTOR RECEPTOR; GENE-PRODUCT; HA-RAS	We have investigated the role of Pas GTPase-activating protein (GAP) in NGF-induced neuronal differentiation by overexpressing both wild-type and membrane-targeted GAP in PC12 cells. Extension of neurites in response to NGF was completely blocked in cells expressing the highest level of membrane-targeted GAP and significantly inhibited in cells expressing either wild-type GAP or lower levels of membrane-targeted GAP. Overexpression of membrane-targeted GAP similarly inhibited induction of differentiation by src, but not by ras or raf oncogenes, indicating that GAP inhibits differentiation of PC12 cells by downregulating Ras function. GAP overexpression also inhibited stimulation of mitogen-activated protein (MAP) kinase and induction of immediate-early genes in response to NGF. In cells expressing wild-type GAP or lower levels of membrane-targeted GAP, the initial activation of MAP kinase and immediate-early gene expression were only partially inhibited. However, GAP expression in these cells resulted in substantial inhibition of sustained MAP kinase activity following NGF treatment, consistent with the inhibition of neurite extension in these cell lines. These results indicate that GAP acts as a negative regulation, rather than an effector, of Ras signaling in PC12 cells.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALALAWI N, 1993, MOL CELL BIOL, V13, P2497, DOI 10.1128/MCB.13.4.2497; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	58	19	20	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1607	1614						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478585				2022-12-17	WOS:A1995TC53500019
J	MAMAJIWALLA, SN; BURGESS, DR				MAMAJIWALLA, SN; BURGESS, DR			DIFFERENTIAL REGULATION OF THE ACTIVITY OF THE 42 KD MITOGEN-ACTIVATED PROTEIN-KINASE (P42(MAPK)) DURING ENTEROCYTE DIFFERENTIATION IN-VIVO	ONCOGENE			English	Article						MAP KINASE; INTESTINAL EPITHELIUM; DIFFERENTIATION	HUMAN-COLON-CARCINOMA; SERINE THREONINE KINASES; MAP KINASE; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; GROWTH; CELLS; INSULIN; IDENTIFICATION; PHOSPHATASE	The family of mitogen activated protein (MAP) kinases appear to play a central role in relaying signals generated by receptor protein tyrosine kinases (RPTK) from the cell surface to the nucleus, We previously demonstrated that undifferentiated and mitotically active crypt cells have high levels of tyrosine phosphorylated proteins (DR Burgess, W Jiang, S Mamajiwalla and W Kinsey. 1989, J. Cell Biol., 109: 2139) possibly due to the activation of RPTKs and also have high pp60(mapk) protein tyrosine kinase activity (CA Cartwright, SN Mamajiwalla, SA Skolnik, W Eckhart and DR Burgess, 1993. Oncogene. 8: 1033) when compared to differentiated, non-mitotic villus cells. Since activation of RPTKs leading to cell proliferation or differentiation involves activation of the Ras-MAP kinase pathway, we chose to determine in this study if the activity of the MAP kinases were also regulated during differentiation of normal adult enterocytes. Our data show that although the 42 kD MAP kinase (p42(mapk)) was expressed in both crypt and villus cells, it was phosphorylated on tyrosine and active only in the crypt cells, Our data further suggest that p42(mapk) is inactivated during differentiation, possibly by a protein tyrosine phosphatase, Immunofluorescence studies revealed that p42(mapk) localized to the nuclei in both undifferentiated and differentiated enterocytes and colocalized with phosphotyrosine containing proteins at the region of the junctional complex, These results suggest that p42(mapk) and its regulators are tightly controlled during enterocyte differentiation in vivo and implicate p42(mapk) as a key regulatory molecule in the normal development of the epithelium.	UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031643] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31643] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGESS DR, 1989, J CELL BIOL, V109, P2139, DOI 10.1083/jcb.109.5.2139; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CARRASCO D, 1993, CELL GROWTH DIFFER, V4, P849; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FATH KR, 1990, DEVELOPMENT, V109, P449; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Le Blond CP, 1976, STEM CELLS RENEWING, P7; LEE H, 1993, J BIOL CHEM, V268, P8181; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAMAJIWALLA SN, 1992, CURR TOP DEV BIOL, V26, P123, DOI 10.1016/S0070-2153(08)60443-3; MARIAN B, 1989, CANCER RES, V49, P4231; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARK JS, 1993, ONCOGENE, V8, P2627; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; POTTEN CS, 1982, CYTOTOXIC INSULT TIS, P105; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SMITH MW, 1991, CURR TOP MEMBR, V39, P153; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STIDWILL RP, 1986, DEV BIOL, V114, P381, DOI 10.1016/0012-1606(86)90202-2; STURGILL TW, 1991, METHOD ENZYMOL, V200, P342; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; Wilson Clive, 1994, Trends in Cell Biology, V4, P409, DOI 10.1016/0962-8924(94)90094-9; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WRIGHT N, 1973, GUT, V14, P701, DOI 10.1136/gut.14.9.701; WRIGHT NA, 1975, CELL TISSUE KINET, V8, P361, DOI 10.1111/j.1365-2184.1975.tb01500.x; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	65	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					377	386						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542764				2022-12-17	WOS:A1995RK95700018
J	BIESECKER, LG; GIANNOLA, DM; EMERSON, SG				BIESECKER, LG; GIANNOLA, DM; EMERSON, SG			IDENTIFICATION OF ALTERNATIVE EXONS, INCLUDING A NOVEL EXON, IN THE TYROSINE KINASE RECEPTOR GENE ETK2/TYRO3 THAT EXPLAIN DIFFERENCES IN 5' CDNA SEQUENCES	ONCOGENE			English	Note						RECEPTOR; PROTEIN TYROSINE KINASE; BRAIN	CELLS	Protein tyrosine kinase transmembrane receptors trigger signal transduction cascades upon ligand binding, resulting in cellular proliferation, differentiation, differentiation inhibition or apoptosis depending upon the cell target. The ETK2/TYRO3 receptor is a tyrosine kinase expressed in embryonic stem cells, brain and testis that has recently been cloned by several groups. Analysis of cDNA clones isolated from several tissues shows 2 isoforms of the Etk2/tyro3 gene product that result from usage of alternative exons near the 5' end of the gene. In addition, our data suggest that a third alternative exon is positioned between these two alternative exons. This novel exon encodes yet another isoform that predicts a unique amino-terminal protein sequence, The alternative exons (exons 2A, 2B and 2C), predict three isoforms with different initiation codons, signal sequences and lengths. The existence of these multiple isoforms may be important for protein processing, translocation, or function.	UNIV PENN,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,PHILADELPHIA,PA 19104	University of Pennsylvania	BIESECKER, LG (corresponding author), NIH,NATL CTR HUMAN GENOME RES,GENET DIS RES LAB,BETHESDA,MD 20892, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008414] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00042] Funding Source: Medline; NICHD NIH HHS [HD28820] Funding Source: Medline; NIDDK NIH HHS [DK08414] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; DAI W, 1994, ONCOGENE, V9, P975; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GRIBSKOV M, 1992, SEQUENCE ANAL PRIMER; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; LAI C, 1994, ONCOGENE, V9, P2567; MARK MR, 1994, J BIOL CHEM, V269, P10720; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; POLVI A, 1993, GENE, V134, P289, DOI 10.1016/0378-1119(93)90109-G; SCHLESSINGER J, 1991, NEURON, V9, P383; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TAYLOR ICA, 1995, IN PRESS J BIOL CHEM; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	17	19	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2239	2242						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784069				2022-12-17	WOS:A1995RB70300020
J	VAIRO, G; VADIVELOO, PK; ROYSTON, AK; ROCKMAN, SP; ROCK, CO; JACKOWSKI, S; HAMILTON, JA				VAIRO, G; VADIVELOO, PK; ROYSTON, AK; ROCKMAN, SP; ROCK, CO; JACKOWSKI, S; HAMILTON, JA			DEREGULATED C-MYC EXPRESSION OVERRIDES IFN-GAMMA-INDUCED MACROPHAGE GROWTH ARREST	ONCOGENE			English	Article						C-MYC; IFN-GAMMA; CAMP; CELL CYCLE; CSF-1; GROWTH ARREST	COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; CELL-CYCLE ARREST; GENE-EXPRESSION; MITOGENIC RESPONSE; SIGNALING PATHWAYS; FACTOR-BETA; FACTOR-I; S-PHASE; INHIBITION	Induction of c-myc gene expression is an essential response to growth promoting agents, including colony-stimulating factor 1 (CSF-1), Down regulation of c-myc expression occurs in response to a variety of negative growth regulators in many cell types, However, for many of these systems the causal link between c-myc down regulation and growth arrest remains to be established. Here we show for CSF-l-dependent BAC1.2F5 mouse macrophages that interferon-gamma (IFN gamma) results in a midlate GI phase decrease of CSF-l-dependent c-myc mRNA and subsequent cell cycle arrest. Introduction of a deregulated c-myc gene into these cells, which prevents the IFN gamma-mediated decrease in c-myc expression, overrides the cell cycle arrest and restores CSF-l-dependent growth in the presence of the cytokine, This result contrasts with the macrophage growth arrest induced by cAMP elevation, which also suppresses c-myc expression, but is not overcome by a deregulated c-myc gene, These results show that inhibition of c-myc expression is an essential component in IFN gamma-mediated cell cycle arrest and demonstrates that distinct mechanisms contribute to IFN gamma- and cAMP-mediated growth arrest in macrophages.	UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT MED, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, DEPT DIAGNOST HAEMATOL, PARKVILLE, VIC 3050, AUSTRALIA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; St Jude Children's Research Hospital			Jackowski, Suzanne/N-8168-2018; rockman, steve/AAT-5105-2021	Jackowski, Suzanne/0000-0002-6855-1429; Hamilton, John A/0000-0002-9493-9224				ANDERSSON KB, 1993, J CELL PHYSIOL, V157, P61, DOI 10.1002/jcp.1041570108; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEAN M, 1987, ONCOGENE RES, V1, P279; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HAMILTON JA, 1989, J CELL PHYSL, V141, P619; HAMILTON JA, 1991, J IMMUNOL, V148, P4028; HARELBELLAN A, 1988, J IMMUNOL, V141, P1012; HARELBELLAN AH, 1987, J IMMUNOL, V140, P2431; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERTZOG PJ, 1988, CLIN IMMUNOL IMMUNOP, V48, P192, DOI 10.1016/0090-1229(88)90083-9; HOANG T, 1989, J EXP MED, V170, P15, DOI 10.1084/jem.170.1.15; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; JACKOWSKI S, 1990, J BIOL CHEM, V265, P6611; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KNIGHT KR, 1992, J LEUKOCYTE BIOL, V51, P350, DOI 10.1002/jlb.51.4.350; KREK W, 1995, IN PRESS METHODS ENZ; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LONGSTREET M, 1992, ONCOGENE, V7, P1549; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; METCALF D, 1984, HEMOPOIETIC COLONIES; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STAEHLI P, 1990, ADV VIRUS RES, V42, P147; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VAIRO G, 1991, J IMMUNOL, V146, P3469; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VAIRO G, 1992, J CELL PHYSIOL, V151, P630, DOI 10.1002/jcp.1041510324; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	57	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1969	1976						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761098				2022-12-17	WOS:A1995QZ92600011
J	ZHANG, W; GUO, XYD; DEISSEROTH, AB				ZHANG, W; GUO, XYD; DEISSEROTH, AB			THE REQUIREMENT OF THE CARBOXYL-TERMINUS OF P53 FOR DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION DEPENDS ON THE SPECIFIC P53 BINDING DNA ELEMENT	ONCOGENE			English	Article							WILD-TYPE P53; MUTANT P53; GENE AMPLIFICATION; MDM-2 ONCOGENE; LEUKEMIA CELLS; PROTEIN; EXPRESSION; SEQUENCE; SUPPRESSOR; GROWTH	The p53 protein specifically binds DNA sequences and activates transcription. In this study, we investigated the requirement of the carboxyl (C)- or amino (N)-terminal domain of p53 for the binding and transactivation of two DNA elements, p53CON and the ribosomal gene cluster (RGC). Three human p53 mutants with deletion in either the C-terminus or N-terminus were used. Mobility-shift assays showed that the oligomerization-defective mutant p53(1-326), from which the final 67 C-terminal amino acids were deleted, retained the wild-type p53's ability to bind the p53CON element in the presence of anti-p53 monoclonal antibody PAb1801. Also, the transient transfection assays showed that the mutant p53(1-326) activated p53CON-mediated transcription. However, this mutant failed to bind the RGC element and was unable to activate RGC-mediated transcription. Thus, the requirement of the C-terminal region of p53 for DNA binding and transcription activation varies with the p53-binding DNA element under study. In contrast, the N-terminus of p53 contains a common transcription activation domain: deletion of the 80 or 159 N-terminal amino acids inactivated both p53CON- and RGC-mediated transactivation. Furthermore, mobility-shift assays did not detect any binding to p53CON and RGC by either of the two N-terminal-deletion mutants. These results suggest that the N-terminus of p53 affects DNA binding.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [P01 CA55164] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN JY, 1993, ONCOGENE, V8, P2159; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FREBOURG T, 1992, CANCER RES, V52, P6976; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TP, 1992, CELL, V27, P875; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PROSSER J, 1990, ONCOGENE, V5, P1573; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STURZBECHER HW, 1992, ONCOGENE, V7, P1515; TARUNINA M, 1993, ONCOGENE, V8, P3165; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHANG W, 1992, ONCOGENE, V7, P1645; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555; ZHANG W, 1994, IN PRESS EMBO J	62	19	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2513	2521						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058314				2022-12-17	WOS:A1994PC05400010
J	FRANCASTEL, C; GROISMAN, R; PFARR, CM; ROBERTLEZENES, J				FRANCASTEL, C; GROISMAN, R; PFARR, CM; ROBERTLEZENES, J			ANTISENSE C-JUN OVERCOMES A DIFFERENTIATION BLOCK IN A MURINE ERYTHROLEUKEMIA CELL-LINE	ONCOGENE			English	Article							ERYTHROID-DIFFERENTIATION; HEMOGLOBIN-SYNTHESIS; DOWN-REGULATION; PORPHOBILINOGEN DEAMINASE; RECEPTOR ACTIVITY; MYELOID-LEUKEMIA; GENE-EXPRESSION; CONTROL REGION; FOS PROTEINS; GLOBIN	We have studied the expression of the c-jun gene during dimethyl-sulfoxide (DMSO) induced differentiation of Friend erythroleukemia (F-MEL) cells. No expression of c-jun was detected in a differentiation-competent F-MEL cell line (745A) either before or after treatment with DMSO. By contrast, c-jun expression was constitutive in a F-MEL cell line (TFP10) resistant to DMSO-induced differentiation and increased with DMSO. We have investigated the possible role of c-jun in conferring this resistance by stably transfecting either sense or antisense c-jun constructs into both differentiation-sensitive 745A and defective TFP10 cell lines. Inhibition of c-jun expression by antisense transcripts in the TFP10 cells restored their ability to undergo erythroid differentiation when exposed to DMSO while expression of junB or junD antisense vectors failed to do so. In addition, c-jun overexpression in the 745A cells resulted in decreased DMSO-induced differentiation. These results indicate a correlation between the level of c-jun expression and the ability of F-MEL cells to undergo DMSO-induced differentiation and suggest that c-jun may be an important negative regulator in this process.	HOP PAUL BROUSSE,INSERM,U268,ONCOGENESE APPL LAB,F-94800 VILLEJUIF,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,CNRS,UA 1644,F-75724 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)			Pfarr, Curt/HHD-1410-2022; Francastel, Claire/AAI-4798-2021	Groisman, Regina/0000-0003-3990-7622; Francastel, Claire/0000-0002-6353-4320				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLOCH A, 1984, CANCER TREAT REP, V68, P199; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHERN YJ, 1991, BLOOD, V78, P991, DOI 10.1182/blood.V78.4.991.bloodjournal784991; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGLIATI T, 1993, ONCOGENE, V8, P1263; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FRANCASTEL C, 1992, LEUKEMIA, V6, P935; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GRANDCHAMP B, 1985, J BIOL CHEM, V260, P9630; HOUSSET M, 1982, BRIT J HAEMATOL, V51, P125, DOI 10.1111/j.1365-2141.1982.tb07297.x; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JEANNESSON P, 1984, ANTICANCER RES, V4, P47; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MARKS PA, 1987, CANCER RES, V47, P657; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MECHTA F, 1989, New Biologist, V1, P297; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROCHOWNIK EV, 1990, BLOOD, V76, P1830; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; ROBERTLEZENES J, 1988, CANCER RES, V48, P3972; RYSECK RP, 1991, ONCOGENE, V6, P533; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SARTORELLI AC, 1985, BRIT J CANCER, V52, P293, DOI 10.1038/bjc.1985.193; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRENTESAUX C, 1993, LEUKEMIA, V7, P452; TSIFTSOGLOU AS, 1985, ANTICANCER RES, V5, P81; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2	50	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1957	1964						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208542				2022-12-17	WOS:A1994NR68500020
J	WILLIAMS, AC; BROWNE, SJ; MANNING, AM; DAFFADA, P; COLLARD, TJ; PARASKEVA, C				WILLIAMS, AC; BROWNE, SJ; MANNING, AM; DAFFADA, P; COLLARD, TJ; PARASKEVA, C			TRANSFECTION AND EXPRESSION OF MUTANT P53 PROTEIN DOES NOT ALTER THE IN-VIVO OR IN-VITRO GROWTH-CHARACTERISTICS OF THE AA/C1 HUMAN ADENOMA DERIVED CELL-LINE, INCLUDING SENSITIVITY TO TRANSFORMING GROWTH-FACTOR-BETA-1	ONCOGENE			English	Note							WILD-TYPE P53; POLYPOSIS COLI PATIENTS; GENE-MUTATIONS; CANCER CELLS; COLORECTAL-CANCER; SUPPRESSES GROWTH; RAS; CARCINOMAS; PROMOTER; INVITRO	Mutation of the p53 gene is thought to be a late event in human colorectal carcinogenesis, involved in the malignant conversion of the adenoma to the carcinoma. One of the questions that we hoped to address was whether, in vivo, a single mutational event in one p53 gene is sufficient to confer a significant growth advantage on a colonic epithelial cell. Such a growth advantage could result either from an increase in growth rate and/or loss of response to inhibitory growth signals naturally present in the colonic crypt. We therefore introduced the pC53-SCX3 143 (Val-Ala) p53 mutation into a non tumorigenic adenoma derived cell line, AA/C1, which contained a truncating APC mutation, activating K-ras mutation but was wild-type for the p53 protein. High levels of mutant p53 protein were detected in the pC53-SCX3 transfected AA/C1 cell lines but was found not to affect either the in vitro (colony forming efficiency, anchorage independence) or in vivo (tumorigenicity in nude mice) growth, when compared to vector control or the parental AA/C1 cell line. In addition, to test whether the cells become less sensitive to inhibitory growth factors, the response of the cell lines to the naturally occurring growth inhibitor TGF beta was also investigated. Even though TGF beta had previously been implicated in the control of growth of intestinal epithelium, expression of the mutant p53 protein did not affect the sensitivity of the parental AA/C1 cell line to TGF beta. Under the experimental conditions tested expression of the 143 (Val-Ala) p53 protein was unable to affect the in vitro or in vivo growth characteristics of the adenoma derived AA/C1 cell line. When compared to other studies, these results suggest that the genetic background of the individual recipient cell may greatly influence the effect of expression of a particular p53 mutation.			WILLIAMS, AC (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,CRC,COLORECTAL TUMOUR BIOL RES GRP,UNIV WALK,BRISTOL BS8 1TD,ENGLAND.			Williams, Ann/0000-0002-6009-7137				AVERY A, 1993, BRIT J CANCER, V68, P137, DOI 10.1038/bjc.1993.301; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BODNER SM, 1992, ONCOGENE, V7, P743; CAJOT JF, 1992, CANCER RES, V52, P6956; CARDER P, 1993, ONCOGENE, V8, P1397; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; ISAACS WB, 1991, CANCER RES, V51, P4716; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LEIBOVITZ A, 1976, CANCER RES, V36, P3562; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MANNING AM, 1991, ONCOGENE, V6, P1471; MATOZAKI T, 1992, CANCER RES, V52, P4335; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARASKEVA C, 1988, INT J CANCER, V41, P908; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; REISS M, 1993, CANCER RES, V53, P899; RIDGWAY PJ, 1993, ONCOGENE, V8, P1069; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TAKAHASHI K, 1992, JPN J CANCER RES, V83, P358, DOI 10.1111/j.1349-7006.1992.tb00115.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WHITEHEAD RH, 1991, INT J CANCER, V48, P693, DOI 10.1002/ijc.2910480511; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; WILLIAMS AC, 1992, INT J CANCER, V52, P785, DOI 10.1002/ijc.2910520519; WILLSON JKV, 1987, CANCER RES, V47, P2704; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WUYLLIE FS, 1993, MOL CARCINOGEN, V7, P83; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	52	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1479	1485						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152811				2022-12-17	WOS:A1994NH40100022
J	SAIKUMAR, P; GABRIEL, JL; REDDY, EP				SAIKUMAR, P; GABRIEL, JL; REDDY, EP			THE MYB ONCOGENE PRODUCT INDUCES DNA-BENDING	ONCOGENE			English	Article							GENE V-MYB; C-MYB; BINDING DOMAIN; ESCHERICHIA-COLI; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATORS; CELLULAR PROGENITOR; TRANSFORMING GENE; TRANS-ACTIVATION; RNA-POLYMERASE	The nuclear oncogene v-myb and its cellular counterpart c-myb code for proteins that bind to DNA in a sequence specific manner and act as regulators of transcription. The Myb protein contains DNA binding and transregulatory domains which are important for its function. The DNA binding domain of Myb protein has been shown to contain three imperfectly conserved repeats of 50-52 aminoacids that constitute the amino terminal end. In this communication, we show that Myb protein induces conformational change in DNA after protein-DNA complex formation. Circular permutation assays indicate that Myb protein induces DNA bending at the site of binding. Phasing analysis confirm the DNA bending and allowed the detection of relative orientation of bend. Myb proteins which comprise only DNA-binding domains either with three repeats or two repeats also bend DNA in the same orientation as the larger proteins with both DNA-binding and transactivating domains. However, the transactivating region seems to influence the magnitude of bend angle. We used molecular modeling to analyse the structure of Myb-DNA complex formation resulting in the bending of DNA. Data presented here show that Myb protein, like other transcriptional regulators, bends DNA upon binding allowing the interaction of regulatory elements.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P01CA052009, P30CA012227] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 12227, CA 52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BAUR CP, 1988, J MOL BIOL, V203, P1009, DOI 10.1016/0022-2836(88)90125-8; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GABRIEL JL, 1993, P NATL ACAD SCI USA, V90, P4186, DOI 10.1073/pnas.90.9.4186; GABRIEL JL, 1991, J THEOR BIOL, V151, P541, DOI 10.1016/S0022-5193(05)80369-8; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GROTEWOLD E, 1991, P NATL ACAD SCI USA, V88, P4587, DOI 10.1073/pnas.88.11.4587; HEUMANN H, 1988, EMBO J, V7, P4379, DOI 10.1002/j.1460-2075.1988.tb03336.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KERPPOLA T, 1991, CELL, V66, P1; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOSTREWA D, 1991, NATURE, V349, P178, DOI 10.1038/349178a0; LEPRINCE D, 1983, EMBO J, V2, P1073, DOI 10.1002/j.1460-2075.1983.tb01548.x; MAROCCO A, 1989, MOL GEN GENET, V216, P183, DOI 10.1007/BF00334354; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILLIAMS JS, 1988, MOL CELL BIOL, V8, P2763, DOI 10.1128/MCB.8.7.2763; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	69	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1279	1287						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134132				2022-12-17	WOS:A1994NC04800035
J	STACEY, SN; EKLUND, C; JORDAN, D; SMITH, NK; STERN, PL; DILLNER, J; ARRAND, JR				STACEY, SN; EKLUND, C; JORDAN, D; SMITH, NK; STERN, PL; DILLNER, J; ARRAND, JR			SCANNING THE STRUCTURE AND ANTIGENICITY OF HPV-16 E6 AND E7 ONCOPROTEINS USING ANTIPEPTIDE ANTIBODIES	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; SEQUENCE-ANALYSIS PROGRAMS; ANTI-PEPTIDE ANTIBODIES; AMINO-ACID-SEQUENCE; OPEN READING FRAMES; CERVICAL-CANCER; GENE-PRODUCTS; SYNTHETIC PEPTIDES; ESCHERICHIA-COLI; ATOMIC MOBILITY	The structure and antigenicity of the HPV-16 E6 and E7 oncoproteins was studied using a set of antisera against overlapping synthetic peptides. We report that antigenic, mobile regions of the native proteins, as defined by reactivity with antipepide antisera, occur at the N-termini of both E6 and E7 proteins, corresponding to regions of known or suspected protein-protein interactions. The putative zinc finger domains were consistently non-reactive, despite computer predictions of relatively high antigenicity, suggesting that the proposed zinc finger regions are held in stable secondary structures that the peptides were not able to mimic. In E6, the linker region between the two zinc fingers was antigenic, indicating that the two zinc finger structures might be able to articulate relative to one another by a flexible linker region. The highly antigenic N-terminal region of HPV-16 E7 was also found to be antigenic in E7 of both HPV-11 and HPV-18, indicating that the E7 proteins of different HPV types have similar antigenic structures. The identification of antigenic regions of the E6 and E7 proteins should be therefore be useful in the design of site-directed antibodies against E6 and E7 for numerous HPV types.	CHRISTIE HOSP, PATERSON INST CANC RES, CANC RES CAMPAIGN, DEPT IMMUNOL, MANCHESTER M20 9BX, LANCS, ENGLAND; KAROLINSKA INST, DEPT VIROL, STOCKHOLM, SWEDEN	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Karolinska Institutet	STACEY, SN (corresponding author), CHRISTIE HOSP, PATERSON INST CANC RES, CANC RES CAMPAIGN, DEPT MOLEC BIOL, MANCHESTER M20 9BX, LANCS, ENGLAND.							ARMSTRONG DJ, 1992, J GEN VIROL, V73, P1275, DOI 10.1099/0022-1317-73-5-1275; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BURNETT TS, 1983, J GEN VIROL, V64, P1509, DOI 10.1099/0022-1317-64-7-1509; CHAMBERS MA, 1994, J GEN VIROL, V75, P165, DOI 10.1099/0022-1317-75-1-165; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; COMERFORD SA, 1991, J VIROL, V65, P4681, DOI 10.1128/JVI.65.9.4681-4690.1991; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DARMANN K, 1986, VIROLOGY, V151, P124, DOI 10.1016/0042-6822(86)90110-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DILLNER J, 1990, INT J CANCER, V46, P703, DOI 10.1002/ijc.2910460426; DIMAIO D, 1991, ADV CANCER RES, V56, P133; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GAUTHIER JM, 1991, NUCLEIC ACIDS RES, V19, P7073, DOI 10.1093/nar/19.25.7073; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; GHOSH AK, 1993, INT J CANCER, V53, P591, DOI 10.1002/ijc.2910530411; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; GROSSMAN SR, 1989, ONCOGENE, V4, P1089; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; JENISON SA, 1991, J VIROL, V65, P1208, DOI 10.1128/JVI.65.3.1208-1218.1991; JENSON AB, 1990, PAPILLOMAVIRUSES HUM; JOCHMUSKUDIELKA I, 1989, J NATL CANCER I, V81, P1698, DOI 10.1093/jnci/81.22.1698; JONES RE, 1990, J BIOL CHEM, V265, P12782; KANDA T, 1991, VIROLOGY, V182, P723, DOI 10.1016/0042-6822(91)90613-G; KOCHEL HG, 1991, INT J CANCER, V48, P682, DOI 10.1002/ijc.2910480509; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRCHNAK V, 1990, J GEN VIROL, V71, P2719, DOI 10.1099/0022-1317-71-11-2719; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MACKETT M, 1985, DNA CLONING PRACTICA, V11, P191; MALLON RG, 1987, J VIROL, V61, P1655, DOI 10.1128/JVI.61.5.1655-1660.1987; MANN VM, 1990, CANCER RES, V50, P7815; MATLASHEWSKI G, 1989, ANTICANCER RES, V9, P1447; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MULLER M, 1990, J GEN VIROL, V71, P2709, DOI 10.1099/0022-1317-71-11-2709; MULLER M, 1992, VIROLOGY, V187, P508; MUNGER K, 1992, CANCER SURV, V12, P197; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Munoz N, 1992, IARC SCI PUBLICATION; NIEDOBITEK G, 1991, CANCER J - FRANCE, V4, P163; PAGE MJ, 1989, NUCLEIC ACIDS RES, V17, P454, DOI 10.1093/nar/17.1.454; PATRICK DR, 1992, J BIOL CHEM, V267, P6910; RHODES D, 1988, NUCLEIC ACIDS MOL BI, V2; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SECKLER R, 1986, BIOCHEMISTRY-US, V25, P2403, DOI 10.1021/bi00357a016; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STACEY SN, 1993, J MED VIROL, V40, P14, DOI 10.1002/jmv.1890400105; STACEY SN, 1992, J GEN VIROL, V73, P2337, DOI 10.1099/0022-1317-73-9-2337; SUTCLIFFE JG, 1983, SCIENCE, V219, P660, DOI 10.1126/science.6186024; TAINER JA, 1985, ANNU REV IMMUNOL, V3, P501, DOI 10.1146/annurev.iy.03.040185.002441; TAINER JA, 1984, NATURE, V312, P127, DOI 10.1038/312127a0; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TINDLE RW, 1990, J GEN VIROL, V71, P1347, DOI 10.1099/0022-1317-71-6-1347; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187	62	19	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					635	645						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7507231				2022-12-17	WOS:A1994MW24800032
J	CARNAC, G; ALBAGLICURIEL, O; DESCLOZEAUX, M; VANDROMME, M; GLINEUR, C; BEGUE, A; LAUDET, V; BONNIEU, A				CARNAC, G; ALBAGLICURIEL, O; DESCLOZEAUX, M; VANDROMME, M; GLINEUR, C; BEGUE, A; LAUDET, V; BONNIEU, A			OVEREXPRESSION OF C-ERBA PROTOONCOGENE ENHANCES MYOGENIC DIFFERENTIATION	ONCOGENE			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE RECEPTORS; MUSCLE-SPECIFIC GENES; V-ERBA; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTOR; MESSENGER-RNA; SKI ONCOGENE; MYOD1 GENE; EXPRESSION	Triiodothyronine (T3) positively regulates both the expression of the MyoD gene, a key myogenic regulator, and C2 muscle cell differentiation. To directly examine the role of its nuclear receptors in the control of myogenesis, we introduced a c-erbA expression vector into C2 muscle cells by transient or stable transfection. Our results show that c-erbA can play a potent role in the triggering of muscle terminal differentiation since its overexpression leads to: (1) a complete abrogation of the activity of the myogenesis inhibitor Ap-1 (fos/jun) transcription factor; (2) an enhanced induction of MyoD expression upon T3 treatment; (3) the acquisition by T3 of the ability to trigger both growth arrest and terminal differentiation in the presence of large amounts of serum mitogens, a property that is otherwise specific to retinoic acid (RA). Thus, c-erbA is one of the two proto-oncogenes (with c-ski) that acts as positive regulator of muscle differentiation. Furthermore, the fact that c-erbA overexpression allows T3 to largely mimic the RA effects indicates that their biological differences in the modulation of myogenic program primarily rely on the differential expression of their receptors in C2 muscle cells rather than on an intrinsic specificity of their target genes.	INRA,DIFFERENCIAT CELLULAIRE & CROISSANCE LAB,F-34060 MONTPELLIER,FRANCE; CTR RECH BIOCHIM MACROMOLEC,DEPT CELL BIOL,CNRS,INSERM,F-34033 MONTPELLIER,FRANCE; INST PASTEUR,CNRS,URA 1160,ONCOL MOLEC U186,F-59019 LILLE,FRANCE	INRAE; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Vandromme, Marie M/N-6615-2018; Bonnieu, Anne/ABA-7182-2020; Vandromme, Marie/ABC-3003-2021; Carnac, Gilles/N-6744-2018	Carnac, Gilles/0000-0002-3518-8774; vandromme, Marie/0000-0002-5675-7999				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; CARNAC G, 1992, MOL ENDOCRINOL, V6, P1185, DOI 10.1210/me.6.8.1185; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KUWANO Y, 1985, J BIOCHEM-TOKYO, V97, P983, DOI 10.1093/oxfordjournals.jbchem.a135175; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MOORE D D, 1990, New Biologist, V2, P100; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NILSEN DA, 1983, P NATL ACAD SCI USA, V80, P5198; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAIN B, 1990, New Biologist, V2, P284; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	56	19	19	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3103	3110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414512				2022-12-17	WOS:A1993MC09300027
J	HELFTENBEIN, G; ALVAREZ, CV; TUOHIMAA, P; BEATO, M				HELFTENBEIN, G; ALVAREZ, CV; TUOHIMAA, P; BEATO, M			EXPRESSION OF EPITHELIAL PHENOTYPE IS ENHANCED BY V-HA-RAS IN RAT ENDOMETRIAL CELLS IMMORTALIZED BY SV40-T ANTIGEN	ONCOGENE			English	Article							GAP JUNCTION PROTEIN; HORMONAL-REGULATION; MOLECULAR-CLONING; PRIMARY CULTURES; GRANULOSA-CELLS; MESSENGER-RNA; DIFFERENTIATION; ONCOGENES; RECEPTOR; GROWTH	To study the interplay of steroid hormones and oncogenes in the control of endometrial cell proliferation and differentiation we have generated cell lines derived from rat endometrium by expressing the immortalizing oncogenes adeno EIA or SV40 large T antigen. These lines are positive for mesenchymal markers and contain very few characteristic epithelial proteins. Cell lines expressing a temperature-sensitive mutant of SV40 T antigen exhibit a temperature-dependent morphology and growth behavior, but do not manifest an epithelial phenotype at the non-permissive temperature. Cell lines additionally infected with retroviral vectors carrying the v-Ha-ras oncogene (p21ras(Arg-12)) no longer express collagen type III and recover part of their epithelial potential by expressing cytokeratins and/or cadherin E. Some of these cells also express characteristic decidual marker proteins such as desmin, whereas others express glandular epithelial markers such as uteroglobin. Uteroglobin mRNA levels in these cells are increased by glucocorticoids. The parental temperature-sensitive cells do not contain progesterone receptor but become positive for progesterone receptor at the permissive temperature after infection with the v-Ha-ras-expressing retrovirus. Our results indicate that there is a fluent transition and overlapping between mesenchymal, glandular epithelial and decidual phenotypes of endometrial cells, suggesting that these three cell types are derived from the same stem/precursor cells. The v-Ha-ras oncogene product appears to act on the differentiation pathway at an early step prior to the distinction between decidual and glandular epithelial lineage.	UNIV MARBURG,INST MOLEKULARBIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY; UNIV TAMPERE,DETP BIOMED SCI,SF-33101 TAMPERE,FINLAND	Philipps University Marburg; Tampere University			Beato, Miguel/B-5564-2015; Alvarez, Clara V/AAN-4173-2020	Beato, Miguel/0000-0002-2878-2222; Alvarez, Clara V/0000-0003-1500-4058				AMSTERDAM A, 1988, P NATL ACAD SCI USA, V85, P7582, DOI 10.1073/pnas.85.20.7582; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; AZUMA C, 1990, J MOL ENDOCRINOL, V5, P103, DOI 10.1677/jme.0.0050103; BEATO M, 1983, REGULATION GENE EXPR, P151; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BREITKREUTZ D, 1991, CANCER RES, V51, P4402; CONTI CJ, 1984, ENDOCRINOLOGY, V114, P345, DOI 10.1210/endo-114-2-345; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; EDELMAN GM, 1983, SCIENCE, V219, P450, DOI 10.1126/science.6823544; FRANKE WW, 1978, P NATL ACAD SCI USA, V75, P5034, DOI 10.1073/pnas.75.10.5034; GERSCHENSON LE, 1979, LIFE SCI, V24, P1337, DOI 10.1016/0024-3205(79)90002-X; GILULA NB, 1972, NATURE, V235, P262, DOI 10.1038/235262a0; GLASSER SR, 1988, J CELL BIOL, V107, P2409, DOI 10.1083/jcb.107.6.2409; GLASSER SR, 1986, BIOL REPROD, V35, P463, DOI 10.1095/biolreprod35.2.463; HACKENBERG R, 1992, J STEROID BIOCHEM, V43, P599, DOI 10.1016/0960-0760(92)90284-P; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HANKINS WD, 1981, CELL, V26, P91, DOI 10.1016/0092-8674(81)90036-2; HELFTENBEIN G, 1991, EUR J CELL BIOL, V56, P49; HOWELLS RD, 1984, P NATL ACAD SCI-BIOL, V81, P7651, DOI 10.1073/pnas.81.23.7651; ISOM HC, 1992, CANCER RES, V52, P940; JIN DF, 1988, ENDOCRINOLOGY, V122, P1466, DOI 10.1210/endo-122-4-1466; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; LIAU G, 1985, J BIOL CHEM, V260, P531; LYNCH MP, 1986, P NATL ACAD SCI USA, V83, P4784, DOI 10.1073/pnas.83.13.4784; Maniatis T., 1982, MOL CLONING; MCCORMACK SA, 1980, ENDOCRINOLOGY, V106, P1634, DOI 10.1210/endo-106-5-1634; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V11, P2849; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; ODIN P, 1988, J HISTOCHEM CYTOCHEM, V36, P729, DOI 10.1177/36.7.3290331; PARK OK, 1991, MOL ENDOCRINOL, V5, P967, DOI 10.1210/mend-5-7-967; PARK OK, 1991, MOL ENDOCRINOL, V5, P1931; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; ROGENSTREIF LJ, 1989, DEV BIOL, V133, P284; ROSEN H, 1990, MOL ENDOCRINOL, V4, P146, DOI 10.1210/mend-4-1-146; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCRATCHARD G, 1949, ANN NY ACAD SCI, V51, P660; STENBERG EA, 1989, MOL CELL BIOL, V9, P594; TABIBZADEH S, 1991, AM J REPROD IMMUNOL, V26, P5, DOI 10.1111/j.1600-0897.1991.tb00693.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TUOHIMAA P, 1992, SERONO S PUBLICATION, V90, P245; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WIEHLE RD, 1990, ONCOGENE, V5, P787; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	53	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2075	2085						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393160				2022-12-17	WOS:A1993LP17100007
J	KOHLHUBER, F; STROBL, LJ; EICK, D				KOHLHUBER, F; STROBL, LJ; EICK, D			EARLY DOWN-REGULATION OF C-MYC IN DIMETHYLSULFOXIDE-INDUCED MOUSE ERYTHROLEUKEMIA (MEL) CELLS IN MEDIATED AT THE P1/P2 PROMOTERS	ONCOGENE			English	Note							RNA POLYMERASE-II; PREMATURE TERMINATION; 5' END; GENE; TRANSCRIPTION; EXPRESSION; DIFFERENTIATION; REQUIREMENTS; ARREST; BLOCK	A block of RNA elongation in exon 1 of the murine c-myc gene has been described for normal mouse fibroblasts, lymphoid and myeloid cell lines and mouse erythroleukemia (MEL) cells. MEL cells differentiate after induction with the chemical agent dimethylsulfoxide (DMSO). The rapid initial down-regulation of c-myc that occurs after treatment with DMSO has been explained by an increase in the block of RNA elongation within the 3' part of c-myc exon 1. In contrast to these reports, we find that down-regulation of c-myc in DMSO-induced MEL cells occurs at the c-myc P1 and P2 promoters. The P1 promoter is repressed by inhibition of initiation, whereas transcription of P2 RNA is blocked by retention of RNA polymerase II at or close to the P2 promoter. The earlier described block of RNA elongation at a run of five thymidines in the 3' part of c-myc exon 1 was not observed.	GSF MUNICH,FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,W-8000 MUNICH 70,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Strobl, Lothar J/M-7357-2014	Strobl, Lothar J/0000-0001-8389-1862				ASSELIN C, 1989, ONCOGENE, V4, P549; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; PLET A, 1992, ONCOGENE, V7, P1847; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SPENCER CA, 1991, ADV CANCER RES, P1; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; WRIGHT S, 1991, P NATL ACAD SCI USA, V88, P11383, DOI 10.1073/pnas.88.24.11383	21	19	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1099	1102						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455938				2022-12-17	WOS:A1993KT22000037
J	KAECH, S; SCHNIERLE, B; WYSS, A; BALLMERHOFER, K				KAECH, S; SCHNIERLE, B; WYSS, A; BALLMERHOFER, K			MYRISTYLATION AND AMINO-TERMINAL PHOSPHORYLATION ARE REQUIRED FOR ACTIVATION OF PP60(C-SRC) DURING MITOSIS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; CYANOGEN-BROMIDE CLEAVAGE; MIDDLE-T-ANTIGEN; SRC FAMILY; MONOCLONAL-ANTIBODIES; LYMPHOCYTES-T; PP60C-SRC; P60C-SRC; RECEPTOR; MUTATION	pp60c-src, a cellular tyrosine kinase homologous to the retroviral v-src oncogene, becomes transiently activated during mitosis. Activation is accompanied by phosphorylation of three sites in the amino-terminal regulatory domain of the protein, threonine 34, threonine 46 and serine 72. These sites can be phosphorylated in vitro by a cell cycle-regulated kinase, p34cdc2, yet this does not result in increased kinase activity of pp60c-src. pp60c-src is negatively regulated by phosphorylation at tyrosine 527, and it has been shown that this site is transiently dephosphorylated in mitotic cells. The importance of tyrosine 527 in the regulation of pp60c-src is also emphasized by the fact that oncogenic mutants of pp60src lacking tyrosine 527 are constitutively active during the entire cell cycle. Here we report that a non-myristylated mutant of pp60c-src is not activated and only partially phosphorylated at the amino terminus in mitotic cells. Additional mutants lacking one (TTAc-src), two (AASc-src) and three (AAAc-src) cdc2 phosphorylation sites had slightly higher kinase activity than wild-type pp60c-src in interphase cells and were not activated during mitosis. However, all four mutant proteins were still transiently dephosphorylated at tyrosine 527 during mitosis, suggesting that myristylation and amino-terminal phosphorylation may be necessary but are clearly not sufficient for mitosis-specific activation.	FRIEDRICH MIESCHER INST, BOX 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			Schnierle, Barbara/AAG-8108-2019	Ballmer-Hofer, Kurt/0000-0002-3800-9129; Kaech Petrie, Stefanie/0000-0002-6246-6434				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1990, PEPTIDES PROTEIN PHO, P86; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EISEMAN E, 1992, NATURE, V355, P78; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO K, 1990, ONCOGENE, V5, P921; LUO KX, 1991, METHOD ENZYMOL, V201, P149; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MUSTELIN T, 1990, ONCOGENE, V5, P809; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PARTANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shaw A, 1991, CURR OPIN CELL BIOL, V3, P862, DOI 10.1016/0955-0674(91)90061-3; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453	45	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					575	581						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	7679790				2022-12-17	WOS:A1993KN00800007
J	WOJTASZEK, PA; STUMPO, DJ; BLACKSHEAR, PJ; MACARA, IG				WOJTASZEK, PA; STUMPO, DJ; BLACKSHEAR, PJ; MACARA, IG			SEVERELY DECREASED MARCK EXPRESSION CORRELATES WITH RAS-REVERSION BUT NOT WITH MITOGENIC RESPONSIVENESS	ONCOGENE			English	Article							PROTEIN-KINASE-C; MAJOR SPECIFIC SUBSTRATE; TRANSFORMED-CELLS; BACTERIAL LIPOPOLYSACCHARIDE; PHOSPHOINOSITIDE HYDROLYSIS; CELLULAR SUBSTRATE; FLAT REVERTANTS; GROWTH-FACTOR; BOVINE BRAIN; GENE-PRODUCT	Phorbol ester-inducible phosphorylation of MARCKS, the '80-kDa' substrate of protein kinase C, was undetectable in several phenotypically dominant, non-transformed revertants independently derived from the ras-transformed cell line NIH3T3 DT-ras. Extremely low expression of MARCKS protein accounted for this apparent lack of phosphorylation. MARCKS-encoding mRNA levels were correspondingly decreased relative to normal and ras-transformed cells in all four ras revertant cell lines studied: C-11 and F-2, derived by 5-azacytidine treatment and selection with ouabain; CHP 9CJ, derived by ethytmethane sulfonate mutagenesis and selection with cis-hydroxy-L-proline; and 12-V3, derived by transfection with the human Krev-1 gene. However, re-expression of MARCKS after transfection of a cloned MARCKS cDNA into the C-11 ras revertant cells was not sufficient to induce retransformation. In fact, no significant difference in sensitivity to mitogenic stimulation by phorbol esters was observed among several cell lines expressing widely varying levels of MARCKS. This evidence argues against a direct role for MARCKS in mitogenic signaling. However, the strong correlation between attentuation of MARCKS expression and phenotypically dominant ras reversion suggests that a common negative regulatory mechanism might be responsible for both effects, presenting a potentially useful strategy for identifying factors involved in transducing the ras signal.	UNIV VERMONT,COLL MED,DEPT PATHOL,BURLINGTON,VT 05405; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710	University of Vermont; Duke University; Howard Hughes Medical Institute			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NCI NIH HHS [CA-43551] Funding Source: Medline; NIEHS NIH HHS [ES 01247] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P61; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KAMATA T, 1987, ONCOGENE, V1, P37; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKALL J, 1979, ANAL BIOCHEM, V95, P270, DOI 10.1016/0003-2697(79)90216-1; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MILLAR JBA, 1989, P NATL ACAD SCI USA, V86, P3204, DOI 10.1073/pnas.86.9.3204; MORRIS JDH, 1989, ONCOGENE, V4, P27; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PIZON V, 1988, ONCOGENE, V3, P201; ROSEN A, 1989, J BIOL CHEM, V264, P9118; Sambrook J., 1989, MOL CLONING LAB MANU; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; YANAGIHARA K, 1990, ONCOGENE, V5, P1179	38	19	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					755	760						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437859				2022-12-17	WOS:A1993KN00800028
J	RUTHER, U; WOODROOFE, C; FATTORI, E; CILIBERTO, G				RUTHER, U; WOODROOFE, C; FATTORI, E; CILIBERTO, G			INDUCIBLE FORMATION OF LIVER-TUMORS IN TRANSGENIC MICE	ONCOGENE			English	Article							C-REACTIVE PROTEIN; EXPRESSION; TUMORIGENESIS; GENES	Transgenic mice have been generated with an inducible SV40 t/T antigen construct with the aim of analysing the early changes that take place in the course of liver tumorigenesis. The strictly liver-specific human C-reactive protein (CRP) gene promoter was chosen for the control of the transgene expression because this promoter can be turned on transiently by injection of bacterial lipopolysaccharide. Among 10 independently derived CRP-Tag mouse lines five showed inducible expression of the CRP-Tag transgene in liver. However, only one had a tight control of the transgene with virtually no expression under physiological conditions and high levels of Tag expression after stimulation. Females of this line were used to analyse the progression of liver alterations upon repeated induction of the t/T antigen for different lengths of time. The first signs of transgene-induced liver alterations could be monitored by the activation of the marker enzyme gamma-glutamyltranspeptidase 30 days after the start of the induction program. After 90 days hepatocellular carcinomas were already detectable. Thus, CRP-Tag mice constitute an excellent system to analyse the sequential events that take place during liver carcinogenesis.	IST RIC BIOL MOLEC,DEPT GENET,I-00040 POMEZIA,ITALY; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CILIBERTO G, 1987, EMBO J, V6, P4017, DOI 10.1002/j.1460-2075.1987.tb02745.x; CILIBERTO G, 1987, NUCLEIC ACIDS RES, V15, P5859; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GANTER U, 1989, EMBO J, V8, P3733; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HOGAN B, 1986, MANIPULATION MOUSE E; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; NOWELL PC, 1986, CANCER RES, V46, P2203; OGAWA K, 1980, CANCER RES, V40, P725; RUTENBURG AM, 1969, J HISTOCHEM CYTOCHEM, V17, P517, DOI 10.1177/17.8.517; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SANDGREN EP, 1989, ONCOGENE, V4, P715; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; TONIATTI C, 1990, MOL BIOL MED, V7, P199; TOOZE J, 1990, DNA TUMOR VIRUSES; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	22	19	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					87	93						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423999				2022-12-17	WOS:A1993KN00500010
J	BOISE, LH; GORSE, KM; WESTIN, EH				BOISE, LH; GORSE, KM; WESTIN, EH			MULTIPLE MECHANISMS OF REGULATION OF THE HUMAN C-MYB GENE DURING MYELOMONOCYTIC DIFFERENTIATION	ONCOGENE			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; MOUSE ERYTHROLEUKEMIA-CELLS; PROTO-ONCOGENE PRODUCT; MESSENGER-RNA; TRANS-ACTIVATION; V-MYB; EXPRESSION; PROLIFERATION; TRANSCRIPTION; SEQUENCE	Alterations in expression of c-myb can have profound effects on the growth and differentiation of hematopoietic cells. Thus, it is important to understand the mechanisms by which c-myb is regulated during hematopoietic cell differentiation. Previous studies pertaining to the regulation of c-myb have been carried out with the avian and murine forms of the gene; the current studies were designed to determine the mechanisms of regulation of the human form of c-myb. Transcriptional analysis by nuclear run-on assays revealed that an attenuation of transcription was the means of primary regulation during retinoic acid- and vitamin D3-induced differentiation of HL-60 cells, while other mechanisms in addition to attenuation were active during dimethyl sulfoxide (DMSO)- and phorbol ester-induced differentiation. Densitometric analysis of the changes in c.myb transcription caused by phorbol ester suggested that the c-myb promoter may be down-regulated during phorbol ester-induced differentiation of HL-60. Additional studies exhibited post-transcriptional regulation by phorbol ester. DMSO was also shown to regulate c-myb at the post-transcriptional level. Interestingly, the post-transcriptional regulation of c-myb by DMSO required continuous transcription. This requirement was shared for c-myc but not ornithine decarboxylase expression. The transcriptional dependency of c-myb post-transcriptional regulation did not equate to translational dependency, thus a novel post-transcriptional regulatory mechanism may control c-myb gene expression. The multiple levels of regulation of c-myb suggest the importance of proper control for hematopoietic cell differentiation.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University			Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007087] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 07087] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; Dalla-Favera R, 1983, Haematol Blood Transfus, V28, P247; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAYWARD WS, 1989, MOL CELL BIOL, V9, P837; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	36	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1817	1825						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323820				2022-12-17	WOS:A1992JJ37600018
J	DO, MS; FITZERATTAS, C; GUBBAY, J; GREENFELD, L; FELDMAN, M; EISENBACH, L				DO, MS; FITZERATTAS, C; GUBBAY, J; GREENFELD, L; FELDMAN, M; EISENBACH, L			MOUSE PLATELET-DERIVED GROWTH FACTOR-ALPHA RECEPTOR - SEQUENCE, TISSUE-SPECIFIC EXPRESSION AND CORRELATION WITH METASTATIC PHENOTYPE	ONCOGENE			English	Article							TUMOR-CELL LINES; PDGF-RECEPTOR; TYROSINE KINASE; SARCOMA-VIRUS; STRUCTURAL SIMILARITY; SIGNAL TRANSDUCTION; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; TRANSFORMING GENE; PROTEIN-KINASE	High- and low-metastatic cells derived from metastatic murine tumors were screened for the differential expression of proto-oncogenes which may code for cell-surface receptors to growth factors. We found that metastatic clones of 3LL carcinoma and T10 sarcoma but not non-metastatic clones of these tumors express a 6.5-kb mRNA that is recognized by a v-fms probe containing a tyrosine kinase domain. The cloning and sequence analysis of a full-length cDNA clone corresponding to the v-fms-related 6.5-kb transcript showed that this transcript is the murine homolog of platelet-derived growth factor alpha (PDGF-alpha) receptor. The cDNA contains an open reading frame that predicts a 1089 amino acid protein. Comparison with the human and rat PDGF-alpha receptor reveals an overall amino acid sequence identity of 91% and 94% respectively. Northern blot analysis shows that this gene is preferentially expressed in the high-metastatic clones and is also selectively expressed in normal mouse tissues. Immunoprecipitation using anti-PDGF-alpha receptor serum shows that 185-kDa and 170-kDa proteins were specifically precipitated from cells of the high-metastatic D122 but not from the low-metastatic A9 cells. The possibility that overexpression of PDGF-alpha receptor in high-metastatic clones may contribute to an increase in the capacity of tumor cells to generate metastases in the lung is discussed.	WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Eisenbach, Lea R/0000-0002-4816-1968; Fitzer-Attas, Cheryl/0000-0002-8709-1384	NCI NIH HHS [CA28139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BEVEREN CV, 1981, NATURE, V289, P258; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEBAETSELIER P, 1980, NATURE, V288, P179; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; EISENBACH L, 1986, NATO ASI SER, V121, P57; EISENBACH L, 1983, J CANCER, V32, P3293; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FRANCHINI G, 1982, MOL CELL BIOL, V2, P1014, DOI 10.1128/MCB.2.8.1014; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HARSH GR, 1990, J NEURO-ONCOL, V8, P1; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Hart I R, 1982, Cancer Metastasis Rev, V1, P5, DOI 10.1007/BF00049477; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LEVEEN P, 1990, INT J CANCER, V46, P1066, DOI 10.1002/ijc.2910460620; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MALIK R, 1991, CANCER RES, V51, P5626; Maniatis T., 1982, MOL CLONING; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1990, INT J CANCER, V46, P16, DOI 10.1002/ijc.2910460106; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORI S, 1991, J BIOL CHEM, V266, P21158; MOSHIER JA, 1987, GENE, V58, P19, DOI 10.1016/0378-1119(87)90025-4; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NISTER M, 1991, MOL BASIS HUMAN CANC, P62; Paget S., 1889, 1889 CANC METASTASIS, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; Sjolund M, 1990, GROWTH FACTORS, V3, P191, DOI 10.3109/08977199009043904; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SUGIURA K, 1955, CANCER RES, V15, P38; TARIN D, 1984, CANCER RES, V44, P3584; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; WANG JL, 1990, INT J CANCER, V46, P772, DOI 10.1002/ijc.2910460504; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	64	19	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1567	1575						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321404				2022-12-17	WOS:A1992JE81300013
J	AMLER, LC; SCHWAB, M				AMLER, LC; SCHWAB, M			MULTIPLE AMPLICONS OF DISCRETE SIZES ENCOMPASSING N-MYC IN NEUROBLASTOMA-CELLS EVOLVE THROUGH DIFFERENTIAL RECOMBINATION FROM A LARGE PRECURSOR DNA	ONCOGENE			English	Note							NEURO-BLASTOMA; AMPLIFICATION; GENE; ONCOGENE	Human neuroblastoma cells often carry cytogenetic abnormalities signaling amplification of the gene N-myc. In most cell lines amplified N-myc is localized in homogeneously staining regions (HSRs). Varying proportions of the amplified DNA consist of multiple tandem arrays of DNA segments encompassing N-myc. Here we report the cloning and sequencing of a DNA breakpoint which represents the joint of the tandem repeats of a 280-kb amplicon of neuroblastoma line NMB. The breakpoint is located in the first intron of the N-myc gene and leads to the deletion of the 5' region of N-myc in this 20-copy amplicon. The representation of DNA derived from the non-N-myc part of the novel joint in the different amplicons suggests that an increase in N-myc copy numbers involves a multistep process proceeding from large 'precursors' to smaller multicopy amplicons.			AMLER, LC (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,INST EXPTL PATHOL,W-6900 HEIDELBERG,GERMANY.							AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; HILLER S, 1991, ONCOGENE, V6, P969; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; Maniatis T., 1982, MOL CLONING; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160	13	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					807	809						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565478				2022-12-17	WOS:A1992HQ68200028
J	BAI, W; SINGH, B; YANG, Y; RAMAGLI, LS; NASH, M; HERZOG, NK; ARLINGHAUS, RB				BAI, W; SINGH, B; YANG, Y; RAMAGLI, LS; NASH, M; HERZOG, NK; ARLINGHAUS, RB			THE PHYSICAL INTERACTIONS BETWEEN P37ENV-MOS AND TUBULIN STRUCTURES	ONCOGENE			English	Article							PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; V-MOS; SACCHAROMYCES-CEREVISIAE; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; ONCOGENE PRODUCT; XENOPUS OOCYTES; BETA-TUBULIN; P85GAG-MOS	The c-mos protein has been reported to be complexed with tubulin and to co-localize with microtubules in unfertilized Xenopus eggs as well as in NIH3T3 cells transformed by the Xenopus c-mos gene. We performed experiments to determine whether the viral mos protein, p37v-mos, also associates with tubulin. Both mouse c-mos and v-mos proteins synthesized in vitro co-polymerized with tubulin. Upon incubation at 37-degrees-C, essentially all of the mos protein (both viral and cellular) co-polymerized with tubulin, while more than 50% of the tubulin remained in the depolymerized state. The mos-tubulin interaction was specific, as indicated by the insolubility of the v-mos protein following a second cycle of temperature-dependent depolymerization/polymerization. Beta-tubulin was shown to co-precipitate with p37v-mos and to be phosphorylated by the mos kinase in vitro. Although both v-mos and c-mos proteins co-polymerize with tubulin, p37v-mos behaved differently from p39c-mos on gel filtration columns under conditions that favor disassembly of microtubules. Like Xenopus c-mos, the bulk of the mouse c-mos protein synthesized in vitro appeared in structures that fractionate at about 500 kDa. In contrast to c-mos, the majority of the v-mos protein, either isolated from stably transformed NIH3T3 cells or synthesized in vitro, eluted in the 100 kDa fraction, cofractionating with tubulin dimers. Therefore, the v-mos protein appears to have a higher affinity for unpolymerized tubulin than c-mos, under conditions that favor disassembly of microtubules.	UNIV TEXAS, MD ANDERSON CANCER CTR,DEPT MOLEC PATHOL,BOX 89, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA45125, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAI WL, 1991, ONCOGENE, V6, P1715; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1991, MOL CELL BIOL, V11, P1713, DOI 10.1128/MCB.11.3.1713; FRIEL J, 1987, J VIROL, V61, P889, DOI 10.1128/JVI.61.3.889-897.1987; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; HERZOG NK, 1988, ONCOGENE, V3, P225; HERZOG NK, 1990, J VIROL, V64, P3093, DOI 10.1128/JVI.64.6.3093-3096.1990; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KATZ W, 1990, MOL CELL BIOL, V10, P5286, DOI 10.1128/MCB.10.10.5286; KLOETZER WS, 1983, P NATL ACAD SCI-BIOL, V80, P412, DOI 10.1073/pnas.80.2.412; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LIU JX, 1990, ONCOGENE, V5, P171; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1991, CELL GROWTH DIFFER, V2, P115; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WONG PKY, 1978, J VIROL, V25, P187, DOI 10.1128/JVI.25.1.187-192.1978; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	41	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					493	500						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1532247				2022-12-17	WOS:A1992HK00500014
J	ADACHI, M; RYO, R; YOSHIDA, A; SUGANO, W; YASUNAGA, M; SAIGO, K; YAMAGUCHI, N; SATO, T; SANO, K; KAIBUCHI, K; TAKAI, Y				ADACHI, M; RYO, R; YOSHIDA, A; SUGANO, W; YASUNAGA, M; SAIGO, K; YAMAGUCHI, N; SATO, T; SANO, K; KAIBUCHI, K; TAKAI, Y			INDUCTION OF SMG P21/RAP1A P21/KREV-1 P21 GENE-EXPRESSION DURING PHORBOL ESTER-INDUCED DIFFERENTIATION OF A HUMAN MEGAKARYOCYTIC LEUKEMIA-CELL LINE	ONCOGENE			English	Article							GTP-BINDING PROTEIN; PUTATIVE EFFECTOR DOMAIN; RAS-RELATED PROTEIN; ACTIVATING PROTEIN; BOVINE BRAIN; HUMAN-PLATELETS; KINASE-C; TYROSINE PHOSPHORYLATION; NUCLEOTIDE-SEQUENCE; MOLECULAR-WEIGHT	smg p21A and -B (smg p21s) are ras p21-like small GTP-binding proteins (G proteins) with the same putative effector domain as ras p21s. Both smg p21A mRNA and smg p21B mRNA were detected in CMK, a human megakaryocytic leukemia cell line, and their levels were markedly elevated by treatment with 12-O-tetradecanoyl-phorbol-13-acetate (TPA), which caused the differentiation of this cell line into more mature megakaryocytes. The smg p21 protein molecules also increased during the TPA-induced differentiation of CMK cells. The mRNA level of glycoprotein IIb (GPIIb), a typical marker of the megakaryocytes, was increased by this treatment, but the time course of the increase in the smg p21 mRNA levels as more rapid than that of the increase in the GPIIb mRNA level. Ha-ras p21 mRNA was undetectable, but both Ki- and N-ras p21 mRNAs were detected in CMK cells and their levels were also increased during TPA-induced differentiation of CMK cells, although to a lesser extent than those of smg p21 mRNAs. Protein kinase C inhibitors inhibited the basal and TPA-induced smg p21A mRNA level, but cyclic AMP-elevating prostaglandin E1 or Ca2+-mobilizing ionomycin did not inhibit them. Cycloheximide enhanced the basal and TPA-induced smg p21A mRNA levels. Actinomycin D blocked the TPA-induced smg p21A mRNA levels, but showed no detectable effect on the elevated smg p21A mRNA level which was induced by pretreatment with TPA. A dramatic increase in the smg p21 mRNA levels was also observed in other leukemia cell lines during TPA-induced differentiation. These results suggest that TPA stimulated expression of the smg p21A gene, presumably through the action of protein kinase C at the transcriptional level rather than at the post-transcriptional level, in hematopoietic leukemia cells.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT LAB MED,KOBE 650,JAPAN; KOBE UNIV HOSP,BLOOD TRANSFUS SERV,KOBE 650,JAPAN; CHIBA UNIV,SCH MED,DEPT PEDIAT,CHIBA 280,JAPAN; KOBE UNIV,SCH MED,DEPT PEDIAT,KOBE 650,JAPAN	Kobe University; Kobe University; Kobe University; Chiba University; Kobe University								ADACHI M, 1989, CANCER RES, V49, P3805; ADACHI M, 1988, ACTA HAEMATOL JAPON, V51, P1069; ADACHI M, 1991, IN PRESS EXP HEMATOL; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BRETONGORIUS J, 1986, SEMIN HEMATOL, V23, P43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FERRERO D, 1983, BLOOD, V61, P171; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HIROSE M, 1983, ACTA HAEMATOL JAPON, V46, P729; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KAWATA M, 1991, ONCOGENE, V6, P841; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOMATSU N, 1989, BLOOD, V74, P42; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MAZUR EM, 1987, EXP HEMATOL, V15, P348; MIZOGUCHI A, 1989, MOL BRAIN RES, V5, P31, DOI 10.1016/0169-328X(89)90015-6; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NAGASAWA K, 1981, J CELL PHYSIOL, V109, P181, DOI 10.1002/jcp.1041090120; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHMORI T, 1988, BIOCHEM BIOPH RES CO, V157, P670, DOI 10.1016/S0006-291X(88)80302-4; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; PONCZ M, 1987, J BIOL CHEM, V262, P8476; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RYO R, 1991, CANCER, V67, P960, DOI 10.1002/1097-0142(19910215)67:4<960::AID-CNCR2820670418>3.0.CO;2-V; RYO R, 1990, EXP HEMATOL, V18, P271; SACCHI N, 1984, CELL IMMUNOL, V84, P65, DOI 10.1016/0008-8749(84)90077-7; SAKAGAMI H, 1984, LEUKEMIA RES, V8, P187, DOI 10.1016/0145-2126(84)90142-5; Sambrook J., 1989, MOL CLONING LAB MANU; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TAKAI Y, 1991, IN PRESS INT REV CYT; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; YAMASHITA T, 1988, J BIOL CHEM, V263, P17181	61	19	20	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					323	329						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549353				2022-12-17	WOS:A1992HG98200018
J	BAI, WL; SINGH, B; KARSHIN, WL; SHONK, RA; ARLINGHAUS, RB				BAI, WL; SINGH, B; KARSHIN, WL; SHONK, RA; ARLINGHAUS, RB			PHOSPHORYLATION OF V-MOS SER 47 BY THE MITOTIC FORM OF P34CDC2	ONCOGENE			English	Article							PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; MATURATION-PROMOTING FACTOR; CELL-CYCLE CONTROL; ONCOGENE PRODUCT; NUCLEOTIDE-SEQUENCE; MEIOTIC MATURATION; XENOPUS HOMOLOG; GENE; OOCYTES	P85gag-mos is hyperphosphorylated during mitosis in normal rat kidney (NRK) cells transformed by Moloney murine sarcoma virus ts110. We now report that P85gag-mos is phosphorylated in vitro by the mitotic form of the cdc2 kinase (p34cdc2, known as M-phase kinase) derived from virus-transformed cells. The major site of P85gag-mos phosphorylation by the M-phase kinase in vitro lies within the amino-terminal portion of the viral mos protein sequence spanning residues 45-53, as determined by tryptic peptide mapping. A synthetic peptide corresponding to amino acids 37-55 of v-mos was specifically phosphorylated by the M-phase kinase, whereas v-mos peptides either lacking Ser 47 or substituted with Ala at residue 47 were not phosphorylated. Protein sequencing analyses established that the M-phase kinase specifically phosphorylates Ser 47. Tryptic phosphopeptide mapping of the in vivo-phosphorylated gag-mos protein from mitotic cells indicated that the 45-53 v-mos region was also phosphorylated within mitotic cells. These findings demonstrate that the M-phase kinase phosphorylates the viral mos protein at Ser 47. These results were unexpected in view of earlier reports regarding cdc2 kinase activation/stabilization by the c-mos kinase in maturing oocytes.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC PATHOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NCI NIH HHS [CA16672, CA45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAGDADI F, 1990, ONCOGENE, V5, P1251; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HARLOW E, 1988, ANTIBODIES LABORATOR; HERZOG NK, 1988, ONCOGENE, V3, P225; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIU JX, 1990, ONCOGENE, V5, P171; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PANTAZIS P, 1981, J BIOL CHEM, V256, P4669; PAULES RS, 1988, ONCOGENE, V3, P59; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WEINMASTER G, 1983, J VIROL, V46, P29, DOI 10.1128/JVI.46.1.29-41.1983; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHAO X, 1990, ONCOGENE, V5, P1727	48	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1715	1723						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1833715				2022-12-17	WOS:A1991GX11800001
J	THORN, JT; TODD, AV; WARRILOW, D; WATT, F; MOLLOY, PL; ILAND, HJ				THORN, JT; TODD, AV; WARRILOW, D; WATT, F; MOLLOY, PL; ILAND, HJ			CHARACTERIZATION OF THE HUMAN N-RAS PROMOTER REGION	ONCOGENE			English	Article							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR BINDS; DNA-BINDING; PROTO-ONCOGENE; CELL-LINE; C-FOS; PROENKEPHALIN GENE; DELETION ANALYSIS; UPSTREAM ELEMENT; GROWTH-FACTOR	Overexpression of ras proto-oncogenes has been implicated in cancer development. We therefore initiated a study of the human N-ras promoter to determine the regions that control N-ras expression and their potential for interaction with DNA-binding proteins. N-ras CAT constructs were stably integrated into K562 cells by electric field-mediated gene transfer in order to determine functional regions within the human N-ras promoter. A significant proportion of promoter activity was found to lie within a 439 bp fragment comprising an untranslated exon (exon 1) with the adjacent 5' sequence and a small CpG island. A 107 bp fragment at the 5' end of exon 1 was essential for promoter activity, while a 44 bp deletion from within this region decreased promoter activity by two-thirds. Unlike the human H-ras and mouse K-ras promoters, the N-ras promoter did not exhibit bidirectional activity. DNAase footprinting of the 439 bp fragment revealed seven protected regions, many of which contain sequences homologous to known DNA-binding protein sites (MLTF/myc, CREB/ATF, AP-1, AP-2, myb and E4TF1). In contrast, four putative Sp1 sites did not footprint. Using purified MLTF and appropriate competitors in gel shift and DNAase footprinting assays, we demonstrated binding of MLTF to the MLTF consensus sequence within exon 1.	ROYAL PRINCE ALFRED HOSP, KANEMATSU LABS, MISSENDEN RD, CAMPERDOWN, NSW 2050, AUSTRALIA; CSIRO, DIV BIOMOLEC ENGN, N RYDE, NSW 2113, AUSTRALIA	University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Molloy, Peter L/H-7931-2013	Molloy, Peter L/0000-0002-7788-3417				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; CROAKER GM, 1990, LEUKEMIA, V4, P502; DONIGER J, 1987, ONCOGENE, V1, P331; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HOFLER H, 1988, VIRCHOWS ARCH B, V55, P355; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; JORDANO J, 1988, ONCOGENE, V2, P359; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; PACIUCCI R, 1991, MOL CELL BIOL, V11, P1334, DOI 10.1128/MCB.11.3.1334; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SAWADOGO M, 1986, CANCER CELL, V4, P147; SAWODOGO M, 1985, R G CELL, V43, P165; Sharpiro DJ, 1988, DNA CELL BIOL, V7, P47; SHI XP, 1986, NUCLEIC ACIDS RES, V14, P3729, DOI 10.1093/nar/14.9.3729; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SPANDIDOS DA, 1986, FEBS LETT, V203, P169, DOI 10.1016/0014-5793(86)80736-0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUAREZ HG, 1989, CANCER RES, V49, P1223; TANAKA T, 1986, CANCER RES, V46, P1465; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0; TRIMBLE WS, 1987, FEBS LETT, V219, P70, DOI 10.1016/0014-5793(87)81192-4; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YAMAMOTO F, 1988, ONCOGENE RES, V3, P125	60	19	19	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1843	1850						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923508				2022-12-17	WOS:A1991GX11800017
J	LARCHER, JC; VAYSSIERE, JL; LOSSOUARN, L; GROS, F; CROIZAT, B				LARCHER, JC; VAYSSIERE, JL; LOSSOUARN, L; GROS, F; CROIZAT, B			REGULATION OF C-MYC AND N-MYC EXPRESSION DURING INDUCED-DIFFERENTIATION OF MURINE NEUROBLASTOMA-CELLS	ONCOGENE			English	Article							NEURO-BLASTOMA CELLS; ACID-INDUCED DIFFERENTIATION; RNA; ONCOGENES; INDUCTION; MEMBRANE; GENES; DNA	Using clones N1E-115 and N1A-103 from mouse neuroblastoma C1300, a comparative analysis of c- and N-myc gene expression was undertaken both in proliferating cells and in cultures exposed to conditions which induce differentiation. Under the latter conditions, while N1E-115 cells extend abundant neurites and express many biochemical features of mature neurons, clone N1A-103 stops dividing and expresses certain neurospecific markers but is unable to differentiate morphologically. In both clones, chemical agents, i.e. 1-methyl cyclohexane carboxylic acid (CCA) or dimethyl sulfoxide (DMSO), induce a decrease in c-myc expression. Similar results were found for N-myc gene in N1E-115 cells, but in contrast, in clone N1A-103, N-myc expression is increased with CCA and not modified with DMSO. Globally, this study favours the hypothesis that changes in c-myc expression would correspond to cell division blockade and differentiation, while modulations in N-myc are more closely related to an early phase of terminal differentiation.			LARCHER, JC (corresponding author), COLL FRANCE, BIOCHIM CELLULAIRE LAB, 11 PL MARCELIN BERTHELOT, F-75231 PARIS 05, FRANCE.							AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; AUGUSTIT.G, 1969, P NATL ACAD SCI USA, V64, P311, DOI 10.1073/pnas.64.1.311; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BAUMGOLD J, 1987, J NEUROCHEM, V48, P1264, DOI 10.1111/j.1471-4159.1987.tb05656.x; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; CROIZAT B, 1979, CR ACAD SCI D NAT, V289, P1283; CROIZAT B, 1977, EUR J BIOCHEM, V74, P405, DOI 10.1111/j.1432-1033.1977.tb11405.x; EDDE B, 1987, DEV BIOL, V123, P549, DOI 10.1016/0012-1606(87)90413-1; GRIEP AE, 1986, P NATL ACAD SCI USA, V83, P5539, DOI 10.1073/pnas.83.15.5539; HANLEY MR, 1988, NEURON, V1, P175, DOI 10.1016/0896-6273(88)90137-7; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HENRIKSSON M, 1988, ONCOGENE, V3, P587; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; JALAVA AM, 1988, EXP CELL RES, V179, P10, DOI 10.1016/0014-4827(88)90343-6; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LUCAS M, 1988, DEV NEUROSCI-BASEL, V10, P91, DOI 10.1159/000111960; Maniatis T., 1982, MOL CLONING; MAURO F, 1970, CANCER RES, V30, P1397; MCCACHREN SS, 1988, BIOCHEM BIOPH RES CO, V151, P574, DOI 10.1016/0006-291X(88)90633-X; PALFREY C, 1977, BIOCHEM BIOPH RES CO, V76, P937, DOI 10.1016/0006-291X(77)91592-3; PORTIER MM, 1982, FEBS LETT, V146, P283, DOI 10.1016/0014-5793(82)80935-6; SCHUBERT D, 1971, DEV BIOL, V25, P514, DOI 10.1016/0012-1606(71)90004-2; SEJERSEN T, 1987, EXP CELL RES, V172, P304, DOI 10.1016/0014-4827(87)90389-2; SERRANO L, 1989, EXP CELL RES, V181, P263, DOI 10.1016/0014-4827(89)90200-0; SHIMA H, 1989, P NATL ACAD SCI USA, V86, P7442, DOI 10.1073/pnas.86.19.7442; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; VAYSSIERE JL, 1987, BIOCHEM BIOPH RES CO, V145, P443, DOI 10.1016/0006-291X(87)91341-6; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; WHITE BA, 1982, J BIOL CHEM, V257, P8569; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; ZISAPEL N, 1979, EUR J BIOCHEM, V95, P51, DOI 10.1111/j.1432-1033.1979.tb12938.x	36	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					633	638						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030913				2022-12-17	WOS:A1991FR93900019
J	ZIEGLER, SF; PLEIMAN, CM; PERLMUTTER, RM				ZIEGLER, SF; PLEIMAN, CM; PERLMUTTER, RM			STRUCTURE AND EXPRESSION OF THE MURINE HCK GENE	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; COLONY-STIMULATING FACTOR; NF-KAPPA-B; TERMINAL REGION; CD4 RECEPTOR; CELL-LINE; C-SRC; ACTIVATION; SEQUENCE; IDENTIFICATION	The hck gene encodes a src-like protein-tyrosine kinase that is expressed predominantly in cells of myeloid origin. To examine the molecular basis of hck expression, we have cloned and characterized the murine hck gene and defined a set of transcriptional regulatory sequences. Transcripts from the hck gene have heterogeneous 5' ends, with one major and several minor transcriptional start sites. The promoter lacks a TATA-like sequence, but has three Sp-1 and two AP-2 binding sites. Constructs containing 2.5 Kb or 0.6 Kb of sequence 5' to the major transcription start site were capable of directing expression of a reporter gene transfected into fibroblasts. Expression of the former construct, but not the latter, was inducible with LPS. We conclude that LPS induction of hck transcripts, previously demonstrated in myeloid cells, results from the presence of an LPS-responsive element located within the hck promoter.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	ZIEGLER, SF (corresponding author), IMMUNEX CORP,DEPT MOLEC BIOL,51 UNIV ST,SEATTLE,WA 98101, USA.							ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; COOKE M P, 1989, New Biologist, V1, P66; COOPER JA, 1988, PEPTIDES PROTEIN PHO; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GRAVALLESE EM, 1989, MOL CELL BIOL, V9, P3184, DOI 10.1128/MCB.9.8.3184; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8315; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; INTRONA M, 1986, J IMMUNOL, V137, P2711; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KLEMSZ MJ, 1987, NUCLEIC ACIDS RES, V15, P9600, DOI 10.1093/nar/15.22.9600; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; METCALF D, 1985, LEUKEMIA RES, V9, P35, DOI 10.1016/0145-2126(85)90020-7; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NIGHIZAWA M, 1986, MOL CELL BIOL, V6, P511; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; PATEL M, 1990, ONCOGENE, V5, P201; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RAHMSDORF HJ, 1986, J IMMUNOL, V136, P2293; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHENONG GLC, 1987, P NATL ACAD SCI USA, V84, P199, DOI 10.1073/pnas.84.1.199; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TSUCHIYA M, 1987, EUR J BIOCHEM, V165, P7, DOI 10.1111/j.1432-1033.1987.tb11187.x; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; YI TL, 1989, ONCOGENE, V4, P1081; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	41	19	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					283	288						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1705689				2022-12-17	WOS:A1991FZ13400014
J	KHAZAIE, K; PANAYOTOU, G; AGUZZI, A; SAMARUT, J; GAZZOLO, L; JURDIC, P				KHAZAIE, K; PANAYOTOU, G; AGUZZI, A; SAMARUT, J; GAZZOLO, L; JURDIC, P			EGF PROMOTES INVIVO TUMORIGENIC GROWTH OF PRIMARY CHICKEN-EMBRYO FIBROBLASTS EXPRESSING V-MYC AND ENHANCES INVITRO TRANSFORMATION BY THE V-ERBA ONCOGENE	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; C-MYC; LEUKEMIA VIRUSES; HORMONE RECEPTOR; THYROID-HORMONE; CELLS; GENE; PROLIFERATION; RAS; RESPONSIVENESS	We report that the activation of the endogenous chicken EGF receptor leads to the tumorigenic growth in vivo of early passage chicken embryo fibroblasts (CEFs) that express a nonsarcomagenic oncogene, v-myc. To provide a continuous paracrine source of this growth factor in vivo, we employed irradiated Rat-1 cells which had been stably transfected with a synthetic cDNA to human EGF. Expression of another non-sarcomagenic nuclear oncogene, v-erbA, prones the CEFs to in vitro transformation by EGF, but does not cause EGF dependent tumorigenicity in vivo. The short period of incubation in the in vivo assay employed by our study (10 days), together with the genetic stability of primary chicken embryo fibroblasts, make it very likely that the reported alterations in cellular behaviour are a direct and primary effect of the expression of the relevant oncogenes and their cooperation with the EGF induced response. Dose response and ligand binding assays suggest that the EGF response is transmitted via the chicken c-erbB molecule, which by virtue of its preference for TGF-alfa is distinct from the mammalian EGF receptors studied so far. The level of expression of the endogenous chicken EGF receptor is within the same range as that reported for primary human fibroblasts (5-7 x 10(3) per cell). The cooperative effect of v-myc with chicken c-erbB probably takes place at a post receptor level, as its expression did not affect the steady state level or affinity for ligand of the chicken EGF receptor.	UNIV CLAUDE BERNARD LYON,FAC MED ALEXIS CARREL,CNRS,UMR 0005,F-69372 LYONS 8,FRANCE; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; ECOLE NORM SUPER,F-69364 LYONS 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ludwig Institute for Cancer Research; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Ecole Normale Superieure de Lyon (ENS de LYON)			Aguzzi, Adriano/A-3351-2008; Samarut, Jacques/AAD-2587-2019	Aguzzi, Adriano/0000-0002-0344-6708				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P290; BISHOP JM, 1982, MOL BIOL TUMOR VIRUS, V1, P1047; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; Colburn N H, 1985, Carcinog Compr Surv, V10, P235; COMPERE SJ, 1989, P NATL ACAD SCI USA, V86, P2224, DOI 10.1073/pnas.86.7.2224; CROOK T, 1989, P NATL ACAD SCI USA, V86, P5713, DOI 10.1073/pnas.86.15.5713; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; ENGELBRETH-HOLM J., 1935, Acta Pathologica et Microbiologica Scandinavica, V12, P352; ENGSTROM W, 1986, J CELL SCI, V86, P47; FRYKBERG L, 1987, ONCOGENE, V1, P415; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FULTON R, 1987, NATURE, V326, P190, DOI 10.1038/326190a0; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GHYSDAEL J, 1981, VIROLOGY, V111, P386, DOI 10.1016/0042-6822(81)90342-1; GRAF T, 1977, CANCER RES, V37, P59; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1982, BIOCHIM BIOPHYS ACTA, V651, P245, DOI 10.1016/0304-419X(82)90014-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; HAMBURGER V, 1960, MANUAL EXPT EMBRYOLO, P160; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; JANSSON M, 1987, ONCOGENE, V1, P167; KHAN P, 1986, ONCOGENES GROWTH CON; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; MELLON P, 1978, P NATL ACAD SCI USA, V75, P5874, DOI 10.1073/pnas.75.12.5874; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MOSCOVICI C, 1978, NEW MICROBIOL, V1, P1; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; ROYERPOKORA B, 1977, CELL, V13, P751; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1987, ONCOGENE, V1, P271; VENNSTROM B, 1980, J VIROL, V36, P575; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; VOGT P, 1965, FUNDAMENTAL TECHNIQU, P198; VONWEIZSACKER F, 1986, EMBO J, V5, P1521, DOI 10.1002/j.1460-2075.1986.tb04392.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; ZELLER NK, 1980, VIROLOGY, V104, P239, DOI 10.1016/0042-6822(80)90383-9; ZERLIN M, 1987, ONCOGENE, V1, P19	55	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					21	28						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1671532				2022-12-17	WOS:A1991EY03900003
J	FRY, DG; MILAM, LD; DILLBERGER, JE; MAHER, VM; MCCORMICK, JJ				FRY, DG; MILAM, LD; DILLBERGER, JE; MAHER, VM; MCCORMICK, JJ			MALIGNANT TRANSFORMATION OF AN INFINITE LIFE-SPAN HUMAN FIBROBLAST CELL STRAIN BY TRANSFECTION WITH V-KI-RAS	ONCOGENE			English	Note									MICHIGAN STATE UNIV,DEPT MICROBIOL,CARCINOGENESIS LAB,FEE HALL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University; Michigan State University					NATIONAL CANCER INSTITUTE [R01CA021289] Funding Source: NIH RePORTER; NCI NIH HHS [CA21289] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Battey, 1986, BASIC METHODS MOL BI; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CARLONI G, 1988, FEBS LETT, V229, P333, DOI 10.1016/0014-5793(88)81151-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; HURLIN PJ, 1987, CANCER RES, V47, P5237; NAMBA M, 1988, MUTAT RES, V199, P415, DOI 10.1016/0027-5107(88)90218-7; NAMBA M, 1986, INT J CANCER, V37, P419, DOI 10.1002/ijc.2910370314; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; TSUCHIDA N, 1981, J VIROL, V38, P720, DOI 10.1128/JVI.38.2.720-727.1981; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; WILSON DM, 1990, IN PRESS CANCER RES	13	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1415	1418						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216465				2022-12-17	WOS:A1990EC24100022
J	MILLER, M; KENNEWELL, A; TAKAYAMA, Y; BRUSKIN, A; BISHOP, JM; JOHNSON, G; SYMONDS, G				MILLER, M; KENNEWELL, A; TAKAYAMA, Y; BRUSKIN, A; BISHOP, JM; JOHNSON, G; SYMONDS, G			TRANSFORMATION OF EARLY ERYTHROID PRECURSOR CELLS (BFU-E) BY A RECOMBINANT MURINE RETROVIRUS CONTAINING V-ERB-B	ONCOGENE			English	Article									CHILDRENS MED RES FDN,POB 61,CAMPERDOWN,NSW 2050,AUSTRALIA; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143	Children's Medical Research Institute - Australia; University of California System; University of California San Francisco; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA025972, R35CA044338] Funding Source: NIH RePORTER; NCI NIH HHS [CA44338, CA25972] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; Beug H., 1982, CANCER SURV, V1, P205; BISHOP JM, 1985, MOL BIOL TUMOR VIR S, P766; BROWN AMC, 1987, DNA CLONING, V3, P189; BRUSKIN A, 1990, ONCOGENE, V5, P15; CHUNG SW, 1988, BLOOD, V71, P973; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COPELAND NG, 1980, J VIROL, V33, P1199, DOI 10.1128/JVI.33.3.1199-1202.1980; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GAZIT A, 1986, J VIROL, V60, P19, DOI 10.1128/JVI.60.1.19-28.1986; GAZZOLO L, 1980, CELL, V22, P683, DOI 10.1016/0092-8674(80)90544-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HANKINS DW, 1982, MOL CELL BIOL, V2, P138; HANKINS WD, 1980, CELL, V22, P693; HANKINS WD, 1978, NATURE, V276, P506, DOI 10.1038/276506a0; HANKINS WD, 1981, CELL, V26, P91, DOI 10.1016/0092-8674(81)90036-2; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1986, TRENDS GENET, V2, P260, DOI 10.1016/0168-9525(86)90259-3; JOHNSON GR, 1977, P NATL ACAD SCI USA, V74, P3879, DOI 10.1073/pnas.74.9.3879; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1989, J VIROL, V63, P1489, DOI 10.1128/JVI.63.3.1489-1492.1989; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MOSCOVICI C, 1985, RETROVIRUSES HUMAN P, P177; PIERCE JH, 1986, CURR TOP MICROBIOL, V132, P55; PRIVALSKY ML, 1983, CELL, V32, P1257, DOI 10.1016/0092-8674(83)90307-0; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SEALY L, 1983, VIROLOGY, V130, P179, DOI 10.1016/0042-6822(83)90126-5; SYMONDS G, 1989, ONCOGENE, V4, P285; SYMONDS G, 1984, MOL CELL BIOL, V4, P1627, DOI 10.1128/MCB.4.8.1627; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VENNSTROM B, 1980, J VIROL, V36, P575; WANECK GL, 1981, CELL, V26, P79, DOI 10.1016/0092-8674(81)90035-0; WANECK GL, 1986, CELL, V44, P337, DOI 10.1016/0092-8674(86)90768-3; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8	43	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1125	1131						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2168027				2022-12-17	WOS:A1990DX36100003
J	ADAMKIEWICZ, J; BRULLER, HJ; GAUSEPOHL, H; FRANK, R; MULLER, R				ADAMKIEWICZ, J; BRULLER, HJ; GAUSEPOHL, H; FRANK, R; MULLER, R			MAPPING OF FUNCTIONAL DOMAINS IN FOS AND JUN PROTEINS USING EPITOPE-SPECIFIC ANTIBODIES	ONCOGENE			English	Article									EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	ADAMKIEWICZ, J (corresponding author), UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADAMSON ED, 1985, EMBO J, V4, P941, DOI 10.1002/j.1460-2075.1985.tb03722.x; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CASTRO B, 1977, J CHEM RES, V182, P2118; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FRANK R, 1988, MODERN METHODS PROTE, V3, P42; FRANZA BR, 1987, ONCOGENE, V1, P213; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MULLER R, 1987, ONCOGENE RES, V2, P19; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RISSE G, 1989, IN PRESS EMBO J; RIVIER J, 1984, J CHROMATOGR, V288, P303, DOI 10.1016/S0021-9673(01)93709-4; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; Stewart JM, 1984, SOLID PHASE PEPTIDE; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	45	19	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					525	533						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1691478				2022-12-17	WOS:A1990DB85300011
J	ESPINO, PC; HARVEY, R; SCHWEICKHARDT, RL; WHITE, GA; SMITH, AE; CHENG, SH				ESPINO, PC; HARVEY, R; SCHWEICKHARDT, RL; WHITE, GA; SMITH, AE; CHENG, SH			THE AMINO-TERMINAL REGION OF PP60C-SRC HAS A MODULATORY ROLE AND CONTAINS MULTIPLE SITES OF TYROSINE PHOSPHORYLATION	ONCOGENE			English	Article									GENZYME CORP,CELLULAR REGULAT LAB,1 MT RD,FRAMINGHAM,MA 01701; GENZYME CORP,DNA CHEM LAB,FRAMINGHAM,MA 01701	Sanofi-Aventis; Genzyme Corporation; Sanofi-Aventis; Genzyme Corporation			Cheng, Seng H/AAC-6564-2022		NATIONAL CANCER INSTITUTE [R01CA043186] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 43186-03, N44 CP 85655] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROWN DJ, 1984, J BIOL CHEM, V259, P9580; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHAKALAPARAMPIL I, 1988, CELL, V52, P801; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1984, MOL CELL BIOL, V4, P1213, DOI 10.1128/MCB.4.7.1213; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HIROTA Y, 1988, MOL CELL BIOL, V8, P1826, DOI 10.1128/MCB.8.4.1826; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; Patchinsky T., 1986, J VIROL, V59, P73; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1986, MOL CELL BIOL, V6, P2033, DOI 10.1128/MCB.6.6.2033; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Potts W M, 1988, Oncogene Res, V3, P343; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RYDER JW, 1987, MOL CELL BIOL, V7, P1139, DOI 10.1128/MCB.7.3.1139; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SATO M, 1989, J VIROL, V63, P638; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568	56	19	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					283	293						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1690377				2022-12-17	WOS:A1990CW41500005
J	KLEMENZ, R; HOFFMANN, S; JAGGI, R; WERENSKIOLD, AK				KLEMENZ, R; HOFFMANN, S; JAGGI, R; WERENSKIOLD, AK			THE V-MOS AND C-HA-RAS ONCOPROTEINS EXERT SIMILAR EFFECTS ON THE PATTERN OF PROTEIN-SYNTHESIS	ONCOGENE			English	Article									LUDWIG INST CANC RES, CH-3010 BERN, SWITZERLAND	Ludwig Institute for Cancer Research								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; HIROMI Y, 1985, EMBO J, V4, P1681, DOI 10.1002/j.1460-2075.1985.tb03837.x; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; IVARIE RD, 1978, CELL, V13, P41, DOI 10.1016/0092-8674(78)90136-8; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KARLIK CC, 1984, CELL, V38, P711, DOI 10.1016/0092-8674(84)90266-6; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KLOETZER WS, 1983, P NATL ACAD SCI-BIOL, V80, P412, DOI 10.1073/pnas.80.2.412; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MASON PJ, 1984, MOL GEN GENET, V194, P73, DOI 10.1007/BF00383500; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OMAR RA, 1984, CANCER RES, V44, P3976; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANTAREN JF, 1986, EMBO J, V5, P877, DOI 10.1002/j.1460-2075.1986.tb04298.x; SANTAREN JF, 1987, EXP CELL RES, V168, P494, DOI 10.1016/0014-4827(87)90022-X; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SIROTKIN K, 1982, DEV BIOL, V89, P196, DOI 10.1016/0012-1606(82)90307-4; SIROTKIN K, 1982, HEAT SHOCK BACTERIA, P69; ZIMMERMAN JL, 1983, CELL, V32, P1161	36	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1989	4	6					799	803						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2525241				2022-12-17	WOS:A1989AA66000017
J	KANNER, SB; GILMER, TM; REYNOLDS, AB; PARSONS, JT				KANNER, SB; GILMER, TM; REYNOLDS, AB; PARSONS, JT			NOVEL TYROSINE PHOSPHORYLATIONS ACCOMPANY THE ACTIVATION OF PP60C-SRC DURING CHEMICAL CARCINOGENESIS	ONCOGENE			English	Article									UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,CTR CANC,CHARLOTTESVILLE,VA 22908; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	University of Virginia; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)					NATIONAL CANCER INSTITUTE [P01CA040042, R01CA029243, R37CA029243, F32CA008316] Funding Source: NIH RePORTER; NCI NIH HHS [CA29243, CA08316, CA40042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BARRETT JC, 1979, CANCER RES, V39, P1504; BARRETT JC, 1980, CANCER RES, V40, P91; BARRETT JC, 1987, MECHANISMS ENV CARCI, V2; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER JA, 1983, METHODS ENZYMOLOGY; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; EKM B, 1984, J BIOL CHEM, V259, P11145; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; GILMER TM, 1987, CANCER RES, V47, P4663; GILMER TM, 1985, MOL CELL BIOL, V5, P1707, DOI 10.1128/MCB.5.7.1707; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HESTERBERG TW, 1984, CANCER RES, V44, P2170; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1988, ONCOGENE, V2, P327; KOI M, 1986, P NATL ACAD SCI USA, V83, P5992, DOI 10.1073/pnas.83.16.5992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARTINEZ R, 1982, MOL CELL BIOL, V2, P653, DOI 10.1128/MCB.2.6.653; MCLACHLAN JA, 1982, CANCER RES, V42, P3040; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; OHTSUKA M, 1984, INT J CANCER, V34, P855, DOI 10.1002/ijc.2910340618; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; OSHIMURA M, 1986, CANCER GENET CYTOGEN, V22, P225, DOI 10.1016/0165-4608(86)90159-7; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	33	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					295	300						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2468123				2022-12-17	WOS:A1989U567600004
J	COLLART, MA; BELIN, D; BRIOTTET, C; THORENS, B; VASSALLI, JD; VASSALLI, P				COLLART, MA; BELIN, D; BRIOTTET, C; THORENS, B; VASSALLI, JD; VASSALLI, P			RECEPTOR-MEDIATED PHAGOCYTOSIS BY MACROPHAGES INDUCES A CALCIUM-DEPENDENT TRANSIENT INCREASE IN C-FOS TRANSCRIPTION	ONCOGENE			English	Article									UNIV GENEVA, SCH MED, DEPT PATHOL, 1 RUE MICHEL SERVET, CH-1211 GENEVA 4, SWITZERLAND; UNIV GENEVA, SCH MED, INST HISTOL & EMBRYOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva; University of Geneva								BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; COLLART MA, 1987, J IMMUNOL, V139, P949; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; GALLIN EK, 1986, J LEUKOCYTE BIOL, V39, P241, DOI 10.1002/jlb.39.3.241; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GORDON S, 1974, J EXP MED, V140, P995, DOI 10.1084/jem.140.4.995; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAMILTON TA, 1987, IMMUNOL TODAY, V8, P151, DOI 10.1016/0167-5699(87)90145-9; HIDAKA H, 1980, MOL PHARMACOL, V17, P66; HORWITZ SB, 1981, J CELL BIOL, V91, P798, DOI 10.1083/jcb.91.3.798; KASSIS S, 1982, J BIOL CHEM, V257, P2148; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; MCNEIL PL, 1986, J CELL BIOL, V102, P1586, DOI 10.1083/jcb.102.5.1586; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MONTESANO R, 1983, J CELL BIOL, V96, P1227, DOI 10.1083/jcb.96.5.1227; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULLER R, 1986, TRENDS BIOCHEM SCI, V11, P129, DOI 10.1016/0968-0004(86)90066-6; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PRENTKI M, 1983, J BIOL CHEM, V258, P7597; RADZIOCH D, 1987, MOL CELL BIOL, V7, P595, DOI 10.1128/MCB.7.2.595; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; RESINK TJ, 1986, EUR J BIOCHEM, V154, P451, DOI 10.1111/j.1432-1033.1986.tb09418.x; ROUSSEAU GG, 1984, BIOCHEM J, V224, P1; ROUXLOMBARD P, 1986, CELL IMMUNOL, V97, P286, DOI 10.1016/0008-8749(86)90399-0; SANO U, 1982, J BIOL CHEM, V257, P7847; SCHATZMAN RC, 1983, BIOCHIM BIOPHYS ACTA, V755, P144, DOI 10.1016/0304-4165(83)90284-2; SCHNYDER J, 1978, J EXP MED, V148, P1449, DOI 10.1084/jem.148.6.1449; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WRIGHT SD, 1983, J EXP MED, V158, P2016, DOI 10.1084/jem.158.6.2016; YAMAMOTO K, 1984, J EXP MED, V159, P405, DOI 10.1084/jem.159.2.405; YOUNG JDE, 1984, P NATL ACAD SCI-BIOL, V81, P5430, DOI 10.1073/pnas.81.17.5430	43	19	19	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1989	4	2					237	241						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2538793				2022-12-17	WOS:A1989U567500016
J	RIGHI, M; PIERANI, A; BOGLIA, A; DELIBERO, G; MORI, L; MARINI, V; RICCIARDICASTAGNOLI, P				RIGHI, M; PIERANI, A; BOGLIA, A; DELIBERO, G; MORI, L; MARINI, V; RICCIARDICASTAGNOLI, P			GENERATION OF NEW ONCOGENIC MURINE RETROVIRUSES BY COTRANSFECTION OF CLONED AKR AND MH2 PROVIRUSES	ONCOGENE			English	Article											RIGHI, M (corresponding author), UNIV MILAN, DEPT PHARMACOL, CNR, CTR CYTOPHARMACOL, I-20129 MILAN, ITALY.		Pierani, Alessandra/O-6136-2017; Righi, Marco Giovanni Enea/M-9003-2019; Righi, Marco Giovanni Enea/G-5171-2011; Righi, Marco/P-4332-2019	Pierani, Alessandra/0000-0002-4872-4791; Righi, Marco Giovanni Enea/0000-0003-1181-0327; Righi, Marco Giovanni Enea/0000-0003-1181-0327; 				ALEXANDER RW, 1979, J NATL CANCER I, V62, P359; ANDERSON RA, 1982, P NATL ACAD SCI-BIOL, V79, P2748, DOI 10.1073/pnas.79.9.2748; ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BLASI E, 1986, LEUKOCYTES HOST DEFE, P275; CARR JG, 1960, BRIT J CANCER, V14, P77, DOI 10.1038/bjc.1960.9; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DODEMONT HJ, 1982, EMBO J, V1, P167, DOI 10.1002/j.1460-2075.1982.tb01142.x; GALIBERT F, 1984, EMBO J, V3, P1333, DOI 10.1002/j.1460-2075.1984.tb01972.x; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P49; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HARTLEY JW, 1975, VIROLOGY, V65, P128, DOI 10.1016/0042-6822(75)90013-6; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; JOYNER A, 1983, NATURE, V305, P556, DOI 10.1038/305556a0; KAN NC, 1983, P NATL ACAD SCI-BIOL, V80, P6566, DOI 10.1073/pnas.80.21.6566; KAN NC, 1984, P NATL ACAD SCI USA, V81, P3004; KESKIOJA J, 1982, J CELL BIOCHEM, V20, P139, DOI 10.1002/jcb.240200206; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; KRETSCHMER PJ, 1981, NUCLEIC ACIDS RES, V9, P6199, DOI 10.1093/nar/9.22.6199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; LOWY DR, 1980, P NATL ACAD SCI-BIOL, V77, P614, DOI 10.1073/pnas.77.1.614; MORI L, 1985, EMBO J, V4, P2025, DOI 10.1002/j.1460-2075.1985.tb03887.x; PERUCHO M, 1980, CELL, V22, P309, DOI 10.1016/0092-8674(80)90178-6; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; ROSS J, 1971, NATURE-NEW BIOL, V231, P163, DOI 10.1038/newbio231163a0; SAULE S, 1984, EXP CELL RES, V155, P496, DOI 10.1016/0014-4827(84)90209-X; SHEVACH EM, 1984, FUNDAMENTAL IMMUNOLO, P61; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	45	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					223	230						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2927945				2022-12-17	WOS:A1989U567500014
J	BADING, H; BEUTLER, C; MOELLING, K				BADING, H; BEUTLER, C; MOELLING, K			MAPPING OF A SMALL PHOSPHOPEPTIDE AT THE CARBOXYTERMINUS OF THE VIRAL MYB PROTEIN BY MONOCLONAL-ANTIBODIES	ONCOGENE			English	Article											BADING, H (corresponding author), MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,D-1000 BERLIN 33,FED REP GER.							BADING H, 1987, ONCOGENE, V1, P395; BADING H, 1988, ONCOGENE, V3, P257; BADING H, 1988, NUCLEIC ACIDS RES, V16, P5241, DOI 10.1093/nar/16.12.5241; BADING H, 1987, MODERN TRENDS HUMAN, V7, P488; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DUESBERG PH, 1980, P NATL ACAD SCI-BIOL, V77, P5120, DOI 10.1073/pnas.77.9.5120; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Maniatis T., 1982, MOL CLONING LAB MANU; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587	28	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					33	38						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2464784				2022-12-17	WOS:A1989U567400005
J	EINAT, M; KIMCHI, A				EINAT, M; KIMCHI, A			TRANSFECTION OF FIBROBLASTS WITH ACTIVATED C-MYC CONFERS RESISTANCE TO ANTIGROWTH EFFECTS OF INTERFERON	ONCOGENE			English	Article									WEIZMANN INST SCI,DEPT VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Friedman-Einat, Miriam/0000-0002-9451-1025				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BALKWILL F, 1978, NATURE, V274, P798, DOI 10.1038/274798a0; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DRON D, 1986, MOL CELL BIOL, V6, P1374; EBSWORTH N, 1986, EXP CELL RES, V165, P255, DOI 10.1016/0014-4827(86)90549-5; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; GEWERT DR, 1984, EUR J BIOCHEM, V139, P619, DOI 10.1111/j.1432-1033.1984.tb08049.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAU LF, 1987, P NATL ACAD SCI US, V82, P7608; LEOF EB, 1987, MOL CELL BIOL, V7, P2649, DOI 10.1128/MCB.7.7.2649; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; MOORE G, 1984, EUR J BIOCHEM, V139, P627, DOI 10.1111/j.1432-1033.1984.tb08050.x; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SREEVALSAN T, 1980, J CELL PHYSIOL, V104, P1, DOI 10.1002/jcp.1041040102; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TAYLORPAPADIMITRIOU J, 1981, J INTERFERON RES, V1, P401, DOI 10.1089/jir.1981.1.401; YARDEN A, 1984, EMBO J, V3, P969, DOI 10.1002/j.1460-2075.1984.tb01915.x; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823; ZERLIN M, 1987, ONCOGENE, V1, P19	32	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					485	491						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2453829				2022-12-17	WOS:A1988N434800010
J	Battaglin, F; Chan, P; Pan, YZ; Soni, S; Qu, M; Spiller, ER; Castanon, S; Torres, ETR; Mumenthaler, SM; Kay, SA; Lenz, HJ				Battaglin, Francesca; Chan, Priscilla; Pan, Yuanzhong; Soni, Shivani; Qu, Meng; Spiller, Erin R.; Castanon, Sofi; Torres, Evanthia T. Roussos; Mumenthaler, Shannon M.; Kay, Steve A.; Lenz, Heinz-Josef			Clocking cancer: the circadian clock as a target in cancer therapy	ONCOGENE			English	Review								Disruption of the cellular pathway modulating endogenous 24-h rhythms, referred to as "the circadian clock", has been recently proven to be associated with cancer risk, development, and progression. This pathway operates through a complex network of transcription-translation feedback loops generated by a set of interplaying proteins. The expression of core circadian clock genes is frequently dysregulated in human tumors; however, the specific effects and underlying mechanisms seem to vary depending on the cancer types and are not fully understood. In addition, specific oncogenes may differentially induce the dysregulation of the circadian clock in tumors. Pharmacological modulation of clock components has been shown to result in specific lethality in certain types of cancer cells, and thus holds great promise as a novel anti-cancer therapeutic approach. Here we present an overview of the rationale and current evidence for targeting the clock in cancer treatment.	[Battaglin, Francesca; Soni, Shivani; Castanon, Sofi; Torres, Evanthia T. Roussos; Mumenthaler, Shannon M.; Lenz, Heinz-Josef] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Div Oncol, Los Angeles, CA 90007 USA; [Chan, Priscilla; Pan, Yuanzhong; Qu, Meng; Kay, Steve A.] Univ Southern Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90007 USA; [Spiller, Erin R.; Mumenthaler, Shannon M.] Univ Southern Calif, Lawrence J Ellison Inst Transformat Med, Los Angeles, CA 90007 USA	University of Southern California; University of Southern California; University of Southern California	Lenz, HJ (corresponding author), Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Div Oncol, Los Angeles, CA 90007 USA.	lenz@med.usc.edu	Kay, Steve A/F-6025-2011; Mumenthaler, Shannon M/AGY-8535-2022; Battaglin, Francesca/C-2746-2017; Spiller, Erin/GWZ-2718-2022; Qu, Meng/Q-9933-2017	Kay, Steve A/0000-0002-0402-2878; Battaglin, Francesca/0000-0002-9869-0163; Roussos Torres, Evanthia/0000-0002-0740-5102; Spiller, Erin/0000-0003-3958-3904; Pan, Yuanzhong/0000-0002-6642-758X; Qu, Meng/0000-0002-1361-5392; Chan, Priscilla/0000-0003-1338-363X	USC/Norris Translational Team Accelerator Project Initiative; National Cancer Institute [P30CA014089, UG1CA180830, R01CA23866201]; National Institute of Neurological Disorders and Stroke [1F31NS120654-01]; Gloria Borges WunderGlo Foundation; Gene Gregg Pancreas Research Fund; Victoria Wilson Research Fund	USC/Norris Translational Team Accelerator Project Initiative; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Gloria Borges WunderGlo Foundation; Gene Gregg Pancreas Research Fund; Victoria Wilson Research Fund	Partly supported by the USC/Norris Translational Team Accelerator Project Initiative, the National Cancer Institute (grant numbers P30CA014089, UG1CA180830, R01CA23866201), the National Institute of Neurological Disorders and Stroke (grant number 1F31NS120654-01), the Gloria Borges WunderGlo Foundation, the Gene Gregg Pancreas Research Fund, and the Victoria Wilson Research Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute of the National Institutes of Health.	Altman BJ, 2015, CELL METAB, V22, P1009, DOI 10.1016/j.cmet.2015.09.003; Amir M, 2018, CELL REP, V25, P3733, DOI 10.1016/j.celrep.2018.11.101; Ashrafizadeh M, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050110; Battaglin F, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3576; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Benna C, 2017, ONCOTARGET, V8, P23978, DOI 10.18632/oncotarget.15074; Bibian M, 2013, BIOORG MED CHEM LETT, V23, P4374, DOI 10.1016/j.bmcl.2013.05.075; Burgermeister E, 2019, EBIOMEDICINE, V45, P139, DOI 10.1016/j.ebiom.2019.07.004; Cadenas C, 2014, CELL CYCLE, V13, P3282, DOI 10.4161/15384101.2014.954454; Cao Q, 2009, CANCER RES, V69, P7619, DOI 10.1158/0008-5472.CAN-08-4199; Cao XM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021174118; Chen PW, 2020, CANCER DISCOV, V10, P371, DOI 10.1158/2159-8290.CD-19-0400; Chun SK, 2015, BIOCHEM BIOPH RES CO, V467, P441, DOI 10.1016/j.bbrc.2015.09.103; Chun SK, 2014, ACS CHEM BIOL, V9, P703, DOI 10.1021/cb400752k; De Mei C, 2015, ONCOGENE, V34, P2597, DOI 10.1038/onc.2014.203; Dierickx P, 2019, P NATL ACAD SCI USA, V116, P12147, DOI 10.1073/pnas.1904226116; Dong Z, 2019, CANCER DISCOV, V9, P1556, DOI 10.1158/2159-8290.CD-19-0215; Duda P, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051110; Duffy DJ, 2014, MOL CANCER THER, V13, P454, DOI 10.1158/1535-7163.MCT-13-0560-T; Fekry B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06648-6; Flynn-Evans EE, 2013, JNCI-J NATL CANCER I, V105, P1292, DOI 10.1093/jnci/djt169; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Gery S, 2007, ONCOGENE, V26, P7916, DOI 10.1038/sj.onc.1210585; He BK, 2016, CELL METAB, V23, P610, DOI 10.1016/j.cmet.2016.03.007; Hirota T, 2012, SCIENCE, V337, P1094, DOI 10.1126/science.1223710; Hirota T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000559; Hirota T, 2008, P NATL ACAD SCI USA, V105, P20746, DOI 10.1073/pnas.0811410106; Huber AL, 2016, MOL CELL, V64, P774, DOI 10.1016/j.molcel.2016.10.012; Hwang-Verslues WW, 2013, P NATL ACAD SCI USA, V110, P12331, DOI 10.1073/pnas.1222684110; Kettner NM, 2016, CANCER CELL, V30, P909, DOI 10.1016/j.ccell.2016.10.007; Kinouchi K, 2020, NAT REV CANCER, V20, P645, DOI 10.1038/s41568-020-0291-9; Kitabayashi T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46454-8; Kojetin D, 2011, ACS CHEM BIOL, V6, P131, DOI 10.1021/cb1002575; Kondratov RV, 2003, GENE DEV, V17, P1921, DOI 10.1101/gad.1099503; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee JW, 2019, J MED CHEM, V62, P1989, DOI 10.1021/acs.jmedchem.8b01541; Lee JW, 2015, CHEMMEDCHEM, V10, P1489, DOI 10.1002/cmdc.201500260; Lee S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010995; Li WH, 2016, BIOCHEM BIOPH RES CO, V472, P156, DOI 10.1016/j.bbrc.2016.02.087; Li Y, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101551; Lian Haiwei, 2019, Asian Pac J Cancer Prev, V20, P23; Liu N, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00159; Lo WY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070198; Luciano AK, 2018, J BIOL CHEM, V293, P9126, DOI 10.1074/jbc.RA117.000773; Mannic T, 2013, J CLIN ENDOCR METAB, V98, P4446, DOI 10.1210/jc.2013-2568; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; Miller S, 2020, CELL CHEM BIOL, V27, P1192, DOI 10.1016/j.chembiol.2020.05.008; Miller S, 2020, NAT CHEM BIOL, V16, P676, DOI 10.1038/s41589-020-0505-1; Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128; de Assis LVM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00185; Noel R, 2012, BIOORG MED CHEM LETT, V22, P3739, DOI 10.1016/j.bmcl.2012.04.023; OSHIMA T, 2019, SCI TRANSL MED, V5, DOI DOI 10.1126/sciadv.aau9060; Oshima T, 2015, ANGEW CHEM INT EDIT, V54, P7193, DOI 10.1002/anie.201502942; Ozturk N, 2009, P NATL ACAD SCI USA, V106, P2841, DOI 10.1073/pnas.0813028106; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; Papagiannakopoulos T, 2016, CELL METAB, V24, P324, DOI 10.1016/j.cmet.2016.07.001; Pariollaud M, 2020, CANCER DISCOV, V10, P1455, DOI 10.1158/2159-8290.CD-20-0413; Puram RV, 2016, CELL, V165, P303, DOI 10.1016/j.cell.2016.03.015; Qu FL, 2016, SCI REP-UK, V6, DOI 10.1038/srep22424; Qu M, 2018, P NATL ACAD SCI USA, V115, pE12305, DOI 10.1073/pnas.1816411115; Ramos CA, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100839; Roenneberg T, 2016, CURR BIOL, V26, pR432, DOI 10.1016/j.cub.2016.04.011; Rosenberg LH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac8773; Sancar A, 2021, SCIENCE, V371, P42, DOI 10.1126/science.abb0738; Sato F, 2016, J CANCER, V7, P153, DOI 10.7150/jca.13748; Schernhammer ES, 2006, EPIDEMIOLOGY, V17, P108, DOI 10.1097/01.ede.0000190539.03500.c1; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Sha Z, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.565225; Shafi AA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20513-5; Shen WT, 2020, THERANOSTICS, V10, P4466, DOI 10.7150/thno.42478; Shostak A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11807; Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030; Solt LA, 2011, FUTURE MED CHEM, V3, P623, DOI [10.4155/FMC.11.9, 10.4155/fmc.11.9]; Straif K, 2007, LANCET ONCOL, V8, P1065, DOI 10.1016/S1470-2045(07)70373-X; Sulli G, 2019, TRENDS CANCER, V5, P475, DOI 10.1016/j.trecan.2019.07.002; Sulli G, 2018, TRENDS PHARMACOL SCI, V39, P812, DOI 10.1016/j.tips.2018.07.003; Sulli G, 2018, NATURE, V553, P351, DOI 10.1038/nature25170; Takahashi JS, 2017, NAT REV GENET, V18, P164, DOI 10.1038/nrg.2016.150; Tamaru T, 2009, NAT STRUCT MOL BIOL, V16, P446, DOI 10.1038/nsmb.1578; Taniguchi H, 2009, CANCER RES, V69, P8447, DOI 10.1158/0008-5472.CAN-09-0551; Tao LL, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0168-5; Tao NN, 2020, CANCER LETT, V481, P1, DOI 10.1016/j.canlet.2020.03.028; Tong H, 2020, ONCOTARGETS THER, V13, P3931, DOI 10.2147/OTT.S237804; Tsuchiya Y, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000305; van der Watt PJ, 2020, MOL CANCER RES, V18, P1340, DOI 10.1158/1541-7786.MCR-19-1074; Viswanathan AN, 2007, CANCER RES, V67, P10618, DOI 10.1158/0008-5472.CAN-07-2485; Walasa WM, 2018, OCCUP ENVIRON MED, V75, P344, DOI 10.1136/oemed-2017-104657; Wang YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034921; Wang YJ, 2010, ACS CHEM BIOL, V5, P1029, DOI 10.1021/cb100223d; Wegrzyn LR, 2017, AM J EPIDEMIOL, V186, P532, DOI 10.1093/aje/kwx140; Westermaier Y, 2017, J COMPUT AID MOL DES, V31, P755, DOI 10.1007/s10822-017-0040-7; Wu YC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02451; Xiong YP, 2019, ONCOTARGETS THER, V12, P993, DOI 10.2147/OTT.S193024; Yang MY, 2015, ANTICANCER RES, V35, P6615; Ye YQ, 2018, CELL SYST, V6, P314, DOI 10.1016/j.cels.2018.01.013; Yeh CM, 2014, INT J ONCOL, V45, P2101, DOI 10.3892/ijo.2014.2627; Yoshitane H, 2009, MOL CELL BIOL, V29, P3675, DOI 10.1128/MCB.01864-08; Yu H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0056514, 10.1371/journal.pone.0080815]; Yuan FF, 2020, BIOCHEM BIOPH RES CO, V523, P809, DOI 10.1016/j.bbrc.2019.12.105; Zhang SJ, 2016, ONCOTARGET, V7, P66087, DOI 10.18632/oncotarget.11807; Zhang YM, 2019, ONCOL REP, V41, P3545, DOI 10.3892/or.2019.7088; Zou K, 2017, ACTA PHARMACOL SIN, V38, P157, DOI 10.1038/aps.2016.125	102	18	20	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3187	3200		10.1038/s41388-021-01778-6	http://dx.doi.org/10.1038/s41388-021-01778-6		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846572	Green Accepted			2022-12-17	WOS:000639635100006
J	Chen, YY; Cheng, WY; Shi, HY; Huang, SS; Chen, HR; Liu, DB; Xu, WQ; Yu, J; Wang, JG				Chen, Yiyun; Cheng, Wing Yin; Shi, Hongyu; Huang, Shengshuo; Chen, Huarong; Liu, Dabin; Xu, Weiqi; Yu, Jun; Wang, Jiguang			Classifying gastric cancer using FLORA reveals clinically relevant molecular subtypes and highlights LINC01614 as a biomarker for patient prognosis	ONCOGENE			English	Article								Molecular-based classifications of gastric cancer (GC) were recently proposed, but few of them robustly predict clinical outcomes. While mutation and expression signature of protein-coding genes were used in previous molecular subtyping methods, the noncoding genome in GC remains largely unexplored. Here, we developed the fast long-noncoding RNA analysis (FLORA) method to study RNA sequencing data of GC cases, and prioritized tumor-specific long-noncoding RNAs (lncRNAs) by integrating clinical and multi-omic data. We uncovered 1235 tumor-specific lncRNAs, based on which three subtypes were identified. The lncRNA-based subtype 3 (L3) represented a subgroup of intestinal GC with worse survival, characterized by prevalent TP53 mutations, chromatin instability, hypomethylation, and over-expression of oncogenic lncRNAs. In contrast, the lncRNA-based subtype 1 (L1) has the best survival outcome, while LINC01614 expression further segregated a subgroup of L1 cases with worse survival and increased chance of developing distal metastasis. We demonstrated that LINC01614 over-expression is an independent prognostic factor in L1 and network-based functional prediction implicated its relevance to cell migration. Over-expression and CRISPR-Cas9-guided knockout experiments further validated the functions of LINC01614 in promoting GC cell growth and migration. Altogether, we proposed a lncRNA-based molecular subtype of GC that robustly predicts patient survival and validated LINC01614 as an oncogenic lncRNA that promotes GC proliferation and migration.	[Chen, Yiyun; Shi, Hongyu; Huang, Shengshuo; Wang, Jiguang] Hong Kong Univ Sci & Technol, Ctr Syst Biol & Human Hlth, Div Life Sci, Hong Kong, Peoples R China; [Chen, Yiyun; Shi, Hongyu; Huang, Shengshuo; Wang, Jiguang] Hong Kong Univ Sci & Technol, Ctr Syst Biol & Human Hlth, Dept Chem & Biol Engn, State Key Lab Mol Neurosci, Hong Kong, Peoples R China; [Cheng, Wing Yin; Chen, Huarong; Liu, Dabin; Xu, Weiqi; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China; [Cheng, Wing Yin; Chen, Huarong; Liu, Dabin; Xu, Weiqi; Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,CUHK Shenzhen Res Inst, Hong Kong, Peoples R China; [Xu, Weiqi] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Oncol,Dept Hepat Surg, Shanghai, Peoples R China; [Wang, Jiguang] Hong Kong Ctr Neurodegenerat Dis, Hong Kong Sci Pk, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Chinese University of Hong Kong; Chinese University of Hong Kong; Fudan University	Wang, JG (corresponding author), Hong Kong Univ Sci & Technol, Ctr Syst Biol & Human Hlth, Div Life Sci, Hong Kong, Peoples R China.; Wang, JG (corresponding author), Hong Kong Univ Sci & Technol, Ctr Syst Biol & Human Hlth, Dept Chem & Biol Engn, State Key Lab Mol Neurosci, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,CUHK Shenzhen Res Inst, Hong Kong, Peoples R China.; Wang, JG (corresponding author), Hong Kong Ctr Neurodegenerat Dis, Hong Kong Sci Pk, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk; jgwang@ust.hk	Chen, Huarong/ABZ-5810-2022; Liu, Dabin/GNH-2648-2022; chen, huarong/ABH-8561-2020; Jun, Yu/D-8569-2015	chen, huarong/0000-0003-2192-1864; Liu, Dabin/0000-0002-3811-8317; Chen, Yiyun/0000-0003-3886-2100; Jun, Yu/0000-0001-5008-2153	NSFC Excellent Young Scientists Fund (Hong Kong and Macau) [31922088]; HK CRF [C4039-19GF, C7065-18GF]; Hong Kong Epigenomics Project [LKCCFL18SC01-E]; HK ITC grant [ITCPD/17-9]; Department of Science and Technology of Guangdong Province [2020A0505090007]; HK RGC-CRF Fund [C6021-19EF]	NSFC Excellent Young Scientists Fund (Hong Kong and Macau); HK CRF; Hong Kong Epigenomics Project; HK ITC grant; Department of Science and Technology of Guangdong Province; HK RGC-CRF Fund	The authors were supported by NSFC Excellent Young Scientists Fund (Hong Kong and Macau) (No. 31922088), HK CRF grants (Nos. C4039-19GF and C7065-18GF), the Hong Kong Epigenomics Project (LKCCFL18SC01-E), HK ITC grant (ITCPD/17-9), and grants from the Department of Science and Technology of Guangdong Province (No. 2020A0505090007). This research made use of the computing resources of the X-GPU cluster supported by the HK RGC-CRF Fund: C6021-19EF.	Arnes L, 2019, GUT, V68, P499, DOI 10.1136/gutjnl-2017-314353; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; Gan L, 2019, INT J ONCOL, V54, P2157, DOI 10.3892/ijo.2019.4773; Hajjari M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0670-0; Hashad D, 2016, J CLIN LAB ANAL, V30, P1100, DOI 10.1002/jcla.21987; He CY, 2020, CLIN TRANSL MED, V10, P353, DOI 10.1002/ctm2.32; Hu WL, 2018, NAT CELL BIOL, V20, P492, DOI 10.1038/s41556-018-0066-7; Huang GW, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4058-6; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Khan MR, 2019, DATABASE-OXFORD, DOI 10.1093/database/bay136; Lei ZD, 2013, GASTROENTEROLOGY, V145, P554, DOI 10.1053/j.gastro.2013.05.010; Li XC, 2016, CANCER RES, V76, P1724, DOI 10.1158/0008-5472.CAN-15-2443; Liu AN, 2018, J CELL MOL MED, V22, P4034, DOI 10.1111/jcmm.13483; Liu G, 2016, ONCOL RES, V23, P99, DOI 10.3727/096504015X14496932933575; Liu Y, 2018, CANCER CELL, V33, P721, DOI 10.1016/j.ccell.2018.03.010; Ma HW, 2017, ONCOTARGET, V8, P52211, DOI 10.18632/oncotarget.11075; O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189; Oh SC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04179-8; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Pefanis E, 2014, NATURE, V514, P389, DOI 10.1038/nature13580; Petrelli F, 2017, J GASTROINTEST ONCOL, V8, P148, DOI 10.21037/jgo.2017.01.10; Qiu M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.203; Raveh E, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0458-2; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Serra O, 2019, CANCER TREAT REV, V77, P29, DOI 10.1016/j.ctrv.2019.05.005; Sohn BH, 2017, CLIN CANCER RES, V23, P4441, DOI 10.1158/1078-0432.CCR-16-2211; Sun ZF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14595-3; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Xavier-Magalhaes Ana, 2018, Oncotarget, V9, P15740, DOI 10.18632/oncotarget.24597; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Yoon SJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06814-4; Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098; Zhang EB, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1523-0; Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221; Zhou XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11516	39	18	18	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2898	2909		10.1038/s41388-021-01743-3	http://dx.doi.org/10.1038/s41388-021-01743-3		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742127	hybrid, Green Published			2022-12-17	WOS:000630675000005
J	Meng, CJ; Zhan, J; Chen, DL; Shao, GZ; Zhang, HQ; Gu, W; Luo, JY				Meng, Chunjie; Zhan, Jun; Chen, Delin; Shao, Genze; Zhang, Hongquan; Gu, Wei; Luo, Jianyuan			The deubiquitinase USP11 regulates cell proliferation and ferroptotic cell death via stabilization of NRF2 USP11 deubiquitinates and stabilizes NRF2	ONCOGENE			English	Article								The transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) plays a key role in cancer progression and is tightly regulated by the proteasome pathway. E3 ligases that mediate NRF2 ubiquitination have been widely reported, but the mechanism of NRF2 deubiquitination remains largely unclear. Here, we identified ubiquitin-specific-processing protease 11 (USP11) in NRF2 complexes and confirmed an interaction between these two proteins. We further found that USP11 deubiquitinates NRF2; this modification stabilizes NRF2. Functionally, USP11 depletion contributes to the suppression of cell proliferation and induction of ferroptotic cell death due to ROS-mediated stress, which can be largely abrogated by overexpression of NRF2. Finally, immunohistochemical staining of USP11 and NRF2 was performed using a lung tissue microarray, which revealed that USP11 is highly expressed in patients with NSCLC and positively correlated with NRF2 expression. Together, USP11 stabilizes NRF2 and is thus an important player in cell proliferation and ferroptosis.	[Meng, Chunjie; Luo, Jianyuan] Peking Univ, Beijing Key Lab Prot Posttranslat Modificat & Cel, Dept Biochem & Biophys, Dept Med Genet,Ctr Med Genet,Hlth Sci Ctr, Beijing, Peoples R China; [Zhan, Jun; Zhang, Hongquan] Peking Univ, Dept Human Anat Histol & Embryol, Key Lab Carcinogenesis & Translat Res, Minist Educ,Hlth Sci Ctr, Beijing, Peoples R China; [Zhan, Jun; Zhang, Hongquan] Peking Univ, State Key Lab Nat & Biomimet Drugs, Hlth Sci Ctr, Beijing, Peoples R China; [Chen, Delin; Gu, Wei] Columbia Univ, Dept Pathol & Cell Biol, Inst Canc Genet, New York, NY USA; [Shao, Genze] Peking Univ, Sch Basic Med Sci, Dept Cell Biol, Hlth Sci Ctr, Beijing, Peoples R China	Peking University; Peking University; Peking University; Columbia University; Peking University	Luo, JY (corresponding author), Peking Univ, Beijing Key Lab Prot Posttranslat Modificat & Cel, Dept Biochem & Biophys, Dept Med Genet,Ctr Med Genet,Hlth Sci Ctr, Beijing, Peoples R China.	luojianyuan@bjmu.edu.cn		Shao, Genze/0000-0002-4374-3969; Gu, Wei/0000-0002-1480-2368	National Natural Science Foundation of China [81874147, 81671389, 81621063, 81773199]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from National Natural Science Foundation of China (81874147, 81671389, 81621063, 81773199). We thank core facility at Peking University Health Science Center for experiment help. We thank members in Wei Gu's Lab (Columbia University Medical school) for helps to finish the project.	Bai XP, 2016, DRUG METAB REV, V48, P541, DOI 10.1080/03602532.2016.1197239; Chen DL, 2017, MOL CELL, V68, P224, DOI 10.1016/j.molcel.2017.09.009; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dodson M, 2019, REDOX BIOL, V23, DOI 10.1016/j.redox.2019.101107; Fan Z, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.65; Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337; Hammad A, 2019, CANCER LETT, V467, P40, DOI 10.1016/j.canlet.2019.09.016; Hanpude P, 2015, IUBMB LIFE, V67, P544, DOI 10.1002/iub.1402; Harris IS, 2019, CELL METAB, V29, P1166, DOI 10.1016/j.cmet.2019.01.020; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Hussain S, 2009, CELL CYCLE, V8, P1688, DOI 10.4161/cc.8.11.8739; Jayakumar S, 2015, MUTAT RES-FUND MOL M, V779, P33, DOI 10.1016/j.mrfmmm.2015.06.007; Jeong Y, 2017, CANCER DISCOV, V7, P86, DOI 10.1158/2159-8290.CD-16-0127; Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014; Kapadia B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03028-y; Kobayashi EH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11624; Lee EW, 2015, CELL DEATH DIFFER, V22, P1463, DOI 10.1038/cdd.2014.234; Lewerenz J, 2013, ANTIOXID REDOX SIGN, V18, P522, DOI 10.1089/ars.2011.4391; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lignitto L, 2019, CELL, V178, P316, DOI 10.1016/j.cell.2019.06.003; Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37; Liu BY, 2019, ONCOGENE, V38, P2501, DOI 10.1038/s41388-018-0605-5; Liu PF, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101702; Liu T, 2019, CANCER RES, V79, P1913, DOI 10.1158/0008-5472.CAN-18-3037; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Niture SK, 2012, J BIOL CHEM, V287, P9873, DOI 10.1074/jbc.M111.312694; Orthwein A, 2015, NATURE, V528, P422, DOI 10.1038/nature16142; Ou Y, 2016, P NATL ACAD SCI USA, V113, pE6806, DOI 10.1073/pnas.1607152113; Park MK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08481-x; Roh JL, 2017, REDOX BIOL, V11, P254, DOI 10.1016/j.redox.2016.12.010; Schoenfeld AR, 2004, MOL CELL BIOL, V24, P7444, DOI 10.1128/MCB.24.17.7444-7455.2004; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; Tao S, 2014, CANCER RES, V74, P7430, DOI 10.1158/0008-5472.CAN-14-1439; Ting X, 2019, NUCLEIC ACIDS RES, V47, P9721, DOI 10.1093/nar/gkz726; Villeneuve NF, 2013, MOL CELL, V51, P68, DOI 10.1016/j.molcel.2013.04.022; Wang D, 2018, J MOL CELL BIOL, V10, P60, DOI 10.1093/jmcb/mjx034; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wiel C, 2019, CELL, V178, P330, DOI 10.1016/j.cell.2019.06.005; Wu HC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4214; Xia XJ, 2019, CURR GENE THER, V19, P117, DOI 10.2174/1566523219666190628152137; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yu M, 2016, J BIOL CHEM, V291, P959, DOI 10.1074/jbc.M114.624478; Zhan J, 2019, THERANOSTICS, V9, P2084, DOI 10.7150/thno.29463; Zhang YL, 2019, CELL CYCLE, V18, P773, DOI 10.1080/15384101.2019.1597506	52	18	18	1	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1706	1720		10.1038/s41388-021-01660-5	http://dx.doi.org/10.1038/s41388-021-01660-5		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33531626				2022-12-17	WOS:000613991700002
J	Wang, ZL; Shi, YP; Ying, CT; Jiang, Y; Hu, JF				Wang, Zhenlin; Shi, Yuping; Ying, Chenting; Jiang, Yang; Hu, Jiangfeng			Hypoxia-induced PLOD1 overexpression contributes to the malignant phenotype of glioblastoma via NF-kappa B signaling	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; CELL; EXPRESSION; PROGRESSION; LANDSCAPE; DIFFERENTIATION; ANGIOGENESIS; METASTASIS; PROGNOSIS; SUBTYPES	Procollagen lysyl hydroxylase 1 (PLOD1) is highly expressed in malignant tumors such as esophageal squamous cell carcinoma, gastric cancer, and colorectal cancer. Bioinformatics analysis revealed that PLOD1 is associated with the progression of GBM, particularly the most malignant mesenchymal subtype (MES). Moreover, in the TCGA and CGGA datasets, the mean survival time of patients with high PLOD1 expression was significantly shorter than that of patients with low expression. The clinical samples confirmed this result. Therefore, we aimed to investigate the effect of PLOD1 on the development of mesenchymal GBM in vitro and in vivo and its possible mechanisms. Molecular experiments were conducted on the patient-derived glioma stem cells and found that PLOD1 expressed higher in tumor tissues and cancer cell lines of patients with GBM, especially in the MES. PLOD1 also enhanced tumor viability, proliferation, migration, and promoted MES transition while inhibited apoptosis. Tumor xenograft results also indicated that PLOD1 overexpression significantly promotes malignant behavior of tumors. Mechanistically, bioinformatics analysis further revealed that PLOD1 expression was closely associated with the NF-kappa B signaling pathway. Besides, we also found that hypoxic environments also enhanced the tumor-promoting effects of PLOD1. In conclusion, overexpression of PLOD1 may be an important factor in the enhanced invasiveness and MES transition of GBM. Thus, PLOD1 is a potential treatment target for mesenchymal GBM or even all GBM.	[Wang, Zhenlin] Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Shanghai Gen Hosp, 100 Haining Rd, Shanghai, Peoples R China; [Shi, Yuping] Shanghai Jiao Tong Univ, Shanghai TongRen Hosp, Dept Nephrol, Sch Med, 1111 Xianxia Rd, Shanghai, Peoples R China; [Ying, Chenting] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, 100 Haining Rd, Shanghai, Peoples R China; [Jiang, Yang] Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, Sch Med, Shanghai 200072, Peoples R China; [Hu, Jiangfeng] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gastroenterol, Sch Med, 100 Haining Rd, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University; Shanghai Jiao Tong University	Jiang, Y (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, Sch Med, Shanghai 200072, Peoples R China.; Hu, JF (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gastroenterol, Sch Med, 100 Haining Rd, Shanghai, Peoples R China.	windjy0523@qq.com; doctorhjf@foxmail.com			National Natural Science Foundation of China [81900544]; Shanghai Sailing Program [19YF1439000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program	We thank Zhitao Jing at the Department of Neurosurgery, The First Affiliated Hospital of China Medical University for molecular experimental technical support. This work was sponsored by grants from the National Natural Science Foundation of China (Grant 81900544) and Shanghai Sailing Program (Grant 19YF1439000).	Auffinger Brenda, 2012, F1000 Med Rep, V4, P18; Behnan J, 2019, BRAIN, V142, P847, DOI 10.1093/brain/awz044; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bush NAO, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0585-6; Cai X., 2018, ONCOTARGET, V9, P9540, DOI [10.18632/oncotarget.23476, DOI 10.18632/ONCOTARGET.23476]; Cheng P, 2016, CANCER RES, V76, P7219, DOI 10.1158/0008-5472.CAN-15-2860; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Du HZ, 2017, BIOMED PHARMACOTHER, V90, P670, DOI 10.1016/j.biopha.2017.04.023; Engler JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043339; Friedmann-Morvinski D, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501292; Gilkes DM, 2013, MOL CANCER RES, V11, P456, DOI 10.1158/1541-7786.MCR-12-0629; Giunta C, 2005, MOL GENET METAB, V86, P269, DOI 10.1016/j.ymgme.2005.04.014; Han S, 2014, BRIT J CANCER, V110, P2560, DOI 10.1038/bjc.2014.162; Hofbauer KH, 2003, EUR J BIOCHEM, V270, P4515, DOI 10.1046/j.1432-1033.2003.03846.x; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huse JT, 2011, GLIA, V59, P1190, DOI 10.1002/glia.21165; Ji XJ, 2014, INT J CANCER, V135, P574, DOI 10.1002/ijc.28699; Jiang Y, 2019, J PATHOL, V249, P26, DOI 10.1002/path.5278; Jiang Y, 2019, CANCER RES, V79, P2593, DOI 10.1158/0008-5472.CAN-18-3297; Jiang Y, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0210-1; Kundu S, 2016, MOL CANCER RES, V14, P1243, DOI 10.1158/1541-7786.MCR-16-0223; Li B, 2012, CLIN CANCER RES, V18, P5595, DOI 10.1158/1078-0432.CCR-12-1427; Li LW, 2017, AM J TRANSL RES, V9, P3741; Li W, 2012, NEURO-ONCOLOGY, V14, P958, DOI 10.1093/neuonc/nos116; Liu P, 2018, MED SCI MONITOR, V24, P2098, DOI 10.12659/MSM.906945; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110; Moreno M, 2017, CELL REP, V21, P2183, DOI 10.1016/j.celrep.2017.10.083; Moresco EMY, 2011, CURR BIOL, V21, pR488, DOI 10.1016/j.cub.2011.05.039; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Oudin MJ, 2016, CANCER DISCOV, V6, P516, DOI 10.1158/2159-8290.CD-15-1183; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Qi YF, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00066; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198-009-1066-z; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Song YF, 2020, NEURO-ONCOLOGY, V22, P46, DOI 10.1093/neuonc/noz136; Srivastava C, 2018, INT J CANCER, V142, P805, DOI 10.1002/ijc.31092; Sun L, 2016, BIOMED PHARMACOTHER, V81, P145, DOI 10.1016/j.biopha.2016.03.053; Trong PD, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102903; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Venteicher AS, 2017, SCIENCE, V355, DOI 10.1126/science.aai8478; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wade A, 2013, FEBS J, V280, P2399, DOI 10.1111/febs.12109; Waghmare I, 2014, STEM CELL TRANSL MED, V3, P1262, DOI 10.5966/sctm.2014-0086; Wang DZ, 2018, GENET TEST MOL BIOMA, V22, P366, DOI 10.1089/gtmb.2018.0009; Wang HX, 2015, NEOPLASIA, V17, P239, DOI 10.1016/j.neo.2015.02.002; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xue H, 2016, AUTOPHAGY, V12, P1129, DOI 10.1080/15548627.2016.1178446; Yamada Y, 2019, MOL ONCOL, V13, P1898, DOI 10.1002/1878-0261.12532; Yamini B, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7090125; Zhang YS, 2018, BIOMED PHARMACOTHER, V104, P566, DOI 10.1016/j.biopha.2018.05.079; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	58	18	18	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1458	1475		10.1038/s41388-020-01635-y	http://dx.doi.org/10.1038/s41388-020-01635-y		JAN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33420370	Green Published, hybrid			2022-12-17	WOS:000607346000006
J	Chen, Y; Xu, L; Lin, RYT; Muschen, M; Koeffler, HP				Chen, Ye; Xu, Liang; Lin, Ruby Yu-Tong; Muschen, Markus; Koeffler, H. Phillip			Core transcriptional regulatory circuitries in cancer	ONCOGENE			English	Review							SUPER-ENHANCERS; TAL1 COMPLEX; NETWORK; IDENTITY; ELEMENTS; AMPLIFICATION; PLURIPOTENCY; ACETYLATION; LANDSCAPE; PROGRAM	Transcription factors (TFs) coordinate the on-and-off states of gene expression typically in a combinatorial fashion. Studies from embryonic stem cells and other cell types have revealed that a clique of self-regulated core TFs control cell identity and cell state. These core TFs form interconnected feed-forward transcriptional loops to establish and reinforce the cell-type-specific gene-expression program; the ensemble of core TFs and their regulatory loops constitutes core transcriptional regulatory circuitry (CRC). Here, we summarize recent progress in computational reconstitution and biologic exploration of CRCs across various human malignancies, and consolidate the strategy and methodology for CRC discovery. We also discuss the genetic basis and therapeutic vulnerability of CRC, and highlight new frontiers and future efforts for the study of CRC in cancer. Knowledge of CRC in cancer is fundamental to understanding cancer-specific transcriptional addiction, and should provide important insight to both pathobiology and therapeutics.	[Chen, Ye; Xu, Liang; Lin, Ruby Yu-Tong; Koeffler, H. Phillip] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore; [Xu, Liang; Muschen, Markus] City Hope Comprehens Canc Ctr, Dept Syst Biol, Monrovia, CA 91016 USA; [Xu, Liang] Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Peoples R China; [Koeffler, H. Phillip] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Koeffler, H. Phillip] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Singapore 119074, Singapore	National University of Singapore; Zhejiang University; Cedars Sinai Medical Center; National University of Singapore	Chen, Y; Xu, L (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore.; Xu, L (corresponding author), City Hope Comprehens Canc Ctr, Dept Syst Biol, Monrovia, CA 91016 USA.; Xu, L (corresponding author), Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Peoples R China.	csicye@nus.edu.sg; csixl@nus.edu.sg	Xu, Liang/I-9877-2014	Xu, Liang/0000-0002-2700-4840; Lin, Ruby/0000-0003-3229-4659	National Institute of Health [R01-CA200992-03, R35CA197628, R01CA137060, R01CA157644, R01CA172558, R01CA213138]; Howard Hughes Medical Institute [HHMI-55108547]; National Research Foundation Singapore under its Singapore Translational Research (STaR) Investigator Award [NMRC/STaR/0021/2014]; Singapore Ministry of Education Academic Research Fund Tier 2 [MOE2017-T2-1-033]; Singapore Ministry of Health's National Medical Research Council (NMRC) Centre Grant; National Research Foundation Singapore; Singapore Ministry of Education under its Research Centres of Excellence initiatives; NMRC Open Fund Young Individual Research Grant [MOH-OFYIRG18May-0001]; Seed Funding Program within the NCIS Centre Grant; NCIS Yong Siew Yoon Research grant; Wendy Walk Foundation; Wellcome Trust Senior Investigator Award [WT101880]; Leukemia and Lymphoma Scholar award; Norman and Sadie Lee Foundation; Falk Trust through a Falk Medical Research Trust Catalyst Award; Pediatric Cancer Research Foundation; Cancer Research Institute through a Clinic and Laboratory Integration Program grant; California Institute for Regenerative Medicine [DISC2-10061]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Research Foundation Singapore under its Singapore Translational Research (STaR) Investigator Award(National Research Foundation, Singapore); Singapore Ministry of Education Academic Research Fund Tier 2(Ministry of Education, Singapore); Singapore Ministry of Health's National Medical Research Council (NMRC) Centre Grant(Ministry of Health-SingaporeNational Medical Research Council, Singapore); National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centres of Excellence initiatives(Ministry of Education, Singapore); NMRC Open Fund Young Individual Research Grant; Seed Funding Program within the NCIS Centre Grant; NCIS Yong Siew Yoon Research grant; Wendy Walk Foundation; Wellcome Trust Senior Investigator Award(Wellcome Trust); Leukemia and Lymphoma Scholar award(Leukemia and Lymphoma Society); Norman and Sadie Lee Foundation; Falk Trust through a Falk Medical Research Trust Catalyst Award; Pediatric Cancer Research Foundation; Cancer Research Institute through a Clinic and Laboratory Integration Program grant; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine)	This work is funded by the National Institute of Health (R01-CA200992-03 to HPK; R35CA197628, R01CA137060, R01CA157644, R01CA172558, and R01CA213138 to MM), the Howard Hughes Medical Institute (HHMI-55108547 to MM), National Research Foundation Singapore under its Singapore Translational Research (STaR) Investigator Award (NMRC/STaR/0021/2014 to HPK), the Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2017-T2-1-033 to HPK), the Singapore Ministry of Health's National Medical Research Council (NMRC) Centre Grant awarded to National University Cancer Institute of Singapore (NCIS), the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiatives, and is additionally supported by NMRC Open Fund Young Individual Research Grant (MOH-OFYIRG18May-0001 to LX), a Seed Funding Program within the NCIS Centre Grant, a NCIS Yong Siew Yoon Research grant through donations from the Yong Loo Lin Trust, and the Wendy Walk Foundation. MM is also supported by a Wellcome Trust Senior Investigator Award (WT101880), a Leukemia and Lymphoma Scholar award, the Norman and Sadie Lee Foundation (for Pediatric Cancer), the Falk Trust through a Falk Medical Research Trust Catalyst Award, the Pediatric Cancer Research Foundation, the Cancer Research Institute through a Clinic and Laboratory Integration Program grant, and the California Institute for Regenerative Medicine through DISC2-10061. MM is a Howard Hughes Medical Institute (HHMI) Faculty Scholar.	Adamson DC, 2010, CANCER RES, V70, P181, DOI 10.1158/0008-5472.CAN-09-2331; Aldiri I, 2017, NEURON, V94, P550, DOI 10.1016/j.neuron.2017.04.022; Ang YS, 2011, CELL, V145, P183, DOI 10.1016/j.cell.2011.03.003; Assi SA, 2019, NAT GENET, V51, P151, DOI 10.1038/s41588-018-0270-1; Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335; Bleu M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11672-1; Boeva V, 2017, NAT GENET, V49, P1408, DOI 10.1038/ng.3921; Boon K, 2005, CANCER RES, V65, P703; Boulay G, 2017, CELL, V171, P163, DOI 10.1016/j.cell.2017.07.036; Boulay G, 2017, CANCER DISCOV, V7, P288, DOI 10.1158/2159-8290.CD-16-0844; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Chen L, 2020, GUT, V69, P630, DOI 10.1136/gutjnl-2019-318325; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Chen Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09257-z; Chia NY, 2015, GUT, V64, P707, DOI 10.1136/gutjnl-2013-306596; Cho WK, 2018, SCIENCE, V361, P412, DOI 10.1126/science.aar4199; Choi A, 2017, BLOOD, V130, P1722, DOI 10.1182/blood-2017-03-775536; Chong SS, 2018, SCIENCE, V361, DOI 10.1126/science.aar2555; Cole MF, 2008, COLD SH Q B, V73, P183, DOI 10.1101/sqb.2008.73.027; Decaesteker B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06699-9; DRIMAN D, 1994, CANCER, V73, P2231, DOI 10.1002/1097-0142(19940415)73:8<2231::AID-CNCR2820730832>3.0.CO;2-E; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Durbin AD, 2018, NAT GENET, V50, P1240, DOI 10.1038/s41588-018-0191-z; Endoh M, 2008, DEVELOPMENT, V135, P1513, DOI 10.1242/dev.014340; Fournier M, 2016, SCI REP-UK, V6, DOI 10.1038/srep34962; Garancher A, 2018, CANCER CELL, V33, P435, DOI 10.1016/j.ccell.2018.02.006; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gheorghe M, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gky1210; Girardi T, 2017, BLOOD, V129, P1113, DOI 10.1182/blood-2016-10-706465; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Gryder BE, 2019, NAT GENET, V51, P1714, DOI 10.1038/s41588-019-0534-4; Gryder BE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11046-7; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hemming ML, 2018, P NATL ACAD SCI USA, V115, pE5746, DOI 10.1073/pnas.1802079115; Huang ML, 2018, NUCLEIC ACIDS RES, V46, pD71, DOI 10.1093/nar/gkx796; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Jiang YY, 2020, GASTROENTEROLOGY, V159, P1311, DOI 10.1053/j.gastro.2020.06.050; Jiang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06081-9; Jin Y, 2018, BLOOD, V131, P2138, DOI 10.1182/blood-2017-09-808063; Joo MS, 2019, EBIOMEDICINE, V40, P488, DOI 10.1016/j.ebiom.2018.12.056; Kunarso G, 2010, NAT GENET, V42, P631, DOI 10.1038/ng.600; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; Leong WZ, 2017, GENE DEV, V31, P2343, DOI 10.1101/gad.302646.117; Li XZ, 2012, CELL STEM CELL, V11, P163, DOI 10.1016/j.stem.2012.04.023; Lim CY, 2008, CELL STEM CELL, V3, P543, DOI 10.1016/j.stem.2008.08.004; Lin CY, 2016, NATURE, V530, P57, DOI 10.1038/nature16546; Lin DC, 2018, GUT, V67, P1769, DOI 10.1136/gutjnl-2017-314607; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Mack SC, 2018, NATURE, V553, P101, DOI 10.1038/nature25169; Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Mercado N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12559-x; Neph S, 2012, CELL, V150, P1274, DOI 10.1016/j.cell.2012.04.040; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Odom Duncan T, 2006, Mol Syst Biol, V2; Oldridge DA, 2015, NATURE, V528, P418, DOI 10.1038/nature15540; Olson CM, 2018, NAT CHEM BIOL, V14, P163, DOI [10.1038/NCHEMBIO.2538, 10.1038/nchembio.2538]; Ott CJ, 2018, CANCER CELL, V34, P982, DOI 10.1016/j.ccell.2018.11.001; Pan J, 2020, CANCER RES, V80, P2722, DOI 10.1158/0008-5472.CAN-20-0390; Ngoc PCT, 2018, LEUKEMIA, V32, P2138, DOI 10.1038/s41375-018-0110-4; Pijnappel WWMP, 2013, NATURE, V495, P516, DOI 10.1038/nature11970; Pott S, 2015, NAT GENET, V47, P8, DOI 10.1038/ng.3167; Ramsey SA, 2010, BIOINFORMATICS, V26, P2071, DOI 10.1093/bioinformatics/btq405; Ran LL, 2018, CANCER DISCOV, V8, P234, DOI 10.1158/2159-8290.CD-17-0468; Riddick G, 2017, SCI REP-UK, V7, DOI 10.1038/srep43605; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; Saint-Andre V, 2016, GENOME RES, V26, P385, DOI 10.1101/gr.197590.115; Sanda T, 2017, EXP HEMATOL, V53, P7, DOI 10.1016/j.exphem.2017.06.001; Sanda T, 2012, CANCER CELL, V22, P209, DOI 10.1016/j.ccr.2012.06.007; Skapek SX, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-018-0051-2; Tan SH, 2016, LEUKEMIA, V30, P959, DOI 10.1038/leu.2015.195; Tsuzuki S, 2020, BLOOD CANCER DISCOV, V1, P82, DOI 10.1158/2643-3249.BCD-19-0080; van Groningen T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09470-w; Wang L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13515-5; Wang L, 2018, CELL REP, V22, P2601, DOI 10.1016/j.celrep.2018.01.075; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004; Wontakal SN, 2012, P NATL ACAD SCI USA, V109, P3832, DOI 10.1073/pnas.1121019109; Xie W, 2009, MOL CELL, V33, P417, DOI 10.1016/j.molcel.2009.02.004; Yohe ME, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan4470; Zhang SH, 2014, NUCLEIC ACIDS RES, V42, P12380, DOI 10.1093/nar/gku923; Zhang XY, 2018, CANCER DISCOV, V8, P108, DOI 10.1158/2159-8290.CD-17-0532; Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470	87	18	18	5	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6633	6646		10.1038/s41388-020-01459-w	http://dx.doi.org/10.1038/s41388-020-01459-w		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32943730	hybrid, Green Published			2022-12-17	WOS:000571161500001
J	Qi, YJ; Ma, YZ; Peng, ZQ; Wang, L; Li, LX; Tang, YL; He, JQ; Zheng, JF				Qi, Yijun; Ma, Yuanzhen; Peng, Zhiqiang; Wang, Lei; Li, Lanxin; Tang, Yilan; He, Junqi; Zheng, Junfang			Long noncoding RNA PENG upregulates PDZK1 expression by sponging miR-15b to suppress clear cell renal cell carcinoma cell proliferation	ONCOGENE			English	Article							COMPETING ENDOGENOUS RNA; ESTROGEN; CANCER; NEPHRECTOMY; HYPOTHESIS; BIOMARKERS; PREDICTS; SURVIVAL; GENE	PDZK1 downregulation was reported to independently predict poor prognosis of clear cell renal cell carcinoma (ccRCC) patients and induce ccRCC development and progression. However, the underlying mechanism of PDZK1 downregulation remains unknown. Competing endogenous RNA (ceRNA) networks are emerging as new players in gene regulation and are associated with cancer development. ceRNAs regulate other RNA transcripts by competing for shared miRNAs. To investigate the role and mechanism of ceRNAs in PDZK1 downregulation and the development of ccRCC, we searched databases for miRNAs and lncRNAs that regulate PDZK1 expression in ccRCC tissues and assessed their effects in ccRCC. We found that miR-15b was expressed at higher levels in ccRCC tissues, and its upregulation was clinically associated with lower PDZK1 level, larger tumor size and shorter survival time of ccRCC patients. Conversely, a novel lncRNA (lncPENG) was expressed at a lower level in ccRCC tissues, and its downregulation was associated with the same effects as upregulation of miR-15b. Downregulation of miR-15b and upregulation of lncPENG resulted in a significant increase in PDZK1 level and inhibition of proliferation in vitro and in vivo. Mechanistically, lncPENG directly bound to miR-15b and effectively functioned as a sponge for miR-15b to modulate the expression of PDZK1. Thus, lncPENG may function as a ceRNA to attenuate miR-15b-dependent PDZK1 downregulation and inhibit cell proliferation, suggesting that it may be clinically valuable as a therapeutic target and a prognostic biomarker of ccRCC.	[Qi, Yijun; Ma, Yuanzhen; Peng, Zhiqiang; Li, Lanxin; Tang, Yilan; He, Junqi; Zheng, Junfang] Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing Key Lab Canc Invas & Metastasis Res, Beijing 100069, Peoples R China; [Wang, Lei] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing 100050, Peoples R China	Capital Medical University; Capital Medical University	Zheng, JF (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing Key Lab Canc Invas & Metastasis Res, Beijing 100069, Peoples R China.	zhengjf@ccmu.edu.cn		Zheng, Junfang/0000-0003-4071-4764; He, jq/0000-0002-5921-1297	National Natural Science Foundation of the People's Republic of China [81672521, 81974415, 81372739]; Natural Science Foundation of Beijing [7192021]	National Natural Science Foundation of the People's Republic of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Beijing(Beijing Natural Science Foundation)	This work was supported by grants from the National Natural Science Foundation of the People's Republic of China (Nos. 81672521, 81974415, 81372739) and the Natural Science Foundation of Beijing (No. 7192021).	Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chen Y, 2015, MED SCI MONITOR, V21, P1864, DOI 10.12659/MSM.893082; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Eggener SE, 2006, J CLIN ONCOL, V24, P3101, DOI 10.1200/JCO.2005.04.8280; Ellinger J, 2015, EXPERT REV MOL DIAGN, V15, P505, DOI 10.1586/14737159.2015.1019477; Flanigan RC, 2004, CLIN CANCER RES, V10, p6335S, DOI 10.1158/1078-0432.CCR-sup-040026; Ghosh MG, 2000, CANCER RES, V60, P6367; Hadoux J, 2010, CLIN MED INSIGHTS-ON, V4, P143, DOI 10.4137/CMO.S4482; Hirata H, 2015, CANCER RES, V75, P1322, DOI 10.1158/0008-5472.CAN-14-2931; Inoue J, 2004, AM J PATHOL, V165, P71, DOI 10.1016/S0002-9440(10)63276-2; Karreth FA, 2015, CELL, V161, P319, DOI 10.1016/j.cell.2015.02.043; Kim H, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0589-7; Kim HY, 2013, MOL MED, V19, P253, DOI 10.2119/molmed.2011.00001; Kocher O, 1998, LAB INVEST, V78, P117; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu CY, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.114; Ma YZ, 2019, FREE RADICAL BIO MED, V134, P468, DOI 10.1016/j.freeradbiomed.2019.01.030; Miah S, 2012, BRIT J CANCER, V107, P123, DOI 10.1038/bjc.2012.221; MINASIAN LM, 1993, J CLIN ONCOL, V11, P1368, DOI 10.1200/JCO.1993.11.7.1368; Olejniczak M, 2018, CELL MOL LIFE SCI, V75, P177, DOI 10.1007/s00018-017-2591-0; Pantuck AJ, 2001, J UROLOGY, V166, P1611, DOI 10.1016/S0022-5347(05)65640-6; Pennisi E, 2012, SCIENCE, V337, P1159, DOI 10.1126/science.337.6099.1159; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Prestin K, 2017, AM J PHYSIOL-RENAL, V313, pF973, DOI 10.1152/ajprenal.00650.2016; Rashid F, 2016, GENOM PROTEOM BIOINF, V14, P73, DOI 10.1016/j.gpb.2016.03.005; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Satzger I, 2010, INT J CANCER, V126, P2553, DOI 10.1002/ijc.24960; Schmitz U, 2016, BRIEF BIOINFORM, V17, P380, DOI 10.1093/bib/bbv061; Tachibana K, 2008, FEBS LETT, V582, P3884, DOI 10.1016/j.febslet.2008.10.027; Tao T, 2017, ONCOGENE, V36, P6119, DOI 10.1038/onc.2017.199; Walker G, 2007, GYNECOL ONCOL, V106, P461, DOI 10.1016/j.ygyno.2007.05.009; Weirauch U, 2013, NEOPLASIA, V15, P783, DOI 10.1593/neo.13172; Wen LZ, 2018, CANCER RES, V78, P4680, DOI 10.1158/0008-5472.CAN-17-3896; Xia T, 2015, SCI REP-UK, V5, DOI 10.1038/srep13445; Xiao HB, 2015, ONCOTARGET, V6, P38005, DOI 10.18632/oncotarget.5357; Yang C, 2016, ONCOTARGET, V7, P13479, DOI 10.18632/oncotarget.7266; Yu G, 2014, MOL CANCER THER, V13, P3086, DOI 10.1158/1535-7163.MCT-14-0245; Zhao C, 2016, TUMOR BIOL, V37, P177, DOI 10.1007/s13277-015-4269-2; Zheng JF, 2017, EBIOMEDICINE, V15, P62, DOI 10.1016/j.ebiom.2016.12.003; Zhu HX, 2012, CANCER BIOL THER, V13, P401, DOI 10.4161/cbt.19291	40	18	18	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4404	4420		10.1038/s41388-020-1297-1	http://dx.doi.org/10.1038/s41388-020-1297-1		APR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32341409				2022-12-17	WOS:000528992700001
J	Zhao, CG; Yang, LH; Zhou, F; Yu, Y; Du, XJ; Xiang, YQ; Li, CL; Huang, XY; Xie, CY; Liu, ZG; Lin, JY; Wang, LX; Liang, G; Cui, R				Zhao, Chengguang; Yang, Lehe; Zhou, Feng; Yu, Yun; Du, Xiaojing; Xiang, Youqun; Li, Chenglong; Huang, Xiaoying; Xie, Congying; Liu, Zhiguo; Lin, Jiayuh; Wang, Liangxing; Liang, Guang; Cui, Ri			Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells	ONCOGENE			English	Article							DRUG-RESISTANCE; TUMOR-GROWTH; PROMOTES; THERAPY; MEK; NAPABUCASIN; LIGANDS; PATHWAY	Pancreatic cancer is one of the world's leading causes of cancer-related death. Activation of STAT3 has been reported as a major contributor in pancreatic cancer tumorigenesis and chemoresistance. However, treatment of advanced pancreatic cancer patients with STAT3 inhibitors often meets drug resistance and heterogeneous response. We found that EGFR activation is a main cause for resistance to STAT3 inhibitors in pancreatic cancer cells, regardless of KRAS mutation status. Mechanistically, inhibition of STAT3 promotes STAT1- and STAT4-mediated TGF-alpha expression, leading to activation of the EGFR pathway. Combined treatment of pancreatic cancer cells with EGFR and STAT3 inhibitors persistently blocks EGFR and STAT3 signaling, and exerts synergistic antitumor activity both in vitro and in vivo, with or without KRAS mutation. Our results indicate that reciprocal cross-talk between STAT3 and EGFR pathways is a key molecular mechanism leading to resistance in pancreatic cancer cells. Furthermore, the study shows that combined inhibition of both EGFR and STAT3 might overcome drug resistance encountered during treatment with single agent alone. This study suggests an improved therapeutic strategy, through combined treatment with STAT3 and EGFR inhibitors, for pancreatic cancer patients.	[Zhao, Chengguang; Yang, Lehe; Zhou, Feng; Yu, Yun; Liu, Zhiguo; Liang, Guang; Cui, Ri] Wenzhou Med Univ, Sch Pharmaceut Sci, Canc & Anticanc Drug Res Ctr, Wenzhou 325035, Zhejiang, Peoples R China; [Zhao, Chengguang; Yang, Lehe; Zhou, Feng; Du, Xiaojing; Xiang, Youqun; Huang, Xiaoying; Xie, Congying; Liu, Zhiguo; Wang, Liangxing; Cui, Ri] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China; [Zhao, Chengguang; Liang, Guang; Cui, Ri] Wenzhou Univ Wenzhou Med Univ Collaborat Innovat, Wenzhou 325035, Zhejiang, Peoples R China; [Yang, Lehe; Lin, Jiayuh] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Li, Chenglong] Univ Florida, Coll Pharm, Gainesville, FL 32610 USA	Wenzhou Medical University; Wenzhou Medical University; University System of Maryland; University of Maryland Baltimore; State University System of Florida; University of Florida	Liang, G; Cui, R (corresponding author), Wenzhou Med Univ, Sch Pharmaceut Sci, Canc & Anticanc Drug Res Ctr, Wenzhou 325035, Zhejiang, Peoples R China.; Wang, LX; Cui, R (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.; Liang, G; Cui, R (corresponding author), Wenzhou Univ Wenzhou Med Univ Collaborat Innovat, Wenzhou 325035, Zhejiang, Peoples R China.	wzyxywlx@163.com; wzmcliangguang@163.com; wzmucuiri@163.com	Zhao, Chengguang/AAK-2981-2021		National Natural Science Foundation of China [81672305, 81773579]; Natural Science Foundation of Zhejiang Province [LY17B020008, LY18H160047]; Medical Scientific Research Fund of Zhejiang Province [2019322308]; Wenzhou science and technology project [Y20190179]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Medical Scientific Research Fund of Zhejiang Province; Wenzhou science and technology project	This research was supported by National Natural Science Foundation of China (81672305 and 81773579), Natural Science Foundation of Zhejiang Province (LY17B020008 and LY18H160047), Medical Scientific Research Fund of Zhejiang Province (2019322308) and Wenzhou science and technology project (Y20190179).	Bai LC, 2019, CANCER CELL, V36, P498, DOI 10.1016/j.ccell.2019.10.002; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bressy C, 2018, CANCER RES, V78, P909, DOI 10.1158/0008-5472.CAN-15-2790; Choi S, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1018-y; Delgoffe Greg M, 2013, JAKSTAT, V2, pe23060, DOI 10.4161/jkst.23060; Engle DD, 2019, SCIENCE, V364, P1156, DOI 10.1126/science.aaw3145; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200; Hong D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5272; Hubbard JM, 2017, DRUGS, V77, P1091, DOI 10.1007/s40265-017-0759-4; Jiang H, 2020, GUT, V69, P122, DOI 10.1136/gutjnl-2018-317424; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Jonker DJ, 2018, LANCET GASTROENTEROL, V3, P263, DOI 10.1016/S2468-1253(18)30009-8; Laklai H, 2016, NAT MED, V22, P497, DOI 10.1038/nm.4082; Lankadasari MB, 2018, THERANOSTICS, V8, P3824, DOI 10.7150/thno.25308; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y; Ligorio M, 2019, CELL, V178, P160, DOI 10.1016/j.cell.2019.05.012; Maretzky T, 2011, ONCOGENE, V30, P611, DOI 10.1038/onc.2010.443; Milagrel CS, 2015, CANCER RES, V75, P1255, DOI 10.1158/0008-5472.CAN-14-1801; Nagathihalli NS, 2018, CANCER RES, V78, P6235, DOI 10.1158/0008-5472.CAN-18-0634; Nagathihalli NS, 2014, CANCER RES, V74, P2062, DOI 10.1158/0008-5472.CAN-13-2329; Rath KS, 2014, CANCER RES, V74, P2316, DOI 10.1158/0008-5472.CAN-13-2433; Sahu N, 2017, MOL CANCER THER, V16, P1729, DOI 10.1158/1535-7163.MCT-17-0009; Shi Y, 2019, NATURE, V569, P131, DOI 10.1038/s41586-019-1130-6; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032; Wang XC, 2016, ONCOTARGET, V7, P21496, DOI 10.18632/oncotarget.7452; Wormann SM, 2016, GASTROENTEROLOGY, V151, P180, DOI 10.1053/j.gastro.2016.03.010; Wu P, 2015, TRENDS PHARMACOL SCI, V36, P422, DOI 10.1016/j.tips.2015.04.005; Xiao H, 2015, J BIOL CHEM, V290, P3418, DOI 10.1074/jbc.M114.616748; Yang LH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1015-9; Yu WY, 2013, J MED CHEM, V56, P4402, DOI 10.1021/jm400080c; Zhang ZK, 2017, CANCER LETT, V402, P213, DOI 10.1016/j.canlet.2017.05.006; Zhang ZL, 2016, CANCER LETT, V382, P53, DOI 10.1016/j.canlet.2016.08.023; Zhao CG, 2016, TRENDS PHARMACOL SCI, V37, P47, DOI 10.1016/j.tips.2015.10.001; Zhao CG, 2015, ONCOTARGET, V6, P14472, DOI 10.18632/oncotarget.3991; Zhao CG, 2010, EUR J MED CHEM, V45, P5773, DOI 10.1016/j.ejmech.2010.09.037; Zheng HL, 2019, MOL CARCINOGEN, V58, P565, DOI 10.1002/mc.22951	40	18	18	4	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					3997	4013		10.1038/s41388-020-1271-y	http://dx.doi.org/10.1038/s41388-020-1271-y		APR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32242147				2022-12-17	WOS:000522996500001
J	Hazawa, M; Sakai, K; Kobayashi, A; Yoshino, H; Iga, Y; Iwashima, Y; Lim, KS; Voon, DCC; Jiang, YY; Horike, S; Lin, DC; Wong, RHW				Hazawa, Masaharu; Sakai, Kie; Kobayashi, Akiko; Yoshino, Hironori; Iga, Yoshihiro; Iwashima, Yuki; Lim, Kee Sing; Voon, Dominic Chih-Cheng; Jiang, Yan-Yi; Horike, Shin-ichi; Lin, De-Chen; Wong, Richard W.			Disease-specific alteration of karyopherin-alpha subtype establishes feed-forward oncogenic signaling in head and neck squamous cell carcinoma	ONCOGENE			English	Article							NUCLEAR-LOCALIZATION SIGNAL; NF-KAPPA-B; PORE COMPLEX; STEM-CELLS; PHOSPHORYLATION; DIFFERENTIATION; MAINTENANCE; INHIBITION; ACTIVATION; CONVERSION	Nuclear import, mediated in part by karyopherin-alpha (KPNA)/importin-alpha subtypes, regulates transcription factor access to the genome and determines cell fate. However, the cancer-specific changes of KPNA subtypes and the relevancy in cancer biology remain largely unknown. Here, we report that KPNA4, encoding karyopherin-alpha 4 (KPNA4), is exclusively amplified and overexpressed in head and neck of squamous cell carcinoma (HNSCC). Depletion of KPNA4 attenuated nuclear localization signal-dependent transport activity and suppressed malignant phenotypes and induced epidermal differentiation. Mechanistically, KPNA4-mediated nuclear transport of Ras-responsive element-binding protein (RREB1), which sustains Ras/ERK pathway signaling through repressing miR-143/145 expression. Notably, MAPK signaling enhanced trafficking activity of KPNA4 via phosphorylation of KPNA4 at Ser60. These data reveal that KPNA4 establishes a feed-forward cascade that potentiates Ras/ERK signaling in HNSCC.	[Hazawa, Masaharu; Sakai, Kie; Horike, Shin-ichi; Wong, Richard W.] Kanazawa Univ, Inst Frontier Sci Initiat, Cell Bionom Res Unit, Kanazawa, Ishikawa, Japan; [Hazawa, Masaharu; Iga, Yoshihiro; Iwashima, Yuki; Wong, Richard W.] Kanazawa Univ, Inst Sci & Engn, Sch Nat Syst, Mol Cell Biol Lab, Kanazawa, Ishikawa, Japan; [Hazawa, Masaharu; Kobayashi, Akiko; Lim, Kee Sing; Wong, Richard W.] Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa, Japan; [Yoshino, Hironori] Hirosaki Univ, Dept Radiat Sci, Grad Sch Hlth Sci, 66-1 Hon Cho, Hirosaki, Aomori 0368564, Japan; [Voon, Dominic Chih-Cheng] Kanazawa Univ, Inst Frontier Sci Initiat, Canc Model Res Innovat Unit, Kanazawa, Ishikawa, Japan; [Jiang, Yan-Yi; Lin, De-Chen] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Horike, Shin-ichi] Kanazawa Univ, Inst Gene Res, Adv Sci Res Ctr, Kanazawa, Ishikawa, Japan	Kanazawa University; Kanazawa University; Kanazawa University; Hirosaki University; Kanazawa University; Cedars Sinai Medical Center; Kanazawa University	Hazawa, M; Wong, RHW (corresponding author), Kanazawa Univ, Inst Frontier Sci Initiat, Cell Bionom Res Unit, Kanazawa, Ishikawa, Japan.; Hazawa, M; Wong, RHW (corresponding author), Kanazawa Univ, Inst Sci & Engn, Sch Nat Syst, Mol Cell Biol Lab, Kanazawa, Ishikawa, Japan.; Hazawa, M; Wong, RHW (corresponding author), Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa, Japan.	masaharu.akj@gmail.com; rwong@staff.kanazawa-u.ac.jp	HAZAWA, Masaharu/A-6520-2016; Lim, Kee Siang/AAH-1407-2019; Wong, Richard W./E-9155-2011; Yoshino, Hironori/E-7961-2013; Hazawa, M/AAA-2712-2021	Yoshino, Hironori/0000-0003-2705-9929; Wong, Richard/0000-0002-2131-6595; Voon, Dominic Chih-Cheng/0000-0002-2963-9305	Infiniti Grant; Japan Society for Promotion of Science [17K16332, 17H05874, 17K08655]; Ichiro Kanehara Foundation; Hokuriku bank young investigator foundation	Infiniti Grant; Japan Society for Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ichiro Kanehara Foundation; Hokuriku bank young investigator foundation	This work was funded by an Infiniti Grant and in part by Grants-in-Aid for scientific research (JSPS KAKENHI Grant Number 17K16332) and (JSPS KAKENHI Grant Number 17H05874, 17K08655) from the Japan Society for Promotion of Science. This research was supported by the grant provided by The Ichiro Kanehara Foundation as well as Hokuriku bank young investigator foundation. We thank the Edanz Group (www.edanzediting.com/ac) for proof reading of this paper.	[Anonymous], 2017, NATURE, V541, P169, DOI [DOI 10.1038/nature20805, DOI 10.1038/NATURE20805]; Borlido J, 2018, NAT IMMUNOL, V19, P594, DOI 10.1038/s41590-018-0103-5; Czimmerer Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055168; Fagerlund R, 2005, J BIOL CHEM, V280, P15942, DOI 10.1074/jbc.M500814200; Funasaka T, 2011, CANCER METAST REV, V30, P239, DOI 10.1007/s10555-011-9287-y; Haverty PM, 2004, NUCLEIC ACIDS RES, V32, pW213, DOI 10.1093/nar/gkh402; Hazawa M, 2017, ONCOGENE, V36, P2243, DOI 10.1038/onc.2016.377; Hazawa M, 2018, EMBO REP, V19, P73, DOI 10.15252/embr.201744523; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; Hoelz A, 2016, NAT STRUCT MOL BIOL, V23, P624, DOI 10.1038/nsmb.3244; Jiang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06081-9; Kent OA, 2013, ONCOGENE, V32, P2576, DOI 10.1038/onc.2012.266; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kosyna FK, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110221; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lee CS, 2014, NAT GENET, V46, P1060, DOI 10.1038/ng.3091; Liang SH, 1999, ONCOGENE, V18, P2163, DOI 10.1038/sj.onc.1202350; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Liu ZX, 2019, NEURON, V102, P587, DOI 10.1016/j.neuron.2019.02.018; Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008-5472.CAN-04-0852; Ma AH, 2019, ONCOGENE, V38, P2405, DOI 10.1038/s41388-018-0590-8; Masre SF, 2017, ONCOGENE, V36, P2529, DOI 10.1038/onc.2016.402; Mohamed MS, 2017, ACS NANO, V11, P5567, DOI 10.1021/acsnano.7b00906; Noetzel E, 2012, ONCOGENE, V31, P2101, DOI 10.1038/onc.2011.403; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Raices M, 2017, DEV CELL, V41, P540, DOI 10.1016/j.devcel.2017.05.007; Rodriguez-Bravo V, 2018, CELL, V174, P1200, DOI 10.1016/j.cell.2018.07.015; Saladi SV, 2017, CANCER CELL, V31, P35, DOI 10.1016/j.ccell.2016.12.001; Tang YW, 2018, CELL REP, V24, P1355, DOI 10.1016/j.celrep.2018.06.116; Toda T, 2017, CELL STEM CELL, V21, P618, DOI 10.1016/j.stem.2017.08.012; Wong RW, 2015, CHEM BIOL, V22, P1285, DOI 10.1016/j.chembiol.2015.10.001; Xiang SS, 2019, ONCOGENE, V38, P1269, DOI 10.1038/s41388-018-0494-7; Xie JJ, 2018, GASTROENTEROLOGY, V154, P2137, DOI 10.1053/j.gastro.2018.02.018; Yang J, 2017, ONCOGENE, V36, P2868, DOI 10.1038/onc.2016.440; Yang J, 2019, ONCOGENE, V38, P4700, DOI 10.1038/s41388-019-0745-2; Yasuhara N, 2007, NAT CELL BIOL, V9, P72, DOI 10.1038/ncb1521; Yasuhara N, 2013, DEV CELL, V26, P123, DOI 10.1016/j.devcel.2013.06.022; Yoneda Y, 1996, ARCH HISTOL CYTOL, V59, P97, DOI 10.1679/aohc.59.97; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhu JR, 2019, ONCOGENE, V38, P2736, DOI 10.1038/s41388-018-0621-5; Zhu ZC, 2018, ONCOGENE, V37, P2936, DOI 10.1038/s41388-018-0180-9	43	18	18	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2212	2223		10.1038/s41388-019-1137-3	http://dx.doi.org/10.1038/s41388-019-1137-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31822798	hybrid, Green Published			2022-12-17	WOS:000518584000014
J	Li, Y; Zhang, HB; Fan, L; Mou, JH; Yin, Y; Peng, C; Chen, YX; Lu, HL; Zhao, LT; Tao, ZT; Chen, J; Wang, YZ; Qi, XM; Huang, RM; Ren, J				Li, Yu; Zhang, Huibiao; Fan, Lei; Mou, Jiahui; Yin, Yue; Peng, Chao; Chen, Yuxiang; Lu, Henglei; Zhao, Liting; Tao, Zhouteng; Chen, Jing; Wang, Yizheng; Qi, Xinming; Huang, Ruimin; Ren, Jin			MiR-629-5p promotes the invasion of lung adenocarcinoma via increasing both tumor cell invasion and endothelial cell permeability	ONCOGENE			English	Article							UP-REGULATION; CANCER; METASTASIS; EXPRESSION; TARGETS; GROWTH; CELSR1; ANGIOGENESIS; SUPPRESSES; MIGRATION	Tumor invasion underlies further metastasis, the leading cause for cancer-related deaths. Deregulation of microRNAs has been identified associated with the malignant behavior of various cancers, including lung adenocarcinoma (LUAD), the major subtype of lung cancer. Here, we showed the significantly positive correlation between miR-629-5p level and tumor invasion in LUAD specimens (n = 49). In a human LUAD metastasis mouse model, H1650 cells (high level of miR-629-5p) were more aggressive than A549 cells (low level of miR-629-5p) in vivo, including higher incidence of vascular invasion and pulmonary colonization. Ectopic expression of miR-629-5p in A549 cells also increased their invasive capability. Then we identified that miR-629-5p promotes LUAD invasion in a mode of dual regulation via tumor cells invasion and endothelial cells permeability, respectively. In tumor cells, miR-629-5p enhanced motility and invasiveness of tumor cells by directly targeting PPWD1 (a cyclophilin), which clinically related to tumor invasion in LUAD specimens. Restoring PPWD1 protein significantly attenuated the invasion-promoting effects of miR-629-5p. Besides, exosomal-miR-629-5p secreted from tumor cells could be transferred to endothelial cells and increased endothelial monolayers permeability by suppressing CELSR1 (a nonclassic-type cadherin), which had a low level in the endothelial cells of invasive LUAD specimens. Activating the expression of CELSR1 in endothelial cells markedly blocked the effect of miR-629-5p. Our study suggests the dual roles of miR-629-5p in tumor cells and endothelial cells for LUAD invasion, implying a therapeutic option to targeting miR-629-5p using the "one stone, two birds" strategy in LUAD.	[Li, Yu; Fan, Lei; Mou, Jiahui; Chen, Yuxiang; Lu, Henglei; Tao, Zhouteng; Chen, Jing; Qi, Xinming; Ren, Jin] Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Drug Safety Evaluat & Res, State Key Lab Drug Res, Shanghai 201203, Peoples R China; [Li, Yu; Fan, Lei; Mou, Jiahui; Tao, Zhouteng; Chen, Jing; Qi, Xinming; Huang, Ruimin; Ren, Jin] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Zhang, Huibiao] Fudan Univ, Huadong Hosp, Dept Thorac Surg, Shanghai 200040, Peoples R China; [Yin, Yue] Natl Facil Prot Sci Shanghai, Zhangjiang Lab, Shanghai 201210, Peoples R China; [Peng, Chao] Chinese Acad Sci, Shanghai Sci Res Ctr, Shanghai 201204, Peoples R China; [Lu, Henglei] Shanghai Univ Chinese Med, Shanghai 201203, Peoples R China; [Zhao, Liting] Fudan Univ, Huadong Hosp, Dept Nursing, Shanghai 200040, Peoples R China; [Wang, Yizheng] Beijing Inst Basic Med Sci, Brain Sci Ctr, Beijing 100730, Peoples R China; [Huang, Ruimin] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Fudan University; Chinese Academy of Sciences; Shanghai University of Traditional Chinese Medicine; Fudan University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Ren, J (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Drug Safety Evaluat & Res, State Key Lab Drug Res, Shanghai 201203, Peoples R China.; Huang, RM; Ren, J (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Huang, RM (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.	rmhuang@simm.ac.cn; jren@cdser.simm.ac.cn		yin, yue/0000-0002-7693-3910	National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program," China [2018ZX09101001-003-007, 2018ZX09711002-010-001]; National Natural Science Foundation of china [91859106]; One Hundred Talent Program of Chinese Academy of Sciences; State Key Laboratory of Drug Research; Shanghai Committee of Science and Technology, China [18DZ2290200]	National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program," China; National Natural Science Foundation of china(National Natural Science Foundation of China (NSFC)); One Hundred Talent Program of Chinese Academy of Sciences(Chinese Academy of Sciences); State Key Laboratory of Drug Research; Shanghai Committee of Science and Technology, China(Shanghai Science & Technology Committee)	This work was supported by the National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program," China (2018ZX09101001-003-007 and 2018ZX09711002-010-001), "the National Natural Science Foundation of china (91859106)," One Hundred Talent Program of Chinese Academy of Sciences, the Fundamental and Open Research Funds from the State Key Laboratory of Drug Research, and the grant from Shanghai Committee of Science and Technology, China (Grant No.: 18DZ2290200). We thank the Electron Microscopy System and Animal Facility at the National Facility for Protein Science in Shanghai (NFPS), Zhangjiang Lab, China, and the Institutional Technology Service Center of Shanghai Institute of Materia Medica, Chinese Academy of Sciences for technical supports.	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Bica-Pop C, 2018, CELL MOL LIFE SCI, V75, P3539, DOI 10.1007/s00018-018-2877-x; Bielenberg DR, 2015, CANCER J, V21, P267, DOI 10.1097/PPO.0000000000000138; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brzoska HL, 2016, KIDNEY INT, V90, P1274, DOI 10.1016/j.kint.2016.07.011; Chang TH, 2017, CANCER LETT, V402, P190, DOI 10.1016/j.canlet.2017.06.002; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Chorti Angeliki, 2018, Microrna, V7, P167, DOI 10.2174/2211536607666180525073302; Davis TL, 2008, FEBS J, V275, P2283, DOI 10.1111/j.1742-4658.2008.06381.x; Duncan JS, 2017, DEV BIOL, V423, P126, DOI 10.1016/j.ydbio.2017.01.020; Faict S, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0139-7; Goffinet AM, 2017, SEMIN CELL DEV BIOL, V69, P102, DOI 10.1016/j.semcdb.2017.07.014; Graner MW, 2018, SEMIN IMMUNOPATHOL, V40, P505, DOI 10.1007/s00281-018-0689-6; Han ML, 2016, ONCOL REP, V35, P73, DOI 10.3892/or.2015.4360; Ito M, 2014, BLOOD, V123, P1499, DOI 10.1182/blood-2013-09-527739; Jenkinson EM, 2018, CLIN GENET, V93, P228, DOI 10.1111/cge.13025; Jin K, 2017, J PATHOL, V241, P567, DOI 10.1002/path.4871; Jingushi K, 2015, MOL CANCER RES, V13, P565, DOI 10.1158/1541-7786.MCR-14-0300; Kaemmerer D, 2014, CLIN EXP METASTAS, V31, P817, DOI 10.1007/s10585-014-9672-3; Kang YY, 2018, NATURE, V558, P553, DOI 10.1038/s41586-018-0215-y; Lee SW, 2009, INT J MOL MED, V23, P279, DOI 10.3892/ijmm_00000128; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu K, 2016, CHINESE MED J-PEKING, V129, P442, DOI 10.4103/0366-6999.176076; Lu J, 2018, BIOSCIENCE REP, V38; Maishi N, 2017, CANCER SCI, V108, P1921, DOI 10.1111/cas.13336; Miao LL, 2016, BBA-GENE REGUL MECH, V1859, P650, DOI 10.1016/j.bbagrm.2016.02.016; Myers D. J., 2019, CANC LUNG ADENOCARCI; Nagao Y, 2012, MODERN PATHOL, V25, P112, DOI 10.1038/modpathol.2011.142; Naik MU, 2006, J CELL SCI, V119, P490, DOI 10.1242/jcs.02771; Paliouras AR, 2018, CANCER LETT, V421, P152, DOI 10.1016/j.canlet.2018.02.029; Poel D, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.288; Posorski N, 2011, CLIN EXP METASTAS, V28, P637, DOI 10.1007/s10585-011-9397-5; Pu MF, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006896; Qi LQ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-163; Rajiv C, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040161; Riihimaki M, 2014, LUNG CANCER, V86, P78, DOI 10.1016/j.lungcan.2014.07.020; Shao LP, 2017, DNA CELL BIOL, V36, P1108, DOI 10.1089/dna.2017.3904; Singleton PA, 2014, ADV CANCER RES, V123, P191, DOI 10.1016/B978-0-12-800092-2.00007-1; Tan XH, 2014, J CUTAN PATHOL, V41, P630, DOI 10.1111/cup.12332; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Tornavaca O, 2015, J CELL BIOL, V208, P821, DOI 10.1083/jcb.201404140; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002; Wang T, 2017, ONCOGENE, V36, P3240, DOI 10.1038/onc.2016.468; Wen J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705761; Yan HJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.525; Yan LX, 2016, INT J ONCOL, V48, P471, DOI 10.3892/ijo.2015.3287; Yang H, 2013, HEPATOLOGY, V58, P205, DOI 10.1002/hep.26315; Yang L, 2012, CARCINOGENESIS, V33, P338, DOI 10.1093/carcin/bgr272; Yang N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.358; Yu SJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3930-0; Zeng ZC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07810-w; Zhan YH, 2016, BIOCHEMISTRY-MOSCOW+, V81, P591, DOI 10.1134/S0006297916060055; Zhang BG, 2012, ONCOL REP, V27, P1019, DOI 10.3892/or.2012.1645; Zhao YJ, 2015, CANCER METAST REV, V34, P265, DOI 10.1007/s10555-015-9553-5; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhuang BF, 2019, MOL MED REP, V19, P3933, DOI 10.3892/mmr.2019.9990	60	18	19	5	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3473	3488		10.1038/s41388-020-1228-1	http://dx.doi.org/10.1038/s41388-020-1228-1		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32108166				2022-12-17	WOS:000516891300003
J	Jin, Y; Bao, H; Le, XN; Fan, XJ; Tang, M; Shi, X; Zhao, J; Yan, JR; Xu, Y; Quek, K; Elamin, YY; Zhang, J; Futreal, PA; Wistuba, II; Heymach, JV; Lou, GY; Shao, L; He, Q; Lin, C; Wu, X; Shao, YW; Wang, XN; He, JC; Chen, YM; Stebbing, J; Chen, M; Zhang, JJ; Yu, XM				Jin, Ying; Bao, Hua; Le, Xiuning; Fan, Xiaojun; Tang, Ming; Shi, Xun; Zhao, Jun; Yan, Junrong; Xu, Yang; Quek, Kelly; Elamin, Yasir Y.; Zhang, Jianhua; Futreal, P. Andrew; Wistuba, Ignacio I.; Heymach, John, V; Lou, Guangyuan; Shao, Lan; He, Qiong; Lin, Chen; Wu, Xue; Shao, Yang W.; Wang, Xiaonan; He, Jiachen; Chen, Yamei; Stebbing, Justin; Chen, Ming; Zhang, Jianjun; Yu, Xinmin			Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; INTRATUMOR GENETIC-HETEROGENEITY; 1ST-LINE TREATMENT; CLINICAL IMPACT; OPEN-LABEL; RESISTANCE; PIK3CA; ADENOCARCINOMAS; DIVERSITY	EGFR-mutant non-small-cell lung cancer (NSCLC) patients inevitably develop drug resistance when treated with EGFR tyrosine kinase inhibitors (TKIs). Systematic genetic analysis is important to understand drug-resistant mechanisms; however, the clinical significance of co-occurring genetic alterations at baseline, co-acquired mutations at progressive disease (PD), and the clonal evolution remain underinvestigated. We performed targeted sequencing of pre-treatment and PD tumor samples from 54 EGFR-mutant NSCLC patients. Ten additional patients were sequenced using whole-exome sequencing to infer the clonal evolution patterns. We observed a domain-dependent effect of PIK3CA mutation at baseline on patient progression-free survival (PFS). In addition, at baseline, 9q34.3/19p13.3 (NOTCH1/STK11/GNA11) showed a co-deletion pattern, which was associated with a significantly worse PFS (p = 0.00079). T790M-postive patients with other concurrent acquired oncogenic mutations had a significantly shorter PFS (p = 0.005). Besides acquired T790M mutation, chromosomal instability (CIN) related genes, including AURKA and TP53 alterations, were the most frequently acquired events. CIN significantly increased during TKI treatment in T790M-negative patients and is a candidate resistance mechanism to the first-generation TKIs. Clonal evolution analyses suggest that the composition and relationship among resistant subclones, particularly relationship with T790M subclone, affect patients' outcomes. Overall, our findings of novel co-occurring alterations and clonal evolution patterns can be served as predictive biomarkers to stratify patients and help to better understand the drug-resistant mechanism to TKIs.	[Jin, Ying; Shi, Xun; Zhao, Jun; Lou, Guangyuan; Shao, Lan; He, Qiong; Lin, Chen; Chen, Yamei; Chen, Ming; Yu, Xinmin] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Zhejiang, Peoples R China; [Jin, Ying; Shi, Xun; Zhao, Jun; Lou, Guangyuan; Shao, Lan; He, Qiong; Lin, Chen; Yu, Xinmin] Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Jin, Ying; Shi, Xun; Zhao, Jun; Lou, Guangyuan; Shao, Lan; He, Qiong; Lin, Chen; Yu, Xinmin] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China; [Jin, Ying; Chen, Yamei; Chen, Ming] Zhejiang Key Lab Radiat Oncol, Hangzhou, Zhejiang, Peoples R China; [Bao, Hua; Fan, Xiaojun; Xu, Yang; Wu, Xue] Geneseeq Technol Inc, Translat Med Res Ctr, Toronto, ON, Canada; [Le, Xiuning; Tang, Ming; Quek, Kelly; Elamin, Yasir Y.; Heymach, John, V; Zhang, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Yan, Junrong; Shao, Yang W.; Wang, Xiaonan; He, Jiachen] Nanjing Geneseeq Technol Inc, Nanjing, Jiangsu, Peoples R China; [Zhang, Jianhua; Futreal, P. Andrew; Zhang, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Stebbing, Justin] Imperial Coll London, ICTEM, Div Canc, Dept Surg & Canc, London W12 0NN, England	Chinese Academy of Sciences; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Zhejiang Cancer Hospital; Geneseeq Technology Inc.; University of Texas System; UTMD Anderson Cancer Center; Geneseeq Technology Inc.; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Imperial College London	Chen, M; Yu, XM (corresponding author), Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Zhejiang, Peoples R China.; Yu, XM (corresponding author), Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China.; Yu, XM (corresponding author), Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China.; Chen, M (corresponding author), Zhejiang Key Lab Radiat Oncol, Hangzhou, Zhejiang, Peoples R China.; Zhang, JJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.; Zhang, JJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.	chenming@zjcc.org.cn; jzhang20@mdanderson.org; yuxm@zjcc.org.cn	Xu, Yang/CAG-8877-2022; Chen, Ming/GYE-1379-2022	Xu, Yang/0000-0003-1670-6131; Chen, Ming/0000-0001-5041-9342; Bao, Hua/0000-0001-5774-8755; Stebbing, Justin/0000-0002-1117-6947	National Natural Science Foundation of China [81702248, 81672972]; Zhejiang Medical and Health Science and Technology Project [2018KY309, 2017KY239]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Medical and Health Science and Technology Project	Professor Stebbing sits on SABs for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. This study was supported by the National Natural Science Foundation of China (Grant nos. 81702248, 81672972), and Zhejiang Medical and Health Science and Technology Project (Grant nos. 2018KY309, 2017KY239).	Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Birkbak NJ, 2011, CANCER RES, V71, P3447, DOI 10.1158/0008-5472.CAN-10-3667; Bivona TG, 2016, NAT MED, V22, P472, DOI 10.1038/nm.4091; Blakely CM, 2017, NAT GENET, V49, P1693, DOI 10.1038/ng.3990; Boolell V, 2015, CANCERS, V7, P1815, DOI 10.3390/cancers7030864; Buermans HPJ, 2014, BBA-MOL BASIS DIS, V1842, P1932, DOI 10.1016/j.bbadis.2014.06.015; Canale M, 2017, CLIN CANCER RES, V23, P2195, DOI 10.1158/1078-0432.CCR-16-0966; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Eng J, 2015, J THORAC ONCOL, V10, P1713, DOI 10.1097/JTO.0000000000000671; Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208; Gill RK, 2011, ONCOGENE, V30, P3784, DOI 10.1038/onc.2011.98; Guo LX, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/520590; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Jackman D, 2010, J CLIN ONCOL, V28, P357, DOI 10.1200/JCO.2009.24.7049; Jin Y, 2016, ONCOTARGET, V7, P61755, DOI 10.18632/oncotarget.11237; Kim HR, 2014, LUNG CANCER, V83, P374, DOI 10.1016/j.lungcan.2013.12.011; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Lee AJX, 2011, CANCER RES, V71, P1858, DOI 10.1158/0008-5472.CAN-10-3604; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liang HR, 2018, J THORAC DIS, V10, P2311, DOI 10.21037/jtd.2018.03.150; Ma GZ, 2017, ONCOTARGET, V8, P99429, DOI 10.18632/oncotarget.19681; Majem M, 2013, TRANSL LUNG CANCER R, V2, P226, DOI 10.3978/j.issn.2218-6751.2013.03.09; Maley CC, 2006, NAT GENET, V38, P468, DOI 10.1038/ng1768; McGranahan N, 2012, EMBO REP, V13, P528, DOI 10.1038/embor.2012.61; McNeill RS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200014; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mroz EA, 2013, CANCER-AM CANCER SOC, V119, P3034, DOI 10.1002/cncr.28150; Mroz EA, 2013, ORAL ONCOL, V49, P211, DOI 10.1016/j.oraloncology.2012.09.007; Nadeu F, 2018, LEUKEMIA, V32, P645, DOI 10.1038/leu.2017.291; Nagano T, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110212; Niknafs N, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004416; Nowell CS, 2017, NAT REV CANCER, V17, P145, DOI 10.1038/nrc.2016.145; Oda K, 2008, CANCER RES, V68, P8127, DOI 10.1158/0008-5472.CAN-08-0755; Ohgaki H, 2004, CANCER LETT, V207, P197, DOI 10.1016/j.canlet.2003.10.020; Pao W., 2005, PLOS MED, V2; Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P821, DOI 10.1002/gcc.22378; Remon J, 2014, CANCER TREAT REV, V40, P93, DOI 10.1016/j.ctrv.2013.06.002; Rosell R, 2013, LANCET, V382, P720, DOI 10.1016/S0140-6736(13)61715-8; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/NMETH.2883, 10.1038/nmeth.2883]; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shah KN, 2019, NAT MED, V25, P111, DOI 10.1038/s41591-018-0264-7; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Toth LN, 2018, HUM PATHOL, V78, P138, DOI 10.1016/j.humpath.2018.04.014; Turajlic S, 2019, NAT REV GENET, V20, P404, DOI 10.1038/s41576-019-0114-6; VanderLaan PA, 2017, LUNG CANCER, V106, P17, DOI 10.1016/j.lungcan.2017.01.011; Wang J, 2016, ONCOTARGETS THER, V9, P3711, DOI 10.2147/OTT.S106399; Westover D, 2018, ANN ONCOL, V29, pI10, DOI 10.1093/annonc/mdx703; Wu SY, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6030038; Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1; Xie M, 2013, EUR J CANCER, V49, P3559, DOI 10.1016/j.ejca.2013.07.007; Yard BD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11428; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zhao RX, 2014, CURR DRUG TARGETS, V15, P32, DOI 10.2174/1389450114666140106095811	64	18	18	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1846	1859		10.1038/s41388-019-1104-z	http://dx.doi.org/10.1038/s41388-019-1104-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31754213				2022-12-17	WOS:000516579800002
J	Sinha, S; Dwivedi, N; Tao, SX; Jamadar, A; Kakade, VR; O'Neil, M; Weiss, RH; Enders, J; Calvet, JP; Thomas, SM; Rao, R				Sinha, Sonali; Dwivedi, Nidhi; Tao, Shixin; Jamadar, Abeda; Kakade, Vijayakumar R.; O'Neil, Maura; Weiss, Robert H.; Enders, Jonathan; Calvet, James P.; Thomas, Sufi M.; Rao, Reena			Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy	ONCOGENE			English	Article							BREAST-CANCER CELLS; PROTEIN-KINASE-A; LUNG-CANCER; CYCLIC-AMP; SIGNALING PATHWAYS; MITOGENIC ACTION; ORAL TOLVAPTAN; INDUCED GROWTH; V-2 RECEPTOR; TUMOR-GROWTH	Arginine vasopressin (AVP) and its type-2 receptor (V2R) play an essential role in the regulation of salt and water homeostasis by the kidneys. V2R activation also stimulates proliferation of renal cell carcinoma (RCC) cell lines in vitro. The current studies investigated V2R expression and activity in human RCC tumors, and its role in RCC tumor growth. Examination of the cancer genome atlas (TCGA) database, and analysis of human RCC tumor tissue microarrays, cDNA arrays and tumor biopsy samples demonstrated V2R expression and activity in clear cell RCC (ccRCC). In vitro, V2R antagonists OPC31260 and Tolvaptan, or V2R gene silencing reduced wound closure and cell viability of 786-O and Caki-1 human ccRCC cell lines. Similarly in mouse xenograft models, Tolvaptan and OPC31260 decreased RCC tumor growth by reducing cell proliferation and angiogenesis, while increasing apoptosis. In contrast, the V2R agonist dDAVP significantly increased tumor growth. High intracellular cAMP levels and ERK1/2 activation were observed in human ccRCC tumors. In mouse tumors and Caki-1 cells, V2R agonists reduced cAMP and ERK1/2 activation, while dDAVP treatment had the reverse effect. V2R gene silencing in Caki-1 cells also reduced cAMP and ERK1/2 activation. These results provide novel evidence for a pathogenic role of V2R signaling in ccRCC, and suggest that inhibitors of the AVP-V2R pathway, including the FDA-approved drug Tolvaptan, could be utilized as novel ccRCC therapeutics.	[Sinha, Sonali; Dwivedi, Nidhi; Tao, Shixin; Jamadar, Abeda; Kakade, Vijayakumar R.; Calvet, James P.; Rao, Reena] Univ Kansas, Med Ctr, Jared Grantham Kidney Inst, Kansas City, KS 66103 USA; [Sinha, Sonali; Dwivedi, Nidhi; Tao, Shixin; Jamadar, Abeda; Kakade, Vijayakumar R.; Rao, Reena] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA; [O'Neil, Maura] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA; [Weiss, Robert H.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA; [Weiss, Robert H.] Univ Calif Davis, Comprehens Canc Ctr, Davis, CA 95616 USA; [Weiss, Robert H.] VA Northern Calif Hlth Care Syst, Med Serv, Sacramento, CA USA; [Enders, Jonathan] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66103 USA; [Calvet, James P.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66103 USA; [Calvet, James P.; Thomas, Sufi M.; Rao, Reena] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA; [Thomas, Sufi M.] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of California System; University of California Davis; University of California System; University of California Davis; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Rao, R (corresponding author), Univ Kansas, Med Ctr, Jared Grantham Kidney Inst, Kansas City, KS 66103 USA.; Rao, R (corresponding author), Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA.; Rao, R (corresponding author), Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA.	rrao@kumc.edu	DWIVEDI, NIDHI/AAE-8717-2019; Jamadar, Abeda/AAL-4581-2021; Thomas, Sufi Mary/AFR-1642-2022	DWIVEDI, NIDHI/0000-0002-7520-5030; Jamadar, Abeda/0000-0002-0887-4613; Thomas, Sufi Mary/0000-0001-5370-0842; Wallace, Darren/0000-0003-4616-7669	NIH [R01-DK083525]; KU Cancer Center; PKD Research and Translation Core Center [P30-DK106912]; KU Biomedical Research and Training Program; American Heart Association	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); KU Cancer Center; PKD Research and Translation Core Center; KU Biomedical Research and Training Program; American Heart Association(American Heart Association)	This study was supported by NIH R01-DK083525, a private donation from the Watts family and a Pilot and Feasibility Grant from the KU Cancer Center and PKD Research and Translation Core Center P30-DK106912 to RR. ND is supported by Postdoctoral Fellowship Grants from the KU Biomedical Research and Training Program and American Heart Association.	Aihara M, 2014, J PHARMACOL EXP THER, V349, P258, DOI 10.1124/jpet.114.213256; Alonso DF, 1999, BREAST CANCER RES TR, V57, P271, DOI 10.1023/A:1006291607871; Bellmunt J, 2014, EUR UROL, V65, P731, DOI 10.1016/j.eururo.2013.10.057; BEPLER G, 1987, CANCER RES, V47, P2371; Berl T, 2010, J AM SOC NEPHROL, V21, P705, DOI 10.1681/ASN.2009080857; Bolignano D, 2010, UROL ONCOL-SEMIN ORI, V28, P642, DOI 10.1016/j.urolonc.2008.12.014; Boone M, 2008, PFLUG ARCH EUR J PHY, V456, P1005, DOI 10.1007/s00424-008-0498-1; BUNN PA, 1994, CANCER RES, V54, P3602; BUNN PA, 1992, CANCER RES, V52, P24; Burst V, 2017, SUPPORT CARE CANCER, V25, P2275, DOI 10.1007/s00520-017-3638-3; Cai Q, 2007, AM J PHYSIOL-RENAL, V293, pF1858, DOI 10.1152/ajprenal.00068.2007; Chang YS, 2007, CANCER CHEMOTH PHARM, V59, P561, DOI 10.1007/s00280-006-0393-4; Chebib FT, 2018, J AM SOC NEPHROL, V29, P2458, DOI 10.1681/ASN.2018060590; Chen FJ, 2016, CELL REP, V14, P2476, DOI 10.1016/j.celrep.2016.02.024; CHOCHUNG YS, 1992, BIOCHEM SOC T, V20, P425, DOI 10.1042/bst0200425; CHOOI KF, 1994, CANCER RES, V54, P6434; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Dicitore A, 2016, ENDOCRINE, V51, P101, DOI 10.1007/s12020-015-0597-7; Dremier S, 2002, ANN NY ACAD SCI, V968, P106, DOI 10.1111/j.1749-6632.2002.tb04330.x; Garona J, 2019, CANCER RES TREAT, V51, P438, DOI 10.4143/crt.2018.040; Garona J, 2015, INT J ONCOL, V46, P2335, DOI 10.3892/ijo.2015.2952; Giron S, 2002, J SURG ONCOL, V81, P38, DOI 10.1002/jso.10141; Gralla RJ, 2017, CANCER MED-US, V6, P723, DOI 10.1002/cam4.805; Gunaratne R, 2010, P NATL ACAD SCI USA, V107, P15653, DOI 10.1073/pnas.1007424107; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Huang D, 2008, CANCER RES, V68, P81, DOI 10.1158/0008-5472.CAN-07-5311; Iannucci NB, 2011, FUTURE MED CHEM, V3, P1987, DOI [10.4155/FMC.11.152, 10.4155/fmc.11.152]; Jeppesen AN, 2010, BRIT J CANCER, V102, P867, DOI 10.1038/sj.bjc.6605563; Kakade VR, 2016, J MOL CELL BIOL, V8, P464, DOI 10.1093/jmcb/mjw022; Kane RC, 2006, CLIN CANCER RES, V12, P7271, DOI 10.1158/1078-0432.CCR-06-1249; Keegan BP, 2006, BREAST CANCER RES TR, V95, P265, DOI 10.1007/s10549-005-9024-8; Khan MI, 2017, RES REP TROP MED, V8, P37, DOI 10.2147/RRTM.S97309; Kim SN, 2001, INT J CANCER, V93, P33, DOI 10.1002/ijc.1308; Kondo K, 1999, BIOORGAN MED CHEM, V7, P1743, DOI 10.1016/S0968-0896(99)00101-7; MacKinnon AC, 2005, BRIT J CANCER, V92, P522, DOI 10.1038/sj.bjc.6602366; North WG, 1998, CANCER RES, V58, P1866; North WG, 2000, EXP PHYSIOL, V85, p27S, DOI 10.1111/j.1469-445X.2000.tb00005.x; North WG, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00016; North WG, 2011, BREAST CANCER RES TR, V127, P631, DOI 10.1007/s10549-010-1009-6; Onitilo AA, 2007, CLIN MED RES, V5, P228, DOI 10.3121/cmr.2007.762; Pantziarka P, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.442; Pequeux C, 2004, ENDOCR-RELAT CANCER, V11, P871, DOI 10.1677/erc.1.00803; Pifano M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00011; Prasad SR, 2007, BRIT J RADIOL, V80, P593, DOI 10.1259/bjr/20129205; R Core Team, 2019, R LANG ENV STAT COMP; Rao R, 2010, J AM SOC NEPHROL, V21, P428, DOI 10.1681/ASN.2009060672; Ricketts CJ, 2018, CELL REP, V23, P313, DOI [10.1016/j.celrep.2018.03.075, 10.1016/j.celrep.2018.06.032]; Ripoll GV, 2013, BREAST CANCER RES TR, V142, P9, DOI 10.1007/s10549-013-2724-6; Rocha AS, 2008, MOL BIOL CELL, V19, P4814, DOI 10.1091/mbc.E08-06-0617; Rodrigues AL, 2018, LIFE SCI, V192, P144, DOI 10.1016/j.lfs.2017.11.040; Ryan MB, 2015, TRENDS CANCER, V1, P183, DOI 10.1016/j.trecan.2015.10.001; Santarpia L, 2012, EXPERT OPIN THER TAR, V16, P103, DOI 10.1517/14728222.2011.645805; Sarmiento JM, 2005, KIDNEY INT, V68, P487, DOI 10.1111/j.1523-1755.2005.00426.x; Schwindt TT, 2003, BIOCHEMISTRY-US, V42, P2116, DOI 10.1021/bi026807g; Seeger-Nukpezah T, 2015, NAT REV NEPHROL, V11, P515, DOI 10.1038/nrneph.2015.46; Seo EJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01030; SETHI T, 1991, CANCER RES, V51, P3621; Shaw TJ, 2002, EXP CELL RES, V273, P95, DOI 10.1006/excr.2001.5426; Shi PP, 2007, AM J PHYSIOL-RENAL, V292, pF1334, DOI 10.1152/ajprenal.00308.2006; Shoaf SE, 2012, EUR J CLIN PHARMACOL, V68, P1595, DOI 10.1007/s00228-012-1295-5; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh SP, 2015, DIS MODEL MECH, V8, P931, DOI 10.1242/dmm.020511; STARZEC AB, 1994, J CELL PHYSIOL, V161, P31, DOI 10.1002/jcp.1041610105; Takahashi H, 2004, ARCH DERMATOL RES, V296, P74, DOI 10.1007/s00403-004-0478-z; Tao SX, 2015, KIDNEY INT, V87, P1164, DOI 10.1038/ki.2014.427; TAYLOR AH, 1990, CANCER RES, V50, P7882; Thibonnier M, 2000, AM J PHYSIOL-HEART C, V279, pH2529, DOI 10.1152/ajpheart.2000.279.5.H2529; Tierney T, 2002, J ENDOCRINOL, V175, P435, DOI 10.1677/joe.0.1750435; Torres VE, 2017, NEW ENGL J MED, V377, P1930, DOI 10.1056/NEJMoa1710030; Vitali E, 2014, MOL CELL ENDOCRINOL, V383, P193, DOI 10.1016/j.mce.2013.12.006; WALLACE AC, 1972, CANCER, V29, P977, DOI 10.1002/1097-0142(197204)29:4<977::AID-CNCR2820290444>3.0.CO;2-P; Watkins PB, 2015, DRUG SAFETY, V38, P1103, DOI 10.1007/s40264-015-0327-3; Yamaguchi T, 2004, J BIOL CHEM, V279, P40419, DOI 10.1074/jbc.M405079200; YAMAMURA Y, 1992, BRIT J PHARMACOL, V105, P787, DOI 10.1111/j.1476-5381.1992.tb09058.x; ZAORAL M, 1985, INT J PEPT PROT RES, V25, P561; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR101, DOI 10.1186/bcr958	78	18	19	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1231	1245		10.1038/s41388-019-1059-0	http://dx.doi.org/10.1038/s41388-019-1059-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31616061	Green Accepted, Green Submitted			2022-12-17	WOS:000526714600005
J	Ganguly, SS; Hostetter, G; Tang, L; Frank, SB; Saboda, K; Mehra, R; Wang, LS; Li, XH; Keller, ET; Miranti, CK				Ganguly, Sourik S.; Hostetter, Galen; Tang, Lin; Frank, Sander B.; Saboda, Kathylynn; Mehra, Rohit; Wang, Lisha; Li, Xiaohong; Keller, Evan T.; Miranti, Cindy K.			Notch3 promotes prostate cancer-induced bone lesion development via MMP-3	ONCOGENE			English	Article							MATRIX METALLOPROTEINASES; CELLS; PROGRESSION; INHIBITION; ASSOCIATION; EXPRESSION; CASTRATION; METASTASES; OSTEOBLAST; INDUCTION	Prostate cancer metastases primarily localize in the bone where they induce a unique osteoblastic response. Elevated Notch activity is associated with high-grade disease and metastasis. To address how Notch affects prostate cancer bone lesions, we manipulated Notch expression in mouse tibia xenografts and monitored tumor growth, lesion phenotype, and the bone microenvironment. Prostate cancer cell lines that induce mixed osteoblastic lesions in bone expressed 5-6 times more Notch3, than tumor cells that produce osteolytic lesions. Expression of active Notch3 (NICD3) in osteolytic tumors reduced osteolytic lesion area and enhanced osteoblastogenesis, while loss of Notch3 in osteoblastic tumors enhanced osteolytic lesion area and decreased osteoblastogensis. This was accompanied by a respective decrease and increase in the number of active osteoclasts and osteoblasts at the tumor-bone interface, without any effect on tumor proliferation. Conditioned medium from NICD3-expressing cells enhanced osteoblast differentiation and proliferation in vitro, while simultaneously inhibiting osteoclastogenesis. MMP-3 was specifically elevated and secreted by NICD3-expressing tumors, and inhibition of MMP-3 rescued the NICD3-induced osteoblastic phenotypes. Clinical osteoblastic bone metastasis samples had higher levels of Notch3 and MMP-3 compared with patient matched visceral metastases or osteolytic metastasis samples. We identified a Notch3-MMP-3 axis in human prostate cancer bone metastases that contributes to osteoblastic lesion formation by blocking osteoclast differentiation, while also contributing to osteoblastogenesis. These studies define a new role for Notch3 in manipulating the tumor microenvironment in bone metastases.	[Ganguly, Sourik S.; Li, Xiaohong; Miranti, Cindy K.] Ctr Canc & Cell Biol, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA; [Ganguly, Sourik S.; Tang, Lin; Frank, Sander B.; Miranti, Cindy K.] Univ Arizona, Canc Ctr, Dept Cellular & Mol Med, Tucson, AZ 85719 USA; [Hostetter, Galen] Van Andel Res Inst, Tissue Repository & Pathol Core, Grand Rapids, MI USA; [Saboda, Kathylynn; Miranti, Cindy K.] Univ Arizona, Canc Ctr, Tucson, AZ 85719 USA; [Mehra, Rohit; Wang, Lisha; Keller, Evan T.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Arizona; Van Andel Institute; University of Arizona; University of Michigan System; University of Michigan	Miranti, CK (corresponding author), Ctr Canc & Cell Biol, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA.; Miranti, CK (corresponding author), Univ Arizona, Canc Ctr, Dept Cellular & Mol Med, Tucson, AZ 85719 USA.; Miranti, CK (corresponding author), Univ Arizona, Canc Ctr, Tucson, AZ 85719 USA.	cmiranti@email.arizona.edu	Miranti, Cindy/AAJ-3783-2020	Frank, Sander/0000-0001-7591-944X; , Xiaohong/0000-0001-5074-193X	DOD [W81XWH-14-1-0479, W81XWH-16-1-0136]; University of Arizona Cancer Center (UACC) [NIH/NCI P30CA023074]; Van Andel Research Institute (VARI); University of Arizona; DOD Prostate Cancer Research Program [W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, W81XWH-15-2-0062]	DOD(United States Department of Defense); University of Arizona Cancer Center (UACC); Van Andel Research Institute (VARI); University of Arizona; DOD Prostate Cancer Research Program	Funding for this project was provided by a DOD Postdoctoral Fellowship W81XWH-16-1-0136 (SSG), DOD W81XWH-14-1-0479 (SBF, LT, CKM), University of Arizona Cancer Center (UACC) NIH/NCI P30CA023074 (KS, CKM), the Van Andel Research Institute (VARI) (GH, XL), and the University of Arizona (CKM). The TMA obtained from the Prostate Cancer Biorepository Network (PCBN) was supported by funds from the DOD Prostate Cancer Research Program: W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, and W81XWH-15-2-0062. We wish to thank the following: Dr Denise Roe, Director of Biostatistics Shared Resource at UACC for biostatistics support; Dr Chunyan Liu at Ventana Medical Services, Oro Valley, AZ for her pathology services; Dr Colm Morrissey in the Department of Urology, University of Washington, Seattle WA, for his assistance with providing pathological assessment of bone metastasis lesions in the PCBN TMA. Alexandra VanderArk, Veronique Schulz, and Ghada Y.T Mohsen at Van Andel Research Institute for their technical expertise; Zachary Madaj for statistical analysis expertise; Lisa Turner, Kristin Feenstra, and Bree Berghuis of the VARI Pathology and Biorepository Core for their pathology and Aperio expertise; Su Yanli and Staff of the VARI Vivarium and Transgenics core for technical assistance with animal experiments; David Nadziejka for technical editing of the paper; Jeanie Wedberg and Michelle Minard at the Van Andel Institute and David Alvarado at University of Arizona for their administrative support.	Ally MMTM, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/183653; Bin Hafeez B, 2009, CLIN CANCER RES, V15, P452, DOI 10.1158/1078-0432.CCR-08-1631; Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cui D, 2015, CLIN CANCER RES, V21, P4619, DOI 10.1158/1078-0432.CCR-15-0242; Cui J, 2018, INT J CANCER, V143, P645, DOI 10.1002/ijc.31346; Dang L, 2006, DEV NEUROSCI-BASEL, V28, P58, DOI 10.1159/000090753; Danza G, 2013, INT J CANCER, V133, P2577, DOI 10.1002/ijc.28293; Edick MJ, 2007, MOL BIOL CELL, V18, P2481, DOI 10.1091/mbc.E06-04-0261; Evans KE, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-4; Frank SB, 2017, J CELL SCI, V130, P1952, DOI 10.1242/jcs.197152; Frank SB, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0341-x; Frank SB, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00273; Frieling JS, 2017, ONCOGENE, V36, P4498, DOI 10.1038/onc.2017.70; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Ganguly SS, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00364; Garcia AJ, 2013, J BONE MINER RES, V28, P283, DOI 10.1002/jbmr.1747; Gilkes DM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101669; Gong YX, 2014, CANCERS, V6, P1298, DOI 10.3390/cancers6031298; Hong MH, 2000, J BONE MINER RES, V15, P911, DOI 10.1359/jbmr.2000.15.5.911; Huang JF, 2016, J BUON, V21, P235; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Ibrahim T, 2010, CANCER-AM CANCER SOC, V116, P1406, DOI 10.1002/cncr.24896; Imamura Y, 2016, INT J UROL, V23, P654, DOI 10.1111/iju.13137; Jin JK, 2011, INT J CANCER, V128, P2545, DOI 10.1002/ijc.26024; Jung K, 1997, INT J CANCER, V74, P220, DOI 10.1002/(SICI)1097-0215(19970422)74:2<220::AID-IJC14>3.0.CO;2-H; Karayi MK, 2004, PROSTATE CANCER P D, V7, P6, DOI 10.1038/sj.pcan.4500697; Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338; Kwon OJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5416; Li XH, 2012, MOL CANCER RES, V10, P494, DOI 10.1158/1541-7786.MCR-11-0506; Long Q, 2011, AM J PATHOL, V179, P46, DOI 10.1016/j.ajpath.2011.03.008; Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013; Mehner Christine, 2015, Genes Cancer, V6, P480; Ross AE, 2011, PROSTATE, V71, P1568, DOI 10.1002/pros.21373; Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140; Sasaki K, 2007, J BIOMED MATER RES B, V80B, P491, DOI 10.1002/jbm.b.30622; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sottnik JL, 2013, CURR MOL MED, V13, P626; Srivastava P, 2013, GENE, V530, P273, DOI 10.1016/j.gene.2013.06.087; Su QT, 2016, HISTOL HISTOPATHOL, V31, P149, DOI 10.14670/HH-11-685; Thalmann GN, 2000, PROSTATE, V44, P91; Wang XD, 2004, J BIOL CHEM, V279, P24733, DOI 10.1074/jbc.M401602200; Ye QF, 2012, ONCOL LETT, V3, P879, DOI 10.3892/ol.2012.572; Yu XB, 2006, STEM CELLS, V24, P876, DOI 10.1634/stemcells.2005-0598; Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285-09; Zhang SB, 2014, NEOPLASIA, V16, P158, DOI 10.1593/neo.131870; Zhang ZY, 2010, AM J PATHOL, V177, P1459, DOI 10.2353/ajpath.2010.090476	50	18	21	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					204	218		10.1038/s41388-019-0977-1	http://dx.doi.org/10.1038/s41388-019-0977-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31467432	Green Accepted, Green Submitted			2022-12-17	WOS:000509849200014
J	Jung, JH; Lee, H; Cao, B; Liao, P; Zeng, SX; Lu, H				Jung, Ji Hoon; Lee, Hyemin; Cao, Bo; Liao, Peng; Zeng, Shelya X.; Lu, Hua			RNA-binding motif protein 10 induces apoptosis and suppresses proliferation by activating p53	ONCOGENE			English	Article							C-MYC; DEGRADATION; PATHWAY; LOOP; MDM2	RNA-binding motif protein 10 (RBM10) is an RNA-binding protein frequently deleted or mutated in lung cancer cells. Recent reports showed that the knockdown of RBM10 in human cancer cells enhances the growth of mouse tumor xenografts, suggesting that RBM10 acts as a tumor suppressor. RBM10 also regulates alternative splicing and controls cancer cell proliferation. However, the underlying molecular mechanisms for its tumor suppression role remain largely unclear. Here, we for the first time report that RBM10 can induce apoptosis and inhibit cancer cell proliferation by activating p53. Our analysis of cancer genomic databases showed that patients with wild-type RBM10 and p53 survive longer than do those with mutated p53 or less RBM10. RBM10 overexpression markedly inhibited mitochondrial respiration, cell migration and proliferation of various cancer cells that harbor wild-type p53. Also, RBM10 overexpression elongated p53's half-life by disrupting MDM2-p53 interaction and subsequently repressing p53 ubiquitination, whereas knockdown of RBM10 decreased p53 stability. Altogether, our results demonstrate that RBM10 inhibits cancer cell proliferation and induces apoptosis in part by blocking the MDM2-p53 feedback loop.	[Jung, Ji Hoon; Lee, Hyemin; Cao, Bo; Liao, Peng; Zeng, Shelya X.; Lu, Hua] Tulane Univ, Dept Biochem & Mol Biol, Sch Med, New Orleans, LA 70112 USA; [Jung, Ji Hoon; Lee, Hyemin; Cao, Bo; Liao, Peng; Zeng, Shelya X.; Lu, Hua] Tulane Univ, Tulane Canc Ctr, Sch Med, New Orleans, LA 70112 USA; [Jung, Ji Hoon] Kyung Hee Univ, Coll Korean Med, Seoul 02447, South Korea	Tulane University; Tulane University; Kyung Hee University	Lu, H (corresponding author), Tulane Univ, Dept Biochem & Mol Biol, Sch Med, New Orleans, LA 70112 USA.; Lu, H (corresponding author), Tulane Univ, Tulane Canc Ctr, Sch Med, New Orleans, LA 70112 USA.	hlu2@tulane.edu	Liao, Peng/Y-1896-2019; CAO, BO/F-6682-2015	Liao, Peng/0000-0002-8409-5574; CAO, BO/0000-0002-4933-6424	National Institutes of Health (NIH)-National Cancer Institute (NCI) [R01CA095441, R01CA172468, R01CA127724]	National Institutes of Health (NIH)-National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Juan Valcarcel for providing us with RBM10 plasmid, Yongbo Wang for providing us with GFP-RBM10, and Xiang Zhou as well as other members of the Lu laboratory for active discussion. This work was supported in part by National Institutes of Health (NIH)-National Cancer Institute (NCI) grants (R01CA095441, R01CA172468, and R01CA127724) to HL and SXZ.	Bechara EG, 2013, MOL CELL, V52, P720, DOI 10.1016/j.molcel.2013.11.010; Bonnal S, 2008, MOL CELL, V32, P81, DOI 10.1016/j.molcel.2008.08.008; Cao B, 2017, ONCOTARGET, V8, P90651, DOI 10.18632/oncotarget.21544; Collins KM, 2017, NUCLEIC ACIDS RES, V45, P6761, DOI 10.1093/nar/gkx225; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; Guan GF, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317691740; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hunziker A, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-94; Jung JH, 2015, CANCER BIOL THER, V16, P412, DOI 10.1080/15384047.2014.1002698; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Liao JM, 2014, ONCOGENE, V33, P4916, DOI 10.1038/onc.2013.430; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Nag S, 2013, J BIOMED RES, V27, P254, DOI 10.7555/JBR.27.20130030; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Sharma N, 2010, DIFFERENTIATION, V79, P218, DOI 10.1016/j.diff.2010.02.001; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang MX, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0646-0; Zhang YH, 2017, GENE DEV, V31, P1243, DOI 10.1101/gad.299388.117; Zhou X, 2013, ONCOGENE, V32, P388, DOI 10.1038/onc.2012.63; Zhou X, 2015, J MOL CELL BIOL, V7, P92, DOI 10.1093/jmcb/mjv014; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	24	18	19	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1031	1040		10.1038/s41388-019-1034-9	http://dx.doi.org/10.1038/s41388-019-1034-9			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591476	Green Accepted			2022-12-17	WOS:000511209700006
J	O'Connor, CM; Leonard, D; Wiredja, D; Avelar, RA; Wang, ZZ; Schlatzer, D; Bryson, B; Tokala, E; Taylor, SE; Upadhyay, A; Sangodkar, J; Gingras, AC; Westermarck, J; Xu, WQ; DiFeo, A; Brautigan, DL; Haider, S; Jackson, M; Narla, G				O'Connor, Caitlin M.; Leonard, Daniel; Wiredja, Danica; Avelar, Rita A.; Wang, Zhizhi; Schlatzer, Daniela; Bryson, Benjamin; Tokala, Eesha; Taylor, Sarah E.; Upadhyay, Aditya; Sangodkar, Jaya; Gingras, Anne-Claude; Westermarck, Jukka; Xu, Wenqing; DiFeo, Analisa; Brautigan, David L.; Haider, Shozeb; Jackson, Mark; Narla, Goutham			Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; PURIFICATION-MASS SPECTROMETRY; A-ALPHA; SUBUNIT INTERACTION; MOLECULAR-DYNAMICS; COMPLEXES; PPP2R1A; OVARIAN; IDENTIFICATION; SIMULATION	The serine/threonine Protein Phosphatase 2A (PP2A) functions as a tumor suppressor by negatively regulating multiple oncogenic signaling pathways. The canonical PP2A holoenzyme comprises a scaffolding subunit (PP2A A alpha/beta), which serves as the platform for binding of both the catalytic C subunit and one regulatory B subunit. Somatic heterozygous missense mutations in PPP2R1A, the gene encoding the PP2A A alpha scaffolding subunit, have been identified across multiple cancer types, but the effects of the most commonly mutated residue, Arg-183, on PP2A function have yet to be fully elucidated. In this study, we used a series of cellular and in vivo models and discovered that the most frequent A alpha R183W mutation formed alternative holoenzymes by binding of different PP2A regulatory subunits compared with wild-type A alpha, suggesting a rededication of PP2A functions. Unlike wild-type A alpha, which suppressed tumorigenesis, the R183W mutant failed to suppress tumor growth in vivo through activation of the MAPK pathway in RAS-mutant transformed cells. Furthermore, cells expressing R183W were less sensitive to MEK inhibitors. Taken together, our results demonstrate that the R183W mutation in PP2A A alpha scaffold abrogates the tumor suppressive actions of PP2A, thereby potentiating oncogenic signaling and reducing drug sensitivity of RAS-mutant cells.	[O'Connor, Caitlin M.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Leonard, Daniel; Taylor, Sarah E.; Jackson, Mark] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Wiredja, Danica; Schlatzer, Daniela] Case Western Reserve Univ, Ctr Prote & Bioinformat, Cleveland, OH 44106 USA; [Avelar, Rita A.; DiFeo, Analisa] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Wang, Zhizhi; Xu, Wenqing] Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; [Bryson, Benjamin; Tokala, Eesha; Upadhyay, Aditya; Jackson, Mark] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Sangodkar, Jaya; Narla, Goutham] Univ Michigan, Dept Internal Med Genet Med, Ann Arbor, MI 48109 USA; [Gingras, Anne-Claude] Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Gingras, Anne-Claude] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Westermarck, Jukka] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Westermarck, Jukka] Abo Akad Univ, Turku, Finland; [DiFeo, Analisa; Narla, Goutham] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA; [DiFeo, Analisa] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; [Brautigan, David L.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA USA; [Haider, Shozeb] UCL, Dept Pharmaceut & Biol Chem, London, England	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle; Case Western Reserve University; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Turku; Abo Akademi University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Virginia; University of London; University College London	Narla, G (corresponding author), Univ Michigan, Dept Internal Med Genet Med, Ann Arbor, MI 48109 USA.; Narla, G (corresponding author), Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.	gnarla@med.umich.edu	Gingras, Anne-Claude/ABA-8341-2020; Gingras, Anne-Claude/E-9982-2010; O'Connor, Caitlin M./AAC-5203-2020; Westermarck, Jukka/AAL-6464-2020; Bryson, Benjamin L/D-1070-2014; Narla, Goutham/AAZ-5710-2020; Haider, Shozeb/B-3452-2015	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437; O'Connor, Caitlin M./0000-0002-7840-6399; Westermarck, Jukka/0000-0001-7478-3018; Bryson, Benjamin L/0000-0003-4131-0200; Narla, Goutham/0000-0003-4098-4203; Haider, Shozeb/0000-0003-2650-2925; DiFeo, Analisa/0000-0001-8319-6763; Taylor, Sarah/0000-0003-2743-8099	NIH/NCI [R01CA181654, T32GM008803]; National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health [4UL1TR000439]; Athymic Animal and Preclinical Therapeutics of the Case Comprehensive Cancer Center at Case Western Reserve University (NIH) [P30 CA043703]; Cytometry and Imaging Microscopy cores of the Case Comprehensive Cancer Center at Case Western Reserve University (NIH) [P30 CA043703]; Pardee-Gerstacker Professorship in Cancer Research	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health; Athymic Animal and Preclinical Therapeutics of the Case Comprehensive Cancer Center at Case Western Reserve University (NIH); Cytometry and Imaging Microscopy cores of the Case Comprehensive Cancer Center at Case Western Reserve University (NIH); Pardee-Gerstacker Professorship in Cancer Research	The authors wish to acknowledge the Young Scientist Foundation and the students who worked on this project through this program, including Aditya Upadhyay. This work was partially supported by the NIH/NCI R01CA181654 (to GN) and T32GM008803 (to CMO). This publication was made possible in part by the Clinical and Translational Science Collaborative of Cleveland, 4UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research. This research was supported by the Athymic Animal and Preclinical Therapeutics and Cytometry and Imaging Microscopy cores of the Case Comprehensive Cancer Center at Case Western Reserve University (funded by NIH P30 CA043703). GN is supported by the Pardee-Gerstacker Professorship in Cancer Research.	ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bonomi M, 2009, J COMPUT CHEM, V30, P1615, DOI 10.1002/jcc.21305; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Casado P, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003573; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Cipriano R, 2011, P NATL ACAD SCI USA, V108, P8668, DOI 10.1073/pnas.1015022108; DeLano WL, 2009, ABSTR PAP AM CHEM S, V238; Doerr S, 2016, J CHEM THEORY COMPUT, V12, P1845, DOI 10.1021/acs.jctc.6b00049; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270; Grinthal A, 2010, P NATL ACAD SCI USA, V107, P2467, DOI 10.1073/pnas.0914073107; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Haesen D, 2016, CANCER RES, V76, P5719, DOI 10.1158/0008-5472.CAN-15-3342; Harvey MJ, 2009, J CHEM THEORY COMPUT, V5, P1632, DOI 10.1021/ct9000685; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Hoang LN, 2015, HISTOPATHOLOGY, V66, P664, DOI 10.1111/his.12581; Holt SV, 2012, CANCER RES, V72, P1804, DOI 10.1158/0008-5472.CAN-11-1780; Horn T, 2011, NAT METHODS, V8, P341, DOI 10.1038/NMETH.1581; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jeong AL, 2016, SCI REP-UK, V6, DOI 10.1038/srep27391; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Junk DJ, 2013, NEOPLASIA, V15, P1086, DOI 10.1593/neo.131114; Kamburov A, 2015, P NATL ACAD SCI USA, V112, pE5486, DOI 10.1073/pnas.1516373112; Kauko O, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1093; Kauko O, 2015, SCI REP-UK, V5, DOI 10.1038/srep13099; Knight JDR, 2017, NAT METHODS, V14, P645, DOI 10.1038/nmeth.4330; Letourneux C, 2006, EMBO J, V33, P3489; McClinch K, 2018, CANCER RES, V78, P2065, DOI 10.1158/0008-5472.CAN-17-0123; Mellacheruvu D, 2013, NAT METHODS, V10, P730, DOI 10.1038/nmeth.2557; Morris JH, 2014, NAT PROTOC, V9, P2539, DOI 10.1038/nprot.2014.164; O'Connor CM, 2019, J BIOL CHEM, V294, P5923, DOI 10.1074/jbc.RA119.007593; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117; Rahman M, 2013, ANTICANCER RES, V33, P113; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Roberts PJ, 2012, CLIN CANCER RES, V18, P5290, DOI 10.1158/1078-0432.CCR-12-0563; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2011, MOL CELL BIOL, V31, P3832, DOI 10.1128/MCB.05744-11; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sangodkar J, 2017, J CLIN INVEST, V127, P2081, DOI 10.1172/JCI89548; Sangodkar J, 2016, FEBS J, V283, P1004, DOI 10.1111/febs.13573; Schlatzer D, 2017, ANAL CHEM, V89, P5325, DOI 10.1021/acs.analchem.6b05070; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shih IM, 2011, AM J PATHOL, V178, P1442, DOI 10.1016/j.ajpath.2011.01.009; Skliros A, 2012, PHYS BIOL, V9, DOI 10.1088/1478-3975/9/1/014001; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Taylor SE, 2019, CANCER RES, V79, P4242, DOI 10.1158/0008-5472.CAN-19-0218; Tsytlonok M, 2013, STRUCTURE, V21, P1954, DOI 10.1016/j.str.2013.08.028; Walter G, 2012, CELL CYCLE, V11, P451, DOI 10.4161/cc.11.3.19057; Wiemann S, 2016, NAT METHODS, V13, P191, DOI 10.1038/nmeth.3776; Wiredja DD, 2017, BIOINFORMATICS; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Zhou J, 2003, BIOCHEM J, V369, P387, DOI 10.1042/BJ20021244	59	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					703	717		10.1038/s41388-019-1012-2	http://dx.doi.org/10.1038/s41388-019-1012-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31541192	Green Accepted, Green Submitted			2022-12-17	WOS:000509718300016
J	Xie, Y; Liu, J; Jiang, HM; Wang, JY; Li, X; Wang, JJ; Zhu, S; Guo, J; Li, T; Zhong, YP; Zhang, QG; Liu, ZQ				Xie, Ying; Liu, Jing; Jiang, Hongmei; Wang, Jingya; Li, Xin; Wang, Jingjing; Zhu, Shuai; Guo, Jing; Li, Tao; Zhong, Yuping; Zhang, Qiguo; Liu, Zhiqiang			Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma	ONCOGENE			English	Article							PHASE-II TRIAL	Multiple myeloma (MM) is still incurable despite the successful application of proteasome inhibitors in clinic. Bortezomib represents the most common chemotherapy for MM, whereas acquired drug resistance and eventually developed relapse remain the major obstruction. In the current study, we established bortezomib-resistant myeloma cell lines and screened gene expression profiles using single cell RNA-sequencing. Resistant MM cells exhibited increased clonogenic potential, specific metabolic, and epigenetic signatures, along with the self-renewal signaling characteristic of MM stem-like cells. Aberrant activation of hedgehog (Hh) signaling was correlated with drug resistance and stem cell-like transcriptional program. The key transcriptional factor GLI2 of the Hh pathway was restricted in the high acetylation and low ubiquitination states in bortezomib-resistant myeloma cells. Further investigation revealed that SIRT1 deacetylates and stabilizes GLI2 protein at lysine 757 and consequentially activates the Hh signaling, and itself serves as a direct target of Hh signaling to format a positive regulating loop. Using combination screening with an epigenetic compound library, we identified the SIRT1 specific inhibitor S1541 and S2804 had very obvious synergetic antimyeloma effect. Sirt1 inhibition could partially impeded the Hh pathway and conferred bortezomib sensitivity in vitro and in vivo. Notably, elevated SIRT1 level was also a prominent hallmark for the resistant myeloma cells, and this expression pattern was confirmed in myeloma patients, but independent of RAS/RAF mutations. Clinically, SIRT1 expression in patients with complete response was suppressed but elevated in relapsed patients, and retrospective analysis showed patients with higher SIRT1 expression had poorer outcomes. In conclusion, the cooperation of SIRT1 and Hh is an important mechanism of drug resistance in myeloma, and therapeutics combining SIRT1 inhibitors will sensitize myeloma cells to proteasome inhibitors.	[Xie, Ying; Liu, Jing; Jiang, Hongmei; Wang, Jingya; Li, Xin; Wang, Jingjing; Zhu, Shuai; Guo, Jing; Liu, Zhiqiang] Tianjin Med Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, Tianjin 300070, Peoples R China; [Li, Tao] Hunan Normal Univ, Sch Med, Changsha 410006, Hunan, Peoples R China; [Zhong, Yuping] Capital Med Univ, Beijing Chao Yang Hosp, Myeloma Res Ctr Beijing, Dept Hematol, Beijing 100020, Peoples R China; [Zhang, Qiguo] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Hematol, Nanjing 210008, Jiangsu, Peoples R China	Tianjin Medical University; Hunan Normal University; Capital Medical University; Nanjing University	Liu, ZQ (corresponding author), Tianjin Med Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, Tianjin 300070, Peoples R China.	zhiqiangliu@tmu.edu.cn	wang, jing/GRS-7509-2022; WANG, JINGYI/GSJ-1241-2022; wang, jing/GVT-8700-2022; Wang, Jin/GYA-2019-2022; Liu, Zhiqiang/E-6950-2014	Liu, Zhiqiang/0000-0002-0677-8097; Xie, Ying/0000-0003-1197-3222; Liu, Jing/0000-0002-2112-2416	National Natural Science Foundation of China [81670201, 81870161]; Natural Science Foundation of Tianjin [16JCYBJC42600]; Talent Project of Tianjin Medical University [11601501/2016KJ0317]; Nanjing Key Medical Science and Technology Development Project [ZKX18023]; Chuzhou Science and Technology Development Project [2018zd004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin); Talent Project of Tianjin Medical University; Nanjing Key Medical Science and Technology Development Project; Chuzhou Science and Technology Development Project	This work was supported by the National Natural Science Foundation of China (81670201, 81870161, ZL), the Natural Science Foundation of Tianjin (16JCYBJC42600, ZL), the Talent Project of Tianjin Medical University (11601501/2016KJ0317, ZL), the Nanjing Key Medical Science and Technology Development Project (ZKX18023, QZ), and the Chuzhou Science and Technology Development Project (2018zd004, QZ).	Amodio N, 2016, MOL CANCER THER, V15, P1364, DOI [10.1158/1535-7163.MCT-15-0985-T, 10.1158/1535-7163.MCT-15-0985]; Armas-Lopez L, 2017, ONCOTARGET, V8, P60684, DOI 10.18632/oncotarget.19527; Avigan D, 2014, NEW ENGL J MED, V371, P961, DOI 10.1056/NEJMe1407442; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Cappellacci L, 2018, CURR MED CHEM, V25, P1; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Chauhan D, 2011, BRIT J HAEMATOL, V155, P588, DOI 10.1111/j.1365-2141.2011.08888.x; Delcuve GP, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-5; Delude C, 2011, NATURE, V480, pS43, DOI 10.1038/480S43a; Gulino A, 2012, VITAM HORM, V88, P211, DOI 10.1016/B978-0-12-394622-5.00009-2; Harada T, 2017, LEUKEMIA, V31, P2670, DOI 10.1038/leu.2017.144; Hatayama M, 2012, VITAM HORM, V88, P73, DOI 10.1016/B978-0-12-394622-5.00004-3; Islam S, 2019, ONCOL LETT, V17, P729, DOI 10.3892/ol.2018.9722; Kumar SK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.46; Laubach JP, 2017, EXPERT REV HEMATOL, V10, P229, DOI 10.1080/17474086.2017.1280388; Li BZ, 2015, J BIOL CHEM, V290, P29854, DOI 10.1074/jbc.M115.664953; Liu H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8949; Liu Z, 2014, ONCOGENE, V33, P65, DOI 10.1038/onc.2012.544; Liu ZQ, 2015, ONCOTARGET, V6, P34329, DOI 10.18632/oncotarget.6020; Liu ZQ, 2014, BLOOD, V124, P2061, DOI 10.1182/blood-2014-03-557298; Niewiadomski P, 2014, CELL REP, V6, P168, DOI 10.1016/j.celrep.2013.12.003; Nunes T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124036; Ohguchi H, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0119-y; Ok CY, 2012, AM J PATHOL, V180, P2, DOI 10.1016/j.ajpath.2011.09.009; Robak P, 2018, CANCER TREAT REV, V70, P199, DOI 10.1016/j.ctrv.2018.09.001; Sari IN, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110208; Simmons GE, 2015, INT J MOL SCI, V16, P950, DOI 10.3390/ijms16010950; Wallington-Beddoe CT, 2018, BRIT J HAEMATOL, V182, P11, DOI 10.1111/bjh.15210; Wolf JL, 2012, LEUKEMIA LYMPHOMA, V53, P1820, DOI 10.3109/10428194.2012.661175; Yazbeck V, 2018, CL LYMPH MYELOM LEUK, V18, P569, DOI 10.1016/j.clml.2018.05.023; Zaal EA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00500	31	18	20	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					922	934		10.1038/s41388-019-1037-6	http://dx.doi.org/10.1038/s41388-019-1037-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31576013				2022-12-17	WOS:000509197200013
J	Ou, WB; Ni, N; Zuo, R; Zhuang, WH; Zhu, MJ; Kyriazoglou, A; Wu, DL; Eilers, G; Demetri, GD; Qiu, HB; Li, B; Marino-Enriquez, A; Fletcher, JA				Ou, Wen-Bin; Ni, Nan; Zuo, Rui; Zhuang, Weihao; Zhu, Meijun; Kyriazoglou, Anastasios; Wu, Duolin; Eilers, Grant; Demetri, George D.; Qiu, Haibo; Li, Bin; Marino-Enriquez, Adrian; Fletcher, Jonathan A.			Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence	ONCOGENE			English	Article							KINASE-C-THETA; CANCER-CELL-GROWTH; IMATINIB MESYLATE; ADIPOCYTIC DIFFERENTIATION; PKC-THETA; EXPRESSION; PROLIFERATION; RESISTANCE; MUTATIONS; OVEREXPRESSION	Oncogenic KIT or PDGFRA tyrosine kinase mutations are compelling therapeutic targets in most gastrointestinal stromal tumors (GISTs), and the KIT inhibitor, imatinib, is therefore standard of care for patients with metastatic GIST. However, some GISTs lose expression of KIT oncoproteins, and therefore become KIT-independent and are consequently resistant to KIT-inhibitor drugs. We identified distinctive biologic features in KIT-independent, imatinib-resistant GISTs as a step towards identifying drug targets in these poorly understood tumors. We developed isogenic GIST lines in which the parental forms were KIT oncoprotein-dependent, whereas sublines had loss of KIT oncoprotein expression, accompanied by markedly downregulated expression of the GIST biomarker, protein kinase C-theta (PRKCQ). Biologic mechanisms unique to KIT-independent GISTs were identified by transcriptome sequencing, qRT-PCR, immunoblotting, protein interaction studies, knockdown and expression assays, and dual-luciferase assays. Transcriptome sequencing showed that cyclin D1 expression was extremely low in two of three parental KIT-dependent GIST lines, whereas cyclin D1 expression was high in each of the KIT-independent GIST sublines. Cyclin D1 inhibition in KIT-independent GISTs had anti-proliferative and pro-apoptotic effects, associated with Rb activation and p27 upregulation. PRKCQ, but not KIT, was a negative regulator of cyclin D1 expression, whereas JUN and Hippo pathway effectors YAP and TAZ were positive regulators of cyclin D1 expression. PRKCQ, JUN, and the Hippo pathway coordinately regulate GIST cyclin D1 expression. These findings highlight the roles of PRKCQ, JUN, Hippo, and cyclin D1 as oncogenic mediators in GISTs that have converted, during TKI-therapy, to a KIT-independent state. Inhibitors of these pathways could be effective therapeutically for these now untreatable tumors.	[Ou, Wen-Bin; Ni, Nan; Zuo, Rui; Zhuang, Weihao; Wu, Duolin] Zhejiang Sci Tech Univ, Coll Life Sci & Med, Zhejiang Prov Key Lab Silkworm Bioreactor & Biome, Hangzhou, Zhejiang, Peoples R China; [Ou, Wen-Bin; Zhu, Meijun; Kyriazoglou, Anastasios; Eilers, Grant; Qiu, Haibo; Li, Bin; Marino-Enriquez, Adrian; Fletcher, Jonathan A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Ou, Wen-Bin; Zhu, Meijun; Kyriazoglou, Anastasios; Eilers, Grant; Demetri, George D.; Marino-Enriquez, Adrian; Fletcher, Jonathan A.] Harvard Med Sch, Boston, MA 02115 USA; [Demetri, George D.] Dana Farber Harvard Canc Ctr, Ludwig Ctr Dana Farber, Boston, MA 02115 USA; [Demetri, George D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Qiu, Haibo] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Li, Bin] Cent S Univ, Xiangya Hosp, Div Oncol, Changsha, Hunan, Peoples R China	Zhejiang Sci-Tech University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; State Key Lab Oncology South China; Sun Yat Sen University; Central South University	Ou, WB (corresponding author), Zhejiang Sci Tech Univ, Coll Life Sci & Med, Zhejiang Prov Key Lab Silkworm Bioreactor & Biome, Hangzhou, Zhejiang, Peoples R China.; Ou, WB; Fletcher, JA (corresponding author), Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.; Ou, WB; Fletcher, JA (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	ouwenbin@tsinghua.org.cn; jfletcher@partners.org		, Wenbin/0000-0002-6311-9442; Marino-Enriquez, Adrian/0000-0002-7680-9901	NIH [1P50CA127003, 1P50CA168512]; GIST Cancer Research Fund; David Foundation; National Natural Science Foundation of China [81728012, 81602061]; Natural Science Foundation of Zhejiang Province [LY18H160065]; Zhejiang medical and health science and technology plan project [2018KY651]; Zhejiang Xinmiao Talents Program [2017R406050]; National Undergraduate Training Program for Innovation and Entrepreneurship, Science Foundation of Zhejiang Sci-Tech University [14042107-Y]; Graduate research and innovation projects of Zhejiang Sci-Tech University, China; SARC; NATIONAL CANCER INSTITUTE [P50CA127003] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GIST Cancer Research Fund; David Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Zhejiang medical and health science and technology plan project; Zhejiang Xinmiao Talents Program; National Undergraduate Training Program for Innovation and Entrepreneurship, Science Foundation of Zhejiang Sci-Tech University; Graduate research and innovation projects of Zhejiang Sci-Tech University, China; SARC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants 1P50CA127003 and 1P50CA168512, and by the GIST Cancer Research Fund, SARC and David Foundation. This research was also supported by National Natural Science Foundation of China (81728012, 81602061), the Natural Science Foundation of Zhejiang Province (LY18H160065), Zhejiang medical and health science and technology plan project (2018KY651), Zhejiang Xinmiao Talents Program (2017R406050), National Undergraduate Training Program for Innovation and Entrepreneurship, Science Foundation of Zhejiang Sci-Tech University (14042107-Y), Graduate research and innovation projects of Zhejiang Sci-Tech University, China. We thank Adalis Maisonet, Terry Haley, and Edward Fox for technical and biostatistical support in the whole transcriptome sequencing.	Barbash O, 2008, CELL CYCLE, V7, P2983, DOI 10.4161/cc.7.19.6775; Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017; Bauer S, 2007, ONCOGENE, V26, P7560, DOI 10.1038/sj.onc.1210558; Blay JY, 2005, ANN ONCOL, V16, P566, DOI 10.1093/annonc/mdi127; Blay P, 2004, CLIN CANCER RES, V10, P4089, DOI 10.1158/1078-0432.CCR-04-0630; Casimiro MC, 2017, CANCER RES, V77, P3391, DOI 10.1158/0008-5472.CAN-16-0425; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri GD, 2009, CLIN CANCER RES, V15, P5902, DOI 10.1158/1078-0432.CCR-09-0482; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Draper N, 2008, HUM PATHOL, V39, P1784, DOI 10.1016/j.humpath.2008.05.007; Duensing A, 2004, CANCER RES, V64, P5127, DOI 10.1158/0008-5472.CAN-04-0559; Essat M, 2011, INT J CANCER, V128, P2202, DOI 10.1002/ijc.25827; Fernando R, 2007, J BIOL CHEM, V282, P28864, DOI 10.1074/jbc.M700785200; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Fletcher J.A., 2003, P AM SOC CLIN ONCOL, V22, P815; Guan LJ, 2007, J BIOL CHEM, V282, P14213, DOI 10.1074/jbc.M610513200; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hizli AA, 2006, J BIOL CHEM, V281, P14596, DOI 10.1074/jbc.M601959200; Huang SF, 1996, AM J PATHOL, V149, P1565; Husson H, 2002, BLOOD, V99, P282, DOI 10.1182/blood.V99.1.282; Jean S, 2001, BBA-GENE STRUCT EXPR, V1522, P89, DOI 10.1016/S0167-4781(01)00326-8; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lee YM, 2006, CELL CYCLE, V5, P2110, DOI 10.4161/cc.5.18.3218; Li HY, 2006, CANCER RES, V66, P11399, DOI 10.1158/0008-5472.CAN-06-2386; Li ZP, 2006, CELL CYCLE, V5, P2440, DOI 10.4161/cc.5.21.3428; Liegl B, 2008, J PATHOL, V216, P64, DOI 10.1002/path.2382; Mariani O, 2007, CANCER CELL, V11, P361, DOI 10.1016/j.ccr.2007.02.007; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Motegi A, 2005, PATHOL INT, V55, P106, DOI 10.1111/j.1440-1827.2005.01806.x; Ou WB, 2008, ONCOGENE, V27, P5624, DOI 10.1038/onc.2008.177; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; Pruneri G, 2003, MODERN PATHOL, V16, P886, DOI 10.1097/01.MP.0000085026.38856.B9; Rubin BP, 2001, CANCER RES, V61, P8118; Serrano C, 2015, J CLIN ONCOL, V33, pE93, DOI 10.1200/JCO.2013.48.7488; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siegmund K, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0100-3; Snyder EL, 2009, J PATHOL, V218, P292, DOI 10.1002/path.2564; Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x; Thomazy VA, 2002, J MOL DIAGN, V4, P201, DOI 10.1016/S1525-1578(10)60704-0; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Yang PP, 2016, ONCOTARGET, V7, P32652, DOI 10.18632/oncotarget.8999; Zhu MJ, 2007, ONCOGENE, V26, P6386, DOI 10.1038/sj.onc.1210464	54	18	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2019	38	39					6615	6629		10.1038/s41388-019-0894-3	http://dx.doi.org/10.1038/s41388-019-0894-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JA5AQ	31371779				2022-12-17	WOS:000487856000004
J	Sun, B; Zhao, XD; Ming, JG; Liu, X; Liu, DM; Jiang, CL				Sun, Bo; Zhao, Xudong; Ming, Jianguang; Liu, Xing; Liu, Daming; Jiang, Chuanlu			Stepwise detection and evaluation reveal miR-10b and miR-222 as a remarkable prognostic pair for glioblastoma	ONCOGENE			English	Article							GLIOMA-CELLS; PTEN; APOPTOSIS; P53; EXPRESSION; PATHWAY; MDM2; TEMOZOLOMIDE; SUPPRESSION; P27(KIP1)	Despite the existence of many clinical and molecular factors reported that contribute to survival in glioblastoma, prevailing studies fell into partial or local feature selection for survival analysis. We proposed a feature selection strategy including not only joint covariate detection but also its evaluations, and performed it on miRNA expression profiles with glioblastoma. MiR-10b and miR-222 were selected as the most significant two-dimensional feature. Crucially, we integrated in vitro experiments on GBM cells and in vivo studies on a mouse model of human glioma to elucidate the synergistic effects between miR-10b and miR-222. Inhibition of miR-10b and miR-222 strongly suppress GBM cells growth, invasion, and induce apoptosis by co-targeting PTEN and leading to activation of p53 ultimately. We also demonstrated that miR-10b and miR-222 co-target BIM to induce apoptosis independent of p53 status. The results define mir-10b and mir-222 important roles in gliomagenesis and provided a reliable survival analysis strategy.	[Sun, Bo; Ming, Jianguang; Liu, Daming; Jiang, Chuanlu] Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin 150086, Heilongjiang, Peoples R China; [Zhao, Xudong] Northeast Forestry Univ, Coll Informat & Comp Engn, Harbin 150040, Heilongjiang, Peoples R China; [Liu, Xing] Beijing Neurosurg Inst, Beijing 100050, Peoples R China	Harbin Medical University; Northeast Forestry University - China; Beijing Neurosurgical Institute	Jiang, CL (corresponding author), Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin 150086, Heilongjiang, Peoples R China.; Zhao, XD (corresponding author), Northeast Forestry Univ, Coll Informat & Comp Engn, Harbin 150040, Heilongjiang, Peoples R China.	zhaoxudong@nefu.edu.cn; jcl6688@163.com			National Key Research and Development Plan [2016YFC0902500]; National Natural Science Foundation of China [81702972, 81572701, 81772666]; Special Fund Project of Translational Medicine in the Chinese-Russian Medical Research Center [CR201417]; Fundamental Research Funds for the Central Universities [2572018BH01]; Specialized Personnel Start-up Grant [41113237]	National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Special Fund Project of Translational Medicine in the Chinese-Russian Medical Research Center; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Specialized Personnel Start-up Grant	This work is supported by the National Key Research and Development Plan (No. 2016YFC0902500); the National Natural Science Foundation of China (No. 81702972, No. 81572701, and No. 81772666); the Special Fund Project of Translational Medicine in the Chinese-Russian Medical Research Center (No. CR201417). Besides, Xudong Zhao would like to thank the financial support of Fundamental Research Funds for the Central Universities (No. 2572018BH01) and Specialized Personnel Start-up Grant (No. 41113237).	Bahena-Ocampo I, 2016, EMBO REP, V17, P648, DOI 10.15252/embr.201540678; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chang CJ, 2004, J BIOL CHEM, V279, P29841, DOI 10.1074/jbc.M401488200; Chen HY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0435-y; Chen LC, 2012, ONCOL REP, V27, P854, DOI 10.3892/or.2011.1535; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng W, 2015, ONCOTARGET, V6, P29285, DOI 10.18632/oncotarget.4978; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Chow LML, 2011, CANCER CELL, V19, P305, DOI 10.1016/j.ccr.2011.01.039; COX DR, 1972, J R STAT SOC B, V34, P187; Duda R.O., 2001, PATTERN CLASSIFICATI, V20; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Gabriely G, 2011, CANCER RES, V71, P3563, DOI 10.1158/0008-5472.CAN-10-3568; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Han B, 2017, AGING-US, V9, P1885, DOI 10.18632/aging.101271; Hombach-Klonisch S, 2018, PHARMACOL THERAPEUT, V184, P13, DOI 10.1016/j.pharmthera.2017.10.017; Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169; Ji YC, 2015, TUMOR BIOL, V36, P4461, DOI 10.1007/s13277-015-3086-y; Kim J, 2014, CANCER RES, V74, P1541, DOI 10.1158/0008-5472.CAN-13-1449; Klein JP, 2014, CH CRC HANDB MOD STA, P1; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Liu X, 2014, ONCOTARGET, V5, P11681, DOI 10.18632/oncotarget.2585; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Ming JG, 2017, AGING-US, V9, P1233, DOI 10.18632/aging.101224; Mure H, 2010, NEURO-ONCOLOGY, V12, P221, DOI 10.1093/neuonc/nop026; Niyazi M, 2016, ONCOTARGET, V7, P45764, DOI 10.18632/oncotarget.9945; Niyazi M, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-153; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Srinivasan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017438; Suh SS, 2012, P NATL ACAD SCI USA, V109, P5316, DOI 10.1073/pnas.1202465109; Sun CQ, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3017948; Terasawa K, 2009, FEBS J, V276, P3269, DOI 10.1111/j.1742-4658.2009.07041.x; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403; Wu YW, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-017-4327-9; Zhang CZ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-367; Zhang CZ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-119; Zhang W, 2012, NEURO-ONCOLOGY, V14, P712, DOI 10.1093/neuonc/nos089; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	45	18	19	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2019	38	33					6142	6157		10.1038/s41388-019-0867-6	http://dx.doi.org/10.1038/s41388-019-0867-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IR6TP	31289362	Green Published, hybrid			2022-12-17	WOS:000481572400005
J	Seshacharyulu, P; Rachagani, S; Muniyan, S; Siddiqui, JA; Cruz, E; Sharma, S; Krishnan, R; Killips, BJ; Sheinin, Y; Lele, SM; Smith, LM; Talmon, GA; Ponnusamy, MP; Datta, K; Batra, SK				Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana; Muniyan, Sakthivel; Siddiqui, Jawed A.; Cruz, Eric; Sharma, Sunandini; Krishnan, Ramakrishnan; Killips, Brigham J.; Sheinin, Yuri; Lele, Subodh M.; Smith, Lynette M.; Talmon, Geoffrey A.; Ponnusamy, Moorthy P.; Datta, Kaustubh; Batra, Surinder K.			FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis	ONCOGENE			English	Article							FARNESYL PYROPHOSPHATE SYNTHASE; ZOLEDRONIC ACID; IN-VITRO; CELL-PROLIFERATION; ISOPRENOID PATHWAY; BINDING; INHIBITION; EXPRESSION; TARGET; BISPHOSPHONATE	Farnesyl diphosphate synthase (FDPS), a mevalonate pathway enzyme, is highly expressed in several cancers, including prostate cancer (PCa). To date, the mechanistic, functional, and clinical significance of FDPS in cancer remains unexplored. We evaluated the FDPS expression and its cancer-associated phenotypes using in vitro and in vivo methods in PTEN-deficient and sufficient human and mouse PCa cells and tumors. Interestingly, FDPS overexpression synergizes with PTEN deficiency in PTEN conditionally knockout mice (P < 0.05) and expressed significantly higher in human (P < 0.001) PCa tissues, cell lines, and murine tumoroids compared to respective controls. In silico analysis revealed that FDPS is associated with increasing Gleason score, PTEN functionally deficient status, and poor survival of PCa. Ectopic overexpression of FDPS promotes oncogenic phenotypes such as colony formation (P < 0.01) and proliferation (P < 0.01) through activation of AKT and ERK signaling by prenylating Rho A, Rho G, and CDC42 small GTPases. Of interest, knockdown of FDPS in PCa cells exhibits decreased colony growth and proliferation (P < 0.001) by modulating AKT and ERK pathways. Further, genetic and pharmacological inhibition of PI3K but not AKT reduced FDPS expression. Pharmacological targeting of FDPS by zoledronic acid (ZOL), which is already in clinics, exhibit reduced growth and clonogenicity of human and murine PCa cells (P < 0.01) and 3D tumoroids (P < 0.02) by disrupting AKT and ERK signaling through direct interference of small GTPases protein prenylation. Thus, FDPS plays an oncogenic role in PTEN-deficient PCa through GTPase/AKT axis. Identifying mevalonate pathway proteins could serve as a therapeutic target in PTEN dysregulated tumors.	[Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana; Muniyan, Sakthivel; Siddiqui, Jawed A.; Cruz, Eric; Sharma, Sunandini; Krishnan, Ramakrishnan; Killips, Brigham J.; Ponnusamy, Moorthy P.; Datta, Kaustubh; Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Sheinin, Yuri; Lele, Subodh M.; Talmon, Geoffrey A.; Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Smith, Lynette M.] Univ Nebraska Med Ctr, Dept Stat, Omaha, NE USA; [Ponnusamy, Moorthy P.; Datta, Kaustubh; Batra, Surinder K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Siddiqui, Jawed/G-9258-2017; Muniyan, Sakthivel/L-3868-2019; Seshacharyulu, Parthasarathy/AGL-7648-2022; Krishnan, Ramakrishnan/AAX-6627-2020	Siddiqui, Jawed/0000-0003-1287-3004; Muniyan, Sakthivel/0000-0001-9405-7857; Seshacharyulu, Parthasarathy/0000-0002-2348-3901; 	United States Department of Defense [PC170891]; National Institutes of Health [P01 CA217798, UO1 CA185148, 1R01CA182435-01A1, P30 GM106397]; NATIONAL CANCER INSTITUTE [U01CA185148, P01CA217798] Funding Source: NIH RePORTER	United States Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work/authors are supported, in parts, by the grants from the United States Department of Defense Grant PC170891, National Institutes of Health (P01 CA217798, UO1 CA185148 and 1R01CA182435-01A1) and P30 GM106397.	Abate M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14495-6; Algur E, 2005, INT J RADIAT ONCOL, V61, P535, DOI 10.1016/j.ijrobp.2004.09.065; Allott EH, 2014, CANCER EPIDEM BIOMAR, V23, P2349, DOI 10.1158/1055-9965.EPI-14-0458; Bastian PJ, 2012, EUR UROL, V61, P1096, DOI 10.1016/j.eururo.2012.02.031; Beier F, 2010, J CELL BIOCHEM, V110, P573, DOI 10.1002/jcb.22604; Bifulco M, 2005, LIFE SCI, V77, P1740, DOI 10.1016/j.lfs.2005.05.017; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen M, 2018, NAT GENET, V50, P206, DOI 10.1038/s41588-017-0027-2; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; Dhar MK, 2013, NEW BIOTECHNOL, V30, P114, DOI 10.1016/j.nbt.2012.07.001; Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gritzalis D, 2015, BIOORG MED CHEM LETT, V25, P1117, DOI 10.1016/j.bmcl.2014.12.089; Hatziieremia S, 2016, MOL CARCINOGEN, V55, P1667, DOI 10.1002/mc.22417; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Hein AL, 2016, CANCER RES, V76, P2243, DOI 10.1158/0008-5472.CAN-15-2119; Hirschey MD, 2015, SEMIN CANCER BIOL, V35, pS129, DOI 10.1016/j.semcancer.2015.10.002; Ishimoto K, 2010, BIOCHEM J, V429, P347, DOI 10.1042/BJ20091511; Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727; Karabulut B, 2009, CELL BIOL INT, V33, P239, DOI 10.1016/j.cellbi.2008.11.011; Kaushik G, 2018, STEM CELLS, V36, P1329, DOI 10.1002/stem.2852; Kijima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064615; Kwak MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053476; Lakshmanan I, 2016, ONCOGENE, V35, P4112, DOI 10.1038/onc.2015.478; Leon CG, 2010, PROSTATE, V70, P390, DOI 10.1002/pros.21072; Li L, 2010, BIOCHEM PHARMACOL, V79, P399, DOI 10.1016/j.bcp.2009.08.033; Liao Chun-Peng, 2010, Hormones & Cancer, V1, P44, DOI 10.1007/s12672-009-0005-y; Long Q, 2014, CANCER RES, V74, P3228, DOI 10.1158/0008-5472.CAN-13-2699; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; Muniyan S, 2015, CELL SIGNAL, V27, P2261, DOI 10.1016/j.cellsig.2015.08.002; Neville-Webbe HL, 2010, BRIT J CANCER, V102, P1010, DOI 10.1038/sj.bjc.6605579; Ottewell PD, 2008, JNCI-J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240; Ozturk OH, 2007, CELL BIOL INT, V31, P1069, DOI 10.1016/j.cellbi.2007.02.004; Reilly JE, 2017, CANCER BIOL THER, V18, P872, DOI 10.1080/15384047.2016.1219817; Sharon C, 2015, ONCOTARGET, V6, P15332, DOI 10.18632/oncotarget.3684; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Souchek JJ, 2014, BRIT J CANCER, V111, P1139, DOI 10.1038/bjc.2014.385; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Taylor LG, 2009, CANCER-AM CANCER SOC, V115, P2388, DOI 10.1002/cncr.24283; Todenhofer T, 2013, WORLD J UROL, V31, P345, DOI 10.1007/s00345-012-0844-y; Ullen A, 2005, ACTA ONCOL, V44, P644, DOI 10.1080/02841860510029617; Wang J, 2008, J PROTEOME RES, V7, P3879, DOI 10.1021/pr8001645; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019	50	18	20	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5265	5280		10.1038/s41388-019-0791-9	http://dx.doi.org/10.1038/s41388-019-0791-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30914801	Green Accepted			2022-12-17	WOS:000473025300011
J	Kim, BR; Park, SH; Jeong, YA; Na, YJ; Kim, JL; Jo, MJ; Jeong, S; Yun, HK; Oh, SC; Lee, DH				Kim, Bo Ram; Park, Seong Hye; Jeong, Yoon A.; Na, Yoo Jin; Kim, Jung Lim; Jo, Min Jee; Jeong, Soyeon; Yun, Hye Kyeong; Oh, Sang Cheul; Lee, Dae-Hee			RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; DEATH RECEPTOR 5; LIGAND (TRAIL)-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR RUNX3; NF-KAPPA-B; ER STRESS; MEDIATED APOPTOSIS; TUMOR-SUPPRESSOR; GENE-EXPRESSION; GASTRIC-CANCER	RUNX3 is frequently inactivated by DNA hypermethylation in numerous cancers. Here, we show that RUNX3 has an important role in modulating apoptosis in immediate response to tumor necrosis factor-related apoptosis-including ligand (TRAIL). Importantly, no combined effect of TRAIL and RUNX3 was observed in non-cancerous cells. We investigated the expression of the death receptors (DRs) DR4 and DR5, which are related to TRAIL resistance. Overexpression of RUNX3 increased DR5 expression via induction of the reactive oxygen species (ROS)-endoplasmic reticulum (ER) stress-effector CHOP. Reduction of DR5 markedly decreased apoptosis enhanced by the combined therapy of TRAIL and RUNX3. Interestingly, RUNX3 induced reactive oxygen species production by inhibiting SOD3 transcription via binding to the Superoxide dismutase 3 (SOD3) promoter. Additionally, the combined effect of TRAIL and RUNX3 decreased tumor growth in xenograft models. Our results demonstrate a direct role for RUNX3 in TRAIL-induced apoptosis via activation of DR5 and provide further support for RUNX3 as an anti-tumor.	[Kim, Bo Ram; Kim, Jung Lim; Jeong, Soyeon; Oh, Sang Cheul; Lee, Dae-Hee] Korea Univ, Coll Med, Guro Hosp, Dept Oncol, Seoul, South Korea; [Park, Seong Hye; Jeong, Yoon A.; Na, Yoo Jin; Jo, Min Jee; Yun, Hye Kyeong] Korea Univ, Grad Sch Med, Coll Med, Seoul, South Korea	Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine)	Oh, SC; Lee, DH (corresponding author), Korea Univ, Coll Med, Guro Hosp, Dept Oncol, Seoul, South Korea.	sachoh@korea.ac.kr; neogene@korea.ac.kr			National Research Foundation (NRF) of Korea [NRF-2017R1A6A3A11030765]; Korea University Grant; project for cooperative R&D between Industry, Academy, and Research Institute [Co558375]	National Research Foundation (NRF) of Korea(National Research Foundation of Korea); Korea University Grant; project for cooperative R&D between Industry, Academy, and Research Institute	This work was supported by a National Research Foundation (NRF) of Korea grant funded the Korean government (MSIP) [NRF-2017R1A6A3A11030765] and was supported by Korea University Grant and was supported by project for cooperative R&D between Industry, Academy, and Research Institute funded Korea ministry of SMES and Startups in 2018 [Grants No. Co558375].	Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Dufour F, 2017, ONCOTARGET, V8, P9974, DOI 10.18632/oncotarget.14285; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Fritsche H, 2015, ONCOTARGET, V6, P9502, DOI 10.18632/oncotarget.3321; Fukai T, 2011, ANTIOXID REDOX SIGN, V15, P1583, DOI 10.1089/ars.2011.3999; Gan HC, 2016, AM J PHYSIOL-LUNG C, V311, pL1101, DOI 10.1152/ajplung.00278.2016; Gan HC, 2015, SCI REP-UK, V5, DOI 10.1038/srep17916; Giambra V, 2012, NAT MED, V18, P1693, DOI 10.1038/nm.2960; Glab JA, 2017, CELL DEATH DIFFER, V24, P944, DOI 10.1038/cdd.2017.53; Guha P, 2017, ONCOTARGET, V8, P68191, DOI 10.18632/oncotarget.19277; Harashima N, 2017, ONCOTARGET, V8, P42887, DOI 10.18632/oncotarget.17157; Hartwig T, 2017, MOL CELL, V65, P730, DOI 10.1016/j.molcel.2017.01.021; He K, 2016, ONCOGENE, V35, P148, DOI 10.1038/onc.2015.79; He L, 2013, MOL CARCINOGEN, V52, P85, DOI 10.1002/mc.21831; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Iurlaro R, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00479-16; Jiang YN, 2017, MOL IMMUNOL, V82, P123, DOI 10.1016/j.molimm.2016.12.023; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Jung EM, 2005, CARCINOGENESIS, V26, P1905, DOI 10.1093/carcin/bgi167; Kadara H, 2007, CANCER BIOL THER, V6, P705, DOI 10.4161/cbt.6.5.3963; Kandasamy K, 2002, CANCER RES, V62, P4929; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kapur A, 2016, SCI REP-UK, V6, DOI 10.1038/srep27530; Kim BR, 2016, ONCOL REP, V36, P2601, DOI 10.3892/or.2016.5086; Kim BR, 2017, ONCOTARGET, V8; Kodach LL, 2010, CARCINOGENESIS, V31, P1567, DOI 10.1093/carcin/bgq147; Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee DH, 2016, J CELL BIOCHEM, V117, P1078, DOI 10.1002/jcb.25289; Lee DH, 2014, TOXICOL APPL PHARM, V279, P253, DOI 10.1016/j.taap.2014.06.030; Lee DH, 2009, BRIT J PHARMACOL, V157, P1189, DOI 10.1111/j.1476-5381.2009.00245.x; Lee JH, 2011, CLIN EXP DERMATOL, V36, P769, DOI 10.1111/j.1365-2230.2011.04069.x; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li TL, 2015, J BIOL CHEM, V290, P11108, DOI 10.1074/jbc.M115.645333; Lim JH, 2009, CARCINOGENESIS, V30, P729, DOI 10.1093/carcin/bgn265; Liu ZX, 2016, CHEM RES TOXICOL, V29, P1510, DOI 10.1021/acs.chemrestox.6b00181; Lotem J, 2015, BBA-REV CANCER, V1855, P131, DOI 10.1016/j.bbcan.2015.01.004; Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312; Ma ZQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep35196; Na YJ, 2017, INT J BIOCHEM CELL B, V89, P147, DOI 10.1016/j.biocel.2017.06.010; Pal S, 2016, CANCER MICROENVIRON, V9, P77, DOI 10.1007/s12307-016-0184-3; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park HS, 2011, BIOCHEM PHARMACOL, V82, P1110, DOI 10.1016/j.bcp.2011.07.085; Park SH, 2016, ONCOTARGET, V7, P59503, DOI 10.18632/oncotarget.11147; Prasad S, 2014, TRENDS PHARMACOL SCI, V35, P520, DOI 10.1016/j.tips.2014.07.004; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Shi K, 2017, THERANOSTICS, V7, P4480, DOI 10.7150/thno.21707; Tian XB, 2011, J BIOL CHEM, V286, P29408, DOI 10.1074/jbc.M110.197665; Toscano F, 2008, ONCOGENE, V27, P4161, DOI 10.1038/onc.2008.52; von Karstedt S, 2015, CANCER CELL, V27, P561, DOI 10.1016/j.ccell.2015.02.014; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Yang F, 2010, CELL DEATH DIFFER, V17, P1354, DOI 10.1038/cdd.2010.29; Zhang KZ, 2010, INT J CLIN EXP MED, V3, P33; ZLOTORYNSKI E, 2014, NAT REV MOL CELL BIO, V15, P498	61	18	20	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3903	3918		10.1038/s41388-019-0693-x	http://dx.doi.org/10.1038/s41388-019-0693-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692634				2022-12-17	WOS:000468035600010
J	Flood, B; Manils, J; Nulty, C; Flis, E; Kenealy, S; Barber, G; Fay, J; Mills, KHG; Kay, EW; Creagh, EM				Flood, Brian; Manils, Joan; Nulty, Ciara; Flis, Ewelina; Kenealy, Sinead; Barber, Gillian; Fay, Joanna; Mills, Kingston H. G.; Kay, Elaine W.; Creagh, Emma M.			Caspase-11 regulates the tumour suppressor function of STAT1 in a murine model of colitis-associated carcinogenesis	ONCOGENE			English	Article							NONCANONICAL INFLAMMASOME ACTIVATION; CELL-PROLIFERATION; INTERFERON-ALPHA; COLON; ANGIOGENESIS; EXPRESSION; LIPOPOLYSACCHARIDE; TUMORIGENESIS; PYROPTOSIS; INNATE	Murine inflammatory caspase-11 has an important role in intestinal epithelial inflammation and barrier function. Activation of the non-canonical inflammasome, mediated by caspase-11, serves as a regulatory pathway for the production of the proinflammatory cytokines IL-1 beta and IL-18, and has a key role in pyroptotic cell death. We have previously demonstrated a protective role for caspase-11 during dextran sulphate sodium (DSS)-induced colitis, however the importance of caspase-11 during colorectal tumour development remains unclear. Here, we show that Casp11(-1-) mice are highly susceptible to the azoxymethane (AOM)-DSS model of colitis-associated cancer (CAC), compared to their wild type (WT) littermates. We show that deficient IL-18 production occurs at initial inflammation stages of disease, and that IL-1 beta production is more significantly impaired in Casp11(-1-) colons during established CAC. We identify defective STAT1 activation in Casp11(-)(1-) colons during disease progression, and show that IL-1 beta signalling induces caspase-11 expression and STAT1 activation in primary murine macrophages and intestinal epithelial cells. These findings uncover an anti-tumour role for the caspase-11 and the non-canonical inflammasome during CAC, and suggest a critical role for caspase-11, linking IL-1 beta and STAT1 signalling pathways.	[Flood, Brian; Manils, Joan; Nulty, Ciara; Flis, Ewelina; Kenealy, Sinead; Barber, Gillian; Mills, Kingston H. G.; Creagh, Emma M.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Dublin 2, Ireland; [Fay, Joanna; Kay, Elaine W.] Royal Coll Surgeons Ireland, Dublin 9, Ireland; [Fay, Joanna; Kay, Elaine W.] Beaumont Hosp, Dublin 9, Ireland	Trinity College Dublin; Royal College of Surgeons - Ireland	Creagh, EM (corresponding author), Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Dublin 2, Ireland.	ecreagh@tcd.ie	Creagh, Emma/AAX-1064-2021; Manils, Joan/I-1258-2015; Mills, Kingston H/F-5684-2013; Manils, Joan/ABC-7884-2021	Creagh, Emma/0000-0001-7631-4370; Manils, Joan/0000-0001-8429-1295; Mills, Kingston H/0000-0003-3646-8222; Manils, Joan/0000-0001-8429-1295; Barber, Gillian/0000-0002-6909-6042	Enterprise Ireland [CF-2015-0061P]; Government of Ireland PRTLI PhD programme [201921, 12259]; EU [721906]; SFI Investigator programme [12/IP/1400]	Enterprise Ireland; Government of Ireland PRTLI PhD programme; EU(European Commission); SFI Investigator programme(Science Foundation Ireland)	We thank the J. Yuan laboratory (Harvard Medical School) for the provision of Caspase-11<SUP>-/-</SUP> mice; and the technical staff of the Comparative Medicine Unit, TCD for their assistance in the backcrossing and breeding of these mice. This study was supported by Enterprise Ireland (CF-2015-0061P). B.F. was supported by a Government of Ireland PRTLI PhD programme (scheme #201921, award #12259). E.F. is an Early Stage Researcher of the EU Horizon 2020 Research and Innovation Programme, TRACT (Marie Sklodowska-Curie grant agreement No 721906). S.K. is funded by an SFI Investigator programme grant (12/IP/1400).	Aachoui Y, 2013, SCIENCE, V339, P975, DOI 10.1126/science.1230751; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Asquith M, 2010, J EXP MED, V207, P1573, DOI 10.1084/jem.20101330; Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721; Bhattacharyya S, 2011, P NATL ACAD SCI USA, V108, P9554, DOI 10.1073/pnas.1017296108; BIASCO G, 1990, CANCER RES, V50, P1156; Boucher D, 2018, J EXP MED, V215, P827, DOI 10.1084/jem.20172222; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Broz P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003144; Carmi Y, 2011, J IMMUNOL, V186, P3462, DOI 10.4049/jimmunol.1002901; Case CL, 2013, P NATL ACAD SCI USA, V110, P1851, DOI 10.1073/pnas.1211521110; Chan SR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3100; Chen GY, 2011, J IMMUNOL, V186, P7187, DOI 10.4049/jimmunol.1100412; Creagh EM, 2014, TRENDS IMMUNOL, V35, P631, DOI 10.1016/j.it.2014.10.004; Crncec I, 2018, MOL ONCOL, V12, P514, DOI 10.1002/1878-0261.12178; Demon D, 2014, MUCOSAL IMMUNOL, V7, P1504, DOI 10.1038/mi.2014.83; Dempoya J, 2012, J VIROL, V86, P12760, DOI 10.1128/JVI.01881-12; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Flood B, 2015, CLIN EXP IMMUNOL, V181, P39, DOI 10.1111/cei.12617; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Fung KYC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120425; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gkouskou KK, 2016, ONCOGENE, V35, P2496, DOI 10.1038/onc.2015.307; Gurung P, 2012, J BIOL CHEM, V287, P16955; Hagar JA, 2013, SCIENCE, V341, P1250, DOI 10.1126/science.1240988; Hou J, 2014, CANCER CELL, V25, P49, DOI 10.1016/j.ccr.2013.11.011; Hu B, 2013, P NATL ACAD SCI USA, V110, P9862, DOI 10.1073/pnas.1307575110; Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108; Huang SY, 2002, ONCOGENE, V21, P2504, DOI 10.1038/sj.onc.1205341; Hur J, 2001, FEBS LETT, V507, P157, DOI 10.1016/S0014-5793(01)02975-1; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kalerl P, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00088; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Lopez-Pastrana J, 2015, J BIOL CHEM, V290, P17485, DOI 10.1074/jbc.M115.641191; Ma YH, 2016, ONCOTARGET, V7, P73003, DOI 10.18632/oncotarget.12193; Man SM, 2015, CELL, V162, P45, DOI 10.1016/j.cell.2015.06.001; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Mattarollo SR, 2011, CANCER RES, V71, P4809, DOI 10.1158/0008-5472.CAN-11-0753; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Nivarthi H, 2016, ONCOTARGET, V7, P51096, DOI 10.18632/oncotarget.9315; Normand S, 2011, P NATL ACAD SCI USA, V108, P9601, DOI 10.1073/pnas.1100981108; Oficjalska K, 2015, J IMMUNOL, V194, P1252, DOI 10.4049/jimmunol.1400501; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Peterson JE, 2012, ANGIOGENESIS, V15, P265, DOI 10.1007/s10456-012-9259-z; Rathinam VAK, 2012, CELL, V150, P606, DOI 10.1016/j.cell.2012.07.007; Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199; Schauvliege R, 2002, J BIOL CHEM, V277, P41624, DOI 10.1074/jbc.M207852200; Simpson JAD, 2010, GUT, V59, P926, DOI 10.1136/gut.2009.194472; Tattoli I, 2016, CELL REP, V14, P2576, DOI 10.1016/j.celrep.2016.02.065; Williams TM, 2015, J IMMUNOL, V194, P3369, DOI 10.4049/jimmunol.1402098; Williams TM, 2015, AM J PHYSIOL-GASTR L, V308, pG139, DOI 10.1152/ajpgi.00234.2014; Wilson JE, 2015, NAT MED, V21, P906, DOI 10.1038/nm.3908; Wu XL, 2014, WORLD J GASTROENTERO, V20, P10440, DOI 10.3748/wjg.v20.i30.10440; Yuasa K, 2016, GENES CELLS, V21, P25, DOI 10.1111/gtc.12316; Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046	62	18	20	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2658	2674		10.1038/s41388-018-0613-5	http://dx.doi.org/10.1038/s41388-018-0613-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30538296	Green Published, hybrid			2022-12-17	WOS:000463335200015
J	Frazier, NM; Brand, T; Gordan, JD; Grandis, J; Jura, N				Frazier, Nicole Michael; Brand, Toni; Gordan, John D.; Grandis, Jennifer; Jura, Natalia			Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SCATTER FACTOR-RECEPTOR; C-MET; LUNG-CANCER; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GENE AMPLIFICATION; CRYSTAL-STRUCTURE; PROGNOSTIC-SIGNIFICANCE; NUCLEAR MET	Ligand-dependent oligomerization of receptor tyrosine kinases (RTKs) results in their activation through highly specific conformational changes in the extracellular and intracellular receptor domains. These conformational changes are unique for each RTK subfamily, limiting cross-activation between unrelated RTKs. The proto-oncogene MET receptor tyrosine kinase overcomes these structural constraints and phosphorylates unrelated RTKs in numerous cancer cell lines. The molecular basis for these interactions is unknown. We investigated the mechanism by which MET phosphorylates the human epidermal growth factor receptor-3 (HER3 or ERBB3), a catalytically impaired RTK whose phosphorylation by MET has been described as an essential component of drug resistance to inhibitors targeting EGFR and HER2. We find that in untransformed cells, HER3 is not phosphorylated by MET in response to ligand stimulation, but rather to increasing levels of MET expression, which results in ligand-independent MET activation. Phosphorylation of HER3 by its canonical coreceptors, EGFR and HER2, is achieved by engaging an allosteric site on the HER3 kinase domain, but this site is not required when HER3 is phosphorylated by MET. We also observe that HER3 preferentially interacts with MET during its maturation along the secretory pathway, before MET is post translationally processed by cleavage within its extracellular domain. This results in accumulation of phosphorylated HER3 in the Golgi apparatus. We further show that in addition to HER3, MET phosphorylates other RTKs in the Golgi, suggesting that this mechanism is not limited to HER3 phosphorylation. These data demonstrate a link between MET overexpression and its aberrant activation in the Golgi endomembranes and suggest that non-canonical interactions between MET and other RTKs occur during maturation of receptors. Our study highlights a novel aspect of MET signaling in cancer that would not be accessible to inhibition by therapeutic antibodies.	[Frazier, Nicole Michael; Jura, Natalia] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA; [Brand, Toni; Grandis, Jennifer] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94113 USA; [Gordan, John D.] Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA 94158 USA; [Jura, Natalia] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Jura, N (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.	natalia.jura@ucsf.edu		Frazier, Nicole/0000-0002-9499-1938	National Institute of General Medical Sciences [R01 GM109176]; Susan G. Komen Foundation [CCR14299947]; Lung Cancer Research Foundation; National Institute of Dental and Craniofacial Research [R01 DE023685]; NATIONAL CANCER INSTITUTE [R35CA231998, R01CA098372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM109176, T32GM007810] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Lung Cancer Research Foundation; National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank M. Moasser for insightful discussions and members of the Jura lab for valuable discussions and input on experimental design and execution. This work was supported partially by the grant from the National Institute of General Medical Sciences to N.J. (R01 GM109176), Susan G. Komen Foundation Career Catalyst Research Grant to N.J. (CCR14299947), Lung Cancer Research Foundation Grant to N.J. and the grant from National Institute of Dental and Craniofacial Research to J.G. (R01 DE023685).	Agarwal S, 2009, BRIT J CANCER, V100, P941, DOI 10.1038/sj.bjc.6604937; Beji A, 2012, CLIN CANCER RES, V18, P956, DOI 10.1158/1078-0432.CCR-11-1186; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bougherara H, 2009, MOL CANCER RES, V7, P1525, DOI 10.1158/1541-7786.MCR-09-0138; Casadevall D, 2015, ONCOTARGET, V6, P16215, DOI 10.18632/oncotarget.3976; Chen R, 2013, J CELL BIOCHEM, V114, P816, DOI 10.1002/jcb.24420; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Cignetto S, 2016, MOL ONCOL, V10, P938, DOI 10.1016/j.molonc.2016.03.004; Citores L, 2007, J CELL PHYSIOL, V212, P148, DOI 10.1002/jcp.21014; Coleman DT, 2016, ONCOTARGET, V7, P32664, DOI 10.18632/oncotarget.8706; Dawson JP, 2005, MOL CELL BIOL, V25, P7734, DOI 10.1128/MCB.25.17.7734-7742.2005; Dieras V, 2015, ANN ONCOL, V26, P1904, DOI 10.1093/annonc/mdv263; Dimou A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107677; Du ZQ, 2016, MOL CANCER THER, V15, P1227, DOI 10.1158/1535-7163.MCT-15-0745; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gherardi E, 2003, P NATL ACAD SCI USA, V100, P12039, DOI 10.1073/pnas.2034936100; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Jura N, 2009, P NATL ACAD SCI USA, V106, P21608, DOI 10.1073/pnas.0912101106; Jura N, 2009, CELL, V137, P1293, DOI 10.1016/j.cell.2009.04.025; Kataoka Y, 2012, INVEST NEW DRUG, V30, P1352, DOI 10.1007/s10637-011-9699-0; Kavran JM, 2014, ELIFE, V3, DOI 10.7554/eLife.03772; Kermorgant S, 2003, J BIOL CHEM, V278, P28921, DOI 10.1074/jbc.M302116200; Kermorgant S, 2008, J CELL BIOL, V182, P855, DOI 10.1083/jcb.200806076; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kim KH, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.17; Kim SM, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.48; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; Lefebvre J, 2012, FASEB J, V26, P1387, DOI 10.1096/fj.11-197723; Li AN, 2015, LUNG CANCER, V90, P375, DOI 10.1016/j.lungcan.2015.10.021; Li YQ, 2015, ONCOTARGET, V6, P13309, DOI 10.18632/oncotarget.3751; Liu SY, 2016, ONCOTARGET, V7, P11251, DOI 10.18632/oncotarget.7081; Liu XD, 2011, CLIN CANCER RES, V17, P7127, DOI 10.1158/1078-0432.CCR-11-1157; Mazot P, 2011, ONCOGENE, V30, P2017, DOI 10.1038/onc.2010.595; McKern NM, 2006, NATURE, V443, P218, DOI 10.1038/nature05106; Menting JG, 2013, NATURE, V493, P241, DOI 10.1038/nature11781; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Rosen LS, 2017, CLIN CANCER RES, V23, P1910, DOI 10.1158/1078-0432.CCR-16-1418; Ruco LP, 1996, J PATHOL, V180, P266, DOI 10.1002/(SICI)1096-9896(199611)180:3<266::AID-PATH658>3.0.CO;2-Q; Schmidt-Arras DE, 2005, MOL CELL BIOL, V25, P3690, DOI 10.1128/MCB.25.9.3690-3703.2005; Seiwert TY, 2009, CANCER RES, V69, P3021, DOI 10.1158/0008-5472.CAN-08-2881; Shah MA, 2017, JAMA ONCOL, V3, P620, DOI 10.1001/jamaoncol.2016.5580; Shah MA, 2016, ONCOLOGIST, V21, P1085, DOI 10.1634/theoncologist.2016-0038; Shi PY, 2016, CANCER LETT, V380, P494, DOI 10.1016/j.canlet.2016.07.021; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Song ZB, 2017, CLIN LUNG CANCER, V18, P213, DOI 10.1016/j.cllc.2016.09.011; Stamos J, 2004, EMBO J, V23, P2325, DOI 10.1038/sj.emboj.7600243; Steinway SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128159; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Tabone-Eglinger S, 2008, CLIN CANCER RES, V14, P2285, DOI 10.1158/1078-0432.CCR-07-4102; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; Tanizaki J, 2011, BRIT J CANCER, V105, P807, DOI 10.1038/bjc.2011.322; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; Tey SK, 2017, CANCER LETT, V411, P150, DOI 10.1016/j.canlet.2017.09.047; Xie YQ, 2014, MOL ENDOCRINOL, V28, P1629, DOI 10.1210/me.2014-1078; Yan SC, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0296-y; Yun C, 2015, MOL CARCINOGEN, V54, P1700, DOI 10.1002/mc.22241; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; ZHU H, 1994, J BIOL CHEM, V269, P29943; Zhu LY, 2016, J CELL SCI, V129, P4238, DOI 10.1242/jcs.191684	69	18	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1936	1950		10.1038/s41388-018-0537-0	http://dx.doi.org/10.1038/s41388-018-0537-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30390071	Green Accepted			2022-12-17	WOS:000461164400011
J	Zhong, YC; Yang, S; Wang, W; Wei, PP; He, SW; Ma, HT; Yang, J; Wang, Q; Cao, LQ; Xiong, W; Zhou, M; Li, GY; Shuai, CJ; Peng, SP				Zhong, Yancheng; Yang, Sheng; Wang, Wei; Wei, Pingpin; He, Shiwei; Ma, Haotian; Yang, Juan; Wang, Qian; Cao, Lanqin; Xiong, Wei; Zhou, Ming; Li, Guiyuan; Shuai, Cijun; Peng, Shuping			The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; STEM-CELLS; RHO-KINASE; ROCK2; RNA; EXPRESSION; REGULATOR; PROMOTES; PROLIFERATION	Ovarian cancer (OC) is the leading cause of death among women with gynecologic malignant diseases, however, the molecular mechanism of ovarian cancer is not well defined. Previous studies have found that RNA binding protein Lin28A is a key factor of maintain the pluripotency of stem cells, and it is positively correlated with the degree of several cancers (breast, prostate, liver cancer, etc). Our previous study shows that Lin28A is highly expressed in OC tissues and is involved in the regulation of OC cell biological behavior. In this study, we confirmed that high expression of Lin28A promoted the survival, invasion, metastasis, and inhibited the apoptosis of OC cells. Lin28A interacts with Rho associated coiled-coil containing protein kinase2 (ROCK2) but not ROCK1 and upregulates the expression of ROCK2 in OC cells. The binding sites of each other were identified by truncated mutations and Immuno-precipitaion (IP) assay. After knock down of ROCK2 in cells with high expression of Lin28A, the survival, invasion, metastasis was significantly inhibited and early apoptosis was increased in OC cells and OC xenograft in nude mice. Our experimental data also showed that knock down of ROCK2 but not ROCK1 inhibited the invasion by decreasing the expression of N-cadherin, Slug, beta-catenin and increasing ZO-1 expression. Simultaneously, knock down of ROCK2 induced cell apoptosis by increasing cleaved Caspase-9, cleaved Caspase-7, and cleaved Caspase-3. Taken together, Lin28A regulated the biological behaviors in OC cells through ROCK2 and the interaction of Lin28A/ROCK2 may be a new target for diagnosis and gene therapy of OC.	[Zhong, Yancheng; Wei, Pingpin; He, Shiwei; Ma, Haotian; Yang, Juan; Xiong, Wei; Zhou, Ming; Li, Guiyuan; Peng, Shuping] Cent South Univ, Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China; [Zhong, Yancheng; Wei, Pingpin; He, Shiwei; Ma, Haotian; Yang, Juan; Xiong, Wei; Zhou, Ming; Li, Guiyuan; Peng, Shuping] Cent South Univ, Affiliated Tumor Hosp, Xiangya Sch Med, Sch Basic Med Sci, Changsha, Hunan, Peoples R China; [Yang, Sheng] Hongkong Univ, Human Reprod Ctr, Shenzhen Hosp, Haiyuan 1 Rd, Shenzhen, Peoples R China; [Wang, Wei] Jining Med Univ, Pathol Dept, Jining, Shandong, Peoples R China; [Wang, Qian; Cao, Lanqin] Cent South Univ, Dept Gynecol, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Shuai, Cijun] Jiangxi Univ Sci & Technol, Ganzhou 341000, Peoples R China	Central South University; Central South University; Jining Medical University; Central South University; Jiangxi University of Science & Technology	Peng, SP (corresponding author), Cent South Univ, Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China.; Peng, SP (corresponding author), Cent South Univ, Affiliated Tumor Hosp, Xiangya Sch Med, Sch Basic Med Sci, Changsha, Hunan, Peoples R China.	shuping@csu.edu.cn	Shuai, Cijun/AAC-9740-2019	Shuai, Cijun/0000-0002-2029-5112	Natural Science Foundation of China [81572577]; Program of Introducing Talents of Discipline to Universities [111-2-12]; Project of Innovation-driven Plan of Central South University [2016CX023]; Hunan Province Natural Science Foundation of China [2016JJ1027]; Fundamental Research Funds for the Central Universities of Central South University [2017zzts371]; Open-End Fund for the Valuable and Precision Instruments of Central South University; High Resolution Mass Spectrometry Laboratory of Advanced Research Center in Central South University	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of Introducing Talents of Discipline to Universities(Ministry of Education, China - 111 Project); Project of Innovation-driven Plan of Central South University; Hunan Province Natural Science Foundation of China(Natural Science Foundation of Hunan Province); Fundamental Research Funds for the Central Universities of Central South University; Open-End Fund for the Valuable and Precision Instruments of Central South University; High Resolution Mass Spectrometry Laboratory of Advanced Research Center in Central South University	This work was supported by Natural Science Foundation of China (81572577), Program of Introducing Talents of Discipline to Universities (111-2-12), the Project of Innovation-driven Plan of Central South University (2016CX023), the Hunan Province Natural Science Foundation of China (2016JJ1027), the Fundamental Research Funds for the Central Universities of Central South University (2017zzts371), the Open-End Fund for the Valuable and Precision Instruments of Central South University. We thank the Professor Li zheng and Dr. Ge Xiaolu for their help in Mass Spectrometry identification. We also want to gratitude the High Resolution Mass Spectrometry Laboratory of Advanced Research Center in Central South University for the technological assistance in proteomic examinations.	Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472; Ben-Shmuel A, 2013, ONCOGENE, V32, P3220, DOI 10.1038/onc.2012.340; Bhuiyan MIH, 2013, NEUROSCIENCE, V248, P448, DOI 10.1016/j.neuroscience.2013.06.023; Boku S, 2013, BRAIN RES, V1492, P7, DOI 10.1016/j.brainres.2012.11.034; Cheng K, 2013, J CLIN ONCOL, V31; Grieco A, 2013, MOL CELL ENDOCRINOL, V365, P241, DOI 10.1016/j.mce.2012.10.025; Hsu KF, 2015, BRIT J CANCER, V113, P414, DOI 10.1038/bjc.2015.254; Huang YQ, 2012, WIRES RNA, V3, P483, DOI 10.1002/wrna.1112; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Iizuka M, 2012, CELL STRUCT FUNCT, V37, P155, DOI 10.1247/csf.12018; Jimenez-Sanchez A, 2017, CELL, V170, P927, DOI 10.1016/j.cell.2017.07.025; Kalender ME, 2009, CANCER RES, V69, p658S; Kalender ME, 2010, ONCOL RES, V18, P583, DOI 10.3727/096504010X12767359113767; Liu TD, 2012, EXP CELL RES, V318, P1994, DOI 10.1016/j.yexcr.2012.04.017; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Nam Y, 2011, CELL, V147, P1080, DOI 10.1016/j.cell.2011.10.020; Olson MF, 2008, CURR OPIN CELL BIOL, V20, P242, DOI 10.1016/j.ceb.2008.01.002; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Patel RA, 2012, CANCER RES, V72, P5025, DOI 10.1158/0008-5472.CAN-12-0954; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Piskounova E, 2008, J BIOL CHEM, V283, P21310, DOI 10.1074/jbc.C800108200; Pisu M, 2017, GYNECOL ONCOL, V147, P433, DOI 10.1016/j.ygyno.2017.08.028; Polesskaya A, 2007, GENE DEV, V21, P1125, DOI 10.1101/gad.415007; Rauh-Hain JA, 2013, GYNECOL ONCOL, V129, P63, DOI 10.1016/j.ygyno.2013.01.009; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Son H, 2010, TOX RESEARCH, V26, P245, DOI 10.5487/TR.2010.26.4.245; Song GL, 2016, INT J ONCOL, V49, P646, DOI 10.3892/ijo.2016.3539; Vigil D, 2012, CANCER RES, V72, P5338, DOI 10.1158/0008-5472.CAN-11-2373; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2010, CELL, V140, P445, DOI 10.1016/j.cell.2010.02.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang QM, 2012, EXPERT OPIN THER TAR, V16, P1013, DOI 10.1517/14728222.2012.715149; Wertel Iwona, 2017, Wiad Lek, V70, P74; Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006; Wong CCL, 2009, HEPATOLOGY, V49, P1583, DOI 10.1002/hep.22836; Xue DB, 2011, HISTOPATHOLOGY, V59, P452, DOI 10.1111/j.1365-2559.2011.03949.x; Yap TA, 2012, CLIN CANCER RES, V18, P3912, DOI 10.1158/1078-0432.CCR-11-3313; Yuan RF, 2014, CANCER RES, V74, P5287, DOI 10.1158/0008-5472.CAN-14-0284; Yugaw T, 2013, MOL CELL BIOL, V33, P4434, DOI 10.1128/MCB.00577-13; Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069; Zhong XM, 2010, J BIOL CHEM, V285, P41961, DOI 10.1074/jbc.M110.169607; Zhong YC, 2016, INT J GYNECOL CANCER, V26, P1564, DOI 10.1097/IGC.0000000000000828; Zlobec I, 2010, ONCOTARGET, V1, P651, DOI 10.18632/oncotarget.199	44	18	18	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1381	1397		10.1038/s41388-018-0512-9	http://dx.doi.org/10.1038/s41388-018-0512-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30266988	Green Published, hybrid			2022-12-17	WOS:000459945800002
J	Sarwar, M; Khaja, ASS; Aleskandarany, M; Karlsson, R; Althobiti, M; Odum, N; Mongan, NP; Dizeyi, N; Johnson, H; Green, AR; Ellis, IO; Rakha, EA; Persson, JL				Sarwar, Martuza; Khaja, Azharuddin Sajid Syed; Aleskandarany, Mohammed; Karlsson, Richard; Althobiti, Maryam; Odum, Niels; Mongan, Nigel P.; Dizeyi, Nisthman; Johnson, Heather; Green, Andrew R.; Ellis, Ian O.; Rakha, Emad A.; Persson, Jenny L.			The role of PIP5K1 alpha/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1 alpha inhibitor	ONCOGENE			English	Article							COMPREHENSIVE MOLECULAR PORTRAITS; ESTROGEN-RECEPTOR; METASTASIS; EXPRESSION; PREVENTION; RESISTANCE; PATHWAY; PROTEIN; ALPHA; BONE	Despite recent improvement in adjuvant therapies, triple-negative, and ER+ subtypes of breast cancer (BC) with metastatic potentials remain the leading cause of BC-related deaths. We investigated the role of phosphatidylinositol-4-phosphate 5-kinase alpha (PIP5K alpha), a key upstream factor of PI3K/AKT, and the therapeutic effect of PIP5K alpha inhibitor on subtypes of BC. The clinical importance of PIP5K1 alpha and its association with survivals were analyzed using three BC cohorts from Nottingham (n = 913), KM plotter (n = 112) and TCGA (n = 817). Targeted overexpression or knockdown of PIP5K1 alpha were introduced into BC cell lines. The effects of PIP5K1 alpha and its inhibitor on growth and invasion of BC were confirmed by using in vitro assays including proliferation, migration, apoptosis and luciferase reporter assays and in vivo xenograft mouse models. All statistical tests were two-sided. PIP5K1 alpha was associated with poor patient outcome in triple-negative BC (for PIP5K1 alpha protein, p = 0.011 and for mRNA expression, p = 0.028, log-rank test). 29% of triple-negative BC had PIP5K1A gene amplification. Elevated level of PIP5K1 alpha increased expression of pSer-473 AKT (p < 0.001) and invasiveness of triple-negative MDA-MB-231 cells (p < 0.001). Conversely, inhibition of PIP5K1 alpha using its inhibitor ISA-2011B, or via knockdown suppressed growth and invasiveness of MDA-MB-231 xenografts (mean vehicle-treated controls = 2160 mm(3), and mean ISA-2011B-treated = 600 mm(3), p < 0.001). ISA-2011B-treatment reduced expression of pSer-473 AKT (p < 0.001) and its downstream effectors including cyclin D1, VEGF and its receptors, VEGFR1 and VEGFR2 (p < 0.001) in xenograft tumors. In ER+ cancer cells, PIP5K1 alpha acted on pSer-473 AKT, and was in complexes with VEGFR2, serving as co-factor of ER-alpha to regulate activities of target genes including cyclin D1 and CDK1. Our study suggests that our developed PIP5K1 alpha inhibitor has a great potential on refining targeted therapeutics for treatment of triple-negative and ER+ BC with abnormal PI3K/AKT pathways.	[Sarwar, Martuza; Persson, Jenny L.] Lund Univ, Clin Res Ctr, Dept Translat Med, Div Expt Canc Res, Malmo, Sweden; [Khaja, Azharuddin Sajid Syed; Karlsson, Richard; Persson, Jenny L.] Umea Univ, Dept Mol Biol, Div Basal Tumor Biol, Umea, Sweden; [Aleskandarany, Mohammed; Althobiti, Maryam; Green, Andrew R.; Ellis, Ian O.; Rakha, Emad A.] Univ Nottingham, Acad Pathol, Sch Med, Div Canc & Stem Cells, Nottingham, England; [Odum, Niels] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark; [Mongan, Nigel P.] Univ Nottingham, Fac Med & Hlth Sci, Sch Vet Med & Sci, Nottingham, England; [Mongan, Nigel P.] Weill Cornell Med, Dept Pharmacol, New York, NY 10065 USA; [Dizeyi, Nisthman] Lund Univ, Clin Res Ctr, Dept Translat Med, Div Reprod Res, Malmo, Sweden; [Johnson, Heather] Beijing Inst Basic Med Sci, Dept Biodiag, Beijing, Peoples R China	Lund University; Umea University; University of Nottingham; University of Copenhagen; University of Nottingham; Cornell University; Lund University; Academy of Military Medical Sciences - China	Persson, JL (corresponding author), Lund Univ, Clin Res Ctr, Dept Translat Med, Div Expt Canc Res, Malmo, Sweden.; Persson, JL (corresponding author), Umea Univ, Dept Mol Biol, Div Basal Tumor Biol, Umea, Sweden.	jenny_l.persson@med.lu.se	Rakha, Emad/Q-5554-2019; Syed Khaja, Azharuddin Sajid/AAF-2693-2021; Green, Andrew/AAF-1991-2020; Aleskandarany, Mohammed/X-8585-2019; Aleskandarany, Mohammed/D-9162-2018	Syed Khaja, Azharuddin Sajid/0000-0003-1594-1826; Ellis, Ian/0000-0001-5292-8474; Aleskandarany, Mohammed/0000-0001-5538-5946; Karlsson, Richard Torbjorn Gustav/0000-0003-0448-6135; Mongan, Nigel/0000-0001-5438-1126; Persson, Jenny/0000-0001-7682-7678; Green, Andrew/0000-0002-0488-5913; Rakha, Emad/0000-0002-5009-5525; JOHNSON, HEATHER/0000-0001-7468-0705	Swedish Cancer Society; Swedish National Research Council; Swedish Children Foundation; Malmo Cancer Foundation; Government Health Innovation Grant; Kempe STF; Umea University; Medical Faculty Grants; Royal Physiographical Foundation; University of Nottingham; Weill Cornell Medicine	Swedish Cancer Society(Swedish Cancer Society); Swedish National Research Council; Swedish Children Foundation; Malmo Cancer Foundation; Government Health Innovation Grant; Kempe STF; Umea University; Medical Faculty Grants; Royal Physiographical Foundation; University of Nottingham; Weill Cornell Medicine	This work was supported by grants from the Swedish Cancer Society, The Swedish National Research Council, The Swedish Children Foundation, Malmo Cancer Foundation, Malmo Cancer Foundation, the Government Health Innovation Grant, Kempe STF, Umea University, Medical Faculty Grants to JLP. The Royal Physiographical Foundation to MS. We acknowledge the support of the University of Nottingham and Weill Cornell Medicine (NPM). The authors sincerely thank Teresa Frisan (Umea University, Umea and Karolinska Institute, Stockholm), Pirkko Harkonen (University of Turku, Turku), Yafang Mei (Umea University, Umea) and Yvonne Lundberg Giwercman (Lund University, Lund) for providing reagents for this study. We also thank Per-Anders Bertilsson, Kristina Ekstrom-Holka and Elise Nilsson for technical help, and the Nottingham Health Science Biobank and Breast Cancer Now Tissue Bank for the provision of tissue samples.	Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004; Aesoy R, 2008, MOL CANCER RES, V6, P1630, DOI 10.1158/1541-7786.MCR-07-2172; Aleskandarany MA, 2016, BREAST CANCER RES TR, V156, P9, DOI 10.1007/s10549-016-3709-z; Aleskandarany MA, 2011, BREAST CANCER RES TR, V127, P407, DOI 10.1007/s10549-010-1012-y; Andruska N, 2012, J BIOMOL SCREEN, V17, P921, DOI 10.1177/1087057112442960; Applanat MP, 2008, ADV EXP MED BIOL, V617, P437, DOI 10.1007/978-0-387-69080-3_42; Auld DS, 2009, P NATL ACAD SCI USA, V106, P3585, DOI 10.1073/pnas.0813345106; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Coleman RE, 2002, AM J CLIN ONCOL-CANC, V25, pS32, DOI 10.1097/00000421-200212001-00006; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Khaja ASS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072210; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lim E, 2012, ONCOLOGY-NY, V26, P688; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Marino N, 2013, AM J PATHOL, V183, P1084, DOI 10.1016/j.ajpath.2013.06.012; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sarwar M, 2016, ONCOTARGET, V7, P63065, DOI 10.18632/oncotarget.11757; Semenas J, 2014, P NATL ACAD SCI USA, V111, pE3689, DOI 10.1073/pnas.1405801111; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Solzak JP, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0016-8; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; Yamaguchi H, 2010, CANCER SCI, V101, P1632, DOI 10.1111/j.1349-7006.2010.01574.x; Yang ZY, 2015, SCI REP-UK, V5, DOI 10.1038/srep07758; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559; Zhang XHF, 2013, CLIN CANCER RES, V19, P6389, DOI 10.1158/1078-0432.CCR-13-0838	36	18	18	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					375	389		10.1038/s41388-018-0438-2	http://dx.doi.org/10.1038/s41388-018-0438-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30104711	hybrid, Green Published			2022-12-17	WOS:000455851200006
J	Hirata, N; Suizu, F; Matsuda-Lennikov, M; Tanaka, T; Edamura, T; Ishigaki, S; Donia, T; Lithanatudom, P; Obuse, C; Iwanaga, T; Noguchi, M				Hirata, Noriyuki; Suizu, Futoshi; Matsuda-Lennikov, Mami; Tanaka, Tsutomu; Edamura, Tatsuma; Ishigaki, Satoko; Donia, Thoria; Lithanatudom, Pathrapol; Obuse, Chikashi; Iwanaga, Toshihiko; Noguchi, Masayuki			Functional characterization of lysosomal interaction of Akt with VRK2	ONCOGENE			English	Article							CELL-DEATH; PROTEIN-KINASE; MAMMALIAN AUTOPHAGY; INHIBITION; CANCER; PHOSPHORYLATION; MTORC1; GROWTH; LINKS; UBIQUITINATION	Serine-threonine kinase Akt (also known as PKB, protein kinase B), a core intracellular mediator of cell survival, is involved in various human cancers and has been suggested to play an important role in the regulation of autophagy in mammalian cells. Nonetheless, the physiological function of Akt in the lysosomes is currently unknown. We have reported previously that PtdIns (3)P-dependent lysosomal accumulation of the Akt-Phafin2 complex is a critical step for autophagy induction. Here, to characterize the molecular function of activated Akt in the lysosomes in the process of autophagy, we searched for the molecules that interact with the Akt complex at the lysosomes after induction of autophagy. By time-of-flight-mass spectrometry (TOF/MS) analysis, kinases of the VRK family, a unique serine-threonine family of kinases in the human kinome, were identified. VRK2 interacts with Akt1 and Akt2, but not with Akt3; the C terminus of Akt and the N terminus of VRK2 facilitate the interaction of Akt and VRK2 in mammalian cells. The kinase-dead form of VRK2A (KD VRK2A) failed to interact with Akt in coimmunoprecipitation assays. Bimolecular fluorescence complementation (BiFC) experiments showed that, in the lysosomes, Akt interacted with VRK2A but not with VRK2B or KD VRK2A. Immunofluorescent assays revealed that VRK2 and phosphorylated Akt accumulated in the lysosomes after autophagy induction. WT VRK2A, but not KD VRK2A or VRK2B, facilitated accumulation of phosphorylated Akt in the lysosomes. Downregulation of VRK2 abrogated the lysosomal accumulation of phosphorylated Akt and impaired nuclear localization of TFEB; these events coincided to inhibition of autophagy induction. The VRK2-Akt complex is required for control of lysosomal size, acidification, bacterial degradation, and for viral replication. Moreover, lysosomal VRK2-Akt controls cellular proliferation and mitochondria) outer-membrane stabilization. Given the roles of autophagy in the pathogenesis of human cancer, the current study provides a novel insight into the oncogenic activity of VRK2-Akt complexes in the lysosomes via modulation of autophagy.	[Hirata, Noriyuki; Suizu, Futoshi; Matsuda-Lennikov, Mami; Tanaka, Tsutomu; Edamura, Tatsuma; Ishigaki, Satoko; Donia, Thoria; Lithanatudom, Pathrapol; Noguchi, Masayuki] Hokkaido Univ, Div Canc Biol, Inst Genet Med, Sapporo, Hokkaido, Japan; [Donia, Thoria] Tanta Univ, Chem Dept, Fac Sci, Tanta, Egypt; [Obuse, Chikashi] Hokkaido Univ, Div Mol Life Sci, Grad Sch Life Sci, Sapporo, Hokkaido, Japan; [Iwanaga, Toshihiko] Hokkaido Univ, Lab Histol & Cytol, Grad Sch Med, Sapporo, Hokkaido, Japan; [Lithanatudom, Pathrapol] Chiang Mai Univ, Dept Biol, Fac Sci, Ctr Excellence Bioresources Agr Ind & Med, Chiang Mai 50200, Thailand	Hokkaido University; Egyptian Knowledge Bank (EKB); Tanta University; Hokkaido University; Hokkaido University; Chiang Mai University	Noguchi, M (corresponding author), Hokkaido Univ, Div Canc Biol, Inst Genet Med, Sapporo, Hokkaido, Japan.	m_noguch@igm.hokudai.ac.jp	Suizu, Futoshi/G-3530-2019; Donia, Thoria/I-7715-2019; LITHANATUDOM, PATHRAPOL/AAQ-1131-2021	Suizu, Futoshi/0000-0003-0206-4289; Donia, Thoria/0000-0002-1629-1290; 	Takeda; Naito Foundation; JSPS; Japan Rheumatism Foundation	Takeda(Takeda Pharmaceutical Company Ltd); Naito Foundation(Naito Memorial Foundation); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Rheumatism Foundation(Japan Rheumatism Foundation)	We thank Hiroyuki Miyoshi for the lentivirus and Dr. G. Napolitano and Dr. A. Ballabio for the anti-TFEB antibody. MN is supported by Takeda and Naito Foundation. FS and NH are supported by JSPS and FS by Japan Rheumatism Foundation.	Antal CE, 2013, MOL CELL PROTEOMICS, V12, P3498, DOI 10.1074/mcp.R113.029819; Arias E, 2015, MOL CELL, V59, P270, DOI 10.1016/j.molcel.2015.05.030; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Bach M, 2011, BIOCHEM J, V440, P283, DOI 10.1042/BJ20101894; Bai Y, 2003, GENE THER, V10, P1446, DOI 10.1038/sj.gt.3302026; BANHAM AH, 1992, VIROLOGY, V191, P803, DOI 10.1016/0042-6822(92)90256-O; Bento CF, 2016, ANNU REV BIOCHEM, V85, P685, DOI 10.1146/annurev-biochem-060815-014556; Blanco S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001660; Blanco S, 2006, FEBS J, V273, P2487, DOI 10.1111/j.1742-4658.2006.05256.x; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Chen W, 2005, J BIOL CHEM, V280, P40985, DOI 10.1074/jbc.M502190200; de Duve C, 2005, NAT CELL BIOL, V7, P847, DOI 10.1038/ncb0905-847; Ebner M, 2017, MOL CELL, V65, P416, DOI 10.1016/j.molcel.2016.12.028; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049; Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007; Hayakawa A, 2004, J BIOL CHEM, V279, P5958, DOI 10.1074/jbc.M310503200; Hayakawa A, 2007, BIOCHEM SOC SYMP, V74, P95, DOI 10.1042/BSS2007c09; Hirata N, 2014, BIOCHEM BIOPH RES CO, V450, P891, DOI 10.1016/j.bbrc.2014.06.077; Jaber N, 2012, P NATL ACAD SCI USA, V109, P2003, DOI 10.1073/pnas.1112848109; Juhasz G, 2008, J CELL BIOL, V181, P655, DOI 10.1083/jcb.200712051; Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kerppola TK, 2008, METHOD CELL BIOL, V85, P431, DOI 10.1016/S0091-679X(08)85019-4; Kim S, 2014, MOL CELL BIOL, V34, P643, DOI 10.1128/MCB.00756-13; Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004; Klerkx EPF, 2009, HISTOL HISTOPATHOL, V24, P749, DOI 10.14670/HH-24.749; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Klionsky DJ, 2005, CURR BIOL, V15, pR282, DOI 10.1016/j.cub.2005.04.013; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; Konig R, 2010, NATURE, V463, P813, DOI 10.1038/nature08699; Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Lee E, 2016, SCI REP-UK, V6, DOI 10.1038/srep29097; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Li LY, 2006, J GEN VIROL, V87, P2869, DOI 10.1099/vir.0.81953-0; Li Y, 2016, NAT CELL BIOL, V18, P1065, DOI 10.1038/ncb3407; Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007; Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Matsuda M, 2010, BIOCHEM BIOPH RES CO, V395, P312, DOI 10.1016/j.bbrc.2010.03.166; Matsuda-Lennikov M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0079795; Menon S, 2014, CELL, V156, P771, DOI 10.1016/j.cell.2013.11.049; Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moffatt MF, 2008, CURR OPIN ALLERGY CL, V8, P411, DOI 10.1097/ACI.0b013e32830f1dc1; Monsalve DM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.40; Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333; Nabar NR, 2017, YALE J BIOL MED, V90, P301; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Noguchi M, 2014, BBA-REV CANCER, V1846, P342, DOI 10.1016/j.bbcan.2014.07.013; Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169; Palmieri M, 2017, CELL CYCLE, V16, P1237, DOI 10.1080/15384101.2017.1337968; Palmieri M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14338; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Planz O, 2013, ANTIVIR RES, V98, P457, DOI 10.1016/j.antiviral.2013.04.008; Rodriguez-Hernandez I, 2013, BMC CLIN PATHOL, V13, DOI 10.1186/1472-6890-13-23; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338; Santanam U, 2016, GENE DEV, V30, P399, DOI 10.1101/gad.274134.115; Sanz-Garcia M., 2010, EMERGING SIGNALING P, P135; Sanz-Garcia M, 2012, J BIOL CHEM, V287, P23757, DOI 10.1074/jbc.M112.353102; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Sha YB, 2017, EMBO J, V36, P2544, DOI 10.15252/embj.201796699; Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226; Singla V, 2010, DEV CELL, V18, P410, DOI 10.1016/j.devcel.2009.12.022; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Suizu F., 2015, AUSTIN J MOL CELL BI, V2, P1004; Suizu F, 2016, EMBO J, V35, P1346, DOI 10.15252/embj.201593003; Suizu F, 2009, DEV CELL, V17, P800, DOI 10.1016/j.devcel.2009.09.007; Sumara G, 2009, CELL, V136, P235, DOI 10.1016/j.cell.2008.11.018; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967; Wei BDL, 2005, J VIROL, V79, P5705, DOI 10.1128/JVI.79.9.5705-5712.2005; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Zhang B, 2015, CANCER LETT, V356, P704, DOI 10.1016/j.canlet.2014.10.016; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056	105	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5367	5386		10.1038/s41388-018-0330-0	http://dx.doi.org/10.1038/s41388-018-0330-0			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29872222	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000446312900001
J	Boetto, J; Apra, C; Bielle, F; Peyre, M; Kalamarides, M				Boetto, Julien; Apra, Caroline; Bielle, Franck; Peyre, Matthieu; Kalamarides, Michel			Selective vulnerability of the primitive meningeal layer to prenatal Smo activation for skull base meningothelial meningioma formation	ONCOGENE			English	Article							CRANIOFACIAL DEVELOPMENT; SHH MEDULLOBLASTOMA; CELL CARCINOMA; MUTATIONS; HEDGEHOG; NF2; MOUSE; IDENTIFICATION; LOCALIZATION; INACTIVATION	Somatic activating mutations of smoothened (SMO), a component of the embryonic sonic hedgehog (SHH) signaling pathway, are found in 3-5% of grade I meningiomas, most of them corresponding to meningothelial meningiomas located at the anterior skull base. By generating different developmental stage-specific conditional activations in mice, we define a restricted developmental window during which conditional activation of Smo in Prostaglandin D2-synthase-positive mesoderm-derived meningeal layer of the skull base results in meningothelial meningioma formation. We show a selective vulnerability of the arachnoid from the skull base to Smo activation to initiate tumor development. This prenatal period and specific topography are correlated to the timing and location of SHH signaling involvement in the formation of craniofacial and meninges patterning, strongly corroborating the hypothesis of a developmental origin for Smo-activated meningiomas. Finally, we provide preclinical in vitro evidence of the efficacy of the SMO-inhibitor Sonidegib, supporting further preclinical and clinical evaluation of targeted treatment for refractory SMO-mutant meningiomas.	[Boetto, Julien; Apra, Caroline; Bielle, Franck; Peyre, Matthieu; Kalamarides, Michel] Sorbonne Univ, Inst Cerveau & Moelle Epiniere, INSERM, U1127,CNRS,UMR 7225,CRICM, F-75013 Paris, France; [Bielle, Franck] Hop La Pitie Salpetriere, AP HP, Dept Pathol, F-75013 Paris, France; [Peyre, Matthieu; Kalamarides, Michel] Hop La Pitie Salpetriere, AP HP, Dept Neurosurg, F-75013 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Kalamarides, M (corresponding author), Sorbonne Univ, Inst Cerveau & Moelle Epiniere, INSERM, U1127,CNRS,UMR 7225,CRICM, F-75013 Paris, France.	michel.kalamarides@aphp.fr	Boetto, Julien/AAG-5777-2021	Boetto, Julien/0000-0003-2572-8594; Bielle, Franck/0000-0001-6564-6388; Peyre, Matthieu/0000-0001-8470-9516; Apra, Caroline/0000-0003-0944-9544	foundation ARC, France. [PJA 20131200431]; UM1 University, Montpellier, France	foundation ARC, France.; UM1 University, Montpellier, France	This work was supported by a grant from the foundation ARC (PJA 20131200431), France. J.B. was funded by a grant from UM1 University, Montpellier, France.	Abedalthagafi M, 2016, NEURO-ONCOLOGY, V18, P649, DOI 10.1093/neuonc/nov316; Boetto J, 2017, NEURO-ONCOLOGY, V19, P345, DOI 10.1093/neuonc/now276; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Clarke VE, 2016, NAT GENET, V48, P1253, DOI 10.1038/ng.3651; Eberhart JK, 2006, DEVELOPMENT, V133, P1069, DOI 10.1242/dev.02281; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; Giovannini M, 2000, GENE DEV, V14, P1617; Huttner HB, 2018, EBIOMEDICINE, V27, P176, DOI 10.1016/j.ebiom.2017.12.020; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Kalamarides M, 2011, ONCOGENE, V30, P2333, DOI 10.1038/onc.2010.609; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Kros J, 2001, J PATHOL, V194, P367, DOI 10.1002/path.909; Le Roux I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9528; Louis D.N., 2016, WHO CLASSIFICATION T; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Marshall GM, 2014, NAT REV CANCER, V14, P277, DOI 10.1038/nrc3679; McBratney-Owen B, 2008, DEV BIOL, V322, P121, DOI 10.1016/j.ydbio.2008.07.016; Migden MR, 2015, LANCET ONCOL, V16, P716, DOI 10.1016/S1470-2045(15)70100-2; Ohli J, 2015, ACTA NEUROPATHOL, V130, P307, DOI 10.1007/s00401-015-1453-9; Peyre M, 2013, ONCOGENE, V32, P4264, DOI 10.1038/onc.2012.436; Reuss DE, 2013, ACTA NEUROPATHOL, V125, P351, DOI 10.1007/s00401-013-1093-x; Rogers L, 2015, J NEUROSURG, V122, P4, DOI 10.3171/2014.7.JNS131644; Samkari A, 2015, EXPERT REV NEUROTHER, V15, P763, DOI 10.1586/14737175.2015.1052796; Sweeney RT, 2014, NAT GENET, V46, P722, DOI 10.1038/ng.2986; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Vitte J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00346-5; Xavier GM, 2016, DEV BIOL, V415, P198, DOI 10.1016/j.ydbio.2016.02.009; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yoshida T, 2008, MECH DEVELOP, V125, P797, DOI 10.1016/j.mod.2008.06.007; Yuzawa S, 2016, MODERN PATHOL, V29, P708, DOI 10.1038/modpathol.2016.81	31	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4955	4963		10.1038/s41388-018-0328-7	http://dx.doi.org/10.1038/s41388-018-0328-7			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29789719	Green Published			2022-12-17	WOS:000443823600004
J	Dai, L; Del Valle, L; Miley, W; Whitby, D; Ochoa, AC; Flemington, EK; Qin, ZQ				Dai, Lu; Del Valle, Luis; Miley, Wendell; Whitby, Denise; Ochoa, Augusto C.; Flemington, Erik K.; Qin, Zhiqiang			Transactivation of human endogenous retrovirus K (HERV-K) by KSHV promotes Kaposi's sarcoma development	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MELANOMA-CELL LINES; ENDOTHELIAL-CELLS; NUCLEAR ANTIGEN; IN-VIVO; ANTIRETROVIRAL THERAPY; DNA-SEQUENCES; CYCLE ARREST; HTDV/HERV-K; KAPPA-B	Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of several human cancers such as Kaposi's sarcoma (KS), which represents the most common AIDS-associated malignancy that lacks effective treatment options. Despite its clear role in AIDS malignancies, the fact that only a small set of KSHV-infected patients will eventually develop these tumors implies that additional co-factors are required for the development of KSHV-related cancers. In the current study, we demonstrate for the first time that KSHV de novo infection or viral latent proteins are able to transactivate human endogenous retrovirus K (HERV-K) through a variety of cellular signaling pathways and transcriptional factors. Moreover, we found that HERV-K transactivation, particularly activation of its encoded oncogenic NP9 protein, plays an important role in KSHV pathogenesis and tumorigenesis in vitro and in vivo. Our data provide innovative insights into the mechanisms of HERV-K transactivation contributing to viral oncogenesis, which may represent a promising target for KS treatment.	[Dai, Lu; Qin, Zhiqiang] Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Genet, 1700 Tulane Ave, New Orleans, LA 70112 USA; [Dai, Lu; Qin, Zhiqiang] Tongji Univ, Sch Med, East Hosp, Dept Pediat,Res Ctr Translat Med, Shanghai 200120, Peoples R China; [Dai, Lu; Qin, Zhiqiang] Tongji Univ, Sch Med, East Hosp, Key Lab Arrhythmias, Shanghai 200120, Peoples R China; [Del Valle, Luis] Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Pathol, 1700 Tulane Ave, New Orleans, LA 70112 USA; [Miley, Wendell; Whitby, Denise] Frederick Natl Lab Canc Res, Viral Oncol Sect, AIDS & Canc Virus Program, Leidos Biomed Res, POB B, Frederick, MD 21702 USA; [Ochoa, Augusto C.] Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Pediat, 1700 Tulane Ave, New Orleans, LA 70112 USA; [Flemington, Erik K.] Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, Dept Pathol, 1700 Tulane Ave, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Tongji University; Tongji University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Tulane University	Qin, ZQ (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Genet, 1700 Tulane Ave, New Orleans, LA 70112 USA.; Qin, ZQ (corresponding author), Tongji Univ, Sch Med, East Hosp, Dept Pediat,Res Ctr Translat Med, Shanghai 200120, Peoples R China.; Qin, ZQ (corresponding author), Tongji Univ, Sch Med, East Hosp, Key Lab Arrhythmias, Shanghai 200120, Peoples R China.	zqin@lsuhsc.edu	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206	DOD Career Development Award [CA140437]; Louisiana Clinical and Translational Science Center Pilot grant [U54GM104940]; LSU LIFT2 funding; NIH [P20-GM121288-01, RO1-AI101046, R01-AI106676, P01CA214091]; Department of Defense [W81XWH-16-1-0318]; National Cancer Institute, NIH [HHSN261200800001E]; National Natural Science Foundation of China [81472547, 81672924, 81400164, 81772930]; NATIONAL CANCER INSTITUTE [P01CA214091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI106676, R01AI101046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104940, P20GM121288, P30GM114732] Funding Source: NIH RePORTER	DOD Career Development Award; Louisiana Clinical and Translational Science Center Pilot grant; LSU LIFT2 funding; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr. Rolf Renne at the University of Florida for his kind gifts of TIVE-LTC and TIVE cells and Dr. Friedrich A. Grasser from Universitatsklinikum des Saarlandes, Germany for kindly providing HERV-K NP9 plasmids and antibody. This work was supported by grants from a DOD Career Development Award to (CA140437 to ZQ); a Louisiana Clinical and Translational Science Center Pilot grant (U54GM104940 from NIH), a LSU LIFT2 funding, and NIH P20-GM121288-01 (PI: Krzysztof Reiss) subproject to ZQ; NIH RO1-AI101046, R01-AI106676, and P01CA214091 and Department of Defense W81XWH-16-1-0318 to EKF; the federal funds from the National Cancer Institute, NIH, under Contract No. HHSN261200800001E to DW; and the awards from the National Natural Science Foundation of China (81472547, 81672924 to ZQ and 81400164, 81772930 to LD). Funding sources had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An FQ, 2006, J VIROL, V80, P4833, DOI 10.1128/JVI.80.10.4833-4846.2006; An FQ, 2005, J BIOL CHEM, V280, P3862, DOI 10.1074/jbc.M407435200; Angelova M, 2014, VIROL J, V11, DOI 10.1186/s12985-014-0218-8; Ariza-Heredia EJ, 2011, TRANSPLANTATION, V92, P837, DOI 10.1097/TP.0b013e31823104ec; Armbruester V, 2002, CLIN CANCER RES, V8, P1800; Benavente Y, 2011, BRIT J CANCER, V105, P1768, DOI 10.1038/bjc.2011.392; Bonnet F, 2004, CANCER-AM CANCER SOC, V101, P317, DOI 10.1002/cncr.20354; Buscher K, 2006, MELANOMA RES, V16, P223; Buscher K, 2005, CANCER RES, V65, P4172, DOI 10.1158/0008-5472.CAN-04-2983; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen T, 2013, LEUKEMIA, V27, P1469, DOI 10.1038/leu.2013.8; Contreras-Galindo R, 2008, J VIROL, V82, P9329, DOI 10.1128/JVI.00646-08; Dai L, 2016, ONCOTARGET, V7, P10459, DOI 10.18632/oncotarget.7227; Dai L, 2015, BLOOD, V126, P2821, DOI 10.1182/blood-2015-07-658823; Dai L, 2015, CANCER LETT, V362, P158, DOI 10.1016/j.canlet.2015.03.034; Dai L, 2012, INT J CANCER, V131, P834, DOI 10.1002/ijc.26428; Depil S, 2002, LEUKEMIA, V16, P254, DOI 10.1038/sj.leu.2402355; Dewannieux M, 2006, GENOME RES, V16, P1548, DOI 10.1101/gr.5565706; Di Bartolo DL, 2008, BLOOD, V111, P4731, DOI 10.1182/blood-2007-09-110544; Do Kim J, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-85; Downey RF, 2015, INT J CANCER, V137, P1249, DOI 10.1002/ijc.29003; Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fuchs NV, 2011, J VIROL, V85, P3436, DOI 10.1128/JVI.02539-10; Gonzalez-Cao M, 2016, CANCER BIOL MED, V13, P483, DOI 10.20892/j.issn.2095-3941.2016.0080; Gonzalez-Hernandez MJ, 2012, J VIROL, V86, P7790, DOI 10.1128/JVI.07215-11; Gross H, 2011, INT J CANCER, V129, P1105, DOI 10.1002/ijc.25760; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; He ML, 2012, CANCER RES, V72, P3582, DOI 10.1158/0008-5472.CAN-11-2876; Hohn O, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00246; Hsiao FC, 2006, J IMMUNOL, V177, P2056, DOI 10.4049/jimmunol.177.4.2056; Hughes JF, 2001, NAT GENET, V29, P487, DOI 10.1038/ng775; Jenkins FJ, 2002, J INFECT DIS, V185, P1238, DOI 10.1086/340237; Kellam P, 1997, J Hum Virol, V1, P19; Kim KY, 2013, J VIROL, V87, P6782, DOI 10.1128/JVI.00011-13; Kraus B, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-21; Labo N, 2015, AIDS, V29, P1217, DOI 10.1097/QAD.0000000000000682; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee YN, 2007, PLOS PATHOG, V3, P119, DOI 10.1371/journal.ppat.0030010; Li SS, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005900; Li W, 2016, ONCOTARGET, V7, P32286, DOI 10.18632/oncotarget.8591; Li ZW, 2010, CANCER INVEST, V28, P1031, DOI 10.3109/07357907.2010.512604; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; LOWER R, 1995, J VIROL, V69, P141; Luppi M, 2000, BLOOD, V96, P3279; Magin C, 1999, J VIROL, V73, P9496, DOI 10.1128/JVI.73.11.9496-9507.1999; Maksakova IA, 2008, CELL MOL LIFE SCI, V65, P3329, DOI 10.1007/s00018-008-8494-3; Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920; Manghera M, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-16; Mbisa GL, 2010, J IMMUNOL METHODS, V356, P39, DOI 10.1016/j.jim.2010.02.015; Mesri EA, 2014, CELL HOST MICROBE, V15, P266, DOI 10.1016/j.chom.2014.02.011; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; Qian LW, 2007, J VIROL, V81, P7001, DOI 10.1128/JVI.00016-07; Qin ZQ, 2013, J VIROL, V87, P621, DOI 10.1128/JVI.01441-12; Qin ZQ, 2010, CANCER RES, V70, P3884, DOI 10.1158/0008-5472.CAN-09-4663; Qin ZQ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000742; Shamay M, 2006, P NATL ACAD SCI USA, V103, P14554, DOI 10.1073/pnas.0604469103; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Sutkowski N, 2001, IMMUNITY, V15, P579, DOI 10.1016/S1074-7613(01)00210-2; Sutkowski N, 2004, J VIROL, V78, P7852, DOI 10.1128/JVI.78.14.7852-7860.2004; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Verma SC, 2004, J VIROL, V78, P10348, DOI 10.1128/JVI.78.19.10348-10359.2004; Wang-Johanning F, 2012, JNCI-J NATL CANCER I, V104, P189, DOI 10.1093/jnci/djr540; Wong JP, 2017, BIOL CHEM, V398, P911, DOI 10.1515/hsz-2017-0101; Ye FC, 2011, ADV VIROL, V2011, DOI 10.1155/2011/193860	67	18	18	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4534	4545		10.1038/s41388-018-0282-4	http://dx.doi.org/10.1038/s41388-018-0282-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743595	Green Accepted			2022-12-17	WOS:000441736700004
J	Pinazza, M; Ghisi, M; Minuzzo, S; Agnusdei, V; Fossati, G; Ciminale, V; Pezze, L; Ciribilli, Y; Pilotto, G; Venturoli, C; Amadori, A; Indraccolo, S				Pinazza, Marica; Ghisi, Margherita; Minuzzo, Sonia; Agnusdei, Valentina; Fossati, Gianluca; Ciminale, Vincenzo; Pezze, Laura; Ciribilli, Yari; Pilotto, Giorgia; Venturoli, Carolina; Amadori, Alberto; Indraccolo, Stefano			Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells	ONCOGENE			English	Article							ACTIVATING MUTATIONS; ACETYLATION; ENDOCYTOSIS; RECEPTOR	Several studies have revealed that endosomal sorting controls the steady-state levels of Notch at the cell surface in normal cells and prevents its inappropriate activation in the absence of ligands. However, whether this highly dynamic physiologic process can be exploited to counteract dysregulated Notch signaling in cancer cells remains unknown. T-ALL is a malignancy characterized by aberrant Notch signaling, sustained by activating mutations in Notch1 as well as overexpression of Notch3, a Notch paralog physiologically subjected to lysosome-dependent degradation in human cancer cells. Here we show that treatment with the pan-HDAC inhibitor Trichostatin A (TSA) strongly decreases Notch3 full-length protein levels in T-ALL cell lines and primary human T-ALL cells xenografted in mice without substantially reducing NOTCH3 mRNA levels. Moreover, TSA markedly reduced the levels of Notch target genes, including pT alpha, CR2, and DTX-1, and induced apoptosis of T-ALL cells. We further observed that Notch3 was post-translationally regulated following TSA treatment, with reduced Notch3 surface levels and increased accumulation of Notch3 protein in the lysosomal compartment. Surface Notch3 levels were rescued by inhibition of dynein with ciliobrevin D. Pharmacologic studies with HDAC1, 6, and 8-specific inhibitors disclosed that these effects were largely due to inhibition of HDAC6 in TALL cells. HDAC6 silencing by specific shRNA was followed by reduced Notch3 expression and increased apoptosis of TALL cells. Finally, HDAC6 silencing impaired leukemia outgrowth in mice, associated with reduction of Notch3 full-length protein in vivo. These results connect HDAC6 activity to regulation of total and surface Notch3 levels and suggest HDAC6 as a potential novel therapeutic target to lower Notch signaling in T-ALL and other Notch3-addicted tumors.	[Pinazza, Marica; Agnusdei, Valentina; Ciminale, Vincenzo; Venturoli, Carolina; Amadori, Alberto; Indraccolo, Stefano] Ist Oncol Veneto IOV IRCCS, Padua, Italy; [Ghisi, Margherita; Minuzzo, Sonia; Ciminale, Vincenzo; Pilotto, Giorgia; Amadori, Alberto] Univ Padua, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy; [Fossati, Gianluca] Italfarmaco SPA, Milan, Italy; [Pezze, Laura; Ciribilli, Yari] Univ Trento, Lab Mol Canc Genet, CIBIO, Trento, Italy; [Ghisi, Margherita] CRCT, Toulouse, France	IRCCS Istituto Oncologico Veneto (IOV); University of Padua; Italfarmaco; University of Trento; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Indraccolo, S (corresponding author), Ist Oncol Veneto IOV IRCCS, Padua, Italy.	stefano.indraccolo@unipd.it	Indraccolo, Stefano/AAE-6261-2021; Minuzzo, Sonia Anna/AAP-2062-2020; Ghisi, Margherita/G-2756-2017; Ciminale, Vincenzo/L-1416-2016; Ciribilli, Yari/K-2751-2018; Agnusdei, Valentina/I-1137-2018	Indraccolo, Stefano/0000-0002-4810-7136; Minuzzo, Sonia Anna/0000-0003-2588-6058; Ciminale, Vincenzo/0000-0001-6197-1802; Ciribilli, Yari/0000-0001-9231-379X; Agnusdei, Valentina/0000-0002-2617-360X; Ghisi, Margherita/0000-0003-0583-9879; Pezze, Laura/0000-0001-8924-0083	AIRC [IG18803]	AIRC(Fondazione AIRC per la ricerca sul cancro)	AIRC (IG18803 to SI).	Agnusdei V, 2014, LEUKEMIA, V28, P278, DOI 10.1038/leu.2013.183; Aldana-Masangkay GI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/875824; Amati B, 2007, NAT CELL BIOL, V9, P729, DOI 10.1038/ncb0707-729; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2003, SEMIN IMMUNOL, V15, P107, DOI 10.1016/S1044-5323(03)00007-1; Bernasconi-Elias P, 2016, ONCOGENE, V35, P6077, DOI 10.1038/onc.2016.133; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Chambers AE, 2003, EUR J CANCER, V39, P1165, DOI 10.1016/S0959-8049(03)00072-8; Conner SD, 2016, INT REV CEL MOL BIO, V323, P107, DOI 10.1016/bs.ircmb.2015.12.002; Deribe YL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000576; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Gao YS, 2010, J BIOL CHEM, V285, P11219, DOI 10.1074/jbc.M109.042754; Graux C, 2006, LEUKEMIA, V20, P1496, DOI 10.1038/sj.leu.2404302; Gu YS, 2016, ONCOTARGET, V7, P29804, DOI 10.18632/oncotarget.7772; Jia LJ, 2009, INT J BIOCHEM CELL B, V41, P2594, DOI 10.1016/j.biocel.2009.08.019; Kanwar R, 2004, CURR BIOL, V14, pR1043, DOI 10.1016/j.cub.2004.11.041; Liu J, 2016, CRIT REV ONCOL HEMAT, V104, P21, DOI 10.1016/j.critrevonc.2016.05.010; Lu H, 2005, NAT CELL BIOL, V7, P1232, DOI 10.1038/ncb1324; Masiero M, 2011, LEUKEMIA, V25, P588, DOI 10.1038/leu.2010.323; McGill MA, 2009, J BIOL CHEM, V284, P26427, DOI 10.1074/jbc.M109.014845; Pacheco MTF, 2016, EXP CELL RES, V340, P248, DOI 10.1016/j.yexcr.2015.12.016; Palermo R, 2012, ONCOGENE, V31, P3807, DOI 10.1038/onc.2011.533; Pasto A, 2014, CANCER RES, V74, P2106, DOI 10.1158/0008-5472.CAN-13-2022; Pinazza M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.394; Sakata T, 2004, CURR BIOL, V14, P2228, DOI 10.1016/j.cub.2004.12.028; Schroter CJ, 1999, J IMMUNOL METHODS, V227, P161, DOI 10.1016/S0022-1759(99)00079-4; Serafin V, 2011, J PATHOL, V224, P448, DOI 10.1002/path.2895; Seugnet L, 1997, DEV BIOL, V192, P585, DOI 10.1006/dbio.1997.8723; Singh BN, 2010, EXPERT REV ANTICANC, V10, P935, DOI 10.1586/ERA.10.62; Sorensen EB, 2010, TRAFFIC, V11, P1234, DOI 10.1111/j.1600-0854.2010.01090.x; Vaccari T, 2008, J CELL BIOL, V180, P755, DOI 10.1083/jcb.200708127; Wang ZW, 2012, FEBS LETT, V586, P1409, DOI 10.1016/j.febslet.2012.03.017; Weber U, 2003, DEV CELL, V5, P559, DOI 10.1016/S1534-5807(03)00273-9; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilkin MB, 2004, CURR BIOL, V14, P2237, DOI 10.1016/j.cub.2004.11.030; Windler SL, 2010, CURR BIOL, V20, P538, DOI 10.1016/j.cub.2010.01.049	36	18	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3839	3851		10.1038/s41388-018-0234-z	http://dx.doi.org/10.1038/s41388-018-0234-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29643474	Green Published, hybrid			2022-12-17	WOS:000438465600006
J	Jia, L; Wu, DL; Wang, YL; You, WX; Wang, Z; Xiao, LJ; Cai, GH; Xu, ZY; Zou, C; Wang, F; Teoh, JYC; Ng, CF; Yu, S; Chan, FL				Jia, Lin; Wu, Dinglan; Wang, Yuliang; You, Wenxing; Wang, Zhu; Xiao, Lijia; Cai, Ganhui; Xu, Zhenyu; Zou, Chang; Wang, Fei; Teoh, Jeremy Yuen-Chun; Ng, Chi-Fai; Yu, Shan; Chan, Franky L.			Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription	ONCOGENE			English	Article							RADICAL PROSTATECTOMY; GENE-EXPRESSION; SELF-RENEWAL; THERAPEUTIC TARGET; CELL-PROLIFERATION; STEM-CELLS; TUMOR; PROGRESSION; AMPLIFICATION; SURVIVAL	The metastatic castration-resistant prostate cancer (CRPC) is a lethal form of prostate cancer, in which the expression of androgen receptor (AR) is highly heterogeneous. Indeed, lower AR expression and attenuated AR signature activity is shown in CRPC tissues, especially in the subset of neuroendocrine prostate cancer (NEPC) and prostate cancer stem-like cells (PCSCs). However, the significance of AR downregulation in androgen insensitivity and de-differentiation of tumor cells in CRPC is poorly understood and much neglected. Our previous study shows that the orphan nuclear receptor TLX (NR2E1), which is upregulated in prostate cancer, plays an oncogenic role in prostate carcinogenesis by suppressing oncogene-induced senescence. In the present study, we further established that TLX exhibited an increased expression in metastatic CRPC. Further analyses showed that overexpression of TLX could confer resistance to androgen deprivation and anti-androgen in androgen-dependent prostate cancer cells in vitro and in vivo, whereas knockdown of endogenous TLX could potentiate the sensitivity to androgen deprivation and anti-androgen in prostate cancer cells. Our study revealed that the TLX-induced resistance to androgen deprivation and anti-androgen was mediated through its direct suppression of AR gene transcription and signaling in both androgen-stimulated and - unstimulated prostate cancer cells. We also characterized that TLX could bind directly to AR promoter and repress AR transcription by recruitment of histone modifiers, including HDAC1, HDAC3, and LSD1. Together, our present study shows, for the first time, that TLX can contribute to androgen insensitivity in CRPC via repression of AR gene transcription and signaling, and also implicates that targeting the druggable TLX may have a potential therapeutic significance in CRPC management, particularly in NEPC and PCSCs.	[Jia, Lin; Wu, Dinglan; Wang, Yuliang; You, Wenxing; Wang, Zhu; Xiao, Lijia; Cai, Ganhui; Xu, Zhenyu; Zou, Chang; Yu, Shan; Chan, Franky L.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Jia, Lin] Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Wu, Dinglan] Southern Med Univ, Shenzhen Key Lab Viral Oncol, Clin Innovat & Res Ctr, Shenzhen Hosp, Shenzhen 518110, Peoples R China; [Wang, Fei] Hosp Hainan Prov, Dept Urol, Haikou 570311, Hainan, Peoples R China; [Teoh, Jeremy Yuen-Chun; Ng, Chi-Fai] Chinese Univ Hong Kong, Fac Med, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; University of Hong Kong; Southern Medical University - China; Chinese University of Hong Kong	Wu, DL; Chan, FL (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.; Wu, DL (corresponding author), Southern Med Univ, Shenzhen Key Lab Viral Oncol, Clin Innovat & Res Ctr, Shenzhen Hosp, Shenzhen 518110, Peoples R China.	teenawu@gmail.com; franky-chan@cuhk.edu.hk	Chi-fai, NG/AAV-8270-2021; Ng, Chi-Fai/E-5134-2011; Chan, Franky L./M-1043-2018; Zou, Chang/AAS-3356-2021; Teoh, Jeremy Yuen Chun/H-5184-2016	Ng, Chi-Fai/0000-0002-1723-9646; Chan, Franky L./0000-0003-0567-2052; Zou, Chang/0000-0002-2003-7834; Teoh, Jeremy Yuen Chun/0000-0002-9361-2342; Wu, Dinglan/0000-0002-5057-9626; Wang, Zhu/0000-0002-5457-3731; Jia, Lin/0000-0002-5501-5029	National Natural Science Foundation of China [81502570, 81760461]; Research Grants Council of Hong Kong [461012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Grants Council of Hong Kong(Hong Kong Research Grants Council)	This work was supported by research grants from the National Natural Science Foundation of China (project number 81502570) (to D.W.), General Research Fund (project number 461012) from the Research Grants Council of Hong Kong (to F.L.C.), and National Natural Science Foundation of China (project number 81760461) (to F.W.). We thank Dr. Vanacker J.M. for the ARE-Luc and Dr. Poletti A. for the pGL3-AR2.4 plasmid, Drs. Kenneth Pienta, Shutung Liao, and Helmet Klocker for the prostatic cell lines.	Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Brown RSD, 2002, J PATHOL, V198, P237, DOI 10.1002/path.1206; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Cai G, 2017, ONCOGENE, V36, P546, DOI 10.1038/onc.2016.227; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chavali PL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.449; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; Corso-Diaz X, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3173-5; Cui Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10637; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; Ferraldeschi R, 2015, ONCOGENE, V34, P1745, DOI 10.1038/onc.2014.115; Fleischmann A, 2011, PROSTATE, V71, P453, DOI 10.1002/pros.21259; Islam MM, 2015, BBA-GENE REGUL MECH, V1849, P210, DOI 10.1016/j.bbagrm.2014.06.001; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Katsogiannou M, 2015, CANCER TREAT REV, V41, P588, DOI 10.1016/j.ctrv.2015.05.003; Knuuttila M, 2014, AM J PATHOL, V184, P2163, DOI 10.1016/j.ajpath.2014.04.010; Koivisto P, 1997, CANCER RES, V57, P314; KOKONTIS J, 1994, CANCER RES, V54, P1566; Komiya A, 2013, MOL CLIN ONCOL, V1, P257, DOI 10.3892/mco.2013.69; Li R, 2004, AM J SURG PATHOL, V28, P928, DOI 10.1097/00000478-200407000-00013; Lin ML, 2015, ONCOTARGET, V6, P21685, DOI 10.18632/oncotarget.3942; Linja MJ, 2001, CANCER RES, V61, P3550; Liu HK, 2010, GENE DEV, V24, P683, DOI 10.1101/gad.560310; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; MASAI M, 1990, PROSTATE, V17, P293, DOI 10.1002/pros.2990170405; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; O'Leary JD, 2018, GENES BRAIN BEHAV, V17, DOI 10.1111/gbb.12357; Palmberg C, 1997, EUR UROL, V31, P216; Paranjape AN, 2016, ONCOGENE, V35, P5963, DOI 10.1038/onc.2015.498; Park HJ, 2010, MOL CELLS, V30, P403, DOI 10.1007/s10059-010-0122-z; PERTSCHUK LP, 1995, LAB INVEST, V73, P302; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Rosner IL, 2007, UROLOGY, V70, DOI 10.1016/j.urology.2007.09.010; Segawa N, 2001, PATHOL INT, V51, P452, DOI 10.1046/j.1440-1827.2001.01226.x; Sun GQ, 2007, P NATL ACAD SCI USA, V104, P15282, DOI 10.1073/pnas.0704089104; Takeda H, 1996, CANCER, V77, P934, DOI 10.1002/(SICI)1097-0142(19960301)77:5<934::AID-CNCR20>3.3.CO;2-Q; Tamburrino L, 2012, STEROIDS, V77, P996, DOI 10.1016/j.steroids.2012.01.008; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teyssier C, 2008, NUCLEIC ACIDS RES, V36, P5350, DOI 10.1093/nar/gkn520; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Vismara G, 2009, NEUROBIOL DIS, V33, P395, DOI 10.1016/j.nbd.2008.11.007; Wang Z, 2018, ENDOCR-RELAT CANCER, V25, P35, DOI 10.1530/ERC-17-0280; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Wise D, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.5054; Wu DL, 2016, BBA-REV CANCER, V1866, P23, DOI 10.1016/j.bbcan.2016.06.001; Wu DL, 2015, J PATHOL, V236, P103, DOI 10.1002/path.4505; Yokoyama A, 2008, MOL CELL BIOL, V28, P3995, DOI 10.1128/MCB.02030-07; Yu S, 2008, ONCOGENE, V27, P3313, DOI 10.1038/sj.onc.1210986; Yu SA, 2007, CANCER RES, V67, P4904, DOI 10.1158/0008-5472.CAN-06-3855; Yu S, 2013, CANCER LETT, V328, P83, DOI 10.1016/j.canlet.2012.09.006; Yu S, 2009, BIOCHEM BIOPH RES CO, V382, P756, DOI 10.1016/j.bbrc.2009.03.110; Zhao C, 2009, NAT STRUCT MOL BIOL, V16, P365, DOI 10.1038/nsmb.1576; Zhu Z, 2014, CELL STEM CELL, V15, P185, DOI 10.1016/j.stem.2014.04.007; Zou C, 2014, J PATHOL, V233, P61, DOI 10.1002/path.4329; Zou YH, 2012, MOL CELL BIOL, V32, P4811, DOI 10.1128/MCB.01122-12	66	18	20	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3340	3355		10.1038/s41388-018-0198-z	http://dx.doi.org/10.1038/s41388-018-0198-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29555975	Green Published, hybrid			2022-12-17	WOS:000436411300002
J	Ding, L; Zhang, YQ; Han, LL; Fu, L; Mei, X; Wang, JJ; Itkow, J; Elabid, AEI; Pang, L; Yu, DN				Ding, Lan; Zhang, Yanqing; Han, Lingling; Fu, Lei; Mei, Xia; Wang, Jijun; Itkow, Jacobi; Elabid, Afaf Elabid Ibrahim; Pang, Lei; Yu, Duonan			Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; DOWN-REGULATION; CELL LYMPHOMAS; MIR-451; CANCER; 14-3-3-ZETA; REPRESSION; DIFFERENTIATION; PROLIFERATION; TUMORIGENESIS	Hyper activity of protooncogene c-Myc is one of the hallmarks of highly aggressive lymphomas. However, the mechanism of how c-Myc is subjected to activation and amplification is still not well defined. In this study, we use gene knockout strategy to show that targeted depletion of a well-conserved microRNA gene locus miR-144/451 initiates tumorigenesis including B-lymphoma development in aged mice. This is due, at least in part, to the direct activation of the c-Myc gene by loss of miR-144/451 expression in hematopoietic cells. Moreover, oncoprotein c-Myc inversely regulates miR-144/451 expression by directly binding to the miR-144/451 promoter region, forming a miRNA-Myc positive feedback loop to safeguard the high level of c-Myc in B-lymphocytes. We also demonstrate that this miRNA-Myc crosstalk is disrupted in human diffuse large B-cell lymphomas with aberrant c-Myc expression. Therefore, our findings provide strong evidence, for the first time, that deficiency of miR-144/451 expression may play a bona fide role in derepression of silenced c-Myc, which contributes to tumor development including B-lymphomagenesis.	[Ding, Lan; Fu, Lei; Mei, Xia] Yangzhou Univ, Jiangdu Peoples Hosp, Dept Pathol, Yangzhou, Jiangsu, Peoples R China; [Zhang, Yanqing; Han, Lingling; Wang, Jijun; Itkow, Jacobi; Elabid, Afaf Elabid Ibrahim; Pang, Lei; Yu, Duonan] Yangzhou Univ, Sch Med, Jiangsu Key Lab Expt & Translat Noncoding RNA Res, Yangzhou, Jiangsu, Peoples R China; [Yu, Duonan] Yangzhou Univ, Inst Translat Med, Sch Med, Yangzhou, Jiangsu, Peoples R China; [Yu, Duonan] Yangzhou Univ, Inst Comparat Med, Yangzhou, Jiangsu, Peoples R China; [Yu, Duonan] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Jiangsu, Peoples R China	Yangzhou University; Yangzhou University; Yangzhou University; Yangzhou University	Yu, DN (corresponding author), Yangzhou Univ, Sch Med, Jiangsu Key Lab Expt & Translat Noncoding RNA Res, Yangzhou, Jiangsu, Peoples R China.; Yu, DN (corresponding author), Yangzhou Univ, Inst Translat Med, Sch Med, Yangzhou, Jiangsu, Peoples R China.; Yu, DN (corresponding author), Yangzhou Univ, Inst Comparat Med, Yangzhou, Jiangsu, Peoples R China.; Yu, DN (corresponding author), Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Jiangsu, Peoples R China.	dnyu@yzu.edu.cn			National Natural Science Foundation of China [81670186, 81470277, 81302041]; Priority Academic Program Development of Jiangsu Higher Education Institution; Natural Science Foundation of Jiangsu Province of China [15KJA320007, BK20130454]; Ministry of Finance of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institution; Natural Science Foundation of Jiangsu Province of China(Natural Science Foundation of Jiangsu Province); Ministry of Finance of China	The authors would like to thank Dr. Mitch Weiss (St. Jude Children's Research Hospital), Dr. Andrei Thomas-Tikhonenko (University of Pennsylvania/Children's Hospital of Philadelphia), and their laboratories for the technical supports. We are grateful to Dr. Robert Auerbach (University of Wisconsin-Madison) for YS-PB11 cells and Dr. Kenneth Dorshkind (University of California) for S17 stromal cells. We are also grateful to Yuanjun Yu for language editing. This work is supported by the National Natural Science Foundation of China (Grant No. 81670186 and 81470277, D.Y.; 81302041, Y.Z.), the Priority Academic Program Development of Jiangsu Higher Education Institution (Veterinary Medicine, D.Y.), the Natural Science Foundation of Jiangsu Province of China (15KJA320007, D.Y.; BK20130454, Y.Z.) and grant from the Ministry of Finance of China for "Biology & Medical Science Innovation Team" program (D.Y.).	ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bergamaschi A, 2012, ONCOGENE, V31, P39, DOI 10.1038/onc.2011.223; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Cheng Y, 2009, GENOME RES, V19, P2172, DOI 10.1101/gr.098921.109; COLLINS LS, 1987, J IMMUNOL, V138, P1082; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Diez-Roux G, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000582; Dore LC, 2008, P NATL ACAD SCI USA, V105, P3333, DOI 10.1073/pnas.0712312105; Du J, 2015, ONCOTARGET, V6, P14993, DOI 10.18632/oncotarget.3802; Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Karube K, 2015, SEMIN HEMATOL, V52, P97, DOI 10.1053/j.seminhematol.2015.01.009; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Korac P, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040115; Li XY, 2011, J EXP MED, V208, P663, DOI 10.1084/jem.20102384; Li YY, 2015, AM J TRANSL RES, V7, P2775; Lu LS, 1998, J IMMUNOL, V161, P1284; Ott G., 2017, BR J HAEMATOL; Ott G, 2013, BLOOD, V122, P3884, DOI 10.1182/blood-2013-05-498329; Patrick DM, 2010, GENE DEV, V24, P1614, DOI 10.1101/gad.1942810; Perez-Chacon G, 2014, PHARMACOL RES, V89, P46, DOI 10.1016/j.phrs.2014.08.005; Rasmussen KD, 2010, J EXP MED, V207, P1351, DOI 10.1084/jem.20100458; Soltani I, 2017, HEMATOLOGY, V22, P201, DOI 10.1080/10245332.2016.1252020; Su R, 2016, ONCOTARGET, V7, P77430, DOI 10.18632/oncotarget.12679; Tao JC, 2014, CELL CYCLE, V13, P191, DOI 10.4161/cc.27646; Wang HY, 2016, CANCER IMMUNOL RES, V4, P337, DOI 10.1158/2326-6066.CIR-15-0161; Wang R, 2011, ONCOGENE, V30, P2644, DOI 10.1038/onc.2010.642; Wang R, 2014, ONCOTARGET, V5, P6113, DOI 10.18632/oncotarget.2176; Yu D, 2003, BLOOD, V101, P1950, DOI 10.1182/blood-2002-06-1797; Yu DN, 2005, CANCER RES, V65, P5454, DOI 10.1158/0008-5472.CAN-04-4197; Yu DN, 2002, ONCOGENE, V21, P1922, DOI 10.1038/sj.onc.1205244; Yu DN, 2010, GENE DEV, V24, P1620, DOI 10.1101/gad.1942110; Yu LL, 2016, EXP CELL RES, V344, P210, DOI 10.1016/j.yexcr.2016.03.006; Yu M, 2009, MOL CELL, V36, P682, DOI 10.1016/j.molcel.2009.11.002; Zhang LB, 2011, GENE DEV, V25, P119, DOI 10.1101/gad.1998711; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003	40	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1293	1307		10.1038/s41388-017-0055-5	http://dx.doi.org/10.1038/s41388-017-0055-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29284789	Green Published, hybrid			2022-12-17	WOS:000427279300003
J	Im, JY; Kim, BK; Lee, JY; Park, SH; Ban, HS; Jung, KE; Won, M				Im, Joo-Young; Kim, Bo-Kyung; Lee, Ji-Young; Park, Seung-Ho; Ban, Hyun Seung; Jung, Kyeong Eun; Won, Misun			DDIAS suppresses TRAIL-mediated apoptosis by inhibiting DISC formation and destabilizing caspase-8 in cancer cells	ONCOGENE			English	Article							DEATH RECEPTOR; DNA-DAMAGE; IN-VIVO; C-JUN; SIGNALING COMPLEX; LUNG-CARCINOMA; PROTEIN-KINASE; KEY REGULATOR; DOCKING SITE; EXPRESSION	DNA damage-induced apoptosis suppressor (DDIAS) has an anti-apoptotic function during DNA damage in lung cancer. However, the anti-apoptotic mechanism of DDIAS in cancer cells under other conditions has not been reported. We report here that DDIAS protects cancer cells from tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by two distinct mechanisms in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) cells. DDIAS depletion sensitized NSCLC and HCC cells to TRAIL-mediated apoptosis, an effect that was abrogated by pharmacological or genetic inhibition of caspase-8 and was independent of caspase-9, p53, or mitogen-activated protein kinase signaling. Interestingly, we found that the N terminus of DDIAS interacted with the death effector domain of Fas-associated protein death domain (FADD) and prevented its recruitment to the death-inducing signaling complex (DISC), thereby blocking caspase-8 activation. DDIAS knockdown also suppressed epidermal growth factor-induced phosphorylation of p90 ribosomal S6 kinase (RSK) 2 and stabilized caspase-8 by preventing its ubiquitination and proteasomal degradation. This effect was abolished by RSK2 overexpression. Taken together, DDIAS has dual functions in inhibiting DISC formation as well as in destabilizing caspase-8, thereby suppressing TRAIL-mediated apoptosis of cancer cells. Thus, we suggest that DDIAS can serve as an effective therapeutic target in the treatment of NSCLC and HCC.	[Im, Joo-Young; Kim, Bo-Kyung; Lee, Ji-Young; Park, Seung-Ho; Won, Misun] KRIBB, Personalized Genom Med Res Ctr, Daejeon, South Korea; [Ban, Hyun Seung] KRIBB, Metab Regulat Res Ctr, Daejeon, South Korea; [Jung, Kyeong Eun] ST Pharm Co Ltd, Sihwa Ind Complex 1, Kyunggido, South Korea; [Won, Misun] Korea Univ Sci & Technol UST, KRIBB Sch Biotechnol, Dept Funct Genom, 217 Gajeong Ro, Daejeon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Science & Technology (UST)	Won, M (corresponding author), KRIBB, Personalized Genom Med Res Ctr, Daejeon, South Korea.; Won, M (corresponding author), Korea Univ Sci & Technol UST, KRIBB Sch Biotechnol, Dept Funct Genom, 217 Gajeong Ro, Daejeon, South Korea.	misun@kribb.re.kr	Ban, Hyun Seung/F-9526-2014	Ban, Hyun Seung/0000-0002-2698-6037	KRIBB Initiative Program [KGM4751713]; National Research Foundation (NRF) [2017R1A2B2011936, 2017M3A9F9030565]; Health Technology RD [HI13C2162]	KRIBB Initiative Program; National Research Foundation (NRF); Health Technology RD	This work was supported by the KRIBB Initiative Program (KGM4751713), National Research Foundation (NRF; 2017R1A2B2011936 and 2017M3A9F9030565), and Health Technology R&D (HI13C2162).	Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cheng HR, 2012, CELL CYCLE, V11, P3312, DOI 10.4161/cc.21670; Cho YY, 2007, CANCER RES, V67, P8104, DOI 10.1158/0008-5472.CAN-06-4668; Cho YY, 2012, CARCINOGENESIS, V33, P2529, DOI 10.1093/carcin/bgs271; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fu K, 2012, ONCOGENE, V31, P1311, DOI 10.1038/onc.2011.315; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038; Im JY, 2016, BBA-GENE REGUL MECH, V1859, P1449, DOI 10.1016/j.bbagrm.2016.07.003; Im JY, 2016, BBA-MOL CELL RES, V1863, P40, DOI 10.1016/j.bbamcr.2015.10.011; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kim BK, 2014, BBA-GENE REGUL MECH, V1839, P364, DOI 10.1016/j.bbagrm.2014.03.004; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Lee MW, 2002, FEBS LETT, V512, P313, DOI 10.1016/S0014-5793(02)02225-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagane M, 2000, CANCER RES, V60, P847; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peng C, 2011, J BIOL CHEM, V286, P6946, DOI 10.1074/jbc.M110.172338; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Soung YH, 2005, CANCER RES, V65, P815; Soung YH, 2005, ONCOGENE, V24, P141, DOI 10.1038/sj.onc.1208244; Sun BK, 2011, ONCOL REP, V25, P537, DOI 10.3892/or.2010.1079; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Won KJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.488; Won KJ, 2014, INT J CANCER, V134, P2595, DOI 10.1002/ijc.28600; Zhang ZZ, 2015, INT J CANCER, V137, P765, DOI 10.1002/ijc.29451	40	18	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1251	1262		10.1038/s41388-017-0025-y	http://dx.doi.org/10.1038/s41388-017-0025-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29242605				2022-12-17	WOS:000426505400009
J	Moon, SJ; Jeong, BC; Kim, HJ; Lim, JE; Kwon, GY; Kim, JH				Moon, Sue Jin; Jeong, Byong Chang; Kim, Hwa Jin; Lim, Joung Eun; Kwon, Ghee Young; Kim, Jeong Hoon			DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7	ONCOGENE			English	Article							RECEPTOR SPLICE VARIANTS; LENGTH ANDROGEN RECEPTOR; CELL-LINES; EXPRESSION; SIRT1; TRANSCRIPTION; ACTIVATION; GENES; P53; IDENTIFICATION	Constitutively active AR-V7, one of the major androgen receptor (AR) splice variants lacking the ligand-binding domain, plays a key role in the development of castration-resistant prostate cancer (CRPC) and anti-androgen resistance. However, our understanding of the regulatory mechanisms of AR-V7-driven transcription is limited. Here we report DBC1 as a key regulator of AR-V7 transcriptional activity and stability in CRPC cells. DBC1 functions as a coactivator for AR-V7 and is required for the expression of AR-V7 target genes including CDH2, a mesenchymal marker linked to CRPC progression. DBC1 is required for recruitment of AR-V7 to its target enhancers and for long-range chromatin looping between the CDH2 enhancer and promoter. Mechanistically, DBC1 enhances DNA-binding activity of AR-V7 by direct interaction and inhibits CHIP E3 ligase-mediated ubiquitination and degradation of AR-V7 by competing with CHIP for AR-V7 binding, thereby stabilizing and activating AR-V7. Importantly, DBC1 depletion suppresses the tumorigenic and metastatic properties of CRPC cells. Our results firmly establish DBC1 as a critical AR-V7 coactivator that plays a key role in the regulation of DNA binding and stability of AR-V7 and has an important physiological role in CRPC progression.	[Moon, Sue Jin; Kim, Hwa Jin; Kim, Jeong Hoon] Sungkyunkwan Univ, Dept Hlth Sci & Technol, Samsung Adv Inst Hlth Sci & Technol, Seoul, South Korea; [Moon, Sue Jin; Kim, Hwa Jin; Kim, Jeong Hoon] Samsung Med Ctr, Samsung Biomed Res Inst, Dept Biomed Sci, Seoul, South Korea; [Jeong, Byong Chang; Lim, Joung Eun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea; [Kwon, Ghee Young] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Kim, JH (corresponding author), Sungkyunkwan Univ, Dept Hlth Sci & Technol, Samsung Adv Inst Hlth Sci & Technol, Seoul, South Korea.; Kim, JH (corresponding author), Samsung Med Ctr, Samsung Biomed Res Inst, Dept Biomed Sci, Seoul, South Korea.	jeongkim@skku.edu			National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [2016R1A2B4008661]; Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI17C0117]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	We thank Dr. Robert Roeder (Rockefeller University) for HA-Ubiquitin expression plasmid. This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning [2016R1A2B4008661]; and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [HI17C0117].	An J, 2014, CELL REP, V6, P657, DOI 10.1016/j.celrep.2014.01.013; Antonarakis ES, 2016, PROSTATE CANCER P D, V19, P231, DOI 10.1038/pcan.2016.17; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; Cardozo CP, 2003, ARCH BIOCHEM BIOPHYS, V410, P134, DOI 10.1016/S0003-9861(02)00680-X; Chini CCS, 2010, J BIOL CHEM, V285, P40830, DOI 10.1074/jbc.M110.153270; Cottard F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063466; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; DePaolo JS, 2016, ONCOTARGET, V7, P71417, DOI 10.18632/oncotarget.12163; Fu JJ, 2009, J BIOL CHEM, V284, P6832, DOI 10.1074/jbc.M808988200; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Imamura Y, 2016, INT J UROL, V23, P654, DOI 10.1111/iju.13137; Jennbacken K, 2010, ENDOCR-RELAT CANCER, V17, P469, DOI 10.1677/ERC-10-0015; Kim HO, 2015, IEEE GEOSC REM SEN M, V3, P34, DOI 10.1109/MGRS.2014.2382652; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001; Kong DJ, 2015, PROSTATE, V75, P161, DOI 10.1002/pros.22901; Krause WC, 2014, INT J BIOCHEM CELL B, V54, P49, DOI 10.1016/j.biocel.2014.06.013; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li ZY, 2009, J BIOL CHEM, V284, P10361, DOI 10.1074/jbc.M900956200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Liu G, 2015, ONCOTARGET, V6, P288, DOI 10.18632/oncotarget.2672; Lu J, 2015, NAT REV UROL, V12, P137, DOI 10.1038/nrurol.2015.13; Lu J, 2015, J UROLOGY, V193, P690, DOI 10.1016/j.juro.2014.08.043; Makkonen H, 2009, NUCLEIC ACIDS RES, V37, P4135, DOI 10.1093/nar/gkp352; Masuda K, 2005, J MOL BIOL, V353, P763, DOI 10.1016/j.jmb.2005.09.009; McClurg UL, 2017, NUCLEIC ACIDS RES, V45, P1793, DOI 10.1093/nar/gkw1162; McGrath MJ, 2013, CANCER RES, V73, P5066, DOI 10.1158/0008-5472.CAN-12-4520; Noh SJ, 2013, PATHOLOGY, V45, P574, DOI 10.1097/PAT.0b013e3283652c7a; Park HS, 2013, TRANSL ONCOL, V6, P370, DOI 10.1593/tlo.13250; Portillo-Lara R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130118; Qin B, 2015, CELL REP, V10, P1324, DOI 10.1016/j.celrep.2015.01.066; Seo WY, 2013, NUCLEIC ACIDS RES, V41, P8526, DOI 10.1093/nar/gkt644; Shafi AA, 2013, PHARMACOL THERAPEUT, V140, P223, DOI 10.1016/j.pharmthera.2013.07.003; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Takayama K, 2007, ONCOGENE, V26, P4453, DOI 10.1038/sj.onc.1210229; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; van de Wijngaart DJ, 2012, MOL CELL ENDOCRINOL, V352, P57, DOI 10.1016/j.mce.2011.08.007; van der Steen T, 2013, INT J MOL SCI, V14, P14833, DOI 10.3390/ijms140714833; Wagle S, 2015, SCI REP-UK, V5, DOI 10.1038/srep13144; Yu EJ, 2016, ONCOGENE, V35, P3410, DOI 10.1038/onc.2015.401; Yu EJ, 2011, NUCLEIC ACIDS RES, V39, P6932, DOI 10.1093/nar/gkr347	45	18	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1326	1339		10.1038/s41388-017-0047-5	http://dx.doi.org/10.1038/s41388-017-0047-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29249800				2022-12-17	WOS:000427279300005
J	Patrussi, L; Capitani, N; Cattaneo, F; Manganaro, N; Gamberucci, A; Frezzato, F; Martini, V; Visentin, A; Pelicci, PG; D'Elios, MM; Trentin, L; Semenzato, G; Baldari, CT				Patrussi, Laura; Capitani, Nagaja; Cattaneo, Francesca; Manganaro, Noemi; Gamberucci, Alessandra; Frezzato, Federica; Martini, Veronica; Visentin, Andrea; Pelicci, Pier Giuseppe; D'Elios, Mario M.; Trentin, Livio; Semenzato, Gianpietro; Baldari, Cosima T.			p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from beta-arrestin at early endosomes	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; CHEMOKINE RECEPTOR; S1P1 EXPRESSION; RAB GTPASES; IN-VIVO; TRAFFICKING; BTK; CHEMOTAXIS; IBRUTINIB; ACTIVATION	Neoplastic cell traffic abnormalities are central to the pathogenesis of chronic lymphocytic leukemia (CLL). Enhanced CXC chemokine receptor- 4 (CXCR4) and chemokine receptor- 7 (CCR7) recycling contributes to the elevated surface levels of these receptors on CLL cells. Here we have addressed the role of p66Shc, a member of the Shc family of protein adaptors the expression of which is defective in CLL cells, in CXCR4/CCR7 recycling. p66Shc reconstitution in CLL cells reduced CXCR4/CCR7 recycling, lowering their surface levels and attenuating B-cell chemotaxis, due to their accumulation in Rab5(+) endosomes as serine-phosphoproteins bound to beta-arrestin. This results from the ability of p66Shc to inhibit Ca2+ and PP2B-dependent CXCR4/CCR7 dephosphorylation and beta-arrestin release. We also show that ibrutinib, a Btk inhibitor that promotes leukemic cell mobilization from lymphoid organs, reverses the CXCR4/CCR7 recycling abnormalities in CLL cells by increasing p66Shc expression. These results, identifying p66Shc as a regulator of CXCR4/CCR7 recycling in B cells, underscore the relevance of its deficiency to CLL pathogenesis and provide new clues to the mechanisms underlying the therapeutic effects of ibrutinib.	[Patrussi, Laura; Capitani, Nagaja; Cattaneo, Francesca; Manganaro, Noemi; Baldari, Cosima T.] Univ Siena, Dept Life Sci, Siena, Italy; [Capitani, Nagaja; D'Elios, Mario M.] Univ Florence, Dept Clin & Expt Med, Florence, Italy; [Gamberucci, Alessandra] Univ Siena, Dept Mol & Dev Med, Siena, Italy; [Frezzato, Federica; Martini, Veronica; Visentin, Andrea; Trentin, Livio; Semenzato, Gianpietro] Venetian Inst Mol Med, Padua, Italy; [Frezzato, Federica; Martini, Veronica; Visentin, Andrea; Trentin, Livio; Semenzato, Gianpietro] Univ Padua, Sch Med, Dept Med, Hematol & Clin Immunol Branch, Padua, Italy; [Pelicci, Pier Giuseppe] European Inst Oncol, Milan, Italy	University of Siena; University of Florence; University of Siena; Veneto Institute Molecular Medicine; University of Padua; IRCCS European Institute of Oncology (IEO)	Patrussi, L; Baldari, CT (corresponding author), Univ Siena, Dept Life Sci, Siena, Italy.	patrussi2@unisi.it; baldari@unisi.it	Pelicci, Pier Giuseppe/AAL-6572-2020; TRENTIN, LIVIO/L-6678-2019; TRENTIN, LIVIO/J-7676-2016; Martini, Veronica/AAV-6339-2020; Visentin, Andrea/M-5872-2019; FREZZATO, Federica/V-5802-2019; Visentin, Andrea/L-7379-2017; D'Elios, Mario Milco/Y-9573-2019; Patrussi, Laura/AAD-4332-2020	TRENTIN, LIVIO/0000-0003-1222-6149; TRENTIN, LIVIO/0000-0003-1222-6149; Visentin, Andrea/0000-0003-0271-7200; FREZZATO, Federica/0000-0001-7093-2493; Visentin, Andrea/0000-0001-6830-6717; D'Elios, Mario Milco/0000-0001-9160-0930; MANGANARO, NOEMI/0000-0001-8512-4704; Patrussi, Laura/0000-0003-1542-6955; Baldari, Cosima/0000-0002-4414-6744	AIRC [IG-15220, IG-15286, IG-15397]; ITT-Regione Toscana; Cariparo; Cariverona	AIRC(Fondazione AIRC per la ricerca sul cancro); ITT-Regione Toscana; Cariparo(Fondazione Cariparo); Cariverona(Fondazione Cariverona)	This work was carried out with the support of grant AIRC IG-15220 and ITT-Regione Toscana to CTB, AIRC IG-15286, Cariparo and Cariverona to GS and AIRC IG-15397 to LT.	Bamidele AO, 2015, J CELL BIOL, V210, P257, DOI 10.1083/jcb.201411045; Berlin I, 2010, J BIOL CHEM, V285, P37895, DOI 10.1074/jbc.M110.129411; Bolinger MT, 2016, MOL CELL BIOL, V36, P2051, DOI 10.1128/MCB.00053-16; Boncristiano M, 2003, J EXP MED, V198, P1887, DOI 10.1084/jem.20030621; Bowman SL, 2016, J CELL BIOL, V214, P797, DOI 10.1083/jcb.201512068; Burkle A, 2007, BLOOD, V110, P3316, DOI 10.1182/blood-2007-05-089409; Burger JA, 2015, NEW ENGL J MED, V373, P2425, DOI 10.1056/NEJMoa1509388; Burger JA, 2014, SEMIN CANCER BIOL, V24, P71, DOI 10.1016/j.semcancer.2013.08.011; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Calebiro D, 2010, TRENDS PHARMACOL SCI, V31, P221, DOI 10.1016/j.tips.2010.02.002; Capitani N, 2012, BLOOD, V120, P4391, DOI 10.1182/blood-2012-04-425959; Capitani N, 2010, BLOOD, V115, P3726, DOI 10.1182/blood-2009-08-239244; Cattaneo F, 2016, ONCOTARGET, V7, P57086, DOI 10.18632/oncotarget.10977; Charest-Morin X, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00122; Cheng S, 2014, LEUKEMIA, V28, P649, DOI 10.1038/leu.2013.358; Comerford I, 2013, CYTOKINE GROWTH F R, V24, P269, DOI 10.1016/j.cytogfr.2013.03.001; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; Finetti F, 2009, NAT CELL BIOL, V11, P1332, DOI 10.1038/ncb1977; Gamberucci A, 2004, CELL CALCIUM, V36, P175, DOI 10.1016/j.ceca.2004.03.002; Gurevich VV, 2015, PROG MOL BIOL TRANSL, V132, P1, DOI 10.1016/bs.pmbts.2015.02.010; Hauser MA, 2016, J LEUKOCYTE BIOL, V99, P869, DOI 10.1189/jlb.2MR0815-380R; Herman SEM, 2015, CLIN CANCER RES, V21, P4642, DOI 10.1158/1078-0432.CCR-15-0781; Hjorto GM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00568; Jin L, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0884-7; Kang DS, 2014, CURR OPIN CELL BIOL, V27, P63, DOI 10.1016/j.ceb.2013.11.005; Kehrl JH, 2009, CURR TOP MICROBIOL, V334, P107, DOI 10.1007/978-3-540-93864-4_5; Kennedy JE, 2015, PROG MOL BIOL TRANSL, V132, P15, DOI 10.1016/bs.pmbts.2015.02.005; Kucia M, 2004, J MOL HISTOL, V35, P233; Kurtova AV, 2009, BLOOD, V114, P4441, DOI 10.1182/blood-2009-07-233718; Lagane B, 2008, BLOOD, V112, P34, DOI 10.1182/blood-2007-07-102103; Lee Chung-Shien, 2016, J Oncol Pharm Pract, V22, P92, DOI 10.1177/1078155214561281; Li LS, 2017, J CELL SCI, V130, P1475, DOI 10.1242/jcs.198937; Lopez-Giral S, 2004, J LEUKOCYTE BIOL, V76, P462, DOI 10.1189/jlb.1203652; MANDERS EMM, 1992, J CELL SCI, V103, P857; Marchese A, 2014, CURR OPIN CELL BIOL, V27, P72, DOI 10.1016/j.ceb.2013.11.011; Martinez-Martinez S, 2004, CURR MED CHEM, V11, P997, DOI 10.2174/0929867043455576; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Murray AJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.122re4; Otero C, 2008, J CELL SCI, V121, P2759, DOI 10.1242/jcs.029074; Otero C, 2006, J IMMUNOL, V177, P2314, DOI 10.4049/jimmunol.177.4.2314; Patrussi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.44; Patrussi L, 2007, BLOOD, V110, P1730, DOI 10.1182/blood-2007-01-068411; Patrussi L, 2017, METHODS MOL BIOL, V1584, P143, DOI 10.1007/978-1-4939-6881-7_10; Patrussi L, 2015, CANCER RES, V75, P4153, DOI 10.1158/0008-5472.CAN-15-0986; Pedersen IM, 2004, LEUKEMIA LYMPHOMA, V45, P2365, DOI 10.1080/10428190412331272703; Plyte S, 2001, J BIOL CHEM, V276, P14350, DOI 10.1074/jbc.M007854200; Redondo-Munoz J, 2008, BLOOD, V111, P383, DOI 10.1182/blood-2007-08-107300; Scarfo L, 2016, CRIT REV ONCOL HEMAT, V104, P169, DOI 10.1016/j.critrevonc.2016.06.003; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Seachrist JL, 2002, J BIOL CHEM, V277, P679, DOI 10.1074/jbc.M109022200; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; Stacchini A, 1999, LEUKEMIA RES, V23, P127, DOI 10.1016/S0145-2126(98)00154-4; Swingle Mark, 2007, V365, P23; ten Hacken E, 2016, BBA-MOL CELL RES, V1863, P401, DOI 10.1016/j.bbamcr.2015.07.009; van IJzendoorn SCD, 2002, DEV CELL, V2, P219, DOI 10.1016/S1534-5807(02)00115-6; Vasudevan NT, 2011, CELL CYCLE, V10, P3684, DOI 10.4161/cc.10.21.18042; Visentin A, 2015, CL LYMPH MYELOM LEUK, V15, P612, DOI 10.1016/j.clml.2015.06.001; Wienands J, 2000, CURR TOP MICROBIOL, V245, P53; Wodarz D, 2014, BLOOD, V123, P4132, DOI 10.1182/blood-2014-02-554220; Zhang YY, 2004, STEM CELLS, V22, P1015, DOI 10.1634/stemcells.22-6-1015; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	62	18	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1534	1550		10.1038/s41388-017-0066-2	http://dx.doi.org/10.1038/s41388-017-0066-2			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29326436	Green Published			2022-12-17	WOS:000427459500010
J	Sun, LL; Yu, SY; Xu, H; Zheng, YW; Lin, JT; Wu, MY; Wang, JD; Wang, AD; Lan, Q; Furnari, F; Cavenee, W; Purow, B; Li, M				Sun, Lili; Yu, Shuye; Xu, Hui; Zheng, Yanwen; Lin, Juntang; Wu, Meiyan; Wang, Jide; Wang, Aidong; Lan, Qing; Furnari, Frank; Cavenee, Webster; Purow, Benjamin; Li, Ming			FHL2 interacts with EGFR to promote glioblastoma growth	ONCOGENE			English	Article							ONLY PROTEIN FHL2; FACTOR RECEPTOR; SCAFFOLD PROTEIN; ACTIVATION; EXPRESSION; TRANSCRIPTION; LOCALIZATION; DEGRADATION; CONTRIBUTES; CANCER	Four-and-a-half LIM protein2 (FHL2) is a member of the LIM-only protein family, which plays a critical role in tumorigenesis. We previously reported that FHL2 is upregulated and plays an oncogenic role in glioblastoma (GBM), the most common and aggressive brain tumor. GBM is also marked by amplification of the epidermal growth factor receptor (EGFR) gene and its mutations, of which EGFRvIII is the most common and functionally significant. Here we report that FHL2 physically interacts with the wild-type EGFR and its mutated EGFRvIII form in GBM cells. Expression of FHL2 caused increased EGFR and EGFRvIII protein levels and this was due to an increase in protein stability rather than an increase in EGFR mRNA expression. In contrast, FHL2 knockdown using RNA interference reduced EGFR and EGFRvIII protein expression and the phosphorylation levels of EGFR and AKT. Consistent with these features, EGFR expression was significantly lower in mouse FHL2-null astrocytes, where reintroduction of FHL2 was able to restore EGFR levels. Using established GBM cell lines and patient-derived neurosphere lines, FHL2 silencing markedly induced cell apoptosis in EGFRvIII-positive cells. Targeting FHL2 significantly prevented EGFRvIII-positive GBM tumor growth in vivo. FHL2 expression also positively correlated with EGFR expression in GBM samples from patients. Taken together, our results demonstrate that FHL2 interacts with EGFR and EGFRvIII to increase their levels and this promotes glioma growth, representing a novel mechanism that may be therapeutically targetable.	[Sun, Lili; Yu, Shuye; Xu, Hui; Zheng, Yanwen; Wang, Aidong; Li, Ming] Soochow Univ, Affiliated Hosp 2, Expt Ctr, Suzhou, Peoples R China; [Yu, Shuye] Soochow Univ, Affiliated Hosp 2, Dept Neurol, Suzhou, Peoples R China; [Xu, Hui; Lan, Qing; Li, Ming] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Peoples R China; [Lin, Juntang] Xinxiang Med Univ, Stem Cells & Biotherapy Engn Res Ctr Henan, Xinxiang, Peoples R China; [Wu, Meiyan; Wang, Jide] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Furnari, Frank; Cavenee, Webster] Univ Calif San Diego, Ludwig Inst Canc Res, San Diego, CA 92103 USA; [Purow, Benjamin; Li, Ming] Univ Virginia, Dept Neurol, Charlottesville, VA 22904 USA	Soochow University - China; Soochow University - China; Soochow University - China; Xinxiang Medical University; Southern Medical University - China; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of Virginia	Li, M (corresponding author), Soochow Univ, Affiliated Hosp 2, Expt Ctr, Suzhou, Peoples R China.; Li, M (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Peoples R China.; Li, M (corresponding author), Univ Virginia, Dept Neurol, Charlottesville, VA 22904 USA.	m2liva@hotmail.com	Sun, lili/GQH-2057-2022	Li, Ming/0000-0002-2540-1738	National Natural Science Foundation of China [81572480, 81172401]; Second Affiliated Hospital of Soochow University Youth pre-Research Fund [SDFEYQN1607]; Jiangsu distinguished Medical Professorship award	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Second Affiliated Hospital of Soochow University Youth pre-Research Fund; Jiangsu distinguished Medical Professorship award	This work was supported by grants from the National Natural Science Foundation of China (81572480 and 81172401, to M.L.) and the Second Affiliated Hospital of Soochow University Youth pre-Research Fund (SDFEYQN1607, to L.S.). We thank Drs. Yu Wei and Ju Chen for the generous gifts of FHL2 null MEF cells and FHL2 knockout newborn mice. M.L. was also partially supported by Jiangsu distinguished Medical Professorship award.	Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; Cvrljevic AN, 2011, J CELL SCI, V124, P2938, DOI 10.1242/jcs.083295; Dahan J, 2013, MOL CELL BIOL, V33, P3299, DOI 10.1128/MCB.00105-13; Davies GC, 2006, ONCOGENE, V25, P6497, DOI 10.1038/sj.onc.1209662; Del Vecchio CA, 2012, EXPERT REV VACCINES, V11, P133, DOI [10.1586/ERV.11.177, 10.1586/erv.11.177]; Fielitz J, 2007, P NATL ACAD SCI USA, V104, P4377, DOI 10.1073/pnas.0611726104; Fomchenko EI, 2006, CLIN CANCER RES, V12, P5288, DOI 10.1158/1078-0432.CCR-06-0438; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gabriel B, 2006, J SOC GYNECOL INVEST, V13, P69, DOI 10.1016/j.jsgi.2005.10.001; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Hiratani I, 2003, DEVELOPMENT, V130, P4161, DOI 10.1242/dev.00621; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hsu SC, 2009, AM J TRANSL RES, V1, P249; Hua G, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.207; Jahani-Asl A, 2016, NAT NEUROSCI, V19, P798, DOI 10.1038/nn.4295; Jin H, 2016, ONCOGENE, V35, P5106, DOI 10.1038/onc.2016.54; Labalette C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003761; Lan Q, 2016, ONCOTARGET, V7, P9680, DOI 10.18632/oncotarget.7109; Latha K, 2013, INT J CANCER, V132, P509, DOI 10.1002/ijc.27690; Li L, 2015, ONCOGENE, V34, P129, DOI 10.1038/onc.2013.534; Li M, 2008, GLIA, V56, P1328, DOI 10.1002/glia.20701; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Liu ZY, 2016, ONCOTARGET, V7, P4680, DOI 10.18632/oncotarget.6730; Nishi H, 2002, CANCER RES, V62, P827; Nouet Y, 2012, J HEPATOL, V57, P1029, DOI 10.1016/j.jhep.2012.06.035; Padfield E, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00005; Paul C, 2006, ONCOGENE, V25, P5475, DOI 10.1038/sj.onc.1209567; Purow BW, 2008, CARCINOGENESIS, V29, P918, DOI 10.1093/carcin/bgn079; Read RD, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000374; Sangadala S, 2006, J BIOL CHEM, V281, P17212, DOI 10.1074/jbc.M511013200; Schildge S, 2013, JOVE-J VIS EXP, DOI 10.3791/50079; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stutz MA, 2008, ONCOGENE, V27, P5741, DOI 10.1038/onc.2008.185; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Thorne AH, 2016, NEURO-ONCOLOGY, V18, P914, DOI 10.1093/neuonc/nov319; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Verset L, 2016, HISTOL HISTOPATHOL, V31, P469, DOI 10.14670/HH-11-709; Vouri M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.66; Wang JD, 2007, GASTROENTEROLOGY, V132, P1066, DOI 10.1053/j.gastro.2006.12.004; Zhu H, 2010, CANCER LETT, V294, P101, DOI 10.1016/j.canlet.2010.01.028	40	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1386	1398		10.1038/s41388-017-0068-0	http://dx.doi.org/10.1038/s41388-017-0068-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29321665	Green Accepted			2022-12-17	WOS:000427279300009
J	Monteverde, T; Tait-Mulder, J; Hedley, A; Knight, JR; Sansom, OJ; Murphy, DJ				Monteverde, T.; Tait-Mulder, J.; Hedley, A.; Knight, J. R.; Sansom, O. J.; Murphy, D. J.			Calcium signalling links MYC to NUAK1	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; TARGETING NUAK1; C-ALPHA; INDUCED APOPTOSIS; POOR-PROGNOSIS; AMPK; CANCER; BETA; EXPRESSION	NUAK1 is a member of the AMPK-related family of kinases. Recent evidence suggests that NUAK1 is an important regulator of cell adhesion and migration, cellular and organismal metabolism, and regulation of TAU stability. As such, NUAK1 may play key roles in multiple diseases ranging from neurodegeneration to diabetes and metastatic cancer. Previous work revealed a crucial role for NUAK1 in supporting viability of tumour cells specifically when MYC is overexpressed. This role is surprising, given that NUAK1 is activated by the tumour suppressor LKB1. Here we show that, in tumour cells lacking LKB1, NUAK1 activity is maintained by an alternative pathway involving calcium-dependent activation of PKC alpha. Calcium/PKC alpha-dependent activation of NUAK1 supports engagement of the AMPK-TORC1 metabolic checkpoint, thereby protecting tumour cells from MYC-driven cell death, and indeed, MYC selects for this pathway in part via transcriptional regulation of PKC alpha and ITPR. Our data point to a novel role for calcium in supporting tumour cell viability and clarify the synthetic lethal interaction between NUAK1 and MYC.	[Monteverde, T.; Tait-Mulder, J.; Sansom, O. J.; Murphy, D. J.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Hedley, A.; Knight, J. R.; Sansom, O. J.; Murphy, D. J.] CRUK Beatson Inst, Garscube Estate, Glasgow, Lanark, Scotland	University of Glasgow; Beatson Institute	Murphy, DJ (corresponding author), Univ Glasgow, Inst Canc Sci, CRUK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	daniel.murphy@glasgow.ac.uk	Murphy, Daniel/V-1079-2019; Knight, John/V-2922-2019	Murphy, Daniel/0000-0002-5538-5468; Knight, John/0000-0002-8771-5484; Sansom, Owen J./0000-0001-9540-3010	British Lung Foundation [APHD13-5]; Wellcome trust [105614/Z/14/Z]; European Commission Marie Curie actions [CIG 618448]; Cancer Research UK [22311] Funding Source: researchfish; Versus Arthritis [21139] Funding Source: researchfish	British Lung Foundation; Wellcome trust(Wellcome Trust); European Commission Marie Curie actions(European Commission); Cancer Research UK(Cancer Research UK); Versus Arthritis(Versus Arthritis)	We acknowledge valuable input from the entire Murphy laboratory and numerous colleagues at the University of Glasgow Institute of Cancer Sciences and CRUK Beatson Institute. Nuak1 inhibitors were generously provided by Nathanael Gray prior to commercial availability. TM was supported by grant APHD13-5 from the British Lung Foundation. Additional support was provided by Wellcome trust grant 105614/Z/14/Z; the European Commission Marie Curie actions CIG 618448 'SERPLUC' to DJM and institutional support provided by the University of Glasgow & CRUK Beatson Institute to DJM.	ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Adey A, 2013, NATURE, V500, P207, DOI 10.1038/nature12064; Banerjee S, 2014, BIOCHEM J, V457, P215, DOI 10.1042/BJ20131152; Barr LF, 1997, CELL GROWTH DIFFER, V8, P381; Bell RE, 2014, J INVEST DERMATOL, V134, P441, DOI 10.1038/jid.2013.340; Benaich N, 2014, CELL REP, V9, P104, DOI 10.1016/j.celrep.2014.08.062; Carling D, 2008, INT J OBESITY, V32, pS55, DOI 10.1038/ijo.2008.124; Cermelli S, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014209; Chen P, 2013, EXP LUNG RES, V39, P9, DOI 10.3109/01902148.2012.744115; Conacci-Sorrell M, 2010, CELL, V142, P480, DOI 10.1016/j.cell.2010.06.037; Courchet J, 2013, CELL, V153, P1510, DOI 10.1016/j.cell.2013.05.021; Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50; DREXLER HG, 1989, BLOOD, V73, P1656; Evan GI, 2005, COLD SH Q B, V70, P263, DOI 10.1101/sqb.2005.70.054; Fisher JS, 2005, AM J PHYSIOL-ENDOC M, V289, pE986, DOI 10.1152/ajpendo.00335.2004; Fogarty S, 2010, BIOCHEM J, V426, P109, DOI 10.1042/BJ20091372; Goodwin JM, 2014, MOL CELL, V55, P436, DOI 10.1016/j.molcel.2014.06.021; Graff JR, 2005, CANCER RES, V65, P7462, DOI 10.1158/0008-5472.CAN-05-0071; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Habib T, 2007, J CELL BIOL, V179, P717, DOI 10.1083/jcb.200704173; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardie DG, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-36; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327; Hirano M, 2006, DEV DYNAM, V235, P2229, DOI 10.1002/dvdy.20823; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Huang X, 2014, INT J MOL MED, V34, P1599, DOI 10.3892/ijmm.2014.1940; Humbert N, 2010, EMBO J, V29, P376, DOI 10.1038/emboj.2009.342; Inazuka F, 2012, J BIOL CHEM, V287, P16379, DOI 10.1074/jbc.M111.302687; Kawakami Y, 2004, J BIOL CHEM, V279, P47720, DOI 10.1074/jbc.M408797200; Kusakai G, 2004, AM J PATHOL, V164, P987, DOI 10.1016/S0002-9440(10)63186-0; Lasagna-Reeves CA, 2016, NEURON, V92, P407, DOI 10.1016/j.neuron.2016.09.022; Li B, 2013, CLIN CANCER RES, V19, P5835, DOI 10.1158/1078-0432.CCR-12-3629; Li RJ, 2016, ELIFE, V5, DOI 10.7554/eLife.19360; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Monteverde T, 2015, FEBS J, V282, P4658, DOI 10.1111/febs.13534; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Muthalagu N, 2014, CELL REP, V8, P1347, DOI 10.1016/j.celrep.2014.07.057; Obayashi M, 2016, ONCOTARGET, V7, P8223, DOI 10.18632/oncotarget.6972; Ohmura T, 2012, DEV DYNAM, V241, P1350, DOI 10.1002/dvdy.23816; Partovian C, 2004, CELL SIGNAL, V16, P951, DOI 10.1016/j.cellsig.2004.01.008; Phippen NT, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2015.00213; Popovics P, 2015, EXPERT OPIN THER TAR, V19, P617, DOI 10.1517/14728222.2015.1005603; Raffeiner P, 2017, ONCOTARGET, V8, P3327, DOI 10.18632/oncotarget.13759; Reihill JA, 2007, BIOCHEM BIOPH RES CO, V354, P1084, DOI 10.1016/j.bbrc.2007.01.110; Reyland ME, 2007, APOPTOSIS CELL SIGNA, V2, P1; Riester M, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju048; Ross FA, 2016, FEBS J, V283, P2987, DOI 10.1111/febs.13698; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shen L, 1999, MOL PHARMACOL, V55, P396, DOI 10.1124/mol.55.2.396; Shi L, 2014, BRIT J CANCER, V111, P2316, DOI 10.1038/bjc.2014.580; Vincent EE, 2015, ONCOGENE, V34, P3627, DOI 10.1038/onc.2014.301; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Whelan RDH, 1999, CELL GROWTH DIFFER, V10, P271; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xiong XK, 2015, BIOCHEM BIOPH RES CO, V465, P262, DOI 10.1016/j.bbrc.2015.08.013; Zagorska A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000616; Zhang HY, 2015, ONCOL REP, V34, P1193, DOI 10.3892/or.2015.4113; Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010	64	18	19	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					982	992		10.1038/onc.2017.394	http://dx.doi.org/10.1038/onc.2017.394			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106388	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000425905700002
J	Song, C; Liang, L; Jin, Y; Li, Y; Liu, Y; Guo, L; Wu, C; Yun, CH; Yin, Y				Song, C.; Liang, L.; Jin, Y.; Li, Y.; Liu, Y.; Guo, L.; Wu, C.; Yun, C-H; Yin, Y.			RCC2 is a novel p53 target in suppressing metastasis	ONCOGENE			English	Article							CHROMOSOME CONDENSATION RCC1; EXTRACELLULAR-MATRIX CUES; CELL-MIGRATION; TRANSCRIPTION TARGET; COLORECTAL-CANCER; RHO-GTPASES; GENE; REGULATOR; INSTABILITY; EXPRESSION	RCC2 (also known as TD60) is a highly conserved protein involved in prognosis in colorectal cancer. However, its relationship with tumor development is less understood. Here we demonstrate a signaling pathway defining regulation of RCC2 and its functions in tumor progression. We report that p53 is a transcriptional regulator of RCC2 that acts through its binding to a palindromic motif in the RCC2 promoter. RCC2 physically interacts and deactivates a small GTPase Rac1 that is known to be involved in metastasis. We solved a high-resolution crystal structure of RCC2 and revealed one RCC1-like domain with a unique beta-hairpin that is requisite for RCC2 interaction with Rac1. p53 or RCC2 deficiency leads to activation of Rac1 and deterioration of extracellular matrix sensing (haptotaxis) of surface-bound gradients. Ectopic expression of RCC2 restores directional migration in p53-null cells. Our results demonstrate that p53 and RCC2 signaling is important for regulation of cell migration and suppression of metastasis. We propose that the p53/RCC2/Rac1 axis is a potential target for cancer therapy.	Peking Univ, Hlth Sci Ctr, Inst Syst Biomed,Peking Tsinghua Ctr Life Sci, Dept Pathol,Sch Basic Med Sci,Beijing Key Lab Tum, Beijing, Peoples R China; Peking Univ, Hlth Sci Ctr, Inst Syst Biomed,Peking Tsinghua Ctr Life Sci, Dept Biophys,Sch Basic Med Sci,Beijing Key Lab Tu, Beijing, Peoples R China	Peking University; Peking University	Yun, CH; Yin, Y (corresponding author), Peking Univ, Hlth Sci Ctr, Inst Syst Biomed, Dept Pathol, 38 XueYuan Rd, Beijing 100191, Peoples R China.	yunch@hsc.pku.edu.cn; yinyuxin@hsc.pku.edu.cn	云, 彩红/E-1437-2018		National Natural Science Foundation of China [81430056, 31420103905, 81301801, 81621063, 31270769]; National Key Research and Development Program of China [2016YFA0500302]; Beijing Natural Science Foundation [7161007]; Lam Chung Nin Foundation for Systems Biomedicine	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Beijing Natural Science Foundation(Beijing Natural Science Foundation); Lam Chung Nin Foundation for Systems Biomedicine	We thank the staff of the Argonne National Laboratory (ID19) and the Shanghai SSRF Beamline (BL17U1 and BL19U1) for technical assistance. We thank X Chen, L Yuan, D Lu, G Wang, J Feng, C Zhang and S He for technical assistance and critical discussion. This work was supported by the following grants to YY including: National Natural Science Foundation of China (Key Grants 81430056, 31420103905, 81301801 and 81621063), National Key Research and Development Program of China (Grant 2016YFA0500302), Beijing Natural Science Foundation (Key Grant 7161007) and the Lam Chung Nin Foundation for Systems Biomedicine. C-HY was supported by the grant 31270769 from the National Natural Science Foundation of China.	Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bosco EE, 2010, BLOOD, V115, P3320, DOI 10.1182/blood-2009-02-202440; Bruun J, 2015, CLIN CANCER RES, V21, P3759, DOI 10.1158/1078-0432.CCR-14-3294; Chan KT, 2014, J CELL BIOL, V207, P299, DOI 10.1083/jcb.201404067; Davis MJ, 2013, P NATL ACAD SCI USA, V110, P912, DOI 10.1073/pnas.1220895110; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Gupton SL, 2006, CELL, V125, P1361, DOI 10.1016/j.cell.2006.05.029; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hompland T, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2983664; Humphries JD, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000396; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Liu WJ, 2012, CANCER CELL, V21, P751, DOI 10.1016/j.ccr.2012.03.048; Liu YX, 2008, MOL CANCER RES, V6, P624, DOI 10.1158/1541-7786.MCR-07-2019; Makde RD, 2010, NATURE, V467, P562, DOI 10.1038/nature09321; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; MIYASHITA T, 1995, CELL, V80, P293; Mollinari C, 2003, DEV CELL, V5, P295, DOI 10.1016/S1534-5807(03)00205-3; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rosasco-Nitcher SE, 2008, SCIENCE, V319, P469, DOI 10.1126/science.1148980; Shen WH, 2006, CANCER RES, V66, P6033, DOI 10.1158/0008-5472.CAN-05-3878; Sun Z, 2014, CELL REP, V6, P844, DOI 10.1016/j.celrep.2014.01.030; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wu CY, 2012, CELL, V148, P973, DOI 10.1016/j.cell.2011.12.034; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Zhao RB, 2000, GENE DEV, V14, P981	41	18	20	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					8	17		10.1038/onc.2017.306	http://dx.doi.org/10.1038/onc.2017.306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869598	Green Published, hybrid			2022-12-17	WOS:000422625000002
J	Do, MT; Chai, TF; Casey, PJ; Wang, M				Do, M. T.; Chai, T. F.; Casey, P. J.; Wang, M.			Isoprenylcysteine carboxylmethyltransferase function is essential for RAB4A-mediated integrin beta 3 recycling, cell migration and cancer metastasis	ONCOGENE			English	Article							GDP DISSOCIATION INHIBITOR; PROSTATE-CANCER; TUMOR-GROWTH; RAB GTPASES; ALPHA-V-BETA-3 INTEGRIN; EPITHELIAL-CELLS; EARLY ENDOSOMES; BREAST-CANCER; PHASE-II; K-RAS	Isoprenylcysteine carboxylmethyltransferase (ICMT) catalyzes the post-translational modification of RAB GTPases that contain C-terminal CXC motifs. However, the functional impact of this modification on RAB proteins has not been actively explored. We found that inhibition of ICMT significantly reduced cell migration in vitro and cancer invasion and metastasis in vivo. This role of ICMT was found to be mediated by RAB4A, an essential regulator of the fast recycling of integrin beta 3. Integrin beta 3 regulates cell polarity and migration when localized appropriately to the plasma membrane, thereby having an essential role in cancer metastasis. ICMT catalyzed carboxylmethylation is critical for RAB4A activation and interaction with effectors, its localization to endosomes and recycling vesicles, and hence important for RAB4A-dependent integrin beta 3 recycling to plasma membrane. These findings bring attention to the effects of C-terminal carboxylmethylation on RAB GTPases and provide a rationale for targeting ICMT in the treatment of metastatic cancer.	[Do, M. T.; Chai, T. F.; Casey, P. J.; Wang, M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore; [Casey, P. J.] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA; [Wang, M.] Natl Univ Singapore, Dept Biochem, Singapore, Singapore	National University of Singapore; Duke University; National University of Singapore	Wang, M (corresponding author), Duke NUS Med Sch, Program Canc Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	mei.wang@duke-nus.edu.sg		Do, Minh Truong/0000-0002-2319-0287; Casey, Patrick/0000-0002-7366-9309	Ministry of Health through CSA scheme; Ministry of Health through Tier II scheme	Ministry of Health through CSA scheme; Ministry of Health through Tier II scheme	This work is supported by Singapore Ministries of Education and Ministry of Health for funding of this project through their Tier II and CSA schemes, respectively. We are grateful for the help on CAM assays by Dr Suhail Ahmed Kabeer Rasheed of Duke-NUS. The authors confirm that neither the submitted manuscript nor any similar manuscript, in whole or in part, is under consideration, in press, or reported elsewhere.	ARAKI S, 1990, J BIOL CHEM, V265, P13007; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Beekman KW, 2006, CLIN GENITOURIN CANC, V4, P299, DOI 10.3816/CGC.2006.n.012; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Cushman I, 2011, CELL ADHES MIGR, V5, P11, DOI 10.4161/cam.5.1.13196; Cushman I, 2009, J BIOL CHEM, V284, P27964, DOI 10.1074/jbc.M109.025296; D'Souza RS, 2014, CURR BIOL, V24, P1187, DOI 10.1016/j.cub.2014.04.003; Deneka M, 2003, EMBO J, V22, P2645, DOI 10.1093/emboj/cdg257; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Frame MC, 2010, NAT REV MOL CELL BIO, V11, P802, DOI 10.1038/nrm2996; Frittoli E, 2014, J CELL BIOL, V206, P307, DOI 10.1083/jcb.201403127; Gruber G, 2005, BRIT J CANCER, V92, P41, DOI 10.1038/sj.bjc.6602278; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hanker AB, 2010, ONCOGENE, V29, P380, DOI 10.1038/onc.2009.336; Hosotani Ryo, 2002, Pancreas, V25, pe30, DOI 10.1097/00006676-200208000-00021; Ignatev A, 2008, J BIOL CHEM, V283, P18377, DOI 10.1074/jbc.M709718200; Knight JB, 2000, ENDOCRINOLOGY, V141, P208, DOI 10.1210/en.141.1.208; Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22; Lau HY, 2014, CANCER BIOL THER, V15, P1280, DOI 10.4161/cbt.29692; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Legler DF, 2001, J CELL SCI, V114, P1545; Leung KF, 2007, J BIOL CHEM, V282, P1487, DOI 10.1074/jbc.M605557200; LI GP, 1993, ARCH BIOCHEM BIOPHYS, V304, P471, DOI 10.1006/abbi.1993.1377; Manu KA, 2017, MOL CANCER THER, V16, P914, DOI 10.1158/1535-7163.MCT-16-0703; McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429; Paul NR, 2015, CURR BIOL, V25, pR1092, DOI 10.1016/j.cub.2015.09.049; Pfeffer S, 2004, NAT REV MOL CELL BIO, V5, P886, DOI 10.1038/nrm1500; Ratajczak MZ, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-95; Reardon DA, 2008, J CLIN ONCOL, V26, P5610, DOI 10.1200/JCO.2008.16.7510; Reynolds AR, 2009, NAT MED, V15, P392, DOI 10.1038/nm.1941; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Serrels B, 2007, NAT CELL BIOL, V9, P1046, DOI 10.1038/ncb1626; Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398; SMELAND TE, 1994, P NATL ACAD SCI USA, V91, P10712, DOI 10.1073/pnas.91.22.10712; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Teh JT, 2015, ONCOGENE, V34, P3296, DOI 10.1038/onc.2014.260; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wang M, 2010, ONCOGENE, V29, P4959, DOI 10.1038/onc.2010.247; Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200; Wang M, 2016, NAT REV MOL CELL BIO, V17, P110, DOI 10.1038/nrm.2015.11; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; White DP, 2007, J CELL BIOL, V177, P515, DOI 10.1083/jcb.200609004; Woods AJ, 2004, EMBO J, V23, P2531, DOI 10.1038/sj.emboj.7600267; Zhu WL, 2011, J BIOL CHEM, V286, P35291, DOI 10.1074/jbc.M111.280990; Zijlstra A, 2002, CANCER RES, V62, P7083	52	18	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5757	5767		10.1038/onc.2017.183	http://dx.doi.org/10.1038/onc.2017.183			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28604748	Green Published, hybrid			2022-12-17	WOS:000412843900009
J	Zamborszky, J; Szikriszt, B; Gervai, JZ; Pipek, O; Poti, A; Krzystanek, M; Ribli, D; Szalai-Gindl, JM; Csabai, I; Szallasi, Z; Swanton, C; Richardson, AL; Szuts, D				Zamborszky, J.; Szikriszt, B.; Gervai, J. Z.; Pipek, O.; Poti, A.; Krzystanek, M.; Ribli, D.; Szalai-Gindl, J. M.; Csabai, I.; Szallasi, Z.; Swanton, C.; Richardson, A. L.; Szuts, D.			Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions (vol 36, pg 746, 2017)	ONCOGENE			English	Correction													Pipek, Orsolya/J-3124-2018; Csabai, Istvan/F-6045-2011; Szuts, David/N-1149-2016	Pipek, Orsolya/0000-0001-8109-0340; Csabai, Istvan/0000-0001-9232-9898; Szallasi, Zoltan/0000-0001-5395-7509; Szuts, David/0000-0001-7985-0136	Novo Nordisk Fonden [NNF15OC0016584] Funding Source: researchfish; The Danish Cancer Society [R90-A6213] Funding Source: researchfish	Novo Nordisk Fonden(Novo Nordisk Foundation); The Danish Cancer Society(Danish Cancer Society)		Zamborszky J, 2017, ONCOGENE, V36, P746, DOI 10.1038/onc.2016.243	1	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5085	5086		10.1038/onc.2017.213	http://dx.doi.org/10.1038/onc.2017.213			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28650471	Green Published, hybrid			2022-12-17	WOS:000408768800015
J	Jalaguier, S; Teyssier, C; Achour, TN; Lucas, A; Bonnet, S; Rodriguez, C; Elarouci, N; Lapierre, M; Cavailles, V				Jalaguier, S.; Teyssier, C.; Achour, T. Nait; Lucas, A.; Bonnet, S.; Rodriguez, C.; Elarouci, N.; Lapierre, M.; Cavailles, V.			Complex regulation of LCoR signaling in breast cancer cells	ONCOGENE			English	Article							RECEPTOR-INTERACTING PROTEIN-140; DEPENDENT COREPRESSOR ACTS; TRANSCRIPTIONAL REPRESSION; ESTROGEN; RIP140; GENE; EXPRESSION; ALPHA; CONTRIBUTES; ACTIVATION	Ligand-dependent corepressor (LCoR) is a transcriptional repressor of ligand-activated estrogen receptors (ERs) and other transcription factors that acts both by recruiting histone deacetylases and C-terminal binding proteins. Here, we first studied LCOR gene expression in breast cancer cell lines and tissues. We detected two mRNAs variants, LCoR and LCoR2 (which encodes a truncated LCoR protein). Their expression was highly correlated and localized in discrete nuclear foci. LCoR and LCoR2 strongly repressed transcription, inhibited estrogen-induced target gene expression and decreased breast cancer cell proliferation. By mutagenesis analysis, we showed that the helix-turn-helix domain of LCoR is required for these effects. Using in vitro interaction, coimmunoprecipitation, proximity ligation assay and confocal microscopy experiments, we found that receptor-interacting protein of 140 kDa (RIP140) is a LCoR and LCoR2 partner and that this interaction requires the HTH domain of LCoR and RIP140 N- and C-terminal regions. By increasing or silencing LCoR and RIP140 expression in human breast cancer cells, we then showed that RIP140 is necessary for LCoR inhibition of gene expression and cell proliferation. Moreover, LCoR and RIP140 mRNA levels were strongly correlated in breast cancer cell lines and biopsies. In addition, RIP140 positively regulated LCoR expression in human breast cancer cells and in transgenic mouse models. Finally, their expression correlated with overall survival of patients with breast cancer. Taken together, our results provide new insights into the mechanism of action of LCoR and RIP140 and highlight their strong interplay for the control of gene expression and cell proliferation in breast cancer cells.	[Jalaguier, S.; Teyssier, C.; Achour, T. Nait; Lucas, A.; Bonnet, S.; Rodriguez, C.; Lapierre, M.; Cavailles, V.] Inst Rech Cancerol Montpellier, Montpellier, France; [Jalaguier, S.; Teyssier, C.; Achour, T. Nait; Lucas, A.; Bonnet, S.; Rodriguez, C.; Lapierre, M.; Cavailles, V.] INSERM, U1194, Montpellier, France; [Jalaguier, S.; Teyssier, C.; Achour, T. Nait; Lucas, A.; Bonnet, S.; Rodriguez, C.; Lapierre, M.; Cavailles, V.] Univ Montpellier, Montpellier, France; [Jalaguier, S.; Teyssier, C.; Achour, T. Nait; Lucas, A.; Bonnet, S.; Rodriguez, C.; Lapierre, M.; Cavailles, V.] Inst Reg Canc Montpellier, Montpellier, France; [Elarouci, N.] Ligue Natl Contre Le Canc, Programme Cartes Identite Tumeurs CIT, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)	Jalaguier, S; Cavailles, V (corresponding author), INSERM, Inst Rech Cancerol Montpellier, U1194, 208 Rue Apothicaires, F-34298 Montpellier 5, France.	stephan.jalaguier@inserm.fr; vincent.cavailles@inserm.fr	Jalaguier, Stéphan/AAC-1847-2020; cavailles, vincent/C-6277-2017; Teyssier, Catherine/AAC-2395-2020; Cavailles, Vincent/Y-5379-2019; Lapierre, Marion/AAB-2845-2020	Teyssier, Catherine/0000-0003-4937-6503; Cavailles, Vincent/0000-0002-7160-3074; Lapierre, Marion/0000-0002-4708-805X; Jalaguier, Stephan/0000-0002-0149-3738	Ligue Nationale contre le Cancer; Association pour la Recherche contre le Cancer; INSERM, Universite de Montpellier; Prix Ruban Rose	Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); INSERM, Universite de Montpellier; Prix Ruban Rose	We thank Dr Arnaud Besson (CRCT, Toulouse, France) for providing MEF cells expressing or not p21, Dylane Detilleux for her help in characterizing stably transfected T47D cell lines. TNA received grants from Ligue Nationale contre le Cancer and Association pour la Recherche contre le Cancer. This work was funded by INSERM, Universite de Montpellier and the Prix Ruban Rose.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Achour TN, 2014, MOL ENDOCRINOL, V28, P183, DOI 10.1210/me.2013-1376; Aravind L, 2005, FEMS MICROBIOL REV, V29, P231, DOI 10.1016/j.fmrre.2004.12.008; Asim M, 2011, J BIOL CHEM, V286, P37108, DOI 10.1074/jbc.M111.292771; Augereau P, 2006, MOL PHARMACOL, V69, P1338, DOI 10.1124/mol.105.017376; Augereau Patrick, 2006, Nucl Recept Signal, V4, pe024; Augereau P, 2006, J STEROID BIOCHEM, V102, P51, DOI 10.1016/j.jsbmb.2006.09.005; Aziz MH, 2015, ONCOTARGET, V6, P39714, DOI 10.18632/oncotarget.5356; Calderon MR, 2014, NUCLEIC ACIDS RES, V42, P7012, DOI 10.1093/nar/gku413; Calderon MR, 2012, J BIOL CHEM, V287, P8662, DOI 10.1074/jbc.M111.311605; Carascossa S, 2006, MOL ENDOCRINOL, V20, P1506, DOI 10.1210/me.2005-0286; Castet A, 2004, NUCLEIC ACIDS RES, V32, P1957, DOI 10.1093/nar/gkh524; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Christian M, 2005, MOL CELL BIOL, V25, P9383, DOI 10.1128/MCB.25.21.9383-9391.2005; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; Ho PC, 2012, NAT IMMUNOL, V13, P379, DOI 10.1038/ni.2238; Jezequel P, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas060; Lapierre M, 2014, J CLIN INVEST, V124, P1899, DOI 10.1172/JCI65178; Lei JJ, 2015, ONCOTARGET, V6, P25701, DOI 10.18632/oncotarget.4573; Madak-Erdogan Z, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.28; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Muranen TA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3015; Nautiyal J, 2013, DEVELOPMENT, V140, P1079, DOI 10.1242/dev.085720; Orlando S, 2015, NUCLEIC ACIDS RES, V43, P6860, DOI 10.1093/nar/gkv593; Palijan A, 2009, J BIOL CHEM, V284, P30275, DOI 10.1074/jbc.M109.051201; Palijan A, 2009, J BIOL CHEM, V284, P30264, DOI 10.1074/jbc.M109.045526; Poulard C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126181; Rosell M, 2011, BBA-MOL BASIS DIS, V1812, P919, DOI 10.1016/j.bbadis.2010.12.016; Savatier J, 2010, BIOCHEMISTRY-US, V49, P772, DOI 10.1021/bi9013006; Song YY, 2012, J HEPATOL, V56, P248, DOI 10.1016/j.jhep.2011.07.014; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Yang XJ, 2008, MOL CELL, V31, P449, DOI 10.1016/j.molcel.2008.07.002	37	18	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4790	4801		10.1038/onc.2017.97	http://dx.doi.org/10.1038/onc.2017.97			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28414308	Green Published, hybrid			2022-12-17	WOS:000407702400011
J	Bado, I; Gugala, Z; Fuqua, SAW; Zhang, XHF				Bado, I.; Gugala, Z.; Fuqua, S. A. W.; Zhang, X. H-F			Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis	ONCOGENE			English	Review							CALCIUM-SENSING RECEPTOR; CANCER RISK; POSTMENOPAUSAL WOMEN; ESR1 MUTATIONS; MAMMARY-GLAND; VITAMIN-D; ER-ALPHA; OSTEOCLAST DIFFERENTIATION; OSTEOPONTIN EXPRESSION; MESENCHYMAL TRANSITION	Bone metastasis is a prominent cause of morbidity and mortality in cancer. High rates of bone colonization in breast cancer, especially in the subtype expressing estrogen receptors (ERs), suggest tissue-specific proclivities for metastatic tumor formation. The mechanisms behind this subtype-specific organ-tropism remains largely elusive. Interestingly, as the major driver of ER+ breast cancer, ERs also have important roles in bone development and homeostasis. Thus, any agents targeting ER will also inevitably affect the microenvironment, which involves the osteoblasts and osteoclasts. Yet, how such microenvironmental effects are integrated with direct therapeutic responses of cancer cells remain poorly understood. Recent findings on ER mutations, especially their enrichment in bone metastasis, raised even more provocative questions on the role of ER in cancer-bone interaction. In this review, we evaluate the importance of ERs in bone metastasis and discuss new avenues of investigation for bone metastasis treatment based on current knowledge.	[Bado, I.; Fuqua, S. A. W.; Zhang, X. H-F] Baylor Coll Med, Lester & Sue Smith Breast Ctr, BCM600,One Baylor Plaza, Houston, TX 77030 USA; [Bado, I.; Fuqua, S. A. W.; Zhang, X. H-F] Dan L Duncan Canc Ctr, Houston, TX USA; [Bado, I.; Zhang, X. H-F] Dept Mol & Cellular Biol, Houston, TX USA; [Gugala, Z.] Univ Texas Med Branch, Dept Orthopaed Surg & Rehabil, Galveston, TX 77555 USA; [Zhang, X. H-F] Baylor Coll Med, McNair Med Inst, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine	Zhang, XHF (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, BCM600,One Baylor Plaza, Houston, TX 77030 USA.	xiangz@bcm.edu	Bado, Igor/AAY-1214-2021; Gugala, Zbigniew/Q-4075-2019	Bado, Igor/0000-0001-8855-4750; Gugala, Zbigniew/0000-0003-2331-7660	NCI NIH HHS [R01 CA183878] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA183878] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlborg HG, 2003, NEW ENGL J MED, V349, P327, DOI 10.1056/NEJMoa022464; Akinyemiju TF, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1282-2; Aktipis C. Athena, 2015, Evolution Medicine and Public Health, P52, DOI 10.1093/emph/eou028; Alluri PG, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0494-7; Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558; Amend K, 2006, CANCER RES, V66, P8327, DOI 10.1158/0008-5472.CAN-06-1927; Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Bado I, 2016, ONCOTARGET, V7, P13599, DOI 10.18632/oncotarget.7300; Barone I, 2010, CLIN CANCER RES, V16, P2702, DOI 10.1158/1078-0432.CCR-09-1753; Batra GS, 2003, J PATHOL, V200, P65, DOI 10.1002/path.1332; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756-3282(02)00953-5; Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309; Bouris P, 2015, MATRIX BIOL, V43, P42, DOI 10.1016/j.matbio.2015.02.008; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Braidman IP, 2001, J BONE MINER RES, V16, P214, DOI 10.1359/jbmr.2001.16.2.214; Buga S, 2012, CANCER CONTROL, V19, P154, DOI 10.1177/107327481201900210; Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585-007-9127-1; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Carneiro RM, 2010, J CLIN ENDOCR METAB, V95, P1767, DOI 10.1210/jc.2009-1518; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chan KM, 2012, DEV CELL, V22, P1176, DOI 10.1016/j.devcel.2012.04.014; Chen WY, 2004, CANCER, V101, P1490, DOI 10.1002/cncr.20499; Chlebowski RT, 2007, JNCI-J NATL CANCER I, V99, P1695, DOI 10.1093/jnci/djm224; Chu D, 2016, CLIN CANCER RES, V22, P993, DOI 10.1158/1078-0432.CCR-15-0943; Clark AG, 2015, CURR OPIN CELL BIOL, V36, P13, DOI 10.1016/j.ceb.2015.06.004; Clatot F, 2016, ONCOTARGET, V7, P74448, DOI 10.18632/oncotarget.12950; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195; Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331; Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44; Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388; Deroo BJ, 2014, NATURE, V116, P561, DOI DOI 10.1172/JCI27987.SELECTIVE; Dougall WC, 2012, CLIN CANCER RES, V18, P326, DOI 10.1158/1078-0432.CCR-10-2507; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Faupel-Badger JM, 2013, JNCI-J NATL CANCER I, V105, P166, DOI 10.1093/jnci/djs505; Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Fontanella C, 2015, CLIN EXP METASTAS, V32, P819, DOI 10.1007/s10585-015-9743-0; Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061; Friebel TM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju091; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; FUNK JL, 1995, CLIN ENDOCRINOL, V43, P373, DOI 10.1111/j.1365-2265.1995.tb02046.x; Fuqua SAW, 2001, J MAMMARY GLAND BIOL, V6, P407, DOI 10.1023/A:1014782813943; Fuqua SAW, 2014, BREAST CANCER RES TR, V144, P11, DOI 10.1007/s10549-014-2847-4; Futakuchi M, 2016, ADV DRUG DELIVER REV, V99, P206, DOI 10.1016/j.addr.2015.11.017; Galea GL, 2013, J BIOL CHEM, V288, P9035, DOI 10.1074/jbc.M112.405456; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Gelsomino L, 2016, BREAST CANCER RES TR, V157, P253, DOI 10.1007/s10549-016-3829-5; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Gluhak-Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807; Gonzalez-Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298-06; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Gu GW, 2016, CLIN CANCER RES, V22, P1034, DOI 10.1158/1078-0432.CCR-15-2549; Guttilla IK, 2012, TRENDS ENDOCRIN MET, V23, P73, DOI 10.1016/j.tem.2011.12.001; Holen I, 2016, CLIN EXP METASTAS, V33, P211, DOI 10.1007/s10585-015-9770-x; Howlader N, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju055; Hwang ES, 2005, ARCH SURG-CHICAGO, V140, P58, DOI 10.1001/archsurg.140.1.58; Ignatiadis M, 2013, NAT REV CLIN ONCOL, V10, P494, DOI 10.1038/nrclinonc.2013.124; Imai Y, 2013, PHYSIOL REV, V93, P481, DOI 10.1152/physrev.00008.2012; Imamura T, 2006, ANIM SCI J, V77, P223, DOI 10.1111/j.1740-0929.2006.00341.x; Islami F, 2015, ANN ONCOL, V26, P2398, DOI 10.1093/annonc/mdv379; Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117; Johnson RW, 2016, NAT CELL BIOL, V18, P1260, DOI 10.1038/ncb3433; Joseph JD, 2016, ELIFE, V5, DOI 10.7554/eLife.15828; Joshi PA, 2015, STEM CELL REP, V5, P31, DOI 10.1016/j.stemcr.2015.05.012; Kagiya T, 2015, J CLIN MED, V4, P1741, DOI 10.3390/jcm4091741; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karsenty G, 2000, NAT MED, V6, P970, DOI 10.1038/79655; Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308; Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215; Khalid AB, 2016, BONE, V87, P130, DOI 10.1016/j.bone.2016.03.016; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Kobayashi S, 2012, BREAST CANCER-TOKYO, V19, P302, DOI 10.1007/s12282-012-0384-8; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kovacs CS, 1997, ENDOCR REV, V18, P832, DOI 10.1210/er.18.6.832; LAVECCHIA C, 1993, INT J CANCER, V53, P215, DOI 10.1002/ijc.2910530207; Lee SJ, 2011, CANCER RES TREAT, V43, P89, DOI 10.4143/crt.2011.43.2.89; Lindberg MK, 2001, J ENDOCRINOL, V171, P229, DOI 10.1677/joe.0.1710229; Lips P, 2011, BEST PRACT RES CL EN, V25, P585, DOI 10.1016/j.beem.2011.05.002; Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254; Lopes N, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3178; Lorenz-Depiereux B, 2006, NAT GENET, V38, P1248, DOI 10.1038/ng1868; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920; Maimoun L, 2011, METABOLISM, V60, P373, DOI 10.1016/j.metabol.2010.03.001; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179; Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McDevitta MA, 2008, MOL CELL ENDOCRINOL, V290, P24, DOI 10.1016/j.mce.2008.04.003; McNamara KM, 2013, J STEROID BIOCHEM, V133, P66, DOI 10.1016/j.jsbmb.2012.08.007; MCNEILLY AS, 1994, ANN NY ACAD SCI, V709, P145, DOI 10.1111/j.1749-6632.1994.tb30394.x; Melville KM, 2014, J BONE MINER RES, V29, P370, DOI 10.1002/jbmr.2082; Mock K, 2015, ONCOTARGET, V6, P14399, DOI 10.18632/oncotarget.3882; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025; Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452; Nampei A, 2004, J BONE MINER METAB, V22, P176, DOI 10.1007/s00774-003-0468-9; Nemir M, 2000, J BIOL CHEM, V275, P969, DOI 10.1074/jbc.275.2.969; Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; O'Brien CA, 2013, BONE, V54, P258, DOI 10.1016/j.bone.2012.08.121; Oesterreich S, 2015, BREAST CANCER RES TR, V154, P263, DOI 10.1007/s10549-015-3608-8; Ogba N, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0489-4; Ottewell PD, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.10; Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078-0432.CCR-13-1246; Pan H, 2014, CANCER EPIDEMIOL, V38, P1, DOI 10.1016/j.canep.2013.11.004; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Press DJ, 2010, EPIDEMIOLOGY, V21, P566, DOI 10.1097/EDE.0b013e3181e08eb3; Price TT, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4059; Prideaux M, 2015, GENE EXPR PATTERNS, V18, P29, DOI 10.1016/j.gep.2015.04.004; Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100; Reed Mary L, 2013, Front Endocrinol (Lausanne), V4, P64, DOI 10.3389/fendo.2013.00064; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; Rodrigues LR, 2007, CANCER EPIDEM BIOMAR, V16, P1087, DOI 10.1158/1055-9965.EPI-06-1008; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; RUBIN CT, 1984, CALCIFIED TISSUE INT, V36, pS11, DOI 10.1007/BF02406128; Sanders JL, 2000, ENDOCRINOLOGY, V141, P4357, DOI 10.1210/en.141.12.4357; Saxon LK, 2012, ENDOCRINOLOGY, V153, P2254, DOI 10.1210/en.2011-1977; Sethi S, 2011, AM J TRANSL RES, V3, P90; Setiawan VW, 2009, AM J EPIDEMIOL, V169, P1251, DOI 10.1093/aje/kwp036; Shenoy PA, 2016, FRONT PHARMACOL, V7, P1; Shore P, 2005, J CELL BIOCHEM, V96, P484, DOI 10.1002/jcb.20557; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Sims NA, 2002, BONE, V30, P18, DOI 10.1016/S8756-3282(01)00643-3; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Sowers MF, 1996, JAMA-J AM MED ASSOC, V276, P549, DOI 10.1001/jama.276.7.549; Spoerke JM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11579; Stark A, 2010, CANCER-AM CANCER SOC, V116, P4926, DOI 10.1002/cncr.25276; Stead LA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2242; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Suzuki R, 2006, INT J CANCER, V119, P1683, DOI 10.1002/ijc.22034; Svejme O, 2014, SCAND J MED SCI SPOR, V24, P159, DOI 10.1111/j.1600-0838.2012.01504.x; Svoronos N, 2016, CANCER DISCOV, V7, P1; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Takeshita T, 2016, ONCOTARGET, V7, P32504, DOI 10.18632/oncotarget.8839; Tan VPS, 2014, J BONE MINER RES, V29, P2161, DOI 10.1002/jbmr.2254; Thomas C, 2015, TRENDS ENDOCRIN MET, V26, P467, DOI 10.1016/j.tem.2015.06.007; Tverberg LA, 2000, ENDOCRINOLOGY, V141, P3696, DOI 10.1210/en.141.10.3696; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Ursini-Siegel J, 2016, CANCER LETT, V380, P281, DOI 10.1016/j.canlet.2015.11.009; Vanhouten JN, 2003, ENDOCRINOLOGY, V144, P5521, DOI 10.1210/en.2003-0892; VanHouten JN, 2013, BEST PRACT RES CL EN, V27, P403, DOI 10.1016/j.beem.2013.02.011; Vidal O, 1999, BIOCHEM BIOPH RES CO, V265, P569, DOI 10.1006/bbrc.1999.1711; Vivar OI, 2010, J BIOL CHEM, V285, P22059, DOI 10.1074/jbc.M110.114116; Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007; Walker VR, 2004, ILAR J, V45, P455, DOI 10.1093/ilar.45.4.455; Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017; Wang XJ, 2004, BREAST CANCER RES TR, V83, P109, DOI 10.1023/B:BREA.0000010703.59483.c0; Wardell SE, 2013, CLIN CANCER RES, V19, P2420, DOI 10.1158/1078-0432.CCR-12-3771; Weidle UH, 2016, CANCER GENOM PROTEOM, V13, P1; Weir HM, 2016, CANCER RES, V76, P3307, DOI 10.1158/0008-5472.CAN-15-2357; Welboren WJ, 2007, MOL ONCOL, V1, P138, DOI 10.1016/j.molonc.2007.04.001; Welsh J, 2007, J BONE MINER RES, V22, pV86, DOI 10.1359/JBMR.07S204; Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730; Windahl SH, 2001, J BONE MINER RES, V16, P1388, DOI 10.1359/jbmr.2001.16.8.1388; Wittrant Y, 2004, BBA-REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002; Wu SG, 2016, ONCOTARGET, V7, P47975, DOI 10.18632/oncotarget.10099; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Wysolmerski JJ, 2010, ANN NY ACAD SCI, V1192, P161, DOI 10.1111/j.1749-6632.2009.05249.x; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yeung C, 2016, CANCER METAST REV, V35, P427, DOI 10.1007/s10555-016-9631-3; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang XHF, 2013, CLIN CANCER RES, V19, P6389, DOI 10.1158/1078-0432.CCR-13-0838; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhou H, 2013, BONE RES, V1, DOI 10.4248/BR201302001; Zinser GM, 2004, MOL ENDOCRINOL, V18, P2208, DOI 10.1210/me.2003-0469; 2002, LANCET LONDON ENGLAN, V360, P187	184	18	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4527	4537		10.1038/onc.2017.94	http://dx.doi.org/10.1038/onc.2017.94			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368409	Bronze, Green Accepted			2022-12-17	WOS:000407246200001
J	Walls, GV; Stevenson, M; Lines, KE; Newey, PJ; Reed, AAC; Bowl, MR; Jeyabalan, J; Harding, B; Bradley, KJ; Manek, S; Chen, J; Wang, P; Williams, BO; Teh, BT; Thakker, RV				Walls, G. V.; Stevenson, M.; Lines, K. E.; Newey, P. J.; Reed, A. A. C.; Bowl, M. R.; Jeyabalan, J.; Harding, B.; Bradley, K. J.; Manek, S.; Chen, J.; Wang, P.; Williams, B. O.; Teh, B. T.; Thakker, R. V.			Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome	ONCOGENE			English	Article							SUPPRESSOR GENE; DOWN-REGULATION; BETA-CATENIN; HUMAN PAF1; HPT-JT; EXPRESSION; PARAFIBROMIN; MUTATIONS; CANCER; HRPT2	The hyperparathyroidism-jaw tumour (HPT-JT) syndrome is an autosomal dominant disorder characterized by occurrence of parathyroid tumours, often atypical adenomas and carcinomas, ossifying jaw fibromas, renal tumours and uterine benign and malignant neoplasms. HPT-JT is caused by mutations of the cell division cycle 73 (CDC73) gene, located on chromosome 1q31.2 and encodes a 531 amino acid protein, parafibromin. To facilitate in vivo studies of Cdc73 in tumourigenesis we generated conventional (Cdc73(+/-)) and conditional parathyroid-specific (Cdc73(+/L)/PTH-Cre and Cdc73(L/L)/PTH-Cre) mouse models. Mice were aged to 18-21 months and studied for survival, tumour development and proliferation, and serum biochemistry, and compared to age-matched wild-type (Cdc73(+/+) and Cdc73(+/+)/PTH-Cre) littermates. Survival of Cdc73(+/)-mice, when compared to Cdc73(+/+) mice was reduced (Cdc73+/-= 80%; Cdc73(+/+) = 90% at 18 months of age, P<0.05). Cdc73(+/-), Cdc73(+/L)/PTH-Cre and Cdc73(L/L)/PTH-Cre mice developed parathyroid tumours, which had nuclear pleomorphism, fibrous septation and increased galectin-3 expression, consistent with atypical parathyroid adenomas, from 9 months of age. Parathyroid tumours in Cdc73(+/-), Cdc73(+/L)/PTH-Cre and Cdc73(L/L)/PTH-Cre mice had significantly increased proliferation, with rates 4fourfold higher than that in parathyroid glands of wild-type littermates (P<0.0001). Cdc73(+/-), Cdc73(+/L)/PTH-Cre and Cdc73(L/L)/PTH-Cre mice had higher mean serum calcium concentrations than wild-type littermates, and Cdc73(+/)-mice also had increased mean serum parathyroid hormone (PTH) concentrations. Parathyroid tumour development, and elevations in serum calcium and PTH, were similar in males and females. Cdc7(3+)/-mice did not develop bone or renal tumours but female Cdc73(+/-)mice, at 18 months of age, had uterine neoplasms comprising squamous metaplasia, adenofibroma and adenomyoma. Uterine neoplasms, myometria and jaw bones of Cdc73(+/)-mice had increased proliferation rates that were 2-fold higher than in Cdc73(+/+) mice (P<0.05). Thus, our studies, which have established mouse models for parathyroid tumours and uterine neoplasms that develop in the HPT-JT syndrome, provide in vivo models for future studies of these tumours.	[Walls, G. V.; Stevenson, M.; Lines, K. E.; Newey, P. J.; Reed, A. A. C.; Bowl, M. R.; Jeyabalan, J.; Harding, B.; Bradley, K. J.; Thakker, R. V.] Univ Oxford, Radcliffe Dept Med, OCDEM, Acad Endocrine Unit,Churchill Hosp, Oxford OX3 7LJ, England; [Manek, S.] John Radcliffe Hosp, Dept Pathol, Headley Way, Oxford, England; [Chen, J.; Wang, P.; Teh, B. T.] Van Andel Res Inst, Lab Canc Genet, Grand Rapids, MI USA; [Williams, B. O.] Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI USA	University of Oxford; University of Oxford; Van Andel Institute; Van Andel Institute	Thakker, RV (corresponding author), Univ Oxford, Radcliffe Dept Med, OCDEM, Acad Endocrine Unit,Churchill Hosp, Oxford OX3 7LJ, England.	rajesh.thakker@ndm.ox.ac.uk	Stevenson, Mark/GRF-5876-2022; Williams, Bart/A-3539-2013	Stevenson, Mark/0000-0001-8616-0205; Williams, Bart/0000-0002-5261-5301; Lines, Kate/0000-0002-0764-8681; Bowl, Michael/0000-0001-7971-445X; Teh, Bin Tean/0000-0003-1514-1124	Medical Research Council (MRC), UK [G9825289/2004, G1000467/2010]; Van Andel Foundation, Grand Rapids, USA; United Kingdom Medical Research Council (MRC) [G9825289, G1000467]; Medical Research Council [G1000467, G9825289] Funding Source: researchfish; National Institute for Health Research [CL-2010-13-004] Funding Source: researchfish; MRC [G1000467, G9825289] Funding Source: UKRI	Medical Research Council (MRC), UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Van Andel Foundation, Grand Rapids, USA; United Kingdom Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Medical Research Council (MRC), UK (grant number G9825289/2004 and G1000467/2010), (GV Walls, M Stevenson, KE Lines, MR Bowl, J Jeyabalan, PJ Newey, AAC Reed, B Harding, KJ Bradley and RV Thakker), and the Van Andel Foundation, Grand Rapids, USA (P Wang, J Chen, BO Williams, BT Teh). GV Walls, PJ Newey and KJ Bradley received MRC Clinical Research Training Fellowships. This work was supported by grants from the United Kingdom Medical Research Council (MRC) (G9825289 and G1000467) to GVW, MS, KEL, PJN, AACR, MRB, JJ, BH, KJB, and RVT; and the Van Andel Foundation, Grand Rapids, USA to JC, PW, BOW and BTT.	Amrich CG, 2012, J BIOL CHEM, V287, P10863, DOI 10.1074/jbc.M111.325647; Arnett-Mansfield RL, 2001, CANCER RES, V61, P4576; Bergero N, 2005, HUM PATHOL, V36, P908, DOI 10.1016/j.humpath.2005.06.020; Bokov AF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026891; Bradley KJ, 2005, J INTERN MED, V257, P18, DOI 10.1111/j.1365-2796.2004.01421.x; Bricaire L, 2013, J CLIN ENDOCR METAB, V98, pE403, DOI 10.1210/jc.2012-2789; Bush BM, 2013, CELL BIOCHEM FUNCT, V31, P228, DOI 10.1002/cbf.2876; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Cetani F, 2016, J ENDOCRINOL INVEST, V39, P595, DOI 10.1007/s40618-016-0447-3; Chan JKC, 2013, DIAGNOSTIC HISTOPATH, V2, P1273; Commandeur AE, 2015, HUM REPROD UPDATE, V21, P593, DOI 10.1093/humupd/dmv030; CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105; CRYNS VL, 1994, J CLIN ENDOCR METAB, V78, P1320, DOI 10.1210/jc.78.6.1320; DeLellis RA, 2004, PATHOLOGY GENETICS T, V8; DeLellis RA, 2011, MODERN PATHOL, V24, pS78, DOI 10.1038/modpathol.2010.132; Duan K, 2015, J CLIN PATHOL, V68, P771, DOI 10.1136/jclinpath-2015-203186; Ensembl, ENSMUSG00000026361; Evans P, 2007, AM FAM PHYSICIAN, V75, P1503; Farber LJ, 2010, MOL CARCINOGEN, V49, P215, DOI 10.1002/mc.20591; FUJIMOTO J, 1995, TUMOR BIOL, V16, P254, DOI 10.1159/000217942; Fukuda K, 1998, GYNECOL ONCOL, V69, P220, DOI 10.1006/gyno.1998.5023; Gill AJ, 2006, AM J SURG PATHOL, V30, P1140; Gill AJ, 2014, ENDOCR PATHOL, V25, P30, DOI 10.1007/s12022-013-9294-3; Givi B, 2010, CLIN ONCOL-UK, V22, P498, DOI 10.1016/j.clon.2010.04.007; Grigorieva IV, 2010, J CLIN INVEST, V120, P2144, DOI 10.1172/JCI42021; Harding B, 2009, ENDOCR-RELAT CANCER, V16, P1313, DOI 10.1677/ERC-09-0082; Haven CJ, 2000, J CLIN ENDOCR METAB, V85, P1449, DOI 10.1210/jc.85.4.1449; Hayes MP, 2010, GYNECOL ONCOL, V116, P286, DOI 10.1016/j.ygyno.2009.11.012; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Howitt BE, 2015, J PATHOL, V235, P37, DOI 10.1002/path.4442; Imanishi Y, 2001, J CLIN INVEST, V107, P1093, DOI 10.1172/JCI10523; Jenkins PJ, 1997, CLIN ENDOCRINOL, V47, P747, DOI 10.1046/j.1365-2265.1997.3421147.x; Juhlin CC, 2011, VIRCHOWS ARCH, V459, P47, DOI 10.1007/s00428-010-1032-3; Juhlin CC, 2009, INT J ONCOL, V34, P481, DOI 10.3892/ijo_00000173; Juodele L, 2011, MEDICINA-LITHUANIA, V47, P635, DOI 10.3390/medicina47110092; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kruijff S, 2014, ANN SURG ONCOL, V21, P426, DOI 10.1245/s10434-013-3288-8; Kumar NS, 1998, CANCER RES, V58, P1860; Kumari N, 2016, ENDOCR PATHOL, V27, P87, DOI 10.1007/s12022-016-9426-7; Libutti SK, 2003, CANCER RES, V63, P8022; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Loffler KA, 2007, ONCOGENE, V26, P4009, DOI 10.1038/sj.onc.1210163; Makinen N, 2011, SCIENCE, V334, P252, DOI 10.1126/science.1208930; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Mosimann C, 2009, MECH DEVELOP, V126, P394, DOI 10.1016/j.mod.2009.02.002; Myant K, 2011, EXP CELL RES, V317, P2725, DOI 10.1016/j.yexcr.2011.08.001; Nesbit MA, 2004, J BIOL CHEM, V279, P22624, DOI 10.1074/jbc.M401797200; Newey PJ, 2010, HUM MUTAT, V31, P295, DOI 10.1002/humu.21188; Parker WH, 2007, FERTIL STERIL, V87, P725, DOI 10.1016/j.fertnstert.2007.01.093; Piret SE, 2011, J ENDOCRINOL, V211, P211, DOI 10.1530/JOE-11-0193; Rather MI, 2014, J BIOL CHEM, V289, P968, DOI 10.1074/jbc.M113.483255; REUBER MD, 1981, J GERONTOL, V36, P663, DOI 10.1093/geronj/36.6.663; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Saggiorato E, 2006, AM J CLIN PATHOL, V126, P59, DOI 10.1309/9NXP7FRF87MU2PCK; Sato M, 2000, ENDOCRINE, V12, P223, DOI 10.1385/ENDO:12:3:223; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Svedlund J, 2014, ENDOCR-RELAT CANCER, V21, P231, DOI 10.1530/ERC-13-0497; SZABO J, 1995, AM J HUM GENET, V56, P944; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; Tesfaye A, 2007, CANCER RES, V67, P3998, DOI 10.1158/0008-5472.CAN-05-1684; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Varghese BV, 2013, P NATL ACAD SCI USA, V110, P2187, DOI 10.1073/pnas.1215759110; Vasef MA, 1999, MODERN PATHOL, V12, P412; Walls GV, 2012, ENDOCRINOLOGY, V153, P5167, DOI 10.1210/en.2012-1675; Wang PF, 2008, MOL CELL BIOL, V28, P2930, DOI 10.1128/MCB.00654-07; Witteveen JE, 2011, MODERN PATHOL, V24, P688, DOI 10.1038/modpathol.2010.236; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Xu Y, 2004, CANCER RES, V64, P3371, DOI 10.1158/0008-5472.CAN-04-0044; Yang Ri-Yao, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000719; Yart A, 2005, MOL CELL BIOL, V25, P5052, DOI 10.1128/MCB.25.12.5052-5060.2005; Yu W, 2015, J CLIN ENDOCR METAB, V100, pE360, DOI 10.1210/jc.2014-3238; Zhang C, 2006, BIOCHEM BIOPH RES CO, V350, P17, DOI 10.1016/j.bbrc.2006.08.169	75	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4025	4036		10.1038/onc.2017.43	http://dx.doi.org/10.1038/onc.2017.43			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288139	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000405379900008
J	Delyon, J; Servy, A; Laugier, F; Andre, J; Ortonne, N; Battistella, M; Mourah, S; Bensussan, A; Lebbe, C; Dumaz, N				Delyon, J.; Servy, A.; Laugier, F.; Andre, J.; Ortonne, N.; Battistella, M.; Mourah, S.; Bensussan, A.; Lebbe, C.; Dumaz, N.			PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma	ONCOGENE			English	Article							IMPROVED SURVIVAL; MEK INHIBITION; CANCER; PHOSPHODIESTERASE-4; GROWTH; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION; PATHWAY; RISK	The cyclic AMP (cAMP) signaling pathway is critical in melanocyte biology for regulating differentiation. It is downregulated by phosphodiesterase (PDE) enzymes, which degrade cAMP itself. In melanoma evidence suggests that inhibition of the cAMP pathway by PDE type 4 (PDE4) favors tumor progression. For example, in melanomas harboring RAS mutations, the overexpression of PDE4 is crucial for MAPK pathway activation and proliferation induced by oncogenic RAS. Here we showed that PDE4D is overexpressed in BRAF-mutated melanoma cell lines, constitutively disrupting the cAMP pathway activation. PDE4D promoted melanoma invasion by interacting with focal adhesion kinase (FAK) through the scaffolding protein RACK1. Inhibition of PDE4 activity or inhibition of PDE4D interaction with FAK reduced invasion. PDE4D expression is increased in patients with advanced melanoma and PDE4D-FAK interaction is detectable in situ in metastatic melanoma. Our study establishes the role of PDE4D in BRAF-mutated melanoma as regulator of cell invasion, and suggests its potential as a target for preventing metastatic	[Delyon, J.; Servy, A.; Laugier, F.; Andre, J.; Mourah, S.; Bensussan, A.; Lebbe, C.; Dumaz, N.] INSERM, Ctr Rech Peau, U976, F-75010 Paris, France; [Delyon, J.; Servy, A.; Laugier, F.; Andre, J.; Mourah, S.; Bensussan, A.; Lebbe, C.; Dumaz, N.] Univ Paris Diderot, Sorbonne Paris Cite, UMR 976, F-75010 Paris, France; [Delyon, J.; Lebbe, C.] Hop St Louis, AP HP, Dept Dermatol, Paris, France; [Ortonne, N.] Hop Henri Mondor, AP HP, Dept Pathol, Creteil, France; [Ortonne, N.] Hop Henri Mondor, AP HP, INSERM, U955,Equipe 9, Creteil, France; [Ortonne, N.] Univ Paris Est Creteil Val de Marne, Fac Med, Creteil, France; [Battistella, M.] Hop St Louis, AP HP, Dept Pathol, Paris, France; [Battistella, M.] Univ Paris Diderot, Sorbonne Paris Cite, INSERM, U1165, Paris, France; [Mourah, S.] Hop St Louis, AP HP, Lab Pharmacol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Dumaz, N (corresponding author), Hop St Louis, INSERM, Ctr Rech Peau, U976, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	nicolas.dumaz@inserm.fr	Battistella, Maxime/K-2949-2012; Dumaz, Nicolas/B-5907-2008; Delyon, Julie/O-5147-2019; Bensussan, Armand/E-5434-2017	Battistella, Maxime/0000-0002-7053-7431; Dumaz, Nicolas/0000-0003-3511-2160; Delyon, Julie/0000-0002-4557-3377; Bensussan, Armand/0000-0002-0409-2497; Ortonne, Nicolas/0000-0003-0111-7422	INSERM; fondation ARC pour la recherche sur le cancer (Poste Accueil); Ligue Contre le Cancer Comite de Paris; GEFLUC Paris-Ile-de-France; fondation ARC pour la recherche sur le cancer; Universite Paris Diderot	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); fondation ARC pour la recherche sur le cancer (Poste Accueil)(Fondation ARC pour la Recherche sur le Cancer); Ligue Contre le Cancer Comite de Paris(Ligue nationale contre le cancer); GEFLUC Paris-Ile-de-France; fondation ARC pour la recherche sur le cancer(Fondation ARC pour la Recherche sur le Cancer); Universite Paris Diderot	Julie Delyon was supported by INSERM and the fondation ARC pour la recherche sur le cancer (Poste Accueil). This research was supported by grants from the Ligue Contre le Cancer Comite de Paris, the GEFLUC Paris-Ile-de-France, the fondation ARC pour la recherche sur le cancer, INSERM and Universite Paris Diderot.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bastiaens MT, 2001, AM J HUM GENET, V68, P884, DOI 10.1086/319500; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Goldhoff P, 2008, CLIN CANCER RES, V14, P7717, DOI 10.1158/1078-0432.CCR-08-0827; Hess AR, 2005, CANCER RES, V65, P9851, DOI 10.1158/0008-5472.CAN-05-2172; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Hu HH, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv340; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Khaled M, 2010, GENE DEV, V24, P2276, DOI 10.1101/gad.1937710; Krayem M, 2014, EUR J CANCER, V50, P1310, DOI 10.1016/j.ejca.2014.01.021; Landi MT, 2006, SCIENCE, V313, P521, DOI 10.1126/science.1127515; Liang SL, 2007, CANCER RES, V67, P5814, DOI 10.1158/0008-5472.CAN-06-4233; Lin DC, 2013, P NATL ACAD SCI USA, V110, P6109, DOI 10.1073/pnas.1218206110; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Lugnier C, 2006, PHARMACOL THERAPEUT, V109, P366, DOI 10.1016/j.pharmthera.2005.07.003; Lyons J, 2013, P NATL ACAD SCI USA, V110, P13845, DOI 10.1073/pnas.1201917110; Marquette A, 2011, NAT STRUCT MOL BIOL, V18, P584, DOI 10.1038/nsmb.2022; Mayer JE, 2014, J AM ACAD DERMATOL, V71, DOI [10.1016/j.jaad.2014.05.045, 10.1016/j.jaad.2014.05.046]; Murata K, 2001, CLIN EXP METASTAS, V18, P599, DOI 10.1023/A:1011926116777; Narita M, 2007, ONCOL REP, V17, P1133; Perego M, 2010, J INVEST DERMATOL, V130, P1877, DOI 10.1038/jid.2010.69; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Powers GL, 2015, MOL CANCER RES, V13, P149, DOI 10.1158/1541-7786.MCR-14-0110; Pullamsetti SS, 2013, ONCOGENE, V32, P1121, DOI 10.1038/onc.2012.136; Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008-5472.CAN-08-3901; Rodriguez CI, 2014, ARCH BIOCHEM BIOPHYS, V563, P22, DOI 10.1016/j.abb.2014.07.003; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Serrels B, 2010, CURR BIOL, V20, P1086, DOI 10.1016/j.cub.2010.04.042; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Takeuchi H, 2003, CANCER RES, V63, P441; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	38	18	19	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3252	3262		10.1038/onc.2016.469	http://dx.doi.org/10.1038/onc.2016.469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28092671				2022-12-17	WOS:000402869800005
J	Main, HG; Xie, J; Muralidhar, GG; Elfituri, O; Xu, H; Kajdacsy-Balla, AA; Barbolina, MV				Main, H. Gurler; Xie, J.; Muralidhar, G. G.; Elfituri, O.; Xu, H.; Kajdacsy-Balla, A. A.; Barbolina, M. V.			Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CX3CR1; PRIMARY DEBULKING SURGERY; NEOADJUVANT CHEMOTHERAPY; CANCER; CX(3)CR1; CELLS; EXPRESSION; MIGRATION; ORIGIN; IDENTIFICATION	Epithelial ovarian carcinoma is the most common cause of death from gynecologic cancers largely due to advanced, relapsed and chemotherapy-resistant peritoneal metastasis, which is refractory to the currently used treatment approaches. Mechanisms supporting advanced and relapsed peritoneal metastasis are largely unknown, precluding development of more effective targeted therapies. In this study, we investigated the function of a potentially targetable fractalkine axis in the formation and the development of advanced and relapsed peritoneal metastasis and its impact on patients' outcomes. Our mouse model studies support a role for the fractalkine receptor (CX(3)CR1) in the initiation of peritoneal adhesion important for recolonization of relapsed peritoneal metastasis. We show that downregulation of CX(3)CR1 results in reduction of metastatic burden at several peritoneal sites commonly colonized by advanced and relapsed metastatic ovarian carcinoma. We show that the chemokine fractalkine (CX(3)CL1), an activating ligand of CX(3)CR1, regulates organ-specific peritoneal colonization. High expression of CX(3)CR1 correlates with significantly shorter survival, specifically in post-menopausal patients with advanced and terminal stages of the disease. Taken together, our studies support a key regulatory role for the fractalkine axis in advanced and relapsed peritoneal metastasis in epithelial ovarian carcinoma.	[Main, H. Gurler; Xie, J.; Muralidhar, G. G.; Barbolina, M. V.] Univ Illinois, Dept Biopharmaceut Sci, 833 South Wood St, Chicago, IL 60612 USA; [Elfituri, O.; Xu, H.; Kajdacsy-Balla, A. A.] Univ Illinois, Dept Pathol, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Barbolina, MV (corresponding author), Univ Illinois, Dept Biopharmaceut Sci, 833 South Wood St, Chicago, IL 60612 USA.	mvb@uic.edu	Xie, Jia/L-5939-2019		National Cancer Institute [CA160917]; Ovarian Cancer Research Foundation Liz Tilberis Scholar Award; NATIONAL CANCER INSTITUTE [R21CA160917] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Foundation Liz Tilberis Scholar Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs William Beck, Joanna Burdette, Jonna Frasor and Peter Penzes for their helpful suggestions on various methods and data analysis as well as critical reading of the manuscript. This study was supported by the National Cancer Institute (grant # CA160917 to MVB) and Ovarian Cancer Research Foundation Liz Tilberis Scholar Award (to MVB).	Auersperg N, 2011, INT J GYNECOL PATHOL, V30, P12, DOI 10.1097/PGP.0b013e3181f45f3e; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bookman MA, 2012, CLIN OBSTET GYNECOL, V55, P96, DOI 10.1097/GRF.0b013e31824b45da; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Burleson KM, 2004, CLIN EXP METASTAS, V21, P685, DOI 10.1007/s10585-004-5768-5; Chang SJ, 2015, J GYNECOL ONCOL, V26, P336, DOI 10.3802/jgo.2015.26.4.336; Chi DS, 2012, GYNECOL ONCOL, V124, P10, DOI 10.1016/j.ygyno.2011.08.014; Colombo PE, 2014, CRIT REV ONCOL HEMAT, V89, P207, DOI 10.1016/j.critrevonc.2013.08.017; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Crum CP, 2013, J PATHOL, V231, P402, DOI 10.1002/path.4263; Davis A, 2014, GYNECOL ONCOL, V133, P624, DOI 10.1016/j.ygyno.2014.02.038; Desjardins M, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-70; Dorgham K, 2009, J LEUKOCYTE BIOL, V86, P903, DOI 10.1189/jlb.0308158; Dubeau L, 2013, ANN ONCOL, V24, P28, DOI 10.1093/annonc/mdt308; Dubeau L, 2008, LANCET ONCOL, V9, P1191, DOI 10.1016/S1470-2045(08)70308-5; Erreni M, 2016, J IMMUNOL, V196, P902, DOI 10.4049/jimmunol.1501335; Gaudin F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021546; Gurler H, 2015, BIOMOLECULES, V5, P3438, DOI 10.3390/biom5043438; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hundhausen Christian, 2003, Blood, V102, P1186; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Iwanicki MP, 2011, CANCER DISCOV, V1, P144, DOI 10.1158/2159-8274.CD-11-0010; Jamieson WL, 2008, CANCER RES, V68, P1715, DOI 10.1158/0008-5472.CAN-07-1315; Jamieson-Gladney WL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3016; Karlstrom S, 2013, J MED CHEM, V56, P3177, DOI 10.1021/jm3012273; Kim M, 2012, MOL CANCER RES, V10, P1419, DOI 10.1158/1541-7786.MCR-12-0361; Kim M, 2012, MOL CANCER RES, V10, P11, DOI 10.1158/1541-7786.MCR-11-0256; Kurman RJ, 2013, ANN ONCOL, V24, P16, DOI 10.1093/annonc/mdt463; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Mantovani A, 2010, CYTOKINE GROWTH F R, V21, P27, DOI 10.1016/j.cytogfr.2009.11.007; Marchesi F, 2008, CANCER RES, V68, P9060, DOI 10.1158/0008-5472.CAN-08-1810; Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61; Medina-Contreras O, 2011, J CLIN INVEST, V121, P4787, DOI 10.1172/JCI59150; Pomel Christophe, 2007, Cancer Imaging, V7, P210, DOI 10.1102/1470-7330.2007.0030; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Rooper L, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-57; Seward SM, 2015, CANCER METAST REV, V34, P5, DOI 10.1007/s10555-014-9536-y; Shen F, 2016, MOL CANCER RES, V14, P518, DOI 10.1158/1541-7786.MCR-16-0013; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tautermann CS, 2014, BIOORG MED CHEM LETT, V24, P4073, DOI 10.1016/j.bmcl.2014.07.009; Thibault B, 2014, CANCER METAST REV, V33, P17, DOI 10.1007/s10555-013-9456-2; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Tsubota K, 2009, INVEST OPHTH VIS SCI, V50, P4753, DOI 10.1167/iovs.08-2596; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Walton J, 2016, CANCER RES, V76, P6118, DOI 10.1158/0008-5472.CAN-16-1272; Wiedemeyer WR, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00034; Wollberg AR, 2014, P NATL ACAD SCI USA, V111, P5409, DOI 10.1073/pnas.1316510111; Zhang Q, 2004, HUM REPROD, V19, P409, DOI 10.1093/humrep/deh085	52	18	18	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3025	3036		10.1038/onc.2016.456	http://dx.doi.org/10.1038/onc.2016.456			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27941884	Green Accepted			2022-12-17	WOS:000402000400010
J	Ambrogio, C; Barbacid, M; Santamaria, D				Ambrogio, C.; Barbacid, M.; Santamaria, D.			In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; K-RAS ONCOGENE; CANCER; MUTANT; INHIBITORS; INDUCTION; CARCINOMA; FEATURES; CELLS; GENE	Activating mutations in KRAS and EGFR, the two most frequent oncogenes in human lung adenocarcinoma, are mutually exclusive, a phenotype attributed to functional redundancy implying lack of positive selection. Employing a mouse model expressing EGFR(L858R) in advanced Kras(G12V)-driven tumors we show that their mutual exclusivity can be explained by detrimental effects of their co-expression in lung adenocarcinoma. In vivo, expression of EGFR(L858R) in Kras(G12V)-driven tumors triggers replicative stress and apoptosis, while the surviving cells enter a transient cytostatic state incompatible with tumor development that is fully reversible upon discontinued EGFR(L858R) expression. Eventually, sustained expression of both mutants induces attenuation of oncogenic signaling to levels compatible with proliferation and tumor growth resulting in high sensitivity to Mek inhibition. Our results indicate that the mutual exclusivity of KRAS and EGFR mutations occurs as a combination of cellular toxicity and signal adjustment resulting in lack of selective advantage for cells expressing both oncogenes.	[Ambrogio, C.; Barbacid, M.; Santamaria, D.] CNIO, Expt Oncol, Mol Oncol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain; [Ambrogio, C.] Dana Farber Canc Inst, Med Oncol, 360 Longwood Ave,LC-4112, Boston, MA 02215 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); Harvard University; Dana-Farber Cancer Institute	Ambrogio, C; Santamaria, D (corresponding author), CNIO, Expt Oncol, Mol Oncol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	chiara_ambrogio@dfci.harvard.edu; dsantamaria@cnio.es	Santamaria, David/D-3930-2011	Santamaria, David/0000-0002-4711-3569	European Research Council [ERC-AG/250297-RAS AEAD]; EU [HEALTH-F2-2010-259770/LUNGTARGET, HEALTH-2010-260791/EUROCANPLATFORM]; Spanish Ministry of Economy and Competitiveness [SAF2011-30173]; Autonomous Community of Madrid [S2011/BDM-2470/ONCO-CYCLE]; Spanish Association Against Cancer (AECC)	European Research Council(European Research Council (ERC)European Commission); EU(European Commission); Spanish Ministry of Economy and Competitiveness(Spanish Government); Autonomous Community of Madrid; Spanish Association Against Cancer (AECC)	We thank J. Haigh for providing Rosa26-LSLrtTA mice. This work was supported by the European Research Council (ERC-AG/250297-RAS AEAD), EU-Framework Programme (HEALTH-F2-2010-259770/LUNGTARGET and HEALTH-2010-260791/EUROCANPLATFORM), Spanish Ministry of Economy and Competitiveness (SAF2011-30173) and Autonomous Community of Madrid (S2011/BDM-2470/ONCO-CYCLE) to MB. CA is the recipient of a postdoctoral fellowship from the Spanish Association Against Cancer (AECC). We thank A. Ventura, O. Segatto and T. Cash for critical reading of the manuscript and S. Anton for constructive discussion.	Ambrogio C, 2015, BIOPROTOCOL, V5, pe1692; Ambrogio C, 2014, CANCER RES, V74, P5978, DOI 10.1158/0008-5472.CAN-14-1606; Anastasi S, 2016, SEMIN CELL DEV BIOL, V50, P115, DOI 10.1016/j.semcdb.2015.10.001; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051; Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Choughule A, 2014, BRIT J CANCER, V111, P2203, DOI 10.1038/bjc.2014.401; Cisowski J, 2015, ONCOGENE, V35, P1; Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008; Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Guha U, 2008, P NATL ACAD SCI USA, V105, P14112, DOI 10.1073/pnas.0806158105; Janne PA, 2013, LANCET ONCOL, V14, P38, DOI 10.1016/S1470-2045(12)70489-8; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Li S, 2014, BRIT J CANCER, V110, P2812, DOI 10.1038/bjc.2014.210; Maity TK, 2015, CANCER DISCOV, V5, P534, DOI 10.1158/2159-8290.CD-14-0750; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pikor LA, 2013, LUNG CANCER, V82, P179, DOI 10.1016/j.lungcan.2013.07.025; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Segatto O, 2011, J CELL SCI, V124, P1785, DOI 10.1242/jcs.083303; Sharifnia T, 2014, P NATL ACAD SCI USA, V111, P18661, DOI 10.1073/pnas.1412228112; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Tam IYS, 2006, CLIN CANCER RES, V12, P1647, DOI 10.1158/1078-0432.CCR-05-1981; Unni AM, 2015, ELIFE, V4, DOI 10.7554/eLife.06907; Xu AM, 2010, CANCER RES, V70, P3857, DOI 10.1158/0008-5472.CAN-10-0163	28	18	18	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2309	2318		10.1038/onc.2016.385	http://dx.doi.org/10.1038/onc.2016.385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27775074				2022-12-17	WOS:000399782700011
J	Song, X; Hao, J; Wang, J; Guo, C; Wang, Y; He, Q; Tang, H; Qin, X; Li, Y; Zhang, Y; Yin, Y				Song, X.; Hao, J.; Wang, J.; Guo, C.; Wang, Y.; He, Q.; Tang, H.; Qin, X.; Li, Y.; Zhang, Y.; Yin, Y.			The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signaling	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; IN-VIVO; MOLECULAR TARGETS; UBIQUITIN LIGASE; MELANOMA-CELLS; BREAST-CANCER; EXPRESSION; ACTIVATION; MOTILITY; DEGRADATION	The biological function of MAGEC2, a cancer/testis antigen highly expressed in various cancers, remains largely unknown. Here we demonstrate that expression of MAGEC2 induces rounded morphology and amoeboid-like movement of tumor cells in vitro and promotes tumor metastasis in vivo. The pro-metastasis effect of MAGEC2 was mediated by signal transducer and activator of transcription 3 (STAT3) activation. Mechanistically, MAGEC2 interacts with STAT3 and inhibits the polyubiquitination and proteasomal degradation of STAT3 in the nucleus of tumor cells, resulting in accumulation of phosphorylated STAT3 and enhanced transcriptional activity. Notably, expression levels of MAGEC2 and phosphorylated STAT3 are positively correlated and both are associated with incidence of metastasis in human hepatocellular carcinoma. This study not only reveals a previously unappreciated role of MAGEC2 in promoting tumor metastasis, but also identifies a new molecular mechanism by which MAGEC2 sustains hyperactivation of STAT3 in the nucleus of tumor cells. Thus, MAGEC2 may represent a new antitumor metastasis target for treatment of cancer.	[Song, X.; Hao, J.; Wang, J.; Guo, C.; Wang, Y.; Tang, H.; Qin, X.; Li, Y.; Zhang, Y.; Yin, Y.] Peking Univ, Sch Basic Med Sci, Dept Immunol, Key Lab Med Immunol,Minist Hlth,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China; [He, Q.] Peking Univ, Hlth Sci Ctr, Ctr Med & Hlth Anal, Beijing, Peoples R China	Peking University; Peking University	Zhang, Y; Yin, Y (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Immunol, Key Lab Med Immunol,Minist Hlth,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	zhangyu007@bjmu.edu.cn; yinyanhui@bjmu.edu.cn	Hao, Jiaqing/F-1266-2017	Hao, Jiaqing/0000-0002-2834-7255; Xiao, Song/0000-0002-3171-4300	National Natural Science Foundation of China [81472645]; Beijing Natural Science Foundation [7142087]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation)	We thank Drs Xinmin Cao (National University of Singapore), Zhijie Chang (Tsinghua University) and Ning Guo (Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences) for providing vectors. This work was supported by grants from National Natural Science Foundation of China (no. 81472645) and Beijing Natural Science Foundation (7142087).	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Ayyoub M, 2014, J IMMUNOTHER, V37, P73, DOI 10.1097/CJI.0000000000000013; Bhatia N, 2013, J INVEST DERMATOL, V133, P759, DOI 10.1038/jid.2012.355; Brantley EC, 2008, CLIN CANCER RES, V14, P4694, DOI 10.1158/1078-0432.CCR-08-0618; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Buettner R, 2002, CLIN CANCER RES, V8, P945; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chomez P, 2001, CANCER RES, V61, P5544; Christoph DC, 2012, BRIT J CANCER, V107, P823, DOI 10.1038/bjc.2012.324; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Curioni-Fontecedro A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021418; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Doyle JM, 2010, MOL CELL, V39, P963, DOI 10.1016/j.molcel.2010.08.029; Elson-Schwab I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013176; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hao JQ, 2015, ONCOTARGET, V6, P42028, DOI 10.18632/oncotarget.5973; Jing N, 2005, ANTI-CANCER DRUG, V16, P601, DOI 10.1097/00001813-200507000-00002; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Kitzing TM, 2010, ONCOGENE, V29, P2441, DOI 10.1038/onc.2009.515; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Li B, 2003, LAB INVEST, V83, P1185, DOI 10.1097/01.LAB.0000080605.73839.96; Liu YJ, 2015, CELL, V160, P659, DOI 10.1016/j.cell.2015.01.007; Marcar L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127713; Pabst C, 2010, EXP MOL PATHOL, V89, P175, DOI 10.1016/j.yexmp.2010.06.011; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Parri M, 2009, CANCER RES, V69, P2072, DOI 10.1158/0008-5472.CAN-08-1845; Pineda CT, 2015, CELL, V160, P715, DOI 10.1016/j.cell.2015.01.034; Pinner S, 2008, J MICROSC-OXFORD, V231, P441, DOI 10.1111/j.1365-2818.2008.02056.x; Riener MO, 2009, INT J CANCER, V124, P352, DOI 10.1002/ijc.23966; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sanz-Moreno V, 2011, CANCER CELL, V20, P229, DOI 10.1016/j.ccr.2011.06.018; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Su SF, 2013, J BIOL CHEM, V288, P24809, DOI 10.1074/jbc.M113.468579; Tanaka T, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001637; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; von Boehmer L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021366; Wang YM, 2014, MOL CELL, V53, P752, DOI 10.1016/j.molcel.2014.01.020; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Weon JL, 2015, CURR OPIN CELL BIOL, V37, P1, DOI 10.1016/j.ceb.2015.08.002; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yang B, 2007, CANCER RES, V67, P9954, DOI 10.1158/0008-5472.CAN-07-1478; Yang F, 2014, BREAST CANCER RES TR, V145, P23, DOI 10.1007/s10549-014-2915-9; Yin B, 2014, INT J CLIN EXP PATHO, V7, P2934; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104; Zhuang Ran, 2006, Cancer Immun, V6, P7	56	18	18	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1476	1486		10.1038/onc.2016.314	http://dx.doi.org/10.1038/onc.2016.314			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27775077				2022-12-17	WOS:000397458100003
J	Molinuevo, R; Freije, A; de Pedro, I; Stoll, SW; Elder, JT; Gandarillas, A				Molinuevo, R.; Freije, A.; de Pedro, I.; Stoll, S. W.; Elder, J. T.; Gandarillas, A.			FOXM1 allows human keratinocytes to bypass the oncogene-induced differentiation checkpoint in response to gain of MYC or loss of p53	ONCOGENE			English	Article							BASAL-CELL CARCINOMAS; EPIDERMAL STEM-CELLS; HUMAN SKIN; C-MYC; TRANSCRIPTION FACTOR; REPLICATION STRESS; INDUCED APOPTOSIS; CANCER; EXPRESSION; PROGRESSION	Tumour suppressor p53 or proto-oncogene MYC is frequently altered in squamous carcinomas, but this is insufficient to drive carcinogenesis. We have shown that overactivation of MYC or loss of p53 via DNA damage triggers an anti-oncogenic differentiation-mitosis checkpoint in human epidermal keratinocytes, resulting in impaired cell division and squamous differentiation. Forkhead box M1 (FOXM1) is a transcription factor recently proposed to govern the expression of a set of mitotic genes. Deregulation of FOXM1 occurs in a wide variety of epithelial malignancies. We have ectopically expressed FOXM1 in keratinocytes of the skin after overexpression of MYC or inactivation of endogenous p53. Ectopic FOXM1 rescues the proliferative capacity of MYC- or p53-mutant cells in spite of higher genetic damage and a larger cell size typical of differentiation. As a consequence, differentiation induced by loss of p53 or MYC is converted into increased proliferation and keratinocytes displaying genomic instability are maintained within the proliferative compartment. The results demonstrate that keratinocyte oncogene-induced differentiation is caused by mitosis control and provide new insight into the mechanisms driving malignant progression in squamous cancer.	[Molinuevo, R.; Freije, A.; de Pedro, I.; Gandarillas, A.] Inst Res Marques Valdecilla IDIVAL, Cell Cycle Stem Cell Fate & Canc Lab, Cardenal Herrera Oria S-N, Santander 39011, Cantabria, Spain; [Stoll, S. W.; Elder, J. T.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; [Elder, J. T.] Dept Ann Arbor Vet Affairs Hlth Syst, Ann Arbor, MI USA; [Gandarillas, A.] INSERM, Montpellier, France	Hospital Universitario Marques de Valdecilla (HUMV); University of Michigan System; University of Michigan; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Gandarillas, A (corresponding author), Inst Res Marques Valdecilla IDIVAL, Cell Cycle Stem Cell Fate & Canc Lab, Cardenal Herrera Oria S-N, Santander 39011, Cantabria, Spain.	agandarillas@idival.org			Instituto de Salud Carlos III ISCIII FIS/FEDER Grants [PI11/02070, PI14/00900]; National Institutes of Health, NIH [R03 AR049420, R01 AR052889]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR049420, R01AR052889] Funding Source: NIH RePORTER	Instituto de Salud Carlos III ISCIII FIS/FEDER Grants; National Institutes of Health, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was funded by Instituto de Salud Carlos III ISCIII FIS/FEDER Grants PI11/02070 and PI14/00900 (to AG) and National Institutes of Health, NIH Awards R03 AR049420 (to SWS) and R01 AR052889 (to JTE).	Alonso-Lecue P, BYPASS MITOTIC UNPUB; Borowiec AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077507; Brash DE, 2006, BRIT J DERMATOL, V154, P8, DOI 10.1111/j.1365-2133.2006.07230.x; Costa RH, 2005, CURR OPIN GENET DEV, V15, P42, DOI 10.1016/j.gde.2004.12.007; Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duarte B, 2014, MOL THER, V22, P1878, DOI 10.1038/mt.2014.187; Freije A, 2012, ONCOGENE, V31, P5180, DOI 10.1038/onc.2012.22; Freije A, 2014, CELL REP, V9, P1349, DOI 10.1016/j.celrep.2014.10.012; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 2000, ONCOGENE, V19, P3278, DOI 10.1038/sj.onc.1203630; Gandarillas A, 2015, MOL CELL ONCOL, V2, DOI 10.1080/23723556.2014.997127; Gandarillas A, 2012, CELL CYCLE, V11, P4507, DOI 10.4161/cc.22529; Gebhardt A, 2006, J CELL BIOL, V172, P139, DOI 10.1083/jcb.200506057; Gemenetzidis E, 2010, CANCER RES, V70, P9515, DOI 10.1158/0008-5472.CAN-10-2173; Halasi M, 2009, CELL CYCLE, V8, P1966, DOI 10.4161/cc.8.12.8708; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Kong XY, 2013, CANCER RES, V73, P3987, DOI 10.1158/0008-5472.CAN-12-3859; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; le Pelletier F, 2001, J INVEST DERMATOL, V117, P1324; Lecona E, 2014, EXP CELL RES, V329, P26, DOI 10.1016/j.yexcr.2014.09.019; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Macias E, 2008, CANCER RES, V68, P162, DOI 10.1158/0008-5472.CAN-07-2461; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Orr-Weaver TL, 2015, TRENDS GENET, V31, P307, DOI 10.1016/j.tig.2015.03.011; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Ren ZP, 1997, AM J PATHOL, V150, P1791; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Rios AC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11400; Ritchie A, 2009, CELL DEATH DIFFER, V16, P838, DOI 10.1038/cdd.2009.13; Rodriguez R, 2011, STEM CELLS, V29, P179, DOI 10.1002/stem.571; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rosa-Garrido M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039371; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; SHEA CR, 1992, AM J PATHOL, V141, P25; Stoll SW, 2016, ONCOGENE, V35, P2075, DOI 10.1038/onc.2015.269; Teh MT, 2002, CANCER RES, V62, P4773; Teh MT, 2013, INT J CANCER, V132, P2095, DOI 10.1002/ijc.27886; Toll A, 2008, CELL CYCLE, V7, P2674, DOI 10.4161/cc.7.17.6523; van Deursen JM, 2007, CANCER CELL, V11, P1, DOI 10.1016/j.ccr.2006.12.006; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Watt FM, 2008, NAT REV CANCER, V8, P234, DOI 10.1038/nrc2328; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Xue YJ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-200; Zanet J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015701	51	18	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					956	965		10.1038/onc.2016.262	http://dx.doi.org/10.1038/onc.2016.262			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27452522	Green Published, hybrid			2022-12-17	WOS:000394169100008
J	Mandato, E; Manni, S; Zaffino, F; Semenzato, G; Piazza, F				Mandato, E.; Manni, S.; Zaffino, F.; Semenzato, G.; Piazza, F.			Targeting CK2-driven non-oncogene addiction in B-cell tumors	ONCOGENE			English	Review							PROTEIN-KINASE CK2; LYMPHOBLASTIC-LEUKEMIA CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; LIGAND-INDUCED APOPTOSIS; SELECTIVE INHIBITOR; CASEIN KINASE-2; DNA-DAMAGE; MESENCHYMAL TRANSITION; THERAPEUTIC TARGETS; TYROSINE KINASE	Genetic mutations of oncogenes often underlie deranged cell growth and altered differentiation pathways leading to malignant transformation of B-lymphocytes. However, addiction to oncogenes is not the only drive to lymphoid tumor pathogenesis. Dependence on non-oncogenes, which act by propelling basic mechanisms of cell proliferation and survival, has also been recognized in the pathobiology of lymphoid leukemias, lymphomas and multiple myeloma. Among the growing number of molecules that may uphold non-oncogene addiction, a key place is increasingly being recognized to the serine-threonine kinase CK2. This enzyme is overexpressed and overactive in B-acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphomas, such as mantle cell, follicular, Burkitt's and diffuse large B-cell lymphomas. In these tumors, CK2 may serve the activity of oncogenes, similar to BCR-ABL and c-MYC, control the activation of critical signaling cascades, such as NF-.B (nuclear factor-.B), STAT3 (signal transducer and activator of transcription 3) and PTEN/PI3K/AKT (phosphatase and tensin homolog protein/phosphoinositide 3-kinase/AKR thymoma), and sustain multiple cellular stress-elicited pathways, such as the proteotoxic stress, unfolded protein and DNA-damage responses. CK2 has also been shown to have an essential role in tuning signals derived from the stromal tumor microenvironment. Not surprisingly, targeting CK2 in lymphoid tumor cell lines or mouse xenograft models can boost the cytotoxic effects of both conventional chemotherapeutics and novel agents, similar to heat-shock protein 90, proteasome and tyrosine kinases inhibitors. In this review, we summarize the evidence indicating how CK2 embodies most of the features of a cancer growth-promoting non-oncogene, focusing on lymphoid tumors. We further discuss the preclinical data of the use of small ATP-competitive CK2 inhibitors, which hold the promise to be additional options in novel drug combinations for the therapy of lymphoid and plasmacellular malignancies.	[Mandato, E.; Manni, S.; Zaffino, F.; Semenzato, G.; Piazza, F.] Univ Padua, Hematol Branch, Dept Med, Via Giustiniani 2, I-35128 Padua, Italy; [Mandato, E.; Manni, S.; Zaffino, F.; Semenzato, G.; Piazza, F.] Venetian Inst Mol Med, Padua, Italy	University of Padua; Veneto Institute Molecular Medicine	Piazza, F (corresponding author), Univ Padua, Hematol Branch, Dept Med, Via Giustiniani 2, I-35128 Padua, Italy.	francesco.piazza@unipd.it	SEMENZATO, GIANPIETRO C/J-7727-2016; Manni, Sabrina/AAE-9182-2021; mandato, elisa/AGI-6364-2022; Piazza, Francesco/AAD-1600-2019; Piazza, Francesco/K-6695-2016	SEMENZATO, GIANPIETRO C/0000-0002-6061-4595; mandato, elisa/0000-0002-7443-2821; Piazza, Francesco/0000-0002-2831-623X; Piazza, Francesco/0000-0002-2831-623X; MANNI, SABRINA/0000-0001-6804-0680	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 14481]; Ministero dell'Istruzione, dell'Universita e della Ricerca Scientifica (FIRB-Futuro in Ricerca) [RBFR086EW9_001]; 'Fondazione Umberto Veronesi', Milan, Italy	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione, dell'Universita e della Ricerca Scientifica (FIRB-Futuro in Ricerca); 'Fondazione Umberto Veronesi', Milan, Italy(Fondazione Umberto Veronesi)	This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) to FP (IG 14481) and GS and from the Ministero dell'Istruzione, dell'Universita e della Ricerca Scientifica (FIRB-Futuro in Ricerca 2008, no. RBFR086EW9_001). SM is supported by a research fellowship from the 'Fondazione Umberto Veronesi', Milan, Italy.	Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Aparicio-Siegmund S, 2014, ONCOTARGET, V5, P2131, DOI 10.18632/oncotarget.1852; Aronson LI, 2012, HAEMATOL-HEMATOL J, V97, P1119, DOI 10.3324/haematol.2012.064923; Austen B, 2008, BRIT J HAEMATOL, V142, P925, DOI 10.1111/j.1365-2141.2008.07281.x; Balakrishnan K, 2015, LEUKEMIA, V29, P1811, DOI 10.1038/leu.2015.105; Buontempo F, 2016, ONCOTARGET, V7, P1323, DOI 10.18632/oncotarget.6361; Caino MC, 2009, APOPTOSIS, V14, P392, DOI 10.1007/s10495-009-0316-z; Castillo JJ, 2016, CANCER J, V22, P34, DOI 10.1097/PPO.0000000000000170; Cottini F, 2015, CANCER DISCOV, V5, P972, DOI 10.1158/2159-8290.CD-14-0943; Cox ML, 2010, CELL SIGNAL, V22, P564, DOI 10.1016/j.cellsig.2009.11.014; Curran E, 2014, CURR OPIN ONCOL, V26, P469, DOI 10.1097/CCO.0000000000000113; Deshiere A, 2013, ONCOGENE, V32, P1373, DOI 10.1038/onc.2012.165; Deshiere A, 2011, MOL CELL BIOCHEM, V356, P11, DOI 10.1007/s11010-011-0942-y; Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604; Di Maira G, 2009, CELL MOL LIFE SCI, V66, P3363, DOI 10.1007/s00018-009-0108-1; Dixit D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.10; Dovat S, 2011, MOL CELL BIOCHEM, V356, P201, DOI 10.1007/s11010-011-0964-5; Drygin D, 2011, BIOCHEM BIOPH RES CO, V415, P163, DOI 10.1016/j.bbrc.2011.10.046; Duncan JS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001682; Duncan JS, 2010, BBA-PROTEINS PROTEOM, V1804, P505, DOI 10.1016/j.bbapap.2009.11.001; Flinn IW, 2014, BLOOD, V123, P3406, DOI 10.1182/blood-2013-11-538546; Fowler N, 2013, HEMATOL-AM SOC HEMAT, P553, DOI 10.1182/asheducation-2013.1.553; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Galluzzi L, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00001; Giusiano S, 2011, EUR J CANCER, V47, P792, DOI 10.1016/j.ejca.2010.11.028; Guerra B, 2014, CANCER LETT, V345, P115, DOI 10.1016/j.canlet.2013.11.008; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herman SEM, 2013, LEUKEMIA, V27, P1769, DOI 10.1038/leu.2013.37; Hill RJ, 2013, INT REV IMMUNOL, V32, P377, DOI 10.3109/08830185.2013.818141; Izeradjene K, 2005, ONCOGENE, V24, P2050, DOI 10.1038/sj.onc.1208397; Izeradjene K, 2004, CLIN CANCER RES, V10, P6650, DOI 10.1158/1078-0432.CCR-04-0576; Jonkers J, 2004, CANCER CELL, V6, P535, DOI 10.1016/j.ccr.2004.12.002; Kalathur M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8227; Kastner P, 2013, AM J BLOOD RES, V3, P1; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Khoronenkova SV, 2012, MOL CELL, V45, P801, DOI 10.1016/j.molcel.2012.01.021; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; Kuiatse I, 2015, CLIN CANCER RES, V21, P2538, DOI 10.1158/1078-0432.CCR-14-1462; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Lu RQ, 2008, TRENDS IMMUNOL, V29, P487, DOI 10.1016/j.it.2008.07.006; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Manni S, 2014, LEUKEMIA, V28, P2094, DOI 10.1038/leu.2014.178; Manni S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075280; Manni S, 2012, CLIN CANCER RES, V18, P1888, DOI 10.1158/1078-0432.CCR-11-1789; Gomes AM, 2014, HAEMATOLOGICA, V99, P1062, DOI 10.3324/haematol.2013.096438; Martins LR, 2014, LEUKEMIA, V28, P179, DOI 10.1038/leu.2013.232; Martins LR, 2010, BLOOD, V116, P2724, DOI 10.1182/blood-2010-04-277947; Maxwell KN, 2012, NAT REV CLIN ONCOL, V9, P520, DOI 10.1038/nrclinonc.2012.123; Melander F, 2008, J CELL BIOL, V181, P213, DOI 10.1083/jcb.200708210; Mishra S, 2007, LEUKEMIA, V21, P178, DOI 10.1038/sj.leu.2404460; Mishra S, 2003, ONCOGENE, V22, P8255, DOI 10.1038/sj.onc.1207156; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Miyata Y, 2004, MOL CELL BIOL, V24, P4065, DOI 10.1128/MCB.24.9.4065-4074.2004; Miyata Y, 2009, CELL MOL LIFE SCI, V66, P1840, DOI 10.1007/s00018-009-9152-0; Montenarh M, 2014, ADV CLIN EXP MED, V23, P153, DOI 10.17219/acem/37040; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Mottet D, 2005, INT J CANCER, V117, P764, DOI 10.1002/ijc.21268; Olsen BB, 2010, ONCOGENE, V29, P6016, DOI 10.1038/onc.2010.337; Olsen BB, 2012, BMC MOL BIOL, V13, DOI 10.1186/1471-2199-13-7; Peng B, 2015, NUCLEIC ACIDS RES, V43, P5936, DOI 10.1093/nar/gkv528; Piazza F, 2012, LEUKEMIA, V26, P1174, DOI 10.1038/leu.2011.385; Piazza FA, 2006, BLOOD, V108, P1698, DOI 10.1182/blood-2005-11-013672; Pizzi M, 2015, ONCOTARGET, V6, P6544, DOI 10.18632/oncotarget.3446; Plotnikov A, 2011, MOL CELL BIOL, V31, P3515, DOI 10.1128/MCB.05424-11; Popescu M, 2009, J BIOL CHEM, V284, P13869, DOI 10.1074/jbc.M900209200; Pospisilova S, 2004, BIOCHEM J, V378, P939, DOI 10.1042/BJ20030662; Prins RC, 2013, LEUKEMIA, V27, P2094, DOI 10.1038/leu.2013.228; Riabinska A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005814; Ruzzene M, 2011, MOL CELL BIOCHEM, V356, P5, DOI 10.1007/s11010-011-0959-2; Ruzzene M, 2010, BBA-PROTEINS PROTEOM, V1804, P499, DOI 10.1016/j.bbapap.2009.07.018; Sawas A, 2011, CURR OPIN HEMATOL, V18, P280, DOI 10.1097/MOH.0b013e328347786d; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; Schevzov G, 2015, MOL BIOL CELL, V26, P2475, DOI 10.1091/mbc.E14-10-1453; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shehata M, 2010, BLOOD, V116, P2513, DOI 10.1182/blood-2009-10-248054; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; Siddiqui-Jain A, 2010, CANCER RES, V70, P10288, DOI 10.1158/0008-5472.CAN-10-1893; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Song CH, 2015, BLOOD, V126, P1813, DOI 10.1182/blood-2015-06-651505; Song Chunhua, 2011, World J Biol Chem, V2, P126, DOI 10.4331/wjbc.v2.i6.126; St-Denis NA, 2009, CELL MOL LIFE SCI, V66, P1817, DOI 10.1007/s00018-009-9150-2; Strom CE, 2011, DNA REPAIR, V10, P961, DOI 10.1016/j.dnarep.2011.07.004; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trembley JH, 2009, CELL MOL LIFE SCI, V66, P1858, DOI 10.1007/s00018-009-9154-y; Trembley JH, 2010, BIOFACTORS, V36, P187, DOI 10.1002/biof.96; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang GX, 2006, CANCER RES, V66, P2242, DOI 10.1158/0008-5472.CAN-05-2772; Wang S, 2006, CURR BIOL, V16, P2239, DOI 10.1016/j.cub.2006.09.034; Wu SY, 2013, MOL CELL, V49, P843, DOI 10.1016/j.molcel.2012.12.006; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Young RM, 2015, SEMIN HEMATOL, V52, P77, DOI 10.1053/j.seminhematol.2015.01.008; Zheng Y, 2011, BLOOD, V118, P156, DOI 10.1182/blood-2010-01-266320	96	18	19	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6045	6052		10.1038/onc.2016.86	http://dx.doi.org/10.1038/onc.2016.86			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27041560				2022-12-17	WOS:000388509800001
J	Bigi, A; Beltrami, E; Trinei, M; Stendardo, M; Pelicci, PG; Giorgio, M				Bigi, A.; Beltrami, E.; Trinei, M.; Stendardo, M.; Pelicci, P. G.; Giorgio, M.			Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis	ONCOGENE			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; MANGANESE SUPEROXIDE-DISMUTASE; BREAST-CANCER; CELL-DEATH; K-RAS; ONCOGENIC RAS; LUNG-CANCER; IN-VIVO; P53; CYCLOSPORINE	Mitochondrial alterations induced by oncogenes are known to be crucial for tumorigenesis. Ras oncogene leads to proliferative signals through a Raf-1/MEK/ERK kinase cascade, whose components have been found to be also associated with mitochondria. The mitochondrial pepdidyl-prolyl isomerase cyclophilin D (CypD) is an important regulator of the mitochondrial permeability transition and a key player in mitochondria physiology; however, its role in cancer is still unclear. Using cellular and in vivo mouse models, we demonstrated that CypD protein upregulation induced by oncogenic Ras through the Raf-1/MEK/ERK pathway has a deterministic role in tumor progression. In fact, targeting CypD gene expression clearly affected RasV12-induced transformation, as showed by in vitro data on murine NIH3T3 and human MCF10A mammary epithelial cells. In addition, studies in xenograft and K-Ras lung cancer mouse models demonstrated that genetic deletion or pharmacological suppression of CypD efficiently prevented Ras-dependent tumor formation. Furthermore, Erbb2-mediated breast tumorigenesis was similarly prevented by targeting CypD. From a mechanistic point of view, CypD expression was associated with a reduced induction of p21(WAF1/CIP1) and p53 functions, unraveling an antagonistic function of CypD on p21-p53-mediated growth suppression. CypD activity is p53 dependent. Interestingly, a physical association between p53 and CypD was detected in mitochondria of MCF10A cells; furthermore, both in vitro and in vivo studies proved that CypD inhibitor-based treatment was able to efficiently impair this interaction, leading to a tumor formation reduction. All together, these findings indicate that the countering effect of CypD on the p53-p21 pathway participates in oncogene-dependent transformation.	[Bigi, A.; Beltrami, E.; Trinei, M.; Stendardo, M.; Pelicci, P. G.; Giorgio, M.] European Inst Oncol, Dept Expt Oncol, Milan, Italy	IRCCS European Institute of Oncology (IEO)	Giorgio, M (corresponding author), European Inst Oncol, Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.	marco.giorgio@ieo.eu	Pelicci, Pier Giuseppe/AAL-6572-2020; Giorgio, Marco/I-9425-2012; beltrami, elena/AAE-9937-2021	Giorgio, Marco/0000-0002-5842-6042; 	Italian Association for Cancer Research (AIRC); Fondazione Umberto Veronesi (FUV)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Umberto Veronesi (FUV)(Fondazione Umberto Veronesi)	This work was supported by the Italian Association for Cancer Research (AIRC) and the Fondazione Umberto Veronesi (FUV) grants awarded to MG. We thank Michael Forte and Paolo Bernardi for helpful discussion and for providing CypDKO mice, Mariano Barbacid for K-Ras/RERT mice, Jacob Tropmair for MEK-1 mutants and Novartis (Basel-Switzerland) for Deb025.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Beltrami E, 2013, AGING CELL, V12, P177, DOI 10.1111/acel.12036; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Chen G, 2009, ANTIOXID REDOX SIGN, V11, P1083, DOI 10.1089/ARS.2008.2321; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Elrod JW, 2013, CIRC J, V77, P1111, DOI 10.1253/circj.CJ-13-0321; Galluzzi L, 2011, ANTIOXID REDOX SIGN, V15, P1691, DOI 10.1089/ars.2010.3504; Gambino V, 2013, AGING CELL, V12, P435, DOI 10.1111/acel.12060; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; HOGAN B, 1994, MANIPULATING MOUSE E; Holley AK, 2010, ANN NY ACAD SCI, V1201, P72, DOI 10.1111/j.1749-6632.2010.05612.x; Holley AK, 2009, FUTURE ONCOL, V5, P117, DOI 10.2217/14796694.5.1.117; Hursting SD, 2002, MOL CARCINOGEN, V33, P16, DOI 10.1002/mc.10020; Jiang K, 2012, INT J MOL MED, V30, P302, DOI 10.3892/ijmm.2012.989; Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028; Kumar P, 2001, BIOCHEM BIOPH RES CO, V284, P219, DOI 10.1006/bbrc.2001.4952; Li B, 2012, BBA-BIOENERGETICS, V1817, P1628, DOI 10.1016/j.bbabio.2012.05.011; Longo Valter D, 2004, Sci Aging Knowledge Environ, V2004, ppe36, DOI 10.1126/sageke.2004.39.pe36; Luvisetto S, 2008, NEUROSCIENCE, V155, P585, DOI 10.1016/j.neuroscience.2008.06.030; Machida K, 2006, J BIOL CHEM, V281, P14314, DOI 10.1074/jbc.M513297200; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marcu R, 2012, BIOELECTROCHEMISTRY, V85, P21, DOI 10.1016/j.bioelechem.2011.11.005; Masuo T, 2009, CANCER LETT, V285, P66, DOI 10.1016/j.canlet.2009.05.001; Murphy ME, 2004, CELL CYCLE, V3, P836; Neuzil J, 2012, CELL RES, V22, P285, DOI 10.1038/cr.2011.160; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Rapino S, 2015, ELECTROCHIM ACTA, V179, P65, DOI 10.1016/j.electacta.2015.04.053; Rasola A, 2010, P NATL ACAD SCI USA, V107, P726, DOI 10.1073/pnas.0912742107; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Senturk S, 2014, P NATL ACAD SCI USA, V111, pE3287, DOI 10.1073/pnas.1321640111; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sperka T, 2012, NAT REV MOL CELL BIO, V13, P579, DOI 10.1038/nrm3420; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tsumura H, 2006, ONCOGENE, V25, P7673, DOI 10.1038/sj.onc.1209749; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Zhao LP, 2013, NEUROCHEM RES, V38, P705, DOI 10.1007/s11064-013-0968-5; Zhao YF, 2002, ONCOGENE, V21, P3836, DOI 10.1038/sj.onc.1205477; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493; Zupanska A, 2005, NEUROCHEM INT, V47, P430, DOI 10.1016/j.neuint.2005.05.010	54	18	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5132	5143		10.1038/onc.2016.42	http://dx.doi.org/10.1038/onc.2016.42			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26973251				2022-12-17	WOS:000384433000005
J	Cai, J; Zuo, Y; Wang, T; Cao, Y; Cai, R; Chen, FL; Cheng, J; Mu, J				Cai, J.; Zuo, Y.; Wang, T.; Cao, Y.; Cai, R.; Chen, F-L; Cheng, J.; Mu, J.			A crucial role of SUMOylation in modulating Sirt6 deacetylation of H3 at lysine 56 and its tumor suppressive activity	ONCOGENE			English	Article							CANCER METABOLISM; LIFE-SPAN; DRIVERS SEAT; DNA-REPAIR; CHROMATIN; SIRTUINS; PROTEIN; IDENTIFICATION; STABILIZATION; LOCALIZATION	Sirt6 is a histone deacetylase with NAD(+)-dependent activity. Sirt6 has been shown as a tumor suppressor partially via inhibiting the expression of c-Myc target genes and ribosome biogenesis. However, how to regulate Sirt6 activity is largely unknown. In this study, we identify that Sirt6 can be modified by small ubiquitin-like modifier. Sirt6 SUMOylation deficiency specifically decreases its deacetylation of H3K56 but not H3K9 in vivo. Mechanistically, we find that SUMOylation deficiency decreases Sirt6 binding with c-Myc, decreasing Sirt6 occupancy on the locus of c-Myc target genes. Therefore, Sirt6 SUMOylation deficiency reduces its deacetylation of H3k56 and its repression of c-Myc target genes. Moreover, Sirt6 SUMOylation deficiency reduces its suppression of cell proliferation and tumorigenesis. Thus, these results reveal that SUMOylation has an important role in regulation of Sirt6 deacetylation on H3K56, as well as its tumor suppressive activity.	[Cai, J.; Zuo, Y.; Wang, T.; Cao, Y.; Cai, R.; Cheng, J.] Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, 280 Chongqing S Rd,Bldg 7 Rm 405, Shanghai 200025, Peoples R China; [Chen, F-L] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 3, Shanghai, Peoples R China; [Mu, J.] Chinese Acad Med Sci, Canc Hosp, Dept Thorac Surg, Beijing 100021, Peoples R China; [Mu, J.] Peking Union Med Coll, Beijing 100021, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Cheng, J (corresponding author), Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, 280 Chongqing S Rd,Bldg 7 Rm 405, Shanghai 200025, Peoples R China.; Mu, J (corresponding author), Chinese Acad Med Sci, Canc Hosp, Dept Thorac Surg, Beijing 100021, Peoples R China.; Mu, J (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.	jkcheng@shsmu.edu.cn; mujuwei@cicams.ac.cn			National Basic Research Program of China (973 Program) [2013CB910902]; National Natural Science Foundation of China [91229202, 81430069]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Chuxia Deng (NIH, Bethesda, MD, USA) for kindly providing for Sirt6-/- MEF cells. This work was supported by National Basic Research Program of China (973 Program; no. 2013CB910902 to JC), National Natural Science Foundation of China (91229202 and 81430069 to JC).	Ardestani PM, 2012, NUCLEUS-PHILA, V3, P442, DOI 10.4161/nucl.21134; Baur JA, 2012, NAT REV DRUG DISCOV, V11, P443, DOI 10.1038/nrd3738; Bosch-Presegue Laia, 2011, Genes Cancer, V2, P648, DOI 10.1177/1947601911417862; Burnett C, 2011, NATURE, V477, P482, DOI 10.1038/nature10296; Chalkiadaki A, 2012, NAT REV ENDOCRINOL, V8, P287, DOI 10.1038/nrendo.2011.225; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Davalos A, 2011, P NATL ACAD SCI USA, V108, P9232, DOI 10.1073/pnas.1102281108; Dominy JE, 2012, MOL CELL, V48, P900, DOI 10.1016/j.molcel.2012.09.030; Dutnall RN, 2001, CELL, V105, P161, DOI 10.1016/S0092-8674(01)00305-1; Escobar-Cabrera E, 2011, J BIOL CHEM, V286, P19816, DOI 10.1074/jbc.M111.231647; Etchegaray JP, 2013, CURR TOP MED CHEM, V13, P2991, DOI 10.2174/15680266113136660213; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gertler AA, 2013, BIOGERONTOLOGY, V14, P629, DOI 10.1007/s10522-013-9478-8; Jiang H, 2013, NATURE, V496, P110, DOI 10.1038/nature12038; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; Kang XL, 2010, MOL CELL, V38, P191, DOI 10.1016/j.molcel.2010.03.005; Kawahara TLA, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002153; Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; Kolesar P, 2012, NUCLEIC ACIDS RES, V40, P7831, DOI 10.1093/nar/gks484; Kugel S, 2014, TRENDS BIOCHEM SCI, V39, P72, DOI 10.1016/j.tibs.2013.12.002; Lefort K, 2013, EMBO J, V32, P2248, DOI 10.1038/emboj.2013.156; Lin ZH, 2013, CELL REP, V5, P1639, DOI 10.1016/j.celrep.2013.11.029; Lombard DB, 2008, J INTERN MED, V263, P128, DOI 10.1111/j.1365-2796.2007.01902.x; Lyssiotis CA, 2012, CELL, V151, P1155, DOI 10.1016/j.cell.2012.11.020; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Sharma A, 2013, J BIOL CHEM, V288, P18439, DOI 10.1074/jbc.M112.405928; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Sundaresan NR, 2012, NAT MED, V18, P1643, DOI 10.1038/nm.2961; Takasaka N, 2014, J IMMUNOL, V192, P958, DOI 10.4049/jimmunol.1302341; Tasselli L, 2012, NATURE, V492, P362, DOI 10.1038/492362a; Tennen RI, 2010, MECH AGEING DEV, V131, P185, DOI 10.1016/j.mad.2010.01.006; Toiber D, 2013, MOL CELL, V51, P454, DOI 10.1016/j.molcel.2013.06.018; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200; Zhang ZG, 2014, MOL MED REP, V9, P882, DOI 10.3892/mmr.2013.1879; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041	40	18	19	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4949	4956		10.1038/onc.2016.24	http://dx.doi.org/10.1038/onc.2016.24			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26898756				2022-12-17	WOS:000383330700012
J	Teng, Y; Pi, W; Wang, Y; Cowell, JK				Teng, Y.; Pi, W.; Wang, Y.; Cowell, J. K.			WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; LAMELLIPODIA FORMATION; PROMOTING PROTEIN; TARGETED THERAPY; GENE; ACTIVATION; EXPRESSION; MIGRATION; WAVE3; HER2	The WASF3 gene is overexpressed in high-grade breast cancer and promotes invasion and metastasis, but does not affect proliferation. The HER2/ERBB2/NEU gene is also frequently overexpressed in breast cancer, and has been shown to promote invasion and metastasis in these tumors. Here, we show that WASF3 is present in the HER2 immunocomplex and suppression of WASF3 function leads to suppression of invasion even in the presence of HER2 expression. Overexpression of both HER2 and WASF3 in non-metastatic MCF7 breast cancer cells promotes invasion and metastasis more significantly than either gene alone. HER2 forms homodimers as well as heterodimers with other HER family members and we now show that the ability of WASF3 to promote invasion is highly dependent on the HER2/HER3 heterodimer. The engagement of WASF3 with the HER2/HER3 complex facilitates its phospho-activation and transcriptional upregulation, which is facilitated by HER2/HER3 activation of JAK/STAT signaling. In breast cancer cells overexpressing HER2, therefore, WASF3 is specifically required to facilitate the invasion/metastasis response. Targeting WASF3, therefore, could be a potential therapeutic approach to suppress metastasis of HER2-overexpressing breast tumors.	[Teng, Y.; Wang, Y.; Cowell, J. K.] Georgia Regents Univ, Ctr Canc, Augusta, GA USA; [Teng, Y.; Pi, W.] Georgia Regents Univ, Dept Biochem & Mol Biol, Augusta, GA USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Teng, Y (corresponding author), Georgia Regents Univ, 1120 15th St, Augusta, GA 30912 USA.	yteng@gru.edu	Teng, Yong/AAK-4160-2020	Teng, Yong/0000-0002-1856-7289	National Institutes of Health [CA120510]; NATIONAL CANCER INSTITUTE [R01CA120510] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by grant CA120510 from the National Institutes of Health. We would like to thank Yun Mei and Hao Zhang for the technical assistance.	Atalay G, 2003, ANN ONCOL, V14, P1346, DOI 10.1093/annonc/mdg365; Barok M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3621; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; Cai Z, 2008, ONCOGENE, V27, P3870, DOI 10.1038/onc.2008.13; Freudenberg JA, 2009, EXP MOL PATHOL, V87, P1, DOI 10.1016/j.yexmp.2009.05.001; Ghoshal P, 2012, INT J CANCER, V131, pE905, DOI 10.1002/ijc.27631; Gomez-Martin C, 2014, CANCER LETT, V351, P30, DOI 10.1016/j.canlet.2014.05.019; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Johnson E, 2010, J BIOL CHEM, V285, P29491, DOI 10.1074/jbc.M110.136770; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Liu JB, 2002, AM J RESP CELL MOL, V27, P306, DOI 10.1165/rcmb.4850; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Modi S, 2011, CLIN CANCER RES, V17, P5132, DOI 10.1158/1078-0432.CCR-11-0072; Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Roses RE, 2009, CANCER EPIDEM BIOMAR, V18, P1386, DOI 10.1158/1055-9965.EPI-08-1101; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Shankaran H, 2006, BIOPHYS J, V90, P3993, DOI 10.1529/biophysj.105.080580; Sossey-Alaoui K, 2005, J BIOL CHEM, V280, P21748, DOI 10.1074/jbc.M500503200; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Sossey-Alaoui K, 2007, J BIOL CHEM, V282, P26257, DOI 10.1074/jbc.M701484200; Sossey-Alaoui K, 2013, SEMIN CELL DEV BIOL, V24, P287, DOI 10.1016/j.semcdb.2012.10.006; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Taylor MA, 2013, BREAST CANCER RES TR, V142, P341, DOI 10.1007/s10549-013-2753-1; Teng Y, 2016, ONCOGENE, V35, P333, DOI 10.1038/onc.2015.86; Teng Y, 2014, ONCOGENE, V33, P203, DOI 10.1038/onc.2012.565; Teng Y, 2010, BRIT J CANCER, V103, P1066, DOI 10.1038/sj.bjc.6605850; Teng Y, 2015, CANC RES; Teng Yong, 2014, JAKSTAT, V3, pe28086, DOI 10.4161/jkst.28086; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Teng Y, 2013, CARCINOGENESIS, V34, P1994, DOI 10.1093/carcin/bgt167; Teng Y, 2012, J BIOL CHEM, V287, P10051, DOI 10.1074/jbc.M111.335000; Teng Y, 2011, INT J CANCER, V129, P2825, DOI 10.1002/ijc.25964; Tsujioka H, 2010, ANTICANCER RES, V30, P3107; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; Vaught DB, 2012, CANCER RES, V72, P2672, DOI 10.1158/0008-5472.CAN-11-3594; Zhang J, 2013, GYNECOL ONCOL, V130, P354, DOI 10.1016/j.ygyno.2013.05.005	43	18	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4633	4640		10.1038/onc.2015.527	http://dx.doi.org/10.1038/onc.2015.527			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26804171	Green Accepted			2022-12-17	WOS:000382336300009
J	Garcia-Limones, C; Lara-Chica, M; Jimenez-Jimenez, C; Perez, M; Moreno, P; Munoz, E; Calzado, MA				Garcia-Limones, C.; Lara-Chica, M.; Jimenez-Jimenez, C.; Perez, M.; Moreno, P.; Munoz, E.; Calzado, M. A.			CHK2 stability is regulated by the E3 ubiquitin ligase SIAH2	ONCOGENE			English	Article							BETA-CATENIN DEGRADATION; DNA-DAMAGE CHECKPOINT; PROLYL-HYDROXYLASES; APOPTOTIC RESPONSE; MURINE HOMOLOGS; CANCER-THERAPY; STRAND BREAKS; KINASE CHK2; PHOSPHORYLATION; HYPOXIA	The serine threonine checkpoint kinase 2 (CHK2) is a critical protein involved in the DNA damage-response pathway, which is activated by phosphorylation inducing cellular response such as DNA repair, cell-cycle regulation or apoptosis. Although CHK2 activation mechanisms have been amply described, very little is known about degradation control processes. In the present study, we identify the ubiquitin E3 ligase SIAH2 as an interaction partner of CHK2, which mediates its ubiquitination and proteasomal degradation. CHK2 degradation is independent of both its activation and its kinase activity, but also of the phosphorylation in S456. We show that SIAH2-deficient cells present CHK2 accumulation together with lower ubiquitination levels. Accordingly, SIAH2 depletion by siRNA increases CHK2 levels. In response to DNA damage induced by etoposide, interaction between both proteins is disrupted, thus avoiding CHK2 degradation and promoting its stabilization. We also found that CHK2 phosphorylates SIAH2 at three residues (Thr26, Ser28 and Thr119), modifying its ability to regulate certain substrates. Cellular arrest in the G2/M phase induced by DNA damage is reverted by SIAH2 expression through the control of CHK2 levels. We observed that hypoxia decreases CHK2 levels in parallel to SIAH2 induction. Similarly, we provide evidence suggesting that resistance to apoptosis induced by genotoxic agents in cells subjected to hypoxia could be partly explained by the mutual regulation between both proteins. These results indicate that SIAH2 regulates CHK2 basal turnover, with important consequences on cell-cycle control and on the ability of hypoxia to alter the DNA damage-response pathway in cancer cells.	[Garcia-Limones, C.; Lara-Chica, M.; Jimenez-Jimenez, C.; Perez, M.; Moreno, P.; Munoz, E.; Calzado, M. A.] Univ Reina Sofia, Univ Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC Hosp, Dept Cell Biol Physiol & Immunol, Cordoba, Spain	Universidad de Cordoba	Calzado, MA (corresponding author), Inst Maimonides Invest Biomed Cordoba IMIBIC, Dept Biol Celular Fisiol & Inmunol, Avda Menendez Pidal S-N, Cordoba 14004, Spain.	mcalzado@uco.es	Munoz, Eduardo/I-5225-2012; Lara Chica, Maribel/GRF-0887-2022; Calzado, Marco A./S-2295-2019	Munoz, Eduardo/0000-0001-8478-5842; Calzado, Marco A./0000-0002-5338-535X; Lara-Chica, Maribel/0000-0003-2908-9929; MORENO, PAULA/0000-0003-4403-7035	FPU fellowship from Ministerio de Educacion [FPU13/03393]; MICINN [SAF2010-17122]; Consejeria de Salud (Junta de Andalucia) [PI-0650-2010, PI-0246-2013]; Instituto de Salud Carlos III grants [PIE14/00005-FLEXI-MET]	FPU fellowship from Ministerio de Educacion(German Research Foundation (DFG)); MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Consejeria de Salud (Junta de Andalucia)(Junta de Andalucia); Instituto de Salud Carlos III grants(Instituto de Salud Carlos III)	We thank David Bowtell, Andreas Moller, ML Schmitz, H Piwnica-Worms, Stephen J Elledge, David F Stern, Frank S Lee, Carol Prives, S-Y Shieh, Laura Zannini and Domenico Delia for providing material. MLC was supported by a FPU fellowship (FPU13/03393) from Ministerio de Educacion. This work was supported by MICINN (SAF2010-17122), Consejeria de Salud (Junta de Andalucia) (PI-0650-2010 and PI-0246-2013) and Instituto de Salud Carlos III (PIE14/00005-FLEXI-MET) grants.	Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Bohgaki M, 2013, CELL DEATH DIFFER, V20, P812, DOI 10.1038/cdd.2013.7; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Carlessi L, 2010, BBA-MOL CELL RES, V1803, P1213, DOI 10.1016/j.bbamcr.2010.06.002; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Choi SY, 2013, NUCLEIC ACIDS RES, V41, P2180, DOI 10.1093/nar/gks1319; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; Feng L, 2012, NAT STRUCT MOL BIOL, V19, P201, DOI 10.1038/nsmb.2211; FRANKENBERGSCHWAGER M, 1991, RADIAT RES, V128, P243, DOI 10.2307/3578046; Frasor J, 2005, P NATL ACAD SCI USA, V102, P13153, DOI 10.1073/pnas.0502782102; Freeman AK, 2010, CELL CYCLE, V9, P736, DOI 10.4161/cc.9.4.10613; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gibson SL, 2005, CANCER RES, V65, P10734, DOI 10.1158/0008-5472.CAN-05-1160; Guo X, 2010, J BIOL CHEM, V285, P33348, DOI 10.1074/jbc.M110.149609; Holloway AJ, 1997, GENOMICS, V41, P160, DOI 10.1006/geno.1997.4642; House CM, 2009, CANCER RES, V69, P8835, DOI 10.1158/0008-5472.CAN-09-1676; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Kass EM, 2007, J BIOL CHEM, V282, P30311, DOI 10.1074/jbc.M704642200; Kass EM, 2009, CELL CYCLE, V8, P430, DOI 10.4161/cc.8.3.7624; Khurana A, 2006, J BIOL CHEM, V281, P35316, DOI 10.1074/jbc.M606568200; Kirkin V, 2011, CURR OPIN GENET DEV, V21, P21, DOI 10.1016/j.gde.2010.10.004; Knauer SK, 2015, CYTOKINE GROWTH F R, V26, P405, DOI 10.1016/j.cytogfr.2015.04.002; Le Moan N, 2011, MOL CELL, V44, P476, DOI 10.1016/j.molcel.2011.08.033; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Li SH, 2002, MOL CELL BIOL, V22, P6854, DOI 10.1128/MCB.22.19.6854-6865.2002; Liao YL, 2013, GENES NUTR, V8, P69, DOI 10.1007/s12263-012-0297-3; Liu J, 2014, BIOCHIM BIOPHYS ACTA, V1855, P50; Lovly CM, 2008, MOL CELL BIOL, V28, P5874, DOI 10.1128/MCB.00821-08; Lukas C, 2001, CANCER RES, V61, P4990; Ma B, 2015, NAT CELL BIOL, V17, P95, DOI 10.1038/ncb3073; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Munoz MA, 2007, CELL CYCLE, V6, P3070, DOI 10.4161/cc.6.24.5021; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Overgaard J, 2007, J CLIN ONCOL, V25, P4066, DOI 10.1200/JCO.2007.12.7878; Pereg Y, 2006, MOL CELL BIOL, V26, P6819, DOI 10.1128/MCB.00562-06; Perez M, 2012, J MOL CELL BIOL, V4, P316, DOI 10.1093/jmcb/mjs047; Sarkar TR, 2012, MOL CELL BIOL, V32, P320, DOI 10.1128/MCB.05790-11; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Soler-Torronteras R, 2014, BBA-MOL CELL RES, V1843, P2730, DOI 10.1016/j.bbamcr.2014.07.005; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stracker TH, 2009, DNA REPAIR, V8, P1047, DOI 10.1016/j.dnarep.2009.04.012; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Taira N, 2010, J BIOL CHEM, V285, P4909, DOI 10.1074/jbc.M109.042341; Terris DJ, 2002, ARCH OTOLARYNGOL, V128, P698, DOI 10.1001/archotol.128.6.698; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Wong CSF, 2013, CANCER RES, V73, P2400, DOI 10.1158/0008-5472.CAN-12-4348; Xie W, 2009, J CELL MOL MED, V13, P1719, DOI 10.1111/j.1582-4934.2008.00423.x; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zannini L, 2014, J MOL CELL BIOL, V6, P442, DOI 10.1093/jmcb/mju045; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhao HL, 2010, BIOCHEM BIOPH RES CO, V399, P623, DOI 10.1016/j.bbrc.2010.07.127	67	18	20	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4289	4301		10.1038/onc.2015.495	http://dx.doi.org/10.1038/onc.2015.495			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26751770				2022-12-17	WOS:000382152100001
J	Kawatsuki, A; Yasunaga, J; Mitobe, Y; Green, PL; Matsuoka, M				Kawatsuki, A.; Yasunaga, J-i; Mitobe, Y.; Green, P. L.; Matsuoka, M.			HTLV-1 bZIP factor protein targets the Rb/E2F-1 pathway to promote proliferation and apoptosis of primary CD4(+) T cells	ONCOGENE			English	Article							RETINOBLASTOMA PROTEIN; MOLECULAR-MECHANISMS; TAX; P53; DEGRADATION; GENE; RNA; HBZ; E2F; REPLICATION	Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic retrovirus that induces a fatal T-cell malignancy, adult T-cell leukemia (ATL). Among several regulatory/accessory genes in HTLV-1, HTLV-1 bZIP factor (HBZ) is the only viral gene constitutively expressed in infected cells. Our previous study showed that HBZ functions in two different molecular forms, HBZ protein and HBZ RNA. In this study, we show that HBZ protein targets retinoblastoma protein (Rb), which is a critical tumor suppressor in many types of cancers. HBZ protein interacts with the Rb/E2F-1 complex and activates the transcription of E2F-target genes associated with cell cycle progression and apoptosis. Mouse primary CD4(+) T cells transduced with HBZ show accelerated G1/S transition and apoptosis, and importantly, T cells from HBZ transgenic (HBZ-Tg) mice also demonstrate enhanced cell proliferation and apoptosis. To evaluate the functions of HBZ protein alone in vivo, we generated a new transgenic mouse strain that expresses HBZ mRNA altered by silent mutations but encoding intact protein. In these mice, the numbers of effector/memory and Foxp3(+) T cells were increased, and genes associated with proliferation and apoptosis were upregulated. This study shows that HBZ protein promotes cell proliferation and apoptosis in primary CD4(+) T cells through activation of the Rb/E2F pathway, and that HBZ protein also confers onto CD4(+) T-cell immunophenotype similar to those of ATL cells, suggesting that HBZ protein has important roles in dysregulation of CD4(+) T cells infected with HTLV-1.	[Kawatsuki, A.; Yasunaga, J-i; Mitobe, Y.; Matsuoka, M.] Kyoto Univ, Inst Virus Res, Lab Virus Control, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan; [Green, P. L.] Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA; [Green, P. L.] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; [Green, P. L.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Kyoto University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Yasunaga, J (corresponding author), Kyoto Univ, Inst Virus Res, Lab Virus Control, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	jyasunag@virus.kyoto-u.ac.jp		Matsuoka, Masao/0000-0002-0473-754X; Mitobe, Yuichi/0000-0001-5200-5362	Ministry of Education, Science, Sports and Culture of Japan [22114003, 26460554]; Takeda Science Foundation; National Institutes of Health [CA100730]; JSPS Core-to-Core Program A, Advanced Research Networks; NATIONAL CANCER INSTITUTE [P01CA100730] Funding Source: NIH RePORTER	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JSPS Core-to-Core Program A, Advanced Research Networks(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Linda Kingsbury and Kathleen Hayes-Ozello for editorial comments and proofreading. This study was supported by grants from the Ministry of Education, Science, Sports and Culture of Japan to MM (22114003) and JY (26460554) and a grant from the Takeda Science Foundation (JY) and a grant from the National Institutes of Health (CA100730) to PLG. This study was performed as a research program of the Platform for Dynamic Approaches to Living System from the Ministry of Education, Culture, Sports, Science and Technology, Japan (AK), and also supported in part by the JSPS Core-to-Core Program A, Advanced Research Networks.	Arnold J, 2008, BLOOD, V112, P3788, DOI 10.1182/blood-2008-04-154286; Arpin-Andre C, 2014, PLASMID, V74, P45, DOI 10.1016/j.plasmid.2014.06.001; Borchert S, 2014, J VIROL, V88, P3144, DOI 10.1128/JVI.02916-13; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Boyer SN, 1996, CANCER RES, V56, P4620; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Davidson W, 2008, CELL CYCLE, V7, P1224, DOI 10.4161/cc.7.9.5786; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fan J, 2010, J VIROL, V84, P7278, DOI 10.1128/JVI.02239-09; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Gillet NA, 2011, BLOOD, V117, P3113, DOI 10.1182/blood-2010-10-312926; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; KATOH T, 1986, INT J CANCER, V38, P265, DOI 10.1002/ijc.2910380218; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Knight JS, 2005, P NATL ACAD SCI USA, V102, P18562, DOI 10.1073/pnas.0503886102; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Matsuoka M, 2013, CURR OPIN VIROL, V3, P684, DOI 10.1016/j.coviro.2013.08.010; Melamed A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003271; Mitobe Y, 2015, CANCER RES, V75, P4143, DOI 10.1158/0008-5472.CAN-15-0942; Munakata T, 2007, PLOS PATHOG, V3, P1335, DOI 10.1371/journal.ppat.0030139; Peloponese JM, 2009, J VIROL, V83, P3238, DOI 10.1128/JVI.01824-08; Philip S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004040; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Satou Yorifumi, 2012, Leuk Res Treatment, V2012, P213653, DOI 10.1155/2012/213653; Satou Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001274; Sawada S, 1998, J EXP MED, V187, P1439, DOI 10.1084/jem.187.9.1439; Swaims AY, 2010, BLOOD, V116, P2994, DOI 10.1182/blood-2009-07-231050; Takeda S, 2004, INT J CANCER, V109, P559, DOI 10.1002/ijc.20007; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vernin C, 2014, CANCER RES, V74, P6082, DOI 10.1158/0008-5472.CAN-13-3564; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamamoto-Taguchi N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003630; Yasunaga J, 2011, INT J HEMATOL, V94, P435, DOI 10.1007/s12185-011-0937-1; Yoshida M, 2008, J VIROL, V82, P9359, DOI 10.1128/JVI.00242-08; Zhao TJ, 2011, BLOOD, V118, P1865, DOI 10.1182/blood-2010-12-326199; Zhao T, 2009, BLOOD, V113, P2755, DOI 10.1182/blood-2008-06-161729	40	18	19	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4509	4517		10.1038/onc.2015.510	http://dx.doi.org/10.1038/onc.2015.510			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26804169	Green Accepted			2022-12-17	WOS:000382153100008
J	Melo, CA; Leveille, N; Rooijers, K; Wijchers, PJ; Geeven, G; Tal, A; Melo, SA; de Laat, W; Agami, R				Melo, C. A.; Leveille, N.; Rooijers, K.; Wijchers, P. J.; Geeven, G.; Tal, A.; Melo, S. A.; de Laat, W.; Agami, R.			A p53-bound enhancer region controls a long intergenic noncoding RNA required for p53 stress response	ONCOGENE			English	Article							CHROMATIN INTERACTIONS; GENE-EXPRESSION; HUMAN-CELLS; GENOME; TRANSCRIPTION; CANCER; CONFORMATION; REPRESSION; OCCUPANCY; LNCRNA	Genome-wide chromatin studies identified the tumor suppressor p53 as both a promoter and an enhancer-binding transcription factor. As an enhancer factor, p53 can induce local production of enhancer RNAs, as well as transcriptional activation of distal neighboring genes. Beyond the regulation of protein-coding genes, p53 has the capacity to regulate long intergenic noncoding RNA molecules (lincRNAs); however, their importance to the p53 tumor suppressive function remains poorly characterized. Here, we identified and characterized a novel p53-bound intronic enhancer that controls the expression of its host, the lincRNA00475 (linc-475). We demonstrate the requirement of linc-475 for the proper induction of a p53-dependent cell cycle inhibitory response. We further confirm the functional importance of linc-475 in the maintenance of CDKN1A/p21 levels, a cell cycle inhibitor and a major p53 target gene, following p53 activation. Interestingly, loss of linc-475 reduced the binding of both p53 and RNA polymerase II (RNAPII) to the promoter of p21, attenuating its transcription rate following p53 activation. Altogether, our data suggest a direct role of p53-bound enhancer domains in the activation of lincRNAs required for an efficient p53 transcriptional response.	[Melo, C. A.; Leveille, N.; Rooijers, K.; Tal, A.; Agami, R.] Netherlands Canc Inst, Div Biol Stress Response, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Wijchers, P. J.; Geeven, G.; de Laat, W.] Hubrecht Inst KNAW, Utrecht, Netherlands; [Wijchers, P. J.; Geeven, G.; de Laat, W.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Melo, S. A.] Univ Porto IPATIMUP, Inst Invest & Inovacao Saude, Inst Pathol & Mol Immunol, Univ Porto, Oporto, Portugal; [Agami, R.] Rotterdam Univ, Dept Genet, Erasmus MC, Rotterdam, Netherlands	Netherlands Cancer Institute; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Erasmus University Rotterdam; Erasmus MC	Leveille, N; Agami, R (corresponding author), Netherlands Canc Inst, Div Biol Stress Response, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	n.leveille@nki.nl; r.agami@nki.nl	agami, reuven/GOG-8289-2022; MELO, SONIA/H-8972-2013	Agami, Reuven/0000-0002-2848-2473; de Laat, Wouter/0000-0002-6393-595X; Leveille, Nicolas/0000-0002-6086-5984; Rooijers, Koos/0000-0002-0412-468X; A. Melo, Carlos/0000-0001-9648-0560; MELO, SONIA/0000-0002-2291-4263; Geeven, Geert/0000-0002-5603-0095				Abdelmohsen K, 2013, AGING CELL, V12, P890, DOI 10.1111/acel.12115; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Allen MA, 2014, ELIFE, V3, DOI 10.7554/eLife.02200; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; de Leeuw J, 2009, J STAT SOFTW, V32, P1; De Santa F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000384; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Grossi E, 2016, BBA-GENE REGUL MECH, V1859, P200, DOI 10.1016/j.bbagrm.2015.07.011; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Kumar PP, 2014, ELIFE, V3, DOI 10.7554/eLife.02805; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lazorthes S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6971; Leveille N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7520; Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210; Marin-Bejar O, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r104; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Rippe K, 2001, TRENDS BIOCHEM SCI, V26, P733, DOI 10.1016/S0968-0004(01)01978-8; Sanchez Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6812; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Schaukowitch K, 2014, MOL CELL, V56, P29, DOI 10.1016/j.molcel.2014.08.023; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shlyueva D, 2014, NAT REV GENET, V15, P272, DOI 10.1038/nrg3682; Splinter E, 2011, EMBO J, V30, P4345, DOI 10.1038/emboj.2011.344; Splinter E, 2011, GENE DEV, V25, P1371, DOI 10.1101/gad.633311; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Zhou X, 2013, NAT METHODS, V10, P375, DOI 10.1038/nmeth.2440; Zuin J, 2014, P NATL ACAD SCI USA, V111, P996, DOI 10.1073/pnas.1317788111	38	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4399	4406		10.1038/onc.2015.502	http://dx.doi.org/10.1038/onc.2015.502			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26776159				2022-12-17	WOS:000382152100011
J	Park, YH; Kim, SU; Kwon, TH; Kim, JM; Song, IS; Shin, HJ; Lee, BK; Bang, DH; Lee, SJ; Lee, DS; Chang, KT; Kim, BY; Yu, DY				Park, Y-H; Kim, S-U; Kwon, T-H; Kim, J-M; Song, I-S; Shin, H-J; Lee, B-K; Bang, D-H; Lee, S-J; Lee, D-S; Chang, K-T; Kim, B-Y; Yu, D-Y			Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway	ONCOGENE			English	Article							H-RAS12V TRANSGENIC MICE; CANCER STEM-CELLS; HEPATOCELLULAR-CARCINOMA; OXIDATIVE STRESS; POOR-PROGNOSIS; TRANSCRIPTION FACTOR; FOXM1; EXPRESSION; ACTIVATION; HEPATOCARCINOGENESIS	The current study was carried out to define the involvement of Peroxiredoxin (Prx) II in progression of hepatocellular carcinoma (HCC) and the underlying molecular mechanism(s). Expression and function of Prx II in HCC was determined using H-ras(G12V)-transformed HCC cells (H-ras(G12V)-HCC cells) and the tumor livers from H-ras(G12V)-transgenic (Tg) mice and HCC patients. Prx II was upregulated in H-ras(G12V)-HCC cells and H-ras(G12V)-Tg mouse tumor livers, the expression pattern of which highly similar to that of forkhead Box M1 (FoxM1). Moreover, either knockdown of FoxM1 or site-directed mutagenesis of FoxM1-binding site of Prx II promoter significantly reduced Prx II levels in H-ras(G12V)-HCC cells, indicating FoxM1 as a direct transcription factor of Prx II in HCC. Interestingly, the null mutation of Prx II markedly decreased the number and size of tumors in H-ras(G12V)-Tg livers. Consistent with this, knockdown of Prx II in H-ras(G12V)-HCC cells reduced the expression of cyclin D1, cell proliferation, anchorage-independent growth and tumor formation in athymic nude mice, whereas overexpression of Prx II increased or aggravated the tumor phenotypes. Importantly, the expression of Prx II was correlated with that of FoxM1 in HCC patients. The activation of extracellular signal-related kinase (ERK) pathway and the expression of FoxM1 and cyclin D1 were highly dependent on Prx II in H-ras(G12V)-HCC cells and H-ras(G12V)-Tg livers. Prx II is FoxM1-dependently- expressed antioxidant in HCC and function as an enhancer of Ras(G12V) oncogenic potential in hepatic tumorigenesis through activation of ERK/FoxM1/cyclin D1 cascade.	[Park, Y-H; Kim, S-U; Kwon, T-H; Shin, H-J; Lee, B-K; Yu, D-Y] Korea Res Inst Biosci & Biotechnol, Aging Intervent Res Ctr, 125 Gwahak Ro, Daejeon 305806, South Korea; [Park, Y-H; Kim, S-U; Chang, K-T] Korea Res Inst Biosci & Biotechnol, Natl Primate Res Ctr, Daejeon, South Korea; [Park, Y-H; Kim, S-U; Yu, D-Y] Univ Sci & Technol, Dept Funct Genom, Daejeon, South Korea; [Kim, J-M] Chungnam Natl Univ, Sch Med, Daejeon, South Korea; [Song, I-S] Inje Univ, Cardiovasc & Metab Dis Ctr, Busan, South Korea; [Bang, D-H] Wonkwang Univ, Sch Med, Iksan, South Korea; [Lee, S-J] Hanyang Univ, Res Inst Nat Sci, Seoul, South Korea; [Lee, D-S] Kyungpook Natl Univ, Coll Nat Sci, Daegu, South Korea; [Kim, B-Y] Korea Res Inst Biosci & Biotechnol, World Class Inst, Ochang, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Science & Technology (UST); Chungnam National University; Inje University; Wonkwang University; Hanyang University; Kyungpook National University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Yu, DY (corresponding author), Korea Res Inst Biosci & Biotechnol, Aging Intervent Res Ctr, 125 Gwahak Ro, Daejeon 305806, South Korea.	dyyu10@kribb.re.kr		KIM, JIN MAN/0000-0003-0905-9730; Lee, Dong Seok/0000-0001-6348-8937	Mid-career Researcher Program through NFR grant - MSIP [OGM0021312]; World Class Institute (WCI) Program of the NRF - MSIP NRF [WCI 2009-002]; National Research Foundation of Korea - Korean government [2010-0020877]; KRIBB Research Initiative Program of Korea [KGM3141312]; Next-Generation BioGreen 21 Program - Rural Development Administration of Korea [PJ0099592015]	Mid-career Researcher Program through NFR grant - MSIP; World Class Institute (WCI) Program of the NRF - MSIP NRF; National Research Foundation of Korea - Korean government(National Research Foundation of KoreaKorean Government); KRIBB Research Initiative Program of Korea; Next-Generation BioGreen 21 Program - Rural Development Administration of Korea	This work was supported by Mid-career Researcher Program through NFR grant funded by the MSIP (OGM0021312), by the World Class Institute (WCI) Program of the NRF, funded by the MSIP NRF (WCI 2009-002), by the National Research Foundation of Korea (2010-0020877), funded by Korean government, by the KRIBB Research Initiative Program (KGM3141312) of Korea, and by the Next-Generation BioGreen 21 Program (PJ0099592015), funded by Rural Development Administration of Korea. We thank Dr Pradip Raychaudhuri (University of Illinois at Chicago) who provided us with pCMV-T7-FoxM1 expression vectors.	Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Calvisi DF, 2009, GUT, V58, P679, DOI 10.1136/gut.2008.152652; Cho HJ, 2002, J BIOL CHEM, V277, P19358, DOI 10.1074/jbc.M200933200; Choi AR, 2012, BIOCHEM BIOPH RES CO, V425, P436, DOI 10.1016/j.bbrc.2012.07.120; Diao S, 2010, PROTEOMICS, V10, P3723, DOI 10.1002/pmic.201000050; Han YH, 2005, FEBS LETT, V579, P4897, DOI 10.1016/j.febslet.2005.07.049; Han YH, 2012, BIOCHEM BIOPH RES CO, V426, P427, DOI 10.1016/j.bbrc.2012.08.113; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Jungst C, 2004, HEPATOLOGY, V39, P1663, DOI 10.1002/hep.20241; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kang DH, 2011, MOL CELL, V44, P545, DOI 10.1016/j.molcel.2011.08.040; KIARIS H, 1995, INT J ONCOL, V7, P413; Kim H, 2011, HEPATOLOGY, V54, P1707, DOI 10.1002/hep.24559; Kim SU, 2011, NEUROBIOL AGING, V32, P1054, DOI 10.1016/j.neurobiolaging.2009.05.017; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; Kwon J, 2003, FREE RADICAL BIO MED, V35, P406, DOI 10.1016/S0891-5849(03)00318-6; Lee KW, 2011, J BIOL CHEM, V286, P8394, DOI 10.1074/jbc.M110.179416; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Li W, 2010, J CLIN INVEST, V120, P3996, DOI 10.1172/JCI42823; Li Y, 2008, PROTEOMICS, V8, P1490, DOI 10.1002/pmic.200700229; Lu Y, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-115; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Park HJ, 2009, EMBO J, V28, P2908, DOI 10.1038/emboj.2009.239; Park JG, 2011, CIRC RES, V109, P739, DOI 10.1161/CIRCRESAHA.111.245530; Park YH, 2013, ANTIOXID REDOX SIGN, V19, P482, DOI 10.1089/ars.2011.4421; Perkins A, 2015, TRENDS BIOCHEM SCI, V40, P435, DOI 10.1016/j.tibs.2015.05.001; Petrovic V, 2008, J BIOL CHEM, V283, P453, DOI 10.1074/jbc.M705792200; Saha B, 2009, HEPATOLOGY, V50, P1547, DOI 10.1002/hep.23180; Shi XK, 2012, ANTIOXID REDOX SIGN, V16, P1215, DOI 10.1089/ars.2012.4529; Sun HC, 2011, ONCOL REP, V25, P1533, DOI 10.3892/or.2011.1230; Sun HN, 2010, J NEUROCHEM, V114, P39, DOI 10.1111/j.1471-4159.2010.06691.x; Tai P, 2011, MOL ENDOCRINOL, V25, P885, DOI 10.1210/me.2010-0489; Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wang AG, 2005, J HEPATOL, V43, P836, DOI 10.1016/j.jhep.2005.04.012; Wang AG, 2011, BIOCHEM BIOPH RES CO, V409, P532, DOI 10.1016/j.bbrc.2011.05.039; Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Xia LM, 2012, J HEPATOL, V57, P600, DOI 10.1016/j.jhep.2012.04.020; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Zhang B, 2009, CANCER LETT, V286, P154, DOI 10.1016/j.canlet.2009.04.043	44	18	20	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3503	3513		10.1038/onc.2015.411	http://dx.doi.org/10.1038/onc.2015.411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26500057				2022-12-17	WOS:000379621500003
J	Fahraeus, R; Marin, M; Olivares-Illana, V				Fahraeus, R.; Marin, M.; Olivares-Illana, V.			Whisper mutations: cryptic messages within the genetic code	ONCOGENE			English	Review							ASH1 MESSENGER-RNA; SYNONYMOUS MUTATIONS; ESCHERICHIA-COLI; SILENT MUTATIONS; IN-VIVO; TRANSLATION RATES; DNA-DAMAGE; YEAST BUD; PROTEIN; P53	Recent years have seen a great expansion in our understandings of how silent mutations can drive a disease and that mRNAs are not only mere messengers between the genome and the encoded proteins but also encompass regulatory activities. This review focuses on how silent mutations within open reading frames can affect the functional properties of the encoded protein. We describe how mRNAs exert control of cell biological processes governed by the encoded proteins via translation kinetics, protein folding, mRNA stability, spatio-temporal protein expression and by direct interactions with cellular factors. These examples illustrate how additional levels of information lie within the coding sequences and that the degenerative genetic code is not redundant and have co-evolved with the encoded proteins. Hence, so called synonymous mutations are not always silent but 'whisper'.	[Fahraeus, R.] Univ Paris 07, IUH Hop St Louis, Inst Genet Mol, Equipe Labellisee Ligue Canc,INSERM UMRS1162, F-75010 Paris, France; [Fahraeus, R.] Masaryk Mem Canc Inst, RECAMO, Zluty Kopec 7, Brno, Czech Republic; [Marin, M.] Univ Republica, Fac Ciencias, Inst Biol, Secc Biquim, Montevideo, Uruguay; [Olivares-Illana, V.] Univ Autonoma San Luis Potosi, Inst Fis, San Luis Potosi 78290, Mexico	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Masaryk Memorial Cancer Institute; Universidad de la Republica, Uruguay; Universidad Autonoma de San Luis Potosi	Fahraeus, R (corresponding author), Univ Paris 07, IUH Hop St Louis, Inst Genet Mol, Equipe Labellisee Ligue Canc,INSERM UMRS1162, F-75010 Paris, France.; Marin, M (corresponding author), Univ Republica, Fac Ciencias, Inst Biol, Secc Biquim, Montevideo, Uruguay.; Olivares-Illana, V (corresponding author), Univ Autonoma San Luis Potosi, Inst Fis, San Luis Potosi 78290, Mexico.	robin.fahraeus@inserm.fr; marin@fcien.edu.uy; vanesa@ifisica.uaslp.mx	Olivares-Illana, Vanesa/AAF-9710-2021; fahraeus, robin/K-8726-2014	Olivares-Illana, Vanesa/0000-0001-6949-5986	 [MEYS-NPS I-LO1413]		Equipe Labellisee La ligue contre le cancer, ECOS-Sud Program Cooperation France-Uruguay, ECOS-Nord Program Cooperation France-Mexico, Inserm and the project MEYS-NPS I-LO1413.	Aguirre B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021035; Aretz S, 2004, HUM MUTAT, V24, P370, DOI 10.1002/humu.20087; Barrick JE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r239; Bartoszewski RA, 2010, J BIOL CHEM, V285, P28741, DOI 10.1074/jbc.M110.154575; Bourougaa K, 2010, MOL CELL, V38, P78, DOI 10.1016/j.molcel.2010.01.041; Breaker RR, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a003566; Breaker RR, 2011, MOL CELL, V43, P867, DOI 10.1016/j.molcel.2011.08.024; Buchan JR, 2007, BIOL CELL, V99, P475, DOI 10.1042/BC20070037; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Chartrand P, 1999, CURR BIOL, V9, P333, DOI 10.1016/S0960-9822(99)80144-4; Cortazzo P, 2002, BIOCHEM BIOPH RES CO, V293, P537, DOI 10.1016/S0006-291X(02)00226-7; Di Liegro CM, 2014, INT J MOL MED, V33, P747, DOI 10.3892/ijmm.2014.1629; Du TG, 2008, EMBO REP, V9, P781, DOI 10.1038/embor.2008.112; Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055; Frieda KL, 2012, SCIENCE, V338, P397, DOI 10.1126/science.1225722; Fung KL, 2014, CANCER RES, V74, P598, DOI 10.1158/0008-5472.CAN-13-2064; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Gartner JJ, 2013, P NATL ACAD SCI USA, V110, P13481, DOI 10.1073/pnas.1304227110; Gingold H, 2014, CELL, V158, P1281, DOI 10.1016/j.cell.2014.08.011; Gonsalvez Graydon B, 2012, F1000 Biol Rep, V4, P16, DOI 10.3410/B4-16; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hasegawa Y, 2008, RNA, V14, P2333, DOI 10.1261/rna.1016508; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Ioannidis P, 2004, CANCER LETT, V209, P245, DOI 10.1016/j.canlet.2003.12.015; Jansen RP, 2012, CURR PROTEIN PEPT SC, V13, P284, DOI 10.2174/138920312801619493; Kim SJ, 2015, SCIENCE, V348, P444, DOI 10.1126/science.aaa3974; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Komar AA, 2007, PHARMACOGENOMICS, V8, P1075, DOI 10.2217/14622416.8.8.1075; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lamolle G, 2006, MUTAT RES-FUND MOL M, V600, P102, DOI 10.1016/j.mrfmmm.2006.03.004; Lazrak A, 2013, FASEB J, V27, P4630, DOI 10.1096/fj.13-227330; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Malbert-Colas L, 2014, MOL CELL, V54, P500, DOI 10.1016/j.molcel.2014.02.035; Mandal M, 2003, CELL, V113, P577, DOI 10.1016/S0092-8674(03)00391-X; Mironov AS, 2002, CELL, V111, P747, DOI 10.1016/S0092-8674(02)01134-0; Mlynarczyk C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6067; Montange RK, 2008, ANNU REV BIOPHYS, V37, P117, DOI 10.1146/annurev.biophys.37.032807.130000; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; Nedialkova DD, 2015, CELL, V161, P1606, DOI 10.1016/j.cell.2015.05.022; Nissley DA, 2014, J AM CHEM SOC, V136, P17892, DOI 10.1021/ja510082j; Noubissi Felicite K, 2010, Genes Cancer, V1, P1074, DOI 10.1177/1947601910395581; O'Connor PBF, 2013, BIOINFORMATICS, V29, P1488, DOI 10.1093/bioinformatics/btt184; Olivier C, 2005, MOL CELL BIOL, V25, P4752, DOI 10.1128/MCB.25.11.4752-4766.2005; Pagani F, 2005, P NATL ACAD SCI USA, V102, P6368, DOI 10.1073/pnas.0502288102; Paquin N, 2007, MOL CELL, V26, P795, DOI 10.1016/j.molcel.2007.05.016; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pechmann S, 2014, NAT STRUCT MOL BIOL, V21, P1100, DOI 10.1038/nsmb.2919; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Pizzo L, 2015, MUTAT RES-FUND MOL M, V775, P19, DOI 10.1016/j.mrfmmm.2015.03.005; Presnyak V, 2015, CELL, V160, P1111, DOI 10.1016/j.cell.2015.02.029; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Rosano GL, 2009, MICROB CELL FACT, V8, DOI 10.1186/1475-2859-8-41; Sauna ZE, 2011, NAT REV GENET, V12, P683, DOI 10.1038/nrg3051; Saunders R, 2010, NUCLEIC ACIDS RES, V38, P6719, DOI 10.1093/nar/gkq495; Shen ZF, 2010, GENE DEV, V24, P1914, DOI 10.1101/gad.1937510; Shepard KA, 2003, P NATL ACAD SCI USA, V100, P11429, DOI 10.1073/pnas.2033246100; Stergachis AB, 2013, SCIENCE, V342, P1367, DOI 10.1126/science.1243490; Supek F, 2014, CELL, V156, P1324, DOI 10.1016/j.cell.2014.01.051; Tafech A, 2007, BBA-GENE STRUCT EXPR, V1769, P49, DOI 10.1016/j.bbaexp.2006.11.009; Takizawa PA, 2000, P NATL ACAD SCI USA, V97, P5273, DOI 10.1073/pnas.080585897; Thanaraj TA, 1996, PROTEIN SCI, V5, P1594, DOI 10.1002/pro.5560050814; Tribouillard-Tanvier D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002174; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Winkler WC, 2002, P NATL ACAD SCI USA, V99, P15908, DOI 10.1073/pnas.212628899; Zalucki YM, 2011, BIOTECHNOL J, V6, P660, DOI 10.1002/biot.201000334; Zhang G, 2009, NAT STRUCT MOL BIOL, V16, P274, DOI 10.1038/nsmb.1554	69	18	18	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3753	3759		10.1038/onc.2015.454	http://dx.doi.org/10.1038/onc.2015.454			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26657150				2022-12-17	WOS:000380753200001
J	Su, Y; Li, J; Shi, C; Hruban, RH; Radice, GL				Su, Y.; Li, J.; Shi, C.; Hruban, R. H.; Radice, G. L.			N-cadherin functions as a growth suppressor in a model of K-ras-induced PanIN	ONCOGENE			English	Article							CONTACT INHIBITION; MESENCHYMAL TRANSITION; PANCREATIC-CANCER; SIGNALING-PATHWAY; PROLIFERATION; EXPRESSION; KI-RAS(G12V); INSTABILITY; SURVIVAL	Cadherin subtype switching from E-cadherin to N-cadherin is associated with the epithelial-to-mesenchymal transition (EMT), a process required for invasion and dissemination of carcinoma cells. We found that N-cadherin is expressed in human and mouse pancreatic intraepithelial neoplasia (PanIN), suggesting that N-cadherin may also have a role in early-stage pancreatic cancer. To investigate the role of N-cadherin in mouse PanIN (mPanIN), we simultaneously activated oncogenic K-ras(G12D) and deleted the N-cadherin (Cdh2) gene in the murine pancreas. Genetic ablation of N-cadherin (N-cad KO) caused hyperproliferation, accelerated mPanIN progression, and early tumor development in K-ras(G12D) mice. Decreased E-cadherin and redistribution of beta-catenin accompanied the loss of N-cadherin in pancreatic ductal epithelial cells (PDEC). Nuclear accumulation of beta-catenin and its transcription co-activator Tcf4 led to activation of Wnt/beta-catenin target genes. Unexpectedly, loss of N-cadherin in the K-rasG12D model resulted in increased mPanIN progression and tumor incidence. These in vivo results demonstrate for the first time that N-cadherin functions as a growth suppressor in the context of oncogenic K-ras.	[Su, Y.; Li, J.; Radice, G. L.] Thomas Jefferson Univ, Ctr Translat Med, Dept Med, Suite 543E Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA; [Shi, C.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Shi, C.; Hruban, R. H.] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD USA; [Shi, C.; Hruban, R. H.] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Oncol, Baltimore, MD USA; [Su, Y.] Fox Chase Canc Ctr, Breast Canc Res Lab, 7701 Burholme Ave, Philadelphia, PA 19111 USA	Jefferson University; Vanderbilt University; Johns Hopkins University; Johns Hopkins University; Fox Chase Cancer Center	Radice, GL (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Med Coll, Ctr Translat Med, Dept Med, Suite 543E Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	glenn.radice@jefferson.edu			NCI Cancer Center [P30 CA56036]; NIH [R21 CA176097]; SPORE grant [CA62924]; NATIONAL CANCER INSTITUTE [P30CA056036, P50CA062924, R21CA176097] Funding Source: NIH RePORTER	NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SPORE grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Frans van Roy, Anil Rustgi and Jennifer Wilson for comments. We thank David Tuveson for the LSL-K-ras<SUP>G12D</SUP> mice, Andrew Lowy for the Pdx1/Cre mice and Michael Goggins for the PanIN microarrays. We are grateful to Mathew Thakur for assistance with PET imaging, and Han Du, Craig Riley and David Kurz for technical assistance. Research in this study includes work carried out by the Jefferson Kimmel Cancer Center Small Animal Imaging Facility, which is supported in part by NCI Cancer Center Support Grant P30 CA56036. This work was supported by NIH R21 CA176097 (GR). This study was also supported by the SPORE grant CA62924 (RH).	Agbunag C, 2004, CANCER RES, V64, P5659, DOI 10.1158/0008-5472.CAN-04-0807; Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Deramaudt TB, 2006, MOL CELL BIOL, V26, P4185, DOI 10.1128/MCB.01055-05; di Magliano MP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001155; Gavard J, 2004, J BIOL CHEM, V279, P36795, DOI 10.1074/jbc.M401705200; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gumbiner BM, 2014, J CELL SCI, V127, P709, DOI 10.1242/jcs.140103; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Johansson JK, 2010, GENESIS, V48, P374, DOI 10.1002/dvg.20628; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Kostetskii I, 2005, CIRC RES, V96, P346, DOI 10.1161/01.RES.0000156274.72390.2c; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Li JF, 2015, CIRC RES, V116, P70, DOI 10.1161/CIRCRESAHA.116.304472; Luo Y, 2005, DEV DYNAM, V232, P336, DOI 10.1002/dvdy.20241; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; McClatchey AI, 2012, CURR OPIN CELL BIOL, V24, P685, DOI 10.1016/j.ceb.2012.06.009; Mui KL, 2015, CELL REP, V10, P1477, DOI 10.1016/j.celrep.2015.02.023; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Qian X, 2014, ONCOGENE, V33, P3411, DOI 10.1038/onc.2013.310; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Shintani Y, 2006, CANCER RES, V66, P11745, DOI 10.1158/0008-5472.CAN-06-2322; Su Y, 2012, ONCOGENE, V31, P4484, DOI 10.1038/onc.2011.574; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Zhang YQ, 2013, CANCER RES, V73, P4909, DOI 10.1158/0008-5472.CAN-12-4384	33	18	18	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3335	3341		10.1038/onc.2015.382	http://dx.doi.org/10.1038/onc.2015.382			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477318	Green Accepted			2022-12-17	WOS:000378306400012
J	Mahajan, K				Mahajan, K.			hPso4/hPrp19: a critical component of DNA repair and DNA damage checkpoint complexes	ONCOGENE			English	Review							PRE-MESSENGER-RNA; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; DOUBLE-STRAND BREAKS; DEPENDENT PROTEIN-KINASE; HEMATOPOIETIC STEM-CELLS; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; U-BOX; BIOCHEMICAL-CHARACTERIZATION; HOMOLOGOUS-RECOMBINATION	Genome integrity is vital to cellular homeostasis and its forfeiture is linked to deleterious consequences-cancer, immunodeficiency, genetic disorders and premature aging. The human ubiquitin ligase Pso4/Prp19 has emerged as a critical component of multiple DNA damage response (DDR) signaling networks. It not only senses DNA damage, binds double-stranded DNA in a sequence-independent manner, facilitates processing of damaged DNA, promotes DNA end joining, regulates replication protein A (RPA2) phosphorylation and ubiquitination at damaged DNA, but also regulates RNA splicing and mitotic spindle formation in its integral capacity as a scaffold for a multimeric core complex. Accordingly, by virtue of its regulatory and structural interactions with key proteins critical for genome integrity-DNA double-strand break (DSB) repair, DNA interstrand crosslink repair, repair of stalled replication forks and DNA end joining-it fills a unique niche in restoring genomic integrity after multiple types of DNA damage and thus has a vital role in maintaining chromatin integrity and cellular functions. These properties may underlie its ability to thwart replicative senescence and, not surprisingly, have been linked to the self-renewal and colony-forming ability of murine hematopoietic stem cells. This review highlights recent advances in hPso4 research that provides a fascinating glimpse into the pleiotropic activities of a ubiquitously expressed multifunctional E3 ubiquitin ligase.	[Mahajan, K.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Tumor Biol, 12902 Magnolia Dr, Tampa, FL 33682 USA; [Mahajan, K.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Oncol Sci, 12902 Magnolia Dr, Tampa, FL 33682 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Mahajan, K (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Dept Tumor Biol, 12902 Magnolia Dr, Tampa, FL 33682 USA.; Mahajan, K (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Dept Oncol Sci, 12902 Magnolia Dr, Tampa, FL 33682 USA.	kiran.mahajan@moffitt.org	Mahajan, Kiran/ABA-3013-2020	Mahajan, Kiran/0000-0001-7192-396X	Department of Defense [W81XWH-12-1-0248, W81XWH-14-1-0251, W81XWH-15-1-0059]	Department of Defense(United States Department of Defense)	I thank Dr Nupam Mahajan and Professor William Kaufmann (UNC Chapel Hill) for critical reading of the manuscript and suggestions. I appreciate Urvashi Mahajan for help with the illustrations. This work is supported in part by Department of Defense Awards W81XWH-12-1-0248, W81XWH-14-1-0251 and W81XWH-15-1-0059 to KM.	Abbas M, 2014, J BIOL CHEM, V289, P14009, DOI 10.1074/jbc.M113.520056; Alvarez-Quilon A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4347; Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beck BD, 2008, J BIOL CHEM, V283, P9023, DOI 10.1074/jbc.M800150200; Beck BD, 2011, BIOCHEMISTRY-US, V50, P4360, DOI 10.1021/bi200333k; Beck BD, 2010, ARCH BIOCHEM BIOPHYS, V498, P89, DOI 10.1016/j.abb.2010.04.011; Benjamin AB, 2014, BIOMED PHARMACOTHER, V68, P463, DOI 10.1016/j.biopha.2014.03.006; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan SP, 2005, J BIOL CHEM, V280, P31190, DOI 10.1074/jbc.M505060200; Chan SP, 2003, SCIENCE, V302, P279, DOI 10.1126/science.1086602; Chan YA, 2014, TRENDS GENET, V30, P245, DOI 10.1016/j.tig.2014.03.005; Cordaux R, 2006, P NATL ACAD SCI USA, V103, P8101, DOI 10.1073/pnas.0601161103; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; DASILVA KVCL, 1995, CURR GENET, V27, P207, DOI 10.1007/BF00326150; David CJ, 2011, GENE DEV, V25, P972, DOI 10.1101/gad.2038011; DEANDRADE HHR, 1989, MOL GEN GENET, V217, P419; Dellago H, 2012, AGING-US, V4, P290, DOI 10.18632/aging.100452; Dellago H, 2011, BIOCHEM J, V438, P81, DOI 10.1042/BJ20110183; Fortschegger K, 2007, MOL CELL BIOL, V27, P3123, DOI 10.1128/MCB.01188-06; Gangi-Peterson L, 1999, J CLIN INVEST, V103, P833, DOI 10.1172/JCI4320; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garinis GA, 2008, NAT CELL BIOL, V10, P1241, DOI 10.1038/ncb1108-1241; Gotzmann J, 2000, EXP CELL RES, V261, P166, DOI 10.1006/excr.2000.5025; Grey M, 1996, NUCLEIC ACIDS RES, V24, P4009, DOI 10.1093/nar/24.20.4009; Grillari J, 2005, NUCLEIC ACIDS RES, V33, P6868, DOI 10.1093/nar/gki986; Grillari J, 2009, J BIOL CHEM, V284, P29193, DOI 10.1074/jbc.M109.036632; Grote M, 2010, MOL CELL BIOL, V30, P2105, DOI 10.1128/MCB.01505-09; Gupta GP, 2013, MOL CELL, V52, P353, DOI 10.1016/j.molcel.2013.09.001; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HENRIQUES JAP, 1989, MUTAT RES, V218, P111, DOI 10.1016/0921-8777(89)90017-7; Hofmann JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074851; Howard SM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004943; Iyama T, 2015, NUCLEIC ACIDS RES, V43, P247, DOI 10.1093/nar/gku1279; Jaehnig EJ, 2013, CELL REP, V4, P174, DOI 10.1016/j.celrep.2013.05.041; Jiang GC, 2013, J BIOL CHEM, V288, P8966, DOI 10.1074/jbc.M112.412650; Kakarougkas A, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130685; Kaufmann WK, 2010, CARCINOGENESIS, V31, P751, DOI 10.1093/carcin/bgp230; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kleinridders A, 2009, MOL CELL BIOL, V29, P3173, DOI 10.1128/MCB.01807-08; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kuo PC, 2009, CANCER RES, V69, P8877, DOI 10.1158/0008-5472.CAN-09-2023; Kuraoka I, 2008, J BIOL CHEM, V283, P940, DOI 10.1074/jbc.M706647200; Lammens K, 2011, CELL, V145, P54, DOI 10.1016/j.cell.2011.02.038; Lee BS, 2013, MOL CELL BIOL, V33, P3568, DOI 10.1128/MCB.00308-13; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Legerski RJ, 2009, CELL CYCLE, V8, P3448, DOI 10.4161/cc.8.21.9760; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu DX, 2007, MOL CELL BIOL, V27, P1125, DOI 10.1128/MCB.01899-06; Loscher M, 2005, BIOCHEM J, V388, P593, DOI 10.1042/BJ20041517; Lu XY, 2007, BIOCHEM BIOPH RES CO, V354, P968, DOI 10.1016/j.bbrc.2007.01.097; Mahajan KN, 1999, P NATL ACAD SCI USA, V96, P13926, DOI 10.1073/pnas.96.24.13926; Mahajan KN, 2003, P NATL ACAD SCI USA, V100, P10746, DOI 10.1073/pnas.1631060100; Makarova OV, 2004, EMBO J, V23, P2381, DOI 10.1038/sj.emboj.7600241; Marechal A, 2014, MOL CELL, V53, P235, DOI 10.1016/j.molcel.2013.11.002; Marin I, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-331; Mateos-Gomez PA, 2015, NATURE, V518, P254, DOI 10.1038/nature14157; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Myung K, 2002, P NATL ACAD SCI USA, V99, P4500, DOI 10.1073/pnas.062702199; Ohi MD, 2005, MOL CELL BIOL, V25, P451, DOI 10.1128/MCB.25.1.451-460.2005; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; Paull TT, 2015, ANNU REV BIOCHEM, V84, P711, DOI 10.1146/annurev-biochem-060614-034335; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; Purugganan MM, 2001, NUCLEIC ACIDS RES, V29, P1638, DOI 10.1093/nar/29.7.1638; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Roman Y, 2007, BIOCHEMISTRY-US, V46, P11369, DOI 10.1021/bi7005477; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Schraml E, 2008, STEM CELLS DEV, V17, P355, DOI 10.1089/scd.2007.0107; Smolka MB, 2007, P NATL ACAD SCI USA, V104, P10364, DOI 10.1073/pnas.0701622104; Song EJ, 2010, GENE DEV, V24, P1434, DOI 10.1101/gad.1925010; Sykora P, 2015, NUCLEIC ACIDS RES, V43, P943, DOI 10.1093/nar/gku1356; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; Tobin LA, 2013, ONCOGENE, V32, P1784, DOI 10.1038/onc.2012.203; Tresini M, 2015, NATURE, V523, P53, DOI 10.1038/nature14512; Vander Kooi CW, 2010, STRUCTURE, V18, P584, DOI 10.1016/j.str.2010.02.015; Vander Kooi CW, 2006, BIOCHEMISTRY-US, V45, P121, DOI 10.1021/bi051787e; Vermeij WP, 2014, CURR OPIN GENET DEV, V26, P124, DOI 10.1016/j.gde.2014.06.006; von Zglinicki T, 2005, MECH AGEING DEV, V126, P111, DOI 10.1016/j.mad.2004.09.034; Wan L, 2014, J BIOL CHEM, V289, P6619, DOI 10.1074/jbc.M113.543439; Williamson EA, 2008, NUCLEIC ACIDS RES, V36, P5822, DOI 10.1093/nar/gkn560; Woods NT, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002255; Wray J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005323; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zha S, 2011, P NATL ACAD SCI USA, V108, P2028, DOI 10.1073/pnas.1019293108; Zha S, 2011, NATURE, V469, P250, DOI 10.1038/nature09604; Zhang JQ, 2015, NAT STRUCT MOL BIOL, V22, P242, DOI 10.1038/nsmb.2956; Zhang NX, 2009, EMBO REP, V10, P1029, DOI 10.1038/embor.2009.122; Zhang NX, 2005, J BIOL CHEM, V280, P40559, DOI 10.1074/jbc.M508453200	94	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2279	2286		10.1038/onc.2015.321	http://dx.doi.org/10.1038/onc.2015.321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26364595				2022-12-17	WOS:000376165000001
J	Kuo, TL; Weng, CC; Kuo, KK; Chen, CY; Wu, DC; Hung, WC; Cheng, KH				Kuo, T-L; Weng, C-C; Kuo, K-K; Chen, C-Y; wu, D-C; Hung, W-C; Cheng, K-H			APC haploinsufficiency coupled with p53 loss sufficiently induces mucinous cystic neoplasms and invasive pancreatic carcinoma in mice	ONCOGENE			English	Article							SOLID-PSEUDOPAPILLARY TUMORS; POLYPOSIS-COLI PROTEIN; SOMATIC MUTATIONS; SIGNALING PATHWAY; WNT/BETA-CATENIN; MOUSE MODEL; CANCER; PROGRESSION; EXPRESSION; GENE	Adenomatous polyposis coli (APC), a tumor-suppressor gene critically involved in familial adenomatous polyposis, is integral in Wnt/beta-catenin signaling and is implicated in the development of sporadic tumors of the distal gastrointestinal tract including pancreatic cancer (PC). Here we report for the first time that functional APC is required for the growth and maintenance of pancreatic islets and maturation. Subsequently, a non-Kras mutation-induced premalignancy mouse model was developed; in this model, APC haploinsufficiency coupled with p53 deletion resulted in the development of a distinct type of pancreatic premalignant precursors, mucinous cystic neoplasms (MCNs), exhibiting pathomechanisms identical to those observed in human MCNs, including accumulation of cystic fluid secreted by neoplastic and ovarian-like stromal cells, with 100% penetrance and the presence of hepatic and gastric metastases in >30% of the mice. The major clinical implications of this study suggest targeting the Wnt signaling pathway as a novel strategy for managing MCN.	[Kuo, T-L; Weng, C-C; Cheng, K-H] Natl Sun Yat Sen Univ, Inst Biomed Sci, 70 Lien Hai Rd, Kaohsiung 80424, Taiwan; [Kuo, K-K] Kaohsiung Med Univ Hosp, Div Hepatobiliopancreat Surg, Dept Surg, Kaohsiung, Taiwan; [Kuo, K-K; Chen, C-Y; wu, D-C; Cheng, K-H] Kaohsiung Med Univ, Ctr Stem Cell Res, Kaohsiung, Taiwan; [Chen, C-Y] Kaohsiung Med Univ Hosp, Dept Med Imaging, Kaohsiung, Taiwan; [wu, D-C] Kaohsiung Med Univ Hosp, Div Gastroenterol, Dept Internal Med, Kaohsiung, Taiwan; [wu, D-C] Kaohsiung Med Univ, Kaohsiung Municipal Hsiao Kang Hosp, Div Internal Med, Kaohsiung, Taiwan; [Hung, W-C] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Cheng, K-H] Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan	National Sun Yat Sen University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital; National Health Research Institutes - Taiwan; Kaohsiung Medical University	Cheng, KH (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, 70 Lien Hai Rd, Kaohsiung 80424, Taiwan.	khcheng@faculty.nsysu.edu.tw			National Science Council, Taiwan ROC [NSC 101-2314-B-110-001-MY2, 101-2628-B-110-001-MY2, MOST 103-2314-B-037-062]; Kaohsiung Medical University, Kaohsiung, Taiwan [KMU-TP103G00, KMU-TP103G01]	National Science Council, Taiwan ROC(Ministry of Science and Technology, Taiwan); Kaohsiung Medical University, Kaohsiung, Taiwan	We gratefully thank Dr Sheau-Fang Yang, at Kaohsiung Medical University for helping us to confirm the histologic features and pathology of MCN mice. This work was supported by grants NSC 101-2314-B-110-001-MY2, 101-2628-B-110-001-MY2 (to KH Cheng) and MOST 103-2314-B-037-062 (to DC Wu and KH Cheng) from the National Science Council, Taiwan ROC, and grants KMU-TP103G00 and KMU-TP103G01 (to DC Wu and KH Cheng) from Kaohsiung Medical University, Kaohsiung, Taiwan.	Abraham SC, 2002, AM J PATHOL, V160, P1361, DOI 10.1016/S0002-9440(10)62563-1; Abraham SC, 2001, AM J PATHOL, V159, P1619, DOI 10.1016/S0002-9440(10)63008-8; Al-Haddad M, 2011, CLIN GASTROENTEROL H, V9, P635, DOI 10.1016/j.cgh.2011.03.005; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Beroud C, 1996, NUCLEIC ACIDS RES, V24, P121, DOI 10.1093/nar/24.1.121; Bonk T, 2002, CLIN BIOCHEM, V35, P87, DOI 10.1016/S0009-9120(02)00279-5; Chiu CY, 2012, MOL CANCER RES, V10, P415, DOI 10.1158/1541-7786.MCR-11-0293; Dessimoz J, 2006, CELL CYCLE, V5, P7, DOI 10.4161/cc.5.1.2293; di Magliano MP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001155; Emmrich S, 2014, GENE DEV, V28, P858, DOI 10.1101/gad.233791.113; Farrell JJ, 2013, GASTROENTEROLOGY, V144, P1303, DOI 10.1053/j.gastro.2013.01.073; Fazeli A, 1997, P NATL ACAD SCI USA, V94, P10199, DOI 10.1073/pnas.94.19.10199; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Guo MZ, 2014, DISCOV MED, V17, P67; Heiser PW, 2006, DEVELOPMENT, V133, P2023, DOI 10.1242/dev.02366; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; HORII A, 1992, CANCER RES, V52, P6696; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Jiang H, 2014, AM J PATHOL, V184, P1355, DOI 10.1016/j.ajpath.2014.01.037; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kuijper S, 2005, DEVELOPMENT, V132, P1601, DOI 10.1242/dev.01735; Kuraguchi M, 2006, PLOS GENET, V2, P1362, DOI 10.1371/journal.pgen.0020146; Lang J, 2013, J NEUROSCI, V33, P3113, DOI 10.1523/JNEUROSCI.3467-12.2013; Le Borgne J, 1997, Chirurgie, V122, P31; Li AH, 2011, AM J PATHOL, V178, P1340, DOI 10.1016/j.ajpath.2010.11.058; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Maitra A, 2005, ADV ANAT PATHOL, V12, P81, DOI 10.1097/01.pap.0000155055.14238.25; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mavila N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050401; Milde-Langosch K, 2014, BREAST CANCER RES TR, V145, P295, DOI 10.1007/s10549-014-2949-z; Mimeault M, 2008, GUT, V57, P1456, DOI 10.1136/gut.2008.150052; Monti P, 2003, CANCER RES, V63, P7451; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Murakami Y, 2006, SURGERY, V140, P448, DOI 10.1016/j.surg.2006.03.017; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Niu JG, 2007, J BIOL CHEM, V282, P6001, DOI 10.1074/jbc.M606878200; PELLEGATA NS, 1994, CANCER RES, V54, P1556; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Pujal J, 2006, BBA-MOL BASIS DIS, V1762, P73, DOI 10.1016/j.bbadis.2005.08.002; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Reilein A, 2005, NAT CELL BIOL, V7, P463, DOI 10.1038/ncb1248; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sano M, 2014, GASTROENTEROLOGY, V146, P257, DOI 10.1053/j.gastro.2013.09.044; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Sekine H, 2012, BIOCHEM BIOPH RES CO, V429, P214, DOI 10.1016/j.bbrc.2012.10.048; Shimada M, 2002, J IMMUNOL, V168, P861, DOI 10.4049/jimmunol.168.2.861; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Strom A, 2007, DEVELOPMENT, V134, P2719, DOI 10.1242/dev.02875; Su HT, 2013, MOL CANCER RES, V11, P768, DOI 10.1158/1541-7786.MCR-12-0511; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tang LH, 2005, AM J SURG PATHOL, V29, P512, DOI 10.1097/01.pas.0000155159.28530.88; Toivonen S, 2013, EXP CELL RES, V319, P2535, DOI 10.1016/j.yexcr.2013.07.007; Tsukamoto N, 2013, PANCREAS, V42, P1027, DOI 10.1097/MPA.0b013e31828804e7; Ueno K, 2011, INT J CANCER, V129, P2360, DOI 10.1002/ijc.25899; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; Zhu M, 2013, J CELL BIOL, V200, P773, DOI 10.1083/jcb.201207050; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	67	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2223	2234		10.1038/onc.2015.284	http://dx.doi.org/10.1038/onc.2015.284			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26411367				2022-12-17	WOS:000374986000008
J	Antonczak, AK; Mullee, LI; Wang, Y; Comartin, D; Inoue, T; Pelletier, L; Morrison, CG				Antonczak, A. K.; Mullee, L. I.; Wang, Y.; Comartin, D.; Inoue, T.; Pelletier, L.; Morrison, C. G.			Opposing effects of pericentrin and microcephalin on the pericentriolar material regulate CHK1 activation in the DNA damage response	ONCOGENE			English	Article							CENTROSOME AMPLIFICATION; MITOTIC ENTRY; CHECKPOINT; SPINDLE; PHOSPHORYLATION; ORGANIZATION; SURVIVAL; DEFECTS; CELLS	Genotoxic stresses lead to centrosome amplification, a frequently-observed feature in cancer that may contribute to genome instability and to tumour cell invasion. Here we have explored how the centrosome controls DNA damage responses. For most of the cell cycle, centrosomes consist of two centrioles embedded in the proteinaceous pericentriolar material (PCM). Recent data indicate that the PCM is not an amorphous assembly of proteins, but actually a highly organised scaffold around the centrioles. The large coiled-coil protein, pericentrin, participates in PCM assembly and has been implicated in the control of DNA damage responses (DDRs) through its interactions with checkpoint kinase 1 (CHK1) and microcephalin (MCPH1). CHK1 is required for DNA damage-induced centrosome amplification, whereas MCPH1 deficiency greatly increases the amplification seen after DNA damage. We found that the PCM showed a marked expansion in volume and a noticeable change in higher-order organisation after ionising radiation treatment. PCM expansion was dependent on CHK1 kinase activity and was potentiated by MCPH1 deficiency. Furthermore, pericentrin deficiency or mutation of a separase cleavage site blocked DNA damage-induced PCM expansion. The extent of nuclear CHK1 activation after DNA damage reflected the level of PCM expansion, with a reduction in pericentrin-deficient or separase cleavage site mutant-expressing cells, and an increase in MCPH1-deficient cells that was suppressed by the loss of pericentrin. Deletion of the nuclear export signal of CHK1 led to its hyperphosphorylation after irradiation and reduced centrosome amplification. Deletion of the nuclear localisation signal led to low CHK1 activation and low centrosome amplification. From these data, we propose a feedback loop from the PCM to the nuclear DDR in which CHK1 regulates pericentrin-dependent PCM expansion to control its own activation.	[Antonczak, A. K.; Mullee, L. I.; Wang, Y.; Morrison, C. G.] Natl Univ Ireland Galway, Sch Nat Sci, Ctr Chromosome Biol, Galway, Ireland; [Comartin, D.; Pelletier, L.] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Inoue, T.] Johns Hopkins Univ, Dept Cell Biol, Baltimore, MD USA	Ollscoil na Gaillimhe-University of Galway; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Johns Hopkins University	Morrison, CG (corresponding author), Natl Univ Ireland Galway, Ctr Chromosome Biol, Biosci Bldg, Galway, Ireland.	Ciaran.Morrison@nuigalway.ie	Pelletier, Laurence/F-8858-2013; Morrison, Ciaran/AAH-2034-2019; Morrison, Ciaran/B-6568-2008	Morrison, Ciaran/0000-0003-2401-7029; Morrison, Ciaran/0000-0003-2401-7029	EMBO Long-term Postdoctoral Fellowship; Journal of Cell Science; National University of Ireland; Science Foundation Ireland [08/IN.1/B1029, 10/IN.1/B2972]	EMBO Long-term Postdoctoral Fellowship(European Molecular Biology Organization (EMBO)); Journal of Cell Science; National University of Ireland; Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	We are grateful to Alex Bird, David Drechsel, Fanni Gergely, Andreas Merdes and Eric Tippmann for reagents and to Brian McStay and Noel Lowndes for critically reading the manuscript. AKA received an EMBO Long-term Postdoctoral Fellowship and a Travelling Fellowship from the Journal of Cell Science. LIM received a Travelling Studentship from the National University of Ireland. This work was supported by Science Foundation Ireland Principal Investigator awards 08/IN.1/B1029 and 10/IN.1/B2972.	Agircan FG, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004672; Alderton GK, 2006, NAT CELL BIOL, V8, P725, DOI 10.1038/ncb1431; Anderhub SJ, 2012, CANCER LETT, V322, P8, DOI 10.1016/j.canlet.2012.02.006; Barr AR, 2010, J CELL BIOL, V189, P23, DOI 10.1083/jcb.200912163; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; Bird AW, 2008, J CELL BIOL, V182, P289, DOI 10.1083/jcb.200802005; Bourke E, 2010, ONCOGENE, V29, P616, DOI 10.1038/onc.2009.340; Bourke E, 2007, EMBO REP, V8, P603, DOI 10.1038/sj.embor.7400962; Brown JAL, 2010, ONCOGENE, V29, P5537, DOI 10.1038/onc.2010.302; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Fu JY, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120104; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Griffith E, 2008, NAT GENET, V40, P232, DOI 10.1038/ng.2007.80; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kushner EJ, 2014, J CELL BIOL, V206, P257, DOI 10.1083/jcb.201311013; Lawo S, 2012, NAT CELL BIOL, V14, P1148, DOI 10.1038/ncb2591; Lee K, 2012, CELL CYCLE, V11, P2476, DOI 10.4161/cc.20878; Lee K, 2011, J CELL BIOL, V195, P1093, DOI 10.1083/jcb.201106093; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Loffler H, 2013, ONCOGENE, V32, P2963, DOI 10.1038/onc.2012.310; Loffler H, 2007, CELL CYCLE, V6, P2541; Loncarek J, 2008, NAT CELL BIOL, V10, P322, DOI 10.1038/ncb1694; Matsuo K, 2012, CURR BIOL, V22, P915, DOI 10.1016/j.cub.2012.03.048; Matsuyama M, 2011, J CELL SCI, V124, P2113, DOI 10.1242/jcs.086488; Mennella V, 2012, NAT CELL BIOL, V14, P1159, DOI 10.1038/ncb2597; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2009, CELL, V139, P663, DOI 10.1016/j.cell.2009.10.036; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; Palazzo RE, 2000, CURR TOP DEV BIOL, V49, P449; Pedelacq JD, 2006, NAT BIOTECHNOL, V24, P79, DOI 10.1038/nbt1172; Pihan GA, 2001, CANCER RES, V61, P2212; Prosser SL, 2012, J CELL SCI, V125, P5353, DOI 10.1242/jcs.106096; Prosser SL, 2009, MOL CELL BIOL, V29, P1760, DOI 10.1128/MCB.01124-08; Robinson HMR, 2007, CELL CYCLE, V6, P982, DOI 10.4161/cc.6.8.4111; Sonnen KF, 2012, BIOL OPEN, V1, P965, DOI 10.1242/bio.20122337; Stephan AK, 2011, MOL CELL BIOL, V31, P1369, DOI 10.1128/MCB.00786-10; Tibelius A, 2009, J CELL BIOL, V185, P1149, DOI 10.1083/jcb.200810159; Wang Y- D, 2006, REV PROTOCOLS DT40 R, P439; Wang YF, 2013, CELL CYCLE, V12, P635, DOI 10.4161/cc.23516; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003	47	18	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					2003	2010		10.1038/onc.2015.257	http://dx.doi.org/10.1038/onc.2015.257			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26165835				2022-12-17	WOS:000374010300013
J	Zhu, S; Chen, Z; Katsha, A; Hong, J; Belkhiri, A; El-Rifai, W				Zhu, S.; Chen, Z.; Katsha, A.; Hong, J.; Belkhiri, A.; El-Rifai, W.			Regulation of CD44E by DARPP-32-dependent activation of SRp20 splicing factor in gastric tumorigenesis	ONCOGENE			English	Article							DIFFERENTIAL EXPRESSION; CANCER; DARPP-32; OVEREXPRESSION; RESISTANCE; CD44V8-10; VARIANTS; RECEPTOR; ISOFORM; MARKER	CD44E is a frequently overexpressed variant of CD44 in gastric cancer. Mechanisms that regulate CD44 splicing and expression in gastric cancer remain unknown. Herein, we investigated the role of DARPP-32 (dopamine and cyclic adenosine monophosphate-regulated phosphoprotein, Mr 32000) in promoting tumor growth through regulation of CD44 splicing. Using western blot and quantitative real-time PCR analysis, our results indicated that knockdown of endogenous DARPP-32 markedly reduces the expression of CD44 V8-V10 (CD44E). Using a quantitative splicing luciferase reporter system, we detected a significant increase in the reporter activity following DARPP-32 overexpression (P < 0.001). Conversely, knocking down endogenous DARPP-32 significantly attenuated the splicing activity (P < 0.001). Further experiments showed that DARPP-32 regulates the expression of SRp20 splicing factor and co-exists with it in the same protein complex. Inhibition of alternative splicing with digitoxin followed by immunoprecipitation and immunoblotting indicated that DARPP-32 has an important role in regulating SRp20 protein stability. The knockdown of endogenous DARPP-32 confirmed that DARPP-32 regulates the SRp20-dependent CD44E splicing. Using tumor xenograft mouse model, knocking down endogenous DARPP-32 markedly reduced SRp20 and CD44E protein levels with a decreased tumor growth. The reconstitution of SRp20 expression in these cells rescued tumor growth. In addition, we also demonstrated frequent co-overexpression and positive correlation of DARPP-32, SRp20 and CD44E expression levels in human gastric primary tumors. Our novel findings establish for the first time the role of DARPP-32 in regulating splicing factors in gastric cancer cells. The DARPP-32-SRp20 axis has a key role in regulating the CD44E splice variant that promotes gastric tumorigenesis.	[Zhu, S.; Chen, Z.; Katsha, A.; Hong, J.; Belkhiri, A.; El-Rifai, W.] Vanderbilt Univ, Med Ctr, Dept Surg, 2220 Pierce Ave,760 Preston Res Bldg, Nashville, TN 37232 USA; [El-Rifai, W.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; [El-Rifai, W.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	El-Rifai, W (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, 2220 Pierce Ave,760 Preston Res Bldg, Nashville, TN 37232 USA.	wael.el-rifai@vanderbilt.edu			National Institutes of Health [R01CA93999]; Vanderbilt SPORE in Gastrointestinal Cancer [P50 CA95103]; Vanderbilt Ingram Cancer Center [P30 CA68485]; Vanderbilt Digestive Disease Research Center [DK058404]; Department of Veterans Affairs; NATIONAL CANCER INSTITUTE [R01CA093999, P50CA095103, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER; Veterans Affairs [IK6BX003787] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt SPORE in Gastrointestinal Cancer; Vanderbilt Ingram Cancer Center; Vanderbilt Digestive Disease Research Center; Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by grants from the National Institutes of Health (R01CA93999); Vanderbilt SPORE in Gastrointestinal Cancer (P50 CA95103); Vanderbilt Ingram Cancer Center (P30 CA68485); the Vanderbilt Digestive Disease Research Center (DK058404), and the Department of Veterans Affairs. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health, Department of Veterans Affairs or Vanderbilt University.	Anderson ES, 2012, RNA, V18, P1041, DOI 10.1261/rna.032912.112; Beckler A, 2003, CANCER, V98, P1547, DOI 10.1002/cncr.11654; Belkhiri A, 2005, CANCER RES, V65, P6583, DOI 10.1158/0008-5472.CAN-05-1433; Belkhiri A, 2008, CLIN CANCER RES, V14, P4564, DOI 10.1158/1078-0432.CCR-08-0121; Biamonti G, 1998, CLIN EXP RHEUMATOL, V16, P317; Bourguignon Lilly Y. W., 1998, Frontiers in Bioscience, V3, pD637; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Cohen-Eliav M, 2013, J PATHOL, V229, P630, DOI 10.1002/path.4129; da Cunha CB, 2010, LAB INVEST, V90, P1604, DOI 10.1038/labinvest.2010.155; El-Rifai W, 2002, CANCER RES, V62, P4061; Erkelenz S, 2013, RNA, V19, P96, DOI 10.1261/rna.037044.112; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; Hamel S, 2010, BREAST CANCER RES TR, V120, P47, DOI 10.1007/s10549-009-0364-7; HEIDER KH, 1993, CANCER RES, V53, P4197; Hiraga T, 2013, CANCER RES, V73, P4112, DOI 10.1158/0008-5472.CAN-12-3801; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jia R, 2010, INT J BIOL SCI, V6, P806; Jia R, 2009, J VIROL, V83, P167, DOI 10.1128/JVI.01719-08; Klingbeil P, 2010, BREAST CANCER RES TR, V120, P95, DOI 10.1007/s10549-009-0380-7; Lau WM, 2014, CANCER RES, V74, P2630, DOI 10.1158/0008-5472.CAN-13-2309; Long JC, 2009, BIOCHEM J, V417, P15, DOI 10.1042/BJ20081501; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Miwa T, 1996, CANCER, V77, P25, DOI 10.1002/(SICI)1097-0142(19960101)77:1<25::AID-CNCR6>3.0.CO;2-M; Mukherjee K, 2010, SURGERY, V148, P354, DOI 10.1016/j.surg.2010.05.011; Muramaki M, 2004, J UROLOGY, V171, P426, DOI 10.1097/01.ju.0000093446.54115.b6; Omara-Opyene AL, 2004, LAB INVEST, V84, P894, DOI 10.1038/labinvest.3700112; Pall T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029305; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Prochazka L, 2014, CELL SIGNAL, V26, P2234, DOI 10.1016/j.cellsig.2014.07.011; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; TAKEUCHI K, 1995, JPN J CANCER RES, V86, P292, DOI 10.1111/j.1349-7006.1995.tb03053.x; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang MSJ, 2005, INT J CLIN PRACT, V59, P58, DOI 10.1111/j.1742-1241.2004.00305.x; Xi LQ, 2008, NUCLEIC ACIDS RES, V36, P6535, DOI 10.1093/nar/gkn697; Younis I, 2010, MOL CELL BIOL, V30, P1718, DOI 10.1128/MCB.01301-09; Zhu SM, 2013, MOL CANCER RES, V11, P86, DOI 10.1158/1541-7786.MCR-12-0243-T; Zhu SM, 2011, GASTROENTEROLOGY, V141, P1738, DOI 10.1053/j.gastro.2011.06.070	39	18	19	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1847	1856		10.1038/onc.2015.250	http://dx.doi.org/10.1038/onc.2015.250			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26119931	Green Accepted			2022-12-17	WOS:000373610400010
J	Zane, M; Scavo, E; Catalano, V; Bonanno, M; Todaro, M; De Maria, R; Stassi, G				Zane, M.; Scavo, E.; Catalano, V.; Bonanno, M.; Todaro, M.; De Maria, R.; Stassi, G.			Normal vs cancer thyroid stem cells: the road to transformation	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; ULTIMOBRANCHIAL BODY CYST; GENE-EXPRESSION; SIDE POPULATION; IMMUNOHISTOCHEMICAL DETECTION; TRANSCRIPTION FACTORS; BETA-CATENIN; DIFFERENTIATION; GENERATION; CARCINOMA	Recent investigations in thyroid carcinogenesis have led to the isolation and characterisation of a subpopulation of stem-like cells, responsible for tumour initiation, progression and metastasis. Nevertheless, the cellular origin of thyroid cancer stem cells (SCs) remains unknown and it is still necessary to define the process and the target population that sustain malignant transformation of tissue-resident SCs or the reprogramming of a more differentiated cell. Here, we will critically discuss new insights into thyroid SCs as a potential source of cancer formation in light of the available information on the oncogenic role of genetic modifications that occur during thyroid cancer development. Understanding the fine mechanisms that regulate tumour transformation may provide new ground for clinical intervention in terms of prevention, diagnosis and therapy.	[Zane, M.; Scavo, E.; Catalano, V.; Bonanno, M.; Todaro, M.; Stassi, G.] Univ Palermo, Dept Surg & Oncol Sci, Via Vespro 131, I-90127 Palermo, Italy; [Zane, M.] Univ Padua, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy; [De Maria, R.] Regina Elena Inst Canc Res, Rome, Italy	University of Palermo; University of Padua; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Stassi, G (corresponding author), Univ Palermo, Dept Surg & Oncol Sci, Via Vespro 131, I-90127 Palermo, Italy.; De Maria, R (corresponding author), Regina Elena Inst Canc Res, Rome, Italy.	demaria@ifo.it; giorgio.stassi@unipa.it	Todaro, Matilde/K-9523-2016; todaro, matilde/AAC-1003-2022; De Maria, Ruggero/S-6385-2019; Stassi, Giorgio/AAC-1175-2022	todaro, matilde/0000-0001-8686-8043; De Maria, Ruggero/0000-0003-2255-0583; Zane, Mariangela/0000-0001-6766-4686	Italian Association for Cancer Research (AIRC) [IG 12819]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Italian Association for Cancer Research (AIRC) to GS (AIRC IG 12819). We thank Tatiana Terranova for her editorial assistance and all the colleagues who actively contributed to the completion of this review.	Ahn SH, 2014, J CLIN ENDOCR METAB, V99, P536, DOI 10.1210/jc.2013-2558; Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Antonica Francesco, 2012, Nature, V491, P66, DOI 10.1038/nature11525; Arufe MC, 2009, BIOCHEM BIOPH RES CO, V381, P264, DOI 10.1016/j.bbrc.2009.02.035; Brafman DA, 2013, STEM CELL REP, V1, P464, DOI 10.1016/j.stemcr.2013.09.005; Buehler D, 2013, MODERN PATHOL, V26, P54, DOI 10.1038/modpathol.2012.137; Burstein DE, 2004, HUM PATHOL, V35, P465, DOI 10.1016/j.humpath.2003.10.027; Cameselle-Teijeiro J, 2005, HUM PATHOL, V36, P590, DOI 10.1016/j.humpath.2005.02.010; Carina V, 2013, THYROID, V23, P829, DOI 10.1089/thy.2012.0372; Cassinelli G, 2009, NEOPLASIA, V11, P10, DOI 10.1593/neo.08916; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Ciarrocchi A, 2011, EUR J CANCER, V47, P934, DOI 10.1016/j.ejca.2010.11.009; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; COCLET J, 1989, CLIN ENDOCRINOL, V31, P655, DOI 10.1111/j.1365-2265.1989.tb01290.x; D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; Davies TF, 2011, J CLIN ENDOCR METAB, V96, P2692, DOI 10.1210/jc.2011-1047; De Felice M, 2004, ENDOCR REV, V25, P722, DOI 10.1210/er.2003-0028; Deleu S, 2002, EXP CELL RES, V279, P62, DOI 10.1006/excr.2002.5589; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Fagman H, 2011, J MOL ENDOCRINOL, V46, pR33, DOI 10.1677/JME-10-0084; Fierabracci A, 2008, J ENDOCRINOL, V198, P471, DOI 10.1677/JOE-07-0552; Friedman S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005395; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Gibelli B, 2009, ACTA OTORHINOLARYNGO, V29, P290; Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007; Green MD, 2011, NAT BIOTECHNOL, V29, P267, DOI 10.1038/nbt.1788; Hannan NRF, 2013, STEM CELL REP, V1, P293, DOI 10.1016/j.stemcr.2013.09.003; Hardin H, 2013, HUM PATHOL, V44, P1707, DOI 10.1016/j.humpath.2013.01.009; Hardy RG, 2007, AM J PATHOL, V171, P1037, DOI 10.2353/ajpath.2007.061211; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Hoshi N, 2007, ENDOCRINOLOGY, V148, P4251, DOI 10.1210/en.2006-0490; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Inaba M, 2012, CELL STEM CELL, V11, P461, DOI 10.1016/j.stem.2012.09.003; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Ke CC, 2013, EUR J NUCL MED MOL I, V40, P61, DOI 10.1007/s00259-012-2242-5; Kebebew E, 2004, J CLIN ENDOCR METAB, V89, P6105, DOI 10.1210/jc.2004-1234; Klonisch T, 2009, THYROID, V19, P1303, DOI 10.1089/thy.2009.1604; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kusakabe T, 2006, DEV DYNAM, V235, P1300, DOI 10.1002/dvdy.20655; Lan L, 2007, J CLIN ENDOCR METAB, V92, P3681, DOI 10.1210/jc.2007-0281; Lan L, 2013, INT J ONCOL, V43, P113, DOI 10.3892/ijo.2013.1913; LEDOUARIN N, 1974, HISTOCHEMISTRY, V38, P297, DOI 10.1007/BF00496718; Li W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065095; Lin RY, 2011, NAT REV ENDOCRINOL, V7, P609, DOI 10.1038/nrendo.2011.127; Lin RY, 2003, ENDOCRINOLOGY, V144, P2644, DOI 10.1210/en.2002-0122; Liu J, 2010, INT J CLIN EXP PATHO, V3, P755; Longmire TA, 2012, CELL STEM CELL, V10, P398, DOI 10.1016/j.stem.2012.01.019; Ma RS, 2013, THYROID, V23, P385, DOI 10.1089/thy.2012.0644; Malaguarnera R, 2011, J CLIN ENDOCR METAB, V96, P766, DOI 10.1210/jc.2010-1255; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Mitsutake N, 2007, ENDOCRINOLOGY, V148, P1797, DOI 10.1210/en.2006-1553; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142; Nikiforova MN, 2009, THYROID, V19, P1351, DOI 10.1089/thy.2009.0240; Nikiforova MN, 2004, CANCER LETT, V209, P1, DOI 10.1016/j.canlet.2003.12.004; Okamoto M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080801; Onyshchenko MI, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/634914; Ozaki T, 2012, ENDOCRINOLOGY, V153, P2514, DOI 10.1210/en.2011-1365; Ozaki T, 2011, LAB INVEST, V91, P138, DOI 10.1038/labinvest.2010.137; Paez D, 2012, CLIN CANCER RES, V18, P645, DOI 10.1158/1078-0432.CCR-11-2186; Preto A, 2004, MODERN PATHOL, V17, P819, DOI 10.1038/modpathol.3800124; Quiros RM, 2005, CANCER-AM CANCER SOC, V103, P2261, DOI 10.1002/cncr.21073; Raimondi C, 2010, CURR CANCER DRUG TAR, V10, P496, DOI 10.2174/156800910791517154; Reis JS, 2003, MODERN PATHOL, V16, P43, DOI 10.1097/01.MP.0000047306.72278.39; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Moreno MJR, 2011, ENDOCR PATHOL, V22, P35, DOI 10.1007/s12022-010-9145-4; Rivera M, 2008, CANCER-AM CANCER SOC, V113, P48, DOI 10.1002/cncr.23515; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Sastre-Perona Ana, 2012, Front Endocrinol (Lausanne), V3, P31, DOI 10.3389/fendo.2012.00031; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Shahriyari L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076195; Sosa MS, 2011, CLIN CANCER RES, V17, P5850, DOI 10.1158/1078-0432.CCR-10-2574; Sun YR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005498; Takano T, 2005, THYROID, V15, P432, DOI 10.1089/thy.2005.15.432; Takano T, 2007, SEMIN CANCER BIOL, V17, P233, DOI 10.1016/j.semcancer.2006.02.001; Thomas D, 2008, ENDOCR-RELAT CANCER, V15, P51, DOI 10.1677/ERC-07-0210; Thomas T, 2006, THYROID, V16, P537, DOI 10.1089/thy.2006.16.537; Todaro M, 2010, CANCER RES, V70, P8874, DOI 10.1158/0008-5472.CAN-10-1994; Tseng LM, 2012, J PHARMACOL EXP THER, V341, P410, DOI 10.1124/jpet.111.188730; Van Vliet G, 2003, CLIN GENET, V63, P445; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Vermeulen L, 2008, CELL DEATH DIFFER, V15, P947, DOI 10.1038/cdd.2008.20; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Visvader JE, 2010, MOL ONCOL, V4, P369, DOI 10.1016/j.molonc.2010.07.001; Yamashita YM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001313; Zeuner A, 2011, CELL STEM CELL, V9, P289, DOI 10.1016/j.stem.2011.09.006; Zhang P, 2006, PATHOL INT, V56, P240, DOI 10.1111/j.1440-1827.2006.01959.x; Zheng XQ, 2010, INT J ONCOL, V37, P307, DOI 10.3892/ijo_00000679; Zito G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003544	95	18	18	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					805	815		10.1038/onc.2015.138	http://dx.doi.org/10.1038/onc.2015.138			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961919	Green Published			2022-12-17	WOS:000370332200001
J	Maeng, YS; Aguilar, B; Choi, SI; Kim, EK				Maeng, Y-S; Aguilar, B.; Choi, S-I; Kim, E. K.			Inhibition of TGFBIp expression reduces lymphangiogenesis and tumor metastasis	ONCOGENE			English	Article							CELL-ADHESION; VEGF-C; VASCULAR-PERMEABILITY; MOLECULAR-MECHANISMS; ENDOTHELIAL-CELLS; BREAST-CANCER; BETA-IG-H3; BETA; PROTEIN; GROWTH	Transforming growth factor-beta-induced protein (TGFBIp) is an extracellular matrix protein that has a role in a wide range of pathological conditions. However, the role of TGFBIp signaling in lymphangiogenesis is poorly understood. The purpose of this study was therefore to analyze the effects of TGFBIp on lymphangiogenesis and determine whether TGFBIp-related lymphangiogenesis is important for the metastasis of tumor cells. TGFBIp increased adhesion, migration, and morphologic differentiation of human lymphatic endothelial cells (LECs), consistent with an increase in lymphatic vessel sprouting in a three-dimensional lymphatic ring assay. TGFBIp also induced phosphorylation of intracellular signaling molecules SRC, FAK, AKT, JNK and ERK. TGFBIp-induced lymphatic vessel sprouting was inhibited by addition of anti-integrin beta 3 antibody and pharmacologic inhibitors of FAK, AKT, JNK or ERK. TGFBIp increased both CCL21 expression in LECs, a chemokine that actively recruits tumor cells expressing the cognate chemokine receptors to lymphatic vessels and LEC permeability by inducing the dissociation of VE-cadherin junctions between LECs via the activation of SRC signaling. In vivo, inhibition of TGFBIp expression in SW620 cancer cells dramatically reduced tumor lymphangiogenesis and metastasis. Collectively, our findings demonstrate that TGFBIp is a lymphangiogenic factor contributing to tumor dissemination and represents a potential target to inhibit metastasis.	[Maeng, Y-S; Choi, S-I; Kim, E. K.] Yonsei Univ, Coll Med, Dept Ophthalmol, Corneal Dystrophy Res Inst, Seoul 120752, South Korea; [Aguilar, B.] Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; [Kim, E. K.] Yonsei Univ, Coll Med, Brain Korea Plus Project Med Sci 21, Severance Biomed Sci Inst, Seoul, South Korea	Yonsei University; Yonsei University Health System; University of California System; University of California San Diego; Yonsei University; Yonsei University Health System	Kim, EK (corresponding author), Yonsei Univ, Coll Med, Dept Ophthalmol, 250 Seongsanno, Seoul 120752, South Korea.	eungkkim@yuhs.ac		choi, seung-il/0000-0001-7168-8795; Maeng, Yong-Sun/0000-0003-1694-8405; Kim, Eung Kweon/0000-0002-1453-8042	National Research Foundation of Korea (NRF) grant - Korea government (MEST) [2011-0028699]	National Research Foundation of Korea (NRF) grant - Korea government (MEST)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2011-0028699).	Aguilar B, 2012, CANCER RES, V72, P5833, DOI 10.1158/0008-5472.CAN-12-1229; Albrecht I, 2011, INT J DEV BIOL, V55, P483, DOI 10.1387/ijdb.103226ia; Bae JS, 2002, BIOCHEM BIOPH RES CO, V294, P940, DOI 10.1016/S0006-291X(02)00576-4; Baluk P, 2007, J EXP MED, V204, P2349, DOI 10.1084/jem.20062596; Becker J, 2006, CANCER RES, V66, P5314, DOI 10.1158/0008-5472.CAN-05-3049; Boensch C, 1999, J BIOL CHEM, V274, P10582, DOI 10.1074/jbc.274.15.10582; Bruyere F, 2008, NAT METHODS, V5, P431, DOI [10.1038/nmeth.1205, 10.1038/NMETH.1205]; Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB; Christiansen Ailsa, 2011, Genes Cancer, V2, P1146, DOI 10.1177/1947601911423028; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; FIDLER IJ, 1987, CURR PROB SURG, V24, P137, DOI 10.1016/0011-3840(87)90002-5; Hewitt RE, 2000, J PATHOL, V192, P446; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2003, ONCOGENE, V22, P2045, DOI 10.1038/sj.onc.1206269; Kim YH, 2012, J BIOL CHEM, V287, P38957, DOI 10.1074/jbc.M112.357863; Lee AS, 2011, CANCER RES, V71, P4506, DOI 10.1158/0008-5472.CAN-10-3787; Maeng YS, 2009, BLOOD, V113, P233, DOI 10.1182/blood-2008-06-162891; Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood-2006-06-029298; Miyagaki T, 2011, J INVEST DERMATOL, V131, P1927, DOI 10.1038/jid.2011.135; Mohammed RAA, 2007, BRIT J CANCER, V96, P1092, DOI 10.1038/sj.bjc.6603678; Nam JO, 2003, J BIOL CHEM, V278, P25902, DOI 10.1074/jbc.M300358200; Park SW, 2004, EXP MOL MED, V36, P211, DOI 10.1038/emm.2004.29; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Schoppmann SF, 2006, SURGERY, V139, P839, DOI 10.1016/j.surg.2005.12.008; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; Sleeman JP, 2009, INT J CANCER, V125, P2747, DOI 10.1002/ijc.24702; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Stacker SA, 2002, FASEB J, V16, P922, DOI 10.1096/fj.01-0945rev; Thapa N, 2007, INT J BIOCHEM CELL B, V39, P2183, DOI 10.1016/j.biocel.2007.06.004; Wartiovaara U, 1998, THROMB HAEMOSTASIS, V80, P171, DOI 10.1055/s-0037-1615158; Ween MP, 2012, INT J MOL SCI, V13, P10461, DOI 10.3390/ijms130810461; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Zhang Y, 2009, CANCER RES, V69, P37, DOI 10.1158/0008-5472.CAN-08-1648	35	18	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					196	205		10.1038/onc.2015.73	http://dx.doi.org/10.1038/onc.2015.73			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25772247				2022-12-17	WOS:000368193900006
J	Dong, H; Tian, L; Li, R; Pei, C; Fu, Y; Dong, X; Xia, F; Wang, C; Li, W; Guo, X; Gu, C; Li, B; Liu, A; Ren, H; Wang, C; Xu, H				Dong, H.; Tian, L.; Li, R.; Pei, C.; Fu, Y.; Dong, X.; Xia, F.; Wang, C.; Li, W.; Guo, X.; Gu, C.; Li, B.; Liu, A.; Ren, H.; Wang, C.; Xu, H.			IFNg-induced Irgm1 promotes tumorigenesis of melanoma via dual regulation of apoptosis and Bif-1-dependent autophagy	ONCOGENE			English	Article							INTERFERON-GAMMA; BIF-1/ENDOPHILIN B1; CELL-PROLIFERATION; TUMOR-DEVELOPMENT; FACTOR (IRF)-1; GTPASE IRGM1; T-CELL; GROWTH; EXPRESSION; MYCOBACTERIA	Interferon gamma (IFNg) has been known as the regulator for both tumor immune surveillance and tumorgenesis. However, mechanisms underlying the resistance of tumor cell to IFNg have yet been fully understood. In the current study, we showed that immunity-related GTPase family member 1 (mouse: Irgm1; human: IRGM) is essential for IFNg-mediated regulation of tumor cell growth in melanoma. IRGM/Irgm1 was highly expressed in human and mouse melanoma. IFNg and starvation synergistically induced Irgm1 expression in melanoma B16 cells. In vivo, injection of Irgm1-siRNA-treated cells significantly reduced the number of tumor nodules and prolonged the mice survival. In vitro, knockdown endogenous or IFNg-induced Irgm1 significantly decreases the proliferation and increases apoptosis of B16 cells. In addition, suppressing Irgm1 decreased the IFNg/starvation-induced autophagy, while overexpressing Irgm1 significantly increased autophagy and rescued starvation-challenged cells. Moreover, IFNg and starvation-induced the co-localization of Irgm1 with Bax-interacting factor 1 (Bif-1). Knockdown of Bif-1 decreased Irgm1-mediated tumor cell autophagy. Taken together, these data reveal an Irgm1-dependent mechanism that promotes the tumorigenesis of melanoma via dual regulation of apoptosis and Bif-1-dependent autophagy.	[Dong, H.; Tian, L.; Pei, C.; Fu, Y.; Dong, X.; Xia, F.; Wang, C.; Li, W.; Guo, X.; Gu, C.; Li, B.; Ren, H.; Xu, H.] Harbin Med Univ, Dept Immunol, Heilongjiang Prov Key Lab Infect & Immun, Harbin 150086, Heilongjiang, Peoples R China; [Dong, H.; Wang, C.] Fujian Med Univ, Dept Neurol, Affiliated Sanming Hosp 1, Sanming, Fujian, Peoples R China; [Li, R.] McGill Univ, Neuroinflammat Unit, Montreal Neurol Inst, Montreal, PQ, Canada; [Liu, A.] Harbin Med Univ, Dept Hematol, Affiliated Tumor Hosp, Harbin, Peoples R China	Harbin Medical University; Fujian Medical University; McGill University; Harbin Medical University	Xu, H (corresponding author), Harbin Med Univ, Dept Immunol, Heilongjiang Prov Key Lab Infect & Immun, 157 Baojian Rd, Harbin 150086, Heilongjiang, Peoples R China.	cdongwang01@126.com; hongwei56@hotmail.com	Li, Rui/O-7397-2016; Xu, Hongwei/S-3865-2018; Ren, Huan/O-5727-2017	Li, Rui/0000-0002-7210-8358; Ren, Huan/0000-0001-7114-2012; Xu, Hongwei/0000-0001-5763-3894	National Natural Science Foundation Projects [81071949, 31371080]; Heilongjiang Provincial Natural Science Foundation [D201004]; National Natural Science Foundation Project [81371320]	National Natural Science Foundation Projects(National Natural Science Foundation of China (NSFC)); Heilongjiang Provincial Natural Science Foundation(Natural Science Foundation of Heilongjiang Province); National Natural Science Foundation Project(National Natural Science Foundation of China (NSFC))	We thank Dr Zhiheng Xu and Professor Hulun Li for project discussion and technical support. These studies were funded by the National Natural Science Foundation Projects (Nos. 81071949 and 31371080) and Heilongjiang Provincial Natural Science Foundation (D201004) to Dr Hongwei Xu and the National Natural Science Foundation Project (No. 81371320) to Dr Chaodong Wang.	Altman BJ, 2009, AUTOPHAGY, V5, P569, DOI 10.4161/auto.5.4.8254; Bernabei P, 2001, J LEUKOCYTE BIOL, V70, P950; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Feng CG, 2008, NAT IMMUNOL, V9, P1279, DOI 10.1038/ni.1653; Feng CG, 2008, CELL STEM CELL, V2, P83, DOI 10.1016/j.stem.2007.10.007; Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019; He SY, 2012, AUTOPHAGY, V8, P1621, DOI 10.4161/auto.21561; He YF, 2005, CANCER IMMUNOL IMMUN, V54, P891, DOI 10.1007/s00262-004-0654-1; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; LOLLINI PL, 1993, INT J CANCER, V55, P320, DOI 10.1002/ijc.2910550224; Overwijk W W, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2001s39; Seliger B, 2008, ADV CANCER RES, V101, P249, DOI 10.1016/S0065-230X(08)00407-7; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; Street SEA, 2001, BLOOD, V97, P192, DOI 10.1182/blood.V97.1.192; Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Takahashi Y, 2009, CELL DEATH DIFFER, V16, P947, DOI 10.1038/cdd.2009.19; Takahashi Y, 2008, AUTOPHAGY, V4, P121, DOI 10.4161/auto.5265; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; TANIGUCHI K, 1987, P NATL ACAD SCI USA, V84, P3405, DOI 10.1073/pnas.84.10.3405; Taylor GA, 1996, J BIOL CHEM, V271, P20399, DOI 10.1074/jbc.271.34.20399; Tiwari S, 2009, NAT IMMUNOL, V10, P907, DOI 10.1038/ni.1759; Wang Y, 2007, CANCER RES, V67, P2535, DOI 10.1158/0008-5472.CAN-06-3530; Xia FC, 2013, SCI REP-UK, V3, DOI 10.1038/srep01867; Xu HW, 2010, FASEB J, V24, P1583, DOI 10.1096/fj.09-137323; Yi Y, 2013, ANN SURG ONCOL, V20, P267, DOI 10.1245/s10434-012-2487-z; Yin XC, 2011, EMBO REP, V12, P727, DOI 10.1038/embor.2011.79; Zaidi MR, 2011, NATURE, V469, P548, DOI 10.1038/nature09666	34	18	18	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5363	5371		10.1038/onc.2014.459	http://dx.doi.org/10.1038/onc.2014.459			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25619828				2022-12-17	WOS:000363479200006
J	Ruiz-Saenz, A; Sandhu, M; Carrasco, Y; Maglathlin, RL; Taunton, J; Moasser, MM				Ruiz-Saenz, A.; Sandhu, M.; Carrasco, Y.; Maglathlin, R. L.; Taunton, J.; Moasser, M. M.			Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum	ONCOGENE			English	Article							FACTOR-RECEPTOR MUTATIONS; BREAST-CANCER; GENE AMPLIFICATION; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODY; TYROSINE KINASE; ERBB3 ANTIBODY; ONCOGENIC UNIT; UP-REGULATION; COLON-CANCER	There is increasing evidence implicating human epidermal growth factor receptor 3 (HER3) in several types of cancer. However, the development of targeted therapies to inactivate HER3 function has been a challenging endeavor. Its kinase domain functions in allostery not catalysis, and the classical ATP-analog class of tyrosine kinase inhibitors fail to inactivate it. Here we describe a novel approach that eliminates HER3 expression. The small-molecule cotransin CT8 binds the Sec61 translocon and prevents the signal peptide of the nascent HER3 protein from initiating its cotranslational translocation, resulting in the degradation of HER3 but not the other HER proteins. CT8 treatment suppresses the induction of HER3 that accompanies lapatinib treatment of HER2-amplified cancers and synergistically enhances the apoptotic effects of lapatinib. The target selectivities of cotransins are highly dependent on their structure and the signal sequence of targeted proteins and can be narrowed through structure-function studies. Targeting Sec61-dependent processing identifies a novel strategy to eliminate HER3 function.	[Ruiz-Saenz, A.; Sandhu, M.; Moasser, M. M.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA 94143 USA; [Carrasco, Y.; Maglathlin, R. L.; Taunton, J.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; [Taunton, J.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Moasser, MM (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, UCSF Box 1387,2340 Sutter St,Room N-144, San Francisco, CA 94143 USA.	mark.moasser@ucsf.edu	Sandhu, Manbir/AAI-2124-2019; Ruiz-Saenz, Ana/U-3220-2017	Sandhu, Manbir/0000-0003-1182-7268; Ruiz-Saenz, Ana/0000-0001-6033-6153	National Institutes of Health [CA122216, CA112970]; Howard Hughes Medical Institute; Fundacion Ramon Areces Fellowship; NATIONAL CANCER INSTITUTE [U54CA112970, R01CA122216] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Fundacion Ramon Areces Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health CA122216 and CA112970 (to MMM), Howard Hughes Medical Institute (to JT) and a Fundacion Ramon Areces Fellowship (to ARS).	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Amin DN, 2012, BIOCHEM J, V447, P417, DOI 10.1042/BJ20120724; Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Beji A, 2012, CLIN CANCER RES, V18, P956, DOI 10.1158/1078-0432.CCR-11-1186; Besemer J, 2005, NATURE, V436, P290, DOI 10.1038/nature03670; Blackburn E, 2012, BREAST CANCER RES TR, V134, P53, DOI 10.1007/s10549-011-1908-1; Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349; Chen Y, 2002, J AM CHEM SOC, V124, P5431, DOI 10.1021/ja020166v; Fattore L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-180; Foreman PK, 2012, MOL CANCER THER, V11, P1411, DOI 10.1158/1535-7163.MCT-12-0068; Frederick L, 2000, CANCER RES, V60, P1383; Garner AP, 2013, CANCER RES, V73, P6024, DOI 10.1158/0008-5472.CAN-13-1198; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Garrison JL, 2005, NATURE, V436, P285, DOI 10.1038/nature03821; Gerbin CS, 2010, CELL STRESS CHAPERON, V15, P529, DOI 10.1007/s12192-009-0166-1; Gespach C, 2012, CLIN CANCER RES, V18, P917, DOI 10.1158/1078-0432.CCR-11-3143; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; GIARETTI W, 1994, METHOD CELL BIOL, V41, P389; Harant H, 2006, J BIOL CHEM, V281, P30492, DOI 10.1074/jbc.M607243200; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hulleman JD, 2013, J BIOMOL SCREEN, V18, P647, DOI 10.1177/1087057112469405; Jura N, 2009, P NATL ACAD SCI USA, V106, P21608, DOI 10.1073/pnas.0912101106; Kugel CH, 2014, CANCER RES, V74, P4122, DOI 10.1158/0008-5472.CAN-14-0464; Lee H, 1998, ONCOGENE, V16, P3243, DOI 10.1038/sj.onc.1201866; Lee H, 2001, CANCER RES, V61, P4467; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Licitra L, 2011, ANN ONCOL, V22, P1078, DOI 10.1093/annonc/mdq588; Littlefield P, 2014, CHEM BIOL, V21, P453, DOI 10.1016/j.chembiol.2014.02.011; Lopez-Gines C, 2005, CLIN NEUROPATHOL, V24, P209; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MacKinnon AL, 2007, J AM CHEM SOC, V129, P14560, DOI 10.1021/ja076250y; MacKinnon AL, 2014, ELIFE, V3, DOI 10.7554/eLife.01483; Maifeld SV, 2011, CHEM BIOL, V18, P1082, DOI 10.1016/j.chembiol.2011.06.015; McDonagh CF, 2012, MOL CANCER THER, V11, P582, DOI 10.1158/1535-7163.MCT-11-0820; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Reschke M, 2008, CLIN CANCER RES, V14, P5188, DOI 10.1158/1078-0432.CCR-08-0186; Santin AD, 2005, CANCER-AM CANCER SOC, V104, P1391, DOI 10.1002/cncr.21308; Schoeberl B, 2010, CANCER RES, V70, P2485, DOI 10.1158/0008-5472.CAN-09-3145; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Tao JJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005125; Vaught DB, 2012, CANCER RES, V72, P2672, DOI 10.1158/0008-5472.CAN-11-3594; Yano T, 2006, ONCOL REP, V15, P65; Yao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078086; Zhang L, 2014, MOL CANCER THER, V13, P1345, DOI 10.1158/1535-7163.MCT-13-1033	52	18	18	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5288	5294		10.1038/onc.2014.455	http://dx.doi.org/10.1038/onc.2014.455			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25619841	Green Accepted, Green Submitted			2022-12-17	WOS:000362575400008
J	Haney, SL; Hlady, RA; Opavska, J; Klinkebiel, D; Pirruccello, SJ; Dutta, S; Datta, K; Simpson, MA; Wu, L; Opavsky, R				Haney, S. L.; Hlady, R. A.; Opavska, J.; Klinkebiel, D.; Pirruccello, S. J.; Dutta, S.; Datta, K.; Simpson, M. A.; Wu, L.; Opavsky, R.			Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; DE-NOVO; DNA METHYLATION; GENE; MUTATIONS; TUMORIGENESIS; EXPRESSION; MICE; TRANSCRIPTION; PATHOGENESIS	DNA methyltransferase 3A (DNMT3A) catalyzes cytosine methylation of mammalian genomic DNA. In addition to myeloid malignancies, mutations in DNMT3A have been recently reported in T-cell lymphoma and leukemia, implying a possible involvement in the pathogenesis of human diseases. However, the role of Dnmt3a in T-cell transformation in vivo is poorly understood. Here we analyzed the functional consequences of Dnmt3a inactivation in a mouse model of MYC-induced T-cell lymphomagenesis (MTCL). Loss of Dnmt3a delayed tumorigenesis by suppressing cellular proliferation during disease progression. Gene expression profiling and pathway analysis identified upregulation of 17 putative tumor suppressor genes, including DNA methyltransferase Dnmt3b, in Dnmt3a-deficient lymphomas as molecular events potentially responsible for the delayed lymphomagenesis in Dnmt3a(Delta/Delta) mice. Interestingly, promoter and gene body methylation of these genes was not substantially changed between control and Dnmt3a-deficient lymphomas, suggesting that Dnmt3a may inhibit their expression in a methylation-independent manner. Re-expression of both wild type and catalytically inactive Dnmt3a in Dnmt3a(Delta/Delta) lymphoma cells in vitro inhibited Dnmt3b expression, indicating that Dnmt3b upregulation may be directly repressed by Dnmt3a. Importantly, genetic inactivation of Dnmt3b accelerated lymphomagenesis in Dnmt3a(Delta/Delta) mice, demonstrating that upregulation of Dnmt3b is a relevant molecular change in Dnmt3a-deficient lymphomas that inhibits disease progression. Collectively, our data demonstrate an unexpected oncogenic role for Dnmt3a in MTCL through methylation-independent repression of Dnmt3b and possibly other tumor suppressor genes.	[Haney, S. L.; Opavsky, R.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA; [Hlady, R. A.; Opavska, J.; Opavsky, R.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Klinkebiel, D.; Dutta, S.; Datta, K.] Univ Nebraska Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Pirruccello, S. J.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Simpson, M. A.] Univ Nebraska, Dept Biochem, Lincoln, NE 68583 USA; [Wu, L.] Rutgers New Jersey Med Sch, Ctr Canc, Dept Microbiol & Mol Genet, Newark, NJ USA; [Opavsky, R.] Univ Nebraska Med Ctr, Ctr Lymphoma & Leukemia Res, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Lincoln; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Nebraska System; University of Nebraska Medical Center	Opavsky, R (corresponding author), Univ Nebraska Med Ctr, DRCII, Eppley Inst Res Canc & Allied Dis, 985950 Nebraska Med Ctr,Room 4031, Omaha, NE 68198 USA.	ropavsky@unmc.edu			NCI NIH HHS [T32 CA009476] Funding Source: Medline; NIGMS NIH HHS [P30 GM110768, P20 GM103471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103471, P30GM110768] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Borgel J, 2010, NAT GENET, V42, P1093, DOI 10.1038/ng.708; Challen GA, 2012, NAT GENET, V44, P23, DOI 10.1038/ng.1009; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Couronne L, 2012, NEW ENGL J MED, V366, P95, DOI 10.1056/NEJMc1111708; Datta J, 2005, CANCER RES, V65, P10891, DOI 10.1158/0008-5472.CAN-05-1455; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fernandez AF, 2012, TRENDS GENET, V28, P474, DOI 10.1016/j.tig.2012.05.006; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Hervouet E, 2009, EPIGENETICS-US, V4, P487, DOI 10.4161/epi.4.7.9883; Hlady RA, 2012, J CLIN INVEST, V122, P163, DOI 10.1172/JCI57292; Iskander K, 2008, CANCER RES, V68, P7915, DOI 10.1158/0008-5472.CAN-08-0766; Kim SJ, 2013, BLOOD, V122, P4086, DOI 10.1182/blood-2013-02-483487; Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Li HX, 2014, BLOOD, V123, P1487, DOI 10.1182/blood-2013-05-500264; Lin WQ, 2013, EMBO J, V32, P1425, DOI 10.1038/emboj.2013.88; Liu JG, 2004, J IMMUNOL, V173, P1184, DOI 10.4049/jimmunol.173.2.1184; Neumann M, 2013, BLOOD, V121, P4749, DOI 10.1182/blood-2012-11-465138; Odejide O, 2014, BLOOD, V123, P1293, DOI 10.1182/blood-2013-10-531509; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Opavsky R, 2007, PLOS GENET, V3, P1757, DOI 10.1371/journal.pgen.0030167; Opavsky R, 2007, P NATL ACAD SCI USA, V104, P15400, DOI 10.1073/pnas.0706307104; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Palamarchuk A, 2012, P NATL ACAD SCI USA, V109, P2555, DOI 10.1073/pnas.1200003109; Peters SL, 2014, LEUKEMIA, V28, P1138, DOI 10.1038/leu.2013.364; Peters SL, 2013, MOL CELL BIOL, V33, P4321, DOI 10.1128/MCB.00776-13; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Puto LA, 2008, GENE DEV, V22, P998, DOI 10.1101/gad.1632208; Ramkumar C, 2012, CANCER RES, V72, P2714, DOI 10.1158/0008-5472.CAN-11-3773; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robinson MD, 2007, BIOINFORMATICS, V23, P2881, DOI 10.1093/bioinformatics/btm453; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Russler-Germain DA, 2014, CANCER CELL, V25, P442, DOI 10.1016/j.ccr.2014.02.010; Schaetzlein S, 2013, P NATL ACAD SCI USA, V110, pE2470, DOI 10.1073/pnas.1308512110; Schuster C, 2011, BLOOD, V118, P4635, DOI 10.1182/blood-2010-10-313098; Shang QJ, 2012, MOL MED REP, V5, P1401, DOI 10.3892/mmr.2012.844; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Thorns C, 2007, GENE CHROMOSOME CANC, V46, P37, DOI 10.1002/gcc.20386; Vasanthakumar A, 2013, BLOOD, V121, P2059, DOI 10.1182/blood-2012-04-421065; Walter MJ, 2011, LEUKEMIA, V25, P1153, DOI 10.1038/leu.2011.44; Wang Y, 2010, ONCOGENE, V29, P3044, DOI 10.1038/onc.2010.78; Wang YA, 2005, CANCER BIOL THER, V4, P1138, DOI 10.4161/cbt.4.10.2073; Weis B, 2015, ONCOGENE, V34, P1822, DOI 10.1038/onc.2014.114; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485	50	18	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5436	5446		10.1038/onc.2014.472	http://dx.doi.org/10.1038/onc.2014.472			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25639876	Green Accepted			2022-12-17	WOS:000363479700004
J	Kobayashi, S; Kasaishi, Y; Nakada, S; Takagi, T; Era, S; Motegi, A; Chiu, RK; Takeda, S; Hirota, K				Kobayashi, S.; Kasaishi, Y.; Nakada, S.; Takagi, T.; Era, S.; Motegi, A.; Chiu, R. K.; Takeda, S.; Hirota, K.			Rad18 and Rnf8 facilitate homologous recombination by two distinct mechanisms, promoting Rad51 focus formation and suppressing the toxic effect of nonhomologous end joining	ONCOGENE			English	Article							STRAND BREAK REPAIR; UBIQUITIN-CONJUGATING ENZYME; DNA-DAMAGE RESPONSE; TOPOISOMERASE-I; CELLS; UBC13; UBIQUITYLATION; MAINTENANCE; INHIBITORS; PATHWAYS	The E2 ubiquitin conjugating enzyme Ubc13 and the E3 ubiquitin ligases Rad18 and Rnf8 promote homologous recombination (HR)-mediated double-strand break (DSB) repair by enhancing polymerization of the Rad51 recombinase at.-ray-induced DSB sites. To analyze functional interactions between the three enzymes, we created RAD18(-/-), RNF8(-/-), RAD18(-/-) /RNF8(-/-) and UBC13(-/-) clones in chicken DT40 cells. To assess the capability of HR, we measured the cellular sensitivity to camptothecin (topoisomerase I poison) and olaparib (poly(ADP ribose) polymerase inhibitor) because these chemotherapeutic agents induce DSBs during DNA replication, which are repaired exclusively by HR. RAD18(-/-), RNF8(-/-) and RAD18(-/-) /RNF8(-/-) clones showed very similar levels of hypersensitivity, indicating that Rad18 and Rnf8 operate in the same pathway in the promotion of HR. Although these three mutants show less prominent defects in the formation of Rad51 foci than UBC13(-/-) cells, they are more sensitive to camptothecin and olaparib than UBC13(-/-) cells. Thus, Rad18 and Rnf8 promote HR-dependent repair in a manner distinct from Ubc13. Remarkably, deletion of Ku70, a protein essential for nonhomologous end joining (NHEJ) significantly restored tolerance of RAD18(-/-) and RNF8(-/-) cells to camptothecin and olaparib without affecting Rad51 focus formation. Thus, in cellular tolerance to the chemotherapeutic agents, the two enzymes collaboratively promote DSB repair by HR by suppressing the toxic effect of NHEJ on HR rather than enhancing Rad51 focus formation. In contrast, following exposure to gamma-rays, RAD18(-/-), RNF8(-/-), RAD18(-/-) /RNF8(-/-) and UBC13(-/-) cells showed close correlation between cellular survival and Rad51 focus formation at DSB sites. In summary, the current study reveals that Rad18 and Rnf8 facilitate HR by two distinct mechanisms: suppression of the toxic effect of NHEJ on HR during DNA replication and the promotion of Rad51 focus formation at radiotherapy-induced DSB sites.	[Kobayashi, S.; Kasaishi, Y.; Era, S.; Motegi, A.; Takeda, S.; Hirota, K.] Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Kyoto 6068501, Japan; [Nakada, S.] Keio Univ, Sch Med, Ctr Integrated Med Res, Tokyo, Japan; [Takagi, T.; Hirota, K.] Tokyo Metropolitan Univ, Grad Sch Sci & Engn, Dept Chem, Tokyo 158, Japan; [Chiu, R. K.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands	Kyoto University; Keio University; Tokyo Metropolitan University; University of Groningen	Hirota, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan.	stakeda@rg.med.kyoto-u.ac.jp; khirota@rg.med.kyoto-u.ac.jp	OsakaU/AAY-3661-2020	Nakada, Shinichiro/0000-0001-9297-1565	Ministry of Education, Sports and Culture of Japan; Uehara Memorial Foundation; Naito Foundation; Sumitomo Foundation; Kurata Fundation	Ministry of Education, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); Naito Foundation(Naito Memorial Foundation); Sumitomo Foundation; Kurata Fundation	This work was supported in part by the grants-in-aid program of the Ministry of Education, Sports and Culture of Japan (for ST). We thank Drs Tadahiro Shiomi and Naoko Shiomi (National Institute of Radiological Sciences, Japan) for providing us with the HCT116 RAD18<SUP>-/-</SUP> and RAD18<SUP>+/+</SUP> cells and Professor Hitoshi Kurumizaka (Waseda University, Japan) for providing us with the anti-Rad51 antibody. Financial support was provided in part by the Uehara Memorial Foundation, the Naito Foundation, Sumitomo Foundation and Kurata Fundation (for KH).	Adachi N, 2004, J BIOL CHEM, V279, P37343, DOI 10.1074/jbc.M313910200; Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fukushima T, 2007, P NATL ACAD SCI USA, V104, P6371, DOI 10.1073/pnas.0700548104; Hochegger H, 2006, EMBO J, V25, P1305, DOI 10.1038/sj.emboj.7601015; Huang J, 2009, NAT CELL BIOL, V11, P592, DOI 10.1038/ncb1865; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Inagaki A, 2009, DNA REPAIR, V8, P190, DOI 10.1016/j.dnarep.2008.10.008; Ji K, 2009, ENVIRON HEALTH PERSP, V117, P1737, DOI 10.1289/ehp.0900842; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Li L, 2010, J EXP MED, V207, P983, DOI 10.1084/jem.20092437; Lu CS, 2012, J BIOL CHEM, V287, P43984, DOI 10.1074/jbc.M112.421545; Lu LY, 2010, DEV CELL, V18, P371, DOI 10.1016/j.devcel.2010.01.010; Luijsterburg MS, 2012, EMBO J, V31, P2511, DOI 10.1038/emboj.2012.104; Maede Y, 2014, MOL CANCER THER, V13, P214, DOI 10.1158/1535-7163.MCT-13-0551; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Oestergaard VH, 2012, DNA REPAIR, V11, P892, DOI 10.1016/j.dnarep.2012.08.005; Palle K, 2011, CELL CYCLE, V10, P1625, DOI 10.4161/cc.10.10.15617; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Saberi A, 2007, MOL CELL BIOL, V27, P2562, DOI 10.1128/MCB.01243-06; Santos MA, 2010, J EXP MED, V207, P973, DOI 10.1084/jem.20092308; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sun JH, 2009, MECH DEVELOP, V126, P173, DOI 10.1016/j.mod.2008.11.004; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Watanabe K, 2009, NUCLEIC ACIDS RES, V37, P2176, DOI 10.1093/nar/gkp082; Wu JX, 2011, NAT STRUCT MOL BIOL, V18, P761, DOI 10.1038/nsmb.2078; Yamamoto M, 2006, NAT IMMUNOL, V7, P962, DOI 10.1038/ni1367; Yamashita YM, 2002, EMBO J, V21, P5558, DOI 10.1093/emboj/cdf534; Yamazoe M, 2004, DNA REPAIR, V3, P1175, DOI 10.1016/j.dnarep.2004.03.039; Yoshimura A, 2006, DNA REPAIR, V5, P1307, DOI 10.1016/j.dnarep.2006.05.045; Zhao GY, 2007, MOL CELL, V25, P663, DOI 10.1016/j.molcel.2007.01.029	35	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4403	4411		10.1038/onc.2014.371	http://dx.doi.org/10.1038/onc.2014.371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25417706	Green Submitted			2022-12-17	WOS:000359494400011
J	Jia, H; Cong, Q; Chua, JFL; Liu, H; Xia, X; Zhang, X; Lin, J; Habib, SL; Ao, J; Zuo, Q; Fu, C; Li, B				Jia, H.; Cong, Q.; Chua, J. F. L.; Liu, H.; Xia, X.; Zhang, X.; Lin, J.; Habib, S. L.; Ao, J.; Zuo, Q.; Fu, C.; Li, B.			p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance	ONCOGENE			English	Article							P57(KIP2) EXPRESSION; INHIBITOR P57(KIP2); CDK INHIBITORS; P38; P57; ATM; DIFFERENTIATION; CANCER; PROLIFERATION; PROTEIN	The DNA damage response (DDR) helps to maintain genome integrity, suppress tumorigenesis and mediate the radiotherapeutic and chemotherapeutic effects on cancer. Here we report that p57Kip2, a cyclin-dependent kinase (CDK) inhibitor implicated in the development of tumor-prone Beckwith-Wiedemann syndrome, is an effector molecule of the DNA-damage response. Genotoxic stress induces p57Kip2 expression via the bone morphogenetic protein-Smad1 and Atm-p38MAPK-Atf2 pathways in p53-proficient or -deficient cells and requires the Smad1-Atf2 complex that facilitates their recruitment to the p57Kip2 promoter. Elevated p57Kip2 induces G1/S phase cell cycle arrest but inhibits cell death in response to DNA damage and acts in parallel with p53 to suppress cell transformation and tumor formation. p57Kip2 is also upregulated in stage I and II clinical rectal tumor samples, likely due to genome instability of precancerous and/or early cancer cells. Targeting p57Kip2 in primary rectal cancer cells and tumor models resulted in increased sensitivity to doxorubicin, suggesting that p57Kip2 has a role in chemoresistance, which is consistent with its pro-survival function. These findings place p57Kip2 in DDR and uncover molecular mechanisms by which p57Kip2 suppresses tumorigenesis and causes chemoresistance.	[Jia, H.; Cong, Q.; Liu, H.; Xia, X.; Zhang, X.; Lin, J.; Li, B.] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai 200240, Peoples R China; [Chua, J. F. L.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; [Habib, S. L.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; [Habib, S. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Ao, J.] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai 200240, Peoples R China; [Zuo, Q.; Fu, C.] Second Mil Med Univ, Changhai Hosp, Dept Colorectal Surg, Shanghai, Peoples R China	Shanghai Jiao Tong University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; Shanghai Jiao Tong University; Naval Medical University	Li, B (corresponding author), Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Dongchuan Rd 800, Shanghai 200240, Peoples R China.	libj@sjtu.edu.cn	Cong, Qian/AAZ-4404-2021	Zuo, Qiao/0000-0003-4512-6363; Jia, Hao/0000-0003-1856-6013; Cong, Qian/0000-0002-9493-5784	Ministry of Science and Technology of China [2012CB966901]; National Natural Science Foundation of China [81130039, 31071229, 81121001]; Veterans Affairs [I01BX000924] Funding Source: NIH RePORTER	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Veterans Affairs(US Department of Veterans Affairs)	We thank Lina Gao, IH In, C Deyu, GC Hong, L Soh, J Lin and T Cheng for technical assistance and Boehringer Ingelheim, Novartis, Dr Michael D. Schneider, Dr Ye-Guang Chen, Dr Yibin Wang, Dr Nelson J Dusetti, Dr Olivier Delattre, Dr Philipp Kaldis and Dr Michael Kastan for providing constructs, reagents and mice. The work was supported by grants from the Ministry of Science and Technology of China (The National Key Scientific Program (2012CB966901 to BL) and the National Natural Science Foundation of China (81130039, 31071229 and 81121001).	Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Barascu A, 2012, EMBO J, V31, P1080, DOI 10.1038/emboj.2011.492; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Belyi VA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001198; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bhoumik A, 2005, MOL CELL, V18, P577, DOI 10.1016/j.molcel.2005.04.015; Bhoumik A, 2008, J BIOL CHEM, V283, P17605, DOI 10.1074/jbc.M802030200; Borriello A, 2007, CELL CYCLE, V6, P1053, DOI 10.4161/cc.6.9.4142; Borriello A, 2011, MOL CANCER RES, V9, P1269, DOI 10.1158/1541-7786.MCR-11-0220; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Caspary T, 1999, GENE DEV, V13, P3115, DOI 10.1101/gad.13.23.3115; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Chau JFL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1832; Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Engel FB, 2005, GENE DEV, V19, P1175, DOI 10.1101/gad.1306705; Furutachi S, 2013, EMBO J, V32, P970, DOI 10.1038/emboj.2013.50; Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26; Giovannini C, 2012, AM J PATHOL, V181, P413, DOI 10.1016/j.ajpath.2012.04.019; Gosselet FP, 2007, CELL SIGNAL, V19, P731, DOI 10.1016/j.cellsig.2006.09.006; Gozdecka M, 2012, BIOCHEM SOC T, V40, P230, DOI 10.1042/BST20110630; Gu J, 2013, COLORECTAL DIS, V07, P677; Hopker K, 2012, EMBO J, V31, P3961, DOI 10.1038/emboj.2012.236; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Joaquin M, 2012, EMBO J, V31, P2952, DOI 10.1038/emboj.2012.122; Kavanagh E, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.51; Kavanagh E, 2011, BBA-REV CANCER, V1816, P50, DOI 10.1016/j.bbcan.2011.03.002; Lai KP, 2010, EMBO J, V29, P2994, DOI 10.1038/emboj.2010.166; Li Shuangwei, 2010, Genes Cancer, V1, P316; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Mairet-Coello G, 2012, DEVELOPMENT, V139, P475, DOI 10.1242/dev.067314; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Matsumoto A, 2011, CELL STEM CELL, V9, P262, DOI 10.1016/j.stem.2011.06.014; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Pateras IS, 2006, INT J CANCER, V119, P2546, DOI 10.1002/ijc.22214; Pateras IS, 2009, MOL CANCER RES, V7, P1902, DOI 10.1158/1541-7786.MCR-09-0317; Raman M, 2007, EMBO J, V26, P2005, DOI 10.1038/sj.emboj.7601668; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Sugihara E, 2006, CANCER RES, V66, P4020, DOI 10.1158/0008-5472.CAN-05-3250; Susaki E, 2009, CELL CYCLE, V8, P2497, DOI 10.4161/cc.8.16.9330; Susaki E, 2009, P NATL ACAD SCI USA, V106, P5192, DOI 10.1073/pnas.0811712106; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tremblay KD, 2001, DEVELOPMENT, V128, P3609; Ullah Z, 2008, GENE DEV, V22, P3024, DOI 10.1101/gad.1718108; Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Vlachos P, 2007, CELL DEATH DIFFER, V14, P1497, DOI 10.1038/sj.cdd.4402158; Wang QE, 2013, NUCLEIC ACIDS RES, V41, P1722, DOI 10.1093/nar/gks1312; Xie M, 2006, P NATL ACAD SCI USA, V103, P17378, DOI 10.1073/pnas.0604708103; Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062527; Zhao RY, 2013, CELL CYCLE, V12, P935, DOI 10.4161/cc.23883	62	18	18	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3568	3581		10.1038/onc.2014.287	http://dx.doi.org/10.1038/onc.2014.287			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25195859				2022-12-17	WOS:000357434900009
J	Habel, N; Vilalta, M; Bawa, O; Opolon, P; Blanco, J; Fromigue, O				Habel, N.; Vilalta, M.; Bawa, O.; Opolon, P.; Blanco, J.; Fromigue, O.			Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors	ONCOGENE			English	Article							PRO-ANGIOGENIC ACTIVITIES; IMMEDIATE-EARLY GENE; GROWTH-FACTOR VEGF; ENDOTHELIAL-CELLS; POOR-PROGNOSIS; BREAST-CANCER; UP-REGULATION; CCN1 CYR61; EXPRESSION; INTEGRIN	Osteosarcoma is the most prevalent primary pediatric cancer-related bone disease. These tumors frequently develop resistance to chemotherapy and are highly metastatic, leading to poor outcome. Thus, there is a need for new therapeutic strategies that can prevent cell dissemination. We previously showed that CYR61/CCN1 expression in osteosarcoma cells is correlated to aggressiveness both in vitro and in vivo in mouse models, as well as in patients. In this study, we found that CYR61 is a critical contributor to the vascularization of primary tumor. We demonstrate that silencing CYR61, using lentiviral transduction, leads to a significant reduction in expression level of pro-angiogenic markers such as VEGF, FGF2, PECAM and angiopoietins concomitantly to an increased expression of major anti-angiogenic markers such as thrombospondin-1 and SPARC. Matrix metalloproteinase-2 family member expression, a key pathway in osteosarcoma metastatic capacity was also downregulated when CYR61 was downregulated in osteosarcoma cells. Using a metastatic murine model, we show that CYR61 silencing in osteosarcoma cells results in reduced tumor vasculature and slows tumor growth compared with control. We also find that microvessel density correlates with lung metastasis occurrence and that CYR61 silencing in osteosarcoma cells limits the number of metastases. Taken together, our data indicate that CYR61 silencing can blunt the malignant behavior of osteosarcoma tumor cells by limiting primary tumor growth and dissemination process.	[Habel, N.; Fromigue, O.] Inst Cancerol Gustave Roussy, INSERM, U981, F-94805 Villejuif, France; [Habel, N.; Bawa, O.; Opolon, P.; Fromigue, O.] Gustave Roussy, Villejuif, France; [Habel, N.; Bawa, O.; Opolon, P.; Fromigue, O.] Univ Paris 11, Orsay, France; [Habel, N.] Univ Paris Diderot, Paris, France; [Vilalta, M.; Blanco, J.] CSIC, Inst Adv Chem Catalonia, Cell Therapy Grp, Barcelona, Spain; [Bawa, O.; Opolon, P.] Gustave Roussy, IRCIV, Lab Pathol Expt, Villejuif, France; [Blanco, J.] Networking Biomed Res Ctr Bioengn Biomat & Nanome, Barcelona, Spain	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); CSIC - Instituto de Quimica Avanzada de Cataluna (IQAC); UNICANCER; Gustave Roussy; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN	Fromigue, O (corresponding author), Inst Cancerol Gustave Roussy, INSERM, U981, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	olivia.fromigue@inserm.fr	Blanco, Jeronimo/H-2764-2015; Fromigue, Olivia/B-8225-2013	Blanco, Jeronimo/0000-0003-3765-0640; Fromigue, Olivia/0000-0002-3050-6155; habel, nadia/0000-0002-4083-8495	Ministere de la Recherche (Paris, France); Inserm (France); Fondation de l'Avenir pour la Recherche Medicale Appliquee (Paris, France); Red Tematica de Investigacion Cooperativa (TERCEL, Spain); MINECO (Spain) [SAF2012-33404]	Ministere de la Recherche (Paris, France)(Ministry of Research, France); Inserm (France)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation de l'Avenir pour la Recherche Medicale Appliquee (Paris, France); Red Tematica de Investigacion Cooperativa (TERCEL, Spain); MINECO (Spain)	NH is a recipient of a PhD award from the Ministere de la Recherche (Paris, France). This work was supported in part by Inserm (France), by Fondation de l'Avenir pour la Recherche Medicale Appliquee (Paris, France), by Red Tematica de Investigacion Cooperativa (TERCEL, Spain) and SAF2012-33404 from MINECO (Spain). We thank the Department of Medical Biology and Pathology of Gustave Roussy Institute (Dr Adam; Villejuif, France) for their contribution.	Athanasopoulos AN, 2007, J BIOL CHEM, V282, P26746, DOI 10.1074/jbc.M705200200; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Babkina IV, 2009, B EXP BIOL MED+, V148, P246, DOI 10.1007/s10517-009-0710-0; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Chen D, 2013, TUMOR BIOL, V34, P1895, DOI 10.1007/s13277-013-0733-z; Chen NY, 2004, J BIOL CHEM, V279, P44166, DOI 10.1074/jbc.M406813200; Cheng YY, 2004, PEDIATR BLOOD CANCER, V42, P410, DOI 10.1002/pbc.20019; DuBois S, 2007, CANCER-AM CANCER SOC, V109, P813, DOI 10.1002/cncr.22455; Estrada R, 2009, J CELL PHYSIOL, V219, P563, DOI 10.1002/jcp.21701; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Foukas AF, 2002, J BONE JOINT SURG BR, V84B, P706, DOI 10.1302/0301-620X.84B5.12512; Fromigue O, 2008, J BIOL CHEM, V283, P30549, DOI 10.1074/jbc.M801436200; Fromigue O, 2011, J BONE MINER RES, V26, P1533, DOI 10.1002/jbmr.343; Gomes N, 2005, CLIN EXP METASTAS, V22, P215, DOI 10.1007/s10585-005-7359-5; Grignani G, 2012, ANN ONCOL, V23, P508, DOI 10.1093/annonc/mdr151; Hara H, 2006, ANTICANCER RES, V26, P4307; Huang YP, 2008, ONKOLOGIE, V31, P535, DOI 10.1159/000151685; Jiang WG, 2004, ENDOCR-RELAT CANCER, V11, P781, DOI 10.1677/erc.1.00825; Kaya M, 2000, CLIN CANCER RES, V6, P572; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kreuter M, 2004, CLIN CANCER RES, V10, P8531, DOI 10.1158/1078-0432.CCR-04-0969; Lammli J, 2012, INT ORTHOP, V36, P2307, DOI 10.1007/s00264-012-1629-z; Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3; Lee YH, 1999, EUR J CANCER, V35, P1089, DOI 10.1016/S0959-8049(99)00073-8; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Li C, 2013, EUR REV MED PHARMACO, V17, P2804; Maris JM, 2008, PEDIATR BLOOD CANCER, V50, P581, DOI 10.1002/pbc.21232; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; Meyuhas R, 2008, MOL CANCER RES, V6, P1397, DOI 10.1158/1541-7786.MCR-07-2086; Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008-5472.CAN-04-2463; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; North S, 2005, CANCER LETT, V218, P1, DOI 10.1016/j.canlet.2004.08.007; Oda Y, 2006, MODERN PATHOL, V19, P738, DOI 10.1038/modpathol.3800587; Odagiri H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004612; Pignochino Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-118; Rastogi S, 2012, INT ORTHOP, V36, P2315, DOI 10.1007/s00264-012-1663-x; Ren T, 2014, CANCER SCI, V105, P186, DOI 10.1111/cas.12334; Roman I, 2007, BIOMATERIALS, V28, P2718, DOI 10.1016/j.biomaterials.2007.02.011; Sabile AA, 2012, J BONE MINER RES, V27, P58, DOI 10.1002/jbmr.535; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sun ZJ, 2008, BRIT J CANCER, V99, P1656, DOI 10.1038/sj.bjc.6604712; Tsou R, 2001, MOL CELL BIOCHEM, V224, P81, DOI 10.1023/A:1011947301849; Vilalta M, 2008, STEM CELLS DEV, V17, P993, DOI 10.1089/scd.2007.0201; Wagner L, 2013, PEDIATR BLOOD CANCER, V60, P1447, DOI 10.1002/pbc.24547; Wang CT, 2013, J ORTHOP RES, V31, P335, DOI 10.1002/jor.22218; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070689; Wen XY, 2014, TUMOR BIOL, V35, P845, DOI 10.1007/s13277-013-1116-1; Wilkinson-Berka JL, 2006, INVEST OPHTH VIS SCI, V47, P1600, DOI 10.1167/iovs.05-1314; Xin ZF, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-105; Yang JL, 2011, CANCER-AM CANCER SOC, V117, P4925, DOI 10.1002/cncr.26116; Zhou QA, 2011, SURG ONCOL, V20, P13, DOI 10.1016/j.suronc.2009.09.002	52	18	21	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3207	3213		10.1038/onc.2014.232	http://dx.doi.org/10.1038/onc.2014.232			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25065593				2022-12-17	WOS:000356101100012
J	Marfil, V; Blazquez, M; Serrano, F; Castell, JV; Bort, R				Marfil, V.; Blazquez, M.; Serrano, F.; Castell, J. V.; Bort, R.			Growth-promoting and tumourigenic activity of c-Myc is suppressed by Hhex	ONCOGENE			English	Article							HEX HOMEOBOX GENE; RICH HOMEODOMAIN PROTEIN; MESSENGER-RNA TRANSPORT; CELL-CYCLE; TUMOR-CELLS; EXPRESSION; PROLIFERATION; TRANSCRIPTION; APOPTOSIS; SIZE	c-Myc transcription factor is a key protein involved in cellular growth, proliferation and metabolism. c-Myc is one of the most frequently activated oncogenes, highlighting the need to identify intracellular molecules that interact directly with c-Myc to suppress its function. Here we show that Hhex is able to interact with the basic region/helix-loop-helix/leucine zipper of c-Myc. Knockdown of Hhex increases proliferation rate in hepatocellular carcinoma cells, whereas Hhex expression cell-autonomously reduces cell proliferation rate in multiple cell lines by increasing G1 phase length through a c-Myc-dependent mechanism. Global transcriptomic analysis shows that Hhex counter-regulates multiple c-Myc targets involved in cell proliferation and metabolism. Concomitantly, Hhex expression leads to reduced cell size, lower levels of cellular RNA, downregulation of metabolism-related genes, decreased sensitivity to methotrexate and severe reduction in the ability to form tumours in nude mouse xenografts, all indicative of decreased c-Myc activity. Our data suggest that Hhex is a novel regulator of c-Myc function that limits c-Myc activity in transformed cells.	[Marfil, V.; Blazquez, M.; Serrano, F.; Castell, J. V.; Bort, R.] CIBERehd, Unidad Hepatol Expt, Inst Invest Sanitaria La Fe, Valencia 46026, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD	Bort, R (corresponding author), CIBERehd, Unidad Hepatol Expt, Inst Invest Sanitaria La Fe, Avda Fernando Abril Martorell 106,Torre A Despach, Valencia 46026, Spain.	bort_ber@gva.es	Bort, Roque/Y-5466-2019; Castell, Jose V/I-9529-2016	Bort, Roque/0000-0002-7285-0536; Castell, Jose V/0000-0003-1179-6430	Ministerio de Ciencia e Innovacion [SAF2010-15376, SAF2011-29718]	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government)	We thank Dr Di Crocce for providing c-Myc truncated plasmids and Dr Ken Zaret for providing total RNA from Hhex-deficient E9.5 mouse embryos. We also thank Dr Laia Tolosa for assistance with Olympus ScanR screening station, Juan Jose Lozano for microarray analysis, Cristina Corchero for assistance in qRT-PCR and Ana Flores and M<SUP>a</SUP> Jesus Segui (Cell Culture and Cell Sorting facility at the SCSIE from Universidad de Valencia) for assistance in flow cytometry and cell sorting. VM and FS were recipients of pre-doctoral fellowships from the Ministerio de Ciencia e Innovacion. This work was supported by the Ministerio de Ciencia e Innovacion (grant number SAF2010-15376 and SAF2011-29718).	Baena E, 2005, P NATL ACAD SCI USA, V102, P7286, DOI 10.1073/pnas.0409260102; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; Bazarov AV, 2001, CANCER RES, V61, P1178; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bort R, 2006, DEV BIOL, V290, P44, DOI 10.1016/j.ydbio.2005.11.006; Bort R, 2004, DEVELOPMENT, V131, P797, DOI 10.1242/dev.00965; Brickman JM, 2000, DEVELOPMENT, V127, P2303; Buschbeck M, 2007, ONCOGENE, V26, P3415, DOI 10.1038/sj.onc.1210128; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cai H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053388; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; D'Elia AV, 2002, J CLIN ENDOCR METAB, V87, P1376, DOI 10.1210/jc.87.3.1376; Desjobert C, 2009, BIOCHEM J, V417, P121, DOI 10.1042/BJ20080872; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eekels JJM, 2012, GENE THER, V19, P1058, DOI 10.1038/gt.2011.191; Foley AC, 2005, GENE DEV, V19, P387, DOI 10.1101/gad.1279405; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GERDES J, 1984, J IMMUNOL, V133, P1710; Guiral M, 2001, J BIOL CHEM, V276, P2961, DOI 10.1074/jbc.M004948200; Guo Y, 2003, BLOOD, V102, P2428, DOI 10.1182/blood-2003-02-0634; Hammoudeh DI, 2009, J AM CHEM SOC, V131, P7390, DOI 10.1021/ja900616b; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jimenez RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009084; Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Mannava S, 2008, CELL CYCLE, V7, P2392, DOI 10.4161/cc.6390; Marfil V, 2010, J BIOL CHEM, V285, P5726, DOI 10.1074/jbc.M109.046649; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Minami T, 2004, J BIOL CHEM, V279, P20626, DOI 10.1074/jbc.M308730200; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Morrish F, 2009, ONCOGENE, V28, P2485, DOI 10.1038/onc.2009.112; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Ni M, 2013, GENE DEV, V27, P734, DOI 10.1101/gad.209569.112; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Noy P, 2010, MOL CELL BIOL, V30, P2120, DOI 10.1128/MCB.01511-09; Obinata A, 2002, DEV GROWTH DIFFER, V44, P281; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Paz H, 2010, BLOOD, V116, P1254, DOI 10.1182/blood-2009-11-254383; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; PROUTY SM, 1993, ONCOGENE, V8, P899; Puppin C, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-192; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Seol Dongrim, 2011, BMC Res Notes, V4, P162, DOI 10.1186/1756-0500-4-162; Serrano F, 2013, STEM CELLS, V31, P71, DOI 10.1002/stem.1272; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Sims RJ, 2003, BIOTECHNIQUES, V34, P938, DOI 10.2144/03345bm07; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Swingler TE, 2004, J BIOL CHEM, V279, P34938, DOI 10.1074/jbc.M404488200; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Xu CR, 2011, SCIENCE, V332, P963, DOI 10.1126/science.1202845; Zanet J, 2005, J CELL SCI, V118, P1693, DOI 10.1242/jcs.02298; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	18	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3011	3022		10.1038/onc.2014.240	http://dx.doi.org/10.1038/onc.2014.240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25220416				2022-12-17	WOS:000356100500007
J	Guerrero, PA; Yin, W; Camacho, L; Marchetti, D				Guerrero, P. A.; Yin, W.; Camacho, L.; Marchetti, D.			Oncogenic role of Merlin/NF2 in glioblastoma	ONCOGENE			English	Article							NF2 TUMOR-SUPPRESSOR; CELL-GROWTH; AKT PHOSPHORYLATION; CONTACT INHIBITION; GENE-PRODUCT; PROTEIN; PROLIFERATION; MUTATIONS; BINDING; KINASE	Glioblastoma is the most common and aggressive primary brain tumor in adults, with a poor prognosis because of its resistance to radiotherapy and chemotherapy. Merlin/NF2 (moesin-ezrin-radixin-like protein/neurofibromatosis type 2) is a tumor suppressor found to be mutated in most nervous system tumors; however, it is not mutated in glioblastomas. Merlin associates with several transmembrane receptors and intracellular proteins serving as an anchoring molecule. Additionally, it acts as a key component of cell motility. By selecting sub-populations of U251 glioblastoma cells, we observed that high expression of phosphorylated Merlin at serine 518 (S518-Merlin), NOTCH1 and epidermal growth factor receptor (EGFR) correlated with increased cell proliferation and tumorigenesis. These cells were defective in cell-contact inhibition with changes in Merlin phosphorylation directly affecting NOTCH1 and EGFR expression, as well as downstream targets HES1 (hairy and enhancer of split-1) and CCND1 (cyclin D1). Of note, we identified a function for S518-Merlin, which is distinct from what has been reported when the expression of Merlin is diminished in relation to EGFR and NOTCH1 expression, providing first-time evidence that demonstrates that the phosphorylation of S518-Merlin in glioblastoma promotes oncogenic properties that are not only the result of inactivation of the tumor suppressor role of Merlin but also an independent process implicating a Merlin-driven regulation of NOTCH1 and EGFR.	[Guerrero, P. A.; Yin, W.; Camacho, L.; Marchetti, D.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Marchetti, D.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marchetti, D (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Mail Stop 315,BCM Taub Bldg,Suite T240, Houston, TX 77030 USA.	marchett@bcm.edu	Camacho, Laura/M-2071-2015	Camacho, Laura/0000-0002-5911-1616	Shared Resources CPRIJ grant; NCI Grant [CA016672]; NIH [RO1 CA160335]; NATIONAL CANCER INSTITUTE [R01CA160335, P30CA016672] Funding Source: NIH RePORTER	Shared Resources CPRIJ grant; NCI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs F Giancotti and D Trono for providing vectors and reagents. We thank Jason Ngo, Andres Espinoza and Flavio Palalon for technical assistance. We also thank BCM Integrated Microscopy Core Facility at BCM supported by Shared Resources CPRIJ grant. The Characterized Cell Line Core at MDACC is supported by NCI Grant CA016672. This work was supported by NIH RO1 CA160335 (to DM).	Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Eldridge R, 1981, Adv Neurol, V29, P57; Fassl A, 2012, ONCOGENE, V31, P4698, DOI 10.1038/onc.2011.615; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Gonzales AJ, 2005, EXP CELL RES, V303, P56, DOI 10.1016/j.yexcr.2004.08.040; Gronholm M, 2006, ONCOGENE, V25, P4389, DOI 10.1038/sj.onc.1209475; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Houshmandi SS, 2009, MOL CELL BIOL, V29, P1472, DOI 10.1128/MCB.01392-08; Jacoby LB, 1996, GENE CHROMOSOME CANC, V17, P45, DOI 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2; Kang CS, 2006, CANCER GENE THER, V13, P530, DOI 10.1038/sj.cgt.7700932; Lau YKI, 2008, CANCER RES, V68, P5733, DOI 10.1158/0008-5472.CAN-08-0190; Laulajainen M, 2008, ONCOGENE, V27, P3233, DOI 10.1038/sj.onc.1210988; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Lino MM, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-72; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; Mazzone M, 2010, P NATL ACAD SCI USA, V107, P5012, DOI 10.1073/pnas.1000896107; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Morrow KA, 2011, J BIOL CHEM, V286, P40376, DOI 10.1074/jbc.M111.250035; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Noda N, 2011, GENES CELLS, V16, P704, DOI 10.1111/j.1365-2443.2011.01518.x; Okada M, 2009, CANCER RES, V69, P4043, DOI 10.1158/0008-5472.CAN-08-3931; Okada T, 2007, TRENDS CELL BIOL, V17, P222, DOI 10.1016/j.tcb.2007.03.006; Pecina-Slaus N, 2013, PATHOL ONCOL RES, V19, P365, DOI 10.1007/s12253-013-9644-y; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sherman LS, 2001, TRENDS CELL BIOL, V11, P442, DOI 10.1016/S0962-8924(01)02128-6; Stamenkovic I, 2010, CURR PROTEIN PEPT SC, V11, P471, DOI 10.2174/138920310791824011; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Takebe N, 2014, PHARMACOL THERAPEUT, V141, P140, DOI 10.1016/j.pharmthera.2013.09.005; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Thaxton C, 2007, MOL CELL NEUROSCI, V34, P231, DOI 10.1016/j.mcn.2006.11.003; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Visser-Grieve S, 2012, ONCOGENE, V31, P1189, DOI 10.1038/onc.2011.318; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598	39	18	19	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2621	2630		10.1038/onc.2014.185	http://dx.doi.org/10.1038/onc.2014.185			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043298	Green Accepted			2022-12-17	WOS:000354541300008
J	Weis, B; Schmidt, J; Maamar, H; Raj, A; Lin, H; Toth, C; Riedmann, K; Raddatz, G; Seitz, HK; Ho, AD; Lyko, F; Linhart, HG				Weis, B.; Schmidt, J.; Maamar, H.; Raj, A.; Lin, H.; Toth, C.; Riedmann, K.; Raddatz, G.; Seitz, H-K; Ho, A. D.; Lyko, F.; Linhart, H. G.			Inhibition of intestinal tumor formation by deletion of the DNA methyltransferase 3a	ONCOGENE			English	Article							DE-NOVO METHYLATION; IN-VIVO; DNMT3A; CANCER; MOUSE; GENE; HYPOMETHYLATION; OVEREXPRESSION; EXPRESSION; 3B	Aberrant de novo methylation of DNA is considered an important mediator of tumorigenesis. To investigate the role of de novo DNA methyltransferase 3a (Dnmt3a) in intestinal tumor development, we analyzed the expression of Dnmt3a in murine colon crypts, murine colon adenomas and human colorectal cancer using RNA fluorescence in situ hybridization (FISH), quantitative PCR and immunostaining. Following conditional deletion of Dnmt3a in the colon of APC((Min/+)) mice, we analyzed tumor numbers, genotype of macroadenomas and laser dissected microadenomas, global and regional DNA methylation and gene expression. Our results showed increased Dnmt3a expression in colon adenomas of APC((Min/+)) mice and human colorectal cancer samples when compared with control tissue. Interestingly, in tumor tissue, RNA FISH analysis showed highest Dnmt3a expression in Lgr5-positive stem/progenitor cells. Deletion of Dnmt3a in APC((Min/+)) mice reduced colon tumor numbers by similar to 40%. Remaining adenomas and microadenomas almost exclusively contained the non-recombined Dnmt3a allele; no tumors composed of the inactivated Dnmt3a allele were detected. DNA methylation was reduced at the Oct4, Nanog, Tff2 and Cdkn1c promoters and expression of the tumor-suppressor genes Tff2 and Cdkn1c was increased. In conclusion, our results show that Dnmt3a is predominantly expressed in the stem/progenitor cell compartment of tumors and that deletion of Dnmt3a inhibits the earliest stages of intestinal tumor development.	[Weis, B.; Schmidt, J.; Riedmann, K.; Raddatz, G.; Lyko, F.; Linhart, H. G.] German Canc Res Ctr, Div Epigenet A130, D-69120 Heidelberg, Germany; [Maamar, H.; Raj, A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Lin, H.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA; [Toth, C.] Heidelberg Univ, Dept Pathol, Natl Ctr Tumor Dis NCT, Tissue Bank, Heidelberg, Germany; [Toth, C.] Univ Dusseldorf, Dept Pathol, Dusseldorf, Germany; [Seitz, H-K; Linhart, H. G.] Heidelberg Univ, Dept Med, Salem Med Ctr, Alcohol Res Ctr, Heidelberg, Germany; [Ho, A. D.; Linhart, H. G.] Heidelberg Univ, Dept Hematol Oncol, Med Ctr, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Pennsylvania; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Linhart, HG (corresponding author), German Canc Res Ctr, Div Epigenet A130, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	heinz.linhart@nct-heidelberg.de		Raj, Arjun/0000-0002-2915-6960; Lin, Haijiang/0000-0003-2931-468X	DKFZ Light Microscopy Facility; Helmholtz International Graduate School for Cancer Research; Burroughs-Wellcome Fund Career Award at the Scientific Interface; NIH [1DP2OD008514-01]; Lautenschlager foundation; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD008514] Funding Source: NIH RePORTER	DKFZ Light Microscopy Facility; Helmholtz International Graduate School for Cancer Research; Burroughs-Wellcome Fund Career Award at the Scientific Interface(Burroughs Wellcome Fund); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lautenschlager foundation; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Support by the DKFZ Light Microscopy Facility is gratefully acknowledged. We also thank E Herpel and the tissue bank of the NCT Heidelberg for providing human tissue samples and for technical support in histology and immunohistochemistry. We also thank J Gutekunst for bioinformatical support and R Jaenisch for critical discussions. This study was supported by a graduate scholarship from the Helmholtz International Graduate School for Cancer Research (B Weis), a Burroughs-Wellcome Fund Career Award at the Scientific Interface (A Raj, H Maamar), a NIH Director's New Innovator award (1DP2OD008514-01 to A Raj) and the Lautenschlager foundation (HK Seitz).	Bai XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040024; Figliola R, 2008, J MOL BIOL, V380, P265, DOI 10.1016/j.jmb.2008.05.004; Fujimoto K, 2002, GASTROENTEROLOGY, V123, P1941, DOI 10.1053/gast.2002.37065; Gao Q, 2011, P NATL ACAD SCI USA, V108, P18061, DOI 10.1073/pnas.1114946108; He SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027684; Hlady RA, 2012, J CLIN INVEST, V122, P163, DOI 10.1172/JCI57292; Hon GC, 2013, NAT GENET, V45, P1198, DOI 10.1038/ng.2746; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Jeong M, 2014, NAT GENET, V46, P17, DOI 10.1038/ng.2836; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006; Katoh M, 2003, INT J MOL MED, V12, P3; Kavanagh E, 2011, BBA-REV CANCER, V1816, P50, DOI 10.1016/j.bbcan.2011.03.002; Kinney SM, 2011, J BIOL CHEM, V286, P24685, DOI 10.1074/jbc.M110.217083; Kinney SRM, 2008, MOL CANCER RES, V6, P1365, DOI 10.1158/1541-7786.MCR-08-0040; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Li JY, 2007, MOL CELL BIOL, V27, P8748, DOI 10.1128/MCB.01380-07; Lin HJ, 2006, MOL CELL BIOL, V26, P2976, DOI 10.1128/MCB.26.8.2976-2983.2006; Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007; Luczak MW, 2012, INT J ONCOL, V40, P860, DOI 10.3892/ijo.2011.1183; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Nguyen' S, 2007, DEV DYNAM, V236, P1663, DOI 10.1002/dvdy.21176; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Peterson AJ, 2010, GASTROENTEROLOGY, V139, P2005, DOI 10.1053/j.gastro.2010.08.043; Qu Y, 2010, AM J CLIN PATHOL, V134, P826, DOI 10.1309/AJCPHGQ69FXDFWII; Raddatz G, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003146; Rahman MM, 2010, HUM PATHOL, V41, P1069, DOI 10.1016/j.humpath.2010.01.011; Raj A, 2008, NAT METHODS, V5, P877, DOI 10.1038/NMETH.1253; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Samuel MS, 2009, GASTROENTEROLOGY, V137, P902, DOI 10.1053/j.gastro.2009.05.042; Steine EJ, 2011, J CLIN INVEST, V121, P1748, DOI 10.1172/JCI43169; Tang YA, 2012, CLIN CANCER RES, V18, P4325, DOI 10.1158/1078-0432.CCR-11-2617; Weis B, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-75; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Yamada Y, 2007, CANCER SCI, V98, P6, DOI 10.1111/j.1349-7006.2006.00348.x; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032	38	18	18	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1822	1830		10.1038/onc.2014.114	http://dx.doi.org/10.1038/onc.2014.114			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24837369				2022-12-17	WOS:000352158000009
J	Collins, DC; Cocchiglia, S; Tibbitts, P; Solon, G; Bane, FT; McBryan, J; Treumann, A; Eustace, A; Hennessy, B; Hill, AD; Young, LS				Collins, D. C.; Cocchiglia, S.; Tibbitts, P.; Solon, G.; Bane, F. T.; McBryan, J.; Treumann, A.; Eustace, A.; Hennessy, B.; Hill, A. D.; Young, L. S.			Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer	ONCOGENE			English	Article						human epidermal growth factor receptor; estrogen receptor; Myc; SMRT; trastuzumab; cross talk	ACQUIRED-RESISTANCE; OPEN-LABEL; REPRESSION; LAPATINIB; HER2; SENSITIVITY; MECHANISMS; INHIBITOR; COMPLEX; DRIVEN	Treatment with tyrosine kinase inhibitors (TKIs) including trastuzumab has revolutionized the management of HER2-positive breast cancer. Recent evaluation of clinical trial data suggests that a subset of HER2/ER double-positive cancers may not receive significant benefit from the TKI therapy. Here we investigate the cross talk between HER2 and ER in breast cancer and monitor the effect of trastuzumab on the tyrosine kinase effector transcription factor Myc. In HER2-positive breast cancer patients treated with neoadjuvant trastuzumab, steroid receptor-negative status (ER and PR negative) of pre-treatment biopsies predicted pathological complete response (pCR) (n = 31 patients, P = 0.0486), whereas elevated Myc protein inversely associated with pCR (P = 0.0446). Liquid chromatography mass spectrometry identified the corepressor SMRT as a novel Myc-interacting protein. Trastuzumab treatment enhanced Myc-SMRT interactions in HER2-overexpressing breast cancer cells (LCC1) and inhibited expression of the Myc target gene survivin. In HER2-low, ER-positive steroid-dominant cells (MCF7), trastuzumab therapy repressed Myc-SMRT interactions and upregulated survivin expression. Trastuzumab treatment induced ER-CBP interactions, enhanced ER transcriptional activity and upregulated expression of the ER target gene pS2. The absence of pS2 expression in pre-treatment biopsies predicted pCR to neoadjuvant trastuzumab in breast cancer patients (n = 25, P = 0.0089) and pS2 expression associated with residual cancer burden (P = 0.0196). Furthermore, metastatic tissues from patients who had failed trastuzumab therapy were pS2 positive. In HER2-overexpressing cells, trastuzumab treatment can repress Myc transcriptional activity and clinical response is favorable. However, with co-expression of the steroid pathway, this inhibition is lost and response to treatment is often poor.	[Collins, D. C.; Cocchiglia, S.; Tibbitts, P.; Solon, G.; Bane, F. T.; McBryan, J.; Hill, A. D.; Young, L. S.] Royal Coll Surgeons Ireland, Dept Surg, Dublin 2, Ireland; [Treumann, A.] Royal Coll Surgeons Ireland, Dept Mass Spectrometry Unit, Dublin 2, Ireland; [Eustace, A.; Hennessy, B.] Royal Coll Surgeons Ireland, Dept Med, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland	Young, LS (corresponding author), Royal Coll Surgeons Ireland, Dept Surg, York House,York St, Dublin 2, Ireland.	lyoung@rcsi.ie		Hennessy, Bryan/0000-0002-7871-6477; McBryan, Jean/0000-0002-7568-2208; Eustace, Alex/0000-0002-4092-1360; Treumann, Achim/0000-0002-9417-3505	Science Foundation Ireland [08-IN1-B1853]; Health Research Board of Ireland [HRB/POR/2012/101]; Irish Cancer Society Collaborative Cancer Research Centre grant [CCRC13GAL]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board of Ireland; Irish Cancer Society Collaborative Cancer Research Centre grant	We thank Lance Hudson for his technical expertise and thank Dr Robert Clarke, Georgetown, Washington, for his kind gift of the LCC1 cells. We kindly acknowledge the funding support from Science Foundation Ireland (08-IN1-B1853) and the Health Research Board of Ireland (HRB/POR/2012/101). This material is also based on works supported by the Irish Cancer Society Collaborative Cancer Research Centre grant, CCRC13GAL.	Adams BD, 2009, MOL ENDOCRINOL, V23, P1215, DOI 10.1210/me.2009-0062; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Brennan K, 2013, ONCOGENE, V32, P2799, DOI 10.1038/onc.2012.276; Chakrabarty A, 2013, CANCER RES, V73, P1190, DOI 10.1158/0008-5472.CAN-12-2440; Chen FL, 2008, CLIN CANCER RES, V14, P6730, DOI 10.1158/1078-0432.CCR-08-0581; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Coombes RC, 2013, ANN ONCOL, V24, P924, DOI 10.1093/annonc/mds594; Cosgrave N, 2006, J MOL ENDOCRINOL, V37, P377, DOI 10.1677/jme.1.02118; Guarneri V, 2012, J CLIN ONCOL, V30, P1989, DOI 10.1200/JCO.2011.39.0823; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kim C, 2005, BREAST CANCER RES TR, V94, pS6; Leary AF, 2010, CLIN CANCER RES, V16, P1486, DOI 10.1158/1078-0432.CCR-09-1764; Lobo VJSA, 2013, ONCOGENE, V32, P5261, DOI 10.1038/onc.2012.621; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; McBryan J, 2012, CANCER RES, V72, P548, DOI 10.1158/0008-5472.CAN-11-2073; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nahta R, 2012, BREAST CANCER RES TR, V135, P39, DOI 10.1007/s10549-012-2067-8; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Peck B, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00096; Perez EA, 2011, J CLIN ONCOL, V29, P651, DOI 10.1200/JCO.2010.30.2125; Pinzone JJ, 2004, MOL CELL BIOL, V24, P4605, DOI 10.1128/MCB.24.11.4605-4612.2004; Rexer Brent N., 2012, Critical Reviews in Oncogenesis, V17, P1; Sabnis G, 2009, CANCER RES, V69, P1416, DOI 10.1158/0008-5472.CAN-08-0857; Sankar N, 2008, ONCOGENE, V27, P5717, DOI 10.1038/onc.2008.181; Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371; Xia W, 2006, P NATL ACAD SCI USA, V103, P7795, DOI 10.1073/pnas.0602468103	26	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					525	530		10.1038/onc.2013.586	http://dx.doi.org/10.1038/onc.2013.586			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469058				2022-12-17	WOS:000348451300013
J	Kang, Z; Yu, Y; Zhu, YJ; Davis, S; Walker, R; Meltzer, PS; Helman, LJ; Cao, L				Kang, Z.; Yu, Y.; Zhu, Y. J.; Davis, S.; Walker, R.; Meltzer, P. S.; Helman, L. J.; Cao, L.			Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma	ONCOGENE			English	Article						IGF1R; IGFBP2; rhabdomyosarcoma; antibody therapy; drug resistance; drug combination	GROWTH-FACTOR-I; FACTOR-BINDING PROTEIN-2; FACTOR RECEPTOR INHIBITORS; CHILDRENS ONCOLOGY GROUP; PHASE-II; CANDIDATE BIOMARKER; MONOCLONAL-ANTIBODY; PROSTATE-CANCER; INSULIN; TARGET	Agents targeting the insulin-like growth factor-1 receptor (IGF1R) are in clinical development, but, despite some initial success of single agents in sarcoma, response rates are low with brief durations. Thus, it is important to identify markers predictive of response, to understand mechanisms of resistance, and to explore combination therapies. In this study, we found that, although associated with PAX3-FKHR translocation, increased IGF1R level is an independent prognostic marker for worse overall survival, particularly in patients with PAX3-FKHR-positive rhabdomyosarcoma (RMS). IGF1R antibody-resistant RMS cells were generated using an in vivo model. Expression analysis indicated that IGFBP2 is both the most affected gene in the insulin-like growth factor (IGF) signaling pathway and the most significantly downregulated gene in the resistant lines, indicating that there is a strong selection to repress IGFBP2 expression in tumor cells resistant to IGF1R antibody. IGFBP2 is inhibitory to IGF1R phosphorylation and its signaling. Similar to antibodies to IGF1/2 or IGF2, the addition of exogenous IGFBP2 potentiates the activity of IGF1R antibody against the RMS cells, and it reverses the resistance to IGF1R antibody. In contrast to IGF1R, lower expression of IGFBP2 is associated with poorer overall survival, consistent with its inhibitory activity found in this study. Finally, blocking downstream Protein kinase B (AKT) activation with Phosphatidylinositide 3-kinases (PI3K)- or mammalian target of rapamycin (mTOR)-specific inhibitors significantly sensitized the resistant cells to the IGF1R antibody. These findings show that constitutive IGFBP2 downregulation may represent a novel mechanism for acquired resistance to IGF1R therapeutic antibody in vivo and suggest various drug combinations to enhance antibody activity and to overcome resistance.	[Kang, Z.; Yu, Y.; Zhu, Y. J.; Davis, S.; Walker, R.; Meltzer, P. S.; Cao, L.] NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Kang, Z.] Leidos Biomed Res Inc, Canc Res Technol Program, Frederick, MD USA; [Helman, L. J.] NCI, Ctr Canc Res, Pediatr Oncol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cao, L (corresponding author), NCI, Genet Branch, 37 Convent Dr,MSC 4265, Bethesda, MD 20892 USA.	caoli@mail.nih.gov	Davis, Sean/AAD-1801-2021; Cao, Liang/K-7806-2017	Davis, Sean/0000-0002-8991-6458; Kang, zhigang/0000-0003-3444-4315; Walker, Robert/0000-0001-8235-4686; Cao, Liang/0000-0001-7293-8338	Intramural Research Program of the US National Cancer Institute (NCI); NCI; NIH [N01-CO-12400]; NATIONAL CANCER INSTITUTE [ZICBC011048] Funding Source: NIH RePORTER	Intramural Research Program of the US National Cancer Institute (NCI); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the US National Cancer Institute (NCI). This project was also funded in part with federal funds from the NCI, NIH, under contract N01-CO-12400.	Arai T, 1996, ENDOCRINOLOGY, V137, P4571, DOI 10.1210/en.137.11.4571; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; Bhat RV, 1997, J PHARMACOL EXP THER, V281, P522; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Clemmons DR, 2007, NAT REV DRUG DISCOV, V6, P821, DOI 10.1038/nrd2359; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; Davicioni E, 2010, J CLIN ONCOL, V28, P1240, DOI 10.1200/JCO.2008.21.1268; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Garofalo C, 2011, ONCOGENE, V30, P2730, DOI 10.1038/onc.2010.640; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Hedbacker K, 2010, CELL METAB, V11, P11, DOI 10.1016/j.cmet.2009.11.007; Hendrickson AW, 2009, CURR OPIN INVEST DR, V10, P1032; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; Hoeflich A, 2001, CANCER RES, V61, P8601; Hoflich A, 1998, FEBS LETT, V434, P329, DOI 10.1016/S0014-5793(98)01011-4; Huang F, 2010, CANCER RES, V70, P7221, DOI 10.1158/0008-5472.CAN-10-0391; Kurmasheva RT, 2006, BBA-REV CANCER, V1766, P1, DOI 10.1016/j.bbcan.2006.05.003; Martin JL, 2007, ENDOCRINOLOGY, V148, P2532, DOI 10.1210/en.2006-1335; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; Mayeenuddin LH, 2010, ONCOGENE, V29, P6367, DOI 10.1038/onc.2010.364; Mehrian-Shai R, 2007, P NATL ACAD SCI USA, V104, P5563, DOI 10.1073/pnas.0609139104; Moore LM, 2009, P NATL ACAD SCI USA, V106, P16675, DOI 10.1073/pnas.0900807106; Olmos D, 2010, MOL CANCER THER, V9, P2447, DOI 10.1158/1535-7163.MCT-10-0719; Olmos D, 2010, LANCET ONCOL, V11, P129, DOI 10.1016/S1470-2045(09)70354-7; Pappo AS, 2011, J CLIN ONCOL, V29, P4541, DOI 10.1200/JCO.2010.34.0000; Petricoin EF, 2007, CANCER RES, V67, P3431, DOI 10.1158/0008-5472.CAN-06-1344; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Potratz JC, 2010, CANCER RES, V70, P8770, DOI 10.1158/0008-5472.CAN-10-1093; Ramalingam SS, 2011, J CLIN ONCOL, V29, P4574, DOI 10.1200/JCO.2011.36.6799; Reidy DL, 2010, J CLIN ONCOL, V28, P4240, DOI 10.1200/JCO.2010.30.4154; Shariat SF, 2002, J CLIN ONCOL, V20, P833, DOI 10.1200/JCO.20.3.833; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Tolcher AW, 2009, J CLIN ONCOL, V27, P5800, DOI 10.1200/JCO.2009.23.6745; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963; Yee D, 2012, JNCI-J NATL CANCER I, V104, P975, DOI 10.1093/jnci/djs258; Yuen JSP, 2008, EXPERT OPIN THER TAR, V12, P589, DOI 10.1517/14728222.12.5.589 ; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	43	18	20	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5697	5705		10.1038/onc.2013.509	http://dx.doi.org/10.1038/onc.2013.509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24292683	Green Accepted			2022-12-17	WOS:000346089300005
J	Nadratowska-Wesolowska, B; Haugsten, EM; Zakrzewska, M; Jakimowicz, P; Zhen, Y; Pajdzik, D; Wesche, J; Wiedlocha, A				Nadratowska-Wesolowska, B.; Haugsten, E. M.; Zakrzewska, M.; Jakimowicz, P.; Zhen, Y.; Pajdzik, D.; Wesche, J.; Wiedlocha, A.			RSK2 regulates endocytosis of FGF receptor 1 by phosphorylation on serine 789	ONCOGENE			English	Article						FGF1; FGFR1; signaling; ERK1/2; RSK2; serine phosphorylation; endocytosis	GROWTH-FACTOR RECEPTOR; RIBOSOMAL S6 KINASE; EPITHELIAL-CELLS; CANCER; PROTEIN; SITE; UBIQUITINATION; ACTIVATION; INHIBITOR; MUTATIONS	FGFR1 (fibroblast growth factor receptor 1) regulates many key cellular responses including proliferation, migration and differentiation through activation of signaling pathways. Irregularities in FGFR1 signaling have been implicated in several pathological conditions, including human cancer. In order to discover novel regulators of FGFR1 signaling, we performed yeast two-hybrid screens and identified RSK2 (p90 ribosomal S6 kinase 2) as a potential FGFR1 interaction partner. RSK2 belongs to the family of serine/threonine kinases that are activated through the Ras-MAPK signal transduction pathway. Both in vitro and in vivo experiments confirmed the interaction and we show that phosphorylated RSK2 binds to and phosphorylates serine 789 in the C-terminal tail of FGFR1. Inhibition of RSK2 activity led to prolonged tyrosine transphosphorylation of FGFR1. Furthermore, prevention of FGFR1 phosphorylation by inhibition of RSK2 activity or mutation of serine 789 to alanine reduced FGFR1 endocytosis and ubiquitination explaining mechanistically the prolonged signaling activity. We propose a novel regulatory mechanism whereby activated RSK2 directly interacts with and phosphorylates FGFR1, thereby modulating receptor signaling through regulation of endocytosis.	[Nadratowska-Wesolowska, B.; Haugsten, E. M.; Zhen, Y.; Wesche, J.; Wiedlocha, A.] Univ Oslo, Fac Med, Ctr Canc Biomed, Oslo, Norway; [Nadratowska-Wesolowska, B.; Haugsten, E. M.; Zhen, Y.; Wesche, J.; Wiedlocha, A.] Oslo Univ Hosp, Inst Canc Res, Dept Biochem, N-0379 Oslo, Norway; [Zakrzewska, M.] Univ Wroclaw, Fac Biotechnol, Dept Prot Engn, PL-50138 Wroclaw, Poland; [Jakimowicz, P.; Pajdzik, D.] Univ Wroclaw, Fac Biotechnol, Dept Prot Biotechnol, PL-50138 Wroclaw, Poland	University of Oslo; University of Oslo; University of Wroclaw; University of Wroclaw	Wiedlocha, A (corresponding author), Oslo Univ Hosp, Inst Canc Res, Dept Biochem, N-0379 Oslo, Norway.	Antoni.Wiedlocha@rr-research.no	Wesche, Jorgen/ABH-7524-2020; Nadratowska-Wesolowska, Beata/B-7613-2015	Wesche, Jorgen/0000-0002-9200-9162; Zakrzewska, Malgorzata/0000-0001-8214-1533; Haugsten, Ellen Margrethe/0000-0002-3111-5092	Norway through the Norwegian Financial Mechanism within the Polish-Norwegian Research Fund [PNRF-87-AI-1/07]; Polish Ministry of Science and Higher Education [0627/IP1/2011/71]; South-Eastern Norway Regional Health Authority	Norway through the Norwegian Financial Mechanism within the Polish-Norwegian Research Fund; Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); South-Eastern Norway Regional Health Authority	This work was supported by grant PNRF-87-AI-1/07 from Norway through the Norwegian Financial Mechanism within the Polish-Norwegian Research Fund and by the Polish Ministry of Science and Higher Education (grant 0627/IP1/2011/71). The skilful technical assistance of Anne Gro Bergersen and Anne-Mari G. Pedersen is gratefully acknowledged. JW holds a senior scientist grant from South-Eastern Norway Regional Health Authority.	Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Goh LK, 2010, J CELL BIOL, V189, P871, DOI 10.1083/jcb.201001008; Haglund K, 2012, J CELL SCI, V125, P265, DOI 10.1242/jcs.091280; Haugsten EM, 2008, MOL BIOL CELL, V19, P3390, DOI 10.1091/mbc.E07-12-1219; Haugsten EM, 2010, MOL CANCER RES, V8, P1439, DOI 10.1158/1541-7786.MCR-10-0168; Haugsten EM, 2005, J CELL SCI, V118, P3869, DOI 10.1242/jcs.02509; Jang MH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3239; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kang SM, 2007, CANCER CELL, V12, P201, DOI 10.1016/j.ccr.2007.08.003; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Oksvold MP, 2003, ONCOGENE, V22, P8509, DOI 10.1038/sj.onc.1207117; Pan ZZ, 2004, MOL BIOL CELL, V15, P3106, DOI 10.1091/mbc.E04-01-0043; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Persaud A, 2011, EMBO J, V30, P3259, DOI 10.1038/emboj.2011.234; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; Sapkota GP, 2007, BIOCHEM J, V401, P29, DOI 10.1042/BJ20061088; Smith JA, 2005, CANCER RES, V65, P1027; Sorensen V, 2008, MOL CELL BIOL, V28, P4129, DOI 10.1128/MCB.02117-07; Sun QX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012819; THEROUX SJ, 1992, MOL ENDOCRINOL, V6, P1849, DOI 10.1210/me.6.11.1849; Tsang M., 2004, SCI STKE, V2004, pE17; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wesche J, 2011, BIOCHEM J, V437, P199, DOI 10.1042/BJ20101603; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Xian W, 2009, CANCER RES, V69, P2244, DOI 10.1158/0008-5472.CAN-08-3398; Zakrzewska M, 2004, PROTEIN ENG DES SEL, V17, P603, DOI 10.1093/protein/gzh076; Zakrzewska M, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003087	36	18	18	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4823	4836		10.1038/onc.2013.425	http://dx.doi.org/10.1038/onc.2013.425			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24141780				2022-12-17	WOS:000343240100004
J	Witkiewicz, AK; Cox, DW; Rivadeneira, D; Ertel, AE; Fortina, P; Schwartz, GF; Knudsen, ES				Witkiewicz, A. K.; Cox, D. W.; Rivadeneira, D.; Ertel, A. E.; Fortina, P.; Schwartz, G. F.; Knudsen, E. S.			The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer	ONCOGENE			English	Article						tumor suppressor; epithelial-to-mesenchymal transition; cyclin-dependent kinase; cell cycle; E2F; CDK4/6; PD-0332991	CARCINOMA IN-SITU; GENE AMPLIFICATION; BASAL-LIKE; LUMINAL-B; HER-2 NEU; EXPRESSION; RB; MORPHOGENESIS; PROGRESSION; INHIBITION	The processes that control the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer remain poorly understood. Epidermal growth factor receptor 2 (ErbB2) overexpression is common in DCIS, as is disruption of the retinoblastoma tumor suppressor (RB) pathway. Here, we examined the cooperative impact of ErbB2 and RB deregulation on facets of disease progression. Our studies demonstrate that RB deficiency altered the expression of key molecules needed for proper cellular organization and epithelial cell-cell adhesion as part of a program related to the epithelial-to-mesenchymal transition (EMT). An increase in the invasive potential of ErbB2-overexpressing cells was observed upon RB depletion. Further, stable knockdown of RB resulted in invasive lesions in orthotopic xenograft assays, compared with DCIS-like lesions developing from RB-proficient cells. Conversely, the invasive phenotype observed in ErbB2-positive cancer models was inhibited through CDK4/6 inhibition in an RB-dependent manner. Finally, in a cohort of DCIS cases, we show that, although elevated levels of ErbB2 are associated with increased risk of a subsequent DCIS recurrence, it is not associated with progression to invasive disease. In contrast, RB loss in ErbB2-positive DCIS cases was associated with increased risk for invasive breast cancer. Taken together, these data demonstrate a key role for the RB pathway in invasion associated with breast tumor progression, and shed light on the key molecular events that promote the progression of DCIS to invasive disease.	[Witkiewicz, A. K.; Cox, D. W.; Knudsen, E. S.] UT Southwest Med Ctr, Dept Pathol, Dallas, TX 75390 USA; [Witkiewicz, A. K.; Knudsen, E. S.] UT Southwest Med Ctr, Simmons Canc Ctr, Dallas, TX USA; [Rivadeneira, D.; Ertel, A. E.; Fortina, P.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA USA; [Schwartz, G. F.] Thomas Jefferson Univ, Dept Surg, Philadelphia, PA USA	Jefferson University; Jefferson University	Witkiewicz, AK (corresponding author), UT Southwest Med Ctr, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	agnes.witkiewicz@utsouthwestern.edu	Fortina, Paolo/ABE-8350-2020	Fortina, Paolo/0000-0002-5898-2081	NIH [RO1-CA129134, RO1-CA137494, RO1-CA163863]; NATIONAL CANCER INSTITUTE [R01CA129134, R01CA137494, R01CA163863, P30CA142543] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all of our colleagues who contributed to this study. This work was supported by NIH grants to ESK (RO1-CA129134 and RO1-CA137494) and AKW (RO1-CA163863).	Allegra CJ, 2010, J NATL CANCER I, V102, P161, DOI 10.1093/jnci/djp485; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; BETSILL WL, 1978, JAMA-J AM MED ASSOC, V239, P1863, DOI 10.1001/jama.239.18.1863; Carlson RW, 2009, J NATL COMPR CANC NE, V7, P122, DOI 10.6004/jnccn.2009.0012; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Correa C, 2010, J NATL CANC I MONOGR, V2010, P162, DOI [DOI 10.1093/JNCIMONOGRAPHS/LGQ039, DOI 10.1093/JNCIM0N0GRAPHS/LGQ039]; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Erbas B, 2006, BREAST CANCER RES TR, V97, P135, DOI 10.1007/s10549-005-9101-z; Ernster VL, 2002, J NATL CANCER I, V94, P1546; Franke WW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003061; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gauthier ML, 2007, CANCER CELL, V12, P479, DOI 10.1016/j.ccr.2007.10.017; Hackstadt AJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-11; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; Hoque A, 2002, CANCER EPIDEM BIOMAR, V11, P587; Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490; Jones JL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1397; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kerlikowske K, 2003, JNCI-J NATL CANCER I, V95, P1692, DOI 10.1093/jnci/djg097; Kerlikowske K, 2010, JNCI-J NATL CANCER I, V102, P627, DOI 10.1093/jnci/djq101; Kim YS, 2008, J KOREAN MED SCI, V23, P414, DOI 10.3346/jkms.2008.23.3.414; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen ES, 2012, JNCI-J NATL CANCER I, V104, P1825, DOI 10.1093/jnci/djs446; Knudsen ES, 2012, BREAST CANCER RES TR, V133, P1009, DOI 10.1007/s10549-011-1894-3; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Lee S, 2012, CANCER RES, V72, P4574, DOI 10.1158/0008-5472.CAN-12-0636; Leonard GD, 2004, JNCI-J NATL CANCER I, V96, P906, DOI 10.1093/jnci/djh164; McClendon AK, 2011, GASTROENTEROLOGY, V141, P1439, DOI 10.1053/j.gastro.2011.06.046; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Rakovitch E, 2012, BRIT J CANCER, V106, P1160, DOI 10.1038/bjc.2012.41; Rivadeneira DB, 2010, GASTROENTEROLOGY, V138, P1920, DOI 10.1053/j.gastro.2010.01.007; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Romero L, 2004, AM J SURG, V188, P371, DOI 10.1016/j.amjsurg.2004.06.034; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Schnitt Stuart J., 2010, Journal of the National Cancer Institute Monographs, P158, DOI 10.1093/jncimonographs/lgq031; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sotgia F, 2006, AM J PATHOL, V168, P292, DOI 10.2353/ajpath.2006.050429; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sutherland RL, 2004, J MAMMARY GLAND BIOL, V9, P95, DOI 10.1023/B:JOMG.0000023591.45568.77; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thangavel C, 2011, ENDOCR-RELAT CANCER, V18, P333, DOI 10.1530/ERC-10-0262; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Virnig BA, 2010, J NATL CANCER I, V102, P170, DOI 10.1093/jnci/djp482; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Witkiewicz AK, 2011, AM J PATHOL, V179, P1171, DOI 10.1016/j.ajpath.2011.05.043; Wu M, 2009, P NATL ACAD SCI USA, V106, P7022, DOI 10.1073/pnas.0811785106; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhurinsky J, 2000, J CELL SCI, V113, P3127	55	18	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3980	3991		10.1038/onc.2013.367	http://dx.doi.org/10.1038/onc.2013.367			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24121271	Green Accepted			2022-12-17	WOS:000339394700010
J	Wang, W; Zhong, Q; Teng, L; Bhatnagar, N; Sharma, B; Zhang, X; Luther, W; Haynes, LP; Burgoyne, RD; Vidal, M; Volchenboum, S; Hill, DE; George, RE				Wang, W.; Zhong, Q.; Teng, L.; Bhatnagar, N.; Sharma, B.; Zhang, X.; Luther, W., II; Haynes, L. P.; Burgoyne, R. D.; Vidal, M.; Volchenboum, S.; Hill, D. E.; George, R. E.			Mutations that disrupt PHOXB interaction with the neuronal calcium sensor HPCAL1 impede cellular differentiation in neuroblastoma	ONCOGENE			English	Article						PHOX2B; HPCAL1; neuroblastoma; neuronal calcium sensor; differentiation; network perturbation	CENTRAL-HYPOVENTILATION-SYNDROME; BETA-HYDROXYLASE GENE; NEUROTRANSMITTER BIOSYNTHETIC GENES; ONSET CENTRAL-HYPOVENTILATION; VISININ-LIKE PROTEINS; HOMEOBOX GENE; POLYALANINE EXPANSIONS; FRAMESHIFT MUTATIONS; EDGETIC PERTURBATION; HOMEODOMAIN PROTEINS	Heterozygous germline mutations in PHOX2B, a transcriptional regulator of sympathetic neuronal differentiation, predispose to diseases of the sympathetic nervous system, including neuroblastoma and congenital central hypoventilation syndrome (CCHS). Although the PHOX2B variants in CCHS largely involve expansions of the second polyalanine repeat within the C-terminus of the protein, those associated with neuroblastic tumors are nearly always frameshift and truncation mutations. To test the hypothesis that the neuroblastoma-associated variants exert their effects through loss or gain of protein-protein interactions, we performed a large-scale yeast two-hybrid screen using both wild-type (WT) and six different mutant PHOX2B proteins against over 10 000 human genes. The neuronal calcium sensor protein HPCAL1 (VILIP-3) exhibited strong binding to WT PHOX2B and a CCHS-associated polyalanine expansion mutant but only weakly or not at all to neuroblastoma-associated frameshift and truncation variants. We demonstrate that both WT PHOX2B and the neuroblastoma-associated R100L missense and the CCHS-associated alanine expansion variants induce nuclear translocation of HPCAL1 in a Ca2+-independent manner, while the neuroblastoma-associated 676delG frameshift and K155X truncation mutants impair subcellular localization of HPCAL1, causing it to remain in the cytoplasm. HPCAL1 did not appreciably influence the ability of WT PHOX2B to transactivate the DBH promoter, nor did it alter the decreased transactivation potential of PHOX2B variants in 293T cells. Abrogation of the PHOX2B-HPCAL1 interaction by shRNA knockdown of HPCAL1 in neuroblastoma cells expressing PHOX2B led to impaired neurite outgrowth with transcriptional profiles indicative of inhibited sympathetic neuronal differentiation. Our results suggest that certain PHOX2B variants associated with neuroblastoma pathogenesis, because of their inability to bind to key interacting proteins such as HPCAL1, may predispose to this malignancy by impeding the differentiation of immature sympathetic neurons.	[Wang, W.; Bhatnagar, N.; Sharma, B.; Luther, W., II; George, R. E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Zhong, Q.; Vidal, M.; Hill, D. E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA; [Zhong, Q.; Vidal, M.; Hill, D. E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Teng, L.; Volchenboum, S.] Univ Chicago, Chicago Ctr Childhood Canc & Blood Dis, Chicago, IL 60637 USA; [Zhang, X.] Chinese Acad Sci, High Field Magnet Lab, Hefei, Peoples R China; [Haynes, L. P.; Burgoyne, R. D.] Univ Liverpool, Inst Translat Med, Dept Cellular & Mol Physiol, Liverpool L69 3BX, Merseyside, England	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago; Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; University of Liverpool	George, RE (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Dana 640E,450 Brookline Ave, Boston, MA 02115 USA.	rani_george@dfci.harvard.edu	Zhang, Xin/AAB-9359-2020; Burgoyne, Robert D/P-6641-2019; zhong, quan/AAE-8893-2021; George, Rani/AAG-7635-2019	Zhang, Xin/0000-0002-3499-2189; Burgoyne, Robert D/0000-0002-9219-0387; Zhong, Quan/0000-0003-2910-5597	Alex's Lemonade Stand Foundation; Abraham Research Fund; National Cancer Institute [R33CA132073]; National Human Genome Research [R01HG001715, P50HG004233]; Ellison Foundation; NATIONAL CANCER INSTITUTE [R33CA132073] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001715, P50HG004233] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation; Abraham Research Fund; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Human Genome Research; Ellison Foundation(Lawrence Ellison Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Dr Christo Goridis for the generous gift of the PHOX2B antibody. We thank Stacey Frumm and Dr Kimberly Stegmaier for data regarding the neuroblastoma cell differentiation signature before publication. This study was supported by Alex's Lemonade Stand Foundation (to REG), Abraham Research Fund (to WW), National Cancer Institute Grant R33CA132073 (to MV), National Human Genome Research Grants R01HG001715 and P50HG004233 (to MV and DEH) and The Ellison Foundation (to MV).	Adachi M, 2000, DNA CELL BIOL, V19, P539, DOI 10.1089/104454900439773; Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Bachetti T, 2005, HUM MOL GENET, V14, P1815, DOI 10.1093/hmg/ddi188; Braunewell KH, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.20; Braunewell KH, 2009, CELL TISSUE RES, V335, P301, DOI 10.1007/s00441-008-0716-3; Burgoyne RD, 2007, NAT REV NEUROSCI, V8, P182, DOI 10.1038/nrn2093; Dreze M, 2010, METHOD ENZYMOL, V470, P281, DOI 10.1016/S0076-6879(10)70012-4; Dreze M, 2009, NAT METHODS, V6, P843, DOI [10.1038/NMETH.1394, 10.1038/nmeth.1394]; Dubreuil V, 2000, DEVELOPMENT, V127, P5191; Frumm SM, 2013, CHEM BIOL, V20, P713, DOI 10.1016/j.chembiol.2013.03.020; Hansford LM, 2003, CYTOGENET GENOME RES, V101, P17, DOI 10.1159/000073412; Haynes LP, 2008, NAT CHEM BIOL, V4, P90, DOI 10.1038/nchembio0208-90; Hong SJ, 2008, BIOCHEM BIOPH RES CO, V368, P650, DOI 10.1016/j.bbrc.2008.01.165; Ikura M, 2000, NAT STRUCT BIOL, V7, P525, DOI 10.1038/76721; Ikura M, 2002, BIOESSAYS, V24, P625, DOI 10.1002/bies.10105; Jheng FF, 2006, PROTEIN J, V25, P250, DOI 10.1007/s10930-006-9008-5; Lamesch P, 2007, GENOMICS, V89, P307, DOI 10.1016/j.ygeno.2006.11.012; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; Lim J, 2008, NATURE, V452, P713, DOI 10.1038/nature06731; Lo LC, 1999, NEURON, V22, P693, DOI 10.1016/S0896-6273(00)80729-1; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Matera I, 2004, J MED GENET, V41, P373, DOI 10.1136/jmg.2003.015412; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Nagashimada M, 2012, J CLIN INVEST, V122, P3145, DOI 10.1172/JCI63401; O'Callaghan DW, 2003, J CELL BIOL, V163, P715, DOI 10.1083/jcb.200306042; Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014; Paterlini M, 2000, NEUROSCIENCE, V99, P205, DOI 10.1016/S0306-4522(00)00201-3; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Pei DS, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003533; Raabe EH, 2008, ONCOGENE, V27, P469, DOI 10.1038/sj.onc.1210659; Reiff T, 2010, J NEUROSCI, V30, P905, DOI 10.1523/JNEUROSCI.5368-09.2010; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Spilker C, 2002, BBA-PROTEINS PROTEOM, V1600, P118, DOI 10.1016/S1570-9639(02)00452-1; Swanson DJ, 1997, J BIOL CHEM, V272, P27382, DOI 10.1074/jbc.272.43.27382; Taraviras S, 2002, EUR J CELL BIOL, V81, P363, DOI 10.1078/0171-9335-00250; Trang H, 2004, PEDIATR PULM, V38, P349, DOI 10.1002/ppul.20074; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; van Limpt V, 2005, CANCER LETT, V228, P59, DOI 10.1016/j.canlet.2005.02.050; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527; Wu HT, 2009, HUM MUTAT, V30, P655, DOI 10.1002/humu.20929; Yang CY, 1998, J NEUROCHEM, V71, P1813; Zellmer E, 1995, J NEUROSCI, V15, P8109; Zhong Q, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.80	45	18	18	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3316	3324		10.1038/onc.2013.290	http://dx.doi.org/10.1038/onc.2013.290			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23873030	Green Accepted			2022-12-17	WOS:000338443400011
J	Zhu, Y; Yao, Z; Wu, Z; Mei, Y; Wu, M				Zhu, Y.; Yao, Z.; Wu, Z.; Mei, Y.; Wu, M.			Role of tumor necrosis factor alpha-induced protein 1 in paclitaxel resistance	ONCOGENE			English	Article						TNFAIP1; tubulin; paclitaxel resistance	HELA-CELLS; POLYMERIZED TUBULIN; NATURAL-PRODUCTS; MITOTIC ARREST; BETA-TUBULIN; TAXOL; CANCER; MICROTUBULES; EXPRESSION; DEATH	Paclitaxel has been extensively used as an antitumor drug to treat a broad range of epithelial cancers, including breast and cervical cancers. However, the efficacy of this drug is greatly limited by the development of acquired resistance. Identification of the underlying resistance mechanisms may inform the development of new therapies that elicit long-term response of tumors to paclitaxel treatment. Here we report that increased expression of TNFAIP1 (tumor necrosis factor alpha-induced protein 1) confers acquired resistance to paclitaxel. TNFAIP1 is shown to compete with paclitaxel for binding to beta-tubulin, thereby preventing paclitaxel-induced tubulin polymerization, cell cycle arrest and ultimate cell death. We also show that expression of TNFAIP1 is regulated by the transcriptional factor Sp1. In a xenograft mouse model, increased expression of TNFAIP1 decreases, whereas knockdown of TNFAIP1 increases tumor response to paclitaxel. Therefore, these results reveal tnfaip1 as a novel paclitaxel-resistance associated gene and suggest that TNFAIP1 may represent a valuable therapeutic target for the treatment of cancer.	[Zhu, Y.; Yao, Z.; Mei, Y.; Wu, M.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; [Zhu, Y.; Yao, Z.; Mei, Y.; Wu, M.] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; [Wu, Z.] Anhui Med Univ, Dept Pathol, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University	Mei, Y (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, 96 Huangshan Rd, Hefei 230027, Anhui, Peoples R China.	meiyide@ustc.edu.cn; wumian@ustc.edu.cn	Mei, Yide/M-4468-2013; Wu, Mian/H-2494-2018; Yao, Zhan/AAK-6756-2020	Wu, Mian/0000-0002-2714-0500; YAO, ZHAN/0000-0001-5391-5691	National Natural Science Foundation of China [31030046, 31171316]; Ministry of Science and Technology of China [2010CB912804, 2011CB966302]; Chinese Academy of Sciences [XDA01020104]; Fundamental Research Funds for Central Universities [WK2060190018]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences); Fundamental Research Funds for Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by grants from National Natural Science Foundation of China 31030046 (to MW) and 31171316 (to YM); the Ministry of Science and Technology of China (2010CB912804 and 2011CB966302); Chinese Academy of Sciences (XDA01020104) and the Fundamental Research Funds for Central Universities (WK2060190018).	Bai ZG, 2010, MOL MED REP, V3, P1071, DOI 10.3892/mmr.2010.371; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; Burkhart C.A., 2001, BIOCHIM BIOPHYS ACTA, V1471, P1; CAMBRAYDEAKIN MA, 1987, J CELL BIOL, V104, P1569, DOI 10.1083/jcb.104.6.1569; CERNY T, 1994, BRIT J CANCER, V70, P384, DOI 10.1038/bjc.1994.311; Cheung CHA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012564; DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; Dong Y, 2010, CANCER RES, V70, P2624, DOI 10.1158/0008-5472.CAN-09-3415; Duan ZF, 2006, CANCER CHEMOTH PHARM, V57, P25, DOI 10.1007/s00280-005-0026-3; Einzig A I, 1991, Cancer Treat Res, V58, P89; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; HENNEQUIN C, 1995, BRIT J CANCER, V71, P1194, DOI 10.1038/bjc.1995.232; Horwitz Susan Band, 1993, Journal of the National Cancer Institute Monographs, V0, P55; Ilson DH, 2007, ANN ONCOL, V18, P898, DOI 10.1093/annonc/mdm004; Jordan MA, 1996, CANCER RES, V56, P816; Kamath K, 2005, J BIOL CHEM, V280, P12902, DOI 10.1074/jbc.M414477200; Kim DM, 2009, INT J CANCER, V125, P2520, DOI 10.1002/ijc.24617; Lih CJ, 2006, GENE DEV, V20, P2082, DOI 10.1101/gad.1441306; Lin MC, 2005, WORLD J GASTROENTERO, V11, P7564, DOI 10.3748/wjg.v11.i48.7564; Link CD, 2003, NEUROBIOL AGING, V24, P397, DOI 10.1016/S0197-4580(02)00224-5; Liu MJ, 2010, MOL BIOL REP, V37, P1699, DOI 10.1007/s11033-009-9588-1; Milross CG, 1996, JNCI-J NATL CANCER I, V88, P1308, DOI 10.1093/jnci/88.18.1308; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Ojima I, 1999, P NATL ACAD SCI USA, V96, P4256, DOI 10.1073/pnas.96.8.4256; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; Rowinsky EK, 1997, ANNU REV MED, V48, P353; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SEIDMAN AD, 1995, CLIN CANCER RES, V1, P247; Seve P, 2010, LUNG CANCER, V67, P136, DOI 10.1016/j.lungcan.2009.09.007; SLICHENMYER WJ, 1990, J CLIN PHARMACOL, V30, P770, DOI 10.1002/j.1552-4604.1990.tb01873.x; Stordal B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040717; Suzuki M, 2003, JPN J CLIN ONCOL, V33, P297, DOI 10.1093/jjco/hyg054; Torres K, 1998, CANCER RES, V58, P3620; Wang JX, 2012, STEM CELLS, V30, P1405, DOI 10.1002/stem.1121; Wang YQ, 2006, BIOCHEMISTRY-US, V45, P185, DOI 10.1021/bi051207d; Wang YQ, 2005, BBA-MOL CELL RES, V1744, P245, DOI 10.1016/j.bbamcr.2004.12.003; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WOLF FW, 1992, J BIOL CHEM, V267, P1317; Yao Z, 2007, EMBO J, V26, P1068, DOI 10.1038/sj.emboj.7601571; Yin SH, 2010, MOL CANCER THER, V9, P327, DOI 10.1158/1535-7163.MCT-09-0674; Zhou JL, 2005, J EXP ZOOL PART A, V303A, P227, DOI 10.1002/jez.a.150	42	18	20	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3246	3255		10.1038/onc.2013.299	http://dx.doi.org/10.1038/onc.2013.299			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23912453				2022-12-17	WOS:000338443400004
J	Guo, Y; Chirieac, LR; Bueno, R; Pass, H; Wu, W; Malinowska, IA; Kwiatkowski, DJ				Guo, Y.; Chirieac, L. R.; Bueno, R.; Pass, H.; Wu, W.; Malinowska, I. A.; Kwiatkowski, D. J.			Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma	ONCOGENE			English	Article						TSC1; TSC2; mesothelioma; rapamycin; mTOR	MALIGNANT PLEURAL MESOTHELIOMA; TUBEROUS SCLEROSIS; GENE NF2; CELLS; SURVIVAL; PATHWAY; MTORC1; ACTIVATION; GROWTH; MODEL	Mesothelioma is diagnosed in similar to 2500 patients in the United States every year, most often arising in the pleural space, but also occurring as primary peritoneal mesothelioma. The vast majority of patients with mesothelioma die of their disease within 3 years. We developed a new mouse model of mesothelioma by bladder or intraperitoneal injection of adenovirus Cre into mice with conditional alleles of each of Tp53 and Tsc1. Such mice began to develop malignant ascites about 6 months after injection, which was due to peritoneal mesothelioma, on the basis of tumor morphology and immunohistochemical staining. Mesothelioma cell lines were established, which showed loss of both Tsc1 and Tp53, with mammalian target of rapamycin complex (mTORC)1 activation. Treatment of mice with malignant ascites due to mesothelioma with rapamycin led to a marked reduction in ascites, extended survival and a 95-99% reduction in the mesothelioma tumor volume, in comparison with vehicle-treated mice. To see whether TSC1/TSC2 loss was a common genetic event in human mesothelioma, we examined nine human mesothelioma cell lines, and found that four of nine showed persistent activation of mTORC1, although none had loss of TSC1 or TSC2. A tissue microarray analysis of 198 human mesothelioma specimens showed that 33% of cases had reduced TSC2 expression and 60% showed activation of mTOR, indicating that mTOR activation is common in human mesothelioma, suggesting that it is a potential therapeutic target.	[Guo, Y.; Wu, W.; Malinowska, I. A.; Kwiatkowski, D. J.] Brigham & Womens Hosp, Dept Med, Div Translat Med, Boston, MA 02115 USA; [Guo, Y.; Wu, W.; Malinowska, I. A.; Kwiatkowski, D. J.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Chirieac, L. R.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Bueno, R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA; [Pass, H.] NYU, Dept Cardiothorac Surg, Langone Med Ctr, New York, NY USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; New York University; NYU Langone Medical Center	Kwiatkowski, DJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Translat Med, Boston, MA 02115 USA.	dk@rics.bwh.harvard.edu	Malinowska, Izabela/A-4816-2013; Chirieac, Lucian R./AAD-2030-2019	Pass, Harvey/0000-0003-3222-3471	National Institutes of Health [1P01CA120964, 2P50CA090578]; Chip Thayer Fund; NATIONAL CANCER INSTITUTE [P50CA090578, P01CA120964] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chip Thayer Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Nathanael Gray (Dana Farber Cancer Institute, Boston, MA, USA) for kindly providing mTOR inhibitor Torin1 used in this study. This work was supported by Grants 1P01CA120964 and 2P50CA090578 from the National Institutes of Health, and the Chip Thayer Fund.	Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Auricchio N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031900; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Brevet M, 2011, J THORAC ONCOL, V6, P864, DOI 10.1097/JTO.0b013e318215a07d; Burt BM, 2011, CANCER-AM CANCER SOC, V117, P5234, DOI 10.1002/cncr.26143; Dickson MA, 2013, INT J CANCER, V132, P1711, DOI 10.1002/ijc.27800; Ettinger DS, 2012, J NATL COMPR CANC NE, V10, P26, DOI 10.6004/jnccn.2012.0006; Goto J, 2011, P NATL ACAD SCI USA, V108, pE1070, DOI 10.1073/pnas.1106454108; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hoda MA, 2011, J THORAC ONCOL, V6, P852, DOI 10.1097/JTO.0b013e31820e1a25; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Jagadeeswaran R, 2006, CANCER RES, V66, P352, DOI 10.1158/0008-5472.CAN-04-4567; James MF, 2009, MOL CELL BIOL, V29, P4250, DOI 10.1128/MCB.01581-08; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Liang MC, 2010, ONCOGENE, V29, P1588, DOI 10.1038/onc.2009.452; Lopez-Lago MA, 2009, MOL CELL BIOL, V29, P4235, DOI 10.1128/MCB.01578-08; Marino S, 2000, GENE DEV, V14, P994; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; Menges CW, 2012, MOL CANCER RES, V10, P1178, DOI 10.1158/1541-7786.MCR-12-0082; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Opitz I, 2008, EUR J CARDIO-THORAC, V33, P501, DOI 10.1016/j.ejcts.2007.09.045; Penno M B, 1995, Cancer J Sci Am, V1, P196; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Qin W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024919; REDDEL RR, 1989, J NATL CANCER I, V81, P945, DOI 10.1093/jnci/81.12.945; Seager C., 2010, CURR PROTOC PHARM; SEKIDO Y, 1995, CANCER RES, V55, P1227; Suzuki Y, 2009, MOL MED REP, V2, P181, DOI 10.3892/mmr_00000081; Thiele E, 2010, TUBEROUS SCLEROSIS C, P3; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Tsao AS, 2009, J CLIN ONCOL, V27, P2081, DOI 10.1200/JCO.2008.19.8523; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wagner AJ, 2010, J CLIN ONCOL, V28, P835, DOI 10.1200/JCO.2009.25.2981; Wilson SM, 2008, AM J RESP CELL MOL, V39, P576, DOI 10.1165/rcmb.2007-0460OC	35	18	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3151	3160		10.1038/onc.2013.280	http://dx.doi.org/10.1038/onc.2013.280			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851502	Green Accepted, Green Submitted			2022-12-17	WOS:000338410000008
J	Yang, XW; Wang, P; Liu, JQ; Zhang, H; Xi, WD; Jia, XH; Wang, KK				Yang, X-W; Wang, P.; Liu, J-Q; Zhang, H.; Xi, W-D; Jia, X-H; Wang, K-K			Coordinated regulation of the immunoproteasome subunits by PML/RAR alpha and PU.1 in acute promyelocytic leukemia	ONCOGENE			English	Article						immunoproteasome subunits; PML/RAR alpha; PU.1; APL; ATRA	TRANS-RETINOIC ACID; ACUTE MYELOID-LEUKEMIA; I PRESENTATION PATHWAY; LONG-TERM EFFICACY; RAR-ALPHA; GRANULOCYTIC DIFFERENTIATION; CELL-DEVELOPMENT; FUSION PROTEIN; HLA-DR; PML	Recognition and elimination of malignant cells by cytotoxic T lymphocytes depends on antigenic peptides generated by proteasomes. It has been established that impairment of the immunoproteasome subunits, that is, PSMB8, PSMB9 and PSMB10 (PSMBs), is critical for malignant cells to escape immune recognition. We report here the regulatory mechanism of the repression of PU.1-dependent activation of PSMBs by PML/RAR alpha in the pathogenesis of acute promyelocytic leukemia (APL) and the unidentified function of all-trans retinoic acid (ATRA) as an immunomodulator in the treatment of APL. Chromatin immunoprecipitation and luciferase reporter assays showed that PU.1 directly bound to and coordinately transactivated the promoters of PSMBs, indicating that PSMBs were transcriptional targets of PU.1 and PU.1 regulated their basal expression. Analysis of expression profiling data from a large population of acute myeloid leukemia (AML) patients revealed that the expression levels of PSMBs were significantly lower in APL patients than in non-APL AML patients. Further evidence demonstrated that the decrease in their expression was achieved through PML/RAR alpha-mediated repression of both PU.1-dependent transactivation and PU.1 expression. Moreover, ATRA but not arsenic trioxide induced the expression of PSMBs in APL cells, indicating that ATRA treatment might activate the antigen-processing/ presentation machinery. Finally, the above observations were confirmed in primary APL samples. Collectively, our data demonstrate that PML/RARa suppresses PU.1-dependent activation of the immunosubunits, which may facilitate the escape of APL cells from immune surveillance in leukemia development, and ATRA treatment is able to reactivate their expression, which would promote more efficient T-cell-mediated recognition in the treatment.	[Yang, X-W; Wang, P.; Liu, J-Q; Zhang, H.; Xi, W-D; Jia, X-H; Wang, K-K] Shanghai Jiao Tong Univ, Sch Med SJTU SM, Ruijin Hosp, State Key Lab Med Genom,Shanghai Inst Hematol, Shanghai 200025, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University	Wang, KK (corresponding author), Shanghai Jiao Tong Univ, Sch Med SJTU SM, Ruijin Hosp, State Key Lab Med Genom,Shanghai Inst Hematol, 197 Ruijin Rd 2, Shanghai 200025, Peoples R China.	kankanwang@shsmu.edu.cn	Xi, Wenda/GYR-3972-2022		Ministry of Science and Technology Grants of China [2009CB825607, 2012AA02A211, 2011CB910202]; National Natural Science Foundation Grants of China [31171257, 81270625, 31100942]	Ministry of Science and Technology Grants of China; National Natural Science Foundation Grants of China(National Natural Science Foundation of China (NSFC))	This work was supported, in part, by Ministry of Science and Technology Grants of China (2009CB825607, 2012AA02A211 and 2011CB910202) and National Natural Science Foundation Grants of China (31171257, 81270625 and 31100942).	Aptsiauri N, 2007, INT REV CYTOL, V256, P139, DOI 10.1016/S0074-7696(07)56005-5; Carotta S, 2010, IMMUNOL REV, V238, P63, DOI 10.1111/j.1600-065X.2010.00955.x; Carotta S, 2010, IMMUNITY, V32, P628, DOI 10.1016/j.immuni.2010.05.005; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Collins SJ, 2008, CURR OPIN HEMATOL, V15, P346, DOI 10.1097/MOH.0b013e3283007edf; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Goldberg AL, 1995, COLD SPRING HARB SYM, V60, P479, DOI 10.1101/SQB.1995.060.01.052; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Hallermalm K, 2001, BLOOD, V98, P1108, DOI 10.1182/blood.V98.4.1108; Hoemme C, 2008, BLOOD, V111, P2887, DOI 10.1182/blood-2007-03-079921; Hu J, 2009, P NATL ACAD SCI USA, V106, P3342, DOI 10.1073/pnas.0813280106; Hu ZB, 1998, BLOOD, V92, P1768, DOI 10.1182/blood.V92.5.1768.417k19_1768_1775; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Idres N, 2001, CANCER RES, V61, P700; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; JINNAI I, 1990, LEUKEMIA RES, V14, P227, DOI 10.1016/0145-2126(90)90130-2; Kanada S, 2011, BLOOD, V117, P2211, DOI 10.1182/blood-2010-06-291898; LARSEN F, 1993, HUM MOL GENET, V2, P1589, DOI 10.1093/hmg/2.10.1589; LECCHI M, 1989, LEUKEMIA RES, V13, P221, DOI 10.1016/0145-2126(89)90015-5; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Lloberas J, 1999, IMMUNOL TODAY, V20, P184, DOI 10.1016/S0167-5699(99)01442-5; Lowenberg Bob, 2003, Hematology Am Soc Hematol Educ Program, P82; Maeda Y, 1996, BRIT J HAEMATOL, V93, P973, DOI 10.1046/j.1365-2141.1996.d01-1749.x; Meijerink J, 2001, J MOL DIAGN, V3, P55, DOI 10.1016/S1525-1578(10)60652-6; Nigten J, 2005, LEUKEMIA, V19, P799, DOI 10.1038/sj.leu.2403699; Olive V, 2007, DEVELOPMENT, V134, P3815, DOI 10.1242/dev.003467; Padua RA, 2003, NAT MED, V9, P1413, DOI 10.1038/nm949; Promsuwicha O, 2009, ASIAN PAC J ALLERGY, V27, P209; Robin M, 2006, BLOOD, V108, P1972, DOI 10.1182/blood-2006-03-013177; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Ross ME, 2004, BLOOD, V104, P3679, DOI 10.1182/blood-2004-03-1154; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Schlenk RF, 2004, LEUKEMIA, V18, P1798, DOI 10.1038/sj.leu.2403528; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Shen ZX, 2004, P NATL ACAD SCI USA, V101, P5328, DOI 10.1073/pnas.0400053101; Singh H, 2008, J IMMUNOL, V181, P1595, DOI 10.4049/jimmunol.181.3.1595; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Spain LM, 1999, J IMMUNOL, V163, P2681; Tomasson MH, 2008, BLOOD, V111, P4797, DOI 10.1182/blood-2007-09-113027; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Vertuani S, 2003, CANCER RES, V63, P8006; Wang KK, 2010, CANCER CELL, V17, P186, DOI 10.1016/j.ccr.2009.12.045; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Wouters BJ, 2009, BLOOD, V113, P3088, DOI 10.1182/blood-2008-09-179895; Zhang YM, 2013, CANCER-AM CANCER SOC, V119, P115, DOI 10.1002/cncr.27650; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zheng PZ, 2005, P NATL ACAD SCI USA, V102, P7653, DOI 10.1073/pnas.0502825102; Zheng XM, 2007, HAEMATOLOGICA, V92, P323, DOI 10.3324/haematol.10541; Zhu XH, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-22; Zou DD, 2012, LEUKEMIA RES, V36, P219, DOI 10.1016/j.leukres.2011.09.012	52	18	19	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2700	2708		10.1038/onc.2013.224	http://dx.doi.org/10.1038/onc.2013.224			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23770850				2022-12-17	WOS:000337231700003
J	Wu, CF; Liu, S; Lee, YC; Wang, R; Sun, S; Yin, F; Bornmann, WG; Yu-Lee, LY; Gallick, GE; Zhang, W; Lin, SH; Kuang, J				Wu, C. F.; Liu, S.; Lee, Y-C; Wang, R.; Sun, S.; Yin, F.; Bornmann, W. G.; Yu-Lee, L-Y; Gallick, G. E.; Zhang, W.; Lin, S-H; Kuang, J.			RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B	ONCOGENE			English	Article						RSK; Cdc25; activating phosphorylation; mitosis; G2/M transition; cell cycle	SIGNAL-REGULATED KINASE; XENOPUS OOCYTE MATURATION; ELEMENT-BINDING PROTEIN; CELL-CYCLE PROGRESSION; MAP KINASE; G(2)/M TRANSITION; DNA-DAMAGE; INHIBITORY KINASE; CANCER-CELLS; AURORA-A	Activation of the mitogen-activated protein kinase ( MAPK) cascade in mammalian cell lines positively regulates the G2/M transition. The molecular mechanism underlying this biological phenomenon remains poorly understood. Ribosomal S6 kinase (RSK) is a key downstream element of the MAPK cascade. Our previous studies established roles of RSK2 in Cdc25C activation during progesterone-induced meiotic maturation of Xenopus oocytes. In this study we demonstrate that both recombinant RSK and endogenous RSK in Xenopus egg extracts phosphorylate all three isoforms of human Cdc25 at a conserved motif near the catalytic domain. In human HEK293 and PC-3mm2 cell lines, RSK preferentially phosphorylates Cdc25A and Cdc25B in mitotic cells. Phosphorylation of the RSK sites in these Cdc25 isoforms increases their M-phase-inducing activities. Inhibition of RSK-mediated phosphorylation of Cdc25 inhibits G2/M transition. Moreover, RSK is likely to be more active in mitotic cells than in interphase cells, as evidenced by the phosphorylation status of T359/S363 in RSK. Together, these findings indicate that RSK promotes G2/M transition in mammalian cells through activating phosphorylation of Cdc25A and Cdc25B.	[Wu, C. F.; Wang, R.; Sun, S.; Bornmann, W. G.; Kuang, J.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Liu, S.; Yin, F.; Zhang, W.] Beijing Normal Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat & Regulat Biol, Beijing 100875, Peoples R China; [Lee, Y-C; Lin, S-H] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Sun, S.; Gallick, G. E.; Lin, S-H; Kuang, J.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Yu-Lee, L-Y] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Gallick, G. E.] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Dept Genitourinary Med Oncol Res, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Beijing Normal University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	slin@mdanderson.org; jkuang@mdanderson.org	Liu, Shuaishuai/AAB-3256-2020; Wang, Ruoning/C-1683-2014		Department of Defense (DOD) Prostate Cancer Research Program (PCRP) [W81XWH-09-1-0274, W81XWH-09-1-0272]; National Natural Science Foundation of China [30300173]; Beijing Talents Foundation [20071D0503100293]; PCF Challenge grant; NCI [CA140388, CA 16672]; Cancer Center [CA016672]; NATIONAL CANCER INSTITUTE [P50CA140388, P30CA016672] Funding Source: NIH RePORTER	Department of Defense (DOD) Prostate Cancer Research Program (PCRP); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Talents Foundation; PCF Challenge grant; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Department of Defense (DOD) Prostate Cancer Research Program (PCRP) grants W81XWH-09-1-0274 (JK) and W81XWH-09-1-0272 (S-HL), by grant 30300173 from the National Natural Science Foundation of China and grant 20071D0503100293 from the Beijing Talents Foundation (WZ), and a PCF Challenge grant and NCI CA140388 (GEG). DNA sequencing was performed by the DNA Analysis Facility of UT MD Anderson Cancer Center supported by NCI grant CA 16672. The Translational Chemistry Core Facility at the MD Anderson Cancer Center was supported by the Cancer Center support grant CA016672.	Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Aressy B, 2008, CELL CYCLE, V7, P2234, DOI 10.4161/cc.7.14.6305; Aressy B, 2008, ANTI-CANCER AGENT ME, V8, P818, DOI 10.2174/187152008786847756; Bhatt RR, 2000, J BIOL CHEM, V275, P32983, DOI 10.1074/jbc.M006386200; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Cangi MG, 2008, INT J CANCER, V123, P1466, DOI 10.1002/ijc.23659; Carriere A, 2008, FRONT BIOSCI-LANDMRK, V13, P4258, DOI 10.2741/3003; Castro A, 2001, BIOL CELL, V93, P15, DOI 10.1016/S0248-4900(01)01128-5; Cazales M, 2005, CELL CYCLE, V4, P1233, DOI 10.4161/cc.4.9.1964; Chen Y, 2008, FRONT BIOSCI-LANDMRK, V13, P5016; Clark DE, 2005, CANCER RES, V65, P3108; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Dumont J, 2005, J CELL BIOL, V169, P227, DOI 10.1083/jcb.200501027; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Eisenmann KM, 2003, CANCER RES, V63, P8330; Foijer F, 2008, ONCOGENE, V27, P1142, DOI 10.1038/sj.onc.1210724; Fox KE, 2008, J BIOL CHEM, V283, P35096, DOI 10.1074/jbc.M806423200; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Gebauer F, 1997, BIOESSAYS, V19, P23, DOI 10.1002/bies.950190106; GOTOH Y, 1995, MOL REPROD DEV, V42, P486, DOI 10.1002/mrd.1080420417; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; Hauge C, 2006, J CELL SCI, V119, P3021, DOI 10.1242/jcs.02950; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Kang SM, 2010, J CLIN INVEST, V120, P1165, DOI 10.1172/JCI40582; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Knauf JA, 2006, J BIOL CHEM, V281, P3800, DOI 10.1074/jbc.M511690200; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003; Maller J L, 1985, Dev Biol (N Y 1985), V1, P289; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Moritz A., 2010, SCI SIGNAL, V24, P3; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nam HJ, 2008, CELL SIGNAL, V20, P1349, DOI 10.1016/j.cellsig.2008.03.008; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Palmer A, 2000, Prog Cell Cycle Res, V4, P131; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; RIME H, 1994, BIOL CELL, V82, P11, DOI 10.1016/0248-4900(94)90061-2; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; SETH A, 1992, J BIOL CHEM, V267, P24796; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; Varmeh S, 2008, MOL CANCER THER, V7, P3789, DOI 10.1158/1535-7163.MCT-08-0838; Wang RN, 2007, CELL, V128, P1119, DOI 10.1016/j.cell.2006.11.053; Wang RN, 2010, P NATL ACAD SCI USA, V107, P19885, DOI 10.1073/pnas.1003528107; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	64	18	20	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2385	2394		10.1038/onc.2013.182	http://dx.doi.org/10.1038/onc.2013.182			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23708659	Green Accepted			2022-12-17	WOS:000335451800011
J	Wang, H; Han, M; Whetsell, W; Wang, J; Rich, J; Hallahan, D; Han, Z				Wang, H.; Han, M.; Whetsell, W., Jr.; Wang, J.; Rich, J.; Hallahan, D.; Han, Z.			Tax-interacting protein 1 coordinates the spatiotemporal activation of Rho GTPases and regulates the infiltrative growth of human glioblastoma	ONCOGENE			English	Article						ARHGEF7; cell migration; glioblastoma; rhotekin; tax-interacting protein-1; Rho GTPases	CELL POLARIZATION; BETA-CATENIN; ASTROCYTE MIGRATION; EXCHANGE FACTOR; ALPHA-CATENIN; CANCER CELLS; PDZ-DOMAINS; C-TERMINUS; TIP-1; EXPRESSION	PDZ domains represent one group of the major structural units that mediate protein interactions in intercellular contact, signal transduction and assembly of biological machineries. Tax-interacting protein (TIP)-1 protein is composed of a single PDZ domain that distinguishes TIP-1 from other PDZ domain proteins that more often contain multiple protein domains and function as scaffolds for protein complex assembly. However, the biological functions of TIP-1, especially in cell transformation and tumor progression, are still controversial as observed in a variety of cell types. In this study, we have identified ARHGEF7, a guanine nucleotide exchange factor for Rho GTPases, as one novel TIP-1-interacting protein in human glioblastoma cells. We found that the presence of TIP-1 protein is essential to the intracellular redistribution of ARHGEF7 and rhotekin, one Rho effector and the spatiotemporally coordinated activation of Rho GTPases (RhoA, Cdc42 and Rac1) in migrating glioblastoma cells. TIP-1 knockdown resulted in both aberrant localization of ARHGEF7 and rhotekin, as well as abnormal activation of Rho GTPases that was accompanied with impaired motility of glioblastoma cells. Furthermore, TIP-1 knockdown suppressed tumor cell dispersal in orthotopic glioblastoma murine models. We also observed high levels of TIP-1 expression in human glioblastoma specimens, and the elevated TIP-1 levels are associated with advanced staging and poor prognosis in glioma patients. Although more studies are needed to further dissect the mechanism(s) by which TIP-1 modulates the intracellular redistribution and activation of Rho GTPases, this study suggests that TIP-1 holds potential as both a prognostic biomarker and a therapeutic target of malignant gliomas.	[Wang, H.; Han, M.; Han, Z.] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA; [Wang, H.; Han, Z.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Han, M.] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming Inst Zool, Kunming, Peoples R China; [Han, M.] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; [Whetsell, W., Jr.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; [Wang, J.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37232 USA; [Wang, J.; Han, Z.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Rich, J.] Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, Cleveland, OH 44106 USA; [Hallahan, D.] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA	Vanderbilt University; Vanderbilt University; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Vanderbilt University; Vanderbilt University; Vanderbilt University; Cleveland Clinic Foundation; Washington University (WUSTL)	Han, Z (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, 1301 Med Ctr Dr,B902 TVC, Nashville, TN 37232 USA.	zhaozhong.han@vanderbilt.edu	Wang, Hailun/T-5696-2019; Rich, Jeremy/AAM-1445-2021	Wang, Hailun/0000-0001-8651-2856	NIH [R01CA127482, P50 CA128323, R01CA112385]; NATIONAL CANCER INSTITUTE [R01CA125757, R01CA127482, P50CA128323, R01CA112385] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Drs Barbara Fingleton, Steven K Hanks and Mike Freeman (Vanderbilt) for critical reading and discussions of this manuscript. We are grateful to Dr Paul A Welling at University of Maryland for the kind gift of TIP-1-expressing constructs. We appreciate the technical assistance and advices from Dr Ling Geng (Pathology, Vanderbilt University) in the animal studies, Dr Heping Yan (Washington University at St Louis) in the antibody development, Dr Bret Mobley (Pathology, Vanderbilt University) in the microscopic examination of tissue blocks and the technical staffs at the Cell Imaging, Histology and Genomics Cores of the Vanderbilt-Ingram Cancer Center. This study was supported in part by NIH Grants R01CA127482 (Z Han), P50 CA128323 (Gore) and R01CA112385 (DE Hallahan).	Akella NS, 2006, J NEUROSCI METH, V153, P183, DOI 10.1016/j.jneumeth.2005.10.026; Alewine C, 2006, MOL BIOL CELL, V17, P4200, DOI 10.1091/mbc.E06-02-0129; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Besser J, 2007, DEV GROWTH DIFFER, V49, P205, DOI 10.1111/j.1440-169x.2007.00921.x; Beuming T, 2005, BIOINFORMATICS, V21, P827, DOI 10.1093/bioinformatics/bti098; BURGER PC, 1983, J NEUROSURG, V58, P159, DOI 10.3171/jns.1983.58.2.0159; CAVENEE WK, 2000, PATHOLOGY GENETICS T, P10; Dickinson DJ, 2011, SCIENCE, V331, P1336, DOI 10.1126/science.1199633; Durney MA, 2009, J BIOMOL NMR, V45, P329, DOI 10.1007/s10858-009-9361-8; Etienne-Manneville S, 2006, METHOD ENZYMOL, V406, P565, DOI 10.1016/S0076-6879(06)06044-7; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Garcia-Mata R, 2007, TRENDS CELL BIOL, V17, P36, DOI 10.1016/j.tcb.2006.11.004; Geng L, 2006, INT J RADIAT ONCOL, V64, P263, DOI 10.1016/j.ijrobp.2005.08.025; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hampson L, 2004, INT J ONCOL, V25, P1249; Hampson L, 2009, BRIT J CANCER, V101, P829, DOI 10.1038/sj.bjc.6605208; Han MJ, 2013, CANCER LETT, V328, P55, DOI 10.1016/j.canlet.2012.09.011; Han MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045402; Han MJ, 2012, BIOCHEM BIOPH RES CO, V422, P139, DOI 10.1016/j.bbrc.2012.04.123; Hwang SL, 2004, EJSO-EUR J SURG ONC, V30, P68, DOI 10.1016/j.ejso.2003.10.018; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Kanamori M, 2003, J BIOL CHEM, V278, P38758, DOI 10.1074/jbc.M306324200; Machacek M, 2009, NATURE, V461, P99, DOI 10.1038/nature08242; Mayhew MW, 2006, J PROTEOME RES, V5, P2417, DOI 10.1021/pr060140t; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Olalla L, 2001, FEBS LETT, V488, P116, DOI 10.1016/S0014-5793(00)02373-5; Olalla L, 2008, J NEUROSCI RES, V86, P281, DOI 10.1002/jnr.21505; Oliver AW, 2011, BRIT J CANCER, V104, P324, DOI 10.1038/sj.bjc.6606026; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; Rincon E, 2011, J CELL SCI, V124, P776, DOI 10.1242/jcs.072447; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Salhia B, 2008, AM J PATHOL, V173, P1828, DOI 10.2353/ajpath.2008.080043; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Subbaiah VK, 2011, BIOCHEM J, V439, P195, DOI 10.1042/BJ20110903; ten Klooster JP, 2006, J CELL BIOL, V172, P759, DOI 10.1083/jcb.200509096; Wang HL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012051; Zencir S, 2011, BIOCHEM BIOPH RES CO, V411, P792, DOI 10.1016/j.bbrc.2011.07.029; Zhang JX, 2008, J MOL BIOL, V384, P255, DOI 10.1016/j.jmb.2008.09.034	46	18	19	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1558	1569		10.1038/onc.2013.97	http://dx.doi.org/10.1038/onc.2013.97			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23563176	Green Accepted			2022-12-17	WOS:000333244200009
J	Little, JL; Serzhanova, V; Izumchenko, E; Egleston, BL; Parise, E; Klein-Szanto, AJ; Loudon, G; Shubina, M; Seo, S; Kurokawa, M; Ochs, MF; Golemis, EA				Little, J. L.; Serzhanova, V.; Izumchenko, E.; Egleston, B. L.; Parise, E.; Klein-Szanto, A. J.; Loudon, G.; Shubina, M.; Seo, S.; Kurokawa, M.; Ochs, M. F.; Golemis, E. A.			A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice	ONCOGENE			English	Article						breast cancer; HER2; mammary precursor cells; drug resistance	FOCAL ADHESION KINASE; EPITHELIAL-SPECIFIC DISRUPTION; SUBSTRATE LYMPHOCYTE TYPE; DOCKING PROTEIN HEF1; HUMAN-BREAST; TRANSCRIPTOME ANALYSES; ANTIGEN RECEPTOR; CANCER; MOUSE; INTEGRIN	Overexpression of the NEDD9/HEF1/Cas-L scaffolding protein is frequent, and drives invasion and metastasis in breast, head and neck, colorectal, melanoma, lung and other types of cancer. We have examined the consequences of genetic ablation of Nedd9 in the MMTV-HER2/ERBB2/neu mouse mammary tumor model. Unexpectedly, we found that only a limited effect on metastasis in MMTV-neu;Nedd9(-/-) mice compared with MMTV-neu;Nedd9(-/-) mice, but instead a dramatic reduction in tumor incidence (18 versus 80%), and a significantly increased latency until tumor appearance. Orthotopic reinjection and tail-vein injection of cells arising from tumors, coupled with in vivo analysis, indicated tumors arising in MMTV-neu;Nedd9(-/-) mice had undergone mutational selection that overcame the initial requirement for Nedd9. To better understand the defects in early tumor growth, we compared mammary progenitor cell pools from MMTV-neu;Nedd9(-/-) versus MMTV-neu;Nedd9(-/-) mice. The MMTV-neu;Nedd9(-/-) genotype selectively reduced both the number and colony-forming potential of mammary luminal epithelial progenitor cells, while not affecting basal epithelial progenitors. MMTV-neu;Nedd9(-/-) mammospheres had striking defects in morphology and cell polarity. All of these defects were seen predominantly in the context of the HER2/neu oncogene, and were not associated with randomization of the plane of mitotic division, but rather with depressed expression the cell attachment protein FAK, accompanied by increased sensitivity to small molecule inhibitors of FAK and SRC. Surprisingly, in spite of these significant differences, only minimal changes were observed in the gene expression profile of Nedd9(-/-) mice, indicating critical Nedd9-dependent differences in cell growth properties were mediated via post-transcriptional regulation of cell signaling. Coupled with emerging data indicating a role for NEDD9 in progenitor cell populations during the morphogenesis of other tissues, these results indicate a functional requirement for NEDD9 in the growth of mammary cancer progenitor cells.	[Little, J. L.; Serzhanova, V.; Izumchenko, E.; Egleston, B. L.; Klein-Szanto, A. J.; Shubina, M.; Golemis, E. A.] Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA; [Parise, E.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA; [Little, J. L.; Loudon, G.] Bryn Mawr Coll, Dept Biol, Bryn Mawr, PA 19010 USA; [Seo, S.; Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo, Japan; [Ochs, M. F.] Johns Hopkins Univ, Dept Oncol Informat, Baltimore, MD USA; [Ochs, M. F.] Johns Hopkins Univ, Dept Hlth Sci Informat, Baltimore, MD USA	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Bryn Mawr College; University of Tokyo; Johns Hopkins University; Johns Hopkins University	Golemis, EA (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	EA_Golemis@fccc.edu	Little, Joy/K-1463-2015; Egleston, Brian L./P-1000-2019; Little, Joy/AAY-4795-2021	Egleston, Brian L./0000-0002-1633-799X; Golemis, Erica/0000-0003-3618-3673	Pennsylvania Tobacco Settlement funding; NIH [CA06927, T32 CA009035, F32 CA150553]; Pew Charitable Fund; American Associates, Ben-Gurion University of the Negev; Fox Chase Cancer Center Undergraduate Student Summer Fellowship Program;  [R01s CA63366];  [CA113342];  [U54 CA149147];  [R21 LM009382]; NATIONAL CANCER INSTITUTE [T32CA009035, R01CA113342, F32CA150553, P30CA006927, U54CA149147, R29CA063366, R01CA063366] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R21LM009382] Funding Source: NIH RePORTER	Pennsylvania Tobacco Settlement funding; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pew Charitable Fund; American Associates, Ben-Gurion University of the Negev; Fox Chase Cancer Center Undergraduate Student Summer Fellowship Program; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We are grateful to Emmanuelle Nicolas (Genotyping and Real-Time-PCR Facility of FCCC), Jianming Pei (Cytogenetics and Chromosome Microarray Analysis Facility of FCCC) and Yue-Sheng Liu (Expression Microarray Facility of FCCC), Anthony Lerro and Jackie Valvardi (Laboratory Animal Facility of FCCC), James Oesterling (Cell Sorting Facility of FCCC), Jin Fang (Cell Culture Facility of FCCC), Catherine Renner (Histopathology Facility), Marina Boushra (from Cornell University), Christiaan Honig (from Germantown Academy) and Nicolas G Day (from St John's College) for technical help. We particularly acknowledge Edna Cukierman for expert advice with analysis of microscopic images. R01s CA63366 and CA113342, a U54 CA149147 subcontract, and Pennsylvania Tobacco Settlement funding (to EAG); and NIH core Grant CA06927 and the Pew Charitable Fund (to Fox Chase Cancer Center) supported this work. JLL was supported by NIH T32 CA009035 and F32 CA150553; EI by the American Associates, Ben-Gurion University of the Negev; EP by the Fox Chase Cancer Center Undergraduate Student Summer Fellowship Program. MFO was supported by R21 LM009382.	Aquino JB, 2009, NEUROSCIENCE, V162, P1106, DOI 10.1016/j.neuroscience.2009.05.035; Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Astsaturov I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001083; Baselga J, 2010, ANN ONCOL, V21, P36, DOI 10.1093/annonc/mdq421; Castello-Cros R, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-94; Dadke D, 2006, MOL BIOL CELL, V17, P1204, DOI 10.1091/mbc.E05-03-0237; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Fashena SJ, 2002, J CELL SCI, V115, P99; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hao Y, 2010, CURR BIOL, V20, P1809, DOI 10.1016/j.cub.2010.09.032; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Keller PJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2755; Kong CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022666; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2012.147, 10.1038/onc.2011.439]; Luo M, 2009, CANCER RES, V69, P466, DOI 10.1158/0008-5472.CAN-08-3078; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Nagashima Takeshi, 2008, Cancer Genomics & Proteomics, V5, P161; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pontier SM, 2009, J CELL SCI, V122, P207, DOI 10.1242/jcs.040394; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Seo S, 2005, J IMMUNOL, V175, P3492, DOI 10.4049/jimmunol.175.6.3492; Seo S, 2011, CANCER SCI, V102, P2109, DOI 10.1111/j.1349-7006.2011.02066.x; Shults J, 2007, STATA J, V7, P147, DOI 10.1177/1536867X0700700201; Singh MK, 2010, CANCER RES, V70, P8907, DOI 10.1158/0008-5472.CAN-10-0353; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl John, 2005, Methods Mol Biol, V290, P249; Tikhmyanova N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022102; Tikhmyanova N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012369; Tikhmyanova N, 2010, CELL MOL LIFE SCI, V67, P1025, DOI 10.1007/s00018-009-0213-1; Tondeur S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008990; Vaillant F, 2007, STEM CELL REV, V3, P114, DOI 10.1007/s12015-007-0018-2; van Miltenburg MHAM, 2009, FASEB J, V23, P3482, DOI 10.1096/fj.08-123398; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; Vogel T, 2010, CEREB CORTEX, V20, P661, DOI 10.1093/cercor/bhp134; Worthington J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-490	56	18	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					411	420		10.1038/onc.2012.607	http://dx.doi.org/10.1038/onc.2012.607			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318423	Green Accepted			2022-12-17	WOS:000330214600002
J	Penicud, K; Behrens, A				Penicud, K.; Behrens, A.			DMAP1 is an essential regulator of ATM activity and function	ONCOGENE			English	Article						DMAP1; ATM; TIP60; double-strand break	HISTONE ACETYLTRANSFERASE COMPLEX; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; KINASE-ACTIVITY; ACTIVATES ATM; SANT DOMAIN; ACETYLATION; REPAIR; TIP60	The hereditary autosomal recessive disease ataxia telangiectasia (A-T) is caused by mutation in the DNA damage kinase ATM. ATM's main function is to orchestrate DNA repair, thereby maintaining genomic stability. ATM activity is increased in response to several stimuli, including ionising radiation (IR) and hypotonic stress. DNMT1-associated protein 1 (DMAP1) is a member of the TIP60-p400 histone acetyl transferase (HAT) complex, which acetylates histone H4 at lysine 16 (H4K16) to affect chromatin relaxation and modulate ATM activation. Here we demonstrate that DMAP1 is required for both modes of ATM activation. Knockdown of DMAP1 impaired IR-induced ATM activation and consequently resulted in radiosensitivity and impaired the G2/M checkpoint. Moreover, DMAP1 was also required for efficient ATM signalling in response to hypotonic stress. Overexpression of DMAP1 increased IR-induced ATM substrate phosphorylation, suggesting that DMAP1 function is rate limiting for ATM signalling. DMAP1 associated with TIP60-dependent HAT activity, and depletion of DMAP1 reduced H4K16 acetylation in response to DNA damage. Treatment with histone deacetylase inhibitors rescued IR-induced ATM signalling in Dmap1-depleted cells. These results suggest that DMAP1 is a critical regulator of ATM activity and function.	[Penicud, K.; Behrens, A.] Canc Res UK London Res Inst, Mammalian Genet Lab, London WC2A 3LY, England	Cancer Research UK	Behrens, A (corresponding author), Canc Res UK London Res Inst, Mammalian Genet Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.	axel.behrens@cancer.org.uk		Behrens, Axel/0000-0002-1557-1143	Experimental HistoPathology Unit, Bioinformatics and Biostatistics; Equipment Park, Biological Resources; FACS Lab in the London Research Institute (CR-UK); ERC [281661 ATMINDDR]; Cancer Research UK; Cancer Research UK [15679] Funding Source: researchfish	Experimental HistoPathology Unit, Bioinformatics and Biostatistics; Equipment Park, Biological Resources(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); FACS Lab in the London Research Institute (CR-UK); ERC(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	Support was given from the Experimental HistoPathology Unit, Bioinformatics and Biostatistics, the Equipment Park, Biological Resources and the FACS Lab in the London Research Institute (CR-UK). We thank Dr Cremona and Dr Kanu for critical reading of the manuscript and the Mammalian Genetics Lab for input and discussions. This work was supported by an ERC grant (281661 ATMINDDR) to AB. The London Research Institute is funded by Cancer Research UK.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Boyer LA, 2004, NAT REV MOL CELL BIO, V5, P158, DOI 10.1038/nrm1314; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; Cai Y, 2003, J BIOL CHEM, V278, P42733, DOI 10.1074/jbc.C300389200; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Frappart PO, 2006, NEUROMOL MED, V8, P495, DOI 10.1385/NMM:8:4:495; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim YC, 2009, NAT CELL BIOL, V11, P92, DOI 10.1038/ncb1817; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Negishi M, 2009, GENES CELLS, V14, P1347, DOI 10.1111/j.1365-2443.2009.01352.x; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sharma GG, 2010, MOL CELL BIOL, V30, P3582, DOI 10.1128/MCB.01476-09; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SHILOH Y, 1982, EXP CELL RES, V140, P191, DOI 10.1016/0014-4827(82)90169-0; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wu JX, 2011, NAT STRUCT MOL BIOL, V18, P761, DOI 10.1038/nsmb.2078	29	18	19	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					525	531		10.1038/onc.2012.597	http://dx.doi.org/10.1038/onc.2012.597			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318425	Green Accepted			2022-12-17	WOS:000330214600013
J	Conforti, F; Yang, AL; Piro, MC; Mellone, M; Terrinoni, A; Candi, E; Tucci, P; Thomas, GJ; Knight, RA; Melino, G; Sayan, BS				Conforti, F.; Yang, Ai Li; Piro, M. Cristina; Mellone, M.; Terrinoni, A.; Candi, E.; Tucci, P.; Thomas, G. J.; Knight, R. A.; Melino, G.; Sayan, B. S.			PIR2/Rnf144B regulates epithelial homeostasis by mediating degradation of p21WAF1 and p63	ONCOGENE			English	Article						PIR2; Rnf144B; p63; p21(WAF1); squamous cell carcinoma (SCC); skin	SQUAMOUS-CELL CARCINOMA; E3 UBIQUITIN LIGASE; STEM-CELLS; DIFFERENTIATION; PROTEASOME; APOPTOSIS; PROTEIN; CANCER; CYCLE; EXPRESSION	Delta Np63 is a transcription factor that is critical for the development of stratified epithelia and is overexpressed or amplified in >80% of squamous cell carcinomas (SCCs). We identified the RING finger E3 ubiquitin ligase PIR2/Rnf144b as a direct transcriptional target of Delta Np63 alpha and showed that its expression parallels that of Delta Np63 alpha in keratinocytes, SCC cell lines and SCCs. We used primary keratinocytes as a model system to investigate the function of PIR2/Rnf144b in stratified epithelia. Depletion of PIR2/Rnf144b severely impaired keratinocyte proliferation and differentiation, associated with accumulation of p21(WAF1/CIP1); a known target of PIR2/Rnf144b. More importantly, we found that PIR2/Rnf144b binds and mediates proteasomal degradation of Delta Np63 alpha, generating a hitherto unknown auto-regulatory feedback loop. These findings substantiate PIR2/Rnf144b as a potentially critical component of epithelial homeostasis, acting downstream of Delta Np63 alpha to regulate cellular levels of p21(WAF1/CIP1) and Delta Np63 alpha.	[Conforti, F.; Mellone, M.; Thomas, G. J.; Sayan, B. S.] Univ Southampton, Fac Med, Canc Sci Unit, Southampton SO16 6YD, Hants, England; [Yang, Ai Li; Tucci, P.; Knight, R. A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Piro, M. Cristina; Terrinoni, A.; Candi, E.; Tucci, P.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, IDI IRCCS, Biochem Lab, Rome, Italy	University of Southampton; University of Leicester; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata	Sayan, BS (corresponding author), Univ Southampton, Fac Med, Canc Sci Unit, Somers Canc Res Bldg,Tremona Rd,MP824, Southampton SO16 6YD, Hants, England.	b.s.sayan@soton.ac.uk	PIRO, MARIA CRISTINA/GVT-4380-2022; TERRINONI, Alessandro/J-1533-2012	PIRO, MARIA CRISTINA/0000-0003-3004-367X; TERRINONI, Alessandro/0000-0002-7442-2252; mellone, massimiliano/0000-0002-4964-9340; TUCCI, PAOLA/0000-0002-9349-5203	University of Southampton; Medical Research Council, UK; 'Alleanza contro il Cancro' [ACC12]; MIUR/PRIN [RBIP06LCA9_0023]; AIRC [2008-2010_33-08]; Italian Human ProteomeNet RBRN07BMCT; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	University of Southampton; Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); 'Alleanza contro il Cancro'; MIUR/PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC(Fondazione AIRC per la ricerca sul cancro); Italian Human ProteomeNet RBRN07BMCT; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has been supported by funding from the University of Southampton to BSS and by the Medical Research Council, UK; 'Alleanza contro il Cancro' (ACC12), MIUR/PRIN (RBIP06LCA9_0023), AIRC (2008-2010_33-08), Italian Human ProteomeNet RBRN07BMCT to GM.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Benard G, 2010, EMBO J, V29, P1458, DOI 10.1038/emboj.2010.39; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Ciechanover A, 2005, CELL DEATH DIFFER, V12, P1178, DOI 10.1038/sj.cdd.4401692; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Graziano V, 2011, BBA-REV CANCER, V1816, P57, DOI 10.1016/j.bbcan.2011.04.002; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Huang J, 2006, FEBS LETT, V580, P940, DOI 10.1016/j.febslet.2005.09.105; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Li YC, 2009, MOL CELL BIOL, V29, P3953, DOI 10.1128/MCB.00449-09; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Ng CC, 2003, ONCOGENE, V22, P4449, DOI 10.1038/sj.onc.1206586; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Okuyama R, 2004, J INVEST DERM SYMP P, V9, P248, DOI 10.1111/j.1087-0024.2004.09308.x; Ponassi R, 2006, BIOCHEM PHARMACOL, V72, P1417, DOI 10.1016/j.bcp.2006.07.031; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Sayan AE, 2007, ANN NY ACAD SCI, V1095, P315, DOI 10.1196/annals.1397.035; Sayan AE, 2010, BIOCHEM BIOPH RES CO, V394, P824, DOI 10.1016/j.bbrc.2010.03.084; Sayan BS, 2010, P NATL ACAD SCI USA, V107, P12877, DOI 10.1073/pnas.0911828107; Schavolt KL, 2007, ONCOGENE, V26, P6125, DOI 10.1038/sj.onc.1210441; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Taebunpakul P, 2012, APOPTOSIS, V17, P762, DOI 10.1007/s10495-012-0720-7; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Vanbokhoven H, 2011, J INVEST DERMATOL, V131, P1196, DOI 10.1038/jid.2011.84; Watt FM, 2006, CURR OPIN GENET DEV, V16, P518, DOI 10.1016/j.gde.2006.08.006; Weinberg WC, 2002, CRIT REV ORAL BIOL M, V13, P453, DOI 10.1177/154411130201300603; Westra WH, 2009, HEAD NECK PATHOL, V3, P78, DOI 10.1007/s12105-009-0100-y; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539	42	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2013	32	40					4758	4765		10.1038/onc.2012.497	http://dx.doi.org/10.1038/onc.2012.497			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23128396				2022-12-17	WOS:000325274700004
J	Monaghan-Benson, E; Burridge, K				Monaghan-Benson, E.; Burridge, K.			Mutant B-RAF regulates a Rac-dependent cadherin switch in melanoma	ONCOGENE			English	Article						B-RAF; melanoma; Rac; cadherin; Tiam1	CELL-CELL ADHESION; SMALL-MOLECULE INHIBITOR; MALIGNANT-MELANOMA; EPITHELIAL-CELLS; SMALL GTPASES; RATIONAL DESIGN; MDCK CELLS; RHO; MIGRATION; INVASION	The ability of cells to invade into the dermis is a critical event in the development of cutaneous melanoma and ultimately an indicator of poor prognosis. However, the molecular events surrounding the acquisition of this invasive phenotype remain incompletely understood. Mutations in B-RAF are frequent in melanoma and are known to regulate the invasive phenotype. In this study, we sought to determine the molecular mechanisms controlling melanoma invasion. We found that mutant B-RAF signaling regulates a cadherin switch. In melanoma cells expressing mutant B-RAF we observed high levels of N-cadherin and low levels of E-cadherin. Depletion of mutant B-RAF, by small interfering RNA, caused a decrease in the levels of N-cadherin and an increase in the levels of E-cadherin. Mechanistically, we found that this cadherin switch required the activity of Rac1 and its GEF, Tiam1, both of which show suppressed activity in the presence of mutant B-RAF. Consistent with the work of others, we found that depletion of mutant B-RAF decreased the invasive capacity of the melanoma cells. However, simultaneous depletion of B-RAF and Rac or Tiam1 resulted in invasive capacity similar to that of control cells. Taken together, our results suggest that mutant B-RAF signaling downregulates Tiam1/Rac activity resulting in an increase in N-cadherin levels and a decrease in E-cadherin levels and ultimately enhanced invasion.	[Monaghan-Benson, E.; Burridge, K.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Monaghan-Benson, E.; Burridge, K.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Monaghan-Benson, E (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, 12-026 Lineberger,CB 7295, Chapel Hill, NC 27599 USA.	ebenson@med.unc.edu			NIH [GM029860, HL080166]; American Cancer Society [PF-09_119-01-CSM]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL080166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grants GM029860 and HL080166 to KB. E M-B is supported by American Cancer Society PF-09_119-01-CSM.	Akbar H, 2006, METHOD ENZYMOL, V406, P554, DOI 10.1016/S0076-6879(06)06043-5; ALBINO AP, 1989, ONCOGENE, V4, P1363; Alsina J, 2003, CLIN CANCER RES, V9, P6419; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Garcia-Mata R, 2006, METHOD ENZYMOL, V406, P425, DOI 10.1016/S0076-6879(06)06031-9; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Klein RM, 2008, MOL BIOL CELL, V19, P498, DOI 10.1091/mbc.E07-09-0895; Klein RM, 2009, CANCER RES, V69, P2224, DOI 10.1158/0008-5472.CAN-08-3201; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Li G, 2002, CRIT REV ORAL BIOL M, V13, P62, DOI 10.1177/154411130201300107; Li G, 2001, CANCER RES, V61, P3819; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Michiels Frits, 1999, P125; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Ray RM, 2007, CELL MOTIL CYTOSKEL, V64, P143, DOI 10.1002/cm.20172; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sandig M, 1997, CELL MOTIL CYTOSKEL, V38, P351, DOI 10.1002/(SICI)1097-0169(1997)38:4<351::AID-CM5>3.3.CO;2-Z; Sauter ER, 1998, MOL CARCINOGEN, V23, P132, DOI 10.1002/(SICI)1098-2744(199811)23:3<132::AID-MC2>3.0.CO;2-1; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TANG A, 1994, J CELL SCI, V107, P983; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Uhlenbrock K, 2004, J CELL SCI, V117, P4863, DOI 10.1242/jcs.01367; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Zhang JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022176; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	47	18	19	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4836	4844		10.1038/onc.2012.492	http://dx.doi.org/10.1038/onc.2012.492			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23208503	Green Accepted, Green Submitted			2022-12-17	WOS:000325274700012
J	Saunders, PO; Weiss, J; Welschinger, R; Baraz, R; Bradstock, KF; Bendall, LJ				Saunders, P. O.; Weiss, J.; Welschinger, R.; Baraz, R.; Bradstock, K. F.; Bendall, L. J.			RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine	ONCOGENE			English	Article						acute lymphoblastic leukemia; RAD001; mTOR inhibitors; chemotherapy; checkpoint regulation; mitosis	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-DAMAGE RESPONSE; MAMMALIAN TARGET; MITOTIC CATASTROPHE; AURORA-B; PROGRESSION; INHIBITORS; APOPTOSIS; MTOR; ACTIVATION	More than 50% of adults and similar to 20% of children with pre-B acute lymphoblastic leukemia (ALL) relapse following treatment. Dismal outcomes for patients with relapsed or refractory disease mandate novel approaches to therapy. We have previously shown that the combination of the mTOR inhibitor RAD001 (everolimus) and the chemotherapeutic agent vincristine increases the survival of non-obese diabetic/severe combined immuno-deficient (NOD/SCID) mice bearing human ALL xenografts. We have also shown that 16 mu M RAD001 synergized with agents that cause DNA damage or microtubule disruption in pre-B ALL cells in vitro. Here, we demonstrate that RAD001 has dose-dependent effects on the cell cycle in ALL cells, with 1.5 mu M RAD001 inhibiting pRb, Ki67 and PCNA expression and increasing G(0/1) cell cycle arrest, whereas 16 mu M RAD001 increases pRb, cyclin D1, Ki67 and PCNA, with no evidence of an accumulation of cells in G(0/1). Transition from G(2) into mitosis was promoted by 16 mu M RAD001 with reduced phosphorylation of cdc2 in cells with 4N DNA content. However, 16 mu M RAD001 preferentially induced cell death in cells undergoing mitosis. When combined with vincristine, 16 mu M RAD001 reduced the vincristine-induced accumulation of cells in mitosis, probably as a result of increased death in this population. Although 16 mu M RAD001 weakly activated Chk1 and Chk2, it suppressed strong vincristine-induced activation of these cell cycle checkpoint regulators. We conclude that RAD001 enhances chemosensitivity at least in part through suppression of cell cycle checkpoint regulation in response to vincristine and increased progression from G(2) into mitosis.	[Saunders, P. O.; Weiss, J.; Welschinger, R.; Baraz, R.; Bradstock, K. F.; Bendall, L. J.] Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Bendall, LJ (corresponding author), Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, POB 412 Darcy Rd, Westmead, NSW 2145, Australia.	linda_bendall@wmi.usyd.edu.au			University of Sydney; NHMRC CDA2 [511965]; NHMRC [352326]; Leukemia and Lymphoma Society Translational Program [6105-08]	University of Sydney(University of Sydney); NHMRC CDA2(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Leukemia and Lymphoma Society Translational Program(Leukemia and Lymphoma Society)	RAD001 (everolimus) was kindly provided by Novartis. This work was supported by a University of Sydney Postgraduate Award (PS), NHMRC CDA2 No. 511965 (LB) and project grant no. 352326 (RB, JW), and the Leukemia and Lymphoma Society Translational Program grant no. 6105-08 (RW).	Avellino R, 2005, BLOOD, V106, P1400, DOI 10.1182/blood-2005-03-0929; BENDALL LJ, 1993, BLOOD, V82, P3125; Blajeski AL, 2002, J CLIN INVEST, V110, P91, DOI 10.1172/JCI200213275; Bradstock K, 1996, LEUKEMIA, V10, P813; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Crazzolara R, 2009, AUTOPHAGY, V5, P727, DOI 10.4161/auto.5.5.8507; Crazzolara R, 2009, BLOOD, V113, P3297, DOI 10.1182/blood-2008-02-137752; Ehrhardt H, 2011, BLOOD, V118, P6123, DOI 10.1182/blood-2010-02-269811; Gao N, 2003, BIOCHEM BIOPH RES CO, V310, P1124, DOI 10.1016/j.bbrc.2003.09.132; Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003; Gokbuget N, 2009, SEMIN HEMATOL, V46, P64, DOI 10.1053/j.seminhematol.2008.09.003; Grunwald V, 2002, CANCER RES, V62, P6141; Haritunians T, 2007, LEUKEMIA, V21, P333, DOI 10.1038/sj.leu.2404471; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hawkins DS, 1996, CANCER RES, V56, P892; Ito D, 2010, ADV EXP MED BIOL, V676, P15; Juarez J, 2003, LEUKEMIA, V17, P1294, DOI 10.1038/sj.leu.2402998; Law M, 2006, CANCER RES, V66, P1070, DOI 10.1158/0008-5472.CAN-05-1672; Mabuchi S, 2007, CLIN CANCER RES, V13, P4261, DOI 10.1158/1078-0432.CCR-06-2770; Moricke A, 2010, LEUKEMIA, V24, P265, DOI 10.1038/leu.2009.257; MORICE WG, 1993, J BIOL CHEM, V268, P3734; Nguyen K, 2008, LEUKEMIA, V22, P2142, DOI 10.1038/leu.2008.251; Peng A, 2010, ONCOGENE, V29, P5977, DOI 10.1038/onc.2010.371; Peponi E, 2006, AM J PATHOL, V169, P2171, DOI 10.2353/ajpath.2006.051078; Petersen J, 2007, NAT CELL BIOL, V9, P1263, DOI 10.1038/ncb1646; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Portugal J, 2010, CURR PHARM DESIGN, V16, P69, DOI 10.2174/138161210789941801; Saunders P, 2011, HAEMATOL-HEMATOL J, V96, P69, DOI 10.3324/haematol.2010.026997; Segurado M, 2009, BIOL CELL, V101, P617, DOI 10.1042/BC20090053; Silverman LB, 2010, LEUKEMIA, V24, P320, DOI 10.1038/leu.2009.253; Song JX, 2007, NAT IMMUNOL, V8, P64, DOI 10.1038/ni1413; Su WC, 2009, FEBS LETT, V583, P2793, DOI 10.1016/j.febslet.2009.07.027; Tavernier E, 2007, LEUKEMIA, V21, P1907, DOI 10.1038/sj.leu.2404824; Teachey DT, 2008, BLOOD, V112, P2020, DOI 10.1182/blood-2008-02-137141; Wanner K, 2006, BRIT J HAEMATOL, V134, P475, DOI 10.1111/j.1365-2141.2006.06210.x; Wu MYW, 2007, EMBO J, V26, P371, DOI 10.1038/sj.emboj.7601487; Yang CY, 2011, MOL CELL, V44, P597, DOI 10.1016/j.molcel.2011.09.016	38	18	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4789	4797		10.1038/onc.2012.498	http://dx.doi.org/10.1038/onc.2012.498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23128395				2022-12-17	WOS:000325274700007
J	Wolyniec, K; Levav-Cohen, Y; Jiang, YH; Haupt, S; Haupt, Y				Wolyniec, K.; Levav-Cohen, Y.; Jiang, Y-H; Haupt, S.; Haupt, Y.			The E6AP E3 ubiquitin ligase regulates the cellular response to oxidative stress	ONCOGENE			English	Article						reactive oxygen species; cellular senescence; anti-oxidants; oxidative stress; cell death; peroxiredoxin 1	INDUCED DNA-DAMAGE; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; TUMOR SUPPRESSION; GROWTH ARREST; INDUCE SENESCENCE; FIBROBLAST CELLS; CERVICAL-CANCER; C-MYC; P53	The E6AP E3 ubiquitin ligase has been linked to the regulation of cell growth and to the cellular stress response. However, the specific stress conditions that are controlled by E6AP have not been defined. An important stress condition that controls cell growth is oxidative stress, where the levels of intracellular reactive oxygen species (ROS) regulate the appropriate cellular response. Here, we describe a novel role for E6AP in the control of oxidative stress response. Cells lacking E6AP expression have reduced capacity to accumulate ROS, and oxidative DNA damage, in response to 20% cell culture oxygen levels, treatment with hydrogen peroxide and expression of oncogenic RAS. This effect of E6AP is associated with the regulation of the anti-oxidant enzyme, Prx1, a previously identified target of E6AP, and can be corrected by downregulation of Prx1 or by reconstitution of E6AP expression. Consequently, cells with compromised E6AP have impaired senescent and apoptotic response to sub-lethal and lethal doses of oxidative stress, respectively. In a xenograft model, downregulation of E6AP renders transplanted tumours refractory to growth-suppressive effects of hydrogen peroxide. Our results provide the first demonstration that E6AP is an important regulator of ROS-mediated cellular senescence and cell death.	[Wolyniec, K.; Haupt, S.; Haupt, Y.] Peter MacCallum Canc Ctr, Tumour Suppress Lab, East Melbourne, Vic, Australia; [Wolyniec, K.; Haupt, S.; Haupt, Y.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Levav-Cohen, Y.] Hebrew Univ Jerusalem Hadassah Hosp & Med Sch, Sch Med, Jerusalem, Israel; [Jiang, Y-H] Duke Univ, Sch Med, Dept Pediat & Neurobiol, Div Med Genet, Durham, NC USA; [Haupt, Y.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Haupt, Y.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Hebrew University of Jerusalem; Hadassah University Medical Center; Duke University; University of Melbourne; Monash University	Haupt, Y (corresponding author), Peter MacCallum Canc Ctr, Tumour Suppress Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.	ygal.haupt@petermac.org		Haupt, Ygal/0000-0001-5925-0096	National Health and Medical Research Council (NHMRC) of Australia [509196, 509197, 1026990, 1026988]; Cancer Council Victoria; VESKI award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043494] Funding Source: NIH RePORTER	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); VESKI award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank Scott Lowe, Martin Scheffner and Ikuo Shoji who generously provided plasmids. This work was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia to YH (NHMRC #509196, #509197, #1026990, #1026988), by a grant from the Cancer Council Victoria, and by the VESKI award. YH is NHMRC Senior Research Fellow.	Bacsi A, 2007, MECH AGEING DEV, V128, P637, DOI 10.1016/j.mad.2007.09.005; Beaudenon S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S4; BENYOSEPH O, 1994, BRIT J CANCER, V70, P1131, DOI 10.1038/bjc.1994.460; Bertram C, 2008, BIOL CHEM, V389, P211, DOI 10.1515/BC.2008.031; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Busuttil RA, 2003, AGING CELL, V2, P287, DOI 10.1046/j.1474-9728.2003.00066.x; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Cha MK, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-93; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Egler RA, 2005, ONCOGENE, V24, P8038, DOI 10.1038/sj.onc.1208821; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Howley Peter M, 2006, Trans Am Clin Climatol Assoc, V117, P113; Jones FS, 2001, CIRC RES, V89, P131, DOI 10.1161/hh1401.093582; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Levav-Cohen Y, 2012, ONCOGENE, V31, P2199, DOI 10.1038/onc.2011.402; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lu T, 2008, EXP CELL RES, V314, P1918, DOI 10.1016/j.yexcr.2008.01.011; Matentzoglu K, 2008, BIOCHEM SOC T, V36, P797, DOI 10.1042/BST0360797; Nasu J, 2010, J CELL BIOCHEM, V111, P676, DOI 10.1002/jcb.22752; NATHAN CF, 1981, J EXP MED, V154, P1539, DOI 10.1084/jem.154.5.1539; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Ramamoorthy S, 2012, BREAST CANCER RES TR, V132, P97, DOI 10.1007/s10549-011-1567-2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SUGIURA K, 1958, NATURE, V182, P1310, DOI 10.1038/1821310a0; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; van Loon B, 2010, DNA REPAIR, V9, P604, DOI 10.1016/j.dnarep.2010.03.004; Vurusaner B, 2012, FREE RADICAL BIO MED, V52, P7, DOI 10.1016/j.freeradbiomed.2011.09.035; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Wolyniec K, 2009, ONCOGENE, V28, P2502, DOI 10.1038/onc.2009.101; Yoshizaki K, 2009, BIOSCI BIOTECH BIOCH, V73, P311, DOI 10.1271/bbb.80517; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584	43	18	18	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3510	3519		10.1038/onc.2012.365	http://dx.doi.org/10.1038/onc.2012.365			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22986523				2022-12-17	WOS:000322220800004
J	Ling, H; Jolicoeur, P				Ling, H.; Jolicoeur, P.			Notch-1 signaling promotes the cyclinD1-dependent generation of mammary tumor-initiating cells that can revert to bi-potential progenitors from which they arise	ONCOGENE			English	Article						mammary tumors; Notch1; Cyclin D1 addiction; tumor-initiating cells	CANCER STEM-CELLS; BREAST-CANCER; STEM/PROGENITOR CELLS; GLAND DEVELOPMENT; HETEROGENEITY; FATE; IDENTIFICATION; TUMORIGENESIS; POPULATION; PHENOTYPE	In a previous work, we reported that young transgenic (Tg) mice expressing the intracellular domain of Notch1 (N1(IC)) showed expansion of lin(-) CD24(+) CD29(high) mammary cells enriched for stem cells and later developed mammary tumors. Mammary tumor formation was abolished or greatly reduced in cyclin D1(-/-) or cyclin D1(+/-) N1(IC) Tg mice, respectively. Here, we studied the epithelial cell subsets present in N1(IC)-induced tumors. CD24(-) CD29(int) and CD24(+) CD29(high) cells were found to be present at low numbers in tumors. The latter had the same properties as those expanded in young Tg females, and neither cell population showed tumor-initiating potential nor were they required for maintenance of tumors after transplantation. CD24(int) CD29(int) cells were identified as tumor-initiating and mammosphere-forming cells and represent a large percentage tumor cells in this model. Their number was significantly lower in tumors from cyclin D1(+/-) N1(IC) Tg mice. Using cyclin D1 shRNA knockdown, we also show that N1(IC)-induced tumor cells remain addicted to cyclin D1 for growth and survival. Interestingly, at lower levels of cyclin D1 or after transplantation in the presence of normal mammary cells, these N1(IC)-expressing tumor cells reverted to a state of low malignancy and differentiate into duct-like structures. They seem to adopt the fate of bi-potential stem/progenitor cells similar to that of the expanded CD24(+) CD29(high) stem/progenitor cells from which they are likely to be derived. Our data indicate that decreasing cyclin D1 levels would be an efficient treatment for tumors induced by N1 signaling.	[Ling, H.; Jolicoeur, P.] Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; [Jolicoeur, P.] McGill Univ, Div Expt Med, Montreal, PQ, Canada; [Jolicoeur, P.] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Universite de Montreal	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	Paul.Jolicoeur@ircm.qc.ca			Canadian Institute of Health Research (CIHR); Canada Research Chair	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	This work was supported by grant to PJ from the Canadian Institute of Health Research (CIHR). PJ is a recipient of a Canada Research Chair. We thank Jean-Rene Sylvestre for excellent animal care. We are grateful to Annie Lavallee as well as to Eric Massicotte and Julie Lord for their excellent assistance with tissue sections and flow cytometry, respectively.	Baker M, 2008, NATURE, V454, P556, DOI [10.1038/454556a, 10.1038/456553a]; Booth BW, 2011, ONCOGENE, V30, P679, DOI 10.1038/onc.2010.439; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Bussard KM, 2010, CANCER RES, V70, P6336, DOI 10.1158/0008-5472.CAN-10-0591; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; DEOME KB, 1959, CANCER RES, V19, P515; Dirks PB, 2006, NATURE, V444, P687, DOI 10.1038/444687a; Dontu G, 2005, J MAMMARY GLAND BIOL, V10, P75, DOI 10.1007/s10911-005-2542-5; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; HEPPNER GH, 1984, CANCER RES, V44, P2259; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; ILLMENSEE K, 1976, P NATL ACAD SCI USA, V73, P549, DOI 10.1073/pnas.73.2.549; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Li Z, 2007, CANCER CELL, V12, P542, DOI 10.1016/j.ccr.2007.11.012; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Ling H, 2010, ONCOGENE, V29, P4543, DOI 10.1038/onc.2010.186; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Smith GH, 2001, MICROSC RES TECHNIQ, V52, P190, DOI 10.1002/1097-0029(20010115)52:2<190::AID-JEMT1005>3.0.CO;2-O; Smith GH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1856; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353; Zheng XS, 2007, CANCER RES, V67, P3691, DOI 10.1158/0008-5472.CAN-06-3912	49	18	19	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2013	32	29					3410	3419		10.1038/onc.2012.341	http://dx.doi.org/10.1038/onc.2012.341			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22907433	Green Accepted			2022-12-17	WOS:000322014900002
J	van der Weyden, L; Rust, AG; McIntyre, RE; Robles-Espinoza, CD; Velasco-Herrera, MD; Strogantsev, R; Ferguson-Smith, AC; McCarthy, S; Keane, TM; Arends, MJ; Adams, DJ				van der Weyden, L.; Rust, A. G.; McIntyre, R. E.; Robles-Espinoza, C. D.; Velasco-Herrera, M. del Castillo; Strogantsev, R.; Ferguson-Smith, A. C.; McCarthy, S.; Keane, T. M.; Arends, M. J.; Adams, D. J.			Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity	ONCOGENE			English	Article						p53; Jdp2; transposon; heterozygosity; lymphoma; mice	RETROVIRAL INSERTIONAL MUTAGENESIS; JUN DIMERIZATION PROTEIN-2; AP-1 REPRESSOR PROTEIN; WILD-TYPE P53; BREAST-CANCER; CELL; MUTATIONS; GENES; SUPPRESSION; PROGRESSION	We performed a genetic screen in mice to identify candidate genes that are associated with leukaemogenesis in the context of Trp53 heterozygosity. To do this we generated Trp53 heterozygous mice carrying the T2/Onc transposon and SB11 transposase alleles to allow transposon-mediated insertional mutagenesis to occur. From the resulting leukaemias/lymphomas that developed in these mice, we identified nine loci that are potentially associated with tumour formation in the context of Trp53 heterozygosity, including AB041803 and the Jun dimerization protein 2 (Jdp2). We show that Jdp2 transcriptionally regulates the Trp53 promoter, via an atypical AP-1 site, and that Jdp2 expression negatively regulates Trp53 expression levels. This study is the first to identify a genetic mechanism for tumour formation in the context of Trp53 heterozygosity. Oncogene (2013) 32, 397-402; doi:10.1038/onc.2012.56; published online 27 February 2012	[van der Weyden, L.; Rust, A. G.; McIntyre, R. E.; Robles-Espinoza, C. D.; Velasco-Herrera, M. del Castillo; McCarthy, S.; Keane, T. M.; Adams, D. J.] Wellcome Trust Sanger Inst, Cambridge, England; [Strogantsev, R.; Ferguson-Smith, A. C.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England; [Arends, M. J.] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England	Wellcome Trust Sanger Institute; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Adams, DJ (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton CB10 1HH, Cambs, England.	da1@sanger.ac.uk	Robles-Espinoza, Carla Daniela/L-2560-2019; van der Weyden, Louise/AAV-5711-2021	Robles-Espinoza, Carla Daniela/0000-0003-3277-7466; van der Weyden, Louise/0000-0002-0645-1879; Del Castillo Velasco Herrera, Martin/0000-0001-5956-0211; Rust, Alistair/0000-0001-7287-192X; McCarthy, Shane/0000-0002-2715-4187; Ferguson-Smith, Anne/0000-0002-7608-5894; Adams, David/0000-0001-9490-0306	Cancer Research UK; Wellcome Trust; Kay Kendall Leukaemia Fund; Consejo Nacional de Ciencia y Tecnologia (CONACYT); MRC [G0800024] Funding Source: UKRI; Cancer Research UK [13031, 14356] Funding Source: researchfish; Medical Research Council [G0800024] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission); Kay Kendall Leukaemia Fund; Consejo Nacional de Ciencia y Tecnologia (CONACYT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	DJA was supported by Cancer Research UK and the Wellcome Trust. LvdW was supported by the Kay Kendall Leukaemia Fund. CDRE was supported by Consejo Nacional de Ciencia y Tecnologia (CONACYT) and the Wellcome Trust. MJA and REM were supported by Cancer Research UK.	Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bitton-Worms K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-54; Collier LS, 2009, CANCER RES, V69, P8429, DOI 10.1158/0008-5472.CAN-09-1760; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Dail M, 2010, P NATL ACAD SCI USA, V107, P5106, DOI 10.1073/pnas.1001064107; de Ridder J, 2006, PLOS COMPUT BIOL, V2, P1530, DOI 10.1371/journal.pcbi.0020166; Demarest RM, 2008, ONCOGENE, V27, P5082, DOI 10.1038/onc.2008.222; Donehower LA, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001081; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Dube N, 2008, CELL SIGNAL, V20, P1608, DOI 10.1016/j.cellsig.2008.05.006; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giguere A, 2011, GENE CHROMOSOME CANC, V50, P228, DOI 10.1002/gcc.20848; Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784; Gutierrez A, 2011, J EXP MED, V208, P1595, DOI 10.1084/jem.20101691; Iwasaki M, 2010, BIOCHEM BIOPH RES CO, V400, P413, DOI 10.1016/j.bbrc.2010.08.092; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; Nakade K, 2009, J BIOL CHEM, V284, P10808, DOI 10.1074/jbc.M808333200; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Pan J, 2010, ONCOGENE, V29, P6245, DOI 10.1038/onc.2010.355; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Rasmussen MH, 2009, NUCLEIC ACIDS RES, V37, P4657, DOI 10.1093/nar/gkp469; Robles AI, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001016; Sedlacek Z, 1998, BRIT J CANCER, V77, P1034, DOI 10.1038/bjc.1998.172; Severson EA, 2009, MOL BIOL CELL, V20, P1916, DOI 10.1091/mbc.E08-10-1014; Stewart M, 2007, CANCER RES, V67, P5126, DOI 10.1158/0008-5472.CAN-07-0433; Trbusek M, 2011, J CLIN ONCOL, V29, P2703, DOI 10.1200/JCO.2011.34.7872; Uren AG, 2005, ONCOGENE, V24, P7656, DOI 10.1038/sj.onc.1209043; Uren AG, 2008, CELL, V133, P727, DOI 10.1016/j.cell.2008.03.021; Uren AG, 2009, NAT PROTOC, V4, P789, DOI 10.1038/nprot.2009.64; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Wang SW, 2011, CURR PHARM DESIGN, V17, P2278, DOI 10.2174/138161211797052394; Xu YH, 2010, INT J BIOL MARKER, V25, P136, DOI 10.1177/172460081002500303; Zheng BH, 2002, CANCER BIOL THER, V1, P433, DOI 10.4161/cbt.1.4.24	42	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					397	402		10.1038/onc.2012.56	http://dx.doi.org/10.1038/onc.2012.56			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370638	Green Published, hybrid			2022-12-17	WOS:000314736600013
J	Miao, B; Skidan, I; Yang, J; You, Z; Fu, X; Famulok, M; Schaffhausen, B; Torchilin, V; Yuan, J; Degterev, A				Miao, B.; Skidan, I.; Yang, J.; You, Z.; Fu, X.; Famulok, M.; Schaffhausen, B.; Torchilin, V.; Yuan, J.; Degterev, A.			Inhibition of cell migration by PITENINs: the role of ARF6	ONCOGENE			English	Article						ARF6 guanine nucleotide exchange factor; ARNO/GRP1 membrane translocation; lamellipodia suppression; anti-angiogenesis; anti-metastasis	GUANINE-NUCLEOTIDE-EXCHANGE; RIBOSYLATION FACTOR 6; PLECKSTRIN-HOMOLOGY DOMAINS; PLASMA-MEMBRANE; MAMMALIAN-CELLS; PATHWAY; PROTEINS; BINDING; SEC7; ARNO	We have reported previously the development of small-molecule phosphatidylinositol-3,4,5-trisphosphate (PIP3) antagonists (PITs) that block pleckstrin homology (PH) domain interaction, including activation of Akt, and show anti-tumor potential. Here we show that the same molecules inhibit growth factor-induced actin remodeling, lamellipodia formation and, ultimately, cell migration and invasion, consistent with an important role of PIP3 in these processes. In vivo, a PIT-1 analog displays significant inhibition on tumor angiogenesis and metastasis. ADP ribosylation factor 6 (ARF6) was recently identified as an important mediator of cytoskeleton and cell motility, which is regulated by PIP3-dependent membrane translocation of the guanine nucleotide exchange factors (GEFs), such as ADP-ribosylation factor nucleotide binding site opener (ARNO) and general receptor for 3-phosphoinositides (GRP1). We demonstrate that PITs inhibit PIP3/ARNO or GRP1 PH domain binding and membrane localization, resulting in the inhibition of ARF6 activation. Importantly, we show that expression of the constitutively active mutant of ARF6 attenuates inhibition of lamellipodia formation and cell migration by PITs, confirming that inhibition of ARF6 contributes to inhibition of these processes by PITs. Overall, our studies demonstrate the feasibility of developing specific small-molecule targeting PIP3 binding by PH domains as potential anticancer agents that can simultaneously interfere with cancer development at multiple points. Oncogene (2012) 31, 4317-4332; doi:10.1038/onc.2011.593; published online 19 December 2011	[Miao, B.; You, Z.; Schaffhausen, B.; Degterev, A.] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; [Skidan, I.; Torchilin, V.] Northeastern Univ, Dept Pharmaceut Sci, Ctr Pharmaceut Biotechnol & Nanomed, Boston, MA 02115 USA; [Skidan, I.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurosci Ctr, Charlestown, MA USA; [Fu, X.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; [Famulok, M.] Univ Bonn, Program Unit Chem Biol & Med Chem, LIMES Inst, Bonn, Germany; [Yuan, J.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA	Tufts University; Northeastern University; Harvard University; Massachusetts General Hospital; Tufts University; United States Department of Agriculture (USDA); University of Bonn; Harvard University; Harvard Medical School	Degterev, A (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.	alexei.degterev@tufts.edu	fu, xueyan/C-1126-2012		Smith Family Award for Excellence in Biomedical Research; National Institute on Aging Mentored Research Scientist Career Development Award; US Army [DAMD17-02-1-0403]; National Cancer Institute [RO1 CA34722/PO1-50661]; National Institute on Aging [R37 AG012859]; NATIONAL CANCER INSTITUTE [R01CA034722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012859] Funding Source: NIH RePORTER	Smith Family Award for Excellence in Biomedical Research; National Institute on Aging Mentored Research Scientist Career Development Award; US Army(United States Department of DefenseUnited States Army); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr Joan Brugge (Harvard Medical School), Dr Tamas Balla (National Institutes of Health) and Dr Philippe Chavrier (Institut Curie) for the gifts of plasmids and cells. We thank Dr Jeff Peterson (Fox Chase Cancer Center, Philadelphia, PA, USA) for providing valuable comments. This work was supported by Smith Family Award for Excellence in Biomedical Research and National Institute on Aging Mentored Research Scientist Career Development Award (to AD), an Innovator Award from US Army (DAMD17-02-1-0403), National Cancer Institute (RO1 CA34722/PO1-50661) (to BSS) and the National Institute on Aging (R37 AG012859) (to JY).	Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Balana ME, 2005, J CELL SCI, V118, P2201, DOI 10.1242/jcs.02351; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cox R, 2004, MOL BIOL CELL, V15, P1487, DOI 10.1091/mbc.E03-06-0443; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Esteban PF, 2006, J CELL BIOL, V173, P291, DOI 10.1083/jcb.200512013; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Gillingham AK, 2007, ANNU REV CELL DEV BI, V23, P579, DOI 10.1146/annurev.cellbio.23.090506.123209; Hafner M, 2006, NATURE, V444, P941, DOI 10.1038/nature05415; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Hu B, 2009, CANCER RES, V69, P794, DOI 10.1158/0008-5472.CAN-08-2110; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; Macia E, 2008, J BIOL CHEM, V283, P19836, DOI 10.1074/jbc.M800781200; Miao BC, 2010, P NATL ACAD SCI USA, V107, P20126, DOI 10.1073/pnas.1004522107; Muralidharan-Chari V, 2009, CANCER RES, V69, P2201, DOI 10.1158/0008-5472.CAN-08-1301; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Park WS, 2008, MOL CELL, V30, P381, DOI 10.1016/j.molcel.2008.04.008; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Tague SE, 2004, P NATL ACAD SCI USA, V101, P9671, DOI 10.1073/pnas.0403531101; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Viaud J, 2007, P NATL ACAD SCI USA, V104, P10370, DOI 10.1073/pnas.0700773104; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006	38	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	39					4317	4332		10.1038/onc.2011.593	http://dx.doi.org/10.1038/onc.2011.593			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22179837	Green Accepted, Green Submitted			2022-12-17	WOS:000309520200006
J	Pichierri, P; Nicolai, S; Cignolo, L; Bignami, M; Franchitto, A				Pichierri, P.; Nicolai, S.; Cignolo, L.; Bignami, M.; Franchitto, A.			The RAD9-RAD1-HUS1 (9.1.1) complex interacts with WRN and is crucial to regulate its response to replication fork stalling	ONCOGENE			English	Article						RecQ helicases; replication checkpoint; genome instability; Werner syndrome	WERNER-SYNDROME PROTEIN; DNA-POLYMERASE-BETA; GENOMIC INSTABILITY; HELICASE ACTIVITY; CHK1 ACTIVATION; COMMON PATHWAY; MRE11 COMPLEX; MOUSE HUS1; CELL-CYCLE; S-PHASE	The WRN protein belongs to the RecQ family of DNA helicases and is implicated in replication fork restart, but how its function is regulated remains unknown. We show that WRN interacts with the 9.1.1 complex, one of the central factors of the replication checkpoint. This interaction is mediated by the binding of the RAD1 subunit to the N-terminal region of WRN and is instrumental for WRN relocalization in nuclear foci and its phosphorylation in response to replication arrest. We also find that ATR-dependent WRN phosphorylation depends on TopBP1, which is recruited by the 9.1.1 complex in response to replication arrest. Finally, we provide evidence for a cooperation between WRN and 9.1.1 complex in preventing accumulation of DNA breakage and maintaining genome integrity at naturally occurring replication fork stalling sites. Taken together, our data unveil a novel functional interplay between WRN helicase and the replication checkpoint, contributing to shed light into the molecular mechanism underlying the response to replication fork arrest. Oncogene (2012) 31, 2809-2823; doi:10.1038/onc.2011.468; published online 17 October 2011	[Pichierri, P.] Ist Super Sanita, Sect Expt & Computat Carcinogenesis, Dept Environm & Primary Prevent, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Pichierri, P (corresponding author), Ist Super Sanita, Sect Expt & Computat Carcinogenesis, Dept Environm & Primary Prevent, Viale Regina Elena 299, I-00161 Rome, Italy.	pietro.pichierri@iss.it	Pichierri, Pietro/AAA-5476-2021; Franchitto, Annapaola/K-7564-2016	Pichierri, Pietro/0000-0002-2702-3523; Franchitto, Annapaola/0000-0003-4232-4727	Fondazione Telethon [GGP04094]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG9294, IG4400]	Fondazione Telethon(Fondazione TelethonEuropean Commission); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We are grateful to Drs L Comai and M Lalle for providing recombinant proteins and Drs D Toniolo and M Rocchi for providing BACs for FISH analysis. This work was supported by Fondazione Telethon to PP (Grant no. GGP04094) and, in part, by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) to PP (Grant no. IG9294) and AF (Grant no. IG4400).	Ammazzalorso F, 2010, EMBO J, V29, P3156, DOI 10.1038/emboj.2010.205; Bao SL, 2004, ONCOGENE, V23, P5586, DOI 10.1038/sj.onc.1207753; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Cheng WH, 2007, EXP GERONTOL, V42, P871, DOI 10.1016/j.exger.2007.04.011; Cheng WH, 2004, J BIOL CHEM, V279, P21169, DOI 10.1074/jbc.M312770200; Cheng WH, 2003, MOL CELL BIOL, V23, P6385, DOI 10.1128/MCB.23.18.6385-6395.2003; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; Dore AS, 2009, MOL CELL, V34, P735, DOI 10.1016/j.molcel.2009.04.027; Franchitto A, 2004, CELL CYCLE, V3, P1331, DOI 10.4161/cc.3.10.1185; Franchitto A, 2008, J CELL BIOL, V183, P241, DOI 10.1083/jcb.200803173; Furuya K, 2004, GENE DEV, V18, P1154, DOI 10.1101/gad.291104; Glover TW, 2005, HUM MOL GENET, V14, pR197, DOI 10.1093/hmg/ddi265; Guan X, 2007, NUCLEIC ACIDS RES, V35, P2463, DOI 10.1093/nar/gkm075; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harrigan JA, 2006, NUCLEIC ACIDS RES, V34, P745, DOI 10.1093/nar/gkj475; Hopkins KM, 2004, MOL CELL BIOL, V24, P7235, DOI 10.1128/MCB.24.16.7235-7248.2004; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lee J, 2007, J BIOL CHEM, V282, P28036, DOI 10.1074/jbc.M704635200; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Machwe A, 2006, BIOCHEMISTRY-US, V45, P13939, DOI 10.1021/bi0615487; Martin GM, 2000, NATURE, V408, P263, DOI 10.1038/35041705; Mordes DA, 2008, GENE DEV, V22, P1478, DOI 10.1101/gad.1666208; Muftuoglu M, 2008, HUM GENET, V124, P369, DOI 10.1007/s00439-008-0562-0; Muftuoglu M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001918; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Perry JJP, 2006, NAT STRUCT MOL BIOL, V13, P414, DOI 10.1038/nsmb1088; Pichierri P, 2004, EMBO J, V23, P3154, DOI 10.1038/sj.emboj.7600277; Pichierri P, 2003, ONCOGENE, V22, P1491, DOI 10.1038/sj.onc.1206169; Pichierri Pietro, 2007, Ital J Biochem, V56, P130; Pirzio LM, 2008, J CELL BIOL, V180, P305, DOI 10.1083/jcb.200705126; Rodriguez-Lopez AM, 2003, MECH AGEING DEV, V124, P167, DOI 10.1016/S0047-6374(02)00131-8; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Sidorova JM, 2008, DNA REPAIR, V7, P1776, DOI 10.1016/j.dnarep.2008.07.017; Toueille M, 2004, NUCLEIC ACIDS RES, V32, P3316, DOI 10.1093/nar/gkh652; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; Weiss RS, 2000, GENE DEV, V14, P1886; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Xu M, 2009, J BIOL CHEM, V284, P20457, DOI 10.1074/jbc.C109.022384; Zhu M, 2007, MOL BIOL CELL, V18, P1044, DOI 10.1091/mbc.E06-10-0957; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	48	18	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	23					2809	2823		10.1038/onc.2011.468	http://dx.doi.org/10.1038/onc.2011.468			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	22002307	Green Accepted			2022-12-17	WOS:000305277900002
J	Zhang, J; Zhu, F; Li, X; Dong, Z; Xu, Y; Peng, C; Li, S; Cho, YY; Yao, K; Zykova, TA; Bode, AM; Dong, Z				Zhang, J.; Zhu, F.; Li, X.; Dong, Z.; Xu, Y.; Peng, C.; Li, S.; Cho, Y-Y; Yao, K.; Zykova, T. A.; Bode, A. M.; Dong, Z.			Rack1 protects N-terminal phosphorylated c-Jun from Fbw7-mediated degradation	ONCOGENE			English	Article						cell transformation; Rack1; c-Jun; phosphorylation; degradation	UBIQUITIN LIGASE; JNK; RAS; AP-1; RECOGNITION; ACTIVATION; RECEPTOR; TARGETS	The c-Jun transcription factor is a highly unstable oncoprotein. Several ubiquitin ligases mediate c-Jun degradation. However, c-Jun can be stabilized once it is phosphorylated at the N-terminus by c-Jun N-terminal kinases (JNKs) or other protein kinases. This phosphorylation decreases c-Jun ubiquitination and degradation. The underlying mechanism for this phenomenon is still unknown. Here, we show that receptor for activated C-kinase 1 (Rack1) can bind with c-Jun and ubiquitin ligase Fbw7 to form a complex. When c-Jun is phosphorylated at the N-terminus, c-Jun is released from the complex and cannot be ubiquitinated by Fbw7, which leads to increased stabilization and accumulation of c-Jun. These results reveal that Rack1 has a very important role in tumorigenesis by maintaining the stability of c-Jun that has been phosphorylated at its N-terminus by JNKs or other kinases. Oncogene (2012) 31, 1835-1844; doi: 10.1038/onc.2011.369; published online 22 August 2011	[Zhang, J.; Zhu, F.; Li, X.; Xu, Y.; Peng, C.; Li, S.; Cho, Y-Y; Yao, K.; Zykova, T. A.; Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, Dept Cellular & Mol Biol, 801 16th Ave NE, Austin, MN 55912 USA; [Li, X.; Dong, Z.] Zhengzhou Univ, Basic Med Sch, Zhengzhou, Peoples R China; [Cho, Y-Y] Catholic Univ Korea, Coll Pharm, Gyeonggi Do, South Korea	University of Minnesota System; Zhengzhou University; Catholic University of Korea	Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, Dept Cellular & Mol Biol, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	ZHU, Feng/C-1303-2010; zhang, jinhui/GXF-6528-2022; Cho, Yong-Yeon/AAD-4263-2020; ZHU, Feng/G-3567-2010	Zhu, Feng/0000-0003-1172-0102; Cho, Yong-Yeon/0000-0003-1107-2651	The Hormel Foundation; National Institutes of Health [CA077646, CA111536, CA120388, ES016548, R37 CA081064]; NATIONAL CANCER INSTITUTE [R37CA081064, R01CA077646, R01CA111536, R01CA120388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016548] Funding Source: NIH RePORTER	The Hormel Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Wang Luhai and Dr Ronai Ze'ev for providing the HA-FL-Rack1, HA-WD1-4-Rack1 and HA-WD5-7-Rack1 vectors and Dr Wei Wenyi for providing the Flag-wt-c-Jun, Flag-Delta JNK-c-Jun, Flag-AF-c-Jun and Flag-AF-Delta JNK-c-Jun plasmids. We also thank Dr Bohmann Dirk for providing the c-Jun<SUP>Ala</SUP> and c-Jun<SUP>Asp</SUP> mutant c-Jun plasmids. This study was supported by The Hormel Foundation and National Institutes of Health grants CA077646, CA111536, CA120388, ES016548 and R37 CA081064.	Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Cao XX, 2010, BREAST CANCER RES TR, V123, P375, DOI 10.1007/s10549-009-0657-x; Cao XX, 2010, INT J CANCER, V127, P1172, DOI 10.1002/ijc.25120; Cho YY, 2009, CANCER RES, V69, P272, DOI 10.1158/0008-5472.CAN-08-3125; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Dong Z, 1994, EARLY DETECTION CANC, P123; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Egidy G, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-34; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nagashio R, 2010, LUNG CANCER, V69, P54, DOI 10.1016/j.lungcan.2009.09.015; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Thornton C, 2004, J BIOL CHEM, V279, P31357, DOI 10.1074/jbc.M402316200; Vomastek T, 2007, MOL CELL BIOL, V27, P8296, DOI 10.1128/MCB.00598-07; Wang Z, 2008, MOL CELL PROTEOMICS, V7, P1639, DOI 10.1074/mcp.M700520-MCP200; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200	36	18	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1835	1844		10.1038/onc.2011.369	http://dx.doi.org/10.1038/onc.2011.369			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860413				2022-12-17	WOS:000302785200009
J	Rowh, MAW; DeMicco, A; Horowitz, JE; Yin, B; Yang-Iott, KS; Fusello, AM; Hobeika, E; Reth, M; Bassing, CH				Rowh, M. A. W.; DeMicco, A.; Horowitz, J. E.; Yin, B.; Yang-Iott, K. S.; Fusello, A. M.; Hobeika, E.; Reth, M.; Bassing, C. H.			Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations	ONCOGENE			English	Article						p53; B lineage lymphomas; Igh/c-myc translocations	DOUBLE-STRAND BREAKS; GENOMIC INSTABILITY; V(D)J RECOMBINATION; TRANSGENIC MICE; DNA BREAKS; GENE AMPLIFICATION; CRE RECOMBINASE; HISTONE H2AX; P53; MYC	Inactivating Tp53 mutations are frequent genetic lesions in human tumors that harbor genomic instability, including B lineage lymphomas with IG translocations. Antigen receptor genes are assembled and modified in developing lymphocytes by RAG/AID-initiated genomic rearrangements that involve the induction of DNA double strand breaks (DSBs). Although TP53 inhibits the persistence of DSBs and induces apoptosis to protect cells from genomic instability and transformation, the development of spontaneous tumors harboring clonal translocations has not been reported in mice that only lack wild-type Tp53 protein or express Tp53 mutants. Tp53-deficient (Tp53(-/-)) mice succumb to T lineage lymphomas lacking clonal translocations but develop B lymphoid tumors containing immunoglobulin (Ig) translocations upon combined inactivation of DSB repair factors, RAG mutation or AID overexpression; mice expressing apoptosis-defective Tp53 mutants develop B cell lymphomas that have not been characterized for potential genomic instability. As somatic rather than germline inactivating mutations of TP53 are typically associated with human cancers and Tp53 deletion has cellular context dependent effects upon lymphocyte transformation, we generated mice with conditional Tp53 deletion in lineage-committed B lymphocytes to avoid complications associated with defective Tp53 responses during embryogenesis and/or in multilineage potential cells and, thereby, directly evaluate the potential physiological role of Tp53 in suppressing translocations in differentiated cells. These mb1-cre: Tp53(flox)/(flox) mice succumbed to lymphoid tumors containing Ig gene rearrangements and immunophenotypes characteristic of B cells from various developmental stages. Most mb1-cre: Tp53(flox)/(flox) tumors harbored clonal translocations, including Igh/c-myc or other oncogenic translocations generated by the aberrant repair of RAG/AID-generated DSBs. Our data indicate that Tp53 serves critical functions in B lineage lymphocytes to prevent transformation caused by translocations in cell populations experiencing physiological levels of RAG/AID-initiated DSB intermediates, and provide evidence that the somatic TP53 mutations found in diffuse large B-cell lymphoma and Burkitt's lymphoma may contribute to the development of these human malignancies. Oncogene (2011) 30, 4757-4764; doi:10.1038/onc.2011.191; published online 30 May 2011	[Bassing, C. H.] Univ Penn, Dept Pathol, CHOP, Immunol Grad Grp,Sch Med, Philadelphia, PA 19104 USA; [Rowh, M. A. W.; DeMicco, A.; Horowitz, J. E.; Yin, B.; Yang-Iott, K. S.; Fusello, A. M.; Bassing, C. H.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Dept Pathol & Lab Med, Div Canc Pathobiol, Philadelphia, PA 19104 USA; [Rowh, M. A. W.; DeMicco, A.; Horowitz, J. E.; Yin, B.; Yang-Iott, K. S.; Fusello, A. M.; Bassing, C. H.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [DeMicco, A.; Yin, B.; Bassing, C. H.] Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; [Hobeika, E.; Reth, M.] Univ Freiburg, BIOSS, Ctr Biol Signaling Studies, D-79106 Freiburg, Germany; [Hobeika, E.; Reth, M.] Max Planck Inst Immunobiol, Freiburg, Germany	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Freiburg; Max Planck Society	Bassing, CH (corresponding author), Univ Penn, Dept Pathol, CHOP, Immunol Grad Grp,Sch Med, 4054 Colket Translat Res Bldg,421 Curie Blvd,3501, Philadelphia, PA 19104 USA.	bassing@email.chop.edu	hobeika, elias/AAV-6663-2021	Rowh, Marta/0000-0001-9584-7826	University of Pennsylvania [5T32-AR007442-23, GM-07229]; Cancer Research Institute; Department of Pathology and Laboratory Medicine; Center for Childhood Cancer Research of the Children's Hospital of Philadelphia Research Institute; Abramson Family Cancer Research Institute of the University of Pennsylvania School of Medicine; Pennsylvania Department of Health; Leukemia and Lymphoma Society; National Institutes of Health [R01 CA125195]; NATIONAL CANCER INSTITUTE [R01CA125195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007442] Funding Source: NIH RePORTER	University of Pennsylvania; Cancer Research Institute; Department of Pathology and Laboratory Medicine; Center for Childhood Cancer Research of the Children's Hospital of Philadelphia Research Institute; Abramson Family Cancer Research Institute of the University of Pennsylvania School of Medicine; Pennsylvania Department of Health; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the Training Program Rheumatic Disease of the University of Pennsylvania (5T32-AR007442-23 to MAWR), the Training Grant TG GM-07229 of the University of Pennsylvania (AD), the Cancer Research Institute Pre-doctoral Emphasis Pathway in Tumor Immunology Training Grant awarded to the University of Pennsylvania (BY); the Department of Pathology and Laboratory Medicine and the Center for Childhood Cancer Research of the Children's Hospital of Philadelphia Research Institute, the Abramson Family Cancer Research Institute of the University of Pennsylvania School of Medicine, a grant from the Pennsylvania Department of Health, a Leukemia and Lymphoma Society Scholar Award (CHB), and the National Institutes of Health Grant R01 CA125195 (CHB).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2008, BLOOD, V111, P2163, DOI 10.1182/blood-2007-08-104760; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Cheung AMY, 2002, CANCER RES, V62, P6194; Cheung KJJ, 2009, BRIT J HAEMATOL, V146, P257, DOI 10.1111/j.1365-2141.2009.07739.x; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dujka ME, 2010, ONCOGENE, V29, P957, DOI 10.1038/onc.2009.394; Fishler T, 2010, ONCOGENE, V29, P4007, DOI 10.1038/onc.2010.163; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Giblin W, 2009, BLOOD, V113, P2965, DOI 10.1182/blood-2008-07-165167; Gladdy RA, 2003, CANCER CELL, V3, P37, DOI 10.1016/S1535-6108(02)00236-2; Hobeika E, 2006, P NATL ACAD SCI USA, V103, P13789, DOI 10.1073/pnas.0605944103; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; MacPherson D, 2004, EMBO J, V23, P3689, DOI 10.1038/sj.emboj.7600363; Nepal RM, 2008, ONCOGENE, V27, P4752, DOI 10.1038/onc.2008.111; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Robbiani DF, 2009, MOL CELL, V36, P631, DOI 10.1016/j.molcel.2009.11.007; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Ryu CJ, 2006, CANCER CELL, V9, P109, DOI 10.1016/j.ccr.2006.01.004; Santos MA, 2010, J EXP MED, V207, P973, DOI 10.1084/jem.20092308; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Slatter TL, 2010, CELL DEATH DIFFER, V17, P540, DOI 10.1038/cdd.2009.136; Smith DP, 2005, ONCOGENE, V24, P3544, DOI 10.1038/sj.onc.1208399; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang JH, 2009, NATURE, V460, P231, DOI 10.1038/nature08159; Wang JH, 2008, J EXP MED, V205, P3079, DOI 10.1084/jem.20082271; Wu C, 2003, IMMUNITY, V18, P75, DOI 10.1016/S1074-7613(02)00515-0; Yin B, 2010, BLOOD OCT, V117, P175; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	39	18	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	47					4757	4764		10.1038/onc.2011.191	http://dx.doi.org/10.1038/onc.2011.191			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21625223				2022-12-17	WOS:000298033700008
J	Kim, HD; Kim, TS; Kim, J				Kim, H. D.; Kim, T-S; Kim, J.			Aberrant ribosome biogenesis activates c-Myc and ASK1 pathways resulting in p53-dependent G1 arrest	ONCOGENE			English	Article						ASK1; c-Myc; p53; rpL11; rpS3; ribosomal stress	DIAMOND-BLACKFAN ANEMIA; RIBOTOXIC STRESS-RESPONSE; CELL-CYCLE; MESSENGER-RNA; PROTEIN L26; P53; TRANSLATION; CANCER; CHECKPOINT; L11	The largest energy consumer in the cell is the ribosome biogenesis whose aberrancy elicits various diseases in humans. It has been recently revealed that p53 induction, along with cell cycle arrest, is related with abnormal ribosome biogenesis, but the exact mechanism still remains unknown. In this study, we have found that aberrant ribosome biogenesis activates two parallel cellular pathways, c-Myc and ASK1/p38, which result in p53 induction and G1 arrest. The c-Myc stabilizes p53 by rpL11-mediated HDM2 inhibition, and ASK1/p38 activates p53 by phosphorylation on serine 15 and 33. Our studies demonstrate the relationship between these two pathways and p53 induction. The changes caused by impaired ribosomal stress, such as p53 induction and G1 arrest, were completely disappeared by inhibition of either pathway. These findings suggest a monitoring mechanism of c-Myc and ASK1/p38 against abnormal ribosome biogenesis through controlling the stability and activity of p53 protein. Oncogene (2011) 30, 3317-3327; doi:10.1038/onc.2011.47; published online 7 March 2011	[Kim, J.] Korea Univ, Biochem Lab, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; [Kim, J.] Korea Univ, BioInst, Seoul 136701, South Korea	Korea University; Korea University	Kim, J (corresponding author), Korea Univ, Biochem Lab, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	joonkim@korea.ac.kr			Ministry of Education and Science of Korea [FPR08B1-230, 2008-0059301, 2009-0086319]	Ministry of Education and Science of Korea(Ministry of Education (MOE), Republic of Korea)	We thank Professor E-J Choi (Korea University, Seoul, Korea) for the kind gifts of ASK1 antibody and GST-MKK6 protein. This work was supported in part by FPR08B1-230, 2008-0059301 and 2009-0086319 NRF Grants from Ministry of Education and Science of Korea.	Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Anderson SJ, 2007, IMMUNITY, V26, P759, DOI 10.1016/j.immuni.2007.04.012; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Belin S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007147; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Cazzaniga G, 2005, BLOOD, V106, P1419, DOI 10.1182/blood-2005-03-0899; Cleveland JL, 2004, CANCER CELL, V6, P309, DOI 10.1016/j.ccr.2004.09.020; Dai MS, 2007, CELL CYCLE, V6, P2735, DOI 10.4161/cc.6.22.4895; Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895; Ellis SR, 2008, CURR TOP DEV BIOL, V82, P217, DOI 10.1016/S0070-2153(07)00008-7; Fromont-Racine M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Granneman S, 2004, EXP CELL RES, V296, P43, DOI 10.1016/j.yexcr.2004.03.016; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Idol RA, 2007, BLOOD CELL MOL DIS, V39, P35, DOI 10.1016/j.bcmd.2007.02.001; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Kim HD, 2010, J CELL BIOCHEM, V110, P294, DOI 10.1002/jcb.22537; Kim TS, 2009, BBA-MOL CELL RES, V1793, P395, DOI 10.1016/j.bbamcr.2008.10.017; Kim TS, 2006, MOL BIOL CELL, V17, P824, DOI 10.1091/mbc.E05-08-0713; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; Laskin JD, 2002, TOXICOL SCI, V69, P289, DOI 10.1093/toxsci/69.2.289; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Liu JM, 2006, BLOOD, V107, P4583, DOI 10.1182/blood-2005-12-4831; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Maggi LB, 2005, CANCER INVEST, V23, P599, DOI 10.1080/07357900500283085; Menne TF, 2007, NAT GENET, V39, P486, DOI 10.1038/ng1994; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Oliver ER, 2004, DEVELOPMENT, V131, P3907, DOI 10.1242/dev.01268; Opferman JT, 2006, CELL DEATH DIFFER, V13, P898, DOI 10.1038/sj.cdd.4401923; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Robledo S, 2008, RNA, V14, P1918, DOI 10.1261/rna.1132008; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sulic S, 2005, GENE DEV, V19, P3070, DOI 10.1101/gad.359305; Sumbayev VV, 2005, ARCH BIOCHEM BIOPHYS, V436, P406, DOI 10.1016/j.abb.2005.02.021; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zimmermann RA, 2003, CELL, V115, P130, DOI 10.1016/S0092-8674(03)00804-3	45	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	30					3317	3327		10.1038/onc.2011.47	http://dx.doi.org/10.1038/onc.2011.47			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21383696				2022-12-17	WOS:000293215700002
J	Roberts, CG; Millar, EKA; O'Toole, SA; McNeil, CM; Lehrbach, GM; Pinese, M; Tobelmann, P; McCloy, RA; Musgrove, EA; Sutherland, RL; Butt, AJ				Roberts, C. G.; Millar, E. K. A.; O'Toole, S. A.; McNeil, C. M.; Lehrbach, G. M.; Pinese, M.; Tobelmann, P.; McCloy, R. A.; Musgrove, E. A.; Sutherland, R. L.; Butt, A. J.			Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer	ONCOGENE			English	Article						PUMA; breast cancer; tamoxifen	ENDOCRINE RESISTANCE; BH3-ONLY PROTEIN; C-MYC; EXPRESSION; P53; SURVIVAL; THERAPY; DETERMINANTS; NETWORKS	Recognition of the pivotal role of estrogen in the aetiology of breast cancer has led to the development of antiestrogens (AE), such as tamoxifen (TAM) as effective therapies for the treatment and prevention of this disease. However, despite their widespread clinical efficacy, response to AEs is often short-lived, and acquired or innate therapeutic resistance remains a major obstacle in the successful treatment of breast cancer. Thus, delineating the intracellular pathways that mediate the cellular response to estrogen could potentially lead to new, more effective approaches to the treatment of breast cancer, particularly endocrine-resistant disease. Here, we have identified the BCL-2 homology 3 (BH3)-only, proapoptotic regulator, PUMA (p53 upregulated modulator of apoptosis) as an estrogen target gene that is acutely downregulated in response to estrogen in breast cancer cell lines, independently of their p53 status. PUMA is transcriptionally upregulated following treatment with TAM, and knock down of PUMA expression in these cells attenuates the apoptotic response to TAM. Furthermore, low PUMA expression in breast carcinomas is significantly associated with breast cancer-specific death (P=0.0014 and P=0.0115, for mRNA and protein, respectively), and worse outcome in TAM-treated patients (mRNA, P=1.49e-05). These findings suggest that the dysregulation of apoptotic signaling pathways such as those executed through PUMA, can significantly impact on both the progression and therapeutic responsiveness of breast cancer. Moreover, they provide a convincing rationale for exploring new therapeutic approaches involving endocrine and non-endocrine therapies that target apoptotic pathways as an effective strategy for tackling endocrine refractory disease. Oncogene (2011) 30, 3186-3197; doi:10.1038/onc.2011.36; published online 7 March 2011	[Butt, A. J.] St Vincents Hosp, Garvan Inst Med Res, Apoptosis Res Grp, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Millar, E. K. A.] St George Hosp, S Eastern Area Lab Serv, Dept Anat Pathol, Kogarah, NSW, Australia; [Millar, E. K. A.; Musgrove, E. A.; Sutherland, R. L.; Butt, A. J.] Univ Western Sydney, Sch Med, Campbelltown, NSW, Australia; [O'Toole, S. A.] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [O'Toole, S. A.] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW 2050, Australia; [O'Toole, S. A.] Univ Sydney, Sydney Med Sch, Cent Clin Sch, Sydney, NSW 2006, Australia; [McNeil, C. M.] Westmead Hosp, Dept Med Oncol, Westmead, NSW 2145, Australia; [McNeil, C. M.] Univ Sydney, Western Clin Sch, Sydney, NSW 2006, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; St George Hospital; Western Sydney University; University of New South Wales Sydney; University of Sydney; University of Sydney; University of Sydney; University of Sydney	Butt, AJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Apoptosis Res Grp, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	abutt@garvan.org.au	Millar, Ewan/ABE-9127-2020; Sutherland, Robert L/A-8378-2008	Millar, Ewan/0000-0002-9778-3253; Pinese, Mark/0000-0001-5078-6687; Butt, Alison/0000-0002-6216-5105; McCloy, Rachael/0000-0001-7791-4044	National Health and Medical Research Council (NHMRC) of Australia [535903]; Australian Cancer Research Fund; RT Hall Trust; Petre Foundation	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Cancer Research Fund; RT Hall Trust; Petre Foundation	This research was supported by a National Health and Medical Research Council (NHMRC) of Australia Program Grant 535903, the Australian Cancer Research Fund, the RT Hall Trust, the Petre Foundation, a Cancer Institute NSW Career Development and Support Fellowship (AJB), Cancer Institute NSW Clinical Research Fellowships (EKAM and SAO'T) and an NHMRC health professional training fellowship (SAO'T).	Anderson LR, 2010, ONCOGENE, V29, P527, DOI 10.1038/onc.2009.362; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Butt AJ, 2008, ADV EXP MED BIOL, V630, P189; Butt AJ, 2006, MOL CANCER THER, V5, P2300, DOI 10.1158/1535-7163.MCT-06-0170; Butt AJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1779; Cannings E, 2007, BREAST CANCER RES TR, V102, P173, DOI 10.1007/s10549-006-9323-8; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Ellis MJ, 2003, J STEROID BIOCHEM, V86, P301, DOI 10.1016/S0960-0760(03)00371-6; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hammerich-Hille S, 2010, J BIOL CHEM, V285, P3608, DOI 10.1074/jbc.M109.066431; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Hurvitz SA, 2008, CANCER-AM CANCER SOC, V113, P2385, DOI 10.1002/cncr.23875; JEFFERS JR, 2003, CANCER RES, V52, P5204; Jordan VC, 2009, CANCER RES, V69, P1243, DOI 10.1158/0008-5472.CAN-09-0029; Karst AM, 2005, ONCOGENE, V24, P1111, DOI 10.1038/sj.onc.1208374; MILLAR EKA, 2008, BRIT J CANCER, V100, P123; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Musgrove EA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002987; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naresh A, 2008, CANCER RES, V68, P6387, DOI 10.1158/0008-5472.CAN-08-0538; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Reimer T, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr456; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Swaby RF, 2007, REV ENDOCR METAB DIS, V8, P229, DOI 10.1007/s11154-007-9034-4; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vousden KH, 2005, SCIENCE, V309, P1685, DOI 10.1126/science.1118232; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	36	18	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	28					3186	3197		10.1038/onc.2011.36	http://dx.doi.org/10.1038/onc.2011.36			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21383694				2022-12-17	WOS:000292726300007
J	Neumann, M; Klar, S; Wilisch-Neumann, A; Hollenbach, E; Kavuri, S; Leverkus, M; Kandolf, R; Brunner-Weinzierl, MC; Klingel, K				Neumann, M.; Klar, S.; Wilisch-Neumann, A.; Hollenbach, E.; Kavuri, S.; Leverkus, M.; Kandolf, R.; Brunner-Weinzierl, M. C.; Klingel, K.			Glycogen synthase kinase-3 beta is a crucial mediator of signal-induced RelB degradation	ONCOGENE			English	Article						RelB; NF-kappa B; GSK-3 beta; proteasomal degradation	NF-KAPPA-B; LIVER DEGENERATION; MICE LACKING; KINASE; PHOSPHORYLATION; GLYCOGEN-SYNTHASE-KINASE-3-BETA; TRANSCRIPTION; REQUIREMENT; INHIBITION; GSK-3-BETA	The immediate early transcription factor nuclear factor (I kappa Bs) kappa B (NF-kappa B) is crucially involved in the regulation of numerous physiological or pathophysiological processes such as inflammation and tumourigenesis. Therefore, the control of NF-kappa B activity, which is mainly regulated by signal-induced degradation of cytoplasmic inhibitors of NF-kappa B (I kappa Bs), is of high relevance. One known alternative pathway of NF-kappa B regulation is the stimulus-induced proteasomal degradation of RelB, a component of the NF-kappa B dimer. Here, we identified the serine/threonine protein kinase glycogen synthase kinase-3 beta (GSK-3 beta) as a critical signalling component leading to RelB degradation. In Jurkat leukaemic T cells as well as in primary human T cells, tetradecanoylphorbolacetate/ionomycinand CD3/CD28-induced RelB degradation were impaired by a GSK-3 beta-specific pharmacological inhibitor, an ectopically expressed dominant-negative GSK-3 beta mutant and by small-interfering RNA-mediated silencing of GSK-3 beta expression. Furthermore, a physical interaction between RelB and GSK-3 beta was shown by co-immunoprecipitation, which was already notable in unstimulated cells. Most importantly, as demonstrated by in vitro kinase assays, human RelB is inducibly phosphorylated by GSK-3 beta, indicating a direct substrate-enzyme relationship. The serine residue 552 is a target of GSK-3 beta-mediated phosphorylation in vitro and in vivo. We conclude that GSK-3 beta is a crucial regulator of RelB degradation, stressing the relevant linkage between the NF-kappa B system and GSK-3 beta. Oncogene (2011) 30, 2485-2492; doi:10.1038/onc.2010.580; published online 10 January 2011	[Neumann, M.; Kandolf, R.; Klingel, K.] Univ Tubingen, Univ Hosp, Inst Pathol, Dept Mol Pathol, D-72076 Tubingen, Germany; [Klar, S.] Robert Koch Inst, D-1000 Berlin, Germany; [Wilisch-Neumann, A.] Otto von Guericke Univ, Inst Neuropathol, Magdeburg, Germany; [Hollenbach, E.] Univ Leipzig, Univ Hosp, Intens Care Unit, Leipzig, Germany; [Kavuri, S.; Leverkus, M.] Univ Heidelberg, Med Fac Mannheim, Dept Dermatol Venereol & Allergol, Mol Dermatol Sect, Heidelberg, Germany; [Brunner-Weinzierl, M. C.] Otto von Guericke Univ, Dept Pediat, Magdeburg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Robert Koch Institute; Otto von Guericke University; Leipzig University; Ruprecht Karls University Heidelberg; Otto von Guericke University	Neumann, M (corresponding author), Univ Tubingen, Univ Hosp, Inst Pathol, Dept Mol Pathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.	manfred.neumann@med.uni-tuebingen.de	Brunner-Weinzierl, Monika/AAB-8813-2019	Brunner-Weinzierl, Monika/0000-0002-6838-3568; Klar, Stefanie/0000-0001-5852-5692	Deutsche Forschungsgemeinschaft [NE608/3-2, LE953/5-1]; DFG [SFB-TR19]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG(German Research Foundation (DFG))	This work was supported by grants from the Deutsche Forschungsgemeinschaft (NE608/3-2 to MN; LE953/5-1 to ML) and by DFG grant SFB-TR19 (to KK and RK). We thank Sandra Bundschuh, Beatrix Kramer and Konstantin Klein for their excellent technical assistance.	Avraham E, 2005, J BIOL CHEM, V280, P42877, DOI 10.1074/jbc.M505608200; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Billadeau DD, 2007, PANCREATOLOGY, V7, P398, DOI 10.1159/000108955; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Dar AA, 2009, ONCOGENE, V28, P866, DOI 10.1038/onc.2008.434; DEGROOT RP, 1993, ONCOGENE, V8, P841; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; Forde JE, 2007, CELL MOL LIFE SCI, V64, P1930, DOI 10.1007/s00018-007-7045-7; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Marienfeld R, 2001, ONCOGENE, V20, P8142, DOI 10.1038/sj.onc.1204884; Marienfeld R, 2003, J BIOL CHEM, V278, P19852, DOI 10.1074/jbc.M301945200; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev; Ougolkov AV, 2007, BLOOD, V110, P735, DOI 10.1182/blood-2006-12-060947; Schwabe RF, 2005, FASEB J, V19, P1758, DOI 10.1096/fj.05-3736fje; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Vincent T, 2008, ONCOGENE, V27, P5254, DOI 10.1038/onc.2008.152; Yuan J, 2005, CELL DEATH DIFFER, V12, P1097, DOI 10.1038/sj.cdd.4401652	28	18	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	21					2485	2492		10.1038/onc.2010.580	http://dx.doi.org/10.1038/onc.2010.580			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21217772				2022-12-17	WOS:000291008000010
J	Fernandez, RMH; Ruiz-Miro, M; Dolcet, X; Aldea, M; Gari, E				Fernandez, R. M. H.; Ruiz-Miro, M.; Dolcet, X.; Aldea, M.; Gari, E.			Cyclin D1 interacts and collaborates with Ral GTPases enhancing cell detachment and motility	ONCOGENE			English	Article						cyclin D1; Ral GTPases; exocyst; cell motility cell adhesion; tumor spreading	MIGRATION; PHOSPHORYLATION; ACTIVATION; EXOCYST; CANCER; INDUCTION; COMPLEXES; INVASION; FILAMIN; NUMBER	Alterations in the levels of adhesion and motility of cells are critical events in the development of metastasis. Cyclin D1 (CycD1) is one of the most frequently amplified oncogenes in many types of cancers and it is also associated with the development of metastasis. Despite this, we still do not know which are all the relevant pathways by which CycD1 induces oncogenic processes. CycD1 functions can be either dependent or independent of the cyclin-dependent kinase Cdk4, and they affect several cellular aspects such as proliferation, cell attachment and migration. In this work, we reveal a novel function of CycD1 that fosters our understanding of the oncogenic potential of CycD1. We show that CycD1 binds to the small GTPases Ral A and B, which are involved, through exocyst regulation, in the progression of metastatic cancers, inducing anchorage-independent growth and cell survival of transformed cells. We show that CycD1 binds active Ral complexes and the exocyst protein Sec6, and co-localizes with Ral GTPases in trans-Golgi and exocyst-rich regions. We have also observed that CycD1-Cdk4 phosphorylates the Ral GEF Rgl2 'in vitro' and that CycD1-Cdk4 activity stimulates accumulation of the Ral GTP active forms. In accordance with this, our data suggest that CycD1-Cdk4 enhances cell detachment and motility in collaboration with Ral GTPases. This new function may help explain the contribution of CycD1 to tumor spreading. Oncogene (2011) 30, 1936-1946; doi: 10.1038/onc.2010.577; published online 17 January 2011	[Fernandez, R. M. H.; Ruiz-Miro, M.; Dolcet, X.; Aldea, M.; Gari, E.] Univ Lleida, Fac Med, Dept Ciencies Med Basiques, IRBLleida, Lleida 25008, Catalonia, Spain; [Dolcet, X.] IRBLleida, Oncol Pathol Grp, Catalonia, Spain; [Aldea, M.] CSIC, Inst Biol Mol Barcelona, Barcelona, Spain	Institut de Recerca Biomedica - IRB Lleida; Universitat de Lleida; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Gari, E (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, IRBLleida, Montserrat Roig 2, Lleida 25008, Catalonia, Spain.	eloi.gari@cmb.udl.cat	Garí, Eloi/A-5996-2010; Fernández Hernández, Rita María/C-4477-2011; Dolcet, Xavi/B-5665-2009; Aldea, Marti/K-3962-2014	Garí, Eloi/0000-0002-3505-4901; Dolcet, Xavi/0000-0003-1921-0449; Aldea, Marti/0000-0002-8710-5336	Ministry of Education and Science of Spain [BFU2007-65640/BMC, BFU2007-67929-C02- 01]; Consolider-Ingenio [CSD2007-00015]	Ministry of Education and Science of Spain(Spanish Government); Consolider-Ingenio(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	We thank N Agell, C Yeaman, JL Bos, M Matsuda, X Bustelo, P Crespo, MA del Pozo and J Herreros for the gift of plasmids and reagents, and also N Eritja, MBozic, JM Valdivielso, Lluis Fajas, Eloi Montanez and SaraWickstrom for technical advice. We are grateful to J Odajima and P Sicinski for providing CCND1<SUP>-/-</SUP> and CCND1<SUP>+/+</SUP> immortalized MEFs, and M Hendrix and E Seftor for providing R3327-50A cells. We thank S Rius, I Navarro, I Montoliu and MA Cornado for their technical assistance and the members of CYC lab for helpful discussions. This work was funded by the Ministry of Education and Science of Spain BFU2007-65640/BMC (Eloi Gari) and BFU2007-67929-C02- 01 (Marti Aldea) and Consolider-Ingenio 2010 (CSD2007-00015). RMH Fernandez and M Ruiz-Miro were supported by predoctoral fellowships from the Ministry of Education and Science of Spain.	Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-7; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bienvenu F, 2010, NATURE, V463, P374, DOI 10.1038/nature08684; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Day PJ, 2009, P NATL ACAD SCI USA, V106, P4166, DOI 10.1073/pnas.0809645106; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; Knaus M, 2007, EMBO J, V26, P4501, DOI 10.1038/sj.emboj.7601873; Kono K, 2008, MOL BIOL CELL, V19, P1763, DOI 10.1091/mbc.E07-09-0950; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Lalli G, 2009, J CELL SCI, V122, P1499, DOI 10.1242/jcs.044339; Li ZP, 2006, CANCER RES, V66, P9986, DOI 10.1158/0008-5472.CAN-06-1596; Li ZP, 2006, MOL CELL BIOL, V26, P4240, DOI 10.1128/MCB.02124-05; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lu FM, 2003, CANCER RES, V63, P7056; Luo Jan, 1997, Pathol Oncol Res, V3, P264; Marampon F, 2008, MOL BIOL CELL, V19, P2566, DOI 10.1091/mbc.E06-12-1110; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Musgrove EA, 2006, GROWTH FACTORS, V24, P13, DOI 10.1080/08977190500361812; Neumeister P, 2003, MOL BIOL CELL, V14, P2005, DOI 10.1091/mbc.02-07-0102; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Rosse C, 2006, MOL CELL BIOL, V26, P727, DOI 10.1128/MCB.26.2.727-734.2006; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shi JH, 2006, EXP CELL RES, V312, P3432, DOI 10.1016/j.yexcr.2006.07.016; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Spiczka KS, 2008, J CELL SCI, V121, P2880, DOI 10.1242/jcs.031641; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zhong ZJ, 2010, CANCER RES, V70, P2105, DOI 10.1158/0008-5472.CAN-08-1108	48	18	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1936	1946		10.1038/onc.2010.577	http://dx.doi.org/10.1038/onc.2010.577			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21242975				2022-12-17	WOS:000289777700009
J	Heijink, DM; Fehrmann, RSN; de Vries, EGE; Koornstra, JJ; Oosterhuis, D; van der Zee, AGJ; Kleibeuker, JH; de Jong, S				Heijink, D. M.; Fehrmann, R. S. N.; de Vries, E. G. E.; Koornstra, J. J.; Oosterhuis, D.; van der Zee, A. G. J.; Kleibeuker, J. H.; de Jong, S.			A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer	ONCOGENE			English	Article						pathways; microarray; gene set enrichment; adenoma; chemoprevention	DEPENDENT KINASE INHIBITOR; GENE-EXPRESSION; PROTEIN-KINASE; EARLY EVENT; DNA-DAMAGE; RB-PATHWAY; CYCLIN D1; COLON; ADENOMAS; DASATINIB	Comparing normal colorectal mucosa and adenomas focusing on deregulated pathways obtains insight into the biological processes of early colorectal carcinogenesis. Publicly available microarray expression data from 26 normal mucosa and 47 adenoma samples were analyzed. Biological pathways enriched in adenomas were identified with Gene Set Enrichment Analysis (GSEA). The analysis revealed 10, 11 and 16 gene sets distinguishing adenomas from normal mucosa according to Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Map Annotator and Pathway Profiler (GenMAPP) and Biocarta databases, respectively. Biological pathways known to be involved in colon carcinogenesis such as cell cycle (P = 0.002) and Wnt signaling (P = 0.007) were enriched in adenomas. In addition, we found enrichment of novel pathways such as retinoblastoma (Rb) pathway (P = 0.002), Src pathway (P = 0.004), folate biosynthesis (P = 0.019) and Hedgehog signaling (P = 0.037) in adenomas. Microarray results for Rb and Src pathway genes were validated by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on mRNA isolated from an independent set of adenoma and normal colon samples. A high correlation between microarray data and qRT-PCR expression data was found. The relevance of targeting of identified pathways was shown using the Rb pathway inhibitors roscovitine and PD-0332991 and the Src pathway inhibitor dasatinib. All inhibitors used induced cell growth reduction in adenoma cells. This study shows a bioinformatical and functional approach leading to potentially new options for chemoprevention of colorectal cancer. Oncogene (2011) 30, 2026-2036; doi:10.1038/onc.2010.578; published online 10 January 2011	[Heijink, D. M.; Fehrmann, R. S. N.; de Vries, E. G. E.; Oosterhuis, D.; de Jong, S.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands; [Heijink, D. M.; Koornstra, J. J.; Kleibeuker, J. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, NL-9713 GZ Groningen, Netherlands; [Fehrmann, R. S. N.; van der Zee, A. G. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Gynecol Oncol, NL-9713 GZ Groningen, Netherlands; [Fehrmann, R. S. N.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen	de Vries, EGE (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	e.g.e.de.vries@int.umcg.nl	Pillay, Nischalan/F-9536-2012; Fehrmann, Rudolf/E-2551-2011	Fehrmann, Rudolf/0000-0002-7516-315X; de Vries, Elisabeth/0000-0002-8949-7425	Dutch Cancer Society [RUG 2005-3361]	Dutch Cancer Society(KWF Kankerbestrijding)	This study was supported by Grant RUG 2005-3361 from the Dutch Cancer Society.	Aldoss IT, 2009, EXPERT OPIN INV DRUG, V18, P1957, DOI 10.1517/13543780903418445; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Arber N, 2008, GASTROENTEROLOGY, V134, P1224, DOI 10.1053/j.gastro.2008.02.012; Arhel NJ, 2003, INT J CANCER, V106, P364, DOI 10.1002/ijc.11257; Arima Y, 2008, CANCER RES, V68, P5104, DOI 10.1158/0008-5472.CAN-07-5680; Bartkova J, 2001, GASTROENTEROLOGY, V120, P1680, DOI 10.1053/gast.2001.24880; Bild AH, 2006, NAT REV CANCER, V6, P735, DOI 10.1038/nrc1976; Boquoi A, 2009, CANCER PREV RES, V2, P800, DOI 10.1158/1940-6207.CAPR-09-0053; Carey R, 2008, INFLAMM BOWEL DIS, V14, P446, DOI 10.1002/ibd.20342; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Chen R, 2009, BLOOD, V113, P4637, DOI 10.1182/blood-2008-12-190256; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Crijns APG, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-232; Crijns APG, 2009, PLOS MED, V6, P181, DOI 10.1371/journal.pmed.1000024; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Du W, 2009, CURR DRUG TARGETS, V10, P581, DOI 10.2174/138945009788680392; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Einspahr JG, 2006, CANCER EPIDEM BIOMAR, V15, P1443, DOI 10.1158/1055-9965.EPI-06-0144; Fry DW, 2004, MOL CANCER THER, V3, P1427; Fujita T, 2008, AM J PATHOL, V173, P217, DOI 10.2353/ajpath.2008.070957; Galamb O, 2008, DIS MARKERS, V25, P1, DOI 10.1155/2008/586721; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Guillen-Ahlers H, 2008, CARCINOGENESIS, V29, P1421, DOI 10.1093/carcin/bgn123; Hao XP, 1998, VIRCHOWS ARCH, V433, P523, DOI 10.1007/s004280050284; Hong Y, 2007, CLIN CANCER RES, V13, P1107, DOI 10.1158/1078-0432.CCR-06-1633; Imazeki F, 1996, GASTROENTEROLOGY, V110, P362, DOI 10.1053/gast.1996.v110.pm8566581; Jalving M, 2006, CLIN CANCER RES, V12, P4350, DOI 10.1158/1078-0432.CCR-05-2487; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Kantarjian H, 2007, BLOOD, V109, P5143, DOI 10.1182/blood-2006-11-056028; Kita H, 2006, J GASTROENTEROL, V41, P1053, DOI 10.1007/s00535-006-1894-y; Knudsen ES, 2010, CLIN CANCER RES, V16, P1094, DOI 10.1158/1078-0432.CCR-09-0787; Koornstra JJ, 2004, HISTOPATHOLOGY, V44, P9, DOI 10.1111/j.1365-2559.2004.01739.x; Kopetz S, 2009, CANCER RES, V69, P3842, DOI 10.1158/0008-5472.CAN-08-2246; Kwong LN, 2008, ONCOGENE, V27, P1013, DOI 10.1038/sj.onc.1210708; LaPointe LC, 2008, PHYSIOL GENOMICS, V33, P50, DOI 10.1152/physiolgenomics.00185.2006; Li JN, 2010, NAT CHEM BIOL, V6, P291, DOI [10.1038/NCHEMBIO.332, 10.1038/nchembio.332]; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Paulson QX, 2008, ONCOGENE, V27, P4954, DOI 10.1038/onc.2008.138; Payne SR, 2008, MOL CELL BIOL, V28, P258, DOI 10.1128/MCB.01536-07; RENCHER A, 1998, MUTIVARIATE STAT INT; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Serrels A, 2006, MOL CANCER THER, V5, P3014, DOI 10.1158/1535-7163.MCT-06-0382; Sherlock G, 2001, Brief Bioinform, V2, P350, DOI 10.1093/bib/2.4.350; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Timmerbeul I, 2006, P NATL ACAD SCI USA, V103, P14009, DOI 10.1073/pnas.0606316103; van Geelen CMM, 2003, BRIT J CANCER, V89, P363, DOI 10.1038/sj.bjc.6601065; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wai PY, 2006, J BIOL CHEM, V281, P18973, DOI 10.1074/jbc.M511962200; Wesierska-Gadek J, 2011, J CELL PHYSIOL, V226, P341, DOI 10.1002/jcp.22426; Whittaker SR, 2004, CANCER RES, V64, P262, DOI 10.1158/0008-5472.CAN-03-0110; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhao P, 2006, WORLD J GASTROENTERO, V12, P6391, DOI 10.3748/wjg.v12.i39.6391	62	18	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2026	2036		10.1038/onc.2010.578	http://dx.doi.org/10.1038/onc.2010.578			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21217777				2022-12-17	WOS:000289977400006
J	Saether, T; Pattabiraman, DR; Alm-Kristiansen, AH; Vogt-Kielland, LT; Gonda, TJ; Gabrielsen, OS				Saether, T.; Pattabiraman, D. R.; Alm-Kristiansen, A. H.; Vogt-Kielland, L. T.; Gonda, T. J.; Gabrielsen, O. S.			A functional SUMO-interacting motif in the transactivation domain of c-Myb regulates its myeloid transforming ability	ONCOGENE			English	Article						c-Myb; SUMO; SUMO-interacting motif; myeloid; transformation; hematopoiesis	UBIQUITIN-LIKE PROTEINS; TRANSCRIPTION-FACTOR; V-MYB; SACCHAROMYCES-CEREVISIAE; BINDING MOTIF; DNA-BINDING; NF-M; COACTIVATOR; ACTIVATION; LEUKEMIA	c-Myb is an essential hematopoietic transcription factor that controls proliferation and differentiation of progenitors during blood cell development. Whereas sumoylation of the C-terminal regulatory domain (CRD) is known to have a major impact on the activity of c-Myb, no role for noncovalent binding of small ubiquitin-like modifier (SUMO) to c-Myb has been described. Based on the consensus SUMO-interacting motif (SIM), we identified and examined putative SIMs in human c-Myb. Interaction and reporter assays showed that the SIM in the in the transactivation domain of c-Myb (V(267)NIV) is functional. This motif is necessary for c-Myb to be able to interact noncovalently with SUMO, preferentially SUMO2/3. Destroying the SUMO-binding properties by mutation resulted in a large increase in the transactivation potential of c-Myb. Mutational analysis and overexpression of conjugation-defective SUMO argued against intramolecular repression caused by sumoylated CRD and in favor of SUMO-dependent repression in trans. Using both a myeloid cell line-based assay and a primary hematopoietic cell assay, we addressed the transforming abilities of SUMO binding and conjugation mutants. Interestingly, only loss of SUMO binding, and not SUMO conjugation, enhanced the myeloid transformational potential of c-Myb. c-Myb with the SIM mutated conferred a higher proliferative ability than the wild-type and caused an effective differentiation block. This establishes SUMO binding as a mechanism involved in modulating the transactivation activity of c-Myb, and responsible for keeping the transforming potential of the oncoprotein in check. Oncogene (2011) 30, 212-222; doi:10.1038/onc.2010.397; published online 30 August 2010	[Saether, T.; Alm-Kristiansen, A. H.; Vogt-Kielland, L. T.; Gabrielsen, O. S.] Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; [Pattabiraman, D. R.; Gonda, T. J.] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia	University of Oslo; University of Queensland	Saether, T (corresponding author), Univ Oslo, Dept Mol Biosci, POB 1041 Blindern, N-0316 Oslo, Norway.	thomas.sather@imbv.uio.no	Pattabiraman, Diwakar/AAE-6338-2020; Gonda, Thomas J/A-3620-2012	Pattabiraman, Diwakar/0000-0002-2418-6458; Gonda, Thomas/0000-0002-8792-3021; Saether, Thomas/0000-0003-4976-3810	Norwegian Cancer Society; Norwegian Research Council; Leukaemia Foundation	Norwegian Cancer Society(Norwegian Cancer Society); Norwegian Research Council(Research Council of NorwayEuropean Commission); Leukaemia Foundation	We thank Marit Ledsaak for excellent technical assistance and Professor D Livingston, Professor G Del Sal, Professor RT Hay, Professor R Grosschedl and Professor ET Yeh for providing us with relevant expression constructs. This work was supported by the Norwegian Cancer Society (TS) and the FUGE program of the Norwegian Research Council. DRP was supported by a scholarship from The Leukaemia Foundation (Australia).	Alm-Kristiansen AH, 2008, ONCOGENE, V27, P4644, DOI 10.1038/onc.2008.105; Andersson KB, 2003, J BIOL CHEM, V278, P3816, DOI 10.1074/jbc.M209404200; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Brown AL, 2006, J LEUKOCYTE BIOL, V80, P433, DOI 10.1189/jlb.0206112; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; Hannich JT, 2005, J BIOL CHEM, V280, P4102, DOI 10.1074/jbc.M413209200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hecker CM, 2006, J BIOL CHEM, V281, P16117, DOI 10.1074/jbc.M512757200; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; HU YL, 1991, ONCOGENE, V6, P1549; Jin SH, 2010, J CLIN INVEST, V120, P593, DOI 10.1172/JCI38030; Karafiat V, 2001, BLOOD, V98, P3668, DOI 10.1182/blood.V98.13.3668; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Knipscheer P, 2008, MOL CELL, V31, P371, DOI 10.1016/j.molcel.2008.05.022; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; McCormack MP, 2000, BLOOD, V95, P120, DOI 10.1182/blood.V95.1.120.001k08_120_127; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Molvaersmyr AK, 2010, NUCLEIC ACIDS RES, V38, P4970, DOI 10.1093/nar/gkq245; Murati A, 2009, LEUKEMIA, V23, P85, DOI 10.1038/leu.2008.257; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Pattabiraman DR, 2009, MOL CANCER RES, V7, P1477, DOI 10.1158/1541-7786.MCR-09-0070; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Saether T, 2007, J BIOL CHEM, V282, P13994, DOI 10.1074/jbc.M700755200; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Sramko M, 2006, J BIOL CHEM, V281, P40065, DOI 10.1074/jbc.M609404200; Takahashi H, 2005, J BIOL CHEM, V280, P5611, DOI 10.1074/jbc.M408130200; Tatham MH, 2005, NAT STRUCT MOL BIOL, V12, P67, DOI 10.1038/nsmb878; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466	47	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2011	30	2					212	222		10.1038/onc.2010.397	http://dx.doi.org/10.1038/onc.2010.397			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20802522				2022-12-17	WOS:000286438900009
J	Atwood, AA; Sealy, L				Atwood, A. A.; Sealy, L.			Regulation of C/EBPbeta1 by Ras in mammary epithelial cells and the role of C/EBPbeta1 in oncogene-induced senescence	ONCOGENE			English	Article						C/EBPbeta; Ras; senescence; MCF10A; IL6	BINDING-PROTEIN-BETA; DIFFERENTIATION; PROLIFERATION; TUMORIGENESIS; PATHWAY; ALPHA	Overexpression of Ras(V12) in MCF10A cells, an immortalized mammary epithelial cell line, leads to transformation of these cells. We demonstrate that this is accompanied by degradation of C/EBPbeta1. C/EBP beta is a transcription factor in which three protein isoforms exist because of alternative translation at three in-frame methionines. When C/EBPbeta1 is expressed in MCF10A-Ras(V12) cells, immunoblot analysis reveals that C/EBPbeta1 is degraded in these cells. Treatment of MCF10A-Ras(V12)-C/EBPbeta1 cells with the cdk inhibitor roscovitine leads to stabilization of C/EBPbeta1. It has been previously shown that cdk2 phosphorylates C/EBPbeta on Thr235. We demonstrate that mutation of Thr235 to alanine in C/EBPbeta1 is sufficient to restore the stability of C/EBPbeta1 expression in MCF10A-Ras( V12) cells. Overexpression of Ras(V12) in primary cells induces senescence rather than transformation, thus suppressing tumorigenesis. C/EBPbeta is required for Ras(V12)-induced senescence in primary mouse embryonic fibroblasts. Upregulation of interleukin-6 (IL6) by C/EBPbeta has been shown to be necessary for oncogene-induced senescence, but the specific isoform of C/EBPbeta has not been investigated. We show that the C/EBPbeta1 isoform upregulates IL6 when introduced into normal fibroblasts. In addition, we show that C/EBPbeta1 induces senescence. Taken together, degradation of C/EBPbeta1 by Ras activation may represent a mechanism to bypass OIS. Oncogene (2010) 29, 6004-6015; doi:10.1038/onc.2010.336; published online 6 September 2010	[Sealy, L.] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; [Atwood, A. A.; Sealy, L.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Sealy, L (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 23rd Ave S Garland,Light Hall 702, Nashville, TN 37232 USA.	Linda.sealy@vanderbilt.edu			NIH [GM69634]; Cell Biology and Molecular Sciences; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069634] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cell Biology and Molecular Sciences; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Maria Abreu, Kim Boelte, Linda Bundy, Alisha Russell and David Vaught for insightful suggestions and Rachel Jerrell for technical assistance. We thank Gary Nolan (Standford University) for LZRS-BMN-lacZ and Phoenix cells, Scott Lowe (Cold Spring Harbor) for pBABE-Ras(V12)-puromycin, Hal Moses (Vanderbilt University) for WI-38 fibroblasts and S. Akira for CMV-NF-IL6-T235A. We also thank Cathy Alford in the Veterans Affairs flow cytometry core (Nashville, TN) for technical assistance. This work was funded by NIH GM69634 and by the Cell Biology and Molecular Sciences training grant.	Bundy L, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-43; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Calkhoven CF, 2000, GENE DEV, V14, P1920; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; Grignani F, 1998, CANCER RES, V58, P14; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Iavarone A, 1997, NATURE, V387, P417; Koslowski M, 2009, J BIOL CHEM, V284, P28607, DOI 10.1074/jbc.M109.031120; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Li X, 2007, P NATL ACAD SCI USA, V104, P11597, DOI 10.1073/pnas.0703771104; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; Musgrove EA, 2006, GROWTH FACTORS, V24, P13, DOI 10.1080/08977190500361812; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Uematsu S, 2007, J IMMUNOL, V179, P5378, DOI 10.4049/jimmunol.179.8.5378; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	24	18	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6004	6015		10.1038/onc.2010.336	http://dx.doi.org/10.1038/onc.2010.336			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20818427	Green Accepted			2022-12-17	WOS:000284108700003
J	Craik, AC; Veldhoen, RA; Czernick, M; Buckland, TW; Kyselytzia, K; Ghosh, S; Lai, R; Damaraju, S; Underhill, DA; Mackey, JR; Goping, IS				Craik, A. C.; Veldhoen, R. A.; Czernick, M.; Buckland, T. W.; Kyselytzia, K.; Ghosh, S.; Lai, R.; Damaraju, S.; Underhill, D. A.; Mackey, J. R.; Goping, I. S.			The BH3-only protein Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanism	ONCOGENE			English	Article						Bad; taxane; paclitaxel; docetaxel; apoptosis; breast cancer	CELL-SURVIVAL; BH3 DOMAIN; EXPRESSION PATTERNS; MAMMARY-GLAND; MITOTIC BLOCK; APOPTOSIS; PHOSPHORYLATION; BCL-2; DEATH; PACLITAXEL	Antimitotic agents such as taxanes (paclitaxel and docetaxel) have greatly advanced the treatment of breast cancer, although variable patient response and drug toxicity are major limitations. Lack of validated predictive markers for taxane responsiveness precludes a priori identification of patients who are most likely to respond to treatment; thus, a subset of patients endure toxic side effects with marginal benefit. Mechanistic insights into taxane therapeutic activity may lead to rational therapeutic improvements. In this paper we report that the proapoptotic BH3-only protein Bad has a major role in taxane-induced cell death in vitro, and clinically is a prognostic indicator for overall survival of breast cancer patients after adjuvant taxane chemotherapy. Unexpectedly, Bad did not induce the mitochondrial apoptotic machinery in response to taxane treatment. Instead, Bad indirectly facilitated cell death by stimulating cellular proliferation. As dividing cells are the targets of taxane therapy, Bad-stimulated proliferation may be a marker of taxane sensitivity. Our studies indicate that quantification of Bad protein levels may have value as a diagnostic tool. They also suggest that cells expressing Bad are more sensitive to taxanes because of their altered cell cycle dynamics and reveal a clinically relevant proliferative role of Bad in breast cancer. Oncogene (2010) 29, 5381-5391; doi: 10.1038/onc.2010.272; published online 5 July 2010	[Craik, A. C.; Veldhoen, R. A.; Czernick, M.; Buckland, T. W.; Kyselytzia, K.; Goping, I. S.] Univ Alberta, Dept Biochem, Sch Mol & Syst Med, Edmonton, AB T6G 2H7, Canada; [Ghosh, S.; Underhill, D. A.; Mackey, J. R.; Goping, I. S.] Univ Alberta, Dept Oncol, Sch Canc Engn & Imaging Sci Med, Edmonton, AB T6G 2H7, Canada; [Lai, R.; Damaraju, S.] Univ Alberta, Dept Lab Med & Pathol, Sch Clin & Lab Sci, Edmonton, AB T6G 2H7, Canada; [Damaraju, S.; Mackey, J. R.] Cross Canc Inst, Alberta Hlth Serv, PolyomX Program, Edmonton, AB T6G 1Z2, Canada; [Underhill, D. A.] Univ Alberta, Dept Med Genet, Sch Human Dev, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta; University of Alberta; Alberta Health Services (AHS); University of Alberta; University of Alberta	Goping, IS (corresponding author), Univ Alberta, Dept Biochem, Sch Mol & Syst Med, 5-73 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	igoping@ualberta.ca	Veldhoen, Richard/M-8168-2019	Veldhoen, Richard/0000-0003-4643-2960; Underhill, Darrell/0000-0003-0957-7407	QEII; Mary Johnston Melanoma Research Chair; Alberta Cancer Research Institute; Canadian Breast Cancer Foundation	QEII; Mary Johnston Melanoma Research Chair; Alberta Cancer Research Institute; Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS))	We thank Drs Thomas Simmen, Roseline Godbout and Simonetta Sipione for helpful discussions, Ms Yisu Li for assistance with gene expression microarray analysis and Ms Cheryl Santos for excellent technical input. We also thank the anonymous reviewers for insightful suggestions that improved this study. ACC is a recipient of a QEII Graduate Scholarship. DAU is supported by the Mary Johnston Melanoma Research Chair. ISG is a recipient of a Recruitment Award from the Alberta Cancer Research Institute. This work was supported by operating grants from the Alberta Cancer Research Institute and the Canadian Breast Cancer Foundation awarded to ISG.	Aapro MS, 2001, ONCOLOGIST, V6, P36, DOI 10.1634/theoncologist.6-4-376; Al-Bazz YO, 2009, EUR J CANCER, V45, P694, DOI 10.1016/j.ejca.2008.11.044; Andreeff M, 1999, LEUKEMIA, V13, P1881, DOI 10.1038/sj.leu.2401573; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cannings E, 2007, BREAST CANCER RES TR, V102, P173, DOI 10.1007/s10549-006-9323-8; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Chang JC, 2008, BREAST CANCER RES TR, V108, P233, DOI 10.1007/s10549-007-9590-z; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Czernick M, 2009, BIOCHEM BIOPH RES CO, V379, P145, DOI 10.1016/j.bbrc.2008.12.025; Danial NN, 2008, ONCOGENE, V27, pS53, DOI 10.1038/onc.2009.44; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Derry WB, 1998, CANCER RES, V58, P1177; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; Fernando R, 2007, J BIOL CHEM, V282, P28864, DOI 10.1074/jbc.M700785200; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gascoigne KE, 2009, J CELL SCI, V122, P2579, DOI 10.1242/jcs.039719; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; GRAHAM KA, 1986, BREAST CANCER RES TR, V8, P29, DOI 10.1007/BF01805922; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janumyan Y, 2008, J BIOL CHEM, V283, P34108, DOI 10.1074/jbc.M806294200; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kitada S, 1998, AM J PATHOL, V152, P51; Klumpp S, 2003, NEUROCHEM INT, V42, P555, DOI 10.1016/S0197-0186(02)00174-2; Letai AG, 2008, NAT REV CANCER, V8, P121, DOI 10.1038/nrc2297; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Liu QY, 1997, CLIN CANCER RES, V3, P2039; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MATSCHIN.FM, 1968, J BIOL CHEM, V243, P2730; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Noguchi S, 2006, CANCER SCI, V97, P813, DOI 10.1111/j.1349-7006.2006.00265.x; OSBORNE CK, 1987, BREAST CANCER RES TR, V9, P111, DOI 10.1007/BF01807363; Pellegrini F, 2005, CANCER INVEST, V23, P264, DOI 10.1081/CNV-200055970; Perez EA, 1999, SEMIN ONCOL, V26, P1; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Roy SS, 2009, MOL CELL, V33, P377, DOI 10.1016/j.molcel.2009.01.018; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Smith AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006224; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Upreti M, 2008, J BIOL CHEM, V283, P35517, DOI 10.1074/jbc.M805019200; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987	66	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5381	5391		10.1038/onc.2010.272	http://dx.doi.org/10.1038/onc.2010.272			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20603619				2022-12-17	WOS:000282944500005
J	Freeman, MR; Di Vizio, D; Solomon, KR				Freeman, M. R.; Di Vizio, D.; Solomon, K. R.			The Rafts of the Medusa: cholesterol targeting in cancer therapy	ONCOGENE			English	Editorial Material							PROSTATE-CANCER; CELLS; AKT	In this issue of Oncogene, Mollinedo and co-workers present promising evidence that cholesterol-sensitive signaling pathways involving lipid rafts can be therapeutically targeted in multiple myeloma. Because the pathways considered in their study are used by other types of tumor cells, one implication of this report is that cholesterol-targeting approaches may be applicable to other malignancies. Oncogene (2010) 29, 3745-3747; doi: 10.1038/onc.2010.132; published online 3 May 2010	[Freeman, M. R.; Di Vizio, D.; Solomon, K. R.] Childrens Hosp, Urol Dis Res Ctr, Boston, MA 02115 USA; [Freeman, M. R.; Di Vizio, D.; Solomon, K. R.] Harvard Univ, Childrens Hosp, Sch Med, Dept Urol, Boston, MA 02115 USA; [Freeman, M. R.; Di Vizio, D.] Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA; [Freeman, M. R.] Harvard Univ, Childrens Hosp, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Solomon, K. R.] Harvard Univ, Childrens Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Freeman, MR (corresponding author), Childrens Hosp, Urol Dis Res Ctr, Enders 1161,300 Longwood Ave, Boston, MA 02115 USA.	michael.freeman@childrens.harvard.edu						Adam RM, 2007, CANCER RES, V67, P6238, DOI 10.1158/0008-5472.CAN-07-0288; Caldieri G, 2010, TRENDS CELL BIOL, V20, P64, DOI 10.1016/j.tcb.2009.10.006; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood-2005-08-3434; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Mollinedo F, 2010, ONCOGENE, V29, P3748, DOI 10.1038/onc.2010.131; Mondul AM, 2010, CANCER CAUSE CONTROL, V21, P61, DOI 10.1007/s10552-009-9434-8; Platz EA, 2006, JNCI-J NATL CANCER I, V98, P1819, DOI 10.1093/jnci/djj499; Solomon KR, 2009, AM J PATHOL, V174, P1017, DOI 10.2353/ajpath.2009.080551; Zhuang LY, 2005, J CLIN INVEST, V115, P959	10	18	20	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3745	3747		10.1038/onc.2010.132	http://dx.doi.org/10.1038/onc.2010.132			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440260				2022-12-17	WOS:000279385200002
J	Julian, E; Dave, RK; Robson, JP; Hallahan, AR; Wainwright, BJ				Julian, E.; Dave, R. K.; Robson, J. P.; Hallahan, A. R.; Wainwright, B. J.			Canonical Notch signaling is not required for the growth of Hedgehog pathway-induced medulloblastoma	ONCOGENE			English	Article						medulloblastoma; Notch; Hedgehog; therapy; RBP-J	GRANULE NEURON PRECURSORS; POSTNATAL MOUSE-BRAIN; BASAL-CELL CARCINOMA; SONIC-HEDGEHOG; STEM-CELLS; HUMAN HOMOLOG; MUTANT MICE; GLIAL DIFFERENTIATION; GENETIC ALTERATIONS; FATE DETERMINATION	Current treatment for medulloblastoma is successful in more than half of all cases but results in substantial disability in survivors. Accordingly, there is considerable interest in drugs that may target specific signaling pathways activated in the tumors, with inhibitors of both the Hedgehog and Notch pathways currently proposed as possible therapeutics. Here, we tested the hypothesis that Notch pathway inhibition in vivo may block the formation of Hedgehog-dependent medulloblastoma. We took the general approach of using a cre recombinase under the control of the GFAP promoter to generate medulloblastoma in mice carrying a conditional Ptc1 allele and introduced a conditional RBP-J allele to ablate canonical Notch signaling. Loss of RBP-J from the developing cerebellum led to a modest loss of stem cells and an overall developmental delay. These phenotypes could be partially compensated by activation of the Hedgehog pathway. Hedgehog-dependent medulloblastoma were not blocked by loss of RBP-J, indicating that canonical Notch signaling is not required for tumor initiation and growth in this model. Oncogene (2010) 29, 3465-3476; doi:10.1038/onc.2010.101; published online 26 April 2010	[Julian, E.; Dave, R. K.; Robson, J. P.; Wainwright, B. J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Hallahan, A. R.] Univ Queensland, Dept Paediat & Child Hlth, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Wainwright, BJ (corresponding author), Univ Queensland, Inst Mol Biosci, Bldg 80,St Lucia Campus, Brisbane, Qld 4072, Australia.	b.wainwright@imb.uq.edu.au	Hallahan, Andrew R/F-1757-2010	Wainwright, Brandon/0000-0003-0406-2092	National Health and Medical Research Council of Australia; John Trivett Foundation; ARC Special Research Centre for Functional and Applied Genomics; Australian Cancer Research Fund	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); John Trivett Foundation; ARC Special Research Centre for Functional and Applied Genomics(Australian Research Council); Australian Cancer Research Fund	E Julian is an ANZ Trustees Research Scholar. This work was supported by funds from the National Health and Medical Research Council of Australia, The John Trivett Foundation, the ARC Special Research Centre for Functional and Applied Genomics and the Australian Cancer Research Fund. We thank Professor Tasuku Honjo for RBP-J mice and Professor Ryoichiro Kageyama and Dr Zeng-jie Yang for helpful discussions.	Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Adolphe C, 2004, DEVELOPMENT, V131, P5009, DOI 10.1242/dev.01367; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Binning MJ, 2008, CANCER RES, V68, P7838, DOI 10.1158/0008-5472.CAN-08-1899; Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908; Corbin JG, 2008, J NEUROCHEM, V106, P2272, DOI 10.1111/j.1471-4159.2008.05522.x; Dakubo GD, 2006, J NEURO-ONCOL, V79, P221, DOI 10.1007/s11060-006-9132-2; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Dong J, 2000, Hum Mutat, V16, P89, DOI 10.1002/1098-1004(200007)16:1<89::AID-HUMU18>3.3.CO;2-Z; Ellis T, 2003, GENESIS, V36, P158, DOI 10.1002/gene.10208; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Frappart PO, 2007, EMBO J, V26, P2732, DOI 10.1038/sj.emboj.7601703; Fujikura J, 2006, CELL METAB, V3, P59, DOI 10.1016/j.cmet.2005.12.005; Galli R, 2002, DEVELOPMENT, V129, P1633; Gao F, 2009, MOL CELL NEUROSCI, V40, P442, DOI 10.1016/j.mcn.2008.12.008; Garzia L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004998; Gazit R, 2004, DEVELOPMENT, V131, P903, DOI 10.1242/dev.00982; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hurlbut GD, 2007, CURR OPIN CELL BIOL, V19, P166, DOI 10.1016/j.ceb.2007.02.012; Imayoshi I, 2008, DEVELOPMENT, V135, P2531, DOI 10.1242/dev.021535; Ingram WJ, 2008, ONCOGENE, V27, P1489, DOI 10.1038/sj.onc.1210767; Irvin DK, 2004, J NEUROSCI RES, V75, P330, DOI 10.1002/jnr.10843; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Klein AL, 2004, DEV BIOL, V266, P161, DOI 10.1016/j.ydbio.2003.10.017; Komine O, 2007, DEV BIOL, V311, P238, DOI 10.1016/j.ydbio.2007.08.042; Koo BK, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001221; Lelievre V, 2008, DEV BIOL, V313, P359, DOI 10.1016/j.ydbio.2007.10.031; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Lutolf S, 2002, DEVELOPMENT, V129, P373; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Marino S, 2000, GENE DEV, V14, P994; Ong CT, 2006, J BIOL CHEM, V281, P5106, DOI 10.1074/jbc.M506108200; Packer Roger J., 1994, Current Opinion in Oncology, V6, P240, DOI 10.1097/00001622-199405000-00004; Pazzaglia S, 2006, ONCOGENE, V25, P5575, DOI 10.1038/sj.onc.1209544; Pietsch T, 1997, CANCER RES, V57, P2085; Purow B, 2009, CURR PHARM BIOTECHNO, V10, P154, DOI 10.2174/138920109787315060; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Romer J, 2005, CANCER RES, V65, P4975, DOI 10.1158/0008-5472.CAN-05-0481; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Saran A, 2009, CURR MOL MED, V9, P1046, DOI 10.2174/156652409789839080; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Sasai K, 2007, CANCER RES, V67, P3871, DOI 10.1158/0008-5472.CAN-07-0493; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; Sottile V, 2006, BRAIN RES, V1099, P8, DOI 10.1016/j.brainres.2006.04.127; Stump G, 2002, MECH DEVELOP, V114, P153, DOI 10.1016/S0925-4773(02)00043-6; Sweeney C, 2004, FASEB J, V18, P1421, DOI 10.1096/fj.04-1700fje; Talora C, 2008, BBA-MOL BASIS DIS, V1782, P489, DOI 10.1016/j.bbadis.2008.06.008; Tanaka M, 1999, J NEUROBIOL, V41, P524, DOI 10.1002/(SICI)1097-4695(199912)41:4<524::AID-NEU8>3.3.CO;2-9; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Tanori M, 2008, CARCINOGENESIS, V29, P1911, DOI 10.1093/carcin/bgn174; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Thomas WD, 2009, ONCOGENE, V28, P1605, DOI 10.1038/onc.2009.3; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wall DS, 2009, CELL CYCLE, V8, P1301, DOI 10.4161/cc.8.9.8284; Wall DS, 2009, J CELL BIOL, V184, P101, DOI 10.1083/jcb.200805155; Wang JP, 2003, J CLIN INVEST, V112, P535, DOI 10.1172/JCI200318637; Weller M, 2006, DEV NEUROSCI-BASEL, V28, P70, DOI 10.1159/000090754; Wetmore C, 2001, CANCER RES, V61, P513; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; Yamamoto N, 2003, CURR BIOL, V13, P333, DOI 10.1016/S0960-9822(03)00081-2; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yokota N, 2004, ONCOGENE, V23, P3444, DOI 10.1038/sj.onc.1207475; Zhuo L, 2001, GENESIS, V31, P85, DOI 10.1002/gene.10008; Zindy F, 2007, CANCER RES, V67, P2676, DOI 10.1158/0008-5472.CAN-06-3418	71	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2010	29	24					3465	3476		10.1038/onc.2010.101	http://dx.doi.org/10.1038/onc.2010.101			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20418906				2022-12-17	WOS:000278835400002
J	Denes, V; Pilichowska, M; Makarovskiy, A; Carpinito, G; Geck, P				Denes, V.; Pilichowska, M.; Makarovskiy, A.; Carpinito, G.; Geck, P.			Loss of a cohesin-linked suppressor APRIN (Pds5b) disrupts stem cell programs in embryonal carcinoma: an emerging cohesin role in tumor suppression	ONCOGENE			English	Article						APRIN; stem cells; differentiation; cancer; Pds5b; cohesins	PROSTATE-CANCER CELLS; DE-LANGE-SYNDROME; NEURAL DIFFERENTIATION; GENE-EXPRESSION; AT-HOOK; AS3; PROLIFERATION; PATTERNS; NEURONS; PROTEIN	Cohesins appear to have critical functions beyond mitotic cohesion. Our data on a cohesin-associated Pds5-paralog, APRIN, indicate a novel cohesin role in stem cell differentiation. APRIN/Pds5B is lost in many cancers and it is a putative tumor suppressor. Its mutations in the germ line, however, generate birth defects. We reasoned that as both cancer and birth defects share disrupted stem cell differentiation, the data suggest an APRIN/Pds5B cohesin function in stem cells. We used an embryonal carcinoma stem cell model and show here that (i) APRIN expression is precisely coordinated with stem cell differentiation; (ii) this coordination involves surface-contact and endocrine pathways; and (iii) APRIN/Pds5b coordination is critical in stem/progenitor exit decisions. APRIN knockdown disrupted Oct4, Nanog and SOX2 patterns, differentiation failed and the resulting immature proliferative cells did not progress beyond proneural progenitor phase. Furthermore, the phenotype-blocked progenitor exit (Mash-1(+)); failed E-cadherin exit (E-Cadh(low+));incomplete N-cadherin transition (N-Cadh(low+)); retained proliferative capacity (c-myc(+)); irregular stemness (SOX2(late++)) and lost response to contact and hormonal cues-shares similarities with cancer-initiating cells. The data suggest novel APRIN/Pds5B-linked cohesin roles in stem/progenitor programs and a new mechanism in tumor suppression. Oncogene (2010) 29, 3446-3452; doi:10.1038/onc.2010.100; published online 12 April 2010	[Denes, V.; Geck, P.] Tufts Univ, Sch Med, Dept Anat & Cell Biol, Boston, MA 02111 USA; [Pilichowska, M.] Tufts Med Ctr, Dept Pathol, Boston, MA USA; [Makarovskiy, A.; Carpinito, G.] Tufts Med Ctr, Dept Urol, Boston, MA USA	Tufts University; Tufts Medical Center; Tufts Medical Center	Geck, P (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cell Biol, Harrison Ave, Boston, MA 02111 USA.	peter.geck@tufts.edu			The Susan G Komen Breast Cancer Foundation [BCTR0403214, W81XWH-08-1-0575, W81XWH-09-1-0411]; Sanofi-Aventis [IST10257];  [DOD-DAMD17-01-1-0430];  [DOD-DAMD1703-1-0266]	The Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Sanofi-Aventis(Sanofi-Aventis); ; 	We are grateful to Grace Gill, Karina Meiri and Natasha Kreder for critical review of the paper. The technical assistance of Shu Ling Liang and Byung Kyu Kim is greatly appreciated. This work was supported by the following awards: DOD-DAMD17-01-1-0430 (PG); DOD-DAMD1703-1-0266 (PG); The Susan G Komen Breast Cancer Foundation BCTR0403214 (PG); W81XWH-08-1-0575 (PG); W81XWH-09-1-0411 (PG) and Sanofi-Aventis award IST10257 (AM).	Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Berney C, 2006, P ROY SOC B-BIOL SCI, V273, P1867, DOI 10.1098/rspb.2006.3537; Cattaruzzi G, 2007, NUCLEIC ACIDS RES, V35, P1751, DOI 10.1093/nar/gkl1106; DuVall GA, 1996, J CLIN GASTROENTEROL, V22, P131, DOI 10.1097/00004836-199603000-00012; Gao X, 2001, BIOCHEM BIOPH RES CO, V284, P1098, DOI 10.1006/bbrc.2001.5089; Geck P, 1999, J STEROID BIOCHEM, V68, P41, DOI 10.1016/S0960-0760(98)00165-4; Geck P, 1997, J STEROID BIOCHEM, V63, P211, DOI 10.1016/S0960-0760(97)00122-2; Geck P, 2001, AM J HUM GENET, V69, P461, DOI 10.1086/321968; Geck P, 2000, P NATL ACAD SCI USA, V97, P10185, DOI 10.1073/pnas.97.18.10185; Gohlke JM, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-15; Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806; Harada H, 2001, INT J ONCOL, V18, P1003; Itoh F, 1997, TOHOKU J EXP MED, V182, P327, DOI 10.1620/tjem.182.327; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Kim JB, 2008, NATURE, V454, P646, DOI 10.1038/nature07061; Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023; Kumar D, 2004, GENE, V328, P187, DOI 10.1016/j.gene.2003.12.013; Liu J, 2009, CLIN GENET, V76, P303, DOI 10.1111/j.1399-0004.2009.01271.x; Losada A, 2005, J CELL SCI, V118, P2133, DOI 10.1242/jcs.02355; Maffini M, 2008, J STEROID BIOCHEM, V108, P32, DOI 10.1016/j.jsbmb.2007.05.034; Maffini MV, 2002, ENDOCRINOLOGY, V143, P2708, DOI 10.1210/en.143.7.2708; Mani S, 2001, MOL CELL NEUROSCI, V17, P54, DOI 10.1006/mcne.2000.0931; MARUIWA M, 1988, VIRCHOWS ARCH A, V413, P463, DOI 10.1007/BF00716995; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MUMMERY CL, 1991, DIFFERENTIATION, V46, P51, DOI 10.1111/j.1432-0436.1991.tb00865.x; Murthy S, 2005, PROSTATE, V64, P362, DOI 10.1002/pros.20251; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Okita Keisuke, 2006, Curr Stem Cell Res Ther, V1, P103, DOI 10.2174/157488806775269061; Parelho V, 2008, CELL, V132, P422, DOI 10.1016/j.cell.2008.01.011; Reis EM, 2005, CANCER RES, V65, P1693, DOI 10.1158/0008-5472.CAN-04-3506; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; SATO A, 1986, ACTA PATHOL JAPON, V36, P143; Seo MJ, 2005, GYNECOL ONCOL, V96, P621, DOI 10.1016/j.ygyno.2004.11.032; SMITH SC, 1987, J CELL PHYSIOL, V131, P74, DOI 10.1002/jcp.1041310112; SUGITA K, 1986, BRAIN DEV-JPN, V8, P541, DOI 10.1016/S0387-7604(86)80101-2; Suzuki A, 2006, P NATL ACAD SCI USA, V103, P10294, DOI 10.1073/pnas.0506945103; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Teramoto S, 2005, ONCOL REP, V14, P1231; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; Wei Y, 2002, DIFFERENTIATION, V70, P204, DOI 10.1046/j.1432-0436.2002.700409.x; Wendt KS, 2008, NATURE, V451, P796, DOI 10.1038/nature06634; Xia CH, 2007, DIFFERENTIATION, V75, P912, DOI 10.1111/j.1432-0436.2007.00188.x; Zhang B, 2007, DEVELOPMENT, V134, P3191, DOI 10.1242/dev.005884; Zhang B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005232; Zhang Y, 2008, J GENET GENOMICS, V35, P267, DOI 10.1016/S1673-8527(08)60038-7; Zheng MZ, 2008, J CANCER RES CLIN, V134, P453, DOI 10.1007/s00432-007-0306-x	49	18	19	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2010	29	23					3446	3452		10.1038/onc.2010.100	http://dx.doi.org/10.1038/onc.2010.100			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20383194				2022-12-17	WOS:000278622700012
J	Lu, Y; Liu, P; James, M; Vikis, HG; Liu, H; Wen, W; Franklin, A; You, M				Lu, Y.; Liu, P.; James, M.; Vikis, H. G.; Liu, H.; Wen, W.; Franklin, A.; You, M.			Genetic variants cis-regulating Xrn2 expression contribute to the risk of spontaneous lung tumor	ONCOGENE			English	Article						expression; association; lung cancer; mouse	GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCUS; SQUAMOUS DIFFERENTIATION; SEQUENCE VARIANTS; CANCER RISK; MOUSE; NONSMOKERS; ADENOCARCINOMAS; DISEASE; CELLS	Gene expression variation is an important mechanism underlying susceptibility to complex disease. In comparison with tobacco-related lung carcinogenesis, lung cancer in nonsmokers may involve important and etiologically distinct causal pathways. In this study, we conducted a genome-wide association study on spontaneous lung tumor incidence in inbred mice and identified a major susceptibility locus on mouse chromosome 2 (rs27328255, P = 6.68 x 10(-7)). We then evaluated the correlations of polymorphisms with the transcription of positional candidate genes in normal lungs. Single-nucleotide polymorphism rs27328255 was consistently and strongly associated (P = 7.42 x 10(-9)) in cis with transcript levels of Xrn2. We further showed that Xrn2 promotes proliferation and inhibits squamous differentiation in human lung epithelial cells and polymorphisms in human homolog XRN2 are associated with human lung cancer (rs2025811, P = 1.90 x 10(-3), OR = 1.20). We conclude that genetic variants regulating Xrn2 expression in cis are determinants of spontaneous lung tumor susceptibility in mice and have genetic equivalents in lung cancer susceptibility in human beings. Identifying Xrn2 as a major candidate for spontaneous lung cancer has important implications for the diagnosis and treatment of lung cancer as well as delineation of the mechanisms underlying the genesis of lung cancer in nonsmokers. Oncogene (2010) 29, 1041-1049; doi:10.1038/onc.2009.396; published online 16 November 2009	[You, M.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@wudosis.wustl.edu		James, Michael/0000-0002-8112-1108	US National Institutes of Health [CA099187, CA099147, ES012063, ES013340]; NATIONAL CANCER INSTITUTE [R01CA099147, R01CA099187, R01CA139959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013340, R01ES012063] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank the Broad Institute of Harvard/Massachusetts General Hospital and Massachusetts Institute of Technology, the Wellcome Trust Center for Human Genetics at Oxford University, and Perlegen Sciences for releasing inbred laboratory mouse SNP data. We thank the Mouse Phenome Project for collecting mouse SNP data. We thank the International Agency for Research on Cancer (Lyon, France) for releasing lung cancer GWAS data. We also thank investigators for generating spontaneous lung tumor data in inbred mice. The mouse SNP and phenotype data were crucial for the key findings described in this paper. We thank the staff of The Vanderbilt Microarray Shared Resource for microarray processing. MY was supported by grants from the US National Institutes of Health (CA099187, CA099147, ES012063, and ES013340). We thank Dr Jay W Tichelaar for his critical comments on the manuscript.	Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Borczuk Alain C, 2007, Proc Am Thorac Soc, V4, P127, DOI 10.1513/pats.200607-143JG; Clark AG, 2005, GENOME RES, V15, P1496, DOI 10.1101/gr.4107905; Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537; Couzin J, 2007, SCIENCE, V316, P820, DOI 10.1126/science.316.5826.820; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; FOLEY JF, 1991, EXP LUNG RES, V17, P157, DOI 10.3109/01902149109064408; Frazer KA, 2007, NATURE, V448, P1050, DOI 10.1038/nature06067; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kang HM, 2008, GENETICS, V178, P1709, DOI 10.1534/genetics.107.080101; KE Y, 1988, DIFFERENTIATION, V38, P60, DOI 10.1111/j.1432-0436.1988.tb00592.x; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kuntz E, 2006, ARCH BIOCHEM BIOPHYS, V455, P48, DOI 10.1016/j.abb.2006.08.023; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Li JX, 2005, DNA SEQUENCE, V16, P143, DOI 10.1080/10425170500066771; Liu PY, 2008, JNCI-J NATL CANCER I, V100, P1326, DOI 10.1093/jnci/djn268; Liu PY, 2006, NAT GENET, V38, P888, DOI 10.1038/ng1849; Matakidou A, 2005, BRIT J CANCER, V93, P825, DOI 10.1038/sj.bjc.6602769; McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Park MH, 2007, ONCOL REP, V18, P1395; Powell CA, 2003, LUNG CANCER-J IASLC, V39, P23, DOI 10.1016/S0169-5002(02)00384-7; Rafnar T, 2009, NAT GENET, V41, P221, DOI 10.1038/ng.296; SAID JW, 1983, LAB INVEST, V49, P563; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tang H, 2008, DEV BIOL, V318, P73, DOI 10.1016/j.ydbio.2008.03.001; Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846; Thun MJ, 2006, JNCI-J NATL CANCER I, V98, P691, DOI 10.1093/jnci/djj187; Tian JM, 2006, CANCER RES, V66, P10399, DOI 10.1158/0008-5472.CAN-06-1564; Wacholder S, 2008, JNCI-J NATL CANCER I, V100, DOI 10.1093/jnci/djn380; WALTS AE, 1985, J PATHOL, V145, P329, DOI 10.1002/path.1711450406; Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wong MP, 2003, CANCER, V97, P1263, DOI 10.1002/cncr.11183; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; Zeka A, 2006, EPIDEMIOLOGY, V17, P615, DOI 10.1097/01.ede.0000239582.92495.b5	44	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1041	1049		10.1038/onc.2009.396	http://dx.doi.org/10.1038/onc.2009.396			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19915612	Green Accepted			2022-12-17	WOS:000274604400010
J	Zhu, T; Tsuji, T; Chen, C				Zhu, T.; Tsuji, T.; Chen, C.			Roles of PKC isoforms in the induction of apoptosis elicited by aberrant Ras	ONCOGENE			English	Article						PKC isoforms; oncogenic Ras; p73; apoptosis	PROTEIN-KINASE-C; PROTEOLYTIC ACTIVATION; TYROSINE PHOSPHORYLATION; DELTA ACTIVATION; P73; CELLS; GROWTH; ALPHA; TRANSLOCATION; PATHWAY	Emerging evidence indicates that suppression of protein kinase C (PKC) renders the susceptibility of cells expressing mutated ras to apoptosis. Although the effort has been made, the underlying molecular mechanisms are not fully understood. In this study, using small hairpin RNAs (shRNAs) or PKC inhibitor, we show that the concurrent suppression of PKC-alpha and beta induces cells ectopically expressing nu-ras to undergo apoptosis. In this apoptotic process, PKC-delta is upregulated and translocated from the cytosol to the nucleus. The activated PKC-delta associates with and phosphorylates p73 to initiate apoptosis. In this apoptotic process, Akt seems to be downstream of oncogenic Ras. Moreover, overexpression of PKC-delta, without co-suppression of PKC-alpha and beta, is not apoptotic to the cells, suggesting that PKC-delta and PKC-alpha/beta function oppositely to facilitate cells harboring nu-ras to survive. Thus, our study shows that PKC-alpha and beta are necessary for sustaining the homeostasis in cells containing a hyperactive Ras. The abrogation of these two isoforms switches on the p73-regulated apoptotic machinery through the activation of PKC-delta. Oncogene (2010) 29, 1050-1061; doi:10.1038/onc.2009.344; published online 19 October 2009	[Zhu, T.; Tsuji, T.; Chen, C.] Harvard Univ, Sch Med, Dept Radiat Oncol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Chen, C (corresponding author), Harvard Univ, Sch Med, Dept Radiat Oncol, Beth Israel Deaconess Med Ctr, 99 Brookline Ave,RN-325F, Boston, MA 02215 USA.	cchen6@bidmc.harvard.edu			National Institutes of Health [RO1CA100498]; Department of Defense [W81XWH-04-1-0246]; NATIONAL CANCER INSTITUTE [R01CA100498] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Z Luo and Q Yu (Boston University School of Medicine, Boston, MA, USA) for providing various reagents and useful suggestions. This study is supported by the National Institutes of Health (RO1CA100498) and the Department of Defense (W81XWH-04-1-0246).	Aaltonen V, 2007, CANCER LETT, V253, P97, DOI 10.1016/j.canlet.2007.01.011; Agami R, 1999, NATURE, V399, P809; Atten MJ, 2005, INVEST NEW DRUG, V23, P111, DOI 10.1007/s10637-005-5855-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Braun MU, 2003, J MOL CELL CARDIOL, V35, P895, DOI 10.1016/S0022-2828(03)00142-1; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; Chen CY, 1998, CELL DEATH DIFFER, V5, P984, DOI 10.1038/sj.cdd.4400448; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Chen EB, 2001, J IRON STEEL RES INT, V8, P12; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Deng X, 2001, J Natl Cancer Inst Monogr, P30; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; Eitel K, 2003, DIABETES, V52, P991, DOI 10.2337/diabetes.52.4.991; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FUKASAWA K, 1995, ONCOGENE, V10, P1; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gong JG, 1999, NATURE, V399, P806; Gonzalez S, 2003, MOL CELL BIOL, V23, P8161, DOI 10.1128/MCB.23.22.8161-8171.2003; Guo JJ, 2009, J CELL BIOCHEM, V107, P76, DOI 10.1002/jcb.22102; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kampfer S, 2001, J BIOL CHEM, V276, P42834, DOI 10.1074/jbc.M102047200; Kaul S, 2005, J BIOL CHEM, V280, P28721, DOI 10.1074/jbc.M501092200; Kawakami Y, 2003, P NATL ACAD SCI USA, V100, P9470, DOI 10.1073/pnas.1633695100; Kheifets V, 2006, J BIOL CHEM, V281, P23218, DOI 10.1074/jbc.M602075200; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Mandil R, 2001, CANCER RES, V61, P4612; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; McNeill H, 1999, CURR BIOL, V9, pR176, DOI 10.1016/S0960-9822(99)80107-9; Min BW, 2008, EXP MOL MED, V40, P699, DOI 10.3858/emm.2008.40.6.699; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; Ni HY, 2003, BRIT J HAEMATOL, V121, P849, DOI 10.1046/j.1365-2141.2003.04368.x; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 2007, BIOCHEM SOC T, V35, P1001, DOI 10.1042/BST0351001; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Wang HG, 1998, BIOFACTORS, V8, P13, DOI 10.1002/biof.5520080103; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Xia SH, 2007, J BIOL CHEM, V282, P13199, DOI 10.1074/jbc.M610225200; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Zhang XM, 2005, CANCER CHEMOTH PHARM, V55, P251, DOI 10.1007/s00280-004-0863-5	60	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1050	1061		10.1038/onc.2009.344	http://dx.doi.org/10.1038/onc.2009.344			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19838205	Green Accepted			2022-12-17	WOS:000274604400011
J	Ozer, BH; Wiepz, GJ; Bertics, PJ				Ozer, B. H.; Wiepz, G. J.; Bertics, P. J.			Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain	ONCOGENE			English	Article						EGF receptor (EGFR); glioblastoma multiforme; constitutive activity; duplicate kinase domains	EPIDERMAL-GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; TANDEM DUPLICATION; MALIGNANT GLIOMAS; DOWN-REGULATION; BRAIN-TUMORS; ACTIVATION; INTERNALIZATION; PHOSPHORYLATION	A mutation of the epidermal growth factor receptor (EGFR) that results in a tandem kinase domain duplication (TKD-EGFR) has been described in glioblastoma multiforme biopsies and cell lines. Although the TKD-EGFR confers tumorigenicity, little is known about the molecular underpinnings of receptor dysregulation. Therefore, we transfected B82L mouse fibroblast cells devoid of endogenous EGFR to determine the molecular mechanisms of receptor activation when expressed in cells as well as the contribution of each duplicated kinase domain to receptor phosphorylation. The TKD-EGFR displayed chronically elevated basal autophosphorylation at five known phosphotyrosine sites. The chronically phosphorylated TKD-EGFR was also resistant to competitive inhibition of ligand-binding compared with wild-type EGFR (WT-EGFR) and showed undetectable levels of basal dimerization, suggesting the TKD-EGFR escapes known mechanisms of receptor downregulation. Immunofluorescence analyses revealed a substantial portion of the TKD-EGFR resides in the cytosol in an activated state, although surface-localized subsets of the receptor retain ligand responsiveness. Kinase activity-deficient knockouts of the N-terminal or the C-terminal kinase domains generated TKD-EGFRs that recapitulate the autophosphorylation/localization patterns of a constitutively activated receptor versus a WT-like EGFR, respectively. Investigation of the molecular activity of the TKD-EGFR yields evidence for a unique mechanism of constitutive activity and dual kinase domain activation. Oncogene (2010) 29, 855-864; doi:10.1038/onc.2009.385; published online 16 November 2009	[Bertics, P. J.] Univ Wisconsin, Dept Biomol Chem, Med Sci Ctr 571A, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bertics, PJ (corresponding author), Univ Wisconsin, Dept Biomol Chem, Med Sci Ctr 571A, 1300 Univ Ave, Madison, WI 53706 USA.	pbertics@wisc.edu			NIH [R33 CA122892, R01 CA108467]; NSF [DMR-0520527]; NATIONAL CANCER INSTITUTE [R33CA122892, R01CA108467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank MJ Ciesielski and RA Fenstermaker for generously providing the pLXIN plasmids of the TKD-EGFR mutant. In addition, we thank CR Peet for her helpful discussions and assistance in reviewing the paper and TL Becker for her advice on statistical analyses. This work was supported in part by grants from the NIH (R33 CA122892, R01 CA108467), and from the NSF (MRSEC Award DMR-0520527).	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bondy ML, 2008, CANCER-AM CANCER SOC, V113, P1953, DOI 10.1002/cncr.23741; Brockmann MA, 2003, NEUROSURGERY, V52, P1391, DOI 10.1227/01.NEU.0000064806.87785.AB; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Ciesielski MJ, 2000, ONCOGENE, V19, P810, DOI 10.1038/sj.onc.1203409; Collins VP, 2004, J NEUROL NEUROSUR PS, V75, P2, DOI 10.1136/jnnp.2004.040337; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; Edwin Francis, 2006, V327, P1; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Fenstermaker RA, 1998, ONCOGENE, V16, P3435, DOI 10.1038/sj.onc.1202156; Fenstermaker RA, 2007, CURR GENOMICS, V8, P163, DOI 10.2174/138920207780833838; Frederick L, 2000, CANCER RES, V60, P1383; GILL GN, 1984, J BIOL CHEM, V259, P7755; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Jensen RL, 1998, SURG NEUROL, V49, P189, DOI 10.1016/S0090-3019(97)00218-8; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Landau M, 2004, STRUCTURE, V12, P2265, DOI 10.1016/j.str.2004.10.006; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; POLLACK IF, 1991, J NEUROSURG, V75, P284, DOI 10.3171/jns.1991.75.2.0284; Poppleton HM, 1999, ARCH BIOCHEM BIOPHYS, V363, P227, DOI 10.1006/abbi.1998.1095; Riese DJ, 2007, BIOESSAYS, V29, P558, DOI 10.1002/bies.20582; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Sato J D, 1983, Mol Biol Med, V1, P511; Sihto H, 2005, J MOL MED, V83, P976, DOI 10.1007/s00109-005-0699-4; Smith KJ, 2004, STRUCTURE, V12, P1067, DOI 10.1016/j.str.2004.02.040; Tang P, 1997, J NEURO-ONCOL, V35, P303, DOI 10.1023/A:1005824802617; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	34	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					855	864		10.1038/onc.2009.385	http://dx.doi.org/10.1038/onc.2009.385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915609	Green Accepted			2022-12-17	WOS:000274397800008
J	Scheller, H; Tobollik, S; Kutzera, A; Eder, M; Unterlehberg, J; Pfeil, I; Jungnickel, B				Scheller, H.; Tobollik, S.; Kutzera, A.; Eder, M.; Unterlehberg, J.; Pfeil, I.; Jungnickel, B.			c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma	ONCOGENE			English	Article						somatic hypermutation; germinal center; Burkitt's lymphoma; c-Myc	INDUCED CYTIDINE DEAMINASE; B-CELL LYMPHOMAS; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN ENHANCERS; ANTIGEN RECEPTOR; ACTIVATION; GENE; EXPRESSION; BCL-6; REGION	The germinal center (GC) reaction has a pivotal function in human B-cell lymphomagenesis. Genetic aberrations occurring during somatic hypermutation and class switch recombination deregulate key factors controlling B-cell physiology and proliferation. Several human lymphoma entities are characterized by a constitutive GC phenotype and ongoing somatic hypermutation, but the molecular basis for this phenomenon is only partly understood. We have investigated the reasons for a constitutive GC-like program in Burkitt's lymphoma cells. Here, overexpression of c-Myc leads to a centroblast phenotype, promotes high constitutive expression of the key GC factors Bcl-6, E2A and activation-induced cytidine deaminase and contributes to proliferation and somatic hypermutation. Our findings elucidate how the activity of a pivotal transcription factor may freeze B-cell lymphoma cells in a constitutive GC-like state that is even maintained at an extrafollicular location. Oncogene (2010) 29, 888-897; doi:10.1038/onc.2009.377; published online 2 November 2009	[Scheller, H.; Tobollik, S.; Kutzera, A.; Eder, M.; Unterlehberg, J.; Pfeil, I.; Jungnickel, B.] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Inst Clin Mol Biol, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Jungnickel, B (corresponding author), German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Inst Clin Mol Biol, Marchioninistr 25, D-81377 Munich, Germany.	jungnickel@helmholtz-muenchen.de	Scheller, Henrik/AAH-4770-2020; Jungnickel, Berit/AAU-5297-2021	Scheller, Henrik/0000-0002-6702-3560; 	German Jose Carreras Leukemia Foundation [SP/03/10, R05/10v]; Wilhelm Sander foundation [2003.046.2]; Deutsche Forschungsgemeinschaft [TRR54-TPA4]	German Jose Carreras Leukemia Foundation; Wilhelm Sander foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Sabine Fischer-Burkart for expert technical assistance, Torsten Thiel for contributions to the RNAi system, Maren Mierau and Dirk Eick for discussion and support, and Ursula Zimber-Strobl, Georg Bornkamm and Ralf Kuppers for critical reading of the manuscript. This work was supported by grants from the German Jose Carreras Leukemia Foundation (SP/03/10 and R05/10v), the Wilhelm Sander foundation (2003.046.2) and the Deutsche Forschungsgemeinschaft (TRR54-TPA4).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; AIELLO A, 1990, HEMATOL ONCOL, V8, P229, DOI 10.1002/hon.2900080407; Bachl J, 1999, EUR J IMMUNOL, V29, P1383, DOI 10.1002/(SICI)1521-4141(199904)29:04<1383::AID-IMMU1383>3.3.CO;2-O; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Chapman CJ, 1998, LEUKEMIA LYMPHOMA, V30, P257, DOI 10.3109/10428199809057539; Chesi M, 2008, CANCER CELL, V13, P167, DOI 10.1016/j.ccr.2008.01.007; Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dedeoglu F, 2004, INT IMMUNOL, V16, P395, DOI 10.1093/intimm/dxh042; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Faili A, 2002, NAT IMMUNOL, V3, P815, DOI 10.1038/ni826; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; JOHNSTON JM, 1991, BLOOD, V78, P2419; Khuda SE, 2008, J IMMUNOL, V181, P7537, DOI 10.4049/jimmunol.181.11.7537; KLEIN U, 1995, MOL MED, V1, P495, DOI 10.1007/BF03401587; Klein U, 2003, P NATL ACAD SCI USA, V100, P2639, DOI 10.1073/pnas.0437996100; Klein U, 1998, IMMUNOL REV, V162, P261; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Lee SC, 2006, MOL IMMUNOL, V43, P1965, DOI 10.1016/j.molimm.2005.11.017; Liu M, 2008, NATURE, V451, P841, DOI 10.1038/nature06547; MartinezValdez H, 1996, J EXP MED, V183, P971, DOI 10.1084/jem.183.3.971; Mierau M, 2008, NUCLEIC ACIDS RES, V36, P5591, DOI 10.1093/nar/gkn542; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Pajic A, 2001, INT J CANCER, V93, P810, DOI 10.1002/ijc.1404; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Refaeli Y, 2008, PLOS BIOL, V6, P1208, DOI 10.1371/journal.pbio.0060152; Ruckerl F, 2006, MOL IMMUNOL, V43, P1645, DOI 10.1016/j.molimm.2005.09.011; Rutherford MN, 1998, AM J PATHOL, V153, P165, DOI 10.1016/S0002-9440(10)65557-5; Saito M, 2007, CANCER CELL, V12, P280, DOI 10.1016/j.ccr.2007.08.011; Sayegh CE, 2003, NAT IMMUNOL, V4, P586, DOI 10.1038/ni923; Schoetz U, 2006, J IMMUNOL, V177, P395, DOI 10.4049/jimmunol.177.1.395; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Teng G, 2008, IMMUNITY, V28, P621, DOI 10.1016/j.immuni.2008.03.015; Thorley-Lawson DA, 2008, NAT REV MICROBIOL, V6, P913, DOI 10.1038/nrmicro2015; Toyama H, 2002, IMMUNITY, V17, P329, DOI 10.1016/S1074-7613(02)00387-4; Wagner SD, 2007, LEUKEMIA LYMPHOMA, V48, P1510, DOI 10.1080/10428190701458491; Wang CL, 2005, J IMMUNOL, V174, P5650, DOI 10.4049/jimmunol.174.9.5650; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Zhang W, 2001, INT IMMUNOL, V13, P1175, DOI 10.1093/intimm/13.9.1175	51	18	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					888	897		10.1038/onc.2009.377	http://dx.doi.org/10.1038/onc.2009.377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19881537				2022-12-17	WOS:000274397800011
J	Anderson, LR; Sutherland, RL; Butt, AJ				Anderson, L. R.; Sutherland, R. L.; Butt, A. J.			BAG-1 overexpression attenuates luminal apoptosis in MCF-10A mammary epithelial cells through enhanced RAF-1 activation	ONCOGENE			English	Article						BAG-1; breast cancer; apoptosis; RAF-1; ERK; MCF-10A	HUMAN BREAST-CANCER; PROTEASOME PATHWAY; SIGNALING PATHWAY; PROGNOSTIC VALUE; LUMEN FORMATION; PROTEIN-KINASE; EXPRESSION; GROWTH; BIM; PROLIFERATION	Although the multi-functional, prosurvival protein, Bcl-2-associated anthanogene 1 (BAG-1) is frequently overexpressed in breast cancers, its role in the development or maintenance of the malignant state remains unclear. Here, we have used the established MCF-10A 3-dimensional (3D) model of mammary morphogenesis as a biologically relevant system to determine how BAG-1 expression may influence the development of breast cancer. When cultured in 3D, MCF-10A cells undergo a highly regulated morphogenic program leading to the development of polarized acinar structures containing a central, hollow lumen formed, in part, through the induction of BIM-dependent apoptosis. BAG-1 overexpression resulted in an attenuation of this normal apoptotic program characterized by a significantly increased number of acini with filled lumens-a phenotype commonly observed in ductal carcinoma in situ. BAG-1's effects were associated with an activation of RAF-1-a known binding partner of BAG-1, enhanced signaling through the MAP kinase pathway and a decrease in BIM expression. Reversal of the BAG-1-associated survival phenotype by the mitogen-activated kinase/ERK kinase inhibitor, U0126, implicates the RAF-1-extracellular signal-regulated kinase signaling pathway as a major mediator of BAG-1's effects in this model. As BAG-1 expression is often elevated in preinvasive breast cancers, these findings support a possible role for BAG-1 as an early contributor to the malignant process in the breast. Oncogene (2010) 29, 527-538; doi: 10.1038/onc.2009.362; published online 2 November 2009	[Anderson, L. R.; Sutherland, R. L.; Butt, A. J.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; [Sutherland, R. L.; Butt, A. J.] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney	Butt, AJ (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	abutt@garvan.org.au	Anderson, Luke/D-1780-2012; Sutherland, Robert L/A-8378-2008	Anderson, Luke/0000-0003-3654-1258; Butt, Alison/0000-0002-6216-5105	Cancer Institute NSW; Australian Postgraduate Award; National Health and Medical Research Council (Australia) [535903]; RT Hall Trust	Cancer Institute NSW; Australian Postgraduate Award(Australian Government); National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia); RT Hall Trust	We gratefully acknowledge the assistance of Drs Will Hughes and James Burchfield (Garvan Institute) with confocal microscopy, and Professor Graham Packham (University of Southampton) for useful discussions. This study was supported by Cancer Institute NSW Postgraduate Scholarship and Australian Postgraduate Award (LRA); Cancer Institute NSW Career Development and Support Fellowship (AJB); National Health and Medical Research Council (Australia) Program Grant 535903; RT Hall Trust.	Arhel NJ, 2003, INT J CANCER, V106, P364, DOI 10.1002/ijc.11257; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Caldon CE, 2008, CANCER RES, V68, P3026, DOI 10.1158/0008-5472.CAN-07-3079; Cutress RI, 2003, ONCOGENE, V22, P4973, DOI 10.1038/sj.onc.1206688; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Elliott E, 2009, FEBS LETT, V583, P229, DOI 10.1016/j.febslet.2008.12.009; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris J, 1999, DIS BREAST; Hohfeld J, 1998, BIOL CHEM, V379, P269; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Kudoh M, 2002, CANCER RES, V62, P1904; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Mailleux AA, 2008, CELL CYCLE, V7, P57, DOI 10.4161/cc.7.1.5150; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Meller R, 2006, J BIOL CHEM, V281, P7429, DOI 10.1074/jbc.M512138200; MILLAR EKA, 2008, BRIT J CANCER, V100, P123; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nadler Y, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1998; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Salh B, 1999, ANTICANCER RES, V19, P731; Sharp Adam, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007537; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Sutherland R.L., 1999, HUMAN CELL CULTURE, P79; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Townsend PA, 2003, CANCER RES, V63, P4150; Townsend PA, 2003, BBA-REV CANCER, V1603, P83, DOI 10.1016/S0304-419X(03)00002-7; Townsend PA, 2002, J PATHOL, V197, P51, DOI 10.1002/path.1081; Turner BC, 2001, J CLIN ONCOL, V19, P992, DOI 10.1200/JCO.2001.19.4.992; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Wang XH, 2009, BRIT J CANCER, V100, P1347, DOI 10.1038/sj.bjc.6604985; Yang XL, 1999, CLIN CANCER RES, V5, P1816; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	45	18	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					527	538		10.1038/onc.2009.362	http://dx.doi.org/10.1038/onc.2009.362			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881545				2022-12-17	WOS:000274084600006
J	Baras, A; Yu, Y; Filtz, M; Kim, B; Moskaluk, CA				Baras, A.; Yu, Y.; Filtz, M.; Kim, B.; Moskaluk, C. A.			Combined genomic and gene expression microarray profiling identifies ECOP as an upregulated gene in squamous cell carcinomas independent of DNA amplification	ONCOGENE			English	Article						squamous cell carcinoma; tobacco; microarray; ECOP; EGFR	CANCER; MARKERS; NECK; HEAD	To identify dysregulated genes that may play a role in the pathogenesis of tobacco-related human squamous cell carcinoma (SCC), a cohort of SCCs from smokers (29 SCC of the head and neck, 3 SCC of the esophagus and 46 SCC of the lungs) were concomitantly analyzed for gene expression using Affymetrix U133A 2.0 arrays and for genomic variation using Affymetrix Human Mapping 100K set. Gene expression profiling clearly separated benign squamous mucosa (BSM) from SCC and identified several candidate genes relevant to the biology of SCC. The single-nucleotide polymorphism array data adapted for copy number analysis identified two discrete areas of high-level genomic amplification, including 7p11.2 (EGFR (epidermal growth factor receptor)) and 11q13.3 (CCND1 (cyclin D1)). When gene expression measures were correlated with amplification status at 7p11.2 locus, EGFR overexpression in relation to benign tissue was dependent on amplification and occurred in only 9% of cases. However, an adjacent gene (similar to 0.4 Mb), EGFR-co-amplified and overexpressed protein (ECOP), showed strong over-expression in the majority (90%) of SCCs regardless of gene amplification status. This finding was corroborated with quantitative real-time PCR assays and protein immunoblots. Interestingly, small interfering RNA-mediated knockdown of ECOP gene products in a SCC cell line (SCC-9) resulted in increased cell death. The results of these studies identify ECOP as a protein relevant to the biology of SCC. Oncogene (2009) 28, 2919-2924; doi:10.1038/onc.2009.150; published online 15 June 2009	[Baras, A.; Yu, Y.; Filtz, M.; Kim, B.; Moskaluk, C. A.] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; [Moskaluk, C. A.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Moskaluk, CA (corresponding author), Univ Virginia, Dept Pathol, 3024 Univ Hosp,POB 800214, Charlottesville, VA 22908 USA.	cam5p@virginia.edu			National Institutes of Health (USA) [T32 GM008715]; Virginia Tobacco Settlement Foundation; University of Virginia; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK067629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267, T32GM008715] Funding Source: NIH RePORTER	National Institutes of Health (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Virginia Tobacco Settlement Foundation; University of Virginia; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We wish to thank Ms Angela Miller for her support of the histological techniques required to carry out these studies. We wish to thank Dr Patcharin Pramoonjago for assistance in the creation and evaluation of antibody reagents to the ECOP protein. Alex Baras is a member of the Biotechnology Training Program at The University of Virginia, supported by training grant, T32 GM008715, from the National Institutes of Health (USA). These studies were primarily supported by a grant from the Virginia Tobacco Settlement Foundation. This project was also supported, in part, by a gift provided to the University of Virginia by Philip Morris USA. The review and approval process was overseen by an External Advisory Committee without any affiliation with the University, PM USA, or any other tobacco company. Funding for this project was based upon independent intramural and extramural reviews.	Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Eley GD, 2002, NEURO-ONCOLOGY, V4, P86, DOI 10.1093/neuonc/4.2.86; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Park S, 2005, ONCOGENE, V24, P2495, DOI 10.1038/sj.onc.1208496; Singh B, 2008, J SURG ONCOL, V97, P634, DOI 10.1002/jso.21024; Stewart Sherri L., 2008, Morbidity and Mortality Weekly Report, V57, P1; Talbot SG, 2005, CANCER RES, V65, P3063, DOI 10.1158/0008-5472.CAN-04-1985; Toruner GA, 2004, CANCER GENET CYTOGEN, V154, P27, DOI 10.1016/j.cancergencyto.2004.01.026; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176	10	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2919	2924		10.1038/onc.2009.150	http://dx.doi.org/10.1038/onc.2009.150			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19525979				2022-12-17	WOS:000268917100008
J	Thornber, K; Colomba, A; Ceccato, L; Delsol, G; Payrastre, B; Gaits-Iacovoni, F				Thornber, K.; Colomba, A.; Ceccato, L.; Delsol, G.; Payrastre, B.; Gaits-Iacovoni, F.			Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas	ONCOGENE			English	Article						anaplastic large cell lymphomas; NPM-ALK; lipoxygenases; ROS	5-LIPOXYGENASE; KINASE; INHIBITION; ROS	The chimera nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), the tyrosine kinase activity of which is constitutively upregulated, is the causative agent of 75% of the anaplastic large-cell lymphomas (ALCLs). We have demonstrated that NPM-ALK induces the production of reactive oxygen species (ROS) by a pathway involving the arachidonic acid-metabolizing enzymes of the lipoxygenase (LOX) family. The use of the LOX inhibitor nordihydroguaiaretic acid (NDGA) and of the antioxidant N-acetylcysteine (NAC) demonstrated that ROS are important in maintaining the ALK kinase active. Consistent with this, NDGA treatment resulted in the inhibition of key pathways, such as Akt, signal transducer and activator of transcription factor 3 (STAT3) and extracellular signal-regulated kinase (ERK), which are involved in NPM-ALK antiapoptotic and pro-mitogenic functions. Conversely, the stress-activated kinase p38, described in some instances as a mediator of apoptosis, was activated. Interestingly, 5-LOX, an isoform involved in many cancers, was found to be activated in NPM-ALK(+) cells. Functional studies have shown that transforming properties, namely proliferation and resistance to apoptosis, were abrogated by treatment with either NDGA or the 5-LOX inhibitor (N-(3-phenoxycinnamyl)-acetohydroxamic acid) (BW A4C). Together, these data point to the ROS/LOX pathway as a potential new target for therapy in NPM-ALK-positive tumors. Oncogene (2009) 28, 2690-2696; doi: 10.1038/onc.2009.125; published online 8 June 2009	[Gaits-Iacovoni, F.] CHU Purpan, INSERM, U563, Dpt Oncogenese Signalisat & Innovat Therapeut, F-31024 Toulouse 3, France; [Thornber, K.; Colomba, A.; Ceccato, L.; Delsol, G.; Payrastre, B.; Gaits-Iacovoni, F.] Univ Toulouse 3, Ctr Physiopathol Toulouse Purpan, F-31062 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Gaits-Iacovoni, F (corresponding author), CHU Purpan, INSERM, U563, Dpt Oncogenese Signalisat & Innovat Therapeut, BP 3028, F-31024 Toulouse 3, France.	frederique.gaits@inserm.fr	Payrastre, Bernard/M-5295-2014	Gaits-Iacovoni, Frederique/0000-0002-9853-0442; , Kelly/0000-0003-0484-8458; , Bernard/0000-0002-8693-0190	INSERM; 'Ministre de la Recherche et de la Technologie; ARC; INCa; La Ligue contre le Cancer; Canceropole GSO; 'Pole de competitivite Cancer-Biosante/Fonds uniques interministeriels des poles de competitivite	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); 'Ministre de la Recherche et de la Technologie; ARC(Australian Research Council); INCa(Institut National du Cancer (INCA) France); La Ligue contre le Cancer(Ligue nationale contre le cancer); Canceropole GSO; 'Pole de competitivite Cancer-Biosante/Fonds uniques interministeriels des poles de competitivite	We thank E Espinos for providing pBSK-NPM-ALK, D Ramel and the group 'Signaling and Phosphoinosites in normal and pathologic hematopoietic cells' for helpful discussions. This work was supported by grants from the INSERM, 'Ministre de la Recherche et de la Technologie', ARC, INCa, La Ligue contre le Cancer, Canceropole GSO and the 'Pole de competitivite Cancer-Biosante/Fonds uniques interministeriels des poles de competitivite'.	AGGARWAL BB, 2004, ANTICANCER RES, V26, P503; Ambrogio C, 2005, BLOOD, V106, P3907, DOI 10.1182/blood-2005-03-1204; Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Claesson HE, 2008, FEBS J, V275, P4222, DOI 10.1111/j.1742-4658.2008.06570.x; Colomba A, 2008, ONCOGENE, V27, P2728, DOI 10.1038/sj.onc.1210921; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; Flamand N, 2002, MOL PHARMACOL, V62, P250, DOI 10.1124/mol.62.2.250; Furstenberger G, 2006, INT J CANCER, V119, P2247, DOI 10.1002/ijc.22153; Honorat JF, 2006, BLOOD, V107, P4130, DOI 10.1182/blood-2005-06-2421; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Koptyra M, 2006, BLOOD, V108, P319, DOI 10.1182/blood-2005-07-2815; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Radmark O, 2007, TRENDS BIOCHEM SCI, V32, P332, DOI 10.1016/j.tibs.2007.06.002; TATESON JE, 1988, BRIT J PHARMACOL, V94, P528, DOI 10.1111/j.1476-5381.1988.tb11557.x; Vincent C, 2008, LEUKEMIA RES, V32, P1756, DOI 10.1016/j.leukres.2008.05.005; Voena C, 2007, CANCER RES, V67, P4278, DOI 10.1158/0008-5472.CAN-06-4350; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Wu XJ, 2007, CANCER BIOL THER, V6, P646, DOI 10.4161/cbt.6.5.4092	19	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2690	2696		10.1038/onc.2009.125	http://dx.doi.org/10.1038/onc.2009.125			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19503098				2022-12-17	WOS:000268211200007
J	Zhang, X; Zhu, Y; Geng, L; Wang, H; Legerski, RJ				Zhang, X.; Zhu, Y.; Geng, L.; Wang, H.; Legerski, R. J.			Artemis is a negative regulator of p53 in response to oxidative stress	ONCOGENE			English	Article						Artemis; p53; DNA-PKcs; oxidative stress	DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; DNA-DAMAGE; V(D)J RECOMBINATION; TUMOR-SUPPRESSOR; CELL-DEATH; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; MITOCHONDRIA	Artemis is a multifunctional phospho-protein with roles in V(D)J recombination, repair of double-strand breaks by nonhomologous end-joining and regulation of cell-cycle checkpoints after DNA damage. Here, we describe a new function of Artemis as a negative regulator of p53 in response to oxidative stress in both primary cells and cancer cell lines. We show that depletion of Artemis under typical culture conditions (21% oxygen) leads to a spontaneous phosphorylation and stabilization of p53, and resulting cellular G1 arrest and apoptosis. These effects are suppressed by co-depletion of DNA-PKcs, but not ATM, indicating that Artemis is an inhibitor of DNA-PKcs-mediated stabilization of p53. Culturing of cellsat 3% oxygen or treatment with an antioxidant abrogated p53 stabilization, indicating that oxidative stress is the responsible cellular stimulus. Treatment with ionizing radiation or hydrogen peroxide did not cause activation of this signaling pathway, whereas inhibitors of mitochondrial electron transport were effective in reducing its activation. In addition, we show that p53-inducible genes involved in reducing reactive oxygen species are upregulated by Artemis depletion. These findings indicate that Artemis and DNA-PKcs participate in a new, signaling pathway to modulate p53 function in response to oxidative stress produced by mitochondrial respiration. Oncogene (2009) 28, 2196-2204; doi: 10.1038/onc.2009.100; published online 27 April 2009	[Zhang, X.; Zhu, Y.; Geng, L.; Wang, H.; Legerski, R. J.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Legerski, RJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlegersk@mdanderson.org			National Cancer Institute [CA096574]; NATIONAL CANCER INSTITUTE [P01CA097175, R01CA096574] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank G Lozano for helpful discussions of the paper. This work was supported by National Cancer Institute grant CA096574 (RJL).	Anwar A, 2003, J BIOL CHEM, V278, P10368, DOI 10.1074/jbc.M211981200; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chen L, 2005, CANCER SCI, V96, P134, DOI 10.1111/j.1349-7006.2005.00019.x; Geng LY, 2007, MOL CELL BIOL, V27, P2625, DOI 10.1128/MCB.02072-06; Guzy RD, 2006, EXP PHYSIOL, V91, P807, DOI 10.1113/expphysiol.2006.033506; Karawajew L, 2005, BLOOD, V105, P4767, DOI 10.1182/blood-2004-09-3428; Kondoh H, 2005, CANCER RES, V65, P177; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Ma YM, 2005, J BIOL CHEM, V280, P33839, DOI 10.1074/jbc.M507113200; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; MONTES DOL, 1995, NATURE, V378, P203; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2000, HUM MOL GENET, V9, P583, DOI 10.1093/hmg/9.4.583; Poinsignon C, 2004, EUR J IMMUNOL, V34, P3146, DOI 10.1002/eji.200425455; Punj V, 2003, CELL MICROBIOL, V5, P225, DOI 10.1046/j.1462-5822.2003.00269.x; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Sarkaria JN, 1998, CANCER RES, V58, P4375; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; Soutoglou E, 2008, SCIENCE, V320, P1507, DOI [10.1126/science.1159051, 10.1126/science.ll59051]; Tian H, 2000, CANCER RES, V60, P679; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004	39	18	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	22					2196	2204		10.1038/onc.2009.100	http://dx.doi.org/10.1038/onc.2009.100			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19398950	Green Accepted			2022-12-17	WOS:000266640300002
J	Sui, X; Shin, S; Zhang, R; Firozi, PF; Yang, L; Abbruzzese, JL; Reddy, SAG				Sui, X.; Shin, S.; Zhang, R.; Firozi, P. F.; Yang, L.; Abbruzzese, J. L.; Reddy, S. A. G.			Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; hdm2; K-Ras; c-Jun; cyclin D1; c-Myc	MDM2 SPLICE VARIANTS; NF-KAPPA-B; C-MYC; MESSENGER-RNA; MUTANT P53; DUCTAL ADENOCARCINOMA; INDUCED APOPTOSIS; DOWN-REGULATION; EXPRESSION; ACTIVATION	There is emerging evidence that the oncogenic potential of hdm2 (human and/or murine double minute-2 protein) stems not only from its ability to counteract tumor suppressor p53 but also from its less understood p53-independent functions. Surprisingly, little is known about the role and regulation of hdm2 in pancreatic tumors, a large proportion (50-75%) of which contain mutant p53. In this study, we determined that hdm2 was expressed in a Ras-signaling-dependent manner in various pancreatic cancer cell lines. As p53 was mutated and inactive in these cells, the expression of hdm2 was seemingly redundant. Indeed, the proliferation and survival of cell lines such as Panc-1 and Panc-28 could be inhibited by PRIMA-1 (mutant p53 activator) but not by Nutlin-3 (inhibitor of the hdm2-p53 interaction). Unexpectedly, however, the proliferation of both cell lines was strongly inhibited by hdm2-specific RNAi. Our data also revealed cyclin D1, c-Jun and c-Myc to be novel targets of hdm2 and suggested that they might mediate hdm2's role in cellular proliferation and/or survival. We conclude from our results that hdm2 is expressed in pancreatic cancer cells as a result of activated Ras signaling, and that it regulates cellular proliferation and the expression of three novel target genes by p53-independent mechanisms.	[Reddy, S. A. G.] Univ Texas MD Anderson Canc Ctr, Unit 426, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Reddy, SAG (corresponding author), Univ Texas MD Anderson Canc Ctr, Unit 426, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	sa08366@odin.mdacc.tmc.edu	qiao, zhixin/I-3408-2012		Lustgarten Foundation for Pancreatic Cancer Research (SAGR); Topfer Fund for Pancreatic Cancer Research (SAGR); University Cancer Foundation at The University of Texas M. D. Anderson Cancer Center (SAGR), NCI SPORE [CA101936]; NCI [CA016672]; University of Texas M. D. Anderson Cancer Center; NATIONAL CANCER INSTITUTE [P20CA101936, P30CA016672] Funding Source: NIH RePORTER	Lustgarten Foundation for Pancreatic Cancer Research (SAGR); Topfer Fund for Pancreatic Cancer Research (SAGR); University Cancer Foundation at The University of Texas M. D. Anderson Cancer Center (SAGR), NCI SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Texas M. D. Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs Frank McCormick and Martin McMahon (University of California, San Francisco, CA, USA) for the hdm2 P2 promoter reporter constructs, Johannes Bos (Utrecht University) for the Raf1 GST-RBD plasmid and Gigi Lozano (M. D. Anderson Cancer Center, Houston, TX, USA) for the p53 and pCMV-hdm2 expression vectors. We also thank P. zer (CI-1040), Dr Bryant Darnay (pMX-BGD vector) and Dr F-X Claret (pSRa-c-Jun) for other reagents; Dr Baoan Ji for assistance with the qPCR assays and Beth L Notzon and Angelique L Geehan (M. D. Anderson Cancer Center) for editorial assistance. This work was supported by the Lustgarten Foundation for Pancreatic Cancer Research (SAGR), the Topfer Fund for Pancreatic Cancer Research (SAGR), the University Cancer Foundation at The University of Texas M. D. Anderson Cancer Center (SAGR), NCI SPORE CA101936 in Pancreatic Cancer (JLA) and NCI Grant CA016672 (DNA sequencing and media preparation facilities, The University of Texas M. D. Anderson Cancer Center).	Agrawal S, 2001, INT J ONCOL, V18, P1061; Ambrosini G, 2007, ONCOGENE, V26, P3473, DOI 10.1038/sj.onc.1210136; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Bai JX, 2006, J PHARMACOL EXP THER, V319, P1435, DOI 10.1124/jpet.106.110007; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brunner TB, 2005, CANCER RES, V65, P8433, DOI 10.1158/0008-5472.CAN-05-0158; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Carroll VA, 2008, CANCER RES, V68, P545, DOI 10.1158/0008-5472.CAN-06-4738; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; Deb SP, 2003, MOL CANCER RES, V1, P1009; EBERT M, 1994, INT J ONCOL, V5, P1279; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fridman JS, 2003, CANCER RES, V63, P5703; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Harris LC, 2005, CURR CANCER DRUG TAR, V5, P21, DOI 10.2174/1568009053332654; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Jackson P, 2003, PROSTATE CANCER P D, V6, P174, DOI 10.1038/sj.pcan.4500634; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Konnikova L, 2005, CANCER RES, V65, P6516, DOI 10.1158/0008-5472.CAN-05-0924; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; LaRusch GA, 2007, CANCER RES, V67, P450, DOI 10.1158/0008-5472.CAN-06-2710; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Levav-Cohen Y, 2005, GROWTH FACTORS, V23, P183, DOI 10.1080/08977190500196218; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Natsume A, 2005, CANCER RES, V65, P7573, DOI 10.1158/0008-5472.CAN-05-0036; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Phelps M, 2005, J BIOL CHEM, V280, P16651, DOI 10.1074/jbc.M412334200; Phelps M, 2003, CANCER RES, V63, P2616; Phillips A, 2006, FEBS LETT, V580, P300, DOI 10.1016/j.febslet.2005.12.026; Prives C, 1999, J PATHOL, V187, P112; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Ruggeri BA, 1997, CANCER, V79, P700, DOI 10.1002/(SICI)1097-0142(19970215)79:4<700::AID-CNCR7>3.0.CO;2-H; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Shmueli A, 2007, MOL CELL, V25, P794, DOI 10.1016/j.molcel.2007.03.006; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Weis B, 1999, ONCOGENE, V18, P2579, DOI 10.1038/sj.onc.1202602; Zhang Z, 2004, CLIN CANCER RES, V10, P1263, DOI 10.1158/1078-0432.CCR-0245-03; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814	53	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					709	720		10.1038/onc.2008.423	http://dx.doi.org/10.1038/onc.2008.423			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19029954				2022-12-17	WOS:000263076400008
J	Ehnman, M; Li, H; Fredriksson, L; Pietras, K; Eriksson, U				Ehnman, M.; Li, H.; Fredriksson, L.; Pietras, K.; Eriksson, U.			The uPA/uPAR system regulates the bioavailability of PDGF-DD: implications for tumour growth	ONCOGENE			English	Article						PDGF-D; uPA/uPAR; PDGFR beta; retention motif; proteolytic processing; tumorigenesis	UROKINASE PLASMINOGEN-ACTIVATOR; CELL-SURFACE; RECEPTOR; IDENTIFICATION; RETENTION; LIGAND; PROGRESSION; MECHANISM; ISOFORMS; SIGNAL	Members of the platelet-derived growth factor (PDGF) family are mitogens for cells of mesenchymal origin and have important functions during embryonic development, blood vessel maturation, fibrotic diseases and cancer. In contrast to the two classical PDGFs, the novel and less well-characterized members, PDGF-CC and PDGF-DD, are latent factors that need to be processed extracellularly by activating proteases, before they can mediate PDGF receptor activation. Here, we elucidate the structural requirements for urokinase plasminogen activator (uPA)-mediated activation of PDGF-DD, as well as the intricate interplay with uPA receptor (uPAR) signalling. Furthermore, we show that activated PDGF-DD, in comparison to latent, more potently transforms NIH/3T3 cells in vitro. Conversely, xenograft studies in nude mice demonstrate that cells expressing latent PDGF-DD are more tumorigenic than those expressing activated PDGF-DD. These findings imply that a fine-tuned proteolytic activation, in the local milieu, controls PDGF-DD bioavailability. Moreover, we suggest that proteolytic activation of PDGF-DD reveals a retention motif mediating interactions with pericellular components. Our proposed mechanism, where uPA not only generates active PDGF-DD, but also regulates its spatial distribution, provides novel insights into the biological function of PDGF-DD.	[Eriksson, U.] Ludwig Inst Canc Res Ltd, Karolinska Inst, Stockholm Branch, S-17177 Stockholm, Sweden	Karolinska Institutet; Ludwig Institute for Cancer Research	Eriksson, U (corresponding author), Ludwig Inst Canc Res Ltd, Karolinska Inst, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.	ulf.eriksson@licr.ki.se	Pietras, Kristian/ABE-8727-2020; Pietras, Kristian/ABG-2097-2021; Ehnman, Monika/R-3687-2016	Pietras, Kristian/0000-0001-6738-4705; Ehnman, Monika/0000-0003-0468-2531; Fredriksson, Linda/0000-0003-4952-2742	Swedish Cancer Foundation; Swedish Research Council; Novo Nordisk Foundation; Karolinska Institutet	Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Karolinska Institutet(Karolinska Institutet)	We thank Carl-Henrik Heldin (Ludwig Institute for Cancer Research Ltd, Uppsala Branch) for kindly providing PAE cell lines, R33 antiserum against human PDGFRb and purified PDGF-BB protein. Soheilla Rezaian and Sara Cunha helpfully assisted with PDGF-DD protein puri. cation and tissue preparations; Erika Folestad and Christina Fieber generously provided us with human PDGF-D and VEGF-B plasmids. The Swedish Cancer Foundation, the Swedish Research Council, the Novo Nordisk Foundation and Karolinska Institutet supported this study.	Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Fredriksson L, 2005, J BIOL CHEM, V280, P26856, DOI 10.1074/jbc.M503388200; Fredriksson L, 2004, EMBO J, V23, P3793, DOI 10.1038/sj.emboj.7600397; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LaRochelle WJ, 2002, CANCER RES, V62, P2468; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Li H, 2003, ONCOGENE, V22, P1501, DOI 10.1038/sj.onc.1206223; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Miyake H, 1999, PROSTATE, V39, P123, DOI 10.1002/(SICI)1097-0045(19990501)39:2<123::AID-PROS7>3.0.CO;2-2; Mondino A, 2004, TRENDS IMMUNOL, V25, P450, DOI 10.1016/j.it.2004.06.004; Olofsson B, 1996, J BIOL CHEM, V271, P19310, DOI 10.1074/jbc.271.32.19310; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Ustach CV, 2005, MOL CELL BIOL, V25, P6279, DOI 10.1128/MCB.25.14.6279-6288.2005; Workman P, 1998, BRIT J CANCER, V77, P1; Xu L, 2005, CANCER RES, V65, P5711, DOI 10.1158/0008-5472.CAN-04-4313	28	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					534	544		10.1038/onc.2008.410	http://dx.doi.org/10.1038/onc.2008.410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997817				2022-12-17	WOS:000262866500007
J	Leeman, JR; Weniger, MA; Barth, TF; Gilmore, TD				Leeman, J. R.; Weniger, M. A.; Barth, T. F.; Gilmore, T. D.			Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL	ONCOGENE			English	Article						c-Rel; NF-kappa B; alternative splicing; lymphoma; transactivation; inhibition	TRANSCRIPTION FACTOR REL; C-REL; V-REL; PHOSPHORYLATION; INDUCTION; CELLS; PROLIFERATION; STIMULATION; RESIDUES; DEFECTS	Misregulation of REL, a nuclear factor-kappa B family transcription factor, has been implicated in several human lymphoid malignancies. REL has a conserved N-terminal DNA-binding/dimerization domain called the Rel homology domain (RHD) and a C-terminal transactivation domain (TAD). Here, we define the sequences (amino acids (aa) 323-422) between the RHD and TAD as a REL inhibitory domain (RID) because deletion of these sequences increases both REL transactivation and DNA binding. Furthermore, we have characterized two REL mRNA splice variants that encode proteins with alterations near RID: one lacking exon 9 sequences (aa 308-330; RELD9) and one with an exonized Alu fragment insertion of 32 aa after aa 307 (REL + Alu). Deletion of RID or exon 9-encoded sequences increases transactivation by GAL4-REL by approximately threefold. Moreover, deletion of RID or exon 9 sequences increases transactivation by full-length REL from certain kappa B site-containing promoters and increases DNA binding by REL. Deletion of RID does not affect REL's ability to transform chicken spleen cells. Reverse transcriptase-polymerase chain reaction analysis of mRNA from both primary lymphoma samples and several transformed tissue culture cell lines indicates that the RELD9 splice variant is preferentially expressed in lymphoma, suggesting that the REL transcript lacking exon 9 could serve as a marker for certain types of lymphoid tumors.	[Leeman, J. R.; Gilmore, T. D.] Boston Univ, Dept Biol, Boston, MA 02215 USA; [Weniger, M. A.; Barth, T. F.] Univ Ulm, Dept Pathol, Ulm, Germany	Boston University; Ulm University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NIH [CA47763]; Deutsche Krebshilfe [108060]; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Krebshilfe(Deutsche Krebshilfe); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Mike Garbati, Melanie Herscovitch, Daniel Starczynowski and Francis Wolenski for helpful discussions, and Michaela Buck, Karola Dorsch, Iwona Nerbas and Ingo Melzner for technical assistance. This work was supported by NIH Grant CA47763 (TDG) and a grant from Deutsche Krebshilfe (108060; TFB).	Abid MR, 2004, J BIOL CHEM, V279, P44030, DOI 10.1074/jbc.M408285200; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brown PJ, 2008, BLOOD, V111, P2816, DOI 10.1182/blood-2007-09-115113; BROWNELL E, 1989, ONCOGENE, V4, P935; Bundesarztekammer ZEbd, 2003, DTSCH ARZTEBL, V100, pA1632; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GRUMONT RJ, 1994, CELL GROWTH DIFFER, V5, P1321; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LEEMAN JR, 2008, GENE IN PRESS; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; O'Rourke JP, 2008, MOL CELL BIOL, V28, P2091, DOI 10.1128/MCB.01870-07; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sanchez-Aguilera A, 2006, ONCOGENE, V25, P2565, DOI 10.1038/sj.onc.1209282; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; Starczynowski DT, 2007, ONCOGENE, V26, P2685, DOI 10.1038/sj.onc.1210089; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Stoilov P, 2002, DNA CELL BIOL, V21, P803, DOI 10.1089/104454902320908450; Yu SH, 2004, J MOL MED, V82, P621, DOI 10.1007/s00109-004-0559-7; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	31	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6770	6781		10.1038/onc.2008.284	http://dx.doi.org/10.1038/onc.2008.284			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18695674	Green Accepted			2022-12-17	WOS:000260866200007
J	Mao, JH; Wu, D; DelRosario, R; Castellanos, A; Balmain, A; Perez-Losada, J				Mao, J. H.; Wu, D.; DelRosario, R.; Castellanos, A.; Balmain, A.; Perez-Losada, J.			Atm heterozygosity does not increase tumor susceptibility to ionizing radiation alone or in a p53 heterozygous background	ONCOGENE			English	Article						Ataxia-Telangiectasia; ATM/Atm; P53; lymphoma; loss-of-heterozygosity; genetic-background	ATAXIA-TELANGIECTASIA HETEROZYGOTES; FAMILIAL BREAST-CANCER; INDUCED MAMMARY-TUMORS; DEFICIENT MICE; EARLY-ONSET; GENE; HAPLOINSUFFICIENCY; TUMORIGENESIS; MUTATIONS; RISK	Ataxia-Telangiectasia (A-T) is an autosomal recessive human disease characterized by genetic instability, radiosensitivity, immunodeficiency and cancer predisposition, because of mutation in both alleles of the ATM (ataxia-telangiectasia mutated) gene. The role of Atm heterozygosity in cancer susceptibility is controversial, in both human and mouse. Earlier studies identified deletions near the Atm gene on mouse chromosome 9 in radiation-induced lymphomas from p53 heterozygous mice. To determine whether Atm was the target of these deletions, Atm heterozygous as well as Atm/P53 double heterozygous mice were treated with ionizing radiation. There were no significant differences in tumor latency, progression and lifespan after gamma-radiation in Atm heterozygous mice compared with their wild-type control counterparts. Deletions were found on chromosome 9 near the Atm locus in radiation-induced tumors, but in 50% of the cases the deletion included the knockout allele, and the expression of Atm was maintained in the tumors indicating that loss of heterozygosity on chromosome 9 is not driven by Atm, but by an alternative tumor suppressor gene located near Atm on this chromosome. We conclude that Atm heterozygosity does not confer an increase in tumor susceptibility in this context.	[Castellanos, A.; Perez-Losada, J.] Univ Salamanca, Dept Med, Fac Med, E-37008 Salamanca, Spain; [Mao, J. H.; Wu, D.; DelRosario, R.; Balmain, A.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA	University of Salamanca; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Perez-Losada, J (corresponding author), Univ Salamanca, Dept Med, Fac Med, Campus Miguel Unamuno Sn, E-37008 Salamanca, Spain.	jperezlosada@usal.es	2008, Ibsal/A-1268-2012; Pérez-Losada, Jesús/A-5883-2019; Castellanos, Andres/F-3302-2016; Mao, Jian-Hua/EIZ-8595-2022; Castellanos, Antonio/J-4830-2013	Pérez-Losada, Jesús/0000-0003-2400-624X; Castellanos, Andres/0000-0003-2864-7271; Mao, Jian-Hua/0000-0001-9320-6021; Castellanos, Antonio/0000-0001-9291-0930	Spanish 'Ministerio de Educacion y Ciencia; European Community; Fondo de Investigaciones Sanitarias [PI070057]; NCI [U01 CA84244]; DOE [DE-FG02-03ER63630]; UCSF Research-Evaluation Allocation Committee (REAC); NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER	Spanish 'Ministerio de Educacion y Ciencia(Spanish Government); European Community(European Commission); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOE(United States Department of Energy (DOE)); UCSF Research-Evaluation Allocation Committee (REAC); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Gonzalez-Sarmiento, Dr Sanchez-Garcia and Dr Cobaleda for useful comments; and Dr Kogan for tumor pathology analysis. Dr Balmain acknowledges support from the Barbara Bass Bakar Chair of Cancer Genetics. Dr Perez-Losada is an investigator of the 'Programa Ramon y Cajal' from the Spanish 'Ministerio de Educacion y Ciencia' and the European Community, his study is partially supported by the 'Fondo de Investigaciones Sanitarias' (PI070057). Dr Castellanos is supported by the 'Fondo de Investigaciones Sanitarias' ( PI070057). These studies were also supported by NCI grant U01 CA84244 and the DOE (DE-FG02-03ER63630) to Dr Balmain, and the UCSF Research-Evaluation Allocation Committee (REAC) to Dr Mao.	Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Bishop DT, 1997, NAT GENET, V15, P226, DOI 10.1038/ng0397-226; Bowen TJ, 2005, CANCER RES, V65, P8736, DOI 10.1158/0008-5472.CAN-05-1598; BURNS PA, 1991, ENVIRON HEALTH PERSP, V93, P41, DOI 10.2307/3431166; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Chen JD, 1998, CANCER RES, V58, P1376; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; Connolly L, 2006, RADIAT RES, V166, P39, DOI 10.1667/RR3578.1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Hansel DE, 2003, ANNU REV GENOM HUM G, V4, P237, DOI 10.1146/annurev.genom.4.070802.110341; Inskip HM, 1999, BRIT J CANCER, V79, P1304, DOI 10.1038/sj.bjc.6690209; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Karabinis ME, 2001, CARCINOGENESIS, V22, P343, DOI 10.1093/carcin/22.2.343; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Lu S, 2006, CARCINOGENESIS, V27, P848, DOI 10.1093/carcin/bgi302; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Nakamura Y, 1998, NAT MED, V4, P1231, DOI 10.1038/3207; Olsen JH, 2001, JNCI-J NATL CANCER I, V93, P121, DOI 10.1093/jnci/93.2.121; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G; Umesako S, 2005, BREAST CANCER RES, V7, pR164, DOI 10.1186/bcr968; Vorechovsky I, 1996, CANCER RES, V56, P2726; Westphal CH, 1998, CANCER RES, V58, P5637; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WOOSTER R, 1993, HUM GENET, V92, P91, DOI 10.1007/BF00216153; Worgul BV, 2002, P NATL ACAD SCI USA, V99, P9836, DOI 10.1073/pnas.162349699; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yu YJ, 2001, CANCER RES, V61, P1820	38	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2008	27	51					6596	6600		10.1038/onc.2008.280	http://dx.doi.org/10.1038/onc.2008.280			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18679420				2022-12-17	WOS:000260501700007
J	Hirose, K; Abramovich, C; Argiropoulos, B; Humphries, RK				Hirose, K.; Abramovich, C.; Argiropoulos, B.; Humphries, R. K.			Leukemogenic properties of NUP98-PMX1 are linked to NUP98 and homeodomain sequence functions but not to binding properties of PMX1 to serum response factor	ONCOGENE			English	Article						homeodomain; nucleoporin; hematopoiesis	ACUTE MYELOID-LEUKEMIA; NUCLEAR-PORE COMPLEX; FUSION GENE; HOX GENES; HOMEOBOX GENE; FG REPEATS; PROTEIN; NUCLEOPORIN; TRANSCRIPTION; MEIS1	PMX1 is a member of a non-clustered homeobox gene family, not normally expressed in hematopoietic cells, and first identified for its role in enhancing the binding of the serum response factor (SRF) to the serum responsive element (SRE). PMX1 has never been linked to leukemia on its own, raising the possibility of unique mechanisms underlying the oncogenicity of NUP98-PMX1. To elucidate the leukemogenic potential of NUP98-PMX1, we compared the effects of PMX1 and NUP98-PMX1 and, through strategic mutations, the involvement of the SRE in NUP98-PMX1-mediated leukemia. NUP98-PMX1, but not PMX1, had potent ability to impair differentiation, promote proliferation of myeloid progenitors, induce lethal myeloproliferative disease and to activate a number of genes previously linked to leukemic stem cells. Similar to NUP98-HOX fusions, the transforming potential of NUP98-PMX1 required the NUP98 portion and DNA-binding capability of the PMX1 homeodomain and collaborated with Meis1 to induce more rapid onset myeloproliferative-like myeloid leukemia. The transforming activity of NUP98-PMX1 was independent of its ability to interact with SRF. These findings provide novel evidence of the contributory role of the NUP98 sequence in conferring leukemogenic properties on a partner gene and point to common leukemogenic pathways for NUP98-PMX1 and NUP98-clustered HOX fusions.	[Hirose, K.; Abramovich, C.; Argiropoulos, B.; Humphries, R. K.] British Columbia Canc Res Ctr, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; [Humphries, R. K.] Univ British Columbia, Dept Med, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia	Humphries, RK (corresponding author), British Columbia Canc Res Ctr, Terry Fox Lab, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	khumphri@bccrc.ca	Hirose, Koichi/I-1506-2017	Hirose, Koichi/0000-0001-7498-9630; Humphries, Richard/0000-0003-0540-7005	Terry Fox Foundation of Canada; Canadian Institutes of Health for Research; Leukemia and Lymphoma Society of Canada	Terry Fox Foundation of Canada; Canadian Institutes of Health for Research(Canadian Institutes of Health Research (CIHR)); Leukemia and Lymphoma Society of Canada	This work was supported by the Terry Fox Foundation of Canada and by the Canadian Institutes of Health for Research. KH and BA were recipients of fellowships from the Leukemia and Lymphoma Society of Canada. We thank Drs Florian Kuchenbauer and Eric Yung for technical assistance.	ALEXANDRE C, 1991, ONCOGENE, V6, P543; Argiropoulos B, 2007, ONCOGENE, V26, P6766, DOI 10.1038/sj.onc.1210760; Bai XT, 2006, CANCER RES, V66, P4584, DOI 10.1158/0008-5472.CAN-05-3101; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Eklund EA, 2007, CURR OPIN HEMATOL, V14, P85, DOI 10.1097/MOH.0b013e32801684b6; Eklund EA, 2006, CURR OPIN HEMATOL, V13, P67, DOI 10.1097/01.moh.0000208467.63861.d6; Ghannam G, 2004, J BIOL CHEM, V279, P866, DOI 10.1074/jbc.M307280200; Griffis ER, 2003, MOL BIOL CELL, V14, P600, DOI 10.1091/mbc.E02-09-0582; Griffis ER, 2002, MOL BIOL CELL, V13, P1282, DOI 10.1091/mbc.01-11-0538; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Gurevich RM, 2004, BLOOD, V104, P1127, DOI 10.1182/blood-2003-10-3550; Jankovic D, 2008, BLOOD, V111, P5672, DOI 10.1182/blood-2007-09-108175; Jeganathan KB, 2005, NATURE, V438, P1036, DOI 10.1038/nature04221; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; KERN MJ, 1994, GENOMICS, V19, P334, DOI 10.1006/geno.1994.1066; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; Martin KA, 1997, DNA CELL BIOL, V16, P653, DOI 10.1089/dna.1997.16.653; McKean DM, 2003, J CELL BIOL, V161, P393, DOI 10.1083/jcb.jcb.200302126; Nakamura T, 2005, INT J HEMATOL, V82, P21, DOI 10.1532/IJH97.04160; Nakamura T, 1999, BLOOD, V94, P741, DOI 10.1182/blood.V94.2.741.414k04_741_747; Palmqvist L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000768; Pineault N, 2004, MOL CELL BIOL, V24, P1907, DOI 10.1128/MCB.24.5.1907-1917.2004; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Romana SP, 2006, LEUKEMIA, V20, P696, DOI 10.1038/sj.leu.2404130; Saito S, 2004, INT J CANCER, V111, P501, DOI 10.1002/ijc.20296; Simon KJ, 1997, MOL CELL BIOL, V17, P6653, DOI 10.1128/MCB.17.11.6653; Slape C, 2004, LEUKEMIA LYMPHOMA, V45, P1341, DOI 10.1080/10428190310001659325; ten Berge D, 1998, DEVELOPMENT, V125, P3831; ten Berge D, 2001, DEVELOPMENT, V128, P2929; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Wang GG, 2006, MOL CELL BIOL, V26, P3902, DOI 10.1128/MCB.26.10.3902-3916.2006; Wu XS, 2001, P NATL ACAD SCI USA, V98, P3191, DOI 10.1073/pnas.051631598; Zhang L, 2007, CANCER GENET CYTOGEN, V178, P42, DOI 10.1016/j.cancergencyto.2007.06.012	40	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6056	6067		10.1038/onc.2008.210	http://dx.doi.org/10.1038/onc.2008.210			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18604245				2022-12-17	WOS:000259891600008
J	Fanta, S; Sonnenberg, M; Skorta, I; Duyster, J; Miething, C; Aulitzky, WE; van der Kuip, H				Fanta, S.; Sonnenberg, M.; Skorta, I.; Duyster, J.; Miething, C.; Aulitzky, W. E.; van der Kuip, H.			Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells	ONCOGENE			English	Article						imatinib mesylate; c-Abl; DNA repair; genetic stability	CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; IMATINIB MESYLATE; MUTATOR PHENOTYPE; DAMAGE; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; GROWTH; STI571	Imatinib inhibits the kinase activity of Bcr-Abl and is currently the most effective drug for treatment of chronic myeloid leukemia (CML). Imatinib also blocks c-Abl, a physiological tyrosine kinase activated by a variety of stress signals including damaged DNA. We investigated the effect of pharmacological inhibition of c-Abl on the processing of irradiation-induced DNA damage in Bcr-Abl-negative cells. Cell lines and peripheral blood mononuclear cells (PBMCs) from healthy volunteers were treated with imatinib or dasatinib before gamma-irradiation. Inhibition of c-Abl caused an enhanced irradiation-induced mutation frequency and slowdown of DNA repair, whereas imatinib was ineffective in cells expressing a T315I variant of c-Abl. Mutation frequency and repair kinetics were also studied in c-Abl-/- murine embryonic fibroblasts (MEFs) retransfected with wild-type c-Abl (wt-Abl) or a kinase-defect variant of Abl (KD-Abl). Enhanced mutation frequency as well as delayed DNA repair was observed in cells expressing KD-Abl. These data indicate that pharmacological inhibition of c-Abl compromises DNA-damage response.	[Fanta, S.; Sonnenberg, M.; Skorta, I.; van der Kuip, H.] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany; [Fanta, S.; Sonnenberg, M.; Skorta, I.; van der Kuip, H.] Univ Tubingen, Stuttgart, Germany; [Duyster, J.] Tech Univ Munich, Dept Internal Med 3, Munich, Germany; [Miething, C.] Cold Spring Harbor Lab, Ctr Canc, Cold Spring Harbor, NY 11724 USA; [Aulitzky, W. E.] Robert Bosch Krankenhaus, Dept Int Med Oncol & Hematol 2, Stuttgart, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Technical University of Munich; University of Munich; Cold Spring Harbor Laboratory; Bosch; Robert Bosch Krankenhaus	van der Kuip, H (corresponding author), Dr Margarete Fischer Bosch Inst Clin Pharmacol, Auerbachstr 112, D-70376 Stuttgart, Germany.	heiko.van-der-kuip@ikp-stuttgart.de	Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805				Andersen MK, 2002, LEUKEMIA, V16, P1390, DOI 10.1038/sj.leu.2402634; Buchdunger E, 1996, CANCER RES, V56, P100; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Cheng WH, 2003, MOL CELL BIOL, V23, P6385, DOI 10.1128/MCB.23.18.6385-6395.2003; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Imam SZ, 2007, NUCLEIC ACIDS RES, V35, P4941, DOI 10.1093/nar/gkm386; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669; Moehring A, 2005, CELL DEATH DIFFER, V12, P627, DOI 10.1038/sj.cdd.4401608; Picard S, 2007, BLOOD, V109, P3496, DOI 10.1182/blood-2006-07-036012; Salloukh HF, 2000, LEUKEMIA, V14, P1401, DOI 10.1038/sj.leu.2401855; Shaul Y, 2005, CELL RES, V15, P33, DOI 10.1038/sj.cr.7290261; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Terre C, 2004, LEUKEMIA, V18, P1340, DOI 10.1038/sj.leu.2403399; Uemura N, 2000, BLOOD, V96, P3294; van der Kuip H, 2004, LEUKEMIA RES, V28, P405, DOI 10.1016/j.leukres.2003.08.012; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wei G, 2005, J BIOL CHEM, V280, P12271, DOI 10.1074/jbc.M409522200; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799	27	18	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4380	4384		10.1038/onc.2008.68	http://dx.doi.org/10.1038/onc.2008.68			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362889				2022-12-17	WOS:000257691100013
J	Sasaki, H; Hayakawa, J; Terai, Y; Kanemura, M; Tanabe-Kimura, A; Kamegai, H; Seino-Noda, H; Ezoe, S; Matsumura, I; Kanakura, Y; Sakata, M; Tasaka, K; Ohmichi, M				Sasaki, H.; Hayakawa, J.; Terai, Y.; Kanemura, M.; Tanabe-Kimura, A.; Kamegai, H.; Seino-Noda, H.; Ezoe, S.; Matsumura, I.; Kanakura, Y.; Sakata, M.; Tasaka, K.; Ohmichi, M.			Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines	ONCOGENE			English	Article						ovarian cancer; estrogen; raloxifene; SRC-1	HEALTHY POSTMENOPAUSAL WOMEN; RANDOMIZED CONTROLLED-TRIAL; VASCULAR ENDOTHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; BREAST-CANCER; C-MYC; CYCLE PROGRESSION; RECEPTOR-ALPHA; PROTEIN-KINASE; GROWTH-FACTORS	Although there is growing evidence that estrogens promote tumor progression in epithelial ovarian cancer, the molecular mechanisms accounting for this are still unclear. Selective estrogen receptor modulators ( SERMs) mimic estrogen action in certain tissues while opposing it in others. The molecular mechanisms of the effects of SERMs such as raloxifene on the tumor progression of epithelial ovarian cancer are also still unclear. Here, we show that various genomic actions of estrogen differ from those of raloxifene in human ovarian cancer cell lines expressing estrogen receptor alpha (ER alpha). 17 beta-Estradiol (E2) induced the gene expression of c-Myc and IGF-1 and increased the binding of ER alpha to the AP1 site of the promoters of c-Myc and IGF-1. ER alpha silencing abolished the E2-stimulated c-Myc expression. E2 induced the recruitment of co-activators such as SRC-1, SRC-3 and CBP to the promoters of c-Myc and IGF-1, and SRC-1 silencing abolished both the E2-stimulated c-Myc expression and cell-cycle progression. In contrast, although raloxifene increased the binding of ER alpha to the AP1 site of the promoters of c-Myc and IGF-1, raloxifene had no effect on the gene expression of c-Myc or IGF-1. Raloxifene induced the recruitment of co-repressors such as HDAC2, N-CoR and SMRT to the promoter of IGF-1. Thus, the difference between the genomic actions exerted by estrogen and raloxifene in human ovarian cancer cell lines expressing ERa appear to be dependent on the recruitment of co-regulators.	[Sasaki, H.; Terai, Y.; Kanemura, M.; Tanabe-Kimura, A.; Kamegai, H.; Ohmichi, M.] Osaka Med Coll, Dept Obstet & Gynecol, Takatsuki, Osaka 5698686, Japan; [Hayakawa, J.; Seino-Noda, H.; Sakata, M.; Tasaka, K.] Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 565, Japan; [Ezoe, S.; Matsumura, I.; Kanakura, Y.] Osaka Univ, Sch Med, Dept Hematol & Oncol, Suita, Osaka 565, Japan	Osaka Medical College; Osaka University; Osaka University	Ohmichi, M (corresponding author), Osaka Med Coll, Dept Obstet & Gynecol, 2-7 Daigakutyou, Takatsuki, Osaka 5698686, Japan.	masa@gyne.med.osaka-u.ac.jp						Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Bardin A, 2004, CANCER RES, V64, P5861, DOI 10.1158/0008-5472.CAN-04-0552; BERNS EMJJ, 1992, INT J CANCER, V52, P218, DOI 10.1002/ijc.2910520211; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; CELANO P, 1989, BIOTECHNIQUES, V7, P942; Chow SN, 1996, INT SURG, V81, P152; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cunat S, 2004, GYNECOL ONCOL, V94, P25, DOI 10.1016/j.ygyno.2004.03.026; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; DUBIK D, 1992, ONCOGENE, V7, P1587; Girault I, 2003, CLIN CANCER RES, V9, P1259; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; HAMILTON TC, 1985, BIOCHEM PHARMACOL, V34, P2583, DOI 10.1016/0006-2952(85)90551-9; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Hewitt SC, 2005, SCIENCE, V307, P1572, DOI 10.1126/science.1110345; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Hussein-Fikret S, 2005, MOL CELL ENDOCRINOL, V229, P149, DOI 10.1016/j.mce.2004.08.005; Kawagoe J, 2003, J BIOL CHEM, V278, P43363, DOI 10.1074/jbc.M304363200; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; Kimura A, 2004, ONCOGENE, V23, P4505, DOI 10.1038/sj.onc.1207582; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LACEY JV, 2002, JAMA-J AM MED ASSOC, V288, P3344; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P1302, DOI 10.1210/en.2003-0709; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P49, DOI 10.1210/en.2003-0792; Mawson A, 2005, MOL CELL ENDOCRINOL, V229, P161, DOI 10.1016/j.mce.2004.08.002; MURPHY LJ, 1991, J STEROID BIOCHEM, V40, P223, DOI 10.1016/0960-0760(91)90186-9; Neven P, 2002, GYNECOL ONCOL, V85, P388, DOI 10.1006/gyno.2001.6578; Oishi A, 2004, BIOCHEM BIOPH RES CO, V324, P193, DOI 10.1016/j.bbrc.2004.09.032; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VANDAM PA, 1994, J CLIN PATHOL, V47, P914, DOI 10.1136/jcp.47.10.914; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; Webb Paul, 2003, Nucl Recept, V1, P4, DOI 10.1186/1478-1336-1-4; Weiss NS, 2001, LANCET, V358, P438, DOI 10.1016/S0140-6736(01)05669-0	38	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2737	2745		10.1038/sj.onc.1210926	http://dx.doi.org/10.1038/sj.onc.1210926			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18193094				2022-12-17	WOS:000255259500008
J	Lehnert, S; Gotz, C; Kartarius, S; Schafer, B; Montenarh, M				Lehnert, S.; Goetz, C.; Kartarius, S.; Schaefer, B.; Montenarh, M.			Protein kinase CK2 interacts with the splicing factor hPrp3p	ONCOGENE			English	Article						protein kinase CK2; hPrp3p; splicing factor; phosphorylation; protein -protein interaction	CARBOXYL-TERMINAL DOMAIN; RNA-POLYMERASE-II; DOMINANT RETINITIS-PIGMENTOSA; BETA-SUBUNIT; CASEIN KINASE-2; CYCLIN-H; PHOSPHORYLATION; EXPRESSION; SUBSTRATE; BINDING	Numerous signalling pathways in cells are influenced by the ubiquitous Ser/ Thr protein kinase CK2. Protein kinase CK2 is composed of two regulatory beta-subunits and two catalytic alpha- or alpha'- subunits. Several of the known CK2 substrates are proteins known to regulate transcriptional events. Here, we describe that protein kinase CK2 interacts with the splicing factor hPrp3p, which is important for the assembly of the spliceosome. In a two-hybrid screen hPrp3p is exclusively bound to the catalytic alpha- or alpha'- subunits of CK2 but not to the regulatory beta-subunit. The interaction was confirmed by coimmunoprecipitation experiments in vitro and in vivo. Moreover, both proteins colocalized in nuclear speckles which is typical for splicing factor compartments within the nucleus. Phosphorylation experiments revealed that hPrp3p is also a substrate of protein kinase CK2. The main phosphorylation site was mapped to C- terminal residues. In vitro and in vivo splicing assays showed that the splicing activity is significantly influenced by the CK2 - hPrp3p interaction. Thus, these data showed that CK2 is involved in the regulation of RNA processing.	[Lehnert, S.; Goetz, C.; Kartarius, S.; Schaefer, B.; Montenarh, M.] Univ Saarland, D-66421 Homburg, Germany	Saarland University	Montenarh, M (corresponding author), Univ Saarland, Gebaude 44, D-66421 Homburg, Germany.	Montenarh@uks.eu	Montenarh, Mathias/AAB-6689-2020					Bosc DG, 2000, J BIOL CHEM, V275, P14295, DOI 10.1074/jbc.275.19.14295; BURNETT G, 1954, J BIOL CHEM, V211, P969; Cabrejos ME, 2004, J CELL BIOCHEM, V93, P2, DOI 10.1002/jcb.20209; Chakarova CF, 2002, HUM MOL GENET, V11, P87, DOI 10.1093/hmg/11.1.87; Faust M, 1999, FEBS LETT, V462, P51, DOI 10.1016/S0014-5793(99)01492-1; Faust M, 2002, BIOCHEM BIOPH RES CO, V269, P6; Gonzalez-Santos JM, 2002, J BIOL CHEM, V277, P23764, DOI 10.1074/jbc.M111461200; Gotz C, 2005, MOL CELL BIOCHEM, V274, P181, DOI 10.1007/s11010-005-2950-2; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; Guerra B, 1998, ACTA CRYSTALLOGR D, V54, P143, DOI 10.1107/S0907444997010184; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Krempler A, 2005, CELL MOL LIFE SCI, V62, P1379, DOI 10.1007/s00018-005-5023-5; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; Li MF, 1999, J MOL BIOL, V293, P1067, DOI 10.1006/jmbi.1999.3207; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Liu SB, 2006, RNA, V12, P1418, DOI 10.1261/rna.55406; Maita H, 2004, EXP CELL RES, V300, P283, DOI 10.1016/j.yexcr.2004.07.029; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; Messenger MM, 2002, J BIOL CHEM, V277, P23054, DOI 10.1074/jbc.M200111200; Palancade B, 2002, J BIOL CHEM, V277, P36061, DOI 10.1074/jbc.M205192200; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; Penner CG, 1997, J CELL BIOCHEM, V64, P525; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Schneider E, 2002, ONCOGENE, V21, P5031, DOI 10.1038/sj.onc.1205690; SCHNEIDER HR, 1988, BIOCHEM BIOPH RES CO, V156, P1390, DOI 10.1016/S0006-291X(88)80786-1; Schuster N, 1999, FEBS LETT, V447, P160, DOI 10.1016/S0014-5793(99)00273-2; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Trembley JH, 2005, MOL CELL BIOL, V25, P1446, DOI 10.1128/MCB.25.4.1446-1457.2005; Trembley JH, 2003, J BIOL CHEM, V278, P2265, DOI 10.1074/jbc.M207518200	35	18	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2390	2400		10.1038/sj.onc.1210882	http://dx.doi.org/10.1038/sj.onc.1210882			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	18026141				2022-12-17	WOS:000254844900004
J	Myatt, SS; Burchill, SA				Myatt, S. S.; Burchill, S. A.			The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38MAPK activity	ONCOGENE			English	Article						p38MAPK; EWS-Fli1; ROS; fenretinide; apoptosis; ESFT	PHASE-I TRIAL; RNA INTERFERENCE; N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED APOPTOSIS; SUSTAINED-ACTIVATION; ORAL FENRETINIDE; CANCER-CELLS; SOLID TUMORS; GROWTH; NEUROBLASTOMA; PHENOTYPE	The Ewing's sarcoma family of tumours (ESFT) are small round cell tumours characterized by the non-random EWS-ETS gene rearrangements. We have previously demonstrated that ESFT are highly sensitive to fenretinide-induced death, effected in part through a reactive oxygen species (ROS)-dependent pathway. Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG. This decrease in cell death was independent of the level of ROS produced following exposure to fenretinide, but was effected through EWSFli1-dependent modulation of p38(MAPK) activity. Furthermore, inhibition of p38(MAPK) activity and knockdown of EWS-Fli1 reduced fenretinide- induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38(MAPK) is critical for activation of the death cascade by fenretinide in ESFT cells. These data demonstrate that expression of EWS-Fli1 enhances fenretinide-induced cell death in ESFT and that this is effected at least in part through modulation of p38(MAPK) activity.	[Myatt, S. S.; Burchill, S. A.] St James Hosp, Candlelighters Childrens Can Res Lab, Canc Res UK Cllin Care, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Burchill, SA (corresponding author), St James Hosp, Candlelighters Childrens Can Res Lab, Canc Res UK Cllin Care, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	s.a.burchill@leeds.ac.uk						Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Boya P, 2003, ONCOGENE, V22, P6220, DOI 10.1038/sj.onc.1206827; Burchill SA, 2003, J CLIN PATHOL, V56, P96, DOI 10.1136/jcp.56.2.96; BURCHILL SA, 1994, INT J CANCER, V57, P671, DOI 10.1002/ijc.2910570510; Chansky HA, 2004, J ORTHOPAED RES, V22, P910, DOI 10.1016/j.orthres.2003.12.008; Chiesa F, 2005, INT J CANCER, V115, P625, DOI 10.1002/ijc.20923; Corazzari M, 2005, BIOCHEM BIOPH RES CO, V331, P810, DOI 10.1016/j.bbrc.2005.03.184; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Dohjima T, 2003, MOL THER, V7, P811, DOI 10.1016/S1525-0016(03)00101-1; FORMELLI F, 1993, J CLIN ONCOL, V11, P2036, DOI 10.1200/JCO.1993.11.10.2036; Garaventa A, 2003, CLIN CANCER RES, V9, P2032; Horbinski C, 2005, FREE RADICAL BIO MED, V38, P2, DOI 10.1016/j.freeradbiomed.2004.09.030; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Huang SL, 2004, J BIOL CHEM, V279, P36490, DOI 10.1074/jbc.M401208200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kim HJ, 2006, ONCOGENE, V25, P2785, DOI 10.1038/sj.onc.1209303; Malone W, 2003, EXPERT OPIN INV DRUG, V12, P1829, DOI 10.1517/13543784.12.11.1829; Matsunobu T, 2006, CANCER RES, V66, P803, DOI 10.1158/0008-5472.CAN-05-1972; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mittal V, 2004, NAT REV GENET, V5, P355, DOI 10.1038/nrg1323; Myatt SS, 2005, CLIN CANCER RES, V11, P3136, DOI 10.1158/1078-0432.CCR-04-2050; O'Donnell PH, 2002, LEUKEMIA, V16, P902, DOI 10.1038/sj.leu.2402485; Osone S, 2004, INT J CANCER, V112, P219, DOI 10.1002/ijc.20412; Pienta KJ, 1997, AM J CLIN ONCOL-CANC, V20, P36, DOI 10.1097/00000421-199702000-00008; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Simeone AM, 2005, CARCINOGENESIS, V26, P1000, DOI 10.1093/carcin/bgi038; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Villablanca JG, 2006, J CLIN ONCOL, V24, P3423, DOI 10.1200/JCO.2005.03.9271; Westerhout EM, 2005, NUCLEIC ACIDS RES, V33, P796, DOI 10.1093/nar/gki220; Williamson AJK, 2004, J BIOL CHEM, V279, P47912, DOI 10.1074/jbc.M409035200; Won JS, 2006, FREE RADICAL BIO MED, V40, P1875, DOI 10.1016/j.freeradbiomed.2006.01.035; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yeny CT, 2005, CANCER RES, V65, P8698, DOI 10.1158/0008-5472.CAN-05-1704; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; Zanardi S, 2006, ENDOCR-RELAT CANCER, V13, P51, DOI 10.1677/erc.1.00938	41	18	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					985	996		10.1038/sj.onc.1210705	http://dx.doi.org/10.1038/sj.onc.1210705			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700534				2022-12-17	WOS:000252946300010
J	Woo, Y; Wright, SM; Maas, SA; Alley, TL; Caddle, LB; Kamdar, S; Affourtit, J; Foreman, O; Akeson, EC; Shaffer, D; Bronson, RT; Morse, HC; Roopenian, D; Mills, KD				Woo, Y.; Wright, S. M.; Maas, S. A.; Alley, T. L.; Caddle, L. B.; Kamdar, S.; Affourtit, J.; Foreman, O.; Akeson, E. C.; Shaffer, D.; Bronson, R. T.; Morse, H. C., III; Roopenian, D.; Mills, K. D.			The nonhomologous end joining factor Artemis suppresses multi-tissue tumor formation and prevents loss of heterozygosity	ONCOGENE			English	Article						nonhomologous end joining; RS-SCID; Artemis; loss of heterozygosity; p53	QUANTITATIVE GENE-EXPRESSION; DNA BREAKS; P53; IMMUNODEFICIENCY; TRANSLOCATIONS; REPAIR; AMPLIFICATION; INSTABILITY; LYMPHOCYTE; DEFICIENT	Nonhomologous end joining ( NHEJ) is a critical DNA repair pathway, with proposed tumor suppression functions in many tissues. Mutations in the NHEJ factor ARTEMIS cause radiation- sensitive severe combined immunodeficiency in humans and may increase susceptibility to lymphoma in some settings. We now report that deficiency for Artemis (encoded by Dclre1c/Art in mouse) accelerates tumorigenesis in several tissues in a Trp53 heterozygous setting, revealing tumor suppression roles for NHEJ in lymphoid and non- lymphoid cells. We also show that B- lineage lymphomas in these mice undergo loss of Trp53 heterozygosity by allele replacement, but arise by mechanisms distinct from those in Art Trp53 double null mice. These findings demonstrate a general tumor suppression function for NHEJ, and reveal that interplay between NHEJ and Trp53 loss of heterozygosity influences the sequence of multi-hit oncogenesis. We present a model where p53 status at the time of tumor initiation is a key determinant of subsequent oncogenic mechanisms. Because Art deficient mice represent a model for radiation-sensitive severe combined immunodeficiency, our findings suggest that these patients maybe at risk for both lymphoid and non- lymphoid cancers.	Jackson Lab, Bar Harbor, ME 04609 USA; Univ Maine, Functional Genom PhD Program, Orono, ME USA; Bar Harbor Biotechnol, Trenton, NJ USA; Tufts Univ, Sch Vet Med, Cummings Sch, Dept Biomed Sci, North Grafton, MA 01536 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; NIAID, Immunopathol Lab, Rockville, MD USA	Jackson Laboratory; University of Maine System; University of Maine Orono; Tufts University; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Mills, KD (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	kevin.mills@jax.org		Morse, Herbert/0000-0002-9331-3705	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007065] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA115665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA115665] Funding Source: Medline; NICHD NIH HHS [T32 HD07065-27, T32 HD007065] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akeson EC, 2006, GENOMICS, V87, P311, DOI 10.1016/j.ygeno.2005.09.022; Akeson EC, 2001, CYTOGENET CELL GENET, V93, P270, DOI 10.1159/000056997; Akilesh S, 2003, GENOME RES, V13, P1719, DOI 10.1101/gr.533003; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Churchill GA, 2004, BIOTECHNIQUES, V37, P173, DOI 10.2144/04372TE01; de Villartay JP, 2003, CURR OPIN IMMUNOL, V15, P592, DOI 10.1016/S0952-7915(03)00101-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Eilers PHC, 2005, BIOINFORMATICS, V21, P1146, DOI 10.1093/bioinformatics/bti148; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Hart GT, 2004, INFECT IMMUN, V72, P4471, DOI 10.1128/IAI.72.8.4471-4479.2004; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Holcomb VB, 2006, ONCOGENE, V25, P7159, DOI 10.1038/sj.onc.1209704; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Jeggo PA, 2006, DNA REPAIR, V5, P1192, DOI 10.1016/j.dnarep.2006.05.011; Jiang WD, 2001, P NATL ACAD SCI USA, V98, P9790, DOI 10.1073/pnas.171066498; Kerr M K, 2001, Biostatistics, V2, P183, DOI 10.1093/biostatistics/2.2.183; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Liang L, 2002, MUTAT RES-FUND MOL M, V502, P69, DOI 10.1016/S0027-5107(02)00029-5; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Mostoslavsky G, 2006, P NATL ACAD SCI USA, V103, P16406, DOI 10.1073/pnas.0608130103; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; Olivier M, 2003, CANCER RES, V63, P6643; Rooney S, 2004, IMMUNOL REV, V200, P115, DOI 10.1111/j.0105-2896.2004.00165.x; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Stark JM, 2003, MOL CELL BIOL, V23, P733, DOI 10.1128/MCB.23.2.733-743.2003; Tischfield JA, 2003, NAT GENET, V33, P5, DOI 10.1038/ng0103-5; WU H, 2003, ANAL GENE EXPRESSION; Yan CT, 2006, P NATL ACAD SCI USA, V103, P7378, DOI 10.1073/pnas.0601938103; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	37	18	18	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6010	6020		10.1038/sj.onc.1210430	http://dx.doi.org/10.1038/sj.onc.1210430			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384673				2022-12-17	WOS:000249277200004
J	Rose-Hellekant, TA; Schroeder, MD; Brockman, JL; Zhdankin, O; Bolstad, R; Chen, KS; Gould, MN; Schuler, LA; Sandgren, EP				Rose-Hellekant, T. A.; Schroeder, M. D.; Brockman, J. L.; Zhdankin, O.; Bolstad, R.; Chen, K. S.; Gould, M. N.; Schuler, L. A.; Sandgren, E. P.			Estrogen receptor-positive mammary tumorigenesis in TGF alpha transgenic mice progresses with progesterone receptor loss	ONCOGENE			English	Article						breast cancer; mammary cancer; TGF alpha; transgenic mice; estrogen receptor; progesterone receptor	GROWTH-FACTOR-ALPHA; BREAST-CANCER CELLS; C-MYC; MOUSE MAMMARY; EXPRESSION; PROLACTIN; OVEREXPRESSION; INDUCTION; PHENOTYPE; CARCINOMA	We characterized the novel NRL-transforming growth factor alpha (NRL-TGF alpha) transgenic mouse model in which growth factor - steroid receptor interactions were explored. The NRL promoter directs transgene expression to mammary ductal and alveolar cells and is nonresponsive to estrogen manipulations in vitro and in vivo. NRL-TGF alpha mice acquire proliferative hyperplasias as well as cystic and solid tumors. Quantitative transcript analysis revealed a progressive decrease in estrogen receptor alpha ( ER) and progesterone receptor (PR) mRNA levels with tumorigenesis. However, ER protein was evident in all lesion types and in surrounding stromal cells using immunohistochemistry. PR protein was identified in normal epithelial cells and in very few cells of small epithelial hyperplasias, but never in stromal or tumor cells. Prophylactic ovariectomy significantly delayed tumor development and decreased incidence. Finally, while heterozygous (+/- ) p53 mice did not acquire mammary lesions, p53 +/- mice carrying the NRL-TGF alpha transgene developed ER negative/PR negative undifferentiated carcinomas. These data demonstrate that unregulated TGF alpha expression in the mammary gland leads to oncogenesis that is dependent on ovarian steroids early in tumorigenesis. Resulting tumors resemble a clinical phenotype of ER+/ PR-, and when combined with a heterozygous p53 genotype, ER-/PR-.	Univ Minnesota, Sch Med, Dept Physiol & Pharmacol, Duluth, MN 55812 USA; Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI USA; Univ Wisconsin, Sch Med, Dept Oncol, Madison, WI USA	University of Minnesota System; University of Minnesota Duluth; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rose-Hellekant, TA (corresponding author), Univ Minnesota, Sch Med, Dept Physiol & Pharmacol, Duluth, MN 55812 USA.	trosehel@d.umn.edu	Gould, Michael N/C-7414-2014		NATIONAL CANCER INSTITUTE [R01CA078312, R01CA058328, R01CA064843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009090] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078312-03S2, R01-CA78312, R01 CA078312-03S1, R01 CA078312-03, R01-CA58328, R01-CA64843, R01 CA078312, R01 CA078312-04A1, R01 CA078312-02S1] Funding Source: Medline; NCRR NIH HHS [K01-RR00145] Funding Source: Medline; NIEHS NIH HHS [ES09090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAN RAH, 1992, J BIOL CHEM, V267, P3771; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Arendt LM, 2006, AM J PATHOL, V168, P1365, DOI 10.2353/ajpath.2006.050861; Arpino G, 2005, JNCI-J NATL CANCER I, V97, P1254, DOI 10.1093/jnci/dji249; Bieche I, 2003, INT J CANCER, V106, P758, DOI 10.1002/ijc.11273; Blackburn AC, 2003, CANCER RES, V63, P2364; Blackburn AC, 2002, BREAST CANCER RES, V4, P98; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Gee JM, 2005, ENDOCR-RELAT CANCER, V12, pS99, DOI 10.1677/erc.1.01005; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Grippo PJ, 2000, AM J PATHOL, V157, P805, DOI 10.1016/S0002-9440(10)64594-4; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; GURURAJ AE, 2006, CLIN CANC RES, V12; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Hewitt SC, 2002, CANCER RES, V62, P2798; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Medina D, 2003, CANCER RES, V63, P6140; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Pierson-Mullany Lisa K, 2003, Breast Dis, V18, P21; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Rose-Hellekant TA, 2002, AM J PATHOL, V161, P1439, DOI 10.1016/S0002-9440(10)64419-7; Rose-Hellekant TA, 2000, ONCOGENE, V19, P1092, DOI 10.1038/sj.onc.1203350; Rudland PS, 1995, BIOMED PHARMACOTHER, V49, P389, DOI 10.1016/0753-3322(96)82676-X; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Stoesz SP, 1995, ONCOGENE, V11, P2233; Zhang XM, 2005, ONCOGENE, V24, P4220, DOI 10.1038/sj.onc.1208597	38	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5238	5246		10.1038/sj.onc.1210340	http://dx.doi.org/10.1038/sj.onc.1210340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17334393	Green Accepted			2022-12-17	WOS:000248674200007
J	Jiao, R; Harrigan, JA; Shevelev, I; Dietschy, T; Selak, N; Indig, FE; Piotrowski, J; Janscak, P; Bohr, VA; Stagljar, I				Jiao, R.; Harrigan, J. A.; Shevelev, I.; Dietschy, T.; Selak, N.; Indig, F. E.; Piotrowski, J.; Janscak, P.; Bohr, V. A.; Stagljar, I.			The Werner syndrome protein is required for recruitment of chromatin assembly factor 1 following DNA damage	ONCOGENE			English	Article						WRN; CAF-1; DNA damage; chromatin assembly; genome stability	SYNDROME GENE-PRODUCT; NUCLEOTIDE EXCISION-REPAIR; BLOOM-SYNDROME HELICASES; FUNCTIONAL INTERACTION; IN-VIVO; HUMAN-CELLS; FLAP ENDONUCLEASE-1; POLYMERASE-BETA; WRN HELICASES; STRAND BREAKS	The Werner syndrome protein (WRN) and chromatin assembly factor 1 (CAF-1) are both involved in the maintenance of genome stability. In response to DNA-damaging signals, both of these proteins relocate to sites where DNA synthesis occurs. However, the interaction between WRN and CAF-1 has not yet been investigated. In this report, we show that WRN interacts physically with the largest subunit of CAF-1, hp150, in vitro and in vivo. Although hp150 does not alter WRN catalytic activities in vitro, and the chromatin assembly activity of CAF-1 is not affected in the absence of WRN in vivo, this interaction may have an important role during the cellular response to DNA replication fork blockage and/or DNA damage signals. In hp150 RNA-mediated interference (RNAi) knockdown cells, WRN partially formed foci following hydroxyurea (HU) treatment. However, in the absence of WRN, hp150 did not relocate to form foci following exposure to HU and ultraviolet light. Thus, our results demonstrate that WRN responds to DNA damage before CAF-1 and suggest that WRN may recruit CAF-1, via interaction with hp150, to DNA damage sites during DNA synthesis.	Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Dept Biochem, Toronto, ON M5S 3E1, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 3E1, Canada; Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100080, Peoples R China; Chinese Acad Sci, State Key Lab Brain & Cognit Sci, Inst Biophys, Beijing 100080, Peoples R China; NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M4X 1K9, Canada; Friedrich Miescher Inst Biomed Res, Basel, Switzerland; NIA, Res Resources Branch, NIH, Baltimore, MD 21224 USA; Univ Zurich, Inst Mol Canc Res, CH-8006 Zurich, Switzerland	University of Toronto; University of Toronto; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Toronto; Friedrich Miescher Institute for Biomedical Research; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Zurich	Jiao, R (corresponding author), Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Dept Biochem, 160 Coll St, Toronto, ON M5S 3E1, Canada.	rjiao@sun5.ibp.ac.cn; igor.stagljar@utoronto.ca	Bohr, Vilhelm/AAP-5931-2020; Jiao, Renjie/AAE-8902-2019; Janscak, Pavel/G-6189-2014; Janscak, Pavel/Q-3795-2018	Janscak, Pavel/0000-0002-1748-7789	NATIONAL INSTITUTE ON AGING [Z01AG000615, ZICAG000615] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Bohr VA, 2005, MUTAT RES-FUND MOL M, V577, P252, DOI 10.1016/j.mrfmmm.2005.03.021; Bradshaw PS, 2005, NAT GENET, V37, P193, DOI 10.1038/ng1506; Cheng WH, 2004, J BIOL CHEM, V279, P21169, DOI 10.1074/jbc.M312770200; Doherty KM, 2005, J BIOL CHEM, V280, P29494, DOI 10.1074/jbc.M500653200; Franchitto A, 2004, CELL CYCLE, V3, P1331, DOI 10.4161/cc.3.10.1185; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Garcia PL, 2004, NUCLEIC ACIDS RES, V32, P3771, DOI 10.1093/nar/gkh709; Green CM, 2003, EMBO J, V22, P5163, DOI 10.1093/emboj/cdg478; Guay D, 2006, INT J BIOCHEM CELL B, V38, P1300, DOI 10.1016/j.biocel.2006.01.008; Harrigan JA, 2006, NUCLEIC ACIDS RES, V34, P745, DOI 10.1093/nar/gkj475; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Jiao RJ, 2004, MOL CELL BIOL, V24, P4710, DOI 10.1128/MCB.24.11.4710-4719.2004; Karmakar P, 2005, MECH AGEING DEV, V126, P1146, DOI 10.1016/j.mad.2005.06.004; Karmakar P, 2002, NUCLEIC ACIDS RES, V30, P3583, DOI 10.1093/nar/gkf482; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Krude T, 1999, EUR J BIOCHEM, V263, P1, DOI 10.1046/j.1432-1327.1999.00508.x; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Laud PR, 2005, GENE DEV, V19, P2560, DOI 10.1101/gad.1321305; Lee JW, 2005, J BIOL CHEM, V280, P39627, DOI 10.1074/jbc.M506112200; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; LI L, 2005, J CELL SCI, V118, P4153; Linger J, 2005, GENETICS, V171, P1513, DOI 10.1534/genetics.105.043000; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; Nabatiyan A, 2004, MOL CELL BIOL, V24, P2853, DOI 10.1128/MCB.24.7.2853-2862.2004; Nabatiyan A, 2006, MOL CELL BIOL, V26, P1839, DOI 10.1128/MCB.26.5.1839-1849.2006; Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023; Opresko PL, 2004, J BIOL CHEM, V279, P18099, DOI 10.1074/jbc.R300034200; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Oshima J, 2002, CANCER RES, V62, P547; Ozgenc A, 2005, MUTAT RES-FUND MOL M, V577, P237, DOI 10.1016/j.mrfmmm.2005.03.020; Pedrazzi G, 2003, BIOL CHEM, V384, P1155, DOI 10.1515/BC.2003.128; Petkovic M, 2005, J CELL SCI, V118, P4261, DOI 10.1242/jcs.02556; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Rodriguez-Lopez AM, 2003, MECH AGEING DEV, V124, P167, DOI 10.1016/S0047-6374(02)00131-8; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Sharma S, 2004, HUM MOL GENET, V13, P2247, DOI 10.1093/hmg/ddh234; Sharma S, 2005, NUCLEIC ACIDS RES, V33, P6769, DOI 10.1093/nar/gki1002; Sharma S, 2004, J BIOL CHEM, V279, P9847, DOI 10.1074/jbc.M309898200; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Tyler JK, 2001, MOL CELL BIOL, V21, P6574, DOI 10.1128/MCB.21.19.6574-6584.2001; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; von Kobbe C, 2004, NUCLEIC ACIDS RES, V32, P4003, DOI 10.1093/nar/gkh721; von Kobbe C, 2003, MOL CELL BIOL, V23, P8601, DOI 10.1128/MCB.23.23.8601-8613.2003; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wolffe AP., 1998, CHROMATIN STRUCTURE; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	69	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3811	3822		10.1038/sj.onc.1210150	http://dx.doi.org/10.1038/sj.onc.1210150			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173071				2022-12-17	WOS:000247026400005
J	Nekhai, S; Bhat, UG; Ammosova, T; Radhakrishnan, SK; Jerebtsova, M; Niu, X; Foster, A; Layden, TJ; Gartel, AL				Nekhai, S.; Bhat, U. G.; Ammosova, T.; Radhakrishnan, S. K.; Jerebtsova, M.; Niu, X.; Foster, A.; Layden, T. J.; Gartel, A. L.			A novel anticancer agent ARC antagonizes HIV-1 and HCV	ONCOGENE			English	Article						HIV; HCV; anticancer drug; nucleoside analog	RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; CYCLIN T1; P-TEFB; LARGE SUBUNIT; TAT; TRANSCRIPTION; PROTEIN; HEPATITIS; INTERACTS	Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) pose major public health concerns worldwide. HCV is clearly associated with the occurrence of hepatocellular carcinoma, and recently HIV infection has also been linked to the development of a multitude of cancers. Previously, we identified a novel nucleoside analog transcriptional inhibitor ARC (4-amino-6-hydrazino-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carboxamide) that exhibited proapoptotic and antiangiogenic properties in vitro. Here, we evaluated the effect of ARC on HIV-1 transcription and HCV replication. Using reporter assays, we found that ARC inhibited HIV-1 Tat-based transactivation in different cell systems. Also, using hepatoma cells that harbor subgenomic and full-length replicons of HCV, we found that ARC inhibited HCV replication. Together, our data indicate that ARC could be a promising candidate for the development of antiviral therapeutics against HIV and HCV.	Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Howard Univ, Coll Med, Ctr Sickle Cell Dis, Washington, DC 20059 USA; Howard Univ, Coll Med, Dept Biochem & Mol Biol, Washington, DC 20059 USA; CRI Ctr, Childrens Natl Med Ctr, Washington, DC 20059 USA; Howard Univ, Coll Med, Dept Microbiol, Washington, DC 20059 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Howard University; Howard University; Children's National Health System; Howard University	Nekhai, S (corresponding author), Univ Illinois, Coll Med, Dept Med, 840 S Wood,Room 1041, Chicago, IL 60612 USA.	snekhai@howard.edu; agartel@uic.edu	Ammosova, Tatiana/J-7564-2018; , nekhai/AFO-2652-2022; , nekhai/AAW-3105-2021	Ammosova, Tatiana/0000-0001-8777-1032; Radhakrishnan, Senthil/0000-0002-5211-9498	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UH1HL003679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI056973] Funding Source: NIH RePORTER; NHLBI NIH HHS [UH1HL 03679] Funding Source: Medline; NIAID NIH HHS [R21 AI056973, R21 AI156973-01, R21 AI056973-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammosova T, 2005, J BIOL CHEM, V280, P36364, DOI 10.1074/jbc.M503673200; Ammosova T, 2003, J BIOL CHEM, V278, P32189, DOI 10.1074/jbc.M300521200; Bark-Jones SJ, 2006, ONCOGENE, V25, P1775, DOI 10.1038/sj.onc.1209205; Berretta M, 2003, ONCOGENE, V22, P6646, DOI 10.1038/sj.onc.1206771; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brady J, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-69; Brigati C, 2003, FEMS MICROBIOL LETT, V220, P57, DOI 10.1016/S0378-1097(03)00067-3; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Giacca Mauro, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P277, DOI 10.2174/1568008043339767; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Lau JYN, 2002, HEPATOLOGY, V35, P1002, DOI 10.1053/jhep.2002.32672; Levrero M, 2006, ONCOGENE, V25, P3834, DOI 10.1038/sj.onc.1209562; Liang Chen, 2002, AIDS Reviews, V4, P41; Liang TJ, 2004, GASTROENTEROLOGY, V127, pS62, DOI 10.1053/j.gastro.2004.09.017; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Marcello A, 2001, IUBMB LIFE, V51, P175, DOI 10.1080/152165401753544241; Nekhai S, 2000, PEPTIDES, V21, P1449, DOI 10.1016/S0196-9781(00)00297-7; PETRYSHYN R, 1984, BIOCHEM BIOPH RES CO, V119, P891, DOI 10.1016/0006-291X(84)90857-X; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Radhakrishnan SK, 2006, CANCER RES, V66, P3264, DOI 10.1158/0008-5472.CAN-05-3940; Radhakrishnan SK, 2004, VIROLOGY, V323, P173, DOI 10.1016/j.virol.2004.02.021; Roden R, 2006, NAT REV CANCER, V6, P753, DOI 10.1038/nrc1973; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Tamrakar S, 2005, J VIROL, V79, P15477, DOI 10.1128/JVI.79.24.15477-15493.2005; Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266-7279.2001; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Zhou MS, 2006, J VIROL, V80, P4781, DOI 10.1128/JVI.80.10.4781-4791.2006	34	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3899	3903		10.1038/sj.onc.1210158	http://dx.doi.org/10.1038/sj.onc.1210158			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173067				2022-12-17	WOS:000247026400013
J	Chebotaev, D; Yemelyanov, A; Zhu, L; Lavker, RM; Budunova, I				Chebotaev, D.; Yemelyanov, A.; Zhu, L.; Lavker, R. M.; Budunova, I.			The tumor suppressor effect of the glucocorticoid receptor in skin is mediated via its effect on follicular epithelial stem cells	ONCOGENE			English	Article						epidermis; stem cells; glucocorticoid receptor; skin carcinogenesis	LABEL-RETAINING CELLS; GROWTH-FACTOR; TRANSCRIPTION FACTORS; KAPPA-B; CARCINOGENESIS; APOPTOSIS; ERYTHROPOIESIS; IDENTIFICATION; DEXAMETHASONE; PROLIFERATION	Glucocorticoids are potent inhibitors of mouse skin tumorigenesis. The glucocorticoid control of cellular functions is mediated via the glucocorticoid receptor ( GR), a well-known transcription factor. Recently, we generated transgenic mice overexpressing GR under control of the keratin5 ( K5) promoter, and showed that K5. GR animals are resistant to skin carcinogenesis. Follicular epithelial stem cells ( SCs), located in the bulge region of the hair follicle, are believed to be one of the target cells for skin carcinogenesis. We found that the number of putative hair follicle SC detected as label-retaining cells was significantly less in the K5. GR transgenics compared to wild type ( w.t.) littermates. We also showed that GR overexpression led to a reduction in the clonogenicity of the follicular epithelial SCs. We evaluated the global effect of GR on gene expression in a population of follicular SC-enriched bulge keratinocytes isolated by fluorescence activated cell sorting. We found that GR affected the expression of numerous bulge SC 'signature' genes, genes involved in the maintenance of SC and progenitor cells of non-epidermal origin and proapoptotic genes. Our findings underscore the important role of GR signaling in the homeostasis of follicular epithelial SCs, and suggest that the reduction in their number may underlie the tumor suppressor effect of GR in the skin.	Northwestern Univ, Feinberg Med Sch, Dept Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Bioinformat Core, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University	Budunova, I (corresponding author), Northwestern Univ, Feinberg Med Sch, Dept Dermatol, Ward Bldg 9-332,303 E Chicago Ave, Chicago, IL 60611 USA.	i-budunova@northwestern.edu		Zhu, Lihua/0000-0001-7416-0590				Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BICKENBACH JR, 1984, J INVEST DERMATOL, V82, P618, DOI 10.1111/1523-1747.ep12261460; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Budunova IV, 1997, MOL CARCINOGEN, V18, P177, DOI 10.1002/(SICI)1098-2744(199703)18:3<177::AID-MC7>3.3.CO;2-U; Budunova IV, 2003, ONCOGENE, V22, P3279, DOI 10.1038/sj.onc.1206383; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Davies TH, 2005, BIOCHEMISTRY-US, V44, P2030, DOI 10.1021/bi048503v; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Derfoul A, 2006, STEM CELLS, V24, P1487, DOI 10.1634/stemcells.2005-0415; Dumitriu B, 2006, BLOOD, V108, P1198, DOI 10.1182/blood-2006-02-004184; Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534-5807(01)00022-3; Herold MJ, 2006, CELL MOL LIFE SCI, V63, P60, DOI 10.1007/s00018-005-5390-y; Hubler TR, 2004, CELL STRESS CHAPERON, V9, P243, DOI 10.1379/CSC-32R.1; Ito C, 2003, BONE MARROW TRANSPL, V32, P391, DOI 10.1038/sj.bmt.1704152; Lavker RM, 2003, J INVEST DERM SYMP P, V8, P28, DOI 10.1046/j.1523-1747.2003.12169.x; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; Li BG, 2005, INT J BIOCHEM CELL B, V37, P2207, DOI 10.1016/j.biocel.2005.04.008; Li GY, 2003, J BIOL CHEM, V278, P41779, DOI 10.1074/jbc.M305350200; Ligon KL, 2006, P NATL ACAD SCI USA, V103, P7853, DOI 10.1073/pnas.0511001103; Lu JH, 2006, FEBS LETT, V580, P3539, DOI 10.1016/j.febslet.2006.05.031; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; MORRIS RJ, 1985, J INVEST DERMATOL, V84, P277, DOI 10.1111/1523-1747.ep12265358; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; Necela Brian M, 2004, Proc Am Thorac Soc, V1, P239, DOI 10.1513/pats.200402-005MS; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Perez P, 2001, FASEB J, V15, P2030, DOI 10.1096/fj.00-0772fje; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; SCHWARZ JA, 1977, CHEM-BIOL INTERACT, V17, P331, DOI 10.1016/0009-2797(77)90096-5; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Smith E, 2004, J LEUKOCYTE BIOL, V75, P973, DOI 10.1189/jlb.1103554; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; Takayama S, 2006, J BIOL CHEM, V281, P17856, DOI 10.1074/jbc.M602290200; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; VERMA AK, 1983, CANCER RES, V43, P3045; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Yao RS, 2004, ONCOGENE, V23, P7746, DOI 10.1038/sj.onc.1207985; Yemelyanov A, 2006, ONCOGENE, V25, P387, DOI 10.1038/sj.onc.1209066	44	18	20	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					3060	3068		10.1038/sj.onc.1210108	http://dx.doi.org/10.1038/sj.onc.1210108			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17146443				2022-12-17	WOS:000246395400011
J	Rojas, P; Cadenas, MB; Lin, PC; Benavides, F; Conti, CJ; Rodriguez-Puebla, ML				Rojas, P.; Cadenas, M. B.; Lin, P. -C; Benavides, F.; Conti, C. J.; Rodriguez-Puebla, M. L.			Cyclin D2 and cyclin D3 play opposite roles in mouse skin carcinogenesis	ONCOGENE			English	Article						cyclin D3; cyclin D2; skin; DMBA; keratinocytes; papillomas	DEPENDENT KINASE-ACTIVITY; SQUAMOUS-CELL CARCINOMA; TUMOR-DEVELOPMENT; IN-VIVO; TRANSGENIC MICE; EXPRESSION; PROLIFERATION; D1; DIFFERENTIATION; PROGRESSION	D-type cyclins are components of the cell-cycle engine that link cell signaling pathways and passage throughout G1 phase. We previously described the effects of overexpression cyclin D1, D2 or D3 in mouse epidermis and tumor development. We now asked whether cyclin D2 and/or cyclin D3 play a relevant role in ras-dependent tumorigenesis. Here, we described the effect of cyclin D3 and cyclin D2 overexpression in mouse skin tumor development. Notably, overexpression of cyclin D3 results in reduced tumor development and malignant progression to squamous cell carcinomas (SCC). Biochemical analysis of keratinocytes shows that overexpression of cyclin D3 results in strong reduction of cyclin D2 and its associated kinase activity. Furthermore, we found that reinstatement of cyclin D2 level in the cyclin D3/cyclin D2 bigenic mice results in a complete reversion of the inhibitory action of cyclin D3. Supporting these results, ablation of cyclin D2 results in reduced tumorigenesis and malignant progression. On the other hand, overexpression of cyclin D2 results in an increased number of papillomas and malignant progression. We conclude that cyclin D3 and cyclin D2 play opposite roles in mouse skin tumor development and that the suppressive activity of cyclin D3 is associated with cyclin D2 downregulation.	N Carolina State Univ, Coll Vet Med, Ctr Comparat Med & Translat Res Mol Biomed Sci, CVM, Raleigh, NC 27606 USA; MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Div, Smithville, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of North Carolina; North Carolina State University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rodriguez-Puebla, ML (corresponding author), N Carolina State Univ, Coll Vet Med, Ctr Comparat Med & Translat Res Mol Biomed Sci, CVM, 4700 Hillsborough St, Raleigh, NC 27606 USA.	marcelo_rodriguez-puebla@ncsu.edu	Lin, Pei-Chun/A-3200-2013	Benavides, Fernando/0000-0003-1275-4320	NATIONAL CANCER INSTITUTE [R01CA116328] Funding Source: NIH RePORTER; NCI NIH HHS [CA116328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Cheung TH, 2001, CANCER LETT, V166, P199, DOI 10.1016/S0304-3835(01)00457-8; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; de Marval PLM, 2004, ONCOGENE, V23, P1863, DOI 10.1038/sj.onc.1207309; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Filipits M, 2002, CLIN CANCER RES, V8, P729; Fujii M, 2001, CANCER LETT, V172, P187, DOI 10.1016/S0304-3835(01)00651-6; Hedberg Y, 2002, ACTA ONCOL, V41, P175, DOI 10.1080/028418602753669562; HOULDSWORTH J, 1997, CELL GROWTH DIFFER, V8, P292; Ito Y, 2001, ANTICANCER RES, V21, P1043; KIESS M, 1995, ONCOGENE, V10, P159; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Mariappan I, 2005, MOL BIOL CELL, V16, P1948, DOI 10.1091/mbc.E04-02-0154; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Pruneri G, 2005, CLIN CANCER RES, V11, P242; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; Rodriguez-Puebla ML, 1999, CELL GROWTH DIFFER, V10, P467; Rodriguez-Puebla ML, 2000, AM J PATHOL, V157, P1039, DOI 10.1016/S0002-9440(10)64616-0; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1999, GENE DEV, V10, P1491; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J	33	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1723	1730		10.1038/sj.onc.1209970	http://dx.doi.org/10.1038/sj.onc.1209970			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983339				2022-12-17	WOS:000244955600006
J	Achison, M; Boylan, MT; Hupp, TR; Spruce, BA				Achison, M.; Boylan, M. T.; Hupp, T. R.; Spruce, B. A.			HIF-1 alpha contributes to tumour-selective killing by the sigma receptor antagonist rimcazole	ONCOGENE			English	Article						HIF-1 alpha; hypoxia; rimcazole; p53	HYPOXIA-INDUCIBLE FACTOR-1; GROWTH-FACTOR EXPRESSION; HUMAN CANCER-CELLS; TRANSCRIPTIONAL REPRESSION; FACTOR 1-ALPHA; P53; CARCINOMA; APOPTOSIS; HIF-1; DEATH	We have previously reported tumour-selective killing by the sigma(sigma) receptor ligand rimcazole. We now report that rimcazole elevates hypoxia inducible factor-1 alpha (HIF-1 alpha) protein levels under normoxic conditions in colorectal (HCT-116) and mammary carcinoma (MDA MB 231) cells but fails to induce HIF-1 alpha in normal fibroblasts or mammary epithelial cells. Combining the sigma-1 agonist (+)-pentazocine with rimcazole substantially reduces the accumulation of HIF-1 alpha, confirming that the effect is mediated at least partly by antagonism of sigma-1 sites. HIF-1 alpha knockdown by RNA interference attenuates rimcazole-induced cell death in both cell types. Thus, the induction of HIF-1 alpha by rimcazole contributes to tumour cell killing. In a comparison of HCT-116p53(+/+) and HCT-116p53(-/-) cells, HIF-1 alpha levels are consistently higher after rimcazole treatment in HCT-116p53(+/+) cells. Furthermore, although rimcazole kills HCT-116p53(-/-) cells, it has a more potent apoptosis-inducing effect in HCT-116p53+/+ cells. This suggests that the presence of functional p53 protein may enhance death induction by rimcazole in part through greater induction of HIF-1 alpha p53 is not required, however, for the rimcazole-induced engagement of HIF-1 alpha in proapoptotic mode as HIF-1 alpha knockdown attenuates rimcazole-induced death to comparable extents in p53 mutant and wild-type cell systems. Knowledge of HIF-1 alpha involvement may assist the re-pro. ling of rimcazole and other sigma ligands as cancer therapeutics.	Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Edinburgh, Western Gen Hosp, CRUK Canc Res Labs, Signal Transduct Unit P53, Edinburgh, Midlothian, Scotland	University of Dundee; University of Edinburgh	Spruce, BA (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.	b.a.spruce@dundee.ac.uk						Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arends JW, 2000, J PATHOL, V190, P412; Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Fels DR, 2005, TRENDS BIOCHEM SCI, V30, P426, DOI 10.1016/j.tibs.2005.06.009; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giaccia AJ, 1998, SCIENCE, V279, P12; Gilmore DL, 2004, CNS DRUG REV, V10, P1; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Krishnamachary B, 2003, CANCER RES, V63, P1138; Langa F, 2003, EUR J NEUROSCI, V18, P2188, DOI 10.1046/j.1460-9568.2003.02950.x; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Schmid T, 2004, BIOCHEM J, V380, P289, DOI 10.1042/BJ20031299; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Spruce BA, 2004, CANCER RES, V64, P4875, DOI 10.1158/0008-5472.CAN-03-3180; WALDMAN T, 1995, CANCER RES, V55, P5187; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Yim S, 2003, J BIOL CHEM, V278, P38260, DOI 10.1074/jbc.M306016200; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598	34	18	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1137	1146		10.1038/sj.onc.1209890	http://dx.doi.org/10.1038/sj.onc.1209890			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924239				2022-12-17	WOS:000244406400004
J	Karakas, B; Weeraratna, A; Abukhdeir, A; Blair, BG; Konishi, H; Arena, S; Becker, K; Wood, W; Argani, P; De Marzo, AM; Bachman, KE; Park, BH				Karakas, B.; Weeraratna, A.; Abukhdeir, A.; Blair, B. G.; Konishi, H.; Arena, S.; Becker, K.; Wood, W., III; Argani, P.; De Marzo, A. M.; Bachman, K. E.; Park, B. H.			Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells	ONCOGENE			English	Article						p21; TGF-beta; IL-1alpha; breast cancer	BREAST-CANCER CELLS; TGF-BETA; CYCLE ARREST; EXPRESSION; BINDING; GENE; REPRESSION; TGF-BETA-1; LINES; CDK	Transforming growth factor-beta type 1 (TGF-beta) has been implicated as both a tumor suppressor and a tumor promoter in many solid epithelial cancers. We have previously demonstrated that the cyclin dependent kinase (CDK) inhibitor p21 acts as a molecular switch in determining a growth inhibitory versus growth proliferative response to TGF-beta in the spontaneously immortalized human mammary epithelial cell line MCF-10A. We now demonstrate that this proliferative effect of TGF-beta is mediated through the proinflammatory cytokine, interleukin-1 alpha (IL-1 alpha). Using gene expression array analysis, we identified IL-1 alpha as a cytokine specifically upregulated only in cells lacking p21 and only upon TGF-beta stimulation. Cell proliferation assays verified that recombinant IL-1 alpha was capable of inducing a growth proliferative response in p21 null MCF-10A cells, while neutralizing antibodies against IL-1 alpha prevented the growth proliferative effects of TGF-beta. Mechanistically, both the CDK and proliferating cell nuclear antigen (PCNA) inhibitory functions of p21 were responsible for preventing TGF-beta induced cell proliferation, but only PCNA inhibition by p21 regulated IL-1 alpha gene expression. These studies demonstrate a novel role for IL-1 alpha in mediating a proliferative response to TGF-beta signaling, and suggest that therapies directed against IL-1 alpha could abate the growth proliferative effects of TGF-beta without compromising its tumor suppressive function.	Johns Hopkins Univ, Dept Oncol, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA; NIA, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Pathol, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	Park, BH (corresponding author), Johns Hopkins Univ, Dept Oncol, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, 1650 Orleans St,Room 1M42, Baltimore, MD 21231 USA.	bpark2@jhmi.edu	Arena, Sabrina/H-4985-2012	Arena, Sabrina/0000-0002-1318-2494; Abukhdeir, Abde/0000-0003-1172-5819; Konishi, Hiroyuki/0000-0003-1131-4905; Becker, Kevin/0000-0002-6794-6656	NATIONAL CANCER INSTITUTE [R01CA109274, P50CA088843] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [P50 CA88843, R01CA109274-01A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Bachman KE, 2004, CANCER BIOL THER, V3, P221, DOI 10.4161/cbt.3.2.666; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Grille SJ, 2003, CANCER RES, V63, P2172; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Iavarone A, 1997, NATURE, V387, P417; Islam S, 2000, J CELL BIOCHEM, V78, P141, DOI 10.1002/(SICI)1097-4644(20000701)78:1<141::AID-JCB13>3.0.CO;2-R; KLOEN P, 1994, EUR J CANCER, V30A, P678, DOI 10.1016/0959-8049(94)90544-4; KLOEN P, 1994, INT J CANCER, V58, P440, DOI 10.1002/ijc.2910580323; Lei XF, 2002, ONCOGENE, V21, P7514, DOI 10.1038/sj.onc.1205966; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Theocharis SE, 2004, HISTOPATHOLOGY, V45, P103, DOI 10.1111/j.1365-2559.2004.01922.x; TURNER M, 1989, J IMMUNOL, V143, P3556; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	23	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5561	5569		10.1038/sj.onc.1209540	http://dx.doi.org/10.1038/sj.onc.1209540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619041				2022-12-17	WOS:000240370400009
J	Bianchi, T; Rufer, N; MacDonald, HR; Migliaccio, M				Bianchi, T.; Rufer, N.; MacDonald, H. R.; Migliaccio, M.			The tumor suppressor p16(Ink4a) regulates T lymphocyte survival	ONCOGENE			English	Article						p16(Ink4a); T lymphocyte; apoptosis; cell stress	OXIDATIVE-STRESS; INK4 FAMILY; APOPTOSIS; MICE; TUMORIGENESIS; FIBROBLASTS; SENESCENCE; EXPRESSION; INHIBITORS; DEATH	In contrast to other cell cycle inhibitors, the tumor suppressor p16(Ink4a) is not detectable or expressed at very low levels in embryonic and adult mouse tissues, and therefore it has often been considered as a specialized checkpoint protein that does not participate in the control of normal cell cycle progression. However, Ink4a(-/-) mice possess increased thymus size and cellularity, thus suggesting the involvement of p16(Ink4a) in the control of thymocyte proliferation. In this study, we found increased numbers of CD8 and CD4 T lymphocytes in thymus and spleen from Ink4a(-/-) mice. Unexpectedly, this was not related to an increase in T-cell division rates, which were similar in lymphoid organs of Ink4a(-/-) and wild-type mice. In contrast, T-cell apoptosis rates were significantly decreased in thymus and spleen from Ink4a(-/-) mice. Moreover, whereas p16(Ink4a)-deficient and wild-type T cells were equally sensitive to Fas or TCR-mediated apoptosis, the former were clearly more resistant to apoptosis induced by oxidative stress or gamma irradiation. Our results indicate that p16(Ink4a) function is associated with T-cell apoptosis, and subsequently contributes to the control of T-cell population size in lymphoid organs.	Swiss Inst Expt Canc Res, NCCR, Mol Oncol Program, Swiss Natl Sci Fdn, CH-1066 Epalinges, Switzerland; Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research; Ludwig Institute for Cancer Research	Migliaccio, M (corresponding author), Swiss Inst Expt Canc Res, NCCR, Mol Oncol Program, Swiss Natl Sci Fdn, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	marcomv@romandie.com						Al-Mohanna MA, 2004, ONCOGENE, V23, P201, DOI 10.1038/sj.onc.1206927; Amstad PA, 2001, REDOX REP, V6, P351, DOI 10.1179/135100001101536535; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Azenabor AA, 1999, J APPL PHYSIOL, V86, P1823, DOI 10.1152/jappl.1999.86.6.1823; Cayota A, 1996, BLOOD, V87, P4746, DOI 10.1182/blood.V87.11.4746.bloodjournal87114746; Cemerski S, 2003, EUR J IMMUNOL, V33, P2178, DOI 10.1002/eji.200323898; Chazal M, 2002, ONCOGENE, V21, P2652, DOI 10.1038/sj.onc.1205349; Chen JH, 2004, J BIOL CHEM, V279, P49439, DOI 10.1074/jbc.M409153200; Cope AP, 2002, ARTHRITIS RES THER, V4, pS197, DOI 10.1186/ar557; de Magalhaes JP, 2002, FEBS LETT, V523, P157, DOI 10.1016/S0014-5793(02)02973-3; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Hingorani R, 2000, J IMMUNOL, V164, P4032, DOI 10.4049/jimmunol.164.8.4032; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Kim HJ, 2005, J IMMUNOL, V175, P2948, DOI 10.4049/jimmunol.175.5.2948; Lagresle C, 2002, J IMMUNOL, V168, P2325, DOI 10.4049/jimmunol.168.5.2325; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Marrack P, 2004, ANNU REV IMMUNOL, V22, P765, DOI 10.1146/annurev.immunol.22.012703.104554; Migliaccio M, 2005, J IMMUNOL, V174, P3335, DOI 10.4049/jimmunol.174.6.3335; Quadrilatero J, 2004, BIOCHEM BIOPH RES CO, V319, P894, DOI 10.1016/j.bbrc.2004.05.068; Remans PHJ, 2004, J IMMUNOL, V173, P920, DOI 10.4049/jimmunol.173.2.920; Rodriguez-Mora OG, 2005, FREE RADICAL BIO MED, V38, P1653, DOI 10.1016/j.freeradbiomed.2005.02.035; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Sachs Z, 2004, J VIROL, V78, P3304, DOI 10.1128/JVI.78.7.3304-3311.2004; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	29	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4110	4115		10.1038/sj.onc.1209437	http://dx.doi.org/10.1038/sj.onc.1209437			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491120				2022-12-17	WOS:000238802400011
J	Zhou, YT; Guy, GR; Low, BC				Zhou, YT; Guy, GR; Low, BC			BNIP-S alpha induces cell rounding and apoptosis by displacing p50RhoGAP and facilitating RhoA activation via its unique motifs in the BNIP-2 and Cdc42GAP homology domain	ONCOGENE			English	Article						BNIP-S; RhoA; BCH domain; p50RhoGAP/Cdc42GAP; cell rounding; apoptosis	AKT PHOSPHORYLATION; BCL-2 EXPRESSION; FAMILY PROTEINS; F-ACTIN; GTPASES; KINASE; GROWTH; TRANSLOCATION; BINDING; HOMOLOGY/SEC14P-LIKE	Changes in cell morphology are linked to many cellular events including cytokinesis, differentiation, migration and apoptosis. We recently showed that BNIP-S alpha induced cell rounding that leads to apoptosis via its BNIP-2 and Cdc42GAP Homology (BCH) domain, but the underlying mechanism has not been determined. Here, we have identified a unique region (amino acid 133-177) of the BNIP-S alpha BCH domain that targets RhoA, but not Cdc42 or Rac1 and only the dominant-negative form of RhoA could prevent the resultant cell rounding and apoptotic effect. The RhoA-binding region consists of two parts; one region (residues 133-147) that shows some homology to part of the RhoA switch I region and an adjacent sequence (residues 148-177) that resembles the REM class I RhoA-binding motif. The sequence 133-147 is also necessary for its heterophilic interaction with the BCH domain of the Rho GTPase-activating protein, p50RhoGAP/Cdc42GAP. These overlapping motifs allow tripartite competition such that overexpression of BNIP-S alpha could reduce p50RhoGAP binding to RhoA and restore RhoA activation. Furthermore, BNIP-Sa mutants lacking the RhoA-binding motif completely failed to induce cell rounding and apoptosis. Therefore, via unique binding motifs within its BCH domain, BNIP-S alpha could interact and activate RhoA while preventing its inhibition by p50RhoGAP. This concerted mechanism could allow effective propagation of the RhoA pathway for cell rounding and apoptosis.	Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, Singapore 117548, Singapore; Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117548, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Low, BC (corresponding author), Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, 14 Sci Dr 4, Singapore 117548, Singapore.	dbslowbc@nus.edu.sg	Low, Boon Chuan/H-8049-2012; Low, Boon Chuan/AAU-7685-2021	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X; Zhou, Yi-Ting/0000-0003-4543-3099				Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Bando M, 2002, BIOCHEM BIOPH RES CO, V290, P268, DOI 10.1006/bbrc.2001.6199; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Coleman ML, 2002, CELL DEATH DIFFER, V9, P493, DOI 10.1038/sj.cdd.4400987; Collard JG, 2004, NATURE, V428, P705, DOI 10.1038/428705a; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Dvorsky R, 2004, EMBO REP, V5, P1130, DOI 10.1038/sj.embor.7400293; Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057; Fiorentini C, 1998, INFECT IMMUN, V66, P2660, DOI 10.1128/IAI.66.6.2660-2665.1998; Flusberg DA, 2001, MOL BIOL CELL, V12, P3087, DOI 10.1091/mbc.12.10.3087; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gourlay CW, 2005, J CELL SCI, V118, P2119, DOI 10.1242/jcs.02337; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Kim SJ, 2003, J BIOL CHEM, V278, P42448, DOI 10.1074/jbc.M304887200; Korichneva I, 1999, J CELL SCI, V112, P2521; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Low BC, 1999, J BIOL CHEM, V274, P33123, DOI 10.1074/jbc.274.46.33123; Low BC, 2000, J BIOL CHEM, V275, P14415, DOI 10.1074/jbc.275.19.14415; Low BC, 2000, J BIOL CHEM, V275, P37742, DOI 10.1074/jbc.M004897200; Lua BL, 2004, MOL BIOL CELL, V15, P2873, DOI 10.1091/mbc.E04-02-0141; Melamed I, 1999, CELL IMMUNOL, V194, P136, DOI 10.1006/cimm.1999.1506; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Posey SC, 1999, J BIOL CHEM, V274, P4259, DOI 10.1074/jbc.274.7.4259; Qin WX, 2003, BIOCHEM BIOPH RES CO, V308, P379, DOI 10.1016/S0006-291X(03)01387-1; Reuveny M, 2004, FEBS LETT, V569, P129, DOI 10.1016/j.febslet.2004.05.035; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Saeki N, 2005, J BIOL CHEM, V280, P10128, DOI 10.1074/jbc.M413415200; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Shang X, 2003, J BIOL CHEM, V278, P45903, DOI 10.1074/jbc.M304514200; Song YH, 2002, EXP CELL RES, V278, P45, DOI 10.1006/excr.2002.5565; Spector D. L., 1998, CELLS LAB MANUAL; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Suria H, 1999, LIFE SCI, V65, P2697, DOI 10.1016/S0024-3205(99)00538-X; Surks HK, 2003, J BIOL CHEM, V278, P51484, DOI 10.1074/jbc.M305622200; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tosello-Trampont AC, 2003, J BIOL CHEM, V278, P49911, DOI 10.1074/jbc.M306079200; Ueda H, 2004, EXP CELL RES, V298, P207, DOI 10.1016/j.yexcr.2004.04.015; Wang L, 2006, BLOOD, V107, P98, DOI 10.1182/blood-2005-05-2171; Wang L, 2005, P NATL ACAD SCI USA, V102, P13484, DOI 10.1073/pnas.0504420102; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; White SR, 2001, AM J RESP CELL MOL, V24, P282, DOI 10.1165/ajrcmb.24.3.3995; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246; Zhou Yi Ting, 2005, Experimental Cell Research, V303, P263, DOI 10.1016/j.yexcr.2004.08.044; Zhou YT, 2002, J BIOL CHEM, V277, P7483, DOI 10.1074/jbc.M109459200	58	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2393	2408		10.1038/sj.onc.1209274	http://dx.doi.org/10.1038/sj.onc.1209274			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331259				2022-12-17	WOS:000236764300011
J	Nagano, K; Itagaki, C; Izumi, T; Nunomura, K; Soda, Y; Tani, K; Takahashi, N; Takenawa, T; Isobe, T				Nagano, K; Itagaki, C; Izumi, T; Nunomura, K; Soda, Y; Tani, K; Takahashi, N; Takenawa, T; Isobe, T			Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase	ONCOGENE			English	Article						Rb; Abl; tyrosine phosphorylation; chronic myelogenous leukemia; apoptosis	RETINOBLASTOMA PROTEIN; C-ABL; HISTONE DEACETYLASE; SUPPRESSOR; E2F; INHIBITION; MECHANISMS; APOPTOSIS; PEPTIDE; BINDING	The retinoblastoma (Rb) gene product is a tumor suppressor that is mutated or inactivated in many types of human cancers. Although Rb is known to be an upstream negative regulator of Abl protein tyrosine kinase, we propose here that Rb also functions as a downstream effector of Abl that plays a positive role in survival of Abl-dependent human tumor cells, including Bcr/Abl-positive chronic myelogenous leukemia (CML). We show that Rb is constitutively phosphorylated at tyrosine in Abl-dependent tumor cells, and that Abl phosphorylates Rb specifically at Y805 within the C-terminal domain of the molecule. We also show that ectopic expression of Rb induces apoptosis in Abl-dependent tumor cells by inhibiting the Abl tyrosine kinase activity, and that Rb-induced apoptosis is compromised by Abl-catalysed phosphorylation of Rb at Y805. Furthermore, the silencing of endogenous Rb by RNA interference induced apoptosis in Abl-dependent tumor cells. Thus, our findings suggest that Abl-catalysed tyrosine phosphorylation of Rb is necessary for survival of Abl-dependent human tumor cells, and raises the possibility that this phosphorylated Rb can be a molecular target for cancer therapy aimed at inducing apoptosis of Abl-dependent tumor cells, such as Bcr/Abl-positive CML.	Univ Tokyo, Inst Med Sci, Div Prote Res, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Div Mol Therapy, Adv Clin Res Ctr, Minato Ku, Tokyo 1088639, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Adv Mol & Cell Therapy, Higashi Ku, Fukuoka 812, Japan; Tokyo Univ Agr & Technol, Dept Appl Biol Sci, Fuchu, Tokyo 183, Japan; Univ Tokyo, Inst Med Sci, Div Biochem, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; Kyushu University; Tokyo University of Agriculture & Technology; University of Tokyo	Isobe, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Prote Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	isobe-toshiaki@c.metro-u.ac.jp	TAKAHASHI, Nobuhiro/G-1129-2013					BALTIMORE D, 1995, ANN NY ACAD SCI, V758, P339, DOI 10.1111/j.1749-6632.1995.tb24839.x; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bowen C, 2002, J BIOL CHEM, V277, P44969, DOI 10.1074/jbc.M202000200; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Cujec TP, 2002, CHEM BIOL, V9, P253, DOI 10.1016/S1074-5521(02)00098-4; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Guo XYD, 1999, ONCOGENE, V18, P1589, DOI 10.1038/sj.onc.1202479; Harata M, 2004, BLOOD, V104, P1442, DOI 10.1182/blood-2004-02-0588; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; NEVINS JR, 1992, SCIENCE, V258, P424; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Taoka M, 2003, J BIOL CHEM, V278, P5864, DOI 10.1074/jbc.M211509200; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318	35	18	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					493	502		10.1038/sj.onc.1208996	http://dx.doi.org/10.1038/sj.onc.1208996			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16158058				2022-12-17	WOS:000234897400001
J	Tsuda, M; Watanabe, T; Seki, T; Kimura, T; Sawa, H; Minami, A; Akagi, T; Isobe, K; Nagashima, K; Tanaka, S				Tsuda, M; Watanabe, T; Seki, T; Kimura, T; Sawa, H; Minami, A; Akagi, T; Isobe, K; Nagashima, K; Tanaka, S			Induction of p21(WAF1/CIP1) by human synovial sarcoma-associated chimeric oncoprotein SYT-SSX1	ONCOGENE			English	Article						p21(WAF1/CIP1); Sp1; synovial sarcoma; SYT-SSX	PROMOTER ACTIVITY; NIH3T3 CELLS; LIFE-SPAN; SYT; P53; SENESCENCE; PROTEINS; FUSION; SSX; EXPRESSION	Oncogenic protein provokes cell cycle arrest termed premature senescence. In this process Ras has been known to induce cyclin-dependent kinase inhibitor (CKI) p16(INK4A) in primary fibroblasts. Here, we present a novel finding that human chimeric oncoprotein SYT-SSX1 induces CKI p21(WAF1/CIP1) (p21) for suppression of cell growth. In human synovial sarcoma cell lines, the expression levels of p21 were high and the transcriptional activity of the p21 gene promoter was significantly elevated. The transient expression of SYT- SSX1-induced activation of the p21 gene promoter in human diploid fibroblasts. The N-terminus deletion form of SYT-SSX1, which failed to bind to hBRM one of the chromatin remodeling factors, preserved the p21 induction ability. This effect of SYT-SSX1 was similar in extent in both wild-type and p53-deficient HCT116 cell lines. Furthermore, the introduction of mutation in Sp1/Sp3 binding sites of the p21 gene promoter abolished the SYT-SSX1-induced transcriptional activity of its promoter. In SW13 cells, the stable expression of SYT-SSX1 suppressed cell growth in culture. These results suggest that SYT-SSX1 is able to induce p21 in a manner independent on hBRM and p53 but dependent on Sp1/Sp3.	Hokkaido Univ, Grad Sch Med, Lab Mol & Cellular Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Dept Orthoped Surg, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Osaka Biosci Inst, Osaka 5650874, Japan; Natl Inst Lingev Sci, Dept Basic Gerontol, Obu 4748511, Japan	Hokkaido University; Hokkaido University	Tanaka, S (corresponding author), Hokkaido Univ, Grad Sch Med, Lab Mol & Cellular Pathol, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.	tanaka@med.hokudai.ac.jp	Sawa, Hirofumi/AAW-8816-2021; Tanaka, Shinya/D-3586-2011; Sawa, Hirofumi/F-6954-2012	Sawa, Hirofumi/0000-0003-2569-2755				AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Lloyd AC, 2002, NAT CELL BIOL, V4, pE25, DOI 10.1038/ncb0202-e25; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nishio J, 2002, INT J ONCOL, V21, P17; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pollock RE, 1996, ONCOGENE, V12, P2035; Sandberg AA, 2002, CANCER GENET CYTOGEN, V133, P1, DOI 10.1016/S0165-4608(01)00626-4; Schneider-Stock R, 1999, VIRCHOWS ARCH, V435, P407, DOI 10.1007/s004280050418; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; WEISS SW, 2001, ENZINGER WEISSS SOFT; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158	27	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7984	7990		10.1038/sj.onc.1208942	http://dx.doi.org/10.1038/sj.onc.1208942			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16103879				2022-12-17	WOS:000233656600005
J	Markova, M; Koratkar, RA; Silverman, KA; Sollars, VE; Mac-Phee-Pellini, M; Walters, R; Palazzo, JP; Buchberg, AM; Siracusa, LD; Farber, SA				Markova, M; Koratkar, RA; Silverman, KA; Sollars, VE; Mac-Phee-Pellini, M; Walters, R; Palazzo, JP; Buchberg, AM; Siracusa, LD; Farber, SA			Diversity in secreted PLA(2)-IIA activity among inbred mouse strains that are resistant or susceptible to Apc(Min/+) tumorigenesis	ONCOGENE			English	Article						APC; PLA2; phospholipase; Mom1; intestine; cancer; mouse; BODIPY	PHOSPHOLIPASE A(2); INTESTINAL NEOPLASIA; GROUP-II; GROUP-V; MAJOR MODIFIER; LOCUS; GENE; ENZYMES; IDENTIFICATION; BIOSYNTHESIS	The secreted phospholipase A(2) type IIA (Pla2g2a) gene was previously identified as a modifier of intestinal adenoma multiplicity in Apc(Min/+) mice. To determine if intestinal secreted phospholipase A(2) (sPLA(2)) activity was also attenuated in susceptible strains, we developed a sensitive assay to directly quantitate sPL2 activity in the murine intestinal tract utilizing a fluorescent BODIPY-labeled phospholipid substrate. Here, we report assay conditions that distinguish between secreted and cytosolic PLA(2) enzyme activities in extracts of intestinal tissue. The small intestine exhibited higher activity levels than the large intestine. Consistent with predictions from the sPLA(2)-IIA gene sequence in inbred strains, we detected low levels of enzyme activity in inbred strains containing sPLA(2)-IIA mutations; these strains were also associated with greater numbers of intestinal polyps. Additionally, the assay was able to distinguish differences in levels of sPLA(2) activity between neoplasia-resistant strains, which were then shown by sequencing to carry variant wild-type sPLA(2)-IIA alleles. Immunohistochemical analyses of intestinal tissues were consistent with sPLA(2)-IIA activity levels. This approach enables further studies of the mechanisms of sPLA(2) action influencing the development and tumorigenesis of the small intestine and colon in both mice and humans.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Surg Pathol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Siracusa, LD (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	siracusa@mail.jci.tju.edu; farber@ciwemb.edu	Sollars, Vincent/R-3769-2019; Farber, Steven A/G-5851-2012	Farber, Steven A/0000-0002-8037-7312; Sollars, Vincent/0000-0002-5602-3610; Buchberg, Arthur/0000-0002-0543-5631	NCI NIH HHS [P01CA72027, R01 CA89560] Funding Source: Medline; NIDDK NIH HHS [R01 DK060369] Funding Source: Medline; NINDS NIH HHS [F32 NS010326] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089560, P01CA072027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010326] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Dahim M, 2002, BIOPHYS J, V83, P1511, DOI 10.1016/S0006-3495(02)73921-0; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Farber SA, 1999, J BIOL CHEM, V274, P19338, DOI 10.1074/jbc.274.27.19338; Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418; GELB MH, 1994, FASEB J, V8, P916, DOI 10.1096/fasebj.8.12.8088457; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; Gould KA, 1997, P NATL ACAD SCI USA, V94, P5848, DOI 10.1073/pnas.94.11.5848; Gould KA, 1996, GENETICS, V144, P1769; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; Hendrickson HS, 1999, ANAL BIOCHEM, V276, P27, DOI 10.1006/abio.1999.4280; Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Kirtane BM, 2002, J BIOSCIENCES, V27, P489, DOI 10.1007/BF02705045; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Koratkar R, 2004, GENOMICS, V84, P844, DOI 10.1016/j.ygeno.2004.07.010; Koratkar R, 2002, CANCER RES, V62, P5413; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Rouault M, 2003, BIOCHEMISTRY-US, V42, P11494, DOI 10.1021/bi0349930; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Silver L.M., 1995, MOUSE GENETICS CONCE; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4	36	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6450	6458		10.1038/sj.onc.1208791	http://dx.doi.org/10.1038/sj.onc.1208791			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007193	Green Accepted			2022-12-17	WOS:000232038200012
J	Simbulan-Rosenthal, CM; Trabosh, V; Velarde, A; Chou, FP; Daher, A; Tenzin, F; Tokino, T; Rosenthal, DS				Simbulan-Rosenthal, CM; Trabosh, V; Velarde, A; Chou, FP; Daher, A; Tenzin, F; Tokino, T; Rosenthal, DS			Id2 protein is selectively upregulated by UVB in primary, but not in immortalized human keratinocytes and inhibits differentiation	ONCOGENE			English	Article						Id2; keratinocyte; differentiation; promoter; ETS	LOOP-HELIX PROTEINS; HUMAN-PAPILLOMAVIRUS; ULTRAVIOLET-B; TRANSCRIPTIONAL ACTIVATION; EPIDERMAL DIFFERENTIATION; 5-FLANKING REGION; ENHANCER-BINDING; GENE-EXPRESSION; CELL-GROWTH; DNA-BINDING	Solar ultraviolet B (UVB) acts as both an initiator and promoter in models of multistage skin carcinogenesis. We found that, whereas UVB induces apoptosis in human papillomavirus-16 E6/7-immortalized keratinocytes, it inhibits markers of differentiation in human foreskin keratinocytes (HFK). Potential mechanisms for this differential response were examined by DNA microarray, which revealed that UVB alters the expression of three of the four human inhibitor of differentiation/DNA binding (Id) proteins that comprise a class of helix-loop-helix family of transcription factors involved in proliferation, differentiation, apoptosis, and carcinogenesis. These results were verified by RT-PCR and immunoblot analysis of control and UVB-irradiated primary and immortalized keratinocytes. Whereas Id1 was down-regulated in both cell types, Id2 expression was upregulated in primary HFK, but not immortalized cells. In contrast, Id3 expression was significantly increased only in immortalized cells. The differential expression pattern of Id2 in response to UVB was recapitulated in reporter constructs containing the 5' regulatory regions of this gene. Id2 promoter activity increased in response to UVB in HFK, but not in immortalized cells. To identify the regulatory elements in the Id2 promoter that mediate transcriptional activation by UVB in HFK, promoter deletion/mutation analysis was performed. Deletion analysis revealed that transactivation involves a 166 bp region immediately upstream to the Id2 transcriptional start site and is independent of c-Myc. The consensus E twenty-six (ETS) binding site at -120 appears to mediate UVB transcriptional activation of Id2 because point mutations at this site completely abrogated this response. Chromatin immunoprecipitation and electrophoretic mobility-shift assays verified that the Id2 promoter interacts with known Id2 promoter (ETS) binding factors Erg1/2 and Fli1, but not with c-Myc; and this interaction is enhanced after UVB exposure. Similar to the effects of UVB exposure, ectopic expression of Id2 protein in primary HFK resulted in inhibition of differentiation, as shown by decreased levels of the terminal differentiation marker keratin K1 and inhibition of involucrin crosslinking. Reduction of Id2 expression by small interfering RNAs attenuated the UVB-induced inhibition of differentiation in these cells. These results suggest that UVB-induced inhibition of differentiation of primary HFK is at least, in part, due to the upregulation of Id2, and that upregulation of Id2 by UVB might predispose keratinocytes to carcinogenesis by preventing their normal differentiation program.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Sapporo Med Univ, Sch Med, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan	Georgetown University; Sapporo Medical University	Rosenthal, DS (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	rosenthd@georgetown.edu	Feng-Pai, Chou/AGS-4250-2022; Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014; Tokino, Takashi/AAI-9887-2021	Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342; Rosenthal, Dean/0000-0002-7624-0209	NCI NIH HHS [R01 CA100443-04, R01 CA100443-02, R01 CA100443, R01 CA100443-03, R01 CA100443-05, 5R01 CA100443-02, R01 CA100443-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; BAGHDOYAN S, 2005, J BIOL CHEM, V3, P3; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bavinck JNB, 2000, BRIT J DERMATOL, V142, P103, DOI 10.1046/j.1365-2133.2000.03248.x; Bernerd F, 1997, DEV BIOL, V183, P123, DOI 10.1006/dbio.1996.8465; Brellier F, 2004, CANCER RES, V64, P2699, DOI 10.1158/0008-5472.CAN-03-3477; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BROWN L, 1994, MOL CELL BIOL, V14, P1245, DOI 10.1128/MCB.14.2.1245; Brown VL, 2004, J INVEST DERMATOL, V122, P1284, DOI 10.1111/j.0022-202X.2004.22501.x; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHIARAMELLO A, 1995, MOL CELL BIOL, V15, P6036; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; D'Errico M, 2004, BRIT J DERMATOL, V150, P47, DOI 10.1111/j.1365-2133.2004.05714.x; Dazard JE, 2003, ONCOGENE, V22, P2993, DOI 10.1038/sj.onc.1206537; de Gruijl FR, 2001, J PHOTOCH PHOTOBIO B, V63, P19, DOI 10.1016/S1011-1344(01)00199-3; Del Bino S, 2004, BRIT J DERMATOL, V150, P658, DOI 10.1111/j.0007-0963.2004.05886.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; ELIEZRI YD, 1990, J AM ACAD DERMATOL, V23, P836, DOI 10.1016/0190-9622(90)70299-W; Ezura Y, 1997, J BIOL CHEM, V272, P29865, DOI 10.1074/jbc.272.47.29865; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; GUERINREVERCHON I, 1990, J CANCER RES CLIN, V116, P295, DOI 10.1007/BF01612906; Hacker C, 2003, NAT IMMUNOL, V4, P380, DOI 10.1038/ni903; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Karen J, 1999, CANCER RES, V59, P474; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; KETTLER AH, 1990, ARCH DERMATOL, V126, P777, DOI 10.1001/archderm.126.6.777; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kleeff J, 1998, CANCER RES, V58, P3769; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KURABAYASHI M, 1995, GENE, V156, P311, DOI 10.1016/0378-1119(95)00017-Z; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Ling G, 2001, AM J PATHOL, V159, P1247, DOI 10.1016/S0002-9440(10)62511-4; Liu J, 2000, BIOCHEM BIOPH RES CO, V273, P1042, DOI 10.1006/bbrc.2000.3055; Maki K, 2004, MOL CELL BIOL, V24, P3227, DOI 10.1128/MCB.24.8.3227-3237.2004; Mammone T, 2000, CELL BIOL TOXICOL, V16, P293, DOI 10.1023/A:1026746330146; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; MURAKAMI K, 1993, ONCOGENE, V8, P1559; Murphy DJ, 2004, MOL CELL BIOL, V24, P2083, DOI 10.1128/MCB.24.5.2083-2090.2004; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; Norton JD, 2000, J CELL SCI, V113, P3897; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Opitz OG, 2001, J CLIN INVEST, V108, P725, DOI 10.1172/JCI11909; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Poignee M, 2001, CANCER RES, V61, P7118; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Rundhaug JE, 2005, MOL CARCINOGEN, V42, P40, DOI 10.1002/mc.20064; Sablitzky F, 1998, CELL GROWTH DIFFER, V9, P1015; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Simbulan-Rosenthal CM, 2002, J BIOL CHEM, V277, P24709, DOI 10.1074/jbc.M200281200; Steenbergen RDM, 1998, INT J CANCER, V76, P412, DOI 10.1002/(SICI)1097-0215(19980504)76:3<412::AID-IJC20>3.0.CO;2-B; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; Stratton S P, 2001, Curr Oncol Rep, V3, P295, DOI 10.1007/s11912-001-0080-x; Takao J, 2002, PHOTODERMATOL PHOTO, V18, P5, DOI 10.1034/j.1600-0781.2002.180102.x; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; TORNALETTI S, 1993, ONCOGENE, V8, P2051; Tsai KY, 2004, AM J MED GENET C, V131C, P82, DOI 10.1002/ajmg.c.30037; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; Wilson JW, 2001, CANCER RES, V61, P8803; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wingender Edgar, 2004, In Silico Biology, V4, P55; Xiao XD, 2003, EXP MOL PATHOL, V75, P238, DOI 10.1016/S0014-4800(03)00092-3; Yeh KC, 2000, GENE, V254, P163, DOI 10.1016/S0378-1119(00)00274-2; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	89	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5443	5458		10.1038/sj.onc.1208709	http://dx.doi.org/10.1038/sj.onc.1208709			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007217				2022-12-17	WOS:000231222300005
J	Nilsen, H; An, Q; Lindahl, T				Nilsen, H; An, Q; Lindahl, T			Mutation frequencies and AID activation state in B-cell lymphomas from Ung-deficient mice	ONCOGENE			English	Article						Ung; Aid; c-myc; bcl-6	CLASS-SWITCH RECOMBINATION; CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; EXPRESSION; ENZYME; GENES	B-cell lymphomas arising in lymph nodes and spleen of aging mice deficient in the Ung DNA glycosylase were recovered, dispersed, grown in short-term culture, and CD19-positive B-cells retrieved and analysed. Several tumors as well as controls only expressed detectable amounts of the Aid deaminase after mitogenic stimulation, as estimated by real-time PCR of transcripts. However, one unusually large lymph node tumor expressed a high level of Aid constitutively. This particular tumor also showed a substantially increased mutation frequency in the Aid gene itself as well as in the bcl-6 and c-myc genes, but not in the p53 gene, consistent with aberrant somatic hypermutation. Other B-cell lymphomas from Ung(-/-) mice exhibited a modest increase in mutation frequency.	CR UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		Lindahl, T (corresponding author), CR UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	tomas.lindahl@cancer.org.uk	Nilsen, Hilde/F-6432-2014	Nilsen, Hilde/0000-0003-2115-2663				Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Coleman AE, 2000, GENE CHROMOSOME CANC, V29, P70, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1009>3.0.CO;2-C; Gearhart PJ, 2003, ONCOGENE, V22, P5379, DOI 10.1038/sj.onc.1206874; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 2003, ONCOGENE, V22, P5381, DOI 10.1038/sj.onc.1206860; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Pasqualucci L, 2004, BLOOD, V104, P3318, DOI 10.1182/blood-2004-04-1558; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L	15	18	19	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3063	3066		10.1038/sj.onc.1208480	http://dx.doi.org/10.1038/sj.onc.1208480			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735713				2022-12-17	WOS:000228649500017
J	Vannucchi, S; Chiantore, MV; Fiorucci, G; Percario, ZA; Leone, S; Affabris, E; Romeo, A				Vannucchi, S; Chiantore, MV; Fiorucci, G; Percario, ZA; Leone, S; Affabris, E; Romeo, A			TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells	ONCOGENE			English	Article						TRAIL; IFN-ss; apoptosis; cell cycle; SCC	NF-KAPPA-B; UP-REGULATION; LIGAND; EXPRESSION; INDUCTION; RECEPTORS; CANCER; DEATH; ACTIVATION; FAMILY	Interferon (IFN)-beta induces S-phase slowing and apoptosis in human papilloma virus (HPV)-positive cervical carcinoma cell line ME-180. Here, we show that apoptosis is a consequence of the S-phase lengthening imposed by IFN-beta, demonstrating the functional correlation between S-phase alteration and apoptosis induction. In ME-180 cells, where p53 function is inhibited by HPV E6 oncoprotein, IFN-beta effects on cell cycle and apoptosis occur independently of p53. The apoptosis due to IFN-beta is mediated by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in a manner dependent on the S-phase deregulation. IFN-beta appears to increase TRAIL expression both directly at the mRNA level and indirectly by augmenting surface protein levels as a consequence of the induced S-phase cell accumulation. Moreover, the alteration of the S-phase due to IFN-beta promotes TRAIL-dependent apoptosis by potentiating cell sensitivity to TRAIL, possibly through induction of a proapoptotic NF-KB activity and TRAIL-R2 receptor expression. Interestingly, IFN-beta-induced TRAIL-dependent apoptotic events strongly differ in the requirement of caspase activity. These results show that IFN-beta may induce an apoptotic response by deregulating cell cycle. Understanding the linkage between these mechanisms appears to be of primary importance in the search for new IFN-based therapeutic strategies to circumvent cancer disease or improve clinical outcome.	Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy; CNR, Inst Mol Biol & Pathol, Rome, Italy; Univ Roma Tre, Dept Biol, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Roma Tre University	Romeo, A (corresponding author), Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy.	romeo@iss.it	Fiorucci, Gianna/B-3064-2013; CHIANTORE, MARIA VINCENZA/C-2948-2016; romeo, giovanna/P-8348-2015	CHIANTORE, MARIA VINCENZA/0000-0001-5163-2698; Leone, Stefano/0000-0001-6339-6397; romeo, giovanna/0000-0002-7638-1001; AFFABRIS, Elisabetta/0000-0001-5142-8144				ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Baetu TM, 2002, CYTOKINE GROWTH F R, V13, P199, DOI 10.1016/S1359-6101(02)00006-0; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chawla-Sarkar M, 2002, J IMMUNOL, V169, P847, DOI 10.4049/jimmunol.169.2.847; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Choi EA, 2003, CANCER RES, V63, P5299; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; FIORUCCI G, 2005, IN PRESS CURR PHARM, V10; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ghosh SK, 2003, BLOOD, V101, P2321, DOI 10.1182/blood-2002-08-2525; Giandomenico V, 1998, EUR CYTOKINE NETW, V9, P619; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gong B, 2000, BIOCHEM BIOPH RES CO, V278, P747, DOI 10.1006/bbrc.2000.3872; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Oshima K, 2001, CYTOKINE, V14, P193, DOI 10.1006/cyto.2001.0873; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Sato K, 2001, EUR J IMMUNOL, V31, P3138, DOI 10.1002/1521-4141(200111)31:11<3138::AID-IMMU3138>3.0.CO;2-B; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sedger LM, 1999, J IMMUNOL, V163, P920; Sheikh MS, 1998, CANCER RES, V58, P1593; Shetty S, 2002, APOPTOSIS, V7, P413, DOI 10.1023/A:1020031023947; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; Shin EC, 2002, EXP MOL MED, V34, P114, DOI 10.1038/emm.2002.17; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038/sj.onc.1204895; Vannucchi S, 2000, ONCOGENE, V19, P5041, DOI 10.1038/sj.onc.1203883; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; Younes A, 2003, J CLIN ONCOL, V21, P3526, DOI 10.1200/JCO.2003.09.037	41	18	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2536	2546		10.1038/sj.onc.1208403	http://dx.doi.org/10.1038/sj.onc.1208403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735750				2022-12-17	WOS:000228180600011
J	Sphyris, N; Harrison, DJ				Sphyris, N; Harrison, DJ			p53 deficiency exacerbates pleiotropic mitotic defects, changes in nuclearity and polyploidy in transdifferentiating pancreatic acinar cells	ONCOGENE			English	Article						pancreas acinar-ductal transdifferentiation; mitosis; centrosomes; polyploidy; aneuploidy; p53	KINASE INHIBITOR P21; CENTROSOME AMPLIFICATION; TRANSGENIC MICE; TETRAPLOIDY CHECKPOINT; EXOCRINE PANCREAS; CYCLE PROGRESSION; EXPRESSION; DIFFERENTIATION; NEOPLASIA; ARREST	In a primary culture model for pancreatic acinar-ductal transdifferentiation, cells exhibited increased proliferation, changes in nuclearity and polyploidy. We identify the `nucleus to centrosome' ratio of the progenitor cell, the dissemination of centrosomes at spindle poles and cytokinesis failure as critical determinants of mitosis outcome and centrosome inheritance. Abortive cytokinesis of mononuclear cells contributes to the binuclear cell pool, whereas enclosure of entire mitotic formations, within a single nuclear envelope, perpetuates polyploidization. Binuclear cell nuclei combine their genomes on a single metaphase plate, doubling descendant ploidy. Moreover, similar to 42% of binuclear and tetraploid cells assemble aberrant spindles with up to 8 centrosomes/poles. These phenotypes were exacerbated in p53-deficient cultures exhibiting increased S-phase entry, giant nuclei, multinucleation, multipolar mitoses and centrosome hyperamplification. The tendency of p53-proficient cells to spontaneously evade the tetraploidy checkpoint degenerates to uncontrolled polyploid progression in p53-deficient cultures, explaining why p53 abrogation alone rapidly descends to aneuploidy in this system. We detected constitutively nuclear mdm2, which may circumvent endogenous cell-cycle checkpoints, and pronounced accumulation of p21 and p27 in multinuclear cells and giant nuclei, consistent with roles in polyploidization. This in vitro model may recapitulate the processes underlying genomic instability in pancreatic tumours in vivo, and attests to the existence of a p53-dependent polyploidy checkpoint acting to limit the degree of polyploidization.	Univ Edinburgh, Sch Mol & Clin Med, Div Pathol, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Harrison, DJ (corresponding author), Univ Edinburgh, Sch Mol & Clin Med, Div Pathol, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	David.Harrison@ed.ac.uk	SPHYRIS, NATHALIE/GQY-6349-2022	Sphyris, Nathalie/0000-0003-1860-1958				Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; ARIAS AE, 1993, LAB INVEST, V69, P518; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; CLARKE AR, 1995, ONCOGENE, V11, P1913; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; DELISLE RC, 1990, EUR J CELL BIOL, V51, P64; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; HALL PA, 1992, J PATHOL, V166, P97, DOI 10.1002/path.1711660203; Haroske G, 1998, ANAL CELL PATHOL, V17, P189, DOI 10.1155/1998/390837; Hong FD, 1999, CARCINOGENESIS, V20, P1161, DOI 10.1093/carcin/20.7.1161; HOSHI H, 1993, AM J PHYSIOL, V265, pG1177, DOI 10.1152/ajpgi.1993.265.6.G1177; Khan SH, 1998, CANCER RES, V58, P396; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; Poluha W, 1996, MOL CELL BIOL, V16, P1335; PURDIE CA, 1994, ONCOGENE, V9, P603; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RAMEL S, 1995, PANCREAS, V11, P213, DOI 10.1097/00006676-199510000-00001; Rooney RJ, 2001, CELL GROWTH DIFFER, V12, P505; Roy L, 2001, BLOOD, V97, P2238, DOI 10.1182/blood.V97.8.2238; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; Sato N, 1999, CLIN CANCER RES, V5, P963; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; SCARPELLI DG, 1984, ENV HLTH PERSPECT, V56, P217; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; SPHYRIS N, 2005, IN PRESS PANCREAS, V30; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; VILA MR, 1994, LAB INVEST, V71, P423; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245	44	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2184	2194		10.1038/sj.onc.1208249	http://dx.doi.org/10.1038/sj.onc.1208249			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735758				2022-12-17	WOS:000227857900006
J	Iwata, S; Souta-Kuribara, A; Yamakawa, A; Sasaki, T; Shimizu, T; Hosono, O; Kawasaki, H; Tanaka, H; Dang, NH; Watanabe, T; Arima, N; Morimoto, C				Iwata, S; Souta-Kuribara, A; Yamakawa, A; Sasaki, T; Shimizu, T; Hosono, O; Kawasaki, H; Tanaka, H; Dang, NH; Watanabe, T; Arima, N; Morimoto, C			HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L)	ONCOGENE			English	Article						ATL; Tax; HTLV-I; NF-kappa B; Cas-L; HEF1	T-CELL LEUKEMIA; VIRUS TYPE-I; MEDIATED TYROSINE PHOSPHORYLATION; FOCAL ADHESION KINASE; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; GENE-EXPRESSION; PROTEIN; ACTIVATION; TRANSACTIVATION	Crk-associated substrate lymphocyte type (Cas-L) is a docking protein that is heavily tyrosine phosphorylated by the engagement of beta1 integrins in T cells. In the present study, we attempted to evaluate the role of Cas-L in the pathophysiology of adult T-cell leukemia (ATL). Examination of peripheral blood mononuclear cells from ATL patients as well as ATL-derived T cell lines showed an elevation of Cas-L in these cells. We showed that tyrosine phosphorylation as well as expression of Cas-L was markedly elevated through the induction of human T-lymphotropic virus type I ( HTLV-I) Tax in JPX-9 cells, with these cells showing marked motile behavior on the ligands for integrins. We next performed yeast two-hybrid screening of cDNA library from an HTLV-I-transformed T cell line, which resulted in the identification of Tax as a putative binding partner for Cas-L. Co-precipitation experiments revealed that the serine-rich region of Cas-L might serve as the binding site with the highest afinity for Tax. Co-localization study showed that Tax and Cas-L partly merged in the cytoplasm. Finally, we showed that exogenous Cas-L inhibited Tax-mediated transactivation of nuclear factor kappaB ( NF-kappaB), while Tax-independent activation of NF-kappaB remained intact, hence indicating that Cas-L might specically regulate Tax-NF-kappaB pathway.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Keio Univ, Sch Med, Dept Internal Med, Shinjyuku Ku, Tokyo 1608582, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA; Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Lab Tumor Cell Biol,Minato Ku, Tokyo 1088639, Japan; Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Div Host Response, Kagoshima 8908520, Japan	University of Tokyo; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Keio University; University of Texas System; UTMD Anderson Cancer Center; University of Tokyo; Kagoshima University	Morimoto, C (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	morimoto@ims.u-tokyo.ac.jp	Iwata, Satoshi/A-8819-2011					ALBRECHT H, 1992, J VIROL, V66, P6191, DOI 10.1128/JVI.66.10.6191-6193.1992; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Chun ACS, 2000, AIDS RES HUM RETROV, V16, P1689, DOI 10.1089/08892220050193155; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISHIKAWA T, 1993, BLOOD, V82, P1590; Ishino M, 1995, ONCOGENE, V11, P2331; Iwata S, 2002, EUR J IMMUNOL, V32, P1328, DOI 10.1002/1521-4141(200205)32:5<1328::AID-IMMU1328>3.0.CO;2-6; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; Law SF, 1996, MOL CELL BIOL, V16, P3327; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; Miyake-Nishijima R, 2003, ARTHRITIS RHEUM, V48, P1890, DOI 10.1002/art.11047; Mori N, 1998, CANCER RES, V58, P3993; Mori N, 2002, BLOOD, V99, P1341, DOI 10.1182/blood.V99.4.1341; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; Ohashi Y, 1999, J IMMUNOL, V163, P3727; Ohashi Y, 1998, J BIOL CHEM, V273, P6446, DOI 10.1074/jbc.273.11.6446; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SATO T, 1995, J IMMUNOL, V155, P2938; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Uchiyama T, 1996, J CLIN IMMUNOL, V16, P305, DOI 10.1007/BF01541665; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; YAMASHITA I, 1994, BLOOD, V84, P1573; YODOI J, 1986, IMMUNOL REV, V92, P135, DOI 10.1111/j.1600-065X.1986.tb01498.x; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; Zheng MZ, 2002, J BIOL CHEM, V277, P39599, DOI 10.1074/jbc.M202263200	47	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1262	1271		10.1038/sj.onc.1208261	http://dx.doi.org/10.1038/sj.onc.1208261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592516				2022-12-17	WOS:000226898700013
J	Craig, AL; Hupp, TR				Craig, AL; Hupp, TR			The regulation of CHK2 in human cancer	ONCOGENE			English	Editorial Material						CHK2; ATM; p53; cancer; kinase; radiation	TUMOR-SUPPRESSOR; PROTEIN-KINASE; DNA-DAMAGE; CHECKPOINT PATHWAY; SPLICE VARIANTS; PHOSPHORYLATION; P53; ATM; ACTIVATION; MDM2	Exceptional progress has been made in the past two decades in mapping oncogenes and tumour suppressors, de. ning a function for these master switches, and identifying novel anti-cancer drug targets. The p53 tumour suppressor is a central component of a DNA-damage-inducible pathway controlled by the ataxia telangiectasia mutated (ATM) and CHK2 protein kinases that have a central role in cancer suppression. One limitation of current human cancer research is the difficulty in developing genetic models that reveal the post-translational regulation of a growth suppressor like CHK2 within the microenvironment of a human tumour. Gaining such insights is important since yeast models and human tissue culture cell lines do not necessarily predict how enzymes like CHK2 are regulated in vivo, and therefore what factors can affect CHK2 tumour suppressor function. Translational cancer research aims to link basic research methodologies and clinical biology by uncovering cancer-specific pathways not revealed by other approaches. This approach is exemplified by two studies in this edition of Oncogene: both use a set of well-characterized human cancers with the objective of identifying novel post-translational control of the tumour suppressor CHK2. The authors have revealed two unexpected epigenetic modi. cations of the CHK2 pathway in vivo: ( 1) constitutive phosphorylation of CHK2 at its ATM-activated site in the absence of exogenous DNA damage; and ( 2) the production of hyper-spliced and inactive isoforms of CHK2. These studies highlight the need to develop model systems to understand why CHK2-activating pathways are being triggered or suppressed in different human cancers and whether the splicing machinery can be manipulated to control the activity of CHK2 for therapeutic benefit.	Univ Edinburgh, CRUK Canc Res Ctr, Signal transduct Grp P53, Edinburgh, Midlothian, Scotland	University of Edinburgh	Hupp, TR (corresponding author), Univ Edinburgh, CRUK Canc Res Ctr, Signal transduct Grp P53, S Crewe Rd, Edinburgh, Midlothian, Scotland.	Ted.Hupp@cancer.org.uk						Abdu U, 2002, CURR BIOL, V12, P1645, DOI 10.1016/S0960-9822(02)01165-X; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bartel F, 2004, MOL CANCER RES, V2, P29; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, MOL CELL BIOL, V23, P8846, DOI 10.1128/MCB.23.23.8846-8861.2003; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; FABBRO M, 2004, J BIOL CHEM     0524; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Fridman JS, 2003, CANCER RES, V63, P5703; Higashitani A, 2000, FEBS LETT, V485, P35, DOI 10.1016/S0014-5793(00)02178-5; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Kim WS, 2003, INT J MOL MED, V12, P827; Koslowski M, 2002, CANCER RES, V62, P6750; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; Rhind N, 2000, J CELL SCI, V113, P3889; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tereshko V, 2001, NAT STRUCT BIOL, V8, P899, DOI 10.1038/nsb1001-899; Theard D, 2001, BIOCHEM BIOPH RES CO, V289, P1199, DOI 10.1006/bbrc.2001.6095; Tyler LN, 2003, MODERN PATHOL, V16, P660, DOI 10.1097/01.MP.0000077516.90063.7D; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Wang Y, 2000, GENE DEV, V14, P927; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhang PL, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-14; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	58	18	19	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8411	8418		10.1038/sj.onc.1208035	http://dx.doi.org/10.1038/sj.onc.1208035			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361833				2022-12-17	WOS:000224870700001
J	Schwarzbach, MHM; Koesters, R; Germann, A; Mechtersheimer, G; Geisbill, J; Winkler, S; Niedergethmann, M; Ridder, R; Buechler, MW; Doeberitz, MVK; Willeke, F				Schwarzbach, MHM; Koesters, R; Germann, A; Mechtersheimer, G; Geisbill, J; Winkler, S; Niedergethmann, M; Ridder, R; Buechler, MW; Doeberitz, MVK; Willeke, F			Comparable transforming capacities and differential gene expression patterns of variant FUS/CHOP fusion transcripts derived from soft tissue liposarcomas	ONCOGENE			English	Article						liposarcoma; FUS/CHOP; fusion transcript; transformation	RNA-BINDING PROTEIN; MYXOID LIPOSARCOMA; TLS-CHOP; ONCOGENIC TRANSFORMATION; TRANSLOCATIONS; IDENTIFICATION; BREAKPOINTS; INHIBITION; INDUCTION; T(12-16)	The chromosomal translocation t(12; 16)(q13; p11) is a common genetic alteration in myxoid and round-cell liposarcomas. It results in transcription of various chimeric FUS/CHOP fusion transcripts that encode different oncogenic proteins. Recent reports suggest that these may have different neoplastic transformation activities. To audit this hypothesis, we transfected expression plasmids for the two major variant FUS/ CHOP transcripts I and II in NIH 3T3 cells and determined the number of outgrowing foci as well as their growth potential in soft agar. In addition, we compared tumour growth in nude mice upon subcutaneous injection of the respective transfectants. No significant differences in transformation assays in vitro and in vivo were observed, suggesting that both variant transcripts confer comparable transforming activities. The histopathological picture of tumours derived from both cell populations resembles high-grade spindle cell sarcomas. This suggests that both FUS/ CHOP variants cause similar patterns of differential gene expression. This hypothesis was confirmed by mRNA-expression profiles of the respective cell clones. Strong overexpression of the pentaxin-related gene (PTX), the osteoblast-specific factor 2 (osf-2), the basic Kruppel-like factor (bklf), the leucoprotease inhibitor, and the cyclophilin B were observed in both types of FUS/ CHOP-transfected cell clones. Taken together, our data suggest that different FUS/ CHOP variants cause transformation of mesenchymal cells via the same pathways with comparable efficacy.	Heidelberg Univ, Inst Mol Pathol, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Surg, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Pathol, D-69120 Heidelberg, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany; Heidelberg Univ, Mannheim Univ Clin, Dept Surg, D-68135 Mannheim, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Doeberitz, MVK (corresponding author), Heidelberg Univ, Inst Mol Pathol, INF 220-221, D-69120 Heidelberg, Germany.	knebel@med.uni-heidelberg.de	von Knebel Doeberitz, Magnus/D-2372-2016	von Knebel Doeberitz, Magnus/0000-0002-0498-6781				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Antonescu CR, 2001, CLIN CANCER RES, V7, P3977; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; BUTTERWITH SC, 1994, PHARMACOL THERAPEUT, V61, P399, DOI 10.1016/0163-7258(94)90018-3; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Domoto H, 2002, PATHOL INT, V52, P497, DOI 10.1046/j.1440-1827.2002.01391.x; Eng C, 1996, NEW ENGL J MED, V335, P943, DOI 10.1056/NEJM199609263351307; Genini M, 1996, INT J CANCER, V66, P571; Gohara R, 2002, J IMMUNOTHER, V25, P439, DOI 10.1097/00002371-200209000-00008; Gomi S, 1999, J IMMUNOL, V163, P4994; Ito T, 2002, KIDNEY INT, V62, P763, DOI 10.1046/j.1523-1755.2002.00533.x; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; KURODA M, 1995, AM J PATHOL, V147, P1221; Kuroda M, 1997, AM J PATHOL, V151, P735; Kuroda M, 1999, P NATL ACAD SCI USA, V96, P5025, DOI 10.1073/pnas.96.9.5025; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; Panagopoulos I, 1997, ONCOGENE, V15, P1357, DOI 10.1038/sj.onc.1201281; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Schneider-Stock R, 1999, CANCER GENET CYTOGEN, V111, P130, DOI 10.1016/S0165-4608(98)00197-6; Thelin-Jarnum S, 1999, INT J CANCER, V83, P30, DOI 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Willeke F, 1998, CLIN CANCER RES, V4, P1779; YOSHIKAWA H, 1994, CANCER, V73, P85, DOI 10.1002/1097-0142(19940101)73:1<85::AID-CNCR2820730116>3.0.CO;2-8; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	32	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6798	6805		10.1038/sj.onc.1207840	http://dx.doi.org/10.1038/sj.onc.1207840			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15286712				2022-12-17	WOS:000223653600011
J	Saran, A; Spinola, M; Pazzaglia, S; Peissel, B; Tiveron, C; Tatangelo, L; Mancuso, M; Covelli, V; Giovannelli, L; Pitozzi, V; Pignatiello, C; Milani, S; Dolara, P; Dragani, TA				Saran, A; Spinola, M; Pazzaglia, S; Peissel, B; Tiveron, C; Tatangelo, L; Mancuso, M; Covelli, V; Giovannelli, L; Pitozzi, V; Pignatiello, C; Milani, S; Dolara, P; Dragani, TA			Loss of tyrosinase activity confers increased skin tumor susceptibility in mice	ONCOGENE			English	Article						polymorphism; genetic predisposition; animal models	CANCER MODIFIER LOCI; OUTBRED MICE; COMET ASSAY; MOUSE; RESISTANCE; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; CARCINOGENESIS; MUTATION; GENETICS; DAMAGE	The tyrosinase (Tyr) gene encodes the enzyme tyrosinase that catalyses the conversion of L-tyrosine into DOPA (3,4-dihydroxyphenylalanine)- quinone. The albino mutation abrogates functional activity of tyrosinase resulting in deficiency of melanin pigment production in skin and retina. Tyr maps to a region in the central position of Chromosome 7 that contains a skin tumor-modi. er locus. We rescued the albino mutation in transgenic mice to assess a possible role of Tyr gene in two-stage skin carcinogenesis. Transgenic expression of the functional Tyr(Cys) allele in albino mice (Tyr(Ser)) caused a reduction in skin papilloma multiplicity, in four independent experiments and at three dose levels of DMBA (9,10-dimethyl-1,2- benzanthracene). In vitro mechanistic studies demonstrated that transfection of the Tyr(Cys) allele in a human squamous cell carcinoma cell line (NCI-H520) increases tyrosinase enzyme activity and confers resistance to hydrogen peroxide-induced oxidative DNA damage. These results provide direct evidence that the Tyr gene can act as a skin cancer-modifier gene, whose mechanism of action may involve modulation of oxidative DNA damage.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; ENEA CR Casaccia, Biotechnol Unit, Rome, Italy; Ist Regina Elena, Transgen Mice Serv Ctr, I-00161 Rome, Italy; Univ Florence, Dept Pharmacol, Florence, Italy; Univ Milan, Inst Med Stat & Biometry, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Florence; University of Milan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	dragani@istitutotumori.mi.it	Dragani, Tommaso A./K-4493-2016; Peissel, Bernard/E-8187-2017; Giovannelli, Lisa/H-3766-2012; milani, silvano/I-7889-2012	Dragani, Tommaso A./0000-0001-5915-4598; Peissel, Bernard/0000-0001-9233-3571; milani, silvano/0000-0002-5677-1758; Saran, Anna/0000-0002-5587-064X; Giovannelli, Lisa/0000-0002-4027-4693	Telethon [B.55] Funding Source: Medline	Telethon(Fondazione Telethon)		Angel JM, 1997, MOL CARCINOGEN, V20, P162, DOI 10.1002/(SICI)1098-2744(199710)20:2<162::AID-MC2>3.0.CO;2-P; Collins AR, 1997, MUTAT RES-FUND MOL M, V375, P183, DOI 10.1016/S0027-5107(97)00013-4; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Darvasi A, 2002, TRENDS GENET, V18, P489, DOI 10.1016/S0168-9525(02)02767-1; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Dragani TA, 2003, CANCER RES, V63, P3011; Draper N. R., 2014, APPL REGRESSION ANAL; FRENKEL K, 1995, FREE RADICAL BIO MED, V19, P373, DOI 10.1016/0891-5849(95)00046-Z; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; Giovannelli L, 2003, MUTAT RES-GEN TOX EN, V538, P71, DOI 10.1016/S1383-5718(03)00090-1; HOGAN B, 1994, MANIPULATING MOUSE E; Lutsenko EA, 2002, J BIOL CHEM, V277, P16895, DOI 10.1074/jbc.M201151200; Manenti G, 1997, MAMM GENOME, V8, P801, DOI 10.1007/s003359900582; Maria DA, 2003, ONCOGENE, V22, P426, DOI 10.1038/sj.onc.1206157; Mock BA, 1998, CARCINOGENESIS, V19, P1109, DOI 10.1093/carcin/19.6.1109; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Nagase H, 2001, CANCER RES, V61, P1305; Park KK, 2003, MUTAT RES-GEN TOX EN, V542, P89, DOI 10.1016/j.mrgentox.2003.09.001; Peissel B, 2000, MAMM GENOME, V11, P979, DOI 10.1007/s003350010184; Peissel B, 2001, MAMM GENOME, V12, P291, DOI 10.1007/s003350010274; PERIN F, 1994, CANCER RES, V54, P4635; Saran A, 2000, INT J CANCER, V88, P424, DOI 10.1002/1097-0215(20001101)88:3<424::AID-IJC15>3.0.CO;2-D; SEARLE AG, 1990, OPHTHALMIC PAED GEN, V11, P159, DOI 10.3109/13816819009020974; Shi YL, 2002, LIFE SCI, V70, P1595, DOI 10.1016/S0024-3205(01)01546-6; SLAGA TJ, 1995, ADV EXP MED BIOL, V369, P167; Steinmetz LM, 2002, NATURE, V416, P326, DOI 10.1038/416326a; WEI HC, 1993, CARCINOGENESIS, V14, P1195, DOI 10.1093/carcin/14.6.1195; WINDER AJ, 1994, J BIOCHEM BIOPH METH, V28, P173, DOI 10.1016/0165-022X(94)90014-0; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293	29	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4130	4135		10.1038/sj.onc.1207565	http://dx.doi.org/10.1038/sj.onc.1207565			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15007389				2022-12-17	WOS:000221520200011
J	Herzog, CR; Bodon, N; Pittman, B; Maronpot, RR; Massey, TE; Anderson, MW; You, M; Devereux, TR				Herzog, CR; Bodon, N; Pittman, B; Maronpot, RR; Massey, TE; Anderson, MW; You, M; Devereux, TR			Carcinogen-specific targeting of chromosome 12 for loss of heterozygosity in mouse lung adenocarcinomas: implications for chromosome instability and tumor progression	ONCOGENE			English	Article						loss of heterozygosity; chromosome instability; lung carcinogenesis; chromosome 12	HOMOLOGOUS RECOMBINATION; GENETIC ALTERATIONS; ALLELIC LOSSES; HIGH-FREQUENCY; DNA-DAMAGE; CANCER; SELECTION; MICE; SUSCEPTIBILITY; MECHANISMS	Genotoxic carcinogens exert their tumorigenic effects in part by inducing genomic instability. We recently showed that loss of heterozygosity (LOH) on chromosome 12 associates significantly with the induction of chromosome instability (CIN) by the likely human lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and vinyl carbamate (VC) during mouse lung carcinogenesis. Here, we demonstrate the carcinogen specificity of this event and its effect on lung tumor evolution. LOH on chromosome 12 was observed in 45% of NNK-induced, 59% of VC-induced, 58% of aflatoxin B1 (AFB1)-induced, 14% of N-ethyl-N-nitrosourea (ENU)-induced and 12% of spontaneous lung adenocarcinomas. The frequency of LOH in each of the carcinogen-induced groups, except ENU, was significantly higher than in the spontaneous group (P<0.001). Deletion mapping revealed four potential candidate regions of 1-4 centiMorgans suspected to contain targeted tumor suppressor genes, with at least one expected to have a role in CIN. The relationship between LOH on chromosome 12 and additional chromosomal alterations occurring during lung tumor progression was also examined. LOH on chromosomes 1 and 14 were moderately frequent during malignant progression in tumors from all treatment groups, occurring in 21-35 and 18-33% of tumors. However, these alterations showed significant concurrence with LOH on chromosome 12 in VC-, NNK- and AFB1-induced tumors (P<0.05). The results suggest that a carcinogen-selective mechanism of lung cancer induction involves the frequent inactivation of genes on chromosome 12, including a stability gene that evidently promotes the evolutionary selection of additional chromosomal alterations during malignant progression.	Inst Canc Prevent, Valhalla, NY 10595 USA; NIEHS, Res Triangle Pk, NC 27709 USA; Queens Univ, Kingston, ON K7L 3N6, Canada; Univ Cincinnati, Cincinnati, OH 45267 USA; Washington Univ, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Queens University - Canada; University System of Ohio; University of Cincinnati; Washington University (WUSTL)	Herzog, CR (corresponding author), Inst Canc Prevent, Valhalla, NY 10595 USA.	cherzog@ifcp.us			NCI NIH HHS [CA17613] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA017613] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON LM, 1978, CANCER LETT, V5, P55, DOI 10.1016/S0304-3835(78)80011-1; Ballering LAP, 1997, ENVIRON MOL MUTAGEN, V30, P321, DOI 10.1002/(SICI)1098-2280(1997)30:3<321::AID-EM11>3.0.CO;2-F; Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Bishop AJR, 2000, CANCER RES, V60, P395; BRANCH P, 1995, CANCER RES, V55, P2304; BRANSTETTER DG, 1987, CANCER RES, V47, P348; Breivik J, 1999, SEMIN CANCER BIOL, V9, P245, DOI 10.1006/scbi.1999.0123; Breivik J, 2001, P NATL ACAD SCI USA, V98, P5379, DOI 10.1073/pnas.101137698; Cheng KC, 1997, CURR TOP MICROBIOL, V221, P5; Claij N, 2003, CANCER RES, V63, P2062; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; DIPPLE A, 1995, CARCINOGENESIS, V16, P437, DOI 10.1093/carcin/16.3.437; Fijneman RJA, 1998, CANCER RES, V58, P4794; Girard L, 2000, CANCER RES, V60, P4894; Gisselsson D, 2003, ADV CANCER RES, V87, P1; Hecht SS, 1999, MUTAT RES-FUND MOL M, V424, P127, DOI 10.1016/S0027-5107(99)00014-7; HECHT SS, 1978, J NATL CANCER I, V60, P819, DOI 10.1093/jnci/60.4.819; HEGI ME, 1994, CANCER RES, V54, P6257; Herzog CR, 1997, J CELL BIOCHEM, P49; Herzog CR, 2002, CANCER RES, V62, P6424; Herzog CR, 1999, MOL CARCINOGEN, V25, P92, DOI 10.1002/(SICI)1098-2744(199906)25:2<92::AID-MC3>3.0.CO;2-2; Herzog CR, 1996, MOL CARCINOGEN, V16, P83, DOI 10.1002/(SICI)1098-2744(199606)16:2<83::AID-MC4>3.0.CO;2-O; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loeb LA, 1998, ADV CANCER RES, V72, P25, DOI 10.1016/S0065-230X(08)60699-5; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Pataer A, 1997, CANCER RES, V57, P2904; Powell SN, 2002, MOL CELL, V10, P1262, DOI 10.1016/S1097-2765(02)00789-X; Ricordy R, 2002, MUTAGENESIS, V17, P241, DOI 10.1093/mutage/17.3.241; Sargent LM, 2002, CANCER RES, V62, P1152; SHEN HM, 1995, CARCINOGENESIS, V16, P419, DOI 10.1093/carcin/16.2.419; Sipowicz MA, 1997, CANCER LETT, V117, P87, DOI 10.1016/S0304-3835(97)00208-5; Tam AS, 1999, CANCER RES, V59, P3634; TRUSHIN N, 1994, CANCER RES, V54, P1205; Wong MP, 2002, CANCER RES, V62, P4464	41	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3033	3039		10.1038/sj.onc.1207431	http://dx.doi.org/10.1038/sj.onc.1207431			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14755239				2022-12-17	WOS:000220845200007
J	Yanamandra, N; Kondraganti, S; Srinivasula, SM; Gujrati, M; Olivero, WC; Dinh, DH; Rao, JS				Yanamandra, N; Kondraganti, S; Srinivasula, SM; Gujrati, M; Olivero, WC; Dinh, DH; Rao, JS			Activation of caspase-9 with irradiation inhibits invasion and angiogenesis in SNB19 human glioma cells	ONCOGENE			English	Article						caspase 9; radiation; in version angiogenesis; glioma	BROMODEOXYURIDINE LABELING INDEX; CYTOCHROME-C; IN-VIVO; GLIOBLASTOMA-MULTIFORME; BASEMENT-MEMBRANE; INDUCED APOPTOSIS; MALIGNANT GLIOMA; DEATH; RADIATION; MIGRATION	Glioblastoma multiforme, the most common brain tumor, typically exhibits markedly increased angiogenesis, which is crucial for tumor growth and invasion. Antiangiogenic strategies based on disruption of the tumor microvasculature have proven effective for the treatment of experimental brain tumors. Here, we have overexpressed human caspase-9 by stable transfection in the SNB19 glioblastoma cell line, which normally expresses low levels of caspase-9. Our studies revealed that overexpression of caspase-9 coupled with radiation has a synergistic effect on the inhibition of glioma invasion as demonstrated by Matrigel assay (465%). Furthermore, sense caspase stable clones cocultured with fetal rat brain aggregates along with radiation showed complete inhibition as compared to the parental and vector controls. During in vitro angiogenesis, SNB19 cells cocultured with human microvascular endothelial cells (HMEC) showed vascular network formation after 48-72 h. In contrast, these capillary-like structures were inhibited when HMEC cells were cocultured with sense caspase stable SNB19 cells. This effect was further enhanced by radiation (5 Gy). Signaling mechanisms revealed that apoptosis is induced by cleavage of caspase-9 by radiation, loss of mitochondrial membrane potential and activation of caspase-3. These results demonstrate that activation of caspase-9 disrupts glioma cell invasion and angiogenesis in vitro. Hence, overexpression of proapoptotic molecules such as caspase-9 may be an important determinant of the therapeutic effect of radiation in cancer therapy.	Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; NCI, Lab Immune Cell Biol, NIH, Bethesda, MD USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu			NATIONAL CANCER INSTITUTE [R01CA095058, R01CA092393, R01CA075557, ZIABC010629, Z01BC010629, R01CA085216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699] Funding Source: NIH RePORTER; NCI NIH HHS [CA 95058, CA 75557, CA 92393, CA 85216] Funding Source: Medline; NINDS NIH HHS [NS 47699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAE SN, 1993, BREAST CANCER RES TR, V24, P241, DOI 10.1007/BF01833264; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; DURAND RE, 1972, EXP CELL RES, V71, P75, DOI 10.1016/0014-4827(72)90265-0; Eshleman JS, 2002, CANCER RES, V62, P7291; Giese A, 2001, J CANCER RES CLIN, V127, P217, DOI 10.1007/s004320000188; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LABROUSSE F, 1991, J NEUROSURG, V75, P202, DOI 10.3171/jns.1991.75.2.0202; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; MAJACK RA, 1984, J CELL PHYSIOL, V118, P253, DOI 10.1002/jcp.1041180306; MELCHIORI A, 1987, ANTICANCER RES, V7, P475; MOHANAM S, 1993, CANCER RES, V53, P4143; Motyl T, 1999, REPROD NUTR DEV, V39, P49, DOI 10.1051/rnd:19990103; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nor JE, 2002, GENE THER, V9, P444, DOI 10.1038/sj.gt.3301671; ONDA K, 1994, CANCER, V74, P1921, DOI 10.1002/1097-0142(19941001)74:7<1921::AID-CNCR2820740716>3.0.CO;2-9; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PEDERSEN PH, 1993, CANCER RES, V53, P5158; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; RAMPLING R, 1994, INT J RADIAT ONCOL, V29, P427, DOI 10.1016/0360-3016(94)90432-4; Sarkar R, 1996, CIRC RES, V78, P225, DOI 10.1161/01.RES.78.2.225; Shinoura N, 2002, BRIT J CANCER, V86, P587, DOI 10.1038/sj.bjc.6600061; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; SUIT HD, 1990, INT J RADIAT ONCOL, V18, P365, DOI 10.1016/0360-3016(90)90102-P; TAGHIAN A, 1995, INT J RADIAT ONCOL, V32, P99, DOI 10.1016/0360-3016(94)00494-6; Uchida H, 2002, BIOCHEM BIOPH RES CO, V292, P347, DOI 10.1006/bbrc.2002.6643; Vajkoczy P, 1999, INT J DEV NEUROSCI, V17, P557, DOI 10.1016/S0736-5748(99)00021-0; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	42	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2339	2346		10.1038/sj.onc.1207406	http://dx.doi.org/10.1038/sj.onc.1207406			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14767475				2022-12-17	WOS:000220427700008
J	Dentelli, P; Rosso, A; Calvi, C; Ghiringhello, B; Garbarino, G; Camussi, G; Pegoraro, L; Brizzi, MF				Dentelli, P; Rosso, A; Calvi, C; Ghiringhello, B; Garbarino, G; Camussi, G; Pegoraro, L; Brizzi, MF			IL-3 affects endothelial cell-mediated smooth muscle cell recruitment by increasing TGF beta activity: potential role in tumor vessel stabilization	ONCOGENE			English	Article						tumor angiogenesis; IL-3; TGF beta; smooth muscle cells; endothelial cells	FIBROBLAST-GROWTH-FACTOR; CD4(+)CD25(+) T-CELLS; MATRIX METALLOPROTEINASES; INFILTRATING LYMPHOCYTES; VASCULAR DEVELOPMENT; ACTIVATION; CANCER; INTERLEUKIN-3; MIGRATION; BLOOD	Interleukin-3 (IL-3) express ion by tumor-infiltrating lymphocytes (TILs) and its effects on vessel assembly were evaluated. TILs from 'in situ' human breast cancers expressed CD4/CD25 antigens and IL-3. An injection of Matrigel containing SMC and IL-3 or basic-fibroblast growth factor ( bFGF) into SCID mice confirmed the neoangiogenetic effect of both factors. However, in response to IL-3, but not to bFGF, only few SMC became incorporated into the nascent vessels. To evaluate the possibility that signals emanated by the nascent vasculature in the presence of IL-3 may negatively regulate SMC recruitment, conditioned media ( CM) from IL-3-treated endothelial cells (EC) or SMC were tested for their biological effects on SMC and EC. CM from IL-3-treated SMC stimulated the migration of EC. In contrast, the migration of SMC was not affected by CM from IL-3-stimulated EC; however, it was greatly enhanced by blocking transforming growth factor beta (TGFbeta) activity. TGFbeta immunoenzymatic assay demonstrated the following: (i) the absence of TGFbeta activity in CM from IL-3-stimulated EC; (ii) a barely detectable TGFbeta activity in CM from IL-3-stimulated SMC; and (iii) the presence of TGFbeta activity in the supernatants of SMC stimulated with CM from IL-3-,but not from bFGF-stimulated EC. Increased TGFbeta mRNA expression was only detected in SMC stimulated with CM from IL-3-treated EC. Finally, the inhibitory signals induced by IL-3 in vivo were abrogated by the addition of the neutralizing TGFbeta antibody. Thus, the positive immunostaining for IL-3 by TILs in 'in situ' breast cancers sustains the possibility that early in tumor development, IL-3 can contribute to the chronic immaturity of these vessels.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy; Osped S Anna, Div Pathol, Turin, Italy	University of Turin	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	Camussi, Giovanni/J-7624-2016; Brizzi, Maria Felice/J-7882-2016	Camussi, Giovanni/0000-0003-2795-232X; 				BALCH CM, 1990, ARCH SURG-CHICAGO, V125, P200; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Brizzi MF, 1999, CIRC RES, V84, P785; BRIZZI MF, 1993, J CLIN INVEST, V91, P2887, DOI 10.1172/JCI116534; Brizzi MF, 2001, CIRCULATION, V103, P549, DOI 10.1161/01.CIR.103.4.549; Brizzi MF, 1999, MOL BIOL CELL, V10, P3463, DOI 10.1091/mbc.10.10.3463; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; Darland DC, 1999, J CLIN INVEST, V103, P157, DOI 10.1172/JCI6127; Dentelli P, 1999, J IMMUNOL, V163, P2151; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FINKE JH, 1990, CANCER RES, V50, P2363; Grosskreutz CL, 1999, MICROVASC RES, V58, P128, DOI 10.1006/mvre.1999.2171; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Ishida A, 2001, J CELL PHYSIOL, V188, P359, DOI 10.1002/jcp.1121; ITOH K, 1988, J EXP MED, V168, P1419, DOI 10.1084/jem.168.4.1419; Kenagy RD, 1997, CIRCULATION, V96, P3555; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; KORPELAINEN EI, 1993, P NATL ACAD SCI USA, V90, P11137, DOI 10.1073/pnas.90.23.11137; LEWALLE JM, 1995, J CELL PHYSIOL, V165, P475, DOI 10.1002/jcp.1041650305; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; McCaffrey TA, 2000, CYTOKINE GROWTH F R, V11, P103, DOI 10.1016/S1359-6101(99)00034-9; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nunes I, 1996, INT J OBESITY, V20, pS4; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; PEOPLES GE, 1993, J IMMUNOL, V151, P5481; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; Rowland-Goldsmith MA, 2001, CLIN CANCER RES, V7, P2931; Shevach EM, 2001, J EXP MED, V193, pF41, DOI 10.1084/jem.193.11.F41; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; WIMPERIS JZ, 1989, BLOOD, V74, P1525; WINTZER HO, 1991, J CANCER RES CLIN, V117, P163, DOI 10.1007/BF01613141; Woo EY, 2001, CANCER RES, V61, P4766; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333	49	18	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1681	1692		10.1038/sj.onc.1207290	http://dx.doi.org/10.1038/sj.onc.1207290			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14755254				2022-12-17	WOS:000220029300004
J	Maru, D; Wu, TT; Canada, A; Houlihan, PS; Hamilton, SR; Rashid, A				Maru, D; Wu, TT; Canada, A; Houlihan, PS; Hamilton, SR; Rashid, A			Loss of chromosome 18q and DPC4 (Smad4) mutations in appendiceal adenocarcinomas	ONCOGENE			English	Article						appendix; adenocarcinoma; chromosome 18q loss; beta-catenin; DPC4	TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; FREQUENT LOSS; BETA-CATENIN; TRANSCRIPTIONAL ACTIVATION; GASTRIC-CANCER; COLON-CANCER; ALLELIC LOSS; CARCINOMAS; DCC	Appendiceal adenocarcinomas are uncommon, and the genetic alterations present in these tumors are not well characterized. We studied genetic alterations including loss of chromosome 18q ( location of DCC, DPC4, and JV-18 genes), and mutations of the DPC4 (SMAD4) and beta-catenin genes in 28 appendiceal adenocarcinomas, consisting of 17 mucinous and 11 nonmucinous carcinomas. Chromosome 18q loss was present in 57% (12/21) of appendiceal carcinomas including 54% (7/13) of mucinous and 63% (5/8) of nonmucinous carcinomas. Mutation of the DPC4 gene was present in 14% ( three of 22) of the carcinomas occurring in one tumor with chromosome 18q loss and in two with unassessed chromosome 18q status. beta-catenin gene mutation was present in 0%( 0 of 25) of the carcinomas. Chromosome 18q loss status was not associated with any clinicopathological features. The presence of chromosome 18q loss and DPC4 mutations in appendiceal adenocarcinomas suggests involvement of DPC4 and nearby genes on chromosome 18q ( DCC and/or JV-18) in the pathogenesis of appendiceal adenocarcinomas.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Rashid, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	arashid@mdacc.tmc.edu						Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; Blons H, 2002, ONCOGENE, V21, P5016, DOI 10.1038/sj.onc.1205626; CARR NJ, 2000, PATHOLOGY GENETICS T, P94; Dai JL, 1998, CANCER RES, V58, P4592; DEVILEE P, 1991, ONCOGENE, V6, P311; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Font A, 2001, DIS COLON RECTUM, V44, P549, DOI 10.1007/BF02234328; Fujii H, 1997, AM J PATHOL, V151, P1447; GAO X, 1993, CANCER RES, V53, P2723; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; HOHNE MW, 1992, CANCER RES, V52, P2616; Hugh TJ, 1999, BRIT J CANCER, V80, P1046, DOI 10.1038/sj.bjc.6690461; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Kabbani W, 2002, MODERN PATHOL, V15, P599, DOI 10.1038/modpathol.3880572; Kanazawa T, 2002, INT J CANCER, V102, P225, DOI 10.1002/ijc.10690; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kremmidiotis G, 1998, GENOMICS, V49, P467, DOI 10.1006/geno.1998.5281; Kytola S, 2002, GENE CHROMOSOME CANC, V34, P325, DOI 10.1002/gcc.10081; Lanza G, 1998, INT J CANCER, V79, P390, DOI 10.1002/(SICI)1097-0215(19980821)79:4<390::AID-IJC14>3.3.CO;2-M; Lassus H, 2001, AM J PATHOL, V159, P35, DOI 10.1016/S0002-9440(10)61670-7; Lei JY, 1996, ONCOGENE, V13, P2459; LYSS AP, 1988, SEMIN ONCOL, V15, P129; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McCusker ME, 2002, CANCER, V94, P3307, DOI 10.1002/cncr.10589; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; Powell SM, 1997, CANCER RES, V57, P4221; Rashid A, 2001, CANCER RES, V61, P3406; Roth S, 2000, BRIT J CANCER, V83, P1015, DOI 10.1054/bjoc.2000.1387; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sparks AB, 1998, CANCER RES, V58, P1130; Szych C, 1999, AM J PATHOL, V154, P1849, DOI 10.1016/S0002-9440(10)65442-9; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; UCHINO S, 1992, CANCER RES, V52, P3099; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	42	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					859	864		10.1038/sj.onc.1207194	http://dx.doi.org/10.1038/sj.onc.1207194			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647445				2022-12-17	WOS:000188304900026
J	Tullo, A; Mastropasqua, G; Bourdon, JC; Centonze, P; Gostissa, M; Costanzo, A; Levrero, M; Del Sal, G; Saccone, C; Sbisa, E				Tullo, A; Mastropasqua, G; Bourdon, JC; Centonze, P; Gostissa, M; Costanzo, A; Levrero, M; Del Sal, G; Saccone, C; Sbisa, E			Adenosine deaminase, a key enzyme in DNA precursors control, is a new p73 target	ONCOGENE			English	Article						p73; p53; adenosine deaminase; p53 family; purine metabolism	CANCER CELL-LINE; P53 HOMOLOG; FUNCTIONAL IMPLICATIONS; GENE-EXPRESSION; BINDING-SITE; P63; APOPTOSIS; FAMILY; IDENTIFICATION; ACTIVATION	The discovery of the p73 and p63 genes, homologous to p53 tumor suppressor has uncovered a family of transcription factors and widened the scenario of cell cycle control and apoptosis. We have identified a putative p53-responsive element in the human adenosine deaminase (ADA) gene, an important enzyme involved in nucleotide metabolism, the deficit of which causes the inhibition of DNA synthesis and repair. Here, we demonstrate that the ectopic expression of p73 isoforms leads to the ADA gene upregulation, showing for the first time a correlation between p73 and ADA. W e found that p73 promotes ADA gene expression following a dNTP unbalance generated by ADA enzyme deficiency and 2' deoxyadenosine accumulation. The abrogation of p73 transcriptional activity by the specific dominant-negative p73DD abolishes ADA induction. By contrast, the ADA gene does not appear to be a functional p53 target in the physiological conditions we tested. On the whole, our results contribute to the emerging picture that p73 could play a different role from p53 in normal growth and development by inducing alternative target genes, which are not shared by p53.	CNR, Sez Bari Bioinformat & Genom, Ist Tecnol Biomed, I-70126 Bari, Italy; Univ Bari, Dipartimento Biochim & Biol Mol, I-70125 Bari, Italy; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland; Consorzio Interuniv Biotecnol, Lab Nazl, Trieste, Italy; Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00161 Rome, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34100 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); Universita degli Studi di Bari Aldo Moro; University of Dundee; Sapienza University Rome; University of Rome Tor Vergata; University of Trieste	Tullo, A (corresponding author), CNR, Sez Bari Bioinformat & Genom, Ist Tecnol Biomed, Via Amendola 165-A, I-70126 Bari, Italy.		MASTROPASQUA, Mauro/AAK-8813-2020; JC, Bourdon/A-4439-2008; Sbisa', Elisabetta/AAW-9727-2020; Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; Tullo, Apollonia/AAX-1079-2020; Levrero, Massimo/G-5680-2016	MASTROPASQUA, Mauro/0000-0002-8306-0839; JC, Bourdon/0000-0003-4623-9386; Costanzo, Antonio/0000-0001-9697-2557; Tullo, Apollonia/0000-0002-5081-4745; DEL SAL, GIANNINO/0000-0003-2185-6003; Levrero, Massimo/0000-0002-4978-0875				ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Bemi V, 1998, INT J CANCER, V75, P713, DOI 10.1002/(SICI)1097-0215(19980302)75:5<713::AID-IJC9>3.0.CO;2-1; BENVENISTE P, 1995, P NATL ACAD SCI USA, V92, P8373, DOI 10.1073/pnas.92.18.8373; Bian JH, 1996, CARCINOGENESIS, V17, P2559, DOI 10.1093/carcin/17.12.2559; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; CAMICI M, 1995, INT J CANCER, V62, P176, DOI 10.1002/ijc.2910620212; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; Cristalli G, 2001, MED RES REV, V21, P105, DOI 10.1002/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U; D'Erchia A. M., 2003, Current Genomics, V4, P13, DOI 10.2174/1389202033350173; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Duriez C, 2000, ONCOGENE, V19, P2461, DOI 10.1038/sj.onc.1203580; Dusing MR, 1997, J BIOL CHEM, V272, P26634, DOI 10.1074/jbc.272.42.26634; DUSING MR, 1994, NUCLEIC ACIDS RES, V22, P669, DOI 10.1093/nar/22.4.669; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; GIBLETT ER, 1972, LANCET, V2, P1067; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HE YP, 1993, J NUTR, V123, P1017; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KIZAKI H, 1988, J IMMUNOL, V141, P1652; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moriwaki Y, 1999, HISTOL HISTOPATHOL, V14, P1321, DOI 10.14670/HH-14.1321; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Saccone C, 2002, GENE, V300, P195, DOI 10.1016/S0378-1119(02)01036-3; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sciacchitano S, 2002, MOL ENDOCRINOL, V16, P1577, DOI 10.1210/me.16.7.1577; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Ueda Y, 2001, BIOCHEM BIOPH RES CO, V283, P327, DOI 10.1006/bbrc.2001.4788; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; Vikhanskaya F, 2001, CANCER RES, V61, P935; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WAKADE AR, 1995, J BIOL CHEM, V270, P17986, DOI 10.1074/jbc.270.30.17986; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zheng XJ, 2001, FEBS LETT, V489, P4, DOI 10.1016/S0014-5793(00)02437-6; Zhou HJ, 2001, J MOL BIOL, V306, P227, DOI 10.1006/jmbi.2000.4370	51	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8738	8748		10.1038/sj.onc.1206967	http://dx.doi.org/10.1038/sj.onc.1206967			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647469				2022-12-17	WOS:000186844900012
J	Ischenko, I; Petrenko, O; Gu, HH; Hayman, MJ				Ischenko, I; Petrenko, O; Gu, HH; Hayman, MJ			Scaffolding protein Gab2 mediates fibroblast transformation by the SEA tyrosine kinase	ONCOGENE			English	Article						V-SEA; Gab2; transformation	MACROPHAGE-STIMULATING PROTEIN; CELL ANTIGEN RECEPTOR; GROWTH-FACTOR; DOCKING SITE; C-MET; EPITHELIAL MORPHOGENESIS; GENE-PRODUCT; ONCOPROTEIN; ACTIVATION; PATHWAY	Transformation of fibroblasts by V-SEA involves activation of the ERK and phosphatidylinositol 3-kinase (PI3K) pathways. Effector proteins that are key mediators of the ERK and PI3K pathways, namely Grb2, the tyrosine phosphatase, SHP2 and PI3K, interact with the two phosphotyrosines found in the bidentate motif in the carboxy-terminal region of V-SEA. Genetic analysis demonstrated that while Y557 was a primary binding site and thus activator of the PI3K-Akt pathway, Y564 also contributed to the activation of this pathway. Y564 was located within a Grb2-binding motif, this raised the possibility that a protein that associated with Grb2 might be important for this PI3K activation. The scaffolding proteins Gab1 and/or Gab2 were candidates for this role. In this report, we demonstrate that V-SEA preferentially interacts with Gab2. Furthermore by using Gab2 null fibroblasts, we demonstrate that Gab2 is essential for fibroblast transformation by V-SEA. Using mutant forms of Gab2, we show that activation of the PI3K-Akt pathway via Gab2 is required for V-SEA-induced transformation. However, efficient fibroblast transformation also requires the SHP2 interaction site on Gab2.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Canc Biol Program,Div Hematol Oncol, Boston, MA 02215 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CROWE AJ, 1993, ONCOGENE, V8, P181; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; CROWE AJ, 1993, CELL GROWTH DIFFER, V4, P403; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; MORIMOTO AM, 1994, J VIROL, V68, P1837, DOI 10.1128/JVI.68.3.1837-1842.1994; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Pratt JC, 2000, J IMMUNOL, V165, P4158, DOI 10.4049/jimmunol.165.8.4158; RONSIN C, 1993, ONCOGENE, V8, P1195; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Seiffert M, 2003, MOL CELL BIOL, V23, P2415, DOI 10.1128/MCB.23.7.2415-2424.2003; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Suda Toshio, 1997, Leukemia (Basingstoke), V11, P451; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Wahl RC, 1999, J BIOL CHEM, V274, P26361, DOI 10.1074/jbc.274.37.26361; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZHU H, 1994, J BIOL CHEM, V269, P29943	35	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6311	6318		10.1038/sj.onc.1206742	http://dx.doi.org/10.1038/sj.onc.1206742			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508511				2022-12-17	WOS:000185535300001
J	Johansson, EM; Kannius-Janson, M; Bjursell, G; Nilsson, J				Johansson, EM; Kannius-Janson, M; Bjursell, G; Nilsson, J			The p53 tumor suppressor gene is regulated in vivo by nuclear factor 1-C2 in the mouse mammary gland during pregnancy	ONCOGENE			English	Article						p53; NF1-C2; NF1-A1; mammary gland; development; transcriptional regulation	ESTER LIPASE GENE; HUMAN BREAST-TUMORS; CELL-LINE K562; TRANSCRIPTION FACTOR; WILD-TYPE; KAPPA-B; HA-RAS; EXPRESSION; DIFFERENTIATION; PROMOTER	The p53 tumor suppressor protein plays an important role in preventing cancer development by arresting or killing potential tumor cells. Downregulated p53 levels, or mutations within the p53 gene, leading to the loss of p53 activity, are found in many breast carcinomas. Here we demonstrate that the p53 gene is transcriptionally upregulated in the normal mouse mammary gland at midpregnancy. We show that the specific isoform nuclear factor 1-C2 (NF1-C2) plays an important role in this activation. Functional mutation of the NF1-binding site in the mouse p53 promoter resulted in a reduction of the gene expression to less than 30% in mammary epithelial cells. By the use of two powerful techniques, chromatin immunoprecipitation and oligonucleotide decoy, we verify the importance of NF1-C2 in p53 gene activation in vivo. These findings demonstrate a broader role for NF1-C2 in the mammary gland at midpregnancy, beyond its earlier reported activation of milk protein genes. We also demonstrate that NF1-A1 proteins are produced in the mouse mammary gland. However, due to their lower affinity to the NF1-binding site, these proteins are not involved in the transcriptional upregulation of p53 at midpregnancy. This paper constitutes the first report demonstrating the importance of NF1 proteins in the p53 gene activation in the mouse mammary gland. It is also the first time that p53 gene activation is coupled to a specific, endogenously expressed NF1 isoform.	Dept CMB Mol Biol, S-40530 Gothenburg, Sweden		Johansson, EM (corresponding author), Dept CMB Mol Biol, Box 462, S-40530 Gothenburg, Sweden.	Eva.Johansson@molbio.gu.se	Kannius Janson, Marie/M-3052-2015; Nilsson, Jeanette/M-3051-2015					Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; Balint E, 1996, CANCER RES, V56, P1648; BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; Bengtsson SHM, 2002, BIOCHEM J, V365, P481, DOI 10.1042/BJ20020223; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; COLES C, 1992, CANCER RES, V52, P5291; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Kane R, 2000, ADV EXP MED BIOL, V480, P117; Kannius-Janson M, 1998, BIOCHEM J, V336, P577, DOI 10.1042/bj3360577; Kannius-Janson M, 2002, J BIOL CHEM, V277, P17589, DOI 10.1074/jbc.M105979200; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; Kuperwasser C, 2000, CANCER RES, V60, P2723; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; Lidberg U, 1998, J BIOL CHEM, V273, P31417, DOI 10.1074/jbc.273.47.31417; LIDBERG U, 1992, GENOMICS, V13, P630, DOI 10.1016/0888-7543(92)90134-E; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Mukhopadhyay SS, 2001, MOL CELL BIOL, V21, P6859, DOI 10.1128/MCB.21.20.6859-6869.2001; Nayak BK, 1999, MOL BIOL REP, V26, P223, DOI 10.1023/A:1007006011253; NEBL G, 1994, J BIOL CHEM, V269, P7371; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Osada S, 1999, BIOCHEM J, V342, P189, DOI 10.1042/0264-6021:3420189; Rafty LA, 2002, EMBO J, V21, P334, DOI 10.1093/emboj/21.3.334; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Saifudeen Z, 2002, J CLIN INVEST, V109, P1021, DOI 10.1172/JCI200213972; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SOINI Y, 1992, VIRCHOWS ARCH A, V421, P415, DOI 10.1007/BF01606914; STRANGE R, 1992, DEVELOPMENT, V115, P49; Stromqvist M, 1997, ARCH BIOCHEM BIOPHYS, V347, P30, DOI 10.1006/abbi.1997.0307; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	45	18	19	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6061	6070		10.1038/sj.onc.1206884	http://dx.doi.org/10.1038/sj.onc.1206884			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955085				2022-12-17	WOS:000185137800015
J	Mirzayans, R; Pollock, S; Scott, A; Gao, CQ; Murray, D				Mirzayans, R; Pollock, S; Scott, A; Gao, CQ; Murray, D			Metabolic labeling of human cells with tritiated nucleosides results in activation of the ATM-dependent p53 signaling pathway and acceleration of DNA repair	ONCOGENE			English	Article						radiolabeled nucleosides; growth arrest; nucleotide excision repair; CPDs; UV; p53; p21(WAF1)	NUCLEOTIDE EXCISION-REPAIR; NORMAL HUMAN FIBROBLASTS; GLOBAL GENOMIC REPAIR; LI-FRAUMENI SYNDROME; WILD-TYPE P53; ULTRAVIOLET-LIGHT; GROWTH ARREST; PYRIMIDINE DIMERS; PROTEIN-LEVELS; EXPRESSION	We investigated the effects of metabolic labeling with [H-3]thymidine, [H-3]uridine, and [C-14]thymidine on human cells in terms of cell growth, p53 signaling, and nucleotide excision repair. Labeling with [H-3] nucleosides resulted in growth inhibition by both p53-dependent and -independent mechanisms. Tritium labeling also led to nuclear accumulation of p53 and induction of the p53-regulated gene p2(WAF1) and its encoded protein (p21). ATM-deficient cells, however, did not increase their p53 and p21 protein levels in response to radiolabeling. Thus, labeling of human cells with tritiated nucleosides activates the radiation-responsive, ATM-dependent, DNA-damage surveillance network. Labeling of normal cells with [H-3]thymidine significantly accelerated the repair of ultraviolet (UV) light-induced cyclobutane pyrimidine dimers, as monitored by a sensitive immunofluorescence assay. Unlike [(3H]) labeling, [C-14] labeling did not produce any impact on proliferation, p53 signaling, or DNA repair. In the light of these findings, the validity of results obtained with nucleic acid synthesis and DNA repair assays that involve [H-3] and [C-14] labeling is discussed. Our immunofluorescence approach detected pyrimidine dimers after exposure to UV fluences as low as 1 J/m(2) (the lowest fluence examined). This approach may prove particularly useful for monitoring DNA damage and its repair following exposure to extremely low levels of genotoxic agents.	Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	University of Alberta	Mirzayans, R (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada.							ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Barley RDC, 1998, ONCOGENE, V17, P533, DOI 10.1038/sj.onc.1202271; BICKAR D, 1992, ANAL BIOCHEM, V203, P109, DOI 10.1016/0003-2697(92)90049-D; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; Bowman KK, 2000, MOL CARCINOGEN, V29, P17, DOI 10.1002/1098-2744(200009)29:1<17::AID-MC3>3.3.CO;2-5; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; DOVER R, 1994, J CELL SCI, V107, P1181; Enns L, 2000, PHOTOCHEM PHOTOBIOL, V72, P562, DOI 10.1562/0031-8655(2000)072<0562:LOCBDS>2.0.CO;2; Enns L, 1998, RADIAT RES, V150, P11, DOI 10.2307/3579639; Enns L, 1999, BRIT J CANCER, V81, P959, DOI 10.1038/sj.bjc.6690793; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Gaitonde SV, 2001, CELL GROWTH DIFFER, V12, P19; GALLOWAY AM, 1994, J BIOL CHEM, V269, P974; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hu VW, 2001, FASEB J, V15, P1562, DOI 10.1096/fj.01-0102com; Hu VW, 2000, FASEB J, V14, P448, DOI 10.1096/fasebj.14.3.448; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; MIRZAYANS R, 1992, INT J RADIAT BIOL, V62, P417, DOI 10.1080/09553009214552301; Mirzayans R, 1999, CARCINOGENESIS, V20, P941, DOI 10.1093/carcin/20.6.941; MIRZAYANS R, 1995, ONCOGENE, V11, P1597; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	29	18	18	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5562	5571		10.1038/sj.onc.1206514	http://dx.doi.org/10.1038/sj.onc.1206514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944903				2022-12-17	WOS:000184865900004
J	Xin, H; Pramanik, R; Choubey, D				Xin, H; Pramanik, R; Choubey, D			Retinoblastoma (Rb) protein upregulates expression of the Ifi202 gene encoding an interferon-inducible negative regulator of cell growth	ONCOGENE			English	Article						interferon-inducible p202; cell cycle; cell survival; Rb; JunD/AP-1	NIH 3T3 CELLS; C-JUN; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL REPRESSION; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; INDUCED APOPTOSIS; P202; DIFFERENTIATION; INHIBITION	Studies have indicated that ectopic expression of p202, an interferon (IFN)-inducible retinoblastoma (Rb)-binding protein, in cultured cells retards cell proliferation and modulates cell survival. Consistent with a role of p202 in cell cycle regulation, levels of p202 increase in cells arrested in the G(0)/G(1) phase of cell cycle after withdrawal of serum growth factors. However, a role for p202 in cell growth arrest remains to be defined. Moreover, it remains unclear how levels of p202 are upregulated during the cell growth arrest. Here, we report that Rb upregulates expression of Ifi202 gene. We found that basal as well as IFN-induced levels of p202 were significantly higher in wild-type (Rb+/+) mouse embryonic fibroblasts (MEFs) than isogenic Rb-/- MEFs. Consistent with the regulation of Ifi202 gene by Rb, expression of functional Rb, but not a pocket mutant of it, stimulated the activity of a reporter whose expression was driven by the 5'-regulatory region of Ifi202 gene. Importantly, the stimulation by Rb was dependent, in part, on a JunD/AP-1 DNA-binding site present in the 5-regulatory region of the Ifi202 gene. Moreover, basal levels of p202 were significantly higher in wild-type (JunD(+/+)) than isogenic JunD(-/-) MEFs. Additionally, we found that increased expression of p202 potentiated the Rb-mediated inhibition of cell growth and mutations in the Rb-binding motif (LxCxE) of p202 significantly reduced cell survival. Together, our observations support the idea that the transcriptional activation of Ifi202 gene by Rb/JunD may be important for the regulation of cell growth and survival.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA	Loyola University Chicago	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, 2160 S 1st Ave,Bldg 1,Mail Code 114B, Maywood, IL 60153 USA.		Choubey, Divaker/A-4771-2008		NCI NIH HHS [CA69031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Berry DE, 1996, ONCOGENE, V12, P1809; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; Choubey D, 2002, FRONT BIOSCI-LANDMRK, V7, pE252, DOI 10.2741/choubey; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Decesse JT, 2001, ONCOGENE, V20, P962, DOI 10.1038/sj.onc.1204169; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Geng YB, 2000, CELL GROWTH DIFFER, V11, P475; Grander D, 1997, EUR J HAEMATOL, V59, P129; GRIBAUDO G, 1987, J BIOL CHEM, V262, P11878; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HAMEL PA, 1992, ONCOGENE, V7, P693; HAPUT Y, 1995, ONCOGENE, V10, P1563; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KRATZKE RA, 1994, ONCOGENE, V9, P1321; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Li H, 2001, ARCH BIOCHEM BIOPHYS, V394, P1, DOI 10.1006/abbi.2001.2518; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Min W, 1996, MOL CELL BIOL, V16, P359; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; Pennaneach V, 2001, MOL CELL, V7, P715, DOI 10.1016/S1097-2765(01)00217-9; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAMANTA H, 1986, J BIOL CHEM, V261, P1849; Sen GC, 2000, SEMIN CANCER BIOL, V10, P93, DOI 10.1006/scbi.2000.0312; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Wang J, 1997, CANCER RES, V57, P351; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Xin H, 2003, J CELL BIOCHEM, V88, P191, DOI 10.1002/jcb.10372; Xin H, 2001, ONCOGENE, V20, P6828, DOI 10.1038/sj.onc.1204844; YEE AS, 1998, FRONT BIOSCI, V3, P532; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	59	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4775	4785		10.1038/sj.onc.1206780	http://dx.doi.org/10.1038/sj.onc.1206780			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894219				2022-12-17	WOS:000184344600001
J	Atlas, E; Bojanowski, K; Mehmi, I; Lupu, R				Atlas, E; Bojanowski, K; Mehmi, I; Lupu, R			A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity	ONCOGENE			English	Article						HRG; mutants; drug resistance; doxorubicin; estrogen dependence; antiestrogen resistance; breast cancer	TOPOISOMERASE-II; GROWTH-FACTOR; ESTROGEN-RECEPTOR; EXPRESSION; APOPTOSIS; INDUCTION; ONCOGENE; LINE; DIFFERENTIATION; PROLIFERATION	Heregulin (HRG) is an activator of the erbB2-, erbB3- and erB4-(erbB-2/3/4) signaling pathway. Transfection of full-length HRG cDNA into the estrogen (E2)-dependent cell line MCF-7 promoted an invasive E2-independent phenotype, as well as persistent activation of the erbB-2/3/4 receptors. Moreover, HRG expression in MCF-7 cells renders the cells sensitive to the topoisomerase 11 inhibitor doxorubicin (Doxo). In an attempt to dissociate the tumorigenic effect of HRG from the sensitizing effect to chemotherapy, we constructed a structural deletion mutant of HRG. Transfection of the deletion mutant of HRG described in this study (HRG/M) into MCF-7 cells resulted in the dissociation of the tumor-promoting activity of HRG from the sensitization to Doxo, that is, although the cells did not become more aggressive or E2-independent they became more sensitive to Doxo. HRG/M was unable to autophosphorylate the erbB receptors and did not affect the level of MAPK phosphorylation. Furthermore, the intracellular localization of the protein was different from that of the full-length protein. Our data show that the HRG/M sequences are sufficient to sensitize MCF-7 cells to Doxo, and provide evidence that this sensitization is independent of erbB2 activation.	Northwestern Univ, Evanston NW Healthcare Res Inst, Evanston, IL 60201 USA	Northwestern University	Lupu, R (corresponding author), Northwestern Univ, Evanston NW Healthcare Res Inst, 1001 Univ Pl,2650 Ridge Ave, Evanston, IL 60201 USA.							Alper O, 2000, INT J CANCER, V88, P566, DOI 10.1002/1097-0215(20001115)88:4<566::AID-IJC8>3.0.CO;2-D; Aoyama M, 1998, BIOCHEM J, V336, P727, DOI 10.1042/bj3360727; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; Grimm S, 1998, J EXP MED, V188, P1535, DOI 10.1084/jem.188.8.1535; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Harris LN, 1998, CLIN CANCER RES, V4, P1005; Harris LN, 2001, CLIN CANCER RES, V7, P1497; Hijazi MM, 2000, INT J ONCOL, V17, P629; Keir M, 2000, STEM CELLS, V18, P422, DOI 10.1634/stemcells.18-6-422; Krane IM, 1996, ONCOGENE, V12, P1781; Lessor T, 1998, J CELL BIOCHEM, V70, P587, DOI 10.1002/(SICI)1097-4644(19980915)70:4<587::AID-JCB14>3.0.CO;2-E; Li WL, 1996, ONCOGENE, V12, P2473; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; Matsumoto Y, 1999, J NEURO-ONCOL, V45, P37, DOI 10.1023/A:1006346624083; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Paik S, 2000, J NATL CANCER I, V92, P1991, DOI 10.1093/jnci/92.24.1991; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Talukder AH, 2000, CANCER RES, V60, P276; Tang CK, 1996, CANCER RES, V56, P3350; Tsai MS, 2000, CANCER RES, V60, P5603; Wang JY, 2001, J BIOL CHEM, V276, P2841, DOI 10.1074/jbc.M005700200; Weinstein EJ, 2000, CANCER RES, V60, P3856; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; Xiong SB, 2001, CANCER RES, V61, P1727	27	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3441	3451		10.1038/sj.onc.1206410	http://dx.doi.org/10.1038/sj.onc.1206410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776196				2022-12-17	WOS:000183128500011
J	Fenton, JAL; Pratt, G; Rawstron, AC; Sibley, K; Rothwell, D; Yates, Z; Dring, A; Richards, SJ; Ashcroft, AJ; Davies, FE; Owen, RG; Child, JA; Morgan, GJ				Fenton, JAL; Pratt, G; Rawstron, AC; Sibley, K; Rothwell, D; Yates, Z; Dring, A; Richards, SJ; Ashcroft, AJ; Davies, FE; Owen, RG; Child, JA; Morgan, GJ			Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism	ONCOGENE			English	Article						primary translocation; class switch recombination; myeloma; t(4;14)	CLASS-SWITCH RECOMBINATION; B-CELLS; TRANSLOCATIONS; REGION; FREQUENT; GENE; DYSREGULATION; MUTATIONS; SEQUENCES	Using FISH-based techniques, rearrangements of the immunoglobulin heavy-chain (IgH) locus at 14q32 have been found in the majority of cases of multiple myeloma (MM). Some of these IgH translocations are recurrent and we have characterized the genomic breakpoints of seven t(4;14) translocations from MM patients, using a combination of vectorette and conventional polymerase chain reaction methods, the aim being to understand the molecular mechanism leading to MM. Conventionally, the chromosome 14q32 breakpoints in these reciprocal translocations are believed to be located in the IgH p switch (S) region and a further downstream S region with deletion of intervening DNA occurring as a result of aberrant class switch recombination (CSR); this was seen in five of the cases analysed. However, in two patients it was possible to demonstrate that the rearranged hybrid switch region sequence was joined to DNA from chromosome 4p16, suggesting that IgH translocations can occur in B cells that have already undergone legitimate CSR. The complex nature of these rearrangements leads us to speculate that primary IgH translocations may occur at different time points in the development in MM plasma cells, either at the time of physiological CSR or at a later stage, possibly involving a different mechanism.	Univ Leeds, Acad Unit Haematol & Oncol, Leeds LS2 9JT, W Yorkshire, England; Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England	University of Leeds; Paterson Institute for Cancer Research	Fenton, JAL (corresponding author), Univ Leeds, Acad Unit Haematol & Oncol, Algernon Firth Bldg, Leeds LS2 9JT, W Yorkshire, England.	jamesf@lrf.leeds.ac.uk		morgan, gareth/0000-0002-4271-6360; Richards, Stephen/0000-0002-8421-5353; Davies, Faith/0000-0002-3971-2393; Rawstron, Andy/0000-0003-0798-9790				Avet-Loiseau H, 2002, BLOOD, V99, P2185, DOI 10.1182/blood.V99.6.2185; Avet-Loiseau H, 1998, CANCER RES, V58, P5640; Avet-Loiseau H, 2001, BLOOD, V98, P3082, DOI 10.1182/blood.V98.10.3082; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Chen XC, 2001, P NATL ACAD SCI USA, V98, P13860, DOI 10.1073/pnas.241524898; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; Ehrenstein MR, 1999, EMBO J, V18, P3484, DOI 10.1093/emboj/18.12.3484; Ehrenstein MR, 2001, P NATL ACAD SCI USA, V98, P14553, DOI 10.1073/pnas.241525998; Endele S, 1999, GENOMICS, V60, P218, DOI 10.1006/geno.1999.5881; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Ho PJ, 2001, BLOOD, V97, P490, DOI 10.1182/blood.V97.2.490; Kinoshita K, 1999, COLD SPRING HARB SYM, V64, P217, DOI 10.1101/sqb.1999.64.217; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Lee CG, 1998, CURR BIOL, V8, P227, DOI 10.1016/S0960-9822(98)70087-9; LIDA S, 1997, NAT GENET, V17, P226; MANDLER R, 1993, J IMMUNOL, V150, P407; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nishida K, 1997, BLOOD, V90, P526, DOI 10.1182/blood.V90.2.526.526_526_534; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Proffitt J, 1999, LEUKEMIA, V13, P1100, DOI 10.1038/sj.leu.2401465; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Ronchetti D, 1999, BLOOD, V93, P1330, DOI 10.1182/blood.V93.4.1330.404k04_1330_1337; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Sibley K, 2002, BRIT J HAEMATOL, V118, P514, DOI 10.1046/j.1365-2141.2002.03618.x; ZHANG K, 1995, J IMMUNOL, V154, P2237	34	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					1103	1113		10.1038/sj.onc.1206335	http://dx.doi.org/10.1038/sj.onc.1206335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592397				2022-12-17	WOS:000180926100016
J	Mukai, T; Sekiguchi, M				Mukai, T; Sekiguchi, M			Gene silencing in phenomena related to DNA repair	ONCOGENE			English	Article						DNA methylation; histone methylation; cancer; Mgmt; Mlh1; animal model	HUMAN O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; CHEMOTHERAPEUTIC ALKYLATING-AGENTS; HMLH1 PROMOTER HYPERMETHYLATION; NONPOLYPOSIS COLORECTAL-CANCER; SYNDROME IMPRINTING-CENTER; MISMATCH REPAIR; HISTONE H3; CPG-ISLAND; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; MICROSATELLITE INSTABILITY	DNA methylation is essential for embryonic development and important for transcriptional repression, as observed in several biological phenomena. These include genomic imprinting, X-inactivation and carcinogenesis. The basic mechanism by which DNA methlyation silences transcription is generally understood, but there is still much to be learned about how DNA methyltransferase is targeted to a specific region of the gene. Silencing by DNA methylation occurs at an early stage of carcinogenesis, when the DNA repair genes, MGMT and hMLH1, are frequently inactivated, resulting in mutations in key cancer-related genes in cells. Mice defective in Mgmt and/or Mlh1 gave clear evidence of the significant roles of these proteins in carcinogenesis. Recently, it has been demonstrated that DNA methylation is linked to histone methylation in fungi and plants, although it remains unknown whether this mechanism occurs in mammalian systems.	Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, Saga 8498501, Japan; Biomol Engn Res Inst, Suita, Osaka 5650874, Japan	Saga University	Mukai, T (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, 5-1-1 Nabeshima, Saga 8498501, Japan.							ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Ben-Porath I, 2000, CURR OPIN GENET DEV, V10, P550, DOI 10.1016/S0959-437X(00)00126-X; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Brockdorff N, 2002, TRENDS GENET, V18, P352, DOI 10.1016/S0168-9525(02)02717-8; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHEN B, 1994, CARCINOGENESIS, V15, P2031, DOI 10.1093/carcin/15.9.2031; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; DAY RS, 1979, NATURE, V279, P797, DOI 10.1038/279797a0; De Smet C, 1999, MOL CELL BIOL, V19, P7327; de Wind N, 1998, CANCER RES, V58, P248; Deng GR, 1999, CANCER RES, V59, P2029; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; El-Maarri O, 2001, NAT GENET, V27, P341, DOI 10.1038/85927; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Esteller M, 2000, CANCER RES, V60, P2368; Fleisher AS, 2000, CANCER RES, V60, P4864; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1995, CANCER RES, V55, P4525; Iwakuma T, 1997, CARCINOGENESIS, V18, P1631, DOI 10.1093/carcin/18.8.1631; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kane MF, 1997, CANCER RES, V57, P808; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOIKE G, 1990, J BIOL CHEM, V265, P14754; KOLODNER RD, 1995, CANCER RES, V55, P242; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MATSUKARA S, 2003, IN PRESS BRIT J CANC; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Papadopoulos N, 1997, HUM MUTAT, V10, P89, DOI 10.1002/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.3.CO;2-K; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Qian XLC, 1997, CANCER RES, V57, P3672; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Riggs A. D., 1996, EPIGENETIC MECH GENE, P29; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sakumi K, 1997, CANCER RES, V57, P2415; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Shiraishi A, 2000, CARCINOGENESIS, V21, P1879, DOI 10.1093/carcin/21.10.1879; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Wolf P, 2001, CANCER RES, V61, P8113; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	97	18	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2002	21	58					9033	9042		10.1038/sj.onc.1206095	http://dx.doi.org/10.1038/sj.onc.1206095			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483518				2022-12-17	WOS:000179889500013
J	Zhou, H; Liu, LL; Lee, KY; Qin, XS; Grasso, AW; Kung, HJ; Willis, JE; Kern, J; Wagner, T; Gerson, SL				Zhou, H; Liu, LL; Lee, KY; Qin, XS; Grasso, AW; Kung, HJ; Willis, JE; Kern, J; Wagner, T; Gerson, SL			Lung tumorigenesis associated with erb-B-2 and erb-B-3 overexpression in human erb-B-3 transgenic mice is enhanced by methylnitrosourea	ONCOGENE			English	Article						transgenic mice; erb-B-2; erb-B-3; lung tumor; methylnitrosourea; K-ras	HUMAN MGMT; CELL-LINES; EXPRESSION; GENE; RECEPTOR; HEREGULIN; CANCER; MOUSE; ALKYLTRANSFERASE; EPITHELIUM	Erb-B-3 overexpression is associated with poor prognosis in non-small cell lung cancer and is often overexpressed in breast cancers. MMTVhuman-erb-B-3 transgenic mice were generated to evaluate the impact of erb-B-3 overexpression on lung and mammary gland tumorigenesis. These transgenic mice developed a high incidence of lung adenocarcinomas but not mammary gland tumors. The tumors overexpressed transgenic human [h]-erb-B-3 but also overexpressed endogenous erb-B-2, indicating that the heterodimer of h-erb-B-3-erb-B-2 was required for proliferative signal transduction to the nucleus. Lung tumor latency was shorter and the incidence higher in erb-B-3 transgenic mice treated with the methylating agent, methylnitrosourea [MNU]. In MNU treated mice, K-ras activating point mutations in codon 12, synergized with h-erb-B-3 in lung tumorogenesis. In bitransgenic MMTVrat-erb-B2/MMTV-human-erb-B-3 mice, lung tumor latency was also significantly shortened. Unlike over-expression of rat-erb-B-2, overexpression of h-erb-B-3 did not alter the incidence or latency of mammary tumors. Coupled erb-B-2 and erb-B-3 overexpression as well as K-ras activation induced signaling through mitogen-activated protein kinase (MAPK). This animal model links erb-B-3 with lung cancer, suggests that erbB-2 and erb-B-3 heterodimerization is a necessary intermediate, and documents latency shortening by methylating agent-induced mutation of K-ras. This erb-B-3 mouse lung cancer model will help dissect genetic changes in lung tumorigenesis and may be useful for chemoprevention studies.	Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Greenville Hosp Syst, Oncol Res Inst, Greenville, SC 29605 USA; Univ Calif Davis, Ctr Canc, Sacramento, CA 95819 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Div Pulm Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Microbiol & Mol Biol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Greenville Health System; University of California System; University of California Davis; University Hospitals of Cleveland; Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University	Gerson, SL (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, BRB-3W,10900 Euclid Ave, Cleveland, OH 44106 USA.	slg5@po.cwru.edu		Kern, Jeffrey/0000-0001-9709-9622	NATIONAL CANCER INSTITUTE [P30CA043703, R01CA073062, R01CA063193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA73062, R01CA63193, P30CA43703] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamson ED, 1997, CURR TOP DEV BIOL, V35, P71, DOI 10.1016/S0070-2153(08)60257-4; Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Al Moustafa AE, 1999, ANTICANCER RES, V19, P481; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; DEVEREUX TR, 1991, CARCINOGENESIS, V12, P299, DOI 10.1093/carcin/12.2.299; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hung MC, 1999, SEMIN ONCOL, V26, P51; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Kiguchi K, 2000, ONCOGENE, V19, P4243, DOI 10.1038/sj.onc.1203778; Kristiansen G, 2001, EUR J CANCER, V37, P1089, DOI 10.1016/S0959-8049(01)00096-X; Liu LL, 1999, CARCINOGENESIS, V20, P279, DOI 10.1093/carcin/20.2.279; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Patel NV, 2000, AM J RESP CELL MOL, V22, P432, DOI 10.1165/ajrcmb.22.4.3854; Peterson LA, 2001, CANCER RES, V61, P5757; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Polosa R, 2000, J ALLERGY CLIN IMMUN, V106, P1124; Qin XS, 1999, ONCOGENE, V18, P4394, DOI 10.1038/sj.onc.1202798; Qin XS, 1999, CARCINOGENESIS, V20, P1667, DOI 10.1093/carcin/20.9.1667; Reese JS, 2001, ONCOGENE, V20, P5258, DOI 10.1038/sj.onc.1204700; Reinmuth N, 2000, EUR RESPIR J, V16, P991, DOI 10.1183/09031936.00.16599100; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Sundaresan S, 1998, ENDOCRINOLOGY, V139, P4756, DOI 10.1210/en.139.12.4756; Weinstein EJ, 2000, CANCER RES, V60, P3856; Yi ES, 1997, MODERN PATHOL, V10, P142; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; Zhou H, 2001, ONCOGENE, V20, P6009, DOI 10.1038/sj.onc.1204830	29	18	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8732	8740		10.1038/sj.onc.1205984	http://dx.doi.org/10.1038/sj.onc.1205984			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483526				2022-12-17	WOS:000179734400007
J	Kirch, HC; Ruschen, S; Brockmann, D; Esche, H; Horikawa, I; Barrett, JC; Opalka, B; Hengge, UR				Kirch, HC; Ruschen, S; Brockmann, D; Esche, H; Horikawa, I; Barrett, JC; Opalka, B; Hengge, UR			Tumor-specific activation of hTERT-derived promoters by tumor suppressive E1A-mutants involves recruitment of p300/CBP/HAT and suppression of HDAC-1 and defines a combined tumor targeting and suppression system	ONCOGENE			English	Article						E1A; tumor suppressor; hTERT promoter; tumor-specific expression; histone deacetylase	REVERSE-TRANSCRIPTASE GENE; ADENOVIRUS-5 E1A GENE; HISTONE DEACETYLASE; ONCOPROTEIN E1A; MELANOMA-CELLS; C-MYC; TELOMERASE; TRANSFORMATION; PROTEIN; REPRESSION	Adenovirus (Ad) E1A proteins are transcriptional regulators with antioncogenic but also transforming properties. We have previously shown that transformation-defective Ad5 E1A-derivatives are excellent tumor suppressors. For tumor-specific expression of the E1A-derivatives we intend to use tumor specific human telomerase reverse transcriptase (hTER7) core promoters. Here, we show that Spm2 and other E1A proteins with an intact amino terminus activated all hTERT constructs 10-20-fold in malignant tumor cells but not in primary fibroblasts, without affecting the activity of endogenous telomerase. The transcription rate in tumor cells was in the range of transcription from the SV40 promoter, which qualifies an E1A-hTERT system as a putative tumor targeting/expression system. The activation of the hTERT promoter by E1A was enhanced upon deletion of the Wilms' tumor I negative regulatory element and maintained high after deletion of the adjacent c-Myc-responsive E-box, demonstrating an important role of the remaining sequences that contain several Sp1-motifs. E1A-mediated hTERT activation was independent from the presence of the conserved region 3 (CR3) of E1A but dependent on E1A's binding to p300/CBP and recruitment of its histone acetyltransferase activity. Moreover, E1A-Spm2 and histone deacetylase-1 behaved as antagonists with respect to the regulation of transcription from the hTERT promoter. Overall, hTERT promoter/E1A-Spm2 systems may turn out to be excellent tools for transcriptionally targeted anticancer gene therapy.	Univ Essen Gesamthsch, Dept Internal Med Canc Res, D-45147 Essen, Germany; Univ Essen Gesamthsch, Inst Mol Biol Canc Res, D-45147 Essen, Germany; NCI, Canc Res Ctr, Lab Biosyst & Canc Res, NIH, Bethesda, MD 20892 USA; Univ Essen Gesamthsch, Dept Dermatol, D-45147 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Duisburg Essen	Kirch, HC (corresponding author), Univ Essen Gesamthsch, Dept Internal Med Canc Res, Hufelandstr 55, D-45147 Essen, Germany.							Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; DENT J, 2002, CANCER RES, V62, P346; Dickopp A, 2000, CANCER GENE THER, V7, P1043, DOI 10.1038/sj.cgt.7700206; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Fax P, 2000, J BIOL CHEM, V275, P40554, DOI 10.1074/jbc.M004626200; Frisch SM, 2001, ADV CANCER RES, V80, P39, DOI 10.1016/S0065-230X(01)80011-7; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1995, CANCER RES, V55, P5551; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Gu J, 2000, CANCER RES, V60, P5359; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Horikawa I, 1999, CANCER RES, V59, P826; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Komata T, 2002, ONCOGENE, V21, P656, DOI 10.1038/sj.onc.1205072; Komata T, 2001, CANCER RES, V61, P5796; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Mymryk JS, 1996, ONCOGENE, V13, P1581; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Rumpf H, 1999, VIROLOGY, V257, P45, DOI 10.1006/viro.1999.9651; Schuierer M, 2001, J BIOL CHEM, V276, P27944, DOI 10.1074/jbc.M100070200; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Strom AC, 1998, J VIROL, V72, P5978; Sundqvist A, 2001, EXP CELL RES, V268, P284, DOI 10.1006/excr.2001.5280; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; vanGroningen JJM, 1996, BIOCHEM BIOPH RES CO, V225, P808, DOI 10.1006/bbrc.1996.1255; VANMUIJEN GNP, 1991, CLIN EXP METASTAS, V9, P259, DOI 10.1007/BF01753729; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598	39	18	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					7991	8000		10.1038/sj.onc.1205965	http://dx.doi.org/10.1038/sj.onc.1205965			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439749				2022-12-17	WOS:000179097200008
J	Mark, SC; Sandercock, LE; Luchman, HA; Baross, A; Edelmann, W; Jirik, FR				Mark, SC; Sandercock, LE; Luchman, HA; Baross, A; Edelmann, W; Jirik, FR			Elevated mutant frequencies and predominance of G : C to A : T transition mutations in Msh6(-/-) small intestinal epithelium	ONCOGENE			English	Article						DNA mismatch repair; Msh6; lacI; transgenic shuttle-phage; small intestinal epithelium; Big Blue (TM)	DNA MISMATCH REPAIR; MSH2 DEFICIENT MICE; TRANSGENIC MICE; IN-VIVO; HUMAN-CELLS; GENE PMS2; CANCER; RODENTS; MOUSE; BETA	The DNA mismatch repair (MMR) system is primarily responsible for purging newly synthesized DNA of errors incurred during semi-conservative replication. Lesion recognition is initially carried out by one of two heterodimeric protein complexes, MutSalpha, or MutSbeta. While the former, comprised of MSH2 and MSH6, recognizes mispairs as well as short (1-2 nucleotide) insertions/deletions (IDLs), the latter, made up of MSH2 and MSH3, is primarily responsible for recognizing 2-6 nucleotide IDLs. As most of the functional information on these heterodimers is derived from in vitro studies, it was of interest to study the in vivo consequences of a lack of MutSalpha To this end, Big Blue(TM) mice, that carry a lacI(+) transgenic lambda shuttle-phage mutational reporter, were crossed with Msh6(-/-)mice to evaluate the specific contribution of MutSalpha to genome integrity. Consistent with the importance of MutSalpha in lesion surveillance, small intestine epithelial cell DNA derived from lacI(+) Msh6(-/-) mice exhibited striking increases (average of 41-fold) in spontaneous mutant frequencies. Furthermore, the lacI gene mutation spectrum was dominated by G:C to A:T transitions, highlighting the critical importance of the MutSalpha complex in suppressing this frequently observed type of spontaneous mutation.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	University of Calgary; Yeshiva University; Albert Einstein College of Medicine	Jirik, FR (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.				NATIONAL CANCER INSTITUTE [R01CA076329] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76329] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Aquilina G, 2001, J CELL PHYSIOL, V187, P145, DOI 10.1002/jcp.1067; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Baross-Francis A, 1998, P NATL ACAD SCI USA, V95, P8739, DOI 10.1073/pnas.95.15.8739; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Cariello NF, 1996, ENVIRON MOL MUTAGEN, V28, P397, DOI 10.1002/(SICI)1098-2280(1996)28:4<397::AID-EM14>3.0.CO;2-A; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cosentino L, 2000, MUTAT RES-FUND MOL M, V454, P1, DOI 10.1016/S0027-5107(00)00125-1; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 2000, CANCER RES, V60, P803; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CANCER RES, V59, P5068; Kuraguchi M, 2001, CANCER RES, V61, P7934; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marra G, 1999, BIOCHEM J, V338, P1, DOI 10.1042/0264-6021:3380001; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Monroe JJ, 2001, MUTAT RES-FUND MOL M, V476, P1, DOI 10.1016/S0027-5107(01)00081-1; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Peltomaki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735; PROVOST GS, 1993, MUTAT RES, V288, P133; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Skopek T, 1998, MUTAT RES-FUND MOL M, V400, P77, DOI 10.1016/S0027-5107(98)00040-2; Umar A, 1998, GENETICS, V148, P1637; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Zhang SL, 2001, ENVIRON MOL MUTAGEN, V37, P141, DOI 10.1002/em.1021	43	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7126	7130		10.1038/sj.onc.1205861	http://dx.doi.org/10.1038/sj.onc.1205861			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370835				2022-12-17	WOS:000178424900016
J	Lee, D; Kim, JW; Kim, K; Joe, CO; Schreiber, V; Menissier-de Murcia, J; Choe, J				Lee, D; Kim, JW; Kim, K; Joe, CO; Schreiber, V; Menissier-de Murcia, J; Choe, J			Functional interaction between human papillomavirus type 18 E2 and poly(ADP-ribose) polymerase 1	ONCOGENE			English	Article						PARP; HPV; transcriptional activation	CALCIUM-INDUCED DIFFERENTIATION; HUMAN KERATINOCYTES; ADP-RIBOSYLATION; TRANSCRIPTIONAL REPRESSOR; CELL-DIFFERENTIATION; MAMMALIAN-CELLS; E7 ONCOPROTEIN; E6 ONCOPROTEIN; EARLY PROMOTER; HELA-CELLS	Human papillomavirus E2 protein is a transcription factor of viral gene expression and DNA replication. Here we show that PARP is a positive regulator of the E2 protein of human papillomavirus type 18 (HPV-18). PARP interacted with the COOH terminal region of HPV-18 E2 in vitro. The E2 interaction domain within PARP is located in the NH2-terminal zinc finger motif and the BRCT motif included in the automodification domain. Overexpression of either wild type or the NH2-terminal region of PARP containing zinc finger and BRCT stimulated E2-dependent transcription. Gel retardation assay indicates that PARP augments DNA binding activity of E2 in vitro. We also show that PARP-1 is recruited to E2-dependent promoter in vivo using ChIP assay. These results suggest that PARP serves a transcriptional co-activator in E2-dependent transcription by interacting directly with the HPV E2 protein.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Univ Strasbourg 1, UPR 9003, CNRS,Ecole Super Biotechnol, Lab Convent Commissariat Energie Atom, F-67400 Illkirch Graffenstaden, France	Korea Advanced Institute of Science & Technology (KAIST); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Lee, Daeyoup/C-1653-2011; Choe, Joonho/F-3066-2011; Kim, Karam/K-1412-2018; Schreiber, Valérie/M-5007-2016; Joe, Cheol O/C-1917-2011; KIM, JIN WOO/C-1655-2011	Lee, Daeyoup/0000-0003-2006-1823; Kim, Karam/0000-0002-1886-5163; Schreiber, Valérie/0000-0003-0507-639X; KIM, JIN WOO/0000-0003-0767-1918				Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; BERNARD BA, 1989, J VIROL, V63, P4317, DOI 10.1128/JVI.63.10.4317-4324.1989; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DEMERET C, 1994, J VIROL, V68, P7075, DOI 10.1128/JVI.68.11.7075-7082.1994; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; di Fagagna FD, 1999, NAT GENET, V23, P76; FERRO AM, 1984, J BIOL CHEM, V259, P547; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; HULETSKY A, 1985, EUR J BIOCHEM, V146, P277, DOI 10.1111/j.1432-1033.1985.tb08650.x; Jones DL, 1999, VIROLOGY, V258, P406, DOI 10.1006/viro.1999.9733; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kim JW, 2000, J BIOL CHEM, V275, P8121, DOI 10.1074/jbc.275.11.8121; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee D, 2002, J BIOL CHEM, V277, P6483, DOI 10.1074/jbc.M105085200; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Masutani M, 2001, MUTAT RES-FUND MOL M, V477, P111, DOI 10.1016/S0027-5107(01)00112-9; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; OHASHI Y, 1986, BIOCHEM BIOPH RES CO, V140, P666, DOI 10.1016/0006-291X(86)90783-7; OHASHI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7132, DOI 10.1073/pnas.81.22.7132; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; Pugh B F, 1995, Methods Mol Biol, V37, P349; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Sherman L, 1997, VIROLOGY, V237, P296, DOI 10.1006/viro.1997.8778; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Simbulan-Rosenthal CM, 1999, ONCOGENE, V18, P5015, DOI 10.1038/sj.onc.1202900; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Stubenrauch F, 1998, J VIROL, V72, P1071, DOI 10.1128/JVI.72.2.1071-1077.1998; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	54	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5877	5885		10.1038/sj.onc.1205723	http://dx.doi.org/10.1038/sj.onc.1205723			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185587				2022-12-17	WOS:000177520900007
J	Sansom, OJ; Clarke, AR				Sansom, OJ; Clarke, AR			The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice	ONCOGENE			English	Article						mismatch repair; apoptosis; P53; clonogenic survival; cisplatin	DNA MISMATCH REPAIR; MURINE SMALL-INTESTINE; DRUG-RESISTANCE; MUTATION FREQUENCY; ANTICANCER AGENTS; GAMMA-IRRADIATION; HMLH1 EXPRESSION; TUMOR-CELLS; DAMAGE; CISPLATIN	Apoptosis and long term enterocyte survival were examined in vivo after exposure to three cytotoxic agents (Cisplatin, Nitrogen Mustard and N-methyl-N-nitrosourea (NMNU/MNU)) within mice either singly or doubly mutant for p53 and Msh2. P53 deficiency caused abrogation of the immediate apoptotic response to each agent, but only led to increased survival after cisplatin treatment. Msh2 deficiency reduced the apoptotic response to each agent, but only led to increased crypt survival after NMNU treatment. Following cisplatin treatment, the response of (Msh2(-/-), p53(-/-)) mice paralleled that of the p53(-/-) mice. A delayed wave of apoptosis was observed in both p53(-/-) and (Msh2(-/-), p53(-/-)) mice demonstrating this phenomenon to be independent of functional Mismatch repair (MMR). We conclude that loss of either p53 or Msh2 dependent apoptosis does not predict long-term crypt survival in vivo, however genetic status clearly can modulate survival for some agents such as cisplatin.	Univ Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland	Cardiff University; University of Edinburgh	Clarke, AR (corresponding author), Univ Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010				Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; BOSARI S, 1995, VIRCHOWS ARCH, V427, P229; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Brown JM, 1999, CANCER RES, V59, P1391; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Fink D, 1998, CLIN CANCER RES, V4, P1; FLEISCHHACKER M, 1994, MODERN PATHOL, V7, P435; Gong JG, 1999, NATURE, V399, P806; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Hemminki K., 1994, V125, P313; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kasparkova J, 2001, J BIOL CHEM, V276, P16064, DOI 10.1074/jbc.M101224200; Lin XJ, 2001, CANCER RES, V61, P1508; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Ochs K, 2000, CANCER RES, V60, P5815; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1985, CELL CLONES MANUAL M; Pritchard DM, 1998, CANCER RES, V58, P5453; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2001, ONCOGENE, V20, P3580, DOI 10.1038/sj.onc.1204449; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675	37	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5934	5939		10.1038/sj.onc.1205760	http://dx.doi.org/10.1038/sj.onc.1205760			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185594				2022-12-17	WOS:000177520900014
J	Zhang, ZQ; Wang, Y; Herzog, CR; Liu, GJ; Lee, HW; DePinho, RA; You, M				Zhang, ZQ; Wang, Y; Herzog, CR; Liu, GJ; Lee, HW; DePinho, RA; You, M			A strong candidate gene for the Papg1 locus on mouse chromosome 4 affecting lung tumor progression	ONCOGENE			English	Article						Cdkn2a; p16(INK4a); ARF; genetic variants; mouse lung tumors; pulmonary adenoma progression 1; quantitative trait locus	CELL-CYCLE CONTROL; SUPPRESSOR GENE; PLASMACYTOMA SUSCEPTIBILITY; STABILIZES P53; MDM2; P19(ARF); CANCER; P16(INK4A); CDKN2A; MICE	Lung cancer is the leading cause of cancer death among both men and women, accounting for more than 28% of all cancer deaths. In fact, more people die of lung cancer than of colon, breast, and prostate cancers combined. Although lung cancer is largely induced by smoking, there is strong evidence for genetic susceptibility and gene-environment interactions in the development of lung cancer. Inbred mouse models offer an effective means of identifying candidate lung cancer susceptibility loci since genetic heterogeneity and enormous variation in exposure levels to environmental agents make it difficult to identify lung cancer susceptibility loci in humans. Papg-1 (pulmonary adenoma progression 1) was previously mapped to a region on mouse chromosome 4. This locus contains a candidate gene, Cdkn2a also referred to as Ink4a/Arf, which dually encodes two established tumor suppressors p16(INK4a) and ARE Cdkn2a became a primary candidate for Papg-1 for two reasons: (1) two haplotypes of mouse Cdkn2a were found to segregate with differential genetic susceptibility to lung tumor progression in mice; and (2) in vitro studies showed that the p16(INK4a) allele from the BALB/cJ mouse had a significantly decreased ability to bind and inhibit CDK6 and to suppress cell growth when compared with the p16(INK4a) allele from the A/J mouse. Here, we report that mice with a heterozygous deficiency for the A/J Cdkn2a allele were significantly more susceptible to lung tumor progression than mice with a heterozygous deficiency for a BALB/cJ Cdkn2a allele, when compared to their respective wild type mice. These results offer strong evidence that naturally occurring variation of p16(INK4a) influences susceptibility to enhance lung tumor progression making it a strong candidate for the lung tumor progression locus, Papg-1.	Ohio State Univ, Div Human Canc Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Sch Publ Hlth, Ctr Comprehens Canc, Columbus, OH 43210 USA; Amer Hlth Fdn, Valhalla, NY 10595 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; American Health Foundation; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	You, M (corresponding author), Ohio State Univ, Div Human Canc Genet, Ctr Comprehens Canc, 420 W 12th Ave, Columbus, OH 43210 USA.			DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [R01CA78797, R01CA58554, P30CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058554, P30CA016058, R01CA078797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERVONT HB, 1938, PUBLIC HLTH REP, V53, P232; Festing MFW, 1998, GENOMICS, V53, P129, DOI 10.1006/geno.1998.5450; Herzog CR, 1997, J CELL BIOCHEM, P49; HERZOG CR, 1994, CANCER RES, V54, P4007; Herzog CR, 1997, MAMM GENOME, V8, P65, DOI 10.1007/s003359900352; Herzog CR, 1999, MOL CARCINOGEN, V25, P92, DOI 10.1002/(SICI)1098-2744(199906)25:2<92::AID-MC3>3.0.CO;2-2; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Manenti G, 1997, CANCER RES, V57, P4164; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; QUELLE DE, 1995, CELL, V83, P993; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SELLERS TA, 1992, GENET EPIDEMIOL, V9, P261, DOI 10.1002/gepi.1370090405; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHIMKIN MB, 1955, ADV CANCER RES, V3, P223, DOI 10.1016/S0065-230X(08)60921-5; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu XF, 1997, CANCER, V79, P1527, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1527::AID-CNCR13>3.0.CO;2-#; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	32	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5960	5966		10.1038/sj.onc.1205725	http://dx.doi.org/10.1038/sj.onc.1205725			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185599				2022-12-17	WOS:000177520900019
J	Piu, F; Magnani, M; Ader, ME				Piu, F; Magnani, M; Ader, ME			Dissection of the cytoplasmic domains of cytokine receptors involved in STAT and Ras dependent proliferation	ONCOGENE			English	Article						cytokine receptor; proliferation; STAT; Ras	COLONY-STIMULATING FACTOR; FACTOR G-CSF; SIGNAL-TRANSDUCTION; ALPHA-SUBUNIT; THROMBOPOIETIN RECEPTOR; TYROSINE-PHOSPHORYLATION; MUSCARINIC RECEPTORS; HEMATOPOIETIC-CELLS; DISTINCT REGIONS; BETA-CHAIN	Cytokine receptors have different signaling requirements which ultimately lead to various physiological responses. In an effort to precisely characterize the molecular determinants involved in the proliferative response mediated by cytokines, we examine dose-dependent proliferation of the betac (GM-CSF, IL-3, IL-5) and homodimeric (G-CSF, TPO) cytokine receptors. Here we report that all cytokine receptors tested activate mostly STAT3 and STAT5. While STAT3 had a positive effect on betac cytokine receptor dependent proliferation, STAT5 was strongly inhibitory. Similarly, G-CSF and TPO lead to activation of STAT3 and STAT5 but, unlike the betac cytokine receptors, both stimulated cellular growth. On the other hand, Ras activation was necessary for all receptor mediated proliferation with the exception of G-CSF R. Truncated mutants of the receptors intracellular domains were used to delineate the functional domains involved in JAK/STAT and Ras activation linked to cellular growth. For instance, we revealed a critical role for the specific alpha subunit of the betac receptors in triggering receptor activation, STAT3 stimulation and proliferation, while Ras activation originates from the distal intracellular portion of the betac subunit. Finally, we showed that proximal STAT activation is the triggering event of G-CSF and TPO receptor function.	ACADIA Pharmaceut Inc, Signal Transduct Grp, San Diego, CA 92121 USA		Piu, F (corresponding author), ACADIA Pharmaceut Inc, Signal Transduct Grp, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.	fpiu@acadia-pharm.com	Magnani, Mauro/A-1919-2008					Adachi T, 1999, J IMMUNOL, V162, P1496; Adachi T, 1999, J IMMUNOL, V163, P939; Barge RMY, 1996, BLOOD, V87, P2148, DOI 10.1182/blood.V87.6.2148.bloodjournal8762148; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1997, J NEUROCHEM, V68, P525; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; deKoning JP, 1996, BLOOD, V87, P132; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Downward J, 1996, CANCER SURV, V27, P87; Doyle SE, 1998, BLOOD, V92, P867; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Kasper B, 1999, INT J HEMATOL, V70, P241; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; Muto A, 1995, J ALLERGY CLIN IMMUN, V96, P1100, DOI 10.1016/S0091-6749(95)70195-8; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Porteu F, 1996, MOL CELL BIOL, V16, P2473; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; RONCO LV, 1994, J BIOL CHEM, V269, P277; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Silvennoinen O, 1997, APMIS, V105, P497, DOI 10.1111/j.1699-0463.1997.tb05047.x; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Ward AC, 1998, BIOCHEM BIOPH RES CO, V251, P117, DOI 10.1006/bbrc.1998.9441; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; WEISS M, 1993, BLOOD, V82, P3298; Wilks AF, 1996, CANCER SURV, V27, P139; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yoshimura A, 1998, Curr Opin Hematol, V5, P171, DOI 10.1097/00062752-199805000-00004	54	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3579	3591		10.1038/sj.onc.1205444	http://dx.doi.org/10.1038/sj.onc.1205444			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032860				2022-12-17	WOS:000175793700009
J	Appl, H; Klempnauer, KH				Appl, H; Klempnauer, KH			Targeted disruption of c-myb in the chicken pre B-cell line DT40	ONCOGENE			English	Article						c-myb; DT40 cells; homologous recombination; pre B-cell; Pdcd4	V-MYB; MIM-1 GENE; C/EBP-BETA; TRANSCRIPTIONAL ACTIVATION; SYNERGISTIC ACTIVATION; MYELOMONOCYTIC CELLS; PDCD4 GENE; NF-M; EXPRESSION; ONCOGENE	The c-myb proto-oncogene is highly expressed in a wide variety of immature hematopoietic cells and plays a key role in the development of the hematopoietic system. c-myb and its retroviral counterpart v-myb encode transcription factors which have been implicated in the regulation of certain target genes. Targeting of c-myb in mouse embryonic stem cells by homologous recombination has provided clear evidence that c-myb is necessary for the proper development of most myeloid lineages of the hematopoietic system as well as of T-lymphocytes. Here we have explored the function of c-myb in the B-lymphoid lineage. We have used the chicken DT40 cells, a pre B-cell line which shows extremely high efficiencies of homologous recombination, as a model system to disrupt c-myb. DT40 cells lacking a functional c-myb gene are viable and show only minor perturbations of their growth parameters, indicating that c-myb is not an essential gene in these cells. We have used the c-myb null DT40 cells to analyse the expression of genes which have been previously been identified as myb target genes. Neither c-myc nor bcl-2, two putative myb targets, showed altered expression in the cells lacking c-myb. However, expression of the Pdcd4 gene, a myb target gene originally identified in a myelomonocytic cell line expressing a conditional form of v-myb, was diminished in the absence of c-myb. The c-myb knock-out cells described here should provide a useful model system for the identification and characterization of c-myb target genes in B-lymphoid cells.	Westfal Wilhelms Univ, Inst Biochem, D-48143 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Westfal Wilhelms Univ, Inst Biochem, Wilhelm Klemm Str 2, D-48143 Munster, Germany.	klempna@uni-muenster.de						Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DESBIENS X, 1991, DEVELOPMENT, V111, P699; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PRESS RD, 1995, ONCOGENE, V11, P525; QUEVA C, 1992, DEVELOPMENT, V114, P125; Reizis B, 2001, J EXP MED, V194, P979, DOI 10.1084/jem.194.7.979; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Sitzmann J, 1995, ONCOGENE, V11, P2273; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Smith MR, 1997, J VIROL, V71, P6534, DOI 10.1128/JVI.71.9.6534-6540.1997; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wang QF, 2000, MOL CELL BIOL, V20, P9203, DOI 10.1128/MCB.20.24.9203-9211.2000; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	50	18	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3076	3081		10.1038/sj.onc.1205427	http://dx.doi.org/10.1038/sj.onc.1205427			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082539				2022-12-17	WOS:000175262700016
J	Chizhikov, V; Chikina, S; Gasparian, A; Zborovskaya, I; Steshina, E; Ungiadze, G; Samsonova, M; Chernyaev, A; Chuchalin, A; Tatosyan, A				Chizhikov, V; Chikina, S; Gasparian, A; Zborovskaya, I; Steshina, E; Ungiadze, G; Samsonova, M; Chernyaev, A; Chuchalin, A; Tatosyan, A			Molecular follow-up of preneoplastic lesions in bronchial epithelium of former Chernobyl clean-up workers	ONCOGENE			English	Article						lung cancer; preneoplastic lesions; radiation; smoking; loss of heterozygosity; FHIT expression	K-RAS GENES; LUNG-CANCER; SMOKING; P53; EXPOSURE; PCR	Ionizing radiation is a potent lung carcinogen, but the precise molecular damage associated with it is still unknown. In this study we investigated cancer-related molecular abnormalities including K-ras (codon 12) mutation, p16(INK4A) promoter hypermethylation and microsatellite alterations at seven chromosomal regions in successive biopsies obtained from former Chernobyl cleanup workers in comparison with smokers and nonsmokers who have never had radiation exposure. Our results indicate that prolonged persistence of inhaled radioactive particles is associated with appearance of allelic loss at 3p12, 3p14.2 (FHIT), 3p21, 3p22-24 (hMLH1) and 9p21 (p16(INK4A)) in bronchial epithelium of former Chernobyl clean-up workers. The prevalence of 3p14.2 allelic loss was associated with decreased expression of the FHIT mRNA in their bronchial epithelium in comparison with control group of smokers. During several years of our monitoring samples of epithelium were collected from the same area of bronchial tree. In epithelium exposed to carcinogens (tobacco smoke and/or radioactivity) the total number of molecular abnormalities was significantly higher in dysplasia and in morphologically normal foci progressed later to dysplasia than in these samples which never showed evidence of such progression. Our findings indicate that extensive cancer-related molecular abnormalities sequentially occur in radiation damaged bronchial epithelium of former Chernobyl clean-up workers.	RAMS, Canc Res Ctr, Inst Carcinogenesis, Moscow 117449, Russia; Inst Pulmonol, Moscow, Russia	Russian Academy of Medical Sciences	Tatosyan, A (corresponding author), RAMS, Canc Res Ctr, Inst Carcinogenesis, Kashirskoye Shosse 24, Moscow 117449, Russia.	tatosyan@space.ru	Chikina, Svetlana/GZH-0832-2022; Chikina, Svetlana Yu./P-5646-2018; Cucalin, Aleksandr/P-5678-2018	Chikina, Svetlana Yu./0000-0002-5536-9388; Chizhikov, Victor/0000-0003-2338-1267; Cucalin, Aleksandr/0000-0002-6808-5528				ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; AUERBACH O, 1961, NEW ENGL J MED, V265, P253, DOI 10.1056/NEJM196108102650601; Battey, 1986, BASIC METHODS MOL BI; Brambilla E, 1999, CLIN CANCER RES, V5, P243; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; Chizhikov V, 2001, MOL CARCINOGEN, V30, P151, DOI 10.1002/mc.1023; CHUCHALIN AG, 1995, STEM CELLS, V13, P276, DOI 10.1002/stem.5530130734; Chuchalin AG, 1997, SCHWEIZ MED WSCHR, V127, P165; Gealy R, 1999, CANCER EPIDEM BIOMAR, V8, P297; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Israel Yu.A., 1987, METEOROL J HYDROL, V2, P5; Ji L, 1999, CANCER RES, V59, P3333; JIANG W, 1989, ONCOGENE, V4, P923; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KAHN SM, 1991, ONCOGENE, V6, P1079; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Lam S, 1999, JNCI-J NATL CANCER I, V91, P691, DOI 10.1093/jnci/91.8.691; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LANG S, 1995, ENVIRON HEALTH PERSP, V103, P920, DOI 10.2307/3432738; Little JB, 1997, P NATL ACAD SCI USA, V94, P5996, DOI 10.1073/pnas.94.12.5996; LUNDGREN DL, 1982, RADIAT RES, V90, P374, DOI 10.2307/3575715; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; Pasanen M, 1995, ENVIRON RES, V70, P126, DOI 10.1006/enrs.1995.1057; SACCOMANNO G, 1974, CANCER-AM CANCER SOC, V33, P256, DOI 10.1002/1097-0142(197401)33:1<256::AID-CNCR2820330139>3.0.CO;2-G; Sanchez-Cespedes M, 2001, CANCER RES, V61, P2092; SANDERS CL, 1993, INT J RADIAT BIOL, V134, P29; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366	32	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2398	2405		10.1038/sj.onc.1205310	http://dx.doi.org/10.1038/sj.onc.1205310			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948423				2022-12-17	WOS:000174635600012
J	Perez-Mancera, PA; Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Flores, T; Battaner, E; Gutierrez-Adan, A; Pintado, B; Sanchez-Garcia, I				Perez-Mancera, PA; Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Flores, T; Battaner, E; Gutierrez-Adan, A; Pintado, B; Sanchez-Garcia, I			Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice	ONCOGENE			English	Article						chromosomal abnormality; malignant solid tumors; adipose tissue; cancer development	HUMAN MYELOID-LEUKEMIA; RNA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; MYXOID LIPOSARCOMA; FUS/TLS-CHOP; GENE; ERG; TRANSLOCATION; C/EBP; MALIGNANCIES	Fusion proteins created by chromosomal abnormalities are key components of mesenchymal cancer development. The most common chromosomal translocation in liposarcomas, t(12;16)(q13;p11), creates the FUS-CHOP fusion gene. In the past, we generated FUS-CHOP and CHOP transgenic mice and have shown that while FUS-CHOP transgenic develop liposarcomas, mice expressing CHOP, which lacks the FUS domain, display essentially normal white adipose tissue (WAT) development, suggesting that the FUS domain of FUS-CHOP plays a specific and critical role in the pathogenesis of liposarcoma. To test the significance of FUS and CHOP domain interactions within a living mouse, we generated mice expressing the FUS domain and crossed them with CHOP-transgenic mice to generate double-transgenic FUSxCHOP animals. Here we report that expression of the FUS domain restores liposarcoma development in CHOP-transgenic mice. Our results provide genetic evidence that FUS and CHOP domains function in trans for the mutual restoration of liposarcoma. These results identify a new mechanism of tumor-associated fusion genes and might have impact beyond myxoid liposarcoma.	Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Salamanca 37007, Spain; Univ Salamanca, Serv Anat Patol, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Campus Unamuno, Salamanca 37007, Spain.	isg@gugu.usal.es	Sanchez-Martin, Manuel/N-5327-2016; Gutierrez-Adan, Alfonso/A-1485-2014; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Pintado, Belen/N-3233-2014; Pérez-Losada, Jesús/A-5883-2019	Sanchez-Martin, Manuel/0000-0001-8370-1336; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; Pintado, Belen/0000-0002-8485-2520; Pérez-Losada, Jesús/0000-0003-2400-624X; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER; NCI NIH HHS [1 R01 CA79955-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHANG HR, 1989, CANCER, V64, P1514, DOI 10.1002/1097-0142(19891001)64:7<1514::AID-CNCR2820640726>3.0.CO;2-2; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KNIGHT JC, 1995, CANCER RES, V55, P24; MACK TM, 1995, CANCER-AM CANCER SOC, V75, P211, DOI 10.1002/1097-0142(19950101)75:1+<211::AID-CNCR2820751309>3.0.CO;2-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Perez-Losada J, 2000, ONCOGENE, V19, P6015, DOI 10.1038/sj.onc.1204018; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; PRASAD DDK, 1994, ONCOGENE, V9, P3717; PRICE BD, 1992, CANCER RES, V52, P3814; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	25	18	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1679	1684		10.1038/sj.onc.1205220	http://dx.doi.org/10.1038/sj.onc.1205220			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896599				2022-12-17	WOS:000174214200006
J	Suprynowicz, FA; Baege, A; Sunitha, I; Schlegel, R				Suprynowicz, FA; Baege, A; Sunitha, I; Schlegel, R			c-Src Activation by the E5 oncoprotein enables transformation independently of PDGF receptor activation	ONCOGENE			English	Article						ES oncoprotein; Src; papillomavirus; transformation	GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; FACTOR-BETA RECEPTOR; PROTEIN-TYROSINE KINASE; OPEN READING FRAME; BOVINE PAPILLOMAVIRUS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; BINDING; PHOSPHORYLATION	The E5 oncoprotein of bovine papillornavirus type I is a Golgi-resident, hydrophobic polypeptide that can transform immortalized fibroblasts by activating endogenous platelet-derived growth factor receptor P (PDGF-R). However, the existence of E5 mutants that dissociate transformation from PDGF-R activation implies that there are additional mechanism(s) by which E5 can transform cells. We now show that both wt E5, and transforming E5 mutants that are defective for PDGF-R activation, constitutively activate endogenous c-Src in NIH3T3 cell lines to levels normally associated with acute growth factor stimulation. The ubiquitous Src family protein tyrosine kinase (PTK) Fyn is not activated by these E5 constructs, nor are focal adhesion kinase and endogenous receptor PTKs for insulin, epidermal growth factor, basic fibroblast growth factor and insulin-like growth factor. We further demonstrate that transforming activity of the L26A E5 mutant, which is highly defective for PDGF-R activation, depends on its ability to activate Src. L26A E5 does not transform SYF cells that are deficient for Src, Fyn and Yes, unless Src expression is reconstituted, and does not transform NIH3T3 cells in which Src PTK activity is maintained at a basal level by means of kinase-defective K295R Src overexpression.	Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA	Georgetown University	Schlegel, R (corresponding author), Georgetown Univ, Med Ctr, Dept Pathol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	schleger@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA053371] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA53371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHEN EY, 1982, NATURE, V299, P529, DOI 10.1038/299529a0; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DiMaio D, 2000, CYTOKINE GROWTH F R, V11, P283, DOI 10.1016/S1359-6101(00)00012-5; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; Gazit A, 1996, BIOORGAN MED CHEM, V4, P1203, DOI 10.1016/0968-0896(96)00107-1; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KOVALENKO M, 1994, CANCER RES, V54, P6106; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; LANCASTER WD, 1982, MICROBIOL REV, V46, P191, DOI 10.1128/MMBR.46.2.191-207.1982; LIN PH, 1995, ONCOGENE, V10, P401; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MEISCHKE HRC, 1979, J GEN VIROL, V43, P473, DOI 10.1099/0022-1317-43-3-473; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SOLTOFF SP, 1992, COLD SPRING HARB SYM, V57, P75, DOI 10.1101/SQB.1992.057.01.010; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPARKOWSKI J, 1995, EMBO J, V14, P3055, DOI 10.1002/j.1460-2075.1995.tb07308.x; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; Suprynowicz FA, 2000, J BIOL CHEM, V275, P5111, DOI 10.1074/jbc.275.7.5111; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0	72	18	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1695	1706		10.1038/sj.onc.1205223	http://dx.doi.org/10.1038/sj.onc.1205223			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896601				2022-12-17	WOS:000174214200008
J	Honore, B; Baandrup, U; Nielsen, S; Vorum, H				Honore, B; Baandrup, U; Nielsen, S; Vorum, H			Endonuclein is a cell cycle regulated WD-repeat protein that is up-regulated in adenocarcinoma of the pancreas	ONCOGENE			English	Article						cell cycle regulated protein; nucleus, endoplasmic reticulum; signal transduction; chaperone activity	HUMAN CALUMENIN; CANCER; EXPRESSION; FAMILY; GENE; IDENTIFICATION; SECRETION; SURVIVAL; BINDING; MEMBERS	The transcript encoding endonuclein, the human homolog of yeast PWP1, was previously found up-regulated in pancreatic cancer tissue. By immunohistochemistry we detected a ubiquitous presence in several tissues examined: skin, liver, thyroid gland, heart muscle, neurons, kidney, bladder, pancreas, adrenal gland, ovary, uterus, testis and prostate gland. We especially noticed that normal pancreatic exocrine cells exhibited low protein levels while pancreatic adenocarcinoma cells revealed high levels. We found a heterogeneous subcellular distribution, especially with varying nuclear levels. In proliferating cells endonuclein protein expression and localization was cell cycle dependent, with increasing levels and nuclear focusing during the interphase toward mitosis. Ultrastructural analysis revealed ER and nuclear localization. Endonuclein contains five WD-repeats, indicating a putative role in crucial regulatory activities in the nucleus as well as in the ER.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Inst Anat, Dept Cell Biol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Pathol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University; Aarhus University	Honore, B (corresponding author), Aarhus Univ, Dept Med Biochem, Ole Worms Alle,Bldg 170, DK-8000 Aarhus C, Denmark.		Honoré, Bent/ABF-3650-2021	Honore, Bent/0000-0002-3459-7429				BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELIS JE, 1994, CELL BIOL LAB HDB, V1, P288; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; Coppola D, 2000, Cancer Control, V7, P421; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; Gress TM, 1996, ONCOGENE, V13, P1819; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Honore B, 1999, FEBS LETT, V456, P274, DOI 10.1016/S0014-5793(99)00911-4; HONORE B, 1995, J BIOL CHEM, V270, P28780; HONORE B, 1994, GENE, V151, P291, DOI 10.1016/0378-1119(94)90673-4; Kang SA, 1996, BRIT J PHARMACOL, V117, P1780, DOI 10.1111/j.1476-5381.1996.tb15354.x; Kore M, 1992, J CLIN INVEST, V90, P1352; Kornmann M, 1998, ONCOLOGY-BASEL, V55, P363, DOI 10.1159/000011879; LIU QY, 1995, ONCOGENE, V10, P619; MURR MM, 1994, CA-CANCER J CLIN, V44, P304, DOI 10.3322/canjclin.44.5.304; MYERS MH, 1989, CA-CANCER J CLIN, V39, P21, DOI 10.3322/canjclin.39.1.21; Naka T, 1998, INT J ONCOL, V12, P1111; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1993, NAT GENET, V5, P3, DOI 10.1038/ng0993-3; SIMON B, 1994, GASTROENTEROLOGY, V106, P1645, DOI 10.1016/0016-5085(94)90422-7; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; Vorum H, 1998, BBA-PROTEIN STRUCT M, V1386, P121, DOI 10.1016/S0167-4838(98)00089-2	27	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1123	1129		10.1038/sj.onc.1205186	http://dx.doi.org/10.1038/sj.onc.1205186			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850830				2022-12-17	WOS:000173580100016
J	de The, H; Chelbi-Alix, MK				de The, H; Chelbi-Alix, MK			APL, a model disease for cancer therapies?	ONCOGENE			English	Article						leukemia; PML/RAR alpha; differentiation; apoptosis; arsenic; retinoic acid	ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID; RAR-ALPHA; HISTONE DEACETYLASE; INTERACTING PROTEIN; NUCLEAR-BODIES; PML; APOPTOSIS; DAXX; NB4		Hop St Louis, CNRS UPR 9051, F-75475 Paris 10, France; Inst Andre Lwoff, CNRS UPR 9045, F-94801 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	de The, H (corresponding author), Hop St Louis, CNRS UPR 9051, 1 Ave C Vellefaux, F-75475 Paris 10, France.	dethe@jupiter.chu-stlouis.fr; mchelbi@infobiogen.fr						Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; de The G., 1960, B ASSOC FR ETUD CANC, V47, P570; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LANOTTE M, 1991, BLOOD, V77, P1080; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Quignon F, 1997, BBA-REV CANCER, V1333, pM53, DOI 10.1016/S0304-419X(97)00025-5; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; TERRIS B, 1995, CANCER RES, V55, P1590; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	26	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7136	7139		10.1038/sj.onc.1204851	http://dx.doi.org/10.1038/sj.onc.1204851			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704841				2022-12-17	WOS:000171891900001
J	Chaussade, L; Eymin, B; Brambilla, E; Gazzeri, S				Chaussade, L; Eymin, B; Brambilla, E; Gazzeri, S			Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status	ONCOGENE			English	Article						p(15INK4b); p16(INK4a); p14(ARF); expression; methylation; lung tumour	DEPENDENT KINASE INHIBITORS; CPG ISLAND METHYLATION; CELL-CYCLE ARREST; CDK INHIBITORS; BETA-TRANSCRIPT; P16(INK4) GENE; HUMAN CANCERS; TGF-BETA; INACTIVATION; SUPPRESSOR	The cell cycle inhibitor p15(INK4B) is frequently inactivated by homozygous deletions together with p16(INK4a)/14(ARF) in many tumour types. Although it is now well established that p16(INK4a) and p14(ARF) act as tumour suppressor genes, the role of p15(INK4b) remains to be well defined. In order to explore the possibility of a selective deregulation of p15(INK4b) in human lung carcinogenesis, we studied p15INK4b status in neuroendocrine (NE) lung tumours where homozygous deletions of the p16(INK4a)/p14(ARF) locus are rarely observed. Expressions of p15 and p15.5 protein isoforms were analysed in a series of eight control normal lung, 12 tumour-associated normal lung, five low grade and 15 high grade neuroendocrine (NE) lung tumours and relationship with a specific p15(INK4b) methylation status was studied. Using Western blot analysis, we showed that p15 and p15.5 isoforms displayed a high heterogeneous pattern of expression in both normal and tumour tissues. P15 and p15.5 expressions were correlated in control normal lung (P < 0.04) whereas they were not in tumours and associated normal lung. The level of p15.5 was significantly higher in associated normal lung and in tumours (P < 0.02 respectively), specially in low grade tumours (P < 0.01), than in control normal lung. Furthermore, p15.5 expression was more variable in tumours than in normal lung (P < 0.01) and in low grade than in high grade NE lung tumours (P < 0.02). Levels of p15 and p15.5 were distinct (up- or downregulated) from those observed in paired normal lung in 4/12 (33%) and 10/12 (83%) tumours respectively. Aberrant methylation at the 5 ' end of P15(INK4b) gene was observed in 15% of NE lung tumours using PCR-based assay, in a region proximal to the translation start where methylation did not occur in control and associated normal lung. However, no correlation could be assessed with protein status. MSP analysis of CpG islands proximal to the transcription start revealed methylation in all normal and tumour samples. No correlation was found between p15(INK4b) and p16(INK4a) or p14(ARF) status. These data suggest that complex deregulation of p15.5 is implicated in the carcinogenesis of human NE lung tumours independently of p16(INK4a) and p14(ARF) status.	Inst Albert Bonniot, INSERM EMI 9925, Grp Rech Canc Poumon, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM EMI 9925, Grp Rech Canc Poumon, F-38706 La Tronche, France.		Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; gazzeri, sylvie/M-1961-2013; Brambilla, Elisabeth MP/L-8796-2013; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810				Aggerholm A, 1999, CANCER RES, V59, P436; Anbazhagan R, 1999, CANCER RES, V59, P5119; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dosaka-Akita H, 2000, CANCER, V88, P550, DOI 10.1002/(SICI)1097-0142(20000201)88:3<550::AID-CNCR9>3.0.CO;2-D; Fuxe J, 2000, ONCOGENE, V19, P1724, DOI 10.1038/sj.onc.1203496; Gazzeri S, 1998, CANCER RES, V58, P3926; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; GLENDENING JM, 1995, CANCER RES, V55, P5531; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GrayBablin J, 1997, CANCER RES, V57, P604; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Iravani M, 1997, ONCOGENE, V15, P2609, DOI 10.1038/sj.onc.1201428; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; OKAMOTO A, 1995, CANCER RES, V55, P1448; Packenham JP, 1995, CLIN CANCER RES, V1, P687; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rusin MR, 1996, INT J CANCER, V65, P734, DOI 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, ONCOGENE, V11, P987; TRAVIS WD, 1999, EMBO J, V18, P4280; Tsubari M, 1997, CANCER RES, V57, P2966; WASHIMI O, 1995, CANCER RES, V55, P514; XIAO S, 1995, CANCER RES, V55, P2968; Yuan JP, 1999, J PATHOL, V189, P358	44	18	20	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6587	6596		10.1038/sj.onc.1204798	http://dx.doi.org/10.1038/sj.onc.1204798			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641784				2022-12-17	WOS:000171404200012
J	Miyaki, M; Iijima, T; Shiba, K; Aki, T; Kita, Y; Yasuno, M; Mori, T; Kuroki, T; Iwama, T				Miyaki, M; Iijima, T; Shiba, K; Aki, T; Kita, Y; Yasuno, M; Mori, T; Kuroki, T; Iwama, T			Alterations of repeated sequences in 5 ' upstream and coding regions in colorectal tumors from patients with hereditary nonpolyposis colorectal cancer and Turcot syndrome	ONCOGENE			English	Article						mutation; repeated sequence; 5 ' upstream region; HNPCC; Turcot; Dukes stage	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; MICROSATELLITE MUTATOR PHENOTYPE; COLON-CANCER; FRAMESHIFT MUTATIONS; BAX GENE; INSTABILITY; CASPASE-5; RECEPTOR; HOMOLOG	One of the characteristics of tumors from patients with germline mutations of DNA mismatch repair genes is instability at microsatellite regions (MSI). We analysed alterations at repeated sequences of coding regions, as well as those of 5' upstream regions, in 29 MSI-High colorectal tumors from patients with hereditary nonpolyposis colorectal cancer (HNPCC) and Turcot syndrome. We found that repeated sequences in 5' upstream regions were altered in these tumors, at considerable frequencies. The (A)(10) repeat in the promoter region (position - 178 similar to - 169) of the GAPDH gene was altered in 17% of the tumors. The (A)(10)(TA)(9) in the 5' upstream region (position -318 similar to -291) of the mitochondrial isoleucyl tRNA synthetase gene (IIeRS-A), coded in nuclear DNA, was altered in 59% of the tumors, whereas (A)(9) in the 5' upstream region (position -859 similar to -851) of cytoplasmic isoleucyl tRNA synthetase gene (IIeRS-B) was not altered. Alteration at repeated sequences in the coding regions were 72% at TGF beta RII(A)(10), 24% at IGFIIR(G)(8), 45% at BAX(G)(8), 55% at E2F4(CAG)(13), 66% at caspase-5 (A)(10), 31% at MBD4(A)(10), 55% at hMSH3(A)(8) and 34% at hMSH6(C)(8). The number of altered genes increased with the advancement of carcinoma according to Dukes categories: mean numbers of altered genes within these 10 genes were 2.6 for Dukes A, 4.7 for Dukes B and 7.8 for Dukes C. The mean number for adenomas was 2.0. These results suggest that the MSI phenotype also causes alteration of 5' upstream regions which may affect apoptosis and some mitochondrial functions in HNPCC and Turcot tumors, and that accumulation of altered genes with repeated sequences is associated with the progression of HNPCC and Turcot colorectal tumors.	Tokyo Metropolitan Inst Med Sci, Komagome Hosp, Bunkyo Ku, Tokyo 1138677, Japan; Tokyo Metropolitan Inst Med Sci, Dept Surg, Bunkyo Ku, Tokyo 1138677, Japan; Inst Canc Res, Tokyo 1708455, Japan; Yamaguchi Univ, Ube, Yamaguchi 7550805, Japan; Showa Univ, Inst Mol Oncol, Tokyo 1428666, Japan; Kyoundo Hosp, Sasaki Inst, Tokyo 1010062, Japan	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Japanese Foundation for Cancer Research; Yamaguchi University; Showa University	Miyaki, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Komagome Hosp, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.		Kuroki, Toshio/A-9500-2011; Shiba, Kiyotaka/I-9588-2014	Kuroki, Toshio/0000-0001-6369-4351; Shiba, Kiyotaka/0000-0001-6459-0204				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aki T, 1997, J BIOCHEM, V122, P271; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kamada S, 1997, CELL DEATH DIFFER, V4, P473, DOI 10.1038/sj.cdd.4400268; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.0.CO;2-5; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIYAKI M, 1995, J MOL MED-JMM, V73, P515; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Miyaki M, 1997, ONCOGENE, V15, P2877, DOI 10.1038/sj.onc.1201668; MIYASHITA T, 1995, CELL, V80, P293; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Schwartz S, 1999, CANCER RES, V59, P2995; SHIBA K, 1994, P NATL ACAD SCI USA, V91, P7435, DOI 10.1073/pnas.91.16.7435; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544	23	18	22	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5215	5218		10.1038/sj.onc.1204578	http://dx.doi.org/10.1038/sj.onc.1204578			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526511				2022-12-17	WOS:000170464000016
J	Ndisang, D; Budhram-Mahadeo, V; Pedley, B; Latchman, DS				Ndisang, D; Budhram-Mahadeo, V; Pedley, B; Latchman, DS			The Brn-3a transcription factor plays a key role in regulating the growth of cervical cancer cells in vivo	ONCOGENE			English	Article						cervical cancer; human papilloma virus; Brn-3a transcription factor; tumour growth	NEURONAL CELLS; POU-DOMAIN; INTRAEPITHELIAL NEOPLASIA; PAPILLOMAVIRUS INFECTION; GENE-EXPRESSION; DNA; POLYMORPHISM; CARCINOMA; PROMOTER; DISTINCT	The cellular Brn-3a transcription factor is known to activate transcription of the genes encoding the human papilloma virus E6 and E7 proteins and is over-expressed in women with cervical neoplasia. We show that cervical cell hues with reduced Brn-3a expression show a greatly reduced ability to form tumours in nude mice compared to control cells and also show reduced expression of the HPV E6 and cellular Bcl-2 oncogenes. These effects are also observed in cervical cells over-expressing the related Brn-3b factor, which is known to antagonize activation of HPV gene expression by Brn-3a. These results demonstrate, for the first time, that inhibition of Brn-3a expression or enhanced Brn-3b expression can inhibit cervical cell-derived tumour growth in vivo as well as in vitro. Hence they establish Brn-3a as a key factor in cervical tumorigenesis and as a potential therapeutic target in human cervical neoplasia.	Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; UCL Royal Free & Univ Coll Med Sch, Dept Oncol, London NW3, England	University of London; University College London; University of London; University College London; UCL Medical School	Latchman, DS (corresponding author), Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.							BURGHARDT E, 1984, CLIN OBSTET GYNAECOL, V11, P239; COX MF, 1986, LANCET, V2, P157; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MEANWELL CA, 1987, LANCET, V1, P703; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Ndisang D, 2000, CLIN SCI, V98, P601, DOI 10.1042/CS19990350; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; van Duin M, 2000, J GEN VIROL, V81, P317, DOI 10.1099/0022-1317-81-2-317; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8	18	18	20	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4899	4903		10.1038/sj.onc.1204634	http://dx.doi.org/10.1038/sj.onc.1204634			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521202				2022-12-17	WOS:000170271800015
J	Muller, C; Monferran, S; Gamp, AC; Calsou, P; Salles, B				Muller, C; Monferran, S; Gamp, AC; Calsou, P; Salles, B			Inhibition of Ku heterodimer DNA end binding activity during granulocytic differentiation of human promyelocytic cell lines	ONCOGENE			English	Article						double strand breaks; ionizing radiation; DNA repair; non homologous; end joining-differentiation	DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; POLY(ADP-RIBOSE) POLYMERASE; CATALYTIC SUBUNIT; LEUKEMIA-CELLS; HL-60; AUTOANTIGEN; APOPTOSIS; RECOMBINATION; SENSITIVITY	The heterodimeric Ku protein (composed of the Ku 86 and Ku 70 sub-units) is a nuclear protein which binds to DNA termini without sequence specificity, Ku is the DNA-targeting component of the large catalytic sub-unit of the DNA-dependent protein kinase complex that is required for the repair of DNA double-strand breaks in mammalian cells. We studied the expression and function of Ku/DNA-PK during granulocytic differentiation of two human promyelocytic cell lines, HL60 and NB4, a process associated to decreased radiation resistance. After 3 days exposure to differentiating agents (either all-trans-retinoic acid or DMSO), Ku binding to double stranded (ds)-DNA ends declined dramatically whereas Ku protein levels remain unchanged, The nuclear, but not cytoplasmic, fraction of differentiated HL60 cells extracts exhibited a heat-sensitive inhibitory activity towards DNA binding of recombinant Ku heterodimer, We further demonstrate that immunoprecipitation of Ku is impaired in extracts from differentiated cells by using two antibodies that recognize epitopes within the C-terminus DNA binding domains of Ku 70 and Ku 86 proteins, These results favor the hypothesis of a protein interacting with Ku that would prevent DNA binding of heterodimerized Ku protein by steric hindrance.	Inst Pharmacol & Biol Struct, CNRS, UPR 9062, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Salles, B (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UPR 9062, 205 Route Narbonne, F-31077 Toulouse, France.		Monferran, Sylvie/M-3445-2014; MULLER, Catherine/M-2185-2018; MULLER, Catherine/E-2060-2011; salles, bernard/B-8531-2008; calsou, patrick/AAB-5123-2020	Calsou, Patrick/0000-0001-7951-9806; Monferran, Sylvie/0000-0002-7062-7437				ANDERSON CW, 1994, J PROTEIN CHEM, V13, P500; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; BHATIA M, 1995, BIOCHEM J, V308, P131, DOI 10.1042/bj3080131; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Burgman P, 1997, CANCER RES, V57, P2847; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; COLLINS SJ, 1987, BLOOD, V70, P1233; Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084; FALZON M, 1993, J BIOL CHEM, V268, P10546; FARNAZEH F, 1987, NUCLEIC ACIDS RES, V15, P3493; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; GALLAGHER R, 1979, BLOOD, V54, P713; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; ISLAS AL, 1995, CANCER RES, V55, P336; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; KANAI M, 1982, BIOCHEM BIOPH RES CO, V105, P404, DOI 10.1016/0006-291X(82)91448-6; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; LANOTTE M, 1991, BLOOD, V77, P1080; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; McConnell KR, 1997, J IMMUNOL, V158, P2083; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; MINORI T, 1986, J BIOL CHEM, V261, P10375; Morio T, 1999, IMMUNITY, V11, P339, DOI 10.1016/S1074-7613(00)80109-0; Muller C, 1998, ONCOGENE, V16, P1553, DOI 10.1038/sj.onc.1201676; Muller C, 1999, BIOCHIMIE, V81, P117, DOI 10.1016/S0300-9084(99)80044-3; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; Muller C, 1997, ONCOGENE, V15, P2343, DOI 10.1038/sj.onc.1201402; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PLOEMACHER R, 1992, INT J RADIAT BIOL, V61, P488; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Romero F, 1996, MOL CELL BIOL, V16, P37; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Tai YT, 2000, J IMMUNOL, V165, P6347, DOI 10.4049/jimmunol.165.11.6347; TOFILON PJ, 1988, EXP CELL RES, V174, P502, DOI 10.1016/0014-4827(88)90319-9; Vral A, 2001, INT J RADIAT BIOL, V77, P329, DOI 10.1080/0955300001004237; WAGEMAKER G, 1995, STEM CELLS, V13, P257, DOI 10.1002/stem.5530130731; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; WANG JS, 1994, J CELL SCI, V107, P3223; WHEELER KT, 1983, RADIAT ENVIRON BIOPH, V22, P3, DOI 10.1007/BF01323757; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	63	18	18	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4373	4382		10.1038/sj.onc.1204571	http://dx.doi.org/10.1038/sj.onc.1204571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466618				2022-12-17	WOS:000169912600011
J	Yamato, K; Hashimoto, S; Imamura, T; Uchida, H; Okahashi, N; Koseki, T; Ishisaki, A; Kizaki, M; Miyazono, K; Ikeda, Y; Nishihara, T				Yamato, K; Hashimoto, S; Imamura, T; Uchida, H; Okahashi, N; Koseki, T; Ishisaki, A; Kizaki, M; Miyazono, K; Ikeda, Y; Nishihara, T			Activation of the p21(CIP1/WAF1) promoter by bone morphogenetic protein-2 in mouse B lineage cells	ONCOGENE			English	Article						BMP; p21(CIP1/WAF1); transcription; promoter; Smad	GROWTH-FACTOR-BETA; SMAD-BINDING-ELEMENT; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL-ANALYSIS; INHIBITOR P21; DNA-DAMAGE; APOPTOSIS; ARREST; DIFFERENTIATION	BMPs exert a negative growth effect on various types of cells. We have previously reported that BMP-2 inhibited the growth of HS-72 mouse hybridoma cells by inducing p21(CIP1/WAF1) expression. In the present study, we demonstrated that BMP-2 activated the mouse p21(CIP1/WAF1) promoter in MS-72 cells, and that a 29-base pair (b) region of the promoter (-1928/-1900 relative to the TATA box), conserved between mice and humans, was responsive to BMP-2 as well as expression of Smad1, Smad4, and constitutively active mutants of BMP type I receptors, Furthermore, an oligonucleotide containing the 29-b region was found to be associated with Smad4 and phosphorylated Smad1 in the nuclear extract of BMP-2-stimulated HS-72 cells, These results suggested that BMP-2 might activate p21(CIP1/WAF1) transcription by inducing a binding of Smad4 and Smad1 to the 29-b region in HS-72 cells.	Tokyo Med & Dent Univ, Grad Sch, Div Oral Hlth Sci, Sect Mol Cellular Oncol & Microbiol,Bunkyo Ku, Tokyo 1138549, Japan; Natl Inst Infect Dis, Dept Oral Sci, Tokyo 1628640, Japan; JFCR, Inst Canc, Dept Biochem, Tokyo 1708455, Japan; Keio Univ, Sch Med, Div Hematol, Tokyo 1608582, Japan; Natl Inst Biosci & Human Technol, Biosignaling Dept, Tsukuba, Ibaraki 3058566, Japan; Kyushu Dent Coll, Dept Oral Microbiol, Fukuoka 8038580, Japan	Tokyo Medical & Dental University (TMDU); National Institute of Infectious Diseases (NIID); Japanese Foundation for Cancer Research; Keio University; National Institute of Advanced Industrial Science & Technology (AIST); Kyushu Dental University	Yamato, K (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Div Oral Hlth Sci, Sect Mol Cellular Oncol & Microbiol,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.		okahashi, nobuo/A-4032-2010	okahashi, nobuo/0000-0002-8045-7021; Ishisaki, Akira/0000-0001-6704-4436				Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Jernvall J, 1998, DEVELOPMENT, V125, P161; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Massague J, 2000, GENE DEV, V14, P627; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NISHIHARA T, 1995, J INTERF CYTOK RES, V15, P509, DOI 10.1089/jir.1995.15.509; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Tada K, 1999, GENES CELLS, V4, P731, DOI 10.1046/j.1365-2443.1999.00293.x; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yamato K, 2000, EXP CELL RES, V257, P198, DOI 10.1006/excr.2000.4876; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	41	18	18	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4383	4392		10.1038/sj.onc.1204572	http://dx.doi.org/10.1038/sj.onc.1204572			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466619				2022-12-17	WOS:000169912600012
J	Sansom, OJ; Toft, NJ; Winton, DJ; Clarke, AR				Sansom, OJ; Toft, NJ; Winton, DJ; Clarke, AR			Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner	ONCOGENE			English	Article						mismatch repair; apoptosis; mutation; heterozygosity; cisplatin; alkylation	DNA MISMATCH REPAIR; COLORECTAL-CANCER; MSH2-DEFICIENT MICE; DRUG-RESISTANCE; YEAST STRAINS; TUMOR-CELLS; MLH1; P53; HETEROZYGOSITY; PHENOTYPES	Mice deficient for the mismatch repair (MMR) gene Msh2 show accelerated tumourigenesis and a reduced apoptotic response to DNA damage of methylation type, Here we examine the effect of mutation for Msh2 on in vivo mutation frequencies in the intestine as determined by loss of function at the Dolichos biflorus (Dlb-1) locus. Spontaneous mutation frequencies were scored in cohorts of ageing mice either wild type or mutant for Msh2. In mice less than 1 year old, mutation frequencies were only elevated in Msh2 null mice. However, beyond this age heterozygous Msh2 mice showed significantly higher mutation frequencies than controls. These findings implicate a gene dose dependent requirement for Msh2 in mutation suppression and prompted an analysis of young Msh2 mutants following exposure to DNA damage. Following exposure to N-methyl-N ' -nitro-N-nitrosoguanidine (MNNG), Msh2 deficient mice show a reduced apoptotic response and an increase in mutation frequency. Heterozygotes did not differ from controls. Following exposure to cisplatin, no significant elevation was seen in mutation frequencies, even within homozygotes. This is particularly surprising given the association between cisplatin resistance and MMR deficiency, These findings therefore demonstrate a complex reliance upon functional Msh2 in mutation surveillance. We have identified three separate scenarios. First, where retention of both Msh2 alleles ol er an extended period of time appears critical to the suppression of spontaneous mutation; second, 3 weeks following exposure to MNNG, where only complete loss of Msh2 results in elevated mutation; and finally following cisplatin exposure, where induced levels of mutation are independent of Msh2 status.	Cardiff Univ, Sch Biosci, Cardiff C10 3US, S Glam, Wales; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Cambridge, Addenbrookes Hosp, Canc Res Campaign, Human Genet Res Grp, Cambridge CB2 2QQ, England	Cardiff University; University of Edinburgh; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; CRUK Cambridge Institute; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, POB 911, Cardiff C10 3US, S Glam, Wales.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X				Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; de Wind N, 1998, CANCER RES, V58, P248; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drotschmann K, 1999, P NATL ACAD SCI USA, V96, P2970, DOI 10.1073/pnas.96.6.2970; Drotschmann K, 2000, TOXICOL LETT, V112, P239, DOI 10.1016/S0378-4274(99)00276-3; Fink D, 1998, CLIN CANCER RES, V4, P1; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Reitmair AH, 1996, CANCER RES, V56, P3842; Reitmair AH, 1997, CANCER RES, V57, P3765; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Shcherbakova PV, 1999, MOL CELL BIOL, V19, P3177; SHOEMAKER AR, 1995, CANCER RES, V55, P4479; STRATHDEE G, 2001, IN PRESS ONCOGENE; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Wheeler JMD, 2000, GUT, V47, P148, DOI 10.1136/gut.47.1.148; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0	24	18	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3580	3584		10.1038/sj.onc.1204449	http://dx.doi.org/10.1038/sj.onc.1204449			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429706				2022-12-17	WOS:000169478300015
J	Nagasawa, M; Gelfand, EW; Lucas, JJ				Nagasawa, M; Gelfand, EW; Lucas, JJ			Accumulation of high levels of the p53 and p130 growth-suppressing proteins in cell lines stably over-expressing cyclin-dependent kinase 6 (cdk6)	ONCOGENE			English	Article						cyclin-dependent kinase 6; growth control; p53 protein; p130 protein	CDK-ACTIVATING KINASE; DIFFERENTIAL REGULATION; RETINOBLASTOMA-PROTEIN; G1 PHASE; PHOSPHORYLATION; PROGRESSION; POLYMERASE; IDENTIFICATION; MECHANISMS; INHIBITION	Cyclin-dependent kinase 6(cdk6) is present in randomly proliferating cultures of 3T3 cells but has little detectable enzymatic activity, Significant activity is detected only during a short period in early G1 phase. To examine the possible functions of cdk6 in 3T3 cells, lines stably over-expressing cdk6 were constructed and compared to normal 3T3 cells or cell lines with reduced cdk6 levels due to expression of a dominant-negative form of the protein, Over-expression of cdk6 in cells, which led to high levels of activity even in proliferating cultures, had dramatic effects, Cell lines stably over-expressing wild-type cdk6 had a markedly reduced growth rate compared to parental 3T3 cells or lines expressing a dominant-negative form of cdk6. They also over-produced the p53 and p130 proteins and had increased sensitivity to UV-irradiation. Irradiation resulted in accumulation of the Bas protein and rapid cell death, Levels of p53 and p130 proteins were downregulated and the growth rate of the cells was increased by introduction of the dominant-negative form of cdk6 into cells over-expressing cdk6, indicating that cdk6 is involved in the overproduction of p53 and p130. The results suggest that cdk6, through regulation of growth suppressing molecules, may play a role in halting cellular growth when proliferation is inappropriate. Oncogene, (2001) 20, 2889-2899.	Natl Jewish Med& Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	National Jewish Health	Lucas, JJ (corresponding author), Natl Jewish Med& Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.		Nagasawa, Masayuki/CAI-8101-2022; Nagasawa, Masayuki/AAX-1734-2020	Nagasawa, Masayuki/0000-0002-8085-4940	NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042246, R01AI042246] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline; NHLBI NIH HHS [HL-36577] Funding Source: Medline; NIAID NIH HHS [AI-42246] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; BATES S, 1994, ONCOGENE, V9, P71; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; ELDIERY WS, 1993, CELL, V75, P917; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Howard CM, 2000, CANCER RES, V60, P2737; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LeCouter JE, 1996, ONCOGENE, V12, P1433; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; LUCAS JJ, 1995, BLOOD, V86, P2268, DOI 10.1182/blood.V86.6.2268.bloodjournal8662268; LUCAS JJ, 1995, J CELL PHYSIOL, V165, P406, DOI 10.1002/jcp.1041650222; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIYASHITA T, 1995, CELL, V80, P293; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nagasawa M, 1997, J IMMUNOL, V158, P5146; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Ojala PM, 1999, CANCER RES, V59, P4984; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PINES J, 1990, New Biologist, V2, P389; PINES J, 1994, SEMIN CELL BIOL, V5, P339; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Rickert P, 1996, ONCOGENE, V12, P2631; Sergere JC, 2000, BIOCHEM BIOPH RES CO, V276, P271, DOI 10.1006/bbrc.2000.3395; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SZEPESI A, 1994, BLOOD, V84, P3413; Tang D, 1996, Prog Cell Cycle Res, V2, P205; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; TERADA N, 1991, J IMMUNOL, V147, P698; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	76	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2889	2899		10.1038/sj.onc.1204396	http://dx.doi.org/10.1038/sj.onc.1204396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420701				2022-12-17	WOS:000168901800004
J	Makino, K; Yu, DH; Hung, MC				Makino, K; Yu, DH; Hung, MC			Transcriptional upregulation and activation of p55Cdc via p34(cdc2) in Taxol-induced apoptosis	ONCOGENE			English	Article						cDNA array; Taxol; p55Cdc; p34(cdc2); apoptosis	GENE-EXPRESSION PATTERNS; DNA MICROARRAY; MITOTIC BLOCK; MYELOID CELLS; KINASE; PROTEIN; PHOSPHORYLATION; OVEREXPRESSION; MECHANISM; COMPLEX	Paclitaxel (Taxol) is a potent and highly effective antineoplastic agent for the treatment of advanced, drug-refractory, metastatic breast cancers. Taxol not only induces tubulin polymerization, stabilizes microtubules, blocks cell cycle progression, and induces apoptosis, but it also alters gene expression. Here, we have identified that Taxol can upregulate expression of the gene encoding the cell cycle protein p55Cdc by using cDNA array technique. Taxol induced p55Cdc mRNA expression through activation of the p55Cdc promoter, which led to increase p55Cdc protein expression. Taxol also activated p55Cdc-associated kinase, In addition, overexpression of the p55Cdc gene resulted in cell death in both HeLa cells and NIH3T3 cells in a dose-dependent manner. A dominant-negative mutant of p34(cdc2) blocked Taxol-induced p55Cdc activation and inhibited p55Cdc-induced and Taxol-induced cell death. Our data suggest that transcriptional upregulation of p55Cdc and activation of p55Cdc by Taxol-mediated p34(cdc2) activation play a critical role in Taxol-induced cell death.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [P50CA083639, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [CA58880, P50 CA83639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGDAN C, 1992, J LEUKOCYTE BIOL, V52, P119, DOI 10.1002/jlb.52.1.119; CHOI WJ, 1990, BIOCHEM BIOPH RES CO, V172, P1324, DOI 10.1016/0006-291X(90)91594-I; DeRisi J, 1996, NAT GENET, V14, P457; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kao CT, 1996, ONCOGENE, V13, P1221; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; KUMAR N, 1981, J BIOL CHEM, V256, P435; Lin M, 1998, EXP HEMATOL, V26, P1000; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V260, P193, DOI 10.1006/bbrc.1999.0884; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Weinstein J, 1998, MOL GENET METAB, V64, P52, DOI 10.1006/mgme.1998.2698; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359	29	18	21	2	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2537	2543		10.1038/sj.onc.1204366	http://dx.doi.org/10.1038/sj.onc.1204366			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420663	Bronze			2022-12-17	WOS:000168652500004
J	Suen, TC; Goss, PE				Suen, TC; Goss, PE			Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene	ONCOGENE			English	Article						BRCA1; breast cancer; transcriptional regulation; intron; repressor	SPORADIC BREAST-CANCER; RNA-POLYMERASE-II; OVARIAN-CANCER; CELL-CYCLE; MESSENGER-RNA; NUCLEAR PHOSPHOPROTEIN; GROWTH-RETARDATION; SOMATIC MUTATIONS; EPITHELIAL-CELLS; PROMOTER REGION	Loss or lowered expression of BRCA1 in non-familial breast cancer has been shown in several recent studies. Understanding how BRCA1 expression is regulated should provide new insights into the role of BRCA1 in sporadic breast cancer. We have recently identified a critical 18-base pair (bp) DNA element within the minimal BRCA1 promoter whereupon the formation of a specific protein-DNA complex and transcription of BRCA1 is dependent. We now report a non tissue-specific transcriptional repressor activity, located more than 500 bp into the first intron of BRCA1. Progressive deletions from the 3'-end of intron I and reporter gene assays localized the repressor activity to an 83-bp region. Electrophoretic mobility shift assays with this 83 bp DNA and various sub-fragments of it showed binding of nuclear proteins to a 36 bp BstNI-BseRI fragment. Functional transcriptional repression by this 36 bp DNA could be conferred on a heterologous thymidine kinase promoter. Analysis of multiple reporter gene constructs containing the BRCA1 genomic region driving transcription in both directions suggests that the putative negative regulatory element functions to block transcription only in the BRCA1 direction, although the promoter is shared by the divergently transcribed NBR2 gene.	Toronto Hosp, Oncol Res Labs, Breast Canc Prevent Program, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Dept Med Oncol, Breast Grp, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Goss, PE (corresponding author), Toronto Hosp, Oncol Res Labs, Breast Canc Prevent Program, Toronto, ON M5G 2M9, Canada.							Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Berchuck A, 1998, CLIN CANCER RES, V4, P2433; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen YM, 1996, CANCER RES, V56, P3168; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobrovic A, 1997, CANCER RES, V57, P3347; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Husain A, 1998, CANCER RES, V58, P1120; Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rao VN, 1996, ONCOGENE, V12, P523; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; Suen TC, 2000, J BIOL CHEM, V275, P6600, DOI 10.1074/jbc.275.9.6600; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; van der Looij M, 2000, GENE CHROMOSOME CANC, V27, P295, DOI 10.1002/(SICI)1098-2264(200003)27:3<295::AID-GCC10>3.0.CO;2-F; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	64	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					440	450		10.1038/sj.onc.1204078	http://dx.doi.org/10.1038/sj.onc.1204078			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313975				2022-12-17	WOS:000166562500004
J	Lecureur, V; Thottassery, JV; Sun, D; Schuetz, EG; Lahti, J; Zambetti, GP; Schuetz, JD				Lecureur, V; Thottassery, JV; Sun, D; Schuetz, EG; Lahti, J; Zambetti, GP; Schuetz, JD			Mdr1b facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo	ONCOGENE			English	Article						apoptosis; MDR; diethylnitrosamine	WILD-TYPE P53; RESISTANCE GENE-EXPRESSION; DNA-BINDING DOMAIN; RAT HEPATOMA-CELLS; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; LIVER CELLS; APOPTOSIS; PROTEIN; INDUCTION	The mdr1b gene is thought to be a "stress-responsive" gene, however it is unknown if this gene is regulated by p53 in the whole animal. Moreover, it is unknown if overexpression of mdr1b affects cell survival. The dependence of mdr1b upon p53 for upregulation was evaluated in p53 knockout mice. Wild-type (wt) or p53-/- mice were treated singly or in combination with gamma irradiation (IR) and/or the potent DNA damaging agent, diethylnitrosoamine (DEN), Both IR and DEN induced mdr1b in wild-type animals, but not in the p53-/- mice. IR also upregulated endogenous mdr lb in the H35 liver cell line, and the mdr lb promoter was activated by IR and activation correlated with p53 levels; moreover activation required an intact p53 binding site. Colony survival studies revealed that co-transfection of both mdr1b and p53 dramatically reduced colony numbers compared to cells transfected with either p53 or mdr1b alone and cells microinjected with both mdr1b and p53 had a more dramatic loss in viability compared to cells injected with either expression vector alone. Further studies using acridine orange and ethidium bromide to measure apoptosis revealed that mdr1b caused apoptosis and this was enhanced by p53, however the increased apoptosis required a functional p53 transactivation domain. These studies indicate that mdr1b is a downstream target of p53 in the whole animal and expression of mdr1b facilitates p53-mediated cell death.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.		Zambetti, Gerard/N-8093-2018; Schuetz, John D/N-2692-2018; Schuetz, Erin/N-8087-2018; LECUREUR, Valérie/J-9095-2015	Zambetti, Gerard/0000-0002-0929-5007; 	NCI NIH HHS [CA63203] Funding Source: Medline; NIEHS NIH HHS [ES08658, ES05851] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008658, R29ES005851, R01ES005851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bond TD, 1998, J PHYSIOL-LONDON, V508, P333, DOI 10.1111/j.1469-7793.1998.333bq.x; Chin LS, 1997, J NEUROSCI RES, V48, P122, DOI 10.1002/(SICI)1097-4547(19970415)48:2<122::AID-JNR4>3.0.CO;2-E; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DMITRIEVA N, 2000, IN PRESS J BIOL CHEM; Fardel O, 1998, BIOCHEM BIOPH RES CO, V245, P85, DOI 10.1006/bbrc.1998.8388; Furuya KN, 1997, CANCER RES, V57, P3708; Furuya KN, 1997, J BIOL CHEM, V272, P11518; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Kojima H, 1998, J BIOL CHEM, V273, P16647, DOI 10.1074/jbc.273.27.16647; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN J, 1995, GENE DEV, V8, P1235; LOTHSTEIN L, 1989, J BIOL CHEM, V264, P16054; MacCallum DE, 1996, ONCOGENE, V13, P2575; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Ralhan R, 1999, INT J CANCER, V84, P80, DOI 10.1002/(SICI)1097-0215(19990219)84:1<80::AID-IJC15>3.0.CO;2-G; Rasola A, 1999, FASEB J, V13, P1711, DOI 10.1096/fasebj.13.13.1711; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; Roemer K, 1996, ONCOGENE, V12, P2069; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHINKEL AH, 1995, EUR J CANCER, V31A, P1295, DOI 10.1016/0959-8049(95)00130-B; Schrenk D, 1996, BIOCHEM PHARMACOL, V52, P1453, DOI 10.1016/S0006-2952(96)00512-6; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; SINGH J, 1991, MUTAGENESIS, V6, P117, DOI 10.1093/mutage/6.2.117; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; SPECTOR DL, 1998, CELLS CULTURE BIOCH; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; Valverde MA, 1996, EMBO J, V15, P4460, DOI 10.1002/j.1460-2075.1996.tb00823.x; Weisburg JH, 1999, J BIOL CHEM, V274, P10877, DOI 10.1074/jbc.274.16.10877; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhou G, 1998, J BIOL CHEM, V273, P15387, DOI 10.1074/jbc.273.25.15387; Ziemann C, 1999, CARCINOGENESIS, V20, P407, DOI 10.1093/carcin/20.3.407	46	18	18	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					303	313		10.1038/sj.onc.1204065	http://dx.doi.org/10.1038/sj.onc.1204065			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313959				2022-12-17	WOS:000166411000004
J	Lu, ML; Arrick, BA				Lu, ML; Arrick, BA			Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms	ONCOGENE			English	Article						BRCA1; transcriptional activation; p21; alternative splicing	SPORADIC BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; RING FINGER; MUTATIONS; PROTEIN; LOCALIZATION; EXPRESSION; INTERACT; GROWTH; CYCLE	We have evaluated the transcriptional activation of a human p21 promoter reporter construct by transfection of BRCA1 expression constructs into tumorigenic and nontumorigenic human breast cell lines. Two cell lines with wildtype p53 (MCF-7 and MCF10A) demonstrated: transcriptional activation of the p21 promoter by full-length BRCA1 (BRCA1(L)) as well as by two splice variants that lack most of exon 11 (BRCA1(S) and BRCA1(S-9,10)). In contrast, two cell lines with mutant p53 (MDA-231 and HCC1937) were inactive. Co-transfection of BRCA1L with BRCA1(S) or BRCA1(S-9,10) exhibited synergistic p21 promoter activation, due to augmented expression of the cytomegalovirus promoter-based BRCA1 expression constructs. We examined the transcriptional activity of two known sequence alterations in BRCA1, one that results in a carboxy-terminal truncation of BRCA1 and is clearly pathogenic, and the other a missense mutation that is suspected of predisposing to cancer. Although both mutations have been shown to be defective in some assays of transactivation, we observed both mutations to be fully active in activation of the p21 promoter when incorporated in the full-length BRCA1(L). In contrast, these mutations rendered BRCA1(S) inactive. These observations indicate that such transcriptional assays cannot serve as the basis for a functional appraisal of BRCA1 sequence alterations encountered in the course of genetic testing.	Dartmouth Med Sch, Dept Med, Hanover, NH 03755 USA	Dartmouth College	Arrick, BA (corresponding author), Dartmouth Med Sch, Dept Med, Kellogg Box 0128, Hanover, NH 03755 USA.				NCI NIH HHS [R01 CA-77772] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077772] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Frank TS, 1998, J CLIN ONCOL, V16, P2417, DOI 10.1200/JCO.1998.16.7.2417; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Hayes F, 2000, CANCER RES, V60, P2411; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Klemp J, 2000, EUR J CANCER, V36, P1209, DOI 10.1016/S0959-8049(00)00112-X; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lu ML, 1996, CANCER RES, V56, P4578; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.0.CO;2-3; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.3.CO;2-8; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wilson E.O., 1997, BIODIVERSITY, P1; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	33	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6351	6360		10.1038/sj.onc.1204025	http://dx.doi.org/10.1038/sj.onc.1204025			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175350	Bronze			2022-12-17	WOS:000166210500019
J	Baeckstrom, D; Lu, PJ; Taylor-Papadimitriou, J				Baeckstrom, D; Lu, PJ; Taylor-Papadimitriou, J			Activation of the alpha(2)beta(1) integrin prevents c-erbB2-induced scattering and apoptosis of human mammary epithelial cells in collagen	ONCOGENE			English	Article						epithelial-mesenchymal conversion; E-cadherin; heregulin; morphogenesis; anchorage-independent growth	PHOSPHOINOSITIDE 3-OH KINASE; EPIDERMAL GROWTH-FACTOR; EXTRACELLULAR-MATRIX; TYROSINE KINASE; CARCINOMA-CELLS; ERBB RECEPTORS; BREAST-CANCER; TUMOR-CELLS; EXPRESSION; ADHESION	Constitutive overexpression of C-erbB2 in the mammary epithelial cell line MTSV1-7 has been shown to result in epithelial-mesenchymal conversion, anchorage-independent growth and loss of organized morphogenesis in collagen. To elucidate the events leading to this drastic change, MTSV1-7 cells and its subclone HB2 (which shows a more strictly epithelial phenotype) were transfected with the hybrid trk-neu receptor consisting of the extracellular domain of the trkA nerve growth factor (NGF) receptor and the transmembrane and cytoplasmic domains of c-erbB2 (neu), In cells expressing this construct, c-erbB2 homodimerization can be mimicked by addition of NGF, In trk-neu transfectants of HB2 cells, modest expression led to increased cell proliferation upon NGF treatment. When clones with higher expression levels were grown in collagen, NGF instead induced cell scattering, diminished viability and dramatically increased apoptosis, Interestingly, both the dissociation of colonies and loss of cell viability could be completely reversed by treatment of the cells with antibodies that activate the adhesive capacity of the alpha(2)beta(1) integrin, Long-term NGF treatment of high-expressing transfectants generated fibroblastic clones displaying a reduced expression of integrin alpha(2) and E-cadherin, and extensive apoptosis in collagen. These results, which indicate that strong c-erbB2 signalling may lead to downregulation and/or inactivation of the alpha(2)beta(1) integrin, promoting apoptosis in collagen, provide one possible explanation to the increased apoptosis frequently seen in early tumour development.	Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden; Guys Hosp, Imperial Canc Res Fund, Breast Canc Biol Lab, London SE1 9RT, England	University of Gothenburg; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust	Baeckstrom, D (corresponding author), Univ Gothenburg, Dept Biochem Med, Box 440, SE-40530 Gothenburg, Sweden.							Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Alford D, 1998, J CELL SCI, V111, P521; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Baasner S, 1996, ONCOGENE, V13, P901; Baeckstrom D, 2000, INT J ONCOL, V16, P1081; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Berdichevsky Feodor, 1994, Molecular and Cellular Differentiation, V2, P255; DEPOTTER CR, 1995, VIRCHOWS ARCH, V426, P107, DOI 10.1007/BF00192631; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DSOUZA B, 1993, ONCOGENE, V8, P1797; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Genersch E, 1996, J MOL MED-JMM, V74, P609, DOI 10.1007/s001090050064; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Krensel K, 1999, INT J CANCER, V80, P546, DOI 10.1002/(SICI)1097-0215(19990209)80:4<546::AID-IJC11>3.0.CO;2-9; LAUEROVA L, 1988, HYBRIDOMA, V7, P495, DOI 10.1089/hyb.1988.7.495; Lo SS, 1999, MOL CARCINOGEN, V25, P150; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nowak F, 1997, EXP CELL RES, V231, P251, DOI 10.1006/excr.1996.3468; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Sambrook J., MOL CLONING LAB MANU; Shak S, 1999, SEMIN ONCOL, V26, P71; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Soini Y, 1998, AM J PATHOL, V153, P1041, DOI 10.1016/S0002-9440(10)65649-0; Tagliabue E, 1996, BRIT J CANCER, V74, P1427, DOI 10.1038/bjc.1996.560; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; Ye JP, 1996, MOL CELL BIOL, V16, P6178; ZUTTER MM, 1993, AM J PATHOL, V142, P1439	33	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4592	4603		10.1038/sj.onc.1203792	http://dx.doi.org/10.1038/sj.onc.1203792			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030148				2022-12-17	WOS:000089438200005
J	Fenstermaker, RA; Ciesielski, MJ				Fenstermaker, RA; Ciesielski, MJ			Deletion and tandem duplication of exons 2-7 in the epidermal growth factor receptor gene of a human malignant glioma	ONCOGENE			English	Article						epidermal growth factor receptor; EGFR-vIII; glioma; oncogene; recombination; V(D)J	HUMAN GLIOBLASTOMA CELLS; CONFERS ENHANCED TUMORIGENICITY; CENTRAL-NERVOUS-SYSTEM; EGF-RECEPTOR; TYROSINE KINASE; FACTOR-ALPHA; EXPRESSION; TRANSFORMATION; AMPLIFICATION; RECOMBINATION	The epidermal growth factor receptor (EGFR) gene is frequently amplified and rearranged in malignant gliomas with expression of oncogenic deletion mutants (DM). The most common mutant EGFRvIII, which contains a deletion of exons 2-7, is constitutively autophosphorylated and inefficiently do downregulated. Other less common EGFR mRNA species in gliomas contain tandem duplication of exons, which encode the tyrosine kinase (TK) and calcium mediated receptor internalization (CAIN) domains of the molecule. We examined a panel of human malignant gliomas and found one tumor that expressed four related EGFR proteins, including 125-, 140-, 170-, and 180-kDa species. This tumor also contained four EGFR-related mRNA species, including both wild type EGFR and EGFRvIII transcripts. A third transcript contained a deletion of exons 2-7 and 12-13 corresponding to the 125-kDa protein. A fourth transcript contained an in-frame, tandem duplication of exons 2-7 (EGFR,TDM/2-7). The 180-kDa, tandem duplication mutant (TDM) exhibited enhanced basal phosphorylation and impaired downregulation, In contrast to the 140-kDa EGFRvIII; however, phosphorylation of the 180-kDa EGFR.TDM/2-7 was strongly induced by ligand, Expression of both deletion and tandem duplication mutants in the same tumor suggests that the mechanisms responsible for DM and TDM formation might be closely related.	Roswell Pk Canc Inst, Dept Neurosurg, Buffalo, NY 14263 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14209 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Fenstermaker, RA (corresponding author), Roswell Pk Canc Inst, Dept Neurosurg, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056-22] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI T, 1991, BIOCHEM BIOPH RES CO, V181, P151, DOI 10.1016/S0006-291X(05)81394-4; Bailin T, 1999, MOL CELL BIOL, V19, P4664; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BIGNER SH, 1990, CANCER RES, V50, P8017; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Ciesielski MJ, 2000, ONCOGENE, V19, P810, DOI 10.1038/sj.onc.1203409; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Fenstermaker RA, 1998, ONCOGENE, V16, P3435, DOI 10.1038/sj.onc.1202156; Frederick L, 2000, CANCER RES, V60, P1383; Frisa PS, 1996, CELL GROWTH DIFFER, V7, P223; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; HUMPHREY PA, 1988, CANCER RES, V48, P2231; LEBEAU MM, 1986, ADV HUM GENET, V15, P1; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MARUNO M, 1991, J NEUROSURG, V75, P97, DOI 10.3171/jns.1991.75.1.0097; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; PANNEERSELVAM K, 1995, EUR J BIOCHEM, V230, P951, DOI 10.1111/j.1432-1033.1995.tb20641.x; SCHLEGEL J, 1994, INT J CANCER, V56, P72; STECK PA, 1988, CANCER RES, V48, P5433; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; TASHIRO S, 1994, ONCOGENE, V9, P1939; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	36	18	24	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4542	4548		10.1038/sj.onc.1203802	http://dx.doi.org/10.1038/sj.onc.1203802			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002427				2022-12-17	WOS:000089236800011
J	Liu, SL; Rand, A; Kelm, RJ; Getz, MJ				Liu, SL; Rand, A; Kelm, RJ; Getz, MJ			The retinoblastoma gene family members pRB and p107 coactivate the AP-1-dependent mouse tissue factor promoter in fibroblasts	ONCOGENE			English	Article						tissue factor; adenovirus EIA; retinoblastoma tumor suppressor; pRB; p107; AP-1	GROWTH-FACTOR-BETA; SERUM-STIMULATED FIBROBLASTS; TUMOR-SUPPRESSOR PROTEIN; CREB BINDING-PROTEIN; C-FOS; TRANSCRIPTION FACTOR; CELL-GROWTH; BLOOD-COAGULATION; ENDOTHELIAL-CELLS; EXPRESSION	Serum-stimulation of quiescent mouse fibroblasts results in transcriptional activation of tissue factor (TF), the cellular initiator of blood coagulation. This requires the rapid entry of c-Fos into specific AP-1 DNA-binding complexes and can be strongly inhibited by the adenovirus E1A 12S gene product. In this study, we utilized a panel of E1A mutants deficient in cellular protein binding to analyse the molecular basis for E1A inhibition of a minimal, c-Fos-dependent TF promoter/reporter construct in mouse AKR-2B fibroblasts, Mutations which impaired binding of the retinoblastoma tumor suppressor protein family members pRB, p107, and p130 relieved E1A-mediated inhibition of transcription in response to serum-stimulation or c-Fos overexpression. Inhibition was restricted to the G(0) to G(1) transition, consistent with the specificity of E1A for hypophosphorylated forms of RE proteins. Although E1A mutants deficient in CBP/p300 binding retained the ability to inhibit TF transcription, deletion of the aminoterminal portion of the CBP/p300 interaction domain was required to permit rescue of TF promoter activity by coexpression of pRB, Moreover, ectopic p107 could effectively substitute for pRB in relieving E1A-mediated repression. In primary mouse embryo fibroblasts, activity of the minimal AP(-/-) dependent TF promoter was suppressed in Rb-/- cells compared to parallel Rb+/- and Rh+/+ transfectants, Ectopic expression of either PRB or p107 markedly enhanced TF promoter activity in Rh-/- fibroblasts. Collectively, these data imply that pRB and p107 can cooperate with c-Fos to activate TF gene transcription in fibroblasts and suggest a requirement for another, as yet unidentified, E1A-binding protein.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Program Tumor Biol, Rochester, MN 55905 USA	Mayo Clinic	Kelm, RJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Program Tumor Biol, Rochester, MN 55905 USA.				NCI NIH HHS [T32 CA09441, CA76083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076083, T32CA009441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARBEAU D, 1994, ONCOGENE, V9, P359; BISPHOPRIC NH, 1997, J BIOL CHEM, V272, P20584; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; Erlich J, 1999, P NATL ACAD SCI USA, V96, P8138, DOI 10.1073/pnas.96.14.8138; Felts SJ, 1997, ONCOGENE, V14, P1679, DOI 10.1038/sj.onc.1201006; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Giannini G, 1997, J BIOL CHEM, V272, P5313, DOI 10.1074/jbc.272.8.5313; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; Kingston RE, 1999, NATURE, V399, P199, DOI 10.1038/20302; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; NEVINS JR, 1992, SCIENCE, V258, P424; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; REDDY JC, 1995, J BIOL CHEM, V270, P29976; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Vrana JA, 1996, CANCER RES, V56, P5063; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9	57	18	18	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3352	3362		10.1038/sj.onc.1203675	http://dx.doi.org/10.1038/sj.onc.1203675			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918592				2022-12-17	WOS:000088198100003
J	Brown, A; Browes, G; Mitchell, M; Montano, X				Brown, A; Browes, G; Mitchell, M; Montano, X			c-abl is involved in the association of p53 and trk A	ONCOGENE			English	Article						c-abl; phosphorylation; p53 and trk A association; c-abl and trk A association	NERVE GROWTH-FACTOR; WILD-TYPE P53; TYROSINE KINASE-ACTIVITY; DNA-DAMAGE; PC12 CELLS; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; GENOTOXIC STRESS; PROTEIN-BINDING	The p53 tumour suppressor phosphoprotein associates with proteins involved in DNA replication, transcription, cell cycle machinery and regulation of its own expression, Recently it has been shown that p53 can also bind to trk A tyrosine kinase which is the receptor for nerve growth factor (NGF). This study demonstrates that p53 appears to associate with trk A via c-abl, Endogenous c-abl was detected when the trk A and p53 complex was immunoprecipitated from lysates of NGF stimulated NIH3T3 cells expressing trk A or NIH3T3 cells expressing trk A and a temperature sensitive p53 (val 135), Endogenous c-abl and trk A association was observed in NGF stimulated p53 negative fibroblasts transfected with trk A alone; suggesting that c-abl can independently bind to trk A in the absence of p53. Interestingly, association between endogenous p53 and trk A was not detected in NGF stimulated abl negative fibroblasts transfected with trk A or when these cells were exposed to gamma radiation, This result suggests that p53 preferentially binds to trk A in the presence of c-abl and that p53 and trk A do not appear to associate directly even if p53 is activated and its levels increased by gamma radiation, Overall, these data suggest that c-abl is possibly acting as an adaptor or bridge between p53 and trk A.	Newcastle Univ, Sch Med, Canc Res Unit, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Imperial Canc Res Fund, London WC2A 3PX, England	Newcastle University - UK; Cancer Research UK	Montano, X (corresponding author), Newcastle Univ, Sch Med, Canc Res Unit, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.							Agami R, 1999, NATURE, V399, P809; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; GOGA A, 1995, ONCOGENE, V11, P791; Goldsmith BA, 1997, J NEUROCHEM, V69, P1014; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATTIONI T, 1995, ONCOGENE, V10, P1325; MICHALOWITZ D, 1990, CELL, V620, P671; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Montano X, 1997, ONCOGENE, V15, P245, DOI 10.1038/sj.onc.1201215; Nakamura T, 1996, ONCOGENE, V13, P1111; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Prives C, 1999, J PATHOL, V187, P112; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; VAMBUTAS V, 1995, J BIOL CHEM, V270, P25629, DOI 10.1074/jbc.270.43.25629; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZERRAHN J, 1992, ONCOGENE, V7, P1371	62	18	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3032	3040		10.1038/sj.onc.1203619	http://dx.doi.org/10.1038/sj.onc.1203619			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871855				2022-12-17	WOS:000087581400010
J	Wang, HL; Kurtz, A				Wang, HL; Kurtz, A			Breast cancer growth inhibition by delivery of the MDGI-derived peptide P108	ONCOGENE			English	Article						growth inhibitor; peptide delivery; differentiation; experimental therapy	ACID-BINDING PROTEIN; BOVINE HEART; MAMMARY; CELLS; GENE; CLONING; TISSUE	Mammary derived growth inhibitor (MDGI) is a member of the family of cytoplasmic fatty acid binding proteins (FABPs), which bind hydrophobic ligands such as fatty acids, retinoids, eicosanoids and prostaglandines. MDGI and an 11 amino acid MDGI-derived conserved C-terminal peptide (P108) inhibits growth of normal mammary epithelial cells in tissue and organ culture, but fails to inhibit proliferation of many breast cancer cell Lines in vitro, Here, the effects of peptide P108 on tumor growth of MCF-7, MDA-MB468 and MDA-MB231 human breast cancer cell lines in nude mice were tested. To deliver P108 into tumors, a novel peptide production system was applied for expression and secretion of small bioactive peptides in mammalian cells. Functional differentiation was observed in MCF-7 and MDA-MB468 cells upon P108 expression, In addition, EGF-dependent colony formation in soft agar by MDA-MB468 cells was inhibited by secreted P108, Tumor growth in athymic nude mice was suppressed in all three cell lines tested, Furthermore, P108 expressed by MCF-7/P108 cells caused paracrine tumor growth inhibition of MDA-MB231 cells. These results indicate that breast cancer inhibition by P108 is independent of binding to hydrophobic ligands and is perhaps mediated by interference with EGF-dependent signaling pathways.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University	Kurtz, A (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Pharmacol, TRB W208,3970 Reservoir Rd NW, Washington, DC 20007 USA.			Kurtz, Andreas/0000-0003-3301-6546				BILLICH S, 1988, EUR J BIOCHEM, V175, P549, DOI 10.1111/j.1432-1033.1988.tb14227.x; BOEHMER F-D, 1988, Journal of Cellular Biochemistry, V38, P199; BOEHMER FD, 1987, J BIOL CHEM, V262, P15137; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; BRANDT R, 1992, BIOCHEM BIOPH RES CO, V189, P406, DOI 10.1016/0006-291X(92)91573-9; Brandt R, 1998, Prog Mol Subcell Biol, V20, P197; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; ERVIN PR, 1989, SCIENCE, V244, P1585, DOI 10.1126/science.2662405; Glatz JFC, 1997, PROSTAG LEUKOTR ESS, V57, P373, DOI 10.1016/S0952-3278(97)90413-0; Grosse R, 1992, Cancer Treat Res, V61, P69; Huynh H, 1996, CANCER RES, V56, P4865; HUYNH HT, 1995, CANCER RES, V55, P2225; KURTZ A, 1990, J CELL BIOL, V110, P1779, DOI 10.1083/jcb.110.5.1779; KURTZ A, 1997, BIOCH SOC S, V69, P51; LASSEN D, 1995, EUR J BIOCHEM, V230, P266, DOI 10.1111/j.1432-1033.1995.tb20560.x; LEHMANN W, 1989, BIOMED BIOCHIM ACTA, V48, P143; Liu XH, 1996, CLIN EXP METASTAS, V14, P145, DOI 10.1007/BF00121211; NATARAJAN R, 1998, FRONT BIOSCI, V3, P81; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Phelan CM, 1996, GENOMICS, V34, P63, DOI 10.1006/geno.1996.0241; Phelan CM, 1996, GENOMICS, V36, P377, DOI 10.1006/geno.1996.0481; RYTOMAA T, 1979, MECH AGEING DEV, V9, P471, DOI 10.1016/0047-6374(79)90087-3; SILBERSTEIN G, 1987, SCIENCE, V37, P291; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TREUNER M, 1994, GENE, V147, P237, DOI 10.1016/0378-1119(94)90073-6; VEERKAMP JH, 1995, J CELL BIOL, V127, P1097; VERKAMP J, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1; WALLUKAT G, 1991, MOL CELL BIOCHEM, V102, P49; YANG Y, 1995, J CELL BIOL, V127, P1097; ZSCHIESCHE W, 1995, HISTOCHEM CELL BIOL, V103, P147, DOI 10.1007/BF01454012	30	18	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2455	2460		10.1038/sj.onc.1203575	http://dx.doi.org/10.1038/sj.onc.1203575			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828888				2022-12-17	WOS:000087018400011
J	Lee, TA; Farnham, PJ				Lee, TA; Farnham, PJ			Exogenous E2F expression is growth inhibitory before, during, and after cellular transformation	ONCOGENE			English	Article						E2F; Ras; Neu; NIH3T3; transformation; tumor suppressor	MAMMARY EPITHELIAL-CELLS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; DNA-BINDING; SUBCELLULAR-LOCALIZATION; NUCLEAR-LOCALIZATION; MEMBRANE-PROTEIN; FAMILY PROTEINS; NEU ONCOGENE; GENE FAMILY	To gain insight into the tumor suppressor properties of E2F1, we investigated growth inhibition by the E2F family of transcription factors using a tissue culture model system, We first show that exogenous E2F expression causes an 80% decrease in NIH3T3 colony formation and activated c-Ha-Ras-mediated focus formation. Inhibition of Ras-mediated transformation was dependent upon E2F DNA binding activity but did not require amino- or carboxy-terminal E2F1 protein interaction domains. Because E2F upregulation has been suggested to be associated with a neoplastic phenotype, it was possible that increased E2F activity would not be inhibitory to previously transformed cells. However, we found that exogenous E2F was also inhibitory to growth of NIH3T3 cells previously transformed by Ras or Neu. Further characterization revealed that exogenous E2F expression is inhibitory at very early times after transfection, causing dramatic losses in transfected cell populations. Interestingly, those few cells which do establish appear to be unaffected by the overexpressed E2F, Therefore, we propose that increased E2F activity may only be tolerated in a subset of cells which have acquired specific alterations that are dominant over E2F-mediated growth inhibition.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA.			Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA09135, CA07175, CA22484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Brideau AD, 1998, J VIROL, V72, P4560, DOI 10.1128/JVI.72.6.4560-4570.1998; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Magae J, 1996, J CELL SCI, V109, P1717; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Muller H, 1997, MOL CELL BIOL, V17, P5508; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sambrook J., 1982, MOL CLONING; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WANG BC, 1991, CANCER RES, V51, P2642; WANG BC, 1991, CANCER RES, V51, P5649; Wells J, 1996, MOL CELL BIOL, V16, P634; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	47	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2257	2268		10.1038/sj.onc.1203556	http://dx.doi.org/10.1038/sj.onc.1203556			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822376				2022-12-17	WOS:000086974100011
J	Shennan, MG; Badin, AC; Walsh, S; Summers, A; From, L; McKenzie, M; Goldstein, AM; Tucker, MA; Hogg, D; Lassam, N				Shennan, MG; Badin, AC; Walsh, S; Summers, A; From, L; McKenzie, M; Goldstein, AM; Tucker, MA; Hogg, D; Lassam, N			Lack of germline CDK6 mutations in familial melanoma	ONCOGENE			English	Article						familial melanoma; CDK6	DEPENDENT KINASE CDK6; TUMOR-SUPPRESSOR; CYCLIN-D; P16; RETINOBLASTOMA; BINDING; P16(INK4A); PREVALENCE; INHIBITION; PROTEIN	Germline mutations in genes encoding several components of the retinoblastoma pathway have been linked with inherited predisposition to melanoma, Most commonly, such mutations involve CDKN2A, a cyclin-dependant kinase inhibitor of two kinases, CDK4 and CDK6, which phosphorylate the retinoblastoma protein (pRB) and thereby promote passage through the G(1)/S cell-cycle restriction point. Less frequently, germline mutations in the CDK4 gene have also been linked with an increased risk of melanoma, Despite the sequence and functional homology between CDK4 and CDK6, the role of germline mutations in CDK6 in melanoma predisposition is unknown. We detected no CDK6 mutations within the p16 (CDKN2A) binding domain in index cases from 60 melanoma-prone kindreds that lacked germline mutations in the coding regions of either CDKN2A or within the entire CDK4 coding region. We conclude that germline mutations in CDK6 do not make a significant contribution to melanoma predisposition.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; New York Gen Hosp, New York, NY USA; Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Dermatol, Toronto, ON, Canada; Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON, Canada; NCI, Bethesda, MD 20892 USA	University of Toronto; University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lassam, N (corresponding author), Univ Toronto, Dept Med, Room 7360,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.		Tucker, Margaret A/B-4297-2015		NATIONAL CANCER INSTITUTE [ZIACP004410, Z01CP004410] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATAILLE V, 1995, BRIT J DERMATOL, V132, P134, DOI 10.1111/j.1365-2133.1995.tb08639.x; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; Ceha HM, 1998, BIOCHEM BIOPH RES CO, V249, P550, DOI 10.1006/bbrc.1998.9183; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; Dracopoli NC, 1996, CANCER SURV, V26, P115; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; GOLDSTEIN AM, 1995, DERMATOL CLIN, V13, P605, DOI 10.1016/S0733-8635(18)30066-4; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KATO J, 1993, GENE DEV, V7, P331; LIU L, 1995, ONCOGENE, V11, P405; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; TRABOULSI EI, 1988, ARCH OPHTHALMOL-CHIC, V106, P1059; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	24	18	19	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1849	1852		10.1038/sj.onc.1203507	http://dx.doi.org/10.1038/sj.onc.1203507			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777219				2022-12-17	WOS:000086292500013
J	Fuxe, J; Raschperger, E; Pettersson, RF				Fuxe, J; Raschperger, E; Pettersson, RF			Translation of p15.5(INK4B), an N-terminally extended and fully active form of p15(INK4B), is initiated from an upstream GUG codon	ONCOGENE			English	Article						cell cycle control; cell cycle inhibitors; replicative senescence; non-AUG translation initiation	DEPENDENT KINASE INHIBITORS; FIBROBLAST GROWTH-FACTOR; CELL-CYCLE ARREST; NUCLEAR-LOCALIZATION; CDK INHIBITORS; SUBCELLULAR-LOCALIZATION; TGF-BETA; IN-VIVO; CANCER; P15	The expression of the cyclin-dependent kinase inhibitor p15(INK4B) in normal cells after induction with TGF-beta 1, or following overexpression from an adenovirus-encoded cDNA, appears on an SDS-polyacrylamide gel as a doublet. Here, the underlying mechanism behind the synthesis of the two species has been studied. By expressing cDNAs truncated at their 5' end, we found that the synthesis of the more slowly migrating form, called p15.5(INK4B), is dependent on a sequence upstream of the first AUG codon thought to initiate translation of p15(INK4B). Two potential, in frame, alternative upstream initiation codons, AUG and GUG, were individually changed to GCA encoding alanine, Analysis by in vitro translation, or immunoblotting of lysates from transfected 293 cells, showed that translation of p15.5(INK4B) is initiated at the GUG located 13 codons upstream of the first AUG. When this AUG was mutated, p15(INK4B) was no longer made. Instead, a shorter form, initiated at an in frame AUG located seven codons downstream was synthesized. Finally, when both these AUGs were mutated, only p15.5(INK4B) was generated. Both p15(INK4B) and p15.5(INK4B) bound to CDK4 and CDK6, inhibited DNA synthesis, and caused replicative senescence of a human glioma cell line. We thus conclude that p15(INK4B) and p15.5(INK4B), encoded by the CDKN2B gene, are functionally indistinguishable as based on these assays.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research	Pettersson, RF (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.		Fuxe, Jonas/T-4433-2017	Fuxe, Jonas/0000-0003-4576-9377				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CAO YH, 1993, GROWTH FACTORS, V8, P277, DOI 10.3109/08977199308991573; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HALL M, 1995, ONCOGENE, V11, P1581; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Nister M, 1994, ATLAS HUMAN TUMOR CE, P17, DOI [10.1016/B978-0-12-333530-2.50005-8, DOI 10.1016/B978-0-12-333530-2.50005-8]; Parry D, 1996, MOL CELL BIOL, V16, P3844; QUELLE DE, 1995, ONCOGENE, V11, P635; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, ONCOGENE, V11, P987; Tsubari M, 1997, CANCER RES, V57, P2966; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391	28	18	18	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1724	1728		10.1038/sj.onc.1203496	http://dx.doi.org/10.1038/sj.onc.1203496			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763830				2022-12-17	WOS:000086083800013
J	Kim, KE; Gu, CY; Thakur, S; Vieira, E; Lin, JC; Rabson, AB				Kim, KE; Gu, CY; Thakur, S; Vieira, E; Lin, JC; Rabson, AB			Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes	ONCOGENE			English	Article						NF-kappa B; NF-kappa B-2; lymphoma transcription; protooncogene	NF-KAPPA-B; DNA-BINDING ACTIVITY; T-CELL LYMPHOMA; FUNCTIONAL-CHARACTERIZATION; CHROMOSOMAL TRANSLOCATION; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; REL PROTEINS; NFKB2 GENE	C-terminal truncations of the NFKB2 p100 gene product have been observed in a number of cases of human cutaneous T cell lymphomas, as well as human B-cell lymphomas and myelomas, The contribution of these alterations to lymphomagenesis is not understood; however, truncation at amino acid 666 to generate 80-85 kh) proteins in the HUT78 cell line is associated with addition of a short (serine-alanine-serine) fusion at the 3' end of p80HT, as well as with increased expression of NFKB2 mRNA, We therefore examined the effects of p80HT on the regulation of NFKB2 expression, as well ms the properties of a series of other tumor-associated, and site directed mutations of NFKB2, While p80HT had not itself acquired novel transcriptional activation properties with respect to the NFKB2 Pt or P2 promoters or the IL-6 kappa B promoter, p80HT had lost tate potent inhibitory (I kappa B-like) activity associated with the wild-type, p100 gene product. Loss of the inhibitory property depended on the SAS residues in the fusion protein, direct truncation at aa666 was fully inhibitory, as was a substitution of three alanines for the SAS residues. The presence of as few as two C-terminal ankyrin motifs was sufficient for inhibition of NF-kappa B-mediated transcriptional activation, Assays of a series of additional lymphoma-associated NF-kappa B-2 truncation suggested that the C-terminal truncation associated with these proteins was also associated with a loss of the I kappa B-like activities of p100 NF-kappa B-2, for at least some NF-kappa B target promoters. Thus, the loss of I kappa B-like activity of lymphoma-associated NFKB2 mutations may play an important role in the genesis of a subset of human lymphomas.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Inst Canc, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Rabson, AB (corresponding author), CABM, 679 Hoes Lane, Piscataway, NJ 08854 USA.				NATIONAL CANCER INSTITUTE [R01CA068333] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68333] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FINGER LR, 1988, P NATL ACAD SCI USA, V85, P9158, DOI 10.1073/pnas.85.23.9158; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1996, ONCOGENE, V13, P1367; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; LUQUE I, 1977, SEMIN CANCER BIOL, V8, P103; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; MARTIN MA, 1981, P NATL ACAD SCI-BIOL, V78, P4892, DOI 10.1073/pnas.78.8.4892; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; NAGATANI T, 1994, SEMIN DERMATOL, V13, P216; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1993, ONCOGENE, V8, P2275; NERI A, 1995, BLOOD, V86, P3160, DOI 10.1182/blood.V86.8.3160.bloodjournal8683160; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; THAKUR S, 1994, ONCOGENE, V9, P2335; Tolomeo M, 1998, CELL DEATH DIFFER, V5, P735, DOI 10.1038/sj.cdd.4400406; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547; ZHANG JD, 1994, ONCOGENE, V9, P1931; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148	80	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1334	1345		10.1038/sj.onc.1203432	http://dx.doi.org/10.1038/sj.onc.1203432			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713675				2022-12-17	WOS:000085743800010
J	Rao, RN; Stamm, NB; Otto, K; Kovacevic, S; Watkins, SA; Rutherford, P; Lemke, S; Cocke, K; Beckmann, RP; Houck, K; Johnson, D; Skidmore, BJ				Rao, RN; Stamm, NB; Otto, K; Kovacevic, S; Watkins, SA; Rutherford, P; Lemke, S; Cocke, K; Beckmann, RP; Houck, K; Johnson, D; Skidmore, BJ			Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene	ONCOGENE			English	Article						cyclin D1; cdk4; transformation; cell models	DEPENDENT KINASE-4 CDK4; BREAST-CARCINOMA CELLS; RETINOBLASTOMA-PROTEIN; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; TRANSGENIC MICE; CRYSTAL-STRUCTURE; HA-RAS; MALIGNANT TRANSFORMATION; PHYSICAL INTERACTION	Cyclin D1 gene overexpression is a frequent event in a number of human cancers. These observations have led to the suggestion that cyclin D1 alterations might play a role in the etiology of cancer. This possibility is supported by the finding that transfection of mammalian cells with cyclin D1 can accelerate progression through the G1 phase of the cell cycle. Moreover, cyclin D1 can function as an oncogene by cooperating with activated Ha-ras to transform primary rat embryo fibroblasts (REFs). In addition, cyclin D1 transgenics develop hyperplasia and neoplasia of the thymus and mammary gland. We have constructed a novel fusion gene consisting of full-length human cyclin D1 and cdk4 genes. This fusion gene was expressed in insect cells and the fusion protein was shown to be enzymatically active. The fusion gene was expressed in mammalian cells under the control of tet-repressor. This fusion gene immortalized primary REFs, and cooperated with activated Haras to transform primary REFs, in terms of anchorage-independent growth in vitro and formation of tumors in vivo. Utilizing a tet-regulated gene expression system, we have shown that proliferation of stably transfected primary REFs in vitro and in vivo is dependent on the continued expression of the cyclin D1-cdk4 fusion gene. These cell lines could be useful in the discovery of novel cancer therapeutics to modulate cyclin D1.cdk4 activity.	Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Indianapolis, IN 46285 USA; Lilly Res Labs, Res Technol & Prot, Indianapolis, IN 46285 USA; Sphinx Pharmaceut, Durham, NC 27707 USA	Eli Lilly; Eli Lilly	Rao, RN (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Drop Code 0424, Indianapolis, IN 46285 USA.		Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249; Johnson, David/0000-0002-6223-1790				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Andersen G, 1996, FEBS LETT, V397, P65, DOI 10.1016/S0014-5793(96)01143-X; Arber N, 1997, CANCER RES, V57, P1569; Arguello F, 1998, BLOOD, V91, P2482; BIGGS JR, 1995, J MOL MED-JMM, V73, P509; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Carlson BA, 1996, CANCER RES, V56, P2973; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fahraeus R, 1998, ONCOGENE, V16, P587, DOI 10.1038/sj.onc.1201580; FIFE RS, 1995, J LAB CLIN MED, V125, P407; Fife RS, 1998, CANCER LETT, V127, P37, DOI 10.1016/S0304-3835(98)00003-2; FILMUS J, 1994, ONCOGENE, V9, P3627; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harlow E, 1999, USING ANTIBODIES LAB, P495; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAMA T, 1995, BLOOD, V86, P841; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JIANG W, 1993, ONCOGENE, V8, P3447; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; Kim HG, 1998, BIOCHEMISTRY-US, V37, P2666, DOI 10.1021/bi972399i; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Konstantinidis AK, 1998, J BIOL CHEM, V273, P26506, DOI 10.1074/jbc.273.41.26506; KROON AM, 1984, CANCER LETT, V25, P33, DOI 10.1016/S0304-3835(84)80023-3; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1992, SCIENCE, V258, P424; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OBrien K, 1997, GENE, V184, P115, DOI 10.1016/S0378-1119(96)00583-5; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Petronio J, 1996, J NEUROSURG, V84, P1020, DOI 10.3171/jns.1996.84.6.1020; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SAUTER C, 1988, BRIT J CANCER, V57, P514, DOI 10.1038/bjc.1988.117; SCHMIDT TGM, 1994, J CHROMATOGR A, V676, P337, DOI 10.1016/0021-9673(94)80434-6; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH MC, 1988, J BIOL CHEM, V263, P7211; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TUCKER RW, 1977, CANCER RES, V37, P1571; VANDENBOGERT C, 1986, CANCER RES, V46, P3283; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WORZALLA JF, 1990, INVEST NEW DRUG, V8, P241; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	91	18	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6343	6356		10.1038/sj.onc.1203009	http://dx.doi.org/10.1038/sj.onc.1203009			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597234				2022-12-17	WOS:000083934100019
J	Ronai, Z				Ronai, Z			Deciphering the mammalian stress response - a stressful task	ONCOGENE			English	Editorial Material						stress response; DNA damage; stress kinases; PI3K; PKR; p53			CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400					0	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6084	6086		10.1038/sj.onc.1203175	http://dx.doi.org/10.1038/sj.onc.1203175			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557098	Bronze			2022-12-17	WOS:000083447100001
J	Sleeman, JP; Kim, U; LePendu, J; Howells, N; Coquerelle, T; Ponta, H; Herrlich, P				Sleeman, JP; Kim, U; LePendu, J; Howells, N; Coquerelle, T; Ponta, H; Herrlich, P			Inhibition of MT-450 rat mammary tumour growth by antibodies recognising subtypes of blood group antigen B	ONCOGENE			English	Article						blood group antigens; tumour progression; metastasis; subtractive immunization	COLON-CARCINOMA CELLS; MONOCLONAL-ANTIBODIES; PROSTATIC-CANCER; ABERRANT GLYCOSYLATION; FUCOSYL-TRANSFERASE; BREAST-CANCER; EXPRESSION; METASTASIS; BINDING; ABH	Using subtractive immunization to identify cell surface epitopes expressed in a metastasis-specific fashion on cells of the rat MT-W9 mammary carcinoma model, we generated a monoclonal antibody called M-N#1. This antibody binds specifically to metastasizing cells of the MT-W9 series and also to certain other metastasizing rat mammary carcinoma cell lines. We demonstrate that the M-N#1 antibody recognizes a fucosylated N-glycosyl sugar modification, and furthermore show that the epitope specificity of the M-N#1 antibody is for blood group antigen B subtypes 2, 3 and 4 with slight cross-reactivity with blood group antigen A subtype 2. The expression of these carbohydrate epitopes on MT-450 cells is functionally important, because the M-N#1 antibody efficiently inhibits MT-450 tumour growth in spontaneous metastasis assays. These results suggest that expression of the subtypes of blood group antigen B recognized by the M-N#1 antibody does not directly participate in the metastatic cascade but rather confers a growth or survival advantage on the tumour cells.	Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; INSERM, U419, Inst Biol, F-44035 Nantes, France	Helmholtz Association; Karlsruhe Institute of Technology; Institut National de la Sante et de la Recherche Medicale (Inserm)	Sleeman, JP (corresponding author), Forschungszentrum Karlsruhe, Inst Genet, POB 3640, D-76021 Karlsruhe, Germany.		Sleeman, Jonathan P/H-2515-2013; Le Pendu, Jacques/F-4760-2013	Sleeman, Jonathan P/0000-0003-1718-7687; Le Pendu, Jacques/0000-0002-4856-0387				Akahani S, 1997, CANCER RES, V57, P5272; AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; BYRNE G, 1986, DEV BIOL, V117, P442, DOI 10.1016/0012-1606(86)90313-1; CHAMMAS R, 1991, J BIOL CHEM, V266, P3349; CHATTERJEE SK, 1978, J NATL CANCER I, V61, P151, DOI 10.1093/jnci/61.1.151; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; DABELSTEEN E, 1988, CANCER RES, V48, P181; DALL P, 1995, INT J CANCER, V60, P471, DOI 10.1002/ijc.2910600408; DENK H, 1974, EUR J CANCER, V10, P487, DOI 10.1016/0014-2964(74)90071-1; GHOSH SK, 1983, IN VITRO CELL DEV B, V19, P919; Goupille C, 1997, GLYCOBIOLOGY, V7, P221, DOI 10.1093/glycob/7.2.221; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hakomori S, 1996, CANCER RES, V56, P5309; HALLOUIN F, 1998, IN PRESS GLYCOCONJ J; HARLOW E, 1988, COLD SPRING HARBOR L; HOLMES EH, 1990, CARCINOGENESIS, V11, P89, DOI 10.1093/carcin/11.1.89; ICHIKAWA T, 1991, CANCER RES, V51, P3788; ICHIKAWA T, 1992, CANCER RES, V52, P3486; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; ISAACS JT, 1978, CANCER RES, V38, P4353; KIM U, 1986, J SURG ONCOL, V33, P151, DOI 10.1002/jso.2930330303; KING MJ, 1994, BBA-REV BIOMEMBRANES, V1197, P15, DOI 10.1016/0304-4157(94)90017-5; LABARRIERE N, 1994, CANCER RES, V54, P6275; LEE AK, 1985, AM J CLIN PATHOL, V83, P308, DOI 10.1093/ajcp/83.3.308; LeMarer N, 1996, J CELL PHYSIOL, V168, P51, DOI 10.1002/(SICI)1097-4652(199607)168:1<51::AID-JCP7>3.0.CO;2-7; LICHTNER RB, 1987, INVAS METAST, V7, P73; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; NERI A, 1981, CANCER RES, V41, P5082; Ogawa J, 1996, CANCER RES, V56, P325; ORIOL R, 1984, LAB INVEST, V50, P514; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RUDY W, 1993, CANCER RES, V53, P1262; SATO S, 1992, J BIOL CHEM, V267, P6983; SCHOENTAG R, 1987, CANCER RES, V47, P1695; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; STRAUCHEN JA, 1980, CANCER, V45, P2149, DOI 10.1002/1097-0142(19800415)45:8<2149::AID-CNCR2820450823>3.0.CO;2-7; SUN J, 1995, P NATL ACAD SCI USA, V92, P5724, DOI 10.1073/pnas.92.12.5724; URA Y, 1992, INT J CANCER, V50, P57, DOI 10.1002/ijc.2910500113; VERMA M, 1994, CANCER BIOCHEM BIOPH, V14, P151; VOWDEN P, 1986, BRIT J CANCER, V53, P313, DOI 10.1038/bjc.1986.54; WANG JW, 1995, CANCER RES, V55, P3654; WILLIAMS CV, 1992, BIOTECHNIQUES, V12, P842; Xing RH, 1996, INT J CANCER, V67, P423, DOI 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; YUAN M, 1985, CANCER RES, V45, P4499; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	49	18	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4485	4494		10.1038/sj.onc.1202808	http://dx.doi.org/10.1038/sj.onc.1202808			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442639				2022-12-17	WOS:000081813500010
J	Muhlner, U; Mohle-Steinlein, U; Wizigmann-Voos, S; Christofori, G; Risau, W; Wagner, EF				Muhlner, U; Mohle-Steinlein, U; Wizigmann-Voos, S; Christofori, G; Risau, W; Wagner, EF			Formation of transformed endothelial cells in the absence of VEGFR-2/Flk-1 by Polyoma middle T oncogene	ONCOGENE			English	Article						polyoma middle T; VEGFR-2/Flk-1; angiogenesis; vascular tumors	RECEPTOR TYROSINE KINASES; EMBRYONIC STEM-CELLS; GROWTH-FACTOR VEGF; SIGNAL-TRANSDUCTION; AUTOCRINE MECHANISM; IN-VITRO; ANGIOGENESIS; EXPRESSION; MICE; DIFFERENTIATION	The middle T antigen of murine Polyomavirus (PymT) rapidly transforms endothelial cells leading to vascular malformations reminiscent of endothelial tumors or hemangiomas, Flk-1, a receptor tyrosine kinase which is activated upon binding of its ligand VEGF, is predominantly expressed in endothelial cells and essential for the formation of blood vessels since absence of Flk-1 prevents the development of mature endothelial cells in mice and in ES-cell differentiation experiments, To investigate the role of Flk-1 in PymT-induced vascular tumor formation, we studied the expression of Flk-1 and VEGF in PymT-transformed endothelial cells (Endothelioma cells, END. cells). The receptor and its ligand were both expressed in END, cells suggesting that a VEGF/Flk-1 autocrine loop might be causally involved in the formation of vascular tumors. To test this hypothesis, ES cells lacking Flk-1 were generated and the transforming potential of PymT was analysed after in vitro differentiation. Flk-1-/- END. cell lines were established which are morphologically identical to flk-1+/+ END. cells and which express several markers characteristic for endothelial cells, This result suggests that PymT functionally replaces the requirement of Flk-1 in expansion and/or survival of endothelial progenitor cells. Therefore, flk-1-/- END. cells provide a powerful tool to dissect the downstream signaling pathways of Flk-1.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Max Planck Inst Physiol & Clin Res, Dept Mol & Cell Biol, D-61231 Bad Nauheim, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Wagner, Erwin F/0000-0001-7872-0196				Bronson R, 1997, P NATL ACAD SCI USA, V94, P7954, DOI 10.1073/pnas.94.15.7954; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Choi K, 1998, DEVELOPMENT, V125, P725; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; DiMaio D, 1998, ANNU REV MICROBIOL, V52, P397, DOI 10.1146/annurev.micro.52.1.397; DUBOISSTRINGFELLOW N, 1994, AM J PATHOL, V144, P796; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; Gotsch U, 1997, J CELL SCI, V110, P583; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hashimoto M, 1995, LAB INVEST, V73, P859; Hatzopoulos AK, 1998, DEVELOPMENT, V125, P1457; HILBERG F, 1992, ONCOGENE, V7, P2371; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Jones Cindy L. A., 1996, Current Opinion in Oncology, V8, P54, DOI 10.1097/00001622-199601000-00010; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; KIEFER F, 1994, CURR BIOL, V4, P100, DOI 10.1016/S0960-9822(94)00025-4; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Pepper MS, 1997, TUMOUR ANGIOGENESIS, P309; RAK J, 1995, CANCER RES, V55, P4575; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Schuh AC, 1999, P NATL ACAD SCI USA, V96, P2159, DOI 10.1073/pnas.96.5.2159; SEETHARAM L, 1995, ONCOGENE, V10, P135; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; WAGNER EF, 1994, SEMIN CANCER BIOL, V5, P137; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; XIE Y, 1993, P NATL ACAD SCI USA, V90, P5569, DOI 10.1073/pnas.90.12.5569; YOUNG AT, 1995, P NATL ACAD SCI USA, V92, P11613, DOI 10.1073/pnas.92.25.11613	57	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4200	4210		10.1038/sj.onc.1203014	http://dx.doi.org/10.1038/sj.onc.1203014			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435633				2022-12-17	WOS:000081542400004
J	Iben, S; Royer-Pokora, B				Iben, S; Royer-Pokora, B			Analysis of native WT1 protein from frozen human kidney and Wilms' tumors	ONCOGENE			English	Article						Wilms' tumor; WT1 protein; gelfiltration	DNA-BINDING; GENE WT1; TRANSCRIPTION; PHOSPHORYLATION; LOCALIZATION; INITIATION; EXPRESSION; INHIBITION; PRODUCT; P53	The Wilms' tumor susceptibility gene, WT1, is altered in a subset of Wilms' tumors and encodes a transcription factor with four zinc fingers. Here we describe the isolation of native WT1 protein from frozen normal human kidney and Wilms' tumor samples. Through size exclusion chromatography and Western blot analysis we determined the elution pattern of WT1, The majority of WT1 from adult kidney and Wilms' tumor specimens was found to elute at a size of approximately 120 kDa, consistent with a WT1 homodimer and some WT1 protein was also found in a higher molecular weight complex, In 14 week fetal kidney the majority of the WT1 protein eluted at a size of 80 kDa, suggesting that at this developmental stage the WT1 protein is not present as a homodimer, The identity of complexing partners can now be studied using this approach.	Univ Dusseldorf, Inst Human Genet & Anthropol, D-40001 Dusseldorf, Germany; Univ Heidelberg, Inst Human Genet & Anthropol, D-69120 Heidelberg, Germany	Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg	Royer-Pokora, B (corresponding author), Univ Dusseldorf, Inst Human Genet & Anthropol, Postfach 101007, D-40001 Dusseldorf, Germany.			Royer-Pokora, Brigitte/0000-0001-5114-7801				BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRENNER B, 1992, ONCOGENE, V7, P1431; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUBB GR, 1994, LAB INVEST, V71, P472; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Renshaw J, 1997, GENE CHROMOSOME CANC, V19, P256, DOI 10.1002/(SICI)1098-2264(199708)19:4<256::AID-GCC8>3.0.CO;2-W; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; Schumacher V, 1997, P NATL ACAD SCI USA, V94, P3972, DOI 10.1073/pnas.94.8.3972; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x	26	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2533	2536		10.1038/sj.onc.1202618	http://dx.doi.org/10.1038/sj.onc.1202618			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229205				2022-12-17	WOS:000079703300014
J	Zhang, N; Shen, WF; Hawley, RG; Lu, M				Zhang, N; Shen, WF; Hawley, RG; Lu, M			HOX11 interacts with CTF1 and mediates hematopoietic precursor cell immortalization	ONCOGENE			English	Article						HOX11 oncogene; transcription factor; DNA binding; protein-protein interaction; cell immortalization	DNA-BINDING SPECIFICITY; TRANSCRIPTIONAL ACTIVATION; HOMEODOMAIN PROTEINS; HOMEOBOX GENE; LEUKEMIA; EXTRADENTICLE; CLONING; ENCODES; FAMILY	HOX11 is a homeodomain-containing oncogenic transcription factor that immortalizes hematopoietic precursor cells. The mechanism by which HOX11 facilitates this initial step of leukemogenesis is, however, not well understood. We have used a DNA binding site selection assay to investigate cooperative DNA binding by HOX11 with other transcription factors. A consensus sequence was derived and identified as the binding site for the CCAAT-box-binding transcription factors (CTF), HOX11 was shown to interact in vitro and in vivo with CTF1. Retrovirus-mediated transduction of an antisense CTF1 cDNA dramatically reduced the proliferative capacity of HOX11-immortalized hematopoietic precursor cells. CTF1 is, therefore, the first HOX11 protein partner identified that plays an important role in hematopoietic precursor cell immortalization.	Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Francisco, Vet Adm Med Ctr, San Francisco, CA 94121 USA; Toronto Hosp, Oncol Gene Therapy Program, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M1, Canada	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Lu, M (corresponding author), Univ Calif San Diego, Ctr Canc, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Hawley, Robert/0000-0003-3512-5818	NIDDK NIH HHS [DK49619] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049619] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hawley RG, 1997, CANCER RES, V57, P337; HAWLEY RG, 1993, J EXP MED, V178, P1175, DOI 10.1084/jem.178.4.1175; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MING L, 1992, ONCOGENE, V7, P1325; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; Zhang N, 1996, ONCOGENE, V13, P1781; ZHANG N, 1993, ONCOGENE, V8, P3265	22	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	1999	18	13					2273	2279		10.1038/sj.onc.1202545	http://dx.doi.org/10.1038/sj.onc.1202545			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327073				2022-12-17	WOS:000079525100011
J	Angrist, M; Bolk, S; Bentley, K; Nallasamy, S; Halushka, MK; Chakravarti, A				Angrist, M; Bolk, S; Bentley, K; Nallasamy, S; Halushka, MK; Chakravarti, A			Genomic structure of the gene for the SH2 and pleckstrin homology domain-containing protein GRB10 and evaluation of its role in Hirschsprung disease	ONCOGENE			English	Article						Hirschsprung disease; GRB10; GRB-IR; RET receptor tyrosine kinase; mutation detection; genomic structure; mapping	ENDOTHELIN-B RECEPTOR; MICE LACKING GDNF; TYROSINE KINASE; RET PROTOONCOGENE; MUTATION ANALYSIS; INSULIN-RECEPTOR; BINDING-PROTEIN; GROWTH; FAMILY; CLONING	Hirschsprung disease (HSCR), or congenital aganglionic megacolon, is the most frequent cause of congenital bowel obstruction. Germline mutations in the RET receptor tyrosine kinase have been shown to cause HSCR. Mice that carry null alleles for RET or for its ligand, glial cell line-derived neurotrophic factor (GDNF), both exhibit complete intestinal aganglionosis and renal defects. Recently, the Src homology 2 (SH2) domain-containing protein Grb10 has been shown to interact with RET in vitro and in vivo, early in development. We have confirmed the map location of GRB10 on human chromosome 7, isolated human BACs containing the gene, elucidated its genomic structure, isolated a highly polymorphic microsatellite marker adjacent to exon 14 and scanned the gene for mutations in a large panel of HSCR patients. No evidence of linkage was detected in HSCR kindreds and no mutations were found in patients. These data suggest that while GRB10 may be important for signal transduction in developing embryos, it does not play an obvious role in HSCR.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Chakravarti, A (corresponding author), Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.			Halushka, Marc/0000-0002-7112-7389	NICHD NIH HHS [HD-28088] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028088] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Angrist M, 1995, GENOMICS, V30, P623, DOI 10.1006/geno.1995.1289; ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; Angrist M, 1998, GENOMICS, V48, P354, DOI 10.1006/geno.1997.5191; ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; Angrist M, 1996, NAT GENET, V14, P341, DOI 10.1038/ng1196-341; ANGRIST M, 1996, THESIS CASE W RESERV; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BADNER JA, 1990, AM J HUM GENET, V46, P568; BODIAN M, 1963, ANN HUM GENET, V26, P261, DOI 10.1111/j.1469-1809.1963.tb01983.x; Bolande RP, 1997, PEDIATR PATHOL LAB M, V17, P1, DOI 10.1080/107710497174994; Bouffard GG, 1997, GENOME RES, V7, P673, DOI 10.1101/gr.7.7.673; Chakravarti A, 1996, HUM MOL GENET, V5, P303; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; HOLSCHNEIDER AM, 1982, HIRSCHSPRUNGS DIS; Jerome CA, 1997, GENOMICS, V40, P215, DOI 10.1006/geno.1996.4535; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Kusafuka T, 1997, J PEDIATR SURG, V32, P501, DOI 10.1016/S0022-3468(97)90616-3; Kusafuka T, 1996, HUM MOL GENET, V5, P347, DOI 10.1093/hmg/5.3.347; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; Martin RE, 1997, DYSPHAGIA, V12, P2, DOI 10.1007/PL00009513; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Okamoto E, 1967, J PEDIATR SURG, V2, P437; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Seri M, 1997, HUM MUTAT, V9, P243; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; SPOUGE D, 1985, TERATOLOGY, V32, P171, DOI 10.1002/tera.1420320204; WEBSTER W, 1973, J EMBRYOL EXP MORPH, V30, P573	50	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	1998	17	23					3065	3070		10.1038/sj.onc.1202226	http://dx.doi.org/10.1038/sj.onc.1202226			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881709				2022-12-17	WOS:000077427800014
J	Reed, MF; Liu, VF; Ladha, MH; Ando, K; Griffin, JD; Weaver, DT; Ewen, ME				Reed, MF; Liu, VF; Ladha, MH; Ando, K; Griffin, JD; Weaver, DT; Ewen, ME			Enforced CDK4 expression in a hematopoietic cell line confers resistance to the G1 arrest induced by ionizing radiation	ONCOGENE			English	Article						CDK4; p53; p21; ionizing radiation	CYCLIN-DEPENDENT KINASES; P53-DEPENDENT G(1) ARREST; WILD-TYPE P53; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; GROWTH ARREST; DNA-DAMAGE; ULTRAVIOLET-IRRADIATION; CANCER-CELLS; INHIBITION	In hematopoietic cells, gamma-irradiation causes a p53-dependent transient G1 phase cell cycle arrest. Various extracellular growth inhibitory signals elicit G1 arrest by targeting CDK4. Here we show that in a myeloid cell line, 32D cl 3, enforced expression of CDK4, but not cyclins D2 nor D3, overrides the gamma-irradiation-induced G1 arrest. CDK4 does not confer resistance to the radiation-induced G2 block observed in parental cells. Ectopic expression of CDK4 overcomes the ionizing radiation-induced inhibition of CDK4 and CDK2 kinase activity. The levels of CDK4 protein do not change after exposure to ionizing radiation in either parental cells or those overexpressing CDK4. Ionizing radiation induces the expression of both p53 and p21, and in cells constitutively synthesizing exogenous CDK4, the return of p53 protein levels to baseline is prolonged. Increased levels of p21 are found associated with CDK4, and not CDK2, in the lines overexpressing CDK4, compared to the parental line, after exposure to ionizing radiation. Enforced expression of CDK4 may therefore overcome a gamma-irradiation-induced G1 arrest through the titration of the CDK inhibitor p21 allowing both CDK4 and CDK2 to remain active.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Ewen, ME (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.			Reed, Michael/0000-0001-8478-8605	NATIONAL CANCER INSTITUTE [T32CA009535, R01CA065842] Funding Source: NIH RePORTER; NCI NIH HHS [CA65842, CA09535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANDO K, 1995, ONCOGENE, V10, P751; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; EPPERLY M, 1995, RADIAT RES, V143, P245, DOI 10.2307/3579210; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HE J, 1994, CANCER RES, V54, P5804; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HUPPI K, 1994, ONCOGENE, V9, P3017; JIANG W, 1993, ONCOGENE, V8, P3447; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KHATIB ZA, 1993, CANCER RES, V53, P5535; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREK W, 1995, METHOD ENZYMOL, V254, P114; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NAKAWAKI T, 1995, BRIT J HAEMATOL, V91, P139, DOI 10.1111/j.1365-2141.1995.tb05259.x; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUELLE DE, 1995, ONCOGENE, V11, P635; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	65	18	20	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					2961	2971		10.1038/sj.onc.1202450	http://dx.doi.org/10.1038/sj.onc.1202450			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881698				2022-12-17	WOS:000077427800003
J	Piovesan, B; Pennell, N; Berinstein, NL				Piovesan, B; Pennell, N; Berinstein, NL			Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity	ONCOGENE			English	Article						apoptosis; mutated p53; cisplatin; lymphoblastoid cell lines	WILD-TYPE P53; CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; DNA-DAMAGING AGENTS; HUMAN B-CELLS; THYMOCYTE APOPTOSIS; UV IRRADIATION; IN-VIVO; MUTATIONS; LYMPHOMA	Human lymphoblastoid cells were transfected with expression vectors containing p53 cDNA mutated at either codon 135 or 246. The cells were subjected to cisplatin treatment or gamma-radiation and observed for changes in the cell cycle arrest and apoptosis, We found that compared to the parental cell line, cells overexpressing mutant p53 (either 246(val) or 135(ser)) exhibited decreased apoptosis in response to gamma-radiation or cisplatin as measured by: propidium iodide (PI) staining of the cellular DNA (cell cycle analysis) and decrease in PARP (poly ADP-ribose polymerase) cleavage as detected by Western blotting. Interestingly the cells expressing mutant p53(135(ser)) protein were less resistant to cisplatin-induced apoptosis than the p53(246(val))-bearing cell line. A significant decrease in the G1/S arrest assayed by bromodeoxyuridine and PI staining (cell cycle/proliferation assay) was also observed in response to irradiation and cisplatin in cell lines expressing either of the mutant p53 constructs. A lower basal level and reduced magnitude of protein induction of the cell cycle inhibitor p21/Waf1 was seen both after cisplatin and gamma-radiation treatment in the mutant p53 expressing lymphoblastoid variant when compared to the wild type p53 parental cell line but induction of the p53 regulator MDM2 was comparable in both. No increase in basal levels of Bc12 protein in wild type or mutant p53 expressing cells was observed in response to cisplatin or irradiation. Unexpectedly, following cisplatin treatment we observed an increase in mutant and wild type p53 RNA steady state levels in addition to increased levels of p53 protein. These results suggest that irradiation or cisplatin treatment may not only stabilize wild type p53 protein but also may increase the steady state p53 RNA levels. Finally these results indicate that both irradiation and cisplatin should be used with caution in the treatment of lymphoid tumors bearing mutations of p53.	Univ Toronto, Dept Med, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M4N 3M5, Canada; Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Berinstein, NL (corresponding author), Univ Toronto, Dept Med, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.			Pennell, Nancy/0000-0002-1556-3506				ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; EASTMAN A, 1985, BIOCHEMISTRY-US, V24, P5027, DOI 10.1021/bi00340a011; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FARRUGIA MM, 1994, BLOOD, V83, P191; FUJIWARA T, 1994, CANCER RES, V54, P2287; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Hawkins DS, 1996, CANCER RES, V56, P892; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang TS, 1996, ONCOGENE, V13, P625; KASTAN MB, 1991, CANCER RES, V51, P6304; Kondo S, 1996, ONCOGENE, V13, P1279; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LI CCH, 1995, LEUKEMIA, V9, P650; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORMEROD MG, 1994, BRIT J CANCER, V69, P93, DOI 10.1038/bjc.1994.14; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; Perego P, 1996, CANCER RES, V56, P556; Pocard M, 1996, ONCOGENE, V12, P875; Roberts J J, 1979, Prog Nucleic Acid Res Mol Biol, V22, P71, DOI 10.1016/S0079-6603(08)60799-0; RODRIGUEZ MA, 1995, J CLIN ONCOL, V13, P1734, DOI 10.1200/JCO.1995.13.7.1734; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; SUGIMOTO K, 1991, BLOOD, V77, P1153; TWEEDDALE ME, 1987, BLOOD, V69, P1307; VAZIRI H, 1997, EMBO J, V16, P6818; VELASQUEZ WS, 1988, BLOOD, V71, P117; VOELKERDING KV, 1995, ONCOGENE, V10, P515; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zhang N, 1996, ONCOGENE, V13, P655; ZINZANI PL, 1994, AM J HEMATOL, V47, P301, DOI 10.1002/ajh.2830470410	45	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2339	2350		10.1038/sj.onc.1202147	http://dx.doi.org/10.1038/sj.onc.1202147			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811465				2022-12-17	WOS:000076723300008
J	Su, LK; Wang, SC; Qi, Y; Luo, WP; Hung, MC; Lin, SH				Su, LK; Wang, SC; Qi, Y; Luo, WP; Hung, MC; Lin, SH			Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression	ONCOGENE			English	Article						BRCA2; tumor suppressor gene; breast cancer; cell cycle	BREAST-CANCER FAMILIES; MUTATIONS; GENE; PROTEIN; ASHKENAZI; MICE; PROLIFERATION; PROGRESSION; PHENOTYPES; 6174DELT	People carrying a mutant BRCA2 gene are susceptible to breast, ovarian, pancreatic and other tumors. Many facets of BRCA2 have been studied, including its mutation in human cancers, its role in mouse embryogenesis and its RNA expression in different tissues and different mouse embryogenesis stages. However, there has been very little characterization of BRCA2 protein. We investigated the biochemical and biological properties of BRCA2 by using a monoclonal antibody we generated against the N-terminal portion of BRCA2, We discovered that the detection of BRCA2 by immunoblot analysis was sensitive to the temperature used to denature the samples before gel electrophoresis. BRCA2 was easily detectable when samples were denatured at low temperature instead of boiling. Although the precise mechanism underlying this observation is not clear yet, this finding mill significantly improve our ability to study BRCA2, We examined the expression of BRCA2 using an immunoblot analysis protocol modified according to this observation. We showed that BRCA2 was presented in every human cell lines examined, including Capan-1, which expressed a truncated BRCA2 due to a BRCA2 frameshift mutation. We also showed that the expression of BRCA2 was cell-cycle regulated. Our results suggest that BRCA2 has an important role in cell growth regulation.	Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Su, LK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021; Wang, Shao-Chun/P-9904-2019	Hung, Mien-Chie/0000-0003-4317-4740; Wang, Shao-Chun/0000-0002-5477-1682	NATIONAL CANCER INSTITUTE [R01CA064856, R29CA070371, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 70371, CA 64856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abeliovich D, 1997, AM J HUM GENET, V60, P505; Berman DB, 1996, CANCER RES, V56, P3409; Bertwistle D, 1997, CANCER RES, V57, P5485; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; Friedman LS, 1998, CANCER RES, V58, P1338; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Liang TC, 1996, ARCH BIOCHEM BIOPHYS, V329, P208, DOI 10.1006/abbi.1996.0210; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; RON D, 1992, BIOTECHNIQUES, V13, P866; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vaughn JP, 1996, CANCER RES, V56, P4590; Wang SC, 1997, BIOCHEM BIOPH RES CO, V234, P247, DOI 10.1006/bbrc.1997.6544; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	33	18	18	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2377	2381		10.1038/sj.onc.1202162	http://dx.doi.org/10.1038/sj.onc.1202162			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811469				2022-12-17	WOS:000076723300012
J	Tanaka, M; Wang, DY; Kamo, T; Igarashi, H; Wang, Y; Xiang, YY; Tanioka, F; Naito, Y; Sugimura, H				Tanaka, M; Wang, DY; Kamo, T; Igarashi, H; Wang, Y; Xiang, YY; Tanioka, F; Naito, Y; Sugimura, H			Interaction of EphB2-tyrosine kinase receptor and its ligand conveys dorsalization signal in Xenopus laevis development	ONCOGENE			English	Article						Eph; Ephrin; dorsalization; secondary axis	PROTEIN-TYROSINE KINASE; NEURAL CREST CELLS; EPH-FAMILY; TRANSMEMBRANE LIGANDS; EXPRESSION CLONING; COMMISSURAL AXONS; SPEMANN ORGANIZER; IN-VITRO; GENE; GUIDANCE	The Eph class is the largest family of receptor tyrosine kinases and has been shown to play various roles in neural development including axon pathfinding and neural crest migration, EphB2 associates with transmembrane ligands Ephrin-B1 and -B2, which leads to tyrosine phosphorylation of both the ligands and receptor and is presumed to regulate cell-to-cell interactions by bidirectional signaling. We have investigated the biological effects of the EphB2-induced signal in the early stage of Xenopus laevis development. Xenopus EphB2 transcripts were detected maternally and were expressed at equal levels between the ventral and dorsal halves of the gastrulae, with expression increasing after the late gastrula stage. EphB2 mRNA expression in dorsal marginal zone explants from gastrulae increases during later development while that in ventral explants does not, We show here that microinjection of RNA encoding EphB2 into a ventral blastomere of embryos induced a partial secondary dorsal axis which consisted of neural tissues, notochord and somites, Analysis with molecular markers verified that the microinjected EphB2 dorsalized the mesoderm of ventral marginal zone explants, These dorsalizing effects of EphB2 in both the whole embryo and ventral explants were inhibited by the coinjection of RNA encoding the soluble form of Ephrin-B1, Furthermore, co-injection of EphB2 and Ephrin-B1 RNAs synergistically enhanced the dorsalization effect, These data show that the interaction between EphB2 and its ligands including Ephrin-B1 causes signaling events which lead to dorsal development, and strongly suggests the existence of proteins which mediate the dorsalization induced by EphB2 in early stage embryos of Xenopus laevis.	Hamamatsu Univ Sch Med, Dept Pathol 1, Hamamatsu, Shizuoka 43131, Japan	Hamamatsu University School of Medicine	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol 1, 3600 Handa Cho, Hamamatsu, Shizuoka 43131, Japan.		Wang, Dong-Yu/C-6307-2019	Wang, Dong-Yu/0000-0002-5434-287X				BRANDLI AW, 1995, DEV DYNAM, V203, P119; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EASTY DJ, 1995, CANCER RES, V55, P2528; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HARLOW E, 1988, ANTIBODIES; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; IKEGAKI N, 1995, HUM MOL GENET, V4, P2033, DOI 10.1093/hmg/4.11.2033; JONES CM, 1995, DEVELOPMENT, V121, P3651; Jones TL, 1997, ONCOGENE, V14, P2159, DOI 10.1038/sj.onc.1201082; JONES TL, 1995, ONCOGENE, V10, P1111; Jones TL, 1998, P NATL ACAD SCI USA, V95, P576, DOI 10.1073/pnas.95.2.576; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Sambrook J., 1989, MOL CLONING; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCALES JB, 1995, ONCOGENE, V11, P1745; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; Weinstein DC, 1996, MECH DEVELOP, V57, P133, DOI 10.1016/0925-4773(96)00536-9; WINNING RS, 1994, MECH DEVELOP, V46, P219, DOI 10.1016/0925-4773(94)90072-8; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005	41	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1509	1516		10.1038/sj.onc.1202068	http://dx.doi.org/10.1038/sj.onc.1202068			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794228	Bronze			2022-12-17	WOS:000076089900003
J	Tanaka, Y; Fujii, M; Hayashi, K; Chiba, N; Akaishi, T; Shineha, R; Nishihira, T; Satomi, S; Ito, Y; Watanabe, T; Satake, M				Tanaka, Y; Fujii, M; Hayashi, K; Chiba, N; Akaishi, T; Shineha, R; Nishihira, T; Satomi, S; Ito, Y; Watanabe, T; Satake, M			The chimeric protein, PEBP2 beta/CBF beta-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation	ONCOGENE			English	Article						PEBP2 beta/CBF beta; chimeric gene; acute myeloid leukemia; stress fibers; immunocytochemistry; transcription factor	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; BINDING-FACTOR-BETA; DNA-BINDING; FUSION TRANSCRIPT; AML1 GENE; SUBCELLULAR-LOCALIZATION	The chromosomal inversion 16(p13;q22) associated with human acute myeloid leukemia generates the chimeric PEBP2 beta/CBF beta-SMMHC gene. The PEBP2 beta/CBF beta portion of the chimeric polypeptide harbors most of the amino acid sequence of the PEBP2 beta/CBF beta protein, the non-DNA. binding subunit of the heterodimeric transcription factor, PEBP2/CBF, whereas the SMMHC portion of the chimera consists of the rod domain of the smooth muscle myosin heavy chain molecule. In this study we examined the subcellular localization of the chimeric protein land its effect both on stress fibers and transcriptional activation by transfecting cDNA into tissue culture cells. The localization of the chimera was investigated by immunocytochemical staining of cells and was found to be both cytoplasmic and nuclear, One aspect of the effect of expression of the chimera was a drastic alteration of cell morphology, The cells appeared elongated and possessed long cytoplasmic processes. Double fluorescent labeling revealed disorganization of the stress fibers and an altered F-actin staining pattern in the transfected cells. Studies using a deletion mutant showed that both the PEBP2 beta/CBF beta and SMMHC domains are necessary for the induction of the morphological alteration, A significant proportion of the chimeric protein was retained in the cytoskeleton after detergent extraction of the cells and could be recuperated as a membrane fraction, suggesting that this is one of the probable sites of action of the PEBP2 beta/CBF beta-SMMHC protein. Another effect of the chimeric protein was inhibition of transcriptional activation dependent on the PEBP2/CBF binding DNA sequence. However, deregulation of PEBP2/CBF site dependent transcription by itself was not sufficient to induce cell morphological changes. Taken together, these results indicate that the PEBP2 beta/CBF beta-SMMHC chimeric protein acts at two levels, at the level of stress fiber organization and at the level of transcriptional activation. We suggest that the action of PEBP2 beta/CBF beta-SMMHC depends to a great extent on whether it is located in the cytoplasm or in the nucleus.	Tohoku Univ, Sch Med, Dept Surg 2, Aoba Ku, Sendai, Miyagi 98077, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 60601, Japan; Tohoku Univ, Dept Mol Immunol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 98077, Japan	Tohoku University; Kyoto University; Tohoku University	Satake, M (corresponding author), Tohoku Univ, Dept Mol Immunol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 98077, Japan.							Aelst L, 1997, GENE DEV, V11, P2295; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; CLAXTON DF, 1994, BLOOD, V83, P1750; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; LENNY N, 1995, ONCOGENE, V11, P1761; Leung T, 1996, MOL CELL BIOL, V16, P5313; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; LU J, 1995, MOL CELL BIOL, V15, P1651; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sacchi N, 1996, ONCOGENE, V12, P437; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SALGIA R, 1995, ONCOGENE, V11, P1149; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; YANAGISAWA K, 1991, BLOOD, V78, P451; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	55	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					699	708		10.1038/sj.onc.1201985	http://dx.doi.org/10.1038/sj.onc.1201985			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715271				2022-12-17	WOS:000075337200004
J	Bandera, CA; Muto, MG; Welch, WR; Berkowitz, RS; Mok, SC				Bandera, CA; Muto, MG; Welch, WR; Berkowitz, RS; Mok, SC			Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum	ONCOGENE			English	Article						allelic loss; chromosome 17; microsatellite instability; peritoneal neoplasia; ovarian cancer	EPITHELIAL OVARIAN-CARCINOMA; UNIFOCAL ORIGIN; PROPHYLACTIC OOPHORECTOMY; CANCER; HETEROZYGOSITY; FAMILIES; BREAST	We extend the evaluation of allelic loss patterns on chromosome 17 to Dapillary serous carcinoma of the peritoneum (PSCP) which is histologically identical to papillary serous ovarian carcinoma (PSOC), DNA was obtained from 11 archival cases of PSCP, with 1-11 tumor sites per case. Using ten loci spanning chromosome 17, loss of heterozygosity (LOH) was identified in all 11 cases (100%). Furthermore, 75-100% of informative cases exhibited LOH at the loci p53, D17S1322 (intragenic to the tumor suppressor gene BRCA1), D17S1327 and MPO. PSCP cases exhibit a higher rate of LOH at most loci when compared with PSOC, Alternating allelic loss at different tumor sites was identified in three cases supporting a multifocal origin of PSCP, Microsatellite instability (MI) is an uncommon event which was identified in four cases. These data implicate chromosome 17 as a potential Location of genetic events important in the pathogenesis of PSCP as well as ovarian cancer.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Lab Div Gynecol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Womens & Perinatal Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mok, SC (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Lab Div Gynecol Oncol, Boston, MA 02115 USA.				NCI NIH HHS [R01CA69453, R01CA63381, R01CA69291] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069291, R01CA069453, R01CA063381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTARAS MM, 1991, GYNECOL ONCOL, V40, P230, DOI 10.1016/0090-8258(91)90322-V; CHEN KTK, 1985, OBSTET GYNECOL, V66, P935; DALRYMPLE JC, 1989, CANCER, V64, P110, DOI 10.1002/1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0.CO;2-5; EASTON DF, 1993, AM J HUM GENET, V52, P678; ECCLES DM, 1990, ONCOGENE, V5, P1599; ECCLES DM, 1992, ONCOGENE, V7, P1069; GREENBLATT MS, 1994, CANCER RES, V54, P4855; JACOBS IJ, 1992, J NATL CANCER I, V84, P1793, DOI 10.1093/jnci/84.23.1793; Kowalski LD, 1997, CANCER, V79, P1587, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1587::AID-CNCR22>3.3.CO;2-S; LEE JH, 1990, CANCER RES, V50, P2724; LI SB, 1993, GYNECOL ONCOL, V51, P21, DOI 10.1006/gyno.1993.1240; LYNCH HT, 1986, AM J MED, V81, P1073, DOI 10.1016/0002-9343(86)90411-0; MOK CH, 1992, CANCER RES, V52, P5119; MUTO MG, 1995, CANCER RES, V55, P490; NAROD SA, 1995, AM J HUM GENET, V56, P254; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P2751, DOI 10.1002/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J; SATO T, 1991, CANCER RES, V51, P5118; TAKAHASHI H, 1995, CANCER RES, V55, P2998; TOBACMAN JK, 1982, LANCET, V2, P795; TRUONG LD, 1990, HUM PATHOL, V21, P99, DOI 10.1016/0046-8177(90)90081-F; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; Wertheim I, 1996, ONCOGENE, V12, P2147	22	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3455	3459		10.1038/sj.onc.1201901	http://dx.doi.org/10.1038/sj.onc.1201901			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692553				2022-12-17	WOS:000074544100012
J	Connolly, JA; Morgan, IM; Jackson, ME; Campo, MS				Connolly, JA; Morgan, IM; Jackson, ME; Campo, MS			The BPV-4 co-carcinogen quercetin induces cell cycle arrest and up-regulates transcription from the LCR of BPV-4	ONCOGENE			English	Article						BPV-4; cell transformation; transcriptional regulation; transcription factors; quercetin; co-carcinogens	BOVINE PAPILLOMAVIRUS TYPE-4; LONG CONTROL REGION; ESTROGEN-BINDING SITES; COLON-CANCER; TRANSFORMATION INVITRO; TUMOR PROMOTION; PROTEIN; DNA; INHIBITION; COMPLEX	Bracken fern is the environmental co-carcinogen of BPV-4 in the induction of neoplasias of the upper alimentary canal of cattle. The flavonoid quercetin is one of the most potent and best characterised mutagens present in the fern. We have shown that transfection with BPV-4 DNA and exposure to a single dose of quercetin leads to tumorigenic transformation of primary bovine cells. We now show that quercetin induces cell cycle arrest and up-regulates transcription from the BPV-4 long control region (LCR). This up-regulation is mediated by a 21 nucleotide-long cis-element in the LCR, designated QRE-1, which is located immediately downstream of the TATA box. Cellular proteins bind to QRE-1 and removal or substitution of QRE-1 lead to the abrogation of the response to quercetin. As expression of the viral oncogenes is controlled by the LCR, perturbation in this control and increased oncoprotein expression are likely to contribute to fully malignant cell transformation by overcoming the cell cycle arrest induced by quercetin, thus forcing damaged cells to proliferate.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Campo, MS (corresponding author), Beatson Inst Canc Res, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.							AHMED MS, 1994, CARCINOGENESIS, V15, P1627, DOI 10.1093/carcin/15.8.1627; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AVILA MA, 1994, CANCER RES, V54, P2425; BJIELDANES LF, 1977, SCIENCE, V197, P577; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAIRNEY M, 1995, CARCINOGENESIS, V16, P1997, DOI 10.1093/carcin/16.8.1997; CAMPO MS, 1994, CARCINOGENESIS, V15, P1597, DOI 10.1093/carcin/15.8.1597; CONNOLLY JA, 1997, THESIS U GLASGOW GLA; CUTHILL S, 1993, MOL CARCINOGEN, V8, P96, DOI 10.1002/mc.2940080206; DOEBERITZ MV, 1994, J VIROL, V68, P2811; FAZAL F, 1990, CARCINOGENESIS, V11, P2005, DOI 10.1093/carcin/11.11.2005; GRAZIANI Y, 1983, EUR J BIOCHEM, V135, P583, DOI 10.1111/j.1432-1033.1983.tb07692.x; GSCHWENDT M, 1984, BIOCHEM BIOPH RES CO, V124, P63, DOI 10.1016/0006-291X(84)90916-1; HOSOKAWA N, 1990, INT J CANCER, V45, P1119, DOI 10.1002/ijc.2910450622; JACKSON ME, 1993, CRIT REV ONCOGENESIS, V4, P277; JACKSON ME, 1991, J GEN VIROL, V72, P877, DOI 10.1099/0022-1317-72-4-877; JACKSON ME, 1995, J VIROL, V69, P6038, DOI 10.1128/JVI.69.10.6038-6046.1995; JAGGAR RT, 1990, J GEN VIROL, V71, P3041, DOI 10.1099/0022-1317-71-12-3041; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KATO R, 1983, CARCINOGENESIS, V4, P1301, DOI 10.1093/carcin/4.10.1301; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Knowles G, 1996, J VIROL, V70, P8451, DOI 10.1128/JVI.70.12.8451-8458.1996; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; MCCAFFERY RE, 1994, J GEN VIROL, V75, P3047, DOI 10.1099/0022-1317-75-11-3047; NAKAYASU M, 1986, MUTAT RES, V174, P79, DOI 10.1016/0165-7992(86)90081-3; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; PENNIE WD, 1992, VIROLOGY, V190, P861, DOI 10.1016/0042-6822(92)90926-G; Pereira MA, 1996, CARCINOGENESIS, V17, P1305, DOI 10.1093/carcin/17.6.1305; PIANTELLI M, 1995, J INVEST DERMATOL, V105, P248, DOI 10.1111/1523-1747.ep12317599; Plaumann B, 1996, ONCOGENE, V13, P1605; RAHMAN A, 1990, CARCINOGENESIS, V11, P2001, DOI 10.1093/carcin/11.11.2001; RANELLETTI FO, 1992, INT J CANCER, V50, P486, DOI 10.1002/ijc.2910500326; SAKAI A, 1990, TERATOGEN CARCIN MUT, V10, P333, DOI 10.1002/tcm.1770100406; SCAMBIA G, 1990, Anti-Cancer Drugs, V1, P45, DOI 10.1097/00001813-199010000-00008; SCAMBIA G, 1993, INT J CANCER, V54, P462, DOI 10.1002/ijc.2910540318; SMITH KT, 1987, CANC CELLS PAPILLOMA, P267; Trujillo JM, 1996, VIROLOGY, V220, P1, DOI 10.1006/viro.1996.0279; VANWARTHOOD JE, 1989, ONCOGENE, V4, P1267; WITHAM SE, 1986, BIOCHEM J, V240, P913	41	18	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2739	2746		10.1038/sj.onc.1201796	http://dx.doi.org/10.1038/sj.onc.1201796			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652740				2022-12-17	WOS:000073812200005
J	Wang, QM; Luo, X; Kheir, A; Coffman, FD; Studzinski, GP				Wang, QM; Luo, X; Kheir, A; Coffman, FD; Studzinski, GP			Retinoblastoma protein-overexpressing HL60 cells resistant to 1,25-dihydroxyvitamin D-3 display increased CDK2 and CDK6 activity and shortened G1 phase	ONCOGENE			English	Article						retinoblastoma; vitamin D; human leukemia; cell cycle; cyclins	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; HL-60 CELLS; CYCLE PROGRESSION; RESTRICTION POINT; GENE-EXPRESSION; SP1-MEDIATED TRANSCRIPTION; MONOCYTIC DIFFERENTIATION; MACROPHAGE PROLIFERATION; LINE HL-60	Drug resistance that occurs during cancer chemotherapy has been a major problem in controlling neoplastic progression. To study the cellular mechanisms of acquired drug resistance we developed 1,25-dihydroxy-vitamin D-3 (1,25D(3))-resistant sublines of promyelocytic leukemia HL60 cells which have increased proliferation rates (Exp, Cell Xes., 224, 312, 1996; Cancer Res., 50, 5513, 1996), We report here that the resistant sublines display varying degrees of shortening of the G1 phase as compared to the parental HL60-G cells. Protein levels of cyclins E, D1, D2 and D3 are elevated in these resistant cell lines, and cyclin D1 is especially high in 40AF cells, which has the shortest G1 length. The protein levels of cyclin-dependent kinase (Cdk)2, Cdk4 and Cdk6 are not altered in the resistant sublines. Both Cdk2 and Cdk6-associated kinase activites are increased in the resistant sublines, but not Cdk4 kinase activity. Protein levels of p27(Kip1) are not consistently altered in the resistant sublines as compared to the parental HL60-G cells, but are reduced relative to HL60-G cells arrested by 96 h treatment with 1,25D(3). Interestingly, the resistant cell lines constitutively express high levels of retinoblastoma protein (pRb), and pRb is highly phosphorylated, indicating that the G1 cyclin/Cdk complexes in the resistant cells are physiologically active. The results suggest that the increased activity of cyclin D/Cdk6, and perhaps cyclin E/Cdk2, lead to rapid hyperphosphorylation of pRb and consequently a shorter early G1 phase, and that in the resistant cells the increased ratio of cyclin E to p27(Kip1) results in activation of Cdk2 and contributes to the abrogation of the 1,25D(3)-induced block to the S phase entry. Additionally, it is apparent that constitutively increased levels of pRb are compatible with increased rates of cell proliferation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Studzinski, GP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, 185 S Orange Ave, Newark, NJ 07103 USA.				PHS HHS [R01-44722] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bergh G, 1997, BLOOD, V89, P2938, DOI 10.1182/blood.V89.8.2938; BRELVI ZS, 1986, J CELL BIOL, V102, P2234, DOI 10.1083/jcb.102.6.2234; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DOU QP, 1993, CANCER RES, V53, P1493; GALLAGHER R, 1979, BLOOD, V54, P713; GODYN JJ, 1994, CELL PROLIFERAT, V27, P37, DOI 10.1111/j.1365-2184.1994.tb01404.x; GONG J, 1995, LEUKEMIA, V9, P893; HAUSSLER MR, 1969, P NATL ACAD SCI USA, V62, P155, DOI 10.1073/pnas.62.1.155; HOLICK MF, 1971, BIOCHEMISTRY-US, V10, P2799; HUME DA, 1982, ADV EXP MED BIOL, V155, P261; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, ONCOGENE, V8, P3447; Juan G, 1996, CELL PROLIFERAT, V29, P259, DOI 10.1046/j.1365-2184.1996.01000.x; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kolla Sarah S, 1994, Molecular and Cellular Differentiation, V2, P169; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KURIBAYASHI T, 1983, ENDOCRINOLOGY, V113, P1992, DOI 10.1210/endo-113-6-1992; LASKY SR, 1994, BLOOD, V84, P4238; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; SAWYER RT, 1986, J LEUKOCYTE BIOL, V39, P77, DOI 10.1002/jlb.39.1.77; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SLADEK TL, 1992, J VIROL, V66, P1059, DOI 10.1128/JVI.66.2.1059-1065.1992; Studzinski George P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P279; Studzinski GP, 1997, EXP CELL RES, V232, P376, DOI 10.1006/excr.1997.3484; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; Wajchman HJ, 1996, EXP CELL RES, V224, P312, DOI 10.1006/excr.1996.0141; Wang QM, 1997, CANCER RES, V57, P2851; Wang QM, 1996, CANCER RES, V56, P264; Wang XN, 1997, J NATL CANCER I, V89, P1199, DOI 10.1093/jnci/89.16.1199; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yang Xiao-He, 1995, Gene Expression, V4, P195; ZHANG F, 1994, CELL PROLIFERAT, V27, P643, DOI 10.1111/j.1365-2184.1994.tb01379.x	53	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2729	2737		10.1038/sj.onc.1201803	http://dx.doi.org/10.1038/sj.onc.1201803			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652739				2022-12-17	WOS:000073812200004
J	Petti, LM; Irusta, PM; DiMaio, D				Petti, LM; Irusta, PM; DiMaio, D			Oncogenic activation of the PDGF beta receptor by the transmembrane domain of p185(neu)	ONCOGENE			English	Article						growth factor receptor; cell transformation; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; PAPILLOMAVIRUS-E5 TRANSFORMING PROTEIN; CHRONIC MYELOMONOCYTIC LEUKEMIA; TYROSINE KINASE-ACTIVITY; SIMIAN SARCOMA-VIRUS; SIGNAL-TRANSDUCTION; TUMORIGENIC TRANSFORMATION; INSULIN-RECEPTOR; POINT MUTATION; E5 PROTEIN	We replaced the transmembrane domain of the wild type murine PDGF beta receptor with that of p185(neu*), the oncogenic form of p185(neu), thereby generating a constitutively activated chimeric receptor PR/neu*. Unlike the wild type PDGF beta receptor or a Chimeric receptor containing the transmembrane domain of wild type p185(neu) (PR/neu), PR/neu* induced morphologic transformation, focus formation, and tumorigenicity in mouse C127 fibroblasts. Expression of PR/neu* in mouse Ba/F3 hematopoietic cells, which normally depend on IL-3 for survival and sustained proliferation, induced proliferation in the absence of IL-3. The PR/neu chimera conferred limited IL-3-independent growth of Ba/F3 cells. Only PR/neu* and not PR/neu displayed significantly increased levels of phosphotyrosine compared to the wild type PDGF receptor in C127 and Ba/F3 cells. In addition, PR/neu* immune complexes displayed increased levels of kinase activity in vitro compared to immune complexes of the wild type receptor. Furthermore, novel tyrosine phosphorylated proteins of approximately 60 kDa appeared to specifically complex with PR/neu*, suggesting that PR/neu* may activate distinct signaling pathways. We speculate that the p185(neu*) transmembrane domain in the context of the PDGF beta receptor facilitates receptor homodimerization, thereby inducing tyrosine autophosphorylation followed by association with important signaling substrates and transforming activity. Thus, PR/neu* should be a useful reagent for further characterizing activation and signaling mechanisms of the PDGF beta receptor.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	Yale University	Petti, LM (corresponding author), Albany Med Coll, Dept Microbiol Immunol & Mol Genet, A-68,47 New Scotland Ave, Albany, NY 12208 USA.				NATIONAL CANCER INSTITUTE [R37CA037157, P01CA016038, R01CA037157] Funding Source: NIH RePORTER; NCI NIH HHS [CA16038, CA37157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1992, J BIOL CHEM, V267, P20489; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; ESCOBEDO JA, MOL CELL BIOL, V10, P3858; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; LEE AW, 1992, J BIOL CHEM, V267, P16472; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1991, J VIROL, V66, P1833; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; RIESE DJ, 1995, ONCOGENE, V10, P1431; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; YAMADA K, 1992, J BIOL CHEM, V267, P12452; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	43	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					843	851		10.1038/sj.onc.1201590	http://dx.doi.org/10.1038/sj.onc.1201590			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484775				2022-12-17	WOS:000072053200003
J	Kleymenova, EV; Yuan, XQ; LaBate, ME; Walker, CL				Kleymenova, EV; Yuan, XQ; LaBate, ME; Walker, CL			Identification of a tumor-specific methylation site in the Wilms tumor suppressor gene	ONCOGENE			English	Article						EcoRI restriction enzyme; rat model; mesothelioma; renal cell carcinoma; leiomyoma/leiomyosarcoma	DNA METHYLATION; MALIGNANT MESOTHELIOMA; HUMAN NEOPLASIA; GROWTH-FACTOR; WT1 GENE; EXPRESSION; CANCER; CELLS; DELETION; RAT	Malignant mesothelioma is one of the very few extrarenal neoplasms in which the Wilms tumor suppressor gene (wt1) is expressed. We examined wt1 for alterations in rat mesotheliomas, a well characterized animal model for the human disease. Southern analysis revealed a 3.5 kb EcoRI wt1 fragment readily detectable in majority of mesothelioma cell lines and primary mesotheliomas but not in normal rat tissues. Cloning and sequencing of this fragment revealed that the presence of this EcoRI fragment resulted from an inability of this enzyme to cut at a EcoRI site in intron 1 of wt1. This site contains potential motifs for cytosine methylation and treatment of mesothelioma cells with 5-azadeoxycytosine restored the normal EcoRI digestion pattern of wt1 in these cells indicating that cleavage was inhibited by methylation at this site. Southern analysis using HpaII/MspI digestion revealed no differences in methylation between mesothelioma cell lines and normal mesothelium at other CpG sites in wt1 5' region. Renal cell carcinoma lines which did not express wt1 were also methylated at this EcoRI site. Our identification of a site frequently methylated in malignant cells, independent of gene expression, provides a new model system to study determinants of site-specific methylation in tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Kleymenova, EV (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA.				NCI NIH HHS [CA63613] Funding Source: Medline; NIEHS NIH HHS [ES06658] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006658] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANTMAN KH, 1993, CANC PRINCIPLES PRAC, P1489; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BERMUDEZ E, 1990, EXP CELL RES, V190, P91, DOI 10.1016/0014-4827(90)90148-4; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHENG JQ, 1994, CANCER RES, V54, P5547; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWELL JK, 1991, ONCOGENE, V6, P595; CRAIGHEAD JE, 1987, AM J PATHOL, V129, P448; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FREED J, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P317; FUNAKI K, 1991, CANCER RES, V51, P4059; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOWE SR, 1995, AM J PATHOL, V146, P1568; Jones PA, 1996, CANCER RES, V56, P2463; KIKUCHI H, 1992, AM J PATHOL, V140, P781; Kleymenova EV, 1997, MOL CARCINOGEN, V18, P54, DOI 10.1002/(SICI)1098-2744(199701)18:1<54::AID-MC7>3.3.CO;2-U; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIYAGI T, 1993, LEUKEMIA, V7, P970; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; PALEKAR LD, 1988, BIOL INTERACTION INH, P355; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; RAINIER S, 1994, JNCI-J NATL CANCER I, V86, P753, DOI 10.1093/jnci/86.10.753; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; SEKIDO Y, 1995, CANCER RES, V55, P1227; SHARMA PM, 1992, CANCER RES, V52, P6407; SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A; WAGNER J C, 1960, Br J Ind Med, V17, P260; WALKER C, 1994, CANCER RES, V54, P3101; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; XIAO S, 1995, ONCOGENE, V11, P511	44	18	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					713	720		10.1038/sj.onc.1201583	http://dx.doi.org/10.1038/sj.onc.1201583			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488035				2022-12-17	WOS:000071931800003
J	Pitkanen, K; Haapajarvi, T; Laiho, M				Pitkanen, K; Haapajarvi, T; Laiho, M			UVC-induction of p53 activation and accumulation is dependent on cell cycle and pathways involving protein synthesis and phosphorylation	ONCOGENE			English	Article						transcriptional regulation; DNA damage; post-transcriptional modification; staurosporine	TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; DNA-BINDING FUNCTION; CASEIN KINASE-II; DAMAGING AGENTS; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; POTENT INHIBITOR; MAMMALIAN-CELLS	Transcriptional activation and stabilization of p53 is a major response of mammalian cells to U.V.-light induced genetic damages, and possibly responsible for cell damage control. We have studied here by gel mobility shift and immunoblotting assays the activation and accumulation of p53 by U.V.C. and its dependency on cell cycle, protein synthesis and protein phosphorylation. In G(0)/G(1) synchronized cells U.V.C.-induced p53 DNA-binding activity, but not its accumulation, whereas both events took place in G(1)/S and S-phase cells. The kinetics of p53 activation by U.V.C. were slow requiring at least 1 h and slowly increasing thereafter with full activation observed at 6 h. Treatment of cells with cycloheximide (CHX) prevented the activation of p53 in all phases of the cell cycle and its accumulation in G(1)/S and S. However, removing CHX-block allowed full activation and accumulation of p53 with fast kinetics even if 4 h had lapsed since the initial U.V.C. insult. This suggests that the protein synthesis-dependent signal initiating p53 activation by U.V.C. remains continuous in the cells, The requirement of protein phosphorylation as mediator of p53 activation by U.V.C. was studied by using chemical protein kinase inhibitors. Of the tested inhibitors, only staurosporine, a known inhibitor of protein kinase C (PKC) and various other kinases, inhibited both p53 activation and accumulation, whereas specific PKC inhibitors, tyrosine kinase inhibitors and a serine/threonine kinase inhibitor did not. PKC-mediation of the p53 U.V.-response was further ruled out by the reactivity of the activated p53 to C-terminal antibody PAb 421. Kinetic studies shelved that staurosporine-mediated inhibition of p53 function is an early event in cell damage response, Thus dual, kinetically different events, de novo protein synthesis and staurosporine-inhibited protein phosphorylation are required for p53 activation and accumulation in all phases of the cell cycle, Notably, in the absence of U.V.-induced accumulation in G(0)/G(1) cells, p53 activation is still subject to inhibition of protein synthesis.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland	University of Helsinki	Laiho, M (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							ADDISON C, 1990, ONCOGENE, V5, P423; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAKALKIN, 1994, P NATL ACAD SCI US, V1, P413; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bond J, 1996, ONCOGENE, V13, P2097; BRUNO S, 1992, CANCER RES, V52, P470; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRITSCHE M, 1993, ONCOGENE, V8, P307; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lane DP, 1996, ONCOGENE, V12, P2461; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MIYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PRICE BD, 1993, ONCOGENE, V8, P3055; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1995, ONCOGENE, V10, P1053; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TARUNINA M, 1993, ONCOGENE, V8, P3165; TISHLER RB, 1993, CANCER RES, V53, P2212; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	75	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					459	469		10.1038/sj.onc.1201528	http://dx.doi.org/10.1038/sj.onc.1201528			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484835	Bronze			2022-12-17	WOS:000071739400004
J	He, LM; Cui, HM; Walsh, C; Mattsson, R; Lin, WL; Anneren, G; Pfeifer-Ohlsson, S; Ohlsson, R				He, LM; Cui, HM; Walsh, C; Mattsson, R; Lin, WL; Anneren, G; Pfeifer-Ohlsson, S; Ohlsson, R			Hypervariable allelic expression patterns of the imprinted IGF2 gene in tumor cells	ONCOGENE			English	Article						genomic imprinting; epigenetic; choriocarcinoma; activation; silencing	GROWTH FACTOR-II; H19 GENE; CHORIOCARCINOMA	The IGF2 gene, which encodes a growth factor, is subject to genomic imprinting, The frequently observed loss of IGF2 imprinting in a variety of tumors has been suggested to contribute to neoplasia, Since these reports have not documented the imprinting status of IGF2 at the cellular level, it cannot be excluded that the imprinting status might vary within the tumor, The possibility that loss of IGF2 imprinting in neoplastic cells reflects random imprinting patterns, was therefore addressed, We show here that individual cell populations of the JEG-3 choriocarcinoma cell line display heterogenous imprinting patterns of both IGF2 and H19, In addition, a lack of correlation between IGF2 and H19 imprinting status suggests that any regional parental imprint has been functionally lost, This notion is reinforced by the observation that JEG-3 cell subclones display a range of promoter-specific IGF2 allele usage, Moreover, we observed that the imprinting status of H19 and IGF2 were differentially modulated in JEG-3-derived tumors generated in nude mice, The results suggest that allele-specific expression of IGF2 operates in the absence of a parental imprint, Finally, our observations urge caution with respect to the general interpretation of biallelic expression as 'loss of imprinting'.	Uppsala Univ, Dept Anim Dev & Genet, S-75236 Uppsala, Sweden; Columbia Univ, Dept Genet & Dev, New York, NY USA; Univ Uppsala Hosp, Dept Paediat, S-75185 Uppsala, Sweden	Uppsala University; Columbia University; Uppsala University; Uppsala University Hospital	Ohlsson, R (corresponding author), Uppsala Univ, Dept Anim Dev & Genet, Norbyvagen 18A, S-75236 Uppsala, Sweden.		Walsh, Colum/ABD-7013-2020; Cui, Hengmi/A-2598-2008	Walsh, Colum/0000-0001-9921-7506; 				Adam GIR, 1996, DEVELOPMENT, V122, P839; Barletta JM, 1997, CANCER RES, V57, P48; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; DOUCRASY S, 1996, ONCOGENE, V12, P324; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; FEINBERG AP, 1994, COLD SPRING HARB SYM, V59, P357, DOI 10.1101/SQB.1994.059.01.040; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LYON MF, 1995, GENOMIC IMPRINTING C, P129; Mannens M, 1997, NAT GENET, V15, P113, DOI 10.1038/ng0297-113; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1989, EMBO J, V8, P1993, DOI 10.1002/j.1460-2075.1989.tb03606.x; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; OHLSSON R, 1995, GENOMIC IMPRINTING C, P1; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; TYCKO B, 1994, AM J PATHOL, V144, P431; ZHANG YH, 1993, AM J HUM GENET, V53, P113	20	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					113	119		10.1038/sj.onc.1201501	http://dx.doi.org/10.1038/sj.onc.1201501			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467950				2022-12-17	WOS:000071236800014
J	Wang, QJ; Acs, P; Goodnight, JA; Blumberg, PM; Mischak, H; Mushinski, JF				Wang, QJ; Acs, P; Goodnight, JA; Blumberg, PM; Mischak, H; Mushinski, JF			The catalytic domain of PKC-epsilon, in reciprocal PKC-delta and -epsilon chimeras, is responsible for conferring tumorgenicity to NIH3T3 cells, whereas both regulatory and catalytic domains of PKC-epsilon contribute to in vitro transformation	ONCOGENE			English	Article						chimeric PKC; PKC-epsilon; PKC-delta; transformation; tumorgenicity; NIH3T3	PROTEIN-KINASE-C; FIBROBLASTS; NUCLEAR; ISOFORM; RAS	Protein kinase C-epsilon (PKC-epsilon) has been shown to increase growth and cause malignant transformation when overexpressed in NIH3T3 cells, whereas PKC-delta reduced fibroblast growth, Two reciprocal chimeric proteins (PKC-epsilon delta and PKC-delta epsilon were constructed by exchanging the regulatory and catalytic domains of PKC-delta and -epsilon and were stably overexpressed in NIH3T3 cells, Fibroblasts that overexpressed either chimera showed maximum cell density and morphology that were intermediate between cells overexpressing PKC-delta and those that overexpressed PKC-epsilon, Moreover, all lines that expressed chimeras were capable of anchorage-independent growth in the presence of TPA, which indicated that both the regulatory and catalytic domains of PKC-epsilon could independently induce NIH3T3 transformation, although the combination of both domains, as found in PKC-epsilon, was the most active form, In contrast, the translocation pattern and ability to induce tumors in nude mice was attributable to the catalytic domains exclusively, In particular, cells that expressed PKC-delta epsilon retained PKC-epsilon's full potency of tumorgenicity when injected into nude mice, In sum, our findings not only reinforce the concept that only certain PKC isozymes contribute to carcinogenesis but also show that different domains of PKCs mediate the physiologically distinguishable events of transformation and tumorgenesis.	NCI, Genet Lab, Bethesda, MD 20892 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mushinski, JF (corresponding author), NCI, Genet Lab, Bethesda, MD 20892 USA.		Wang, Qiming Jane/B-6064-2012; Mischak, Harald/E-8685-2011	Wang, Qiming Jane/0000-0002-9502-4851; Mischak, Harald/0000-0003-0323-0306				Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; ZUALI G, 1996, BRIT J HAEMATOL, V92, P530	15	18	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					53	60		10.1038/sj.onc.1201507	http://dx.doi.org/10.1038/sj.onc.1201507			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467942				2022-12-17	WOS:000071236800006
J	Wu, Y; Liu, JX; Arlinghaus, RB				Wu, Y; Liu, JX; Arlinghaus, RB			Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase	ONCOGENE			English	Article						Bcr serine/threonine kinase; Bcr tyrosine residues; tyrosine phosphorylation of Bcr; inhibition of Bcr serine kinase by Bcr-Ab1; kinase role of Bcr tyrosines 328 and 360	MUSCLE PYRUVATE-KINASE; ABL ONCOPROTEINS; GENE ENCODES; P160 BCR; PHOSPHORYLATION; LEUKEMIA; CELLS	Bcr is a novel serine/threonine protein kinase that is believed to require two cysteine pairs for activity (Maru and Witte, Cell, 67, 459, 1991), Tyrosine phosphorylated Bcr has dramatically reduced kinase activity, and tyrosine 360 of Bcr, which is one of the sites of phosphorylation by the Bcr - Abl oncoprotein, is required for transkinase activity (Liu et al., Mel. Cell Biol,, 16, 998, 1996), Results presented here indicate that Bcr tyrosine 328 is also phosphorylated within Bcr-Abl expressing cells and is required for Bcr's serine/threonine kinase activity, Bcr Y328F, like Bcr Y360F, had defective transkinase activity but can autophosphorylate. However, the Y328F/Y360F double mutant of Bcr is defective in both trans-and autokinase activities, Taken together with the kinase inhibitory effects of tyrosine phosphorylation of Bcr by Bcr-Abl, our studies with tyrosine to phenylalanine Bcr mutants indicate that the hydroxyl residues of tyrosines 328 and 360 play crucial roles in Bcr's kinase activity.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA65611, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065611, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; CAMPBELL ML, 1991, ADV CANCER RES, V57, P227; CAMPBELL ML, 1990, ONCOGENE, V5, P773; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; LI WJ, 1989, ONCOGENE, V4, P127; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TOMICH JM, 1981, BIOCHEMISTRY-US, V20, P6711, DOI 10.1021/bi00526a029	18	18	18	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					141	146		10.1038/sj.onc.1201524	http://dx.doi.org/10.1038/sj.onc.1201524			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467953				2022-12-17	WOS:000071236800017
J	Jackson, JH; Vollenweider, M; Hill, J; Rodriguez, H; Schwabacher, AW; Mitra, G; Kuo, CY				Jackson, JH; Vollenweider, M; Hill, J; Rodriguez, H; Schwabacher, AW; Mitra, G; Kuo, CY			Stimulated human leukocytes cause activating mutations in the K-ras protooncogene	ONCOGENE			English	Article						inflammation; carcinogenesis; oxidants; DNA damage; K-ras	POLYMERASE CHAIN-REACTION; SITE-SPECIFIC MUTAGENESIS; C-HA-RAS; MAMMALIAN-CELLS; TUMOR PROMOTER; DNA TEMPLATES; POLYMORPHONUCLEAR LEUKOCYTES; IONIZING-RADIATION; ULCERATIVE-COLITIS; OXIDATIVE DAMAGE	Human tissues which are chronically infiltrated with inflammatory leukocytes are more likely to develop malignancies than non-inflamed tissues, however the mechanism(s) by which leukocytes contribute to carcinogenesis is unknown. Stimulated human leukocytes release superoxide anion and hydrogen peroxide which, in the presence of iron, can be converted into the potent oxidant, hgdroxyl radical (. OH). Previous studies have shown that leukocyte-derived . OH (or a . OH-Like species) can cause DIVA damage, however a relationship between leukocyte-induced DNA damage and carcinogenesis has not been established. The present report demonstrates that leukocyte-derived . OH-induced DNA damage can cause K-ras oncogene activation, and suggests that there may be a characteristic pattern of . OH-induced k-ras oncogene activation. Since activation of the k-ras oncogene is believed to play a crucial role in the pathogenesis of many human malignancies . OH induced K-ras oncogene activation could be an important mechanism by which human leukocytes contribute to carcinogenesis.	PRINCETON UNIV, DEPT CHEM, PRINCETON, NJ 08544 USA; PROMEGA CORP, MADISON, WI 53711 USA	Princeton University; Promega Corporation	Jackson, JH (corresponding author), Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, BOX 1MM 12, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA-54298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; BERKOW RL, 1983, J LAB CLIN MED, V102, P732; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004; BOS JL, 1989, CANCER RES, V49, P4682; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHENG KC, 1992, J BIOL CHEM, V267, P166; DEVROEDE GJ, 1971, NEW ENGL J MED, V285, P17, DOI 10.1056/NEJM197107012850103; FLOYD RA, 1986, BIOCHEM BIOPH RES CO, V137, P841, DOI 10.1016/0006-291X(86)91156-3; FRENKEL K, 1986, CANCER RES, V46, P5533; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GREENSTEIN AJ, 1979, GASTROENTEROLOGY, V77, P290; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HAYES RC, 1988, J MOL BIOL, V201, P239, DOI 10.1016/0022-2836(88)90135-0; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JACKSON JH, 1989, J CLIN INVEST, V84, P1644, DOI 10.1172/JCI114342; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAMIYA H, 1992, CANCER RES, V52, P3483; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LEWIS JG, 1985, CANCER RES, V45, P1270; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NASSICALO L, 1989, CARCINOGENESIS, V10, P1055, DOI 10.1093/carcin/10.6.1055; ORITA S, 1991, VIRUS GENES, V5, P75, DOI 10.1007/BF00571733; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; SUZUKI Y, 1990, ONCOGENE, V5, P1037; VOUSDEN KH, 1986, P NATL ACAD SCI USA, V83, P1222, DOI 10.1073/pnas.83.5.1222; WEITBERG AB, 1983, NEW ENGL J MED, V308, P26, DOI 10.1056/NEJM198301063080107; WEITZMAN SA, 1985, SCIENCE, V227, P1231, DOI 10.1126/science.3975611; WEITZMAN SA, 1990, BLOOD, V76, P655; WEITZMAN SA, 1982, J IMMUNOL, V128, P2770; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; ZIMMERMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P2085, DOI 10.1073/pnas.81.7.2085	47	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2803	2808		10.1038/sj.onc.1201118	http://dx.doi.org/10.1038/sj.onc.1201118			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190896				2022-12-17	WOS:A1997XD64300008
J	Plet, A; Huet, X; Algarte, M; Rech, J; Imbert, J; Philips, A; Blanchard, JM				Plet, A; Huet, X; Algarte, M; Rech, J; Imbert, J; Philips, A; Blanchard, JM			Relief of cyclin A gene transcriptional inhibition during activation of human primary T lymphocytes via CD2 and CD28 adhesion molecules	ONCOGENE			English	Article						cyclin A; primary T lymphocytes adhesion	DNA-BINDING ACTIVITY; CELL-CYCLE; A GENE; RETINOBLASTOMA PROTEIN; S-PHASE; EXPRESSION; KINASE; REPLICATION; FAMILY; E2F	Cyclin A transcription is cell cycle regulated and induced by cell proliferative signals. To understand the mechanisms underlined in this regulation in normal human cells, we have analysed in vivo protein-DNA interactions at the Cyclin A locus in primary T lymphocytes. Stimulation of purified T lymphocytes by a combination of monoclonal antibodies directed at CD2 and CD28 adhesion molecules gives rise to a long lasting proliferation in the absence of accessory cells. Cyclin A was observed after 4 days of costimulation with anti CD2+ CD28 whereas stimulation by anti CD2 or anti CD28 alone was not effective. In vivo genomic DMS footprinting revealed upstream of the major transcription initiation sites, the presence of at least three protein binding sites, two of which were constitutively occupied. They bind in vitro respectively ATF-1 and NF-Y proteins. The third site was occupied in quiescent cells or in cells stimulated by anti CD2 or anti CD28 alone. The mitogenic combination of anti CD2+ anti CD28 released the footprint as cells were committed to proliferation. Consistent with theses results, nuclear extracts prepared from quiescent cells formed a specific complex with this element, whereas extracts prepared from cells treated with anti CD2+ anti CD28 failed to do so after cells entered-a proliferative state.	CNRS, UMR 5535, INST GENET MOL MONTPELLIER, F-34033 MONTPELLIER 1, FRANCE; INSERM, U119, F-13009 MARSEILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm)			Imbert, Jean/G-3248-2013; Imbert, Jean/AAG-1165-2020; PHILIPS, Alexandre/AAB-6047-2020	Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; 				ALGARTE M, 1995, EMBO J, V14, P5060, DOI 10.1002/j.1460-2075.1995.tb00188.x; BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CERDAN C, 1991, J IMMUNOL, V146, P560; COSTELLO R, 1993, CELL GROWTH DIFFER, V4, P329; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HORI T, 1987, BLOOD, V70, P1069; Huet X, 1996, MOL CELL BIOL, V16, P3789; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; NEVINS JR, 1992, SCIENCE, V258, P424; OLIVE D, 1994, FUND CLIN IMMUNOL, V2, P185; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WALKER RA, 1995, CELL, V354, P314; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	41	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	1997	14	21					2575	2583		10.1038/sj.onc.1201103	http://dx.doi.org/10.1038/sj.onc.1201103			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191057				2022-12-17	WOS:A1997XA94900009
J	Aasheim, HC; Pedeutour, F; Smeland, EB				Aasheim, HC; Pedeutour, F; Smeland, EB			Characterization, expression and chromosomal localization of a human gene homologous to the mouse Lsc oncogene, with strongest expression in hematopoetic tissues	ONCOGENE			English	Article						Lsc homologue; Rho GEF; Dbl-family; hematopoetic expression	GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; CELL POLARITY; LYMPHOCYTES-B; RHO; CDC42; RAS; CLONING; YEAST; REGULATORS	A human cDNA clone, denoted sub1.5, was isolated from cDNA library generated from human T cells, The sub1.5 cDNA sequence was novel and was not identical to any known cDNA sequences in the GenBank. Recently, however, a mouse cDNA (Lsc) with high homology to sub1.5 was identified, indicating that the sub1.5 sequence may represent the human homologue of the mouse Lsc gene. The sub1.5 cDNA includes an open reading frame of 875 amino acids, predicting a protein with molecular weight of 97 kDa. Like Lsc, sub1.5 shows homology to the previous described oncogene Lbc, in particular to two functional domains in the Lbc protein; the Dbl protooncogene homology domain and the pleckstrin homology domain. Lsc is proposed to be an oncogene and is a member of a growing family of proteins that may function as activators of the Rho family GTPases. Members of the Rho family regulates the polymerization of actin to produce stress fibers. Activation of Rho GTPases by sub1.5 is also indicated by our studies, as stress fiber formation is observed in serum-starved stable NIH3T3 sub1.5 transfectants. Sub1.5 cDNA hybridizes to two major transcripts of 3.5 and 5 kb size and the strongest expression is seen in hematopoietic tissues like thymus, lymph nodes, peripheral blood leukocytes and spleen. We also show that both purified B and T cells express sub1.5. In addition, our data indicate that sub1.5 mRNA is abundantly expressed in CD34(+) human progenitor cells. Fluorescent in situ hybridisation, using sub1.5 cDNA as a probe on human metaphases, shows that the sub1.5 gene is localized to chromosome 19q13.13.	FAC MED,URA CNRS 1462,NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	Aasheim, HC (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,DEPT IMMUNOL,N-0310 OSLO,NORWAY.		Smeland, Erlend/AAO-3214-2020					AASHEIM HC, 1994, BIOTECHNIQUES, V16, P716; AASHEIM HC, 1969, METHODS MOL BIOL CDN, V69; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHAN AML, 1994, ONCOGENE, V9, P1057; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEDEUTOUR F, 1994, GENOMICS, V19, P31, DOI 10.1006/geno.1994.1008; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RASMUSSEN AM, 1992, J IMMUNOL METHODS, V146, P195, DOI 10.1016/0022-1759(92)90228-L; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUSTEN LS, 1994, BLOOD, V84, P1473; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TOKSOZ D, 1994, ONCOGENE, V9, P621; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	36	18	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1747	1752		10.1038/sj.onc.1200994	http://dx.doi.org/10.1038/sj.onc.1200994			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135076				2022-12-17	WOS:A1997WR89300013
J	BenYosef, T; Yanuka, O; Benvenisty, N				BenYosef, T; Yanuka, O; Benvenisty, N			ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast	ONCOGENE			English	Article						Gcn4; c-Jun; c-Myc; oncogenesis; targets; transcription	HELIX-LOOP-HELIX; DNA-BINDING; CELL-LINE; N-MYC; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; EMBRYONIC LETHALITY; CONTINUOUS CULTURE; GENERAL CONTROL; PROTEIN-KINASE	myc oncogenes are transcription factors regulating the level of expression of other genes, Using a subtraction/coexpression strategy, a murine genetic target for Myc regulation was isolated, To further characterize this target gene, named ECA39, we have recently isolated the human, nematode and budding yeast homologs of the mouse gene, The recognition site for Myc binding, located 3' to the start site of transcription in the mouse gene, is conserved in the human homolog, Transfection experiments demonstrated that the Myc binding site of the human gene, mediates activation of a reporter gene in response to over-expression of c-myc, The activation was better executed when the c-Myc binding element was positioned downstream to the promoter, which is the usual position of the c-Myc DNA binding element in its genetic targets, The tissue specific expression of human ECA39 during embryogenesis is similar to that of the mouse homolog, Moreover, ECA39 is expressed in c-myc induced human tumors, It is expressed in Burkitt's lymphoma (where c-myc is translocated and activated) but not in non Burkitt's B-cell lymphoma or in T-cell lymphoma, Thus, it seems that ECA39 is a target for c-myc oncogenesis in humans, In yeast, where c-myc is absent, the ECA39 sequences lack the c-Myc binding element, However, the promoter region of the yeast ECA39 harbors several Gcn4 binding elements, Moreover, ECA39 is markedly down regulated in cells deleted for gcn4, and deletion of Gcn4 binding elements down regulated the transcription from ECA39 promoter, We thus suggest that ECA39 is a target for c-Myc regulation in mammals, while in yeast the regulator is not c-Myc but the c-Jun/c-Fos homolog - Gcn4.	HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BENBASSAT H, 1980, INT J CANCER, V25, P583, DOI 10.1002/ijc.2910250506; BENBASSAT H, 1992, LEUKEMIA LYMPHOMA, V6, P513, DOI 10.3109/10428199209053591; BENVENISTY N, 1995, GROWTH FACTORS, V12, P49, DOI 10.3109/08977199509003213; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DAVIS LJ, 1993, ONCOGENE, V8, P125; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERIN M, 1988, ONCOGENE RES, V3, P21; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANDSCHULTZ WH, 1987, SCIENCE, V240, P1759; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MIFFLIN D, 1988, BIOSCIENCE REP, V8, P415, DOI 10.1007/BF01121638; Miller JH, 1972, EXPT MOL GENETICS; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1989, NATURE, V341, P362; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROSE MD, 1990, METHODS YEAST GENETI; SARID J, 1988, NUCLEIC ACIDS RES, V16, P4725, DOI 10.1093/nar/16.10.4725; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; SHILO BZ, 1982, P NATL ACAD SCI USA, V78, P6789; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STEINITZ M, 1975, P NATL ACAD SCI USA, V72, P8515; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WALKER CW, 1992, ONCOGENE, V7, P2007	64	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1859	1866						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934531				2022-12-17	WOS:A1996VR79500004
J	Kolch, W; Philipp, A; Mischak, H; Dutil, EM; Mullen, TM; Feramisco, JR; Meinkoth, JL; Rose, DW				Kolch, W; Philipp, A; Mischak, H; Dutil, EM; Mullen, TM; Feramisco, JR; Meinkoth, JL; Rose, DW			Inhibition of Raf-1 signaling by a monoclonal antibody, which interferes with Raf-1 activation and with Mek substrate binding	ONCOGENE			English	Article						Raf-1 signaling; antibody microinjection; Mek	PROTEIN-KINASE KINASE; SERINE-THREONINE KINASE; C-FOS PROMOTER; TRANSCRIPTION FACTOR; TERNARY COMPLEX; GROWTH-FACTOR; V-RAF; TYROSINE KINASE; PLASMA-MEMBRANE; EARLY RESPONSE	Raf-1 is a serine/threonine specific kinase that integrates signaling by a large number of mitogens to elicit a transcriptional response in the nucleus, Activated Raf-1 phosphorylates and activates MAPK/ERK kinase (Mek), thus initiating the Mek-->MAP kinase cascade, which ultimately results in the phosphorylation and activation of transcription factors by MAP kinase. Here we have characterized the mechanism by which monoclonal antibody URP26K, which binds to an epitope in the Raf-1 kinase domain, inhibits intracellular signal transduction. This antibody preferentially immunoprecipitated the underphosphorylated, non-activated form of Raf-1 from quiescent cells. Baculovirus-expressed Raf-1 immunoprecipitated with URP26K was Largely refractory to. phosphorylation and activation mediated by protein kinase C (PKC)alpha or the tyrosine kinase Lck. In addition, URP26K reduced the binding of Raf-1 to its vitro, but did not disturb the Ras. Microinjection of with cells blocked DIVA synthesis initiated by serum, insulin and various purified growth factors, but it did not block DNA synthesis initiated by v-ras. Microinjected URP26K also impaired the expression of stably transfected beta-galactosidase reporter genes regulated by minimal promoter elements. These results demonstrate, (i) that the URP26K monoclonal antibody inhibits Raf-1 by preventing activating Raf-1 phosphorylation and/or association with its substrate Mek, (ii) that inhibition of Raf-1 by URP26K does not interfere with Ras-induced DNA synthesis. In contrast to dominant negative Raf-1 mutants, which also block Ras signaling by binding to the Ras effector domain, antibody mediated Raf-1 inhibition thus reveals branchpoint of mitogenic signaling at the level of Ras.	UNIV CALIF SAN DIEGO, WHITTIER DIABET PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; UNIV PENN, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA; GSF MUNICH, HAEMATOLOGIKUM, INST KLIN MOL BIOL & TUMORGENET, D-81377 MUNICH, GERMANY	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Pennsylvania; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Mischak, Harald/E-8685-2011; Meinkoth, Judy L/G-2900-2010; Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022	Mischak, Harald/0000-0003-0323-0306; MULLEN, Tina-Marie/0000-0001-6150-8084; Kolch, Walter/0000-0001-5777-5016				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BRENNSCHEIDT U, 1994, CELL GROWTH DIFFER, V5, P367; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KOLCH W, 1990, ONCOGENE, V5, P713; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, ONCOGENE, V8, P361; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1991, ONCOGENE, V6, P495; RIM M, 1992, ONCOGENE, V7, P2065; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VICIANA PR, 1994, NATURE, V370, P527; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; XIAO S, 1994, J BIOL CHEM, V269, P21244	57	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1305	1314						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808705				2022-12-17	WOS:A1996VJ20200022
J	Noguchi, K; Naito, M; Kugoh, H; Oshimura, M; Mashima, T; Fujita, N; Yonehara, S; Tsuruo, T				Noguchi, K; Naito, M; Kugoh, H; Oshimura, M; Mashima, T; Fujita, N; Yonehara, S; Tsuruo, T			Chromosome 22 complements apoptosis in Fas- and TNF-resistant mutant UK110 cells	ONCOGENE			English	Article						microcell-fusion; chromosome 22; Fas; TNF; apoptosis	TUMOR-NECROSIS-FACTOR; DEATH GENE CED-3; INSITU HYBRIDIZATION; RECEPTOR; ANTIGEN; INDUCTION; HYBRIDS; HT1080; DOMAIN; ENZYME	Fas and p55 tumor necrosis factor receptor (TNFR) transfer an apoptosis signal when they are crosslinked with their ligands or agonistic antibodies, However, the signal transduction mechanism of apoptosis via Fas and p55 TNFR has not yet been elucidated, We previously described a recessive mutant UK110 from the human monocytic leukemia U937 cell line, that showed resistance against Fas- and p55 TNFR-mediated apoptosis. By cytogenetic analysis and microcell-fusion method, we demonstrate here that introduction of chromosome 22 can specifically restore the sensitivity to Fas- and TNF-mediated apoptosis in UK110 cells, Moreover, introduction of chromosome 22 into UK110 can complement the processing of interleukin-1 beta converting enzyme (ICE)-like proteases, such as CPP32/Yama/Apopain and ICH-1L, after treatment with anti-Pas and anti-p55 TNFR antibodies, These results suggest that the product of a gene located on chromosome 22 participates in the Fas-and p55 TNFR-mediated apoptosis at a point upstream of ICE-like proteases.	UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,LAB BIOMED RES,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,DEPT MOLEC & CELL GENET,TOTTORI 683,JAPAN; KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOKYO 170,JAPAN	University of Tokyo; Tottori University; Kyoto University; Japanese Foundation for Cancer Research								BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BENEDICT WF, 1984, CANCER RES, V44, P3471; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FUCHS P, 1992, GENOMICS, V13, P219, DOI 10.1016/0888-7543(92)90226-I; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KUGOH HM, 1990, ONCOGENE, V5, P1637; KUMAR S, 1995, HUM GENET, V95, P641; KURAHASHI H, 1994, HUM GENET, V93, P248, DOI 10.1007/BF00212017; KURIMASA A, 1994, HUM GENET, V93, P21; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOGUCHI K, 1995, CELL GROWTH DIFFER, V6, P1271; PEREIRA LD, 1991, GENOMICS, V9, P229, DOI 10.1016/0888-7543(91)90246-B; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	43	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					39	46						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700552				2022-12-17	WOS:A1996UX31900005
J	Kees, UR; Ranford, PR; Hatzis, M				Kees, UR; Ranford, PR; Hatzis, M			Deletions of the p16 gene in pediatric leukemia and corresponding cell lines	ONCOGENE			English	Article						p16; pediatric leukemia; cell lines	LYMPHOBLASTIC-LEUKEMIA; SHORT ARM; ESTABLISHMENT; ABNORMALITIES; CHROMOSOME-9; PHENOTYPE; RECEPTOR	The p16 gene (MTS1 or CDK41) encoding an inhibitor of cyclin-dependent kinase 4 (cdk4), has been reported to be deleted in various tumor cell lines, including lines derived from leukemic cells, The reported frequency of p16 gene Toss Is much higher in established cell lines than in primary tumor specimens, We investigated the status of the p16 gene in pediatric leukemias using 12 established cell lines of differing phenotypes and their corresponding primary leukemic cells, Six: of 12 cell lines, including acute lymphoblastic leukemia (ALL) lines of T-cell (three of four), of precursor-B cell (two of four) and of mixed phenotype (one of four), showed homozygous deletion of the p16 gene using PCR and Southern blotting, Comparison of the cell lines with their corresponding primary leukemic cells clearly showed that in all 12 paired samples there were identical findings with respect to the presence or absence of the p16 gene, demonstrating that loss of the gene was a feature of the primary leukemic cells, This is the first study to show this correlation using a panel of paired samples, indicating that p16 gene deletions were not an artifact of in vitro cell culture, Furthermore, the survival of ALL patients with p16 gene deletions was significantly inferior to those without deletions, suggesting that this genetic alteration may be a clinical prognostic factor.	TVWT,INST CHILD HLTH RES,DIV CHILDRENS LEUKAEMIA & CANC RES,PERTH,WA,AUSTRALIA	Telethon Kids Institute; University of Western Australia								CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAYUELA JM, 1995, BLOOD, V85, P854, DOI 10.1182/blood.V85.3.854a.bloodjournal853854a; DURO D, 1994, CR ACAD SCI III-VIE, V317, P913; FIZZOTTI M, 1995, BLOOD, V85, P2685, DOI 10.1182/blood.V85.10.2685.bloodjournal85102685; GONZALEZREDONDO JM, 1988, BLOOD, V72, P1007; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEES UR, 1990, LEUKEMIA, V4, P292; KEES UR, 1988, BLOOD, V72, P1524; KEES UR, 1990, CANCER GENET CYTOGEN, V46, P201, DOI 10.1016/0165-4608(90)90105-J; KEES UR, 1989, BLOOD, V74, P369; KEES UR, 1995, GENE CHROMOSOME CANC, V12, P201, DOI 10.1002/gcc.2870120307; KEES UR, 1987, LEUKEMIA RES, V11, P489, DOI 10.1016/0145-2126(87)90082-8; KEES UR, 1987, CANCER RES, V47, P3088; KEES UR, 1993, LEUKEMIA RES, V17, P51, DOI 10.1016/0145-2126(93)90141-7; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OGAWA S, 1995, BLOOD, V86, P1548, DOI 10.1182/blood.V86.4.1548.bloodjournal8641548; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OTSUKI T, 1995, CANCER RES, V55, P1436; POLLAK C, 1987, LEUKEMIA, V1, P541; QUESNEL B, 1995, BLOOD, V85, P657, DOI 10.1182/blood.V85.3.657.bloodjournal853657; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; ZHANG SY, 1994, CANCER RES, V54, P5050	28	18	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2235	2239						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668350				2022-12-17	WOS:A1996UP28300023
J	Greulich, H; Reichman, C; Hanafusa, H				Greulich, H; Reichman, C; Hanafusa, H			Delay in serum stimulation of Erk activity caused by oncogenic transformation	ONCOGENE			English	Article						Erk; Crk; signal transduction; mitogenesis	EPIDERMAL GROWTH-FACTOR; GTPASE-ACTIVATING PROTEIN; MAP KINASE; NUCLEOTIDE EXCHANGE; GUANINE-NUCLEOTIDES; GENE-PRODUCT; V-CRK; TYROSINE; PHOSPHORYLATION; FIBROBLASTS	Mitogenic growth factor stimulation activates several signal transduction pathways, including the well-characterized Ras-Erk pathway, resulting in transient activation of Erk1 and Erk2. Oncogenic transformation, however, causes constitutive activation of growth signalling pathways, resulting in an accelerated rate of cell division. We investigated the effects of transformation on serum and growth factor stimulation of Erk1 and Erk2, and show that stimulation of these MAP kinases, as well as the Erk activator Mek, is delayed in oncogene transformed cells. Possible mechanisms of this delay are explored. In addition, our data indicate that prolonged mitogenic stimulation does not necessarily result in constitutive activation of Erk1 and Erk2.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021	Rockefeller University					NCI NIH HHS [CA09673-19, CA44356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WELHAM MJ, 1990, ONCOGENE, V5, P161; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	38	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1689	1695						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622889				2022-12-17	WOS:A1996UG45800011
J	CorbalanGarcia, S; Degenhardt, KR; BarSagi, D				CorbalanGarcia, S; Degenhardt, KR; BarSagi, D			Insulin-induced dissociation of Sos from Grb2 does not contribute to the down regulation of Ras activation	ONCOGENE			English	Article						Sos; Grb2; ras; insulin; MAP kinase	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; DEPENDENT ACTIVATION; POLYACRYLAMIDE GELS; PROTEIN; INHIBITION; P21RAS; BINDS; CAMP	Activation of Ras by a number of receptor tyrosine kinases is mediated by the guanine nucleotide exchange factor Sos. This activation is thought to occur as a result of the recruitment to the plasma membrane of a complex consisting of Sos and the adaptor molecule Grb2. Growth factor stimulation has been shown to induce the rapid phosphorylation of Sos on serine and threonine residues. In rat L6 cells, insulin-induced Sos phosphorylation is accompanied by a partial dissociation of the Grb2-Sos complex. In this study we have investigated the relationship between Sos phosphorylation and Grb2 association. To this end, we have utilized cAMP because it has been demonstrated that elevation of cytoplasmic levels of cAMP inhibits growth factor-induced Sos phosphorylation. We show that in rat L6 cells, cAMP treatment prevents both the insulin-stimulated Sos phosphorylation and Grb2 dissociation. However, cAMP treatment has no effect on the duration of insulin-induced Ras activation. These results suggest that the kinetics of Ras activation are independent of the phosphorylation-induced dissociation of Sos from Grb2.	SUNY STONY BROOK, DEPT MOLEC GENET & MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Corbalan-Garcia, Senena/C-6477-2009	Corbalan-Garcia, Senena/0000-0003-1840-5578; Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA055360, R01CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, CELL, V11, P1327; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	28	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1063	1068						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649797				2022-12-17	WOS:A1996UA88400014
J	Lengye, E; Singh, B; Gum, R; Nerlov, C; Sabichi, A; Birrer, M; Boyd, D				Lengye, E; Singh, B; Gum, R; Nerlov, C; Sabichi, A; Birrer, M; Boyd, D			Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene	ONCOGENE			English	Article						urokinase; mos; MAPK; AP-1	PROTEIN-KINASE ACTIVITY; GENE-EXPRESSION; MAP KINASE; PHORBOL-ESTER; SARCOMA-VIRUS; C-JUN; TRANSFORMATION; PRODUCT; RAS; FOS	We undertook a study to determine if the serine-threonine kinase-encoding v-mos oncogene regulated the expression of the urokinase-type plasminogen activator. An expression vector encoding v-mos, but not a kinase-inactive mutant, stimulated urokinase promoter activity in CAT assays employing a squamous cell carcinoma cell line, The induction of urokinase promoter activity by v-mos was mediated, in part, via an increased AP-1 activity since (a) mutation of 2 AP-1 binding sites (at -1967 and -1885), or the co-expression of a transactivation domain-lacking c-jun mutant reduced the induction of the urokinase promoter by v-mos and (b) expression of v-mos increased the activity of a CAT reporter driven by three AP-1 tandem repeats, The stimulation of the urokinase promoter by v-mos was partially countered by co-expression of an ERK1/ERK2-inactivating phosphatase. Western blotting and zymographic analysis indicated that v-mos-transformed NM3T3 cells (MSV NIH-3T3) secreted more urokinase compared with NIH3T3 cells and this was associated with a higher level of activated ERK1 and ERK2, Expression of a catalytically-inactive MAPKK mutant reduced the activity of a urokinase promoter-driven CAT reporter in the MSV NIH-3T3 cells, In conclusion, the data herein indicate that urokinase expression is regulated by v-mos through a MAPKK-dependent signaling pathway.	MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG,HOUSTON,TX 77030; MD ANDERSON CANC CTR,DEPT MOLEC BIOL,HOUSTON,TX 77030; UNIV COPENHAGEN,INST MICROBIOL,COPENHAGEN,DENMARK; NIH,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Copenhagen; National Institutes of Health (NIH) - USA			Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDREASEN PA, 1990, ENDOCRINOLOGY, V126, P2567, DOI 10.1210/endo-126-5-2567; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BELL SM, 1990, J BIOL CHEM, V265, P1333; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; BROWN PH, 1993, ONCOGENE, V8, P877; CHAN JC, 1992, J BIOL CHEM, V267, P1099; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; KAMADA S, 1994, J BIOL CHEM, V269, P4565; KASAI S, 1985, J BIOL CHEM, V260, P2382; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LIOTTA LA, 1981, CANCER RES, V41, P4629; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NAKAGAWA J, 1988, J BIOL CHEM, V263, P2460; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SALO T, 1982, INT J CANCER, V30, P669, DOI 10.1002/ijc.2910300520; SCHONTHAL A, 1990, New Biologist, V2, P143; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1992, MOL CARCINOGEN, V6, P182, DOI 10.1002/mc.2940060303; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; STACEY DW, 1991, ONCOGENE, V6, P2297; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; TESTA JE, 1989, INT J CANCER, V43, P816, DOI 10.1002/ijc.2910430513; TOURAY M, 1991, ONCOGENE, V6, P211; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x	53	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2639	2648						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545121				2022-12-17	WOS:A1995TP18800020
J	KORTENJANN, M; SHAW, PE				KORTENJANN, M; SHAW, PE			RAF-1 KINASE AND ERK2 UNCOUPLED FROM MITOGENIC SIGNALS IN RAT FIBROBLASTS	ONCOGENE			English	Article						C-FOS; CELL PROLIFERATION; SIGNAL CASCADE; MAP KINASES	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; MAP KINASE; C-FOS; GROWTH-FACTOR; TRANSDUCTION PATHWAY; IN-VITRO; V-RAF; CELLS; PHOSPHORYLATION	The MAP kinase pathway impinging on ERK2 has been shown to be integrally associated with mitogenic signalling in many cell types. Previously, we and others have demonstrated that oncogenic forms of Raf-1 kinase, when expressed in fibroblasts, lead to the constitutive activation of ERK2, the de-regulation of c-fos expression and increased cell proliferation. Here we describe an exception to this scenario. In Rat6 cells, although both ERK1 and ERK2 are activated in response to mitogens that induce c-fos expression, such as Epidermal Growth Factor (EGF), lysophosphatidic acid (LPA) or serum, expression of v-Raf fails to induce c-fos expression and increase proliferation. However, ERK2 is activated by v-Raf expression. The co-transfection of an interfering mutant of ERK2 has no effect on the level of c-fos reporter expression in Rat6 cells whereas the analogous ERK1 mutant reduces its expression. Furthermore, the spontaneous focus formation observed in Rat6 cells is susceptible to the interfering mutant of ERK1 but resistant to that of ERK2. Thus, not only do mitogenic signals appear to by-pass both Raf-1 kinase and ERK2, the Raf-1-ERK2 pathway seems to be functionally compromised in Rat6 cells as its activation leads neither to c-fos expression nor to increased proliferation.	MAX PLANCK INST IMMUNBIOL,SPEMANN LABS,D-79108 FREIBURG,GERMANY	Max Planck Society				SHAW, Peter/0000-0002-2598-4283				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CHOI KY, 1994, CELL, V78, P499; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GILLE H, 1995, UNPUB; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAGGI R, 1986, EMBO J, V55, P2609; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OTSU M, 1993, FEBS LETT, V320, P246, DOI 10.1016/0014-5793(93)80596-M; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V113, P3003; PAPIN C, 1995, ONCOGENE, V10, P1647; PERKINS LM, 1994, NUCLEIC ACIDS RES, V22, P450, DOI 10.1093/nar/22.3.450; PHAM CD, 1995, ONCOGENE, V10, P1683; PRINTEN JA, 1994, GENETICS, V138, P609; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROZAKISADOCK M, 1992, NATURE, V260, P689; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WU J, 1993, ADV SEC MESS PHOSPH, V28, P219; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	71	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2105	2112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478530				2022-12-17	WOS:A1995TF29700021
J	SEIMIYA, H; SAWABE, T; TOHO, M; TSURUO, T				SEIMIYA, H; SAWABE, T; TOHO, M; TSURUO, T			PHORBOL ESTER-RESISTANT MONOBLASTOID LEUKEMIA-CELLS WITH A FUNCTIONAL MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE BUT WITHOUT RESPONSIVE PROTEIN-TYROSINE PHOSPHATASES	ONCOGENE			English	Article						TPA; MAP KINASE; PTPASE	COMMON ANTIGEN CD45; PHOSPHOTYROSINE PHOSPHATASE; INDUCED DIFFERENTIATION; CYTOSKELETAL ORGANIZATION; SEQUENCE SIMILARITY; C ACTIVATION; U937 CELLS; SH2 DOMAIN; MOTH-EATEN; RECEPTOR	Human monoblastoid leukemia U937 cells differentiate to monocyte/macrophage upon treatment with phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). Previous studies, including our own, have demonstrated that drug-induced differentiation of leukemia cells is associated with genetic and enzymatic activations of protein tyrosine phosphatases (PTPases). In this study, to further investigate a relationship between PTPase activation and leukemic differentiation, we established TPA-resistant U937 variant UT16 cells. Unlike known TPA-resistant cells whose resistance is mainly due to lack or down modulation of protein kinase C (PKC), UT16 cells showed TPA-induced activation of PKC, Raf-1, and ERK/MAP kinases similar to the parental U937 cells. Interestingly, however, UT16 cells exhibited altered binding activity of AP-1 complexes, decreased ability to induce c-jun and c-fos gene expressions, and failure to differentiate to a monocytic lineage. Based on these observations, UT16 cells could be considered a novel type of TPA-resistant cell. Among UT16 cells, most of TPA-inducible PTPase genes, PTP-1C, PTP-MEG2, P19-PTP, HPTP epsilon, and PTP-U1, did not respond to TPA. Consistently, TPA increased PTPase enzymatic activity in U937 but not in UT16 cells. Taken together, activation of PTPases is well correlated with TPA-induced differentiation of U937 cells. These findings indicate that gene expression and enzymatic activity of some PTPase isozymes described here are regulated by a TPA-mediated signaling event and are likely to be used as biomarkers for the monocytic differentiation of myeloid leukemia cells.	UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; JAPANESE FDN CANC RES, CTR CANC CHEMOTHERAPY, TOSHIMA KU, TOKYO 170, JAPAN	University of Tokyo; Japanese Foundation for Cancer Research				Seimiya, Hiroyuki/0000-0003-3314-9736				ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER TM, 1990, CANCER RES, V50, P6323; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHIDA K, 1986, CANCER RES, V46, P1055; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FRANK DA, 1988, CANCER RES, V48, P52; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HALL LR, 1988, J IMMUNOL, V141, P2781; HASS R, 1991, CELL GROWTH DIFFER, V2, P541; HASS R, 1989, EUR J CELL BIOL, V48, P282; HASS R, 1993, CELL GROWTH DIFFER, V4, P657; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1988, COLD SPRING HARB SYM, V53, P447, DOI 10.1101/SQB.1988.053.01.052; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEIMIYA H, 1995, ONCOGENE, V10, P1731; SEIMIYA H, 1993, CELL GROWTH DIFFER, V4, P1033; SEIMIYA H, 1993, J BIOCHEM-TOKYO, V113, P687, DOI 10.1093/oxfordjournals.jbchem.a124104; SHEN SH, 1991, NATURE, V353, P868, DOI 10.1038/353868b0; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SOZERI O, 1992, ONCOGENE, V7, P2259; STONE RL, 1994, J BIOL CHEM, V269, P31323; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; TSUNEIZUMI K, 1994, FEBS LETT, V347, P9, DOI 10.1016/0014-5793(94)00491-9; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WATANABE T, 1985, BIOCHEM BIOPH RES CO, V126, P999, DOI 10.1016/0006-291X(85)90284-0; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	61	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					2047	2054						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478524				2022-12-17	WOS:A1995TF29700015
J	ZHU, TH; BODEM, J; KEPPEL, E; PARO, R; ROYERPOKORA, B				ZHU, TH; BODEM, J; KEPPEL, E; PARO, R; ROYERPOKORA, B			A SINGLE ANCESTRAL GENE OF THE HUMAN LIM DOMAIN ONCOGENE FAMILY LMO IN DROSOPHILA - CHARACTERIZATION OF THE DROSOPHILA DLMO GENE	ONCOGENE			English	Article						TTG/RBTN T CELL ONCOGENES; LIM PROTEINS; STRUCTURAL CONSERVATION	CYSTEINE-RICH PROTEIN; 5' NONCODING REGION; MESSENGER-RNA; SECONDARY STRUCTURE; INSULIN GENE; CELL; MOTIF; TRANSLOCATIONS; MELANOGASTER; CHROMOSOME	Members of the human TTG/RBTN family, now renamed 'LMO' for LIM-only proteins, encode proteins with two tandem copies of a LIM motif. There are three members of this family, two have been isolated at the sites of chromosomal translocations in T-cell leukaemia. The function of the LIM motifs is at present unknown. We found that the LMO-2 gene is highly conserved between mammals, Drosophila and yeast. As a first step to obtain a model system for studying the function of the LIM motifs we have isolated the Drosophila homologue Dlmo. In contrast to mammals Drosophila appears to have only one lmo gene. A 2087 bp cDNA clone was isolated from a larval cDNA library, encoding a protein of 266 amino acids. A second transcript with an alternative 5' end was identified in RNA from embryos. The Drosophila Imo protein consists of two tandem copies of the conserved LIM domain characteristic of the human LMO family and an extended amino and carboxy terminus, which is not present in the human proteins. The amino acid sequence similarity with human LMO-1 and LMO-2 in LIM 1 is 79% and 69% and in LIM-2 90% and 60%, respectively. In addition a short stretch of 25 nucleotides with a homology of 83% between LMO-2 and Dlmo is found in the 3' UTR. Dlmo, like LMO-1, has an intron after the second LIM encoding region, which is not present in LMO-2. It is expressed maternally and at a high level in early embryogenesis as well as in adults. Interestingly we observed that the Dlmo protein is immunologically related to LMO-2 and can be detected by immunohistochemistry in early cellular blastoderm embryos. The gene was localised to a genetically well characterized region (17C on the X chromosome) opening the way for identification of mutations.	UNIV HEIDELBERG,INST HUMAN GENET,HEIDELBERG,GERMANY; UNIV HEIDELBERG,CTR MOLEC BIOL,W-6900 HEIDELBERG,GERMANY; NANKAI UNIV,INST MED,TIANJIN,PEOPLES R CHINA	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Nankai University				Bodem, Jochen/0000-0003-1908-4091				Baptiste J, 1991, NUCLEIC ACIDS RES, V19, P5227; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; EBERL DF, 1992, GENETICS, V130, P569; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HALUSKA FG, 1987, TRENDS GENET, V3, P11, DOI 10.1016/0168-9525(87)90155-7; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KIESS M, 1995, ONCOGENE, V10, P61; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MARIOL MC, 1987, MOL CELL BIOL, V7, P3244, DOI 10.1128/MCB.7.9.3244; MATTOX WW, 1984, MOL CELL BIOL, V4, P1343, DOI 10.1128/MCB.4.7.1343; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MIZUNO K, 1994, ONCOGENE, V9, P1605; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; NALIK P, 1989, MOL CELL ENDOCRINOL, V62, P235, DOI 10.1016/0303-7207(89)90010-5; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROYERPOKORA B, 1995, ONCOGENE, V10, P1353; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; 1994, DROSOPHILA GENETIC D	42	18	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1283	1290						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478548				2022-12-17	WOS:A1995RY96700008
J	KNIPPSCHILD, U; KOLZAU, T; DEPPERT, W				KNIPPSCHILD, U; KOLZAU, T; DEPPERT, W			CELL-SPECIFIC TRANSCRIPTIONAL ACTIVATION OF THE MDM2-GENE BY ECTOPICALLY EXPRESSED WILD-TYPE FORM OF A TEMPERATURE-SENSITIVE MUTANT P53	ONCOGENE			English	Article						TEMPERATURE-SENSITIVE MUTANT P53; P53 TRANSCRIPTIONAL ACTIVITY; CELL-SPECIFIC REGULATION OF P53-DEPENDENT TRANSCRIPTION; PHOSPHORYLATION OF P53; P53 TARGET GENES; MDM2-GENE EXPRESSION	TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; AUTOREGULATORY FEEDBACK LOOP; DNA-BINDING; PHOSPHORYLATION SITE; MDM-2 ONCOGENE; GROWTH ARREST; BREAST-CANCER; GENE; CYCLE	The temperature-sensitive mutant p53 tsp53(val135) (tsp53) displays a mutant phenotype at 38 degrees C, but assumes properties of a wild-type (wt) p53 at 32 degrees C. We analysed the cellular responses of two cell lines which ectopically overexpress tsp53, and dramatically differ in their responses to tsp53 expressed at 32 degrees C. Clone 6 (cl6) cells [precrisis rat embryo fibroblasts transformed by tsp53(val135) and an activated ras oncogene at 38 degrees C (Michalovitz et al., 1990. Cell 62, 671-680)] stop to grow and arrest mainly in the G(1) phase of the cell cycle, whereas MethAp53ts cells [BALB/c mouse MethA tumor cells, transfected with the same tsp53 encoding vector as cl6 cells (Otto and Deppert, 1993. Oncogene 8, 2591-2603)] do not growth arrest at 32 degrees C. Both cell lines expressed similar amounts of tsp53, which was mainly cytoplasmic at 38 degrees C and mainly nuclear at 32 degrees C. At 32 degrees C, both cell lines contained similar amounts of waf1/ cip1 mRNA. However, the amount of mdm2 mRNA in MethAp53ts cells was considerably higher compared to that in cl6 cells. The different transcriptional regulation of the mdm2-gene in cl6 and MethAp53ts cells at 32 degrees C indicated that the tsp53 proteins in these cells were functionally different. This assumption was supported by our finding that at 32 degrees C phosphorylation of the tsp53 in these cells was markedly different. We conclude that the cellular environment is an important determinant of p53 function.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg								BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARAK Y, 1983, EMBO J, V12, P461; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1990, ONCOGENE, V5, P893; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN JY, 1993, ONCOGENE, V8, P2159; DELPHIN C, 1994, J BIOL CHEM, V249, P29579; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1988, ONCOGENE, V3, P313; FAKHARZADEH SS, 1991, EMBO J, V19, P1565; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FISCELLA M, 1993, ONCOGENE, V8, P1519; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MARX J, 1993, SCIENCE, V261, P1385, DOI 10.1126/science.8367721; MATLZMAN W, 1984, MOL CELL BIOL, V4, P1689; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, P293; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; OTTO A, 1993, ONCOGENE, V8, P2591; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Sambrook J, 1989, J SAMBROOK MOL CLONI; SEGAL PB, 1993, ONCOGENE, V8, P3417; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1990, ONCOGENE, V5, P795; THUT CJ, 1994, SCIENCE, V267, P100; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZERRAHN J, 1992, ONCOGENE, V7, P1371	77	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					683	690						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651732				2022-12-17	WOS:A1995RQ46900010
J	JONES, DE; CUI, DM; MILLER, DM				JONES, DE; CUI, DM; MILLER, DM			EXPRESSION OF BETA-GALACTOSIDASE UNDER THE CONTROL OF THE HUMAN C-MYC PROMOTER IN TRANSGENIC MICE IS INHIBITED BY MITHRAMYCIN	ONCOGENE			English	Article						C-MYC; TRANSCRIPTION; TRANSGENIC; MITHRAMYCIN	RNA STABILITY INVITRO; TRANSCRIPTIONAL ACTIVITY; GENE; BINDING; CELLS; ONCOGENE; PROTEIN; INVIVO; MAX	In order to assess the functional contribution of the human c-myc promoter region in the expression of the c-myc gene, transgenic mouse lines containing a bacterial lac Z gene encoding beta-galactosidase under the control of the human c-myc protooncogene promoter were generated. Transgenic mouse embryos heterozygous for the human c-myc Z transgene demonstrate high amounts of beta-galactosidase activity as early as day 11 of embryogenesis by histochemical staining of whole embryos using 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) as substrate, localizing specifically to early spinal cord tissue. beta-galactosidase activity can be demonstrated by histochemical staining in brain tissue of day 14 embryos, localizing mainly to the prefrontal cortex region, while relative amounts of beta-galactosidase in spinal cord tissue are reduced. Determination of specific activity of beta-galactosidase using resorufin-beta galactopyranoside as substrate in homogenates of whole embryos heterozygous for the human c-myc/lac Z transgene demonstrates significantly elevated beta-galactosidase activity over control embryos in day 11 and day 14 embryos. Surprisingly, cell homogenates of brain tissue from adult G(1) generation mice heterozygous for the human c-myc/lac Z transgene demonstrate greater than 10-foId higher specific activity of beta-galactosidase over normal control brain tissue. Specific inhibition of the c-myc/lac Z transgene was also demonstrated in developing embryos using mithramycin given at a dose of 150 mu g kg(-1) d(-1) intraperitoneal to pregnant females on days 7-13 of gestation. Both histochemical staining of beta-galactosidase and specific activity assays of day 14 embryos demonstrated significantly lower levels of beta-galactosidase than untreated controls. These results are unique since we are able to detect expression of beta-galactosidase in developing embryonic central nervous system tissue along with adult brain tissue of animals carrying the human c-myc Z transgene and we are able to specifically inhibit expression of the transgene using mithramycin administered in utero.	UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT BIOCHEM & MOLEC GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, BOLDEN LAB, BIRMINGHAM, AL 35294 USA; VET AFFAIRS MED CTR, BIRMINGHAM, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [CA-42664, CA-42337] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042664, R01CA042337] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAMPBELL VW, 1994, AM J MED SCI, V307, P167, DOI 10.1097/00000441-199403000-00002; CHANG Y, 1991, ONCOGENE, V6, P1979; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAVENU A, 1994, ONCOGENE, V9, P527; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; RAY R, 1990, AM J MED SCI, V300, P203, DOI 10.1097/00000441-199010000-00001; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; Sambrook J., 1989, MOL CLONING LAB MANU; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; SNYDER RC, 1991, BIOCHEMISTRY-US, V30, P4290, DOI 10.1021/bi00231a027; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7	28	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2323	2330						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784080				2022-12-17	WOS:A1995RE54300007
J	PEEBLES, RS; MALISZEWSKI, CR; SATO, TA; HANLEYHYDE, J; MAROULAKOU, IG; HUNZIKER, R; SCHNECK, JP; GREEN, JE				PEEBLES, RS; MALISZEWSKI, CR; SATO, TA; HANLEYHYDE, J; MAROULAKOU, IG; HUNZIKER, R; SCHNECK, JP; GREEN, JE			ABNORMAL B-CELL FUNCTION IN HTLV-I-TAX TRANSGENIC MICE	ONCOGENE			English	Article						HTLV-I; GROWTH FACTORS; B-CELLS; TRANSGENIC MICE; LYMPHOPROLIFERATION; AUTOIMMUNE DISEASE	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; COLONY-STIMULATING FACTOR; PRIMARY SJOGRENS-SYNDROME; EPSTEIN-BARR-VIRUS; HEPATITIS-C VIRUS; INTERLEUKIN-2 RECEPTOR; MOUSE MODEL; ACTIVATION; GENE	Transgenic mice that carry the HTLV-I Tax gene develop an exocrinopathy with some similarities to Sjoegren's syndrome. Our experiments reveal that these mice have lymphadenopathy and splenomegaly composed primarily of B lymphocytes, as well as abnormal levels of secreted immunoglobulins. To gain insight into whether the lymphadenopathy manifested by these transgenic mice was the result of induction of cytokines by Tax, we utilized cell lines from these mice to study in vitro B-cell responses. Conditioned media (CM) derived from the cell lines caused B-cells to proliferate when a second signal, surface Ig cross-linking, was provided. The CM also caused a marked enhancement of IgM secretion by spleen cells or by purified B-cells treated with supplemental cytokines. The B-cell proliferative response and enhanced IgM secretion have not been attributed to a known cytokine. These results suggest that the CM from the cell lines contain a factor(s) involved in novel pathways of B-cell growth and differentiation that may participate in the pathologic development of autoimmune disease.	NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21224; NCI,GENET LAB,BETHESDA,MD 20892; IMMUNEX CORP,DEPT CELLULAR IMMUNOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Immunex Corporation								ABBAS AK, 1991, CELLULAR MOL IMMUNOL, P186; BABOONIAN C, 1990, ARTHRITIS RHEUM, V33, P1749, DOI 10.1002/art.1780331122; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; EGUCHI K, 1992, ANN RHEUM DIS, V51, P769, DOI 10.1136/ard.51.6.769; FLESCHER E, 1992, ARTHRITIS RHEUM, V35, P1068, DOI 10.1002/art.1780350912; FOX RI, 1993, J RHEUMATOL, V20, P764; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GARRY RF, 1990, SCIENCE, V250, P1127, DOI 10.1126/science.1701273; GESSAIN A, 1985, LANCET, V2, P407; GREEN JE, 1992, AM J PATHOL, V140, P1401; GREEN JE, 1991, MOL CELL BIOL, V11, P4635, DOI 10.1128/MCB.11.9.4635; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITESCU S, 1991, RHEUM DIS CLIN N AM, V17, P99; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KARAMERIS A, 1992, CLIN EXP RHEUMATOL, V10, P327; LAVOIE TB, 1992, J IMMUNOL, V1148, P503; LILENBAUM A, 1990, J VIROL, V64, P256; LINDAHL G, 1985, CLIN EXP IMMUNOL, V61, P475; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MARIETTE X, 1993, ARTHRITIS RHEUM, V36, P280, DOI 10.1002/art.1780360225; MARKUSSE HM, 1993, CLIN IMMUNOL IMMUNOP, V66, P26, DOI 10.1006/clin.1993.1004; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OUTSCHOORN I, 1993, CLIN IMMUNOL IMMUNOP, V66, P59, DOI 10.1006/clin.1993.1008; PFLUGFELDER SC, 1993, AM J PATHOL, V143, P49; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROUSSEAU PG, 1989, MOL IMMUNOL, V26, P993, DOI 10.1016/0161-5890(89)90118-1; SHATTLES WG, 1991, CLIN EXP IMMUNOL, V89, P46; SPRIGGS MK, 1992, P NATL ACAD SCI USA, V89, P6070, DOI 10.1073/pnas.89.13.6070; TALAL N, 1990, CLIN EXP RHEUMATOL, V8, P23; TALAL N, 1991, B RHEUM DIS, V40, P6; TATEISHI M, 1993, ARTHRITIS RHEUM, V36, P827, DOI 10.1002/art.1780360614; YOUNG NS, 1972, J CLIN INVEST, V51, P1790, DOI 10.1172/JCI106980; YUAN D, 1992, INT IMMUNOL, V4, P1373, DOI 10.1093/intimm/4.12.1373	40	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1045	1051						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700628				2022-12-17	WOS:A1995QN35300003
J	DEVRIESSMITS, AMM; PRONK, GJ; MEDEMA, JP; BURGERING, BMT; BOS, JL				DEVRIESSMITS, AMM; PRONK, GJ; MEDEMA, JP; BURGERING, BMT; BOS, JL			SHC ASSOCIATES WITH AN UNPHOSPHORYLATED FORM OF THE P21RAS GUANINE-NUCLEOTIDE EXCHANGE FACTOR MSOS	ONCOGENE			English	Article						EGF RECEPTOR; INSULIN RECEPTOR; SIGNAL TRANSDUCTION	EPIDERMAL GROWTH-FACTOR; INSULIN-RECEPTOR SUBSTRATE-1; SIGNAL-REGULATED KINASE-2; TYROSINE KINASES; MITOGENIC SIGNAL; RAS; PROTEIN; GRB2; ACTIVATION; PHOSPHORYLATION	Association of the p21ras guanine nucleotide exchange factor mSOS with tyrosine-phosphorylated She has been implicated in the activation of p21ras, In addition, after growth factor stimulation mSOS becomes phosphorylated as indicated by the appearance of a form of mSOS with reduced electrophoretic mobility. This phosphorylation is delayed with respect to Shc-Grb2-mSOS complex formation and activation of p21ras. To investigate the role of mSOS phosphorylation in further detail we have investigated the effect of phosphorylation on mSOS complex formation and p21ras activation, We found that She is associated with the unphosphorylated, faster migrating form of mSOS. Furthermore, although there is a correlation between the amount of complexes formed and the activation of p21ras, there is no such a correlation between mSOS phosphorylation and p21ras activation. In addition, inhibition of mSOS phosphorylation did not affect complex formation of mSOS with tyrosine phosphorylated She. Also, induction of mSOS phosphorylation prior to complex formation did not affect EGF-induced association of mSOS with She significantly, and She still associated predominantly with the faster migrating form of mSOS. From these results we conclude that the unphosphorylated form of mSOS is associated with She and that perhaps a phosphorylation-dephosphorylation step is part of the mSOS activation-inactivation cycle.	UNIV UTRECHT,PHYSIOL CHEM LAB,3508 TA UTRECHT,NETHERLANDS	Utrecht University				Medema, Jan Paul/0000-0003-3045-2924				BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MEYER MG, 1994, MOL CELL BIOL, V14, P3577; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TOBE K, 1993, J BIOL CHEM, V268, P11167; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F	30	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					919	925						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898933				2022-12-17	WOS:A1995QL03800013
J	ANTELMAN, D; MACHEMER, T; HUYGHE, BG; SHEPARD, HM; MANEVAL, D; JOHNSON, DE				ANTELMAN, D; MACHEMER, T; HUYGHE, BG; SHEPARD, HM; MANEVAL, D; JOHNSON, DE			INHIBITION OF TUMOR-CELL PROLIFERATION IN-VITRO AND IN-VIVO BY EXOGENOUS P110(RB), THE RETINOBLASTOMA TUMOR-SUPPRESSOR PROTEIN	ONCOGENE			English	Article						RETINOBLASTOMA; TUMOR SUPPRESSOR; PROTEIN THERAPY	BLADDER-CARCINOMA CELLS; RB GENE SUPPRESSES; SUSCEPTIBILITY GENE; GROWTH SUPPRESSION; ALTERED EXPRESSION; CANCER-CELLS; LUNG-CANCER; TAT PROTEIN; G1 PHASE; PRODUCT	Reconstitution of retinoblastoma gene (RE) deficient tumor cells with RE generally leads to growth suppression in vitro and/or reduced tumorigenicity in nude mice. An alternate approach to gene replacement is the delivery of the RE gene product (p110(RB)) into cells lacking its expression. In this report we demonstrate that exogenously added p110(RB) is taken up by and localized to the nucleus of cultured cells and has growth suppression properties similar to endogenous RE. RE-negative (RB(neg)) tumor cells are preferentially growth inhibited while most RE-positive (RB(pos)) tumor cells and normal cells are much less sensitive. We have extended these studies to relevant nude mouse xenograft models for human lung cancer. Local or systemic administration of p110(RB) inhibits armor growth in treated animals. These results represent the first use of a tumor suppressor protein as a potential cancer therapeutic.			ANTELMAN, D (corresponding author), CANJI INC,3030 SCI PK RD,SUITE 310,SAN DIEGO,CA 92121, USA.							AURUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334; BAILYES EM, 1982, BIOCHEM J, V203, P245, DOI 10.1042/bj2030245; BANERJEE A, 1992, CANCER RES, V52, P6297; BODYCOTE J, 1986, P NATL ACAD SCI USA, V83, P4749, DOI 10.1073/pnas.83.13.4749; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOOKSTEIN R, 1990, MOL CELL BIOL, V9, P1628; CASEY G, 1991, ONCOGENE, V6, P1791; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; FUNG YKT, 1993, ONCOGENE, V8, P2659; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KORNBLAU SM, 1994, CANCER RES, V54, P242; KORNBLAU SM, 1992, CANCER RES, V52, P4587; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; NEVINS JR, 1992, SCIENCE, V258, P424; OLDHAM KG, 1971, ANAL BIOCHEM, V44, P143, DOI 10.1016/0003-2697(71)90355-1; OOKAWA K, 1993, ONCOGENE, V8, P2175; PEREZ F, 1992, J CELL SCI, V102, P717; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REISSMANN PT, 1993, ONCOGENE, V8, P1913; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIMIZU E, 1994, ONCOGENE, V9, P2441; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WANG NP, 1993, ONCOGENE, V8, P279; WEN SF, 1994, J IMMUNOL METHODS, V169, P231, DOI 10.1016/0022-1759(94)90267-4; XU HJ, 1993, INT J CANCER, V53, P781, DOI 10.1002/ijc.2910530513; YONEMURA Y, 1993, INT J ONCOL, V3, P71; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	51	18	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					697	704						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862447				2022-12-17	WOS:A1995QH61200009
J	NAKAJIMA, T; OHI, N; ARAI, T; NOZAKI, N; KIKUCHI, A; ODA, K				NAKAJIMA, T; OHI, N; ARAI, T; NOZAKI, N; KIKUCHI, A; ODA, K			ADENOVIRUS E1A-INDUCED APOPTOSIS ELICITS A STEEP DECREASE IN THE TOPOISOMERASE II-ALPHA LEVEL DURING THE LATENT PHASE	ONCOGENE			English	Article						ADENOVIRUS E1A; APOPTOSIS; TOPOISOMERASE II-ALPHA	HUMAN PAPILLOMAVIRUS TYPE-16; PROGRAMMED CELL-DEATH; P53 TUMOR-SUPPRESSOR; DNA TOPOISOMERASES; INDUCE APOPTOSIS; E6 ONCOPROTEIN; E1A PROTEINS; LP+ LOCUS; GENE; EXPRESSION	The human KB derivative cell line MA1, established by introduction of the adenovirus E1A 12S cDNA linked to the hormone-inducible promoter, elicits apoptosis upon treatment with dexamethasone. The cell lines partially refractory to apoptosis were established by introducing the expression plasmid for the adenovirus E1B 19k protein to MA1 cells. After induction of E1A in MA1 cells by dexamethasone, the level of p53 increased to about 10-fold within 24 h, and morphological changes characteristics of apoptosis began to be observed within 48h. Most of cells were killed at 72 h releasing apoptotic bodies. The level of topoisomerase II alpha began to decrease steeply within 36 h, preceding the onset of DNA degradation while its mRNA level unchanged throughout the apoptotic process, E1B 19k protected the decrease in topoisomerase II alpha as well as DNA fragmentation depending on its expression levels. Topoisomerase II alpha is induced specifically at G2/M, and computer search revealed the presence of cyclin B type destruction box in topoisomerase II alpha. These results strongly suggest that E1A or E1A stabilized p53 induces apoptosis by targeting topoisomerase II alpha to the ubiquitination pathway and E1B 19k alleviates its action,	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN; SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	Tokyo University of Science; Tokyo University of Science								ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EBERT SN, 1994, J VIROL, V68, P1010, DOI 10.1128/JVI.68.2.1010-1020.1994; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1988, ANTIBODIES LABORATOR; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HSIANG YH, 1988, CANCER RES, V48, P3230; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V13, P4129; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MANSER T, 1984, P NATL ACAD SCI-BIOL, V81, P2470, DOI 10.1073/pnas.81.8.2470; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAKAI E, 1992, ONCOGENE, V7, P927; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAACK J, 1990, J VIROL, V64, P78, DOI 10.1128/JVI.64.1.78-85.1990; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; TAKEMORI N, 1984, J VIROL, V52, P793, DOI 10.1128/JVI.52.3.793-805.1984; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WALKER PR, 1991, CANCER RES, V51, P1078; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1986, MOL CELL BIOL, V6, P3763, DOI 10.1128/MCB.6.11.3763; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	66	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					651	662						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862442				2022-12-17	WOS:A1995QH61200004
J	KADOHAMA, T; TSUJI, K; OGAWA, K				KADOHAMA, T; TSUJI, K; OGAWA, K			INDISTINCT CELL-CYCLE CHECKPOINT AFTER UV DAMAGE IN H-RAS-TRANSFORMED MOUSE-LIVER CELLS DESPITE NORMAL P53 GENE-EXPRESSION	ONCOGENE			English	Article							WILD-TYPE P53; ATAXIA-TELANGIECTASIA; DNA DAMAGE; HEPATOCELLULAR-CARCINOMA; MONOCLONAL-ANTIBODY; IONIZING-RADIATION; GROWTH ARREST; PROTEIN; AMPLIFICATION; INDUCTION	Growth arrest after u.v. damage was investigated in C3H mouse primary cultured hepatocytes, spontaneously immortalized liver epithelial cells and their H-ras-transformed derivatives. All cells except for one of the transformed lines had the wild type p53 gene considered necessary for the G1-S checkpoint. Growth arrest and accumulation of p53 protein with an abnormally-extended half-life were observed after 8 J/m(2) u.v. treatment in primary hepatocytes and immortalized cells, but the arrest was much less evident in H-ras-transformed cells, in spite of the presence of the wild type p53 gene and accumulation of p53. Thus, the signal transduction upstream of p53 in the p53-mediated G1-S checkpoint may be retained in these transformed cell lines, although its downstream signal transduction or a pathway totally independent of this system could be altered. The transformed cells showed a much wider distribution of chromosomal number as compared to normal and immortalized cells, indicating that progression from the immortal to transformed state is associated with chromosomal instability, together with much decrease in the cell cycle checkpoint function.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA 078,HOKKAIDO,JAPAN	Asahikawa Medical College				Kadohama, Takayuki/0000-0002-5175-748X				BAARK Y, 1993, EMBO J, V12, P461; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUKUDA I, 1993, MOL CARCINOGEN, V7, P257, DOI 10.1002/mc.2940070408; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, ONCOGENE, V8, P2457; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P926; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE GH, 1989, CANCER RES, V49, P403; LEE GH, 1991, INT J CANCER, V47, P60, DOI 10.1002/ijc.2910470112; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NISHIMORI H, IN PRESS INT J CANCE; OLSON DC, 1993, ONCOGENE, V8, P2353; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; POPESCU NC, 1972, CYTOGENETICS, V11, P500, DOI 10.1159/000130216; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; TISHLER RB, 1993, CANCER RES, V53, P2212; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; TOKUMITSU M, 1994, MOL CARCINOGEN, V10, P52, DOI 10.1002/mc.2940100109; TSUJI K, 1994, MOL CARCINOGEN, V9, P167, DOI 10.1002/mc.2940090308; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	41	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2845	2852						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084590				2022-12-17	WOS:A1994PG82200010
J	SANDMOLLER, A; HALTER, R; GOMEZLAHOZ, E; GRONE, HJ; SUSKE, G; PAUL, D; BEATO, M				SANDMOLLER, A; HALTER, R; GOMEZLAHOZ, E; GRONE, HJ; SUSKE, G; PAUL, D; BEATO, M			THE UTEROGLOBIN PROMOTER TARGETS EXPRESSION OF THE SV40 T-ANTIGEN TO A VARIETY OF SECRETORY EPITHELIAL-CELLS IN TRANSGENIC MICE	ONCOGENE			English	Article							TISSUE-SPECIFIC EXPRESSION; RABBIT UTEROGLOBIN; GENE REGION; HORMONAL-REGULATION; RIBONUCLEIC-ACID; RAT; PROTEIN; LUNG; TRANSCRIPTION; ENDOMETRIUM	Adenocarcinomas derived from the lining epithelia of various organs are the most common malignant tumors in human pathology and about 50% are hormone dependent. The tissue-specific and hormally regulated expression of the rabbit uteroglobin gene is secretory epithelial cells could provide a means of establishing in vivo models for a variety of human tumors originating from such tissues. We have generated trangenic mice inheriting a hybrid gene containing 4.7 kb of the rabbit uteroglobin 5'-flanking sequences fused to the SV40 T antigen encoding region. All transgenic founders examined exhibited bronchio-alveolar adenocarcinomas, probably due to expression of the transgene in Clara cells. Most founders also developed tumors of the submandibular salivary gland, and adenocarcinomas of the stomach. Adenocarcinomas and dysplasias in epithelial cells of the male and female genital tract were found in single founders. Immunohistochemical analysis showed that T antigen expression interfered with stable maintenance of the differentiated phenotype as documented by expression of the endogenous uteroglobin gene. One founder gave rise to a mouse Line, UT7.1. Transgenic descendants of UT7.1 developed lung adenocarcinomas and, depending on the genetic background, exhibited tumors of the stomach, the salivery gland and the pancreas. Sporadically male descendants developed prostatic adenocarcinoma whereas females developed dysplasias and adenocarcinomas of the uterus and the oviduct. Thus, the UT7.1 mouse line could be a useful model for several epithelial neoplasias.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; FRAUNHOFER INST TOXIKOL & MOLEK BIOL,D-30625 HANNOVER 41,GERMANY; UNIV MARBURG,MED ZENTRUM PATHOL,D-35033 MARBURG,GERMANY	Philipps University Marburg; Fraunhofer Gesellschaft; Philipps University Marburg			Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222; Suske, Guntram/0000-0002-4807-0513				BEATO M, 1978, J REPROD FERTIL, V53, P305; BEATO M, 1983, REGULATION GENE EXPR, P151; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BEIER HM, 1975, CELL TISSUE RES, V165, P1; CATO ACB, 1984, EMBO J, V3, P2771, DOI 10.1002/j.1460-2075.1984.tb02208.x; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEHARO MSL, 1985, BIOCHEM J, V225, P255; DEHARO MSL, 1988, BIOCHEM J, V250, P647, DOI 10.1042/bj2500647; DEMAYO FJ, 1991, AM J PHYSIOL, V261, pL70, DOI 10.1152/ajplung.1991.261.2.L70; DEMAYO FJ, 1991, MOL ENDOCRINOL, V5, P311, DOI 10.1210/mend-5-3-311; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HEINS B, 1981, MOL CELL ENDOCRINOL, V17, P71; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HELFTENBEIN G, 1991, EUR J CELL BIOL, V56, P49; HELFTENBEIN G, 1993, ONCOGENE, V8, P2075; Hogan B., 1986, MANIPULATING MOUSE E; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; JEFFERY PK, 1983, AM REV RESPIR DIS, V128, P14; KAY E, 1972, BIOCHIM BIOPHYS ACTA, V271, P436, DOI 10.1016/0005-2795(72)90219-X; KIRCHNER C, 1976, CELL TISSUE RES, V170, P415, DOI 10.1007/BF00219420; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; KULKA U, 1993, MUTAGENESIS, V8, P193, DOI 10.1093/mutage/8.3.193; KURMAN RJ, 1987, ENDOMETRIAL CARCINOM; Maniatis T., 1982, MOL CLONING; MARGRAF LR, 1993, AM J RESP CELL MOL, V9, P231, DOI 10.1165/ajrcmb/9.3.231; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V19, P2849, DOI 10.1093/nar/19.11.2849; MULLER H, 1980, EUR J BIOCHEM, V112, P235, DOI 10.1111/j.1432-1033.1980.tb07199.x; NOSKE IG, 1976, BIOL REPROD, V15, P704, DOI 10.1095/biolreprod15.5.704; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PAUL D, 1988, EXP CELL RES, V175, P334; RAY MK, 1993, BIOCHEM BIOPH RES CO, V197, P163, DOI 10.1006/bbrc.1993.2455; RENKAWITZ R, 1984, CELL, V37, P503, DOI 10.1016/0092-8674(84)90380-5; SANDMOLLER A, 1991, MECH DEVELOP, V34, P57, DOI 10.1016/0925-4773(91)90091-J; SAVOURET JF, 1980, J BIOL CHEM, V255, P4131; SINGH G, 1984, J HISTOCHEM CYTOCHEM, V32, P49, DOI 10.1177/32.1.6418790; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; Suske Guntram, 1992, Gene Expression, V2, P339; WAREMBOURG M, 1986, ENDOCRINOLOGY, V119, P1632, DOI 10.1210/endo-119-4-1632; WEINBERG RA, 1991, ORIGINS OF HUMAN CANCER, P1; WIEHLE RD, 1990, ONCOGENE, V5, P787	41	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2805	2815						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084586				2022-12-17	WOS:A1994PG82200006
J	HIGINBOTHAM, KG; RICE, JM; BUZARD, GS; PERANTONI, AO				HIGINBOTHAM, KG; RICE, JM; BUZARD, GS; PERANTONI, AO			ACTIVATION OF THE K-RAS GENE BY INSERTION MUTATIONS IN CHEMICALLY-INDUCED RAT RENAL MESENCHYMAL TUMORS	ONCOGENE			English	Article							HA-RAS; POINT MUTATIONS; ONCOGENE; CARCINOGENESIS; PROGRESSION; CARCINOMAS; INITIATION; AMPLIFICATION; MECHANISMS; METHYLUREA	Previously we reported the detection of transforming K-ras sequences in methyl(methoxymethyl)nitrosamine (DMN-OMe)-induced rat renal mesenchymal tumors by NIH3T3 transfection assays. Subsequent analysis by selective oligonucleotide hybridization revealed a variety of activating point mutations in codon 12 of K-ras in most of these tumors and in their NIH3T3 transformants, but in some, point mutations could not be detected by this technique. In the current study, insertion mutations were detected in two DMN-OMe-induced tumors from this group with previously undefined transforming K-ras alterations. These primary tumors and their NIH3T3 transformants contained K-ras sequences with either a 9 bp or a 12 bp repeat in exon one, both of which included codon 12. No other mutations in the entire coding region of the K-ras gene were observed. Site-directed mutagenesis studies by others have determined that deletions and insertions near codon 12 can activate the ras gene, but this is the first demonstration of insertional activation of K-ras in a chemically induced rat tumor.	NCI,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702; PRI DYNCORP,BCDP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [N01-CO-7412] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; AUSUBEL FM, 1989, CURRENT PROTOCOLS S9, V1; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CHIPPERFIELD RG, 1985, MOL CELL BIOL, V5, P1809, DOI 10.1128/MCB.5.8.1809; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; ENOMOTO T, 1990, CANCER RES, V50, P6139; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HIGINBOTHAM KG, 1992, MOL CARCINOGEN, V5, P136, DOI 10.1002/mc.2940050209; HIGINBOTHAM KG, 1992, CANCER RES, V52, P4747; JEGO N, 1993, ONCOGENE, V8, P209; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; MCMAHON G, 1987, P NATL ACAD SCI USA, V84, P4974, DOI 10.1073/pnas.84.14.4974; PERANTONI AO, UNPUB; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SLOAN SR, 1990, MOL CELL BIOL, V10, P405, DOI 10.1128/MCB.10.1.405; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; SUKUMAR S, 1986, MOL CELL BIOL, V6, P2716, DOI 10.1128/MCB.6.7.2716; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WIEST JS, 1994, IN PRESS ONCOGENE, V9; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	30	18	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2455	2459						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058308				2022-12-17	WOS:A1994PC05400004
J	QUINLAN, MP				QUINLAN, MP			ENHANCED PROLIFERATION, GROWTH-FACTOR INDUCTION AND IMMORTALIZATION BY ADENOVIRUS E1A 12S IN THE ABSENCE OF E1B	ONCOGENE			English	Article							PRIMARY EPITHELIAL-CELLS; TUMOR-ANTIGEN; MORPHOLOGICAL TRANSFORMATION; 19-KILODALTON PROTEIN; MOLECULAR MECHANISMS; GENE-EXPRESSION; E1A-12S PROTEIN; DNA-SYNTHESIS; P53; TYPE-5	Immortalization and transformation of primary epithelial cells requires expression of the adenovirus E1A and E1B genes, respectively. The E1A gene is involved in growth stimulatory processes. Little is known about the mechanism utilized by E1B, however, roles in growth stimulatory processes have also been implied. To determine whether there are any functional interactions between E1A 12S and the E1B 55K and 19K polypeptides, primary epithelial cells were infected with 12S viruses with different E1B regions. In the absence of both E1B proteins, there was an increase in 12S expression. This resulted in increased levels of DNA synthesis, entry into S-phase of the cell cycle and increased levels of proliferation, in the presence or absence of serum. There was also a higher induction of growth factor activity. In the presence of the 55K and absence of the 19K protein, there was a decrease in 12S expression. However, the highest induction of proliferative responses was observed. This suggests that expression of the 19K polypeptide inhibits 12S function directly. The lack of 19K expression also enabled the epithelial cells to have a much higher plating efficiency, achieve a greater cell density and reach the immortalized state faster. Although some modest differences in p53 expression were observed when compared to mock, they could not be correlated with any phenotype.			QUINLAN, MP (corresponding author), UNIV TENNESSEE, DEPT MICROBIOL & IMMUNOL, 858 MADISON AVE, MEMPHIS, TN 38163 USA.				NCI NIH HHS [CA50540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CAIRNS J, 1978, CANCER SOC; DEPPERT W, 1990, ONCOGENE, V5, P1701; Flint S. J, 1981, DNA TUMOR VIRUSES; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GIORDANO A, 1991, ONCOGENE, V6, P481; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KUPPUSWAMY M, 1988, ONCOGENE, V2, P613; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1993, ONCOGENE, V8, P3289; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1993, ONCOGENE, V8, P257; QUINLAN MP, 1986, CANCER CELL, V4, P27; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SENEAR AW, 1986, MOL CELL BIOL, V6, P1253, DOI 10.1128/MCB.6.4.1253; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SHENK T, 1991, ADV CANCER RES, V57, P47; SHIMOJO H, 1968, VIROLOGY, V36, P422, DOI 10.1016/0042-6822(68)90167-0; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAUB M, 1984, METHODS SERUM FREE C; TELLING GC, 1993, J VIROL, V67, P1600, DOI 10.1128/JVI.67.3.1600-1611.1993; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; Weinberg R. A., 1989, ONCOGENES MOL ORIGIN; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WHITE E, 1986, MOL CELL BIOL, V6, P3763, DOI 10.1128/MCB.6.11.3763; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	53	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2639	2647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058328				2022-12-17	WOS:A1994PC05400024
J	GRIMM, S; BAEUERLE, PA				GRIMM, S; BAEUERLE, PA			FAILURE OF THE SPLICING VARIANT P65-DELTA OF THE NF-KAPPA-B SUBUNIT P65 TO TRANSFORM FIBROBLASTS	ONCOGENE			English	Note							REL ONCOGENE ENCODES; PROTEIN KINASE-C; DNA-BINDING; TRANSCRIPTION FACTOR; TUMORIGENIC CONVERSION; THYMIDINE KINASE; GENE-EXPRESSION; ACTIVATION; CELLS; TRANSLOCATION	A naturally occurring splice variant of the p65 subunit of the inducible transcription factor NK-kappa B, called p65 Delta, has recently been reported to transform rat-1 fibroblasts in transfection experiments. Criteria for transformation included focus formation, growth in soft agar and tumor formation in athymic mice. In the present study we provide evidence that p65 Delta cannot transform either rat-1 or rat-2 cells although p65 Delta was efficiently expressed and showed all transcriptional activities reported previously. Eleven rat-1 fibroblast cells lines selected for stably overexpressing p65 Delta also showed neither focus formation nor anchorage-independent growth in soft agar. No transformation of primary rat fibroblasts was evident when p65 Delta was cotransfected with either ras or myc oncogenes, whereas a combination of the two oncogenes caused focus formation. We submit that the transforming potential of p65 Delta is highly conditional and presumably restricted to a particular subclone of rat-1 cells.	UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY	University of Freiburg								BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWNELL E, 1988, ONCOGENE, V2, P527; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MATHEW S, 1993, ONCOGENE, V8, P191; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YACOPOULOS GD, 1985, P NATL ACAD SCI USA, V83, P5455; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZERLIN M, 1987, ONCOGENE, V1, P19	36	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2391	2398						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036023				2022-12-17	WOS:A1994NX62900034
J	SHERRINGTON, PD; FISCH, P; TAYLOR, AMR; RABBITTS, TH				SHERRINGTON, PD; FISCH, P; TAYLOR, AMR; RABBITTS, TH			CLONAL EVOLUTION OF MALIGNANT AND NONMALIGNANT T-CELLS CARRYING T(1414) AND T(X14) IN PATIENTS WITH ATAXIA-TELANGIECTASIA	ONCOGENE			English	Note							ALPHA-CHAIN LOCUS; MOLECULAR ANALYSIS; LYMPHOPROLIFERATIVE DISORDERS; CHROMOSOME-14 INVERSION; LYMPHOCYTIC-LEUKEMIA; GENE REARRANGEMENTS; RECEPTOR; TRANSLOCATION; IMMUNOGLOBULIN; SEQUENCES	People with ataxia telangiectasia (AT) are at a higher than normal risk of T cell leukaemia and often have either non-malignant or malignant T cells with chromosomal abnormalities, typically t(14;14), inversion 14 or more rarely t(X;14). This provides a chance to study the pre-leukaemic phase of the disease. T cells have been studied with either t(14;14)(q11;q32.1) or t(X;14)(q28;q11) from two AT sisters of which the latter developed T cell leukaemia. The telomeric breakpoint of the t(14;14) was cloned and found to occur at 14q32.1 where known tumour-associated breakpoints are located, but the patient remains asymptomatic for leukaemia. Analysis of T cell populations in both patients showed that the cells containing the translocation became oligoclonal with respect to T cell receptor beta rearrangement and complete T cell receptor beta clonality was only established in the patient with t(X;14) by onset of overt disease. Therefore in these chronic diseases, chromosomal translocations can precede T cell receptor rearrangement suggesting a role for these abnormalities as early events of malignant outgrowth.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,CAMBS,ENGLAND; UNIV BIRMINGHAM,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND	MRC Laboratory Molecular Biology; University of Birmingham			Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				BAER R, 1988, EMBO J, V7, P1661, DOI 10.1002/j.1460-2075.1988.tb02993.x; BAER R, 1987, P NATL ACAD SCI USA, V84, P9069, DOI 10.1073/pnas.84.24.9069; BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287; DENNY CT, 1986, NATURE, V320, P549, DOI 10.1038/320549a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCH P, 1993, ONCOGENE, V8, P3271; FOA R, 1986, BLOOD, V67, P247; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GIBSON TJ, 1987, GENE, V53, P283, DOI 10.1016/0378-1119(87)90017-5; HEPPELL A, 1988, HUM GENET, V79, P360; KARN J, 1984, GENE, V32, P217, DOI 10.1016/0378-1119(84)90049-0; KORSMEYER SJ, 1992, BLOOD, V80, P879; MCCAW BK, 1975, P NATL ACAD SCI USA, V83, P2071; MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; OCONNOR NTJ, 1985, LANCET, V1, P1295; OLSON MV, 1979, J MOL BIOL, V132, P387, DOI 10.1016/0022-2836(79)90267-5; OXFORD JM, 1975, J MED GENET, V12, P251, DOI 10.1136/jmg.12.3.251; RABBITTS TH, 1985, EMBO J, V4, P2217, DOI 10.1002/j.1460-2075.1985.tb03917.x; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; STERN MH, 1993, ONCOGENE, V8, P2475; TAYLOR AMR, 1992, LEUKEMIA, V6, P961; TAYLOR AMR, 1986, CANCER, V27, P511; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275; YOSHIKAI Y, 1986, J EXP MED, V164, P90, DOI 10.1084/jem.164.1.90	34	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2377	2381						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036021				2022-12-17	WOS:A1994NX62900032
J	AMARAVADI, L; KING, MW				AMARAVADI, L; KING, MW			CHARACTERIZATION AND EXPRESSION OF THE XENOPUS C-MYB HOMOLOG	ONCOGENE			English	Note							PROTO-ONCOGENE; HEMATOPOIETIC-CELLS; NUCLEOTIDE-SEQUENCE; DNA; GENE; PROLIFERATION; TRANSCRIPTION; ORGANIZATION; ACTIVATION; PROTEINS	The c-Myb protein is a sequence specific DNA-binding transcriptional regulator that is critically involved in the regulation of hematopoietic differentiation. Its role in these processes suggests that the function of c-Myb may be important early in the establishment of the hematopoietic lineage. We have isolated cDNA and partial genomic clones representing the Xenopus c-Myb homolog (Xc-Myb) in order to examine the role this gene plays in early mesodermal patterning in the frog embryo. The establishment of these clones as c-Myb homologs, as opposed to Myb-related sequences, is based upon both predicted amino acid sequences and the location of the exon-intron boundaries within the Xc-Myb gene. Maternally derived Xc-Myb RNA is degraded following fertilization then, beginning at midblastula, re-accumulates throughout early development. Xc-Myb RNA is localized to the animal cap region of the early blastula. Following the onset of gastrulation expression predominates in the ventral half of the embryo. During neurulation expression of Xc-Myb is observed in both the anterior dorsal and ventral vegetal regions of the embryo. Expression of Xc-Myb occurs in several adult tissues, the highest levels of which are in the intestine, heart, liver, lung and ovary. Xc-Myb encodes a protein of 624 amino acids and exhibits a mobility in SDS-PAGE of approximately 75 kDa, identical with that of the murine c-Myb protein. Xc-Myb protein exhibits 70% identity with avian and 67% identity with mammalian c-Myb proteins.	INDIANA UNIV,SCH MED,TERRE HAUTE CTR MED SCI,DEPT BIOCHEM & MOLEC BIOL,TERRE HAUTE,IN 47809; INDIANA STATE UNIV,DEPT LIFE SCI,TERRE HAUTE,IN 47809	Indiana University System; Indiana State University								ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BANKER DE, 1991, MOL CELL BIOL, V11, P5079, DOI 10.1128/MCB.11.10.5079; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DESBIENS X, 1991, DEVELOPMENT, V111, P699; DUPASQUIER L, 1989, ANNU REV IMMUNOL, V7, P251, DOI 10.1146/annurev.immunol.7.1.251; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREEN N, 1979, Cellular Immunology, V48, P59, DOI 10.1016/0008-8749(79)90099-6; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; KATAGIRI C, 1986, CURR TOP DEV BIOL, V98, P315; KING MW, 1993, CELL GROWTH DIFFER, V4, P85; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NIEUWKOOP PD, 1967, NORMAL TABLE XENOPUS, P162; REILLY CF, 1989, J BIOL CHEM, V264, P6990; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; THEILE CJ, 1988, MOL CELL BIOL, V8, P1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043	30	18	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					971	974						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	7509053				2022-12-17	WOS:A1994MW55100036
